<SEC-DOCUMENT>0001564590-18-004163.txt : 20180301
<SEC-HEADER>0001564590-18-004163.hdr.sgml : 20180301
<ACCEPTANCE-DATETIME>20180301172818
ACCESSION NUMBER:		0001564590-18-004163
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		112
CONFORMED PERIOD OF REPORT:	20171231
FILED AS OF DATE:		20180301
DATE AS OF CHANGE:		20180301

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SANGAMO THERAPEUTICS, INC
		CENTRAL INDEX KEY:			0001001233
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				680359556
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-30171
		FILM NUMBER:		18659092

	BUSINESS ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804
		BUSINESS PHONE:		5109706000

	MAIL ADDRESS:	
		STREET 1:		501 CANAL BLVD
		STREET 2:		POINT RICHMOND TECH CNTR.
		CITY:			RICHMOND
		STATE:			CA
		ZIP:			94804

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SANGAMO BIOSCIENCES INC
		DATE OF NAME CHANGE:	20000208
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>sgmo-10k_20171231.htm
<DESCRIPTION>2017 10-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-10k_20171231.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:left;border-top:Solid 0.75pt #000000;padding-top:0pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> &#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:16.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington,&#160;D.C. 20549 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:16.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Form&#160;10-K </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-size:11.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:11.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11.5pt;"><font style="font-weight:bold;">ANNUAL REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the fiscal year ended December&#160;31, 2017 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">or </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:4pt;font-size:11.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:11.5pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"></font><font style="font-size:11pt;font-family:'Times New Roman'">&#9744;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:4pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11.5pt;"><font style="font-weight:bold;">TRANSITION REPORT PURSUANT TO SECTION&#160;13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 </font></p></td></tr></table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the transition period from&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; to&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Commission file number: 000-30171 </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:21.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter) </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;line-height:4pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">68-0359556</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">incorporation or organization)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(I.R.S. Employer<br />Identification No.)</p></td>
</tr>
<tr style="height:4.05pt;">
<td valign="middle"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
<td valign="middle"  style="width:49%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:3pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">501 Canal Boulevard,</p>
<p style="text-align:center;margin-bottom:1pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Richmond, California</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">94804</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Address of principal executive offices)</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Zip Code)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(510)&#160;970-6000 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code) </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(b) of the Act: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title of Each Class</font></p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:7.5pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:7.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Name of Each Exchange on Which Registered</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock, $0.01&#160;par value per share</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Nasdaq Global Select Market</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Securities registered pursuant to Section&#160;12(g) of the Act: None </p>
<p style="text-align:center;border-bottom:Solid 1pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:40%;margin-right:40%;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Exchange Act.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12&#160;months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90&#160;days.&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark if disclosure of delinquent filers pursuant to Item&#160;405 of Regulation&#160;S-K (<font style="font-family:Arial;">&#167;</font> 229.405 of this chapter)&nbsp;&nbsp;is not contained herein, and will not be contained, to the best of registrant&#8217;s knowledge, in definitive proxy or information statements incorporated by reference in Part&#160;III of this Form&#160;10-K or any amendment to this Form&#160;10-K.&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or emerging growth company. See definition of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Large&#160;accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accelerated filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">&#160;&#160;</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-accelerated&#160;filer</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font><font style="font-family:Times New Roman;">&#160;&#160;(Do not check if a smaller reporting company)</font></p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Smaller&#160;reporting&#160;company</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company</p></td>
<td valign="bottom"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.<font style="margin-left:36pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font></p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act).&#160;&#160;&#160;&#160;Yes&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9744;</font></font>&#160;&#160;&#160;&#160;No&#160;&#160;<font style="font-family:'Times New Roman';"><font style="font-size:8pt;font-family:'Times New Roman'">&#9746;</font></font> </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate market value of the voting stock held by non-affiliates of the registrant based upon the closing sale price of the common stock on June&#160;30, 2017 (the last business day of the registrant&#8217;s most recently completed second fiscal quarter), as reported on the Nasdaq Global Select Market was $734,155,954. For purposes of this calculation, directors and executive officers of the registrant have been deemed affiliates. This determination of affiliate status is not necessarily a conclusive determination for other purposes. </p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 15, 2018, a total of 86,338,976 shares of common stock $0.01 par value per share were outstanding.</p>
<p style="margin-bottom:0pt;margin-top:3pt;text-indent:3.33%;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:4pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DOCUMENTS INCORPORATED BY REFERENCE </p>
<p style="margin-bottom:0pt;margin-top:4pt;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">Certain information required by Part III, Items 10-14 of this Form 10-K is incorporated by reference to the registrant&#8217;s definitive Proxy Statement for the 2018 Annual Meeting of Stockholders to be filed with the Securities and Exchange Commission pursuant to Regulation 14A not later than 120 days after the end of the fiscal year covered by this Form 10-K, provided that if such Proxy Statement is not filed within such period, such information will be included in an amendment to this Form 10-K to be filed within such 120-day period<font style="font-weight:bold;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:2pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top"  style="width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="width:2%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:49%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:9pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-top:0pt;border-top:Solid 0.75pt #000000;padding-top:0pt;text-align:center;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;border-top:Solid 1pt;padding-top:1pt;margin-top:1pt;line-height:1pt;margin-bottom:0pt;text-indent:0%;font-size:4pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:1pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:1pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TABLE OF CONTENTS</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:85%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_I"><font style="text-decoration:none;">PART&#160;I</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Business"><font style="text-decoration:none;">Business</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1A.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Risk_Factors"><font style="text-decoration:none;">Risk Factors</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;1B.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Unresolved_Staff_Comments"><font style="text-decoration:none;">Unresolved Staff Comments</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;2.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Properties"><font style="text-decoration:none;">Properties</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;3.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Legal_Proceedings"><font style="text-decoration:none;">Legal Proceedings</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;4.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Mine_Safety_Disclosures"><font style="text-decoration:none;">Mine Safety Disclosures</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:85%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_II"><font style="text-decoration:none;">PART&#160;II</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Market_for_the_Registrant_Common_Equit"><font style="text-decoration:none;">Market for the Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;6.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Selected_Financial_Data"><font style="text-decoration:none;">Selected Financial Data</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Management_Discussion_and_Analysis_of"><font style="text-decoration:none;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;7A.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Quantitative_and_Qualitative_Disclosures"><font style="text-decoration:none;">Quantitative and Qualitative Disclosures About Market Risk</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;8.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Financial_Statements_and_Supplementary"><font style="text-decoration:none;">Financial Statements and Supplementary Data</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Changes_in_and_Disagreements_with_Accoun"><font style="text-decoration:none;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9A.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Controls_and_Procedures"><font style="text-decoration:none;">Controls and Procedures</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9B.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Other_Information"><font style="text-decoration:none;">Other Information</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:85%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_III"><font style="text-decoration:none;">PART&#160;III</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;10.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Directors_Executive_Officers_and_Corpor"><font style="text-decoration:none;">Directors, Executive Officers and Corporate Governance</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;11.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Executive_Compensation"><font style="text-decoration:none;">Executive Compensation</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;12.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Security_Ownership_of_Certain_Beneficial"><font style="text-decoration:none;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;13.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Certain_Relationships_and_Related_Transa"><font style="text-decoration:none;">Certain Relationships and Related Transactions, and Director Independence</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;14.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Principal_Accounting_Fees_and_Services"><font style="text-decoration:none;">Principal Accounting Fees and Services</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:85%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a href="#PART_IV"><font style="text-decoration:none;">PART&#160;IV</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6pt;">
<td valign="middle"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:5%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;15.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#Exhibits_and_Financial_Statement_Schedul"><font style="text-decoration:none;">Exhibits and Financial Statement Schedules</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Item 16.</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="width:85%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#ITEM_16_FORM_10K_SUMMARY"><font style="text-decoration:none;">Form 10-K Summary</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SPECIAL NOTE&#160;REGARDING FORWARD-LOOKING STATEMENTS </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some statements contained in this report are forward-looking with respect to our business. Forward-looking statements include, but are not limited to, statements about: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our strategy; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product development and commercialization of our products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trials and release of data; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">partnering, acquisition and other strategic transactions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">revenues from existing and new collaborations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our research and development and other expenses; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">manufacturing and supply;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">sufficiency of our cash resources; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our operational and legal risks; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our plans, objectives, expectations and intentions and any other statements that are not historical facts. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some cases, you can identify forward-looking statements by terms such as: &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;continues,&#8221; &#8220;could,&#8221; &#8220;estimates,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;plans,&#8221; &#8220;seeks,&#8221; &#8220;should&#8221; and &#8220;will.&#8221; These forward-looking statements reflect our current views with respect to future events and are based on assumptions and involve known and unknown risks, uncertainties and other factors which may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements. Given these risks and uncertainties, you should not place undue reliance on these forward-looking statements. We discuss many of these risks in greater detail under the headings &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Results of Operations&#8221; in this Form 10-K. Accordingly, the forward-looking statements, which speak only as of the date of this Form&#160;10-K. Except as required by law, we undertake no obligation to update or publicly release any revisions to forward-looking statements to reflect events or circumstances arising after the date of this report. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><a name="PART_I"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_I"></a>P</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ART&#160;I</font><font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Business"></a><a name="Business"></a>ITEM&#160;1 &#8211; BUSINESS<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">OVERVIEW </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients&#8217; lives using our industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, we have accrued significant scientific, manufacturing and regulatory capabilities and know-how that are generally applicable in the broader field of gene therapy and have capitalized this knowledge into a conventional gene therapy platform based on adeno-associated viral vector, or AAV, cDNA gene transfer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to maximize the value and therapeutic use of our technology platforms. In certain therapeutic areas we intend to capture the value of our proprietary genome editing and gene therapy products by forward integrating into manufacturing, development and commercial operations. In other therapeutic areas we intend to partner with biopharmaceutical companies to develop products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the development of human therapeutics for diverse diseases with well-characterized genetic causes. We have several proprietary clinical and preclinical product candidates in development and have strategically partnered certain programs with biopharmaceutical companies to obtain funding for our own programs and to expedite clinical and commercial development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an ongoing Phase 1/2 clinical trial evaluating SB-525, a gene therapy for the treatment of hemophilia A, a bleeding disorder. We have ongoing Phase 1/2 clinical trials evaluating three product candidates using our&#160;proprietary <font style="font-style:italic;">in vivo</font>&#160;genome editing approach: SB-FIX, for the treatment of hemophilia B, a bleeding disorder, SB-318, for the treatment of Mucopolysaccharidosis Type I, or MPS I, and SB-913 for the treatment of Mucopolysaccharidosis Type II, or MPS II.&nbsp;&nbsp;MPS I and MPS II are rare lysosomal storage disorders, or LSDs.&#160;We are also initiating a Phase 1/2 clinical trial evaluating ST-400, developed using our proprietary ZFN-mediated <font style="font-style:italic;">ex vivo</font> cell therapy platform, for the&#160;treatment of beta-thalassemia, a blood disorder. In addition, we have proprietary preclinical and discovery stage programs in other LSDs and monogenic diseases, including certain central nervous system disorders, cancer immunotherapy, immunology and infectious disease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have proprietary preclinical programs in other monogenic diseases and LSDs. Our preclinical discovery efforts include research into potential therapeutic applications of our technology for certain central nervous system disorders, autoimmune disorders, infectious disease, and others.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma, Inc., or Kite, a wholly-owned subsidiary of Gilead Sciences, Inc., or Gilead, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we will work together with Kite on a research program under which we will design ZFNs and AAVs to disrupt and insert certain genes in T cells and natural killer, or NK, cells, including the insertion of genes that encode chimeric antigen receptors, or CARs, T-cell receptors, or TCRs and NK-cell receptors, or NKRs, directed to mutually agreed targets. Kite will be responsible for all clinical development and commercialization of any resulting products.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a new research collaboration and license agreement with Pfizer Inc., or Pfizer, for the development and commercialization of potential gene therapy products that use ZFP TFs to treat amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations of the <font style="font-style:italic;">C9ORF72</font> gene. Under this agreement, we are working with Pfizer on a research program to identify, characterize and preclinically develop ZFP TFs that satisfy pre-agreed criteria. Pfizer is responsible for subsequent development, manufacturing and commercialization of licensed products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, we entered into a global collaboration and license agreement with Pfizer for the research, development and commercialization of SB-525, our gene therapy product candidate for hemophilia A, and closely related products. Under this agreement, we are responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. We and Pfizer may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also established a collaborative partnership with Bioverativ, Inc., or Bioverativ, </font><font style="color:#000000;">to </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">research, develop and commercialize therapeutic gene-edited cell therapy products in hemoglobinopathies</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, including beta-thalassemia and sickle cell disease, or SCD.&#160;We expect to begin enrolling patients in a Phase 1/2 clinical </font><font style="color:#000000;">study in the first half of 2018.&#160;</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bioverativ is responsible for subsequent development, manufacturing and commercialization of licens</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed products.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>We have a substantial intellectual property position in the genome editing field including the design, selection, composition and use of engineered ZFPs to support our research and development activities. As of February 15, 2018, we either owned outright or have exclusively licensed the commercial rights to over 860 patents issued in the United States and foreign jurisdictions, and over 610 patent applications pending worldwide.&nbsp;&nbsp;We continue to license and file new patent applications that strengthen our core and accessory patent portfolio. We believe that our intellectual property position is a critical element in our ability to research,&#160;develop and commercialize products and services based on genome editing, gene therapy, gene regulation and cell therapy.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2017, we changed our corporate name to &#8220;Sangamo Therapeutics, Inc.&#8221; to underscore our focus on clinical development of genomic therapies using our industry-leading platform technologies across genome editing, gene therapy, gene regulation and cell therapy.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INTRODUCTION TO GENOME EDITING, GENE THERAPY, CELL THERAPY AND GENE REGULATION</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">DNA, Genes, and Proteins </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deoxyribonucleic acid, or DNA, is present in all cells except mature red blood cells, and encodes the inherited characteristics of all living organisms. A cell&#8217;s DNA is organized in chromosomes as thousands of individual units called genes. Genes encode proteins, which are assembled through the process of transcription&#8212;whereby DNA is transcribed into ribonucleic acid, or RNA,&#8212;and, subsequently, translation&#8212;whereby RNA is translated into protein (Figure 1). Proteins are involved in virtually all cell functions. DNA, RNA and proteins comprise many of the targets for pharmaceutical drug discovery and therapeutic intervention. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531013631431.jpg" title="" alt="" style="width:607px;height:348px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 1: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schematic of the relationship between the human genome, DNA, RNA and protein </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>The human body is composed of specialized cells that perform different functions and are thus organized into tissues and organs. All somatic cells in an individual&#8217;s body contain the same set of genes. However, only a fraction of these genes are turned on, or expressed, in an individual human cell at any given time. Genes are regulated (<font style="font-style:italic;">i.e.</font> turned on or turned off) by DNA-binding proteins called transcription factors in response to a wide variety of stimuli and developmental signals. Distinct sets of genes are </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expressed in different cell types. It is this pattern of gene expression that determines the structure, biological function and health of all cells, tissues and</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> organisms. The aberrant expression of certain genes can lead to disease. Similarly, a mistake, or mutation in the DNA sequence of a gene, can result in corresponding error in the protein encoded by the gene, which may have serious consequences for the cel</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l and its function. A number of disorders have been identified as caused by the inheritance of a single defective gene. These so-called monogenic diseases include hemophilia A and hemophilia B, LSDs such as MPS I and MPS II, beta-thalassemia, SCD, Huntingt</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on&#8217;s disease and many others.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZFPs are Naturally Occurring Transcription Factors<font style="font-weight:normal;"> </font>in Humans</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A transcription factor recognizes and binds to a specific DNA sequence within or near a particular gene and causes expression of that gene to be &#8220;turned on&#8221; (activated) or &#8220;turned off&#8221; (repressed). ZFPs are the most common class of naturally occurring transcription factors in organisms from yeast to humans. In higher organisms, naturally occurring transcription factors typically comprise two domains: the first is a DNA-binding domain, (designated in Figure 2 as the &#8220;Recognition Domain&#8221;), which recognizes a target DNA sequence and thereby directs the transcription factor to the proper chromosomal location; the second is a functional domain that causes the target gene to be activated or repressed. To these naturally occurring transcription factors, we have added functional domains which enable genome editing at the site determined by the ZFP DNA-binding domain. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531014931432.jpg" title="" alt="" style="width:627px;height:338px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 2: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schematic of the two-domain structure of a ZFP and its therapeutic functional domain </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZFNs can be designed for genome editing and ZFP TFs can be designed for gene regulation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consistent with the modular structure of natural ZFPs, we take a modular approach to the design of the proteins that we engineer. The ZFP portion of our engineered proteins, the DNA-recognition domain, is typically composed of four to six zinc fingers. Each individual finger recognizes and binds to a three or four base pair sequence of DNA and multiple fingers can be linked together to recognize longer stretches of DNA, thereby improving specificity. By modifying the amino acid sequence of a ZFP, we can engineer novel ZFPs capable of recognizing the DNA sequences of a chosen genomic target. We use the engineered ZFP DNA-binding domain to link to a functional domain. The ZFP DNA-binding domain brings the functional domain to the target of interest. Our ability to use our highly specific ZFP technology to precisely target a DNA sequence in a gene of interest provides us with a range of genome editing and gene regulation functions that can be applied in many different cell types. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a>Our engineered ZFPs can be attached to a cleavage domain of a restriction endonuclease, an enzyme that cuts DNA, creating a ZFN. When a pair of ZFNs is bound to the DNA in the correct orientation and spacing, the DNA sequence is cut between the ZFP binding sites. DNA binding by both ZFNs is necessary for cleavage, and both nuclease of the restriction endonuclease must be present in the correct orientation to interact with each other, in order to mediate DNA cleavage. This break in the DNA triggers a natural process of DNA repair in the cell. The repair process can be harnessed to achieve one of several outcomes that may be therapeutically useful (Figure&#160;3). If cells are simply treated with ZFNs alone, the repair process joins the two ends of the broken DNA together and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">frequently results in the loss or addition of a small amount of genetic material at the site of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">break. This disrupts the original DNA sequence and can result in the expression of a truncated or non-functional protein from the targeted gene, effectively &#8220;knocking out&#8221; the gene function. ZFN-mediated genome editing can be used to disrupt genes that are</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> involved in disease pathology. We are using ZFN-mediated genome editing of the </font><font style="font-style:italic;">BCL11A</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> erythroid enhancer in hematopoietic stem progenitor cells, or HSPCs, which is designed to be a single long-lasting treatment for beta-thalassemia (ST-400) and SCD (BIVV-</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">003). </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531016131433.jpg" title="" alt="" style="width:591px;height:365px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Figure 3: </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Schematic of ZFP genome editing and gene regulation</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In contrast, if cells with a mutation in a particular gene are treated not only with ZFNs, but also with a DNA sequence that encodes the correct gene sequence (referred to as a &#8220;donor&#8221; DNA) and with ZFNs that recognize and bind to sequences flanking the mutation, the cell&#8217;s repair machinery can use the donor as a template to correct the mutated gene.&nbsp;&nbsp;This ZFN-mediated gene correction enables the corrected gene to be expressed in its natural chromosomal context and may provide a novel approach for the precise repair of DNA sequence mutations responsible for certain monogenic diseases. In addition to providing a donor sequence that encodes a complete gene, a new copy of a gene can also be precisely added into the genome at a specific location. The ability to precisely place a gene-sized segment of DNA specifically into a pre-determined location in the genome broadens the range of mutations of a gene that can be corrected in a single step. It also reduces the insertional mutagenesis concerns associated with traditional integrating gene replacement approaches such as lentiviruses, in which the insertion of a new corrective copy of the gene typically occurs at random locations in the genome. Our In Vivo Protein Replacement Platform&#8482;, or IVPRP&#8482;, in which our ZFN technology is used to insert a gene encoding a therapeutic protein into a location such as the <font style="font-style:italic;">Albumin</font> gene, is an approach that we are investigating for the treatment of hemophilia B (SB-FIX) and LSDs (SB-318 and SB-913), which may potentially provide a single and potentially curative treatment for these diseases. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also evaluating ZFP TFs with the potential to control or regulate the expression of a target gene in the desired manner (Figure&#160;3). For instance, attaching an activation domain to a ZFP will cause a target gene to be expressed at enhanced levels, relative to expression in an untreated cell. Alternatively, a repression domain causes the gene to be downregulated or completely turned off. Pursuant to a collaboration agreement with Shire International GmbH, or Shire, we have a preclinical program for Huntington&#8217;s disease in which we are evaluating a ZFP TF designed to differentially down regulate the mutated disease-causing <font style="font-style:italic;">Huntingtin</font>, or <font style="font-style:italic;">HTT</font>, gene, while leaving expression of the normal gene unchanged. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZFPs can be designed to accomplish a range of functions in genome editing and gene regulation. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>To date, we and our partners have designed, engineered and assembled thousands of ZFPs and have tested many of these proteins for their affinity, or tightness of binding to their DNA target, as well as their specificity, or preference for their intended DNA target. We have developed methods for the design, selection and assembly of ZFPs capable of binding to a wide spectrum of DNA </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sequences and genes. We have linked ZFPs to endonuclease domains to create highly specific ZFNs and to numerous functional domains to create gene-specific ZFP TFs. We have demonstrated the ability of thes</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e proteins to enable genome editing or gene regulation, of hundreds of genes in dozens of different cell types and in whole organisms, including non-human primates, or NHPs, mice, rats, rabbits, pigs, fruit flies, worms, zebrafish and yeast, and in plant s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pecies including canola and maize. We and our collaborators have published data from many of these studies in peer-reviewed scientific journals. ZFNs are currently being used to generate transgenic animals and cell lines that have specific genetic modifica</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tions that make them useful models of human disease. These high value biologic tools are being used by academic, and biotechnology and pharmaceutical companies for medical research and drug development. Our preclinical data have been reviewed by advisory b</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">odies such as the National Institute of Health, or NIH, Recombinant Advisory Committee, or RAC, and regulatory bodies such as the U.S. Food and Drug Administration, or FDA, and we have ongoing clinical trials to evaluate the safety and efficacy of ZFNs in </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">humans.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have employed several strategies for the application of our ZFNs depending on the disease or indication. We routinely deliver our therapeutics as nucleic acids, either as messenger RNA, or mRNA, or encoded in a viral vector such as AAV that the cell then uses to make the protein form of the ZFN or ZFP TF.&nbsp;&nbsp;We can deliver ZFNs <font style="font-style:italic;">ex vivo</font> (outside the body) to isolated cells of the blood, such as T cells, in the case of our clinical HIV, cancer immunotherapy and immunology programs, and HSPCs for our programs in HIV and monogenic blood diseases such as beta-thalassemia and SCD. We are also developing ZFPs in which we deliver our therapeutic proteins <font style="font-style:italic;">in vivo</font>, either systemically (directly into the blood stream) as in our <font style="font-style:italic;">in vivo</font> genome editing programs in hemophilia and LSD, or directly into a specific tissue such as the brain as in our Huntington&#8217;s disease program. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">ZFPs provide the Opportunity to Develop a New Class of Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our ZFP technology provides a unique and proprietary basis for a broad new class of drugs that have differential technical advantages over small-molecule drugs, protein pharmaceuticals, RNA-based therapeutics, conventional gene therapy approaches and other genome editing platforms, enabling us to develop therapies for a broad range of unmet medical needs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We can generate highly specific ZFNs for genome editing and ZFP TFs for gene regulation and have developed multiple delivery strategies to administer these therapeutics, including using mRNA, AAV, adenovirus, plasmid, and lipid nanoparticles.&nbsp;&nbsp;As more genes and DNA sequences are linked to specific diseases, we believe that the clinical breadth and scope of our ZFP applications will continue to expand. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, ZFPs can: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Enable genome editing and gene regulation strategies to address novel drug targets.</font><font style="font-family:Times New Roman;"> Engineered ZFNs enable the efficient disruption, correction or targeted addition of a gene sequence in a very precise fashion, and ZFP TFs enable either repression or activation of a therapeutically relevant gene in a cell. This gives our technology a degree of flexibility. Direct, targeted modification of the genome cannot be achieved using conventional gene therapy approaches, antisense RNA, siRNA, conventional small molecules, antibodies, or other proteins. Our ZFN genome editing technology, which requires only brief cellular expression of ZFNs, enables the permanent disruption or addition of a therapeutically relevant gene in a highly targeted fashion. For example, our </font><font style="font-style:italic;font-family:Times New Roman;">in vivo</font><font style="font-family:Times New Roman;"> genome editing strategy enables targeted insertion of a therapeutic gene into the genome of liver cells.&nbsp;&nbsp;This strategy has the potential to provide an extended or life-long clinical benefit in the treatment of monogenic diseases, such as hemophilia, without the risk of washout of therapeutic genes delivered using non-integrating vectors such as AAV, or the potentially deleterious issues related to random insertion of therapeutic genes into the genome by randomly integrating viral vectors such as lentiviral vectors.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Provide therapeutic solutions for targets that cannot be effectively addressed by existing drug modalities.</font><font style="font-family:Times New Roman;"> The sequencing and publication of the human genome and growing information generated by genome-wide association studies have enabled the identification of both genes and regulatory sequences as potential new therapeutic targets. Many of these targets have a direct role in disease processes but cannot be bound or modulated for therapeutic purposes by small molecules, monoclonal antibodies or RNA based therapeutics. Alternative therapeutic approaches are required to modulate the biological activity of these so-called &#8220;non-druggable&#8221; targets. One such target is the </font><font style="font-style:italic;font-family:Times New Roman;">BCL11A</font><font style="font-family:Times New Roman;"> erythroid enhancer, a regulatory sequence, which we are disrupting using ZFNs in HSPCs in order to elevate levels of fetal globin.&nbsp;&nbsp;This target is being developed in collaboration with Bioverativ as a therapeutic approach for beta-thalassemia and SCD.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-family:Times New Roman;">Provide high specificity and selectivity for targets.</font><font style="font-family:Times New Roman;"> ZFNs and ZFP TFs can be designed to act with high specificity. In addition, as there are only two copies of each gene in a cell, there are generally only two targets per cell for ZFNs and ZFP TFs, which means that ZFNs and ZFP TFs need only to be available in the cell to engage a small number of targets, which may reduce the risk of toxicity. In contrast, drugs that act on protein and RNA targets that are naturally present in higher cellular concentrations may need to be administered in higher concentrations. In addition, because of the higher specificity there may be fewer &#8220;off-target effects.&#8221; Many small molecule and RNA-based approaches either </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">affect multiple targets demonstrating so-called &#8220;off-target effects&#8221; or may be toxic in the co</font><font style="font-family:Times New Roman;">ncentrations required to be therapeutically effective.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-weight:bold;font-family:Times New Roman;">Provides a genome editing platform with superior qualities for therapeutic development</font><font style="font-family:Times New Roman;">. Unlike other less developed bacterial-based genome editing platforms, such as CRISPR/Cas9 and TALENS, our proprietary ZFN genome editing technology is based on human proteins that have co-evolved with our complex human genome.&nbsp;&nbsp;The relative complexity of the protein-DNA interaction of our ZFN platform and the ability to engineer the entire protein-DNA interface also gives us the ability to optimize the components of our genome editing technology to drive efficient cutting with specificity. The ZFN-mediated mechanism is optimized for both gene insertion and gene knockout and over years of developing this platform, we have engineered our ZFN proteins to provide maximum design density (1:2 base pairs), giving us the capability to target virtually any sequence of interest and to place a ZFN exactly where we choose with single gene specificity. This precision is particularly critical for therapeutic gene insertion and correction</font><font style="font-size:12pt;font-family:Times New Roman;">.&nbsp;&nbsp;</font><font style="font-family:Times New Roman;">Finally, we have an established validated process for rapid development of a ZFN clinical lead and have taken our therapeutics candidates through regulatory review and into human clinical studies where we are able to evaluate both the safety and efficacy of our approach.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">THERAPEUTIC PRODUCT DEVELOPMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Product Development Programs </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531049431434.jpg" title="" alt="" style="width:704px;height:318px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hemophilia A and B </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Hemophilia, a rare bleeding disorder in which the blood does not clot normally. It is also a monogenic disease, or a disease that is caused by a genetic defect in a single gene. There are several types of hemophilia caused by mutations in genes that encode factors which help the blood clot and stop bleeding when blood vessels are injured. Individuals with hemophilia experience bleeding episodes after injuries and spontaneous bleeding episodes that often lead to joint disease such as arthritis. The most severe forms of hemophilia affect males. The standard treatment for individuals with hemophilia is replacement of the defective clotting factor with regular infusion of recombinant clotting factors or plasma concentrates. These therapies are expensive and sometimes stimulate the body to produce antibodies against the factors that inhibit the benefits of treatment. In these situations, other clotting factors such as Factor VII and X may be used to treat patients. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The most prevalent form of the disease, hemophilia A, is caused by a defect in the clotting Factor 8 gene. According to the National Hemophilia Foundation and the World Federation of Hemophilia, hemophilia A occurs in about one in every 5,000 male births in the United States, with approximately 16,000 males currently affected.&nbsp;&nbsp;Defects in clotting Factor 9 gene lead to hemophilia B.&nbsp;&nbsp;Hemophilia B occurs in about one in every 25,000 male births in the United States, with approximately 4,000 males currently affected. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-525 &#8211; Hemophilia A </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing SB-525, a gene therapy product candidate utilizing an AAV carrying a clotting Factor 8 gene construct that is driven by our proprietary synthetic liver specific promoter. In 2016, we presented preclinical data demonstrating production of supraphysiological levels of human Factor VIII clotting protein, or hFVIII, in mice and NHP. In these dose-ranging preclinical studies, mean hFVIII levels of 5 - 230% of normal were observed using AAV doses in the range of 6.00E+11 &#8211; 6.00E+12 vg/kg, the most potent dose response reported in NHPs for a human Factor 8 gene construct at the time.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we initiated a Phase 1/2 clinical trial, the Alta Study, to evaluate the safety and efficacy of SB-525 in adults with severe hemophilia A. The Alta Study is an open-label, ascending-dose study designed to enroll up to 20 adult subjects across six potential dose cohorts. In August 2017, we announced that the first subject was treated in our Alta Study. We expect to release preliminary data from the Alta Study by mid-2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-525 has been granted Orphan Drug and Fast Track designations by FDA as well as Orphan Medicinal Product designation by the European Medicines Agency, or EMA.&nbsp;&nbsp;We are developing SB-525 in collaboration with Pfizer, see &#8220;&#8212;Collaborations&#8212;Pfizer Inc.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-FIX &#8211; Hemophilia B<font style="font-weight:bold;margin-left:134pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing SB-FIX, an<font style="font-style:italic;"> in vivo</font> genome editing product candidate, to treat hemophilia B. Utilizing our ZFN genome editing technology, we are adding a new therapeutic copy of the Factor 9 gene precisely into the <font style="font-style:italic;">Albumin</font> gene locus in liver cells, and using the strong endogenous Albumin promoter to drive expression of the newly inserted gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for chronic infusions of replacement proteins or clotting factor products. We have published data demonstrating the potential utility of this approach for several different monogenic disease applications in addition to hemophilia B.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies of the Albumin genome editing approach have demonstrated that therapeutic levels of Factor IX clotting protein could be generated in a dose-dependent manner in NHPs. There were no significant alterations in circulating Albumin levels.&nbsp;&nbsp;Studies in mice also demonstrated stable Factor IX production for over one year. Preclinical studies in wildtype mice have demonstrated expression of therapeutic levels of human clotting Factor IX protein, or hFIX, from the liver and into the blood for the duration of the 60 week study. Additional preclinical studies in mouse models of hemophilia B demonstrated expression of therapeutic levels of hFIX from the liver and into the blood, which resulted in the correction of the clotting defect in hemophilia B mice treated with a single dose of SB-FIX. SB-FIX was also evaluated in preclinical NHP studies and demonstrated dose-dependent, therapeutic levels of hFIX expression, between 20-50% of normal, in wildtype cynomolgus monkeys, after a single administration of SB-FIX. Levels of hFIX were stable for up to 3 months in treated NHPs. Furthermore, there was a strong dose-response correlation between the level of gene modification at the <font style="font-style:italic;">Albumin</font> locus and the levels of hFIX measured in the blood. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a> In 2016, we initiated a Phase 1/2, open-label, ascending dose clinical trial, the FIXtendz Study, to evaluate safety and efficacy of SB-FIX in adult males with severe hemophilia B. The FIXtendz Study is designed to enroll up to 12 subjects across three dose cohorts. In February 2018, the Medicines and Healthcare Products Regulatory Agency, or MHRA, of the United Kingdom granted the Clinical Trial Authorisation, or CTA, for enrollment of subjects into the ongoing Phase 1/2 clinical trial evaluating SB-FIX for hemophilia B. The CTA permits evaluation of SB-FIX in both adults and adolescents. Once preliminary safety and efficacy have been </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">demonstrated in the ongoing SB-FIX Phase 1/2 clinical trial in adults (18 years of older), we may begin enrolling adolescents (12 - 17 years </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of age) into the study.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-FIX has been granted Orphan Drug and Fast Track designations by the FDA.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Lysosomal Storage Disorders</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">LSD are a heterogeneous group of rare inherited disorders including: MPS I, MPS II, Fabry disease, Gaucher disease; and many others. These disorders are caused by defects in genes that encode proteins known as enzymes, which break down and eliminate unwanted substances in cells. These enzymes are found in structures called lysosomes which act as recycling sites in cells, breaking down unwanted material into simple products. A defect in a lysosomal enzyme leads to the accumulation of toxic levels of the substance that the enzyme would normally eliminate. These toxic levels may cause cell damage which can lead to serious health problems.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MPS I is caused by mutations in the gene encoding the alpha-L-iduronidase, or IDUA, enzyme, resulting in a deficiency of IDUA enzyme, which is required for the degradation of the glycosaminoglycans, or GAGs, dermatan sulfate and heparin sulfate. The inability to degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop enlarged internal organs, joint stiffness, skeletal deformities, corneal clouding, hearing loss and cognition impairments. Three forms of MPS I, in order of increasing severity, include Scheie, Hurler-Scheie and Hurler syndromes. According to the National MPS Society, one in 500,000 births in the United States will result in Scheie syndrome, one in 115,000 births in Hurler/Scheie, and one in 100,000 births results in Hurler syndrome. There are approximately 1,000 MPS I patients in the United States. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MPS II is an X-linked disorder primarily affecting males and caused by mutations in the gene encoding the iduronate-2-sufatase, or IDS, enzyme.&nbsp;&nbsp;This results in a deficiency of IDS enzyme, which is required for the degradation of GAGs. Similar to MPS I, the inability to degrade GAGs leads to their accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Children with MPS II appear normal at birth but begin showing symptoms of developmental delay by age 2 &#8211; 3 years.&nbsp;&nbsp;Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop delayed development, enlarged internal organs, cardiovascular disorders, stunted growth and skeletal abnormalities and hearing loss. The disorder is progressive and symptoms range from mild (normal cognitive function) to severe (cognitively impaired). According to the National MPS Society, one in 100,000 male births in the United States will result in MPS II. There are approximately 500 MPS II patients in the United States. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fabry disease is an X-linked disorder primarily affecting males and caused by a mutation in the gene encoding the alpha-galactosidase A, or alpha-Gal A, enzyme, resulting in a deficiency of alpha-Gal A enzyme, which is required for the degradation of the ganglioside globotriaosylceramide, a particular type of fatty substance. The inability to degrade this fatty substance leads to its accumulation within the lysosomes throughout the body. Individuals with this mutation experience multi-organ dysfunction and damage. Depending on the severity of the mutations and degree of residual enzyme activity, affected individuals may develop progressive kidney damage, heart attack, stroke, gastrointestinal complications, corneal opacity, tinnitus and hearing loss. Milder forms of the disorder present later in life and affect only the heart or kidneys. According to the National Institutes of Health U.S. National Library of Medicine, one in 40,000 to one in 60,000 male births in the United States will result in Fabry disease. There are approximately 2,200 males with Fabry disease in the United States. This mutation can also occur in females, however is less common and the frequency is unknown.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are limited treatments currently available for MPS I, MPS II and Fabry disease.&nbsp;&nbsp;For individuals with MPS I, there are only two options: hematopoietic stem cell transplantation, or HSCT, for those with the most severe form of the disease (Hurler) and enzyme replacement therapy, or ERT, for patients with the attenuated forms of the disease (Hurler-Scheie, Scheie).&nbsp;&nbsp;However, the reported mortality rate after HSCT is approximately 15% and the survival rate with successful engraftment is 56%. Most patients with milder forms of the disease receive weekly ERT, usually in a doctor&#8217;s office. These IDUA enzyme infusions take on average four to six hours to administer. Weekly and bi-weekly ERT infusions are the only available options for MPS II and Fabry disease, respectively. Because of the availability of few treatment options that effectively and safely treat these diseases, there remains significant unmet medical need.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-318 &#8211; MPS I</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing SB-318, an <font style="font-style:italic;">in vivo</font> genome editing product candidate, to treat MPS I.&nbsp;&nbsp;Using the same approach as our hemophilia B product candidate, SB-FIX, we are adding a new therapeutic copy of the IDUA gene precisely into the <font style="font-style:italic;">Albumin</font> gene locus in the genome of liver cells, using the strong endogenous Albumin promoter to drive expression of the newly inserted gene. We believe the potential of this approach to provide a permanent correction for a patient may be optimal for a pediatric population by reducing or eliminating the need for chronic ERT infusions. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.44%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical mouse model data demonstrated robust levels of IDUA enzyme expression in the liver, blood plasma and spleen of SB-318 treated mice, resulting in a 10-fold increase in IDUA activity, with sustained elevated levels in the blood plasma over the </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">course of the two month study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDUA enzyme from the liver into the circulation and secondary tissues, including the spleen, lung, muscle, heart and brain, after</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> a single intravenous administration of SB-318. This resulted in the significant reduction of GAG biomarkers in all of the tissues. Behavioral data from Barnes maze tests, collected at the end of the four month study, demonstrated statistically significant</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> preservation of cognitive learning and memory in mice treated with SB-318, compared to untreated mice. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the EMPOWERS Study, to evaluate SB-318 in adult subjects with attenuated MPS I. The EMPOWERS Study is designed to enroll up to nine subjects across three ascending dose cohorts. We expect to present preliminary safety and efficacy data from the EMPOWERS Study in 2018. We plan to submit a CTA in the first half of 2018 to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical trial.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.4%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-318 MPS I has been granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Medicinal Product designation by the EMA.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">SB-913 &#8211; MPS II</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing SB-913, an <font style="font-style:italic;">in vivo </font>genome editing product candidate, to treat MPS II.&nbsp;&nbsp;Similar to SB-318, we are using our ZFN genome editing technology to add a new therapeutic copy of the IDS gene precisely into the <font style="font-style:italic;">Albumin</font> gene locus in the genome of liver cells, using the strong endogenous Albumin promoter to drive expression of the newly inserted gene. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical mouse model data demonstrated robust levels of IDS enzyme expression in the liver, blood plasma and spleen of SB-913 treated mice, resulting in a 100-fold increase in IDS activity, with sustained elevated levels in the blood plasma over the course of the entire study. Additional preclinical mouse model data demonstrated stable production of therapeutic levels of IDS enzyme from the liver into the circulation and additional secondary tissues, including the spleen, lung, muscle, heart and brain, after a single intravenous administration of SB-913. This resulted in the significant reduction of GAG biomarkers across all the tissues. Behavioral data from Barnes maze tests, collected at the end of the four month study demonstrated statistically significant preservation of cognitive learning and memory in mice treated with SB-913, compared to untreated mice. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2017, we initiated an open-label, dose-ascending Phase 1/2 clinical trial, the CHAMPIONS Study, to evaluate the safety and efficacy of SB-913 in adult male subjects with attenuated MPS II, designed to enroll up to nine subjects across three ascending dose cohorts. In November 2017, we announced that the first subject had been treated in the CHAMPIONS Study. In February 2018, we presented preliminary six-week safety data from the first subject enrolled in the CHAMPIONS Study. The data demonstrated that the subject tolerated the infusion well. Mild (Grade 1) adverse events related to the study drug were reported on the fourth day after dosing. These were dizziness, weakness and frequent urination, all of which resolved within one day without treatment. No other adverse events related to the study drug have been observed. Liver function tests have remained within normal limits for the patient since the infusion. We expect to present additional safety and efficacy data from the EMPOWERS Study by mid 2018. We plan to submit a CTA in the first half of 2018 to initiate enrollment of adolescent and pediatric subjects in the United Kingdom into the Phase 1/2 clinical trial. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-913 has been granted Orphan Drug, Rare Pediatric Disease and Fast Track designations by the FDA, as well as Orphan Medicinal Product designation by the EMA.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">ST-920 &#8212; Fabry Disease</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing ST-920 for Fabry disease, a gene therapy product candidate utilizing an AAV, carrying a galactosidase alpha, or GLA, gene construct, coding for the alpha-Gal A enzyme, driven by our proprietary synthetic liver specific promoter. We are currently conducting IND-enabling studies for ST-920 and expect to file an IND application with the FDA by mid 2018.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Hemoglobinopathies: Beta-thalassemia and Sickle Cell Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mutations in the gene encoding beta-globin, the oxygen carrying protein of red blood cells, lead to hemoglobinopathies such as beta-thalassemia and sickle cell disease, or SCD. Both diseases manifest in the months after birth, when patients switch from producing functional fetal gamma-globin to a mutant form of adult beta-globin, which results in their condition. Naturally occurring increased levels of fetal hemoglobin have been shown to reduce the severity of both beta-thalassemia and SCD.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beta-thalassemia is a rare disorder that results in greatly impaired production of healthy red blood cells despite bone marrow over activity, leading to life-threatening anemia, enlarged spleen, liver and heart, and bone abnormalities. We are focused on Beta-thalassemia major which is a severe form of thalassemia that requires regular, often monthly, blood transfusions and subsequent iron-chelation therapy to treat iron overload. The Centers for Disease Control and Prevention, or CDC, estimates that 1,000 people have beta-thalassemia major in the United States, and an unknown number carry the genetic trait and can pass it on to their children. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In SCD, the mutation causes the red blood cells to form an abnormal sickle or crescent shape. The cells are fragile and deliver less oxygen to the body&#8217;s tissues. They can also get stuck more easily in small blood vessels and break into pieces that can interrupt healthy blood flow which further decrease the amount of oxygen flowing to body tissues. Almost all patients with SCD experience these painful vaso-occlusive crises, which can last from hours to days and may cause irreversible organ damage. Current standard of care is to manage and control symptoms, and to limit the number of crises. Treatments include administration of hydroxyurea, blood transfusions, iron-chelation therapy, pain medications and antibiotics. The CDC estimates that there are 90,000 to 100,000 Americans living with SCD, which occurs in approximately 1 out of every 365 African-American births and 1 out of every 16,300 Hispanic-American births.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">ST-400 &#8211; Beta-thalassemia; BIVV-003 &#8212; SCD</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are developing ST-400 for the treatment of beta-thalassemia and our collaboration partner, Bioverativ, is developing BIVV-003 for the treatment of SCD.&nbsp;&nbsp;Both ST-400 and BIVV-003 are genome-edited cell therapies that use our ZFN genome editing technology to modify a patient&#8217;s own, or autologous, HSPCs to produce functional red blood cells using fetal hemoglobin. Our genome editing technology can be used in HSPCs to precisely disrupt regulatory sequences that control the expression of key transcriptional regulators, such as the <font style="font-style:italic;">BCL11A </font>erythroid enhancer sequence, to reverse the switch from expression of the mutant adult beta-globin back to the production of functional fetal gamma-globin. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The current standard of care for beta-thalassemia includes chronic blood transfusions, while the standard of care for SCD is a bone marrow transplant, or BMT, of HSPCs from a &#8220;matched&#8221; related donor, or an allogeneic BMT. However, these therapies are limited due to the risk of iron overload with blood transfusions, requiring subsequent iron chelation therapy, and the scarcity of matched donors and the significant risk of Graft versus Host Disease, or GvHD, with BMTs after transplantation of the foreign cells. By performing genome editing in HSPCs that are isolated from and subsequently returned to the same patient (<font style="font-style:italic;">i.e.</font>, an autologous HSPC transplant), our approach has the potential to address these limitations. The goal of this approach is to develop a one-time long-lasting treatment for beta-thalassemia and SCD.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical data from clinical-scale <font style="font-style:italic;">in vitro</font> studies have demonstrated that ST-400 and BIVV-003 can be manufactured by reproducible, high-level, ZFN-mediated modification in HSPCs mobilized in peripheral blood at clinical production scale (&gt;10<sup style="font-size:85%; vertical-align:top">8</sup> cells), with an on-target modification efficiency of greater than 80%. Furthermore, erythroid differentiation of enhancer targeted cells showed modification of both <font style="font-style:italic;">BCL11A</font> erythroid enhancer alleles in more than 50% of the erythroid colonies and resulted in a greater than four-fold increase in gamma globin mRNA and protein production, compared to controls. Specificity studies of ST-400 and BIVV-003 revealed no detectable off-target activity using state-of-the art, unbiased, highly sensitive oligo-capture assays.&nbsp;&nbsp;Preclinical data from <font style="font-style:italic;">in vivo</font> studies in immune-deficient mice demonstrated robust long-term (19 weeks) engraftment and that targeted gene modification was maintained through multi-lineage differentiation in the bone marrow and peripheral blood.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our IND for ST-400 was cleared by the FDA in September 2017, and we have designed an open-label, single arm Phase 1/2 clinical trial to evaluate the safety and efficacy of ST-400 in up to 6 adult subjects with beta-thalassemia.&nbsp;&nbsp;We expect to initiate this trial in early 2018. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bioverativ is our partner for ST-400 and is responsible for the clinical development of BIVV-003 for SCD. For more information relating to our collaboration with Bioverativ, see &#8220;&#8212;Collaborations&#8212;Bioverativ.&#8221;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">CNS-Tauopathies</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are using our ZFP-TF gene regulation platform to develop potential gene therapies for tauopathy disorders, including Alzheimer&#8217;s disease and other neurodegenerative diseases. We believe a reduction in tau protein levels can help reduce intracellular tau protein aggregation and the formation of neurofibrillary tangles in neurons, potentially ameliorating or reversing disease progression.&#160;We believe this approach may have a significant advantage compared to monoclonal antibody-based approaches to Alzheimer&#8217;s disease and other tauopathy disorders because it is designed to selectively down-regulate the <font style="font-style:italic;">tau </font>gene in neurons with the goal of reducing all forms of the tau protein globally across the CNS. In contrast, monoclonal antibody-based approaches are limited in that they can only bind to certain forms of tau proteins.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preclinical studies in wildtype mice demonstrated that a single administration of <font style="font-style:italic;">tau-</font>targeting ZFP-TFs resulted in up to 70% reduction of tau mRNA and protein expression across the entire CNS, as well as sustained and well-tolerated ZFP-TF expression with minimal impact on inflammatory markers. Additional preclinical studies in amyloid mouse models of Alzheimer&#8217;s disease demonstrated up to 80% reduction of tau protein levels in the brain and cerebrospinal fluid, as well as significantly reduced neuritic dystrophy after a single administration of ZFP-TFs in mice with established disease pathology.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are currently conducting preclinical studies in NHPs to evaluate our ZFP-TFs in larger mammalian species. We intend to seek a partner with disease area expertise for the clinical development and commercialization of this program.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">C9ORF72&#8211;linked ALS/FTLD </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a research collaboration and license agreement with Pfizer to develop and commercialize gene therapy products that use our ZFP TFs to treat ALS and FTLD linked to mutations of the <font style="font-style:italic;">C9ORF72</font> gene. ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the <font style="font-style:italic;">C9ORF72</font> gene that involve hundreds of additional repetitions of a six base pair sequence of DNA. This ultimately leads to the deterioration of motor neurons, in the case of ALS, or neurons in the frontal and temporal lobes, in the case of FTLD. Currently, there are no cures to halt or reverse the progression of ALS or FTLD. The <font style="font-style:italic;">C9ORF72</font> mutation is linked to approximately one-third of cases of familial ALS. We and Pfizer plan to investigate allele-specific ZFP-TFs with the potential to differentiate the mutant <font style="font-style:italic;">C9ORF72</font> allele from the wildtype allele and to specifically down-regulate expression of the mutant form of the gene.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have research stage programs in other monogenic diseases, immunology and cancer immunotherapy. See &#8220;&#8212;Collaborations&#8212;Pfizer Inc.,&#8221; for more information relating to this agreement.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Huntington&#8217;s Disease </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Huntington&#8217;s disease is an inherited, progressive neurologic disease for which there is no treatment or cure. The disease is caused by a particular type of mutation in a single gene, the <font style="font-style:italic;">HTT</font> gene. Most patients inherit one normal and one defective or mutant copy of the <font style="font-style:italic;">HTT</font> gene, which causes Huntington&#8217;s disease. The mutation is characterized by expansion of a repeated stretch of DNA sequence within the gene called a &#8220;CAG repeat.&#8221; A normal copy of the <font style="font-style:italic;">HTT</font> gene usually has 10 to 29 of these CAG repeats but a defective copy has many more&#8212;generally greater than 39 repeats. While the protein produced by the normal copy of the gene appears to be essential for development (mice lacking the gene do not survive to birth), the product of the mutated gene is damaging to cells. Symptoms, which include deterioration of muscle control, cognition and memory, usually develop between 35 and 44 years of age. It is known that the greater the number of CAG repeats, the earlier the onset. Huntington&#8217;s disease is usually fatal within 15 to 20 years after the onset of symptoms. The disease has a high prevalence for an inherited disorder. According to the Huntington&#8217;s Disease Society of America, approximately 30,000 people in the United States have Huntington&#8217;s disease. In addition, it is estimated that approximately 200,000 people in the United States are at risk of developing the disease.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research in animal models of the disease has shown that lowering the levels of the mutant HTT protein can prevent, or even reverse, disease progression. However, to date most &#8220;HTT-lowering&#8221; methods decrease levels of both the normal and mutant forms of HTT, raising potential safety concerns given the importance of normal HTT protein. In collaboration with Shire, we are developing ZFP TFs that can selectively repress the expression of the mutant disease-causing form of HTT while leaving expression levels of the normal gene unchanged. Preclinical studies in animal models of the disease are ongoing and Shire is responsible for all clinical development activities including filing the IND application.&nbsp;&nbsp;For more information on our collaboration with Shire, see &#8220;&#8212;Collaborations&#8212;Shire International GmbH.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Legacy Clinical Research Programs</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Human Immunodeficiency Virus, or HIV, and Acquired Immunodeficiency Syndrome, or AIDS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>HIV infection results in the death of immune system cells, particularly CD4+ T-cells, and thus leads to AIDS, a condition in which the body&#8217;s immune system is depleted to such a degree that the patient is unable to fight off common infections. Ultimately, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">these patients succumb to opportunistic infections or cancers. According to the most recent data from the CDC, it is estimated that there were 1.0&#160;million people living </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with HIV/AIDS in the United States in 2015, and there are now over 36.7&#160;million people living with HIV and AIDS worldwide.</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Current Treatments and Unmet Medical Need </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Currently, there are over 30 antiretroviral drugs approved by the FDA to treat people infected with HIV. While these drugs can suppress virus in the blood to undetectable levels, they cannot eliminate the reservoir of cells containing genomically-integrated HIV from the body. Hence, individuals infected with HIV need to take antiretroviral drugs continuously. The drugs are expensive and can have significant side effects over time. There is no therapeutic approach available that protects CD4+ T-cells, suppresses viral load, reduces the viral reservoir and does not require daily dosing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-728 &#8211; HIV/AIDS </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SB-728 uses our ZFN-mediated genome editing technology to disrupt the <font style="font-style:italic;">CCR5 </font>gene in cells of a patient&#8217;s immune system to make these cells permanently resistant to HIV infection. CCR5 is a co-receptor for HIV entry into T-cells and if CCR5 is not expressed on the cell surface HIV cannot infect them or infects them with lower efficiency. The aim of this approach is to provide the patient with a population of HIV-resistant cells that can fight HIV and opportunistic infections, by mimicking the naturally occurring <font style="font-style:italic;">CCR5</font> <font style="font-style:italic;">delta-32 </font>mutation that renders a population of individuals largely resistant to infection by the most common strains of HIV. We are evaluating this genome editing approach to disrupt the <font style="font-style:italic;">CCR5 </font>gene in both T cells and HSPCs as two potential therapeutic candidates, SB-728-T and SB-728-HSPC, respectively.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> We have conducted several clinical trials with SB-728-T, which were designed to evaluate safety and tolerability of SB-728-T, as well as the effect of SB-728-T on subjects&#8217; CD4 T-cell counts, levels of CCR5-modified T-cells, viral burden during a treatment interruption (TI) from anti-retroviral therapy, or ART, and measure of the viral reservoir. The data to date have demonstrated an ability to efficiently knock out the <font style="font-style:italic;">CCR5 </font>gene in T-cells by ZFN-driven genome editing and grow the cells <font style="font-style:italic;">ex vivo</font>, that a single infusion of SB-728-T led to proven engraftment, expansion and persistence of T-cells <font style="font-style:italic;">in vivo</font>, sustained increases in CD4 T-cell counts, a significant and continuous decay of the HIV reservoir and the ability of certain subjects to control their viral loads for prolonged periods in the absence of ART. Over 100 subjects have been treated to date and the treatment appears to be well-tolerated.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, we have an ongoing investigator-sponsored Phase 1/2 clinical trial (SB-728mR-HSPC) to investigate SB-728-HSPC as a self-renewable and potentially lifelong source of HIV-resistant immune cells.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We plan to advance the SB-728 program through externally-funded collaborations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COLLABORATIONS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have established collaborative and strategic partnerships for several of our therapeutic programs and also for several non-therapeutic applications of our technology. We will continue to pursue further partnerships when appropriate with selected pharmaceutical and biotechnology to fund internal research and development activities and to assist in product development and commercialization. We are applying our ZFN technology platform to several commercial applications in which our products provide us and our strategic partners and collaborators with potential technical, competitive and economic advantages. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Kite Pharma, Inc.</p>
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into a collaboration and license agreement with Kite, a wholly-owned subsidiary of Gilead, for the research, development and commercialization of potential engineered cell therapies for cancer. Kite will be responsible for all clinical development and commercialization of any resulting products. Except for confidentiality obligations and certain representations, warranties and covenants, which are effective upon execution, the effectiveness of the Kite agreement is subject to the expiration or termination of all applicable waiting periods under the Hart<font style="Background-color:#FFFFFF;color:#000000;">-Scott-Rodino Antitrust Improvements Act of 1976, as amended</font>, and other customary closing conditions.</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="S83134942"></a><a name="S83134942"></a>Subject to the terms of this agreement, we <font style="color:#000000;">will, upon effectiveness of this agreement,&#160;grant</font> Kite an exclusive, royalty-bearing, worldwide, sublicensable license, under our relevant patents and know-how, to develop, manufacture and commercialize, for the purpose of treating cancer, specific cell therapy products that may result from the research program and that are engineered <font style="font-style:italic;">ex vivo</font> using selected ZFNs and AAVs developed under the research program, to express CARs, TCRs or NKRs directed to candidate targets.&nbsp;&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>During the research program term and subject to certain exceptions, except pursuant to this agreement, we will be prohibited from researching, developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of <font style="font-style:italic;">ex vivo</font> genome editing, expresses a CAR, TCR or NKR that is directed to a target expressed on or in a human cancer cell. After the research program term concludes and subject to certain exceptions, except pursuant to this agreement, we will be prohibited </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:10pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from developing, manufacturing and commercializing, for the purpose of treating cancer, any cell therapy product that, as a result of </font><font style="font-style:italic;">ex vivo</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> genome editing, expresses a CAR, TCR or NKR that </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is directed to a candidate target.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Upon the effectiveness of this agreement, we will receive a $150 million upfront payment from Kite. In addition, Kite will reimburse our direct costs to conduct the joint research program, and Kite will be responsible for all subsequent development, manufacturing and commercialization of any licensed products. We are also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01 billion if all of the specified milestones set forth in this agreement are achieved.&#160;Of this amount, approximately $1.26 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75 billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i) only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event.&nbsp;&nbsp;<font style="color:#000000;">In addition, we will be entitled to receive escalating, tiered royalty payments with a percentage in the single digits based on potential future annual worldwide net sales of l</font>icensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kite has the right to terminate this agreement, in its entirety or on a per licensed product or per candidate target basis, for any reason after a specified notice period.&nbsp;&nbsp;Each party has the right to terminate this agreement on account of the other party&#8217;s bankruptcy or material, uncured breach.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Pfizer Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have two separate collaboration agreements with Pfizer Inc., or Pfizer.&nbsp;&nbsp;In May 2017, we entered into an exclusive, global collaboration and license agreement with Pfizer, pursuant to which we established a collaboration for the research, development and commercialization of SB-525, our gene therapy product candidate for hemophilia A, and closely related products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under this agreement, we are responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. We may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received an upfront fee of $70.0 million and are eligible to receive development milestone payments contingent on the achievement of specified clinical development, intellectual property, regulatory and first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in this agreement, is $475.0 million, which includes up to $300.0 million for SB-525 and up to $175.0 million for other products that may be developed under the agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property. In addition, Pfizer agreed to pay us royalties for each potential licensed product developed under the agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the agreement, we granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by us for the purpose of developing, manufacturing and commercializing SB-525 and related products. Pfizer granted us a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the agreement and controlled by Pfizer to manufacture our products that utilize the AAV delivery system. During a specified period, neither we nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the agreement has a term that continues, on a per product and per country basis, until the later of (i) the expiration of patent claims that cover the product in a country, (ii) the expiration of regulatory exclusivity for a product in a country, and (iii) fifteen years after the first commercial sale of a product in a country.&#160; Pfizer has the right to terminate the agreement without cause in its entirety or on a per product or per country basis.&#160; The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party.&#160; Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize SB-525 and related products will automatically terminate.&#160; Upon termination by us for cause or by Pfizer any country or countries, Pfizer will automatically grant us an exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize SB-525 in the terminated country or countries.&#160; </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>In December 2017, we entered into a separate exclusive, global collaboration and license agreement with Pfizer<font style="color:#000000;"> for the development and commercialization of potential gene therapy products that use ZFP-TFs to treat ALS and FTLD linked to mutations </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;">of the </font><font style="font-style:italic;color:#000000;">C9ORF72</font><font style="color:#000000;"> gene. Pursuant to this agreement, we agreed to work with Pfizer on a research program to identify, characteriz</font><font style="color:#000000;">e and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the </font><font style="font-style:italic;color:#000000;">C9ORF72</font><font style="color:#000000;"> gene.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We received a $12.0&#160;million upfront payment from Pfizer and are eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer contingent on the achievement of specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of the licensed products reach specified levels. In addition, Pfizer will pay us royalties based on an escalating tiered,&#160;mid-&#160;to high-single digit percentage of the annual worldwide net sales of the licensed products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of the licensed products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the agreement, we granted Pfizer an exclusive, royalty-bearing, worldwide, license under our relevant patents and&#160;know-how&#160;to develop, manufacture and commercialize gene therapy products that use resulting&#160;ZFP-TFs&#160;that satisfy&#160;pre-agreed&#160;criteria. During a specified period, neither our company nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins that specifically bind to the <font style="font-style:italic;">C9ORF72</font> gene.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Unless earlier terminated, the agreement has a term that continues, on a per licensed product and per country basis, until the later of (i) the expiration of patent claims that cover the licensed product in a country, (ii) the expiration of regulatory exclusivity for a licensed product in a country, and (iii) fifteen years after the first commercial sale of a licensed product in a major market country.&#160; Pfizer also has the right to terminate the agreement without cause in its entirety or on a per product or per country basis.&#160;The agreement may also be terminated by either party based on an uncured material breach by the other party or the bankruptcy of the other party.&#160;The agreement will also terminate if we are unable to identify any lead candidates for development within a specified period of time or if Pfizer elects not to advance a lead candidate beyond a certain development milestone within a specified period of time.&#160;Upon termination for any reason, the license granted by us to Pfizer to develop, manufacture and commercialize licensed products under the agreement will automatically terminate.&#160;Upon termination by us for cause or by Pfizer without cause for any licensed product or licensed products in any country or countries, we will have the right to negotiate with Pfizer to obtain a non-exclusive, royalty-bearing license under certain technology controlled by Pfizer to develop, manufacture and commercialize the licensed product or licensed products in the terminated country or countries.&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Following termination by us for Pfizer&#8217;s material breach, Pfizer <font style="color:#000000;">will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </font><font style="font-style:italic;color:#000000;">C9ORF72</font><font style="color:#000000;"> gene for a period of time. Following termination by Pfizer for our material breach, we will not be permitted to research, develop, manufacture or commercialize ZFPs that specifically bind to the </font><font style="font-style:italic;color:#000000;">C9ORF72</font><font style="color:#000000;"> gene for a period of time.</font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Bioverativ Inc. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to an exclusive worldwide collaboration and license agreement with Bioverativ to develop therapeutics for hemoglobinopathies, focused on beta-thalassemia and SCD. Under the agreement, we are jointly conducting two research programs: the beta-thalassemia program and the SCD program. In the beta-thalassemia program, we are responsible for all discovery, research and development activities through the first human clinical trial. In the SCD program, both parties are responsible for research and development activities through the submission of an IND application for ZFP therapeutics intended to treat SCD. Bioverativ reimburses us for agreed upon internal and external program-related costs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under both programs, Bioverativ is responsible for subsequent worldwide clinical development, manufacturing and commercialization of licensed products developed under the agreement. At the end of the specified research terms for each program or under certain specified circumstances, Bioverativ has the right to step in and take over any of our remaining activities. Furthermore, we have an option to co-promote in the United States any licensed products to treat beta-thalassemia and SCD developed under the agreement, and Bioverativ will compensate us for such co-promotion activities. Subject to the terms of the agreement, we have granted Bioverativ an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by us for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the agreement. We have also granted Bioverativ a non-exclusive, worldwide, royalty-free, fully paid license, with the right to grant sublicenses, under our interest in certain other intellectual property developed pursuant to the agreement. During the term of the agreement, we are not permitted to research, develop, manufacture or commercialize, outside of the agreement, certain gene therapy products that target genes relevant to the licensed products. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the agreement, we received an upfront license fee of $20.0 million and are eligible to receive development and sales milestone payments upon the achievement of specified regulatory, clinical development and sales milestones. The total amount of potential regulatory, clinical development, and sales milestone payments, assuming the achievement of all specified milestones in the agreement, is $276.3 million. In addition, we will receive royalty payments for each licensed product that are a tiered double-digit percentage of annual net sales of each product. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement may be terminated by (i)&#160;us or Bioverativ for the uncured material breach of the other party, (ii)&#160;us or Bioverativ for the bankruptcy or other insolvency proceeding of the</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other party; (iii)&#160;Bioverativ, upon 180 days&#8217; advance written notice to us and (iv)&#160;Bioverativ, for certain safety reasons upon written notice to, and after consultation with, us. As a result, actual future milestone payments could be lower than the amoun</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts stated above. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Shire International GmbH </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are party to a collaboration and license agreement with Shire International GmbH, or Shire, to research, develop and commercialize a ZFP therapeutic for treating Huntington&#8217;s disease. We received an upfront license fee of $13.0 million. Shire does not have any milestone payment obligations, but is required to pay single digit percentage royalties to us, up to a specified maximum cap, on the commercial sales of therapeutic products for Huntington&#8217;s disease. We are required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of therapeutic products from programs returned under the original agreement (which include blood clotting Factors VIII and IX) that use two zinc fingers. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the agreement, we granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use our ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the <font style="font-style:italic;">HTT</font> gene. During the term of the agreement, we are not permitted to research, develop or commercialize, outside of the agreement, certain products that target the <font style="font-style:italic;">HTT</font> gene. We satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. The agreement may be terminated by (i)&#160;us or Shire, in whole or in part, for the uncured material breach of the other party, (ii)&#160;us or Shire for the bankruptcy or other insolvency proceeding of the other party and (iii)&#160;Shire, in its entirety, effective upon at least 90 days&#8217; advance written notice. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Other Partnerships </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our partnerships for the development of human therapeutic applications, we have also licensed our technology in several other areas, such as plant agriculture and research reagents, including the production of transgenic animals and cell-line engineering.&nbsp;&nbsp;These license partners include Dow AgroSciences LLC, Sigma-Aldrich Corporation, Genentech, Inc., Open Monoclonal Technology, Inc. and F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INTELLECTUAL PROPERTY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Patents and licenses are important to our business. Our strategy is to file or license patent applications to protect technology, inventions and improvements to inventions that we consider important for the development of our genome editing and gene regulation technology. We seek patent protection and licenses that relate to our technology and candidates in our pipeline and/or may be important to our future. We have filed numerous patents and patent applications with the United States Patent and Trademark Office, or U.S. PTO, and foreign jurisdictions. This proprietary intellectual property includes methods relating to the design of zinc finger, Transcription activator-like effector, or TALE, proteins and Clustered Regularly Interspaced Short Palindromic Repeats, or CRISPR/Cas editing systems, therapeutic applications of genome editing technology, enabling technologies related to our platform and the use of genome editing across a variety of applications. We rely on a combination of patent, copyright, trademark, proprietary know&#8211;how, continuing technological innovations, trade secret laws, as well as confidentiality agreements, materials transfer agreements, research agreements and licensing agreements, to establish and protect our proprietary rights. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">In-Licensed Technology </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have licensed intellectual property directed to the design, selection, and use of ZFPs, ZFNs and ZFP TFs for genome editing and gene regulation from the Massachusetts Institute of Technology, Johnson &amp; Johnson, The Scripps Research Institute, the California Institute of Technology and the University of Utah. These licenses grant us rights to make, use and sell ZFPs, ZFNs and ZFP TFs under 9 families of patent filings. As of February 15, 2018, these patent filings have resulted in over 10 issued U.S. patents and over 40 granted foreign patents are still active, with 3 currently pending U.S. patent applications and 8 pending applications in foreign patent offices. We have non-exclusive licenses from the NIH for intellectual property related to the composition of the AAV5 vector and to methods of production of AAV, both of which will expire in 2021. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>We entered into a patent license agreement with the Massachusetts Institute of Technology, or MIT, in May 1996, as subsequently amended, whereby MIT granted us a worldwide exclusive license to technology and patents relating to the design, selection and use of ZFPs for all fields of use, including the right to sublicense. Under the patent license agreement, we are obligated to pay an annual license fee, low single-digit royalties of product sales, sublicense issuance fees and annual sublicense maintenance fees, a percentage of our sublicense revenues, and milestone payments upon achievement of certain commercial development milestones. The aggregate milestone payments under the patent license agreement are $450,000, of which $150,000 has been paid. At our request, the patent license has been amended to return some of the intellectual property that was added via amendment after the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">original agreement was put in place.&nbsp;&nbsp;This does not affect the development of our technology. The patent license agreement still expires upon the expira</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tion of the last patent covered by the remainder of patents under the license agreement. Based on currently licensed patents, the patent license agreement will expire in October 2019. MIT may terminate the license agreement upon a material default by us th</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">at remains uncured following written notice. We may terminate the license agreement at any time upon six months&#8217; written notice. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a sublicense agreement with Johnson &amp; Johnson in May 1996, whereby Johnson &amp; Johnson granted us a worldwide exclusive sublicense to technology and patents for the research, development and commercialization of human and animal therapeutic and diagnostic products using engineered ZFPs, including the right to sublicense. These patents were originally exclusively licensed by Johnson &amp; Johnson from The Scripps Research Institute. Under the sublicense agreement, we will pay low single-digit royalty payments based upon sales of license products by us or our sublicensees and a milestone payment upon the achievement of a commercial development milestone. The sublicense agreement expires upon the expiration of the last patent covered by the sublicense agreement. Based on currently issued patents and currently filed patent applications, the sublicense agreement will expire on or about June 5, 2018. Johnson &amp; Johnson has the right to terminate the sublicense agreement upon a breach or default by us that remains uncured following written notice of such default. We may terminate the sublicense agreement at any time upon sixty days&#8217; written notice. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a license agreement with The Scripps Research Institute in March 2000, as subsequently amended, whereby The Scripps Research Institute granted us a worldwide exclusive license to technology and patents for the research, development and commercialization of products and services using engineered ZFPs, excluding the use of these engineered ZFPs in plant agriculture, therapeutics and diagnostics. Under the license agreement, we are required to pay a low-single digit royalty on sales of licensed products by us and our sublicensees, subject to an annual minimum. The license agreement expires upon the expiration of the last patent covered by the license agreement. Based on currently issued patents and currently filed patent applications, the license agreement will expire on or about May 27, 2018. Each party may terminate the license agreement upon a material default by the other party that remains uncured following written notice. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a license agreement with California Institute of Technology, or CalTech, in November 2003, as subsequently amended, whereby CalTech granted us a worldwide exclusive license to certain patents related to chimeric nucleases for genome targeting for all fields of use, including the right to sublicense.&nbsp;&nbsp;In consideration of the license grant, we issued certain shares of our common stock to CalTech, but have no obligations to make milestone or royalty payments to CalTech.&nbsp;&nbsp;The license agreement expires upon the expiration of the intellectual property rights licensed to us. Based on currently issued patents and currently filed patent applications, the license agreement will expire in September 2023. Each party may terminate the license agreement upon a material default by the other party that remains uncured following written notice.&nbsp;&nbsp;We may terminate the agreement at any time upon 30 days written notice.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We entered into a patent license agreement with the University of Utah Research Foundation, in September 2004, as subsequently amended, whereby Utah granted us a worldwide license to technology and patents relating to the use of ZFNs for all fields of use, including the right to sublicense. Under the patent license agreement, we are obligated to pay an annual license fee, low single-digit royalties of product sales, sublicense issuance fees and annual sublicense maintenance fees, a percentage of our sublicense revenues, and milestone payments upon achievement of certain commercial development milestones. The license agreement expires on the expiration of the last patent covered by the patent license agreement.&nbsp;&nbsp;Based on currently issued patents, the license agreement will expire in March 2025.&nbsp;&nbsp;Utah may terminate the license agreement upon a default by us that remains uncured following written notice.&nbsp;&nbsp;We may terminate the agreement at any time upon 90 days written notice.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have entered into licenses potentially useful for specific therapeutic uses of our genome editing technologies with the Regents of the University of California and the Children's Medical Center Corporation.&nbsp;&nbsp;The patents included in these licenses relate to CNS disorders and hemoglobinopathies, respectively. These licenses include 2 patent families, including 3 issued U.S. patents, over 20 pending foreign patents and 2 pending U.S. patents.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Our Intellectual Property </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to our in-licensed patent portfolio, as of February 15, 2018, we had over 150 families of owned or co-owned patent filings, over 180 issued U.S. patents, over 600 granted foreign patents, over 110 pending U.S. patent applications and over 490 pending foreign patent applications. These patent filings are directed to the design, composition and use of ZFPs, ZFNs, ZFP TFs, TALE proteins and CRISPR/Cas systems and other technology related to our programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>Some of the earliest zinc finger patents in our portfolio began expiring in 2015, with the average expiration of our currently issued patents expiring being late-2026. However, we have continued to build on this patent portfolio and have been issued additional </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">patents and have applications pending that provide protection for our ZFP technology. These patents in our portfolio may be subject to Patent Term Adjustment (due to delays in patent prosecution by the USPTO), Patent Term Extension (due to review of a pa</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tented product by a regulatory agency) or terminal disclaimer. Additionally, patents that may be issued from our pending applications will extend the patent exclusivity of our patent estate. Accordingly, all dates given above for patent expirations are est</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">imates and the actual dates of expirations may differ. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We believe that our licensed patents and patent applications, as well as our issued patents and pending patent applications, in the aggregate, will provide us with a substantial intellectual property position in our commercial development of our genome editing, gene therapy, cell therapy and gene regulation programs. In this regard, patents issued to us, applied for by us, or exclusively and non-exclusively licensed to us, cover the following types of inventions, processes and products: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">ZFP and ZFN design, engineered nucleases, and compositions:</font><font style="font-family:Times New Roman;"> includes DNA target site selection and zinc finger binding domain design and nuclease domain design, DNA nickases, target site arrays, ZFP libraries databases and methods of construction, as well as methods to increase zinc finger binding specificity, nuclease, linker designs (see newly issued US9567609) and methods of making modified plant ZFPs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">ZFP targeted regulation of endogenous genes:</font><font style="font-family:Times New Roman;"> methods relating to activation and inhibition of endogenous cellular genes, identification of accessible regions within chromatin, and regulation of endogenous plant genes; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">ZFP Therapeutics:</font><font style="font-family:Times New Roman;"> Treatment of Huntington&#8217;s disease (see U.S. patent publication US2017-0096460), cancer therapeutics, treatment of head and neck cancer, glioblastoma, modulation of cardiac contractility and methods to regulate the glucocorticoid receptor, treatments for HIV, and self-regulating promoters (see newly issued US9624498); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Nuclease Therapeutics:</font><font style="font-family:Times New Roman;"> Treatments for HIV (see newly issued US9566352 and US 9757420), beta-thalassemia and SCD (see newly issued US9650698), hemophilia (see newly issued US9771403, US9777281 for hemophilia B) LSD (see newly issued US9877988), genome editing, Parkinson&#8217;s Disease, regulation of the expression of PD1; Immunomodulatory therapeutics; Cystic Fibrosis; CNS disease; Severe combined immunodeficiency (see newly issued US9161090 and US9833479, Modified T cells (See newly issued US9597357) including HLA knock out (see newly issued US9782437) and methods of editing stem cells (see newly issued US9834787); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Non-Therapeutic Applications of ZFPs:</font><font style="font-family:Times New Roman;"> Identification of genes, analysis of gene regulation, structure and biological function, methods of agricultural biotechnology, methods of altering cellular differentiation state; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Non-Therapeutic Applications of ZFNs:</font><font style="font-family:Times New Roman;"> Methods for identification of regulatory DNA sequences, prediction of patient response to drug therapeutics, and development of cell lines for improved protein production, methods of transgenic animal development (see newly issued UP9567573) , and methods of introducing exogenous nucleic acids of interest into a safe harbor locus, cleavage of specific miRNAs (see newly issued US9574211); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Donor DNA design: </font><font style="font-family:Times New Roman;">Methods for designing optimal donors for transgene delivery; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Pan-nuclease, Non-ZFP nucleases, methods of design and use</font><font style="font-family:Times New Roman;"> (see newly issued US9765361), pan-nuclease nickases (see newly issued US9631186); </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Engineering of stem cells</font><font style="font-family:Times New Roman;"> Methods of modulating stem cell differentiation (see newly issued US9624509); and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-style:italic;font-family:Times New Roman;">Methods for genome editing</font><font style="font-family:Times New Roman;">.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have been advised that certain aspects of our technology can give us and our collaborators independence from third party patent claims to gene sequences. In general, under U.S. patent law, a patent may be obtained for any new and useful process, machine, manufacture, or composition of matter. An underlying theme of U.S. patent law, as related to biotechnology, is that the sequence of a gene, as it exists in the chromosome, is not patentable, even when newly discovered, although a cDNA corresponding to the transcription product of that gene may be in select instances. Accordingly, U.S. patent claims to DNA sequences can cover only isolated cDNAs, or modified nucleic acid sequences (e.g., a purified DNA fragment or a DNA sequence inserted into a vector). We have been advised that U.S. patent claims to DNA sequences do not, and cannot, cover gene sequences as they exist in their natural chromosomal environment, and international patent law is even more stringent than U.S. patent law in this regard. Most current methods for over-expression of a gene or protein involve the introduction into a cell of a vector containing a DNA encoding the protein to be over-expressed. Because such a vector contains isolated cDNA sequences that encode the protein, it would be covered by any patent claims to those sequences. In contrast, our methods for over-expression utilize ZFP TFs that target endogenous genes as they exist in the chromosome. As a result, our gene regulation methods do not require the use of isolated cDNA sequences encoding the protein to be over-expressed and, our counsel has advised us, do not infringe patent claims to such sequences. Notwithstanding this advice, we realize that others could take a contrary position that could result in litigation. While we believe that we would prevail in any such litigation, the uncertainties involved in litigation generally make it impossible to provide assurance as to the ultimate outcome of such matters. See &#8220;<font style="font-style:italic;">Risk Factors&#8212;Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar to ours, we cannot ensure the proprietary protection of our technologies and products.&#8221;</font> </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">T</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he patent positions of pharmaceutical and biotechnology firms, including our patent position, are uncertain and involve complex legal and factual questions for which important legal tenets are largely unresolved and are subject to interpretation and refine</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ment by the court system. Patent applications may not result in the issuance of patents and the coverage claimed in a patent application may be significantly reduced before a patent is issued. Although we have filed for patents on some aspects of our techn</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ology, we cannot provide assurances that patents will be issued as a result of these pending applications or that any patent that has been or may be issued will be upheld. The laws of some foreign countries may not protect our proprietary rights to the sam</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e extent as do the laws of the United States. For example, our issued European patents EP2171052 and EP2527435 have been opposed in Europe. Our EP2281050 case was revoked during Opposition in November 2016.&nbsp;&nbsp;Similarly, EP2171052 and EP2527435 underwent Opp</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">osition hearings in early 2017. Although these cases emerged from the Opposition hearings, the opponent filed appeals that are currently underway, and we do not know what the outcome of these procedures will be. The claims of these patents may be amended s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uch that claim scope is reduced or the patents may be revoked as a result of these procedures. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the future, third parties may assert patent, copyright trademark, and other intellectual property rights to technologies that are important to our business. Any claims asserting that our products infringe or may infringe proprietary rights of third parties, if determined adversely to us, could significantly harm our business. See &#8220;<font style="font-style:italic;">Risk Factors&#8212;Because it is difficult and costly to protect our proprietary rights, and third parties have filed patent applications that are similar to ours, we cannot ensure the proprietary protection of our technologies and products</font>.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">COMPETITION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We, and our licensed partners, are the leaders in the research, development, and commercialization of DNA binding proteins for genome editing and regulation of gene expression. We are aware of several companies focused on other methods for editing genes and regulating gene expression and a limited number of commercial and academic groups pursuing the development of ZFP gene regulation and genome editing technology. The field of applied gene regulation and genome editing is highly competitive and we expect competition to persist and intensify in the future from a number of different sources, including pharmaceutical and biotechnology companies; academic and research institutions; and government agencies that will seek to develop ZFPs as well as technologies that will compete with our ZFP technology platform, such as TALE proteins and the CRISPR/Cas9 system. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, our competitors may succeed in obtaining patent protection, receiving FDA approval, or commercializing competitive products before us. If we commence commercial product sales, we may be competing against companies with greater marketing and manufacturing capabilities, areas in which we have limited or no experience. In addition, any product candidate that we successfully develop may compete with existing products that have long histories of safe and effective use. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we are in the clinical development phase of operations and have no current therapeutic product sales, we believe the following companies, products and/or technologies may potentially be competitive with our technology or our products under development: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Protein pharmaceuticals under development at pharmaceutical and biotechnology companies such as Pfizer, Baxter International Inc., Bayer AG, Novo Nordisk A/S, Genzyme Corp., Shire, BioMarin </font><font style="Background-color:#FFFFFF;font-family:Times New Roman;">Pharmaceutical Inc.</font><font style="font-family:Times New Roman;">, Biogen Inc., Acceleron Pharma Inc. and numerous other pharmaceutical and biotechnology firms. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Gene therapy companies developing gene-based products in clinical trials. uniQure N.V.&#8217;s product for lipoprotein lipase deficiency and GlaxoSmithKline plc&#8217;s, or GSK, product for severe combined immunodeficiency due to adenosine deaminase deficiency are approved in Europe. No other gene therapy products have yet been approved. Our competitors in this category may include, but not be limited to, uniQure N.V., BioMarin </font><font style="Background-color:#FFFFFF;font-family:Times New Roman;">Pharmaceutical Inc.</font><font style="font-family:Times New Roman;">, bluebird bio, Inc., </font><font style="Background-color:#FFFFFF;font-family:Times New Roman;">REGENXBIO Inc.</font><font style="font-family:Times New Roman;">, Spark Therapeutics, Inc., Dimension Therapeutics, Inc., Voyager Therapeutics, Inc., Shire, Pfizer, and GSK. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Cell therapy companies developing cell-based products. Our competitors in this category may include Novartis AG, Adaptimmune Therapeutics PLC, bluebird bio, Inc., Cellectis S.A., Juno Therapeutics, Inc., Kite, Atara Biotherapeutics, Inc., and Iovance Biotechnologies, Inc.. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Nuclease technologies under development for therapeutic applications of genome modification including companies such as Editas Medicine, Inc., CRISPR Therapeutics AG, Caribou Biosciences, Inc. and Intellia Therapeutics, Inc. developing the CRISPR/Cas9 system, Cellectis S.A. developing TALE nucleases and meganucleases, bluebird bio, Inc. developing Homing Endonucleases and MegaTALs and Precision BioSciences, Inc. developing meganucleases. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Antisense therapeutics and RNA interference technology, including RNAi and microRNA, which are technologies that may compete with us in the development of novel therapeutic products acting through the regulation of gene expression. These technologies are being developed by several companies including Alnylam Pharmaceuticals, Inc., Ionis Pharmaceuticals, Inc., Genzyme Corp. and Regulus Therapeutics Inc. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">Small molecules in development </font><font style="font-family:Times New Roman;">from both in-house drug discovery programs of pharmaceutical companies such as Pfizer, Inc., GSK, Novartis AG and Merck&#160;&amp; Co., Inc., as well as from biotechnology companies with expertise and capabilities in small molecule discovery and development such as</font><font style="font-family:Times New Roman;"> Gilead, Genzyme Corp. and Global Blood Therapeutics, Inc., which has a small molecule product in development for SCD. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Monoclonal antibody companies and product candidates from certain biotechnology firms such as Genentech, Inc. and Amgen Inc.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to face intense competition from other companies for collaborative arrangements with pharmaceutical and biotechnology companies for establishing relationships with academic and research institutions, for licenses to proprietary technology and for subjects in our clinical trials of treatments for rare diseases. These competitors, either alone or with their collaborative partners, may succeed in developing technologies or products that are more effective or less costly than ours. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to compete successfully will depend, in part, on our ability to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">develop safe, efficacious and commercially attractive proprietary products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain access to gene transfer technology on commercially reasonable terms; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain required regulatory approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attract and retain qualified scientific and product development personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">enter into collaborative and strategic partnerships with others, including our competitors, to develop our technology and product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain and enforce patents, licenses or other proprietary protection for our products and technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">formulate, manufacture, market and sell any product that we develop; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">develop and maintain products that reach the market first and are technologically superior to or are of lower cost than other products in the market; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recruit subjects into our clinical trials in a timely fashion.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MANUFACTURING</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely on contract manufacturing organizations, or CMOs, to produce our preclinical and clinical product candidates in accordance with FDA and EMA mandated regulations, also known as current good manufacturing practices, or cGMPs.&nbsp;&nbsp;<font style="color:#000000;">We employ a technical operations staff in the areas of process development, analytical development, quality control, quality assurance, project management, and manufacturing to facilitate appropriate oversight of our CMOs, support of our regulatory filings and execution of clinical trials</font>.&#160; In 2017, we expanded our services agreement with Brammer Bio MA, LLC, or Brammer, to provide dedicated capacity to supply our preclinical and clinical programs.&#160;Additionally, we plan to build a cGMP manufacturing facility at our new corporate headquarters in Brisbane, CA.&#160;This facility will be designed to manufacture of Phase 1/2 clinical trial supplies for our pipeline programs.&#160;We believe this balanced approach to manufacturing, investing in internal capacity/capabilities while strengthening our commitment to external capacity, will enable us to meet our anticipated pipeline needs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:2.44%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently leverage two distinct manufacturing platforms: AAV vector production for our genome editing and gene therapy product candidates and HSPC modification for our cell therapy product candidates. We use a commercial scale baculovirus manufacturing platform to manufacture AAV vectors for genome editing and gene therapy, with each AAV vector packaging a different transgene specific to the target indication or ZFN. <font style="color:#000000;">The manufacturing process for our HSPC cell therapy product candidates utilizes the patient&#8217;s own HSPCs. These HSPCs are transfected using mRNA to produce ZFNs that target specific DNA sites, resulting in modified HSPCs. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">GOVERNMENT REGULATION </p>
<p style="margin-bottom:12pt;margin-top:6pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>In the United States, the FDA regulates biologic products including gene therapy products under the Federal Food, Drug, and Cosmetic Act, or the FDCA, the Public Health Service Act, or the PHSA, and regulations and guidance implementing these laws. The FDCA, PHSA and their corresponding regulations govern, among other things, the testing, manufacturing, safety, efficacy, labeling, packaging, storage, record keeping, distribution, reporting, advertising and other promotional practices involving biologic products. Applications to the FDA are required before conducting human clinical testing of biologic products. Additionally, each clinical trial protocol for a gene therapy product candidate is reviewed by the FDA and, in limited instances the National Institutes of Health, or the NIH, through its Recombinant DNA Advisory Committee, or RAC. FDA approval also must be obtained before marketing of biologic products. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:6pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">foreign statutes and regulations require the expenditure of substantial time and financial resources and we may not be able to o</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">btain the required regulatory approvals.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Biologic Products Development Process</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our product candidates must be approved by the FDA before they may be legally marketed in the United States. The process required by the FDA before a biologic product candidate may be marketed in the United States generally involves the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">completion of preclinical laboratory tests and <font style="font-style:italic;">in vivo</font> studies in accordance with the FDA&#8217;s current Good Laboratory Practice, or GLP, regulations and applicable requirements for the humane use of laboratory animals or other applicable regulations;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">submission to the FDA of an application for an IND exemption, which allows human clinical trials to begin unless FDA objects within 30&#160;days;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">approval by an independent institutional review board, or IRB, reviewing each clinical site before each clinical trial may be initiated;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">performance of adequate and well&#8209;controlled human clinical trials according to the FDA&#8217;s GCP regulations, and any additional requirements for the protection of human research subjects and their health information, to establish the safety and efficacy of the proposed biologic product candidate for its intended use;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">preparation and submission to the FDA of a biologics license application (&#8220;BLA&#8221;) for marketing approval that includes substantial evidence of safety, purity and potency from results of nonclinical testing and clinical trials;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">review of the product by an FDA advisory committee, if applicable;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">satisfactory completion of an FDA inspection of the manufacturing facility or facilities where the biologic product candidate is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the biologic product candidate&#8217;s identity, safety, strength, quality, potency and purity;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">potential FDA audit of the nonclinical and clinical trial sites that generated the data in support of the BLA; and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">payment of user fees and FDA review and approval, or licensure, of the BLA.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before testing any biologic product candidate in humans, including a gene therapy product candidate, the product candidate must undergo preclinical testing. Preclinical tests, also referred to as nonclinical studies, include laboratory evaluations of product chemistry, toxicity and formulation, as well as in vivo studies to assess the potential safety and activity of the product candidate and to establish a rationale for therapeutic use. The conduct of the preclinical tests must comply with federal regulations and requirements including GLPs.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually must complete some long&#8209;term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and must also develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, the manufacturer must develop methods for testing the identity, strength, quality and purity of the final drug product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a gene therapy trial is conducted at, or sponsored by, institutions receiving NIH funding for recombinant DNA research, prior to the submission of an IND to the FDA, a protocol and related documents must be submitted to, and the study registered with, the NIH Office of Biotechnology Activities, or the OBA, pursuant to the NIH Guidelines for Research Involving Recombinant DNA Molecules, or the NIH Guidelines. Compliance with the NIH Guidelines is mandatory for investigators at institutions receiving NIH funds for research involving recombinant DNA. However, many companies and other institutions, not otherwise subject to the NIH Guidelines, voluntarily follow them. The NIH is responsible for convening the RAC that discusses protocols that raise novel or particularly important scientific, safety or ethical considerations at one of its quarterly public meetings. The OBA will notify the FDA of the RAC&#8217;s decision regarding the necessity for full public review of a gene therapy protocol. RAC proceedings and reports are posted to the OBA website and may be accessed by the public.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The clinical trial sponsor must submit the results of the preclinical tests, together </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with manufacturing information, analytical data, any available clinical data or literature and a proposed clinical protocol, to the FDA as part of the IND. Some preclinical testing may continue even after the IND is submitted. The IND automatically becomes</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> effective 30&#160;days after receipt by the FDA, unless the FDA places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. With gene therapy protocols, if</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the FDA allows the IND to proceed, but the RAC decides that full public review of the protocol is warranted, the FDA will request at the completion of its IND review that sponsors delay initiation of the protocol until after completion of the RAC review p</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rocess. The FDA also may impose clinical holds on a biologic product candidate at any time before or during clinical trials due to safety concerns or non</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;compliance. If the FDA imposes a clinical hold, trials may not recommence without FDA authorization an</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d then only under terms authorized by the FDA. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical studies to begin, or that, once begun, issues will not arise that suspend or terminate such studies.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Human Clinical Trials Under an IND</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials involve the administration of the biologic product candidate to healthy volunteers or patients under the supervision of qualified investigators which generally are physicians not employed by, or under, the control of the trial sponsor. Clinical trials are conducted under written study protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection and exclusion criteria and the parameters to be used to monitor subject safety, including stopping rules that assure a clinical trial will be stopped if certain adverse events should occur. Each protocol and any amendments to the protocol must be submitted to the FDA as part of the IND. Clinical trials must be conducted and monitored in accordance with the FDA&#8217;s regulations comprising the GCP requirements, including the requirement that all research subjects provide informed consent.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, each clinical trial must be reviewed and approved by an IRB at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers items such as whether the risks to individuals participating in the clinical trials are minimized and are reasonable in relation to anticipated benefits. The IRB also approves the form and content of the informed consent that must be signed by each clinical trial subject, or their legal representative, reviews and approves the study protocol, and must monitor the clinical trial until completed. Clinical trials involving recombinant DNA also must be reviewed by an institutional biosafety committee, or IBC, a local institutional committee that reviews and oversees basic and clinical research that utilizes recombinant DNA at that institution. The IBC assesses the safety of the research and identifies any potential risk to public health or the environment.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Human clinical trials typically are conducted in three sequential phases that may overlap or be combined:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Phase&#160;1.&nbsp;&nbsp;</font>The biologic product candidate initially is introduced into a small number of human subjects and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early understanding of its effectiveness. Phase&#160;1 clinical trials of gene therapies are typically conducted in patients rather than healthy volunteers.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Phase&#160;2.&nbsp;&nbsp;</font>The biologic product candidate is evaluated in a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product candidate for specific targeted diseases and to determine dosage tolerance, optimal dosage and dosing schedule.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8226;</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Phase&#160;3.&nbsp;&nbsp;</font>Phase&#160;3 clinical trials are commonly referred to as &#8220;pivotal&#8221; studies, which typically denotes a study which presents the data that the FDA or other relevant regulatory agency will use to determine whether or not to approve a biologic product. In Phase&#160;3 studies, the biologic product candidate is administered to an expanded patient population, generally at multiple geographically dispersed clinical trial sites in adequate and well&#8209;controlled clinical trials to generate sufficient data to statistically confirm the potency and safety of the product for approval. These clinical trials are intended to establish the overall risk/benefit ratio of the product candidate and provide an adequate basis for product labeling.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Post&#8209;approval clinical trials, sometimes referred to as Phase&#160;4 clinical trials, may be conducted after initial approval. These clinical trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication, particularly for long&#8209;term safety follow&#8209;up.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During all phases of clinical development, regulatory agencies require extensive monitoring and auditing of all clinical activities, clinical data and clinical trial investigators. Annual progress reports detailing the results of the clinical trials must be submitted to the FDA.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>Written IND safety reports must be promptly submitted to the FDA, the NIH and the investigators for: serious and unexpected adverse events; any findings from other trials, in vivo laboratory tests or in vitro testing that suggest a significant risk for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">human subjects; or any clinically important increase in th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sp</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">onsor also must notify the FDA of any unexpected fatal or life</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8209;threatening suspected adverse reaction within seven calendar days after the sponsor&#8217;s initial receipt of the information.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA or the sponsor or its data safety monitoring board may suspend a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the biologic product candidate has been associated with unexpected serious harm to patients.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">FDA usually recommends that sponsors observe subjects for potential gene therapy&#8209;related delayed adverse events for a 15&#8209;year period, including a minimum of five years of annual examinations followed by 10&#160;years of annual queries, either in person or by questionnaire.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Compliance with cGMP Requirements</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturers of biologics must comply with applicable cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Manufacturers and others involved in the manufacture and distribution of such products also must register their establishments with the FDA and certain state agencies. Both domestic and foreign manufacturing establishments must register and provide additional information to the FDA upon their initial participation in the manufacturing process. Establishments may be subject to periodic, unannounced inspections by government authorities to ensure compliance with cGMP requirements and other laws. Discovery of problems may result in a government entity placing restrictions on a product, manufacturer or holder of an approved BLA, and may extend to requiring withdrawal of the product from the market. The FDA will not approve a BLA unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specification.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concurrent with clinical trials, companies usually complete additional preclinical studies and must also develop additional information about the physical characteristics of the biologic product candidate as well as finalize a process for manufacturing the product candidate in commercial quantities in accordance with cGMP requirements. To help reduce the risk of the introduction of adventitious agents or of causing other adverse events with the use of biologic products, the PHSA emphasizes the importance of manufacturing control for products whose attributes cannot be precisely defined. The manufacturing process must be capable of consistently producing quality batches of the product candidate and, among other requirements, the sponsor must develop methods for testing the identity, strength, quality, potency and purity of the final biologic product. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the biologic product candidate does not undergo unacceptable deterioration over its shelf life.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">U.S. Review and Approval Processes</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The results of the preclinical tests and clinical trials, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things, are submitted to the FDA as part of a BLA requesting approval to market the product for one or more indications.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Prescription Drug User Fee Act, or PDUFA, as amended, each BLA must be accompanied by a significant user fee. The FDA adjusts the PDUFA user fees on an annual basis. The PDUFA also imposes an annual program fee for approved biologics. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA reviews a BLA within 60&#160;days of submission to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any BLA that it deems incomplete or not properly reviewable at the time of submission and may request additional information. In that event, the BLA must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. Once the submission is accepted for filing, the FDA begins an in&#8209;depth, substantive review of the BLA.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU26"></a>The FDA reviews the BLA to determine, among other things, whether the proposed product candidate is safe and potent, or effective, for its intended use, has an acceptable purity profile and whether the product candidate is being manufactured in accordance with cGMP to assure and preserve the product candidate&#8217;s identity, safety, strength, quality, potency and purity. The FDA may refer applications for novel biologic products or biologic products that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. During the product approval process, the FDA also will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:12pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determ</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ine whether a risk evaluation and mitigation strategy, or REMS, is necessary to assure the safe use of the product candidate. REMS use risk minimization strategies beyond the professional labeling to ensure that the benefits of the product outweigh the pot</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">adverse events, and whether the product is a new molecular entity. A REMS could include medication guides, physician communication plans and elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimizatio</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n tools. If the FDA concludes a REMS is needed, the sponsor of the BLA must submit a proposed REMS; the FDA will not approve the BLA without a REMS, if required.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before approving a BLA, the FDA will inspect the facilities at which the product candidate is manufactured. The FDA will not approve the product candidate unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product candidate within required specifications. Additionally, before approving a BLA, the FDA typically will inspect one or more clinical sites to assure that the clinical trials were conducted in compliance with IND trial requirements and GCP requirements.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On the basis of the BLA and accompanying information, including the results of the inspection of the manufacturing facilities, the FDA may issue an approval letter or a complete response letter. An approval letter authorizes commercial marketing of the biologic product with specific prescribing information for specific indications. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. If and when those deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If a product candidate receives regulatory approval, the approval may be significantly limited to specific diseases and dosages or the indications for use may otherwise be limited. Further, the FDA may require that certain contraindications, warnings or precautions be included in the product labeling. The FDA may impose restrictions and conditions on product distribution, prescribing or dispensing in the form of a REMS, or otherwise limit the scope of any approval. In addition, the FDA may require post&#8209;marketing clinical trials, sometimes referred to as Phase&#160;4 clinical trials, designed to further assess a biologic product&#8217;s safety and effectiveness, and testing and surveillance programs to monitor the safety of approved products that have been commercialized.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA has agreed to specified performance goals in the review of BLAs under the PDUFA. One such goal is to review standard BLAs in 10&#160;months after the FDA accepts the BLA for filing, and priority BLAs in six months, whereupon a review decision is to be made. The FDA does not always meet its PDUFA goal dates for standard and priority BLAs and its review goals are subject to change from time to time. The review process and the PDUFA goal date may be extended by three months if the FDA requests or the BLA sponsor otherwise provides additional information or clarification regarding information already provided in the submission within the last three months before the PDUFA goal date.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Post&#8209;approval Requirements</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rigorous and extensive FDA regulation of biologic products continues after approval, particularly with respect to cGMP requirements. Manufacturers are required to comply with applicable requirements in the cGMP regulations, including quality control and quality assurance and maintenance of records and documentation. Other post&#8209;approval requirements applicable to biologic products include reporting of cGMP deviations that may affect the identity, potency, purity and overall safety of a distributed product, record&#8209;keeping requirements, reporting of adverse effects, reporting updated safety and efficacy information and complying with electronic record and signature requirements. After a BLA is approved, the product also may be subject to official lot release. If the product is subject to official release by the FDA, the manufacturer submits samples of each lot of product to the FDA, together with a release protocol, showing a summary of the history of manufacture of the lot and the results of all tests performed on the lot. The FDA also may perform certain confirmatory tests on lots of some products before releasing the lots for distribution. In addition, the FDA conducts laboratory research related to the regulatory standards on the safety, purity, potency and effectiveness of biologic products.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A sponsor also must comply with the FDA&#8217;s advertising and promotion requirements, such as the prohibition on promoting products for uses or in patient populations that are not described in the product&#8217;s approved labeling (known as &#8220;off&#8209;label use&#8221;). Discovery of previously unknown problems or the failure to comply with the applicable regulatory requirements may result in restrictions on the marketing of a product or withdrawal of the product from the market as well as possible civil or criminal sanctions. In addition, changes to the manufacturing process or facility generally require prior FDA approval before being implemented and other types of changes to the approved product, such as adding new indications and additional labeling claims, are also subject to further FDA review and approval.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Additional Regulation</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we currently do not have any products on the market, we may be subjec</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t to additional healthcare regulation and enforcement by the federal government and by authorities in the states and foreign jurisdictions in which we conduct our business. Such laws include, without limitation, state and federal anti-kickback, fraud and a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">buse, false claims, privacy and security and physician sunshine laws and regulations, many of which may become more applicable if our product candidates are approved and we begin commercialization. If our operations are found to be in violation of any of s</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">uch laws or any other governmental regulations that apply to us, we may be subject to penalties, including, without limitation, civil and criminal penalties, damages, fines, the curtailment or restructuring of our operations, exclusion from participation i</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n federal and state healthcare programs and imprisonment, and additional reporting requirements and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, any of whic</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">h could adversely affect our ability to operate our business and our financial results. See Risk Factors&#8212;&#8220;</font><font style="font-style:italic;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and reg</font><font style="font-style:italic;">ulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Significant uncertainty exists as to the coverage and reimbursement status of any product candidates for which we obtain regulatory approval, particularly for novel products. In both domestic and foreign markets, sales and reimbursement of any approved products will depend, in part, on the extent to which third-party payors, such as government health programs, commercial insurance and managed healthcare organizations provide coverage, and establish adequate reimbursement levels, for such products. Third-party payors are increasingly challenging the prices charged for medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, or also known as a formulary, which might not include all of the FDA-approved products for a particular indication. Additionally, we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. If third-party payors do not consider our products to be cost-effective compared to other therapies, the payors may not cover our products after approved as a benefit under their plans or, if they do, the level of reimbursement may not be sufficient to allow us to sell our products on a profitable basis. See Risk Factors&#8212;&#8220;<font style="font-style:italic;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from third-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business</font>.&#8221;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EMPLOYEES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February 15, 2018, we had 182 full-time employees, all of whom are located at our headquarters in Richmond, California. None of our employees are represented by a collective bargaining organization or covered by a collective bargaining agreement, nor have we experienced work stoppages. We believe that our relations with our employees are good. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CORPORATE INFORMATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We were incorporated in June 1995 in the state of Delaware and in January 2017, we changed our name from &#8220;Sangamo BioSciences, Inc.&#8221; to &#8220;Sangamo Therapeutics, Inc.&#8221;&nbsp;&nbsp;Our website is http://www.sangamo.com. We make available free of charge, on or through our internet site, our annual, quarterly, and current reports and any amendments to those reports filed or furnished pursuant to Section&#160;13(a) of the Exchange Act as soon as reasonably practicable after we electronically file such material with, or furnish it to, the SEC. Information contained in our website is not part of, nor incorporated by reference into, this report. </p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Risk_Factors"></a><a name="Risk_Factors"></a>ITEM&#160;1A &#8211; RISK FACTORS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An investment in our common stock involves significant risk. This Form 10-K contains forward-looking information based on our current expectations. Because our actual results may differ materially from any forward-looking statements made by or on our behalf, this section includes a discussion of important factors that could affect our actual future results, including, but not limited to, our revenues, expenses, net loss and net loss per share. You should carefully consider the information described in the following risk factors, together with the other information appearing elsewhere in this report, before making an investment decision regarding our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to Development, Commercialization and Regulatory Approval of our Products and Technology </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">Our success depends substantially on the results of clinical trials of our lead therapeutic programs, and we may not be able to demonstrate safety and efficacy of our product candidates. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any products that have gained regulatory approval. We have initiated Phase 1/2 clinical trials evaluating product candidates for the treatment of hemophilia A (SB-525), hemophilia B (SB-FIX), MPS I (SB-318) and MPS II (SB-913). Our business is substantially dependent on our ability to obtain regulatory approval for, and, if approved, to successfully commercialize these product candidates in a timely manner.&nbsp;&nbsp;Our failure to enroll sufficient patients to conduct the trials, demonstrate safety or obtain positive clinical trial results, or our inability to meet the expected timeline of clinical trials or release of data for these programs would have a material adverse effect on our business operations and financial conditions, which may cause a significant decline in our stock price.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to conduct clinical trials successfully and on a timely basis for these programs is subject to a number of additional risks, including but are not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disagreement with the design or implementation of our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ability to identify and recruit sufficient number of acceptable patients to complete enrollment of trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to demonstrate that a product candidate is safe and effective for its proposed indication;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the occurrence of unexpected adverse events or toxicity; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">disagreement with the FDA on the interpretation of data from preclinical studies or our clinical trial results; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure of clinical trials to meet the level of statistical significance required for approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the insufficiency of data collected from clinical trials of our product candidates to support the submission and filing of a BLA or other submission or to obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in the approval policies or regulations that render our preclinical and clinical data insufficient for approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure to obtain approval of our manufacturing processes or facilities of third-party manufacturers with whom we contract for clinical and commercial supplies or our own manufacturing facility;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">defects in the preparation and manufacturing of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure by third parties, including vendors, manufacturers and clinical trial organizations, to provide timely and adequate supplies and services; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">development of similar gene therapies by our competitors;&nbsp;&nbsp;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">unexpected costs and expenses and lack of sufficient funding for these programs; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of licenses to critical intellectual properties.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU28"></a>We have not yet reached agreement with regulatory authorities on the development pathway for our product candidates.&nbsp;&nbsp;As a result, we have not yet determined what endpoints would support approval for certain of our programs. Due to the novelty of certain programs, such as SB-318 and SB-913, the endpoints needed to support regulatory approvals may be different than originally anticipated.&nbsp;&nbsp; Even if we are able to complete phase 1/2 trials for these programs successfully, we will likely be required to conduct additional clinical trials with larger patient populations, before obtaining the necessary regulatory approval to commercialize our products.&nbsp;&nbsp;However, there is no guarantee that the positive results achieved in earlier trials are indicative of long-term efficacy in late stage clinical trials.&nbsp;&nbsp;A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">late stage clinical trials even after achieving promising results in earlier-stage clinical trials. If a larger population of patients does not experience positive results, or if these results are not reproducible, our </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">products may not receive approval from the FDA, which could have a material adverse effect on our business that would cause our stock price to decline significantly.</font></p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if a product candidate were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for one of our product candidates in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding to continue the development of that product or generate revenues attributable to that product candidate. Also, any regulatory approval of our current or future product candidates, once obtained, may be withdrawn.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Success<font style="color:#000000;"> in preclinical studies or early clinical trials may not be indicative of results obtained in later trials.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Results from preclinical studies or previous clinical trials are not necessarily predictive of future clinical trial results, and interim results of a clinical trial are not necessarily indicative of final results. Our product candidates may fail to show the desired safety and efficacy in clinical development despite demonstrating positive results in preclinical studies or having successfully advanced through initial clinical trials or preliminary stages of clinical trials. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">While we have achieved positive results in preclinical studies of our product candidates for hemophilia A (SB-525), hemophilia B (SB-FIX), MPS I (SB-318) and MPS II (SB-913), Phase 1/2 clinical trials have only recently begun and there is no guarantee that we can achieve positive safety and efficacy results.&nbsp;&nbsp;Furthermore, all four programs are novel <font style="font-style:italic;">in-vivo</font> gene therapy or genome editing therapies that utilize AAV to deliver therapeutic levels of ZFN into the patient&#8217;s blood stream.&nbsp;&nbsp;The AAV delivery system has not been validated in human clinical trials previously, and if such delivery system does not meet the safety criteria or cannot produce the desirable efficacy results we expect, we may be forced to suspend or terminate the affected program. </p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There is a high failure rate for drugs, biologic products and cell therapies proceeding through clinical trials. Many companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in late-stage clinical trials even after achieving promising results in preclinical testing and earlier-stage clinical trials. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, we may experience regulatory delays or rejections as a result of many factors, including due to changes in regulatory policy during the period of our product candidate development. Any such delays could materially and adversely affect our business, financial condition, results of operations and prospects.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our potential products are subject to a lengthy and uncertain regulatory approval process.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA must approve any human therapeutic product before it can be marketed in the United States. The process for receiving regulatory approval is long and uncertain, and a potential product may not withstand the rigors of testing under the regulatory approval processes. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before commencing clinical trials in humans, we must submit an Investigational New Drug, or IND, application to the FDA. The FDA has 30 days to comment on the application, and if the agency has no comments, we or our commercial partner may begin clinical trials. While we have stated our intention to file additional IND applications in the future, this is only a statement of intent, and we may not be able to do so because the associated product candidates may not meet the necessary preclinical requirements. In addition, there can be no assurance that, once filed, an IND application will result in the actual initiation of clinical trials or that we will be able to meet our targeted timeline for the initiation of clinical trials. Clinical trials are subject to oversight by institutional review boards and the FDA. In addition, our proposed clinical studies may require review from the Recombinant DNA Advisory Committee, or RAC, which is the advisory board to the NIH focusing on clinical trials involving gene transfer. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Clinical trials: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">must be conducted in conformance with the FDA&#8217;s good clinical practices, within the guidelines of the International Council for Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use, or ICH, and other applicable regulations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">must meet requirements for Institutional Review Board, or IRB, oversight; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">must follow Institutional Biosafety Committee, or IBC, and NIH RAC guidelines where applicable; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">must meet requirements for informed consent; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">are subject to continuing FDA or similar foreign government oversight; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">may require oversight by a Data Monitorin</font><font style="font-family:Times New Roman;">g Committee, or DMC; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">may require large numbers of test subjects;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">may be suspended by a commercial partner, the FDA, or us at any time if it is believed that the subjects participating in these trials are being exposed to unacceptable health risks or if the FDA finds deficiencies in the IND application or the conduct of these trials. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are not able to obtain the necessary regulatory approval to commercialize our products of if such approval is delayed or suspended, it would have an adverse effect on our business operations and trading price of our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter difficulties that may delay, suspend or scale back our efforts to advance additional early research programs through preclinical development and IND application filings and into clinical development. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We intend to advance early research programs through preclinical development and to file new IND applications for human clinical trials evaluating the preclinical candidates in our pipeline. The preparation and submission of IND applications requires us to conduct rigorous and time-consuming preclinical testing, studies, and prepare documentation relating to, among other things, the toxicity, safety, manufacturing, chemistry and clinical protocol of our product candidates. We may experience unforeseen difficulties that could delay or otherwise prevent us from executing this strategy successfully. For example, we may encounter problems in the manufacturing of our products and fail to demonstrate consistency in the formulation of the drug. Our preclinical tests may produce negative or inconclusive results, which may lead us to decide, or regulators may require us, to conduct additional preclinical testing. If we cannot obtain positive results in preclinical testing, we may decide to abandon the projects altogether. In addition, our ability to complete and file certain IND applications depends on the support of our partners and the timely performance of their obligations under relevant collaboration agreements.&#160;If our partners are not able to perform such obligations or if they choose to slow down or delay the progress, we may not be able to prepare and file the intended IND applications on a timely basis or at all. Furthermore, the filing of several IND applications involves significant cost and labor, and we may not have sufficient resources and personnel to complete the filing of all intended IND applications, which may force us to scale back the number of IND applications or forego potential IND applications that we believe are promising. Any delay, suspension or reduction of our efforts to pursue our preclinical and IND strategy could have a material adverse effect on our business and cause our stock price to decline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not successfully identify, acquire, develop or commercialize new potential product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Part of our business strategy is to expand our product candidate pipeline by identifying and validating new product candidates, which we may develop ourselves, in-license or otherwise acquire from others. In addition, in the event that our existing product candidates do not receive regulatory approval or are not successfully commercialized, then the success of our business will depend on our ability to expand our product pipeline through in-licensing or other acquisitions. We may be unable to identify relevant product candidates. If we do identify such product candidates, we may be unable to reach acceptable terms with any third party from which we desire to in-license or acquire them.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may encounter substantial delays in our clinical trials or we may fail to demonstrate safety and efficacy to the satisfaction of <font style="color:#000000;">applicable</font> regulatory authorities.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Before obtaining marketing approval from regulatory authorities for the sale of our product candidates, we must conduct extensive clinical trials to demonstrate the safety and efficacy of the product candidates. Clinical testing is expensive, time consuming and uncertain as to outcome. We cannot guarantee that any clinical trials will be conducted as planned or completed on schedule, if at all. A failure of one or more clinical trials can occur at any stage of testing. Events that may prevent successful or timely completion of clinical development include:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">delays in </font><font style="font-family:Times New Roman;">reaching a consensus with regulatory authorities on trial design;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in reaching agreement on acceptable terms with prospective CROs and clinical trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in opening clinical trial sites or obtaining required IRB or independent ethics committee approval at each clinical trial site;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in recruiting suitable subjects to participate in our clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">imposition of a clinical hold by regulatory authorities as a result of a serious adverse event or after an inspection of our clinical trial operations or trial sites;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">failure by us, any CROs we engage or any other third parties to adhere to clinical trial requirements;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">failure to perform in accordance with FDA good clinical practices, or GCP, or applicable regulatory guidelines in the European Union and other countries;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in the testing, validation, manufacturing and delivery of our product candidates to the clinical sites, including delays by third parties with whom we have contracted to perform certain of those functions;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays in having subjects complete participation in a trial or return for post-treatment follow-up;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">clinical trial sites or subjects dropping out of a trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">selection of clinical endpoints that require prolonged periods of clinical observation or analysis of the resulting data;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">occurrence of serious adverse events associated with the product candidate that are viewed to outweigh its potential benefits;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">occurrence of serious adverse</font><font style="color:#000000;font-family:Times New Roman;"> events in trials of the same class of agents conducted by other sponsors; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">changes in regulatory requirements and guidance that require amending or submitting new clinical protocols.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any inability to successfully complete preclinical and clinical development could result in additional costs to us or impair our ability to generate revenues from product sales, regulatory and commercialization milestones and royalties. In addition, if we make manufacturing or formulation changes to our product candidates, we may need to conduct additional studies to bridge our modified product candidates to earlier versions. Clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do, which could impair our ability to successfully commercialize our product candidates and may harm our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, if the results of our clinical trials are inconclusive or if there are safety concerns or serious adverse events associated with our product candidates, we may:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">be delayed </font><font style="font-family:Times New Roman;">in</font><font style="color:#000000;font-family:Times New Roman;"> obtaining marketing approval for our product candidates, if at all;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">obtain ap</font><font style="font-family:Times New Roman;">proval for indications or patient populations that are not as broad as intended or desired;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to changes in the way the product is administered;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be required to perform additional clinical trials to support approval or be subject to additional post-marketing testing req</font><font style="color:#000000;font-family:Times New Roman;">uirements;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">have </font><font style="font-family:Times New Roman;">regulatory authorities withdraw, or suspend, their approval of the product or impose restrictions on its distribution in the form of a modified risk evaluation and mitigation strategy;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be subject to the addition of labeling statements, such as warnings or contraindications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">be sued; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">experience damage</font><font style="color:#000000;font-family:Times New Roman;"> to our reputation.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be able to find acceptable patients or may experience delays in enrolling patients for our clinical trials, which could delay or prevent us from proceeding with clinical trials of our product candidates. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Identifying and qualifying patients to participate in clinical trials of our product candidates is critical to our success. The timing of our clinical trials depends on our ability to recruit patients to participate as well as completion of required follow-up periods. For example, hemophilia trials often take longer to enroll due to the availability of existing treatments. We have been unable to enroll a patient in our hemophilia B clinical trial. If we are not able to enroll the necessary number of patients in a timely manner, we may not be able to complete the clinical trial. We may face similar challenges or delays in our other or future clinical trials. If patients are unwilling to participate in our gene therapy studies because of negative publicity from adverse events related to the biotechnology or gene therapy fields, competitive clinical trials for similar patient populations or for other reasons, the timeline for recruiting patients, conducting studies and obtaining regulatory approval of our product candidates may be delayed. These delays could result in increased costs, delays in advancing our product candidates, delays in testing the effectiveness of our product candidates or termination of the clinical trials altogether.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may not be able to identify, recruit and enroll a sufficient number of patients, or those with required or desired characteristics, to complete our clinical trials in a timely manner. Patient enrollment and trial completion is affected by factors including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">size of the </font><font style="font-family:Times New Roman;">patient population and process for identifying subjects;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">design of the trial protocol;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">eligibility and exclusion criteria;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">perceived risks and benefits of the product candidate under study;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">perceived risks and benefits of gene therapy-based approaches to treatment of diseases;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of competing therapies and clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">severity of the disease under investigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">availability of genetic testing for potential patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">proximity and availability of clinical trial sites for prospective subjects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to obtain and maintain subject consent;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">risk that enrolled subjects will drop out before completion of the trial;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">patient referral practices of physicians; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">ability to monitor subjects adequately</font><font style="color:#000000;font-family:Times New Roman;"> during and after treatment.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current product candidates are being developed to treat rare conditions. We plan to seek initial regulatory approvals in the United States and, subsequently, the European Union. We may not be able to initiate or continue clinical trials if we cannot enroll a sufficient number of eligible patients to participate in the clinical trials required by regulatory authorities. Our ability to successfully initiate, enroll and complete a clinical trial in any foreign country is subject to numerous risks unique to conducting business in foreign countries, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">difficulty in </font><font style="font-family:Times New Roman;">establishing or managing relationships with contract research organizations, or CROs, and physicians;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">different standards for the conduct of clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">absence in some countries of established groups with sufficient regulatory expertise for review of gene therapy protocols;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our inability to locate qualified local consultants, physicians and partners; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including</font><font style="color:#000000;font-family:Times New Roman;"> the regulation of pharmaceutical and biotechnology products and treatment.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we have difficulty enrolling a sufficient number of patients to conduct our clinical trials as planned, we may need to delay, limit or terminate ongoing or planned clinical trials, any of which would have an adverse effect on our business, financial condition, results of operations and prospects.<font style="color:#000000;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.53%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial potential or result in significant negative consequences following any potential marketing approval.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the conduct of clinical trials, patients report changes in their health, including illnesses, injuries and discomforts, to their study doctor. Often, it is not possible to determine whether or not the product candidate being studied caused these conditions, <font style="color:#000000;">particularly</font> as many of the diseases we are studying have complex comorbidities. If clinical experience indicates that our product candidates have side effects or cause serious or life&#8209;threatening side effects, the development of the product candidate may fail or be delayed, or, if the product candidate has received regulatory approval, such approval may be revoked, which would severely harm our business, prospects, operating results and financial condition.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been several significant adverse side effects in gene therapy treatments in the past, including reported cases of leukemia and death seen in other trials using other genomic therapies. Gene therapy is still a relatively new approach to disease treatment and <font style="color:#000000;">additional</font> adverse side effects could develop. There also is the potential risk of significantly delayed adverse events following exposure to gene therapy products due to persistent biologic activity of the genetic material or other components of products used to carry the genetic material. Possible adverse side effects that could occur with treatment with gene therapy products include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">As we cannot predict whether or when we will obtain regulato</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">ry approval to commercialize our product candidates, we cannot predict the timing of any future revenue from these product candidates. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot commercialize any of our products to generate revenue until the appropriate regulatory authorities have reviewed and approved the applications for the product candidates. We cannot ensure that the regulatory agencies will complete their review processes in a timely manner or that we will obtain regulatory approval for any product candidate that we or our collaborators develop. Satisfaction of regulatory requirements typically takes many years, is dependent upon the type, complexity and novelty of the product and requires the expenditure of substantial resources. Regulatory approval processes outside the United States include all of the risks associated with the FDA approval process. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action or changes in FDA policy during the period of product development, clinical trials and FDA regulatory review. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have limited experience in conducting advanced clinical trials. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have initiated Phase 1/2 clinical trials evaluating product candidates for hemophilia A (SB-525), hemophilia B (SB-FIX), MPS I (SB-318) and MPS II (SB-913).&nbsp;&nbsp;For potential marketing application approval, additional clinical testing will be required, which involves significantly greater resources, commitments and expertise. Therefore, we may be required to scale up our operations and enter into collaborative relationships with pharmaceutical companies that could assume responsibility for late-stage development and commercialization. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have limited experience in conducting advanced clinical trials and may not possess the necessary resources and expertise to complete such trials. We have entered into a collaborative agreements to provide funding and assistance in the development of certain product candidates through the clinical trial process. However, there is no guarantee that we will be able to enter into future collaborative relationships with third parties that can provide us with the funding and expertise for later stage trials. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to obtain additional orphan drug designations or orphan drug exclusivity for any product. If our competitors are able to obtain orphan drug exclusivity for products that constitute the same drug and treat the same indications as our product candidates, we may not be able to have competing products approved by the applicable regulatory authority for a significant period of time.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Regulatory authorities in some jurisdictions, including the United States and the European Union, may designate drugs for relatively small patient populations as orphan drugs. Under the Orphan Drug Act of 1983, the FDA may designate a product candidate as an Orphan Drug if it is intended to treat a rare disease or condition, which is generally defined as having a patient population of fewer than 200,000 individuals in the United States, or a patient population greater than 200,000 in the United States where there is no reasonable expectation that the cost of developing the drug will be recovered from sales in the United States. In the European Union, the EMA&#8217;s Committee for Orphan Medicinal Products grants such designation to promote the development of products that are intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in 10,000 persons in the European Union. Additionally, orphan designation is granted for products intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition and when, without incentives, it is unlikely that sales of the drug in the European Union would be sufficient to justify the necessary investment in developing the drug or biologic product. </p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our four most advanced product candidates, SB-525, SB-FIX, SB-318 and SB-913 have all been granted Orphan Drug Designation by the FDA, and SB-525 and SB-318 and SB-913 have also been designated Orphan Medicinal Products by the EMA.&nbsp;&nbsp;If we request such designation for our other current or future product candidates, there can be no assurances that the FDA or the EMA will grant any of our product candidates such designation. Additionally, such designation does not guarantee that any regulatory agency will accelerate regulatory review of, or ultimately approve, that product candidate, nor does it limit the ability of any regulatory agency to grant such designation to product candidates of other companies that treat the same indications as our product candidates prior to our product candidates receiving exclusive marketing approval.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>Generally, if a product candidate with an orphan drug designation receives the first marketing approval for the indication for which it has such designation, the product is entitled to a period of marketing exclusivity, which precludes the FDA or the EMA from approving another marketing application for a product that constitutes the same drug treating the same indication for that marketing exclusivity period, except in limited circumstances. If another sponsor receives such approval before we do (regardless of our orphan drug designation), we will be precluded from receiving marketing approval for our product for the applicable exclusivity period. The applicable period is seven years in the United States and 10 years in the European Union. The exclusivity period in the United States can be extended by six months if the BLA sponsor submits pediatric data that fairly respond to a written request from the FDA for such data. The exclusivity period in the European Union can be reduced to six years if a product no longer meets the criteria for orphan drug designation or if the product is sufficiently profitable so that market exclusivity is no longer justified. Orphan drug </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exclusivity may be revoked if any regulatory agency determines that the re</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">quest for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the product to meet the needs of patients with the rare disease or condition.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain orphan drug exclusivity for a product candidate, that exclusivity may not effectively protect the product candidate from competition because different drugs can be approved for the same condition. In the United States, even after an orphan drug is approved, the FDA may subsequently approve another drug for the same condition if the FDA concludes that the latter drug is not the same drug or is clinically superior in that it is shown to be safer, more effective or makes a major contribution to patient care. In the European Union, marketing authorization may be granted to a similar medicinal product for the same orphan indication if:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="color:#000000;font-family:Times New Roman;">the second </font><font style="font-family:Times New Roman;">applicant can establish in its application that its medicinal product, although similar to the orphan medicinal product already authorized, is safer, more effective or otherwise clinically superior;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the holder of the marketing authorization for the original orphan medicinal product consents to a second orphan medicinal product application; or</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the holder of the marketing</font><font style="color:#000000;font-family:Times New Roman;"> authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Commercialization of our technologies will depend, in part, on strategic partnering with other companies. If we are not able to find partners in the future or if our partners do not diligently pursue product development efforts, we may not be able to develop our technologies or products, which could slow our growth and decrease the value of our stock. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to rely, to some extent, on our strategic partners to provide funding in support of our research and to perform independent research and preclinical and clinical testing. Our technology is broad-based, and we do not currently possess the resources necessary to fully develop and commercialize potential products that may result from our technologies or the resources or capabilities to complete the lengthy marketing approval processes that may be required for the products. Therefore, we plan to rely on strategic partnerships to help us develop and commercialize our products.&nbsp;&nbsp;We have entered into a collaborative agreements to provide funding and assistance in the development of certain product candidates through the clinical trial process. For example, we have an agreement with Kite for potential engineered cell therapies for cancer, two separate agreements with Pfizer, one for SB-525 for hemophilia A, and another for ALS/FTLD, and an agreement with Bioverativ for our beta-thalassemia and SCD product candidates.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we are unable to find additional partners or if the partners we are unable or unwilling to advance our programs, or if they do not diligently pursue product approval, this may slow our progress and adversely affect our ability to generate revenues. In addition, our partners may sublicense or abandon development programs or we may have disagreements or disputes with our partners, which would cause associated product development to slow or cease.&nbsp;&nbsp;In addition, the business or operations of our partners may change significantly through restructuring, acquisition or other strategic transactions or decisions that may negatively impact their ability to advance our programs. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There can be no assurance that we will be able to establish further strategic collaborations for our products. We may require significant time to secure collaborations or partners because we need to effectively market the benefits of our technology to these future collaborators and partners, which may direct the attention and resources of our research and development personnel and management away from our primary business operations. Further, each collaboration or partnering arrangement will involve the negotiation of terms that may be unique to each collaborator or partner. These business development efforts may not result in a collaboration or partnership. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The loss of partnering agreements may delay or terminate the potential development or commercialization of products we may derive from our technologies, but it may also delay or terminate our ability to test our product candidates. If any partner fails to conduct the collaborative activities successfully or in a timely manner, the preclinical or clinical development or commercialization of the affected product candidates or research programs could be delayed or terminated. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under typical partnering agreements, we would expect to receive revenue for the research and development of our product candidates based on achievement of specific milestones, as well as royalties based on a percentage of sales of the commercialized products. Achieving these milestones will depend, in part, on the efforts of our partner as well as our own. If we, or any partner, fail to meet specific milestones, then the partnership may be terminated, which could reduce our revenues. For more information on risks relating to our third-party collaborative agreements, see &#8220;Risks Relating to our Collaborative Relationships.&#8221; </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to license gene transfer technologies that we may need to commercialize our ZFP technology. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a>In order to regulate or modify a gene in a cell, the ZFP must be efficiently delivered to the cell. We have licensed certain gene transfer technologies for our ZFP in research including AAV and mRNA technology. We are evaluating these systems and other </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">technologies that may need to be used in the delivery of ZFP in</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to cells for </font><font style="font-style:italic;">in vitro</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and </font><font style="font-style:italic;">in vivo</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> applications. However, we may not be able to license the gene transfer technologies required to develop and commercialize our product candidates. We have not developed our own gene transfer technologies, and we rely on our</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> ability to enter into license agreements to provide us with rights to the necessary gene transfer technology. Our approach has been to license appropriate technology as required. The inability to obtain a license to use gene transfer technologies with ent</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ities which own such technology on reasonable commercial terms, if at all, could delay or prevent the preclinical evaluation, drug development collaborations, clinical testing, and/or commercialization of our therapeutic product candidates. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our gene regulation and genome editing technology is relatively new, and if we are unable to use this technology in all our intended applications, it would limit our revenue opportunities. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our technology involves a relatively new approach to gene regulation and genome editing. Although we have generated ZFPs for thousands of gene sequences, we have not created ZFPs for all gene sequences and may not be able do so, which could limit the usefulness of our technology. In addition, while we have demonstrated the function of engineered ZFNs and ZFP TFs in mammalian cells, yeast, insects, plants and animals, we have not yet demonstrated clinical efficacy of this technology in a controlled clinical trial in humans, and the failure to do so could restrict our ability to develop commercially viable products. If we, and our collaborators or strategic partners, are unable to extend our results to new commercially important genes, experimental animal models, and human clinical studies, we may be unable to use our technology in all its intended applications. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The expected value and utility of our ZFNs and ZFP TFs is in part based on our belief that the targeted editing of genes or specific regulation of gene expression may enable us to develop a new therapeutic approach as well as to help scientists better understand the role of genes in disease, and to aid their efforts in drug discovery and development. We also believe that ZFP-mediated targeted genome editing and gene regulation will have utility in agricultural applications. There is only a limited understanding of the role of specific genes in all these fields. Life sciences companies have developed or commercialized only a few products in any of these fields based on results from genomic research or the ability to regulate gene expression. We, our collaborators or our strategic partners, may not be able to use our technology to identify and validate drug targets or to develop commercial products in the intended markets. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Effective delivery of ZFNs and ZFP TFs into the appropriate target cells and tissues is critical to the success of the therapeutic applications of our ZFP technology. In order to have a meaningful therapeutic effect, these products must be delivered to sufficient numbers of cells in the targeted tissue. The ZFN or ZFP TF must be present in that tissue for sufficient time to effect either modification of a therapeutically relevant gene or regulation of its expression. In our current clinical and preclinical programs, we administer these product candidates as a nucleic acid that encodes the ZFN or ZFP TF. We use different formulations to deliver the ZFN or ZFP TF depending on the required duration of expression, the targeted tissue and the indication that we intend to treat, including our proprietary AAV delivery system. However, there can be no assurances that we will be able to effectively deliver our ZFNs and ZFP TFs to produce a beneficial therapeutic effect. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are conducting proprietary research to discover new product candidates. These programs increase our financial risk of product failure, may significantly increase our research expenditures, and may involve conflicts with future collaborators and strategic partners. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our proprietary research programs consist of research that is funded solely by us or by grant funding and in which we retain exclusive rights to therapeutic products generated by such research. This is in contrast to certain of our research programs that may be funded by corporate partners in which we may share rights to any resulting products. Conducting proprietary research programs may not generate corresponding revenue and may create conflicts with our collaborators or strategic partners over rights to our intellectual property with respect to our proprietary research activities. Any conflict with our collaborators or strategic partners could reduce our ability to enter into future collaborations or partnering agreements and negatively impact our relationship with existing collaborators and partners that could reduce our revenue and delay or terminate our product development. As we continue to focus our strategy on proprietary research and therapeutic development, we expect to experience greater business risks, expend significantly greater funds and require substantial commitments of time from our management and staff. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if our technology proves to be effective, it still may not lead to commercially viable products. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if our collaborators or strategic partners are successful in using our ZFP technology in drug discovery, protein production, therapeutic development or other areas in which we have licensed our technology, such as plant agriculture, they may not be able to commercialize the resulting products or may decide to use other methods competitive with our technology. To date, no company has received marketing approval or has developed or commercialized any therapeutic or agricultural products based on our ZFP technology. Should our technology fail to provide safe, effective, useful or commercially viable approaches to the discovery and development of these products, this would significantly limit our business and future growth and would adversely affect our value. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if our product developmen</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">t efforts are successful and even if the requisite regulatory approvals are obtained, our products may not gain market acceptance among physicians, patients, healthcare payers and the medical community. </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for any of our product candidates that we may develop or acquire in the future, the product may not gain market acceptance among physicians, healthcare payors, patients or the medical community. Market acceptance of any of our product candidates for which we receive approval depends on a number of factors, including:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the efficacy and safety of such product candidates as demonstrated in clinical trials;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the clinical indications and patient populations for which the product candidate is approved;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">acceptance by physicians, major cancer treatment centers and patients of the drug as a safe and effective treatment;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the adoption of novel gene therapies by physicians, hospitals and third-party payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the potential and perceived advantages of product candidates over alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the safety of product candidates seen in a broader patient group, including its use outside the approved indications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any restrictions on use together with other medications;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the prevalence and severity of any side effects;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">product labeling or product insert requirements of the FDA or other regulatory authorities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing of market introduction of our products as well as competitive products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the development of manufacturing and distribution processes for our product candidates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of treatment in relation to alternative treatments;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of coverage and adequate reimbursement and pricing by third-party payors and government authorities and the willingness of patients to pay out-of-pocket in the absence of coverage by third-party payors;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">relative convenience and ease of administration; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the effectiveness of our sales and marketing efforts and those of our collaborators.</font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If any of our product candidates are approved but fail to achieve market acceptance among physicians, patients, healthcare payors or treatment centers, we will not be able to generate significant revenues, which would compromise our ability to become profitable. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we are able to commercialize our product candidates, the products may not receive coverage and adequate reimbursement from <font style="color:#000000;">third</font>-party payors in the United States and in other countries in which we seek to commercialize our products, which could harm our business.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our ability to commercialize any product successfully will depend, in part, on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government health administration authorities, private health insurers and other organizations.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Government authorities and third-party payors, such as private health insurers and health maintenance organizations, determine which medications they will cover and establish reimbursement levels. A primary trend in the healthcare industry is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Third-party payors may also seek additional clinical evidence, beyond the data required to obtain regulatory approval, demonstrating clinical benefits and value in specific patient populations before covering our products for those patients. We cannot be sure that coverage and adequate reimbursement will be available for any product that we commercialize and, if reimbursement is available, what the level of reimbursement will be. Coverage and reimbursement may impact the demand for, or the price of, any product candidate for which we obtain regulatory approval. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize any product candidate for which we obtain regulatory approval.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a>There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the drug is approved by the FDA or comparable foreign regulatory authorities. Moreover, eligibility for coverage and reimbursement does not imply that any drug will be paid for in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">also not be sufficient to cover our costs and may only be temporary. Reimbursement rates may vary according to the</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discoun</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors in </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the United States often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and profitable reimbursement rates from both government-funded and private payors for </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recently enacted and future legislation, including potentially unfavorable pricing regulations or other healthcare reform <font style="color:#000000;">initiatives</font>, may increase the difficulty and cost for us to obtain regulatory approval of and commercialize our product candidates and affect the prices we may obtain.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The regulations that govern, among other things, regulatory approvals, coverage, pricing and reimbursement for new drug products vary widely from country to country. In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay regulatory approval of our product candidates, restrict or regulate post-approval activities and affect our ability to successfully sell any product candidates for which we obtain regulatory approval. In particular, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, collectively, the Affordable Care Act, was enacted, which substantially changes the way health care is financed by both governmental and private insurers, and significantly impacts the U.S. pharmaceutical industry. The Affordable Care Act and its implementing regulations, among other things, addressed a new methodology by which rebates owed by manufacturers under the Medicaid Drug Rebate Program are calculated for certain drugs and biologics, including our product candidates, that are inhaled, infused, instilled, implanted or injected, increased the minimum Medicaid rebates owed by manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, provided incentives to programs that increase the federal government<font style="color:#000000;">&#8217;</font>s comparative effectiveness research and established a new Medicare Part D coverage gap discount program, in which manufacturers must agree to offer 50% point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer<font style="color:#000000;">&#8217;</font>s outpatient drugs to be covered under Medicare Part D.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of the provisions of the Affordable Care Act have yet to be fully implemented, and there have been legal and political challenges to certain aspects of the Affordable Care Act. Since January 2017, President Trump has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the Affordable Care Act. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the Affordable Care Act. While Congress has not passed repeal legislation, the Tax Cuts and Jobs Act of 2017 includes a provision repealing, effective January 1, 2019, the tax-based shared responsibility payment imposed by the Affordable Care Act on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate&#8221;. Additionally, on January 22, 2018 President Trump signed a continuing resolution on appropriations for fiscal year 2018 that delayed the implementation of certain Affordable Care Act-mandated fees. Congress may consider other legislation to repeal or replace elements of the Affordable Care Act.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other legislative changes have been proposed and adopted in the United States since the Affordable Care Act was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation<font style="color:#000000;">&#8217;</font>s automatic reduction to several government programs. This includes aggregate reductions of Medicare payments to providers of 2% per fiscal year, which went into effect in April 2013, and, due to subsequent legislative amendments to the statute, including the Bipartisan Budget Act of 2018, will remain in effect through 2027 unless additional Congressional action is taken. In January 2013, President Obama signed into law the American Taxpayer Relief Act of 2012, or the ATRA, which, among other things, further reduced Medicare payments to several providers, including hospitals and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>Also, there has been heightened governmental scrutiny recently over pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. Such scrutiny has resulted in several recent Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for pharmaceutical products, some of which are included in the Trump administration&#8217;s budget proposal for fiscal year 2019. At the federal level, Congress and the Trump administration have each indicated that it will continue to seek new legislative and/or administrative measures to control drug costs. At the state level, legislatures have become increasingly active in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, have been designed to encourage importation from other countries an</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d bulk purchasing.</font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There have been, and likely will continue to be, legislative and regulatory proposals at the foreign, federal and state levels directed at broadening the availability of healthcare and containing or lowering the cost of healthcare. We cannot predict the initiatives that may be adopted in the future. The continuing efforts of the government, insurance companies, managed care organizations and other payors of healthcare services to contain or reduce costs of healthcare and/or impose price controls may adversely affect:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the demand for our product candidates, if we obtain regulatory approval;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to set a price that we believe is fair for our products;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our ability to generate revenue and achieve or maintain profitability;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the level of taxes that we are required to pay; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the availability of capital.</font></p></td></tr></table></div>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors, which may adversely affect our future profitability.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the regulatory approvals of our product candidates, if any, may be.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In the United States, the European Union and other potentially significant markets for our product candidates, government authorities and third-party payors are increasingly attempting to limit or regulate the price of medical products and services, particularly for new and innovative products and therapies, which has resulted in lower average selling prices. For example, in the United States, there have been several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to drug pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs. Furthermore, the increased emphasis on managed healthcare in the United States and on country and regional pricing and reimbursement controls in the European Union will put additional pressure on product pricing, reimbursement and usage, which may adversely affect our future product sales and results of operations. These pressures can arise from rules and practices of managed care groups, judicial decisions and governmental laws and regulations related to Medicare, Medicaid and healthcare reform, pharmaceutical reimbursement policies and pricing in general.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Price controls may be imposed in foreign markets, which may adversely affect our future profitability.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In some countries, particularly member states of the European Union, the pricing of prescription drugs is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after receipt of regulatory approval for a product. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various European Union member states and parallel distribution, or arbitrage between low-priced and high-priced member states, can further reduce prices. In some countries, we, or our collaborators, may be required to conduct a clinical trial or other studies that compare the cost-effectiveness of our product candidates to other available therapies in order to obtain or maintain reimbursement or pricing approval. Publication of discounts by third-party payors or authorities may lead to further pressure on the prices or reimbursement levels within the country of publication and other countries. If reimbursement of our products is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be adversely affected.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we <font style="color:#000000;">complete</font> the necessary preclinical and clinical studies, we cannot predict when or if we will obtain regulatory approval to commercialize a product candidate or the approval may be for a more narrow indication than we expect.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>We cannot commercialize a product until the appropriate regulatory authorities have reviewed and approved the product candidate. Even if our product candidates demonstrate safety and efficacy in clinical studies, the regulatory agencies may not complete their review processes in a timely manner, or we may not be able to obtain regulatory approval. Additional delays may result if an FDA Advisory Committee or other regulatory advisory group or authority recommends non-approval or restrictions on approval. In addition, we may experience delays or rejections based upon additional government regulation from future legislation or administrative action, or changes in regulatory agency policy during the period of product development, clinical studies and the review process. Regulatory agencies also may approve a treatment candidate for fewer or more limited indications than requested or may grant approval subject to the performance of post-marketing studies. In addition, regulatory agencies may not approve the labeling claims that are necessary or desirable for the successful commercialization of our treatment candidates. For example, the development </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">certain product candidates for pediatric use is an important part of our current business strategy, and if we are unable to obtain regulatory approval for the desired age ranges, our business may suffer. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory scrutiny.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if we obtain regulatory approval in a jurisdiction, the regulatory authority may still impose significant restrictions on the indicated uses or marketing of our product candidates, or impose ongoing requirements for potentially costly post-approval studies, post-market surveillance or patient or drug restrictions. For example, the FDA typically advises that patients treated with gene therapy undergo follow-up observations for potential adverse events for a 15-year period. Additionally, the holder of an approved BLA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the BLA. The holder of an approved BLA must also submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with good manufacturing practices, or GMP, and adherence to commitments made in the BLA. If we or a regulatory agency discovers previously unknown problems with a product such as adverse events of unanticipated severity or frequency, or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions relative to that product or the manufacturing facility, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory agency may: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">issue a warning letter asserting that we are in violation of the law; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seek an injunction or impose civil or criminal penalties or monetary fines; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend or withdraw regulatory approval; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">suspend any ongoing clinical studies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to approve a pending marketing application, such as a BLA or supplements to a BLA submitted by us; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">seize product; or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">refuse to allow us to enter into supply contracts, including government contracts. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty descr</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ibed above may inhibit our ability to commercialize our product candidates and generate revenues.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to obtain regulatory approval in international jurisdictions would prevent our product candidates from being marketed abroad.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to regulations in the United States, to market and sell our products in the European Union, many Asian countries and other jurisdictions, we must obtain separate regulatory approvals and comply with numerous and varying regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The regulatory approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. Clinical trials accepted in one country may not be accepted by regulatory authorities in other countries. In addition, many countries outside the United States require that a product be approved for reimbursement before it can be approved for sale in that country. A product candidate that has been approved for sale in a particular country may not receive reimbursement approval in that country. We may not be able to obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. We may not be able to file for regulatory approvals and may not receive necessary approvals to commercialize our products in any market. If we are unable to obtain approval of any of our product candidates by regulatory authorities in the European Union, Asia or elsewhere, the commercial prospects of that product candidate may be significantly diminished, our business prospects could decline and this could materially adversely affect our business, results of operations and financial condition.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our relationships with customers and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Healthcare providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any product candidates for which we obtain regulatory approval. Our current and future arrangements with healthcare providers, third-party payors and customers may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we would market, sell and distribute our products. As a pharmaceutical company, even though we do not and will not control referrals of healthcare services or bill directly to Medicare, Medicaid or other third-party payors, federal and state healthcare laws and regulations pertaining to fraud and abuse and patients<font style="color:#000000;">&#8217;</font> rights are and will be applicable to our business. Restrictions under applicable federal and state healthcare laws and regulations that may affect our ability to operate include the following:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal healthcare Anti-Kickback Statute will constrain our marketing practices, educational programs, pricing policies, and relationships with healthcare providers or other entities, by prohibiting, among other things, persons from knowingly and willfully soliciting, offering, receiving or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, any good or service, for which payment may be made under a federal healthcare program such as Medicare and Medicaid;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">federal civil and criminal false claims laws and civil monetary penalty laws impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the federal government, including the Medicare and Medicaid programs, claims for payment or approval that are false or fraudulent or making a false statement to avoid, decrease or conceal an obligation to pay money to the federal government;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, imposes criminal and civil liability for executing a scheme to defraud any healthcare benefit program and also created federal criminal laws that prohibit knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, also imposes obligations, including mandatory contractual terms, with respect to safeguarding the privacy, security and transmission of individually identifiable health information held by certain healthcare providers, health plans and healthcare clearinghouses and their business associates;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-family:Times New Roman;">the federal Physician Payments Sunshine Act created under the Affordable Care Act requires certain manufacturers of drugs, devices, biologics and medical supplies to report annually to the Centers for Medicare&#160;&amp; Medicaid Services, or </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CMS, information relat</font><font style="font-family:Times New Roman;">ed to payments and other transfers of value to physicians, other healthcare providers, and teaching hospitals, and ownership and investment interests held by physicians and other healthcare providers and their immediate family members and applicable group </font><font style="font-family:Times New Roman;">purchasing organizations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; some state laws require pharmaceutical companies to comply with the pharmaceutical industry</font><font style="color:#000000;font-family:Times New Roman;">&#8217;</font><font style="font-family:Times New Roman;">s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and may require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">state and foreign laws govern the privacy and security of health information in specified circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Efforts to ensure that our business arrangements with third parties will comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, personal imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, additional reporting requirements and oversight if become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations. If any physicians or other healthcare providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could cause significant liability for us and harm our reputation.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are exposed to the risk of employee fraud or other misconduct, including intentional failures to comply with FDA regulations or similar regulations of comparable foreign regulatory authorities, provide accurate information to the FDA or comparable foreign regulatory authorities, comply with manufacturing standards we have established, comply with federal and state healthcare fraud and abuse laws and regulations and similar laws and regulations established and enforced by comparable foreign regulatory authorities, report financial information or data accurately or disclose unauthorized activities to us. Employee misconduct could also involve the improper use of information obtained in the course of clinical trials, which could result in regulatory sanctions and serious harm to our reputation. It is not always possible to identify and deter employee misconduct, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to be in compliance with such laws or regulations. If any such actions are instituted against us, and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant fines or other sanctions.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. Product liability claims may be brought against us by subjects enrolled in our clinical trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreased demand for any product candidates or products that we may develop;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">termination of clinical trial sites or entire trial programs;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">injury to our reputation and significant negative media attention;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">withdrawal of clinical trial participants;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">significant costs to defend the related litigation;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantial monetary awards to trial subjects or patients;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">loss of revenue;</font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">diversion of management and scientific resources from our business operations; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the inability to commercialize any products that we may develop.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently hold product liability insurance coverage at a level that we believe is customary for similarly situated companies and adequate to provide us with insurance coverage for foreseeable risks, but which may not be adequate to cover all liabilities that we may incur. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain regulatory approval for our product candidates in development, but we may be unable to obtain commercially reasonable product liability insurance for any products that receive regulatory approval. Large judgments have been awarded in class action lawsuits based on drugs that had unanticipated side effects. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">We currently rely on third parties to conduct some or all aspects of manufacturing of our product candidates for preclinical and clinical development.&nbsp;&nbsp; </font>If one of our third-party manufacturers fails to perform adequately or fulfill our needs, we may be required to incur significant costs and devote significant efforts, to find new suppliers or manufacturers. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We currently have limited experience in, and we do not own facilities for, clinical-scale manufacturing of our product candidates and we rely upon third-party contract manufacturing organizations to manufacture and supply drug product for our preclinical and clinical studies.&nbsp;&nbsp;The manufacture of pharmaceutical products in compliance with the FDA&#8217;s current good manufacturing practices, or cGMP, requires significant expertise and capital investment, including the development of advanced manufacturing techniques and process controls. Manufacturers of pharmaceutical products often encounter difficulties in production, including difficulties with production costs and yields, quality control, including stability of the product candidate and quality assurance testing, shortages of qualified personnel, as well as compliance with strictly enforced cGMP requirements, other federal and state regulatory requirements and foreign regulations. If our manufacturers were to encounter any of these difficulties or otherwise fail to comply with their obligations to us or under applicable regulations, our ability to provide study drugs in our clinical studies would be jeopardized. Any delay or interruption in the supply of clinical study materials could delay the completion of our clinical studies, increase the costs associated with maintaining our clinical study programs and, depending upon the period of delay, require us to commence new studies at significant additional expense or terminate the studies completely.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All manufacturers of our product candidates must comply with cGMP requirements enforced by the FDA through its facilities inspection program. These requirements include, among other things, quality control, quality assurance and the maintenance of records and documentation. Manufacturers of our product candidates may be unable to comply with these cGMP requirements and with other FDA, state and foreign regulatory requirements. The FDA or similar foreign regulatory agencies may also implement new standards at any time, or change their interpretation and enforcement of existing standards for manufacture, packaging or testing of products. We have limited control over our manufacturers&#8217; compliance with these regulations and standards. Failure to comply with these requirements may result in fines and civil penalties, suspension of production, suspension or delay in product approval, product seizure or recall or withdrawal of product approval. If the safety of any product supplied is compromised due to our manufacturers&#8217; failure to adhere to applicable laws or for other reasons, we may not be able to obtain regulatory approval for or successfully commercialize our products and we may be held liable for any injuries sustained as a result. Any of these factors could cause a delay of clinical studies, regulatory submissions, approvals or commercialization of our product candidates, entail higher costs or impair our reputation.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our current agreements with our suppliers do not provide for the entire supply of the drug product necessary for all anticipated clinical studies or for full scale commercialization. If we and our suppliers cannot agree to the terms and conditions for them to provide the drug product necessary for our clinical and commercial supply needs, we may not be able to manufacture the product candidate until a qualified alternative supplier is identified, which could also delay the development of, and impair our ability to commercialize, our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of third-party suppliers with the necessary manufacturing and regulatory expertise and facilities is limited, and it could be expensive and take a significant amount of time to arrange for alternative suppliers, which could have a material adverse effect on our business. New suppliers of any product candidate would be required to qualify under applicable regulatory requirements and would need to have sufficient rights under applicable intellectual property laws to the method of manufacturing the product candidate. Obtaining the necessary FDA approvals or other qualifications under applicable regulatory requirements and ensuring non-infringement of third-party intellectual property rights could result in a significant interruption of supply and could require the new manufacturer to bear significant additional costs which may be passed on to us.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">There are risks associated with manuf</font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">acturing for clinical and commercial use. Manufacturing biological components at the appropriate scale and quality is complex and difficult.&#160; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are risks associated with manufacturing our products including, among others, GMP compliance, cost overruns, technical problems with process scale-up, process reproducibility, stability issues, lot consistency and timely availability of raw materials. Even if efficacy and safety data from our clinical trials would otherwise support regulatory approval for a product candidate, there is no assurance that we or any third-party manufacturer will be able to manufacture our product candidates to specifications at levels necessary to support or maintain commercial approval by the FDA or other regulatory authorities. In addition, we may not be able to manufacture our product candidates in sufficient quantities to meet the requirements for a potential launch or to meet potential future demand. If we or our third-party manufacturers are unable to produce sufficient quantities of the approved product for commercialization, either on a timely basis or at all, our commercialization efforts would be impaired, which would have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We face uncertainties and risks associated with the manufacture of our pipeline product candidates.&#160;Our product candidates are biologics and their manufacture involves complex processes, including the development of cell lines or cell systems to produce the biologic, with the challenge of significant variability. Further, there are difficulties in growing large quantities of such cells and harvesting and purifying the biologic produced by them. The cost to manufacture biologics is generally far higher than traditional small molecule chemical compounds, and the manufacturing process can be difficult to reproduce. There is no guarantee we will be successful in establishing a larger-scale commercial manufacturing process for our pipeline product candidates or obtaining the needed manufacturing capacity. Due to the high cost to manufacture, inherent uncertainty related to manufacturing costs, and uncertainty in our patient population, there is risk that some of our product candidates may not be commercially viable.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not currently have the infrastructure or capability to manufacture, market and sell therapeutic products on a commercial scale. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In order for us to commercialize our therapeutic products directly, we would need to develop, or obtain through outsourcing arrangements, the capability to manufacture, market and sell our products on a commercial scale. Currently, we do not have the ability nor the financial resources to establish the infrastructure and organizations needed to execute these functions, including such infrastructure needed for the commercialization of any product from our therapeutic program, which can be complex and costly. If we are unable to establish adequate manufacturing, sales, marketing and distribution capabilities, we will not be able to directly commercialize our therapeutics products, which would limit our future growth. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">If we are <font style="Background-color:#FFFFFF;">unable</font> to establish sales and marketing capabilities or enter into agreements with third parties to market and sell our product candidates, we may be unable to generate any revenue.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not currently have an organization for the sale, marketing and distribution of pharmaceutical products and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market any products that may be approved by the FDA and comparable foreign regulatory authorities, we must build our sales, marketing, managerial and other non-technical capabilities or make arrangements with third parties to perform these services. There are significant risks involved in building and managing a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, we may not be able to generate product revenues and may not become profitable. We will be competing with many companies that currently have extensive and well-funded sales and marketing operations. Without an internal commercial organization or the support of a third party to perform sales and marketing functions, we may be unable to compete successfully against these more established companies. If we are not successful in commercializing our current or future product candidates either on our own or through collaborations with one or more third parties, our future product revenue will suffer and we would incur significant additional losses.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">We will need <font style="Background-color:#FFFFFF;">to</font> grow the size of our organization, and we may experience difficulties in managing this growth.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a>As of February 15, 2018, we had 182 full-time employees. We need to grow the size of our organization in order to support our continued development and potential commercialization of our product candidates. In particular, we will need to add substantial numbers of additional personnel and other resources to support our development and potential commercialization of our product candidates. As our development and commercialization plans and strategies continue to develop, or as a result of any future acquisitions, our need for additional managerial, operational, manufacturing, sales, marketing, financial and other resources will </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">increase. Our ma</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nagement, personnel and systems currently in place may not be adequate to support this future growth. Future growth would impose significant added responsibilities on members of management, including:</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">managing our preclinical studies and clinical trials effectively;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">identifying, recruiting, maintaining, motivating and integrating additional employees;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">managing our internal development efforts effectively while complying with our contractual obligations to licensors, licensees, contractors and other third parties;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">improving our managerial, development, operational, information technology, and finance systems; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.67%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">expanding our facilities.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As our operations expand, we will also need to manage additional relationships with various strategic partners, suppliers and other third parties. Our future financial performance and our ability to commercialize our product candidates and to compete effectively will depend, in part, on our ability to manage any future growth effectively. To that end, we must be able to manage our development efforts and preclinical studies and clinical trials effectively and hire, train and integrate additional management, research and development, manufacturing, administrative and sales and marketing personnel. Our failure to accomplish any of these tasks could prevent us from successfully growing our company</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Industry </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If our competitors develop, acquire, or market technologies or products that are more effective than ours, this would reduce or eliminate our commercial opportunity. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Any products that we or our collaborators or strategic partners develop by using our ZFP technology platform will enter into highly competitive markets. Even if we are able to generate products that are safe and effective for their intended use, competing technologies may prove to be more effective or less expensive, which, to the extent these competing technologies achieve market acceptance, will limit our revenue opportunities. In some cases, competing technologies have proven to be effective and less expensive. Competing technologies may include other methods of regulating gene expression or modifying genes. ZFNs and ZFP TFs have broad application in the life sciences industry and compete with a broad array of new technologies and approaches being applied to genetic research by many companies. Competing proprietary technologies with our product development focus include but are not limited to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">For genome editing and gene therapy products: </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">recombinant proteins; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">other gene therapy/cDNAs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">antisense; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">siRNA and microRNA approaches, exon skipping; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">small molecule drugs; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">monoclonal antibodies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">CRISPR/Cas technology; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:9.07%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">TALE proteins, meganucleases, and MegaTALs. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">Our Non-Therapeutic Applications compete against similar technologies: </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to possessing competing technologies, our competitors include pharmaceutical and biotechnology companies with: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">substantially greater capital resources than ours; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">larger research and development staffs and facilities than ours;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">greater experience in product development and in obtaining regulatory approvals and patent protection. </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These organizations also compete with us to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attract qualified personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attract parties for acquisitions, joint ventures or other collaborations;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">license the proprietary technologies of academic and research institutions that are competitive with our technology, which may preclude us from pursuing similar opportunities. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accordingly, our competitors may succeed in obtaining patent protection or commercializing products before us. In addition, any products that we develop may compete with existing products or services that are well established in the marketplace. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our product candidates are based on a novel technology, which makes it difficult to predict the timing and costs of development and of subsequently obtaining regulatory approval.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have concentrated our research and development efforts on genome editing, gene therapy, gene regulation and cell therapy. The regulatory approval process for novel product candidates such as ours is unclear and may be lengthier and more expensive than the process for other, better-known or more extensively studied product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These regulatory review committees and advisory groups, and any new guidelines they promulgate, may lengthen the regulatory review process, require us to perform additional preclinical studies or clinical trials, increase our development costs, lead to changes in regulatory positions and interpretations, delay or prevent approval and commercialization of our current or future product candidates or lead to significant post-approval limitations or restrictions. As we advance our product candidates, we will be required to consult with these regulatory and advisory groups and comply with applicable guidelines. If we fail to do so, we may be required to delay or discontinue development of our product candidates. These additional processes may result in a review and approval process that is longer than we otherwise would have expected. Delay or failure to obtain, or unexpected costs in obtaining, the regulatory approval necessary to bring a potential product to market could decrease our ability to generate sufficient product revenue, and our business, financial condition, results of operations and prospects would be harmed. Even if our product candidates are approved, we expect that the FDA will require us to submit follow-up data regarding our clinical trial subjects for a number of years after approval. If this follow-up data shows negative long-term safety or efficacy outcomes for these patients, the FDA may revoke its approval or change the label of our products in a manner that could have an adverse impact on our business. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, adverse developments in clinical trials of gene therapy products conducted by others may cause the FDA or other oversight bodies to change the requirements for approval of our product candidates.&nbsp;&nbsp;FDA only recently approved the first vector-based gene therapy, LUCTURNA, and only two gene therapy products, uniQure N.V.&#8217;s Glybera and GlaxoSmithKline&#8217;s Strimvelis, have received marketing authorization from the EMA. As a result, it is difficult to determine how long it will take or how much it will cost to obtain regulatory approvals for our product candidates.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our gene therapy approach utilizes vectors derived from viruses, which may be perceived as unsafe or may result in unforeseen adverse events. Negative public opinion and increased regulatory scrutiny of gene therapy may damage public perception of the safety of our product candidates and adversely affect our ability to conduct our business or obtain regulatory approvals for our product <font style="color:#000000;">candidates</font>.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a>Gene therapy remains a novel technology, with only one vector-based gene therapy product approved for a genetic disease to date in the United States and only two gene therapy products for genetic diseases approved to date in the European Union. Public perception may be influenced by claims that gene therapy is unsafe, and gene therapy may not gain the acceptance of the public or the medical community. In particular, our success will depend upon physicians who specialize in the treatment of genetic diseases targeted by our product candidates, prescribing treatments that involve the use of our product candidates in lieu of, or in addition to, existing treatments with which they are familiar and for which greater clinical data may be available. More restrictive government regulations or negative public opinion would have an adverse effect on our business, financial condition, results of operations and prospects and may delay or impair the development and commercialization of our product candidates or demand for any products we may develop. For example, earlier gene therapy trials led to several well-publicized adverse events, including cases of leukemia and death seen in other trials using other vectors. Serious adverse events in our clinical trials, or other clinical trials involving gene therapy products or our competitors&#8217; products, even if not ultimately attributable to the relevant product candidates, and the resulting publicity, could result in increased government regulation, unfavorable public perception, potential regulatory delays in the testing or approval </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our product candidates, stricter labeling requirements for those product candidates that are approved and a d</font><font style="color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ecrease in demand for any such product candidates.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Laws or public sentiment may limit the production of genetically modified agricultural products, and these laws could reduce our partner&#8217;s ability to sell such products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Genetically modified products are currently subject to public debate and heightened regulatory scrutiny, either of which could prevent or delay production of agricultural products. We have exclusive right to use our ZFP technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants or plant cell cultures. The field-testing, production and marketing of genetically modified plants and plant products are subject to federal, state, local and foreign governmental regulation. Regulatory agencies administering existing or future regulations or legislation may not allow production and marketing of our genetically modified products in a timely manner or under technically or commercially feasible conditions. In addition, regulatory action or private litigation could result in expenses, delays or other impediments to our product development programs or the commercialization of resulting products. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The FDA currently applies the same regulatory standards to foods developed through genetic engineering as those applied to foods developed through traditional plant breeding. Genetically engineered food products, however, will be subject to pre-market review if these products raise safety questions or are deemed to be food additives. Governmental authorities could also, for social or other purposes, limit the use of genetically modified products created with our gene regulation technology. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Even if the regulatory approval for genetically modified products developed using our ZFP technology is obtained, our success will also depend on public acceptance of the use of genetically modified products including drugs, plants, and plant products. Claims that genetically modified products are unsafe for consumption or pose a danger to the environment may influence public attitudes. Our genetically modified products may not gain public acceptance. The subject of genetically modified organisms has received negative publicity in the United States and particularly in Europe, and such publicity has aroused public debate. The adverse publicity in Europe could lead to greater regulation and trade restrictions on imports of genetically altered products. Similar adverse public reaction or sentiment in the United States to genetic research and its resulting products could result in greater domestic regulation and could decrease the demand for our technology and products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Finances </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We have incurred significant operating losses since inception and anticipate that we will incur continued losses for the foreseeable future. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have generated operating losses since we began operations in 1995. Our net losses for the years ended December&#160;31, 2017, 2016 and 2015 were $54.6 million, $71.7 million and $40.7 million, respectively. The extent of our future losses and the timing of profitability are uncertain, and we expect to incur losses for the foreseeable future. We have been engaged in developing our ZFP technology since inception, which has and will continue to require significant research and development expenditures. To date, we have generated our funding from issuance of equity securities, revenues derived from collaboration agreements, other strategic partnerships in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. As of December 31, 2017, we had an accumulated deficit of $495.5 million. Since our initial public offering in 2000, we have generated an aggregate of approximately $418.6 million in gross proceeds from the sale of our equity securities. We expect to continue to incur additional operating losses for the next several years as we continue to advance our product candidates. If the time required to generate significant product revenues and achieve profitability is longer than we currently anticipate or if we are unable to generate liquidity through equity financing or other sources of funding, we may be forced to curtail or suspend our operations. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be unable to raise additional capital, which would harm our ability to develop our technology and products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>We have incurred significant operating losses and negative operating cash flows since inception and have not achieved profitability. We expect capital outlays and operating expenditures to increase over the next several years as we expand our infrastructure and research and product development activities. While we believe our financial resources will be adequate to sustain our current operations for at least the next twelve months, we will likely seek additional sources of capital through equity or debt financing. In addition, as we focus our efforts on proprietary human therapeutics, we will need to seek FDA approval of potential products, a process that could cost in excess of hundreds of millions of dollars per product. Furthermore, we may experience difficulties in accessing the capital market due to external factors beyond our control such as volatility in the equity markets for emerging biotechnology companies and general economic and market conditions both in the United States and abroad. We cannot be certain that we will be able to obtain financing on terms acceptable to us, or at all. Our failure to obtain adequate and timely funding will materially adversely affect our business and our ability to develop our technology and products candidates. Furthermore, any sales </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of additional equity securities may result in dilution to our stockholders and any debt financing may include business and financial covenants that restricts our operations. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.54%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We are at the development phase of operations and may not succeed or become profitable. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We began operations in 1995, are in the early phases of product development for the most advanced candidates in our therapeutics pipeline, and we have incurred significant losses since inception. To date, our revenues have been generated from collaboration agreements, other collaborations in non-therapeutic applications of our technology, federal government research grants and grants awarded by research foundations. Our focus on higher-value therapeutic product development and related collaboration requires us to incur substantial expenses associated with product development. In addition, the preclinical or clinical failure of any single product may have a significant effect on the actual or perceived value of our stock. Our business is subject to all of the risks inherent in the development of a new technology, which includes the need to: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">attract and retain qualified scientific and technical staff and management, particularly scientific staff with expertise to develop our early-stage technology into therapeutic products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">obtain sufficient capital to support the expense of developing our technology platform and developing, testing and commercializing products; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">develop a market for our products; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">successfully transition from a company with a research focus to a company capable of supporting commercial activities. </font></p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-right:2.59%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-right:2.59%;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">The recently passed comprehensive tax reform bill could adversely affect our business and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, President Trump signed into law new legislation that significantly revises the Internal Revenue Code of 1986, as amended (the Code). The newly enacted federal income tax law, among other things, contains significant changes to corporate taxation, including adoption of a flat 21% corporate tax rate, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80% of current year taxable income and elimination of carrybacks of such net operating losses, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations, immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits (including reducing the business tax credit for certain clinical testing expenses incurred in the testing of certain drugs for rare diseases or conditions generally referred to as &#8220;orphan drugs&#8221;). Notwithstanding the reduction in the corporate income tax rate, the overall impact of the new federal tax law is uncertain, and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the newly enacted federal tax law. The impact of this tax reform on holders of our common stock is also uncertain and could be adverse. Investors should consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Relationships with Collaborators and Strategic Partners </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If conflicts arise between us and our collaborators or strategic partners, these parties may act in their self-interest, which may limit our ability to implement our strategies. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If conflicts arise between our corporate or academic collaborators or strategic partners and us, the other party may act in its self-interest, which may limit our ability to implement our strategies. Some of our academic collaborators and strategic partners are conducting multiple product development efforts within each area that is the subject of the collaboration with us. Our collaborators or strategic partners may develop, either alone or with others, products in related fields that are competitive with the products or potential products that are the subject of these collaborations. Competing products, either developed by the collaborators or strategic partners or to which the collaborators or strategic partners have rights, may result in the withdrawal of partner support for our product candidates. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Some of our collaborators or strategic partners could also become our competitors in the future. Our collaborators or strategic partners could develop or invest in competing products, preclude us from entering into collaborations with their competitors, fail to obtain timely regulatory approvals, terminate their agreements with us prematurely, or fail to devote sufficient resources to the development and commercialization of products. Any of these developments could harm our product development efforts. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our collaborators and strategic partners may control aspects of our clinical trials, which could result in delays and other obstacles in the commercialization of our proposed products. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We depend on third-party collaborators and strategic partners to design and conduct our clinical trials for some of our therapeutic programs. As a result, we may not be able to conduct these programs in the manner or on the time schedule we currently contemplate, which may negatively impact our business operations. In addition, if any of these collaborators or strategic partners withdraws support for our programs or proposed products or otherwise impair their development; our business could be negatively affected. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, under our agreements with Kite, Pfizer and Bioverativ, they have control and broad discretion over all or certain aspects of the clinical development and commercialization of any product developed under the agreement, and we will have little, if any, influence on how these programs will be conducted. Our lack of control over the clinical development in such agreements could cause delays or other difficulties in the development and commercialization of our product candidates, which may prevent us from completing the intended IND filings in a timely fashion and receiving any milestone, royalty payments and other benefits under the agreement. In addition, under their respective agreements, our third-party collaborators have certain rights to terminate the agreements by providing us with advance notices, therefore, the actual milestone payments that we may receive under these agreements may be lower than the full amounts stated above. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our collaborators or strategic partners may decide to adopt alternative technologies or may be unable to develop commercially viable products with our technology, which would negatively impact our revenues and our strategy to develop these products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborators or strategic partners may adopt alternative technologies, which could decrease the marketability of ZFP&#160;technology. Additionally, because many of our collaborators or strategic partners are likely to be working on more than one development project, they could choose to shift their resources to projects other than those they are working on with us. If they do so, this would delay our ability to test our technology and would delay or terminate the development of potential products based on our ZFP technology. Further, our collaborators and strategic partners may elect not to develop products arising out of our collaborative and strategic partnering arrangements or to devote sufficient resources to the development, manufacturing, marketing or sale of these products. If they terminate the collaborative relationship with us, we will be required to seek the support of other partners or collaborators. We may not have sufficient resources and expertise to develop these programs by ourselves, and we may not be able to identify a suitable partner or negotiate a favorable collaboration agreement to allow us to continue the development of these programs. If any of these events occur, we may not be able to develop our technologies or commercialize our products. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If the licensed products under our non-therapeutic license agreements are not successfully commercialized, or our third-party licensees terminate our agreements, our ability to generate revenue under these license agreements may be limited. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have a number of collaboration agreements with third parties whereby we licensed our ZFP technologies to develop products in non- therapeutic fields, such as laboratory research reagents, protein pharmaceuticals, and, transgenic animals, as well as plant agriculture </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We cannot be certain that we or our collaboration partners will succeed in the development of commercially viable products in these non-therapeutic fields of use, and there is no guarantee that we or our collaboration partners will achieve the milestones set forth in the respective license agreements. To the extent we or our collaboration partners do not succeed in developing and commercializing products or if we or our collaboration partners fail to achieve such milestones, our revenues and benefits under the license agreements will be limited. In the event our third party licensees decide to terminate the license agreements, our ability to generate revenue under such license agreements will cease. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our collaborations with outside scientists may be subject to change, which could limit our access to their expertise. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We work with scientific advisors and collaborators at academic research institutions. These scientists are not our employees and may have other commitments that would limit their availability to us. Although our scientific advisors generally agree not to do competing work, if a conflict of interest between their work for us and their work for another entity arises, we may lose their services. Although our scientific advisors and academic collaborators sign agreements not to disclose our confidential information, it is possible that some of our valuable proprietary knowledge may become publicly known through them, which may cause competitive harm to our business. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Intellectual Property</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Because it is difficult and costly to protect our proprietary rights, and third parties may have filed patent applications that are similar to ours, we cannot guarantee the proprietary protection of our technologies and products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success will depend in part on obtaining patent protection of our technology and successfully defending any of our patents that may be challenged. The patent positions of pharmaceutical and biotechnology companies can be highly uncertain and can involve complex legal and factual questions. No consistent policy regarding the breadth of claims allowed in biotechnology patents has emerged to date. Accordingly, we cannot predict the breadth of claims allowed in patents we own or license that a third party may receive. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As disclosed herein, we are a party to various license agreements that give us rights under specified patents and patent applications. Our current licenses, as our future licenses frequently will, contain performance obligations. If we fail to meet those obligations, the licenses could be terminated. If we are unable to continue to license these technologies on commercially reasonable terms, or at all, we may be forced to delay or terminate aspects of our product development and research activities. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With respect to our present and any future sublicenses, because our rights derive from those granted to our sublicensor, we are subject to the risk that our sublicensor may fail to perform its obligations under the master&#160;license or fail to inform us of useful improvements in, or additions to, the underlying intellectual property owned by the original licensor. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are unable to exercise the same degree of control over intellectual property that we license from third parties as we exercise over our internally developed intellectual property. We do not control the prosecution of certain of the patent applications that we license from third parties; therefore, the patent applications may not be prosecuted as we desire or in a timely manner. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The degree of future protection for our proprietary rights is uncertain, and we cannot ensure that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we or our licensors were the first to make the inventions covered by each of our pending patent applications; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we or our licensors were the first to file patent applications for these inventions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the patents of others will not have an adverse effect on our ability to do business; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">others will not independently develop similar or alternative technologies or reverse engineer any of our products, processes or technologies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any of our pending patent applications will result in issued patents; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any patents issued or licensed to us or our collaborators or strategic partners will provide a basis for commercially viable products or will provide us with any competitive advantages; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any patents issued or licensed to us will not be challenged and invalidated by third parties;&#160;or </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">we will develop additional products, processes or technologies that are patentable. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Others have filed and in the future are likely to file patent applications that are similar to ours. We are aware that there are academic groups and other companies that are attempting to develop technology that is based on the use of zinc finger, TALE, CRISPR/Cas and other DNA-binding proteins, and that these groups and companies have filed patent applications. Several patents have been issued, although we have no current plans to use the associated inventions. If these or other patents issue, it is possible that the holder of any patent or patents granted on these applications may bring an infringement action against our collaborators, strategic partners, or us claiming damages and seeking to enjoin commercial activities relating to the affected products and processes. The costs of litigating the claim could be substantial. Moreover, we cannot predict whether we, our collaborators, or strategic partners would prevail in any actions. In addition, if the relevant patent claims were upheld as valid and enforceable and our products or processes were found to infringe the patent or patents, we or our collaborators could be prevented from making, using, or selling the relevant product or process unless we or our collaborators could obtain a license or were able to design around the patent claims. We can give no assurance that such a license would be available to us and our collaborators on commercially reasonable terms, or at all, or that we would be able to successfully design around the relevant patent claims. There may be significant litigation in the genomics industry regarding patent and other intellectual property rights, which could subject us to litigation. If we become involved in litigation, it could consume a substantial portion of our managerial and financial resources. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>We rely on trade secrets to protect technology where we believe patent protection is not appropriate or obtainable. Trade secrets, however, are difficult to protect. While we require employees, academic collaborators and consultants to enter into confidentiality </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">agreements, we may not be able to adequately protect our trade secrets or</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> other proprietary information or enforce these confidentiality agreements. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our collaborators, strategic partners, and scientific advisors have rights to publish data and information in which we may have rights. If we cannot maintain the confidentiality of our technology and other confidential information in connection with our collaborations and strategic partnerships, then we may not be able to receive patent protection or protect our proprietary information.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we are unable to obtain or protect intellectual property rights related to our product candidates, we may not be able to compete <font style="color:#000000;">effectively</font> in our markets.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our product candidates. The strength of patents in the biotechnology and pharmaceutical field involves complex legal and scientific questions and can be uncertain. The patent applications that we own or in-license may fail to result in issued patents with claims that cover our product candidates in the United States or in other foreign countries. There is no assurance that all of the potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue and even if such patents cover our product candidates, third parties may challenge their validity, enforceability or scope, which may result in such patents being narrowed or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our product candidates or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the patent applications we hold or have in-licensed with respect to our programs or product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for our product candidates, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize, future products. Several patent applications covering our product candidates have been filed recently. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product candidate under patent protection could be reduced. Since patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we were the first to file any patent application related to a product candidate. Furthermore, if third parties have filed such patent applications, an interference proceeding in the United States can be initiated by a third party to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. In addition, patents have a limited lifespan. In the United States, the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available however the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from generic medications.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors and any third parties who have access to our proprietary know-how, information or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret. In addition, others may independently discover our trade secrets and proprietary information. For example, the FDA, as part of its Transparency Initiative, is currently considering whether to make additional information publicly available on a routine basis, including information that we may consider to be trade secrets or other proprietary information, and it is not clear at the present time how the FDA<font style="color:#000000;">&#8217;</font>s disclosure policies may change in the future, if at all.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Further, the laws of some foreign countries do not protect proprietary rights to the same extent or in th</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e same manner as the laws of the United States. As a result, we may encounter significant problems in protecting and defending our intellectual property both in the United States and abroad. If we are unable to prevent material disclosure of the non-patent</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ed intellectual property related to our technologies to third parties, and there is no guarantee that we will have any such enforceable trade secret protection, we may not be able to establish or maintain a competitive advantage in our market, which could </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">materially adversely affect our business, results of operations and financial condition.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third-<font style="color:#000000;">party</font> claims of intellectual property infringement may prevent or delay our development and commercialization efforts.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There is a substantial amount of litigation, both within and outside the United States, involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, <font style="font-style:italic;color:#000000;">ex part</font>e reexaminations, post-grant review, and <font style="font-style:italic;color:#000000;">inter partes</font> review proceedings before the U.S. Patent and Trademark Office, or U.S. PTO, and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are pursuing development candidates. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the patent rights of third parties.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover the manufacturing process of any of our product candidates, any molecules formed during the manufacturing process or any final product itself, the holders of any such patents may be able to block our ability to commercialize such product candidate unless we obtained a license under the applicable patents, or until such patents expire. Similarly, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our formulations, processes for manufacture or methods of use, including combination therapy, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires. In either case, such a license may not be available on commercially reasonable terms or at all.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our product candidates. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys<font style="color:#000000;">&#8217;</font> fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may not be successful in obtaining or maintaining necessary rights to gene therapy product components and processes for our <font style="color:#000000;">development</font> pipeline through acquisitions and in-licenses.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Presently we have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our gene therapy product candidates. Because our programs may involve additional product candidates that may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license or use these proprietary rights. In addition, our product candidates may require specific formulations to work effectively and efficiently and these rights may be held by others. We may be unable to acquire or in-license any compositions, methods of use, processes or other third-party intellectual property rights from third parties that we identify. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources and greater clinical development and commercialization capabilities.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For example, we sometimes collaborate with U.S. and foreign academic institutions to accelerate our preclinical research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution<font style="color:#000000;">&#8217;</font>s rights in technology resulting from the collaboration. Regardless of such right of first negotiation for intellectual property, we may be unable to negotiate a license within the specified time frame or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a>In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment. If we are unable to successfully obtain rights to required third-party intellectual property rights, ou</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r business, financial condition and prospects for growth could suffer.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our licensors, we could lose license rights that are important to our business.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a party to a number of intellectual property license agreements that are important to our business and expect to enter into additional license agreements in the future. Our existing license agreements impose, and we expect that future license agreements will impose, various diligence, milestone, royalty and other obligations on us. If we fail to comply with our obligations under these agreements, or we are subject to a bankruptcy, the licensor may have the right to terminate the license, in which event we would not be able to market products covered by the license. </p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may need to obtain licenses from third parties to advance our research or allow commercialization of our product candidates, and we have done so from time to time. We may fail to obtain any of these licenses at a reasonable cost or on reasonable terms, if at all. In that event, we may be required to expend significant time and resources to develop or license replacement technology. If we are unable to do so, we may be unable to develop or commercialize the affected product candidates, which could harm our business significantly. We cannot provide any assurances that third-party patents do not exist that might be enforced against our current product candidates or future products, resulting in either an injunction prohibiting our sales, or, with respect to our sales, an obligation on our part to pay royalties and/or other forms of compensation to third parties.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In many cases, patent prosecution of our licensed technology is controlled solely by the licensor. If our licensors fail to obtain and maintain patent or other protection for the proprietary intellectual property we license from them, we could lose our rights to the intellectual property or our exclusivity with respect to those rights, and our competitors could market competing products using the intellectual property. In certain cases, we control the prosecution of patents resulting from licensed technology. In the event we breach any of our obligations related to such prosecution, we may incur significant liability to our licensing partners. Licensing of intellectual property is of critical importance to our business and involves complex legal, business and scientific issues and is complicated by the rapid pace of scientific discovery in our industry. Disputes may arise regarding intellectual property subject to a licensing agreement, including: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the scope of rights granted under the license agreement and other interpretation-related issues; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the licensing agreement; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the sublicensing of patent and other rights under our collaborative development relationships; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">our diligence obligations under the license agreement and what activities satisfy those diligence obligations; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the ownership of inventions and know-how resulting from the joint creation or use of intellectual property by our licensors and us and our partners; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the priority of invention of patented technology. </font></p></td></tr></table></div>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time-consuming and unsuccessful.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Competitors may infringe our patents or the patents of our licensors. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive and time-consuming. In addition, in an infringement proceeding, a court may decide that a patent of ours or our licensors is not valid, is unenforceable and/or is not infringed, or may refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation or defense proceedings could put one or more of our patents at risk of being invalidated or interpreted narrowly and could put our patent applications at risk of not issuing.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interference proceedings provoked by third parties or brought by us may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. We may not be able to prevent, alone or with our licensors, misappropriation of our intellectual property rights, particularly in countries where the laws may not protect those rights as fully as in the United States.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during thi</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse eff</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ect on the price of our common stock.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the <font style="color:#000000;">enforcement</font> or defense of our issued patents.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to U.S. patent law, including provisions that affect the way patent applications will be prosecuted and may also affect patent litigation. The U.S. PTO is currently developing regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first to file provisions, were enacted March 16, 2013. However, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed <font style="color:#000000;">confidential</font> information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee<font style="color:#000000;">&#8217;</font>s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We may also be subject to claims that former employees, collaborators or other third parties have an ownership interest in our patents or other intellectual property. Litigation may be necessary to defend against these and other claims challenging inventorship or ownership. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment <font style="color:#000000;">and</font> other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the U.S. PTO and various governmental patent agencies outside of the United States in several stages over the lifetime of the patents and/or applications. We have systems in place to remind us to pay these fees, and we employ an outside firm and rely on our outside counsel to pay these fees due to non-U.S. patent agencies. The U.S. PTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Issued<font style="color:#000000;"> patents covering our product candidates could be found invalid or unenforceable if challenged in court.</font></p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>If we or one of our licensing partners initiated legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid and/or unenforceable. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<hr style="page-break-after:always;width:100%;">
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a vali</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dity challenge could be an alleged failure to meet any of several statutory requirements, including patent eligible subject matter, lack of novelty, obviousness or non-enablement. Grounds for an unenforceability assertion could be an allegation that someon</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e connected with prosecution of the patent withheld relevant information from the U.S. PTO, or made a misleading statement, during prosecution. Third parties may also raise similar claims before administrative bodies in the United States or abroad, even ou</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tside the context of litigation. Such mechanisms include re-examination, post grant review, and equivalent proceedings in foreign jurisdictions (e.g., opposition proceedings). Such proceedings could result in revocation or amendment to our patents in such </font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. With respect to the validity question, for example, we cannot be certain that there is no invalidating prior</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> art, of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity and/or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product cand</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">idates. Such a loss of patent protection would have a material adverse impact on our business.</font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Changes <font style="color:#000000;">in</font> U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As is the case with other biotechnology companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involve both technological and legal complexity, and is therefore obtaining and enforcing biotechnology patents is costly, time-consuming and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by the U.S. Congress, the federal courts, and the U.S. PTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may <font style="color:#000000;">not</font> be able to protect our intellectual property rights throughout the world.</p>
<p style="Background-color:#FFFFFF;margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Filing, prosecuting and defending patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Business Operations<font style="font-weight:normal;"> </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If we use biological and hazardous materials in a manner that causes injury or violates laws, we may be liable for damages. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a>Our research and development activities involve the controlled use of potentially harmful biological materials as well as hazardous materials, chemicals, and various radioactive compounds typically employed in molecular and cellular biology. We routinely use cells in culture and gene delivery vectors, and we employ small amounts of radioisotopes in trace experiments. Although we maintain up-to-date licensing and training programs, we cannot completely eliminate the risk of accidental contamination or injury from the use, storage, handling, or disposal of these materials. In the event of contamination or injury, we could be held liable for </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">damages that result, and any liability could exceed our resources. We currently carry insurance covering certain claims arising from our use of these materials. However, if we are unable to main</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tain our insurance coverage at a reasonable cost and with adequate coverage, our insurance may not cover any liability that may arise. We are subject to federal, state, and local laws and regulations governing the use, storage, handling, and disposal of th</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ese materials and specified waste products. </font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Failure to attract, retain, and motivate skilled personnel and cultivate key academic collaborations will delay our product development programs and our research and development efforts. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our success depends on our continued ability to attract, retain, and motivate highly qualified management and scientific personnel and our ability to develop and maintain important relationships with leading research and academic institutions and scientists. Competition for skilled and qualified personnel and academic and other research collaborations is intense. If we lose the services of personnel with the necessary skills, including the members of our senior management team, it could significantly impede the achievement of our research and development objectives. If we fail to negotiate additional acceptable collaborations with academic and other research institutions and scientists, or if our existing collaborations are unsuccessful, our development programs may be delayed or may not succeed. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Third parties on which we rely and we may be adversely affected by natural disasters and our business continuity and disaster <font style="color:#000000;">recovery</font> plans may not adequately protect us from a serious disaster.</p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:3.33%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Natural disasters could severely disrupt our operations and have a material adverse effect on our business, financial condition, results of operations and prospects. If a natural disaster, power outage or other event occurred that prevented us from using all or a significant portion of our headquarters, that damaged critical infrastructure or that otherwise disrupted operations, it may be difficult or, in certain cases, impossible for us to continue our business for a substantial period of time. The disaster recovery and business continuity plans we have in place currently are limited and may not prove adequate in the event of a serious disaster or similar event. We may incur substantial expenses as a result of the limited nature of our disaster recovery and business continuity plans, which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our internal computer systems, or those of our collaborators or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our internal computer systems and those of our current and any future collaborators and other contractors or consultants are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be harmed and the further development and commercialization of our product candidates could be delayed.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Risks Relating to our Common Stock and Corporate Organization </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our stock price has been volatile and may continue to be volatile, which could result in substantial losses for investors. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our stock price has been volatile and may continue to be volatile, which could cause stockholders to incur substantial losses. An active public market for our common stock may not be sustained, and the market price of our common stock may continue to be highly volatile. The market price of our common stock has fluctuated significantly in response to various factors, some of which are beyond our control, including but not limited to the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcements by us or collaborators providing updates on the progress or development status of product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">data from clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">initiation or termination of clinical trials; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes in market valuations of similar companies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">overall market and economic conditions, including the equity markets for emerging biotechnology companies; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">deviations in our results of operations from the guidance given by us; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">announcements by us or our competitors of new or enha</font><font style="font-family:Times New Roman;">nced products, technologies or services or significant contracts, acquisitions, strategic relationships, joint ventures or capital commitments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">announcement of changes in business and operations by our collaborators and partners, or changes in our existing collaboration agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">regulatory developments; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">changes, by one or more of our security analysts, in recommendations, ratings or coverage of our stock. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">additions or departures of key personnel; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">future sales of our common stock or other securities by us, management or directors, liquidation of institutional funds that comprised large holdings of our stock; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">decreases in our cash balances.</font></p></td></tr></table></div>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Actual or potential sales of our common stock by our employees, including our executive officers, pursuant to pre-arranged stock <font style="color:#000000;">trading</font> plans could cause our stock price to fall or prevent it from increasing for numerous reasons, and actual or potential sales by such persons could be viewed negatively by other investors.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In accordance with the guidelines specified under Rule 10b5-1 of the Securities Exchange Act of 1934, as amended, and our policies regarding stock transactions, a number of our employees, including executive officers and members of our board of directors, have adopted and may continue to adopt stock trading plans pursuant to which they have arranged to sell shares of our common stock from time to time in the future. Generally, sales under such plans by our executive officers and directors require public filings. Actual or potential sales of our common stock by such persons could cause the price of our common stock to fall or prevent it from increasing for numerous reasons.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Future sales and issuances of our common stock or rights to purchase common stock, including pursuant to our equity incentive plans, could result in additional dilution of the percentage ownership of our stockholders and could cause our stock price to fall.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.53%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional capital will be needed in the future to continue our planned operations. To the extent we raise additional capital by issuing equity securities, our stockholders may experience substantial dilution. We may sell common stock, convertible securities or other equity securities in one or more transactions at prices and in a manner we determine from time to time. If we sell common stock, convertible securities or other equity securities in more than one transaction, investors may be materially diluted by subsequent sales. These sales may also result in material dilution to our existing stockholders, and new investors could gain rights superior to our existing stockholders.</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our stock price is also influenced by public perception of gene therapy and government regulation of potential products. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reports of serious adverse events in a retroviral gene transfer trial for infants with X-linked severe combined immunodeficiency (X-linked SCID) in France and subsequent FDA actions putting related trials on hold in the United States had a significant negative impact on the public perception and stock price of certain companies involved in gene therapy. Stock prices of these companies declined whether or not the specific company was involved with retroviral gene transfer for the treatment of infants with X-linked SCID, or whether the specific company&#8217;s clinical trials were placed on hold in connection with these events. Other potential adverse events in the field of gene therapy may occur in the future that could result in greater governmental regulation of our potential products and potential regulatory delays relating to the testing or approval of our potential products. These external events may have a negative impact on public perception of our business, which could cause our stock price to decline. </p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:4.53%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We may be subject to claims for rescission and may be subject to other penalties for shares sold under the ATM Agreement.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>We are a party to an Amended and Restated At-the-Market Offering Program Sales Agreement, or the ATM Agreement, pursuant to which we may sell, from time to time, an aggregate of $75 million of our common stock through the investment bank acting as our sales agent under the ATM Agreement.&nbsp;&nbsp;The shares under the original At-the-Market Offering Program Sales Agreement entered into with the sales agent in December 2016 were initially to be sold pursuant to a shelf registration statement on Form S-3 that initially became effective in February 2014, or the prior registration statement.&nbsp;&nbsp;In March 2017, we sold an aggregate of $3.8 million of our common stock, and received net proceeds of $3.4 million, under the ATM Agreement at an average price per share of $4.39, and at the times of those sales, we believed that the prior registration statement was then effective. However, subsequent to those sales, we were advised that the prior registration statement had in fact expired prior to the time of the sales in March 2017 ATM sales. Because our registration statement had in fact expired prior to the time of such sales, we may be deemed to have violated Section 5 of </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:6pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Securities Act, which requires registration of public offerings of se</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">curities. Consequently, we may be subject to claims for rescission by purchasers who purchased shares of our common stock under the ATM Agreement in March 2017.&nbsp;&nbsp;Under Section 12(a)(1) of the Securities Act, a purchaser of security in a transaction made in</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> violation of Section 5 of the Securities Act may obtain recovery of the consideration paid in connection with its purchase, plus statutory interest, or, if it had already sold the shares, recover damages resulting from its purchase. While we believe it is</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> unlikely that a successful claim will be asserted against us by any purchasers who purchased shares of our common stock under the ATM Agreement in March 2017, we cannot guarantee that no such legal claims will be asserted against us by any purchasers. In </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">addition, we could become subject to enforcement actions and/or penalties and fines by federal authorities, and we are unable to predict the likelihood of any such enforcement actions being brought against us, or the amount of any such potential penalties </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or fines.</font></p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The trading market for our common stock will depend in part on the research and reports that securities or industry analysts publish about us or our business. In the event securities or industry analysts who cover us downgrade our stock or publish inaccurate or unfavorable research about our business, our stock price would likely decline. If one or more of these analysts cease coverage of our company or fail to publish reports on us regularly, demand for our stock could decrease, which might cause our stock price and trading volume to decline.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;color:#000000;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Anti-takeover provisions in our certificate of incorporation and Delaware law could make an acquisition of our company more difficult and could prevent attempts by our stockholders to remove or replace current management. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Anti-takeover provisions of Delaware law and in our certificate of incorporation and our bylaws may discourage, delay or prevent a change in control of our company, even if a change in control would be beneficial to our stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. In particular, under our certificate of incorporation our board of directors may issue up to 5,000,000&#160;shares of preferred stock with rights and privileges that might be senior to our common stock, without the consent of the holders of the common stock. Moreover, without any further vote or action on the part of the stockholders, the board of directors would have the authority to determine the price, rights, preferences, privileges, and restrictions of the preferred stock. This preferred stock, if it is ever issued, may have preference over, and harm the rights of, the holders of common stock. Although the issuance of this preferred stock would provide us with flexibility in connection with possible acquisitions and other corporate purposes, this issuance may make it more difficult for a third party to acquire a majority of our outstanding voting stock. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Similarly, our authorized but unissued common stock is available for future issuance without stockholder approval. Our certificate of incorporation further provides that stockholders may not take action by written consent. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In addition, our amended and restated bylaws, as amended: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">establish advance notice requirements for nominations for election to the board of directors or proposing matters that can be acted upon at stockholders&#8217; meetings;&#160;and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">prohibit stockholders from calling a special meeting of stockholders. </font></p></td></tr></table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are also subject to Section&#160;203 of the Delaware General Corporation Law, which provides, subject to certain exceptions, that if a person acquires 15% of our voting stock, the person is an &#8220;interested stockholder&#8221; and may not engage in &#8220;business combinations&#8221; with us for a period of three years from the time the person acquired 15% or more or our voting stock.&nbsp;&nbsp;The application of Section 203 may, in some circumstances, deter or prevent a change in control of our company even when such change may be beneficial to our stockholders.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Our amended and restated bylaws, as amended, provide that the Court of Chancery of the State of Delaware will be the </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">exclusive forum for the adjudication of certain disputes, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum </font><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">for disputes with us or our directors, officers, or employees. </font></p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our amended and restated bylaws, as amended, provide that the Court of Chancery of the State of Delaware is the sole and exclusive forum for:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any derivative action or proceeding brought on our behalf;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim of breach of a fiduciary duty owed by any director, officer or other employee of Sangamo to us or our stockholders;</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim arising pursuant to any provision of the General Corporation Law of the State of Delaware,; and</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.87%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:3.33%;white-space:nowrap">
<p style="margin-top:6pt;margin-bottom:0pt;font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:'Times New Roman';letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-top:6pt;margin-bottom:0pt;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">any action asserting a claim governed by the internal affairs doctrine.</font></p></td></tr></table></div>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;letter-spacing:-0.1pt;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision further provides that any person or entity that acquires any interest in shares of our capital stock will be deemed to have notice of and consented to the provisions of such provision.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;letter-spacing:-0.1pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers, or other employees, which may discourage lawsuits against us and our directors, officers, and other employees. If a court were to find this provision to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving the dispute in other jurisdictions, which could seriously harm our business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Unresolved_Staff_Comments"></a><a name="Unresolved_Staff_Comments"></a>ITEM&#160;1B &#8211; UNRESOLVED STAFF COMMENTS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. <font style="margin-left:70pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Properties"></a><a name="Properties"></a>ITEM&#160;2 &#8211; PROPERTIES </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our corporate headquarters occupies approximately 45,600&#160;square feet of research and office space located in Richmond, California, subject to leases that expire beginning in August 2019 through July 2021. We also have a build-to-suit lease located in Richmond, California to occupy approximately 41,400 square feet of space that expires in December 2021.&nbsp;&nbsp;We also have a build-to-suit lease located in Brisbane, California to occupy approximately 87,700 square feet of space that expires in May 2029 which we plan to use for our new corporate headquarters by the end of 2018<font style="font-size:9pt;">.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Legal_Proceedings"></a><a name="Legal_Proceedings"></a>ITEM&#160;3 &#8211; LEGAL PROCEEDINGS<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are not a party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Mine_Safety_Disclosures"></a><a name="Mine_Safety_Disclosures"></a>ITEM&#160;4 &#8211; MINE SAFETY DISCLOSURES<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Not Applicable. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_II"></a><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PART&#160;II</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Market_for_the_Registrant_Common_Equit"></a><a name="Market_for_the_Registrant_Common_Equit"></a>ITEM&#160;5 &#8211; MARKET FOR THE REGISTRANT&#8217;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our common stock has traded on the Nasdaq Stock Market under the symbol &#8220;SGMO&#8221; since our initial public offering on April&#160;6, 2000. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The high and low closing prices of our common stock for each quarterly period during the last two fiscal years as reported by the Nasdaq Global Select Market were as follows: </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">High</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Low</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.60</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.00</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.40</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.35</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.05</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.10</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Year ended December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fourth Quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.74</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Third Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.84</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Second Quarter</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.50</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">First Quarter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.95</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Holders </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of February&#160;15, 2018, there were 57 holders of record of our common stock. This number does not include &#8220;street name&#8221; or beneficial holders, whose shares are held of record by banks, brokers, financial institutions and other nominees. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Dividends </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have not paid dividends on our common stock, and currently do not plan to pay any cash dividends in the foreseeable future. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stock Performance Graph </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121532351331435.jpg" title="" alt="" style="width:708px;height:588px;"></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The above Stock Performance Graph and related information shall not be deemed &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, nor shall such information be incorporated by reference into any future filing under the Securities Act of 1933 or Securities Exchange Act of 1934, each as amended, except to the extent that the Company specifically incorporates it by reference into such filing. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><a name="Selected_Financial_Data"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Selected_Financial_Data"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM 6 &#8211; SELECTED FINANCIAL DATA </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following Selected Financial Data should be read in conjunction with &#8220;Item&#160;7&#8212;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; and &#8220;Item&#160;8&#8212;Financial Statements and Supplementary Data&#8221; included elsewhere in this Annual Report on Form&#160;10-K. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Selected Financial Data </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except per share data)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Statement of Operations Data:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,567</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,389</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,539</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45,870</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,133</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,728</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,618</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,198</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,039</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,200</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,330</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,197</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,677</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,800</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,928</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,948</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,395</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72,651</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50,839</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,361</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,559</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,856</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,781</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,706</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other income/(expense)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,793</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,417</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,624</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.02</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.39</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.48</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in computing basic and diluted net loss</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; per share</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,084</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,553</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,757</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,022</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55,974</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">As of December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2014</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2013</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Balance Sheet Data:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash, cash equivalents, marketable securities, and interest</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; receivable</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">244,560</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">142,759</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">209,307</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">226,645</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">131,814</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Working capital</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,538</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,289</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,485</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169,997</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,143</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,741</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,891</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">217,235</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,212</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140,838</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(495,479</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(440,911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(369,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(328,550</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(302,133</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,900</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,195</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,439</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,633</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.68%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121,710</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><a name="Management_Discussion_and_Analysis_of"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Management_Discussion_and_Analysis_of"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM&#160;7 &#8211; MANAGEMENT&#8217;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The discussion in &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; contains trend analysis, estimates and other forward-looking statements within the meaning of Section&#160;27A of the Securities Act of 1933, as amended, and Section&#160;21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements include, without limitation, statements containing the words &#8220;believes,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;continue,&#8221; and other words of similar import or the negative of those terms or expressions. Such forward-looking statements are subject to known and unknown risks, uncertainties, estimates and other factors that may cause the actual results, performance or achievements of the Company, or industry results, to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Actual results could differ materially from those set forth in such forward-looking statements as a result of, but not limited to, the &#8220;Risk Factors&#8221; described in Part&#160;I, Item&#160;1A. You should read the following discussion and analysis along with the &#8220;Selected Financial Data&#8221; and the financial statements and notes attached to those statements included elsewhere in this report. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a clinical stage biotechnology company focused on translating ground-breaking science into genomic therapies that transform patients&#8217; lives using our industry-leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are a leader in the research and development of zinc finger proteins, or ZFPs, a naturally occurring class of proteins found in humans. We have used our knowledge and expertise to develop a proprietary technology platform in both genome editing and gene regulation. ZFPs can be engineered to make zinc finger nucleases, or ZFNs, proteins that can be used to specifically modify DNA sequences by adding or knocking out specific genes, or genome editing, and ZFP transcription factors or ZFP TFs, proteins that can be used to increase or decrease gene expression, or gene regulation. In the process of developing this platform, we have accrued significant scientific, manufacturing and regulatory capabilities and know-how that are generally applicable in the broader field of gene therapy and have capitalized this knowledge into a conventional gene therapy platform based on adeno-associated viral vector, or AAV, cDNA gene transfer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our strategy is to maximize the value and therapeutic use of our technology platforms. In certain therapeutic areas we intend to capture the value of our proprietary genome editing and gene therapy products by forward integrating into manufacturing, development and commercial operations. In other therapeutic areas we intend to partner with biopharmaceutical companies to develop products.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We are focused on the development of human therapeutics for diverse diseases with well-characterized genetic causes. We have several proprietary clinical and preclinical product candidates in development and have strategically partnered certain programs with biopharmaceutical companies to obtain funding for our own programs and to expedite clinical and commercial development. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have an ongoing Phase 1/2 clinical trial evaluating SB-525, a gene therapy for the treatment of hemophilia A, a blood disorder. We have ongoing Phase 1/2 clinical trials evaluating three product candidates using our&#160;proprietary <font style="font-style:italic;">in vivo</font>&#160;genome editing approach: SB-FIX, for the treatment of hemophilia B, a blood disorder, SB-318, for the treatment of Mucopolysaccharidosis Type I, or MPS I, and SB-913 for the treatment of Mucopolysaccharidosis Type II, or MPS II.&nbsp;&nbsp;MPS I and MPS II are rare lysosomal storage disorders, or LSDs.&#160;We are also initiating a Phase 1/2 clinical trial evaluating ST-400, developed using our proprietary ZFN-mediated <font style="font-style:italic;">ex vivo</font> cell therapy platform, for the&#160;treatment of beta-thalassemia, a blood disorder. In addition, we have proprietary preclinical and discovery stage programs in other LSDs and monogenic diseases, including certain central nervous system disorders, cancer immunotherapy, immunology and infectious disease.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, we entered into a global collaboration and license agreement with Kite Pharma, Inc., or Kite, a wholly-owned subsidiary of Gilead Sciences, Inc., or Gilead, for the research, development and commercialization of potential engineered cell therapies for cancer. In this collaboration, we will work together with Kite on a research program under which we will design ZFNs and AAVs to disrupt and insert certain genes in T cells and natural killer, or NK, cells, including the insertion of genes that encode chimeric antigen receptors, or CARs, T-cell receptors, or TCRs and NK-cell receptors, or NKRs, directed to mutually agreed targets. Kite will be responsible for all clinical development and commercialization of any resulting products.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, we entered into a global collaboration and license agreement with Pfizer Inc., or Pfizer, for the research, development and commercialization of SB-525, our gene therapy product candidate for hemophilia A, and closely related products. Under this agreement, we are responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer is responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525. We and Pfizer may also collaborate in the research and development of additional AAV-based gene therapy products for hemophilia A.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, we entered into a new research collaboration and license agreement with Pfizer for the development and commercialization of potential gene therapy products that use ZFP </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">TFs to treat amyotrophic lateral sclerosis, or ALS, and frontotemporal lobar degeneration, or FTLD, linked to mutations of the </font><font style="font-style:italic;">C9ORF72</font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> gene. Under this agreement, we are working with Pfizer on a research program to identify, characterize and preclinically </font><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">develop ZFP TFs that satisfy pre-agreed criteria. Pfizer is responsible for subsequent development, manufacturing and commercialization of licensed products.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have also established a collaborative partnership with Bioverativ, Inc., or Bioverativ, <font style="color:#000000;">to </font>research, develop and commercialize therapeutic gene-edited cell therapy products in hemoglobinopathies, including beta-thalassemia and sickle cell disease, or SCD.&#160;We expect to begin enrolling patients in a Phase 1/2 clinical <font style="color:#000000;">study in the first half of 2018.&#160;</font>Bioverativ is responsible for subsequent development, manufacturing and commercialization of licensed products.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have incurred net losses since inception and expect to incur losses in the future as we continue our research and development activities. To date, we have funded our operations primarily through the issuance of equity securities, revenues from corporate collaborations and research grants. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our revenues have consisted primarily of revenues from our corporate partners for zinc finger nuclease, or ZFN, and zinc finger protein transcription factor, or ZFP TF, programs, contractual payments from strategic partners for research services and research milestones, and research grant funding. We expect revenues will continue to fluctuate from period to period and there can be no assurance that new collaborations or partner funding will continue beyond their initial terms or that we are able to meet the milestones specified in these agreements. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect to continue to devote substantial resources to research and development in the future and expect research and development expenses to increase in the next several years if we are successful in advancing our gene therapy and our genome editing programs in the clinic and if we are able to progress our earlier stage product candidates into clinical trials. Pursuant to the terms of the agreements with Kite and Bioverativ, certain expenses related to research and development activities will be reimbursed to us. The reimbursement funds to be received from Kite and Bioverativ will be recognized as revenue as the costs are incurred and collection is reasonably assured. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses consist primarily of salaries and personnel related expenses for executive, finance and administrative personnel, stock-based compensation expenses, professional fees, allocated facilities expenses, patent prosecution expenses and other general corporate expenses. As we continue to advance our product candidates into and through the clinic, we expect the growth of our business to require increased general administrative expenses. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the year ended December&#160;31, 2017, we incurred a consolidated net loss of $54.6 million, or $0.70 per share, compared to a consolidated net loss of $71.7 million, or $1.02 per share, for the same period in 2016. As of December&#160;31, 2017, we had cash, cash equivalents, marketable securities and interest receivable totaling $244.6&#160;million compared to $142.8 million as of December&#160;31, 2016. As of December&#160;31, 2017, we had an accumulated deficit of $495.5&#160;million. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Critical Accounting Policies and Estimates </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The accompanying discussion and analysis of our financial condition and results of operations are based upon our consolidated financial statements and the related disclosures, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires us to make estimates, assumptions and judgments that affect the reported amounts in our consolidated financial statements and accompanying notes. We base our estimates on historical experience and on various other assumptions that we believe to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates under different assumptions or conditions. We believe the following policies to be the most critical to an understanding of our financial condition and results of operations because they require us to make estimates, assumptions and judgments about matters that are inherently uncertain. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition &#8211; Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011 that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:normal;">including whether the fair value of the d</font><font style="font-style:normal;">elivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition</font><font style="font-style:normal;"> criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, we recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property relate</font><font style="font-style:normal;">d to the license were delivered and over the period of performance obligations if we had continuing performance obligations. We estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these </font><font style="font-style:normal;">estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy, also called the relative selling price method, where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, or TPE, if available and VSOE is not available; or the best estimate of selling price, or ESP, if neither VSOE nor TPE is available; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the selling price hierarchy. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, we allocate revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, we determine the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists, we use ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire in 2012, Biogen in 2014, and Pfizer in May and December of 2017 were evaluated under these accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, we recognize milestone payments, which are subject to substantive contingencies, upon completion of specified milestones, which represents the culmination of an earnings process, according to contract terms. Fees from licensees upon sublicensing our technologies by them to third parties (sublicense fees) are recognized as revenue in the period such fees are due. Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. We recognize cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received which a portion has not been earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014, the Financial Accounting Standards Board, or FASB, issued Accounting Standards Update, or ASU, 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers (Topic 606)</font>,&#160;or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period. Under ASU 2014-09, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASU 2014-09, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. ASU 2014-09 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a>The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017 and any futu</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">re receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined un</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">der ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development rei</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition a</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">djustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research an</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d development reimbursements and up-front payments under ASC 606. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimated impact from the adoption of ASU 2014-09 represent management&#8217;s best estimates at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of our assessment in the first quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We recognize research and development expenses as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of our testing processes and procedures and related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. Expenses resulting from clinical trials are recorded when incurred based in part on factors such as estimates of work performed, patient enrollment, progress of patient studies and other events. We make good faith estimates that we believe to be accurate, but the actual costs and timing of clinical trials are highly uncertain, subject to risks and may change depending upon a number of factors, including our clinical development plan. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We measure and recognize compensation expense for all stock-based payment awards made to our employees and directors, including employee stock options, employee stock purchases related to our Employee Stock Purchase Plan, or ESPP, and restricted stock units, or RSUs, on estimated fair values. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method over the requisite service period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the value of a stock option award and purchases related to ESPP, we use the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from our historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. To estimate the value of RSUs, we use the closing market value of our common stock on the date the award is issued. Further, we account for forfeitures as they occur under our adoption of ASU 2016-09. If factors change and different assumptions are employed in determining the fair value of stock-based awards, the stock-based compensation expense recorded in future periods may differ significantly from what was recorded in the current period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Results of Operations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Years Ended December&#160;31, 2017, 2016 and 2015 </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenues </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="30" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.62%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.12%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.06%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="30" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:63.62%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except percentage values)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.28%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,960</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,881</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,079</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.28%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,881</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,844</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,963</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.84%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.22%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(50</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.3%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research Grants</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.28%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,695</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,187</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.22%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,567</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,389</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17,178</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.28%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,389</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.32%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,539</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(20,150</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.84%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.22%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(51</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.3%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues consisted of revenues from collaboration agreements and research grants. We anticipate revenues over the next several years will be derived primarily from our collaboration agreements with Kite, Pfizer and Bioverativ. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase in revenues from collaborations in 2017 compared to 2016 was primarily due to increases of $17.0 million in revenues related to the hemophilia A Pfizer agreement, $3.4 million from the upfront license payment and research services provided to Bioverativ, partially offset by decreases of $2.1 million in royalty revenue related to our DAS license, $0.8 million related to research services provided to Shire, and $0.5 million in Sigma license and royalty fees. During 2017, revenues related to our collaborative agreements with Pfizer and Bioverativ represented 47% and 34%, respectively, of total revenues.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease in revenues from collaborations in 2016 compared to 2015 was primarily due to decreases of $12.5 million in revenues related to Shire research services, $5.0 million in revenues related to Bioverativ research services, and $3.6 million in Sigma license and royalty fees, partially offset by an increase of $2.1 million in royalty revenue related to our DAS license. During 2016, revenues related to our collaborative agreements with Bioverativ, DAS and Shire represented 46%, 26% and 17%, respectively, of total revenues. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research grant revenues were $0.6 million, $0.5 million, and $1.7 million in 2017, 2016, and 2015, respectively. There were no significant changes in grant revenue from 2016 to 2017. The decrease of $1.2 million in 2016 from 2015 was primarily due to the receipt of funding from a research grant from CIRM for our beta-thalassemia project in 2015. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating Expenses </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="30" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="30" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:64.52%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands, except percentage values)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,728</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,618</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,618</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,198</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,580</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,200</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,330</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">870</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,330</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,197</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,133</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:33.64%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.8%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,928</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,948</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">980</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,948</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,395</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,553</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:5.46%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.64%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.8%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:5.46%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase of $0.1 million in research and development expenses in 2017 was primarily due to increases of $5.5 million in salaries and benefits, $1.1 million in clinical trial and manufacturing expenses related to our hemophilia B and MPS programs, and $1.1 million in facility and operating expenses. This was primarily offset by decreases of $3.4 million in preclinical expenses, $2.5 million in lab supply expenses, $1.4 million in stock-based compensation expense, and $0.3 million in other professional services. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The decrease of $1.6 million in research and development expenses in 2016 was primarily due to decreases of $5.6 million in research expenses related to our preclinical programs, and $0.7 million in license expense. This was primarily offset by increases of $2.0 million in personnel related expenses, including salaries and stock-based compensation expense due to increased headcount, $1.8 million in consulting expenses, $0.6 million in facilities expense, and $0.5 million in lab supply expenses, in each case as we prepared to enter the clinic in 2016. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below shows research and development expenses related to our clinical and preclinical programs. </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Programs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Human Therapeutic Programs</font></p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Hemophilia clinical programs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,521</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; LSD clinical programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,428</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,046</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Beta-thalassemia clinical program</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,354</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; HIV (SB-728) clinical programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,473</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,271</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,654</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Non-human Therapeutic Programs</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Preclinical and research programs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25,414</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43,682</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,513</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; Other clinical programs and non-therapeutic programs</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">344</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,098</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,929</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total research and development expenses</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,728</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,618</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,198</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">General and Administrative Expenses </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase of $0.9 million in 2017 was primarily due to increases of $1.5 million in legal expenses, $1.5 million in corporate expenses, including rebranding in connection with our name change, $1.0 million in salaries and benefits, and $1.0 million in facility expenses. This increase was primarily offset by a decrease of $4.5 million in stock-based compensation expense, as 2016 included approximately $4.1 million of stock-based compensation expense recognized in connection with the transition of our former chief executive officer. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The increase of $7.1 million in 2016 was primarily due to an increase of $6.2 million in personnel related expenses, including $4.1 million in stock-based compensation expense and $2.0 million in salaries and benefits associated with the transition of our chief executive officer in June 2016, and an increase of $1.5 million for professional services, primarily offset by a decrease of $0.6 million in legal expenses. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Interest and other income, net </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net, was $1.8 million in 2017, $0.9 million in 2016 and $0.4 million in 2015 and primarily consisted of interest income resulting from our treasury strategy. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Benefit from income taxes</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes was $0.0 million, $0.0 million, and $5.7 million for 2017, 2016, and 2015, respectively. We recognized an immaterial amount of income tax expense/benefit during both 2017 and 2016. The income tax benefit in 2015 was primarily due to $5.0 million income tax benefit recognized from a claims settlement with certain institutional investors that were beneficial owners of our common stock related to the disgorgement of short swing profits pursuant to Section 16 of the Securities Exchange Act of 1934, as amended. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, we had net operating loss carryforwards for federal and state income tax purposes of approximately $475.0&#160;million and $142.0 million, respectively. If not utilized, the net federal and state operating loss carryforwards will expire in 2018 and 2017, respectively. We also have federal and state research tax credit carryforwards of $10.8 million and $11.8 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of our net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before use.&nbsp;&nbsp;Due to the carryforwards related to the net operating losses and research and development tax credits, we do not expect to pay any taxes related to income in the near future.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a>On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act ("Tax Reform") into legislation.&#160; The Tax Reform makes significant changes to the US corporate income tax law including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21% from 35% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of US subsidiaries.&#160; Under ASC 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted.&#160; In the case of US federal income taxes, the enactment date is the date the bill becomes law.&#160;&#160;&#160; With respect to this legislation, we expect no financial statement impact due to the Company's valuation allowance.&#160; The Company performed a re-measurement of deferred tax assets and liabilities as a result of the decrease in the corporate Federal income tax rate from 35% to 21%. In addition to </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the reduction of U.S</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. federal corporate tax rate, the Company has also considered the impact of the foreign transition tax for which it has estimated that it would not need to accrue any amounts.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No.118 (SAB 118) to provide guidance on the application of the Tax Reform when a company does not have the necessary information available, prepared, or analyzed in reasonable to detail to reflect the effects of the Tax Reform.&#160; SAB 118 provides guidance for companies under the three scenarios (1) measurement of certain income tax effects is complete, (2) measurement of certain income tax effect can be reasonably estimated, and (3) measurement of certain income tax effects cannot be reasonably estimated.&#160; Companies are to complete the accounting under ASC 740 in regards to the Tax Reform within a measurement period that does not extend one year from the date of enactment (i.e., December 22, 2018).&#160; In accordance with SAB 118, companies must reflect the tax effects of the Tax Reform for which the accounting under 740 is complete. If certain income tax effect can be reasonably estimated, then the companies must report provisional amounts in the reporting period in which the companies can determine the reasonable estimate during the measurement period.&#160; In the case that certain income tax effects cannot be reasonably estimated, companies do not have to report effects of the Tax Reform.&#160; However, they should continue to apply ASC 740 based on the rules before the enactment of the Tax Reform and report any income tax effects in the first reporting period in which reasonable estimates become available.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the new law to significantly reduce our tax rate in future periods, and our tax footnote reflects the effects of a Federal tax rate reduction net of our valuation allowance, which resulted in a net overall reduction of $0.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the company has utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries.&#160; In accordance with SAB 118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.&#160; We currently anticipate finalizing and recording any resulting adjustments by year ending December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Liquidity and Capital Resources </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Liquidity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since inception, we have incurred significant net losses and we have funded our operations primarily through the issuance of equity securities, payments from corporate collaborators and strategic partners and research grants. Our most significant use of capital pertains to funding our preclinical and clinical research and development programs, as well as salaries and benefits for employees.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, we had cash, cash equivalents, marketable securities and interest receivable totaling $244.6&#160;million compared to $142.8 million as of December&#160;31, 2016, with the increase primarily attributable to our completion of an underwritten public offering of our common stock in June 2017, in which 11.5 million shares of our common stock were sold at a public offering price of $7.25 per share. Net proceeds after deducting underwriting discounts and commissions and other estimated offering expenses, were appropriately $78.1 million. Cash, cash equivalents, and marketable security further increased attributable to $70.0 million for the upfront license and service fee received from Pfizer pursuant to the hemophilia A Pfizer agreement. Our cash and investment balances are held in a variety of interest bearing instruments, including obligations of U.S. government agencies, U.S. Treasury debt securities, corporate debt securities and money market funds. Cash in excess of immediate requirements is invested in accordance with our investment policy with a view toward capital preservation and liquidity. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>On May 26, 2017, we entered into an Amended and Restated At-the-Market Offering Program Sales Agreement with an investment bank pursuant to which we may issue and sell from time to time shares of our common stock having an aggregate offering price of up to $75.0 million through the investment bank acting as our sales agent, or the 2017 ATM Agreement. Under the 2017 ATM Agreement, if we decide to sell shares, we will notify the sales agent, and the sales agent will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold.&nbsp;&nbsp;Sales of our common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The Nasdaq Global <font style="Background-color:#FFFFFF;color:#000000;">Select </font>Market and sales to or through a market maker other than on an exchange. In addition, with our prior written consent, the sales agent may also sell shares of our common stock in negotiated transactions under the 2017 ATM Agreement. During the three months ended March 31, 2017, we issued a total of 871,149 shares of its common stock under the original At-the-Market Offering Program Sales Agreement entered into during December 2016, and received net proceeds of $3.4 million, after deducting offering expenses, including $0.1 million of commission paid to the sales agent. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior to the time the shares were sold and accordingly, these shares are subject to potential rescission rights, as described in more detail under &#8220;Risk Factors&#8221;. <font style="Background-color:#FFFFFF;color:#000000;">In addition, if it were determined that we sold unregistered securities, we could be subject to enforcement actions or </font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#000000;">penalties and fines by regulatory authorities. </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have </font><font style="color:#000000;">not sold any common stock under the 2017 ATM Agreement and the full </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$75.0 million provided for under the 2017 ATM Agreement remained available for sale thereunder at December</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> 31, 2017.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Since the beginning of 2017, we have received significant amounts of capital as upfront payments under the following collaboration arrangements: $70.0 million received in May 2017 from Pfizer under our hemophilia A agreement; and $12.0 million received in January 2018 under our ALS/FTLD agreement. In addition, in February 2018, we entered into the Kite collaboration agreement pursuant to which upon its effectiveness we will be entitled to receive $150.0 million from Kite. T<font style="color:#000000;">he effectiveness of the Kite agreement is subject to the expiration or termination of all applicable waiting periods under the Hart</font><font style="Background-color:#FFFFFF;">-Scott-Rodino Antitrust Improvements Act of 1976, as amended</font><font style="color:#000000;"> and other customary closing conditions. </font>We anticipate the effectiveness of the Kite agreement to occur in the first half of 2018. Our collaboration agreements provide for the payment of development, regulatory, and commercial milestones. For more information see &#8220;Business &#8211; Collaborations.&#8221; </p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Cash Flow </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Operating activities.<font style="font-weight:normal;font-style:normal;"> Net cash provided by (used in) operating activities primarily reflects our net operating losses adjusted for non-cash items including stock-based compensation expense. Net cash provided by operating activities was $11.2 million in 2017 compared to net cash used in operating activities of $65.9 million in 2016. The increase in net cash provided by operating activities in 2017 was primarily due to the increase in deferred revenues related to the $70.0 million upfront payment from the hemophilia A agreement with Pfizer. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash used in operating activities was $65.9 million in 2016 compared to $33.7 million in 2015. The increase in net cash used in operating activities in 2016 was primarily due to an increase operating expenses and a decrease in deferred revenues related to the recognition of the $20.0 million upfront payment from Bioverativ pursuant to the collaboration and license agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investing activities.<font style="font-weight:normal;font-style:normal;"> Net cash used in investing activities was $80.9 million in 2017. Net cash provided by investing activities was $18.1 million in 2016 and $77.5 million in 2015. Cash flows from investing activities for all periods was primarily related to purchases, sales and maturities of marketable securities and also includes deposits on cash related to lease commitments. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Financing activities.<font style="font-weight:normal;font-style:normal;"> Net cash provided by financing activities was $97.5 million in 2017, $0.3 million in 2016, and $19.7 million in 2015. Net cash provided by financing activities in 2017 was primarily attributable to the completion of an underwritten public offering of our common stock of $78.1 million, net of issuance costs, and $16.6 million in proceeds from the exercise of stock options. Net cash provided by financing activities in 2016 was primarily attributable to $1.1 million proceeds from the exercise of stock options, primarily offset by $0.8 million in taxes paid related to net share settlement of equity awards. Net cash provided by financing activities in 2015 was primarily attributable to a $14.5 million claim settlement with certain institutional investors that were beneficial owners of our common stock related to the disgorgement of short-swing profits pursuant to Section 16 of the Securities Exchange Act of 1934, as amended, as well as proceeds from the exercise of stock options. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:2.26%;text-indent:0%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Operating Capital and Capital Expenditure Requirements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We anticipate continuing to incur operating losses for at least the next several years. While we expect our rate of cash usage to increase in the future, in particular to support our product development endeavors, we believe that the available cash resources as well as funds received from corporate collaborators, strategic partners and research grants will enable us to maintain our currently planned operations through at least the next twelve months from the date the financial statements are issued. Future capital requirements will be substantial and if our capital resources are insufficient to meet future capital requirements, we will need to raise additional capital to fund our operations through equity or debt financing. We regularly consider fund raising opportunities and may decide, from time to time, to raise capital based on various factors, including market conditions and our plans of operation.&#160;Additional capital may not be available on terms acceptable to us, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, our business and our ability to advance our product candidate pipeline would be harmed. Furthermore, any sales of additional equity securities, including any sales under our ATM Agreement, may result in dilution to our stockholders, and any debt financing may include covenants that restrict our business. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our future capital requirements will depend on many forward looking factors, including the following: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the initiation, progress, timing and completion of clinical trials for our product candidates and potential product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the outcome, timing and cost of regulatory approvals; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the success of our collaboration agreements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">delays that may be caused by changing regulatory requirements; </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-family:Times New Roman;">the number of product candidates that we pursue; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the costs involved in filing and prosecuting patent applications and enforcing and defending patent claims; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the timing and terms of future in-licensing and out-licensing transactions; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost and timing of establishing sales, marketing, manufacturing and distribution capabilities; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the cost of procuring clinical and commercial supplies of our product candidates; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the extent to which we acquire or invest in businesses, products or technologies; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">the possible costs of litigation. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Off Balance Sheet Arrangements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We do not have any off balance sheet arrangements as defined in Item 303(a)(4)(ii) of Regulation S-K.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations and Commercial Commitments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, we had contractual obligations and commercial commitments as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="18" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments Due by Period</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Less<font style="font-family:Calibri;">&#160;</font>Than</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1-3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">4-5</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">More<font style="font-family:Calibri;">&#160;</font>Than</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual Obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1 Year</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:8.94%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5 Years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.78%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License obligations</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,216</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,258</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,070</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.78%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total contractual obligations</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,650</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,183</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,776</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,725</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.08%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,966</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating leases consist of base rents for facilities we occupy in Richmond, California and future location in Brisbane, California. The amounts in the table above do not include estimated costs for leasehold improvements. License obligations consist of ongoing license maintenance fees associated with cancelable in-licensed patent agreements. </p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2018 other commitments include $8.8 million for tenant improvements related to the Brisbane build-to-suit lease and $8.7 million as part of our services agreement with Brammer Bio MA, LLC, or Brammer, to provide dedicated capacity to supply our preclinical and clinical programs.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Quantitative_and_Qualitative_Disclosures"></a><a name="Quantitative_and_Qualitative_Disclosures"></a>ITEM&#160;7A &#8211; QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our exposure to market risk relates to our cash, cash equivalents and investments. The goals of our investment policy are preservation of capital, fulfillment of liquidity needs and capturing a market rate of return based on our investment policy parameters and market conditions. We select investments that maximize interest income to the extent possible within these guidelines. To achieve our goals, we maintain a portfolio of cash equivalents and investments in securities of high credit quality and with varying maturities to match projected cash needs. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The securities in our investment portfolio are not leveraged, are classified as available-for-sale and are, due to their short-term nature, subject to minimal interest rate risk. Our investments currently consist of U.S. Treasury securities, U.S. government-sponsored enterprise securities and corporate notes. Our investment policy, approved by our Board of Directors, limits the amount we may invest in any one type of investment issuer, thereby reducing credit risk concentrations. All investments have a fixed interest rate and are carried at market value, which approximates cost. We do not use derivative financial instruments in our investment portfolio. We do not believe that a change in interest rates would have a material negative impact on the value of our investment portfolio. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><a name="Financial_Statements_and_Supplementary"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Financial_Statements_and_Supplementary"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM&#160;8 &#8211; FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">INDEX TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="padding-left:0pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Page</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#REPORT_OF_INDEPENDENT"><font style="text-decoration:none;">Report of Independent Registered Public Accounting Firm</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#BALANCE_SHEETS"><font style="text-decoration:none;">Consolidated Balance Sheets</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STATEMENTS_OF_OPERATIONS"><font style="text-decoration:none;">Consolidated Statements of Operations</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#COMPREHENSIVE_LOSS"><font style="text-decoration:none;">Consolidated Statements of Comprehensive Loss</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#STOCKHOLDERS_EQUITY"><font style="text-decoration:none;">Consolidated Statements of Stockholders&#8217; Equity</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#CASH_FLOWS"><font style="text-decoration:none;">Consolidated Statements of Cash Flows</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p></td>
</tr>
<tr>
<td valign="top"  style="width:94%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#NOTES_"><font style="text-decoration:none;">Notes to Consolidated Financial Statements</font></a></p></td>
<td valign="top"  style="width:1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><a name="REPORT_OF_INDEPENDENT"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="REPORT_OF_INDEPENDENT"></a>R</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors and Stockholders of Sangamo Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Opinion on the Financial Statements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited the accompanying consolidated balance sheets of Sangamo Therapeutics, Inc. (the Company) as of December 31, 2017 and 2016, the related consolidated statements of operations, comprehensive loss, stockholders' equity, and cash flows for each of the three years in the period ended December 31, 2017, and the related notes (collectively referred to as the &#8220;consolidated financial statements&#8221;). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2017 and 2016, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2017, in conformity with U.S. generally accepted accounting principles. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control-Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) and our report dated March 1, 2018 expressed an unqualified opinion thereon.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;ERNST&#160;&amp; YOUNG LLP </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have served as the Company&#8217;s auditor since 1997.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="BALANCE_SHEETS"></a><a name="BALANCE_SHEETS"></a>CONSOLIDATED BALANCE SHEETS<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:9pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">ASSETS</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current assets:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,826</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,061</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">193,482</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">240</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">224</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,343</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,972</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other current assets</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,506</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,849</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">248,397</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">149,580</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities, non-current</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,012</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment, net</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,066</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,557</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,585</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other assets</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,681</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">169</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total assets</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,741</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,891</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">LIABILITIES AND STOCKHOLDERS' EQUITY</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current liabilities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,035</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,479</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,885</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,345</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,145</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total current liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44,859</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,291</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues, non-current</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,244</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,460</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit lease obligation</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,738</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,945</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98,841</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,696</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commitments and contingencies</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stockholders' equity:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common stock, $0.01 par value; 160,000,000 shares authorized, 85,598,534 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; 70,871,902 shares issued and outstanding at December 31, 2017 and</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; December 31, 2016, respectively</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional paid-in capital</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,809</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,377</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated deficit</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(495,479</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(440,911</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accumulated other comprehensive income (loss)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(286</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stockholders' equity</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,900</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,195</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:20.5pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total liabilities and stockholders' equity</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">286,741</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,891</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Consolidated Financial Statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="STATEMENTS_OF_OPERATIONS"></a><a name="STATEMENTS_OF_OPERATIONS"></a>CONSOLIDATED STATEMENTS OF OPERATIONS</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except per share amounts)<font style="font-size:10pt;font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:48.92%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.5%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Revenues:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Collaboration agreements</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35,960</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,881</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,844</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research grants</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">607</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">508</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,695</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36,567</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,389</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,539</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating expenses:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,728</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65,618</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,198</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,200</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,330</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,197</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total operating expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,928</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,948</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86,395</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss from operations</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(56,361</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(72,559</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,856</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest and other income, net</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,793</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">887</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">431</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.06%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Loss before income taxes</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,672</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(46,425</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,722</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic and diluted net loss per share</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.70</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1.02</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.58</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.06%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares used in computing basic and diluted net loss per share</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78,084</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,553</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.68%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.5%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,757</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Consolidated Financial Statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="COMPREHENSIVE_LOSS"></a><a name="COMPREHENSIVE_LOSS"></a>CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in unrealized gain (loss) on available-for-sale</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities, net of tax</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,874</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,638</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,678</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Consolidated Financial Statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="STOCKHOLDERS_EQUITY"></a><a name="STOCKHOLDERS_EQUITY"></a>CONSOLIDATED STATEMENTS OF STOCKHOLDERS&#8217; EQUITY<font style="font-weight:normal;"> </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands, except share amounts)</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;;font-size:8.5pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.9%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Common Stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Additional</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:7.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Paid-in</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Accumulated</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stockholders'</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amount</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Capital</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Deficit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Income/ (Loss)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.96%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Equity</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2014</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,062,394</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">690</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">534,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(328,550</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">206,633</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of stock options and in connection with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; restricted stock units, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,164,033</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,336</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,348</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128,181</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">910</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">911</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims settlement under Section 16(b), net of tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,495</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized loss on marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,678</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,354,608</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">703</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">560,989</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(369,253</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">192,439</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of stock options and in connection with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; restricted stock units, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">314,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(484</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(481</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">202,711</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">815</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized gain on marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,638</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70,871,902</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">709</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">576,377</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(440,911</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">136,195</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock upon exercise</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; of stock options and in connection with</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; restricted stock units, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,101,489</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,099</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; employee stock purchase plan</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">253,994</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">816</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">818</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issuance of common stock under public</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">offering, net of issuance costs</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,371,149</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,449</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,573</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net unrealized loss on marketable</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp; securities, net of tax</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.96%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(306</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:6.96%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Comprehensive loss</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,874</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:40.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Balances at December 31, 2017</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85,598,534</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">856</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">682,809</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(495,479</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(286</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.96%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.96%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,900</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Consolidated Financial Statements.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:3pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="CASH_FLOWS"></a><a name="CASH_FLOWS"></a>CONSOLIDATED STATEMENTS OF CASH FLOWS </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:8.5pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(in thousands)</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Hlk507646522"></a>&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Operating Activities:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(54,568</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(71,658</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(40,703</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,498</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">997</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">988</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of premium (discount) on marketable securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(673</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">221</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">827</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss on disposal of property and equipment</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in fair value of contingent consideration liability</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,800</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible impairment</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,870</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit from income taxes</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net changes in operating assets and liabilities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest receivable</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts receivable</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,629</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,144</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,847</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prepaid expenses and other assets</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(669</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,112</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">376</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,219</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,335</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(764</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued compensation and employee benefits</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,594</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(105</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48,984</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,214</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8,380</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by (used in) operating activities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,179</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(65,883</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(33,720</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Investing Activities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of marketable securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(252,328</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(218,640</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(257,988</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Maturities of marketable securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,675</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">237,497</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337,861</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Purchases of property and equipment</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,751</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(732</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease commitments</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3,500</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Acquisition of Ceregene, Inc. net of cash received</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,411</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash (used in) provided by investing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(80,904</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,125</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77,462</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Financing Activities:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from public offering of common stock, net of issuance costs</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,573</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Taxes paid related to net share settlement of equity awards</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(654</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(776</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,546</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Proceeds from issuance of common stock</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,571</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,113</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,804</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Claims settlement under Section 16(b)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,452</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net cash provided by financing activities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97,490</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">337</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,710</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net increase (decrease) in cash and cash equivalents</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,765</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(47,421</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,452</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, beginning of period</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,061</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,482</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,030</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash and cash equivalents, end of period</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49,826</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,061</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69,482</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Supplemental disclosure of noncash investing activities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment included in accrued liabilities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,214</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Build-to-suit leases included in build-to-suit obligation</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,793</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">See accompanying Notes to Consolidated Financial Statements.</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC. </font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="NOTES_"></a><a name="NOTES_"></a>NOTES&#160;TO CONSOLIDATED FINANCIAL STATEMENTS </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1 &#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc. was incorporated in the State of Delaware on June&#160;22, 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017 (the Company or Sangamo).&nbsp;&nbsp;Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#8217;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). Potential applications of Sangamo&#8217;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&#160;31, 2017, along with expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will need to raise substantial additional capital to fund subsequent operations and complete the development and commercialization of its products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly-owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for acquisitions in accordance with Accounting Standards Codification (ASC) Topic 805, <font style="font-style:italic;">Business Combinations</font> (ASC Topic 805). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts.&nbsp;&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a>The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the sp</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ecific identification method. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-family:Times New Roman;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, </font></p></td></tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">or TPE, if available and VSOE is not available; or the best</font><font style="font-family:Times New Roman;"> estimate of selling price, or ESP, if neither VSOE nor TPE is available; and </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:'Times New Roman';font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#x2022;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:'Times New Roman';font-size:10pt;"><font style="font-family:Times New Roman;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG, or Shire, in January 2012, Biogen MA Inc., or Biogen, in January 2014, and Pfizer Inc., or Pfizer, in May and December of 2017, were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received but not earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of the Company&#8217;s total revenue. During 2016 revenue related to Bioverativ, DAS and Shire represented 46%, 26%, and 17%, respectively, of total revenue.&nbsp;&nbsp;During 2015 revenue related to Shire and Biogen represented 40% and 35%, respectively, of total revenues. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&#8217;s testing processes and procedures as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (RSUs) and employee stock purchases related to the Employee Stock Purchase Plan (ESPP), based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company adopted Accounting Standards Update (ASU) 2016-09 and accounts for forfeitures in the period they occur. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indefinite-Lived Intangible Assets </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Ceregene acquisition the Company recognized indefinite-lived intangible assets for in-process research and development and goodwill as further discussed below. ASC 350 and related updates require companies to test indefinite-lived intangible assets for impairment annually, and more frequently if indicators of impairment exist. ASC 350 includes an optional qualitative assessment for testing indefinite-lived intangible assets for impairment that permits companies to assess whether it is more likely than not (i.e., a likelihood of greater than 50%) that an indefinite-lived intangible asset is impaired. If a company concludes based on the qualitative assessment that it is not more likely than not that the fair value of an indefinite-lived intangible asset or, in the case of goodwill, that the fair value of the related reporting unit, is less than carrying value, it would not have to determine the asset&#8217;s or reporting unit&#8217;s fair value, as applicable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets related to in-process research and development costs, or IPR&amp;D, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company did not believe the programs have an alternative future use for itself or other market participants. Accordingly, the Company recognized a $1.9 million impairment charge related to these assets during the year ended December 31, 2015, which was recognized as research and development (R&amp;D) in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate an impairment of goodwill has occurred. During the fourth quarter of 2017, the Company performed an assessment of the qualitative factors affecting the fair value of its reporting unit and concluded that it was not more likely than not that the fair value of its reporting unit was less than carrying value and that, as a result, it is not more likely than not that goodwill is impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the merger agreement with Ceregene, the Company is required to make contingent earn-out payments if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. These earn-out payments will become payable in the period they are earned. In accordance with ASC Topic 805, the Company determined the fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;D assets acquired from Ceregene.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a>Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options and restricted stock units, which are all anti-dilutive. All stock options and restricted stock units outstanding </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">were excluded from the calculation of diluted net loss per share for all periods presented. Stock options and restricted stock units outstanding at the end of 2017, 2016 and 20</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15 were 8,367,628, 9,578,322, and 9,008,185, respectively. </font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2017 and 2016, all of the Company&#8217;s assets were maintained in the U.S. For the years ended December&#160;31, 2017, 2016 and 2015, substantially all the Company&#8217;s revenues and operating expenses were generated and incurred in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016 the Financial Accounting Standards Board (FASB) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&#160;Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period.&nbsp;&nbsp;The Company adopted the ASU in the first quarter of 2017 and it did not have a material impact on the Company&#8217;s consolidated financial statements. The impact of ASU 2016-09 as it relates to stock-based compensation for deferred tax assets and liabilities balances were not material to the Company's consolidated financial statements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016 the FASB issued ASU No. 2016-02 (ASU 2016-02) &#8220;<font style="font-style:italic;">Leases</font>.&#8221; ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. We are evaluating the impact of the adoption of this standard on our consolidated financial statements, and expect our operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption which will increase our total assets and total liabilities as compared to amounts prior to adoption.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers (Topic 606)</font>, or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a>The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at December 31, 2017 and any future receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined under ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development reimbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition adjustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research and developmen</font><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t reimbursements and up-front payments under ASC 606. </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimates of the expected effects of the Company&#8217;s adoption of ASU 2014-09 represent management&#8217;s best estimates of the effects of adopting ASU 2014-09 at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of the Company&#8217;s assessment in the first quarter of 2018.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2 &#8211;FAIR VALUE MEASUREMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the contingent consideration liability.&#160;Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurements of cash equivalents, available-for-sale securities and the contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,089</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">84</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally classifies its marketable securities as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2013 the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. <font style="letter-spacing:-0.1pt;">The Company has classified this liability as Level 3.</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subsequent changes in the fair value of the contingent consideration liability were recognized as a component of research and development expense line item in the accompanying consolidated statements of operations as operating expenses. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by the total fair value of the contingent consideration of $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;D assets acquired from Ceregene (see Note 6).&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3 &#8211; MARKETABLE SECURITIES </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,365</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,886</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,498</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,749</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,634</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,112</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,005</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,307</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,424</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,416</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, all of the Company&#8217;s investments had maturity dates within two years as of the balance sheet date. The Company had no material realized losses from the sale of available-for-sale securities for the years ended December&#160;31, 2017, 2016 or 2015. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. No investments were other-than-temporarily impaired at either December 31, 2017 or 2016.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4 &#8211; STOCK-BASED COMPENSATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table shows total stock-based compensation expense recognized in the accompanying consolidated statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,463</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,058</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,594</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, total stock-based compensation expense related to unvested stock options to be recognized in future periods was $16.1 million, which is expected to be expensed over a weighted-average period of 2.79 years.&nbsp;&nbsp;As of December&#160;31, 2017, total stock-based compensation expense related to unvested RSUs to be recognized in future periods was $0.7 million, which is expected to be expensed over a weighted-average period of 1.03 years. There was no capitalized stock-based employee compensation expense as of either December&#160;31, 2017, 2016 or 2015 respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation Assumptions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">86</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its determination of e</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xpected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these o</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ptions. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average estimated fair value per share of options granted during 2017, 2016 and 2015 was $4.10, $3.14, and $5.72, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81-2.28%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13-1.61%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46-1.58%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.73-5.83</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28-5.29</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.25-5.31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.72</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.68-0.70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.67</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees purchased approximately 253,994, 202,711 and 128,181 shares of common stock through the 2010 Employee Stock Purchase Plan at an average exercise price of $3.22, $4.04, and $7.10 per share during 2017, 2016 and 2015, respectively. The weighted-average estimated fair value of shares purchased under the Company&#8217;s ESPP during 2017, 2016 and 2015 were $2.37, $2.27 and $4.42, respectively based upon the assumptions used in the Black-Scholes valuation model.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.44-0.76%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41-0.80%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06-0.33%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.82</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.55-0.70</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5 &#8211; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Pfizer Inc. in Human Therapeutics </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-525 Global Collaboration and License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 10, 2017, Sangamo entered into an exclusive, global Collaboration and License Agreement (the &#8220;with Pfizer pursuant to which Sangamo and Pfizer established a collaboration for the research, development and commercialization of SB-525, Sangamo&#8217;s gene therapy product candidate for hemophilia A, and closely related products (the &#8220;hemophilia A Pfizer Agreement&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the hemophilia A Pfizer Agreement, Sangamo will be responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer will be responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525.&nbsp;&nbsp;Sangamo and Pfizer may also collaborate in the research and development of additional adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy products for hemophilia A.&nbsp;&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the&nbsp;&nbsp;hemophilia A Pfizer Agreement, Sanga</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mo received an upfront fee of $70.0 million from Pfizer.&nbsp;&nbsp;In addition, Sangamo is eligible to receive $208.5 million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and $266.5 million in p</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ayments upon the achievement of specified first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assum</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing the achievement of all specified milestones in the hemophilia A Pfizer Agreement, is $475.0 million, which includes up to $300.0 million for SB-525 and up to $175.0 million for other products that may be developed under the hemophilia A Pfizer Agreemen</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t, subject to reduction on account of payments made under certain licenses for third party intellectual property.&nbsp;&nbsp;In addition, Pfizer has agreed to pay Sangamo royalties for each potential licensed product developed under the hemophilia A Pfizer Agreement</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">due to</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intell</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ectual property.&nbsp;&nbsp;To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the hemophilia A Pfizer Agreement. Sangamo in responsible for internal and external research costs a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the hemophilia A Pfizer Agreement, Sangamo granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by Sangamo for the purpose of developing, manufacturing and commercializing SB-525 and related products. Under the hemophilia A Pfizer Agreement, Pfizer granted Sangamo a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the hemophilia A Pfizer Agreement and controlled by Pfizer to manufacture Sangamo&#8217;s products that utilize the AAV delivery system.&nbsp;&nbsp;During a specified period, neither Sangamo nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the hemophilia A Pfizer Agreement as a license to the technology and on-going services. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the hemophilia A Pfizer Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a thirty-two month estimated time over which the Company will perform services under the hemophilia A Pfizer Agreement. The recognition period will be reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the period of performance. As of December 31, 2017, the Company had deferred revenue of $53.0 million related to the hemophilia A Pfizer Agreement. During the year ended December 31, 2017 the Company recognized revenue of $17.0 million related to the upfront fee that was received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">C9ORF72 Research Collaboration and License Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;28, 2017, Sangamo entered into a Research Collaboration and License Agreement with Pfizer for the development and commercialization of potential gene therapy products that use zinc finger protein transcription factors (&#8220;ZFP-TFs&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration, or ALS/ FTLD, linked to mutations of the C9ORF72 gene. Pursuant to this Pfizer Agreement, Sangamo will work together with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the C9ORF72 gene (the &#8220;ALS/ FTLD Pfizer Agreement&#8221;). This agreement was entered into as a separate and distinct agreement apart from the SB-525 Pfizer agreement. The Pfizer C9ORF72 agreement is related to research specific ZFP-TF gene therapy for the C9ORF72 gene, while the SB-525 Pfizer agreement was for the clinical stage development of <font style="color:#000000;">AAV-based gene therapy products for hemophilia A.</font> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo has granted Pfizer an exclusive, royalty-bearing, worldwide, sublicensable license under the Company&#8217;s relevant patents and&#160;know-how&#160;to develop, manufacture and commercialize gene therapy products (&#8220;Licensed Products&#8221;) that use resulting&#160;ZFP-TFs&#160;that satisfy&#160;pre-agreed&#160;criteria. During a specified period, neither Sangamo nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins that specifically bind to the C9ORF72 gene.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the ALS/ FTLD Pfizer Agreement, Sangamo received&nbsp;&nbsp;a $12.0&#160;million upfront payment from Pfizer. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of Licensed Products. Sangamo is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer if a Licensed Product achieves specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of Licensed Products reach specified levels. In addition, Pfizer will pay royalties to Sangamo that are an escalating tiered,&#160;mid-&#160;to high-single digit percentage of the annual worldwide net sales of Licensed Products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Sangamo did not recognize revenue related to this Pfizer agreement as the basic criteria for revenue recognition was not satisfied as of December 31, 2017. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">88</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Bioverativ Inc. in Human Therapeutics </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, the Company entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen (the &#8220;Bioverativ Agreement&#8221;), and in January 2017 this agreement was assigned by Biogen MA Inc. to Biogen&#8217;s blood disorder spin-off, Bioverativ.&nbsp;&nbsp;Pursuant to the Bioverativ Agreement, Sangamo and Bioverativ will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#8217;s zinc finger DNA-binding protein (&#8220;ZFP&#8221;) technology for beta-thalassemia and sickle cell disease (&#8220;SCD&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bioverativ Agreement, Sangamo and Bioverativ jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first therapeutic developed under the Bioverativ Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (&#8220;IND&#8221;) application for a ZFP-based therapeutic intended to treat SCD. For both programs, Bioverativ is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Bioverativ Agreement. At the end of specified research terms for each program or under certain specified circumstances, Bioverativ has the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&#160;licensed products to treat beta-thalassemia and SCD&#160;developed under the Bioverativ Agreement, and Bioverativ agrees to compensate Sangamo for such co-promotion activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo received an upfront license fee of $20.0 million upon entering into the Bioverativ Agreement. In addition, the Company will also be eligible to receive $115.8 million in payments upon the achievement of specified clinical development and regulatory milestones, as well as $160.5 million in payments upon the achievement of specified sales milestones. Bioverativ reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, if products are commercialized under the Bioverativ Agreement, Bioverativ will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Bioverativ Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the parties agreed on an updated beta-thalassemia development plan and budget using the <font style="font-style:italic;">BCL11A</font> erythroid enhancer target. In November 2016, Sangamo and Bioverativ agreed on an updated beta-thalassemia development plan and budget. As a result of this change, the Company updated the estimated performance period of the upfront license through June 2020, and updated the milestones to be received based on the updated schedule and targets under the Bioverativ Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Bioverativ Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Bioverativ Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Bioverativ Agreement, assuming all other applicable revenue recognition criteria have been met. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the Bioverativ Agreement, Sangamo has granted Bioverativ an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Bioverativ Agreement. Sangamo has also granted Bioverativ a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, under Sangamo&#8217;s interest in certain other intellectual property developed pursuant to the Bioverativ Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Bioverativ apart from the research services to be performed pursuant to the Bioverativ Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-four month estimated research term as of the November 2016 modification date, during which time the Company will perform research services. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December 31, 2017, the Company had deferred revenue of $4.6 million related to the Bioverativ Agreement. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the Bioverativ Agreement for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): &#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Bioverativ Collaboration:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,176</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,489</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,565</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,769</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,258</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,886</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,945</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended Collaboration and License Agreement with Shire International GmbH in Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2012, the Company entered into a Collaboration and License Agreement with Shire (the &#8220;Shire Agreement &#8221;), pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#8217;s novel ZFP technology. This agreement was amended on September 1, 2015.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the original Shire Agreement, the Company and Shire agreed to develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets would be used for treating or diagnosing hemophilia A and B. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington&#8217;s disease. Shire had the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Shire Agreement, the Company was responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire was responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimbursed Sangamo for agreed upon internal and external program-related research costs. The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement in 2012. In 2014, Sangamo recognized a $1.0 million milestone payment related to the hemophilia program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2015, the Shire Agreement was amended such that Shire agreed to return to Sangamo the exclusive, world-wide rights to gene targets for the development and commercialization of ZFP therapeutics for hemophilia A and B.&nbsp;&nbsp;Shire retains the rights and will continue to develop a ZFP therapeutic for Huntington&#8217;s disease.&nbsp;&nbsp;Sangamo will provide certain target feasibility services, and upon Shire&#8217;s request, certain research activities according to a research plan as agreed upon by both companies. Such research activities performed by Sangamo will be reimbursed by Shire. Shire&#8217;s rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs, and Shire will reimburse Sangamo for any ongoing services provided by Sangamo for Shire&#8217;s programs. In 2015, Shire reimbursed Sangamo $3.4 million related to obligations prior to the amendment date which was recognized in revenue as the expense related to those obligations was incurred. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs developed by Sangamo under the amended agreement. Under the amended agreement, Shire does not have any milestone payment obligations with respect to the retained programs, but it is required to pay single digit percentage royalties to Sangamo, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products from such programs. Under the Shire Agreement, Sangamo has full control over, and full responsibility for the costs of, the hemophilia programs returned to us, subject to certain diligence obligations and Shire&#8217;s right of first negotiation to obtain a license to such programs under certain circumstances. The Company is required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of ZFP therapeutic products from such returned programs.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire amendment. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3 million of deferred revenue from the upfront payment during the year ended December 31, 2017. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">90</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the Shire Agreement for the years ended December&#160;31, 2017, 2016 and 2015, were as follows </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(in thousands): </font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,181</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,167</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,584</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,449</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Sigma-Aldrich Corporation (Sigma) in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2007, Sangamo entered into a license agreement with Sigma to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to DAS. Sangamo developed laboratory research reagents using its ZFP technology over a three year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. Sangamo does not have additional ongoing performance obligations under the agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2017, 2016 and 2015, were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,277</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,853</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Dow AgroSciences in Plant Agriculture </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2005, Sangamo entered into an exclusive commercial license with<font style="font-weight:bold;font-style:italic;"> </font>Dow AgroSciences, LLC, or DAS, with an initial three year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008 DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3 million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010 the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years unless terminated a</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t any time by DAS. The Company does not have any performance obligations. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues under the agreement with DAS were $3.0 million during 2017 and $5.1 million and $3.0 million during 2016 and 2015, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6 &#8211; ACQUISITION OF CEREGENE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August&#160;2013, Sangamo acquired all the outstanding shares of Ceregene, a privately held biotechnology company focused on the development of AAV gene therapies. The acquired assets included certain intellectual property rights relating to manufacturing of AAV, and toxicology and data from Ceregene&#8217;s human clinical trials. The acquisition closed in October&#160;2013 (the Closing Date). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate consideration transferred or transferable by Sangamo to former Ceregene stockholders at closing consisted of 100,000 shares of Sangamo common stock, with an approximate fair value of $1.2 million and a contingent earn-out of $1.5 million on the Closing Date. The $1.8 million fair value of the contingent earn-out liability was reduced to zero in March 2015 upon Sangamo&#8217;s decision not to pursue development of Ceregene&#8217;s technology as discussed below.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets Acquired</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired included In-Process Research and Development (IPR&amp;D), which consisted of Ceregene&#8217;s two clinical product candidates, CERE-110 for the treatment of AD and CERE-120 for the treatment of Parkinson&#8217;s disease. The Company determined that the combined Closing Date estimated fair values of CERE-110 and CERE-120 was $1.9 million. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the year ended December 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets also included $1.6 million in goodwill, the excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed. Goodwill represents benefits that Sangamo believes will result from combining its operations with the operations of Ceregene and any intangible assets that do not qualify for separate recognition, as well as any future, yet unidentified products.&#160; The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There have been no changes to goodwill since the Closing Date, and no impairment has been recognized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7 &#8211; PROPERTY AND EQUIPMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,572</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,206</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,367</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,048</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,951</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,639</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in Progress</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,650</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,066</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $1.5 million in 2017, $1.0 million in 2016 and $1.0&nbsp;&nbsp;million in 2015.&nbsp;&nbsp;In 2017 the Company capitalized $20.9 million related to the fair value of the Brisbane building and $0.3 million of construction costs in Construction in Progress under the build-to-suit lease guidance (see Note 14). In 2016 the Company capitalized $3.9 million related to the costs of the Richmond construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. Both buildings will depreciate over the period of their lease, respectively. </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8 &#8211; COMMITMENTS AND CONTINGENCIES</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo occupies office and laboratory space under operating leases in Richmond, California. In August&#160;2013, Sangamo amended its lease agreement for our corporate headquarters wherein the lease was extended through August 2019. The Company has three additional properties located in Richmond, CA. This includes two leases, one to occupy approximately 7,700 square feet of research and office space that expires in August 2019, and another to occupy approximately 6,200 square feet of office space that expires in July 2021. Sangamo also has two build-to-suit leases to occupy approximately 41,400 square feet of space in Richmond that expires in December 2021 and approximately 87,700 square feet of space in Brisbane that expires in May 2029. Rent expense related to these lease agreements was $1.1 million, $1.0 million, and $0.9 million for 2017, 2016 and 2015, respectively. Future minimum payments under lease obligations at December&#160;31, 2017 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,685</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,925</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,798</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,434</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For 2018, the company is committed to spend $8.8 million for tenant improvements related to the Brisbane build-to-suit lease and $8.7 million as part of our services agreement with Brammer Bio MA, LLC, or Brammer, to provide dedicated capacity to supply our preclinical and clinical programs.&#160;The Company also has $5.2 million of license commitments related to its intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo is not party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9 &#8211; STOCKHOLDERS&#8217; EQUITY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has 5,000,000 preferred shares authorized, which may be issued at the discretion of the Company&#8217;s Board of Director&#8217;s discretion. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 26, 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5 million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $78.1 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At-the-Market Offering Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2016, we entered into an &#8220;at the market&#8221; offering agreement with an investment bank, pursuant to which we may issue and sell from time to time up to $75.0 million of our common stock through the bank as the sales agent (&#8220;ATM Agreement&#8221;). Under the ATM Agreement, if we decide to sell shares, the sales agent will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us.&nbsp;&nbsp;Sales of the common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The Nasdaq Global Market and any other trading market for the common stock, and sales to or through a market maker other than on an exchange. In addition, with our prior written consent, the sales agent may also sell our common stock in negotiated transactions.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a>On May 26, 2017, the Company entered into an Amended and Restated At-the-Market Offering Program Sales Agreement (the &#8220;2017 ATM Agreement&#8221;) with an investment bank pursuant to which the Company may issue and sell from time to time after the date of the 2017 ATM Agreement, shares of its common stock having an aggregate offering price of up to $75.0 million through the </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">93</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investment bank acting as the Company&#8217;s sal</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es agent. Under the 2017 ATM Agreement, if the Company decides to sell shares, the Company will notify the sales agent, and the sales agent will use its commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares of common stock reque</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sted to be sold.&nbsp;&nbsp;Sales of the Company&#8217;s common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The NA</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SDAQ Global Select Market and sales to or through a market maker other than on an exchange. In addition, with the Company&#8217;s prior written consent, the sales agent may also sell shares of its common stock in negotiated transactions under the 2017 ATM Agreem</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ent.&nbsp;&nbsp;During the three months ended March 31, 2017, the Company issued a total of 871,149 shares of its common stock under the original At-the-Market Offering Program Sales Agreement entered into with the sales agent in December 2016, and received net proc</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eeds of $3.4 million, after deducting offering expenses, including $0.1 million of commission paid to the sales agent. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior to the time the sha</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">res were sold.&nbsp;&nbsp;Consequently, the Company may be subject to claims for rescission by purchasers who purchased shares of common stock under the ATM Agreement in March 2017.&nbsp;&nbsp;Under Section 12(a)(1) of the Securities Act, a purchaser of security in a transact</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion made in violation of Section 5 of the Securities Act may obtain recovery of the consideration paid in connection with its purchase, plus statutory interest, or, if it had already sold the shares, recover damages resulting from its purchase. While the C</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ompany believes it is unlikely that a successful claim will be asserted against the Company by any purchasers who purchased shares of common stock under the ATM Agreement in March 2017, the Company cannot guarantee that no such legal claims will be asserte</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d against the Company by any purchasers. In addition, the Company could become subject to enforcement actions and/or penalties and fines by federal authorities, and the Company is unable to predict the likelihood of any such enforcement actions being broug</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ht, or the amount of any such potential penalties or fines. </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April&#160;2013 Sangamo&#8217;s Board of Directors adopted, subject to stockholder approval, the Company&#8217;s 2013 Stock Incentive Plan (the 2013 Plan) as the successor to the Company&#8217;s 2004 Stock Incentive Plan (the 2004 Plan). At the Annual Meeting of Stockholders held on June&#160;12, 2013, the 2013 Plan was approved by the Company&#8217;s stockholders and became effective. In connection with the approval by stockholders of the 2013 Plan, outstanding awards under the 2004 Plan were transferred to the 2013 Plan. The 2004 Plan was terminated and no further awards will be made pursuant to the 2004 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2013 Plan, the exercise price per share of options granted will generally not be less than 100 percent of the fair value per share of common stock on the grant date, and the option term will not exceed ten years. If the person to whom the option is granted is a 10 percent stockholder, and the option granted qualifies as an Incentive Stock Option Grant, then the exercise price per share will not be less than 110 percent of the fair value per share of common stock on the grant date, and the option term will not exceed five years. Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination. Certain options previously granted under the 2004 Plan to the Company&#8217;s non-employee directors are structured so that they may be exercised prior to vesting, with the related shares subject to Sangamo&#8217;s right to repurchase any shares that have not vested pursuant to the vesting schedule in effect for such award at the exercise price paid if the option holder&#8217;s board service terminates. Approximately 14.1&#160;million shares were initially reserved for issuance under the 2013 Plan, including 9.7&#160;million shares of common stock subject to outstanding awards previously granted under the 2004 Plan that were transferred to the 2013 Plan, and an additional 4.4&#160;million shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock reserved for issuance under the 2013 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;on a 1-for-1 basis for each share of common stock issued pursuant to a full value award granted under the plan prior to the plan effective date, and (iii)&#160;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan on or after the plan effective date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to any outstanding options or other awards under the 2013 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those options or awards will be available for subsequent issuance under the 2013 Plan. Any unvested shares issued under the 2013 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2013 Plan, will be added back to the number of shares reserved for issuance under the 2013 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015 Sangamo&#8217;s stockholders were asked to vote to approve the amendment and restatement of our 2013 Stock Incentive Plan in order to increase the number of shares in our common stock reserved for issuance over the term of the 2013 Plan by 5,300,000 shares. At the Annual Meeting of Stockholders held on June&#160;22, 2015, the amendment and restatement of our 2013 Stock Incentive Plan was approved by the Company&#8217;s stockholders and became effective.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">94</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On November&#160;10, 2017, the Compensation committee of the Company&#8217;s Board of Directors approved the amendment and restatement of the Company&#8217;s Amended and Restated 2013 Stock Incentive Plan, to reserve an additional one million shares of the Company&#8217;s common stock to be used exclusively for grants of awards to individuals who were not previously employees or&#160;non-employee&#160;directors of the Company (or following a bona fide period of&#160;non-employment&#160;with the Company), as an inducement material to each such individual&#8217;s entry into employment with us within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, or Rule 5635(c)(4). The 2013 Plan was amended and restated by the Compensation Committee without stockholder approval pursuant to Rule 5635(c)(4).</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s 2010 Employee Stock Purchase Plan (&#8220;Purchase Plan&#8221;), which supersedes the Company&#8217;s 2000 Employee Stock Purchase Plan, provides a total reserve of 2,100,000&#160;shares of common stock for issuance under the Purchase Plan. Eligible employees may purchase common stock at 85&#160;percent of the lesser of the fair market value of Sangamo&#8217;s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Option Activity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of Sangamo&#8217;s stock option activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual<font style="font-family:Calibri;">&#160;</font>Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In<font style="font-family:Calibri;">&#160;</font>thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2016</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,256,506</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.31</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,125</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.48</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,030,815</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.76</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,029,360</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest at December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,864</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&#8217;s right of repurchase as of December&#160;31, 2017. The intrinsic value of options exercised was $12.3 million, $0.1 million and $6.4 million during 2017, 2016 and 2015, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2017, the aggregate intrinsic values of outstanding and exercisable options were $71.7&#160;million and $28.9 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December 31, 2017, 2016 and 2015 was $71.7 million, $0.0 million and $14.0 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information with respect to stock options outstanding at December&#160;31, 2017: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">95</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding and Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common&#160;stock</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject&#160;to</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.55 &#8211; $3.45</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612,318</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.92</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,920</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.50 &#8211; $3.50</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527,625</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.07</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.55 &#8211; $5.41</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212,567</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.24</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672,930</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.34</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.42 &#8211; $7.07</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501,051</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.53</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">967,506</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.11</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.20 &#8211; $9.41</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,546</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.17</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551,162</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.06</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.45 &#8211; $13.35</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885,599</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.52</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659,946</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.92</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.54 &#8211; $15.00</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,148,250</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668,752</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.07</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15.11 &#8211; $18.26</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,000</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.31</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,561</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.41</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.51 &#8211; $19.51</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,583</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.51</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.80 &#8211; $19.80</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,718</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.80</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, 2016 and 2015, the Company awarded 12,600, 60,000, and 446,000&nbsp;&nbsp;Restricted Stock Units (RSUs), respectively. The RSUs awarded in 2017, 2016 and 2015 had an average grant date fair value per award of $15.85, $5.16 and $9.45, respectively. These awards generally vest as follows: one-third of the award will vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2017, 2016 and 2015 was $1.2 million, $4.8 million and $4.1 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of Sangamo&#8217;s RSU activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate&#160;Intrinsic</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2016</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,816</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,600</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,917</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,327</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested and expected to vest at December 31, 2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs that vested in 2017, 2016 and 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 42,243, 165,181, and 172,807 for 2017, 2016 and 2015, respectively and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities were $0.7 million, $0.8 million and $1.5 million in 2017, 2016 and 2015, respectively and are reflected as a financing activity within the accompanying consolidated statements of cash flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, there were 3,601,633 shares reserved for future awards under the Company&#8217;s 2013 Plan and 835,674 shares of common stock reserved for future issuance under the Purchase Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10 &#8211; INCOME TAXES </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The benefit for income taxes consisted of the following (in thousands):&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes:</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,563</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> State</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax<font style="color:#000000;"> rate </font>(34%)<font style="color:#000000;"> to loss before taxes is explained as follows (in thousands):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at federal statutory rate</p></td>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,553</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,369</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,785</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(747</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Rate Change</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible stock compensation</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,120</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,781</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,085</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research credits</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(869</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,424</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(814</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,773</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets:</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,308</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,222</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,147</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,168</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">934</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,492</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Liabilities:</font></p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability related to intangible assets</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2013, we acquired Ceregene.&nbsp;&nbsp;The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Ceregene. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;D and are considered indefinite-lived assets with no tax basis. In 2015, the Company impaired these intangible assets and reversed the corresponding deferred tax liability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015 the Company received a $14.5 million Section 16(b) disgorgement settlement that was r</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ecognized as additional paid-in capital. The disgorgement settlement was recognized net of taxes of $9.5 million, which resulted in an income tax benefit of $5.0 million being recognized in the accompanying consolidated statements of operations for the yea</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">r ended December 31, 2015.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance (decreased) increased by $(28.9) million, $23.8 million and $5.0 million for the years ended December&#160;31, 2017, 2016 and 2015, respectively. As of December&#160;31, 2017, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $475&#160;million and $142 million, respectively. If not utilized, the net federal and state operating loss carryforwards will expire in 2018 and 2017, respectively. The Company also has federal and state research tax credit carryforwards of $10.8&#160;million and $11.8 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act ("Tax Reform") into legislation.&#160; The Tax Reform makes significant changes to the US corporate income tax law including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21% from 35% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of US subsidiaries.&#160; Under ASC 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted.&#160; In the case of US federal income taxes, the enactment date is the date the bill becomes law.&#160;&#160;&#160; With respect to this legislation, we expect no financial statement impact due to the Company's valuation allowance.&#160; The Company performed a re-measurement of deferred tax assets and liabilities as a result of the decrease in the corporate Federal income tax rate from 35% to 21%. In addition to the reduction of U.S. federal corporate tax rate, the Company has also considered the impact of the foreign transition tax for which it has estimated that it would not need to accrue any amounts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No.118 (SAB 118) to provide guidance on the application of the Tax Reform when a company does not have the necessary information available, prepared, or analyzed in reasonable to detail to reflect the effects of the Tax Reform.&#160; SAB 118 provides guidance for companies under the three scenarios (1) measurement of certain income tax effects is complete, (2) measurement of certain income tax effect can be reasonably estimated, and (3) measurement of certain income tax effects cannot be reasonably estimated.&#160; Companies are to complete the accounting under ASC 740 in regards to the Tax Reform within a measurement period that does not extend one year from the date of enactment (i.e., December 22, 2018).&#160; In accordance with SAB 118, companies must reflect the tax effects of the Tax Reform for which the accounting under 740 is complete. If certain income tax effect can be reasonably estimated, then the companies must report provisional amounts in the reporting period in which the companies can determine the reasonable estimate during the measurement period.&#160; In the case that certain income tax effects cannot be reasonably estimated, companies do not have to report effects of the Tax Reform.&#160; However, they should continue to apply ASC 740 based on the rules before the enactment of the Tax Reform and report any income tax effects in the first reporting period in which reasonable estimates become available.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the new law to significantly reduce our tax rate in future periods, and our tax footnote reflects the effects of a Federal tax rate reduction net of our valuation allowance, which resulted in a net overall reduction of $0.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the company has utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries.&#160; In accordance with SAB 118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.&#160; We currently anticipate finalizing and recording any resulting adjustments by year ending December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files a UK income tax return, and the tax years from 2008 and thereafter remain open to examination.</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">98</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2017, the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">will not be affected.</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,438</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,023</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of prior years</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,335</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions of prior years</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,335</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,659</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11 &#8211; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable and accrued liabilities consist of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,898</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,386</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued liabilities</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,035</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12 &#8211; EMPLOYEE BENEFIT PLAN </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company matched employee contributions equal to 50% for the first 8% in 2017 and 6% in both 2016 and 2015, respectively, up to a limit of $4,000 in 2017 and $3,000 in both 2016 and 2015, respectively. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $0.5 million, $0.3 million, and $0.3 million for the years ended December&#160;31, 2017, 2016 and 2015, respectively. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13 &#8211; QUARTERLY FINANCIAL DATA (UNAUDITED) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2016. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,253</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,812</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,077</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,702</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,823</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,922</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,217</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,021</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,847</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,843</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,623</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,544</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,029</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,752</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,632</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,491</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,354</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,091</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,494</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,575</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,965</p></td>
<td valign="bottom"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,624</p></td>
<td valign="top"  BGCOLOR="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.38</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.27</p></td>
<td valign="bottom"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.14</p></td>
<td valign="top"  BGCOLOR="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU96"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">14 &#8211; BUILD-TO-SUIT LEASE </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Brisbane Build-to-Suit Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 87,700 square feet of space, in Brisbane, California. Substantial completion of the building is estimated to occur in the last quarter of 2018. The lease agreement expires in May 2029, approximately ten years after substantial completion of the building. A letter of credit for $3.5 million was established as the deposit and is classified within other noncurrent assets in the financial statements. The Company has two options to extend the lease term for up to a combined additional ten years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner as a result of the cold shell condition of the building and involvement in the construction process. In connection with the Company&#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation, including interest. Fair value of the building was estimated at $20.9 million using comparable market prices per square foot for similar space for public real estate transactions in the surrounding area and is considered a Level 2 fair value measurement. As of December 31, 2017, $21.2 million was capitalized with a corresponding build-to-suit lease obligation recognized related to this lease for the building and construction costs.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Point Pinole Build-to-Suit Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 41,400 square feet of space, in Richmond, California. Substantial completion of the building was accomplished in December 2016 at which time the lease commenced. The lease agreement expires in December 2021, five years after substantial completion of the building. The Company has two options to extend the lease term for up to a combined additional ten years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner. In connection with the Company&#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. As of December 31, 2016, $3.9 million of costs were capitalized in buildings with a corresponding build-to-suit lease obligation recognized related to this lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction has completed on the facility and as such a portion of the monthly lease payment is allocated to land rent and recorded as an operating lease expense and the non-interest portion of the amortized lease payments to the landlord related to the rent of the building is applied to reduce the build-to-suit lease obligation. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 15 &#8211; CLAIMS SETTLEMENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In September 2015, the Company received $14.5 million as a settlement with certain institutional investors that were beneficial owners of Sangamo&#8217;s common stock related to the disgorgement of short-swing profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.&#160; The settlement of $9.5 million, net of a $5.0 million income tax benefit and certain expenses, was recognized as additional paid-in capital. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 16 &#8211; SUBSEQUENT EVENT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:6.67%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2018, the Company entered into a Collaboration and License Agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc. (&#8220;Gilead&#8221;), for the research, development and commercialization of potential engineered cell therapies for cancer. The Company will work together with Kite on a research program under which the Company ZFNs and AAVs to disrupt and insert certain genes in T cells and NK cells, including the insertion of genes that encode CARs, T-cell receptors (&#8220;TCRs&#8221;) and NK cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets.&nbsp;&nbsp;Kite will be responsible for all clinical development and commercialization of any resulting products. Except for confidentiality obligations and certain representations, warranties and covenants, which are effective upon execution, the effectiveness of the Kite agreement is subject to the expiration or termination of all applicable waiting periods under the Hart<font style="Background-color:#FFFFFF;color:#000000;">-Scott-Rodino Antitrust Improvements Act of 1976, as amended</font> and other customary closing conditions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU97"></a>Under the terms of the Kite agreement, the Company will, upon the effectiveness of the Kite agreement, receive a $150 million upfront payment from Kite. Kite will reimburse the Company&#8217;s direct costs to conduct the joint research program under the Kite agreement, and Kite will be operationally and financially responsible for all subsequent development, manufacturing and commercialization of licensed products. The Company is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01 billion if all of the specified milestones set forth in the Kite agreement are achieved.&#160;Of this amount, approximately $1.26 billion relates to the achievement of specified research, clinical development, regulatory and first </p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">100</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">commercial sale milestones, and approximately $</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.75</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> billion rela</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tes to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i) only once for each licensed product, regardless of the </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone e</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vent.&nbsp;&nbsp;</font><font style="color:#000000;">In addition, </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Company </font><font style="color:#000000;">will be entitled to receive escalating, tiered royalty payments with a percentage in the mid-single digits based on potential future annual worldwide net sales of l</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">icensed products. These royalty payments will be subject to </font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&nbsp;&nbsp;At this time the Company is assessing the accounting impact of the agreement.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU98"></a><a name="Changes_in_and_Disagreements_with_Accoun"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Changes_in_and_Disagreements_with_Accoun"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM&#160;9 &#8211; CHA</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Controls_and_Procedures"></a><a name="Controls_and_Procedures"></a>ITEM&#160;9A &#8211; CONTROLS AND PROCEDURES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Evaluation of Disclosure Controls and Procedures </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We maintain disclosure controls and procedures that are designed to provide reasonable assurance that information required to be disclosed in our Exchange Act reports is recorded, processed, summarized and reported within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the supervision of our principal executive officer and principal financial officer, we evaluated the effectiveness of our disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) of the Exchange Act) as of December 31, 2017.&#160;&#160;Based on that evaluation, as of December 31, 2017,<font style="font-weight:bold;"> </font>our principal executive officer and principal financial officer have concluded that our disclosure controls and procedures were effective at the reasonable assurance level. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Inherent Limitations on Controls and Procedures</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management, including the principal executive officer and principal financial officer, does not expect that our disclosure controls and procedures and our internal control over financial reporting will prevent all error and all fraud. A control system, no matter how well designed and operated, can only provide reasonable assurances that the objectives of the control system are met. The design of a control system reflects resource constraints; the benefits of controls must be considered relative to their costs. Because there are inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, for our company have been or will be detected. As these inherent limitations are known features of the disclosure and financial reporting processes, it is possible to design into the processes safeguards to reduce, though not eliminate, these risks. These inherent limitations include the realities that judgments in decision-making can be faulty and that breakdowns occur because of simple error or mistake. Controls can also be circumvented by the individual acts of some persons, by collusion of two or more people, or by management override of the control. The design of any system of controls is based in part upon certain assumptions about the likelihood of future events. While our disclosure controls and procedures and our internal control over financial reporting are designed to provide reasonable assurance of achieving their objectives, there can be no assurance that any design will succeed in achieving its stated goals under all future conditions. Over time, controls may become inadequate because of changes in conditions or deterioration in the degree of compliance with the policies or procedures. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Management&#8217;s Report on Internal Control over Financial Reporting </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our management is responsible for establishing and maintaining an adequate internal control over financial reporting (as such term is defined in Rules 13a-15(f) and 15d-15(f) of the Exchange Act) for our company. Our management, including our principal executive officer and principal financial officer, conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework set forth in the &#8220;Internal Control&#8212;Integrated Framework&#8221; issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework). Based on an evaluation under that framework, our management concluded that our internal control over financial reporting was effective at the reasonable assurance level as of December&#160;31, 2017.&nbsp;&nbsp; </p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The effectiveness of our internal control over financial reporting as of December&#160;31, 2017 has been audited by Ernst&#160;&amp; Young LLP, an independent registered public accounting firm, as stated in their report, which is included herein.</p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Changes in Internal Control over Financial Reporting</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_294"></a><a name="_cp_text_4_295"></a><a name="_cp_text_1_289"></a><a name="_cp_text_1_292"></a>There have been no changes in our internal control over financial reporting identified in connection with the evaluation required by Rules&#160;13a-15(d) and 15d-15(d) of the Exchange Act that occurred during the three months ended December 31, 2017 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU99"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Report of Independent Registered Public Accounting Firm</font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Board of Directors and Stockholders of Sangamo Therapeutics, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Opinion on Internal Control over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We have audited Sangamo Therapeutics, Inc.&#8217;s internal control over financial reporting as of December 31, 2017, based on criteria established in Internal Control Integrated Framework issued by the Committee of Sponsoring Organizations of the Treadway Commission (2013 framework) (the COSO criteria). In our opinion, Sangamo Therapeutics, Inc. (the Company) maintained, in all material respects, effective internal control over financial reporting as of December 31, 2017, based on the COSO criteria. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We also have audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the 2017 consolidated financial statements of the Company and our report dated March 1, 2018 expressed an unqualified opinion thereon. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Basis for Opinion </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting included in the accompanying Management&#8217;s Report on Internal Control Over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB. &#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Definition and Limitations of Internal Control Over Financial Reporting </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/&#160;ERNST&#160;&amp; YOUNG LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU100"></a><a name="Other_Information"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Other_Information"></a>I</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TEM&#160;9B &#8211; OTHER INFORMATION </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_III"></a><a name="PART_III"></a>PART&#160;III </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Certain information required by Part&#160;III is omitted from this Report on Form&#160;10-K because we intend to file our definitive Proxy Statement for our next Annual Meeting of Stockholders, pursuant to Regulation&#160;14A of the Securities Exchange Act of 1934, as amended (the 2018 Proxy Statement), no later than April&#160;30, 2018, and certain information to be included in the 2018 Proxy Statement is incorporated herein by reference. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Directors_Executive_Officers_and_Corpor"></a><a name="Directors_Executive_Officers_and_Corpor"></a>ITEM&#160;10 &#8211; DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item concerning our directors, executive officers, Section&#160;16 compliance and corporate governance matters is incorporated by reference in our 2018 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Executive_Compensation"></a><a name="Executive_Compensation"></a>ITEM&#160;11 &#8211; EXECUTIVE COMPENSATION<font style="font-weight:normal;"> </font></p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding executive compensation is incorporated by reference in our 2018 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:9.33%;text-indent:-9.33%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Security_Ownership_of_Certain_Beneficial"></a><a name="Security_Ownership_of_Certain_Beneficial"></a>ITEM&#160;12 &#8211; SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding security ownership of certain beneficial owners and management is incorporated by reference in our 2018 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Certain_Relationships_and_Related_Transa"></a><a name="Certain_Relationships_and_Related_Transa"></a>ITEM&#160;13 &#8211; CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding certain relationships and related transactions is incorporated by reference in our 2018 Proxy Statement. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Principal_Accounting_Fees_and_Services"></a><a name="Principal_Accounting_Fees_and_Services"></a>ITEM&#160;14 &#8211; PRINCIPAL ACCOUNTING FEES AND SERVICES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The information required by this item regarding principal accounting fees and services is incorporated by reference in our 2018 Proxy Statement. </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="PART_IV"></a><a name="PART_IV"></a>PART&#160;IV </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:8.54%;text-indent:-8.54%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="Exhibits_and_Financial_Statement_Schedul"></a><a name="Exhibits_and_Financial_Statement_Schedul"></a>ITEM&#160;15 &#8211; EXHIBITS AND FINANCIAL STATEMENT SCHEDULES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) The following documents are included as part of this Annual Report on Form 10-K: </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1. Financial Statements&#8212;See Index to Consolidated Financial Statements in Item&#160;8. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2. Financial Statement Schedules&#8212;Not Applicable. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:9.06%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3. Exhibits </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.54%;">
<tr>
<td valign="bottom"  style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br /><font style="text-decoration:underline;">Number</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:89%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Document</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017017005/sgmo-ex31_651.htm"><font style="text-decoration:none;">Seventh Amended and Restated Certificate of Incorporation, as amended (incorporated by reference to Exhibit&#160;3.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;3.2</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017017005/sgmo-ex32_652.htm"><font style="text-decoration:none;">Second Amended and Restated Bylaws, as amended (incorporated by reference to Exhibit&#160;3.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;&#160;&#160;4.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312517003781/d304900dex41.htm"><font style="text-decoration:none;">Form of Specimen Common Stock Certificate (incorporated by reference to Exhibit&#160;4.1 to the Company&#8217;s Current Report on Form&#160;8-K filed January 6, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.1(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312517342582/d480899dex991.htm"><font style="text-decoration:none;">Amended and Restated 2013 Stock Incentive Plan (the &#8220;2013 Plan&#8221;) (incorporated by reference to Exhibit&#160;99.1 to the Company&#8217;s Current Report on Form&#160;8-K filed November 14, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.2(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex102_368.htm"><font style="text-decoration:none;">Form of Restricted Stock Unit Award Agreement under the 2013 Plan.</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.54%;">
<tr>
<td valign="bottom"  style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br /><font style="text-decoration:underline;">Number</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:89%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Document</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU101"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.3(+)</font></p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513259487/d554133dex103.htm"><font style="text-decoration:none;">Form of Notice of Grant of Stock Option under the 2013 Plan (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.4(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513259487/d554133dex104.htm"><font style="text-decoration:none;">Form of Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.5(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513259487/d554133dex105.htm"><font style="text-decoration:none;">Form of Notice of Grant of Stock Option &#8211; Director Initial Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.5 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.6(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513259487/d554133dex106.htm"><font style="text-decoration:none;">Form of Notice of Grant of Stock Option &#8211; Director Annual Grant under the 2013 Plan (incorporated by reference to Exhibit&#160;10.6 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.7(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513259487/d554133dex107.htm"><font style="text-decoration:none;">Form of Automatic Stock Option Agreement under the 2013 Plan (incorporated by reference to Exhibit&#160;10.7 to the Company&#8217;s Current Report on Form 8-K filed June 14, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.8(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1001233/000119312510088894/ddef14a.htm"><font style="text-decoration:none;">2010 Employee Stock Purchase Plan (incorporated by reference to Appendix B to the Company&#8217;s Definitive Proxy Statement on Schedule 14A filed April 21, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.9(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017010305/sgmo-ex104_8.htm"><font style="text-decoration:none;">Executive Severance Plan (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2017). </font></a> </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.10(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459015006479/sgmo-ex102_19.htm"><font style="text-decoration:none;">Form of Indemnification Agreement (incorporated by reference to Exhibit&#160;10.2 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 6, 2015). </font></a> </p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.11(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459016022708/sgmo-ex101_285.htm"><font style="text-decoration:none;">Employment Agreement between the Company and Alexander (Sandy) Macrae, dated May 17, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 4, 2016).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.12(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017010305/sgmo-ex101_7.htm"><font style="text-decoration:none;">Employment Agreement between the Company and Kathy Yi, dated February 28, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.13(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex1013_620.htm"><font style="text-decoration:none;">Offer Letter between the Company and Curt A. Herberts, dated August 16, 2010.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.14(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017010305/sgmo-ex103_10.htm"><font style="text-decoration:none;">Employment Agreement between the Company and Edward Conner, dated November 1, 2016 (incorporated by reference to Exhibit 10.3 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 10, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.15(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312509043753/dex1026.htm"><font style="text-decoration:none;">Amended and Restated Employment Agreement between the Company and&nbsp;&nbsp;H. Ward Wolff, dated December 31, 2008 (incorporated by reference to Exhibit 10.26 to the Company&#8217;s Annual Report on Form 10-K filed March 3, 2009).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.16(+)</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex1016_688.htm"><font style="text-decoration:none;">Separation Agreement between the Company and Dale Ando, dated February 21, 2017.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.17</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/1001233/000095014900000384/0000950149-00-000384.txt"><font style="text-decoration:none;">Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated May&#160;23, 1997 (incorporated by reference to Exhibit 10.5 to the Company&#8217;s Registration Statement on Form&#160;S-1 (Reg. No.&#160;333-30314), as amended, filed February 24, 2000).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.18</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000095014905000054/f05860exv10w20.htm"><font style="text-decoration:none;">First Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;12, 2004 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form&#160;10-K filed February 23, 2005).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.19</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513425338/d595389dex101.htm"><font style="text-decoration:none;">Second Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated March&#160;15, 2007 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4, 2013).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.20</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312513425338/d595389dex102.htm"><font style="text-decoration:none;">Third Amendment to Triple Net Laboratory Lease between the Company and Point Richmond R&amp;D Associates II, LLC, dated August 1, 2013 (incorporated by reference to Exhibit 10.2 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed November 4).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.21</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex1021_830.htm"><font style="text-decoration:none;">Lease Agreement between the Company and Marina Boulevard Property, LLC dated November 3, 2017.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.22</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312517185733/d261905dex11.htm"><font style="text-decoration:none;">Amended and Restated Sales Agreement between the Company and Cowen LLC, dated May 26, 2017 (incorporated by reference to Exhibit 1.1 to the Company&#8217;s Current Report on Form 8-K filed May 26, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.23</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510089133/dex104.htm"><font style="text-decoration:none;">Patent License Agreement between the Company and Massachusetts Institute of Technology, dated May&#160;9, 1996, as amended by the First Amendment, dated December 10, 1997 (incorporated by reference to Exhibit&#160;10.4 to the Company&#8217;s Annual Report on Form&#160;10-K/A filed April 22, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.24&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex108.htm"><font style="text-decoration:none;">Second Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated December 2, 1998 (incorporated by reference to Exhibit 10.8 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">105</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.54%;">
<tr>
<td valign="bottom"  style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br /><font style="text-decoration:underline;">Number</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:89%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Document</font></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU102"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.25&#8224;</font></p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1010.htm"><font style="text-decoration:none;">Third Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated September&#160;1, 1999 (incorporated by reference to Exhibit 10.10 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.26</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1011.htm"><font style="text-decoration:none;">Fourth Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated February 10, 2000 (incorporated by reference to Exhibit 10.11 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.27&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1014.htm"><font style="text-decoration:none;">Fifth Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, effective as of December 15, 2000 (incorporated by reference to Exhibit 10.14 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.28&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1017.htm"><font style="text-decoration:none;">Sixth Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated September 1, 2005 (incorporated by reference to Exhibit 10.17 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.29&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1020.htm"><font style="text-decoration:none;">Seventh Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated October 27, 2006 (incorporated by reference to Exhibit 10.20 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr style="height:29.25pt;">
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.30</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1023.htm"><font style="text-decoration:none;">Eighth Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated February 1, 2007 (incorporated by reference to Exhibit 10.23 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.31</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312514187386/d699448dex103.htm"><font style="text-decoration:none;">Ninth Amendment to Patent License Agreement between the Company and Massachusetts Institute of Technology, dated March 14, 2014 (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 7, 2014).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.32</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510089133/dex103.htm"><font style="text-decoration:none;">Sublicense Agreement between the Company and Johnson&#160;&amp; Johnson, dated May&#160;9, 1996 (incorporated by reference to Exhibit&#160;10.3 to the Company&#8217;s Annual Report on Form&#160;10-K/A filed April 22, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.33</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1013.htm"><font style="text-decoration:none;">License Agreement between the Company and The Scripps Research Institute, dated March&#160;14, 2000 (incorporated by reference to Exhibit 10.13 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.34&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312510049073/dex1032.htm"><font style="text-decoration:none;">Amendment to License Agreement between the Company and The Scripps Research Institute, dated April 29, 2008 (incorporated by reference to Exhibit 10.32 to the Company&#8217;s Annual Report on Form&#160;10-K filed March&#160;5, 2010).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.35&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459015009009/sgmo-ex101_99.htm"><font style="text-decoration:none;">Amended and Restated Collaboration and License Agreement between the Company and Shire International GmbH, dated September 1, 2015 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed October 30, 2015).</font> </a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.36&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000119312514187386/d699448dex101.htm"><font style="text-decoration:none;">Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated January 8, 2014 (incorporated by reference to Exhibit&#160;10.1 to the Company&#8217;s Quarterly Report on Form&#160;10-Q filed May 7, 2014).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.37&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459016012882/sgmo-ex1063_373.htm"><font style="text-decoration:none;">Letter Amendment to Global Research, Development and Commercialization Collaboration and License Agreement between the Company and Biogen MA Inc. (Bioverativ Inc.), dated December 14, 2015 (incorporated by reference to Exhibit 10.63 to the Company&#8217;s Annual Report on Form 10-K filed February 18, 2016).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:1.3pt;;text-indent:-1.3pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.38&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459016018000/sgmo-ex101_333.htm"><font style="text-decoration:none;">Letter Agreement and Waiver between the Company and Biogen MA Inc. (Bioverativ Inc.), dated March 24, 2016 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed May 5, 2016).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-bottom:6pt;margin-top:6pt;margin-left:1.3pt;;text-indent:-1.3pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.39&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="http://www.sec.gov/Archives/edgar/data/0001001233/000156459017017005/sgmo-ex101_575.htm"><font style="text-decoration:none;">Collaboration and License Agreement between the Company and Pfizer Inc., dated May 10, 2017 (incorporated by reference to Exhibit 10.1 to the Company&#8217;s Quarterly Report on Form 10-Q filed August 9, 2017).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:1.3pt;;text-indent:-1.3pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;10.40&#8224;</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex1040_689.htm"><font style="text-decoration:none;">Research Collaboration and License Agreement between the Company and Pfizer Inc., dated December 28, 2017.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;21.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex211_12.htm"><font style="text-decoration:none;">Subsidiaries of the Company</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;23.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex231_11.htm"><font style="text-decoration:none;">Consent of Independent Registered Public Accounting Firm.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;24.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="#SIGNATURES"><font style="text-decoration:none;">Power of Attorney (included on signature page).</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.1</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex311_10.htm"><font style="text-decoration:none;">Rule&#160;13a-14(a) Certification of Principal Executive Officer.</font></a></p></td>
</tr>
<tr>
<td valign="top"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;31.2</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex312_9.htm"><font style="text-decoration:none;">Rule&#160;13a-14(a) Certification of Principal Financial Officer.</font></a></p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="padding-left:7.2pt;width:11%;white-space:nowrap;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;32.1*</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a href="sgmo-ex321_8.htm"><font style="text-decoration:none;">Certification Pursuant to 18 U.S.C. Section&#160;1350.</font></a></p></td>
</tr></table></div>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106</p>
<hr style="page-break-after:always;width:100%;">
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:98.54%;">
<tr>
<td valign="bottom"  style="width:11%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit<br /><font style="text-decoration:underline;">Number</font></p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:89%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Description of Document</font></p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU103"></a><font style="font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.INS</font></p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Instance Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.SCH</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Schema Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.CAL</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Calculation Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.DEF</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Definition Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.LAB</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Label Linkbase Document</p></td>
</tr>
<tr style="height:6pt;">
<td valign="top"  style="width:11%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101.PRE</p></td>
<td valign="top"  style="width:89%;">
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">XBRL Taxonomy Extension Presentation Linkbase Document</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:11%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:89%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;margin-right:86.67%;text-indent:0%;font-size:6pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8224;</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">Confidential treatment has been granted for certain information contained in this document pursuant to an order of the Securities and Exchange Commission. Such information has been omitted and filed separately with the Securities and Exchange Commission. </font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:-4.54%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(+)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Indicates management contract or compensatory plan or arrangement. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">*</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;"><font style="font-style:italic;">The certifications attached as Exhibit 32.1 accompany this Annual Report on Form 10-K pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, and shall not be deemed &#8220;filed&#8221; by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended.</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"><a name="ITEM_16_FORM_10K_SUMMARY"></a><a name="ITEM_16_FORM_10K_SUMMARY"></a>ITEM 16 &#8211; FORM 10-K SUMMARY</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">107</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU104"></a><a name="SIGNATURES"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="SIGNATURES"></a>SIGNAT</font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">URES </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of Section&#160;13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized, on March 1,&#160;2018. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2018</p>
<div align="right">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td colspan="3" valign="top"  style="width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC.</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:90.54%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;text-align:left;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:6.68%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;text-align:left;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top"  style="width:2.78%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:90.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;&#160;A<font style="font-size:7.5pt;">LEXANDER </font>M<font style="font-size:7.5pt;">ACRAE</font></p></td>
</tr>
<tr>
<td valign="top"  style="width:6.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:90.54%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alexander Macrae</p></td>
</tr>
<tr>
<td valign="top"  style="width:6.68%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="top"  style="width:2.78%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;text-align:left;">&nbsp;</p></td>
<td valign="bottom"  style="width:90.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;font-size:8pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">President, and Chief Executive Officer</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:5.15%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Alexander Macrae, Kathy Y. Yi, and Heather Turner, and each of them, as his or her true and lawful attorneys-in-fact and agents, each with the full power of substitution, for him or her and in his or her name, place or stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or their, his or her substitute or substitutes, may lawfully do or cause to be done by virtue hereof.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom"  style="width:38.44%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Signature</font></p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:41.24%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Title</font></p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:8pt;">&nbsp;</p></td>
<td valign="bottom"  style="padding-left:7.2pt;padding-Right:0pt;padding-Top:0pt;padding-Bottom:0pt;width:18.48%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Date</font></p></td>
</tr>
<tr style="height:5.85pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;&#160;A<font style="font-size:7.5pt;">LEXANDER </font>M<font style="font-size:7.5pt;">ACRAE</font></p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td rowspan="2" valign="bottom"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President,&#160;Chief&#160;Executive&#160;Officer&#160;(Principal&#160;Executive Officer) and Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;&#160;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Alexander Macrae</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:6.75pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;&#160;Kathy Y. Yi</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="bottom"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior&#160;Vice&#160;President&#160;and<br />Chief&#160;Financial&#160;Officer&#160;(Principal&#160;Financial and Accounting Officer)</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Kathy Y. Yi</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;&#160;H. S<font style="font-size:7.5pt;">TEWART</font> P<font style="font-size:7.5pt;">ARKER</font> </p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director and Chairman of the Board</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">H. Stewart Parker</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;<font style="font-variant: small-caps;">Robert F. Carey </font></p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Robert F Carey </p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:4.5pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/&#160;<font style="font-size:7.5pt;">S</font>&#160;/&#160;&#160;&#160;&#160;S<font style="font-size:7.5pt;">TEPHEN</font>&#160; G.&#160;D<font style="font-size:7.5pt;">ILLY</font>,&#160;M.B.B.S,&#160;P<font style="font-size:7.5pt;">H</font>.D</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Stephen G. Dilly, M.B.B.S, Ph.D</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:5.4pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">/s/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-variant: normal;">Roger Jeffs,&#160;P</font><font style="font-size:7.5pt;font-variant: normal;">H</font><font style="font-variant: normal;">.D</font></p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Roger Jeffs, Ph.D</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-variant: small-caps;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;">/s/&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<font style="font-variant: normal;">S</font><font style="font-size:7.5pt;font-variant: normal;">TEVEN</font><font style="font-variant: normal;"> J. M</font><font style="font-size:7.5pt;font-variant: normal;">ENTO</font><font style="font-variant: normal;">, P</font><font style="font-size:7.5pt;font-variant: normal;">H</font><font style="font-variant: normal;">.D</font></p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Steven J. Mento, Ph.D </p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr style="height:3.7pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;S<font style="font-size:7.5pt;">AIRA</font> R<font style="font-size:7.5pt;">AMASASTRY</font>&#160;</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Saira Ramasastry </p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="middle"  style="width:38.44%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:41.24%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
<td valign="middle"  style="width:18.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:6pt;">&nbsp;</p></td>
</tr>
<tr style="height:12pt;">
<td valign="bottom"  style="width:38.44%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/ <font style="font-size:7.5pt;">S</font> /&#160;&#160;&#160;&#160;<font style="font-variant: small-caps;">Joseph S. Zakrzewski</font></p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td rowspan="2" valign="top"  style="width:41.24%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Director</p></td>
<td valign="top"  style="width:0.92%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr>
<td valign="top"  style="width:38.44%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joseph S. Zakrzewski</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:0.92%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
<td valign="top"  style="width:18.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">108</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>2
<FILENAME>sgmo-ex102_368.htm
<DESCRIPTION>EX-10.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex102_368.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">EXHIBIT 10.2</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">SANGAMO therapeutics, INC.</p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><br /><font style="text-decoration:underline;">RESTRICTED STOCK UNIT ISSUANCE AGREEMENT</font></p>
<p style="margin-bottom:0pt;text-align:center;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">The Board has adopted the Plan for the purpose of retaining the services of selected Employees, non-employee members of the Board (or the board of directors of any Parent or Subsidiary) and consultants and other independent advisors who provide services to the Corporation (or any Parent or Subsidiary).</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Participant is to render valuable services to the Corporation (or a Subsidiary), and this Agreement is executed pursuant to, and is intended to carry out the purposes of, the Plan in connection with the Corporation&#8217;s issuance of shares of Common Stock to the Participant under the Stock Issuance Program.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">All capitalized terms in this Agreement shall have the meaning assigned to them in the attached Appendix A.</p></td></tr></table></div>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0.96%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE<font style="font-weight:normal;">, it is hereby agreed as follows:</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">1.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Grant of Restricted Stock Units</font><font style="text-decoration:none;">.&nbsp;&nbsp;The Corporation hereby awards to the Participant, as of the Award Date, Restricted Stock Units under the Plan. Each Restricted Stock Unit represents the right to receive one share of Common Stock on the specified issuance date following the vesting of that unit.&nbsp;&nbsp;The number of shares of Common Stock subject to the awarded Restricted Stock Units, the applicable vesting schedule for those shares, the date on which those vested shares shall become issuable to Participant and the remaining terms and conditions governing the award (the &#8220;Award&#8221;) shall be as set forth in this Agreement.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">AWARD SUMMARY</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:104.4pt;"></td>
<td style="width:374.4pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Award Date:</font></p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Number of Shares Subject to Award: </font></p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ] shares of Common Stock (the &#8220;Shares&#8221;)&nbsp;&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Vesting Schedule:</font></p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided the Participant continues in Service through each date, 50% of the Shares shall vest on the six-month anniversary of the Award Date and 50% of the Shares shall vest on the one-year anniversary of the Award Date.&nbsp;&nbsp;However, one or more Shares may be subject to accelerated vesting in accordance with the provisions of Paragraph 5 of this Agreement. </p></td>
</tr></table></div>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.8pt;;">
<tr>
<td style="width:104.4pt;"></td>
<td style="width:374.4pt;"></td>
</tr>
<tr style="height:108pt;">
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="text-decoration:underline;">Issuance Schedule:</font></p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to Paragraph 7 of this Agreement, each Share in which the Participant vests in accordance with the Vesting Schedule above shall be issued, subject to the Corporation&#8217;s collection of all applicable Withholding Taxes, on the date that particular Share vests or as soon after that scheduled vesting date as administratively practicable (the &#8220;Issue Date&#8221;), but in no event later than the later of (i) the close of the calendar year in which such vesting date occurs or (ii) the fifteenth day of the third calendar month following such vesting date.&nbsp;&nbsp;The issuance of the Shares shall be subject to the Corporation&#8217;s collection of all applicable Withholding Taxes.&nbsp;&nbsp;The procedures pursuant to which the applicable Withholding Taxes are to be collected are set forth in Paragraph 7 of this Agreement.</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.</font><font style="text-decoration:none;margin-left:90pt;"></font><font style="text-decoration:none;font-weight:bold;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Limited Transferability</font><font style="text-decoration:none;">.&nbsp;&nbsp;Prior to the actual issuance of the Shares which vest hereunder, the Participant may not transfer any interest in the Award or the underlying Shares; </font><font style="font-weight:bold;font-style:italic;text-decoration:none;">provided, however,</font><font style="text-decoration:none;"> any Shares which vest hereunder but which otherwise remain unissued at the time of the Participant&#8217;s death may be transferred pursuant to the provisions of the Participant&#8217;s will or the laws of inheritance or to the Participant&#8217;s designated beneficiary or beneficiaries of this Award.&nbsp;&nbsp;The Participant may also direct the Corporation to issue stock certificates for any Shares which in fact vest and become issuable hereunder to one or more designated Family Members or a trust established for the Participant and/or his or her Family Members.&nbsp;&nbsp;The Participant may make a beneficiary designation or certificate directive for this Award at any time by filing the appropriate form with the Plan Administrator or its designee.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Cessation of Service</font><font style="text-decoration:none;">.&nbsp;&nbsp;Except as otherwise provided in Paragraph 5 below, should the Participant cease Service for any reason prior to vesting in one or more Shares subject to this Award, then the Award will be immediately cancelled with respect to those unvested Shares, and the number of Restricted Stock Units will be reduced accordingly.&nbsp;&nbsp;The Participant shall thereupon cease to have any right or entitlement to receive any Shares under those cancelled units.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Stockholder Rights</font><font style="text-decoration:none;">.&nbsp;&nbsp;The holder of this Award shall not have any stockholder rights, including voting or dividend rights, with respect to the Shares subject to the Award until the Participant becomes the record holder of those Shares following their actual issuance upon the Corporation&#8217;s collection of the applicable Withholding Taxes.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">5.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Change in Control</font><font style="text-decoration:none;">. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(a)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">Any Restricted Stock Units subject to this Award at the time of a Change in Control may be assumed by the successor entity or otherwise continued in full force and effect.&nbsp;&nbsp;In the event of such assumption or continuation of the Award, no accelerated vesting of the Restricted Stock Units shall occur at the time of the Change in Control.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(b)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">In the event the Award is assumed or otherwise continued in effect, the Restricted Stock Units subject to the Award shall be adjusted immediately after the consummation of the Change in Control so as to apply to the number and class of securities into which the Shares subject to those units immediately prior to the Change in Control would have been converted in consummation of that Change in Control had those Shares actually been issued and outstanding at that time.</font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">-2-
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="text-decoration:none;">(c)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">If the Restricted Stock Units subject to this Award at the time of the Change in Control are not assumed or o</font><font style="text-decoration:none;">therwise continued in effect in accordance with Paragraph 5(a), then those units will vest immediately upon the closing of the Change in Control. The Shares subject to those vested units will be issued immediately at that time or as soon as administrativel</font><font style="text-decoration:none;">y practicable thereafter, but in no event more than fifteen (15) business days after such closing, or will otherwise be converted into the right to receive the same consideration per share of Common Stock payable to the other shareholders of the Corporatio</font><font style="text-decoration:none;">n in consummation of the Change in Control and distributed at the same time as such stockholder payments, but the distribution to the Participant shall in no event be made later than the </font><font style="font-style:italic;text-decoration:none;">later</font><font style="text-decoration:none;"> of (i) the close of the calendar year in which the Change in Co</font><font style="text-decoration:none;">ntrol is effected or (ii) the fifteenth (15th) day of the third (3rd) calendar month following the effective date of such Change in Control. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(d)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">This Agreement shall not in any way affect the right of the Corporation to adjust, reclassify, reorganize or otherwise change its capital or business structure or to merge, consolidate, dissolve, liquidate or sell or transfer all or any part of its business or assets.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">6.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Adjustment in Shares</font><font style="text-decoration:none;">.&nbsp;&nbsp;Should any change be made to the outstanding Common Stock by reason of any stock split, stock dividend, recapitalization, combination of shares, exchange of shares, spin-off transaction or other change affecting the outstanding Common Stock as a class without the Corporation&#8217;s receipt of consideration, or should the value of the outstanding shares of Common Stock be substantially reduced as a result of a spin-off transaction or an extraordinary dividend or distribution or should there occur any merger, consolidation or other reorganization (including, without limitation, a Change in Control transaction) then equitable adjustments shall be made to the total number and/or class of securities issuable pursuant to this Award in such manner as the Plan Administrator deems appropriate in order to reflect such change and thereby prevent the dilution or enlargement of benefits hereunder.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">7.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Issue Date and Collection of Withholding Taxes</font><font style="text-decoration:none;">.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(a)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">Except as otherwise provided in Paragraph 5, </font><font style="text-decoration:underline;">if</font><font style="text-decoration:none;">:</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(i)</font><font style="text-decoration:none;margin-left:180pt;"></font><font style="text-decoration:none;">this Award is otherwise subject to Withholding Taxes on the Issue Date specified in the Issuance Schedule above in Paragraph 1 (the &#8220;Original Issue Date&#8221;),</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii)</font><font style="text-decoration:none;margin-left:180pt;"></font><font style="text-decoration:none;">the Original Issue Date does not occur (x) during an &#8220;open window period&#8221; applicable to the Participant, as determined by the Corporation in accordance with the Corporation&#8217;s trading policies governing the sale of Common Stock, or (x) on a date when the Participant is otherwise permitted to sell shares of Common Stock on an established stock exchange or stock market (including, but not limited to, under a previously established 10b5-1 trading plan entered into in compliance with the Corporation&#8217;s policies), and </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(iii)</font><font style="text-decoration:none;margin-left:180pt;"></font><font style="text-decoration:none;">the Corporation elects, prior to the Original Issue Date, (x) not to satisfy such Withholding Taxes through the Share Withholding Method (as defined in subparagraph (c) of this Paragraph 7) and (y) not to permit the Participant to pay such Withholding Taxes in cash (or by check), </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">-3-
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="text-decoration:underline;">then</font><font style="text-decoration:none;"> the Shares that would otherwise be issued to the Participant on the Original Issue Date will not be issued to the Participant on the Original Issue Date and will instead </font><font style="text-decoration:none;">be issued to the Participant on the first business day when the Participant is not prohibited from selling shares of Common Stock on an established stock exchange or stock market, but in no event later than the later of (i) the close of the calendar year i</font><font style="text-decoration:none;">n which the vesting date with respect to such Shares occurs or (ii) the fifteenth day of the third calendar month following such vesting date.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(b)</font><font style="text-decoration:none;margin-left:144pt;"></font><font style="text-decoration:none;">Upon the applicable Issue Date, the Corporation shall issue to or on behalf of the Participant a certificate (which may be in electronic form) for the applicable number of underlying shares of Common Stock, subject, however, to the Corporation&#8217;s collection of the applicable Withholding Taxes.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(c)</font><font style="text-decoration:none;margin-left:36pt;">The Withholding Taxes required to be withheld with respect to the issua</font><font style="text-decoration:none;">nce of the vested Shares hereunder shall be collected from the Participant through any of the following alternatives, in the sole discretion of the Corporation:</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(i)</font><font style="text-decoration:none;margin-left:36pt;">the Participant&#8217;s delivery of his or her separate check payable to the Corporation in the a</font><font style="text-decoration:none;">mount of such taxes;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii)</font><font style="text-decoration:none;margin-left:36pt;">the use of the proceeds from a next-day sale of the Shares issued to the Participant, provided and only if (i) such a sale is permissible under the Corporation&#8217;s trading policies governing the sale of Common Stock, (ii) the Partic</font><font style="text-decoration:none;">ipant makes an irrevocable commitment, on or before the Issue Date for those Shares, to effect such sale of the Shares and (iii) the transaction is not otherwise deemed to constitute a prohibited loan under Section 402 of the Sarbanes-Oxley Act of 2002; or</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:30.77%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(iii)</font><font style="text-decoration:none;margin-left:36pt;">through a share withholding procedure pursuant to which the Corporation will withhold, at the time of such issuance, a portion of the Shares with a Fair Market Value (measured as of the issuance date) equal to the amount of those taxes (the &#8220;Share W</font><font style="text-decoration:none;">ithholding Method&#8221;); </font><font style="font-weight:bold;font-style:italic;text-decoration:none;">provided, however</font><font style="text-decoration:none;">, that the amount of any Shares so withheld shall not exceed the amount necessary to satisfy the Corporation&#8217;s required tax withholding obligations using the minimum statutory withholding rates for federal, state, local and foreign tax purposes that are applicable to supplemental taxable income.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(d)</font><font style="text-decoration:none;margin-left:36pt;">Notwithstanding anything to the contrary in this Paragraph 7, the employee portion of the federal, state, local and foreign employment taxes required to be withheld by the C</font><font style="text-decoration:none;">orporation in connection with the vesting of the Shares (the &#8220;Employment Taxes&#8221;) shall in all events be collected from the Participant no later than the last business day of the calendar year in which the Shares vest hereunder.&nbsp;&nbsp;Accordingly, to the extent the Issue Date for one or more vested Shares is to occur in a year subsequent to the calendar year in which those Shares vest, the Participant shall, on or before the last business day of the calendar year in which the Shares vest, deliver to the Corporation a check payable to its order in the dollar amount equal to the Employment Taxes required to be withheld with respect to those Shares.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="text-decoration:none;">(e)</font><font style="text-decoration:none;margin-left:36pt;">Except as otherwise provided in Paragraph 5, the settlement of all Restricted Stock Units which vest under the Awar</font><font style="text-decoration:none;">d shall be made solely in shares of Common Stock.&nbsp;&nbsp;In no event, however, shall any fractional shares be issued.&nbsp;&nbsp;Accordingly, the total number </font></p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">-4-
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">of shares of Common Stock to be issued pursuant to the Award shall, to the extent necessary, be rounded down to t</font><font style="text-decoration:none;">he next whole share in order to avoid the issuance of a fractional share.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">8.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Compliance with Laws and Regulations</font><font style="text-decoration:none;">.&nbsp;&nbsp;The issuance of shares of Common Stock pursuant to the Award shall be subject to compliance by the Corporation and the Participant with all applicable requirements of law relating thereto and with all applicable regulations of any stock exchange on which the Common Stock may be listed for trading at the time of such issuance.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">9.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Notices</font><font style="text-decoration:none;">.&nbsp;&nbsp;Any notice required to be given or delivered to the Corporation under the terms of this Agreement shall be in writing and addressed to the Corporation at its principal corporate offices.&nbsp;&nbsp;Except to the extent electronic notice is expressly authorized hereunder, any notice required to be given or delivered to the Participant shall be in writing and addressed to the Participant at the address indicated below the Participant&#8217;s signature line on this Agreement.&nbsp;&nbsp;All notices shall be deemed effective upon personal delivery (or electronic delivery to the extent authorized hereunder) or upon deposit in the U.S. mail, postage prepaid and properly addressed to the party to be notified.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">10.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Successors and Assigns</font><font style="text-decoration:none;">.&nbsp;&nbsp;Except to the extent otherwise provided in this Agreement, the provisions of this Agreement shall inure to the benefit of, and be binding upon, the Corporation and its successors and assigns and the Participant, the Participant&#8217;s assigns, the legal representatives, heirs and legatees of the Participant&#8217;s estate and any beneficiaries of the Award designated by the Participant.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">11.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Construction</font><font style="text-decoration:none;">.&nbsp;&nbsp;This Agreement and the Award evidenced hereby are made and granted pursuant to the Plan and are in all respects limited by and subject to the terms of the Plan.&nbsp;&nbsp;All decisions of the Committee with respect to any question or issue arising under the Plan or this Agreement shall be conclusive and binding on all persons having an interest in the Award.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">12.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Governing Law</font><font style="text-decoration:none;">.&nbsp;&nbsp;The interpretation, performance and enforcement of this Agreement shall be governed by the laws of the State of California without resort to that State&#8217;s conflict-of-laws rules.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">13.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Employment at Will</font><font style="text-decoration:none;">.&nbsp;&nbsp;Nothing in this Agreement or in the Plan shall confer upon the Participant any right to continue in Service for any period of specific duration or interfere with or otherwise restrict in any way the rights of the Corporation (or any Parent or Subsidiary employing or retaining the Participant) or of the Participant, which rights are hereby expressly reserved by each, to terminate the Participant&#8217;s Service at any time for any reason, with or without cause.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">IN WITNESS WHEREOF</font><font style="font-weight:normal;text-decoration:none;">, the parties have executed this Agreement on the day and year first indicated above.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:46.35%;width:274.5pt;;"></table></div>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-5-
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:46.35%;width:274.5pt;;">
<tr>
<td style="width:58.5pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td style="width:58.5pt;"></td>
<td style="width:216pt;"></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC.</font></p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">Alexander D. Macrae, M.B., Ch.B., Ph.D.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer</p></td>
</tr>
<tr>
<td colspan="2" valign="top" >
<p style="text-align:right;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PARTICIPANT</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:-0.9pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signature:</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address:</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:left;margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">-6-
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p></p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;">APPENDIX A</font><font style="font-weight:bold;font-family:Times New Roman Bold;text-transform:uppercase;font-size:12pt;font-style:normal;font-variant: normal;"><br /></font><font style="text-decoration:underline;"><br />DEFINITIONS</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following definitions shall be in effect under the Agreement:</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">A.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Agreement</font><font style="text-decoration:none;"> shall mean this Restricted Stock Unit Issuance Agreement.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">B.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Award</font><font style="text-decoration:none;"> shall mean the award of Restricted Stock Units made to the Participant pursuant to the terms of this Agreement.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">C.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Award Date</font><font style="text-decoration:none;"> shall mean the date the Restricted Stock Units are awarded to Participant pursuant to the Agreement and shall be the date indicated in Paragraph 1 of the Agreement.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">D.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Board</font><font style="text-decoration:none;"> shall mean the Corporation&#8217;s Board of Directors.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">E.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Change in Control</font><font style="text-decoration:none;"> shall mean a change in ownership or control of the Corporation effected through any of the following transactions:&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(i)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">a merger, consolidation or other reorganization approved</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">by the Corporation&#8217;s stockholders, unless securities representing more than fifty percent (50%) of the total combined voting power of the voting securities of the successor corporation are immediately thereafter beneficially owned, directly or indirectly and in substantially the same proportion, by the persons who beneficially owned the Corporation&#8217;s outstanding voting securities immediately prior to such transaction, or</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">a stockholder-approved sale, transfer or other disposition of all or substantially all of the Corporation&#8217;s assets, or</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(iii)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">the closing of any transaction or series of related transactions pursuant to which any person or any group of persons comprising a &#8220;group&#8221; within the meaning of Rule 13d-5(b)(1) of the 1934 Act (other than the Corporation or a person that, prior to such transaction or series of related transactions, directly or indirectly controls, is controlled by or is under common control with, the Corporation) becomes directly or indirectly the beneficial owner (within the meaning of Rule 13d-3 of the 1934 Act) of securities possessing (or convertible into or exercisable for securities possessing) more than fifty percent (50%) of the total combined voting power of the Corporation&#8217;s securities (as measured in terms of the power to vote with respect to the election of Board members) outstanding immediately after the consummation of such transaction or series of related transactions, whether such transaction involves a direct issuance from the Corporation or the acquisition of outstanding securities held by one or more of the Corporation&#8217;s existing stockholders.</font></p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-1</p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p> </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="text-decoration:none;">F.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Code</font><font style="text-decoration:none;"> shall mean the Internal</font><font style="text-decoration:none;"> Revenue Code of 1986, as amended.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">G.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Corporation</font><font style="text-decoration:none;"> shall mean Sangamo Therapeutics, Inc., a Delaware corporation, and any successor corporate successor to all or substantially all of the assets or voting stock of Sangamo Therapeutics, Inc. which shall by appropriate action adopt the Plan. </font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">H.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Employee</font><font style="text-decoration:none;"> shall mean an individual who is in the employ of the Corporation (or any Parent or Subsidiary), subject to the control and direction of the employer entity as to both the work to be performed and the manner and method of performance.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">I.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Fair Market Value</font><font style="text-decoration:none;"> per share of Common Stock on any relevant date shall be determined in accordance with the following provisions:</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(i)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">If the Common Stock is at the time traded on the Nasdaq Global or Global Select Market, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question, as such price is reported by the National Association of Securities Dealers for that particular Stock Exchange and published in The Wall Street Journal.&nbsp;&nbsp;If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:7.69%;margin-right:7.69%;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">(ii)</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="text-decoration:none;">If the Common Stock is at the time listed on any other Stock Exchange, then the Fair Market Value shall be the closing selling price per share of Common Stock on the date in question on the Stock Exchange determined by the Plan Administrator to be the primary market for the Common Stock, as such price is officially quoted in the composite tape of transactions on such exchange and published in The Wall Street Journal.&nbsp;&nbsp;If there is no closing selling price for the Common Stock on the date in question, then the Fair Market Value shall be the closing selling price on the last preceding date for which such quotation exists.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">J.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Family Member</font><font style="text-decoration:none;"> shall mean any of the following members of the Participant&#8217;s family; any child, stepchild, grandchild, grandparent, parent, stepparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">K.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">1934 Act</font><font style="text-decoration:none;"> shall mean the Securities Exchange Act of 1934, as amended from time to time.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">L.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Parent</font><font style="text-decoration:none;"> shall mean any corporation (other than the Corporation) in an unbroken chain of corporations ending with the Corporation, provided each corporation in the unbroken chain (other than the Corporation) owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one or more of the other corporations in such chain.</font></p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-2</p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p> </p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:none;">M.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Participant</font><font style="text-decoration:none;"> shall mean the person to whom the Award is made pursuant to the Agreement.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">N.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Plan</font><font style="text-decoration:none;"> shall mean the Corporation&#8217;s 2013 Stock Incentive Plan.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">O.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Plan Administrator</font><font style="text-decoration:none;"> shall mean either the Board or a committee of the Board acting in its capacity as administrator of the Plan.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">P.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Service</font><font style="text-decoration:none;"> shall mean the Participant&#8217;s performance of services for the Corporation (or any Parent or Subsidiary) in the capacity of an Employee, a non-employee member of the board of directors or a consultant or independent advisor.&nbsp;&nbsp;Service shall not be deemed to cease during a period of military leave, sick leave or other personal leave approved by the Corporation; provided, however, that except to the extent otherwise required by law or expressly authorized by the Plan Administrator or by the Corporation&#8217;s written policy on leaves of absence, no Service credit shall be given for vesting purposes for any period the Participant is on a leave of absence.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">Q.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Stock Exchange</font><font style="text-decoration:none;"> shall mean the American Stock Exchange, the Nasdaq Global or Global Select Market or the New York Stock Exchange.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">R.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subsidiary</font><font style="text-decoration:none;"> shall mean any corporation (other than the Corporation) in an unbroken chain of corporations beginning with the Corporation, provided each corporation (other than the last corporation) in the unbroken chain owns, at the time of the determination, stock possessing fifty percent (50%) or more of the total combined voting power of all classes of stock in one of the other corporations in such chain.</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-weight:normal;font-family:Times New Roman;text-transform:none;font-size:12pt;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">S.</font><font style="text-decoration:none;margin-left:36pt;"></font><font style="font-weight:bold;text-decoration:underline;">Withholding Taxes</font><font style="font-weight:bold;text-decoration:none;"> </font><font style="text-decoration:none;">shall mean the federal, state, local and foreign income and employment taxes required to be withheld by the Corporation in connection with the vesting and issuance of the shares of Common Stock under the Award.</font></p>
<p style="text-align:center;margin-top:12pt;text-align:justify;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A-3</p>
<p style="text-align:left;line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:8pt;font-family:Times New Roman;">&nbsp;</p> </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>3
<FILENAME>sgmo-ex1013_620.htm
<DESCRIPTION>EX-10.13
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex1013_620.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;font-size:12pt;text-transform:uppercase;font-style:normal;font-variant: normal;">EXHIBIT 10.13</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;font-weight:bold;text-transform:uppercase;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11.5pt;font-family:Arial;font-style:normal;font-variant: normal;"><img src="g2018030121525117431123.jpg" title="" alt="" style="width:151px;height:84px;"><font style="margin-left:36pt;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:9.5pt;font-family:Arial Bold;text-transform:none;font-weight:bold;font-style:normal;font-variant: normal;text-indent:7.69%;">Sangamo BioSciences, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11.5pt;font-family:Arial;font-style:normal;font-variant: normal;text-indent:7.69%;">Point Richmond Tech Center</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11.5pt;font-family:Arial;font-style:normal;font-variant: normal;text-indent:7.69%;">501 Canal Blvd., Suite A100</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11.5pt;font-family:Arial;font-style:normal;font-variant: normal;text-indent:7.69%;">Richmond, CA 94804</p>
<p style="margin-bottom:0pt;border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11.5pt;font-family:Arial;font-style:normal;font-variant: normal;text-indent:7.69%;">510-970-6000 510-236-8951 (Fax)</p>
<p style="text-align:right;margin-bottom:24pt;margin-top:12pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">August 16, 2010</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Curt Herberts</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Curt:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">It is my pleasure to offer you the following position at Sangamo BioSciences, Inc:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">Director, Corporate Development</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reporting to:</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">David Ichikawa, Senior Vice President, Business Development</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Salary:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">$190,000 base pay per annum, (paid semi-monthly) and eligible for annual bonus commencing with the 2011 plan year</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Starting Date:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">On October 11, 2010</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">35,000 shares, subject to the approval of the Board of Directors and rules of vesting schedule described in the Sangamo BioSciences, Inc. Stock Option Plan</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Signing Bonus:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">10,000 (to be repaid in full should you resign your position within 12 months)</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:30.77%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefits:</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Arial;font-size:11.5pt;">A group medical plan is in place with Aetna. Your specific choice of options within the plan determines the employee contribution toward premiums. Other benefits include dental insurance, short-term and long&#173; term disability insurance, life insurance, a Section 125 flexible spending plan, a 401(k) retirement savings plan, employee stock purchase plan, 15 vacation days, 10 paid holidays and 10 sick days per year.</p></td></tr></table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I know you are fully aware of the extraordinary effort required to build a first rate organization. I am confident that you will succeed in the tasks at hand. Please sign and date both copies of this employment offer letter to indicate your acceptance, and return one copy to us for our files.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Edward Lanphier</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Edward Lanphier</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President and Chief Executive Officer</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:99.89%;">
<tr>
<td style="width:47.12%;"></td>
<td style="width:52.78%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cc:personnel file</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">payroll</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accepted: <font style="text-decoration:underline;">/s/ Curt A. Herberts&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 08/19/10</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Curt HerbertsDate</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:11.5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>4
<FILENAME>sgmo-ex1016_688.htm
<DESCRIPTION>EX-10.16
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex1016_688.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.16</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><img src="g2018030121525133431431.jpg" title="" alt="" style="width:341px;height:87px;"><font style="margin-left:36pt;">501 Canal Blvd., Suite A</font><br /><font style="margin-left:36pt;">Richmond, CA 94804</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;">510.970.6000 | </font>sangamo.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:46.15%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">February 17, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dale Ando</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dear Dale:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This letter sets forth the terms of the agreement between you and Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), in connection with the separation of your employment with the Company.&nbsp;&nbsp;This letter agreement provides for all payments to which you may be entitled from the Company and its affiliates, including under the Employment Agreement between you and the Company dated August 2, 2004 and the offer letter agreement between you and the Company dated July 6, 2004 (collectively the &#8220;Employment Documents&#8221;).&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Termination</font>.&nbsp;&nbsp;February 3, 2017 was your last day of employment with the Company (the &#8220;Termination Date&#8221;).&nbsp;&nbsp;Whether or not you sign this letter agreement, on the last day of your employment you will receive payment for all compensation and accrued vacation owed to you through the Termination Date. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Equity Awards; Benefits</font>.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>The vested portion of your options will be exercisable for three (3) months following the Termination Date (i.e., until May 3, 2017), in accordance with the applicable terms set forth in your award agreements.&nbsp;&nbsp;Any such vested portion of your options that is not exercised on or before that date, and any portion of your options that is not exercisable as of the Termination Date, shall be forfeited.&nbsp;&nbsp;In addition, the unvested portion of your restricted stock units as of the Termination Date will be forfeited without any payment.&nbsp;&nbsp;Attached is a schedule of your options and restricted stock units and the vested and unvested portion of each such award as of the Termination Date.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Your group medical insurance benefits will end on February 28, 2017.<font style="font-weight:bold;">&nbsp;&nbsp;</font>Regardless of signing this letter agreement, you may elect to continue receiving group medical insurance pursuant to the federal &#8220;COBRA&#8221; law, 29 U.S.C. &#167; 1161 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>.&nbsp;&nbsp;All premium costs shall be paid by you on a monthly basis for as long as, and to the extent that, you remain eligible for COBRA continuation coverage.&nbsp;&nbsp;You should consult the COBRA materials to be provided by the Company for details regarding COBRA continuation benefits.&nbsp;&nbsp;All other benefits will end on the Termination Date. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>3.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Severance</font>.&nbsp;&nbsp;While the Company is not obligated to provide you with any severance, in order to assist you in making this transition, it is willing to provide you with </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">severance benefits described in Attachment A if you sign this letter agreement and return it to </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aubrey Rhodes </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">within twenty-one </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">days from the date of this letter, and provided you do not thereafter revoke it.&nbsp;&nbsp;The severance benefits will be paid as set forth in Attachment A.&nbsp;&nbsp;If you do not accept this letter agreement within that time, it will become null and void.&nbsp;&nbsp;By signing and </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">returning this letter agreement, you will be entering into a binding agreement with the Company and will be agreeing to the terms and conditions set forth in the paragraphs below, including the release of claims set forth in paragraphs 4 and 5.&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Release</font>.&nbsp;&nbsp;You hereby fully, forever, irrevocably and unconditionally release and discharge the Company, its officers, directors, stockholders, corporate affiliates, subsidiaries, parent companies, agents and employees (each in their individual and corporate capacities) (hereinafter the &#8220;Released Parties&#8221;) from any and all claims, charges, complaints, demands, causes of action, liabilities, and expenses (including attorneys&#8217; fees and costs), of every kind and nature that you ever had or now have against the Released Parties, including, but not limited to, any arising out of your employment with and/or separation from the Company, including, but not limited to, all employment discrimination claims under Title VII of the Civil Rights Act of 1964, 42 U.S.C. &#167;&#160;2000e <font style="text-decoration:underline;">et seq</font>., the Americans With Disabilities Act of 1990, 42 U.S.C. &#167;&#160;12101 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>., the Family and Medical Leave Act, 29 U.S.C. &#167;&#160;2601 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>., the Rehabilitation Act of 1973, 29 U.S.C. &#167; 701 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>., the Age Discrimination in Employment Act, the Older Workers Benefit Protection Act, the California Fair Employment and Housing Act, Cal. Gov&#8217;t Code &#167; 12900 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>., the California Family Rights Act, Cal. Gov&#8217;t Code &#167; 12945.2 and &#167; 19702.3, the California Equal Pay Law, Cal. Labor Code &#167;&#160;1197.5 <font style="text-decoration:underline;">et</font> s<font style="text-decoration:underline;">eq</font>., the California Unruh Civil Rights Act, Cal. Civil Code &#167; 51 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>. and the California Family and Medical Leave Law, Cal. Labor Code &#167;&#167; 233, 7291.16 and 7291.2, all as amended, and all claims arising out of the Fair Credit Reporting Act, 15 U.S.C. &#167;&#160;1681 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>. and the Employee Retirement Income Security Act of 1974 (&#8220;ERISA&#8221;), 29 U.S.C. &#167;&#160;1001 <font style="text-decoration:underline;">et</font> <font style="text-decoration:underline;">seq</font>., all as amended, and all common law claims including, but not limited to, actions in tort, defamation and breach of contract, all claims to any non-vested ownership interest in the Company, contractual or otherwise, including, but not limited to, claims to stock or stock options, and any claim or damage arising out of your employment with and/or separation from the Company (including a claim for retaliation) under any common law theory or any federal, state or local statute or ordinance not expressly referenced above.&nbsp;&nbsp;The only exceptions to this release are any claim(s) you may have for:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>unemployment benefits pursuant to the terms of applicable law (to the extent available to you under applicable law);</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>workers&#8217; compensation insurance benefits pursuant to Division 4 of the California Labor Code or a comparable and applicable state law, under the terms of any worker&#8217;s compensation insurance policy or fund of the Company; </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>continued participation in certain of the Company&#8217;s group health benefit plans pursuant to the terms and conditions of the federal law known as &#8220;COBRA,&#8221; if applicable, and/or any applicable state law counterpart to COBRA; </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>any benefit entitlements vested as of your Termination Date, pursuant to written terms of any applicable employee benefit plan sponsored by the Company; and</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="margin-left:108pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any claims that, as a matter of applicable law, are not waivable.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Waiver</font><font style="text-decoration:underline;"> </font><font style="font-weight:bold;text-decoration:underline;">of Unknown Claims</font>.&nbsp;&nbsp;You understand and agree that the claims released in paragraph 4 above include not only claims presently known to you, but also include all unknown or unanticipated claims, rights, demands, actions, obligations, liabilities, and causes of action of every kind and character that would otherwise come within the scope of the released claims as described in paragraph 4.&nbsp;&nbsp;You understand that you may hereafter discover facts different from what you now believe to be true, which if known, could have materially affected this letter agreement, but you nevertheless waive any claims or rights based on different or additional facts.&nbsp;&nbsp;You knowingly and voluntarily waive any and all rights or benefits that you may now have, or in the future may have, under the terms of Section 1542 of the Civil Code of the State of California, which provides as follows: <font style="margin-left:72pt;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH A CREDITOR DOES NOT KNOW OF OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE WHICH IF KNOWN BY HIM OR HER MUST HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;font-weight:bold;">Confidential Information</font>.&nbsp;&nbsp;You acknowledge and reaffirm your obligation to keep confidential all non-public information concerning the Company that you acquired during the course of your employment with the Company and pursuant to fulfilling your cooperating obligations as set forth in Section 8 below, as stated more fully in the Company&#8217;s Proprietary Information, Invention and Materials Agreement that you entered into as of August 2, 2004 (the &#8220;Proprietary Information, Invention and Materials Agreement&#8221;), which remains in full force and effect.&nbsp;&nbsp;You affirm your obligation to keep all Company Information confidential and not to disclose it to any third party in the future.  You understand that the term &#8220;Company Information&#8221; includes, but is not limited to, the following:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Confidential information, including information received from third parties under confidential conditions; and </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Other technical, scientific, marketing, business, product development or financial information, the use or disclosure of which might reasonably be determined to be contrary to the interests of the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Proprietary Information, Invention and Materials Agreement is incorporated herein by this reference, and you agree to continue to be bound by the terms of that Agreement.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a>7.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Return of Company Property</font>.&nbsp;&nbsp;You confirm that you have returned to the Company in good working order all keys, files, records (and copies thereof), equipment (including, but not limited to, computer hardware, software and printers, wireless handheld devices, cellular phones and pagers), access or credit cards, and any other property in your possession or control belonging to the Company and have left intact all electronic Company documents, including, but not limited to, those that you developed or helped to develop during your employment.&nbsp;&nbsp;You further confirm that you have cancelled all accounts for your benefit, if </p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any, in the Company&#8217;s name, including, but not limited to, c</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">redit cards, telephone charge cards, cellular phone and/or pager accounts and computer accounts.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transition Services</font>.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>You agree, at the Company&#8217;s request, during the period from the Termination Date through August 3, 2017 (the &#8220;Transition Services Period&#8221;), to provide reasonable assistance to the Company to transition to Edward Conner, M.D., and other employees of the Company your responsibilities and projects, including with respect to the completion of certain manuscripts pertaining to the HIV program, and to resolve any technical issues associated with projects on which you worked during the period of your employment with the Company, the scope, timing and frequency of which shall mutually agreeable to you and Mr. Connor.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>You agree, at the Company&#8217;s request, to cooperate, by providing truthful information, documents and testimony, in any Company investigation, litigation, arbitration or regulatory proceeding regarding events that occurred during your employment with the Company.&nbsp;&nbsp;Your requested cooperation may include, for example, making yourself available to consult with the Company&#8217;s counsel, providing truthful information and documents and to appear to give truthful testimony.&nbsp;&nbsp;The Company will reimburse you for reasonable out-of-pocket expenses that you incur in providing any requested cooperation so long as you provide advance written notice to the Company of your request for reimbursement and in all cases you provide satisfactory documentation of the expenses.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font>You understand and agree that the payments described in Annex A include compensation to you for any and all assistance and cooperation the Company may require pursuant to Sections 8(a) and (b) above and that you shall not be entitled to additional compensation during the Transition Services Period for assistance provided by you, if any.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>You agree and acknowledge that (i) you will perform the services during the Transition Services Period as an independent contractor to the Company, (ii) nothing in this letter agreement shall in any way be construed to constitute you as an agent, employee or representative of the Company or its affiliates, (iii) you are not authorized to bind the Company or its affiliates to any liability or obligation or to represent that you have any such authority and, (iv) you are not expected to incur, and are not entitled to reimbursement, for any expenses.&nbsp;&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Business Expenses and Compensation</font>.&nbsp;&nbsp;You acknowledge that you have been reimbursed by the Company for all business expenses incurred in conjunction with the performance of your employment and that no other reimbursements are owed to you.&nbsp;&nbsp;You further acknowledge that you have received payment in full for all services rendered in conjunction with your employment by the Company and that no other compensation, including wages, draws, payment for accrued but unused vacation time or severance payments or benefits pursuant to any plan, policy or practice, is owed to you, with the exception of the severance benefits described in paragraph 3 above.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Further Employment with the Company</font>.&nbsp;&nbsp;You understand and agree that by signing this letter agreement, you are giving up any right you may have to <font style="color:#000000;">reemployment with the Company.&#160; You further agree that you will not seek, accept, or otherwise pursue employment with the Company, and if you do seek such employment, the Company may decline to employ you at any time, and you will have no legal recourse if the Company so declines. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Non-Disparagement</font>.&nbsp;&nbsp;You understand and agree that you shall not make any false, disparaging or derogatory statements to any media outlet, industry group, financial institution or current or former employee, consultant, client, customer of the Company or other person or entity regarding the Company or any of its directors, officers, employees, agents or representatives or about the Company&#8217;s business affairs and financial condition.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Reports to Government Entities</font>.&nbsp;&nbsp;Nothing in this letter agreement, including the Confidential Information and Proprietary Information, Invention and Materials Agreement paragraphs, restricts or prohibits you from initiating communications directly with, responding to any inquiries from, providing testimony before, providing confidential information to, reporting possible violations of law or regulation to, or from filing a claim or assisting with an investigation directly with a self-regulatory authority or a government agency or entity, including the U.S. Equal Employment Opportunity Commission, the Department of Labor, the National Labor Relations Board, the Department of Justice, the Securities and Exchange Commission, the Congress, and any agency Inspector General (collectively, the &#8220;Regulators&#8221;), or from making other disclosures that are protected under the whistleblower provisions of state or federal law or regulation.&nbsp;&nbsp;However, to the maximum extent permitted by law, you are waiving your right to receive any individual monetary relief from the Company or any others covered by the Release resulting from such claims or conduct, regardless of whether you or another party has filed them, and in the event you obtain such monetary relief the Company will be entitled to an offset for the payments made pursuant to this letter agreement.&nbsp;&nbsp;This letter agreement does not limit your right to receive an award from any Regulator that provides awards for providing information relating to a potential violation of law.&nbsp;&nbsp;You do not need the prior authorization of the Company to engage in conduct protected by this paragraph, and you do not need to notify the Company that you have engaged in such conduct.&nbsp;&nbsp;Please take notice that federal law provides criminal and civil immunity to federal and state claims for trade secret misappropriation to individuals who disclose a trade secret to their attorney, a court, or a government official in certain, confidential circumstances that are set forth at 18 U.S.C. &#167;&#167; 1833(b)(1) and 1833(b)(2), related to the reporting or investigation of a suspected violation of the law, or in connection with a lawsuit for retaliation for reporting a suspected violation of the law.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Acknowledgement of Voluntariness and Time to Review and Revoke</font>.&nbsp;&nbsp;You acknowledge that:</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>you read this letter agreement and you understand it;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>you are signing this letter agreement voluntarily in order to release your claims against the Company in exchange for payment that is greater than you would otherwise have received;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">you are signing this letter agreement after the date of your separation from the Company and you were offered at least 21 days to consider your choice to sign this Agreement;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font>the Company advises you to consult with an attorney;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font>you agree that changes to this letter agreement before its execution, whether material or immaterial, do not restart your time to review the letter agreement;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:108pt;"></font>You are not waiving any rights or claims under the Age Discrimination in Employment Act of 1967 (29 U.S.C. &#167; 621 et seq.) that may arise after the date this Agreement is executed; and</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:108pt;"></font>you know that you can revoke this letter agreement within 7 days of signing it and that the letter agreement does not become effective until that 7-day period has passed (the &#8220;Effective Date&#8221;).&nbsp;&nbsp;To revoke this letter agreement, contact Leslie Mesones. </p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Amendment</font>.&nbsp;&nbsp;This letter agreement shall be binding upon the parties and may not be modified in any manner, except by an instrument in writing of concurrent or subsequent date signed by duly authorized representatives of the parties hereto.&nbsp;&nbsp;This letter agreement is binding upon and shall inure to the benefit of the parties and their respective agents, assigns, heirs, executors, successors, and administrators.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Severability</font>.&nbsp;&nbsp;If any provision in this letter agreement is for any reason held to be unenforceable, it shall not affect the enforceability of the remaining provisions and the remaining provisions shall be enforced to the extent permitted by law.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Confidentiality</font>.&nbsp;&nbsp;You understand and agree that as a condition for payment to you of the severance benefits herein described, the terms and contents of this letter agreement, and the contents of the negotiations and discussions resulting in this letter agreement, shall be maintained as confidential by you, your spouse, your attorney or your accountant, and shall not be disclosed except to the extent required by law or as otherwise agreed to in writing by the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Nature of Agreement</font>.&nbsp;&nbsp;You understand and agree that this letter agreement is a severance agreement and does not constitute an admission of liability or wrongdoing on the part of the Company.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Voluntary Assent</font>.&nbsp;&nbsp;You affirm that no other promises or agreements of any kind have been made to or with you by any person or entity whatsoever to cause you to sign this letter agreement, and that you fully understand the meaning and intent of this letter agreement.&nbsp;&nbsp;You further state and represent that you have carefully read this letter agreement, including Attachment A, understand the contents herein, freely and voluntarily assent to all of the terms and conditions hereof, and sign your name of your own free act.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Applicable Law</font>.&nbsp;&nbsp;This letter agreement shall be interpreted and construed by the laws of the State of California, without regard to conflict of laws provisions.&nbsp;&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</font><font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Attorneys Fees</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In the event of any dispute</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> concerning this letter agreement, the prevailing party will be entitled to recover its attorneys&#8217; fees and costs, in addition to any other relief to which such party may be entitled.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;Except as provided in paragraph 6 (Proprietary Information, Invention and Materials Agreement), this letter agreement contains and constitutes the entire understanding and agreement between the parties hereto with respect to your severance benefits and the settlement of claims against the Company and cancels all previous oral and written negotiations, agreements and commitments in connection therewith, including under the Employment Documents.&nbsp;&nbsp;<font style="font-weight:bold;">&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Application of Section 409A of the Internal Revenue Code</font>.&nbsp;&nbsp;This letter agreement is intended to comply with section 409A of the Code and the regulations issued thereunder (&#8220;Section 409A&#8221;), including the six-month delay for certain key employees if applicable, or an exemption.&nbsp;&nbsp;Severance benefits under this letter agreement are intended to be exempt from Section 409A under the &#8220;short-term deferral&#8221; exception, to the maximum extent applicable, and then under the &#8220;separation pay&#8221; exception, to the maximum extent applicable.&nbsp;&nbsp;All payments to be made upon a termination of employment under this letter agreement may only be made upon a &#8220;separation from service&#8221; under Section 409A.&nbsp;&nbsp;For purposes of Section 409A, the right to a series of installment payments under this letter agreement shall be treated as a right to a series of separate payments and each payment shall be treated as a separate payment.&nbsp;&nbsp;With respect to payments that are subject to Section 409A, in no event may you, directly or indirectly, designate the calendar year of a payment, and if a payment that is subject to execution of this letter agreement could be made in more than one taxable year, based on timing of the execution of this letter agreement, payment will be made in the later taxable year.&nbsp;&nbsp;Any reimbursements and in-kind benefits provided under this letter agreement will be made or provided in accordance with the requirements of Section 409A.&nbsp;&nbsp;You will be solely responsible for any tax imposed under Section 409A and in no event will the Company have any liability with respect to any tax, interest or other penalty imposed under Section 409A.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Arbitration</font>.&nbsp;&nbsp;The parties agree that any and all disputes arising out of the terms of this letter agreement and their interpretation, and any of the matters released, shall be subject to final and binding arbitration before the American Arbitration Association under its Employment Arbitration Rules and Mediation Procedures in Contra Costa County, California.&nbsp;&nbsp;THE PARTIES HEREBY AGREE TO WAIVE THEIR RIGHT TO HAVE ANY DISPUTE BETWEEN THEM RESOLVED IN A COURT OF LAW BY A JUDGE OR JURY.&nbsp;&nbsp;This paragraph will not prevent either party from seeking preliminary injunctive relief (or any other provisional remedy) under applicable law from any court having jurisdiction over the parties and the subject matter of their dispute relating to their obligations under this letter agreement or under the Proprietary Information, Invention and Materials Agreement before arbitration or while arbitration is pending.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If you have any questions about the matters covered in this letter agreement, please call </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leslie Mesones. </font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Very truly yours,</p>
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="margin-left:36pt;"></font>&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:46.15%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:&nbsp;&nbsp;&nbsp;&nbsp;<font style="text-decoration:underline;">/s/_Leslie Mesones</font>___________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:39.42%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I hereby agree to the terms and conditions set forth above and I have chosen to execute this on the date below.</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">/s/ Dale G. Ando</font>__________________________<font style="margin-left:36pt;">Date ____</font><font style="text-decoration:underline;">February 21, 2017</font>______</p>
<p style="margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dale G. Ando, M.D.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><br /></p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;text-decoration:underline;">ATTACHMENT A</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">DESCRIPTION OF SEVERANCE BENEFITS</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In exchange for your signing and not revoking this letter agreement, including, but not limited to, your waiver and release of claims described in paragraphs 4 and 5 and your performance of the transition services as described in paragraph 8, the Company hereby agrees to provide you with the following severance benefits:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-weight:bold;text-decoration:underline;">Severance Pay</font>.&nbsp;&nbsp;The Company will continue to pay your base salary as in effect on the Termination Date, less applicable federal, state and local tax deductions, for a period of twenty six (26) weeks following the Termination Date, in accordance with the Company&#8217;s normal payroll practices.&nbsp;&nbsp;The first payment will be made on the first payroll date that is administratively practicable after the Effective Date (and within 30 days after the Termination Date) (such date hereinafter referred to as the &#8220;Initial Payment Date&#8221;) and will include unpaid installments for the period from the Termination Date to the first payment date.&nbsp;&nbsp;In addition, on the Initial Payment Date, the Company will pay you an amount of $121,695, less applicable federal, state and local tax deductions.</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">b.</font></p></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="font-weight:bold;text-decoration:underline;">COBRA Continuation</font>.<font style="font-weight:bold;"> </font> During the period beginning on the Termination Date and ending on the earlier of (i) the date on which you first become covered by any other &#8220;group health plan&#8221; as described in Section 4980B(g)(2) of the Internal Revenue Code of 1986, as amended (the &#8220;Code&#8221;) or (ii) the last day of the seven (7) month period following the Termination Date (the &#8220;Coverage Period&#8221;), if you are eligible and elect to receive continued health coverage under the Company&#8217;s health plan under the Consolidated Omnibus Budget Reconciliation Act (&#8220;COBRA&#8221;) at a level of coverage at or below you level of coverage in effect on the Termination Date, and you pay the full monthly COBRA premium cost for such health coverage, the Company shall reimburse you monthly an amount equal to the monthly COBRA premium paid by you, less the premium charge that is paid by the Company&#8217;s active employees for such coverage as in effect on the Termination Date (the &#8220;COBRA Reimbursement&#8221;).&nbsp;&nbsp;The payments shall commence on the first payroll date that is administratively practicable after the Effective Date (and within 30 days after the Termination Date).&nbsp;&nbsp;The first payment shall include any payments for the period from the Termination Date to the commencement date.&nbsp;&nbsp;The Company shall reimburse you under this subsection only for the portion of the Coverage Period during which you continue coverage under the Company&#8217;s health plan.&nbsp;&nbsp;You agree to promptly notify the Company of your coverage under an alternative health plan upon becoming covered by such alternative plan.&nbsp;&nbsp;The COBRA health care continuation coverage period under section 4980B of the Code shall run concurrently with the Coverage Period.&nbsp;&nbsp;Notwithstanding the foregoing, the Company reserves the right to restructure the foregoing COBRA premium reimbursement arrangement in any manner necessary or appropriate to avoid fines, penalties or negative tax consequences to the Company or you (including, without limitation, to avoid any penalty imposed for violation of the nondiscrimination requirements under the Patient Protection and Affordable Care Act or the guidance issued thereunder), as determined by the Company </p></td></tr></table></div>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap"></td>
<td valign="top">
<p style="margin-bottom:12pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n its sole and absolute discretion, including treating such reimbursements as taxable benefits subject to withholding.&nbsp;&nbsp;</font></p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:right;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>5
<FILENAME>sgmo-ex1021_830.htm
<DESCRIPTION>EX-10.21
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex1021_830.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;">EXHIBIT 10.21</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LEASE AGREEMENT</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">BETWEEN</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MARINA BOULEVARD PROPERTY, LLC,</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS LANDLORD,</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AND</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC.,</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">AS TENANT</p>
<p style="text-align:center;margin-bottom:36pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman Bold;font-style:normal;text-transform:none;font-variant: normal;">DATED</p>
<p style="text-align:center;margin-bottom:16pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">November 3, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Contents</font></p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="mpTableOfContents"></a><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Definitions and Basic Provisions</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Lease Grant1</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tender of Possession; Square Footage of Premises1</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tender of Possession1</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Square Footage of Premises2</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Rent; Abatement of Rent2</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Rent2</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Abatement of Rent2</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Delinquent Payment; Handling Charges2</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Letter of Credit3</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Application of Security3</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Transfer3</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Reduction of Letter of Credit4</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Services; Utilities; Common Areas4</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Services4</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Utility Use4</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Common Areas5</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Alterations; Repairs; Maintenance; Signs5</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Alterations5</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Repairs; Maintenance7</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">By Landlord7</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">By Tenant7</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Performance of Work9</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mechanic&#8217;s Liens9</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Signs10</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">General Signs10</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Building Top Sign(s)10</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Use; Compliance with Laws11</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Assignment and Subletting12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Transfers12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Consent Standards12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Request for Consent12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Conditions to Consent12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Attornment by Subtenants12</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">i</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Contents<br /></font><font style="text-decoration:none;">(continued)</font></p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Transfers</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Additional Compensation14</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Landlord&#8217;s Option14</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Insurance; Waivers; Subrogation; Indemnity14</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Indemnity Agreement14</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tenant&#8217;s Insurance15</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Landlord&#8217;s Insurance16</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">No Subrogation16</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Subordination; Attornment; Notice to Landlord&#8217;s Mortgagee17</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Subordination17</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Attornment17</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Notice to Landlord&#8217;s Mortgagee17</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Rules and Regulations18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Condemnation18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Total Taking18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Partial Taking - Tenant&#8217;s Rights18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Partial Taking - Landlord&#8217;s Rights18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Award18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Repair18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Fire or Other Casualty18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Repair Estimate18</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tenant&#8217;s Rights19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Landlord&#8217;s Rights19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Repair Obligation19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Abatement of Rent19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Waiver of Statutory Provisions19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Personal Property Taxes19</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Events of Default20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Payment Default20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Abandonment20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Intentionally Omitted;20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Insurance20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Mechanic&#8217;s Liens20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Other Defaults20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:11pt;">ii</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Contents<br /></font><font style="text-decoration:none;">(continued)</font></p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Insolvency</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Remedies20</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Payment by Tenant; Non-Waiver; Cumulative Remedies22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Payment by Tenant22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">No Waiver22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Cumulative Remedies22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Intentionally Omitted22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Surrender of Premises22</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Holding Over24</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Certain Rights Reserved by Landlord24</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Building Operations24</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Security25</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Prospective Purchasers and Lenders25</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Prospective Tenants25</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Cell Tower Equipment25</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Hazardous Materials26</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:92.31%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26.</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Miscellaneous28</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Landlord Transfer28</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Landlord&#8217;s Liability28</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Force Majeure28</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Brokerage29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Estoppel Certificates29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Notices29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Separability29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Amendments; Binding Effect29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Quiet Enjoyment29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(j)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">No Merger29</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(k)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">No Offer30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(l)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Entire Agreement30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(m)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Waiver of Jury Trial30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(n)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Governing Law30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(o)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Recording30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(p)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Joint and Several Liability30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(q)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Financial Reports30</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:11pt;">iii</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Contents<br /></font><font style="text-decoration:none;">(continued)</font></p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(r)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Fees</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</font></p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(s)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Telecommunications31</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(t)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Confidentiality31</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(u)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Authority31</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Waiver31</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(w)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tenant Representation32</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Transportation Management32</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">CC&amp;Rs; Disclosure32</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(z)</font></p></td>
<td valign="top">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Disclosure32</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="margin-bottom:6pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:11pt;">iv</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Table of Contents<br /></font><font style="text-decoration:none;">(continued)</font></p>
<p style="text-align:right;margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Page</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU6"></a><font style="text-decoration:underline;">List of Exhibits</font><font style="text-decoration:underline;"><br /></font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All exhibits and attachments attached hereto are incorporated herein by this reference.&nbsp;&nbsp;The following exhibits are attached to and made a part of this Lease:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;A-1 -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Site Plan Depicting Premises and Building</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit A-2 -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Site Plan Depicting Complex</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;B -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Legal Description of the Land</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;C -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Additional Rent, Taxes and Insurance</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;D -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Tenant Work Letter</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;E -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Building Rules and Regulations</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;F -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Form of Confirmation of Commencement Date Letter</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;G -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Form of Tenant Estoppel Certificate</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;H -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Renewal Option</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit&#160;I -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Contractor Insurance Requirements</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit J -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Environmental Questionnaire</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit K -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Location and Size of Cell Tower Equipment</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit L -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Wells Fargo &#8211; Letter of Credit</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit M -</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">ROFO to Purchase</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.38%;white-space:nowrap">
<p style="margin-top:0pt;margin-bottom:6pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exhibit N -</font></p></td>
<td valign="top">
<p style="margin-top:0pt;margin-bottom:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Escrow Agreement</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-size:11pt;">v</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a><font style="text-decoration:underline;">BASIC LEASE INFORMATION</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Basic Lease Information is attached to and incorporated by reference to this Lease (as hereinafter defined) between Landlord and Tenant, as defined below.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:501.85pt;;">
<tr>
<td style="width:100.3pt;"></td>
<td style="width:100.3pt;"></td>
<td style="width:100.4pt;"></td>
<td style="width:2.85pt;"></td>
<td style="width:97.5pt;"></td>
<td style="width:100.5pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MARINA BOULEVARD PROPERTY, LLC,</p>
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC., <br />a Delaware corporation</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Guarantor:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">None.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Premises:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">An area comprising the entire rentable square feet of the building commonly known as 7000 Marina Boulevard, Brisbane, California 94005 (the &#8220;<font style="font-weight:bold;">Building</font>&#8221;), which contains approximately 87,695 rentable square feet in the aggregate, as depicted on <font style="text-decoration:underline;">Exhibit A-1</font>.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Land:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The land on which the Building is located as described in <font style="text-decoration:underline;">Exhibit B</font>.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Project:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Building, the Land and the driveways, parking facilities, and similar improvements and easements associated with the Building, Land and the operation thereof.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complex:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Project and other buildings which comprise Marina Landing, a multi-building complex, subject to the conditions, covenants and restrictions as administered by owners&#8217; associations applicable to the Project, as further set forth and described in <font style="text-decoration:underline;">Exhibit A-2</font>. </p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Term:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">One hundred thirty-two (132) months, commencing on the first day of the month following the Commencement Date (unless the Commencement Date is on the first day of the month, in which case the Term shall commence on the Commencement Date) and ending at 5:00&#160;p.m. local time on the last day of the 132nd full calendar month following the Commencement Date (the &#8220;<font style="font-weight:bold;">Expiration Date</font>&#8221;), subject to extension and earlier termination as provided in the Lease.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commencement Date:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />June 1, 2018.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Delivery Date:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The date that this Lease has been mutually executed and delivered by both parties and the Letter of Credit has been delivered to Landlord.</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Base Rent:</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Month</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Rent</p></td>
<td colspan="2" valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Base Rent</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly<br />Rental Rate<br />Per RSF</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 &#8211; 12*</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2,999,169.00</p></td>
<td colspan="2" valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$249,930.75</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.85</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 &#8211; 24*</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_211"></a><a name="_cp_text_1_211"></a>$3,089,144.07</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_213"></a><a name="_cp_text_1_213"></a>$257,428.67 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.94</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 &#8211; 36 </p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_215"></a><a name="_cp_text_1_215"></a>$3,181,818.39</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_217"></a><a name="_cp_text_1_217"></a>$265,151.53 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.02</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 &#8211; 48 </p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_219"></a><a name="_cp_text_1_219"></a>$3,277,272.94</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_221"></a><a name="_cp_text_1_221"></a>$273,106.08 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.11</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 &#8211; 60 </p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_223"></a><a name="_cp_text_1_223"></a>$3,375,591.13</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_225"></a><a name="_cp_text_1_225"></a>$281,299.26 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.21</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 &#8211; 72</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_227"></a><a name="_cp_text_1_227"></a>$3,476,858.87</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_229"></a><a name="_cp_text_1_229"></a>$289,738.24 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.30</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 &#8211; 84</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_231"></a><a name="_cp_text_1_231"></a>$3,581,164.63</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_233"></a><a name="_cp_text_1_233"></a>$298,430.39 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.40</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 &#8211; 96</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_235"></a><a name="_cp_text_1_235"></a>$3,688,599.57</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_237"></a><a name="_cp_text_1_237"></a>$307,383.30 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.51</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97 &#8211; 108</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_239"></a><a name="_cp_text_1_239"></a>$3,799,257.56</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_241"></a><a name="_cp_text_1_241"></a>$316,604.80 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.61</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:19.95pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109 &#8211; 120</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_243"></a><a name="_cp_text_1_243"></a>$3,913,235.28</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_245"></a><a name="_cp_text_1_245"></a>$326,102.94 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.72</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="bottom" >
<p style="margin-bottom:9pt;margin-top:0pt;margin-left:20.15pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121 &#8211; 132</p></td>
<td valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_247"></a><a name="_cp_text_1_247"></a>$4,030,632.34</p></td>
<td colspan="2" valign="top" >
<p style="text-align:left;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_249"></a><a name="_cp_text_1_249"></a>$335,886.03 </p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.83</p></td>
</tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vii</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:501.85pt;;">
<tr>
<td style="width:100.3pt;"></td>
<td style="width:100.3pt;"></td>
<td style="width:100.4pt;"></td>
<td style="width:2.85pt;"></td>
<td style="width:97.5pt;"></td>
<td style="width:100.5pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_251"></a><a name="_cp_text_1_253"></a><a name="_cp_text_1_257"></a><a name="_cp_text_1_259"></a><a name="_cp_text_1_260"></a><a name="_cp_text_1_262"></a><a name="_cp_text_1_264"></a><a name="_cp_text_1_266"></a>* Monthly Base Rent shall be abated by (i<a name="_cp_text_1_251"></a>) 100% for the second (2nd) full calendar month <a name="_cp_text_1_253"></a>through and including the tenth <a name="_cp_text_1_257"></a>(10th) Lease Month, and (ii) by 50% for the eleventh <a name="_cp_text_1_259"></a>(1<a name="_cp_text_1_260"></a>1th) Lease Month <a name="_cp_text_1_262"></a>through and including the sixteenth <a name="_cp_text_1_264"></a>(1<a name="_cp_text_1_266"></a>6th) Lease Month, pursuant to <font style="text-decoration:underline;">Section 4(b)</font> of the Lease.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As used herein, the term &#8220;<font style="font-weight:bold;">Lease Month</font>&#8221; shall mean each calendar month during the Term (and if the Commencement Date does not occur on the first (1<sup style="font-size:85%; vertical-align:top">st</sup>) day of a calendar month, the period from the Commencement Date to the first (1<sup style="font-size:85%; vertical-align:top">st</sup>) day of the next calendar month shall be included in the first (1<sup style="font-size:85%; vertical-align:top">st</sup>) Lease Month for purposes of determining the duration of the Term and the monthly Base Rent rate applicable for such partial month).</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Security Deposit / Letter of Credit:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br />$3,500,000.00</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additional Rent:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall pay 100% of the costs of Common Area Maintenance Costs, Taxes and Insurance for the Building, and Tenant&#8217;s Proportionate Share of Common Area Maintenance Costs, Taxes, and Insurance for the Complex. </p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Utilities:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall obtain all water, electricity, sewerage, gas, telephone and other utilities for the Premises directly from the public utility company furnishing same.&nbsp;&nbsp;Any meters required in connection therewith shall be installed at Tenant&#8217;s sole cost except as set forth in Section 7(b) of this Lease.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Proportionate Share:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Building &#8211; 100% of the Building. </p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the Complex &#8211; 55% of the Complex.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Permitted Use:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For general office, research and development, lab and production uses, and all other legally permitted uses associated with Tenant&#8217;s business, to the extent permitted by applicable laws and zoning regulations, but for no other purpose whatsoever.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant Improvements:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_273"></a><a name="_cp_text_1_274"></a>Except as otherwise set forth in this Lease, Tenant accepts the Premises in its current &#8220;<font style="font-weight:bold;">AS-IS</font><a name="_cp_text_1_274"></a>&#8221; condition, provided that Tenant shall have the right to construct the Tenant Improvements in accordance with the Work Letter attached hereto as <font style="text-decoration:underline;">Exhibit&#160;D</font>.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parking:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant may use on a non-exclusive basis up to two hundred seventy-eight (278) undesignated automobile parking spaces in the parking area adjacent to the Building (twenty-six (26) of which are located in a secured underground parking garage), at no cost to Tenant during the initial Term.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Renewal Options:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant may renew this Lease for two (2) additional periods of five (5) years each, by delivering written notice of the exercise thereof to Landlord not earlier than fifteen (15) months nor later than nine (9) months before the expiration of the then-current Term, as further set forth in <font style="text-decoration:underline;">Exhibit&#160;H</font>.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ROFO to Purchase:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Provided that Tenant is leasing and physically occupying 87,695 rentable square feet in the Building (including any Permitted Transfers) and has not assigned or subleased any space within the Premises (except for Permitted Transfers), subject to compliance with the California Subdivision Map Act to create a separate legal parcel for the Building, Tenant shall have a one-time right of first offer to purchase the Building exercisable during the first three (3) years following the Commencement Date, subject to the terms and conditions set forth in <font style="text-decoration:underline;">Exhibit&#160;M</font>.</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Broker/Agent:</p></td>
<td colspan="5" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Tenant:&nbsp;&nbsp;Newmark Cornish &amp; Carey</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For Landlord:&nbsp;&nbsp;CBRE, Inc.</p></td>
</tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">viii</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:501.85pt;;">
<tr>
<td style="width:100.3pt;"></td>
<td style="width:100.3pt;"></td>
<td style="width:100.4pt;"></td>
<td style="width:2.85pt;"></td>
<td style="width:97.5pt;"></td>
<td style="width:100.5pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Address for Notices prior to Commencement Date:</font></p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc.<br />501 Canal Boulevard, Suite A100<br />Richmond, CA 94804<br />Attention:&nbsp;&nbsp;Director of Legal<br />Telephone:&nbsp;&nbsp;(510) 970-6000</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant&#8217;s Address for Notices after Commencement Date:</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc.<br />7000 Marina Boulevard<br />Brisbane, CA 94005<br />Attention:&nbsp;&nbsp;Director of Legal<br />Telephone:&nbsp;&nbsp;TBD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile:&nbsp;&nbsp;TBD</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord&#8217;s Address for Notices:</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marina Boulevard Property, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Westport Capital Partners LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2121 Rosecrans Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 4325</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">El Segundo, California 90245</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: Eric Clapp, Managing Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: (310) 294-1239</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (310) 643-7379</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With a copy to:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marina Boulevard Property, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Westport Capital Partners</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40 Danbury Road</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wilton, Connecticut 06897</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Marc Porosoff, Esq.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone:&nbsp;&nbsp;(203) 429-8602</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile: (203) 429-8599</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Additional copy to</font>:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLA Piper US LLP</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">550 South Hope Street, Suite 2300</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Los Angeles, California 90071</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Jackie Park, Esq.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone:&nbsp;&nbsp;(213) 330-7743</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Facsimile:&nbsp;&nbsp;(213) 330-7543</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Rent Payment Address:</p></td>
<td colspan="3" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marina Boulevard Property, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">PO Box 101760<br />Pasadena, California 91189-1760</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td colspan="2" valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">ix</p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU9"></a><font style="text-decoration:underline;">LEASE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Lease Agreement (this &#8220;<font style="font-weight:bold;">Lease</font>&#8221;) is entered into as of November&#160;3, 2017 (the &#8220;<font style="font-weight:bold;">Effective Date</font>&#8221;), between MARINA BOULEVARD PROPERTY, LLC, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392288"></a>1.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Definitions and Basic Provisions</font>.&nbsp;&nbsp;The definitions and basic provisions set forth in the Basic Lease Information (the &#8220;<font style="font-weight:bold;">Basic Lease Information</font>&#8221;) executed by Landlord and Tenant contemporaneously herewith are incorporated herein by reference for all purposes.&nbsp;&nbsp;If any conflict exists between any Basic Lease Information and the Lease, then the Lease shall control.&nbsp;&nbsp;Additionally, the following terms shall have the following meanings when used in this Lease: &#8220;<font style="font-weight:bold;">Affiliate</font>&#8221; means any person or entity which, directly or indirectly, through one or more intermediaries, controls, is controlled by, or is under common control with the party in question (as used herein, the term &#8220;control&#8221; shall mean the possession, direct or indirect, of not less than a majority of the voting rights attributable to the shares of Tenant and a majority of the outstanding capital stock of Tenant, or the power to direct or cause the direction of the management and policies of a Tenant, whether through the ownership of voting shares, by contract or otherwise); &#8220;<font style="font-weight:bold;">Building&#8217;s Structure</font>&#8221; means the Building&#8217;s exterior walls, roof (structure and membrane), elevator shafts (if any), footings, foundations, structural portions of load-bearing walls, structural floors and subfloors, and structural columns and beams; &#8220;<font style="font-weight:bold;">Building&#8217;s Systems</font>&#8221; means the Premises&#8217; and Building&#8217;s HVAC, life-safety, security, plumbing, electrical, mechanical systems, elevator and parking garage rolling gate/access control; &#8220;<font style="font-weight:bold;">Business Day(s)</font>&#8221; means Monday through Friday of each week, exclusive of Holidays; &#8220;<font style="font-weight:bold;">Holidays</font>&#8221; means New Year&#8217;s Day, Memorial Day, Independence Day, Labor Day, Thanksgiving Day, Christmas Day, and any other nationally or regionally recognized holiday; &#8220;<font style="font-weight:bold;">including</font>&#8221; means including, without limitation; &#8220;<font style="font-weight:bold;">Laws</font>&#8221; means all federal, state, and local laws, ordinances, rules and regulations, all court orders, governmental directives, and governmental orders and all interpretations of the foregoing, and all restrictive covenants affecting the Project, and &#8220;<font style="font-weight:bold;">Law</font>&#8221; shall mean any of the foregoing; &#8220;<font style="font-weight:bold;">Rent</font>&#8221; shall collectively refer to Base Rent, Additional Rent, Taxes, and Insurance (each as defined in <font style="text-decoration:underline;">Exhibit&#160;C</font> hereto), and all other sums that Tenant may owe to Landlord or otherwise be required to pay under the Lease; &#8220;<font style="font-weight:bold;">Tenant&#8217;s Off-Premises Equipment</font>&#8221; means any of Tenant&#8217;s equipment or other property that may be located on or about the Project (other than inside the Premises); and &#8220;<font style="font-weight:bold;">Tenant Party</font>&#8221; means any of the following persons:&nbsp;&nbsp;Tenant; any assignees claiming by, through, or under Tenant; any subtenants claiming by, through, or under Tenant; and any of their respective agents, contractors and employees.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392289"></a><a name="_Ref506181942"></a>2.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Lease Grant</font><a name="_Ref506181942"></a>.&nbsp;&nbsp;Subject to the terms of this Lease, Landlord leases to Tenant, and Tenant leases from Landlord, the Premises (as defined in the Basic Lease Information).&nbsp;&nbsp;The Premises are outlined on the plan attached to the Lease as <font style="text-decoration:underline;">Exhibit A&#8209;1</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392290"></a>3.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tender of Possession; Square Footage of Premises</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392291"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tender of Possession</font>.&nbsp;&nbsp;The Premises will be delivered to Tenant in its &#8220;AS-IS&#8221; condition on the Delivery Date.&nbsp;&nbsp;Upon Landlord&#8217;s delivery of the Premises (the &#8220;<font style="font-weight:bold;">Delivery Date</font>&#8221;), Tenant shall have exclusive access to construct the Tenant Improvements (as defined on <font style="text-decoration:underline;">Exhibit&#160;D</font>) in accordance with the terms of the Work Letter attached hereto as <font style="text-decoration:underline;">Exhibit&#160;D</font>.&nbsp;&nbsp;Landlord may send Tenant notice of the occurrence of the Commencement Date in the form of the attached <font style="text-decoration:underline;">Exhibit&#160;F</font>, which notice Tenant shall acknowledge by executing a copy of the notice and returning it to Landlord.&nbsp;&nbsp;If Tenant fails to sign and return the notice to Landlord within ten (10) days of receipt thereof from Landlord, the notice as sent by Landlord shall be deemed to have correctly set forth the Commencement Date.&nbsp;&nbsp;Failure of Landlord to send such notice shall have no effect on the Commencement Date.&nbsp;&nbsp;Any use of the Premises by Tenant prior to the Commencement Date shall be subject to all of the provisions of this Lease excepting only those requiring the payment of Rent.&nbsp;&nbsp;Subject to terms of this Lease, Tenant shall have access to the Building, twenty-four (24) hours per day, seven (7) days per week, every day of the year during the Term.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">1<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392292"></a><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Square Footage of Premises</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;For purposes of this Lease, the &#8220;rentable square feet&#8221; of the Premises and the Complex has been calculated by Landlord pursuant to </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the Building Owners and Managers Association International Standard Method for Measuring Floor Area in Office Buildings, ANSI Z65.1 - 2010 (the &#8220;</font><font style="font-weight:bold;">BOMA Standard</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;The rentable square footage of the Premises set forth in this Lease shall be deemed by Tenant</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be the rentable square footage of the Premises for all purposes.&nbsp;&nbsp;In that regard, Tenant has been given an opportunity to measure the rentable square footage of the Premises prior to execution of this Lease and Tenant hereby waives any rights it may ha</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ve following execution of this Lease to measure the Premises or claim that the rentable square footage of the Premises is other than as set forth in this Lease.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392293"></a>4.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Rent; Abatement of Rent</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392294"></a><a name="_cp_text_1_331"></a><a name="_cp_text_1_332"></a><a name="_cp_text_1_334"></a><a name="_cp_text_4_335"></a><a name="_cp_text_1_336"></a><a name="_cp_text_1_337"></a><a name="_cp_text_1_342"></a><a name="_cp_text_5_344"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Rent</font><a name="_cp_text_1_331"></a>.&nbsp;&nbsp;Commencing on the Commencement Date, subject to <font style="text-decoration:underline;">Section 4(b)</font> below, <a name="_cp_text_1_332"></a>Tenant shall timely pay to Landlord as <a name="_cp_text_1_334"></a>Rent, (i)&#160;Base Rent as set forth in the Basic Lease Information (subject to <font style="text-decoration:underline;">Section 4(b)</font><a name="_cp_text_4_335"></a> below), and (ii)&#160;Additional Rent (as defined in <font style="text-decoration:underline;">Exhibit&#160;C</font><a name="_cp_text_1_336"></a>) as set forth in <font style="text-decoration:underline;">Exhibit&#160;C</font> hereto, without notice, demand, deduction or set-off (except as otherwise expressly provided herein), by good and sufficient check drawn on a national banking association at Landlord&#8217;s address provided for in this Lease or electronically via automatic debit or wire transfer to such account as <a name="_cp_text_1_337"></a>Landlord designates in writing to Tenant, or as otherwise specified in writing by Landlord.&nbsp;&nbsp;The obligations of Tenant to pay Base Rent and other sums to Landlord and the obligations of Landlord under this Lease are independent obligations.&nbsp;&nbsp;Base Rent shal<a name="_cp_text_1_342"></a>l be payable monthly in advance.&nbsp;&nbsp;The first (1st) monthly installment of Base Rent shall be payable contemporaneously with the execution of this Lease; thereafter, Base Rent shall be payable on the first (1st) day of each month beginning on the first (1st) day of the second (2nd) full calendar month of the Term, subject to <font style="text-decoration:underline;">Section 4(b)</font> below.&nbsp;&nbsp;The monthly Base Rent for any partial month at the beginning of the Term shall equal the product of 1/365 of the annual Base Rent in effect during the partial month a<a name="_cp_text_5_344"></a>nd the number of days in the partial month, and shall be due on the Commencement Date.&nbsp;&nbsp;Payments of Base Rent for any fractional calendar month at the end of the Term shall be similarly prorated.&nbsp;&nbsp;Tenant shall pay Additional Rent at the same time and in the same manner as Base Rent.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392295"></a><a name="_Ref506184749"></a><a name="_cp_text_1_346"></a><a name="_cp_text_1_348"></a><a name="_cp_text_1_350"></a><a name="_cp_text_1_352"></a><a name="_cp_text_1_356"></a><a name="_cp_text_1_358"></a><a name="_cp_text_1_359"></a><a name="_cp_text_1_361"></a><a name="_cp_text_1_363"></a><a name="_cp_text_1_365"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Abatement of Rent</font><a name="_Ref506184749"></a>.<a name="_cp_text_1_346"></a>&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Lease, <a name="_cp_text_1_348"></a>and provided that no Event of Default exists, Landlord hereby agrees to abate Tenant&#8217;s obligation to pay Tenant&#8217;s monthly Base Rent (the &#8220;<font style="font-weight:bold;">Abated Rent</font><a name="_cp_text_1_350"></a>&#8221;) by (i) 100% for the second (2nd) full calendar month <a name="_cp_text_1_352"></a>through and including the tenth <a name="_cp_text_1_356"></a>(10th) Lease Month, and (ii) by 50% for the eleventh <a name="_cp_text_1_358"></a>(1<a name="_cp_text_1_359"></a>1th) Lease Month <a name="_cp_text_1_361"></a>through and including the sixteenth <a name="_cp_text_1_363"></a>(1<a name="_cp_text_1_365"></a>6th) Lease Month (the &#8220;<font style="font-weight:bold;">Abatement Period</font>&#8221;).&nbsp;&nbsp;During the Abatement Period, Tenant shall remain responsible for the payment of all of its other monetary obligations under this Lease.&nbsp;&nbsp;If during the Abatement Period an Event of Default (as defined in <font style="text-decoration:underline;">Section&#160;17</font> below) occurs, and Landlord does not elect to terminate this Lease in accordance with <font style="text-decoration:underline;">Article&#160;18</font> below, then the Abated Rent shall reinstate for the remaining Abatement Period as of the date Tenant cures such Event of Default.&nbsp;&nbsp;If at any time during the Term, an Event of Default by Tenant occurs, and Landlord does elect to terminate this Lease in accordance with <font style="text-decoration:underline;">Article 18</font> below, then as a part of the recovery set forth in <font style="text-decoration:underline;">Article&#160;18</font>, Landlord shall be entitled to the recovery of that portion of the unamortized Abated Rent (which Abated Rent shall be amortized on a straight-line basis over the initial Lease Term).</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392296"></a><a name="_cp_text_1_368"></a><a name="_AEIOULastRenderedPageBreakAEIOU11"></a>5.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Delinquent Payment; Handling Charges</font><a name="_cp_text_1_368"></a>.&nbsp;&nbsp;All past due payments required of Tenant hereunder shall bear interest from the date that is three (3) Business Days after Landlord&#8217;s written notice thereof until paid at the lesser of ten percent (10%) per annum or the maximum lawful rate of interest (such lesser amount is referred to herein as the &#8220;<font style="font-weight:bold;">Default Rate</font>&#8221;); additionally, Landlord, in addition to all other rights and remedies available to it, may charge Tenant a fee equal to five percent (5%) of the delinquent payment (the &#8220;<font style="font-weight:bold;">Late Charge</font>&#8221;) to reimburse Landlord for its cost and inconvenience incurred as a consequence of Tenant&#8217;s delinquency.&nbsp;&nbsp;In no event, however, shall the charges permitted under this <font style="text-decoration:underline;">Section&#160;5</font> or elsewhere in this Lease, to the extent they are considered to be interest under applicable Law, </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">2<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exceed the maximum lawful rate of interest</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord shall waive the accrual of the Default Rate and the payment the</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Late Charge once in any given twelve (12) month period</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392297"></a>6.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Letter of Credit</font>.&nbsp;&nbsp;Tenant shall deliver to Landlord, upon Tenant&#8217;s execution of this Lease, a Letter of Credit (as hereinafter defined) in the amount specified in the Basic Lease Information, as additional security for the faithful performance and observance by Tenant of the terms, covenants and conditions of this Lease.&nbsp;&nbsp;The Letter of Credit shall be in the form of a clean, irrevocable, non-documentary and unconditional letter of credit (the &#8220;<font style="font-weight:bold;">Letter of Credit</font>&#8221;) which is attached hereto as <font style="text-decoration:underline;">Exhibit&#160;L</font>, issued by and drawable upon Wells Fargo Bank, N.A. (the &#8220;<font style="font-weight:bold;">Issuing Bank</font>&#8221;).&nbsp;&nbsp;If upon any transfer of the Letter of Credit, any fees or charges shall be so imposed, then such fees or charges shall be payable solely by Tenant and the Letter of Credit shall so specify.&nbsp;&nbsp;The Letter of Credit shall provide that it shall be deemed automatically renewed, without amendment, for consecutive periods of one year each thereafter during the Term (and in no event shall the Letter of Credit expire prior to the forty-fifth (45th) day following the Expiration Date) unless the Issuing Bank sends duplicate notices (the &#8220;<font style="font-weight:bold;">Non-Renewal Notices</font>&#8221;) to Landlord by certified mail, return receipt requested (one of which shall be addressed &#8220;Attention, Chief Legal Officer&#8221; and the other of which shall be addressed &#8220;Attention, Chief Financial Officer&#8221;), not less than forty-five (45) days next preceding the then expiration date of the Letter of Credit stating that the Issuing Bank has elected not to renew the Letter of Credit.&nbsp;&nbsp;The Issuing Bank shall agree with all drawers, endorsers and bona fide holders that drafts drawn under and in compliance with the terms of the Letter of Credit will be duly honored upon presentation to the Issuing Bank at an office location in Los&#160;Angeles, California.&nbsp;&nbsp;The Letter of Credit shall be subject in all respects to the International Standby Practices 1998, International Chamber of Commerce Publication No. 590.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392298"></a><a name="_cp_text_1_384"></a><a name="_cp_text_1_388"></a><a name="_cp_text_1_389"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Application of Security</font>.&nbsp;&nbsp;If (a)&#160;an Event of Default <a name="_cp_text_1_384"></a>by Tenant occurs in the payment or performance of any of the terms, covenants or conditions of this Lease, including the payment of Rent, or (b)&#160;Tenant fails to make any installment of Rent as and when due beyond an applicable notice and cure period, or (c)&#160;Landlord receives a Non-Renewal Notice, Landlord shall have the right by sight draft to draw, at its election, all or a portion of the proceeds of the Letter of Credit and thereafter hold, use, apply, or retain the whole or any part of such proceeds, as the case may be, (x)&#160;to the extent required for the payment of any Rent or any other sum as to which Tenant is in default including (i)&#160;any sum which Landlord may expend or may be required to expend by reason of Tenant&#8217;s Event of Default, and/or (ii)&#160;any damages to which Landlord is entitled pursuant to this Lease, whether such damages accrue before or after summary proceedings or other reentry by Landlord, and/or (y)&#160;as a cash security deposit, unless and until, in the case of clause&#160;(c) above, Tenant delivers to Landlord a substitute Letter of Credit which meets the requirements of this <font style="text-decoration:underline;">Section&#160;6</font><a name="_cp_text_1_388"></a>.&nbsp;&nbsp;If Landlord applies or retains any part of the proceeds of the Letter of Credit, or cash security, Tenant, within five (5) Business Days <a name="_cp_text_1_389"></a>upon written demand, shall deposit with Landlord the amount so applied or retained so that Landlord shall have the full amount thereof on hand at all times during the Term.&nbsp;&nbsp;If Tenant shall comply with all of the terms, covenants and conditions of this Lease, the Letter of Credit or cash security, as the case may be, shall be returned to Tenant within thirty (30) days after the Expiration Date and after delivery of possession of the Premises to Landlord in the manner required by this Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392299"></a><a name="_AEIOULastRenderedPageBreakAEIOU12"></a>(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Transfer</font>.&nbsp;&nbsp;Upon a sale or other transfer of the Building, or any financing of Landlord&#8217;s interest therein, Landlord shall have the right to transfer the Letter of Credit or the cash security to its transferee or lender. With respect to the Letter of Credit, within ten (10) Business Days after notice of such transfer or financing, Tenant, at its sole cost, shall arrange for the transfer of the Letter of Credit to the new landlord or the lender, as designated in writing by Landlord in the foregoing notice or have the Letter of Credit reissued in the name of the new landlord or the lender.&nbsp;&nbsp;Upon such transfer, Tenant shall look solely to the new landlord or lender for the return of the Letter of Credit or such cash security; provided that such new landlord has assumed Landlord&#8217;s obligations hereunder and the provisions hereof shall apply to every transfer or assignment made of the Letter of Credit or such cash security to a new landlord.&nbsp;&nbsp;Tenant shall not assign or encumber or attempt to assign or encumber the Letter of Credit or such cash security and </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">3<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">neither Landlord nor its successors or assigns shall be bound by any such action or attempted assignment, or encumbrance. </font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392300"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Reduction of Letter of Credit</font>.&nbsp;&nbsp;Effective as of the date the Reduction Conditions (as hereinafter defined) are satisfied, the amount of the Letter of Credit shall be reduced to an amount equal to One Million Five Hundred Thousand Dollars ($1,500,000.00).&nbsp;&nbsp;For purposes of this <font style="text-decoration:underline;">Section 6(c)</font>, the &#8220;<font style="font-weight:bold;">Reduction Conditions</font>&#8221; shall mean (i)&#160;Tenant shall have received a Certificate of Occupancy for the Premises and provided Landlord with a copy thereof, and (ii)&#160;Tenant shall have raised Two Hundred Million Dollars ($200,000,000.00) as evidenced by a Security Exchange Commission regulatory filing reflecting an increase in equity of Tenant by Two Hundred Million Dollars ($200,000,000.00) as compared with Tenant&#8217;s audited financial statements for the calendar year ending 2016.&nbsp;&nbsp;There shall be no reduction of the Letter of Credit as set forth herein if, at the time of such reduction, an Event of Default exists under this Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392301"></a><a name="_Ref506184888"></a>7.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Services; Utilities; Common Areas</font><a name="_Ref506184888"></a>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392302"></a><a name="_cp_text_1_398"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Services</font><a name="_cp_text_1_398"></a>.&nbsp;&nbsp;Other than Landlord&#8217;s maintenance obligations expressly set forth in this Lease, Landlord shall not be obligated to provide any services to Tenant, provided that Landlord shall as part of Common Area Maintenance Costs provide electric lighting for all Common Area (including parking area) as Landlord reasonably determines to be standard, including replacement of Building standard lights, bulbs and tubes.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392303"></a><a name="_cp_text_1_401"></a><a name="_cp_text_1_404"></a><a name="_cp_text_4_405"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Utility Use</font>.&nbsp;&nbsp;<a name="_cp_text_1_401"></a>Tenant shall obtain all water, electricity, sewage, gas, telephone and other utilities for the Premises directly from the public utility company furnishing same.&nbsp;&nbsp;Any meters or modifications thereof required in connection therewith shall be installed at Tenant&#8217;s sole cost.&nbsp;&nbsp;Tenant shall pay all utility deposits and fees, and all monthly service charges for water, electricity, sewage, gas, telephone and any other utility services furnished to the Premises during the Term of this Lease.&nbsp;&nbsp;Tenant shall not inst<a name="_cp_text_1_404"></a>all any equipment which exceeds or overloads the capacity of the utility facilities serving the Premises.&nbsp;&nbsp;Tenant agrees that Landlord shall not be liable for damages, by abatement of Rent or otherwise, for failure to furnish or delay in furnishing any service, or for any diminution in the quality or quantity thereof, when such failure or delay or diminution is occasioned, in whole or in part, by breakage, repairs, replacements, or improvements, by act or default of Tenant or other parties, by any Force Majeure Event (as defined in <font style="text-decoration:underline;">Section 26(c)</font>), or by any other cause beyond Landlord&#8217;s reasonable control.&nbsp;&nbsp;Notwithstanding the foregoing, in the event of an interruption of utility service which (i) is the result of Landlord&#8217;s gross negligence or willful misconduct, (ii) continues for more than three (3) consecutive Business Days (&#8220;<font style="font-weight:bold;">Eligibility Period</font><a name="_cp_text_4_405"></a>&#8221;), and (iii) renders the Premises unsuitable for Tenant&#8217;s normal business operations, and (iv)&#160;Tenant actually does not use the Premises or any portion thereof for three (3) consecutive Business Days, then Tenant&#8217;s Base Rent shall be abated or reduced, as the case may be, after expiration of the Eligibility Period for such time that Tenant continues to be so prevented from using, and does not use, the Premises or a portion thereof, in the proportion that the rentable area of the portion of the Premises that Tenant is prevented from using, and does not use, bears to the rentable area of the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant hereby reserves the right, in connection with either its Tenant Improvement electrical tie-in work (pursuant to the terms and conditions of the Tenant Work Letter) or due to applicable governmental code or agency required electrical systems testing, to reasonably shut down power to the Building for a limited time not to exceed four (4) hours per each shut-down, except as otherwise provided in the MOP (as defined).&nbsp;&nbsp;Tenant shall prepare a method of procedure (&#8220;<font style="font-weight:bold;">MOP</font>&#8221;) setting forth the specific terms and conditions of such action, including the specific time of Building power shut-down and re&#8209;start, for Landlord&#8217;s review and approval (which approval shall not be unreasonably withheld) no later than ten (10) business days prior to the anticipated date of shut-down.&nbsp;&nbsp;As long as Tenant complies with the terms and conditions of the MOP as approved by Landlord, Tenant shall not be liable for damages to the Cell Tower Equipment in connection with Tenant&#8217;s shut-down as set forth herein.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">4<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392304"></a><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><a name="_cp_text_1_407"></a><a name="_cp_text_1_408"></a><a name="_cp_text_1_410"></a><a name="_cp_text_1_411"></a><a name="_cp_text_1_413"></a><a name="_cp_text_1_415"></a><a name="_cp_text_1_417"></a><a name="_cp_text_1_418"></a><a name="_cp_text_1_419"></a><a name="_cp_text_1_420"></a><a name="_cp_text_1_421"></a><a name="_cp_text_1_422"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Common Areas</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;</font><font style="font-weight:bold;">Common Area</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; is defined for all purposes of this Lease as that part </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of the Project and/or Complex intended for the common use of all tenants, including among other facilities (as such may be applicable to the Complex), parking areas, private streets and alleys, landscaping, curbs, loading areas, sidewalks, lighting facilit</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_407"></a>ies, drinking fountains, meeting rooms, public toilets, and the like, but excluding:&nbsp;&nbsp;(i)&#160;space in </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_408"></a>buildings (now or hereafter existing) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the Complex </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">designated for rental for commercial purposes, as the same may exist from time to time; (ii)&#160;stree</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts and alleys maintained by a public authority; (iii) areas within the Complex which may from time to time not be owned by Landlord (unless subject to a cross-access or common use agreement benefiting the area which includes the Premises); and (iv) areas l</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eased to a single-purpose user where access is restricted.&nbsp;&nbsp;Landlord reserves the right to change from time to time the dimensions and location of the Common Area, as well as the dimensions, identities, locations and types of any buildings, signs or other </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_410"></a>improvements in the Complex, so long as </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(y) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_411"></a>access to the Premises </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and/or the parking area, or (z)&#160;the size or access to the Premises and/or the parking area </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">is not materially adversely affected thereby.&nbsp;&nbsp;For example, and without limiting the generality of</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_413"></a> the immediately preceding sentence, Landlord </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">shall have no right to move the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_415"></a>parking area </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from the </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Complex.&nbsp;&nbsp;Tenant, and its employees and customers, and when duly authorized pursuant to the provisions of this Lease, its subtenants, licensees and concessi</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_417"></a>onaires, shall have the non-exclusive right to use the parking spaces </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_418"></a>designated in the Basic Lease Information</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_419"></a>in the Common Area (excluding roof(s)) as constituted from time to time)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> and right to designate visitor parking spaces</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> within the parking area</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_420"></a> of the Complex (and the number of visitor parking spaces shall be deducted from the overall two hundred seventy-eight (278) undesignated parking spaces provided to Tenant), such use to be in common with Landlord, other tenants in the Building </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(if any) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/or Complex, as applicable, and other persons permitted by the Landlord to use the same, and subject to rights of governmental authorities, easements, other restrictions of record, and such reasonable rules and regulations governing use as Landlord may fro</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_421"></a>m time to time prescribe</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> subject to </font><font style="text-decoration:underline;">Section 13</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hereof</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_422"></a>.&nbsp;&nbsp;For example, and without limiting the generality of Landlord&#8217;s ability to establish rules and regulations governing all aspects of the Common Area</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> in accordance with </font><font style="text-decoration:underline;">Section 13</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> hereof</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Tenant agrees a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s follows</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">:</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>Landlord may from time to time designate specific areas within the Project or Complex, as applicable, in which automobiles owned by Tenant, its employees, subtenants, licensees, and concessionaires shall be parked; and Tenant agrees that if any automobile or other vehicle owned by Tenant or any of its employees, its subtenants, its licensees or its concessionaires, or their employees, shall at any time be parked in any part of the Project or Complex, as applicable, other than the specified areas designated for employee parking, Landlord may have such vehicle towed at the cost of the owner of same.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>Tenant shall not solicit business within the Common Area nor take any action which would interfere with the rights of other persons to use the Common Area.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font>Landlord may temporarily close any part of the Common Area for such periods of time as may be reasonably necessary to make repairs or alterations or to prevent the public from obtaining prescriptive rights, so long as access to the Premises and/or the parking area is not materially adversely affected thereby.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506185072"></a><a name="_Toc497392305"></a><a name="_Ref506185010"></a>8.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Alterations; Repairs; Maintenance; Signs</font><a name="_Ref506185010"></a>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392306"></a><a name="_cp_text_1_430"></a><a name="_cp_text_1_432"></a><a name="_cp_text_1_434"></a><a name="_cp_text_1_435"></a><a name="_cp_text_1_437"></a><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><a name="_cp_text_1_438"></a><a name="_cp_text_1_439"></a><a name="_cp_text_1_444"></a><a name="_cp_text_1_446"></a><a name="_AEIOULastRenderedPageBreakAEIOU15"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Alterations</font><a name="_cp_text_1_430"></a>.&nbsp;&nbsp;Except for Tenant Improvements and Cosmetic Changes (as hereinafter defined), Tenant shall not make any alterations, additions or improvements to the Premises (collectively, the &#8220;<font style="font-weight:bold;">Alterations</font>&#8221;) without the prior written consent of Landlord, which consent shall not be unreasonably withheld, conditioned or delayed, except for the installation of unattached, movable trade fixtures which may be installed without drilling, cutting or otherwise defacing the Premises. Notwithstanding the foregoing, Tenant shall not be obligated to receive the written consent of Landlord for interior Alterations to the Premises (i)&#160;where the estimated cost of the propose<a name="_cp_text_1_432"></a>d Alteration is Seventy-Five <a name="_cp_text_1_434"></a>Thousand Dollars ($75,000.00<a name="_cp_text_1_435"></a>) or less in any twelve (12) month period<a name="_cp_text_1_437"></a>, (ii)&#160;if said Alterations do not affect the structural components of the Building, or adversely affect the Building&#8217;s Systems or which can be seen </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">5<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">from outsi</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_438"></a>de the Premises, and (iii)&#160;if said Alteration shall not require a building permit or any federal, state, county or local approvals</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> (the &#8220;</font><font style="font-weight:bold;">Cosmetic Changes</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall furnish complete plans and specifications to Landlord for its approval, which approva</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_439"></a>l shall not be unreasonably withheld, conditioned or delayed, at the time it requests Landlord&#8217;s consent to any Alterations</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">if the desired Alterations: (i)&#160;will affect the Building&#8217;s Systems or Building&#8217;s Structure; or (ii)&#160;will require the filing of plan</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">s and specifications with any governmental or quasi-governmental agency or authority; or (iii)&#160;will require a building permit or other federal, state, county or local approvals with respect thereto.&nbsp;&nbsp;Landlord shall either approve or disapprove Tenant&#8217;s pro</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">posed Alteration within five (5) business days of Landlord&#8217;s receipt of Tenant&#8217;s request and Tenant&#8217;s plans and specifications with respect to such proposed Alteration.&nbsp;&nbsp;Subsequent to obtaining Landlord&#8217;s consent and prior to commencement of the Alteration</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_444"></a>s, Tenant shall deliver to Landlord any building permit required by applicable Law and a copy of the executed construction contract(s).&nbsp;&nbsp;Tenant shall reimburse Landlord within ten (10) days after the rendition of a bill for all of Landlord&#8217;s actual </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and rea</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sonable </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">out-of-pocket costs incurred in connection with any Alterations (excluding Cosmetic Changes), including all management, engineering, outside consulting, and construction fees incurred by or on behalf of Landlord for the review and approval of Tenan</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_446"></a>t&#8217;s plans and specifications and for the monitoring of construction of the Alterations, together with a supervision coordination fee to Landlord in an amo</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unt equal to the product of (i)&#160;three </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">percent (3%) and (ii)&#160;the costs of the Alterations.&nbsp;&nbsp;If Landlord</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> consents to the making of any Alteration, such Alteration shall be made by Tenant at Tenant&#8217;s sole cost and expense by contractors and subcontractors approved in writing by Landlord in accordance with </font><font style="text-decoration:underline;">Section 8(b)(iii)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, which approval shall not unreasonab</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ly be withheld, conditioned or delayed.&nbsp;&nbsp;Without Landlord&#8217;s prior written consent, Tenant shall not use any portion of the Common Areas either within or outside the Project or Complex, as applicable, in connection with the making of any Alterations.&nbsp;&nbsp;If th</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e Alterations which Tenant causes to be constructed result in Landlord being required to make any alterations and/or improvements to other portions of the Project or Complex, as applicable, in order to comply with any applicable Laws (provided that such al</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terations and/or improvements are necessitated solely due to Tenant&#8217;s Alterations, and in no event are caused by any violations or non-compliance with applicable Laws which existed on the Delivery Date), then Tenant shall reimburse Landlord within thirty (</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30) days upon written demand for all costs and expenses actually and reasonably incurred by Landlord in making such alterations and/or improvements in the Project or Complex, as applicable.&nbsp;&nbsp;Any Alterations made by Tenant shall become the property of Landl</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ord upon the expiration or sooner termination of this Lease and shall remain on and be surrendered with the Premises upon the expiration or sooner termination of this Lease, except Tenant shall, upon written demand by Landlord, at Tenant&#8217;s sole cost and ex</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">pense, forthwith and with all due diligence (but in any event not later than ten (10) days after the expiration or earlier termination of the Lease) remove all or any portion of any Alterations made by Tenant which are designated by Landlord in writing to </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">be removed (the &#8220;</font><font style="font-weight:bold;">Removal Notice</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) at the time of Landlord&#8217;s consent to such Alterations (including without limitation stairs, bank vaults, and cabling, movable laboratory casework and related appliances, built-in cabinet work and paneling, sinks and relate</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d plumbing fixtures, laboratory benches, exterior venting fume hoods and walk-in freezers and refrigerators, if applicable) and repair any damages to the Premises caused by such removal in a good and workmanlike manner to their original condition, reasonab</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">le wear and tear and Casualty not required to be repaired by Tenant excepted. All construction work done by Tenant within the Premises shall be performed in a good and workmanlike manner with new materials of first-class quality, lien-free and in complianc</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e with all applicable Laws, and in such manner as to cause a minimum of interference with other construction in progress and with the transaction of business in the Project or Complex, as applicable.&nbsp;&nbsp;</font><font style="font-weight:bold;">TENANT AGREES TO INDEMNIFY, DEFEND AND HOLD LANDLORD HA</font><font style="font-weight:bold;">RMLESS AGAINST ANY LOSS, LIABILITY OR DAMAGE RESULTING FROM SUCH WORK EXCEPT TO THE EXTENT ANY SUCH LOSS, LIABILITY OR DAMAGE IS CAUSED BY THE GROSS NEGLIGENCE OR WILLFUL MISCONDUCT OF LANDLORD AND FURTHER SUBJECT TO THE MUTUAL WAIVERS OF SUBROGATION HEREI</font><font style="font-weight:bold;">NAFTER SET FORTH IN </font><font style="font-weight:bold;text-decoration:underline;">SECTION 11(d)</font><font style="font-weight:bold;">, AND TENANT SHALL, IF REQUESTED BY LANDLORD, FURNISH A BOND OR OTHER SECURITY REASONABLY SATISFACTORY TO LANDLORD AGAINST ANY SUCH LOSS, </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">6<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">LIABILITY OR DAMAGE</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">; provided, however, that no bond shall be required in connection </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with any Cosmetic Changes.&nbsp;&nbsp;The foregoing indemnity shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;Landlord&#8217;s consent to or approval of any Alterations, additions or improvements (or the plans therefor) shall not constitute a represent</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ation or warranty by Landlord, nor Landlord&#8217;s acceptance, that the same comply with sound architectural and/or engineering practices or with all applicable Laws, and Tenant shall be solely responsible for ensuring all such compliance.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392307"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Repairs; Maintenance</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392308"></a><a name="_cp_text_1_476"></a><a name="_cp_text_1_477"></a><a name="_cp_text_1_479"></a><a name="_cp_text_1_480"></a><a name="_cp_text_1_481"></a><a name="_cp_text_1_482"></a><a name="_cp_text_1_483"></a>(i)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">By Landlord</font>.&nbsp;&nbsp;Landlord shall, subject to reimbursement under <font style="text-decoration:underline;">Exhibit&#160;C</font><a name="_cp_text_1_476"></a> (to the extent such costs are reimbursable therein), keep the Building&#8217;s Structure in good repair and working condition.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this Lease, any defects in design or construction of the Base, Shell and Core shall be corrected by Landlord at Landlord&#8217;s sole cost.&nbsp;&nbsp;Landlord, however, shall not be required to make any repairs occasioned by the act or negligence of Tenant, its agents, contracto<a name="_cp_text_1_477"></a>rs, employees, subtenants, licensees and concessionaires (including, but not limited to, roof leaks resulting from Tenant&#8217;s installation of air conditioning equipment or any other new roof penetration or placement); and the provisions of the previous sente<a name="_cp_text_1_479"></a>nce are expressly recognized to be subject to <font style="text-decoration:underline;">Sections&#160;14 and 15</font> <a name="_cp_text_1_480"></a>of this Lease.&nbsp;&nbsp;In the event that the Premises should become in need of repairs required to be made by Landlord hereunder, Tenant shall give immediate written notice thereof to Landlord, and Landlord shall have a reasonable time after receipt by Landlord of such written notice in which to make such repairs.&nbsp;&nbsp;Landlord shall not be liable to Tenant for any interruption of Tenant&#8217;s business or inconvenience caused due to any work performed in the<a name="_cp_text_1_481"></a> Premises or in the Complex pursuant to Landlord&#8217;s rights and obligations under the Lease, provided, however, Landlord shall use commercially reasonable efforts to not disturb the normal conduct of Tenant&#8217;s business or Tenant&#8217;s access to the Premises and/or parking areas <a name="_cp_text_1_482"></a>while performing such repairs and maintenance.&nbsp;&nbsp;In addition, Landlord shall maintain the Common Areas of the Project or Complex, as applicable, in a manner consistent with first class office and biotech buildings in Brisbane, California, subject to reimbursement as set forth in <font style="text-decoration:underline;"><a name="_cp_text_1_483"></a>Exhibit&#160;C</font> (to the extent such costs are reimbursable therein).&nbsp;&nbsp;<font style="font-weight:bold;">TENANT HEREBY WAIVES AND RELEASES ITS RIGHT TO MAKE REPAIRS AT LANDLORD&#8217;S EXPENSE UNDER SECTIONS 1941 AND 1942 OF THE CALIFORNIA CIVIL CODE OR UNDER ANY SIMILAR LAW, STATUTE OR ORDINANCE NOW OR HEREAFTER IN EFFECT</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392309"></a><a name="_cp_text_1_484"></a><a name="_cp_text_1_485"></a><a name="_cp_text_1_486"></a><a name="_cp_text_1_488"></a><a name="_cp_text_1_499"></a><a name="_cp_text_1_500"></a><a name="_cp_text_1_501"></a><a name="_cp_text_1_502"></a><a name="_AEIOULastRenderedPageBreakAEIOU16"></a><a name="_cp_text_1_504"></a><a name="_cp_text_1_505"></a><a name="_cp_text_1_506"></a><a name="_cp_text_1_507"></a><a name="_cp_text_1_509"></a><a name="_cp_text_1_511"></a><a name="_cp_text_1_512"></a><a name="_cp_text_1_515"></a>(ii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">By Tenant</font>.&nbsp;&nbsp;<a name="_cp_text_1_484"></a>Tenant shall keep the Premises (other than those portions required to be maintained by Landlord under <font style="text-decoration:underline;">Section 8(b)(i)</font> above), <a name="_cp_text_1_485"></a>in good, clean and habitable condition, and shall at its sole cost and expense keep the same free of dirt, rubbish, ice or snow, insects, rodents, vermin and other pests and make all needed repairs and replacements, including replacement of cracked or broken glass, except for repairs and replacements required t<a name="_cp_text_1_486"></a>o be made by Landlord, and any damage caused by ordinary wear and tear or Casualty.&nbsp;&nbsp;Without limiting the coverage of the previous sentence, it is understood that Tenant&#8217;s responsibilities therein include the repair and replacement in accordance with all a<a name="_cp_text_1_488"></a>pplicable Laws of the Building&#8217;s Systems, including the lighting, heating, air conditioning, life-safety, plumbing and other electrical, mechanical and electromotive installation, equipment and fixtures and also include all utility repairs in ducts, condui<a name="_cp_text_1_499"></a>ts, pipes and wiring, and any sewer stoppage located in, under and above the Premises. All contractors and subcontractors may be subject to Landlord&#8217;s written approval in accordance with <font style="text-decoration:underline;">Section 8(b)(iii)</font>.&nbsp;&nbsp;If any repairs required to be made by Tenant hereunder are not commenced within thirty (30) days (such time period not being subject to the notice and cure provisions of <font style="text-decoration:underline;">Section 17(f)</font>) after written notice delivered to Tenant by Landlord (which shall be given at its reasonable discretion) or are not diligently executed to completion with Tenant using commercially reasonable efforts given the circumstances, Landlord may at its option make such repairs without liability to Tenant for any loss or damage which may result to its stock or business by reason of <a name="_cp_text_1_500"></a>such repairs, unless caused by the gross negligence or willful misconduct of Landlord, its employees, agents or contractors, provided that Landlord shall use commercially reasonable efforts to minimize interference with Tenant&#8217;s use of, or access to, the Premises<a name="_cp_text_1_501"></a>.&nbsp;&nbsp;Tenant shall pay to Landlord within ten (10) days <a name="_cp_text_1_502"></a>upon written demand as Rent hereunder, </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">7<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the cost of such repairs</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> plus interest at the Default Rate, such interest to accrue continuously from the date of payment by Landlord until repayment by Tena</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_504"></a>.&nbsp;&nbsp;Notwithstanding the foregoing, Landlord shall have the right to make such repairs without notice to Tenant in the event of an emergency, or if such repairs relate to the exterior of the Premises.&nbsp;&nbsp;At the expiration </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or earlier termination </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of this Lease</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_505"></a>, Tenant shall surrender the Premises in </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_506"></a>good </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_507"></a>condition</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as existed on the date</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_509"></a> the Tenant Improvements are substantially completed, excepting reasonable wear and tear and casualties not required to be repaired by Tenant.&nbsp;&nbsp;If </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">elects to store any</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> personal property of Tenant, including goods, wares, merchandise, inventory, trade fixtures and other personal property of Tenant, same shall be stored at the sole risk of Tenant.&nbsp;&nbsp;Unless caused by the gross negligence or willful misconduct of Landlord, i</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts employees, agents or contractors, Landlord and its agents shall not be liable for any loss or damage to persons or property resulting from fire, explosion, falling plaster, steam, gas, electricity, water or rain which may leak from any part of the Compl</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ex or from the pipes, appliances or plumbing works therein or from the roof, street or subsurface or from any other places resulting from dampness or any other cause whatsoever, or from the act or negligence of any other tenant or any officer, agent, emplo</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">yee, contractor or guest of any such tenant.&nbsp;&nbsp;It is generally understood that mold spores are present essentially everywhere and that mold can grow in most any moist location.&nbsp;&nbsp;Emphasis is properly placed on prevention of moisture and on good housekeeping </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and ventilation practices.&nbsp;&nbsp;Tenant acknowledges the necessity of housekeeping, ventilation, and moisture control (especially in kitchens, janitor&#8217;s closets, bathrooms, break rooms and around outside walls) for mold prevention.&nbsp;&nbsp;In signing this Lease, Tenan</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t has first inspected the Premises and certifies that it has not observed mold, mildew or moisture within the Premises.&nbsp;&nbsp;Tenant agrees to immediately notify Landlord if it observes mold/mildew and/or moisture conditions (from any source, including leaks), </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_511"></a>and allow Landlord to evaluate and make recommendations and/or take appropriate corrective action.&nbsp;&nbsp;</font><font style="font-weight:bold;">TENANT RELIEVES LANDLORD FROM ANY LIABILITY FOR ANY BODILY INJURY OR DAMAGES TO PROPERTY CAUSED BY OR ASSOCIATED WITH MOISTURE OR THE GROWTH OF OR OCCURRENC</font><font style="font-weight:bold;">E OF MOLD OR MILDEW ON THE PREMISES</font><font style="font-weight:bold;"><a name="_cp_text_1_512"></a>, UNLESS SAME IS IN EXISTENCE ON THE </font><font style="font-weight:bold;">DELIVERY </font><font style="font-weight:bold;"><a name="_cp_text_1_515"></a>DATE OR IS CAUSED BY THE </font><font style="font-weight:bold;">GROSS </font><font style="font-weight:bold;">NEGLIGENCE OR WILLFUL MISCONDUCT OF LANDLORD, ITS EMPLOYEES, AGENTS OR CONTRACTORS</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;In addition, execution of this Lease constitutes acknowledg</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement by Tenant that control of moisture and mold prevention are integral to its Lease obligations</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:30.77%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding Tenant&#8217;s repair and maintenance obligations pursuant to this <font style="text-decoration:underline;">Section 8(b)(ii)</font>, if any item of Tenant&#8217;s repair and maintenance obligations set forth herein involves a capital repair, replacement, improvement and/or equipment under generally accepted accounting principles consistently applied (&#8220;<font style="font-weight:bold;">Tenant Repair Capital Item</font>&#8221;), Tenant shall provide written notice thereof to Landlord.&nbsp;&nbsp;Landlord shall, pursuant to the receipt of such notice from Tenant, make such Tenant Repair Capital Item in a manner such that the Tenant Repair Capital Item to be completed by Landlord shall be similar in size, scope and specifications as the item so repaired by Landlord.&nbsp;&nbsp;Landlord and Tenant shall use their respective commercially reasonable efforts to discuss and come to a mutually acceptable agreement with respect to the size, scope and specifications of the Tenant Repair Capital Item; provided, however, that in no event shall the size, scope and specifications of such Tenant Repair Capital Item exceed the original size, scope and specifications of the item subject to the repair.&nbsp;&nbsp;Following completion of the Tenant Repair Capital Item, Landlord shall provide Tenant with written notice of (i) the total cost of such Tenant Repair Capital Item (&#8220;<font style="font-weight:bold;">Tenant Repair Capital Item Cost</font>&#8221;), (ii) the estimated useful life of such Tenant Repair Capital Item per generally accepted accounting principles consistently applied (&#8220;<font style="font-weight:bold;">Useful Life</font>&#8221;), (iii) the amortization of such Tenant Repair Capital Item Cost over such Useful Life at an interest rate equal to the &#8220;prime rate&#8221; as announced from time to time by Bank of America, N.A., plus one percent (1%) per annum, and (iv) the monthly amount due and payable by Tenant to reimburse Landlord for that portion of the amortized Tenant Repair Capital Item Cost applicable to the remainder of the Lease Term, which monthly amount shall be paid by Tenant to Landlord concurrently with the payment by Tenant to Landlord of the monthly Base Rent.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">8<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392310"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Performance of Work</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;All work described in this </font><font style="text-decoration:underline;">Section&#160;8</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> which affects the Building&#8217;s Structure and/or the Building&#8217;s Systems shall be performed only by contractors and subcontractors approved in writing by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed (which approval or di</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sapproval shall be provided by Landlord within three (3) business days of Landlord&#8217;s receipt of the identity of the applicable contractor and subcontractor).&nbsp;&nbsp;Landlord hereby acknowledges and agrees that Tenant&#8217;s contractors and subcontractors approved by </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord in connection with the design and construction of the Tenant Improvements shall be deemed to be approved in connection with Tenant&#8217;s work in this </font><font style="text-decoration:underline;">Section&#160;8</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall cause all contractors and subcontractors to procure and maintain insurance c</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">overage naming Landlord and Landlord&#8217;s property management company as additional insureds against such risks, in such amounts, on such forms, and with such companies as Landlord may reasonably require as set forth on </font><font style="text-decoration:underline;">Exhibit&#160;I</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> attached hereto.&nbsp;&nbsp;Tenant shal</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">l provide Landlord with the identities, mailing addresses and telephone numbers of all persons performing work or supplying materials prior to beginning such construction and Landlord may post on and about the Premises notices of non-responsibility pursuan</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t to applicable Laws.&nbsp;&nbsp;All such work shall be performed in accordance with all applicable Laws and in a good and workmanlike manner so as not to damage the Building (including the Premises, the Building&#8217;s Structure and the Building&#8217;s Systems).&nbsp;&nbsp;All such wo</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rk which may affect the Building&#8217;s Structure or the Building&#8217;s Systems, at Landlord&#8217;s election, must be performed by Landlord&#8217;s usual contractor for such work or a contractor approved by Landlord, which approval shall not be unreasonably withheld, conditio</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ned or delayed.&nbsp;&nbsp;All work affecting the roof of the Building must be performed by Landlord&#8217;s roofing contractor or a contractor approved by Landlord, which approval shall not be unreasonably withheld, conditioned or delayed, and no such work will be permit</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ted if it would void or reduce the warranty on the roof.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506191804"></a><a name="_Toc497392311"></a><a name="_cp_text_1_522"></a><a name="_AEIOULastRenderedPageBreakAEIOU18"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Mechanic&#8217;s Liens</font>.&nbsp;&nbsp;All work performed, materials furnished, or obligations incurred by or at the request of a Tenant Party shall be deemed authorized and ordered by Tenant only, and Tenant shall not permit any mechanic&#8217;s liens to be filed against the Premises or the Project in connection therewith.&nbsp;&nbsp;Upon completion of any such work, Tenant shall deliver to Landlord final lien waivers from all contractors, subcontractors and materialmen who performed such work.&nbsp;&nbsp;If such a lien is filed, then Tenant shall, within thirty (30) days after Landlord has delivered notice of the filing thereof to Tenant (or such earlier time period as may be necessary to prevent the forfeiture of the Premises, Project or any interest of Landlord therein or the imposition of a civil or criminal fine with respect thereto), either: (1)&#160;pay the amount of the lien and cause the lien to be released of record; or (2)&#160;diligently contest such lien and deliver to Landlord a bond or other security reasonably satisfactory to Landlord.&nbsp;&nbsp;If Tenant fails to timely take either such action, then Landlord may pay the lien claim, and any amounts so paid, including expenses and interest, shall be paid by Tenant to Landlord within thirty (30) days after Landlord has invoiced Tenant therefor.&nbsp;&nbsp;Landlord and Tenant acknowledge and agree that their relationship is and shall be solely that of &#8220;landlord-tenant&#8221; (thereby excluding a relationship of &#8220;owner-contractor,&#8221; &#8220;owner-agent&#8221; or other similar relationships).&nbsp;&nbsp;Accordingly, all materialmen, contractors, artisans, mechanics, laborers and any other persons now or hereafter contracting with Tenant, any contractor or subcontractor of Tenant or any other Tenant Party for the furnishing of any labor, services, materials, supplies or equipment with respect to any portion of the Premises, at any time from the date hereof until the end of the Term, are hereby charged with notice that they look exclusively to Tenant to obtain payment for same.&nbsp;&nbsp;Nothing herein shall be deemed a consent by Landlord to any liens being placed upon the Premises, Project or Landlord&#8217;s interest therein due to any work performed by or for Tenant or deemed to give any contractor or subcontractor or materialman any right or interest in any f<a name="_cp_text_1_522"></a>unds held by Landlord to reimburse Tenant for any portion of the cost of such work.&nbsp;&nbsp;<font style="font-weight:bold;">TENANT SHALL INDEMNIFY, DEFEND AND HOLD HARMLESS LANDLORD, ITS PROPERTY MANAGER, ANY SUBSIDIARY OR AFFILIATE OF THE FOREGOING, AND THEIR RESPECTIVE OFFICERS, DIRECTORS, SHARE-HOLDERS, PARTNERS, EMPLOYEES, MANAGERS, CONTRACTORS, ATTORNEYS AND AGENTS (COLLECTIVELY, THE </font>&#8220;<font style="font-weight:bold;">INDEMNITEES</font>&#8221;<font style="font-weight:bold;">) FROM AND AGAINST ALL CLAIMS, DEMANDS, CAUSES OF ACTION, SUITS, JUDGMENTS, DAMAGES AND EXPENSES (INCLUDING </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">9<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">REASONABLE ATTORNEYS&#8217; FEES) IN ANY WAY</font><font style="font-weight:bold;"> ARISING FROM OR RELATING TO THE FAILURE BY ANY TENANT PARTY TO PAY FOR ANY WORK PERFORMED, MATERIALS FURNISHED, OR OBLIGATIONS INCURRED BY OR AT THE REQUEST OF A TENANT PARTY</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> The foregoing indemnity shall survive termination or expiration of this Lease.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392312"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Signs</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392313"></a><a name="_cp_text_1_526"></a><a name="_cp_text_2_528"></a><a name="_cp_text_1_530"></a><a name="_cp_text_1_531"></a>(i)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">General Signs</font>.&nbsp;&nbsp;<a name="_cp_text_1_526"></a>Tenant shall have the right to place any signs in, on or around the Building so long as (x)&#160;such sign complies with applicable Law, and Tenant shall have received any applicable governmental permit, and (y)&#160;Tenant shall have provided Landlord with notice thereof and a copy of any applicable governmental permit(s).&nbsp;&nbsp;Upon request of Landlord, Tenant shall immediately remove any sign or other materials which Tenant has placed or permitted to be placed upon the exterior or interior surfa<a name="_cp_text_2_528"></a>ce of any door or window inside the Premises, or the exterior of the Building, if required in connection with any repairs to the Building.&nbsp;&nbsp;If Tenant fails to do so, Landlord may without liability unless caused by the gross negligence or willful misconduct<a name="_cp_text_1_530"></a> of Landlord, its employees, agents or contractors, remove the same at Tenant&#8217;s expense.&nbsp;&nbsp;Tenant shall comply with such regulations as may from time to time be promulgated by Landlord and provided to Tenant in writing governing signs, advertising material or lettering of all tenants in the Project or Complex, as applicable.&nbsp;&nbsp;Tenant shall be responsible for the repair, painting or replacement of the Building fascia surface or other portion of the Building where signs are attached and/or any damage to the Pre<a name="_cp_text_1_531"></a>mises to remove signs placed by Tenant, upon vacation of the Premises, or the removal or alteration of its sign for any reason.&nbsp;&nbsp;If Tenant fails to do so, Landlord may have the sign removed and the reasonable cost of removal shall be payable by Tenant within thirty (30) days of invoice.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392314"></a><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>(ii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Building Top Sign(s)</font>.&nbsp;&nbsp;Subject to the terms of this <font style="text-decoration:underline;">Section&#160;8</font> and applicable Laws, Landlord hereby grants Tenant the right, at Tenant&#8217;s sole cost and expense, to install up to two (2) Building top signs at location(s) elected by Tenant (which may include both Tenant&#8217;s name, which shall be restricted to only Sangamo Therapeutics, Inc. and corporate logo) (&#8220;<font style="font-weight:bold;">Building Top Sign(s)</font>&#8221;).&nbsp;&nbsp;Tenant&#8217;s Building Top Sign(s) shall be subject to all applicable Laws and Tenant&#8217;s receipt of any applicable governmental permit(s).&nbsp;&nbsp;The content, size, design, graphics, materials, colors and other specifications of the Building Top Sign(s) (including without limitation, the exact location of any and all of the Building Top Sign(s)) shall be consistent with the exterior design, materials and appearance of the Building and the signage program of the Building, if any.&nbsp;&nbsp;The contractors and/or subcontractors utilized by Tenant in connection with the Building Top Sign(s) may be subject to Landlord&#8217;s written approval in accordance with <font style="text-decoration:underline;">Section 8(b)(iii)</font>.&nbsp;&nbsp;Tenant shall be responsible for all costs and expenses incurred in connection with the design, construction, installation, repair, operation, maintenance, compliance with laws, utilities (including the costs of metering such utilities usage and the cost of the meter) and removal of the Building Top Sign(s).&nbsp;&nbsp;Tenant shall also be responsible for the cost of all utilities (if any) utilized in connection with the Building Top Sign(s).&nbsp;&nbsp;Tenant&#8217;s signage rights set forth in this <font style="text-decoration:underline;">Section 8(d)(ii)</font> shall be personal to the Tenant and may not be assigned to any assignee or any sublessee or any other person or entity (except in connection with a Permitted Transferee).&nbsp;&nbsp;Should the name of Tenant be changed to another name (the &#8220;<font style="font-weight:bold;">New Name</font>&#8221;), Tenant shall be entitled to modify, at Tenant&#8217;s sole cost and expense, Tenant&#8217;s name on the Building Top Sign(s) to reflect Tenant&#8217;s New Name, so long as (a)&#160;the New Name is not an &#8220;<font style="font-weight:bold;">Objectionable Name</font>&#8221;, (b)&#160;Landlord shall have granted its consent to such New Name (which consent Landlord may withhold in its sole and absolute discretion), (c)&#160;Tenant&#8217;s New Name shall be subject to the then existing signage rights of any tenant or occupant within the Complex, (d)&#160;Tenant&#8217;s New Name shall not cause Landlord to be in violation of another lease or agreement which Landlord is a party at the Complex, and (e)&#160;Tenant&#8217;s New Name shall not cause Landlord to be in violation of an exclusivity granted to another tenant at the Complex.&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Objectionable Name</font>&#8221; shall mean any name which relates to an entity which is of a character or reputation, or is associated with a political orientation or faction, which is inconsistent with the quality of the Complex, or which would otherwise reasonably offend a landlord of buildings comparable to and in the vicinity of the Building.&nbsp;&nbsp;In addition, Tenant&#8217;s right to maintain any of the Building Top Sign(s) shall </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">10<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">terminate at any time during the Lease Term during the continuance of an Event of Default under this Lea</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se.&nbsp;&nbsp;Upon the expiration of the Lease Term or the earlier termination of Tenant&#8217;s signage rights under this </font><font style="text-decoration:underline;">Section 8(d)(ii)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Tenant shall, at Tenant&#8217;s sole cost and expense, remove the Building Top Sign(s) and repair any and all damage to the Building cau</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sed by such removal.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392315"></a><a name="_cp_text_1_550"></a><a name="_cp_text_1_551"></a><a name="_cp_text_1_553"></a><a name="_cp_text_1_554"></a><a name="_cp_text_1_558"></a><a name="_cp_text_1_560"></a><a name="_cp_text_1_562"></a><a name="_cp_text_1_563"></a><a name="_cp_text_1_564"></a><a name="_cp_text_1_565"></a><a name="_cp_text_1_566"></a><a name="_cp_text_1_570"></a><a name="_cp_text_1_571"></a><a name="_cp_text_1_572"></a>9.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Use; Compliance with Laws</font><a name="_cp_text_1_550"></a>.&nbsp;&nbsp;Tenant shall use the Premises only for the Permitted Use (as set forth in the Basic Lease Information) and shall comply with all applicable Laws relating to the use, condition, access to, and occupancy of th<a name="_cp_text_1_551"></a>e Premises and will not commit waste, overload the Building&#8217;s Structure or the Building&#8217;s Systems or subject the Premises to any use that would damage the Premises (ordinary wear and tear excepted).&nbsp;&nbsp;Tenant, at its sole cost and expense, shall obtain and keep in effect during the Term, all permits, licenses, and other authorizations necessary to permit Tenant to use and occupy the Premises for the Permitted Use in accordance with applicable Laws.&nbsp;&nbsp;Notwithstanding anything in this Lease to the contrary, as between Landlord and Tenant:&nbsp;&nbsp;(i) Tenant shall bear the risk of complying with Title III of the Americans With Disabilities Act of 1990, any state laws governing handicapped access or architectural barriers, and all rules, regulations, and guidelines promulgated under such laws, as amended from time to time (the &#8220;<font style="font-weight:bold;">Disabilities Acts</font><a name="_cp_text_1_553"></a>&#8221;) with respect to <a name="_cp_text_1_554"></a>the Premises (but not the Common Areas); and (ii) Landlord shall bear the risk of complying with the Disabilities Acts in the Common Areas (subject to <font style="text-decoration:underline;">Exhibit&#160;C</font>),<a name="_cp_text_1_558"></a> other than compliance that is necessitated by Tenant&#8217;s use of the Premises or as a result of the Tenant Improvements as defined on <font style="text-decoration:underline;">Exhibit&#160;D</font><a name="_cp_text_1_560"></a> and any Alterations made by Tenant (which risk and responsibility shall be borne by Tenant).&nbsp;&nbsp;Landlord represents <a name="_cp_text_1_562"></a>and warrants that as of the Delivery Date, the Common Areas shall be in compliance with the Disabilities Acts.&nbsp;&nbsp;The Premises shall not be used for any purpose which releases outside the Premises <a name="_cp_text_1_563"></a>strong, unusual, or offensive odors, fumes, dust or vapors which is objectionable to a typical person<a name="_cp_text_1_564"></a>; which emits outside the Premises <a name="_cp_text_1_565"></a>noise or sounds that are objectionable to a typical person due to intermittence, beat, frequency, shrillness, or loudness; which is associated with indecent or pornographic matters;<a name="_cp_text_1_566"></a> or which involves political or moral issues (such as abortion issues).&nbsp;&nbsp;Tenant shall conduct its business and control each other Tenant Party so as not to create any nuisance or unreasonably interfere with other tenants of the Complex or Landlord in its management of the Building.&nbsp;&nbsp;Tenant shall store all trash and garbage within the Premises or in a trash dumpster or similar container approved by Landlord as to type, location and screening; and Tenant shall arrange for the regular pick-up of such trash and garbage at Tenant&#8217;s expense (unless Landlord finds it necessary to furnish such a service, in which event Tenant shall be charged an equitable portion of the total of the charges to all tenants using the service).&nbsp;&nbsp;Tenant shall not operate an incinerator or burn trash or garbage within the Project or Complex, as applicable.&nbsp;&nbsp;Tenant shall not knowingly conduct or permit to be conducted in the Premises any activity, or place any equipment in or about the Premises or the Building, which will invalidate the insurance coverage in effect or increase the rate of fire insurance or other insurance on the Premises or the Building; provided that the Permitted Use will not be deemed to invalidate such insurance coverage or increase the rate of such insurance on the Pre<a name="_cp_text_1_570"></a>mises or the Building.&nbsp;&nbsp;If any invalidation of coverage or increase in the rate of fire insurance or other insurance occurs or is threatened by any insurance company due to activity conducted from the Premises in violation of this Lease, or any act or omis<a name="_cp_text_1_571"></a>sion by Tenant, or its agents, employees, representatives, or contractors in violation of this Lease, such statement or threat shall be conclusive evidence that the increase in such rate is due to such act of Tenant or the contents or equipment in or about the Premises, and, as a result thereof, Tenant shall be liable for such increase and shall be considered Additional Rent payable with the next monthly installment of Base Rent due under this Lease.&nbsp;&nbsp;In no event shall Tenant introduce or permit to be kept <a name="_cp_text_1_572"></a>on the Premises or brought into the Building any dangerous, noxious, radioactive or explosive substance in violation of <font style="text-decoration:underline;">Section 25</font> herein.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506189428"></a><a name="_Toc497392316"></a>10.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Assignment and Subletting</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506185276"></a><a name="_Toc497392317"></a><a name="_cp_text_1_573"></a><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transfers</font><a name="_cp_text_1_573"></a>.&nbsp;&nbsp;Except for Permitted Transfers, Tenant shall not, without the prior written consent of Landlord, which consent shall not unreasonably be withheld, conditioned or delayed:&nbsp;&nbsp;(1)&#160;assign, transfer, or encumber this Lease or any estate or interest herein, whether directly or by operation of law; (2)&#160;permit any other entity to become Tenant hereunder by merger, consolidation, or other </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">11<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reorganization; (3)&#160;if Tenant is an entity other than a corporation whose stock is publicly traded, permit the transfer of an ownership interest in Tenant so as to result in a change in the current control of</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Tenant; (4)&#160;sublet any portion of the Premises; (5)&#160;grant any license, concession, or other right of occupancy of any portion of the Premises; or (6)&#160;permit the use of the Premises by any parties other than Tenant (any of the events listed in </font><font style="text-decoration:underline;">Section 10(a</font><font style="text-decoration:underline;">)(1)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> through </font><font style="text-decoration:underline;">Section 10(a)(6)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> being a &#8220;</font><font style="font-weight:bold;">Transfer</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392318"></a><a name="_cp_text_1_576"></a><a name="_cp_text_1_578"></a><a name="_cp_text_1_580"></a><a name="_cp_text_1_582"></a><a name="_cp_text_1_584"></a><a name="_cp_text_1_585"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Consent Standards</font>.&nbsp;&nbsp;If a proposed transferee does not meet the following conditions, Landlord shall not be deemed to have been unreasonable in withholding its consent to a Transfer (provided that the follo<a name="_cp_text_1_576"></a>wing list shall not be deemed the exclusive factors for review):&nbsp;&nbsp;(1)&#160;intentionally omitted; (2)&#160;has a good reputation in the business community; (3)&#160;will use the Premises for the Permitted Use and will not use the Premises in any manner that would conflic<a name="_cp_text_1_578"></a>t with any exclusive use agreement or other similar agreement entered into by Landlord with any other tenant of the Project or Complex, as applicable; (4)&#160;will not use the Premises, Project or Complex in a manner that would materially increase the pedestri<a name="_cp_text_1_580"></a>an or vehicular traffic to the Premises, Project or Complex; (5)&#160;is not another occupant of the Building or Complex, as applicable, and there is a comparable space available in the Complex at the time of Tenant&#8217;s request for Landlord&#8217;s consent<a name="_cp_text_1_582"></a>; and (6)&#160;is <a name="_cp_text_1_584"></a>not a person or entity with whom Landlord is then, or has been within the three-month period prior to the time Tenant seeks to enter into such assignment or subletting, negotiating to lease space in the Building or Complex, as applicable, or any Affiliate <a name="_cp_text_1_585"></a>of any such person or entity, and there is a comparable space available in the Complex at the time of Tenant&#8217;s request for Landlord&#8217;s consent.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392319"></a><a name="_cp_text_1_592"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Request for Consent</font>.&nbsp;&nbsp;If Tenant requests Landlord&#8217;s consent to a Transfer, then, at least thirty (30) days prior to the effective date of the proposed Transfer, Tenant shall provide Landlord with a written description of all terms and conditions of the proposed Transfer, copies of the proposed pertinent documentation, and the following information about the proposed transferee: name and address; reasonably satisfactory information about its business and business history; its proposed use of the Premises; banking, financial, and other credit information; and general references sufficient to enable Landlord to determine the proposed transferee&#8217;s creditworthiness and character (collectively, the &#8220;<font style="font-weight:bold;">Transfer Notice</font>&#8221;).&nbsp;&nbsp;Concurrently with the Transfer Notice, Tenant shall pay to Landlord a fee of $2,000 to defray Landlord&#8217;s expenses in reviewing such request, and Tenant shall <a name="_cp_text_1_592"></a>reimburse Landlord within ten (10) days upon request for its reasonable attorneys&#8217; fees incurred in connection with considering any request for consent to a Transfer, not to exceed $2,500 per request.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392320"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Conditions to Consent</font>.&nbsp;&nbsp;If Landlord consents to a proposed Transfer, then the proposed transferee shall deliver to Landlord a written agreement whereby it expressly assumes Tenant&#8217;s obligations hereunder.&nbsp;&nbsp;No Transfer shall release Tenant from its obligations under this Lease, but rather Tenant and its transferee shall be jointly and severally liable therefor.&nbsp;&nbsp;Landlord&#8217;s consent to any Transfer shall not be deemed consent to any subsequent Transfers.&nbsp;&nbsp;Tenant shall pay for the cost of any demising walls or other improvements necessitated by a proposed subletting or assignment.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506189247"></a><a name="_Toc497392321"></a><a name="_AEIOULastRenderedPageBreakAEIOU21"></a><a name="_cp_text_4_604"></a><a name="_cp_text_1_605"></a><a name="_cp_text_4_606"></a><a name="_cp_text_1_607"></a><a name="_cp_text_4_608"></a><a name="_cp_text_1_609"></a><a name="_cp_text_4_610"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Attornment by Subtenants</font>.&nbsp;&nbsp;Each sublease by Tenant hereunder shall be subject and subordinate to this Lease and to the matters to which this Lease is or shall be subordinate, and each subtenant by entering into a sublease is deemed to have agreed that in the event of termination, re-entry or dispossession by Landlord under this Lease, Landlord may, at its option, either terminate the sublease or take over all of the right, title and interest of Tenant, as sublandlord, under such sublease, and such subtenant shall, at Landlord&#8217;s option, attorn to Landlord pursuant to the then executory provisions of such sublease, except that Landlord shall not be: (1)&#160;liable for any previous act or omission of Tenant under such sublease; (2)&#160;subject to any counterclaim, offset or defense that such subtenant might have against Tenant; (3)&#160;bound by any previous modification of such sublease or by any rent or additional rent or advance rent which such subtenant might have paid for more than the current month to Tenant, and all such rent shall remain due and owing, notwithstanding such advance payment; (4)&#160;bound by any security or advance rental deposit made by such subtenant which is not delivered or paid over to Landlord and with respect to which such subtenant shall look solely to Tenant for refund or reimbursement; or (5)&#160;obligated to perform any work in </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">12<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the subleased space or to prepare it for occupancy, and in connection with such attornment, the subtenant shall execute and deliver to Landlord any instruments</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Landlord may reasonably request to evidence and confirm such attornment.&nbsp;&nbsp;Each subtenant or licensee of Tenant shall be deemed, automatically upon and as a condition of its occupying or using the Premises or any part thereof, to have agreed to be bound by</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> the terms and conditions set forth in this </font><font style="text-decoration:underline;">Section 10(e)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The provisions of this </font><font style="text-decoration:underline;">Section 10(e)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be self-operative, and no further instrument shall be required to give effect to this provision</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_604"></a>.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_605"></a>&nbsp;&nbsp;If an Event of Default occurs while the Premises or any part thereof are subject to a </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_606"></a>sublease</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_607"></a>, then Landlord, in addition to its other remedies, may collect directly from such </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_608"></a>subtenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">all rents becoming due to Tenant and apply such rents against Rent.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_609"></a>&nbsp;&nbsp;Tenant authorizes its </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_610"></a>subtenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">to make payments of rent directly to Landlord upon receipt of notice from Landlord to do so following the occurrence of an Event of Default hereunder</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392322"></a><a name="_cp_text_1_613"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Permitted Transfers</font><a name="_cp_text_1_613"></a>.&nbsp;&nbsp;Notwithstanding to the contrary contained in this Lease, Tenant may Transfer all or part of its interest in this Lease or all or part of the Premises (a &#8220;<font style="font-weight:bold;">Permitted Transfer</font>&#8221;) to the following types of entities (a &#8220;<font style="font-weight:bold;">Permitted Transferee</font>&#8221;) without the written consent of Landlord:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font>an Affiliate of Tenant;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_614"></a>(2)<font style="margin-left:36pt;"></font>any persons&nbsp;&nbsp;acquiring a controlling interest in Tenant in connection with a bona fide private equity placement financing or an initial public offering of Tenant&#8217;s stocks on a nationally recognized stock exchange;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;"></font>any corporation, limited partnership, limited liability partnership, limited liability company or other business entity in which or with which Tenant, or its corporate successors or assigns, is merged or consolidated, in accordance with applicable statutory provisions governing merger and consolidation of business entities, so long as (A) Tenant&#8217;s obligations hereunder are assumed by the entity surviving such merger or created by such consolidation; and (B) the Tangible Net Worth of the surviving or created entity is not less than the Tangible Net Worth of Tenant as of the date of execution of this Lease; or</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)<font style="margin-left:36pt;"></font>any corporation, limited partnership, limited liability partnership, limited liability company or other business entity acquiring all or substantially all of Tenant&#8217;s assets if such entity&#8217;s Tangible Net Worth after such acquisition is not less than the Tangible Net Worth of Tenant as of the date of execution of this Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_623"></a><a name="_cp_text_1_624"></a><a name="_cp_text_1_623"></a>Tenant shall promptly notify Landlord of any such Permitted Transfer.&nbsp;&nbsp;Tenant shall remain liable for the performance of all of the obligations of Tenant hereunder, or if Tenant no longer exists because of a merger, consolidation, or acquisition, the surviving or acquiring entity shall expressly assume in writing the obligations of Tenant hereunder.&nbsp;&nbsp;Additionally, the Permitted Transferee shall comply with all of the terms and conditions of this Lease, including the Permitted Use.&nbsp;&nbsp;No later than five (5) Business Days after the effective date of any Permitted Transfer, Tenant agrees to furnish Landlord with (A) copies of the instrument effecting any of the foregoing Transfers, which copies of such instruments may be redacted by Tenant, (B) documentation establishing Tenant&#8217;s satisfaction of the requirements set forth above applicable to any such Transfer, and (C) evidence of insuran<a name="_cp_text_1_624"></a>ce as required under this Lease with respect to the Permitted Transferee, provided that Landlord executes a non-disclosure agreement provided by Tenant.&nbsp;&nbsp;The occurrence of a Permitted Transfer shall not waive Landlord&#8217;s rights as to any subsequent Transfers.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Tangible Net Worth</font>&#8221; means the excess of total assets over total liabilities, in each case as determined in accordance with generally accepted accounting principles consistently applied (&#8220;<font style="font-weight:bold;">GAAP</font>&#8221;).&nbsp;&nbsp;Any subsequent Transfer by a Permitted Transferee shall be subject to the terms of this <font style="text-decoration:underline;">Section 10</font>.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">13<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392323"></a><a name="_AEIOULastRenderedPageBreakAEIOU22"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(g)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Compensation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall pay to Landlord, immediately upon receipt thereof, fifty percent (50%) of the excess of all compensation received by Tenant for a Transfer over the Rent allocable to the po</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rtion of the Premises covered thereby, after deducting the following costs and expenses for such Transfer (which costs will be amortized over the term of the sublease or assignment pursuant to sound accounting principles and deducted monthly from such exce</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ss):&nbsp;&nbsp;(1)&#160;brokerage commissions and reasonable attorneys&#8217; fees; (2) advertising for subtenants or assignees; (3)&#160;the actual costs paid in making any improvements or substitutions in the Premises required by any sublease or assignment; and (4) the costs of </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any inducements or concessions or rental reductions or abatement given to the subtenant or assignee. </font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392324"></a>(h)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Option</font>.&nbsp;&nbsp;Notwithstanding anything to the contrary contained in this <font style="text-decoration:underline;">Article 10</font>, except in connection with Permitted Transfers, Landlord shall have the option, by giving written notice to Tenant within thirty (30) days after receipt of any Transfer Notice with respect to (i) a proposed assignment of this Lease by Tenant, or (ii) a proposed sublease of the entire Premises (the &#8220;<font style="font-weight:bold;">Subject Space</font>&#8221;) to (x) recapture the Subject Space, or (y)&#160;take an assignment or sublease of the Subject Space from Tenant.&nbsp;&nbsp;Such recapture, or sublease or assignment notice shall cancel and terminate this Lease, or create a sublease or assignment, as the case may be, with respect to the Subject Space as of the date stated in the Transfer Notice as the effective date of the proposed Transfer until the last day of the term of the Transfer as set forth in the Transfer Notice.&nbsp;&nbsp;If Landlord declines, or fails to elect in a timely manner to recapture, sublease or take an assignment of the Subject Space under this <font style="text-decoration:underline;">Section 10(h)</font>, then, provided Landlord has consented to the proposed Transfer, Tenant shall be entitled to proceed to transfer the Subject Space to the proposed Transferee, subject to provisions of this <font style="text-decoration:underline;">Section&#160;10</font>.&nbsp;&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392325"></a><a name="_Ref506189464"></a>11.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;"><a name="_Ref506189464"></a>Insurance; Waivers; Subrogation; Indemnity</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392326"></a><a name="_cp_text_1_628"></a><a name="_Ref506189636"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Indemnity Agreement</font>.&nbsp;&nbsp;<font style="font-weight:bold;"><a name="_cp_text_1_628"></a>TO THE FULLEST EXTENT PERMITTED BY LAW AND SUBJECT TO LANDLORD&#8217;S INDEMNIFICATION OBLIGATIONS BELOW AND FURTHER SUBJECT TO THE MUTUAL WAIVERS OF SUBROGATION SET FORTH IN </font><font style="font-weight:bold;text-decoration:underline;">SECTION 11(d)</font><font style="font-weight:bold;">, TENANT WILL DEFEND, INDEMNIFY AND HOLD LANDLORD HARMLESS FROM AND AGAINST ALL CLAIMS (AS DEFINED HEREIN) ARISING OUT OF OR RELATING (DIRECTLY OR INDIRECTLY) TO (I) THE CONDUCT OR MANAGEMENT OF THE PREMISES OR OF ANY BUSINESS THEREIN, OR ANY WORK OR THING WHATSOEVER DONE, OR ANY CONDITION CREATING IN OR ABOUT THE PREMISES DURING THE TERM; (II) ANY ACT, OMISSION, BREACH OF ANY PROVISION OF THIS LEASE, OR NEGLIGENCE OF TENANT OR ANY OF TENANT&#8217;S LICENSEES OR THE PARTNERS, DIRECTORS, OFFICERS, AGENTS, EMPLOYEES, INVITEES OR CONTRACTORS OF TENANT OR ANY OF TENANT&#8217;S LICENSEES; AND (III) ANY ACCIDENT, INJURY OR DAMAGE WHATSOEVER OCCURRING IN OR AT THE PREMISES.&nbsp;&nbsp;TO THE FULLEST EXTENT PERMITTED BY LAW AND SUBJECT TO THE MUTUAL WAIVERS OF SUBROGATION SET FORTH IN </font><font style="font-weight:bold;text-decoration:underline;">SECTION 11(d)</font><font style="font-weight:bold;">, LANDLORD AGREES TO INDEMNIFY TENANT AND TENANT PARTY FROM AND AGAINST ANY AND ALL CLAIMS ARISING FROM INJURY OR DEATH OF ANY PERSON OR DAMAGE TO OR LOSS OF ANY PHYSICAL PROPERTY OCCURRING WITHIN OR ABOUT THE PREMISES, THE BUILDING, THE PROJECT AND/OR THE COMPLEX, TO THE EXTENT ARISING OUT OF LANDLORD&#8217;S OR INDEMNITEES&#8217; GROSS NEGLIGENCE, WILLFUL MISCONDUCT OR BREACH OF THIS LEASE</font><font style="font-weight:bold;color:#000000;"><a name="_Ref506189636"></a>.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392327"></a><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Insurance</font>.&nbsp;&nbsp;Effective as of the Delivery Date and continuing throughout the Term, Tenant shall maintain insurance of the types and in the amounts described below.&nbsp;&nbsp;Insurance shall be obtained from insurance carriers rated not less than A-VIII by A.M. Best Company and licensed to business in the State.&nbsp;&nbsp;Tenant insurance policy deductibles shall be the responsibility of the Tenant and shall be less than $25,000 unless approved by Landlord.&nbsp;&nbsp;Tenant&#8217;s insurance policies shall be primary and not </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">14<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require any contribution by any insurance maintained by Landlord, and Tenant shall requ</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ire the insurer with respect to each policy required in this </font><font style="text-decoration:underline;">Section 11(b)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to waive subrogation rights against Landlord and the other Landlord Parties.&nbsp;&nbsp;If Tenant fails to comply with the foregoing insurance requirements or to deliver to Landlord the certi</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ficates or evidence of coverage required herein, Landlord, in addition to any other remedy available pursuant to this Lease or otherwise, may, but shall not be obligated to, obtain such insurance and Tenant shall pay to Landlord the cost thereof, plus an a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">dministrative fee of three percent (3%) of the cost thereof.&nbsp;&nbsp;It is expressly understood and agreed that the foregoing minimum limits of insurance coverage shall not limit the liability of Tenant for its acts or omissions as provided in this Lease.&nbsp;&nbsp;Tenant</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> may satisfy requirements of this </font><font style="text-decoration:underline;">Section 11(b)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> with policies that cover both the Premises and other properties, on condition that any general aggregate limits under these &#8220;blanket&#8221; policies apply separately to the Premises, the requirements in this </font><font style="text-decoration:underline;">Sectio</font><font style="text-decoration:underline;">n 11(b)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> are otherwise satisfied, and these policies do not otherwise impair the rights of Landlord or violate requirements of this Lease. Certificates for all insurance carried pursuant to this </font><font style="text-decoration:underline;">Section 11(b)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be delivered to Landlord before the Delive</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ry Date and thereafter upon request and (even if not requested) upon the renewal or replacement of any required policy. Tenant shall ensure that Landlord is notified no less than ten (10) days before cancellation of any required policy, and shall cause its</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> certificates of insurance to indicate this.&nbsp;&nbsp;</font><font style="color:#000000;">Failure of Landlord to demand such certificate or other evidence of full compliance with these insurance requirements or failure of Landlord to identify a deficiency from evidence that is provided shall not be </font><font style="color:#000000;">construed as a waiver of Tenant&#8217;s obligation to maintain such insurance.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;These requirements and limits are subject to review and modification by Landlord in its commercially reasonable determination (i)&#160;in recognition of changes in the occupancy, exposure</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, or insurance marketplace, and/or (ii)&#160;as a result of Tenant&#8217;s use of Hazardous Materials or other items in the Premises as set forth in the list of Hazardous Materials in the Environmental Questionnaire attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;J</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to be provided by Tena</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nt to Landlord no later than the Commencement Date.&nbsp;&nbsp;The term &#8220;</font><font style="font-weight:bold;">Landlord Parties</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; means Landlord; Landlord&#8217;s property manager with respect to the Premises; Landlord&#8217;s Mortgagee; other entities or individuals Landlord may designate from time to time to be in</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">cluded as additional insureds (e.g., by requiring that they be listed as additional insureds on certificates of insurance); the successors and assigns, and direct and indirect affiliates, of each of the foregoing; and, with respect to each of the foregoing</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, its shareholders, trustees, beneficiaries, managers, officers, directors, employees, and agents. </font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Commercial General Liability Insurance</font><font style="font-weight:bold;"> </font>written on an occurrence basis, using a form that is at least as broad as ISO commercial general liability form (CG 00 01) and<font style="color:#000000;"> shall cover liability arising from premises, operations, independent contractors, products-completed operations, personal injury and advertising injury, and liability assumed under an insured contract </font>naming the Landlord and the other Landlord Parties as additional insureds on a primary and non-contributory basis with limits of not less than $1,000,000 each occurrence and $2,000,000 aggregate per location shall be maintained.&nbsp;&nbsp;Evidence of commercial general liability insurance granting no less than thirty (30) days&#8217; notice of cancellation for reasons other than non-payment shall be provided by the ISO form (CG 20 11, CG 20 26 11 85, or a substitute providing equivalent coverage and under the commercial umbrella policy) prior to Lease inception and no less than fifteen (15) days prior to each insurance policy renewal during the term of the Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Commercial Auto Liability Insurance</font><font style="font-weight:bold;">, </font>if the Tenant owns any automobiles, written on a coverage form that is at least as broad as the ISO business auto coverage form (CA 00 01) to cover owned, non-owned, hired, and borrowed autos with not less than $1,000,000 combined single limit shall be obtained.&nbsp;&nbsp;If the Tenant does not own any vehicles, non-owned and hired auto liability insurance with a not less than $1,000,000 limit shall be maintained.&nbsp;&nbsp;Tenant shall require similar coverage for any contract vehicles that it engages for transportation of personnel or personal property to or from the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Workers Compensation Insurance</font><font style="font-weight:bold;"> </font>with <font style="color:#000000;">limits</font> as required by statute shall be maintained.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">15<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Employers&#8217; Liability Insurance</font><font style="font-weight:bold;"> </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with limits not less than $1,000,000 per accident for bodily injury by accident, $1,000,000 each employee for bodily injury by disease, and $1,000,000 policy limit for bodily injury by disease sha</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ll be maintained.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Umbrella or Excess Liability Insurance</font><font style="font-weight:bold;"> </font>over (i), (ii), and (iv) with limits of not less than $4,000,000 each occurrence and $4,000,000 aggregate per location. This insurance must also include the Landlord Parties as additional insureds insofar as it is excess over Tenant&#8217;s coverage under clause (i), on a primary and non-contributory basis.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Commercial Property Insurance</font> with a limit equal to the full replacement cost and covering the fixtures, personal property, equipment, Tenant Improvements and <font style="color:#000000;">betterments</font> that will, at a minimum, cover the perils insured under ISO special causes of loss form (CP 10 30) and broad causes of loss form (CP 10 20) shall be provided.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:144pt;"></font>If required by Landlord due to the nature of tenant&#8217;s operation,<font style="font-weight:bold;"> </font><font style="font-weight:bold;text-decoration:underline;">Boiler &amp; Machinery Insurance</font> covering the fixtures, personal property, equipment, tenant improvements and betterments from loss or damage caused by machinery breakdown or the explosion of steam boilers or pipes.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)<font style="margin-left:144pt;"></font>Intentionally omitted.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Business Income insurance</font> with a limit adequate to pay for one year&#8217;s loss of business income resulting from suspension of the Tenant&#8217;s business operations, caused by property damage from a covered cause of loss to the Premises.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392328"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Insurance</font>.&nbsp;&nbsp;Throughout the Term of this Lease, Landlord shall maintain, as a minimum, the following insurance policies.&nbsp;&nbsp;Tenant shall pay its Proportionate Share of the cost of all insurance carried by Landlord with respect to the Project or Complex, as set forth in <font style="text-decoration:underline;">Exhibit&#160;C</font>.&nbsp;&nbsp;Landlord&#8217;s insurance policies shall be for the sole benefit of Landlord and under Landlord&#8217;s sole control, and Tenant shall have no right or claim to any proceeds thereof or any other rights thereunder:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Building Insurance</font><font style="font-weight:bold;"> </font>with a limit equal to full replacement cost less a commercially-reasonable deductible if the Landlord so chooses.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Commercial General Liability and Umbrella Insurance</font> in an amount not less than $5,000,000.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_636"></a>(iii)<font style="margin-left:144pt;"></font><font style="font-weight:bold;text-decoration:underline;">Other insurance</font><font style="font-weight:bold;"> </font><a name="_cp_text_1_636"></a>and additional coverage as Landlord may deem necessary, but not in excess of that incurred by comparable landlords for comparable buildings in the Project&#8217;s market area.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392329"></a><a name="_AEIOULastRenderedPageBreakAEIOU25"></a>(d)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">No Subrogation</font>.&nbsp;&nbsp;<font style="font-weight:bold;">LANDLORD AND TENANT EACH WAIVES ANY CLAIM IT MIGHT HAVE AGAINST THE OTHER FOR ANY DAMAGE TO OR THEFT, DESTRUCTION, LOSS, OR LOSS OF USE OF ANY PROPERTY, TO THE EXTENT THE SAME IS INSURED AGAINST UNDER ANY INSURANCE POLICY THAT COVERS THE BUILDING, THE PREMISES, LANDLORD&#8217;S OR TENANT&#8217;S FIXTURES, PERSONAL PROPERTY, LEASEHOLD IMPROVEMENTS, OR BUSINESS, OR IS REQUIRED TO BE INSURED AGAINST UNDER THE TERMS HEREOF OR UNDER THE TENANT WORK LETTER, REGARDLESS OF WHETHER THE NEGLIGENCE OF THE OTHER PARTY CAUSED SUCH LOSS. TENANT&#8217;S WAIVER IN THIS SECTION EXTENDS TO ALL LANDLORD PARTIES. LANDLORD AND TENANT EACH HEREBY WAIVE ANY RIGHT OF SUBROGATION AND RIGHT OF RECOVERY OR CAUSE OF ACTION FOR INJURY INCLUDING DEATH OR DISEASE TO RESPECTIVE EMPLOYEES OF EITHER AS COVERED BY WORKER&#8217;S COMPENSATION (OR WHICH WOULD HAVE BEEN COVERED IF TENANT OR LANDLORD </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">16<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">AS THE CASE MAY BE, WAS CARRYING THE INSURANCE AS REQUIRED BY THIS LEASE). EACH PA</font><font style="font-weight:bold;">RTY SHALL CAUSE ITS INSURANCE CARRIER TO ENDORSE ALL APPLICABLE POLICIES WAIVING THE CARRIER&#8217;S RIGHTS OF RECOVERY UNDER SUBROGATION OR OTHERWISE AGAINST THOSE IN WHOSE FAVOR IT MAKES THE WAIVER IN THIS SECTION.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392330"></a>12.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subordination; Attornment; Notice to Landlord&#8217;s Mortgagee</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392331"></a><a name="_cp_text_1_639"></a><a name="_cp_text_1_640"></a><a name="_cp_text_1_641"></a><a name="_cp_text_1_643"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subordination</font>.&nbsp;&nbsp;This Lease shall be subordinate to any deed of trust, mortgage, or other security instrument (each, a &#8220;<font style="font-weight:bold;">Mortgage</font>&#8221;), or any ground lease, master lease, or primary lease (each, a &#8220;<font style="font-weight:bold;">Primary Lease</font>&#8221;), that now or hereafter covers all or any part of the Premises (the mortgagee under any such Mortgage, beneficiary under any such deed of trust, or the lessor under any such Primary Lease is referred to herein as a &#8220;<font style="font-weight:bold;">Landlord&#8217;s Mortgagee</font><a name="_cp_text_1_639"></a>&#8221;).&nbsp;&nbsp;The automatic subordination to Landlord&#8217;s Mortgagee provided for in this <font style="text-decoration:underline;">Section&#160;12</font> is expressly conditioned upon such Landlord&#8217;s Mortgagee, agreeing that as long as no Event of Default occurs under this Lease, such Landlord&#8217;s Mortgagee will not disturb Tenant&#8217;s rights of possession under this Lease.&nbsp;&nbsp;Any Landlord&#8217;s Mortgagee may elect at any time, unilaterally, to make this Lease superior to its Mortgage, Primary Lease, or other interest in the Premises by so notifying Tenant in writing.&nbsp;&nbsp;The provisions of this Section shall be self-operative and no fur<a name="_cp_text_1_640"></a>ther instrument of subordination shall be required; however, in confirmation of such subordination, Tenant shall, subject to Tenant&#8217;s receipt of a commercially reasonable non-disturbance agreement,&nbsp;&nbsp;execute and return to Landlord (or such other party desig<a name="_cp_text_1_641"></a>nated in writing <a name="_cp_text_1_643"></a>by Landlord) within ten (10) Business Days after written request therefor such documentation, in recordable form if required, as a Landlord&#8217;s Mortgagee may reasonably request to evidence the subordination of this Lease to such Landlord&#8217;s Mortgagee&#8217;s Mortgage or Primary Lease (including a subordination, non-disturbance and attornment agreement) or, if the Landlord&#8217;s Mortgagee so elects, the subordination of such Landlord&#8217;s Mortgagee&#8217;s Mortgage or Primary Lease to this Lease.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant shall not be obligated to execute any document which alters any material provision of the Lease.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392332"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Attornment</font>.&nbsp;&nbsp;Tenant shall attorn to any party succeeding to Landlord&#8217;s interest in the Premises, whether by purchase, foreclosure, deed in lieu of foreclosure, power of sale, termination of lease, or otherwise, upon such party&#8217;s request, and shall execute such commercially reasonable agreements confirming such attornment as such party may reasonably request.&nbsp;&nbsp;Notwithstanding the foregoing, Tenant shall not be obligated to execute any document which alters any material provision of the Lease.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392333"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Notice to Landlord&#8217;s Mortgagee</font>.&nbsp;&nbsp;Tenant shall not seek to enforce any remedy it may have for any default on the part of Landlord without first giving written notice by certified mail, return receipt requested, specifying the default in reasonable detail, to any Landlord&#8217;s Mortgagee whose address has been given to Tenant, and affording such Landlord&#8217;s Mortgagee a reasonable opportunity to perform Landlord&#8217;s obligations hereunder.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392334"></a><a name="_cp_text_1_645"></a><a name="_cp_text_1_646"></a><a name="_cp_text_1_647"></a><a name="_cp_text_1_648"></a><a name="_cp_text_4_649"></a>13.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Rules and Regulations</font>.&nbsp;&nbsp;<a name="_cp_text_1_645"></a>Tenant shall comply with the rules and regulations of the Building (the &#8220;<font style="font-weight:bold;">Rules and Regulations</font>&#8221;) which are attached hereto as <font style="text-decoration:underline;">Exhibit&#160;E</font>.&nbsp;&nbsp;Landlord may, from time to time, change such rules and regulations <a name="_cp_text_1_646"></a>for the safety, care, or cleanliness of the Building and related facilities, provided that such changes are applicable to all tenants of the Building (if the Building is no longer a single tenant building), will not unreasonably interfere with Tenant&#8217;s use<a name="_cp_text_1_647"></a> of the Premises, will not modify any of the provisions of the Lease, are provided to Tenant in writing and are enforced by Landlord in a non-discriminatory manner.&nbsp;&nbsp;Tenant shall be responsible for the compliance with such rules and regulations by each Ten<a name="_cp_text_1_648"></a>ant Party.<a name="_cp_text_4_649"></a>&nbsp;&nbsp;The Rules and Regulations shall not be construed in any way to modify or amend, in whole or part, the terms, covenants, agreements and conditions of this Lease, and in the event of any conflict between the terms of Rules and Regulations and this Lease, terms of this Lease shall control.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">17<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392335"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.</font><font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Condemnation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392336"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Total Taking</font>.&nbsp;&nbsp;If the entire Building or Premises are taken by right of eminent domain or conveyed in lieu thereof (a &#8220;<font style="font-weight:bold;">Taking</font>&#8221;), this Lease shall terminate as of the date of the Taking.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506191464"></a><a name="_Toc497392337"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Partial Taking - Tenant&#8217;s Rights</font>.&nbsp;&nbsp;If any part of the Building becomes subject to a Taking and such Taking will prevent Tenant from conducting its business in the Premises in a manner reasonably comparable to that conducted immediately before such Taking for a period of more than one hundred twenty (120) days, then Tenant may terminate this Lease as of the date of such Taking by giving written notice to Landlord within thirty (30) days after the Taking, and Rent shall be apportioned as of the date of such Taking.&nbsp;&nbsp;If Tenant does not terminate this Lease, then Rent shall be abated on a reasonable basis as to that portion of the Premises rendered untenantable by the Taking.&nbsp;&nbsp;<font style="font-weight:bold;">TENANT HEREBY WAIVES ANY AND ALL RIGHTS IT MIGHT OTHERWISE HAVE PURSUANT TO SECTION 1265.130 OF THE CALIFORNIA CODE OF CIVIL PROCEDURE. </font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392338"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Partial Taking - Landlord&#8217;s Rights</font>.&nbsp;&nbsp;If any material portion, but less than all, of the Building becomes subject to a Taking, or if Landlord is required to pay any of the proceeds arising from a Taking to a Landlord&#8217;s Mortgagee, then Landlord may terminate this Lease by delivering written notice thereof to Tenant within fifteen (15) days after such Taking, and Rent shall be apportioned as of the date of such Taking.&nbsp;&nbsp;If Landlord does not so terminate this Lease, then this Lease will continue, but if any portion of the Premises has been taken, Rent shall abate as provided in the next to last sentence of <font style="text-decoration:underline;">Section 14(b)</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392339"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Award</font>.&nbsp;&nbsp;If any Taking occurs, then Landlord shall receive the entire award or other compensation for the Land, the Building, and other improvements taken; however, Tenant may separately pursue a claim (to the extent it will not reduce Landlord&#8217;s award) against the condemnor for the value of Tenant&#8217;s personal property which Tenant is entitled to remove under this Lease, moving costs, loss of business, and other claims it may have (excluding any claim related to its leasehold interest).</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392340"></a><a name="_cp_text_1_662"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Repair</font>.&nbsp;&nbsp;If the Lease is not terminated, Landlord shall promptly proceed with reasonable diligence to restore the remaining part of the Premises and Building substantially to their former condition to the extent feasible to constitute a complete and tenantable Building and Premises; provided, however, that Landlord shall only be required to reconstruct building standard leasehold<a name="_cp_text_1_662"></a> improvements existing in the Premises as of the date of the Taking, and Tenant shall be required to pay the cost for restoring any other leasehold improvements, and the Rent shall be decreased proportionately to reflect the loss of any portion of the Premises rendered untenantable during the restoration thereof.&nbsp;&nbsp;In no event shall Landlord be required to spend more than the condemnation proceeds received by Landlord for such repair.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392341"></a>15.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Fire or Other Casualty</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392342"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Repair Estimate</font>.&nbsp;&nbsp;If the Premises or the Building are damaged by fire or other casualty (a &#8220;<font style="font-weight:bold;">Casualty</font>&#8221;), Landlord shall use good faith efforts to deliver to Tenant within sixty (60) days after such Casualty a good faith estimate (the &#8220;<font style="font-weight:bold;">Damage Notice</font>&#8221;) of the time needed to repair the damage caused by such Casualty.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392343"></a><a name="_cp_text_1_663"></a><a name="_cp_text_1_665"></a><a name="_cp_text_1_667"></a><a name="_cp_text_1_669"></a><a name="_cp_text_1_671"></a><a name="_cp_text_1_672"></a><a name="_cp_text_4_673"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Rights</font>.&nbsp;&nbsp;<a name="_cp_text_1_663"></a>If a material portion of the Premises is damaged by Casualty such that Tenant is prevented from conducting its business in the Premises in a manner reasonably comparable to that conducted immediately before such Casualty, <a name="_cp_text_1_665"></a>and Landlord estimates that the damage caused thereby cannot be repaired within two <a name="_cp_text_1_667"></a>hundred seventy <a name="_cp_text_1_669"></a>(270<a name="_cp_text_1_671"></a>) days after the date of the Casualty (the &#8220;<font style="font-weight:bold;">Repair Period</font>&#8221;), then Tenant may terminate this Lease by delivering written notice to Landlord of its electi<a name="_cp_text_1_672"></a>on to terminate within thirty (30) days after the Damage Notice has been delivered to Tenant.&nbsp;&nbsp;Tenant shall also have the right to terminate if Casualty occurs during the last one (1) year of the Term and the Casualty substantially impairs, in Tenant&#8217;s rea<a name="_cp_text_4_673"></a>sonable judgment, Tenant&#8217;s operation of its business in the Premises for more than sixty (60) days.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">18<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392344"></a><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Rights</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If a Casualty damages the Premises or a material portion of the Building and: (1)&#160;Landlord estimates that the damage to the Premises can</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">not be repaired within the Repair Period; (2)&#160;the damage to the Premises exceeds fifty percent (50%) of the replacement cost thereof (excluding foundations and footings), as estimated by Landlord, and such damage occurs during the last eighteen (18) months</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> of the Term (unless Tenant exercises any renewal rights it may have in the Lease); (3)&#160;regardless of the extent of damage to the Premises, Landlord makes a good faith determination that restoring the Building would be uneconomical; or (4)&#160;Landlord is requ</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ired to pay any insurance proceeds arising out of the Casualty to a Landlord&#8217;s Mortgagee, then Landlord may terminate this Lease by giving written notice of its election to terminate within thirty (30) days after the Damage Notice has been delivered to Ten</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ant.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392345"></a><a name="_cp_text_2_681"></a><a name="_cp_text_1_685"></a><a name="_cp_text_1_687"></a><a name="_cp_text_1_689"></a><a name="_cp_text_1_691"></a><a name="_cp_text_1_693"></a><a name="_cp_text_1_695"></a><a name="_cp_text_1_701"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Repair Obligation</font>.&nbsp;&nbsp;If neither party elects to terminate this Lease following a Casualty, then Landlord shall, within a reasonable time after such Casualty, begin to repair the Premises and shall proceed with reasonable diligence to restore the Premis<a name="_cp_text_2_681"></a>es to substantially the same condition as they existed immediately before such Casualty; however, other than building standard leasehold improvements Landlord shall not be required to repair or replace any Tenant Improvements or Alterations or betterments within the Premises (which shall be promptly and with due diligence repaired and restored by Tenant at Tenant&#8217;s sole cost and expense) or any furniture, equipment, trade fixtures or personal property of Tenant or others in the Premises or the Building, and<a name="_cp_text_1_685"></a> Landlord&#8217;s obligation to repair or restore the Premises shall be limited to the extent of the insurance proceeds actually received by Landlord for the Casualty in question.&nbsp;&nbsp;If Landlord fails to complete repairs to the Premises within two <a name="_cp_text_1_687"></a>hundred seventy <a name="_cp_text_1_689"></a>(270<a name="_cp_text_1_691"></a>) days after the date of the Casualty<a name="_cp_text_1_693"></a>, subject to delays caused by Force Majeure Events<a name="_cp_text_1_695"></a>, then Tenant shall have the right to terminate the Lease upon written notice delivered to Landlord at any time after such two hundred seventy (270) day period and p<a name="_cp_text_1_701"></a>rior to Landlord&#8217;s substantial completion of such repairs.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392346"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Abatement of Rent</font>.&nbsp;&nbsp;If the Premises are damaged by Casualty, Rent for the portion of the Premises rendered untenantable by the damage shall be abated on a reasonable basis from the date of damage until the completion of Landlord&#8217;s repairs (or until the date of termination of this Lease by Landlord or Tenant as provided above, as the case may be).</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392347"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Waiver of Statutory Provisions</font>.&nbsp;&nbsp;The provisions of this Lease, including this <font style="text-decoration:underline;">Section&#160;15</font>, constitute an express agreement between Landlord and Tenant with respect to any and all damage to, or destruction of, all or any part of the Premises, the Building or any other portion of the Project, and any statute or regulation of the State of California, including, without limitation, Sections 1932(2) and 1933(4) of the California Civil Code, with respect to any rights or obligations concerning damage or destruction in the absence of an express agreement between the parties, and any other statute or regulation, now or hereafter in effect, shall have no application to this Lease or any damage or destruction to all or any part of the Premises, the Building or any other portion of the Project.&nbsp;&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392348"></a>16.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Personal Property Taxes</font>.&nbsp;&nbsp;Tenant shall be liable for all taxes levied or assessed against personal property, furniture, or fixtures placed by Tenant in the Premises or in or on the Building or Project.&nbsp;&nbsp;If any taxes for which Tenant is liable are levied or assessed against Landlord or Landlord&#8217;s property and Landlord elects to pay the same, or if the assessed value of Landlord&#8217;s property is increased by inclusion of such personal property, furniture or fixtures and Landlord elects to pay the taxes based on such increase, then Tenant shall pay to Landlord, within thirty (30) days following written request therefor, the part of such taxes for which Tenant is primarily liable hereunder.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392349"></a>17.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Events of Default</font>.&nbsp;&nbsp;Each of the following occurrences shall be an &#8220;<font style="font-weight:bold;">Event of Default</font>&#8221;:</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392350"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Payment Default</font>.&nbsp;&nbsp;Tenant&#8217;s failure to pay Rent within five (5) calendar days after Tenant&#8217;s receipt of Landlord&#8217;s written notice that the same is due;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">19<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392351"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Abandonment</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant abandons the Premises or any substantial portion thereof, abandonment being defined as Tenant&#8217;s vacation of the Premises and failure to meet one (1) </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or more lease obligations;</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392352"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font>;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392353"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Insurance</font>.&nbsp;&nbsp;Tenant fails, within ten (10) business days following written notice from Landlord, to procure, maintain and deliver to Landlord evidence of the insurance policies and coverages as required under <font style="text-decoration:underline;">Section 11(b)</font>;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392354"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Mechanic&#8217;s Liens</font>.&nbsp;&nbsp;Tenant fails to pay and release of record, or diligently contest and bond around, any mechanic&#8217;s lien filed against the Premises or the Project for any work performed, materials furnished, or obligation incurred by or at the request of Tenant, within the time and in the manner required by <font style="text-decoration:underline;">Section 8(c)</font>;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392355"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Other Defaults</font>.&nbsp;&nbsp;Tenant&#8217;s failure to perform, comply with, or observe any other agreement or obligation of Tenant under this Lease and the continuance of such failure for a period of thirty (30) calendar days or more after Landlord has delivered to Tenant written notice thereof; provided, however, if such default is of the type which cannot reasonably be cured within thirty (30) days, then Tenant shall have such longer time as is reasonably necessary provided Tenant commences to cure within ten (10) days after receipt of written notice from Landlord and diligently prosecutes such cure to completion; and</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506191823"></a><a name="_Toc497392356"></a>(g)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Insolvency</font>.&nbsp;&nbsp;The filing of a petition by or against Tenant (the term &#8220;<font style="font-weight:bold;">Tenant</font>&#8221; shall include, for the purpose of this <font style="text-decoration:underline;">Section 17(g)</font>, any guarantor of Tenant&#8217;s obligations hereunder): (1)&#160;in any bankruptcy or other insolvency proceeding; (2)&#160;seeking any relief under any state or federal debtor relief law; (3)&#160;for the appointment of a liquidator or receiver for all or substantially all of Tenant&#8217;s property or for Tenant&#8217;s interest in this Lease; or (4)&#160;for the reorganization or modification of Tenant&#8217;s capital structure; however, if such a petition is filed against Tenant, then such filing shall not be an Event of Default unless Tenant fails to have the proceedings initiated by such petition dismissed within one hundred twenty (120) calendar days after the filing thereof.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392357"></a>18.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Remedies</font>.&nbsp;&nbsp;Upon an Event of Default, Landlord shall have, in addition to any other remedies available to Landlord at law or in equity, the option to pursue any one or more of the following remedies, each and all of which shall be cumulative and nonexclusive, without any notice or demand whatsoever. </p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:108pt;"></font>Terminate this Lease, in which event Tenant shall immediately surrender the Premises to Landlord, and if Tenant fails to do so, Landlord may, without prejudice to any other remedy which it may have for possession or arrearages in rent, enter upon and take possession of the Premises and expel or remove Tenant and any other person who may be occupying the Premises or any part thereof, without being liable for prosecution or any claim for damages therefor; and Landlord may recover from Tenant the following:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:144pt;"></font>The worth at the time of award of any unpaid rent which has been earned at the time of such termination; plus</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:144pt;"></font>The worth at the time of award of the amount by which the unpaid rent which would have been earned after termination until the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:144pt;"></font>The worth at the time of award of the amount by which the unpaid rent for the balance of the Lease Term after the time of award exceeds the amount of such rental loss that Tenant proves could have been reasonably avoided; plus</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a>(iv)<font style="margin-left:144pt;"></font>Any other amount necessary to compensate Landlord for all the detriment proximately caused by Tenant&#8217;s failure to perform its obligations under this Lease or which in the ordinary </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">20<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">course of things would be likely to result therefrom, specifically including, but not li</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mited to, brokerage commissions and advertising expenses incurred, expenses of remodeling the Premises or any portion thereof for a new tenant, whether for the same or a different use, and any special concessions made to obtain a new tenant; and</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:144pt;"></font>At Landlord&#8217;s election, such other amounts in addition to or in lieu of the foregoing as may be permitted from time to time by applicable law.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The term &#8220;<font style="font-weight:bold;">rent</font>&#8221; as used in this <font style="text-decoration:underline;">Section&#160;18</font> shall be deemed to be and to mean all sums of every nature required to be paid by Tenant pursuant to the terms of this Lease, whether to Landlord or to others.&nbsp;&nbsp;As used in <font style="text-decoration:underline;">Sections 18(a)(i)</font> and <font style="text-decoration:underline;">(ii)</font> above, the &#8220;worth at the time of award&#8221; shall be computed by allowing interest at the Default Rate, but in no case greater than the maximum amount of such interest permitted by law.&nbsp;&nbsp;As used in <font style="text-decoration:underline;">Section 18(a)(iii)</font> above, the &#8220;worth at the time of award&#8221; shall be computed by discounting such amount at the discount rate of the Federal Reserve Bank of San Francisco at the time of award plus one percent (1%).</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font>Landlord shall have the remedy described in California Civil Code Section 1951.4 (lessor may continue lease in effect after lessee&#8217;s breach and abandonment and recover Rent as it becomes due, if lessee has the right to sublet or assign, subject only to reasonable limitations).&nbsp;&nbsp;Accordingly, if Landlord does not elect to terminate this Lease on account of any Event of Default by Tenant, Landlord may, from time to time, without terminating this Lease, enforce all of its rights and remedies under this Lease, including the right to recover all rent as it becomes due.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Subleases of Tenant</font>.&nbsp;&nbsp;Whether or not Landlord elects to terminate this Lease on account of any Event of Default by Tenant, as set forth in this <font style="text-decoration:underline;">Section&#160;18</font>, Landlord shall have the right to terminate any and all subleases, licenses, concessions or other consensual arrangements for possession entered into by Tenant and affecting the Premises or may, in Landlord&#8217;s sole discretion, succeed to Tenant&#8217;s interest in such subleases, licenses, concessions or arrangements.&nbsp;&nbsp;In the event of Landlord&#8217;s election to succeed to Tenant&#8217;s interest in any such subleases, licenses, concessions or arrangements, Tenant shall, as of the date of notice by Landlord of such election, have no further right to or interest in the rent or other consideration receivable thereunder.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Form of Payment After Default</font>.&nbsp;&nbsp;Following the occurrence of an Event of Default by Tenant, Landlord shall have the right to require that any or all subsequent amounts paid by Tenant to Landlord hereunder, whether in the cure of the default in question or otherwise, be paid in the form of cash, money order, cashier&#8217;s or certified check drawn on an institution reasonably acceptable to Landlord, or by other means approved by Landlord, notwithstanding any prior practice of accepting payments in any different form.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Efforts to Relet</font>.&nbsp;&nbsp;For the purposes of this <font style="text-decoration:underline;">Section&#160;18</font>, Tenant&#8217;s right to possession shall not be deemed to have been terminated by efforts of Landlord to relet the Premises, by its acts of maintenance or preservation with respect to the Premises, or by appointment of a receiver to protect Landlord&#8217;s interests hereunder.&nbsp;&nbsp;The foregoing enumeration is not exhaustive, but merely illustrative of acts which may be performed by Landlord without terminating Tenant&#8217;s right to possession.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU30"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Defaults and Tenant Remedies</font>.&nbsp;&nbsp;Except as otherwise provided in this Lease and specifically subject to <font style="text-decoration:underline;">Section 26(b)</font>, if Landlord fails in the performance of any of Landlord&#8217;s obligations under this Lease and such failure continues for thirty (30) days after Landlord&#8217;s receipt of written notice thereof from Tenant (and an additional reasonable time after such receipt if (A) such failure cannot be cured within such thirty (30) day period, and (B) Landlord commences curing such failure within such thirty (30) day period and thereafter diligently pursues the curing of such failure), then Tenant shall be entitled to exercise any remedies that Tenant may have at law or in equity.&nbsp;&nbsp;<font style="font-weight:bold;">TENANT WAIVES ANY </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">21<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">RIGHT TO OB</font><font style="font-weight:bold;">TAIN ANY CONSEQUENTIAL, SPECIAL, PUNITIVE, EXEMPLARY OR SIMILAR DAMAGES</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392358"></a>19.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Payment by Tenant; Non-Waiver; Cumulative Remedies</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506191940"></a><a name="_Toc497392359"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Payment by Tenant</font>.&nbsp;&nbsp;Upon any Event of Default, Tenant shall pay to Landlord all reasonable costs incurred by Landlord (including court costs and reasonable attorneys&#8217; fees and expenses) in: (1) obtaining possession of the Premises; (2) removing and storing Tenant&#8217;s or any other occupant&#8217;s property; (3) repairing, restoring, altering, remodeling, or otherwise putting the Premises into condition reasonably acceptable to a new tenant (provided that Tenant shall not be responsible for costs to change the character of the Premises from an office use to a primarily retail, industrial or other non-office type of use); (4)&#160;if Tenant is dispossessed of the Premises and this Lease is not terminated, reletting all or any part of the Premises (including brokerage commissions, cost of tenant finish work, and other costs incidental to such reletting); (5)&#160;performing Tenant&#8217;s obligations which Tenant failed to perform; and (6)&#160;enforcing, or advising Landlord of, its rights, remedies, and recourses arising out of the Event of Default.&nbsp;&nbsp;To the full extent permitted by Law, Landlord and Tenant agree the federal and state courts of the state in which the Premises are located shall have exclusive jurisdiction over any matter relating to or arising from this Lease and the parties&#8217; rights and obligations under this Lease.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392360"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Waiver</font>.&nbsp;&nbsp;Landlord&#8217;s acceptance of Rent following an Event of Default shall not waive Landlord&#8217;s rights regarding such Event of Default.&nbsp;&nbsp;No waiver by Landlord of any violation or breach of any of the terms contained herein shall waive Landlord&#8217;s rights regarding any future violation of such term.&nbsp;&nbsp;Landlord&#8217;s acceptance of any partial payment of Rent shall not waive Landlord&#8217;s rights with regard to the remaining portion of the Rent that is due, regardless of any endorsement or other statement on any instrument delivered in payment of Rent or any writing delivered in connection therewith; accordingly, Landlord&#8217;s acceptance of a partial payment of Rent shall not constitute an accord and satisfaction of the full amount of the Rent that is due.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392361"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Cumulative Remedies</font>.&nbsp;&nbsp;Any and all remedies set forth in this Lease:&nbsp;&nbsp;(1) shall be in addition to any and all other remedies Landlord may have at law or in equity; (2) shall be cumulative; and (3) may be pursued successively or concurrently as Landlord may elect.&nbsp;&nbsp;The exercise of any remedy by Landlord shall not be deemed an election of remedies or preclude Landlord from exercising any other remedies in the future.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506192214"></a><a name="_Toc497392362"></a>20.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Intentionally Omitted</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392363"></a>21.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Surrender of Premises</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_792"></a><a name="_cp_text_1_775"></a><a name="_cp_text_4_776"></a><a name="_cp_text_1_777"></a><a name="_cp_text_4_778"></a><a name="_cp_text_1_779"></a><a name="_cp_text_4_780"></a><a name="_cp_text_4_781"></a><a name="_cp_text_1_782"></a><a name="_cp_text_4_783"></a><a name="_cp_text_1_784"></a><a name="_cp_text_4_785"></a><a name="_cp_text_1_786"></a><a name="_cp_text_4_787"></a><a name="_cp_text_1_788"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a><a name="_cp_text_4_789"></a><a name="_cp_text_1_790"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">General</font><a name="_cp_text_4_776"></a>.&nbsp;&nbsp;No act by Landlord shall be deemed an acceptance of a surrender of the Premises, and no agreement to accept a surrender of the Premises shall be valid unless it is in writing and signed by Landlord.&nbsp;&nbsp;At the expiration or termination of this Lease, Tenant s<a name="_cp_text_1_777"></a>hall deliver to Landlord the Premises with all improvements located therein in good repair and condition, free of Hazardous Materials <a name="_cp_text_4_778"></a>for which Tenant has responsibility under this Lease, in broom-clean condition including cleaning of interior surface of a<a name="_cp_text_1_779"></a>ll walls, flooring, ceiling and/ or roof deck due to Tenant&#8217;s specific use (with such cleaning by commercial cleaning application as <a name="_cp_text_4_780"></a>reasonably <a name="_cp_text_4_781"></a>approved by Landlord), reasonable wear and tear <a name="_cp_text_1_782"></a>and condemnation and Casualty damage <a name="_cp_text_4_783"></a>(as to which <font style="text-decoration:underline;">Section 14</font> and <font style="text-decoration:underline;">Section 15</font><a name="_cp_text_1_784"></a> shall control) excepted, and shall deliver to Landlord all keys to the Premises.&nbsp;&nbsp;<a name="_cp_text_4_785"></a>Tenant shall remove all unattached trade fixtures, furniture, and personal property placed in the Premises or elsewhere in the Building by Tenant (but Tenant may not remove any such item which was paid for, in whole or in part, by Landlord or any wiring or cabling unless Landlord requires such removal).&nbsp;&nbsp;Additionally, at Landlord&#8217;s option, Tenant shall (not later than ten (10) days after the expiration or earlier t<a name="_cp_text_1_786"></a>ermination of the Lease) remove such alterations, additions (including stairs and bank vaults), improvements, trade fixtures, personal property, equipment, wiring, conduits, cabling and furniture (including Tenant&#8217;s Off-Premises Equipment) installed by Ten<a name="_cp_text_4_787"></a>ant <a name="_cp_text_1_788"></a>as Landlord may request; however, Tenant shall not be required to remove either the Tenant Improvements or </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">22<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_789"></a>any Alterations </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_790"></a>to the Premises or the Project </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">unless a Removal Notice was provided to Tenant at the time of Landlord&#8217;s consent to installation</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> Tenant shall repair all damage caused by such removal.&nbsp;&nbsp;All items not so removed shall, at Landlord&#8217;s option, be deemed to have been abandoned by Tenant and may be appropriated, sold, stored, destroyed, or otherwise disposed of by Landlord at Tenant&#8217;s cos</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t without notice to Tenant and without any obligation to account for such items; any such disposition shall not be considered a strict foreclosure or other exercise of Landlord&#8217;s rights in respect of the security interest granted under </font><font style="text-decoration:underline;">Section 20</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The pro</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">visions of this </font><font style="text-decoration:underline;">Section 21</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall survive the expiration or earlier termination of the Lease.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_794"></a><a name="_cp_text_1_796"></a><a name="_cp_text_4_797"></a><a name="_cp_text_1_798"></a><a name="_cp_text_4_799"></a><a name="_cp_text_1_800"></a><a name="_cp_text_1_802"></a><a name="_cp_text_1_804"></a>(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Environmental Assessment</font>.&nbsp;&nbsp;Prior to the expiration of the Lease (or within thirty (30) days after any earlier termination) plus additional time (but in no event in excess of thirty (30) days) as may be required by Tenant to obtain governmental sign-offs in connection with the decommissioning, Tenant shall clean and otherwise decommission all interior surfaces (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing in or serving the Premises, and all exhaust or other ductwork in or serving the Premises, in each case that has carried, released or otherwise been exposed to any Hazardous Materials due to Tenant&#8217;s use or occupancy of the Premises, and shall otherwise clean the Premises so as to permit the Environmental Assessment called for by this <font style="text-decoration:underline;">Section 21(b)</font><a name="_cp_text_1_796"></a> to be issued. For the avoidance of doubt, Tenant shall not be liable for any Hazardous Materials (i)&#160;which were placed on<a name="_cp_text_4_797"></a> <a name="_cp_text_1_798"></a>the Premises or the Project <a name="_cp_text_4_799"></a>by Landlord or <a name="_cp_text_1_800"></a>its employees, agents or contractors or any third parties not under Tenant&#8217;s control, (ii) which were located at the Premises or the Project on the Delivery Date, or (iii) which migrated through air, water or soil from a location outside of the Premises through no act, omission or fault of Tenant or Tenant Party.&nbsp;&nbsp;Prior to the expiration of this Lease (or within thirty (30) days after any earlier termination), Tenant, at Tenant&#8217;s expense, shall obtain for Landlord a report (an &#8220;<font style="font-weight:bold;">Environmental Assessment</font>&#8221;) addressed to Landlord (and, at Tenant&#8217;s election, Tenant) by a reputable licensed environmental engineer or industrial hygienist that is designated by Tenant and acceptable to Landlord in Landlord&#8217;s reasonable discretion, which report shall be based on the environmental engineer&#8217;s inspection of the Premises and shall state, to Landlord&#8217;s reasonable satisfaction, that:&nbsp;&nbsp;(a) the Hazardous Materials described in the first sentence of this paragraph, to the extent, if a<a name="_cp_text_1_802"></a>ny, existing prior to such decommissioning, have been removed in accordance with applicable Laws; (b) all Hazardous Materials described in the first sentence of this paragraph, if any, have been removed in accordance with Applicable Laws from the interior <a name="_cp_text_1_804"></a>surfaces of the Premises (including floors, walls, ceilings, and counters), piping, supply lines, waste lines and plumbing, and all such exhaust or other ductwork in the Premises, may be reused by a subsequent tenant or disposed of in compliance with applicable Laws without incurring special costs or undertaking special procedures for demolition, disposal, investigation, assessment, cleaning or removal of such Hazardous Materials and without giving notice in connection with such Hazardous Materials; and (c) the Premises may be reoccupied for office, research and development, or laboratory use, demolished or renovated without incurring special costs or undertaking special procedures for disposal, investigation, assessment, cleaning or removal of Hazardous Materials described in the first sentence of this paragraph and without giving notice in connection with Hazardous Materials.&nbsp;&nbsp;Further, for purposes of clauses (b) and (c), &#8220;special costs&#8221; or &#8220;special procedures&#8221; shall mean costs or procedures, as the case may be, that would not be incurred but for the nature of the Hazardous Materials as Hazardous Materials instead of non-hazardous materials.&nbsp;&nbsp;The report shall also include reasonable detail concerning the clean-up measures taken, the clean-up locations, the tests run and the analytic results.&nbsp;&nbsp;Tenant shall submit to Landlord the identity of the applicable consultants and the scope of the proposed Environmental Assessment for Landlord&#8217;s reasonable review and approval at least thirty (30) days prior to commencing the work described therein or at least sixty (60) days prior to the expiration of the Lease Term, whichever is earlier.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_817"></a><a name="_cp_text_1_805"></a><a name="_cp_text_1_808"></a><a name="_cp_text_1_810"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><a name="_cp_text_1_812"></a>(c)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Remedies</font>.&nbsp;&nbsp;If Tenant fails to perform its obligations under <font style="text-decoration:underline;">Section 21(b)</font>, without limiting any other right or remedy, Landlord may, o<a name="_cp_text_1_808"></a>n five (5) Business Days<a name="_cp_text_1_810"></a>&#8217; prior written notice to Tenant perform such obligations at Tenant&#8217;s expense if Tenant has not commenced to do so within said five (5) Business Day period, and Tenant shall within ten (10) days of written demand reimburse Landlord for all </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">23<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reasonable out-of-pocket costs and expenses incurred by Landlord in connection with such work.&nbsp;&nbsp;Tenant&#8217;s obligations under </font><font style="text-decoration:underline;">Section 21(b)</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall survive the expiration or earlier termination of this Lease.&nbsp;&nbsp;In addition, at Landlord&#8217;s election, Landlo</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_812"></a>rd may inspect the Premises and/or the Project for Hazardous Materials at Landlord&#8217;s cost and expense within sixty (60) days of Tenant&#8217;s surrender of the Premises at the expiration or earlier termination of this Lease.&nbsp;&nbsp;Tenant shall pay for all such </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">reason</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">able </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">costs and expenses incurred by Landlord in connection with such inspection if such inspection reveals that a release or threat of release of Hazardous Materials exists at the Project or Premises as a result of the violation of </font><font style="text-decoration:underline;">Section 25</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> by Tenant or </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Tenant Party.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392364"></a><a name="_cp_text_1_841"></a><a name="_cp_text_1_843"></a><a name="_cp_text_1_845"></a>22.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Holding Over</font>.&nbsp;&nbsp;If Tenant fails to vacate the Premises at the end of the Term, then Tenant shall be a tenant at sufferance and, in addition to all other damages and remedies to which Landlord may be entitled for such holding over, Tenant shall pay, in addition to the other Rent, Base Rent equal to one hundred fifty percent (150%) of the Base Rent payable during the last month of the Term (as applicable, the &#8220;Holdover Rate&#8221;), and Tenant shall otherwise continue to be subject to all of Tenant&#8217;s obligations under this Lease.&nbsp;&nbsp;The provisions of this <font style="text-decoration:underline;">Section 22</font> shall not be deemed to limit or constitute a waiver of any other rights or remedies of Landlord provided herein or at Law.<font style="font-size:10pt;font-family:Arial;"><a name="_cp_text_1_841"></a>&nbsp;&nbsp;</font><font style="font-weight:bold;">IF TENANT FAILS TO SURRENDER THE PREMISES UPON THE TERMINATION OR EXPIRATION OF THIS LEASE <a name="_cp_text_1_843"></a>(EXCEPT AS SET FORTH IN THE FOLLOWING SENTENCE), IN ADDITION TO ANY OTHER LIABILITIES TO LANDLORD ACCRUING THEREFROM, TENANT SHALL PROTECT, DEFEND, INDEMNIFY AND HOLD LANDLORD HARMLESS FROM ALL LOSS, COSTS (INCLUDING REASONABLE ATTORNEYS&#8217; FEES) AND LIABILITY RESULTING FROM SUCH FAILURE, INCLUDING ANY CLAIMS MADE BY ANY SUCCEEDING TENANT FOUNDED UPON SUCH FAILURE TO SURRENDER, AND ANY LOST PROFITS TO LANDLORD RESULTING THEREFROM</font>.&nbsp;&nbsp;Notwithstanding the foregoing, if Tenant remains in t<a name="_cp_text_1_845"></a>he Premises at the end of the Term with the written consent of Landlord, then Tenant shall be a month-to-month tenant at the Holdover Rate, and Tenant shall otherwise continue to be subject to all of Tenant&#8217;s obligations under this Lease.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392365"></a>23.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Certain Rights Reserved by Landlord</font>.&nbsp;&nbsp;Provided that the exercise of such rights does not unreasonably interfere with Tenant&#8217;s access to and occupancy of the Premises, Landlord shall have the following rights:</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392366"></a><a name="_cp_text_1_848"></a><a name="_cp_text_1_849"></a><a name="_cp_text_1_851"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Building Operations</font>.&nbsp;&nbsp;<a name="_cp_text_1_848"></a>To make such inspections, repairs, alterat<a name="_cp_text_1_849"></a>ions, additions, changes, or improvements, whether structural or otherwise, as are expressly provided in this Lease, <a name="_cp_text_1_851"></a>in and about the Project or Complex, as applicable, or any part thereof; to enter upon the Premises (after giving Tenant prior notice thereof, which may be oral notice, except in cases of real or apparent emergency, in which case no notice shall be required) and, during the continuance of any such work, to temporarily close public space; to interrupt or temporarily suspend Building services and facilities; and to change the arrangement and location of entrances or passageways, doors, and doorways, corridors, elevators, stairs, restrooms, or other public parts of the Building (after giving Tenant three (3) business days&#8217; notice thereof, except in cases or real or apparent emergency, in which case no notice shall be required);</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392367"></a>(b)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Security</font>.&nbsp;&nbsp;To take such reasonable security measures as Landlord deems reasonably advisable (provided, however, that any such security measures are for Landlord&#8217;s own protection, and Tenant acknowledges that Landlord is not a guarantor of the security or safety of any Tenant Party and that such security matters are the responsibility of Tenant); including evacuating the Building for cause, suspected cause, or for drill purposes; temporarily denying access to the Building;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392368"></a><a name="_cp_text_1_858"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prospective Purchasers and Lenders</font>.&nbsp;&nbsp;To enter the Premises at all reasonable hours to show the Premises to prospective purchasers or lenders<a name="_cp_text_1_858"></a> upon prior notice (which may be oral notice); and</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392369"></a><a name="_AEIOULastRenderedPageBreakAEIOU33"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Prospective Tenants</font>.&nbsp;&nbsp;At any time during the last nine (9) months of the Term (or earlier if Tenant has notified Landlord in writing that it does not desire to renew the Term) or at any time </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">24<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">following the occurrence of an Event of Default, to enter the Premises at all rea</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sonable hours</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon reasonable advance notice</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> to show the Premises to prospective tenants.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392370"></a>24.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Cell Tower Equipment</font>.&nbsp;&nbsp;Tenant hereby acknowledges that as of the date hereof, there are two cell tower equipment located on the roof of the Building and related equipment located in the electrical room in the underground parking garage (collectively, &#8220;<font style="font-weight:bold;">Cell Tower Equipment</font>&#8221;), which Cell Tower Equipment are owned by Pacific Bell Mobile Services and Spring Spectrum Realty Company L.P. (&#8220;<font style="font-weight:bold;">Cell Tower Owners</font>&#8221;).&nbsp;&nbsp;Landlord hereby represents to Tenant that the location and size of each Cell Tower Equipment on the rooftop and related equipment in the electric room in the underground parking garage on <font style="text-decoration:underline;">Exhibit&#160;K</font> attached to this Lease are accurate depiction of the current location and current size of the Cell Tower Equipment, and that the location or the size of the Cell Tower Equipment shall not be modified during the Term, except as otherwise provided in the following:&nbsp;&nbsp;(i)&#160;Communications Site Lease Agreement dated as of September 18, 1995, as amended, for Pacific Bell Mobile Services, and (ii)&#160;PCS Site Agreement dated as of May 20, 1996, as amended, for Spring Spectrum Realty Group (such items set forth in (i) and (ii) to be collectively referred to as the &#8220;<font style="font-weight:bold;">Cell Tower Leases</font>&#8221;).&nbsp;&nbsp;Tenant shall not have any rights to access, use or have any other right to such Cell Tower Equipment.&nbsp;&nbsp;Tenant shall provide Landlord and the Cell Tower Owners with access to the Cell Tower Equipment (which shall be through the stairway inside the Building) upon reasonable advance notice (which may be oral notice), provided that (i)&#160;Landlord and/or the Cell Tower Owners shall not unreasonably disturb Tenant&#8217;s use of the Premises in connection with their access to the Cell Tower Equipment, and (ii)&#160;Tenant&#8217;s facility manager shall have the right to accompany such Cell Tower Owners to where the Cell Tower Equipment are located.&nbsp;&nbsp;Landlord shall promptly notify Tenant pursuant to Landlord&#8217;s receipt of notification from any Cell Tower Owner that such Cell Tower Owner shall be accessing the Cell Tower Equipment.&nbsp;&nbsp;Except due to the acts, omissions, and/or willful misconduct of Landlord, Landlord Parties or Cell Tower Owners, Tenant shall indemnify, defend, protect and hold harmless Landlord and its partners, trustees and their officers, directors, shareholders, beneficiaries, agents, servants, employees and independent contractors from all claim, loss, cost, damage, expense and liability (including, without limitation, court costs and reasonable attorneys&#8217; fees) incurred in connection with or arising from any willful misconduct or gross negligence of Tenant or its partners, trustees and their officers, directors, shareholders, beneficiaries, agents, servants, employees and independent contractors in connection with the Cell Tower Equipment during the Term of this Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During the Term of this Lease, Landlord hereby agrees that Landlord shall not allow the expansion of any Cell Tower Equipment or location of any additional cell tower equipment and/or related equipment on the roof of the Building, except as otherwise provided in the Cell Tower Leases.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392371"></a>25.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Hazardous Materials</font>.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_870"></a>(a)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Compliance with Environmental Laws</font>.&nbsp;&nbsp;During the term of this Lease, Tenant shall comply with all Environmental Laws and Environmental Permits (each as defined in <font style="text-decoration:underline;">Section 25(h)</font> below) applicable to the operation or use of the Premises, will cause all other persons occupying or using the Premises to comply with all such Environmental Laws and Environmental Permits, will immediately pay or cause to be paid all <a name="_cp_text_1_870"></a>costs and expenses incurred by reason of such compliance (except as limited by <font style="text-decoration:underline;">Section 21</font>), and will obtain and renew all Environmental Permits required for operation or use of the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Restrictions on Use of Hazardous Materials</font>.&nbsp;&nbsp;Tenant shall not generate, use, treat, store, handle, release or dispose of, or permit the generation, use, treatment, storage, handling, release or disposal of Hazardous Materials (as defined in <font style="text-decoration:underline;">Section 25(h)</font> hereof) on the Premises, or the Complex, or transport or permit the transportation of Hazardous Materials to or from the Premises or the Complex except (i)&#160;for limited quantities used or stored at the Premises and required in connection with the routine operation and maintenance of the Premises, and then only upon the written consent of Landlord and in compliance with all applicable Environmental Laws and Environmental Permits, and (ii)&#160;as disclosed by Tenant in the Environmental Questionnaire attached as <font style="text-decoration:underline;">Exhibit&#160;I</font>.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">25<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><a name="_cp_text_1_880"></a><a name="_cp_text_1_881"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Environmental Assessment by Landlord</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font><font style="font-size:10pt;font-family:Arial;">&nbsp;&nbsp;</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At any time and from time to time during the Term of this Lease, if Landlord reasonably believes Tenant is violating the terms of this </font><font style="text-decoration:underline;">Section&#160;25</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, Landlord may perform an environmental site assessment repor</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t concerning the Premises, prepared by an environmental consulting firm chosen by Landlord, indicating the presence or absence of Hazardous Materials caused or permitted by Tenant and the potential cost of any compliance, removal or remedial action in conn</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_880"></a>ection with any such Hazardous Materials on the Premises.&nbsp;&nbsp;Tenant shall grant and hereby grants to Landlord and its agents access to the Premises and specifically grants Landlord an irrevocable non-exclusive license to undertake such an assessment </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">upon rea</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sonable advance notice</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_881"></a> (which may be oral notice).&nbsp;&nbsp;If such assessment report indicates the presence of Hazardous Materials caused or permitted by Tenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">as a result of Tenant&#8217;s violation of this </font><font style="text-decoration:underline;">Section 25</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, then such report shall be at Tenant&#8217;s sole cost </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and expense, and the cost of such assessment shall be immediately due and payable by Tenant to Landlord within thirty (30) days of receipt of an invoice therefor.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Notice to Landlord</font>.&nbsp;&nbsp;Tenant will immediately advise Landlord in writing of any of the following: (1) any pending or threatened in writing Environmental Claim (as defined in <font style="text-decoration:underline;">Section 25(h)</font> below) against Tenant relating to the Premises or the Complex; (2) any condition or occurrence on the Premises or the Complex that (a) results in noncompliance by Tenant with any applicable Environmental Law, or (b) could reasonably be anticipated to form the basis of an Environmental Claim against Tenant or Landlord or the Premises; (3) any condition or occurrence on the Premises or any property adjoining the Premises that could reasonably be anticipated to cause the Premises to be subject to any restrictions on the ownership, occupancy, use or transferability of the Premises under any Environmental Law; and (4) the actual or anticipated taking of any removal or remedial action by Tenant in response to the actual or alleged presence of any Hazardous Material on the Premises or the Complex.&nbsp;&nbsp;All such notices shall describe in reasonable detail the nature of the claim, investigation, condition, occurrence or removal or remedial action and Tenant&#8217;s response thereto.&nbsp;&nbsp;In addition, Tenant will provide Landlord with copies of all communications regarding the Premises with any governmental agency relating to Environmental Laws, all such communications with any person relating to Environmental Claims, and such detailed reports of any such Environmental Claim as may reasonably be requested by Landlord.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">No Change to Permitted Use</font>.&nbsp;&nbsp;Tenant will not change or permit to be changed the Permitted Use of the Premises unless Tenant shall have notified Landlord thereof in writing and provided Landlord an updated Environmental Questionnaire.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_892"></a><a name="_cp_text_1_894"></a><a name="_cp_text_1_895"></a><a name="_AEIOULastRenderedPageBreakAEIOU35"></a>(f)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Indemnification</font>.&nbsp;&nbsp;<font style="font-weight:bold;">TENANT AGREES TO INDEMNIFY, DEFEND AND HOLD HARMLESS THE INDEMNITEES FROM AND AGAINST ALL OBLIGATIONS (INCLUDING REMOVAL AND REMEDIAL ACTIONS), LOSSES, CLAIMS, SUITS, JUDGMENTS, LIABILITIES, PENALTIES, DAMAGES (INCLUDING CONSEQUENTIAL AND PUNITIVE DAMAGES), COSTS AND EXPENSES (INCLUDING REASONABLE ATTORNEYS&#8217; AND CONSULTANTS&#8217; FEES AND EXPENSES) OF ANY KIND OR NATURE WHATSOEVER THAT MAY AT ANY TIME BE INCURRED BY, IMPOSED ON OR ASSERTED AGAINST SUCH INDEMNITEES DIRECTLY OR INDIRECTLY BASED ON, OR ARISING OR RESULTING FROM (A) THE ACTUAL OR ALLEGED PRESENCE OF HAZARDOUS MATERIALS ON THE COMPLEX WHICH IS CAUSED OR PERMITTED BY TENANT OR A TENANT PARTY AND (B) ANY ENVIRONMENTAL CLAIM RELATING IN ANY WAY TO TENANT&#8217;S OPERATION OR USE OF THE PREMISES (THE </font>&#8220;<font style="font-weight:bold;">TENANT HAZARDOUS MATERIALS INDEMNIFIED MATTERS</font>&#8221;<font style="font-weight:bold;"><a name="_cp_text_1_892"></a>).&nbsp;&nbsp;THE FOREGOING INDEMNITY SHALL NOT INCLUDE ANY HAZARDOUS MATERIALS THAT (X) WERE LOCATED <a name="_cp_text_1_894"></a>AT THE PREMISES OR THE PROJECT ON THE DELIVERY DATE, (Y) WERE <a name="_cp_text_1_895"></a>PLACED ON THE PREMISES OR PROJECT BY LANDLORD, ITS EMPLOYEES, AGENTS, OR CONTRACTORS OR ANY THIRD PARTIES NOT UNDER TENANT&#8217;S CONTROL, OR (Z)&#160;MIGRATED THROUGH AIR, WATER OR SOIL FROM A LOCATION OUTSIDE OF THE PREMISES THROUGH NO ACT, OMISSION OR FAULT OF </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">26<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">TENANT OR TENANT PARTY</font><font style="font-weight:bold;">.&nbsp;&nbsp;THE PROVISIONS OF THIS </font><font style="font-weight:bold;text-decoration:underline;">SECTION 25</font><font style="font-weight:bold;"> SHALL SURVIVE THE EXPIRATION OR SOONER TERMINATION OF THIS LEASE.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that the undertaking in the preceding paragraphs may be unenforceable because it is violative of any law or public policy, Tenant will contribute the maximum portion that it is permitted to pay and satisfy under applicable Law to the payment and satisfaction of all Tenant Hazardous Materials Indemnified Matters incurred by the Indemnitees.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_900"></a>(g)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Payments</font><a name="_cp_text_1_900"></a>.&nbsp;&nbsp;All sums paid and costs incurred by Landlord with respect to any Hazardous Materials Indemnified Matter shall be payable within ten (10) days upon written demand.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Definitions</font>.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Hazardous Materials</font>&#8221; means (i) petroleum or petroleum products, natural or synthetic gas, asbestos in any form that is or could become friable, urea formaldehyde foam insulation, and radon gas; (ii) any substances defined as or included in the definition of &#8220;hazardous substances,&#8221; &#8220;hazardous wastes,&#8221; &#8220;hazardous materials,&#8221; &#8220;extremely hazardous wastes,&#8221; &#8220;restricted hazardous wastes,&#8221; &#8220;toxic substances,&#8221; &#8220;toxic pollutants,&#8221; &#8220;contaminants&#8221; or &#8220;pollutants,&#8221; or words of similar import, under any applicable Environmental Law; and (iii) any other substance exposure which is regulated by any governmental authority; (b) &#8220;<font style="font-weight:bold;">Environmental Law</font>&#8221; means any federal, state or local statute, law, rule, regulation, ordinance, code, policy or rule of common law now or hereafter in effect and in each case as amended, and any judicial or administrative interpretation thereof, including any judicial or administrative order, consent decree or judgment, relating to the environment, health, safety or Hazardous Materials, including without limitation, the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, 42 U.S.C. &#167;&#167;&#160;9601 et seq.; the Resource Conservation and Recovery Act, 42 U.S.C. &#167;&#167;&#160;6901 et seq.; the Hazardous Materials Transportation Act, 49 U.S.C. &#167;&#167;&#160;1801 et seq.; the Clean Water Act, 33 U.S.C. &#167;&#167;&#160;1251 et seq.; the Toxic Substances Control Act, 15 U.S.C. &#167;&#167;&#160;2601 et seq.; the Clean Air Act, 42 U.S.C. &#167;&#167;&#160;7401 et seq.; the Safe Drinking Water Act, 42 U.S.C. &#167;&#167;&#160;300f et seq.; the Atomic Energy Act, 42 U.S.C. &#167;&#167;&#160;2011 et seq.; the Federal Insecticide, Fungicide and Rodenticide Act, 7 U.S.C. &#167;&#167;&#160;136 et seq.; the Occupational Safety and Health Act, 29 U.S.C. &#167;&#167;&#160;651 et seq.; (c) &#8220;<font style="font-weight:bold;">Environmental Claims</font>&#8221; means any and all administrative, regulatory or judicial actions, suits, demands, demand letters, claims, liens, notices of non-compliance or violation, investigations, proceedings, consent orders or consent agreements relating in any way to any Environmental Law or any Environmental Permit, including without limitation (i) any and all Environmental Claims by governmental or regulatory authorities for enforcement, cleanup, removal, response, remedial or other actions or damages pursuant to any applicable Environmental Law and (ii) any and all Environmental Claims by any third party seeking damages, contribution, indemnification, cost recovery, compensation or injunctive relief resulting from Hazardous Materials or arising from alleged injury or threat of injury to health, safety or the environment; (d) &#8220;<font style="font-weight:bold;">Environmental Permits</font>&#8221; means all permits, approvals, identification numbers, licenses and other authorizations required under any applicable Environmental Law.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_905"></a><a name="_cp_text_1_906"></a><a name="_cp_text_4_907"></a>(i)<font style="margin-left:108pt;"></font><font style="text-decoration:underline;">Mold Disclosure</font><a name="_cp_text_4_905"></a>.&nbsp;&nbsp;Tenant acknowledges that (i) the Complex consists of property formerly used as a municipal landfill, (ii) methane barriers have been installed beneath the Premises, and (iii)&#160;methane levels are monitored throughout the Complex in accordance with the terms of the CC&amp;Rs.&nbsp;&nbsp;The taking o<a name="_cp_text_1_906"></a>f possession of the Premises by Tenant shall be conclusive evidence that Tenant accepts the same &#8220;AS-IS&#8221; <a name="_cp_text_4_907"></a>(except as otherwise set forth in this Lease) and that the Premises is suited for the use intended by Tenant and is in good and satisfactory condition at the time such possession was taken.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392372"></a>26.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Miscellaneous</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392373"></a>(a)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord Transfer</font>.&nbsp;&nbsp;Landlord may transfer any portion of the Building and any of its rights under this Lease.&nbsp;&nbsp;If Landlord assigns its rights under this Lease, then Landlord shall thereby be released from any further obligations hereunder arising after the date of transfer, provided that the assignee assumes Landlord&#8217;s obligations hereunder in writing.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">27<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392374"></a><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Liability</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The liability of Landlord (and its partners, shareholders or members) to Tenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(or any person or entity claiming by, through or under Tenant) for any default by Landlord under the terms of this Lease or any matter relating to or arising out of the occupancy or use of the Premises and/or other areas of the Building or Complex shall be</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> limited to Tenant&#8217;s actual direct, but not consequential, damages therefor and shall be recoverable only from the interest of Landlord in the Building, and Landlord (and its partners, shareholders or members) shall not be personally liable for any deficie</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ncy.&nbsp;&nbsp;Landlord&#8217;s liability to Tenant shall be further limited to Landlord&#8217;s equity interest in the Project.&nbsp;&nbsp;</font><font style="font-weight:bold;">ADDITIONALLY, TO THE EXTENT ALLOWED BY LAW, TENANT HEREBY WAIVES ANY STATUTORY LIEN IT MAY HAVE AGAINST LANDLORD OR ITS ASSETS, INCLUDING WITHOUT L</font><font style="font-weight:bold;">IMITATION, THE BUILDING</font><font style="font-weight:bold;text-transform:uppercase;">.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392375"></a>(c)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Force Majeure</font>.&nbsp;&nbsp;Other than for Tenant&#8217;s obligations under this Lease that can be performed by the payment of money (e.g., payment of Rent and maintenance of insurance), whenever a period of time is herein prescribed for action to be taken by either party hereto, such party shall not be liable or responsible for, and there shall be excluded from the computation of any such period of time, any delays due to strikes, riots, acts of God, shortages of labor or materials, war, terrorism, governmental laws, regulations, or restrictions, or any other causes of any kind whatsoever which are beyond the control of such party (each a &#8220;<font style="font-weight:bold;">Force Majeure Event</font>&#8221;); provided that in each case, the party seeking the extension of time due to the Force Majeure Event shall have notified the other party of the event or condition giving rise to any such delay within five (5) Business Days after the requesting party learns of the occurrence of the event or condition and thereafter regularly (but in no event less often than weekly) kept the other party apprised of the status.&nbsp;&nbsp;If the party seeking the extension of time due to the Force Majeure Event fails to give notice of an event or condition that otherwise constitutes a Force Majeure Event within five (5) Business Days after it learns of such event or condition or fails to keep the other part regularly apprised of the status of such event or condition, as applicable, then such event or condition shall not constitute a Force Majeure Event hereunder unless and until the requesting party gives a notice that such Force Majeure Event is continuing and specifying the date of onset of the Force Majeure Event, in which event the duration of such Force Majeure Event shall be limited to the period of continuation commencing on the date of such notice of continuation and shall be subject to the continuing obligation that the requesting party thereafter regularly (but no less often than weekly) keeps the other party apprised of the status.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392376"></a><a name="_cp_text_1_916"></a>(d)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Brokerage</font>.&nbsp;&nbsp;Neither Landlord nor Ten<a name="_cp_text_1_916"></a>ant has dealt with any broker or agent in connection with the negotiation or execution of this Lease, other than as set forth in the Basic Lease Information.&nbsp;&nbsp;<font style="font-weight:bold;">EACH PARTY SHALL INDEMNIFY, DEFEND AND HOLD HARMLESS THE OTHER PARTY FROM AND AGAINST ALL COSTS, EXPENSES, ATTORNEYS&#8217; FEES, LIENS AND OTHER LIABILITY FOR COMMISSIONS OR OTHER COMPENSATION CLAIMED BY ANY BROKER OR AGENT CLAIMING THE SAME BY, THROUGH, OR UNDER THE INDEMNIFYING PARTY.</font>&nbsp;&nbsp;The foregoing indemnity shall survive the expiration or earlier termination of the Lease.&nbsp;&nbsp;Landlord shall pay Tenant&#8217;s broker (set forth in the Basic Lease Information) a commission pursuant to a separate agreement.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506191741"></a><a name="_Toc497392377"></a>(e)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Estoppel Certificates</font>.&nbsp;&nbsp;From time to time, Tenant shall furnish to any party designated by Landlord, within ten (10) Business Days after Landlord has made a request therefor, a certificate signed by Tenant confirming and containing such factual certifications and representations as to this Lease as Landlord may reasonably request.&nbsp;&nbsp;Unless otherwise required by Landlord&#8217;s Mortgagee or a prospective purchaser or mortgagee of the Building, the initial form of estoppel certificate to be signed by Tenant is attached hereto as <font style="text-decoration:underline;">Exhibit&#160;G</font>.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392378"></a><a name="_AEIOULastRenderedPageBreakAEIOU37"></a>(f)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Notices</font>.&nbsp;&nbsp;All notices and other communications given pursuant to this Lease shall be in writing and shall be: (1) mailed by first class, United States Mail, postage prepaid, certified, with return receipt requested, and addressed to the parties hereto at the address specified in the Basic Lease Information; (2) hand delivered to the intended addressee; (3) sent by a nationally recognized overnight courier service; or (4) sent by facsimile transmission during normal business hours followed by a copy of </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">28<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">such notice </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sent in another manner permitted hereunder.&nbsp;&nbsp;All notices shall be effective upon the earlier to occur of actual receipt, one (1) Business Day following deposit with a nationally recognized overnight courier service, or three (3) days following deposit in t</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">he United States mail.&nbsp;&nbsp;The parties hereto may change their addresses by giving notice thereof to the other in conformity with this provision.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392379"></a>(g)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Separability</font>.&nbsp;&nbsp;If any clause or provision of this Lease is illegal, invalid, or unenforceable under present or future laws, then the remainder of this Lease shall not be affected thereby and in lieu of such clause or provision, there shall be added as a part of this Lease a clause or provision as similar in terms to such illegal, invalid, or unenforceable clause or provision as may be possible and be legal, valid, and enforceable.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392380"></a>(h)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Amendments; Binding Effect</font>.&nbsp;&nbsp;This Lease may not be amended except by instrument in writing signed by Landlord and Tenant.&nbsp;&nbsp;No provision of this Lease shall be deemed to have been waived by Landlord unless such waiver is in writing signed by Landlord, and no custom or practice which may evolve between the parties in the administration of the terms hereof shall waive or diminish the right of Landlord to insist upon the performance by Tenant in strict accordance with the terms hereof.&nbsp;&nbsp;The terms and conditions contained in this Lease shall inure to the benefit of and be binding upon the parties hereto, and upon their respective successors in interest and legal representatives, except as otherwise herein expressly provided.&nbsp;&nbsp;This Lease is for the sole benefit of Landlord and Tenant, and, other than Landlord&#8217;s Mortgagee, no third party shall be deemed a third party beneficiary hereof.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392381"></a>(i)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Quiet Enjoyment</font>.&nbsp;&nbsp;Provided Tenant has performed all of its obligations hereunder, Tenant shall peaceably and quietly hold and enjoy the Premises for the Term, without hindrance from Landlord or any party claiming by, through, or under Landlord, but not otherwise, subject to the terms and conditions of this Lease.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392382"></a>(j)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Merger</font>.&nbsp;&nbsp;There shall be no merger of the leasehold estate hereby created with the fee estate in the Premises or any part thereof if the same person acquires or holds, directly or indirectly, this Lease or any interest in this Lease and the fee estate in the leasehold Premises or any interest in such fee estate.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392383"></a>(k)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">No Offer</font>.&nbsp;&nbsp;The submission of this Lease to Tenant shall not be construed as an offer, and Tenant shall not have any rights under this Lease unless Landlord executes a copy of this Lease and delivers it to Tenant.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392384"></a>(l)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Entire Agreement</font>.&nbsp;&nbsp;This Lease constitutes the entire agreement between Landlord and Tenant regarding the subject matter hereof and supersedes all oral statements and prior writings relating thereto.&nbsp;&nbsp;Except for those set forth in this Lease, no representations, warranties, or agreements have been made by Landlord or Tenant to the other with respect to this Lease or the obligations of Landlord or Tenant in connection therewith.&nbsp;&nbsp;The normal rule of construction that any ambiguities be resolved against the drafting party shall not apply to the interpretation of this Lease or any exhibits or amendments hereto.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392385"></a>(m)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Waiver of Jury Trial</font>.&nbsp;&nbsp;<font style="font-weight:bold;">TO THE MAXIMUM EXTENT PERMITTED BY LAW, LANDLORD AND TENANT EACH WAIVE ANY RIGHT TO TRIAL BY JURY IN ANY LITIGATION OR TO HAVE A JURY PARTICIPATE IN RESOLVING ANY DISPUTE ARISING OUT OF OR WITH RESPECT TO THIS LEASE OR ANY OTHER INSTRUMENT, DOCUMENT OR AGREEMENT EXECUTED OR DELIVERED IN CONNECTION HEREWITH OR THE TRANSACTIONS RELATED HERETO.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392386"></a>(n)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Governing Law</font>.&nbsp;&nbsp;This Lease shall be governed by and construed in accordance with the laws of the state in which the Premises are located.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392387"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a>(o)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Recording</font>.&nbsp;&nbsp;Tenant shall not record this Lease or any memorandum of this Lease without the prior written consent of Landlord, which consent may be withheld or denied in the sole and absolute discretion of Landlord, and any recordation by Tenant shall be a material breach of this Lease.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">29<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant grants to Landlord a power of attorney to execute and record a release releasing any such recorded instrument o</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">f record that was recorded without the prior written consent of Landlord, which power of attorney is coupled with an interest and is non-revocable during the Term.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392388"></a>(p)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Joint and Several Liability</font>.&nbsp;&nbsp;If Tenant is comprised of more than one (1) party, each such party shall be jointly and severally liable for Tenant&#8217;s obligations under this Lease.&nbsp;&nbsp;All unperformed obligations of Tenant hereunder not fully performed at the end of the Term shall survive the end of the Term, including payment obligations with respect to Rent and all obligations concerning the condition and repair of the Premises.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506192733"></a><a name="_Toc497392389"></a>(q)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Financial Reports</font>.&nbsp;&nbsp;Within thirty (30) days after Landlord&#8217;s request, Tenant will furnish Tenant&#8217;s most recent audited financial statements (including any notes to them) to Landlord, or, if no such audited statements have been prepared, such other financial statements (and notes to them) as may have been prepared by an independent certified public accountant or, failing those, Tenant&#8217;s internally prepared financial statements.  If Tenant is a publicly traded corporation, Tenant may satisfy its obligations hereunder by providing to Landlord Tenant&#8217;s most recent annual and quarterly reports.&nbsp;&nbsp;Landlord will not disclose any aspect of Tenant&#8217;s financial statements that Tenant designates to Landlord as confidential except: (1) to Landlord&#8217;s Mortgagee or prospective mortgagees or purchasers of the Building; (2) in litigation between Landlord and Tenant; and (3) if required by court order.&nbsp;&nbsp;Tenant shall not be required to deliver the financial statements required under this <font style="text-decoration:underline;">Section 26(q)</font> more than once in any twelve (12) month period unless requested by Landlord&#8217;s Mortgagee or a prospective buyer or lender of the Building or a Default occurs.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392390"></a><a name="_cp_text_1_922"></a>(r)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Landlord&#8217;s Fees</font>.&nbsp;&nbsp;Whenever Tenant requests Landlord to take any action not required of it hereunder or give any consent required or permitted under this Lease, Tenant will reimburse Landlord for Landlord&#8217;s reasonable, out-of-pocket costs payable to third parties and incurred by Landlord in reviewing <a name="_cp_text_1_922"></a>the proposed action or consent, including reasonable attorneys&#8217;, engineers&#8217; or architects&#8217; fees, within thirty (30) days after Landlord&#8217;s delivery to Tenant of a statement of such costs (other than in connection with Alterations and Transfers, for which have been paid for by Tenant as specifically set forth in this Lease).&nbsp;&nbsp;Tenant will be obligated to make such reimbursement without regard to whether Landlord consents to any such proposed action.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392391"></a><a name="_cp_text_1_927"></a><a name="_cp_text_1_929"></a><a name="_cp_text_1_931"></a><a name="_cp_text_1_933"></a><a name="_cp_text_4_934"></a>(s)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Telecommunications</font>.&nbsp;&nbsp;All providers of Telecommunications Serv<a name="_cp_text_1_927"></a>ices shall be required to comply with the Rules <a name="_cp_text_1_929"></a>and Regulations <a name="_cp_text_1_931"></a>of the Building and applicable Laws.&nbsp;&nbsp;Tenant acknowledges that Landlord shall not be required to provide or arrange for any Telecommunications Services and that Landlord shall have no liability to any Tenant Party in connection with the installation, operation or maintenance of Telecommunications Services or any equipment or facilities relating thereto.&nbsp;&nbsp;Tenant, at its cost and for its own account, shall be solely responsible for obtaining all <a name="_cp_text_1_933"></a>Telecommunications Services.&nbsp;&nbsp;For the purposes of this provision, &#8220;<font style="font-weight:bold;">Telecommunication Services</font><a name="_cp_text_4_934"></a>&#8221; shall mean telecommunications systems, including voice, video, data, Internet, and any other services provided over wire, fiber optic, microwave, wireless, and any other transmission systems.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>Notwithstanding the foregoing to the contrary, if Tenant requires the installation of one or more satellite dishes or other data transmission equipment on the roof of the Building (collectively, the &#8220;<font style="font-weight:bold;">Telecommunications Equipment</font>&#8221;), then upon thirty (30) days advance written notice to Landlord and subject to available capacity and Tenant&#8217;s compliance with all applicable Laws and Landlord&#8217;s reasonable requirements for property and roof maintenance and repair, Tenant may place such Telecommunications Equipment on the roof of the Premises in a location reasonably approved by Landlord.&nbsp;&nbsp;The installation of the Telecommunications Equipment shall constitute an Alteration and shall be performed in accordance with and subject to the provisions of <font style="text-decoration:underline;">Article 8</font> of this Lease, and the Telecommunications Equipment shall be treated for all purposes of the Lease as if the same were Tenant&#8217;s property.&nbsp;&nbsp;The cost of the Telecommunications Equipment and all costs of installing, maintaining and removing the Telecommunications Equipment shall be borne solely by Tenant.&nbsp;&nbsp;Upon the expiration of the Term or upon </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">30<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">any earlier termination of the Lease, Tenant shall, at Tenant&#8217;s sole cost and expense and subject to the reasonable direction from Landlord, remov</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">e the Telecommunications Equipment, repair any damage caused thereby to the condition existing prior to the installation of the Telecommunications Equipment, reasonable wear and tear excepted. </font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392392"></a>(t)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Confidentiality</font>.&nbsp;&nbsp;Tenant acknowledges that the terms and conditions of this Lease are to remain confidential for Landlord&#8217;s benefit, and may not be disclosed by Tenant to anyone, by any manner or means, directly or indirectly (except to Tenant&#8217;s attorneys and accountants which have been informed of the confidentiality provisions of this Lease and further except as Tenant shall be required under applicable laws including requirements of the Securities and Exchange Commission) without Landlord&#8217;s prior written consent.&nbsp;&nbsp;The consent by Landlord to any disclosures shall not be deemed to be a waiver on the part of Landlord of any prohibition against any future disclosure.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392393"></a><a name="_cp_text_1_944"></a>(u)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Authority</font><a name="_cp_text_1_944"></a>.&nbsp;&nbsp;Each of Landlord and<font style="font-size:10pt;font-family:Arial;"> </font>Tenant (if a corporation, partnership or other business entity) hereby represents and warrants to the other party that it is a duly formed and existing entity qualified to do business in the state in which the Premises are located, that it has full right and authority to execute and deliver this Lease, and that each person signing on behalf of itself is authorized to do so.</p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392394"></a>(v)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Waiver</font>.&nbsp;&nbsp;<font style="font-weight:bold;">LANDLORD AND TENANT EXPRESSLY DISCLAIM ANY IMPLIED WARRANTY THAT THE PREMISES ARE SUITABLE FOR TENANT&#8217;S INTENDED COMMERCIAL PURPOSE, AND TENANT&#8217;S OBLIGATION TO PAY RENT HEREUNDER IS NOT DEPENDENT UPON THE CONDITION OF THE PREMISES OR THE PERFORMANCE BY LANDLORD OF ITS OBLIGATIONS HEREUNDER, AND, EXCEPT AS OTHERWISE EXPRESSLY PROVIDED HEREIN, TENANT SHALL CONTINUE TO PAY THE RENT, WITHOUT ABATEMENT, DEMAND, SETOFF OR DEDUCTION, NOTWITHSTANDING ANY BREACH BY LANDLORD OF ITS DUTIES OR OBLIGATIONS HEREUNDER, WHETHER EXPRESS OR IMPLIED.&nbsp;&nbsp;TO THE EXTENT ALLOWED BY LAW, </font><font style="font-weight:bold;text-transform:uppercase;">Tenant</font><font style="font-weight:bold;"> WAIVES THE BENEFIT OF ANY CONSUMER PROTECTION LAWS.</font></p>
<p style="margin-bottom:6pt;text-align:justify;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392395"></a>(w)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant Representation</font>.&nbsp;&nbsp;Tenant is not a person or entity described by Sec. 1 of the Executive Order (No. 13,224) Blocking Property and Prohibiting Transactions With Persons Who Commit, Threaten to Commit, or Support Terrorism, 66 Fed. Reg. 49,079 (Sept. 24, 2001), and does not engage in any dealings or transactions, and is not otherwise associated, with any such persons or entities.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392396"></a>(x)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Transportation Management</font>.&nbsp;&nbsp;Tenant shall fully comply with all present or future programs intended to manage parking, transportation or traffic in and around the Complex, and in connection therewith, Tenant shall take responsible action for the transportation planning and management of all employees located at the Premises by working directly with Landlord, any governmental transportation management organization or any other transportation-related committees or entities.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392397"></a>(y)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">CC&amp;Rs; Disclosure</font>.&nbsp;&nbsp; Tenant acknowledges that this Lease is subject to (i) that certain Declaration of Covenants, Conditions and Restrictions for Koll Center Sierra Point, dated October 9, 1984, and recorded on October 17, 1984 as Instrument No. 84112690 in the Official Records of San Mateo County, California (as the same has been and may be amended), and (ii) that certain Declaration of Covenants, Conditions and Environmental Restrictions Relating to Environmental Compliance for Sierra Point, dated October 21, 1998 and recorded on October 23, 1998 as Instrument No. 98-172219 in the Official Records of San Mateo County, California (as the same has been and may be amended) (collectively, the &#8220;<font style="font-weight:bold;">CC&amp;Rs</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Toc497392398"></a><a name="_AEIOULastRenderedPageBreakAEIOU40"></a>(z)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Disclosure</font>.&nbsp;&nbsp;For purposes of Section 1938(a) of the California Civil Code, Landlord hereby discloses to Tenant, and Tenant hereby acknowledges, that neither the Complex nor the Premises has undergone inspection by a Certified Access Specialist (CASp) (defined by California Civil Code Section 55.52). Pursuant to California Civil Code Section 1938, Tenant is hereby notified that a CASp can inspect the Premises and determine whether the Premises complies with all of the applicable </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">31<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">construction-related accessibility standards under state law.&nbsp;&nbsp;Although state law does not require a CASp inspect</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion of the Premises, Landlord may not prohibit Tenant from obtaining a CASp inspection of the Premises for the occupancy of the Tenant, if requested by Tenant.&nbsp;&nbsp;Landlord and Tenant shall mutually agree on the arrangements for the time and manner of any CAS</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">p inspection, the payment of the fee for the CASp inspection and the cost of making any repairs necessary to correct violations of construction-related accessibility standards within the Premises.</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">[SIGNATURES ON FOLLOWING PAGE]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">32<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Lease is executed on the respective dates set forth below, but for reference purposes, this Lease shall be dated as of the date first above writ</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ten.&nbsp;&nbsp;If the execution date is left blank, this Lease shall be deemed executed as of the date first written above.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:478.8pt;;">
<tr>
<td style="width:216.9pt;"></td>
<td style="width:261.9pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">LANDLORD:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MARINA BOULEVARD PROPERTY, LLC, <br />a Delaware limited liability company</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Sean Armstrong____&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font>_<font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp; </font><font style="text-decoration:underline;color:#FFFFFF;">. </font><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name: Sean Armstrong</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Peter Aronson_______&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font><font style="text-decoration:underline;color:#FFFFFF;">. </font><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name: Peter Aronson</p>
<p style="margin-bottom:2pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: Authorized Signer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Date:&nbsp;&nbsp;November 3, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC., <br />a Delaware corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By: <font style="text-decoration:underline;">/s/ Sandy Macrae______&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;__&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font><font style="text-decoration:underline;color:#FFFFFF;">. </font><font style="text-decoration:underline;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name: Sandy Macrae</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title: President and Chief Executive Officer</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Date:&nbsp;&nbsp;November 3, 2017<br /></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">[Signature Page to the Lease]<font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="text-decoration:underline;">EXHIBIT A-1</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SITE PLAN DEPICTING PREMISES AND BUILDING</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531377131123.jpg" title="" alt="" style="width:608px;height:787px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT A-1</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT A-2</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">SITE PLAN DEPICTING COMPLEX</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531380031124.jpg" title="" alt="" style="width:605px;height:348px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531381231125.jpg" title="" alt="" style="width:593px;height:432px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT A-2</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT B</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LEGAL DESCRIPTION OF THE LAND</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THE LAND REFERRED TO HEREIN BELOW IS SITUATED IN THE CITY OF BRISBANE, IN THE COUNTY OF SAN MATEO, STATE OF CALIFORNIA, AND IS DESCRIBED AS FOLLOWS:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parcel One</font>:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parcel A as shown on that certain map entitled &#8220;Parcel Map, Lands of Foster Enterprises, a General Partnership&#8221; filed for record in the Office of the Recorder of the County of Sank Mateo, State of California on November 6, 2000 in Book 73 of Parcel Maps at page 27.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excepting all minerals and all mineral rights of every kind and character now known to exist or hereafter discovered, including without limiting the generality of the foregoing, oil and gas and rights thereto, together with the sole, exclusive, and perpetual right to explore for, remove and dispose of said minerals by any means or methods suitable to the grantor, its successors and assigns including lateral or slant drilling, but without entering upon to using the surface of the lands hereby conveyed, and in such manner as not to damage the surface of said lands or any building located thereon or hereafter erected thereon or the substructure of any such building, or to interfere with the use thereof by the grantee, its successors or assigns, as excepted in the following Deeds to Utah Constructing &amp; Mining Co., a Corporation, predecessor in interest to the vestees herein:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. From Marie Louise Philips, dated August 20, 1959 and recorded September 14, 1959, Instrument no. 86272-R, in Book 3670 of Official Records at page 624.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. From John F. Wilcox, dated August 27, 1959 and recorded September 14, 1959, Instrument no. 86273-R, in Book 3670 of Official Records at page 625.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C. From Marita Clark, dated August 20, 1959 and recorded September 14, 1959, Instrument no. 86274-R in Book 3670 of Official Records at page 626.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APN: 007-165-110</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Parcel Two</font>:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parcel B as shown on that certain map entitled &#8220;Parcel Map, Lands of Foster Enterprises, a General Partnership&#8221; filed for record in the Office of the Recorder of the County of Sank Mateo, State of California on November 6, 2000 in Book 73 of Parcel Maps at page 27.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Excepting all minerals and all mineral rights of every kind and character now known to exist or hereafter discovered, including without limiting the generality of the foregoing, oil and gas and rights thereto, together with the sole, exclusive, and perpetual right to explore for, remove and dispose of said minerals by any means or methods suitable to the grantor, its successors and assigns including lateral or slant drilling, but without entering upon or using the surface of the lands hereby conveyed, and in such manner as not to damage the surface of said lands or any building located thereon or hereafter erected thereon or the substructure of any such building, or to interfere with the use thereof by the grantee, its successors or assigns, as excepted in the following Deeds to Utah Constructing &amp; Mining Co., a Corporation, predecessor in interest to the vestees herein:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A. From Marie Louise Philips, dated August 20, 1959 and recorded September 14, 1959, Instrument no. 86272-R, in Book 3670 of Official Records at page 624.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B. From John F. Wilcox, dated August 27, 1959 and recorded September 14, 1959, Instrument no. 86273-R, in Book 3670 of Official Records at page 625.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT B-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><a name="_Ref506102758"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506102758"></a>C. From Marita Clark, dated August 20, 1959 and recorded September 14, 1959, Instrument no. 86274-R in Book 3670 of Official Records at page 626.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APN: 007-165-120</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">APN: 007-165-110, 007-165-120</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT B-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT C</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ADDITIONAL RENT, TAXES, AND INSURANCE</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Additional Rent</font>.&nbsp;&nbsp;Tenant shall pay to Landlord all costs (100%) of Common Area Maintenance Costs, Taxes, and Insurance for the Building, and Tenant&#8217;s Proportionate Share of the annual Common Area Maintenance Costs (defined below) in the Complex (&#8220;<font style="font-weight:bold;">Additional Rent</font>&#8221;).&nbsp;&nbsp;The estimated projected monthly Additional Rent for 2017 is $0.85 per rentable square feet, it being agreed and acknowledged by Tenant that this is only an estimate of the projected Additional Rent for the Complex, is not binding on Landlord and that the actual Additional Rent may be in excess of such estimate.&nbsp;&nbsp;Landlord may make a good faith estimate of the Additional Rent to be due by Tenant for any calendar year or part thereof during the Term and provide such estimate to Tenant.&nbsp;&nbsp;During each calendar year or partial calendar year of the Term, Tenant shall pay to Landlord, in advance concurrently with each monthly installment of Base Rent, an amount equal to the estimated Additional Rent for such calendar year or part thereof divided by the number of months therein.&nbsp;&nbsp;From time to time, Landlord may estimate and re-estimate the Additional Rent to be due by Tenant and deliver a copy of the estimate or re-estimate to Tenant.&nbsp;&nbsp;Thereafter, the monthly installments of Additional Rent payable by Tenant shall be appropriately adjusted in accordance with the estimations so that, by the end of the calendar year in question, Tenant shall have paid all of the Additional Rent as estimated by Landlord.&nbsp;&nbsp;Any amounts paid based on such an estimate shall be subject to adjustment as herein provided when actual Common Area Maintenance Costs are available for each calendar year.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506184461"></a><a name="_cp_text_1_986"></a><a name="_cp_text_1_993"></a><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><a name="_cp_text_1_994"></a>2.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Common Area Maintenance Costs</font>.&nbsp;&nbsp;The term &#8220;<font style="font-weight:bold;">Common Area Maintenance Costs</font>&#8221; shall mean all expenses and disbursements (subject to the limitations set forth below) that Landlord incurs in connection with the ownership, operation, and maintenance of the Project or Complex, as applicable, determined in accordance with sound accounting principles consistently applied, including the following costs:&nbsp;&nbsp;(a)&#160;wages and salaries of all on-site employees at or below the grade of senior building manager engaged in the operation, maintenance, repair or security of the Project or Complex, as applicable (together with Landlord&#8217;s reasonable allocation of expenses of off-site employees at or below the grade of senior building manager who perform a portion of their services in connection with the operation, maintenance or security of the Project or Complex, as applicable), including taxes, insurance and benefits relating thereto; (b)&#160;all supplies and materials used in the operation, maintenance, repair, replacement, and security of the Project or Complex,<a name="_cp_text_1_986"></a> as applicable; (c)&#160;costs for improvements made to the Project or Complex, as applicable which, although capital in nature, all as amortized over the Useful Life of such capital improvement item at an interest rate equal to the &#8220;prime rate&#8221; as announced from time to time by Bank of America, N.A., plus one percent (1%) per annum are (i)&#160;expected to reduce the normal Common Area Maintenance Costs (including all utility costs) of the Project or Complex, taking into consideration the anticipated cost savings, as determined by Landlord using its good faith, commercially reasonable judgment, as well as (ii)&#160;capital improvements made in order to comply with any applicable Law hereafter promulgated by any governmental authority or any interpretation hereafter rendered with respect to any existing Law, as well as (iii)&#160;capital improvements made to improve the health, safety and welfare of the Building and its occupants; (d)&#160;cost of all utilities used in the Common Areas; (e)&#160;repairs, replacements, and general maintenance of the Project or Complex, including common area maintenance fees charged by an owner&#8217;s association and reasonable market-rate property management fees charged by Owner&#8217;s property manager or by Owner, as applicable (which management fee shall not excee<a name="_cp_text_1_993"></a>d three percent (3%) of gross revenues generated by the Project or Complex); (f)&#160;fair market rental for a commercially reasonable amount of space with respect to the management office for the Building or Complex, if any; (g)&#160;service, maintenance and management contracts with independent contractors for the operation, maintenance, management, repair, replacement, or security of the Project or Complex, as applicable, including the Common Areas; and (h)&#160;payments under any easement, license, operating agreement, declaration, restrictive covenant, or instrument now or hereafter affecting the Complex, including, without limitation, the Declaration of Covenants, Conditions and Restrictions for Koll Center Sierra Point, dated October&#160;9, 1984, and recorded </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT C-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on October</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;17, 1984 as Instrument No. 84112690 in the Official Records of San Mateo County, California (as the same has been and may be amended), and the Declaration of Covenants, Conditions and Environmental Restrictions Relating to Environmental Compliance for Sie</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rra Point, dated October&#160;21, 1998 and recorded on October&#160;23, 1998 as Instrument No. 98-172219 in the Official Records of San Mateo County, California (as the same has been and may be amended).&nbsp;&nbsp; If the Building is part of a Complex, Common Area Maintenanc</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_994"></a>e Costs may be prorated among the Project and the other buildings of the Complex, as reasonably </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and equitably </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">determined by Landlord</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_997"></a><a name="_cp_text_1_998"></a><a name="_cp_text_1_999"></a><a name="_cp_text_1_1000"></a><a name="_cp_text_1_1002"></a><a name="_cp_text_1_1003"></a><a name="_cp_text_1_1004"></a><a name="_cp_text_1_1005"></a>Common Area Maintenance Costs shall not include costs for: (1)&#160;repair, replacements and general maintenance paid by procee<a name="_cp_text_1_997"></a>ds of insurance or by Tenant or other third parties; (2)&#160;interest, amortization or other payments on loans to Landlord including principal, fees and penalties; (3)&#160;depreciation; (4)&#160;leasing commissions; (5)&#160;legal expenses; (6)&#160;renovating or otherwise improving space for leased premises of the Project or Complex, as applicable or vacant space in the Project or Complex, as applicable; (7)&#160;Taxes and Insurance which are paid separately pursuant to <font style="text-decoration:underline;">Sections&#160;3</font> and <font style="text-decoration:underline;">4</font><a name="_cp_text_1_998"></a> below; (8)&#160;any net income, franchise, capital stock, estate or inheritance taxes, <a name="_cp_text_1_999"></a>federal income taxes imposed on or measured by the income of Landlord from the operation of the Project or Complex, as applicable or taxes that are the personal obligation of Tenant or of another tenant of the Project or Complex, as applicable; (9)&#160;capital improvements made to the Project or Complex, as applicable, other than capital improvements described in <font style="text-decoration:underline;">Section&#160;2</font> of this Exhibit and except for items which are generally considered maintenance and repair items, such as<a name="_cp_text_1_1000"></a> painting of Common Areas, and the like; (10)&#160;expenses of initial development and construction, including grading, paving, landscaping and decorating (as distinguished from maintenance, repair and replacement of the foregoing) and the cost of correcting de<a name="_cp_text_1_1002"></a>fects in the construction of the Building or in the Building&#8217;s Systems; (11)&#160;salaries of officers and executives of Landlord; (12)&#160;the cost of any work or service performed for any tenant of the Building (other than Tenant) to a materially greater extent or in a materially more favorable manner than that furnished generally to the tenants and other occupants (including Tenant); (13)&#160;all costs of cleanup, removal, investigation and/or remediation (collectively, &#8220;Remediation Costs&#8221;) of any Hazardous Substance<a name="_cp_text_1_1003"></a>s in, on or under the Project and/or the Complex, as applicable, <a name="_cp_text_1_1004"></a>the extent such Hazardous Substances are (x)&#160;in existence as of the Delivery Date and in violation of applicable Laws, or (y)&#160;introduced onto the Project and/or the Complex, as applicable, after the Delivery Date by Landlord or any of Landlord&#8217;s agents, employees, contractors or tenants or other third parties not related to Tenant in violation of applicable Laws; (14)&#160;the cost of any repairs, alterations, additions, changes, replacements and other items which are made in order to prepare for a new tenant&#8217;s occupancy; (15)&#160;any advertising expenses; (16)&#160;any costs included in Common Area Maintenance Costs representing an amount paid to a corporation related to Landlord which is in excess of the amount which would have been paid in the absence of such relationship; (17)&#160;interest and penalties due to late payment of any amounts owed by Landlord, except such as may be incurred as a result of Tenant&#8217;s failure to timely pay its portion of such amounts <a name="_cp_text_1_1005"></a>or as a result of Landlord&#8217;s contesting such amounts in good faith; (18)&#160;costs related to the existence and maintenance of Landlord as a legal entity including professional fees, except to the extent attributable to the operation and management of the Project or Complex, as applicable; (19)&#160;the cost of any work or service performed for any tenant (including Tenant) at such tenant&#8217;s cost; (20)&#160;costs incurred to remedy violations of applicable Laws in the Common Areas or Premises to the extent such violations existed prior to the Delivery Date; (21)&#160;costs of repairs to the extent reimbursed by payment of insurance proceeds received by Landlord; (22)&#160;costs or expenses incurred in connection with the financing or sale of the Project or any portion thereof (it being the intent of the parties hereto that Tenant&#8217;s obligation to pay Taxes shall be covered by the terms and conditions hereinafter set forth in <font style="text-decoration:underline;">Section 3</font> of this <font style="text-decoration:underline;">Exhibit C</font> and that Taxes shall include all taxes, assessments and governmental charges in connection with Proposition 13, as hereinafter defined in <font style="text-decoration:underline;">Section 3</font> of this <font style="text-decoration:underline;">Exhibit C</font>); (23)&#160;costs expressly excluded from Common Area Maintenance Costs elsewhere in this Lease or that are charged to or paid by Tenant under other provisions of this Lease; (23)&#160;any cost incurred in connection with Cell Tower Equipment (including, without limitation, installation of meters and utilities used by Cell Tower Equipment); and (25)&#160;any item that, if included in Common Area Maintenance Costs, would involve a double collection for such item by Landlord. </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT C-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><a name="_cp_text_1_1011"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font><font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Taxes</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;Tenant shall pay all Taxes for the Building, and Tenant&#8217;s Proportionate Share of Taxes for the Complex for each year and partial year falling within the Term.&nbsp;&nbsp;Tenant shall pay Tenant&#8217;s Proportionate Share of Tax</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">es in the same manner as provided above for Tenant&#8217;s Proportionate Share of Common Area Maintenance Costs.&nbsp;&nbsp;&#8220;</font><font style="font-weight:bold;">Taxes</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; shall mean taxes, assessments, and governmental charges or fees whether federal, state, county or municipal, and whether they be by taxing d</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">istricts or authorities presently taxing or by others, subsequently created or otherwise, and any other taxes and assessments (including non-governmental assessments for common charges under a restrictive covenant or other private agreement that are not tr</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eated as part of Common Area Maintenance Costs) now or hereafter attributable to the Project or Complex, as applicable (or its operation), excluding, however, penalties and interest thereon and federal and state taxes on income (if the present method of ta</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">xation changes so that in lieu of or in addition to the whole or any part of any Taxes, there is levied on Landlord a capital tax directly on the rents received therefrom or a franchise tax, assessment, or charge based, in whole or in part, upon such rents</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> for the Project or Complex, as applicable, then all such taxes, assessments, or charges, or the part thereof so based, shall be deemed to be included within the term &#8220;Taxes&#8221; for purposes hereof).&nbsp;&nbsp;Taxes shall include the costs of consultants retained in a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n effort to lower taxes and all costs incurred in disputing any taxes or in seeking to lower the tax valuation of the Project.&nbsp;&nbsp;Taxes shall also include any assessment, tax, fee, levy or charge in addition to, or in substitution, partially or totally, of a</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ny assessment, tax, fee, levy or charge previously included within the definition of real property tax, it being acknowledged by Tenant and Landlord that Proposition 13 was adopted by the voters of the State of California in the June 1978 election (&#8220;</font><font style="font-weight:bold;">Propos</font><font style="font-weight:bold;">ition 13</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) and that assessments, taxes, fees, levies and charges may be imposed by governmental agencies for such services as fire protection, street, sidewalk and road maintenance, conservation, refuse removal and for other governmental services formerly </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provided without charge to property owners or occupants, and, in further recognition of the decrease in the level and quality of governmental services and amenities as a result of Proposition 13, Taxes shall also include any governmental or private assessm</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ents or the Building&#8217;s or Complex&#8217;s contribution towards a governmental or private cost-sharing agreement for the purpose of augmenting or improving the quality of services and amenities normally provided by governmental agencies.&nbsp;&nbsp;It is the intention of T</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1011"></a>enant and Landlord that all such new and increased assessments, taxes, fees, levies, and charges and all similar assessments, taxes, fees, levies and charges be included within the definition of Taxes for purposes of this Lease.&nbsp;&nbsp;</font><font style="font-weight:bold;">FOR PROPERTY TAX PURPOSES,</font><font style="font-weight:bold;"> TO THE EXTENT ALLOWED BY LAW, TENANT WAIVES ALL RIGHTS TO PROTEST OR APPEAL THE APPRAISED VALUE OF THE PREMISES, AS WELL AS THE PROJECT AND COMPLEX, AND ALL RIGHTS TO RECEIVE NOTICES OF REAPPRAISEMENT</font><font style="font-weight:bold;">.</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;Tenant shall reimburse Landlord, as Additional Rent,</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon demand for any and all taxes required to be paid by Landlord (except to the extent included in Taxes for the Complex by Landlord), excluding state, local and federal personal or corporate income taxes measured by the net income of Landlord from all s</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ources, capital stock, franchise and estate and inheritance taxes, whether or not now customary or within the contemplation of the parties hereto, when: (a) said taxes are measured by or reasonably attributable to the cost or value of Tenant&#8217;s equipment, f</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">urniture, fixtures and other personal property located in the Premises, or by the cost or value of any leasehold improvements made in or to the Premises by or for Tenant, including the Tenant Improvements, to the extent the cost or value of such leasehold </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">improvements exceeds the cost or value of a building standard build out as determined by Landlord regardless of whether title to such improvements shall be vested in Tenant or Landlord; (b) said taxes are assessed upon or with respect to the possession, le</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">asing, operation, management, maintenance, alteration, repair, use or occupancy by Tenant of the Premises or any portion of the Complex used by Tenant in connection with this Lease; or (c) said taxes are assessed upon this transaction or any document to wh</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ich Tenant is a party creating or transferring an interest or an estate in the Premises.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a><a name="_cp_text_1_1015"></a>4.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Insurance</font>.&nbsp;&nbsp;Tenant shall pay all Insurance for the Building, and Tenant&#8217;s Proportionate Share of Insurance for the Complex for each year and partial year falling within the Term.&nbsp;&nbsp;Tenant shall pay Tenant&#8217;s Proportionate Share of Insurance in the same manner as provided above for Tenant&#8217;s Proportionate Share of Common Area Maintenance Costs.&nbsp;&nbsp;&#8220;<font style="font-weight:bold;">Insurance</font>&#8221; shall mean property, liability and </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT C-3</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">other insurance coverages c</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1015"></a>arried by Landlord, including without limitation deductibles and risk retention programs and an allocation of a portion of the cost of blanket insurance policies maintained by Landlord and/or its affiliates</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, provided that such insurance deductibles or prem</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iums shall not be in excess of that incurred by comparable landlords for comparable buildings in the Project&#8217;s market area</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Common Area Maintenance, Tax and Insurance Statement</font>.&nbsp;&nbsp;By May&#160;1 of each calendar year, or as soon thereafter as practicable, Landlord shall furnish to Tenant a statement of Common Area Maintenance Costs, Taxes, and Insurance for the Building and the Complex for the previous year, adjusted as provided in <font style="text-decoration:underline;">Section&#160;6</font> of this Exhibit (the &#8220;<font style="font-weight:bold;">Common Area Maintenance, Tax and Insurance Statement</font>&#8221;).&nbsp;&nbsp;If Tenant&#8217;s estimated payments of Common Area Maintenance or Taxes or Insurance for the Building and the Complex under this <font style="text-decoration:underline;">Exhibit&#160;C</font> for the year covered by the Common Area Maintenance Costs, Tax and Insurance Statement exceed Tenant&#8217;s share of such items as indicated in the Common Area Maintenance, Tax and Insurance Statement, then Landlord shall promptly credit or reimburse Tenant for such excess; likewise, if Tenant&#8217;s estimated payments of Common Area Maintenance, Taxes and Insurance under this <font style="text-decoration:underline;">Exhibit&#160;C</font> for such year are less than Tenant&#8217;s share of such items as indicated in the Common Area Maintenance, Tax and Insurance Statement, then Tenant shall promptly pay Landlord such deficiency, notwithstanding that the Term has expired and Tenant has vacated the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref506182257"></a>6.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Gross-Up</font>.&nbsp;&nbsp;With respect to any calendar year or partial calendar year in which the Complex is not occupied to the extent of 95% of the rentable area thereof, or Landlord is not supplying services to 95% of the rentable area thereof, the portion of Common Area Maintenance Costs for the Complex for such period which vary by occupancy shall, for the purposes hereof, be increased to the amount which would have been incurred had the Complex been occupied to the extent of 95% of the rentable area thereof and Landlord had been supplying services to 95% of the rentable area thereof.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="ReviewPeriod"></a><a name="_cp_text_4_1025"></a><a name="_AEIOULastRenderedPageBreakAEIOU50"></a>7.<font style="margin-left:72pt;"></font><font style="font-weight:bold;text-decoration:underline;">Tenant&#8217;s Audit Right</font>.&nbsp;&nbsp;Upon Tenant&#8217;s written request given not more than ninety (90) days after Tenant&#8217;s receipt of the Common Area Maintenance, Tax and Insurance Statement, Landlord shall furnish Tenant with such reasonable supporting documentation in connection with said Common Area Maintenance Costs, Taxes and Insurance as Tenant may reasonably request.&nbsp;&nbsp;Landlord shall provide said information to Tenant within thirty<a name="ReviewPeriod"></a> (30) days after Tenant&#8217;s written request therefor.&nbsp;&nbsp;Within ninety (90) days after receipt of the Common Area Maintenance, Tax and Insurance Statement by Tenant (the &#8220;<font style="font-weight:bold;">Review Period</font>&#8221;), if Tenant disputes the amount of Additional Rent set forth in the Common Area Maintenance, Tax and Insurance Statement, an independent certified public accountant (which accountant (A) is a member of a nationally or regionally recognized accounting firm which has previous experience in reviewing financial operating records of landlords of comparable buildings, (B) shall not have provided primary accounting and/or lease administration services to Tenant in the past three (3) years, and (C) is not working on a contingency fee basis) designated and paid for by Tenant, may, after reasonable notice to Landlord and at reasonable times, inspect Landlord&#8217;s records with respect to the Common Area Maintenance, Tax and Insurance Statement at Landlord&#8217;s corporate offices, provided that Tenant is not in default under the Lease (subject to the applicable notice and cure periods).&nbsp;&nbsp;In connection with such inspection, Tenant and Tenant&#8217;s agents must agree in advance to abide by Landlord&#8217;s reasonable rules and procedures regarding such inspection, and shall execute a commercially reasonable confidentiality agreement regarding such inspection.&nbsp;&nbsp;Such inspection shall be completed in a timely manner but no later than thirty (30) days after the date Tenant&#8217;s accountant commences such inspection.&nbsp;&nbsp;Any audit report prepared by Tenant&#8217;s auditors shall be<a name="_cp_text_4_1025"></a> delivered concurrently to Landlord and Tenant within such thirty (30) day period.&nbsp;&nbsp;Tenant&#8217;s failure to dispute the amount of Additional Rent set forth in any Common Area Maintenance, Tax and Insurance Statement within the Review Period shall be deemed to be Tenant&#8217;s approval of such statement and Tenant, thereafter, waives the right or ability to dispute the amounts set forth in such statement.&nbsp;&nbsp;If after such inspection, Tenant still disputes such Additional Rent, a determination as to the proper amount may be made, at Tenant&#8217;s option and expense, by an independent certified public accountant who (x) is a member of a nationally or regionally recognized accounting firm which has previous experience in reviewing financial operating records of landlords of comparable buildings, (y) is not working </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT C-4</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">on a contingency fee basis and (z)&#160;shall be mutually selected by Landlord and Tenant (the &#8220;</font><font style="font-weight:bold;">Accountant</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;); provided that if such determination by the Accountant proves that Additional Rent for the applicable Expense Year were overstated by more than five percent (5%), then the cost of the Accountant and the cost of such determination shall be paid for by La</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ndlord.&nbsp;&nbsp;In addition, if such audit reveals that Landlord has over-charged Tenant, then within thirty (30) days after the results of such audit are made available to Landlord, Landlord shall reimburse to Tenant the amount of such over-charge.&nbsp;&nbsp;If the audit</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> reveals that the Tenant was under-charged, then within thirty (30) days after the results of such audit are made available to Tenant, Tenant shall reimburse to Landlord the amount of such under-charge.&nbsp;&nbsp;Tenant agrees that this </font><font style="text-decoration:underline;">Section&#160;7</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> shall be the sole </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">method to be used by Tenant to dispute the amount of any Common Area Maintenance Costs, Taxes and Insurance payable or not payable by Tenant pursuant to the terms of the Lease, and Tenant hereby waives any other rights at law or in equity relating thereto.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT C-5</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT D</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">TENANT WORK LETTER</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_367"></a>This Work Letter (this &#8220;<font style="font-weight:bold;">Work Letter</font><a name="_cp_text_1_367"></a>&#8221;) shall set forth the terms and conditions relating to the construction of Tenant Improvements (as defined hereinafter) on the Premises.&nbsp;&nbsp;All references in this Work Letter to the &#8220;<font style="font-weight:bold;">Lease</font>&#8221; shall mean the relevant portions of the Lease to which this Work Letter is attached as <font style="text-decoration:underline;">Exhibit&#160;D</font>.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">section 1<br /><br />BASE, SHELL AND CORE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1035"></a><a name="_cp_text_1_1036"></a><a name="_cp_text_1_1037"></a>Tenant hereby accepts the base, shell and core (i) of the Premises and (ii) of the floor(s) of the Building on which the Premises are located (collectively, the &#8220;<font style="font-weight:bold;">Base, Shell and Core</font><a name="_cp_text_1_1035"></a>&#8221;), in its current &#8220;AS IS<a name="_cp_text_1_1036"></a>&#8221; condition (except as otherwise expressly set forth in this Lease) existing as of the date of the Lease and the Commencement Date.&nbsp;&nbsp;Except for the Tenant Improvement Allowance, the Additional Tenant Improvement Allowance, the Roof Allowance and the HVAC Allowance set forth below, Landlord shall not be obligated to make or pay for any alterations or improvements to the P<a name="_cp_text_1_1037"></a>remises, the Building or the Complex except as otherwise expressly set forth in the Lease.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">section 2<br /><br />TENANT IMPROVEMENTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1042"></a><a name="_cp_text_1_1044"></a><a name="_cp_text_1_1046"></a><a name="_cp_text_1_1047"></a><font style="text-decoration:none;">2.1</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Tenant Improvement Allowance</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;<a name="_cp_text_1_1042"></a>Tenant shall be entitled to a one time tenant improvement allowance (the &#8220;</font><font style="text-decoration:none;">Tenant Improvement Allowance</font><font style="font-weight:normal;text-decoration:none;">&#8221;) in the amount of up to, but not exceeding Sixty Dollars ($60.00) per rentable square foot of the Premises (i.e., up to Five Million Two Hundred Sixty-One Thousand Seven Hundred Dollars ($5,261,700.00), for the costs relating to the initial design and construction<a name="_cp_text_1_1044"></a> of Tenant&#8217;s Improvements (as hereinafter defined) which will be <a name="_cp_text_1_1046"></a>permanently affixed to the Premises.&nbsp;&nbsp;The &#8220;</font><font style="text-decoration:none;">Tenant Improvements</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1047"></a>&#8221; shall mean the scope of such work as set forth in the Approved Working Drawings (as defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 3.4</font><font style="font-weight:normal;text-decoration:none;"> below); provided, however, that Landlord shall have no obligation to disburse (a)&#160;all or any portion of the Tenant Improvement Allowance (or the Additional Tenant Improvement Allowance, as such term is defined below) to Tenant unless Tenant makes a request for disbursement pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2</font><font style="font-weight:normal;text-decoration:none;"> below prior to that date which is nine (9) months after the Commencement Date, or (b)&#160;all or any portion of the HVAC Allowance or the Roof Allowance (as such terms are defined below) to Tenant unless Tenant makes a request for disbursement pursuant to the terms and conditions of </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.3</font><font style="font-weight:normal;text-decoration:none;"> below prior to that date which is nine (9) months after the Commencement Date.&nbsp;&nbsp;In no event shall Landlord be obligated to make disbursements pursuant to this Work Letter in a total amount which exceeds the Tenant Improvement Allowance, the Additional Tenant Improvement Allowance, the Roof Allowance and the HVAC Allowance.&nbsp;&nbsp;Tenant shall not be entitled to receive any cash payment or credit against Rent or otherwise for any unused portion of the Tenant Improvement Allowance (or the Additional Tenant Improvement Allowance) which is not used to pay for the Tenant Improvement Allowance Items (as such term is defined below). </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a><font style="text-decoration:none;">2.1.1</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="font-weight:normal;text-decoration:none;">Concurrent with Tenant&#8217;s execution of this Lease, Tenant shall deposit with an escrow company (&#8220;</font><font style="text-decoration:none;">Escrowee</font><font style="font-weight:normal;text-decoration:none;">&#8221;) mutually selected by Landlord and Tenant an amount equal to One Hundred Dollars ($100.00) per rentable square foot of the Premises (i.e., Eight Million Seven Hundred Sixty-Nine Thousand Five Hundred Dollars ($8,769,500.00) (&#8220;</font><font style="text-decoration:none;">Tenant Contribution</font><font style="font-weight:normal;text-decoration:none;">&#8221;) toward the cost of the Tenant Improvements Allowance Items (as hereinafter defined).&nbsp;&nbsp;Tenant must fulfill the terms and conditions of an &#8220;</font><font style="text-decoration:none;">Escrow Agreement</font><font style="font-weight:normal;text-decoration:none;">&#8221; to be entered into by and among Landlord, Tenant and Escrowee in order to </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">receive any disbursements of the Tenant Contribution which shall be made pursuant to the Escrow Agreement.&nbsp;&nbsp;The form of the Escrow Agreement is attached hereto as </font><font style="text-decoration:underline;font-weight:normal;">Exhibit N</font><font style="font-weight:normal;text-decoration:none;"> and made a part hereof.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1067"></a>Following (i)&#160;disbursement of the full amount of the Tenant Improvement Allowance pursuant to the terms set forth in <font style="text-decoration:underline;">Section 2.2</font> below, and (ii)&#160;the disbursement of the Tenant Contribution pursuant to the terms of the Escrow Agreement, and provided that Tenant is faithfully complying with all terms of the Lease, Tenant may, upon written notice to Landlord, elect to amortize an additional tenant improvement allowance in the amount up to, but not exceeding, Eighty-Five Dollars ($85.00) per rentable square foot of the Premises (<font style="font-style:italic;">i.e.</font>, up to Seven Million Four Hundred Fifty-Four Thousand and Seventy-Five Dollars ($7,454,075)) for additional costs of the Tenant Improvements (the &#8220;<font style="font-weight:bold;">Additional Tenant Improvement Allowance</font>&#8221;), as additional Base Rent to be paid by Tenant to Landlord, which shall be amortized on a straight-line basis over the initial Term of the Lease, together with interest at a rate of eight percent (8%) per annum, and which shall be paid by Tenant to Landlord concurrently with monthly Base Rent as set forth in <font style="text-decoration:underline;">Section 4(a)</font> of the Lease.  Disbursement of the Additional Tenant Improvement Allowance shall be pursuant to the procedures set forth in <font style="text-decoration:underline;">Section 2.2</font><a name="_cp_text_1_1067"></a> below and subject to all other terms of this Tenant Work Letter.&nbsp;&nbsp;Landlord shall send to Tenant a confirmation of the amount of Additional Tenant Improvement Allowance elected to be used by Tenant and the modified Base Rent schedule as a result thereof, which confirmation Tenant shall acknowledge by executing a copy of the confirmation and returning it to Landlord.&nbsp;&nbsp;If Landlord fails to sign and return the confirmation to Landlord within ten (10) days of receipt thereof from Landlord, the confirmation as sent by Landlord shall be deemed to have correctly set forth the modified Base Rent schedule.&nbsp;&nbsp;Failure of Landlord to send such confirmation shall have no effect on the modified Base Rent schedule.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.1.2</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="font-weight:normal;text-decoration:none;">In addition to the Tenant Improvement Allowance, Tenant shall be entitled to a one-time HVAC allowance (the &#8220;</font><font style="text-decoration:none;">HVAC Allowance</font><font style="font-weight:normal;text-decoration:none;">&#8221;) in the amount of up to, but not exceeding $1,005,095.00, for the costs exclusively relating to Tenant&#8217;s purchase and installation of HVAC equipment within the Premises (&#8220;</font><font style="text-decoration:none;">HVAC Work</font><font style="font-weight:normal;text-decoration:none;">&#8221;).&nbsp;&nbsp;Disbursement of the HVAC Allowance shall be pursuant to the procedures set forth in </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.3</font><font style="font-weight:normal;text-decoration:none;"> below and subject to all other terms of this Tenant Work Letter.&nbsp;&nbsp;Tenant shall not be entitled to receive any cash payment or credit against Rent or otherwise for any unused portion of the HVAC Allowance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.1.3</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="font-weight:normal;text-decoration:none;">In addition to the foregoing, Tenant shall be entitled to a one-time roof allowance (the &#8220;</font><font style="text-decoration:none;">Roof Allowance</font><font style="font-weight:normal;text-decoration:none;">&#8221;) in the amount of $250,000.00 for the costs exclusively relating to Tenant&#8217;s repair of the roof of the Building (&#8220;</font><font style="text-decoration:none;">Roof Work</font><font style="font-weight:normal;text-decoration:none;">&#8221;).&nbsp;&nbsp;Disbursement of the Roof Allowance shall be pursuant to the procedures set forth in </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.3</font><font style="font-weight:normal;text-decoration:none;"> below and subject to all other terms of this Tenant Work Letter.&nbsp;&nbsp;Tenant shall not be entitled to receive any cash payment or credit against Rent or otherwise for any unused portion of the Roof Allowance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Disbursement of the Tenant Improvement Allowance</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Tenant Improvement Allowance Items</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Except as otherwise set forth in this Work Letter, the Tenant Improvement Allowance shall be disbursed by Landlord only for the following items and costs (collectively, the &#8220;</font><font style="text-decoration:none;">Tenant Improvement Allowance Items</font><font style="font-weight:normal;text-decoration:none;">&#8221;):</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.1</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">payment of the fees of the &#8220;</font><font style="text-decoration:none;">Architect</font><font style="font-weight:normal;text-decoration:none;">&#8221; and the &#8220;</font><font style="text-decoration:none;">Engineers</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as those terms are defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 3.1</font><font style="font-weight:normal;text-decoration:none;"> of this Work Letter, and payment of the fees incurred by, and the cost of documents and materials supplied by, Landlord and Landlord&#8217;s consultants in connection with the preparation and review of the &#8220;</font><font style="text-decoration:none;">Construction Drawings</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 3.1</font><font style="font-weight:normal;text-decoration:none;"> of this Work Letter;</font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU53"></a><font style="text-decoration:none;">2.2.1.2</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">the payment of plan check, permit and license fees relating to construction of the Tenant Improvements;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1079"></a><a name="_cp_text_1_1080"></a><a name="_cp_text_1_1081"></a><font style="text-decoration:none;">2.2.1.3</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">the cost of construction of the Tenant Improve<a name="_cp_text_1_1079"></a>ments, including, without limitation, costs and expense for labor, material, equipment and fixtures, <a name="_cp_text_1_1080"></a>contractors&#8217; fees and general conditions, testing and inspection costs, costs of utilities, trash removal, parking and hoists, any other services provided by third parties unaffiliated with Tenant in connection with the construction, <a name="_cp_text_1_1081"></a>and the costs of after-hours freight elevator usage (provided that there will be no extra charge for after-hours freight elevator usage);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.4</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">the cost of any changes in the Base, Shell and Core work when such changes are required by the Construction Drawings (including if such changes are due to the fact that such work is prepared on an unoccupied basis), such cost to include all direct architectural and/or engineering fees and expenses incurred in connection therewith;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.5</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">the cost of any changes to the Construction Drawings or Tenant Improvements required by applicable laws;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.6</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">sales and use taxes and Title 24 fees;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.7</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">the &#8220;</font><font style="text-decoration:none;">Coordination Fee</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.2.2</font><font style="font-weight:normal;text-decoration:none;"> of this Work Letter; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.1.8</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="font-weight:normal;text-decoration:none;">all other costs to be expended by Tenant in connection with the construction of the Tenant Improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.2</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Disbursement of Tenant Improvement Allowance</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Subject to </font><font style="text-decoration:underline;font-weight:normal;">Section 2.1</font><font style="font-weight:normal;text-decoration:none;"> above, during the construction of the Tenant Improvements, Landlord shall make monthly disbursements of the Tenant Improvement Allowance for Tenant Improvement Allowance Items for the benefit of Tenant and shall authorize the release of monies for the benefit of Tenant as follows:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><font style="text-decoration:none;">2.2.2.1</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Monthly Disbursements</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;On or before the last day of each calendar month during the construction of the Tenant Improvements (or such other date as Landlord may designate), Tenant shall deliver to Landlord:&nbsp;&nbsp;(i)&#160;a request for payment of the &#8220;</font><font style="text-decoration:none;">Contractor</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 4.1</font><font style="font-weight:normal;text-decoration:none;"> below, approved by Tenant, in a reasonable form to be provided by Landlord, showing the schedule, by trade, of percentage of completion of the Tenant Improvements in the Premises, detailing the portion of the work completed and the portion not completed, and demonstrating that the relationship between the cost of the work completed and the cost of the work to be completed complies with the terms of the &#8220;</font><font style="text-decoration:none;">Final Costs Statement</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.1</font><font style="font-weight:normal;text-decoration:none;"> below; (ii)&#160;invoices from all of &#8220;</font><font style="text-decoration:none;">Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 4.1.2</font><font style="font-weight:normal;text-decoration:none;"> below, for labor rendered and materials delivered to the Premises; (iii)&#160;executed mechanic&#8217;s lien releases from all of Tenant&#8217;s Agents which shall comply with the appropriate provisions, as reasonably determined by Landlord, of California Civil Code Section 8122 et seq.; and (iv)&#160;all other information reasonably requested by Landlord.&nbsp;&nbsp;Tenant&#8217;s request for payment shall be deemed Tenant&#8217;s acceptance and approval of the work furnished and/or the materials supplied as set forth in Tenant&#8217;s payment request.&nbsp;&nbsp;On or before the last day of the following calendar month, Landlord shall deliver a check to Tenant made payable to Tenant in payment of the lesser of (A) the amounts so requested by Tenant, as set forth in this </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.2.1</font><font style="font-weight:normal;text-decoration:none;">, above, less a ten percent (10%) retention (the aggregate amount of such retentions to be known as the &#8220;</font><font style="text-decoration:none;">Final Retention</font><font style="font-weight:normal;text-decoration:none;">&#8221;) and (B) the balance of any remaining available portion of the Tenant Improvement Allowance (not including the Final Retention), provided that Landlord does not dispute any request for payment based on non&#8209;compliance of any work with the &#8220;</font><font style="text-decoration:none;">Approved Working Drawings</font><font style="font-weight:normal;text-decoration:none;">&#8221;, as that term is defined in </font><font style="text-decoration:underline;font-weight:normal;">Section 3.4</font><font style="font-weight:normal;text-decoration:none;"> below.&nbsp;&nbsp;Landlord&#8217;s </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-3</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">payment of such amounts shall not be deemed Landlord&#8217;s approval or acceptance of the work furn</font><font style="font-weight:normal;text-decoration:none;">ished or materials supplied as set forth in Tenant&#8217;s payment request.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.2.2</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Final Retention</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Subject to the provisions of this Work Letter, a check for the Final Retention payable to Tenant shall be delivered by Landlord to Tenant promptly following the completion of construction of the Premises, provided that (i)&#160;Tenant delivers to Landlord properly executed mechanics lien releases in compliance with both California Civil Code Section 8134 and either Section 8136 or Section 8138 and any successor statutes, and (ii)&#160;Landlord has reasonably determined that no substandard work exists which adversely affects the mechanical, electrical, plumbing, heating, ventilating and air conditioning, life safety or other systems of the Building, the curtain wall of the Building, or the structure or exterior appearance of the Building.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.2.3</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Other Terms</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Landlord shall only be obligated to make disbursements from the Tenant Improvement Allowance to the extent costs are incurred by Tenant for Tenant Improvement Allowance Items.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">2.2.3</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Disbursement of HVAC Allowance and Roof Allowance</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Landlord shall make monthly disbursements of the HVAC Allowance for the HVAC Work and Roof Allowance for the Roof Work and shall authorize the release of monies for the benefit of Tenant as follows:&nbsp;&nbsp;On or before the last day of each calendar month during the HVAC Work and/or the Roof Work, as applicable, Tenant shall deliver to Landlord:&nbsp;&nbsp;(i)&#160;invoices from contractors or subcontractors retained by Tenant in connection with the HVAC Work or the Roof Work; (ii)&#160;executed mechanic&#8217;s lien releases from all of Tenant&#8217;s Agents which shall comply with the appropriate provisions, as reasonably determined by Landlord, of California Civil Code Section 8122 et seq.; and (iii)&#160;all other information reasonably requested by Landlord.&nbsp;&nbsp;Tenant&#8217;s request for payment shall be deemed Tenant&#8217;s acceptance and approval of the work furnished and/or the materials supplied as set forth in Tenant&#8217;s payment request.&nbsp;&nbsp;On or before the last day of the following calendar month, Landlord shall deliver a check to Tenant made payable to Tenant in the amounts so requested by Tenant above, less the Final Retention, which Final Retention shall be paid by Landlord to Tenant following the completion of the HVAC Work and the Roof Work provided that (x)&#160;Tenant delivers to Landlord properly executed mechanics&#8217; lien releases in compliance with both California Civil Code Section 8134 and either Section 8136 or 8138 and any successor statutes, and (y)&#160;Landlord has reasonably determined that no substandard work exists which adversely affects the Building&#8217;s Structure or the Building&#8217;s Systems.&nbsp;&nbsp;Landlord&#8217;s payment of such amounts shall not be deemed Landlord&#8217;s approval or acceptance of the work furnished or materials supplied as set forth in Tenant&#8217;s payment request.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">section 3<br /><br />CONSTRUCTION DRAWINGS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1118"></a><a name="_cp_text_1_1119"></a><a name="_cp_text_1_1122"></a><a name="_AEIOULastRenderedPageBreakAEIOU55"></a><font style="text-decoration:none;">3.1</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Selection of Architect/Construction Drawings</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant shall retain the architect/space planner (the &#8220;</font><font style="text-decoration:none;">Architect</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1118"></a>&#8221;) approved by Landlord, which approval shall not be unreasonably withheld and shall be granted or denied within three (3) Business Days upon request<a name="_cp_text_1_1119"></a>, to prepare the Construction Drawings.&nbsp;&nbsp;Landlord&#8217;s failure to respond within such three (3) Business Day period shall be deemed approval by Landlord.&nbsp;&nbsp;Tenant shall retain the engineering consultants (the &#8220;</font><font style="text-decoration:none;">Engineers</font><font style="font-weight:normal;text-decoration:none;">&#8221;) approved by Landlord, which approval shall not be unreasonably withheld and shall be granted or denied within three (3) Business Days upon request, to prepare all plans and engineering working drawings relating to the structural, mechanical, electrical, plumbing, HVAC, life safety, and sprinkler work in the Premises.&nbsp;&nbsp;Landlord&#8217;s failure to respond within such three (3) Business Day period shall be deemed approval by Landlord.&nbsp;&nbsp;The plans and drawings to be prepared by Architect and the Engineers hereunder shall be known collectively as the &#8220;</font><font style="text-decoration:none;">Construction Drawings</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1122"></a>&#8221;.&nbsp;&nbsp;All Construction Drawings shall comply with the drawing format and specifications reasonably determined by Landlord, and shall be subject to Landlord&#8217;s approval </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-4</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">within five (5) Business Days after delivery</font><font style="font-weight:normal;text-decoration:none;"> to Landlord.&nbsp;&nbsp;In the event Landlord fails to respond within such five (5) Business Day period, Tenant shall send a reminder notice to Landlord and Landlord&#8217;s failure to respond to the reminder notice within two (2) Business Days after receipt thereof shal</font><font style="font-weight:normal;text-decoration:none;">l be deemed approval by Landlord.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">Tenant and Architect shall verify, in the field, the dimensions and conditions as shown on the relevant portions of the base building plans, and Tenant and Architect shall be solely responsible for the same, and Landlord </font><font style="font-weight:normal;text-decoration:none;">shall have no responsibility in connection therewith.&nbsp;&nbsp;Landlord&#8217;s review of the Construction Drawings as set forth in this </font><font style="text-decoration:underline;font-weight:normal;">Section&#160;3</font><font style="font-weight:normal;text-decoration:none;">, shall be for its sole purpose and shall not imply Landlord&#8217;s review of the same, or obligate Landlord to review the same, </font><font style="font-weight:normal;text-decoration:none;">for quality, design, Code compliance or other like matters.&nbsp;&nbsp;Accordingly, notwithstanding that any Construction Drawings are reviewed by Landlord or its space planner, architect, engineers and consultants, and notwithstanding any advice or assistance which</font><font style="font-weight:normal;text-decoration:none;"> may be rendered to Tenant by Landlord or Landlord&#8217;s space planner, architect, engineers, and consultants, Landlord shall have no liability whatsoever in connection therewith and shall not be responsible for any omissions or errors contained in the Constru</font><font style="font-weight:normal;text-decoration:none;">ction Drawings</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1125"></a><a name="_cp_text_1_1127"></a><a name="_cp_text_1_1128"></a><font style="text-decoration:none;">3.2</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Final Space Plan</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant shall supply Landlord with four (4) copies signed by Tenant of its final space plan for the Premises before any architectural working drawings or engineering drawings have been commenced.&nbsp;&nbsp;The final space plan (the &#8220;</font><font style="text-decoration:none;">Final Space Plan</font><font style="font-weight:normal;text-decoration:none;">&#8221;) shall include a layout and designation of all offices, rooms and other partitioning, their intended use, and equipment to be contained therein.&nbsp;&nbsp;Landlord may request clarification or more specific drawings for special use items not inc<a name="_cp_text_1_1125"></a>luded in the Final Space Plan.&nbsp;&nbsp;Landlord shall reasonably <a name="_cp_text_1_1127"></a>advise Tenant within five (5) Business Days <a name="_cp_text_1_1128"></a>after Landlord&#8217;s receipt of the Final Space Plan for the Premises if the same is unsatisfactory or incomplete in any respect and the manner in which the Final Space Plan is unsatisfactory or incomplete.&nbsp;&nbsp;If Tenant is so advised, Tenant shall promptly (i) cause the Final Space Plan to be revised to correct any deficiencies or other matters Landlord may reasonably require, and (ii) deliver such revised Final Space Plan to Landlord.&nbsp;&nbsp;In the event Landlord fails to respond within such five (5) Business Day period, Tenant shall send a reminder notice to Landlord and Landlord&#8217;s failure to respond to the reminder notice within two (2) Business Days after receipt thereof shall be deemed approval by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1132"></a><a name="_cp_text_1_1134"></a><a name="_cp_text_1_1135"></a><font style="text-decoration:none;">3.3</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Final Working Drawings</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;After the Final Space Plan has been approved by Landlord and Tenant, Tenant shall promptly cause the Architect and the Engineers to complete the architectural and engineering drawings for the Premises, and cause the Architect to compile a fully coordinated set of architectural, structural, mechanical, electrical and plumbing working drawings in a form which is complete to allow subcontractors to bid on the work and to obtain all applicable permits for the Tenant Improvements (collectively, the &#8220;</font><font style="text-decoration:none;">Final Working Drawings</font><font style="font-weight:normal;text-decoration:none;">&#8221;), and shall submit the same to Landlord for Landlord&#8217;s approval.&nbsp;&nbsp;Tenant shall supply Landlord with four (4) copies signed by Tenant of such Final Working Drawings.&nbsp;&nbsp;Landlord <a name="_cp_text_1_1132"></a>shall reasonably <a name="_cp_text_1_1134"></a>advise Tenant within five (5) Business Days <a name="_cp_text_1_1135"></a>after Landlord&#8217;s receipt of the Final Working Drawings for the Premises if the same is unsatisfactory or incomplete in any respect and the manner in which the Final Working Drawings is unsatisfactory or incomplete.&nbsp;&nbsp;If Tenant is so advised, Tenant shall promptly (i) revise the Final Working Drawings in accordance with such review and any disapproval of Landlord in connection therewith, and (ii) deliver such revised Final Working Drawings to Landlord.&nbsp;&nbsp;In the event Landlord fails to respond within such five (5) Business Day period, Tenant shall send a reminder notice to Landlord and Landlord&#8217;s failure to respond to the reminder notice within two (2) Business Days after receipt thereof shall be deemed approval by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1139"></a><a name="_cp_text_1_1141"></a><a name="_cp_text_1_1144"></a><a name="_AEIOULastRenderedPageBreakAEIOU56"></a><a name="_cp_text_1_1145"></a><a name="_cp_text_2_1146"></a><a name="_cp_text_1_1147"></a><a name="_cp_text_1_1148"></a><font style="text-decoration:none;">3.4</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Approved Working Drawings</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;<a name="_cp_text_1_1139"></a>The Final Working Drawings shall be approved by Landlord in accordance with </font><font style="text-decoration:underline;font-weight:normal;">Section 3.3</font><font style="font-weight:normal;text-decoration:none;"> above (the &#8220;</font><font style="text-decoration:none;">Approved Working Drawings</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1141"></a>&#8221;) prior to the commencement of construction of the Tenant Improvements by Tenant.&nbsp;&nbsp;After approval by Landlord of the Final Working Drawings, Tenant shall promptly submit the same to the appropriate governmental authorities for all applicable building permits.&nbsp;&nbsp;Tenant hereby agrees that neither Landlord nor Landlord&#8217;s consultants sha<a name="_cp_text_1_1144"></a>ll be responsible for obtaining any building permit or certificate of occupancy for the Tenant Improvements and that obtaining the same shall be Tenant&#8217;s responsibility; provided, however, that </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-5</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">Landlord shall cooperate with Tenant in executing permit appli</font><font style="font-weight:normal;text-decoration:none;">cations and performing other ministerial acts reasonably necessary to enable Tenant to obtain any such permit or certificate of occupancy.&nbsp;&nbsp;No changes, modifications or alterations in the Approved Working Drawings may be made without the prior written cons</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1145"></a>ent of Landlord, which consent shall not be unreasonably withheld</font><font style="font-weight:normal;text-decoration:none;">, conditioned, or delayed</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_2_1146"></a>; provided that Landlord may withhold its consent, in its sole discretion, to any change in the Approved Working Drawings, if such change would result in an</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1147"></a> </font><font style="font-weight:normal;text-decoration:none;">Over Allo</font><font style="font-weight:normal;text-decoration:none;">wance Amount </font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1148"></a>(as defined below)</font><font style="font-weight:normal;text-decoration:none;">, and Tenant does not agree in writing to pay such Over Allowance Amount</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_4_1151"></a><a name="_cp_text_1_1152"></a><font style="text-decoration:none;">3.5</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Changes to the Approved Working Drawings</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Any changes to the Approved Working Drawings (each, a &#8220;</font><font style="text-decoration:none;">Change</font><font style="font-weight:normal;text-decoration:none;">&#8221;) shall be requested and instituted in accorda<a name="_cp_text_4_1151"></a>nce with the provisions of this </font><font style="text-decoration:underline;font-weight:normal;"><a name="_cp_text_1_1152"></a>Section 3.5</font><font style="font-weight:normal;text-decoration:none;"> and shall be subject to the written approval of the non-requesting party in accordance with this Work Letter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">3.5.1</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Change Request</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Either Landlord or Tenant may request Changes after Landlord approves the Final Working Drawings by notifying the other party thereof in writing in substantially the same form as the AIA standard change order form (a &#8220;</font><font style="text-decoration:none;">Change Request</font><font style="font-weight:normal;text-decoration:none;">&#8221;), which Change Request shall detail the nature and extent of any requested Changes and any modification of the Approved Working Drawings, as applicable, necessitated by the Change.&nbsp;&nbsp;If the nature of a Change requires revisions to the Approved Working Drawings, then the requesting party shall be solely responsible for the cost and expense of such revisions and any increases in the cost of the Tenant Improvements as a result of such Change.&nbsp;&nbsp;Change Requests shall be signed by the requesting party&#8217;s representative as set forth in </font><font style="text-decoration:underline;font-weight:normal;">Sections 5.1 and 5.2</font><font style="font-weight:normal;text-decoration:none;"> herein.&nbsp;&nbsp;Landlord shall only request a Change if it reasonably believes that such Change is necessary to comply with applicable Laws or to prevent a material adverse impact on the Building&#8217;s Systems; provided, however, that Landlord shall not be responsible for the cost and expense of such revision and/or any increase in the cost of the Tenant Improvements as a result of such Change.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_4_1156"></a><a name="_cp_text_1_1157"></a><a name="_cp_text_4_1158"></a><font style="text-decoration:none;">3.5.2</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Approval of Changes</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_4_1156"></a>.&nbsp;&nbsp;All Change Requests <a name="_cp_text_1_1157"></a>shall be subject to the <a name="_cp_text_4_1158"></a>other party&#8217;s prior written approval, which approval shall not be unreasonably withheld, conditioned or delayed.&nbsp;&nbsp;The non-requesting party shall have three (3) Business Days after receipt of a Change Request to notify the requesting party in writing of the non-requesting party&#8217;s decision either to approve or object to the Change Request.&nbsp;&nbsp;If the non-requesting party fails to respond within such three (3) Business Day period, the requesting party shall send a reminder notice and the non-requesting party&#8217;s failure to respond to the reminder notice within two (2) Business Days after receipt thereof shall be deemed approval by the non-requesting party.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">section 4<br /><br />CONSTRUCTION OF THE TENANT IMPROVEMENTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.1</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Selection of Contractor and Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.1.1</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">The Contractor</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;A general contractor shall be retained by Tenant to construct the Tenant Improvements.&nbsp;&nbsp;Such general contractor (&#8220;</font><font style="text-decoration:none;">Contractor</font><font style="font-weight:normal;text-decoration:none;">&#8221;) shall be subject to Landlord&#8217;s approval, which approval shall not be unreasonably withheld and shall be granted or denied within three (3) Business Days upon request.&nbsp;&nbsp;Landlord&#8217;s failure to respond within such three (3) Business Day period shall be deemed approval by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1169"></a><a name="_cp_text_1_1171"></a><a name="_cp_text_1_1173"></a><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><a name="_cp_text_1_1175"></a><font style="text-decoration:none;">4.1.2</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1169"></a>.&nbsp;&nbsp;A list of all subcontractors, laborers, materialmen, and suppliers used by Tenant (such subcontractors, laborers, materialmen, and suppliers, and the Contractor to be known collectively as &#8220;</font><font style="text-decoration:none;">Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1171"></a>&#8221;) must be provided to the <a name="_cp_text_1_1173"></a>Landlord, which Tenant&#8217;s Agents shall all be licensed, in good standing and have a first-class reputation in their respective area of expertise.&nbsp;&nbsp;In any </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-6</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">event, Tenant must contract with Landlord&#8217;s base building subcontractors for</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1175"></a> any mechanical, electrical, plumbing, life safety, structural, heating, ventilation, and </font><font style="font-weight:normal;text-decoration:none;">air conditioning </font><font style="font-weight:normal;text-decoration:none;">work in the Premises.&nbsp;&nbsp;Tenant&#8217;s Agents shall all be union labor in compliance with the master labor agreements existing between trade unions and the </font><font style="font-weight:normal;text-decoration:none;">local chapter of the Associated General Contractors of America</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Construction of Tenant Improvements by Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_4_1191"></a><a name="_cp_text_1_1192"></a><a name="_cp_text_4_1193"></a><font style="text-decoration:none;">4.2.1</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Cost Budget</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Prior to the commencement of the construction of the Tenant Improvements, and after Tenant has accepted all bids for the Tenant Improvements, Tenant shall provide Landlord with a written detailed cost breakdown (the &#8220;</font><font style="text-decoration:none;">Final Costs Statement</font><font style="font-weight:normal;text-decoration:none;">&#8221;), by trade, of the final costs to be incurred, or which have been incurred, as set forth more particularly in </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.1.1</font><font style="font-weight:normal;text-decoration:none;"> through </font><font style="text-decoration:underline;font-weight:normal;">2.2.1.8</font><font style="font-weight:normal;text-decoration:none;"> above, in connection with the design and construction of the Tenant Improvements to be performed by or at the direction of Tenant or the Contractor (which costs form a basis for the amount of the construction contract with the Contractor, if any (the &#8220;</font><font style="text-decoration:none;">Final Costs</font><font style="font-weight:normal;text-decoration:none;">&#8221;).&nbsp;&nbsp;Tenant shall be responsible for all the Final Costs, and Tenant shall pay all such costs directly to the Contractor or other party requesting payment as and when due, provided that nothing contained in this sentence shall be construed to wa<a name="_cp_text_4_1191"></a>ive Tenant&#8217;s right to receive the Tenant Improvement Allowance, the Additional Tenant Improvement Allowance, the HVAC Allowance or the Roof Allowance.&nbsp;&nbsp;In addition, to the extent the Final Costs <a name="_cp_text_1_1192"></a>exceed the Tenant Improvement Allowance and the Additional Tenant Improvement Allowance (&#8220;</font><font style="text-decoration:none;">Over Allowance Amount</font><font style="font-weight:normal;text-decoration:none;">&#8221;), Tenant shall pay, concurrently with each disbursement by Landlord pursuant to </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.2</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_4_1193"></a>, a pari passu portion of the Tenant Improvement costs subject to such request, equal to the ratio obtained by dividing the Over Allowance Amount by the Final Costs (&#8220;</font><font style="text-decoration:none;">Pro Rata Share</font><font style="font-weight:normal;text-decoration:none;">&#8221;), multiplied by portion of the Tenant Improvement costs subject to such request. For purposes of illustration only, if the Final Costs are $500,000, the total allowance payable by Landlord (i.e., the Tenant Improvement Allowance and the Additional Tenant Improvement Allowance) is $250,000, and the applicable bills and invoices submitted to Landlord for a disbursement pursuant to </font><font style="text-decoration:underline;font-weight:normal;">Section 2.2.2</font><font style="font-weight:normal;text-decoration:none;"> is $100,000, Landlord would disburse $50,000 ($250,000/$500,000 x $100,000), and Tenant would pay the remaining $50,000.&nbsp;&nbsp;In the event that, after the Final Costs have been delivered by Landlord to Tenant, the costs relating to the design and construction of the Tenant Improvements shall change, any additional costs necessary to such design and construction in excess of the Final Costs shall, to the extent they exceed the remaining balance of the Tenant Improvement Allowance, be paid by Tenant to Landlord in the same method as the payment by Tenant of the Over-Allowance Amount set forth herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2.2</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Tenant&#8217;s Agents</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1202"></a><a name="_cp_text_1_1203"></a><a name="_cp_text_1_1205"></a><a name="_cp_text_1_1206"></a><a name="_cp_text_1_1207"></a><a name="_cp_text_1_1208"></a><font style="text-decoration:none;">4.2.2.1</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Landlord&#8217;s General Conditions for Tenant&#8217;s Agents and Tenant Improvement Work</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant&#8217;s and Tenant&#8217;s Agents&#8217; construction of the Tenant Improvements shall comply with the following:&nbsp;&nbsp;(i) the T<a name="_cp_text_1_1202"></a>enant Improvements shall be constructed in strict accordance with the Approved Working Drawings; (ii) Tenant&#8217;s Agents shall submit schedules of all work relating to the Tenant&#8217;s Improvements to Contractor and Contractor shall, within five (5) Business Days <a name="_cp_text_1_1203"></a>of receipt thereof, inform Tenant&#8217;s Agents of any changes which are necessary thereto, and Tenant&#8217;s Agents shall use commercially reasonable efforts to <a name="_cp_text_1_1205"></a>adhere to such corrected schedule; and (iii<a name="_cp_text_1_1206"></a>) Tenant shall abide by all reasonable <a name="_cp_text_1_1207"></a>rules made and provided to Tenant in writing <a name="_cp_text_1_1208"></a>by Landlord&#8217;s Building contractor or Landlord&#8217;s Building manager with respect to the use of freight, loading dock and service elevators (provided that such rules shall not include additional charge for the use of freight, loading dock and service elevators or storage of materials), storage of materials, coordination of work with the contractors of other tenants, and any other matter in connection with this Work Letter, including, without limitation, the construction of the Tenant Improvements.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="text-decoration:none;">4.2.2.2</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Coordination Fee</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant shall pay a logistical coordination fee (the &#8220;</font><font style="text-decoration:none;">Coordination Fee</font><font style="font-weight:normal;text-decoration:none;">&#8221;) to Landlord in an amount equal to the product of (i)&#160;one percent (1%), and (ii)&#160;the </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-7</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">sum of the Tenant Improvement Allowance, the Over Allowance Amount, as</font><font style="font-weight:normal;text-decoration:none;"> such amount may be increased hereunder, and any other amounts expended by Tenant in connection with the design and construction of the Tenant Improvements, which Coordination Fee shall be for services relating to the coordination of the construction of th</font><font style="font-weight:normal;text-decoration:none;">e Tenant Improvements.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;">In addition to the Coordination Fee and other amounts payable by Tenant hereunder, Tenant shall reimburse Landlord for reasonable amounts paid by Landlord in connection with the review of Tenant&#8217;s plans and drawings as referenced in</font><font style="font-weight:normal;text-decoration:none;"> </font><font style="font-weight:normal;text-decoration:underline;">Section&#160;3</font><font style="font-weight:normal;text-decoration:none;"> above, which amounts shall be charged against the Tenant Improvement Allowance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1216"></a><font style="text-decoration:none;">4.2.2.3</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Indemnity</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant&#8217;s indemnity of Landlord as set forth in the Lease shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to any act or omission of Tenant or Tenant&#8217;s Agents, or anyone directly or indirectly employed by any of them, or in connection with Tenant&#8217;s non&#8209;payment of any amount arising out of the Tenant Improvements and/or Tenant&#8217;s disapproval of all or any portion of any request for payment.&nbsp;&nbsp;Such indemnity by Tenant, as set forth in the Lease, shall also apply with respect to any and all costs, losses, damages, injuries and liabilities related in any way to Landlord&#8217;s performance of&nbsp;&nbsp;any ministeri<a name="_cp_text_1_1216"></a>al acts reasonably necessary (i)&#160;to permit Tenant to complete the Tenant Improvements, and (ii)&#160;to enable Tenant to obtain any building permit or certificate of occupancy for the Premises; provided, however, that nothing contained in this Work Letter shall be deemed to indemnify Landlord from or against liability caused by Landlord&#8217;s negligence or willful misconduct.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2.2.4</font><font style="text-decoration:none;margin-left:158pt;"></font><font style="text-decoration:underline;font-weight:normal;">Insurance Requirements</font><font style="font-weight:normal;text-decoration:none;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:33.85%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2.2.4.1</font><font style="text-decoration:none;margin-left:216pt;"></font><font style="text-decoration:underline;font-weight:normal;">General Coverages</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;All of Tenant&#8217;s Agents shall carry worker&#8217;s compensation insurance covering all of their respective employees, and shall also carry commercial general liability insurance, and such other coverages as are required in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit&#160;I</font><font style="font-weight:normal;text-decoration:none;"> to the Lease, all with limits, in form and with companies as are required to be carried under </font><font style="text-decoration:underline;font-weight:normal;">Exhibit&#160;I</font><font style="font-weight:normal;text-decoration:none;"> to&nbsp;&nbsp;the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:33.85%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2.2.4.2</font><font style="text-decoration:none;margin-left:216pt;"></font><font style="text-decoration:underline;font-weight:normal;">Special Coverages</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Tenant shall carry &#8220;Builder&#8217;s All Risk&#8221; insurance in an amount approved by Landlord covering the construction of the Tenant Improvements, and such other insurance as Landlord may require, it being understood and agreed that the Tenant Improvements shall be insured by Tenant pursuant to the Lease immediately upon completion thereof.&nbsp;&nbsp;Such insurance shall be in amounts and shall include such extended coverage endorsements as may be reasonably required by Landlord, and in form and with companies as are required to be carried by Tenant as set forth in the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:33.85%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.2.2.4.3</font><font style="text-decoration:none;margin-left:216pt;"></font><font style="text-decoration:underline;font-weight:normal;">General Terms</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Certificates for all insurance carried pursuant to this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.2.4</font><font style="font-weight:normal;text-decoration:none;"> shall be delivered to Landlord before the commencement of construction of the Tenant Improvements and before the Contractor&#8217;s equipment is moved onto the site.&nbsp;&nbsp;All such policies of insurance must contain a provision that the company writing said policy will give Landlord thirty (30) days&#8217; prior written notice of any cancellation or lapse of the effective date or any reduction in the amounts of such insurance.&nbsp;&nbsp;In the event that the Tenant Improvements are damaged by any cause during the course of the construction thereof, Tenant shall immediately repair the same at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;All policies carried under this </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.2.4</font><font style="font-weight:normal;text-decoration:none;"> shall insure Landlord and Tenant, as their interests may appear, as well as Contractor and Tenant&#8217;s Agents, and shall name as additional insureds all Landlord Parties (as defined in the Lease).&nbsp;&nbsp;All insurance maintained by Tenant&#8217;s Agents shall preclude subrogation claims by the insurer against anyone insured thereunder.&nbsp;&nbsp;Such insurance shall provide that it is primary insurance as respects the Landlord Parties and that any other insurance maintained by Landlord Parties is excess and noncontributing with the insurance required hereunder.&nbsp;&nbsp;The requirements for the foregoing insurance shall not derogate from the provisions for indemnification of Landlord by Tenant under </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.2.3</font><font style="font-weight:normal;text-decoration:none;"> of this Work Letter. </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-8</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="text-decoration:none;">4.2.3</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Governmental Compliance</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;The Tenant Improvements shall comply in all respects with the following:&nbsp;&nbsp;(i)&#160;the Code and other state, federal, city or quasi</font><font style="font-weight:normal;text-decoration:none;">&#8209;governmental laws</font><font style="font-weight:normal;text-decoration:none;">, codes, ordinances and regulations, as each may apply according to the rulings of the controlling public official, agent or other person; (ii)&#160;applicable standards of the American Insurance Association (formerly, the National Board of Fire Underwriters) a</font><font style="font-weight:normal;text-decoration:none;">nd the National Electrical Code; and (iii)&#160;building material manufacturer&#8217;s specifications.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1232"></a><a name="_cp_text_1_1234"></a><a name="_cp_text_1_1235"></a><a name="_cp_text_1_1236"></a><a name="_cp_text_1_1237"></a><font style="text-decoration:none;">4.2.4</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Inspection by Landlord</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;<a name="_cp_text_1_1232"></a>Landlord shall have the right to inspect the Tenant Improvements during normal business hours upon reasonable advance notice, provided however, that Landlord&#8217;s failure to inspect the Tenant Improvements shall in no event constitute a waiver of any of Landlord&#8217;s rights hereunder nor shall Landlord&#8217;s inspection of the Tenant Improvements constitute Landlord&#8217;s approval of the same.&nbsp;&nbsp;Should Landlord disapprove any portion of the Tenant Improvements, Landlord shall notify Tenant in writing of such disapproval and shall specify the items disapproved.&nbsp;&nbsp;Any defects or deviations in, and/or disapproval by Landlord of, the Tenant Improvements shall be rectified by Tenant at no expense to Landlord, provided however, that in the event Landlord determines that a defect or deviation exists or disapproves of any matter in connection with any portion of the Tenant Improvements and such defect, deviation or mat<a name="_cp_text_1_1234"></a>ter might adversely affect the mechanical, electrical, plumbing, heating, ventilating and air conditioning or life safety systems of the Building, the structure or exterior appearance of the Building or any other tenant&#8217;s use of such other tenant&#8217;s leased <a name="_cp_text_1_1235"></a>premises, and Tenant fails to commence to remedy the same within thirty (30) days after Landlord&#8217;s written notice thereof or fails to diligently execute to completion, <a name="_cp_text_1_1236"></a>Landlord may, take such action as Landlord deems reasonably necessary, at Tenant&#8217;s expense and without incurring any liability on Landlord&#8217;s part, to correct any such defect, deviation and/or matter, including, without limitation, causing the cessation of performance of the construction of the Tenant Improvements until such time as the defect<a name="_cp_text_1_1237"></a>, deviation and/or matter is corrected to Landlord&#8217;s reasonable satisfaction.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1240"></a><a name="_cp_text_1_1242"></a><a name="_cp_text_1_1243"></a><a name="_cp_text_1_1244"></a><font style="text-decoration:none;">4.2.5</font><font style="text-decoration:none;margin-left:108pt;"></font><font style="text-decoration:underline;font-weight:normal;">Meetings</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;<a name="_cp_text_1_1240"></a>Commencing upon the execution of the Lease, Tenant shall hold <a name="_cp_text_1_1242"></a>weekly meetings at a reasonable time, with the Architect and the Contractor regarding the progress of the preparation of Construction Drawings and the construction of the Tenant Improvements, which meetings shall be held at the Premises (unless otherwise notified by Tenant to <a name="_cp_text_1_1243"></a>Landlord in writing)<a name="_cp_text_1_1244"></a>, and Landlord and/or its agents shall receive prior notice of, and shall have the right to attend, all such meetings, and, upon Landlord&#8217;s reasonable request, certain of Tenant&#8217;s Agents shall attend such meetings.  In addition, minutes shall be taken at all such meetings, a copy of which minutes shall be promptly delivered to Landlord.&nbsp;&nbsp;One such meeting each month shall include the review of Contractor&#8217;s current request for payment.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">4.3</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Notice of Completion; Copy of &#8220;As Built&#8221; Plans</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Within ten (10) days after completion of construction of the Tenant Improvements, Tenant shall cause a Notice of Completion to be recorded in the office of the Recorder of the County in which the Building is located in accordance with Section 3093 of the Civil Code of the State of California or any successor statute, and shall furnish a copy thereof to Landlord upon such recordation.&nbsp;&nbsp;If Tenant fails to do so, Landlord may execute and file the same on behalf of Tenant as Tenant&#8217;s agent for such purpose, at Tenant&#8217;s sole cost and expense.&nbsp;&nbsp;At the conclusion of construction, (i)&#160;Tenant shall cause the Architect and Contractor (A) to update the Approved Working Drawings as necessary to reflect all changes made to the Approved Working Drawings during the course of construction, (B) to certify to the best of their knowledge that the &#8220;record set&#8221; of as built drawings are true and correct, which certification shall survive the expiration or termination of the Lease, (C)&#160;to deliver to Landlord two (2) sets of sepias of such as built drawings within ninety (90) days following issuance of a certificate of occupancy for the Premises, and (D)&#160;to deliver to Landlord a computer disk containing the Approved Working Drawings in AutoCAD format, and (ii)&#160;Tenant shall deliver to Landlord a copy of all warranties, guaranties, and operating manuals and information relating to the improvements, equipment, and systems in the Premises.</font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-9</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a><a name="_cp_text_1_1254"></a><a name="_cp_text_1_1255"></a><font style="text-decoration:none;">4.4</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Coordination by Tenant&#8217;s Agents with Landlord</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1254"></a>Upon Tenant&#8217;s delivery of the </font><font style="font-weight:normal;text-decoration:none;">Final </font><font style="font-weight:normal;text-decoration:none;">Costs Statement </font><font style="font-weight:normal;text-decoration:none;">to Landlord under </font><font style="text-decoration:underline;font-weight:normal;">Section 4.2.1</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1255"></a> of this Work Letter, Tenant shall furnish Landlord with a schedule </font><font style="font-weight:normal;text-decoration:none;">(the &#8220;</font><font style="text-decoration:none;">Schedule</font><font style="font-weight:normal;text-decoration:none;">&#8221;) </font><font style="font-weight:normal;text-decoration:none;">setting forth the projected date of the completion of the Tenant Improvements and showing the critical time deadlines for ea</font><font style="font-weight:normal;text-decoration:none;">ch phase, item or trade relating to the construction of the Tenant Improvements.&nbsp;&nbsp;Such Schedule is subject to adjustment, and Tenant shall notify Landlord in writing of any adjustment thereto</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:underline;">section 5<br /><br />MISCELLANEOUS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1262"></a><a name="_cp_text_1_1264"></a><font style="text-decoration:none;">5.1</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Representative</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;<a name="_cp_text_1_1262"></a>Tenant will designate its representative within five (5) days after the execution of this Lease who will be <a name="_cp_text_1_1264"></a>its sole representative with respect to the matters set forth in this Work Letter and shall have full authority and responsibility to act on behalf of the Tenant as required in this Work Letter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">5.2</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Landlord&#8217;s Representative</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Landlord has designated Cameron Bassett as its sole representative with respect to the matters set forth in this Work Letter, who, until further notice to Tenant, shall have full authority and responsibility to act on behalf of the Landlord as required in this Work Letter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="text-decoration:none;">5.3</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Time of the Essence in This Work Letter</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Unless otherwise indicated, all references herein to a &#8220;number of days&#8221; shall mean and refer to calendar days.&nbsp;&nbsp;If any item requiring approval is timely disapproved by Landlord, the procedure for preparation of the document and approval thereof shall be repeated until the document is approved by Landlord.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_cp_text_1_1272"></a><a name="_cp_text_1_1274"></a><a name="_cp_text_1_1276"></a><a name="_cp_text_1_1278"></a><a name="_cp_text_1_1280"></a><a name="_cp_text_1_1282"></a><a name="_cp_text_1_1284"></a><a name="_cp_text_1_1285"></a><a name="_cp_text_4_1286"></a><a name="_cp_text_1_1287"></a><font style="text-decoration:none;">5.4</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Tenant&#8217;s Lease Default</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;Notwithstanding any provision to the contrary contained in the Lea<a name="_cp_text_1_1272"></a>se, if an Event <a name="_cp_text_1_1274"></a>of Default <a name="_cp_text_1_1276"></a>by Tenant of this Work Letter or the Lease has occurred at any time on or before the Substantial Completion of the Tenant Improvements, then (i) in addition to all other rights and remedies granted to Landlord pursuant to the Lea<a name="_cp_text_1_1278"></a>se, at law and/or in equity, Landlord shall have the right to withhold payment of all or any portion of the Tenant Improvement Allowance and/or Landlord may cause Contractor to cease the construction of the Tenant Improvements (in which case, Tenant shall <a name="_cp_text_1_1280"></a>be responsible for any delay in the Substantial Completion of the Tenant Improvements caused by such work stoppage), and (ii) all other obligations of Landlord under the terms of this Work Letter shall be forgiven until such time as such default is cured p<a name="_cp_text_1_1282"></a>ursuant to the terms of the Lease&nbsp;&nbsp;(in which case, Tenant shall be responsible for any delay in the Substantial Completion of the Premises caused by such inaction by Landlord).&nbsp;&nbsp;In addition, if the Lease is terminated prior to the Commencement Date, for an<a name="_cp_text_1_1284"></a>y reason due to an Event of Default by Tenant as described in </font><font style="text-decoration:underline;font-weight:normal;">Section&#160;17</font><font style="font-weight:normal;text-decoration:none;"> of the Lease or under this Work Letter, in addition to any other remedies available to Landlord under the Lease, at law and/or in equity, Tenant shall pay to Landlord, as Additional R<a name="_cp_text_1_1285"></a>ent under the Lease, within five (5) days of receipt of a statement therefor, any and all reasonable costs (if any) incurred by Landlord (including any portion of the Tenant Improvement Allowance disbursed by Landlord) and not reimbursed or otherwise paid by Tenant through the date of such termination in connection with the Tenant Improvements to the extent planned, installed and/or constructed as of such date of termination, including, but not limited to, any costs related to the removal of all or any port<a name="_cp_text_4_1286"></a>ion of the Tenant Improvements and restoration costs related thereto. For purposes of this </font><font style="text-decoration:underline;font-weight:normal;"><a name="_cp_text_1_1287"></a>Section&#160;5</font><font style="font-weight:normal;text-decoration:none;">, &#8220;</font><font style="text-decoration:none;">Substantial Completion of the Tenant Improvements</font><font style="font-weight:normal;text-decoration:none;">&#8221; shall mean completion of construction of the Tenant Improvements in the Premises pursuant to the Approved Working Drawings, with the exception of any punch list items.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU61"></a><a name="_cp_text_4_1291"></a><a name="_cp_text_1_1292"></a><a name="_cp_text_4_1293"></a><font style="text-decoration:none;">5.5</font><font style="text-decoration:none;margin-left:72pt;"></font><font style="text-decoration:underline;">Landlord Caused Delays</font><font style="font-weight:normal;text-decoration:none;">.&nbsp;&nbsp;The Commencement Date shall be extended on a day-to-day basis by the number of days of actual delay of the Substantial Completion of the Tenant Improvements in the Premises caused by a Landlord Caused Delay, as that term is defined below, but only to the extent such </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-10</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-decoration:none;">Landlord Caused Delay actually causes the Substantial Completion of the Tenant Improvements to occur after December&#160;1, 2018.&nbsp;&nbsp;As used in this Work Letter,</font><font style="font-weight:normal;text-decoration:none;"> &#8220;</font><font style="text-decoration:none;">Landlord Caused Delay</font><font style="font-weight:normal;text-decoration:none;">&#8221; shall mean delays to the extent resulting from the acts or omissions of Landlord, its agents, employees or contractors, including, but not limited to: (i)&#160;failure of Landlord to timely approve or disapprove any Construction Drawing</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_4_1291"></a>s or any other matter that requires Landlord&#8217;s approval within the time periods set forth in this Work Letter; (ii)&#160;material and unreasonable interference by Landlord, its agents, employees or contractors with </font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_1_1292"></a>construction of the Tenant Improvements</font><font style="font-weight:normal;text-decoration:none;">, inclu</font><font style="font-weight:normal;text-decoration:none;"><a name="_cp_text_4_1293"></a>ding, without limitation, interference relating to access by Tenant, or Tenant&#8217;s Agents to the Building or service; or (iii)&#160;delays due to the acts or failures to act of Landlord with respect to the payment </font><font style="font-weight:normal;text-decoration:none;">of the Tenant Improvement Allowance, </font><font style="font-weight:normal;text-decoration:none;">Additional T</font><font style="font-weight:normal;text-decoration:none;">enant Improvement Allowance and/or HVAC Allowance (except as otherwise allowed under this Work Letter)</font><font style="font-weight:normal;text-decoration:none;">.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:15.38%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">No Landlord Caused Delay shall be deemed to have occurred unless and until Tenant has provided written notice to Landlord specifying the action or inaction that Tenant contends constitutes a Landlord Caused Delay.&nbsp;&nbsp;If such action or inaction is not cured within one (1) Business Day after receipt of such notice, then a Landlord Caused Delay shall be deemed to have occurred commencing as of the date such notice is received and continuing for the number of days the design and construction of the Tenant Improvements was in fact delayed as a direct result of such action or inaction.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT D-11</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT E</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">BUILDING RULES AND REGULATIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following rules and regulations shall apply to the Premises, the Building, the parking area associated therewith, and the appurtenances thereto:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>Sidewalks, main doorways, stairways, and other similar areas shall not be obstructed by Tenant or used by Tenant for purposes other than ingress and egress to and from the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>Plumbing, fixtures and appliances shall be used only for the purposes for which designed, and no sweepings, rubbish, rags or other unsuitable material shall be thrown or deposited therein.&nbsp;&nbsp;Damage resulting to any such fixtures or appliances from misuse by a tenant or its agents, employees or invitees, shall be paid by such tenant.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>No signs, advertisements or notices (other than those that are not visible outside the Premises) shall be painted or affixed on or to any exterior windows or doors or other part of the Building without the prior written consent of Landlord.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>In connection with the movement in or out of the Building of furniture, fixtures or equipment, or dispatch or receipt by Tenant of any bulky material, merchandise or materials, Tenant assumes all risks of and shall be liable for all damage to articles moved and injury to persons or public engaged or not engaged in such movement.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>Landlord may prescribe reasonable weight limitations and reasonably determine the locations for safes and other heavy equipment or items, which shall in all cases be placed in the Building so as to distribute weight in a manner reasonably acceptable to Landlord which may include the use of such supporting devices as Landlord may reasonably require.&nbsp;&nbsp;All damages to the Building caused by Tenant&#8217;s installation or removal of any property of a tenant, or done by a tenant&#8217;s property while in the Building, shall be repaired at the expense of Tenant.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>No birds or animals (other than seeing-eye dogs or service animals) shall be brought into or kept in, on or about any tenant&#8217;s leased premises.&nbsp;&nbsp;No portion of any tenant&#8217;s leased premises shall at any time be used or occupied as sleeping or lodging quarters.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1321"></a><a name="_cp_text_4_1322"></a>7.<font style="margin-left:36pt;"></font>Landlord will not be responsible for lost or stolen personal property, money or jewelry from tenant&#8217;s leased premises or public or common areas regardless of whether such loss occurs when the area is locked against entry or not<a name="_cp_text_1_1321"></a> <a name="_cp_text_4_1322"></a>except to the extent caused by the gross negligence or willful misconduct of Landlord or Landlord&#8217;s agents, employees or contractors.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>Tenant shall not conduct any activity on or about the Premises or Building which will draw pickets, demonstrators, or the like.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.<font style="margin-left:36pt;"></font>All vehicles are to be currently licensed, in good operating condition, parked for business purposes having to do with Tenant&#8217;s business operated in the Premises, parked within designated parking spaces, one vehicle to each space.&nbsp;&nbsp;No vehicles may be stored in the parking areas.&nbsp;&nbsp;No vehicle shall be parked as a &#8220;billboard&#8221; vehicle in the parking lot.&nbsp;&nbsp;Any vehicle parked improperly may be towed away.&nbsp;&nbsp;Tenant, Tenant&#8217;s agents, employees, vendors and customers who do not operate or park their vehicles as required shall subject the vehicle to being towed at the expense of the owner or driver.&nbsp;&nbsp;Landlord may place a &#8220;boot&#8221; on the vehicle to immobilize it and may levy a charge of $50.00 to remove the &#8220;boot&#8221;.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font>Tenant shall not permit its employees, invitees or guests to smoke in the Premises, nor shall any tenant permit its employees, invitees, or guests to loiter at the Building entrances for the purposes of smoking.&nbsp;&nbsp;Landlord may, but shall not be required to, designate an area for smoking outside the Building.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT E-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Canvassing, soliciting or peddling in or about the Premises or the Property is prohibited and Tenant shall cooperate to prevent </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">same</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font>Tenant shall not advertise for temporary laborers giving the Premises or the Project as an address, nor pay such laborers at a location in the Premises or the Project.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13.<font style="margin-left:36pt;"></font>Tenant shall park trailers and other oversized vehicles only in areas designated by Landlord for the parking of trailers or oversized vehicles.&nbsp;&nbsp;Tenant shall not park trailers and other oversized vehicles in streets or other public areas in the Complex.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.<font style="margin-left:36pt;"></font>Tenant shall not utilize the Premises or Project for outside storage except with the written consent of Landlord.&nbsp;&nbsp;The prohibition against outside storage includes, but is not limited to, equipment, materials, vehicles, campers, trailers, boats, barrels, pallets, and trash (other than in containers provided by commercial trash collectors which are picked up on a regularly scheduled basis).</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT E-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT F</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CONFIRMATION OF COMMENCEMENT DATE</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">______________ ___, 20__</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Re:<font style="margin-left:36pt;">Lease Agreement (the &#8220;</font><font style="font-weight:bold;">Lease</font>&#8221;) dated November&#160;3, 2017, between MARINA BOULEVARD PROPERTY, LLC, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Landlord</font>&#8221;), and SANGAMO THERAPEUTICS, INC., a Delaware corporation (&#8220;<font style="font-weight:bold;">Tenant</font>&#8221;).&nbsp;&nbsp;Capitalized terms used herein but not defined shall be given the meanings assigned to them in the Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ladies and Gentlemen:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant agree as follows:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Condition of Premises</font>.&nbsp;&nbsp;Tenant has accepted the Premises pursuant to the Lease.&nbsp;&nbsp;Tenant acknowledges that the Premises are suitable for the Permitted Use.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Commencement Date</font>.&nbsp;&nbsp;The Commencement Date of the Lease is ______________ ___, 20__.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Expiration Date</font>.  The Term is scheduled to expire on the last day of the [*______________ (___)*] full calendar month of the Term, which date is ______________, 20__.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Contact Person</font>.&nbsp;&nbsp;Tenant&#8217;s contact person in the Premises is:</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention: _________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone: ________________</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:9pt;margin-left:23.08%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telecopy: _________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Base Rent</font>.&nbsp;&nbsp;Base Rent shall be payable monthly in advance in accordance with the following schedule:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:501.85pt;;">
<tr>
<td style="width:125.35pt;"></td>
<td style="width:125.5pt;"></td>
<td style="width:125.4pt;"></td>
<td style="width:125.6pt;"></td>
</tr>
<tr>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease Month</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Annual Base Rent</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly Base Rent</p></td>
<td valign="bottom" >
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Monthly<br />Rental Rate<br />Per RSF</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1 &#8211; 12*</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13 &#8211; 24*</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25 &#8211; 36</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37 &#8211; 48</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49 &#8211; 60</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61 &#8211; 72</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73 &#8211; 84</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">85 &#8211; 96</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">97 &#8211; 108</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">109 &#8211; 120</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
<tr>
<td valign="bottom" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:24.45pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">121 &#8211; 132</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>6.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Ratification</font>.&nbsp;&nbsp;Tenant hereby ratifies and confirms its obligations under the Lease, and represents and warrants to Landlord that it has no defenses thereto.&nbsp;&nbsp;Additionally, Tenant further confirms and ratifies that, as of the date hereof, (a)&#160;the Lease is and remains in good standing and in full force and </p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT F-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">effect, and (b)&#160;to Tenant&#8217;s knowledge, Tenant has no claims, counterclaims, set-offs or defenses against Landlord arising out of the Lease or in any way relating thereto or arising out of any other transaction between </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Landlord and Tenant.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Binding Effect; Governing Law</font>.&nbsp;&nbsp;Except as modified hereby, the Lease shall remain in full effect and this letter shall be binding upon Landlord and Tenant and their respective successors and assigns.&nbsp;&nbsp;If any inconsistency exists or arises between the terms of this letter and the terms of the Lease, the terms of this letter shall prevail.&nbsp;&nbsp;This letter shall be governed by the laws of the state in which the Premises are located.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Please indicate your agreement to the above matters by signing this letter in the space indicated below and returning an executed original to us.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:478.8pt;;">
<tr>
<td style="width:252.9pt;"></td>
<td style="width:225.9pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sincerely,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">MARINA LANDING PROPERTY, LLC, <br />a Delaware limited liability company</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Date:<font style="text-decoration:underline;"></font>, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Agreed and accepted:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">TENANT</font><font style="font-weight:normal;">:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">SANGAMO THERAPEUTICS, INC.,</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware corporation</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Printed Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Execution Date:<font style="text-decoration:underline;"></font>, 2017</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT F-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU66"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT G</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">FORM OF TENANT ESTOPPEL CERTIFICATE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The undersigned is the Tenant under the Lease (defined below) between ___________________, a ___________________, as Landlord, and the undersigned as Tenant, for the Premises on the __________ floor(s) of the office building located at _____________________, __________ and commonly known as _______________________, and hereby certifies as follows:</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.<font style="margin-left:36pt;"></font>The Lease consists of the original Lease Agreement dated as of ___________, 20___ between Tenant and Landlord [&#8216;s predecessor-in-interest] and the following amendments or modifications thereto (if none, please state &#8220;none&#8221;): _________________________________________________ ___________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The documents listed above are herein collectively referred to as the &#8220;Lease&#8221; and represent the entire agreement between the parties with respect to the Premises.&nbsp;&nbsp;All capitalized terms used herein but not defined shall be given the meaning assigned to them in the Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.<font style="margin-left:36pt;"></font>The Lease is in full force and effect and has not been modified, supplemented or amended in any way except as provided in <font style="text-decoration:underline;">Section&#160;1</font> above.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.<font style="margin-left:36pt;"></font>The Term commenced on __________________, 20__, and the Term expires, excluding any renewal options, on _____________________, 20__, and Tenant has no option to purchase all or any part of the Premises or the Building or, except as expressly set forth in the Lease, any option to terminate or cancel the Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.<font style="margin-left:36pt;"></font>Tenant currently occupies the Premises described in the Lease and Tenant has not transferred, assigned, or sublet any portion of the Premises nor entered into any license or concession agreements with respect thereto except as follows (if none, please state &#8220;none&#8221;): ________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.<font style="margin-left:36pt;"></font>All monthly installments of Base Rent, all Additional Rent and all monthly installments of estimated Additional Rent have been paid when due through ______________.&nbsp;&nbsp;The current monthly installment of Base Rent is $___________________.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.<font style="margin-left:36pt;"></font>To Tenant&#8217;s knowledge, all conditions of the Lease to be performed by Landlord necessary to the enforceability of the Lease have been satisfied and Landlord is not in default thereunder.&nbsp;&nbsp;In addition, Tenant has not delivered any notice to Landlord regarding a default by Landlord thereunder.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.<font style="margin-left:36pt;"></font>As of the date hereof, to the undersigned&#8217;s knowledge, there are no existing defenses or offsets, or claims or any basis for a claim, that the undersigned has against Landlord and no event has occurred and no condition exists, which, with the giving of notice or the passage of time, or both, will constitute a default under the Lease.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.<font style="margin-left:36pt;"></font>No rental has been paid more than thirty (30) days in advance and no security deposit has been delivered to Landlord except as provided in the Lease.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT G-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.</font><font style="margin-left:36pt;"></font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Tenant is a corporation, partnership or other business entity, Tenant </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">hereby</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> represents and warrants that Tenant is a duly formed and existing entity qualified to do business in the state in which the Premises are located and that Tenant has full right and authority to execute and deliver this Estoppel Certificate and each person </font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">signing on behalf of Tenant is authorized to do so.</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.<font style="margin-left:36pt;"></font>There are no actions pending against Tenant under any bankruptcy or similar laws of the United States or any state.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.<font style="margin-left:36pt;"></font>Other than as permitted by the Lease and used in compliance with all applicable laws and incidental to the ordinary course of the use of the Premises, the undersigned has not used or stored any hazardous substances in the Premises.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12.<font style="margin-left:36pt;"></font>All reimbursements and allowances due to the undersigned under the Lease in connection with any tenant improvement work have been paid in full except for ___________________________.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant acknowledges that this Estoppel Certificate may be delivered to Landlord, Landlord&#8217;s Mortgagee or to a prospective mortgagee or prospective purchaser, and their respective successors and assigns, and acknowledges that Landlord, Landlord&#8217;s Mortgagee and/or such prospective mortgagee or prospective purchaser will be relying upon the statements contained herein in disbursing loan advances or making a new loan or acquiring the property of which the Premises are a part and that receipt by it of this certificate is a condition of disbursing loan advances or making such loan or acquiring such property.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executed as of ________________________, 20__.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:478.8pt;;">
<tr>
<td style="width:252.9pt;"></td>
<td style="width:225.9pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">TENANT:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a <font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT G-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT H</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RENEWAL OPTION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1421"></a><a name="_cp_text_1_1423"></a><a name="_cp_text_1_1425"></a><a name="_cp_text_1_1426"></a><a name="_cp_text_1_1428"></a><a name="_cp_text_1_1429"></a><a name="_cp_text_1_1430"></a><a name="_cp_text_1_1431"></a><a name="_cp_text_1_1432"></a><a name="_cp_text_1_1434"></a><a name="_cp_text_1_1421"></a>If Tenant has not committed a <a name="_cp_text_1_1423"></a>default (which is not cured by the time Tenant exercises its option to renew), and Tenant is occupying the entire Premises at the tim<a name="_cp_text_1_1425"></a>e of such election (provided that Tenant shall be deemed to occupy the entire Premises even if a portion of the Premises is occupied by a Permitted Transferee), Tenant may renew this Lease for two (2) additional period(s) of five (5) years each, by delivering written notice of the exercise thereof to Landlord not earlier than fifteen (15) months nor later than nine (9) months before the expiration of the then-current Term (&#8220;<font style="font-weight:bold;">Tenant&#8217;s Election Notice</font><a name="_cp_text_1_1426"></a>&#8221;).&nbsp;&nbsp;Any extension of the Term shall be on all the same terms and conditions as this Lease, except as expressly set forth herein. <a name="_cp_text_1_1428"></a>The Base Rent payable for each month during such extended Term shall be equal to ninety percent (90%) of the prevailing rental rate (the &#8220;<font style="font-weight:bold;">Prevailing Rental Rate</font>&#8221;), at the commencement of<a name="_cp_text_1_1429"></a> such extended Term, for renewals of space in the Complex and in comparable buildings with comparable life science tenant(s) and comparable build-out (containing the systems and improvements present in the Premises including similar concentration of lab space) <a name="_cp_text_1_1430"></a>located within North San Mateo County, California, of equivalent quality, size, utility, age, level of finish, proximity to amenities and public transit, <a name="_cp_text_1_1431"></a>and location, with the length of the extended Term, any concessions offered to new tenants, (such as free rent, tenant improvement allowances and moving allowances), whether or not there will be a charge for parking, <a name="_cp_text_1_1432"></a>and the credit standing of Tenant to be taken into account (such factors, the &#8220;<font style="font-weight:bold;">Relevant Factors</font>&#8221;).&nbsp;&nbsp;Within fifteen (15) days after recei<a name="_cp_text_1_1434"></a>pt of Tenant&#8217;s Election Notice, Landlord shall deliver to Tenant written notice of the Prevailing Rental Rate and shall advise Tenant of the required adjustment to Base Rent, if any.&nbsp;&nbsp;Tenant shall, within ten (10) days after receipt of Landlord&#8217;s notice, notify Landlord in writing whether Tenant accepts or rejects Landlord&#8217;s determination of the Prevailing Rental Rate.&nbsp;&nbsp;If Tenant timely notifies Landlord that Tenant accepts Landlord&#8217;s determination of the Prevailing Rental Rate, then, on or before the commencement date of the extended Term, Landlord and Tenant shall execute an amendment to this Lease extending the Term on the same terms provided in this Lease, except as follows:</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Base Rent and the annual increase shall be adjusted to the Prevailing Rental Rate;</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Tenant shall have no further renewal option after exercising the second renewal option unless expressly granted by Landlord in writing; and</p>
<p style="margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Landlord shall lease to Tenant the Premises in their then-current condition, and Landlord shall not provide to Tenant any allowances (e.g., moving allowance, construction allowance, and the like) or other tenant inducements.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1446"></a><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>If by the date thirty (30) days following delivery of Tenant&#8217;s Election Notice, Landlord and Tenant have not agreed in writing as to the amount of the Base Rent, the parties shall determine the projected Prevailing Rental Rate in accordance with the following procedure (which procedure is herein referred to as the &#8220;<font style="font-weight:bold;">Three-Appraiser Method</font>&#8221;).&nbsp;&nbsp;Landlord and Tenant shall each appoint one (1) real estate appraiser, and the two (2) so appointed shall select a third.&nbsp;&nbsp;Said real estate appraisers shall each be licensed in the state in which the Premises is located, specializing in the field of commercial real estate in North San Mateo County, California, having no less than ten (10) years&#8217; experience in such field, unaffiliated with either Landlord or Tenant and recognized as ethical and reputable within their field.&nbsp;&nbsp;Landlord and Tenant agree to make their appointments promptly within ten (10) days after expiration of the thirty (30) day negotiation period, or sooner if mutually agreed upon.&nbsp;&nbsp;The two (2) appraisers selected by Landlord and Tenant shall promptly select a third appraiser within fifteen (15) days after they both have been appointed, and each appraiser, within fifteen (15) days after the third appraiser is selected, shall submit his or her determination of the then projected Prevailing Rental Rate<a name="_cp_text_1_1446"></a> after taking into account all the Relevant Factors.&nbsp;&nbsp;Such third appraiser shall choose one of the two (2) Prevailing Rental Rates submitted by the parties which most closely represents the projected prevailing market rate after taking into account all the Relevant Factors.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT H-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Such Prevailing Rental Rate chosen by the appraiser shall be final and binding</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> upon the parties</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If either Landlord or Tenant fails to appoint an appraiser within the time period specified in this paragraph, the appraiser appointed by one of them shall reach a decision, notify Landlord and Tenant thereof, and such appraiser&#8217;s decis</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ion shall be binding upon Landlord and Tenant.&nbsp;&nbsp;Each party shall pay the fees and expenses of the appraiser appointed by or on behalf of it, and each shall pay one-half of the fees and expenses of the third appraiser.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_1448"></a><a name="_cp_text_1_1450"></a><a name="_cp_text_1_1452"></a>Parties <a name="_cp_text_1_1450"></a>shall confirm the parties&#8217; acceptance of the determination of the Prevailing Rental Rate by executing an amendment to this Lease memorializing the same within ten (10) days of such determination (herein the &#8220;<font style="font-weight:bold;">Extension Amendment</font><a name="_cp_text_1_1452"></a>&#8221;).&nbsp;&nbsp;Failure to execute and deliver the Extension Amendment within such 10-day period shall not affect the enforceability of the extension exercised by Tenant.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding anything in the foregoing to the contrary, at Landlord&#8217;s option, and in addition to all of Landlord&#8217;s remedies under this Lease, at law or in equity, the right to extend the Term of this Lease hereinabove granted to Tenant shall not be deemed to be properly exercised if, as of the date Tenant exercises its extension right or on the scheduled commencement date for the applicable option term, Tenant is in default under this Lease beyond any applicable notice and cure period.&nbsp;&nbsp;Further, Tenant&#8217;s rights under this Exhibit shall terminate if (1)&#160;this Lease or Tenant&#8217;s right to possession of the Premises is terminated, (2)&#160;Tenant assigns any of its interest in this Lease or sublets any portion of the Premises to any party other than a Permitted Transferee, or (3)&#160;Tenant fails to timely exercise its option under this Exhibit, time being of the essence with respect to Tenant&#8217;s exercise thereof.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT H-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT I</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">CONTRACTOR INSURANCE REQUIREMENTS</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">I-1.<font style="margin-left:36pt;">The following defined terms apply for purposes of this Exhibit. Other capitalized terms used but not defined in this Exhibit will have the </font>meanings given to such terms in the Lease to which this Exhibit is attached. &#8220;<font style="font-weight:bold;">Work</font>&#8221; means the applicable work to be performed at the Premises, and to which the requirements of this Exhibit relate pursuant to the Lease. &#8220;<font style="font-weight:bold;">Contractor</font>&#8221; means Tenant&#8217;s general contractor with respect to the Work. &#8220;<font style="font-weight:bold;">Subcontractors</font>&#8221; means any person retained by the Contractor as an independent contractor to provide labor, materials, equipment, or services necessary to complete a specific portion of the Work, and their sub-subcontractors of every tier. &#8220;<font style="font-weight:bold;">Landlord Parties</font>&#8221; means Landlord; Landlord&#8217;s property manager with respect to the Premises; Landlord&#8217;s Mortgagee; other entities or individuals Landlord may designate from time to time to be included as additional insureds (e.g., by requiring that they be listed as additional insureds on certificates of insurance); the successors and assigns, and direct and indirect affiliates, of each of the foregoing; and, with respect to each of the foregoing, its shareholders, trustees, beneficiaries, managers, officers, directors, employees, and agents. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">I-2.<font style="margin-left:36pt;">Tenant shall require its Contractor to maintain insurance that satisfies the following requirements (except Landlord may reasonably adjust the minimum limits provided herein from time to time</font> time): </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Commercial general liability insurance on the current ISO CG 00 01 form or an equivalent occurrence form that (i) has limits of not less than the greater of (A) $1,000,000 each occurrence, $1,000,000 personal and advertising injury, $2,000,000 general aggregate (per-project), and $2,000,000 products-completed operations aggregate and (B) the limits the Contractor actually carries, and (ii) includes the Landlord Parties as additional insureds on a primary and noncontributing basis, providing them with coverage at least as broad as that given to the named insured. The Contractor shall maintain its products-completed operations coverage for at least five years after completion of the Work, and shall include the Landlord Parties as additional insureds on a primary and non-contributing basis during this period. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Business auto insurance covering any auto (including owned, hired, and non-owned autos), with a limit of not less than $1,000,000 each accident. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Workers compensation and employers liability insurance for all persons that perform Work for the Contractor. The workers compensation insurance must fulfill applicable statutory requirements. The employers liability insurance must have limits of not less than $1,000,000 each accident, $1,000,000 each employee, and $1,000,000 policy limit. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Commercial excess or umbrella liability insurance on a &#8220;follow form&#8221; basis, with a limit of not less than $10,000,000 each occurrence and annual aggregate. This insurance must provide that aggregate limits of liability apply separately with respect to the Work. Notwithstanding the specified minimum limits in this <font style="text-decoration:underline;">Section I-2</font> for primary commercial general liability, business auto, and employers liability insurance and the separate specified minimum limit for commercial excess or umbrella liability insurance, in each case this <font style="text-decoration:underline;">Section I-2</font> is to be construed as requiring only the combined primary and excess/umbrella minimum limit and that combined minimum limit may be achieved with any combination of primary and excess or umbrella insurance. </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(e)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a>Professional liability insurance, if the Work includes any professional services (including any design-build component of the Work), with limits of not less than $1,000,000 each claim and </p></td></tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT I-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap"></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$1,000,000 annual aggregate. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If the Contractor performs the professional services, then it shall carry this insurance; if a Subcontractor performs the services, then Contractor shall require the Subcontractor to carry this insurance. </font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:3.85%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(f)</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:12pt;">Property insurance for job trailers, machinery, tools, equipment, property of a similar nature owned or leased by the Contractor or Subcontractors and not destined to become a part of the completed construction, and the Contractor must waive, and require its Subcontractors (including lessors of equipment) to waive, all claims against the Landlord Parties for loss or damage to these items, regardless of the cause.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">I-3.<font style="margin-left:36pt;">Tenant shall require the Contractor to waive all rights against the Landlord Parties to the extent any damage is covered by insurance </font>maintained by the Contractor, or is attributable to any deductible or self-insured retention relating to insurance maintained by the Contractor, and shall ensure that its policies permit this waiver of subrogation by endorsement or otherwise.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">I-4.<font style="margin-left:36pt;">Tenant</font> shall require the Contractor, by written agreement, to require its Subcontractors to maintain the insurance and make the waivers required of the Contractor in this Exhibit, except that with respect to Subcontractors&#8217; insurance Tenant may permit its Contractor, with Landlord&#8217;s consent, to reduce or waive the commercial excess or umbrella liability insurance requirement in circumstances where such reduction or waiver for that Subcontractor (given its scope of Work) is commercially reasonable and customary. Tenant shall require the Contractor to obtain certificates of insurance from its Subcontractors evidencing the insurance required under this Exhibit.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:3.85%;">I-5.<font style="margin-left:36pt;">All insurance policies required under this Exhibit must be issued by reputable, financially sound co</font>mpanies that have an A.M. Best rating of A- VIII or better. Before commencement of the Work, Tenant shall require the Contractor to provide to Landlord a certificate of insurance evidencing the required insurance and, if requested, the Contractor&#8217;s additional insured endorsement. Tenant shall require the Contractor to provide an updated certificate of insurance before the expiration of the term of any required coverage, and otherwise upon request. Tenant shall require all policies of insurance required under this Exhibit to contain a provision that the company writing said policy will give Landlord 30&#8217; days&#8217; prior written notice of any cancellation or lapse of the effective date or any reduction in the amounts of such insurance. Tenant shall require the Contractor to provide copies of policies required under this Exhibit if requested. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[<font style="font-style:italic;">Remainder of page intentionally left blank</font>]</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT I-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT J</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ENVIRONMENTAL QUESTIONNAIRE AND DISCLOSURE STATEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The purpose of this form is to obtain information regarding the use of hazardous substances on the Premises.&nbsp;&nbsp;Tenant should answer the questions as they relate to proposed operations on the Premises and should update any information previously submitted.&nbsp;&nbsp;If additional space is needed to answer the questions, you may attach separate sheets of paper to this form.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">1.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">GENERAL INFORMATION</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name of Responding Company:&nbsp;&nbsp;___________________________________________________&nbsp;&nbsp;________________________________________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the Applicable Status:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Prospective Tenant&nbsp;&nbsp;____</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Existing Tenant&nbsp;&nbsp;_____</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mailing Address:&nbsp;&nbsp;__________________________________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Contact Person and Title:&nbsp;&nbsp;___________________________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Telephone Number:&nbsp;&nbsp;(___) ___________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Address of Premises: ________________________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Length of Lease Term: _____ years with ____&nbsp;&nbsp;____ year extension options</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Described the proposed operations to take place on the Premises, including principal products manufactured or services to be conducted.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">2.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">STORAGE OF HAZARDOUS MATERIALS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">2.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Will any hazardous materials be used or stored on-site?</p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Wastes<font style="margin-left:180pt;">Yes&nbsp;&nbsp;____</font><font style="margin-left:252pt;">No&nbsp;&nbsp;____</font></p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:9pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Chemical Products<font style="margin-left:180pt;">Yes&nbsp;&nbsp;____</font><font style="margin-left:252pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">2.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Attach the list of any hazardous materials to be used or stored, the quantities that will be on-site at any time, and the location and method of storage (e.g., 55 gallon drums on concrete pad).</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">STORAGE TANKS &amp; SUMPS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Is any above or below ground storage of gasoline, diesel, or other hazardous substances in tanks or sumps proposed or currently conducted on the Premises?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, describe the materials to be stored, and the type, size and construction of the sump or tank.&nbsp;&nbsp;Attach copies of any permits obtained for the storage of such substances.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Have any of the tanks or sumps been inspected or tested for leakage?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No ____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, attach the results.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"></font><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"></font><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Have any spills or leaks occurred from such tanks or sumps? </font></p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No ____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Is so, describe.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Were any regulatory agencies required to be notified of the spill or leak and did such required notification occur?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, attach copies of any spill reports filed, any clearance letters or other correspondence from regulatory agencies relating to the spill or leak.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">3.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Have any underground storage tanks or sumps been taken out of service or removed?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, attach copies of any closure permits and clearance obtained from regulatory agencies relating to closure and removal of such tanks.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">SPILLS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">During the past year, have any spills occurred on the Premises?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, please describe the spill and attach the results of any testing conducted to determine the extent of such spills.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Were any agencies required to be notified in connection with such spills and did such notification occur?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, attach copies of any spill reports or other correspondence with regulatory agencies.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">4.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Were any clean-up actions undertaken in connection with the spills?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, briefly describe the actions taken.&nbsp;&nbsp;Attach copies of any clearance letters obtained from any regulatory agencies involved and the results of any final soil or groundwater sampling done upon completion of the clean-up work.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">WASTE MANAGEMENT</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has your company been issued an EPA or state Hazardous Waste Generator I.D. Number?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has your company filed any required report as a hazardous waste generator?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, attach a copy of the most recent report filed.</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"></font><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"></font><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Attach the list of the hazardous waste, if any, generat</font><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">ed or to be generated at the Premises, its hazard class and the quantity generated on a monthly basis.</font></p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Describe the method(s) of disposal for each waste.&nbsp;&nbsp;Indicate where and how often disposal will take place.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">______________________________________________________.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Indicate the name of the person(s) responsible for maintaining copies of hazardous waste manifests completed for off-site shipments of hazardous waste.&nbsp;&nbsp;___________________________________</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">5.6</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Is any treatment or processing of hazardous wastes currently conducted or proposed to be conducted at the Premises:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, please describe any existing or proposed treatment methods.&nbsp;&nbsp;_________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attach copies of any hazardous waste permits or licenses issued to your company with respect to its operations on the Premises. ____________________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">WASTEWATER TREATMENT/DISCHARGE</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Do you discharge wastewater to:</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________ storm drain?<font style="margin-left:216pt;">____________ sewer?</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">____________ surface water?<font style="margin-left:216pt;">_______</font>_____&nbsp;&nbsp;no industrial discharge</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Is your wastewater treated before discharge?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If yes, describe the type of treatment conducted. _______________________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">6.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Attach copies of any wastewater discharge permits issued to your company with respect to its operations on the Premises.&nbsp;&nbsp;________________________________</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">AIR DISCHARGES</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Do you have any air filtration systems or stacks that discharge into the air?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Do you operate any of the following types of equipment, or any other equipment requiring an air emissions permit?</p></td></tr></table></div>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ Spray booth</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ Dip tank</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ Drying oven</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ Incinerator</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-align:justify;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ Other (Please Describe)</p>
<p style="margin-top:0pt;text-align:justify;margin-bottom:9pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_____________ No Equipment Requiring Air Permits</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">7.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Are air emissions from your operations monitored?</p></td></tr></table></div>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-3</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____</font><font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, indicate the frequency of monitoring and a description of the monitoring results.&nbsp;&nbsp;__________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attach copies of any air emissions permits pertaining to your operations on the Premises. __________________</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">HAZARDOUS MATERIALS DISCLOSURES</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Does your company handle hazardous materials in a quantity equal to or exceeding an aggregate of 500 pounds, 55 gallons, or 200 cubic feet?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____ <font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has your company prepared a hazardous materials management plan (&#8220;business plan&#8221;) pursuant to County Fire Department requirements?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:3.85%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, attach a copy of the business plan.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">8.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Describe the procedures followed to comply with OSHA Hazard Communication Standard requirements.</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">_________________________________________________________________.</p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;text-indent:0%;text-transform:none;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.<font style="margin-left:36pt;"></font><font style="text-transform:uppercase;">ENFORCEMENT ACTIONS, COMPLAINTS</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.1</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has your company even been subject to any agency enforcement actions, administrative orders, or consent decrees?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, describe the actions and any continuing compliance obligations imposed as a result of these actions.</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.2</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has your company even received requests for information, notice or demand letters, or any other inquiries regarding its operations?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.3</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Have there ever been, or are there now pending, any lawsuits against the company regarding any environmental or health and safety concerns?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.4</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Has an environmental audit even been conducted at your company&#8217;s current facility?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, discuss the results of the audit. ____________________________________</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></td>
<td valign="top" style="width:7.69%;white-space:nowrap">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><font style="font-weight:normal;text-transform:none;font-size:11pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">9.5</font></p></td>
<td valign="top">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;font-weight:normal;text-transform:none;font-style:normal;font-variant: normal;font-family:Times New Roman;font-size:11pt;">Have there been any problems or complaints from neighbors at the company&#8217;s current facility?</p></td></tr></table></div>
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Yes&nbsp;&nbsp;____<font style="margin-left:36pt;">No&nbsp;&nbsp;____</font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-4</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:justify;margin-bottom:9pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If so, describe the problems or complaints. ______________________________</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:0.11%;width:99.89%;">
<tr>
<td style="width:56.89%;"></td>
<td style="width:43%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Company&nbsp;&nbsp;&nbsp;&nbsp;_______________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:_______________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:_______________________________</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:72pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:_______________________________</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-5</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Environmental Questionnaire</font></p>
<p style="margin-bottom:24pt;text-align:center;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LIST OF HAZARDOUS MATERIALS TO BE USED OR STORED ON THE PREMISES</font></p>
<p style="margin-bottom:12pt;text-align:justify;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tenant shall provide to Landlord, no later than the Commencement Date, a list of Hazardous Materials that Tenant shall use at the Premises in connection with Tenant&#8217;s operations within the Premises.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-6</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT K</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LOCATION AND SIZE OF CELL TOWER EQUIPMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531680431126.jpg" title="" alt="" style="width:623px;height:724px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT K-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT L</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">WELLS FARGO - LETTER OF CREDIT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531683131127.jpg" title="" alt="" style="width:608px;height:789px;"></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT L-1</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><img src="g2018030121531685831128.jpg" title="" alt="" style="width:624px;height:807px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-2</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><img src="g2018030121531689031129.jpg" title="" alt="" style="width:624px;height:161px;"></p>
<p style="margin-top:12pt;line-height:10pt; clear:both;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT J-3</font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="text-decoration:underline;">EXHIBIT M</font><font style="text-decoration:underline;"><br /></font><font style="text-decoration:underline;"><br />ROFO TO PURCHASE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(1)<font style="margin-left:108pt;"></font><font style="font-weight:bold;text-decoration:underline;">Right of First Offer to Purchase</font>.&nbsp;&nbsp;If Landlord desires to sell, convey or transfer its fee interest in the Building to a third party during the period commencing on the Commencement Date and expiring on the third (3rd) anniversary of the Commencement Date (&#8220;<font style="font-weight:bold;">ROFO Period</font>&#8221;), subject to compliance with the California Subdivision Map Act to create a separate legal parcel for the Building, Landlord hereby grants Tenant a one-time right of first offer to purchase the Building during the ROFO Period (&#8220;<font style="font-weight:bold;">Right of First Offer</font>&#8221;) pursuant to the terms and provisions of the Right of First Offer Agreement attached hereto as <font style="text-decoration:underline;">Exhibit M-1</font> (&#8220;<font style="font-weight:bold;">ROFO Agreement</font>&#8221;), subject to the following conditions: (a)&#160;Tenant is currently leasing and physically occupying 87,695 rentable square feet in the Building (including any Permitted Transfers); (b)&#160;Tenant has not assigned the Lease nor subleased any portion of the Premises (except for Permitted Transfers); (c)&#160;the Lease is then in full force and effect and no Event of Default by Tenant has occurred and is continuing at the time Tenant exercises its Right of First Offer; (d)&#160;the Right of First Offer is personal to Tenant and may not be exercised or assigned, voluntarily or involuntarily, by, or to, any person or entity other than Tenant; (e)&#160;the Right of First Offer and its exercise thereof by Tenant shall be governed by the terms and conditions of the ROFO Agreement; (f)&#160;the original Landlord named in this Lease owns the fee interest in the Building at the time the Right of First Offer is exercised.&nbsp;&nbsp;The Parties shall execute the ROFO Agreement concurrently with this Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:normal;text-transform:none;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">(2)<font style="margin-left:108pt;"></font>Tenant&#8217;s rights under this <font style="text-decoration:underline;">Exhibit&#160;M</font> shall terminate if (1)&#160;this Lease or Tenant&#8217;s right to possession of the Premises is terminated, (2)&#160;Tenant assigns any of its interest in this Lease or sublets any portion of the Premises to any party (except for Permitted Transfers), or (3)&#160;Tenant fails to timely exercise its option under this <font style="text-decoration:underline;">Exhibit&#160;M</font>, time being of the essence with respect to Tenant&#8217;s exercise thereof.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU83"></a><font style="text-decoration:underline;">EXHIBIT M-1</font><font style="text-decoration:underline;"><br /></font><font style="text-decoration:underline;"><br />ROFO AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">THIS RIGHT OF FIRST OFFER AGREEMENT (this &#8220;<font style="font-weight:bold;">Agreement</font>&#8221;) is entered into this ____ day of _____________, 2017, by and between <font style="font-weight:bold;text-transform:uppercase;">MARINA BOULEVARD Property, LLC</font>, a Delaware limited liability company (&#8220;<font style="font-weight:bold;">Owner</font>&#8221;), and <font style="font-weight:bold;">SANGAMO THERAPEUTICS, INC.</font>, a Delaware corporation (&#8220;<font style="font-weight:bold;">Offeree</font>&#8221;).&nbsp;&nbsp;Owner and Offeree are sometimes hereinafter individually or collectively called a &#8220;<font style="font-weight:bold;">Party</font>&#8221; or the &#8220;<font style="font-weight:bold;">Parties</font>&#8221;.</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">RECITALS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A.<font style="margin-left:72pt;"></font>Offeree has leased from Owner pursuant to that certain Lease Agreement dated November&#160;3, 2017 between Offeror and Offeree (&#8220;<font style="font-weight:bold;">Lease</font>&#8221;) certain real property located in the City of Brisbane, State of California, which is more particularly described on <font style="text-decoration:underline;">Exhibit&#160;A</font> attached hereto and the improvements located thereon (collectively, the &#8220;<font style="font-weight:bold;">Property</font>&#8221;).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">B.<font style="margin-left:72pt;"></font>As an inducement to Offeree to execute the Lease, Owner has agreed not to &#8220;<font style="font-weight:bold;">Transfer</font>&#8221; (as defined below) the Property to a third party during the period commencing on the Commencement Date and expiring on the third (3rd) anniversary of the Commencement Date (&#8220;<font style="font-weight:bold;">ROFO Period</font>&#8221;) without first providing Offeree with a right of first offer (&#8220;<font style="font-weight:bold;">ROFO</font>&#8221;) to purchase the Property, subject to the conditions set forth in <font style="text-decoration:underline;">Exhibit&#160;M</font> to the Lease.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">C.<font style="margin-left:72pt;"></font>This Agreement is subject and subordinate to any Deed of Trust now or hereafter existing on the Property.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">D.<font style="margin-left:72pt;"></font>Initially capitalized terms used herein without definition shall have the meaning set forth in the Lease. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">E.<font style="margin-left:72pt;"></font>Any sale shall be subject to compliance with the California Subdivision Map Act to create a separate legal parcel for the Building. </p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW, THEREFORE, in consideration of the foregoing and other valuable consideration, the receipt of which are hereby acknowledged, Owner hereby grants to Offeree a right of first offer for the Property as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 1.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Grant of Right of First Offer</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1.<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Transfer</font><font style="font-weight:normal;">.&nbsp;&nbsp;During the ROFO Period, Owner shall not Transfer (as hereinafter defined) its fee interest in the Property (hereinafter, the &#8220;</font>Premises<font style="font-weight:normal;">&#8221;) except in accordance with the provisions of this Agreement, subject to the conditions set forth in </font><font style="text-decoration:underline;font-weight:normal;">Exhibit&#160;M</font><font style="font-weight:normal;"> to the Lease.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU84"></a>(a)<font style="margin-left:180pt;"></font><font style="text-decoration:underline;">Procedure</font>.&nbsp;&nbsp;Owner shall give notice to Offeree (the &#8220;<font style="font-weight:bold;">Offer Notice</font>&#8221;) when Owner desires to Transfer the Premises to a third party (i.e., whether or not Owner has received a third party offer it elects to pursue).&nbsp;&nbsp;The Offer Notice shall describe Owner&#8217;s proposed Transfer and all of the economic and non-economic terms and conditions applicable to Offeree&#8217;s purchase of the Premises.&nbsp;&nbsp;For purposes of this Agreement, the term &#8220;<font style="font-weight:bold;">economic terms</font>&#8221; shall be defined to mean only those economic terms that are to be accounted for on a final escrow closing/settlement statement.&nbsp;&nbsp;The &#8220;<font style="font-weight:bold;">non-economic terms</font>&#8221; shall be on terms as set forth in the form purchase and sale agreement (&#8220;<font style="font-weight:bold;">Purchase </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-1</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;">Agreement</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;) to be agreed upon by the parties hereto in their commercially reasonable determination (collectively, the &#8220;</font><font style="font-weight:bold;">Offer Ter</font><font style="font-weight:bold;">ms</font><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:180pt;"></font><font style="text-decoration:underline;">Procedure for Acceptance</font>.&nbsp;&nbsp;Within ten (10) business days after delivery of the Offer Notice (the &#8220;<font style="font-weight:bold;">Offer Election Date</font>&#8221;), Offeree shall deliver written notice to Owner (&#8220;<font style="font-weight:bold;">Offeree&#8217;s Election Notice</font>&#8221;) pursuant to which Offeree shall elect either to (i)&#160;purchase the Premises pursuant to the Offer Terms set forth in the Offer Notice, or (ii)&#160;decline to purchase the Premises, in which event this Agreement and the ROFO set forth herein and in the Lease shall thereupon terminate and be of no further force or effect (unless reinstated pursuant to the below described terms).&nbsp;&nbsp;In the event Offeree elects to purchase the Premises, Offeree shall deliver with Offeree&#8217;s Election Notice to Owner a signed Purchase Agreement with the Offer Terms set forth.&nbsp;&nbsp;If Offeree does not so respond in writing to Owner&#8217;s Offer Notice by the Offer Election Date, Offeree shall be irrevocably deemed to have elected the option described in clause (ii) above, in which event Offeree&#8217;s ROFO set forth herein and in the Lease shall thereupon terminate, subject to reinstatement pursuant to <font style="text-decoration:underline;">Section 1.2</font> below.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:180pt;"></font><font style="text-decoration:underline;">Owner&#8217;s Response</font>.&nbsp;&nbsp;If Offeree elects to purchase the Premises, then within five (5) business days after receipt of Offeree&#8217;s Election Notice, Owner shall return to Offeree and Escrow Holder as identified in the Purchase Agreement a signed counterpart of the Purchase Agreement with the Offer Terms incorporated therein.&nbsp;&nbsp;If the parties have not mutually executed and delivered the Purchase Agreement within thirty (30) days following Offeree&#8217;s Election Notice, or if Offeree does not elect to purchase the Premises, Owner may, at its election, and subject to the terms of this paragraph, during the twelve (12) month period following the date of the Offer Notice, enter into a letter of intent or purchase and sale agreement to sell and thereby Transfer the Premises described in the Offer Notice to any entity at such economic and non-economic terms as are acceptable to Owner and such third party purchaser without any Material Modification (as described in <font style="text-decoration:underline;">Section 1.2</font> below) to the Offer Terms.&nbsp;&nbsp;If Owner does not Transfer the Premises described in the Offer Notice within the above described twelve (12) month period (and subject to <font style="text-decoration:underline;">Section 1.2</font> below), then Owner shall submit to Offeree a new Offer Notice with respect to the Premises prior to selling the Premises upon terms and conditions set forth in the new Offer Notice.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:38.46%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:216pt;"></font>Nothing herein shall prevent or restrict Offeree from making a subsequent offer for the Premises or from participating as a bidder in Owner&#8217;s marketing of the Premises.&nbsp;&nbsp;Owner shall use its reasonable efforts, without any liability for failure to do so, to furnish Offeree with the marketing information related to the Premises.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2.<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Material Modification</font><font style="font-weight:normal;">.&nbsp;&nbsp;For purposes of this Agreement, a Material Modification shall mean any decrease of more than ten percent (10%) in the economic terms (or change in cost allocations of the Purchase Agreement that would have the same effect).&nbsp;&nbsp;If the Owner&#8217;s proposed Transfer is at economic terms of ninety percent (90%) or more than proposed Offer Terms to Offeree set forth in the Offer Notice, Owner shall have no obligation to submit such Transfer to Offeree.&nbsp;&nbsp;If Owner desires to Transfer and such Transfer contains a Material Modification, then prior to execution of a letter of intent or purchase and sale agreement, whichever occurs first, Owner shall provide Offeree with a written notice of the revised economic terms.&nbsp;&nbsp;Offeree shall have five (5) business days to accept such revised terms by written notice to Owner.&nbsp;&nbsp;Five (5) business days shall mean by 5:00&#160;p.m. Pacific time on the fifth (5<sup style="font-size:85%; vertical-align:top">th</sup>) business day following the submission of such revised economic terms to Offeree.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3.<font style="margin-left:144pt;"></font><font style="text-decoration:underline;">Termination of Right of First Offer</font><font style="font-weight:normal;">.&nbsp;&nbsp;If pursuant to this Agreement Owner completes the Transfer of the Premises described in the Offer Notice to a third party, then this Agreement and the ROFO set forth in the Lease shall terminate as to the Premises described in the Offer Notice.&nbsp;&nbsp;This Agreement shall also terminate if Offeree fails to close the purchase pursuant to the Purchase Agreement executed by Offeree and Owner, unless excused thereunder including as a result of Owner&#8217;s default.</font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-2</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU85"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 2.</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Transfer Defined</font><font style="font-weight:normal;">.&nbsp;&nbsp;As used in this Agreement, the term &#8220;</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">transfer</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Transfer</font><font style="font-weight:normal;">&#8221; shall be defined to mean any sale, or other conveyance of fee title, in the Premises to a third party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 3.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Assignment</font><font style="font-weight:normal;">.&nbsp;&nbsp;Offeree and Owner may not voluntarily or by operation of law assign or transfer any right, interest or obligation hereunder without the other party&#8217;s express prior written consent, which consent may be given or withheld in such party&#8217;s sole discretion for any reason whatsoever.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 4.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Notices</font><font style="font-weight:normal;">.&nbsp;&nbsp;Any notice which a Party is required or may desire to give another Party shall be in writing and may be delivered (1)&#160;personally, (2)&#160;by United States registered or certified mail, postage prepaid, or (3)&#160;by Federal Express or other reputable courier service regularly providing evidence of delivery (with charges paid by the Party sending the notice).&nbsp;&nbsp;Any such notice to a Party shall be addressed at the address set forth below (subject to the right of a Party to designate a different address for itself by notice similarly given).&nbsp;&nbsp;Service of any such notice or other communications so made shall be deemed effective on the day of actual delivery (whether accepted or refused), as shown by the addressee&#8217;s return receipt if by certified mail, and as confirmed by the courier service if by courier; provided, however, that if such actual delivery occurs after 5:00 p.m.&nbsp;&nbsp;(local time where received) or on a non-business day, then such notice or demand so made shall be deemed effective on the first business day after the day of actual delivery.&nbsp;&nbsp;Except as expressly provided otherwise in this Agreement, no communications via facsimile or electronic mail shall be effective to give any notice, request, direction, demand, consent, waiver, approval or other communications hereunder.&nbsp;&nbsp;The Parties&#8217; addresses for notices are as follows:</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:-23.08%;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">If to Owner</font>:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.23%;width:501.85pt;;">
<tr>
<td style="width:254.4pt;"></td>
<td style="width:247.45pt;"></td>
</tr>
<tr style="height:89.65pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marina Boulevard Property, LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">c/o Westport Capital Partners LLC</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2121 Rosecrans Avenue</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Suite 4325</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">El Segundo, California&nbsp;&nbsp;90245</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.75pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Attention:&nbsp;&nbsp;Eric Clapp, Managing Director</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:6pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:30.77%;text-indent:-23.08%;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">With Copy to:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;letter-spacing:-0.15pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">DLA Piper LLP (US)<br />550 South Hope Street, Suite 2300<br />Los Angeles, California 90071<br />Attention: Jackie K. Park, Esq.<br />Telephone: (213) 330-7743</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:89.69%;">
<tr>
<td style="width:419.75pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">If to Offeree</font>:</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:36pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc.<br />7000 Marina Boulevard<br />Brisbane, CA 94005<br />Attention:&nbsp;&nbsp;Director of Legal</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU86"></a>Section 5.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Dispute Costs</font><font style="font-weight:normal;">.&nbsp;&nbsp;If either party commences litigation against the other for the specific performance of this Agreement, for damages for the breach hereof or otherwise for enforcement of any remedy hereunder, the parties hereto agree to and hereby do waive any right to a trial by jury and, in the event of any such commencement of litigation, the prevailing party shall be entitled to recover from the </font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-3</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">other party such costs and reasonable attorneys&#8217; fees as may have been incurred.&nbsp;&nbsp;Whenever the term is used in this Agreemen</font><font style="font-weight:normal;">t, the term &#8220;attorneys&#8217; fees&#8221; (and similar references in this instrument to recovery of costs for use of legal counsel) include, without limitation, all attorneys&#8217; and paralegals&#8217; fees and expenses, whether in an action or proceeding, upon appeal therefrom</font><font style="font-weight:normal;">, or in connection with any petition for review or action for rescission, or in connection with any other action to interpret or enforce any of the provisions of this Agreement. This provision is separate and several and shall survive merger of this provis</font><font style="font-weight:normal;">ion into any judgment on this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 6.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Survival</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement and the provisions hereof shall inure to the benefit of and be binding upon the Parties to this Agreement and their respective successors, heirs and permitted assigns.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 7.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Entire Agreement</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement, together with the other written agreements referred to herein and </font><font style="text-decoration:underline;font-weight:normal;">Exhibit&#160;A</font><font style="font-weight:normal;"> attached hereto, is intended by the Parties to be the final expression of their agreement with respect to the subject matter hereof, and is intended as the complete and exclusive statement of the terms of the agreement between the Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 8.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Modifications</font><font style="font-weight:normal;">.&nbsp;&nbsp;No modification of this Agreement shall be effective unless set forth in writing and signed by both Parties.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 9.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Severability</font><font style="font-weight:normal;">.&nbsp;&nbsp;If any provision of this Agreement, or the application thereof, shall for any reason and to any extent be invalid or unenforceable, the remainder of this Agreement and application of such provision to other circumstances, shall be interpreted so as best to reasonably effect the intent of the Parties hereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 10.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Waiver</font><font style="font-weight:normal;">.&nbsp;&nbsp;The waiver by either Party of any breach by the other Party of any term, covenant or condition herein contained or either Party&#8217;s failure or delay to exercise any right, power or privilege hereunder will not be deemed to be a waiver thereof or any subsequent breach, failure or delay.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 11.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Execution; Counterparts</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement may be executed in two (2) or more counterparts, all of which together as to the same such document shall constitute one and the same agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 12.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Interpretation; Governing Law</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement shall be construed as if prepared by both Parties.&nbsp;&nbsp;Accordingly, any rule of law or legal decision that would require interpretation of any ambiguities in this Agreement against the Party that has drafted it is not applicable and is waived.&nbsp;&nbsp;This Agreement shall be construed, interpreted and governed by the laws of the State of California and the laws of the United States of America prevailing in California.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 13.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Further Assurances</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party shall execute such further documents and take such further actions as may be necessary or appropriate to consummate the transaction contemplated by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 14.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Time of the Essence</font><font style="font-weight:normal;">.&nbsp;&nbsp;Time is of the essence of this Agreement and each and every term and provision hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 15.<font style="margin-left:72pt;"></font><font style="text-decoration:underline;">No Third Party Beneficiaries</font><font style="font-weight:normal;">.&nbsp;&nbsp;Except as otherwise expressly set forth herein, Owner and Offeree do not intend, and this Agreement shall not be construed, to create a third-party beneficiary status or interest in, nor give any third-party beneficiary rights or remedies to, any other person or entity not a party to this Agreement.</font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-4</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU87"></a><font style="font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Section 16.</font><font style="margin-left:72pt;"></font><font style="text-decoration:underline;">Memorandum</font><font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement shall not be recorded or placed of public record.&nbsp;&nbsp;Notwithstanding the foregoing, Owner and Offeree agree that, within five (5) business days following the other party&#8217;s request</font><font style="font-weight:normal;"> therefor, to execute and deliver to the requesting party, a memorandum of this Agreement, acceptable to both parties, which may, at the requesting party&#8217;s option, be recorded in the public records of the county in which the Premises is located; provided, </font><font style="font-weight:normal;">however, that the form of memorandum must include a provision pursuant to which Owner can unilaterally record an effective termination thereof upon the expiration thereof and that such offer is contingent upon satisfaction of certain conditions.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[Signatures on following page]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU88"></a><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-5</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the undersigned have executed this Agreement as of the date first above written.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:478.6pt;;">
<tr>
<td style="width:212.75pt;"></td>
<td style="width:265.85pt;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OWNER:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">MARINA BOULEVARD PROPERTY, LLC<font style="font-weight:normal;">,</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">a Delaware limited liability company</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">OFFEREE:</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_28"></a>SANGAMO THERAPEUTICS, INC<font style="font-weight:normal;">.,</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_29"></a><a name="_cp_text_1_29"></a>a Delaware corporation</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Print Name:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU89"></a><font style="text-decoration:underline;"><br /></font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-6</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">EXHIBIT A TO ROFO AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">LEGAL DESCRIPTION OF THE PROPERTY</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT M-1-7</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU90"></a><font style="text-decoration:underline;">EXHIBIT N</font></p>
<p style="text-align:center;margin-bottom:9pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">ESCROW AGREEMENT</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531707031130.jpg" title="" alt="" style="width:587px;height:783px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-1</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU91"></a><img src="g2018030121531709731131.jpg" title="" alt="" style="width:624px;height:819px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-2</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU92"></a><img src="g2018030121531712731132.jpg" title="" alt="" style="width:624px;height:781px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-3</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU93"></a><img src="g2018030121531715831133.jpg" title="" alt="" style="width:624px;height:821px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-4</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU94"></a><img src="g2018030121531718431134.jpg" title="" alt="" style="width:624px;height:510px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-5</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531720831135.jpg" title="" alt="" style="width:624px;height:379px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-6</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU95"></a><img src="g2018030121531722631136.jpg" title="" alt="" style="width:624px;height:826px;"><font style="font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></font></p>
<p style="margin-top:12pt;line-height:10pt;margin-bottom:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="text-decoration:underline;">EXHIBIT N-7</font><font style="margin-left:36pt;"></font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#auto;font-size:8pt;font-family:Times New Roman;letter-spacing:0pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:none;"><strike Style="text-decoration:none;">151177627 v8</strike></font><font style="font-size:11pt;color:#000000;"> </font></p>
<p style="line-height:10pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>6
<FILENAME>sgmo-ex1040_689.htm
<DESCRIPTION>EX-10.40
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex1040_689.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT 10.40</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:11pt;font-variant: small-caps;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:3pt;margin-top:12pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;font-size:12pt;font-weight:bold;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;font-variant: normal;">research collaboration and license AGREEMENT</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">by and between</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Pfizer Inc.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Sangamo Therapeutics, Inc.</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 28, 2017</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><br /></p>
<p style="margin-top:12pt;line-height:10pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:24pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a><font style="font-size:12pt;font-weight:bold;text-transform:uppercase;font-family:Times New Roman;font-style:normal;font-variant: normal;">RESEARCH COLLABORATION AND LICENSE AGREEMENT</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">This Research Collaboration and License Agreement (the &#8220;<font style="text-decoration:underline;">Agreement</font>&#8221;) is entered into as of December 28, 2017 (the &#8220;<font style="text-decoration:underline;">Effective Date</font>&#8221;), by and between <font style="font-weight:bold;">Pfizer Inc.</font>, a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (&#8220;<font style="text-decoration:underline;">Pfizer</font>&#8221;) and <font style="font-weight:bold;">Sangamo Therapeutics, Inc.</font>, a corporation organized and existing under the laws of Delaware and having a principal place of business at 501 Canal Blvd., Richmond, CA 94804 (&#8220;<font style="text-decoration:underline;">Sangamo</font>&#8221;). Pfizer and Sangamo may each be referred to herein individually as a &#8220;<font style="text-decoration:underline;">Party</font>&#8221; and collectively as the &#8220;<font style="text-decoration:underline;">Parties</font>.&#8221; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Sangamo owns or otherwise controls certain patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to the identification, research and development of Compounds<font style="font-weight:bold;font-style:italic;"> </font>(as defined below);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Pfizer has extensive experience and expertise in the development and commercialization of pharmaceutical and biopharmaceutical products; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, subject to the terms of this Agreement, Sangamo wishes to grant to Pfizer, and Pfizer wishes to receive from Sangamo, an exclusive license in the Field (as defined below) in the Territory (as defined below) under Sangamo&#8217;s and its licensors&#8217; patents, patent applications, technology, know-how, scientific and technical information and other proprietary rights and information relating to Compounds and Products to use, research, develop, manufacture and commercialize Products; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, Pfizer and Sangamo wish to engage in collaborative pre-clinical research pursuant to the Research Plan (as defined below) to identify and develop Compounds for inclusion in Products (as defined below) to be advanced to clinical trials for further development and commercialization by Pfizer; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">WHEREAS, subject to the terms of this Agreement, Sangamo wishes to grant to Pfizer, and Pfizer wishes to receive from Sangamo, an exclusive license in the Field in the Territory to use, research, develop, manufacture and commercialize Products.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">NOW THEREFORE, in consideration of the mutual promises and covenants set forth below and other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties hereby agree as follows: </p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 1<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">DEFINITIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;"><font style="font-weight:normal;">Unless the context otherwise requires, the terms in this Agreement with initial letters capitalized shall have the meanings set forth below: </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><a name="_DV_M61"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.1</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Affiliate</font><font style="font-weight:normal;">&#8221; means, with respect to any Person, any other Person that controls, is </font><font style="color:#000000;font-weight:normal;">controlled </font><font style="font-weight:normal;">by, </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">is under common </font><font style="color:#000000;font-weight:normal;">control </font><font style="font-weight:normal;">with</font><font style="font-weight:normal;">, such Person.&nbsp;&nbsp;For purposes of this </font><font style="color:#000000;font-weight:normal;">Agreement</font><font style="font-weight:normal;">, a Person shall be deemed to </font><font style="color:#000000;font-weight:normal;">control </font><font style="font-weight:normal;">another Person if it owns </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">controls, directly </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">indirectly, at least </font><font style="color:#000000;font-weight:normal;">fifty percent (50%) </font><font style="font-weight:normal;">of the equity securities (or other ownership interests, by contract or otherwise</font><font style="font-weight:normal;">) of such other Person entitled to vote in the election of directors (</font><font style="color:#000000;font-weight:normal;">or</font><font style="font-weight:normal;">, in the case that such other Person is not a corporation, for the election of the corresponding managing authority), </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">otherwise has the power to direct the management and policies o</font><font style="font-weight:normal;">f such other Person; </font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;">, </font><font style="font-style:italic;font-weight:normal;">however</font><font style="font-weight:normal;">, that where an entity owns a majority of the voting power necessary to elect a majority of the board of directors or other governing board of another entity, but is restricted from electing such majority by contract o</font><font style="font-weight:normal;"><a name="_DV_M61"></a>r otherwise, such entity will not be considered to be in control of such other entity until such time as such restrictions are no longer in effect</font><font style="font-weight:normal;">.&nbsp;&nbsp;The Parties acknowledge that in the case of certain entities organized under the laws of certain countries </font><font style="font-weight:normal;">outside the United States, the maximum percentage ownership permitted by law for a foreign investor may be less than fifty percent (50%), and that in such case such lower percentage will be substituted in the preceding sentence, provided that such foreign </font><font style="font-weight:normal;">investor has the power to direct the management and policies of such entity.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.2<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Bankruptcy Event</font><font style="font-weight:normal;">&#8221; means the occurrence of any of the following: (a) the institution of any bankruptcy, receivership, insolvency, reorganization or other similar proceedings by or against a Party under any bankruptcy, insolvency, or other similar law now or hereinafter in effect, including any section or chapter of the United States Bankruptcy Code, as amended or under any similar laws or statutes of the United States or any state thereof (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Bankruptcy Code</font><font style="font-weight:normal;">&#8221;), where in the case of involuntary proceedings such proceedings have not been dismissed or discharged within ninety (90) days after they are instituted, (b) the filing of an insolvency proceeding or making of an assignment for the benefit of creditors, (c) appointment of a receiver for all or substantially all of a Party&#8217;s assets or (d) any corporate action taken by the board of directors of a Party in furtherance of any of the foregoing actions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.3<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Binding Obligation</font><font style="font-weight:normal;">&#8221; means, with respect to a Party: (a) any oral or written agreement or arrangement between such Party and an Affiliate of such Party or a Third Party that binds or affects such Party&#8217;s operations or property, including any assignment, license agreement, loan agreement, guaranty, or financing agreement, (b) the provisions of such Party&#8217;s charter, bylaws or other organizational documents or (c) any order, writ, injunction, decree or judgment of any court or Governmental Authority entered against such Party or by which any of such Party&#8217;s operations or property are bound. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_1"></a><a name="_cp_text_1_2"></a>1.4<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Biosimilar Notice</font><font style="font-weight:normal;">&#8221; means a copy of any application submitted by a Third Party to the FDA under 42 U.S.C. &#167; 262(k) of the Public Health Service Act (or, in the case of a country of the Territory outside the United States, any similar law) for Regulatory Approval of a biopharmaceutical product, which application identifies a Product as the Reference Product with respect to such product, and other information that describes the process or processes used to manufacture the biopharmaceutical product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_4"></a><a name="_cp_blt_2_3"></a><a name="_AEIOULastRenderedPageBreakAEIOU5"></a>1.5<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Biosimilar Product</font><font style="font-weight:normal;">&#8221; means, with respect to a Product that is being sold in a country or regulatory jurisdiction in the Territory (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Reference Product</font><font style="font-weight:normal;">&#8221;), any </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">biopharmaceutical product sold by a Third Party (ot</font><font style="font-weight:normal;">her than a Third Party acting on behalf of or in concert with Pfizer or any Pfizer Affiliate or Sublicensee, or that purchased such product in a chain of distribution that included Pfizer or any of its Affiliates or Sublicensees) in such country or regulat</font><font style="font-weight:normal;">ory jurisdiction in the Territory </font><font style="font-weight:normal;">that (i) [ * ] the Reference Product, and (ii) through reference to the BLA of the Reference Product, is eligible for and has achieved Marketing Approval (with all references in such definition to Product to be deemed refe</font><font style="font-weight:normal;">rences to such bio</font><font style="font-weight:normal;">pharmaceutical</font><font style="font-weight:normal;"> product) in such country or regulatory jurisdiction pursuant to an abbreviated follow-on biological approval pathway established by the Regulatory Authority in such country or regulatory jurisdiction pursuant to the applica</font><font style="font-weight:normal;">ble Law, or otherwise is approved for marketing and sale in such country or regulatory jurisdiction by an abridged procedure in reliance, in whole or in part, on the BLA of the Reference Product, including any such biopharmaceutical product </font><font style="font-weight:normal;">that (a) </font><font style="font-weight:normal;">with r</font><font style="font-weight:normal;">espect to such biopharmaceutical product in the United States, </font><font style="font-weight:normal;">has been approved or licensed as a biosimilar or interchangeable product by FDA pursuant to Section 351(k) of the Public Health Service Act (42 U.S.C. </font><font style="font-weight:normal;">&#167;</font><font style="font-weight:normal;">262(k)), </font><font style="font-weight:normal;">as may be amended, or any subseq</font><font style="font-weight:normal;">uent or superseding law, statute or regulation, (b) with respect to such biopharmaceutical product subject to the regulatory jurisdiction of the EMA, has been approved as a similar biological medicine product </font><font style="font-weight:normal;">by EMA </font><font style="font-weight:normal;">as described in CHMP/437/04, issued 30 O</font><font style="font-weight:normal;">ctober 2005, as may be amended, or any subsequent or superseding law, statute or regulation</font><font style="font-weight:normal;">, or (c) </font><font style="font-weight:normal;">with respect to such biopharmaceutical product outside the United States and in a country which is not subject to the regulatory jurisdiction of the EMA, ha</font><font style="font-weight:normal;">s otherwise obtained Marketing Approval</font><font style="font-weight:normal;"> </font><font style="font-weight:normal;">(with all references in such definition to Product to be deemed references to such bio</font><font style="font-weight:normal;">pharmaceutical</font><font style="font-weight:normal;"> product) </font><font style="font-weight:normal;">by Regulatory Authorities in such other jurisdictions under analogous laws and regulations as those descri</font><font style="font-weight:normal;">bed the foregoing subsections (a) or (b).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_6"></a><a name="_cp_blt_2_5"></a>1.6<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">BLA</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Biologic License Application</font><font style="font-weight:normal;">&#8221; means (a) an application requesting permission from the FDA to introduce, or deliver for introduction, a biopharmaceutical product into interstate commerce, or (b) any similar application or submission for Marketing Approval of a biopharmaceutical product filed with a Regulatory Authority in a country or group of countries. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_8"></a><a name="_cp_blt_2_7"></a>1.7<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Business Day</font><font style="font-weight:normal;">&#8221; means a day other than a Saturday, Sunday or a bank or other public holiday in California or New York.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_10"></a><a name="_cp_blt_2_9"></a>1.8<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Calendar Quarter</font><font style="font-weight:normal;">&#8221; means a period of three consecutive calendar months ending on March 31, June 30, September 30 or December 31.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_12"></a><a name="_cp_blt_2_11"></a>1.9<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Calendar Year</font><font style="font-weight:normal;">&#8221; means any twelve (12) month period beginning on January 1 and ending on the first December 31 thereafter.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_2_14"></a><a name="_cp_blt_2_16"></a><a name="_AEIOULastRenderedPageBreakAEIOU6"></a>1.10<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Change of Control</font><font style="font-weight:normal;">&#8221; means, with respect to a Party, (a) a merger, reorganization, combination or consolidation of such Party with a Third Party that results in holders of beneficial ownership (other than by virtue of obtaining irrevocable proxies) of the voting securities or other voting interests of such Party (or, if applicable, the ultimate parent of such Party) immediately prior to such merger, reorganization, combination or consolidation ceasing to hold beneficial ownership of at least fifty percent (50%) of the combined voting power of the surviving entity or the parent of the surviving entity immediately after such merger, reorganization, combination or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">consolidation, (b) a transaction or series of related transactions in which a Third Party, together with its Affiliates, becomes the beneficial owner (other than by virt</font><font style="font-weight:normal;">ue of obtaining irrevocable proxies) of fifty percent (50%) or more of the combined voting power of the outstanding securities or other voting interest of such Party, or (c) the sale, lease, exchange, contribution or other transfer (in one transaction or a</font><font style="font-weight:normal;"> series of related transactions) to a Third Party of all or substantially all of such Party&#8217;s assets to which this Agreement relates, other than a sale or disposition of such assets to an Affiliate of such Party or (d) the approval of any plan or proposal </font><font style="font-weight:normal;">for the liquidation or dissolution of such Party (other than in circumstances where such Party is deemed a debtor pursuant to Section 8.2(c)).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.11<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercialize</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercialization</font><font style="font-weight:normal;">&#8221; means to (a) market, promote, distribute, offer for sale, sell, have sold, import, have imported, export, have exported&nbsp;&nbsp;or otherwise commercialize a compound or product and (b) conduct pre-clinical, clinical and other Development activities with respect to a compound or product, in each case, after such compound or product has received Marketing Approval.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.12<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Commercially Reasonable Efforts</font><font style="font-weight:normal;">&#8221; means, with respect to the efforts to be expended by a Party with respect to any objective, those reasonable, good faith efforts to accomplish such objective as such Party would normally use to accomplish a similar objective under similar circumstances. With respect to any efforts relating to the Development, Marketing Approval, Manufacturing or Commercialization of a Product by a Party, generally or with respect to any particular country in the Territory, such Party will be deemed to have exercised &#8220;Commercially Reasonable Efforts&#8221; if such Party has exercised those efforts that would be normally used by such Party, in the relevant country, with respect to other gene therapy products or gene therapy product candidates, as applicable, (a) of similar modality controlled by such Party; or (b) (i) to which such Party has similar rights, (ii) which is of similar market potential in such country, and (iii) which is at a similar stage in its development or product life cycle, as such Product, in each case, taking into account all Relevant Factors in effect at the time such efforts are to be expended. Further, to the extent that the performance of a Party&#8217;s obligations hereunder is adversely affected by the other Party&#8217;s failure to perform its obligations hereunder, the impact of such performance failure will be taken into account in determining whether such Party has used its Commercially Reasonable Efforts to perform any such affected obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_18"></a><a name="_cp_text_1_22"></a>1.13<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Companion Diagnostic Assay</font><font style="font-weight:normal;">&#8221; means</font> <font style="font-weight:normal;"><a name="_cp_text_1_18"></a>a diagnostic assay for (i) <a name="_cp_text_1_22"></a>[ * ], (ii) [ * ], or (iii) [ * ].&nbsp;&nbsp;For clarity, any such assay may, but need not necessarily, include as a component(s) thereof any component(s) of any Product.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.14<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Compliance</font><font style="font-weight:normal;">&#8221; means, with respect to a Party, the adherence by such Party and its Affiliates in all material respects to all applicable Laws and such Party&#8217;s Party Specific Regulations, in each case with respect to the activities to be conducted under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU7"></a>1.15<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Compound</font><font style="font-weight:normal;">&#8221; means any zinc finger fusion protein which arises from or existed prior to the Effective Date and which is evaluated pursuant to the Research Plan, or is a derivative thereof created by Sangamo pursuant to the Agreement, that (a) specifically binds, as set forth in the Research Plan or otherwise agreed by the Parties, to an allele of the chromosome </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">9 open reading frame 72 gene (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">C9ORF72</font><font style="font-weight:normal;">&#8221;) that contains more than [ * ] hexanucleotide repeats and (b) (i) [ * ] or (ii) [ * ], in each of (i) and (ii) at or ab</font><font style="font-weight:normal;">ove the levels specified in the Research Plan or otherwise agreed by the Parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.16<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Confidential Information</font><font style="font-weight:normal;">&#8221; of a Party means all Know-How, or other information, including proprietary information (whether or not patentable) regarding or embodying such Party&#8217;s or its Representatives&#8217; technology, products, business information or objectives, including but not limited to unpublished patent applications and other non-public information and data of a financial, commercial, business, operational or technical nature (including information comprising or relating to concepts, discoveries, inventions, data, designs or formulae), that is disclosed by or on behalf of such Party or any of its Affiliates or otherwise made available to the other Party or any of its Affiliates, whether made available orally, in writing or in electronic form, in connection with this Agreement on or after the Effective Date (or as otherwise provided in Section 12.12), but only to the extent that such Know-How or other information in written form is marked in writing as &#8220;confidential&#8221; at the time of disclosure, and such Know-How or other information disclosed orally or in non-tangible form is identified by the Disclosing Party as &#8220;confidential&#8221; at the time of disclosure.&nbsp;&nbsp;Failure to mark Confidential Information disclosed in writing hereunder as &#8220;Confidential&#8221; shall not cause the information to be considered non-confidential, with the burden on the disclosing Party to prove such information should have been known by a reasonable person with expertise on the subject matter, based on the nature of the information and the circumstances of its disclosure, to be Confidential Information, provided that the disclosing Party has otherwise made good faith efforts to clearly mark Confidential Information as such.&nbsp;&nbsp;&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.17<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Control</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Controlled</font><font style="font-weight:normal;">&#8221; means, with respect to any Patent Rights, Know-How or other intellectual property right, that a Party (a) owns or (b) has a license (other than a license granted to such Party under this Agreement) to such Patent Rights, Know-How or intellectual property right and, in each case, has the ability to grant to the other Party a license, sublicense or access (as applicable) to the foregoing on the terms and conditions set forth in this Agreement without violating the terms of any then-existing agreement or arrangement with any Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.18<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Cover</font><font style="font-weight:normal;">&#8221; means, with respect to a given Product and Patent Right, that a Valid Claim of such Patent Right would, absent a license thereunder or ownership thereof, be infringed by the making, use, sale, offer for sale or importation of such Product, and for purpose of determining such infringement, considering Valid Claims of pending patent applications, such claims should be considered as if they have already been issued in accordance with the definition of Valid Claim. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.19<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Current License</font><font style="font-weight:normal;">&#8221; means any agreement (i) that Sangamo or its Affiliates has entered into with a Third Party prior to the Effective Date and (ii) pursuant to which Sangamo or its Affiliates have a license from such Third Party to any Licensed Technology or Licensed Companion Diagnostic Technology as of the Effective Date.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.20<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Current Licensor</font><font style="font-weight:normal;">&#8221; means any Third Party that is a party to a Current License.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU8"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.21</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Develop</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Development</font><font style="font-weight:normal;">&#8221; means all development activities for any Product, </font><font style="font-weight:normal;">including conducting pre-clinical and clinical studies, manufacturing process development, and toxicology studies of a Product for use in clinical trials (including placebos and comparators), statistical analyses, and the preparation, filing and prosecutio</font><font style="font-weight:normal;">n of any BLA for a Product, as well as all regulatory activities related to any of the foregoing, in each case prior to Marketing Approval.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.22<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dollar</font><font style="font-weight:normal;">&#8221; means the U.S. dollar, and &#8220;$&#8221; shall be interpreted accordingly.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.23<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">EMA</font><font style="font-weight:normal;">&#8221; means the European Medicines Agency or any successor entity thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_30"></a><a name="_cp_blt_1_34"></a><a name="_cp_blt_2_33"></a><a name="_cp_text_1_32"></a>1.24<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Executive Officers</font><font style="font-weight:normal;"><a name="_cp_text_1_32"></a>&#8221; means, for Sangamo, the Chief Executive Officer or designee, and for Pfizer, the Chief Scientific Officer of the Rare Disease Research Unit, or designee, or the Global President, Rare Disease, or designee, provided in each case that such person is not a member of the JRC at the time that the applicable disagreement arises. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_36"></a><a name="_cp_blt_2_35"></a>1.25<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">FDA</font><font style="font-weight:normal;">&#8221; means the United States Food and Drug Administration or any successor entity thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_38"></a><a name="_cp_blt_2_37"></a>1.26<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Field</font><font style="font-weight:normal;">&#8221; means the treatment of all human disease syndromes or medical conditions in humans, including but not limited to amyotrophic lateral sclerosis (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">ALS</font><font style="font-weight:normal;">&#8221;) and frontotemporal lobar degeneration (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">FTLD</font><font style="font-weight:normal;">&#8221;), and including the use of any related Companion Diagnostic Assay.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_42"></a><a name="_cp_blt_2_41"></a><a name="_cp_text_1_40"></a>1.27<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Filing</font><font style="font-weight:normal;"><a name="_cp_text_1_40"></a>&#8221; of an IND or BLA means the acceptance by a Regulatory Authority of such IND or BLA for filing and review, if applicable, or otherwise the submission of such IND or BLA.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_46"></a><a name="_cp_blt_2_45"></a><a name="_cp_text_1_44"></a>1.28<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">First Commercial Sale</font><font style="font-weight:normal;">&#8221; means, with respect to a particular </font><font style="color:#000000;font-weight:normal;">Product </font><font style="font-weight:normal;">and country of the Territory, the first </font><font style="color:#000000;font-weight:normal;"><a name="_cp_text_1_44"></a>sale of such Product by Pfizer or any of Pfizer&#8217;s Affiliates or Sublicensees to a Third Party in an Indication in the Field </font><font style="font-weight:normal;">in such country after such Product has been granted </font><font style="color:#000000;font-weight:normal;">Marketing Approval and, where necessary, Pricing Approval by the appropriate Regulatory Authority </font><font style="font-weight:normal;">in such country.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_48"></a><a name="_cp_blt_2_47"></a>1.29<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">GAAP</font><font style="font-weight:normal;">&#8221; means the U.S. generally accepted accounting principles, consistently applied. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_50"></a><a name="_cp_blt_2_49"></a>1.30<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Governmental Authority</font><font style="font-weight:normal;">&#8221; means any national, international, federal, state, provincial or local government, or political subdivision thereof, or any multinational organization or any authority, agency or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory or taxing authority or power, any court or tribunal (or any department, bureau or division thereof, or any governmental arbitrator or arbitral body).&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_52"></a><a name="_cp_blt_2_51"></a><a name="_AEIOULastRenderedPageBreakAEIOU9"></a>1.31<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Government Official</font><font style="font-weight:normal;">&#8221;, to be broadly interpreted, means (a) any elected or appointed government official (e.g., a member of a ministry of health), (b) any employee or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">pers</font><font style="font-weight:normal;">on acting for or on behalf of a government official, Governmental Authority, or other enterprise performing a governmental function, (c) any political party, candidate for public office, officer, employee, or person acting for or on behalf of a political p</font><font style="font-weight:normal;">arty or candidate for public office, and (d) any employee or person acting for or on behalf of a public international organization (e.g., the United Nations).&nbsp;&nbsp;For clarity, HCP employed by government-owned hospitals will be considered Government Officials.</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_54"></a><a name="_cp_blt_2_53"></a>1.32<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">IND</font><font style="font-weight:normal;">&#8221; means any investigational new drug application, clinical trial application, clinical trial exemption or similar or equivalent application or submission for approval to conduct human clinical investigations filed with or submitted to a Regulatory Authority in conformance with the requirements of such Regulatory Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_56"></a><a name="_cp_blt_2_55"></a>1.33<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indication</font><font style="font-weight:normal;">&#8221; means a separate, defined, well-categorized class of human disease syndrome or medical condition for which a separate BLA or a supplement thereto may be filed.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_58"></a><a name="_cp_blt_2_57"></a><a name="_cp_blt_1_60"></a><a name="_cp_blt_2_59"></a>1.34<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Initiate</font><font style="font-weight:normal;">&#8221; or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Initiation</font><font style="font-weight:normal;"><a name="_cp_blt_1_60"></a><a name="_cp_blt_2_59"></a>&#8221; means, with respect to a clinical trial of a Product, the [ * ] in such clinical trial. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.35<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Intellectual Property Rights</font><font style="font-weight:normal;">&#8221; means any and all (a) Patent Rights, (b) proprietary rights in Know How, including trade secret rights, (c) proprietary rights associated with works of authorship and software, including copyrights, moral rights, and copyrightable works, and all applications, registrations, and renewals relating thereto, and derivative works thereof, (d) other forms of proprietary or intellectual property rights however denominated throughout the world, other than trademarks, service marks, trade names, domain names and other indicators of origin.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.36<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Invention</font><font style="font-weight:normal;">&#8221; means any invention, discovery, improvement, modification, process, method, assay, design, protocol, formula, data, know-how or trade secret, whether patentable, copyrightable or otherwise, that is discovered, generated, conceived or reduced to practice by or on behalf of a Party or its Affiliate or Sublicensee through activities conducted under this Agreement, including all rights, title and interest in and to the intellectual property rights therein and thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_62"></a><a name="_cp_blt_2_61"></a>1.37<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Know-How</font><font style="font-weight:normal;">&#8221; means any Know-How, whether or not patentable, excluding any Zinc Finger Research Program Know-How, made or created during the Term in connection with the work conducted under or in connection with this Agreement jointly by (a) Sangamo or any of its Representatives and (b) Pfizer or any of its Representatives. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_64"></a><a name="_cp_blt_2_63"></a>1.38<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Patent Right</font><font style="font-weight:normal;">&#8221; means any Patent Right that claims or discloses any invention included in Joint Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_66"></a><a name="_cp_blt_2_65"></a>1.39<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Joint Technology</font><font style="font-weight:normal;">&#8221; means the Joint Know-How and the Joint Patent Rights. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_68"></a><a name="_cp_blt_2_67"></a>1.40<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Know-How</font><font style="font-weight:normal;">&#8221; means any information, including discoveries, improvements, modifications, processes, methods, assays, designs, protocols, formulas, data, inventions, know-how and trade secrets (in each case, patentable, copyrightable or otherwise), but excluding any Patent Rights.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_70"></a><a name="_cp_blt_2_69"></a><a name="_AEIOULastRenderedPageBreakAEIOU10"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.41</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Law</font><font style="font-weight:normal;">&#8221; means any federal, state, local, foreign or multinational law, statute, standard, ordinance, code, rule, regulation, resolution or promulgation, or any order by any Governmental Authority, or any license, franchise, permit or similar right</font><font style="font-weight:normal;"> granted under any of the foregoing, or any similar provision having the force or effect of law. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_71"></a><a name="_cp_text_1_72"></a>1.42<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Lead Development Compound</font><font style="font-weight:normal;">&#8221; means a Compound that satisfies the following criteria: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">[ * ];</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_29"></a>(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;"><a name="_cp_text_1_29"></a>[ * ]; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_36"></a>(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;"><a name="_cp_text_1_36"></a>[ * ]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_37"></a>Notwithstanding the foregoing, a Compound shall be deemed a &#8220;Lead Development Compound&#8221; if Pfizer elects, [ * ], to conduct any [ * ] study of a Product containing such Compound. Upon making such election (a) Pfizer shall provide Sangamo, prior to initiating such study, with written notice that it intends to conduct such study and (b) the first Development Milestone Event set forth in Section 5.2(a) shall be deemed achieved and payable.&#160; [ * ]; however, should Pfizer not conduct a [ * ] study of a Product [ * ], this Agreement will be deemed terminated pursuant to Section 8.2(a)].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.43<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Companion Diagnostic Technology</font><font style="font-weight:normal;">&#8221; means all Know-How and Patent Rights that are Controlled by Sangamo or its Affiliates as of the Effective Date or during the Term, including for the avoidance of doubt Sangamo&#8217;s interest in Joint Technology, that are necessary or useful for the development, manufacture, use, sale, offer for sale, importation or commercialization of Companion Diagnostic Assays in the Field in the Territory; provided, however, that for purposes of this definition: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the Know-How and Patent Rights owned or Controlled by any Third Party that becomes an Affiliate of Sangamo after the Effective Date as a result of a Change of Control of Sangamo shall not be included in the Licensed Companion Diagnostic Technology unless Sangamo or its Affiliates use or develop such Know-How or Patent Rights in the performance of their activities under the Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">notwithstanding the foregoing, Licensed Companion Diagnostic Technology shall not include:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Excluded Upstream IP pursuant to Section 2.5(a); </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>Know-How and Patent Rights Controlled by Sangamo pursuant to [ * ] and [ * ];</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ], including but not limited to [ * ];</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU11"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Know-How and Patent Rights related to [ * ]; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ], including but not limited to [ * ] Know-How and Patent Rights Controlled by Sangamo pursuant to (<font style="color:#000000;">1) [ * ]</font>, and (2) [ * ]; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ]; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.44<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Know-How</font><font style="font-weight:normal;">&#8221; means the Know-How included in the Licensed Technology. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.45<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Patents</font><font style="font-weight:normal;">&#8221; means the Patent Rights included in the Licensed Technology.&nbsp;&nbsp;As of the Effective Date, the Patent Rights listed on </font><font style="text-decoration:underline;">Exhibit A</font><font style="font-weight:normal;"> are Licensed Patents. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_74"></a>1.46<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Licensed Technology</font><font style="font-weight:normal;">&#8221; means all Know-How and Patent Rights that are Controlled by Sangamo or its Affiliates as of the Effective Date or during the Term<a name="_cp_text_1_74"></a>, including, for avoidance of doubt, Sangamo&#8217;s interest in Joint Technology, that are necessary or useful for the Development, Manufacture, use, sale, offer for sale, importation or Commercialization of Products in the Field in the Territory; provided, however, that for purposes of this definition:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the Know-How and Patent Rights owned or Controlled by any Third Party that becomes an Affiliate of Sangamo after the Effective Date as a result of a Change of Control of Sangamo shall not be included in the Licensed Technology unless Sangamo or its Affiliates use or develop such Know-How or Patent Rights in the performance of their activities under the Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">notwithstanding the foregoing, Licensed Technology shall not include: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Excluded Upstream IP pursuant to Section 2.5(a); </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>Know-How and Patent Rights Controlled by Sangamo pursuant to [ * ];</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ], including but not limited to [ * ];</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ]; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(v)<font style="margin-left:36pt;"></font>Know-How and Patent Rights related to [ * ], including but not limited to [ * ] Know-How and Patent Rights Controlled by Sangamo pursuant to (<font style="color:#000000;">1) [ * ]</font> and (2) [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.47<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major EU Countries</font><font style="font-weight:normal;">&#8221; means [ * ] and &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major EU Country</font><font style="font-weight:normal;">&#8221; means any of the foregoing countries. </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU12"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.48</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Major Market Countries</font><font style="font-weight:normal;">&#8221; means [ * ]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.49<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Manufacture</font><font style="font-weight:normal;">&#8221; means to make, produce, manufacture, process, fill, finish, package, label, perform quality assurance testing, release, ship or store a compound or product or any component thereof. When used as a noun, &#8220;Manufacture&#8221; or &#8220;Manufacturing&#8221; means any and all activities involved in the Manufacture of a compound or product or any component thereof. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.50<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Marketing Approval</font><font style="font-weight:normal;">&#8221; means all technical, medical and scientific licenses, registrations, authorizations and approvals (including approvals of BLAs, supplements and amendments, pre- and post- approvals and labeling approvals) of any Regulatory Authority, necessary for the Commercialization of a Product in a given country or regulatory jurisdiction.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.51<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Net Sales</font><font style="font-weight:normal;">&#8221; means: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a) with respect to a Product that is not a Combination Product, the gross receipts from sales by Pfizer and its Affiliates and Sublicensees of such Product to Third Parties in the Territory that is recorded as revenue by Pfizer or its Affiliate or Sublicensee according to such Person&#8217;s revenue recognition policies consistently applied, less in each case, to the extent actually incurred or allowed with respect to such Product, (i) bad debts actually incurred, (ii) sales returns and allowances actually paid, granted or accrued, including trade, quantity and cash discounts and any other adjustments, including those granted on account of price adjustments, billing errors, rejected goods, damaged or defective goods, recalls, returns, rebates, chargeback rebates, reimbursements or similar payments granted or given to wholesalers or other distributors, buying groups, health care insurance carriers, chain pharmacies, mass merchandisers, staff model HMO&#8217;s, pharmacy benefit managers or other institutions, (iii) adjustments arising from consumer discount programs or other similar programs, (iv) customs or excise duties, sales tax, consumption tax, value added tax, and other taxes (except income taxes) or duties relating to sales of such Product, (v) any payment in respect of sales of such Product to the United States government, any state government or any foreign government, or to any other Governmental Authority, or with respect to any government-subsidized program or managed care organization, and (vi) freight and insurance (to the extent that Pfizer, its Affiliates or its Sublicensees bear the cost of freight and insurance for the Product); and </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b) with respect to sales in a particular country and Pfizer Quarter of a product containing a Product and one or more other therapeutically active ingredients, [ * ] (each a &#8220;<font style="text-decoration:underline;">Combination Product</font>&#8221;), the percentage of the Net Sales in such country of such Combination Product (as determined in accordance with clause (a)) that is calculated as follows:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">if the Product and other therapeutically active ingredient(s) of such Combination Product are each sold separately in such country during such Pfizer Quarter, the fraction </font>A/(A+B), where A is the average sale price of the Product as sold separately in such country and Pfizer Quarter and B is the average sale price of the other therapeutically active ingredient(s) in the Combination Product as sold separately in such country and Pfizer Quarter;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU13"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)</font><font style="margin-left:36pt;">if the Product is sold separately in such country and Pfizer Quarter, but the other therapeutically active ingredient(s) of such Combination Product are not sold separately in such country during such Pfizer Quarter, the fraction A</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/C, where A is the average sale price of the Product as sold separately in such country and Pfizer Quarter and C is the average sale price of the Combination Product in such country and Pfizer Quarter;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">if the Product is not sold separately in such co</font>untry and Pfizer Quarter, but the other therapeutically active ingredient(s) of such Combination Product are sold separately in such country during such Pfizer Quarter, the fraction the fraction [ * ], where B is the average sale price in such country and Pfizer Quarter of the other therapeutically active ingredient(s) of such Combination Product and C is the average sale price of the Combination Product in such country and Pfizer Quarter; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;">if neither the Product nor the other therapeutically active</font> ingredient(s) of such Combination Product are sold separately in such country during such Pfizer Quarter, the Parties shall in good faith<font style="font-weight:bold;"> </font>determine such fraction by mutual agreement based on the relative contribution of the Product and the other active ingredient(s) in the Combination Product, and if the Parties fail to agree, the fraction will be determined by an independent expert agreed by the Parties, whose decision will be binding.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net Sales will be determined from books and records maintained in accordance with GAAP, as consistently applied by Pfizer, its Affiliate or Sublicense, as applicable, with respect to sales of the Products.&nbsp;&nbsp; For clarity, Net Sales shall not include (i) sales of any Product made at or below cost under a compassionate use program, (ii) distribution of Samples of any Product, or (iii) donations of any Product, in each case by Pfizer, its Affiliates or Sublicensees.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.52<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Party Specific Regulations</font><font style="font-weight:normal;">&#8221; means all non-monetary judgments, decrees, orders or similar decisions issued by any Governmental Authority specific to a Party, and all consent decrees, corporate integrity agreements, or other agreements or undertakings of any kind by a Party with any Governmental Authority, in each case as the same may be in effect from time to time and applicable to a Party&#8217;s activities contemplated by this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.53<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Patent Rights</font><font style="font-weight:normal;">&#8221; means any and all (a) issued patents, (b)&#160;pending patent applications, including all provisional applications, substitutions, continuations, continuations-in-part, divisions and renewals, and all patents granted thereon, (c) patents-of-addition, reissues, reexaminations and extensions or restorations by existing or future extension or restoration mechanisms, including patent term adjustments, patent term extensions, supplementary protection certificates or the equivalent thereof, (d) inventor&#8217;s certificates, (e) other forms of government-issued rights substantially similar to any of the foregoing and (f) United States and foreign counterparts of any of the foregoing.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.54<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Person</font><font style="font-weight:normal;">&#8221;</font> <font style="font-weight:normal;">means any individual, partnership, limited liability company, firm, corporation, association, trust, unincorporated organization or other entity.</font> </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU14"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.55</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Diligence Obligations</font><font style="font-weight:normal;">&#8221; means Pfizer&#8217;s Development and Marketing Approval diligence obligations under </font><font style="font-weight:normal;">Section 4.2(a) and Pfizer&#8217;s Commercialization diligence obligations under Section 4.2(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.56<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Quarter</font><font style="font-weight:normal;">&#8221; means each of the four (4) thirteen (13) week periods (a) with respect to the United States, commencing on January 1 of any Pfizer Year and (b) with respect to any country in the Territory other than the United States, commencing on December 1.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.57<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Year</font><font style="font-weight:normal;">&#8221; means the twelve month fiscal periods observed by Pfizer (a) commencing on January 1 with respect to the United States and (b) December 1 with respect to any country in the Territory other than the United States.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.58<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pivotal Trial</font><font style="font-weight:normal;">&#8221; means a human clinical trial of a Product that either (a) would satisfy the requirements of 21 C.F.R. 312.21(c) or corresponding foreign regulations; or (b) is intended (as of the time the clinical trial is Initiated) to obtain sufficient data to support the Filing of a BLA for such Product (but may not include the data that may be necessary to support the Pricing Approval).&nbsp;&nbsp;Pivotal Trial may include (i) a clinical trial that is designed to satisfy the requirements of both 21 C.F.R. 312.21(b) and 21 C.F.R. 312.21(c) or corresponding foreign regulations (i.e., a Phase 2/3 trial), or (ii) a Phase 2 clinical trial that is [ * ] to satisfy the requirements of 21 C.F.R. 312.21(c) or to provide sufficient data to support the Filing of a BLA for such Product, in which case such Pivotal Trial shall be deemed to [ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.59<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pricing Approval</font><font style="font-weight:normal;">&#8221; means, in any country where a Governmental Authority authorizes reimbursement for, or approves or determines pricing for, pharmaceutical products, receipt (or, if required to make such authorization, approval or determination effective, publication) of such reimbursement authorization or pricing approval or determination (as the case may be).&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.60<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Product</font><font style="font-weight:normal;">&#8221; means any gene therapy product that [ * ], in each case in a formulation suitable for administration to patients.&nbsp;&nbsp;For clarity, [ * ]. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.61<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Regulatory Authority</font><font style="font-weight:normal;">&#8221;</font> <font style="font-weight:normal;">means with respect to a country in the Territory, any national (e.g., the FDA), supra-national (e.g., the European Commission, the Council of the European Union, or the European Medicines Agency), regional, state or local regulatory agency, department, bureau, commission, council or other Governmental Authority involved in granting Marketing Approvals for Products in such country, including the FDA, the EMA and any corresponding national or regional regulatory authorities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.62<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Regulatory Exclusivity</font><font style="font-weight:normal;">&#8221; means any exclusive marketing rights or data exclusivity rights conferred by any Regulatory Authority with respect to a pharmaceutical product other than Patent Rights, including orphan drug exclusivity, new chemical entity exclusivity, data exclusivity, pediatric exclusivity, rights conferred in the United States under the Hatch-Waxman Act, the FDA Modernization Act of 1997 or the Biologics Price Competition and Innovation Act, or rights similar thereto outside the United States.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU15"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.63</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Regulatory Materials</font><font style="font-weight:normal;">&#8221; means all regulatory applications, submissions, notifications, communications, correspondences, registratio</font><font style="font-weight:normal;">ns, approvals and other filings made to, received from or otherwise conducted with a Regulatory Authority in order to develop, manufacture, or commercialize a Product in a particular country or jurisdiction.&nbsp;&nbsp;&#8220;Regulatory Materials&#8221; includes all INDs, BLAs </font><font style="font-weight:normal;">and Marketing Approvals.</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.64<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Relevant Factors</font><font style="font-weight:normal;">&#8221; means all relevant factors that may affect the Development, Marketing Approval, Pricing Approval or Commercialization of a Product, including (as applicable and without limitation): [ * ].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.65<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Representatives</font><font style="font-weight:normal;">&#8221; means (a) with respect to Pfizer, Pfizer, its Affiliates, its Sublicensees and each of their respective officers, directors, employees, consultants, contractors and agents and (b) with respect to Sangamo, Sangamo, its Affiliates and each of their respective officers, directors, employees, consultants, contractors and agents.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_75"></a><a name="_cp_text_1_76"></a><a name="_cp_text_1_83"></a>1.66<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Program Clinical Candidate Patent Right</font><font style="font-weight:normal;"><a name="_cp_text_1_75"></a>&#8221; means a Zinc Finger Research Program Patent Right that (a) is a Licensed Patent, which (b) [ * ] discloses, and claims or is intended t<a name="_cp_text_1_76"></a>o claim, a specific Compound (which may be a Compound that is being, or is to be, developed as a candidate compound or as a potential back-up to a candidate compound), or claims related thereto, [ * ] methods for expressing such Compound-encoding nucleic acids, a Product comprising a nucleic acid encoding a Compound, and methods of making, using or administering Products; provided that (i) all claims in such Patent Right recite at least one zinc finger protein intended to specifically bind C9ORF72, which for avoidance of doubt may be recitation of nucleic acid encoding such zinc finger protein, as an element in such claims and (ii) none of the claims cover (1) any [ * ] or (2) the [ * ]. For avoidance of doubt, Research Program Clinical Candidate Patent Righ<a name="_cp_text_1_83"></a>ts may include [ * ], provided all such claims recite at least one zinc finger protein intended to specifically bind C9ORF72. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.67<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Program Know-How</font><font style="font-weight:normal;">&#8221; means any and all Know-How, whether or not patentable, (a) made solely by or on behalf of a Party or its representatives in the conduct of activities under the Research Plan or (b) made jointly by or on behalf of (i) Sangamo or its representatives, and (ii) Pfizer or its representatives, in the conduct of activities under the Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.68<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Program Patent Rights</font><font style="font-weight:normal;">&#8221; means any Patent Rights claiming or disclosing any invention included in Research Program Know-How.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.69<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Program Technology</font><font style="font-weight:normal;">&#8221; means Research Program Know-How and Research Program Patent Rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU16"></a>1.70<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Reversion Technology</font><font style="font-weight:normal;">&#8221; means, as of the effective date of termination of this Agreement and with respect to a Continuation Product, (a) any Know-How of Pfizer that was invented, discovered, developed, or used during the Term and in connection with Pfizer&#8217;s or its Affiliates&#8217; activities under the Agreement and (b) any Patent Right of Pfizer if and solely to the extent such Patent Right of Pfizer claims any Know-How of Pfizer described in clause (a) above, </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">in each case of clause (a) and (b) to the extent actually used by Pfizer t</font><font style="font-weight:normal;">o Develop, Commercialize or Manufacture such Continuation Product as of the time of termination.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">1.71<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Samples</font><font style="font-weight:normal;">&#8221; means units of a Product which are not intended to be sold or traded, which are intended to be distributed to authorized healthcare professionals, and which are intended to promote the sale of such Product in accordance with 21 C.F.R. Part 203(d), or any successor provisions to such laws and regulations or in accordance with Applicable Law in any non-U.S. jurisdiction where such Product units are to be distributed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_86"></a><a name="_cp_blt_2_84"></a><a name="_cp_blt_1_88"></a><a name="_cp_blt_2_87"></a>1.72<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Patent Rights</font><font style="font-weight:normal;">&#8221; means any Licensed Patents that are not Research Program Patent Rights. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_91"></a><a name="_cp_blt_2_89"></a><a name="_cp_blt_1_93"></a><a name="_cp_blt_2_92"></a>1.73<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Third Party Agreement</font><font style="font-weight:normal;">&#8221; means any agreement between Sangamo (or any of its Affiliates) and any Third Party (such Third Party, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party Licensor</font><font style="font-weight:normal;">&#8221;) under which such Third Party grants Sangamo a license under any of the Licensed Technology or Licensed Companion Diagnostic Technology, including Upstream Licenses.&nbsp;&nbsp;For clarity, the Sangamo Third Party Agreements consist of the Current Licenses and the Upstream Licenses, and all Current Licensors shall be deemed Third Party Licensors hereunder.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_95"></a><a name="_cp_blt_2_94"></a>1.74<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sublicensee</font><font style="font-weight:normal;">&#8221; means (a) with respect to Pfizer, any Person to whom Pfizer grants or has granted, directly or indirectly, a sublicense of rights licensed by Sangamo to Pfizer under this Agreement or (b) with respect to Sangamo, any Person to whom Sangamo grants or has granted, directly or indirectly, a sublicense of rights licensed by Pfizer to Sangamo under the Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_97"></a><a name="_cp_blt_2_96"></a>1.75<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Territory</font><font style="font-weight:normal;">&#8221; means worldwide. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_99"></a><a name="_cp_blt_2_98"></a>1.76<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Third Party</font><font style="font-weight:normal;">&#8221; means any Person other than a Party or an Affiliate of a Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_101"></a><a name="_cp_blt_2_100"></a><a name="_cp_blt_1_103"></a><a name="_cp_blt_2_102"></a>1.77<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">United States</font><font style="font-weight:normal;">&#8221;</font> <font style="font-weight:normal;">or &#8220;</font><font style="text-decoration:underline;font-weight:normal;">U.S.</font><font style="font-weight:normal;">&#8221; means the United States of America, including its territories and possessions.</font> </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_105"></a><a name="_cp_blt_2_104"></a>1.78<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Upstream Licensor</font><font style="font-weight:normal;">&#8221; means any licensor of an Upstream License. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_107"></a><a name="_cp_blt_2_106"></a><a name="_AEIOULastRenderedPageBreakAEIOU17"></a>1.79<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Valid Claim</font><font style="font-weight:normal;">&#8221; means, with respect to a particular country and Product </font><font style="color:#000000;font-weight:normal;">(a) </font><font style="font-weight:normal;">a claim of an issued and unexpired Patent Right in the Licensed Technology, Research Program Technology or Joint Technology that (i) has not been revoked </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">held unenforceable, unpatentable </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">invalid by a decision of a court </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">other Governmental Authority of competent jurisdiction that is not appealable </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">has not been appealed within the time allowed for appeal, and (ii) that has not been canceled, withdrawn, abandoned, disclaimed, denied </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">admitted to be invalid </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">unenforceable through reissue, re-examination </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">disclaimer </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">otherwise, </font><font style="color:#000000;font-weight:normal;">or (b) </font><font style="font-weight:normal;">a claim of a pending patent application </font><font style="color:#000000;font-weight:normal;">that </font><font style="font-weight:normal;">has not been cancelled, withdrawn, abandoned </font><font style="color:#000000;font-weight:normal;">or </font><font style="font-weight:normal;">finally rejected by an administrative agency action from which no appeal can be taken, </font><font style="Background-color:#FFFFFF;color:#000000;font-weight:normal;">provided that any claim in any patent application pending for more than [ * ] from the earliest date on which such claim claims priority shall not be considered a Valid Claim for purposes of the Agreement from and after such [ * ] date unless and until a patent containing such claim issues </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;color:#000000;font-weight:normal;">from such patent application and solely if such patent issues while another Valid Claim Covers the relevant Product in the relevant country</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_116"></a><a name="_cp_blt_2_115"></a><a name="_cp_text_1_108"></a><a name="_cp_text_1_109"></a><a name="_cp_text_1_111"></a><a name="_cp_text_1_113"></a><a name="_cp_text_1_114"></a>1.80<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Zinc Finger Research Program Know-How</font><font style="font-weight:normal;"><a name="_cp_text_1_108"></a>&#8221; means Research Program Know-How that relates 1) <a name="_cp_text_1_109"></a>to zinc finger proteins, <a name="_cp_text_1_111"></a>or <a name="_cp_text_1_113"></a>2) to improvements to proprietary elements contained <a name="_cp_text_1_114"></a>in a zinc finger expression cassette disclosed, provided, or used by Sangamo under the Research Program, and which are not improvements to proprietary Pfizer expression cassette elements disclosed, provided, or used by Pfizer under the Research Program.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_118"></a><a name="_cp_blt_2_117"></a>1.81<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Zinc Finger Research Program Patent Rights</font><font style="font-weight:normal;">&#8221; means any Patent Rights claiming or disclosing any invention included in Zinc Finger Research Program Know-How. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_120"></a><a name="_cp_blt_2_119"></a>1.82<font style="margin-left:36pt;"></font><font style="font-weight:normal;">&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Zinc Finger Protein Research Technology</font><font style="font-weight:normal;">&#8221; means Zinc Finger Research Program Know-How and Zinc Finger Research Program Patent Rights.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_122"></a><a name="_cp_blt_2_121"></a>1.83<font style="margin-left:36pt;"></font>Interpretation<font style="font-weight:normal;">.&nbsp;&nbsp;Except where the context expressly requires otherwise, (a) the use of any gender herein will be deemed to encompass references to either or both genders, and the use of the singular will be deemed to include the plural (and vice versa), (b) the words &#8220;include&#8221;, &#8220;includes&#8221; and &#8220;including&#8221; will be deemed to be followed by the phrase &#8220;without limitation&#8221;, (c) the word &#8220;will&#8221; will be construed to have the same meaning and effect as the word &#8220;shall&#8221;, (d) any definition of or reference to any agreement, instrument or other document herein will be construed as referring to such agreement, instrument or other document as from time to time amended, supplemented or otherwise modified (subject to any restrictions on such amendments, supplements or modifications set forth herein), (e) any reference herein to any Person will be construed to include the Person&#8217;s successors and assigns, (f) the words &#8220;herein&#8221;, &#8220;hereof&#8221; and &#8220;hereunder&#8221;, and words of similar import, will be construed to refer to this Agreement in its entirety and not to any particular provision hereof, (g) all references herein to Sections or Exhibits will be construed to refer to Sections or Exhibits of this Agreement, and references to this Agreement include all Exhibits hereto, (h) the word &#8220;notice&#8221; means notice in writing (whether or not specifically stated) and will include notices, consents, approvals and other written communications contemplated under this Agreement, (i) provisions that require that a Party, the Parties or any committee hereunder &#8220;agree,&#8221; &#8220;consent&#8221; or &#8220;approve&#8221; or the like will require that such agreement, consent or approval be specific and in writing, whether by written agreement, letter, approved minutes or otherwise (but excluding e-mail and instant messaging), and (j) references to any specific law, rule or regulation, or article, section or other division thereof, will be deemed to include the then-current amendments thereto or any replacement or successor law, rule or regulation thereof.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-family:Times New Roman;font-size:10pt;"><a name="Elo701O"></a><a name="Eloc01O"></a><a name="Eloj01O"></a><a name="Eloo01O"></a>&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref104966575"></a><a name="_AEIOULastRenderedPageBreakAEIOU18"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 2</font><font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">LICENSES; EXCLUSIVITY</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.1<font style="margin-left:36pt;"></font>Licenses to Pfizer.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>License Grants<font style="font-weight:normal;">.&nbsp;&nbsp;Subject to the terms and conditions of this Agreement (including Sangamo&#8217;s retained rights), effective as of the Effective Date and in each case without limiting any other license (or sublicense) granted under this Agreement, Sangamo hereby grants, and will cause its Affiliates to hereby grant, to Pfizer:&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>an exclusive (even as to Sangamo and its Affiliates except as provided in Section 2.1(c)), royalty-bearing license (or, to the extent any Licensed Technology is Controlled by Sangamo or its Affiliates pursuant to a Sangamo Third Party Agreement, a sublicense), with the right to sublicense solely as provided in Section 2.1(b), under the Licensed Technology, to use, have used, Develop, have Developed, Manufacture, have Manufactured, Commercialize, have Commercialized and otherwise exploit Products in the Field in the Territory; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_123"></a><a name="_cp_text_1_125"></a>(ii)<font style="margin-left:36pt;"></font>a fully paid and royalty-free (except to the extent that any payments are owed to any Upstream Licensor with respect to the practice of a sublicense granted pursuant to this subsection (ii)), worldwide, non-exclusive license (or sublicense, as applicable), with the right to sublicense solely as provided in Section 2.1(b), under the Licensed Companion Diagnostic Technology, to use, have used, develop, have developed, make, have made, sell, have sold, offer for sale, im<a name="_cp_text_1_123"></a>port, export, and otherwise exploit Companion Diagnostic Assays for (A) <a name="_cp_text_1_125"></a>use in [ * ] and (B) otherwise for use in connection with the Product in the Field. Notwithstanding any provision to the contrary in this Agreement, the license granted under this Section 2.1(a)(ii) hereof shall be, as of the completion of the Research Term (unless this Agreement has been terminated as contemplated in (X) Section 5.1 because no Compounds have been identified as of such completion date or (Y) Section 1.42 because no Lead Development Compound has been identified as of such completion date), perpetual and irrevocable and shall survive expiration or any other termination of this Agreement.&nbsp;&nbsp;&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Sublicenses.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Subject to the terms and conditions of this <font style="color:#000000;">Agreement </font>and the applicable Sangamo Third Party Agreements, <font style="color:#000000;">Pfizer </font>may grant to its <font style="color:#000000;">Affiliates or Third Parties (through one or more tiers) </font>sublicenses under the licenses granted by Sangamo to <font style="color:#000000;">Pfizer </font>under Sections<font style="color:#000000;"> 2.1(a)(i) and 2.1(a)(ii) upon written notice to Sangamo; provided that Pfizer </font>shall remain responsible for the performance of all of its Sublicensees to the same extent as if such activities were conducted by <font style="color:#000000;">Pfizer</font>, and shall remain responsible for any payments due <font style="color:#000000;">hereunder </font>with respect to activities of any Sublicensees<font style="color:#000000;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU19"></a>(ii)<font style="margin-left:36pt;"></font>Pfizer shall provide Sangamo with a copy of each executed sublicense agreement within [ * ] after execution thereof (excluding any such agreement under which Pfizer grants a sublicense to an Affiliate or solely to conduct Development or </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing on behalf of Pfizer or its Affiliate, unless Sangamo is obligated to provide such copy to a Third Party Licensor in which case Sangamo will obtain the written consent from Pfizer, not to be unreasonably withheld, prior to entering into such</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> license which would obligate Sangamo to provide such copy), which shall be treated by Sangamo as Pfizer&#8217;s Confidential Information, provided that to the extent required by any Sangamo Third Party Agreement, Sangamo shall be permitted to provide a confiden</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tial copy to the applicable Third Party Licensor.&nbsp;&nbsp;Prior to providing a copy of such sublicense agreement to Sangamo, Pfizer may (unless otherwise required by a Sangamo Third Party Agreement and Sangamo has received Pfizer&#8217;s prior written consent) redact c</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ertain terms of any such sublicense agreement to the extent not pertinent to an understanding of a Party&#8217;s obligations or benefits under this Agreement or a verification of compliance with the requirements of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Retained Rights for Exclusive Licenses<font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding the exclusive license granted by Sangamo to Pfizer under Section 2.1(a)(i), Sangamo retains the rights under the Licensed Technology to perform its obligations and to exercise its rights under this Agreement, whether directly or through one or more subcontractors.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_127"></a><a name="_cp_text_1_129"></a><a name="_cp_text_1_131"></a><a name="_cp_text_1_139"></a>(d)<font style="margin-left:36pt;"></font>Sangamo Third Party Agreements<font style="font-weight:normal;">.&nbsp;&nbsp;The licenses granted to Pfizer in Section 2.1(a) include sublicenses under Licensed Technology or Licensed Companion Diagnostic Technology licensed to Sangamo pursuant to the Sangamo Thi<a name="_cp_text_1_127"></a>rd Party Agreements, which sublicenses are subject to the terms of such Sangamo Third Party Agreements. The Sangamo Third Party Agreements in effect as of the Effective Date are listed on Exhibit F and the applicable terms in such Sangamo Third Party Agree<a name="_cp_text_1_129"></a>ments are set forth on </font><font style="text-decoration:underline;">Schedule 2.1(d)</font><font style="font-weight:normal;">, which may be amended by mutual agreement of the Parties for Sangamo Third Party <a name="_cp_text_1_131"></a>Agreements entered into after the Effective Date.&nbsp;&nbsp;Pfizer acknowledges and agrees to be bound by such terms, and agrees not to take or f<a name="_cp_text_1_139"></a>ail to take any action that would cause Sangamo to be in breach of any Sangamo Third Party Agreement, subject to Sangamo&#8217;s compliance with Section 2.7(a).&nbsp;&nbsp;Pfizer acknowledges that certain of the licenses granted to Sangamo under the Sangamo Third Party Licenses are non-exclusive, and that Pfizer&#8217;s license pursuant to Section 2.1(a)(i) with respect to the relevant Licensed Technology are exclusive only with respect to Sangamo, and not with respect to its licensor. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.2<font style="margin-left:36pt;"></font>Reciprocal Non-Exclusive Research License for Disclosed Know-How and Confidential Information.<font style="font-weight:normal;"> Subject to any pre-existing exclusive license grants to Third Parties as of the Effective Date, and excluding any license whose grant or practice would cause Sangamo to be in breach of any exclusivity obligation to any Third Party existing as of the Effective Date, and without limiting any other license granted to either Party under this Agreement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU20"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Pfizer hereby grants and shall cause its Affiliates to hereby grant to Sangamo a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license, with the right to sublicense to Sangamo&#8217;s Affiliates, to use for research purposes (which excludes [ * ]) all Know-How and Confidential Information of Pfizer that is (i) Controlled by Pfizer or its Affiliates and (ii) disclosed to Sangamo or its Affiliates pursuant to this Agreement </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">during the Term; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;"> that nothing in this Section 2.2(a) shall give Sangamo or its Affiliates any right to practice under any Patent Right owned or Controlled by P</font><font style="font-weight:normal;">fizer or its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo hereby grants and shall cause its Affiliates to hereby grant to Pfizer a non-exclusive, irrevocable, perpetual, royalty-free, fully paid-up, worldwide license, with the right to sublicense to Pfizer Affiliates, to use for research purposes (which excludes [ * ]) all Know-How and Confidential Information of Sangamo that is (i) Controlled by Sangamo or its Affiliates and (ii) disclosed to Pfizer or its Affiliates pursuant to this Agreement during the Term; </font><font style="text-decoration:underline;font-weight:normal;">provided</font><font style="font-weight:normal;"> that nothing in this Section 2.2(b) shall give Pfizer or its Affiliates any right to practice under any Patent Right owned or Controlled by Sangamo or its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.3<font style="margin-left:36pt;"></font>No Implied Licenses; Negative Covenant<font style="font-weight:normal;">.&nbsp;&nbsp;Except as expressly set forth herein, neither Party shall acquire any license or other intellectual property interest, by implication or otherwise, under or to any Patent Rights, Know-How, or other intellectual property owned or controlled by the other Party.&nbsp;&nbsp;Neither Party shall, nor shall permit any of its Affiliates or Sublicensees to, practice any Patent Rights or Know-How licensed to it by the other Party outside the scope of the license granted to it under this Agreement, provided that, notwithstanding anything to the contrary in this Agreement, nothing in this Agreement (including but not limited to this Section 2.3) shall be deemed to prevent or restrict in any way the ability of a Party or its Affiliates to conduct any activities in the Territory, which activities would be allowed under any safe harbor, research exemption, government or executive declaration of urgent public health need, or similar right available in law or equity if conducted by a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.4<font style="margin-left:36pt;"></font>Exclusivity<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Exclusivity Obligations<font style="font-weight:normal;">. Subject to Section 2.4(c), during the [ * ], Sangamo and Pfizer shall not, by itself or with or through any Affiliate or Third Party (including through the grant of a license to a Third Party) research, develop, manufacture or commercialize any zinc finger binding protein that specifically binds to C9ORF72 (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Competing Program</font><font style="font-weight:normal;">&#8221;), except for the research, development, manufacture and commercialization of Products in accordance with this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Exception<font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding Section 2.4(a), if a Third Party becomes an Affiliate of a Party during the exclusivity period set forth in Section 2.4(a) through merger, acquisition, consolidation or other similar transaction and such new Affiliate, as of the effective date of such transaction, is engaged, or has a then-existing plan to engage, in the conduct of a Competing Program, then: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU21"></a>(i)<font style="margin-left:36pt;"></font>If such transaction results in a Change of Control of such Party, then such new Affiliate shall have the right to continue such Competing Program and such continuation shall not constitute a breach by such Party of its exclusivity obligation set forth in Section 2.4(a), provided that such new Affiliate conducts such Competing Program independently of the activities under this Agreement and does not use any Licensed Technology, </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Licensed Companion Diagnostic Technology, or the Confide</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ntial Information of the other Party in the conduct of such Competing Program.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>If such transaction does not result in a Change of Control of such Party, then such Party and its new Affiliate shall have [ * ] from the closing date of such transaction to wind down or divest such Competing Program, and its new Affiliate&#8217;s conduct of such Competing Program during such [ * ] period shall not constitute a breach by such Party of its exclusivity obligations set forth in Section 2.4(a), provided that such new Affiliate conducts such Competing Program during such [ * ] period independently of the activities under this Agreement and does not use any Licensed Technology, Licensed Companion Diagnostic Technology, or the Confidential Information of the other Party in the conduct of such Competing Program.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Early Termination<font style="font-weight:normal;">.&nbsp;&nbsp;If this Agreement is terminated prior to the expiration of each Party&#8217;s exclusivity obligations as set forth in Section 2.4(a), then:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>If this Agreement is terminated by Pfizer during the Research Term pursuant to Section 8.2(b), Pfizer&#8217;s exclusivity obligations hereunder shall terminate upon the [ * ] and Sangamo&#8217;s exclusivity obligations hereunder shall terminate upon the [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>If this Agreement is terminated by Sangamo during the Research Term pursuant to Section 8.2(b), Sangamo&#8217;s exclusivity obligations hereunder shall terminate upon the [ * ] and Pfizer&#8217;s exclusivity obligations hereunder shall terminate upon the [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>If this Agreement is terminated as contemplated in (A) Section 5.1 because no Compounds have been identified as of the completion of the Research Term or (B) Section 1.42 because no Lead Development Compound has been identified as of the completion of the extended Research Term, then in either case (A) or (B) each Party&#8217;s exclusivity obligations hereunder shall terminate on the [ * ], provided that in the case of (A) that, if before the [ * ] Sangamo identifies a zinc finger protein that had such zinc finger protein been identified during the Research Term it would have been a Compound, Sangamo shall provide Pfizer with prompt written notice and the Parties shall in good faith negotiate entering into an agreement under substantially similar terms as this Agreement, [ * ], to allow for Pfizer to further research, develop and commercialize such zinc finger protein or a derivative thereof isolated by Sangamo pursuant to the new agreement.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font>If this Agreement is terminated by Pfizer for any other reason, each Party&#8217;s exclusivity obligations hereunder shall terminate upon the [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU22"></a>2.5<font style="margin-left:36pt;"></font>Upstream Licenses<font style="font-weight:normal;">.&nbsp;&nbsp;If, during the Term, Sangamo obtains Control of any intellectual property rights that are owned or controlled by a Third Party and that are necessary or useful for the Development, Manufacture, use, sale, offer for sale, importation or Commercialization of any Compound in the Field in the Territory, then Sangamo shall notify Pfizer in writing, including a description of such intellectual property rights, if they have been non-exclusively (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Non-Exclusive Upstream License</font><font style="font-weight:normal;">&#8221;) or exclusively (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Exclusive Upstream </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;font-weight:normal;">License</font><font style="font-weight:normal;">&#8221;) licensed and, with respect to such non-exclusively licensed intellectual property rights, of any payments that would be due as a result of the grant, maintenance or exercise of a sublicense to Pfizer under such intellectual property </font><font style="font-weight:normal;">rights and a reasonable allocation (based on the scope of the license relative to the scope of the sublicense to Pfizer and provided that Sangamo disclose all the other relevant facts used by Sangamo to determine said reasonable allocation) of any other am</font><font style="font-weight:normal;">ounts payable under such license agreement that do not result solely from activities with respect to a particular product or entity (e.g., upfront fees or annual license fees). Each Non-Exclusive Upstream License for which Pfizer agrees to reimburse Sangam</font><font style="font-weight:normal;">o for payments thereunder pursuant to Section 2.5(a), and each Exclusive Upstream License, will be an &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Upstream License</font><font style="font-weight:normal;">&#8221;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Non-Exclusive Upstream Licenses.&nbsp;&nbsp;<font style="font-weight:normal;">If within [ * ] after the receipt of such notice regarding a Non-Exclusive Upstream License, Pfizer agrees in writing to reimburse Sangamo for all payments due under such license as described above in this Section 2.5, then such intellectual property rights shall be included in the Licensed Technology and sublicensed to Pfizer under the terms and conditions of this Agreement (which sublicense shall be subject and subordinate to the terms and conditions of the Upstream License), and the agreement pursuant to which Sangamo obtained Control of such intellectual property rights shall become an Upstream License under this Agreement.&nbsp;&nbsp;If Pfizer does not agree in writing within such [ * ] to reimburse Sangamo for all such payments, then such intellectual property rights shall be deemed &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Excluded Upstream IP</font><font style="font-weight:normal;">&#8221; and shall be excluded from the Licensed Technology, and the agreement pursuant to which Sangamo obtains Control of such intellectual property rights shall not be included in the Upstream Licenses. For avoidance of doubt, should Pfizer secure a license to any Excluded Upstream IP, [ * ] would apply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Exclusive Upstream Licenses.&nbsp;&nbsp;<font style="font-weight:normal;">If Sangamo obtains an Exclusive Upstream License, such exclusively licensed intellectual property rights shall be included in the Licensed Technology and sublicensed to Pfizer under the terms and conditions of this Agreement (which sublicense shall be subject and subordinate to the terms and conditions of the Upstream License), and the agreement pursuant to which Sangamo obtains Control of such intellectual property rights shall automatically become an Upstream License under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Information<font style="font-weight:normal;">.&nbsp;&nbsp;Pfizer shall (i) provide Sangamo, in a timely manner as necessary for Sangamo to comply with its obligations under each Sangamo Third Party Agreement, with all information needed in order to determine the requirement to make, and the amount of, any payment thereunder, to the extent resulting from the grant, maintenance or exercise of a sublicense to Pfizer and (ii) promptly (but in no event later than [ * ] after Sangamo&#8217;s submission of an invoice therefor) reimburse Sangamo for the full amount of each such payment under a Non-Exclusive Upstream License; provided Sangamo has provided Pfizer the information required under this Section 2.5 and any other information necessary for Pfizer to comply with any payment obligations and in the case of clause (ii), Pfizer has agreed under Section 2.5(a) to make such payments.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU23"></a>2.6<font style="margin-left:36pt;"></font>Direct Licenses to Affiliates<font style="font-weight:normal;">. Pfizer may, from time to time, request that Sangamo grant licenses or sublicenses, to the Licensed Technology or Licensed Companion </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">Diagnostic Technol</font><font style="font-weight:normal;">ogy and of the same or narrowed scope as the licenses granted to Pfizer pursuant to Section 2.1(a), directly to Affiliates of Pfizer by giving written notice, upon receipt of which Sangamo agrees to enter into and sign a separate direct license or sublicen</font><font style="font-weight:normal;">se agreement with such designated Affiliate of Pfizer. All such direct license or sublicense agreements will be consistent with the terms and conditions of this Agreement, except for such modifications as may be required by applicable Laws in the country i</font><font style="font-weight:normal;">n which the direct license or sublicense will be exercised (excluding any such modifications that would require Sangamo to grant additional rights or take on additional obligations beyond what is set forth in this Agreement without any such modifications).</font><font style="font-weight:normal;"> The Parties further agree to make any amendments to this Agreement that are necessary to conform the combined terms of such direct licenses or sublicenses and this Agreement to the terms of this Agreement as set forth on the Effective Date. In connection </font><font style="font-weight:normal;">with any such direct license, Sangamo may require that Pfizer guarantee the performance of its Affiliate.&nbsp;&nbsp;All reasonable costs of making such direct license or sublicense agreement(s) or amending this Agreement, including Sangamo&#8217;s reasonable attorneys&#8217; f</font><font style="font-weight:normal;">ees, under this Section 2.6 will be borne by Pfizer and reimbursed to Sangamo within [ * ] of Sangamo&#8217;s invoice therefor.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.7<font style="margin-left:36pt;"></font>Sangamo Third Party Agreements<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_C629"></a>(a)<font style="margin-left:36pt;"></font>Maintenance of Sangamo Third Party Agreements.<font style="font-weight:normal;"><a name="_DV_C629"></a> Sangamo will maintain in full effect and will perform all of its obligations in a timely manner under each of the Sangamo Third Party Agreements.&nbsp;&nbsp;Absent Pfizer&#8217;s prior written consent (which may be provided, conditioned or withheld in Pfizer&#8217;s sole discretion), Sangamo will not terminate, modify or amend any Sangamo Third Party Agreements in any manner that would (i) adversely affect any of the rights granted to Pfizer under this Agreement,&nbsp;&nbsp;(ii) impose any obligations upon Pfizer hereunder that are in addition to those obligations that exist under this Agreement based on the Current Licenses as they exist on the Effective Date or each Upstream License as it exists when it becomes an Upstream License pursuant to Section 2.5 or (iii) adversely affect Sangamo&#8217;s ability to perform its obligations under this Agreement.&nbsp;&nbsp;Further, Sangamo will not take any action or omit to take any action that would cause it to be in material breach of any Sangamo Third Party Agreements or that would give rise to a right of any Third Party Licensor to terminate the applicable Sangamo Third Party Agreements. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Communications and Performance<font style="font-weight:normal;">. Notwithstanding anything to the contrary in this Agreement, Sangamo will facilitate any communications between Pfizer and any Third Party Licensor required for Pfizer to exercise the rights granted to it pursuant to this Article 2 and will use Commercially Reasonable Efforts to cause each applicable Third Party Licensor to perform all of its obligations under the applicable Sangamo Third Party Agreement that are necessary to effectuate the rights granted to Pfizer under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU24"></a>(c)<font style="margin-left:36pt;"></font>Breach of Sangamo Third Party Agreement<font style="font-weight:normal;">. If Sangamo receives notification from the applicable Third Party Licensor of any actual or potential breach by Sangamo, or otherwise becomes aware of its breach, of any Sangamo Third Party Agreement, which breach if uncured could give rise to the termination of the applicable Sangamo Third Party Agreement, then Sangamo will promptly notify Pfizer of such breach, such notice to include a </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">copy of the notification (if any) received </font><font style="font-weight:normal;">from such Third Party Licensor. To the extent that any act or omission on the part of Pfizer is the cause of such breach of a Sangamo Third Party Agreement, Pfizer will take all actions and provide Sangamo with all cooperation necessary to cure such breach</font><font style="font-weight:normal;">, in each case as reasonably requested by Sangamo and at Pfizer&#8217;s sole cost and expense. To the extent that Pfizer is not the cause of such breach of a Sangamo Third Party Agreement, Sangamo will have the first opportunity to cure such breach in accordance</font><font style="font-weight:normal;"> with a plan to be mutually agreed upon by the Parties in writing, acting reasonably (each, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Cure Plan</font><font style="font-weight:normal;">&#8221;). If (a) Sangamo does not use diligent efforts to cure such breach pursuant to the applicable Cure Plan or (b) Sangamo is unable to cure such breach i</font><font style="font-weight:normal;">n accordance with the applicable Cure Plan or it becomes reasonably apparent that Sangamo will not be able to cure such breach pursuant to the applicable Cure Plan, in each case during the applicable cure period, then Pfizer may, at its election and in its</font><font style="font-weight:normal;"> sole discretion, act reasonably to cure such breach and Sangamo will take all actions and provide Pfizer with all cooperation to cure such breach, in each case as reasonably requested by Pfizer. Further, if Pfizer is not the cause of such breach, then San</font><font style="font-weight:normal;">gamo will, at Pfizer&#8217;s sole election, (i) reimburse Pfizer for all reasonable out-of-pocket costs and expenses incurred by or on behalf of Pfizer or any of its Representatives in connection with curing such breach; or (ii) permit Pfizer to offset any such </font><font style="font-weight:normal;">reasonable out-of-pocket costs and expenses incurred by or on behalf of Pfizer or any of Pfizer&#8217;s Representatives in connection with curing such breach against Pfizer&#8217;s future payment obligations to Sangamo (or any of its successor or assigns) under this A</font><font style="font-weight:normal;">greement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Termination of any Sangamo Third Party Agreement<font style="font-weight:normal;">. In the event that any Sangamo Third Party Agreement is terminated by the applicable Third Party Licensor and this Agreement, as of the effective date of such termination, has not otherwise been terminated in its entirety, Pfizer, to the extent permitted by such Sangamo Third Party Agreement (or if not permitted or addressed in such Sangamo Third Party Agreement, to the extent permitted by the applicable Third Party Licensor), will have the right, at Pfizer&#8217;s election, to convert the sublicenses granted under this Agreement by Sangamo to Pfizer under the Licensed Technology licensed to Sangamo pursuant to such Sangamo Third Party Agreement to a direct license from the applicable Third Party Licensor to Pfizer on the terms and conditions contained in such Sangamo Third Party Agreement (with Pfizer assuming the applicable obligations of Sangamo thereunder) or such other terms and conditions as may be negotiated by Pfizer and the applicable Third Party Licensor.&nbsp;&nbsp;In the event Pfizer enters into any such direct license with a Third Party Licensor, Sangamo will, at Pfizer&#8217;s sole election, (i) reimburse Pfizer for all reasonable out-of-pocket costs and expenses incurred by or on behalf of Pfizer or any of its Representatives in connection with entering into and exercising its rights or performing under such direct license to the extent that Sangamo would have borne such costs if the applicable Sangamo Third Party Agreement had not been terminated; or (ii) permit Pfizer to offset any such reasonable out-of-pocket costs and expenses (to the extent not reimbursed pursuant to clause (i) above) incurred by or on behalf of Pfizer or any of Pfizer&#8217;s Representatives in connection with entering into and exercising its rights or performing under such direct license to the extent that Sangamo would have borne such costs if the applicable Sangamo Third Party Agreement had not been terminated, against Pfizer&#8217;s future payment obligations to Sangamo (or any of its successor or assigns) under this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU25"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Consents and Waivers</font><font style="font-weight:normal;">. In the event that any provision in any Sangamo Third Party Agreement which conflicts with this Agreement or adversely impacts the activities contemplated under this Agreement comes to the attention of </font><font style="font-weight:normal;">either Sangamo or Pfizer, then either the Parties will (i) in Pfizer&#8217;s sole discretion, amend this Agreement to avoid such conflict or (ii) Sangamo, in consultation with Pfizer, will use Commercially Reasonable Efforts to obtain any and all additional requ</font><font style="font-weight:normal;">ired consents or waivers from the applicable Third Party Licensor(s) which may be necessary to align the conflicting provision(s) of the applicable Sangamo Third Party Agreement with this Agreement and to permit the activities contemplated by this Agreemen</font><font style="font-weight:normal;">t.&nbsp;&nbsp;Notwithstanding the foregoing, Sangamo shall not have any obligation to obtain or attempt to obtain any rights to file, prosecute, maintain, enforce, defend or extend any Patent within the Licensed Technology that is non-exclusively licensed to Sangamo</font><font style="font-weight:normal;"> pursuant to a Sangamo Third Party Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.8<font style="margin-left:36pt;"></font>Right of Reference<font style="font-weight:normal;">. Sangamo hereby grants to Pfizer, its Affiliates and its Sublicensees a &#8220;Right of Reference,&#8221; as that term is defined in 21 C.F.R. &#167; 314.3(b) (or any analogous Law recognized outside of the United States), to all regulatory filings Controlled by Sangamo or its Affiliates that relate to any Compound or Product, solely for purposes of Developing, Manufacturing and Commercializing Products in the Field in the Territory, and Sangamo will provide a signed statement to this effect, if requested by Pfizer, in accordance with 21 C.F.R. &#167; 314.50(g)(3) (or any analogous Law outside of the United States).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.9<font style="margin-left:36pt;"></font>Initial Data Transfer<font style="font-weight:normal;">. Within a reasonable time not to exceed [ * ] following the Effective Date, Sangamo will disclose to Pfizer true, accurate and complete copies of all Licensed Know-How, in each case to the extent developed by Sangamo on or prior to the Effective Date and in such format as Pfizer may reasonably request (including by download of digital files to a secure website or e-room designated and controlled by Pfizer).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2.10<font style="margin-left:36pt;"></font>Continuing Disclosure and Knowledge Transfer<font style="font-weight:normal;">. On a [ * ] basis, or more frequently at the reasonable request of Pfizer during the Term, Sangamo, to the extent not previously provided to Pfizer, will provide to Pfizer a written summary of all Licensed Technology other than Research Program Technology developed by Sangamo or that otherwise comes into the Control of Sangamo. Further, Sangamo will make appropriate personnel available to Pfizer at reasonable times and places and upon reasonable prior notice for the purpose of assisting Pfizer to understand and use the Licensed Technology in connection with Pfizer&#8217;s Development of Compounds and Products. </font></p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 3<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">RESEARCH PLAN</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref135582732"></a><a name="_Ref263792247"></a><a name="_Ref263796559"></a><a name="_Ref104966907"></a><a name="_cp_text_1_147"></a><a name="_cp_text_4_148"></a><a name="_cp_text_1_149"></a>3.1<font style="margin-left:36pt;"></font>Scope of Research and Research Plan<a name="_cp_text_1_147"></a>.&nbsp;&nbsp;<font style="font-weight:normal;"><a name="_cp_text_4_148"></a>Beginning <a name="_cp_text_1_149"></a>on the Effective Date and ending on the third anniversary thereof, unless extended to the fourth anniversary pursuant to Section 1.42 (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Term</font><font style="font-weight:normal;">&#8221;), Pfizer and Sangamo will collaborate to conduct research to identify, screen and evaluate Compounds in accordance with a research plan as set forth on </font><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:normal;"> (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Research Plan</font><font style="font-weight:normal;">&#8221;) and the terms and conditions set forth in this Article 3.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263793443"></a><a name="_AEIOULastRenderedPageBreakAEIOU26"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.2</font><font style="margin-left:36pt;"></font><font style="font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allocation of </font><font style="font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Responsibilities</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref135583007"></a><a name="_Ref468669222"></a>(a)<font style="margin-left:36pt;"></font>General<font style="font-weight:normal;">. Each Party will use Commercially Reasonable Efforts to perform its obligations under the Research Plan in a professional and timely manner. Further, each Party will perform its obligations under the Research Plan in compliance with all Laws applicable to its activities under the Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref135583556"></a><a name="_Ref135582896"></a><a name="_Ref268773578"></a>(b)<font style="margin-left:36pt;"></font>Sangamo Research Obligations; Subcontractors<font style="font-weight:normal;"><a name="_Ref135583556"></a>. Sangamo will devote a total of [ * ] full-time equivalents of&nbsp;&nbsp;qualified personnel over the course of the Research Term to conduct Sangamo&#8217;s activities under the Research Plan, each of whom will devote his or her allocated efforts performing such other a<a name="_Ref135582896"></a><a name="_Ref268773578"></a>ctivities as may be required under the Research Plan</font>. <font style="font-weight:normal;">Sangamo will not subcontract any of its responsibilities under the Research Plan without Pfizer&#8217;s prior written consent; </font><font style="font-style:italic;font-weight:normal;">provided</font><font style="font-weight:normal;"> that any subcontractors expressly identified in the Research Plan to conduct specific activities thereunder shall be deemed to have received such consent from Pfizer.&nbsp;&nbsp;Sangamo shall be responsible for the management of all permitted subcontractors. The engagement by Sangamo or its Affiliate of any subcontractor in compliance with this Section 3.2(b) shall not relieve Sangamo of its obligations under this Agreement or the Research Plan.&nbsp;&nbsp;Any agreement between Sangamo or its Affiliate and a permitted subcontractor pertaining to the Research Plan activities shall be consistent with the provisions of this Agreement including (i) an obligation to assign all intellectual property rights generated during its performance of such Research Plan to Sangamo and (ii) terms and conditions under which such Third Party is obligated to preserve the confidentiality of any Confidential Information of Pfizer received by such Third Party from Sangamo that are at least as restrictive as those described in Article 7. Furthermore, unless otherwise agreed by Pfizer in writing, prior to or at the time of engagement of any subcontractor to perform any obligations hereunder, Sangamo or its Affiliate shall cause such subcontractor to agree in writing to be bound by terms providing for Pfizer rights no less favorable to Pfizer than the rights granted to Pfizer in this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Sangamo Personnel Matters<font style="font-weight:normal;">. Sangamo acknowledges and agrees that it is solely responsible for the compensation of its personnel assigned to the Research Plan, and shall be responsible for withholding all national, state, local or other applicable taxes and similar items for such personnel. Sangamo also shall be responsible for all other employer related obligations with respect to such personnel, including providing appropriate insurance coverage and employee benefits, and making all other deductions required by law affecting the gross wages of each employee. Sangamo personnel assigned to the Research Plan activities are not nor shall they be deemed to be employees of Pfizer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font> Oversight of Research Activities<font style="font-weight:normal;">. The JRC will oversee and retain final decision making authority with respect to all research activities performed under this Agreement, in accordance with the terms of this Agreement. Without limiting the foregoing, the JRC will oversee the evaluation of all Compounds identified by Sangamo and will provide feedback and guidance to Sangamo regarding such Compounds.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU27"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Disclosure and Knowledge Transfer Obligations</font><font style="font-weight:normal;">. Without limiting Sangamo&#8217;s obligations pursuant to Section 2.9, Section 2.10, and Section 3.2(b), during the Research Term:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263794790"></a>(i)<font style="margin-left:36pt;"></font>the Parties shall meet [ * ], so that each Party may furnish to the other a presentation describing the data related to the Compounds and Products developed by such Party in connection with the Research Plan, in each case in such format as the Parties may reasonably agree (including by download of digital files to a secure website or e-room designated and controlled by Pfizer);</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_155"></a><a name="_cp_text_1_156"></a><a name="_Ref263794794"></a>(ii)<font style="margin-left:36pt;"></font>in addition to the [ * ] meetings specified in (i), the selected personnel of the Parties shall have calls on a more frequent ad hoc basis for scientific discussion, including discussions related to the development of assays at Pfizer and the transfer of such assays to Sangamo for use under the Research Program; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_157"></a><a name="_cp_text_1_158"></a>(iii)<font style="margin-left:36pt;"></font>Sangamo shall furnish Pfizer complete copies of data generated by Sangamo, if any, pursuant to the [ * ] assays in work package 1 for the up to [ * ] Compounds to be delivered by Sangamo to Pfizer pursuant to the Research Plan, and all assays in work packages 2 and 3 of the Research Plan;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_163"></a><a name="_cp_blt_2_162"></a><a name="_cp_text_1_159"></a><a name="_cp_text_1_161"></a>(iv)<font style="margin-left:36pt;"></font>to the extent provided in the Research Pl<a name="_cp_text_1_159"></a>an, Sangamo shall disclose and provide to Pfizer research grade samples of or nucleic acid sequences of each zinc finger protein identified by Sangamo as a potential Lead <a name="_cp_text_1_161"></a>Development Compound within a commercially reasonable period not to exceed [ * ] of the discovery of each such zinc finger protein;<sup style="font-size:85%; vertical-align:top"> </sup></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_166"></a><a name="_cp_blt_2_165"></a>(v)<font style="margin-left:36pt;"></font> each party shall promptly notify the other Party of any suspected or actual research misconduct, issues pertaining to data integrity or any other information that could reasonably signify or result in a lack of confidence in the accuracy or collection methods of data, each as such may relate to the activities being conducted under the Research Plan; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_1_172"></a><a name="_cp_blt_2_171"></a><a name="_Ref263794902"></a><a name="_cp_text_2_167"></a>(vi)<font style="margin-left:36pt;"></font>Sangamo shall provide Pfizer with all reasonable assistance necessary or desirable (1) to effect the timely<a name="_cp_text_2_167"></a> and orderly transfer of Licensed Technology to Pfizer for Pfizer&#8217;s use under the Research Plan, and (2) to effect the timely and orderly transfer of Licensed Technology and Compounds to Pfizer in order to enable Pfizer to perform its obligations under the Research Plan. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_174"></a><a name="_cp_text_1_175"></a>(f)<font style="margin-left:36pt;"></font>Modifications<font style="font-weight:normal;"><a name="_cp_text_1_175"></a>.&nbsp;&nbsp;Pfizer and its Representatives shall not modify the amino acid sequence of any Compound without the prior written consent of Sangamo.&nbsp;&nbsp;For clarity, Pfizer and its Representatives may modify the nucleic acid sequence encoding a Compound, provided that such modification does not modify the amino acid sequence of such Compound, without the prior written consent of Sangamo.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263792275"></a><a name="_Ref135582785"></a>3.3<font style="margin-left:36pt;"></font>Research Governance<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Collaboration Management.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248138992"></a><a name="_AEIOULastRenderedPageBreakAEIOU28"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="margin-left:36pt;"></font><font style="font-style:italic;">Program Directors</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">. </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Party will appoint a program direc</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">tor to oversee all activities conducted under the Research Plan (each, a &#8220;</font><font style="text-decoration:underline;">Program Director</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221; and together the &#8220;</font><font style="text-decoration:underline;">Program Directors</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8221;).&nbsp;&nbsp;Each Party may change its designated Program Director at any time upon written notice to the other Party. The Program Direct</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ors will coordinate the efforts of their respective Party in conducting activities under the Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248138385"></a>(ii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Alliance Managers</font>. Each Party will appoint a single individual to act as the primary point of contact between the Parties to support the activities under the Research Plan (the &#8220;<font style="text-decoration:underline;">Alliance Managers</font>&#8221;).&nbsp;&nbsp; Each Party may change its designated Alliance Manager at any time upon written notice to the other Party. The Alliance Managers will:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font>use good faith efforts to attend (either in person or by telecommunications) all meetings of the JRC, but will be non-voting members at such meetings; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;"></font>be the first point of referral for all matters of conflict resolution, and bring disputes to the attention of the JRC in a timely manner.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Joint Research Committee.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248138725"></a>(i)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Composition</font>. Within [ * ] after the Effective Date, the Parties will establish a Joint Research Committee, comprised of [ * ] representatives of Sangamo (including the Program Director for Sangamo) and [ * ] representatives of Pfizer (including the Program Director for Pfizer). The JRC representatives for each of Pfizer and Sangamo will be referred to herein as the &#8220;<font style="text-decoration:underline;">Pfizer JRC Members</font>&#8221; and the &#8220;<font style="text-decoration:underline;">Sangamo JRC Members</font>,&#8221; respectively.&nbsp;&nbsp;Each Party may replace its representatives to the JRC at any time upon notice to the other Party, <font style="font-style:italic;">provided that</font> at all times an equal number of representatives from each Party are appointed to the JRC. Each Party may invite non-voting employees and consultants to attend meetings of the JRC. All members of the JRC and any invitees of either Party described above will agree in writing to be bound to obligations of confidentiality and assignment of inventions no less restrictive than those that bind the Parties under this Agreement.<sup style="font-size:85%; vertical-align:top"> </sup></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref248138868"></a>(ii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Committee Chair</font>. The JRC will be chaired by a Pfizer JRC Member (the &#8220;<font style="text-decoration:underline;">JRC Chair</font>&#8221;). Pfizer may replace the JRC Chair at any time upon notice to Sangamo. The responsibilities of the JRC Chair will be:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font>to notify each Party at least [ * ] in advance of each JRC meeting;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;"></font>to collect and organize agenda items for each JRC meeting; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;"></font>to prepare the written minutes of each JRC meeting and circulate such minutes for review and approval by the Parties, and identify action items to be carried out by the Parties.</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU29"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:36pt;"></font><font style="font-style:italic;">Meetings</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;During the Research Term, the JRC will meet on a [</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> * ] basis (or less or more frequently as the JRC so determines), either in-person or by audio or video teleconference. </font><font style="font-weight:bold;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Meetings of the JRC will occur at such times and places as mutually agreed by the Parties; provided, however, that no more than [ * ] i</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n-person meetings will be required in any Calendar Year. Any sub-committees or working groups established in accordance with Section 3.3(b)(iv)(4) may meet via audio or video teleconference on a regular basis and in-person at such times and places as the P</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">arties may agree. Meetings of the JRC will only occur if at least one representative of each Party is present at the meeting or participating by teleconference or videoconference. Each Party will be responsible for, and will not be entitled to any reimburs</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ement from the other Party with respect to, any and all personnel costs or expenses (including travel expenses) which are incurred by or on behalf of its personnel in connection with participation in any JRC meetings or sub-committee or working group meeti</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ngs, or any other travel required to be undertaken by either Party&#8217;s personnel in connection with the performance of the Agreement. The Parties will endeavor to schedule meetings of the JRC at least [ * ] in advance. The JRC Chair will use good faith effor</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ts to (i) prepare and circulate to Sangamo each JRC meeting agenda no later than [ * ] prior to the scheduled date for each JRC meeting and (ii) circulate for review and approval by Sangamo written minutes of each JRC meeting within [ * ] after such meetin</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">g. The Parties will agree on the minutes of each meeting promptly, but in no event later than the next meeting of the JRC.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref468599083"></a>(iv)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Responsibilities</font>. The JRC will coordinate and provide operational and strategic oversight of the activities to be performed under the Research Plan by each Party and, within such scope will:&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)<font style="margin-left:36pt;"></font>monitor and assess the progress of activities under the Research Plan;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)<font style="margin-left:36pt;"></font>revise and approve any revision to the Research Plan;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(3)<font style="margin-left:36pt;"></font>identify potential Compounds;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4)<font style="margin-left:36pt;"></font> form such other committees and sub-committees as the JRC may deem appropriate, <font style="font-style:italic;">provided that </font>such committees and sub-committees may make recommendations to the JRC but may not be delegated JRC decision-making authority;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5)<font style="margin-left:36pt;"></font> address such other matters relating to the activities of the Parties under the Research Plan as either Party may bring before the JRC, including any matters that are expressly for the JRC to decide as provided in this Agreement; and</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6)<font style="margin-left:36pt;"></font>attempt to resolve any disputes between the Parties with respect to the performance of activities under the Research Plan on an informal basis, subject to Section 3.3(b)(v).</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref468599322"></a><a name="_AEIOULastRenderedPageBreakAEIOU30"></a><a name="_cp_text_1_176"></a>(v)<font style="margin-left:36pt;"></font><font style="font-style:italic;font-size:12pt;">Decision-making</font><font style="font-size:12pt;">. Notwithstanding the number of Pfizer JRC Members or Sangamo JRC Members, each Party will have one (1) vote, and the JRC will make </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;">decisions on a unanimous basis. T</font><font style="font-size:12pt;">he JRC will use good faith efforts to reach agreement on any and all matters properly brought before it and within the scope of JRC&#8217;s responsibility.&nbsp;&nbsp;If, despite such good faith efforts, the JRC is unable to reach unanimous agreement on a particular matte</font><font style="font-size:12pt;">r, within [ * ] after the JRC first meets to consider such matter, or such later date as may be mutually acceptable to the Parties (each such matter, a &#8220;</font><font style="text-decoration:underline;font-size:12pt;">Disputed Matter</font><font style="font-size:12pt;"><a name="_cp_text_1_176"></a>&#8221;), then either Party may refer that Disputed Matter for resolution by the </font><font style="font-size:12pt;">appropriate </font><font style="font-size:12pt;">E</font><font style="font-size:12pt;">xecutive Officer of each Party, and such Executive Officers will promptly initiate discussions in good faith to resolve such Disputed Matter. If the Executive Officers of each Party are unable to resolve the Disputed Matter within [ * ] of it being referre</font><font style="font-size:12pt;">d to them, then [ * ] with respect to all Disputed Matters except that [ * ] (a) [ * ] or (b) [ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref220999343"></a>(vi)<font style="margin-left:36pt;"></font><font style="font-style:italic;">Limits on JRC Authority</font>. Notwithstanding any provision of this Section 3.3 to the contrary, (i) each Party will retain the rights, powers and discretion granted to it under this Agreement and no such rights, powers, or discretion will be delegated to or vested in the JRC unless such delegation or vesting of rights is expressly provided for in this Agreement or the Parties expressly so agree in writing, (ii) the JRC will not have the power to amend this Agreement or otherwise modify, waive or determine compliance with this Agreement in any manner and (iii) neither Party will require the other Party to (A)&#160;breach any obligation or agreement that such other Party may have with or to a Third Party to the extent such obligation or agreement existed prior to the Effective Date or (B)&#160;perform any activities that are materially different or greater in scope or more costly than those provided for in the Research Plan then in effect.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font><font style="font-style:italic;">JRC Term</font>. The JRC will be dissolved immediately upon expiration of the Research Term unless the Parties otherwise agree in writing.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">3.4<font style="margin-left:36pt;"></font>Research Plan Expenses.<font style="font-weight:normal;"> Each Party will bear all costs and expenses it incurs in connection with its activities under the Research Plan.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263793539"></a><a name="_Ref475165052"></a>3.5<font style="margin-left:36pt;"></font>Transfer of Materials from Pfizer to Sangamo.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263792126"></a>(a)<font style="margin-left:36pt;"></font>Transfer<font style="font-weight:normal;">. From time to time during the Research Term, Pfizer may, in its sole discretion or as specified in the Research Plan, provide Sangamo with tangible chemical or biological materials (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Materials</font><font style="font-weight:normal;">&#8221;). Pfizer represents and warrants to Sangamo that Pfizer has the right to provide the Pfizer Materials to Sangamo for the uses authorized herein. Except as expressly set forth in the preceding sentence, the Pfizer Materials are provided by Pfizer on an &#8220;as-is&#8221; basis without any representation or warranty of any type, express or implied, including any representation or warranty of merchantability, non-infringement, title or fitness for a particular purpose, each of which is hereby expressly disclaimed by Pfizer.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263791694"></a><a name="_AEIOULastRenderedPageBreakAEIOU31"></a>(b)<font style="margin-left:36pt;"></font>Permitted Use of Pfizer Materials<font style="font-weight:normal;">. Sangamo will use the Pfizer Materials solely in connection with conducting the activities specified in the Research Plan (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Permitted Activities</font><font style="font-weight:normal;">&#8221;). Without limiting the generality of the foregoing, except in the performance of the Permitted Activities, Sangamo will not (a) other than expressly permitted in the Research Plan,</font><font style="border-bottom:double 2.5pt;color:#0000FF;font-weight:normal;"> </font><font style="font-weight:normal;">make or attempt to make any analogues, progeny or derivatives of, or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">modifications to, the Pfizer Materials or attempt to reverse engineer, characterize or in any way try to ascertain the identity, chemical structure, sequence, mechanism of action or composition of the Pfizer Mate</font><font style="font-weight:normal;">rial, or (b) use the Pfizer Materials for Sangamo&#8217;s own benefit or for the benefit of any of its Affiliates or any Third Party. Further, Sangamo will not administer any Pfizer Material to any human. Sangamo will comply with all Laws applicable to the handl</font><font style="font-weight:normal;">ing and use of the Pfizer Materials. Sangamo will retain possession over the Pfizer Materials and not provide any Pfizer Materials to any of its Affiliates or to any Third Party without Pfizer&#8217;s prior written consent, which consent may be withheld in Pfize</font><font style="font-weight:normal;">r&#8217;s sole discretion.</font><font style="font-weight:normal;"> N</font><font style="color:#000000;font-weight:normal;">otwithstanding anything in this Agreement to the contrary, Pfizer shall not be obligated to disclose at any time the identity, structure, composition of, or other information concerning the Pfizer Materials.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263793506"></a>(c)<font style="margin-left:36pt;"></font>Unauthorized Use of Pfizer Materials<font style="font-weight:normal;">. If Sangamo uses any Pfizer Material in any manner other than in the performance of the Permitted Activities, then any and all results of such unauthorized use, whether patentable or not, will belong solely and exclusively to Pfizer. Sangamo, on behalf of itself and its Affiliates, hereby assigns and agrees to assign to Pfizer all of Sangamo&#8217;s and its Affiliates&#8217; right, title and interest in and to all such discoveries and inventions. Sangamo further agrees to cooperate with Pfizer to execute and deliver any and all documents that Pfizer deems reasonably necessary to perfect and enforce Pfizer&#8217;s rights under this Section 3.5(c). Nothing in this Section 3.5(c) will limit in any way any other remedy that Pfizer may have under this Agreement as a result of Sangamo&#8217;s unauthorized use of any Pfizer Materials.</font><font style="color:#000000;font-weight:normal;">&#160;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276112460"></a>(d)<font style="margin-left:36pt;"></font>Title to Pfizer Materials<font style="font-weight:normal;">. All right, title and interest in and to the Pfizer Materials will remain the sole and exclusive property of Pfizer notwithstanding the transfer to and use by Sangamo of the same.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref276112462"></a>(e)<font style="margin-left:36pt;"></font>Return of Pfizer Materials<font style="font-weight:normal;">. At the end of the Research Term (or such earlier time as Pfizer may request in writing), Sangamo will either destroy or return to Pfizer, at Pfizer&#8217;s sole discretion, all unused Pfizer Materials. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263792101"></a><a name="_Ref475165128"></a><a name="_AEIOULastRenderedPageBreakAEIOU32"></a><a name="_cp_text_1_177"></a><a name="_Ref276112465"></a>(f)<font style="margin-left:36pt;"></font>Ownership of Material Improvements<font style="font-weight:normal;">. &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Material Improvement</font><font style="font-weight:normal;">&#8221; means any idea, concept, discovery, invention, Know-How, trade secret, technique, methodology, modification, innovation, result, improvement, writing, documentation, data, research material or right (whether or not protectable under any patent or other intellectual property law) that constitutes any improvement or enhancement to, or a derivative or modification of, any Pfizer Material or any method of making or using any Pfizer Material. For clarity, the insertion by Sangamo of any nucleic acid sequence, whether encoding a Compound, promoter, or other component, into any Pfizer Material [ * ] shall not be deemed an improvement or enhancement to, or a derivative or modification of such Pfizer Material and shall not be deemed a Pfizer Material Improvement.&nbsp;&nbsp;For further clarity, any idea, concept, discovery, invention, Know-How, trade secret, technique, methodology, modification, innovation, result, improvement, writing, documentation, data, research material or right (whether or not protectable under any patent or other intellectual property law) that is conceived, discovered, invented, developed, created, made or reduced to practice or tangible medium by Sangamo in the performance of the Research Plan through the use of or otherwise involving or by reference to </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;"><a name="_cp_text_1_177"></a>any Pfizer Material </font><font style="font-weight:normal;">that is not a Pfizer Material Improvement </font><font style="font-weight:normal;">shall be Research Program Know-How, and ownership of such Research Program Know-How shall be determined in accordance with Section 6.1.&nbsp;&nbsp;Sangamo, </font><font style="font-weight:normal;">on behalf of itself and its Affiliates, hereby assigns and agrees to assign to Pfizer all of Sangamo&#8217;s and its Affiliates&#8217; right, title and interest in and to any and all Pfizer Material Improvements. Sangamo will promptly notify Pfizer of any Pfizer Mater</font><font style="font-weight:normal;">ial Improvement made by Sangamo or its Affiliates and will cooperate fully in obtaining patent and other proprietary protection for such Pfizer Material Improvement. Such protection will be obtained in the name of Pfizer and at Pfizer&#8217;s cost and expense, a</font><font style="font-weight:normal;">nd Sangamo will, and will cause its Affiliates to, execute and deliver all requested applications, assignments and other documents, and take such other actions as Pfizer may reasonably request, in order to perfect and enforce Pfizer&#8217;s rights in any Pfizer </font><font style="font-weight:normal;">Material Improvement.</font><font style="font-weight:normal;"><a name="_Ref276112465"></a> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>Safe Harbor Activities.&nbsp;&nbsp;<font style="font-weight:normal;">Notwithstanding anything to the contrary in this Agreement, nothing in this Agreement shall be deemed to prevent or restrict in any way the ability of Pfizer or its Affiliates or Sangamo or its Affiliates to conduct any activities in the Territory, which activities would be allowed under any safe harbor, research exemption, government or executive declaration of urgent public health need, or similar right available in law or equity if conducted by a Third Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font>Confidentiality<font style="font-weight:normal;">. Sangamo&#8217;s obligations under this Section 3.5 are in addition to, and will in no way limit, its obligations under Article 7 with respect to the Pfizer Materials.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 4<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">PRODUCT DEVELOPMENT AND COMMERCIALIZATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263796070"></a><a name="_Ref135584618"></a>4.1<font style="margin-left:36pt;"></font>General<font style="font-weight:normal;">. Subject to the provisions of Article 3 and Section 4.2, Pfizer will have sole authority over and control of the Development, Manufacture, Regulatory Approval and Commercialization of Products in the Field and will retain final decision-making authority with respect thereto.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263793210"></a><a name="_Ref468669595"></a>4.2<font style="margin-left:36pt;"></font>Diligence<font style="font-weight:normal;">.</font> </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263791815"></a>(a)<font style="margin-left:36pt;"></font>Development Diligence.<font style="font-weight:normal;"> Pfizer will use its Commercially Reasonable Efforts to Develop and seek Regulatory Approval for [ * ] Product [ * ] in the Field [ * ]. Pfizer will [ * ] with respect to the Development or Regulatory Approval of Products under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263791816"></a>(b)<font style="margin-left:36pt;"></font>Commercial Diligence.<font style="font-weight:normal;"> Pfizer will use its Commercially Reasonable Efforts to Commercialize [ * ] Product [ * ] in the Field [ * ] in the Territory where Pfizer or its Affiliates or Sublicensee has received Regulatory Approval for such Product [ * ]. Pfizer will [ * ] with respect to the Commercialization of Products under this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU33"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exceptions to Diligence Obligations. </font><font style="font-weight:normal;">Notwithstanding any provision of this Agreement to the contrary, Pfizer will be relieved of all Pfizer Dilige</font><font style="font-weight:normal;">nce Obligations to the extent that Sangamo fails to fulfill its obligations under the Research Plan and such failure prevents Pfizer from fulfilling such Pfizer Diligence Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263796620"></a>(d)<font style="margin-left:36pt;"></font>[ * ] Pfizer Diligence Obligations. <font style="font-weight:normal;">Without in any way [ * ] obligations under this Agreement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263784808"></a>(i)<font style="margin-left:36pt;"></font>[ * ] described in Section [ * ] Pfizer Diligence Obligations under this Agreement with respect to activities that are [ * ]; and </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>[ * ] as set forth in Section [ * ] Pfizer Diligence Obligations under this Agreement to the date of such payment that are [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the avoidance of doubt, the provisions of Sections 4.2(d)(i) and (ii) are intended only [ * ].<font style="font-weight:bold;"> </font>[ * ] the Pfizer Diligence Obligations [ * ] set forth in Sections 4.2(d)(i) and (ii), above, <font style="font-style:italic;">provided that</font> Pfizer [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263791401"></a><a name="_Ref268773603"></a>(e)<font style="margin-left:36pt;"></font>Assertion of Pfizer Diligence Obligation Claims<font style="font-weight:normal;">.&nbsp;&nbsp;If Sangamo becomes aware of facts that form a reasonable basis to allege that Pfizer has failed to meet any Pfizer Diligence Obligation, then Sangamo will promptly notify Pfizer in writing of such potential alleged performance failure (each such potential alleged performance failure, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Diligence Issue</font><font style="font-weight:normal;">&#8221;). Promptly upon Pfizer&#8217;s receipt of any notice of a Diligence Issue pursuant to this Section 4.2(e), the Pfizer Program Director will contact the Sangamo Program Director to discuss the specific nature of such Diligence Issue and seek to identify an appropriate corrective course of action. If, no later than [ * ] after Pfizer&#8217;s receipt of such a notice, (i) the Parties have not reached consensus regarding whether Pfizer has failed to satisfy its obligations pursuant to Section 4.2(a) and Section 4.2(b) and (ii) the Parties&#8217; respective Program Directors have not agreed upon an appropriate corrective course of action for such Diligence Issue, then at Sangamo&#8217;s request such Diligence Issue will be escalated and resolved pursuant to the dispute resolution provisions set forth in Section 12.6. If Sangamo fails to notify Pfizer of a Diligence Issue pursuant to this Section 4.2(a) and Section 4.2(b) within [ * ] after the date that Sangamo first discovers such Diligence Issue, then [ * ] with respect to such Diligence Issue.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref263793975"></a><a name="_cp_text_1_183"></a><a name="_cp_text_2_184"></a><a name="_cp_text_1_185"></a>(f)<font style="margin-left:36pt;"></font>Remedies for Breach of Pfizer Diligence Obligations<font style="font-weight:normal;">. If Pfizer materially breaches any Pfizer Diligence Obligation with respect to a particular Product in a particular country and fails to remedy such breach within [ * ] of Pfizer&#8217;s receipt of notice of such breach from Sangamo, then Sangamo may, in its sole discretion, elect to either (a) terminate this Agreement pursuant to the provisions of Section 8.2(<a name="_cp_text_1_183"></a>b) on a Product-by-Product and country-by-country basis (for the applicable Product and country) or (b) convert any exclusive license or sublicense granted to Pfizer under this Agreement with respect to the applicable Product in the applicable country in t<a name="_cp_text_2_184"></a>he Territory into non-exclusive license or sublicense, as applicable<a name="_cp_text_1_185"></a>. Notwithstanding, the foregoing, in the event of a good faith dispute regarding any such Pfizer Diligence Obligations, the aforementioned [ * ] cure period shall be tolled pending resolution of such dispute in accordance with the applicable provisions of this Agreement.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU34"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Performance by Pfizer&#8217;s Affiliates or Sublicensees</font><font style="font-weight:normal;">. For avoidance of doubt, any actions taken by Pfizer&#8217;s Affiliates or Sublicensees (or their respective subcontractors) un</font><font style="font-weight:normal;">der this Agreement shall be treated as actions taken by Pfizer in regard to satisfaction of the requirements of this Section 4.2.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref468655070"></a>4.3<font style="margin-left:36pt;"></font>Regulatory Matters<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_188"></a>(a)<font style="margin-left:36pt;"></font>Regulatory Reporting<font style="font-weight:normal;">.&nbsp;&nbsp;Pfizer or its designated Affiliate(s) will have the sole authority to make or file all filings, reports and communications with all Regulatory Authorities with respect to any Product in the Field in the Territory, including all reports required to be filed in order to obtain or maintain any Regulatory Approvals granted for Products in t<a name="_cp_text_1_188"></a>he Field in the Territory and adverse drug experience reports.&nbsp;&nbsp;Upon Pfizer&#8217;s request and at Pfizer&#8217;s sole expense for all hours in excess of the first [ * ], Sangamo will provide to Pfizer any data or other information included within the Licensed Technology in Sangamo&#8217;s possession and otherwise provide reasonable assistance to Pfizer in connection with any such filings, reports and communications.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref440529472"></a>(b)<font style="margin-left:36pt;"></font>Regulatory Approvals<font style="font-weight:normal;">. Pfizer or its designated Affiliate(s) will have the sole authority to prepare and file applications, in its own name, for Regulatory Approval for Products in the Field in the Territory, including communicating with any Regulatory Authority both prior to and following Regulatory Approval.&nbsp;&nbsp;Further, Sangamo will take all actions and provide all assistance reasonably requested by Pfizer and at Pfizer&#8217;s sole expense to effect the assignments in this Section 4.3(b).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Cooperation<font style="font-weight:normal;">. If reasonably requested by Pfizer, Sangamo shall reasonably assist and cooperate with Pfizer in connection with the preparation of filings, reports and communications to Regulatory Authorities with respect to Product in the Field in the Territory, at Pfizer&#8217;s sole expense.&nbsp;&nbsp;Sangamo will and will cause its Affiliates to cooperate with Pfizer and all Pfizer Representatives in the event of any inspection by a Regulatory Authority related to any Product or any activities to be performed under this Agreement, at Pfizer&#8217;s sole expense. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_189"></a>4.4<font style="margin-left:36pt;"></font><a name="_cp_text_1_189"></a>Commercialization Activities. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref265015581"></a>(a)<font style="margin-left:36pt;"></font>General.<font style="font-weight:normal;"> Subject to Section 4.2, Pfizer will have sole and exclusive control over all matters relating to the Commercialization of Products in the Field in the Territory, including sole and exclusive control over (a) pricing of Products and (b) the negotiation of Product pricing with Regulatory Authorities and other Third Parties, in each case in the Field in the Territory.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Branding. <font style="font-weight:normal;">Pfizer or its designated Affiliates or Sublicensees will select and own all Trademarks and Copyrights used in connection with the Commercialization of any and all Products in the Field in the Territory. Neither Sangamo nor its Affiliates will use or seek to register, anywhere in the world, any Trademark which is confusingly similar to any Trademark used by or on behalf of Pfizer, its Affiliates or Sublicensees in connection with any Product.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU35"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Manufacturing. </font><font style="font-weight:normal;">Pfizer will have the exclusive right to Manufacture such Products itself or through one or more Affiliates or Third Parties selected by Pfizer in its sole discretion. For clarity, Pfiz</font><font style="font-weight:normal;">er will have [ * ] with respect to the Manufacture of Products except to the extent necessary to [ * ].</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref135584682"></a><a name="_Ref263794064"></a>4.5<font style="margin-left:36pt;"></font>Progress Reporting.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Development. <font style="font-weight:normal;">Following the Research Term, Pfizer will provide Sangamo with [ * ] presentation summarizing Pfizer&#8217;s, its Affiliates, and its Sublicensees&#8217; Development activities with respect to the Products since the last meeting at a level of detail sufficient to enable Sangamo to determine Pfizer&#8217;s compliance with the Pfizer Diligence Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Commercialization. <font style="font-weight:normal;">After the first approval of a BLA for a Product, Pfizer shall provide Sangamo with [ * ] written reports detailing Pfizer&#8217;s, its Affiliates, and its Sublicensees&#8217; Commercialization activities with respect to the Products at a level of detail sufficient to enable Sangamo to determine Pfizer&#8217;s compliance with the Pfizer Diligence Obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-size:12pt;font-weight:bold;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref265016587"></a>4.6<font style="margin-left:36pt;"></font>Other Pfizer Programs<font style="font-weight:normal;">. Sangamo understands and acknowledges that Pfizer may have present or future initiatives or opportunities, including initiatives or opportunities with its Affiliates or Third Parties, involving products, programs, technologies or processes that are similar to, and in some instances may compete with, a Product, program, technology or process covered by this Agreement. Sangamo acknowledges and agrees that except for Section 2.4, nothing in this Agreement will be construed as a representation, warranty, covenant or inference that Pfizer will not itself Develop, Manufacture or Commercialize or enter into business relationships with one or more of its Affiliates or Third Parties to develop, Manufacture or Commercialize products, programs, technologies or processes that are similar to or that may compete with any Product, program, technology or process covered by this Agreement, provided that, for clarity, Pfizer will not use Sangamo&#8217;s Confidential Information in breach of this Agreement, including in the course of or to further the development, Manufacture or Commercialization of any products, programs, technologies or processes that are similar to or that may compete with any Product.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU36"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 5</font><font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">FINANCIAL PROVISIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.1<font style="margin-left:36pt;"></font>Technology Access Fee.&nbsp;&nbsp;<font style="font-weight:normal;">Pfizer shall make a one-time, non-refundable, non-creditable payment of twelve million U.S. dollars ($12,000,000) to Sangamo within [ * ] after the Effective Date of the Agreement. Should Sangamo not identify any Compounds prior to [ * ], the Parties shall terminate this Agreement and [ * ].&nbsp;&nbsp;The Parties acknowledge that [ * ] may also be needed.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref480127388"></a>5.2<font style="margin-left:36pt;"></font>Milestone Payments.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_190"></a>(a)<font style="margin-left:36pt;"></font>Development Milestones<font style="font-weight:normal;">.&nbsp;&nbsp;Pfizer shall make the following one-time, non-refundable, non-creditable payments (each a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Development Milestone Payment</font><font style="font-weight:normal;"><a name="_cp_text_1_190"></a>&#8221;) to Sangamo within [ * ] following the first occurrence of the applicable event listed below [ * ] Lead Development Compound or Product to achieve such event (each, a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Development Milestone Event</font><font style="font-weight:normal;">&#8221;).</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:96.06%;">
<tr>
<td style="width:75.09%;"></td>
<td style="width:20.97%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Development Milestone Event</font></p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Development Milestone Payment</font></p></td>
</tr>
<tr style="height:31.3pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr style="height:31.3pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr style="height:31.3pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr style="height:31.3pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr style="height:31.3pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total potential Development Milestone Payments</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">$ 60,000,000</p></td>
</tr>
</table></div>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Sales Milestones<font style="font-weight:normal;">.&nbsp;&nbsp;Pfizer shall pay Sangamo the following [ * ] payments when aggregate Net Sales of [ * ] Products in the Territory in a given Pfizer Year first reach the respective thresholds indicated below:</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:95.97%;">
<tr>
<td style="width:75%;"></td>
<td style="width:20.97%;"></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Sales Milestone Event</font></p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:11pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Sales<br />Milestone Payment</font></p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
<tr>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$ [ * ]</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">34</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;text-align:justify;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Notice and Payment<font style="font-weight:normal;">.&nbsp;&nbsp;&nbsp;&nbsp;The Party that achieves any milestone event set forth in Section 5.2(a) or Section 5.2(b) shall notify the other Party in writing within [ * ] after the achievement of any milestone event, and Pfizer shall pay to Sangamo the applicable payment within [ * ] after receipt from Sangamo of a proper invoice pursuant to Section 5.5 for such milestone event.&nbsp;&nbsp;If Sangamo believes any milestone event has occurred and has not received a written notice of same from Pfizer, it may so notify Pfizer in writing and invoice Pfizer for the corresponding payment, and in that case shall provide to Pfizer documentation or other information that supports its belief.&nbsp;&nbsp;Any dispute under this Section 5.2(c) that relates to whether or not a milestone event has occurred shall be resolved in accordance with Section 12.6.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref102923376"></a><a name="_Ref102384824"></a>5.3<font style="margin-left:36pt;"></font>Royalty Payments.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref480127427"></a><a name="_Ref102186094"></a>(a)<font style="margin-left:36pt;"></font>Royalty Rates<font style="font-weight:normal;"><a name="_Ref102186094"></a>.&nbsp;&nbsp;On a Product-by-Product basis, Pfizer shall pay Sangamo non-refundable, non-creditable royalties based on annual aggregate Net Sales of each Product in the Territory during such Product&#8217;s Royalty Term at the following rates:</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:94.27%;">
<tr>
<td style="width:71.2%;"></td>
<td style="width:23.08%;"></td>
</tr>
<tr style="height:33.6pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Amount of Aggregate Territory-wide Net Sales </font></p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Royalty Rate</font></p></td>
</tr>
<tr style="height:33.6pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net sales up to and including [ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]%</p></td>
</tr>
<tr style="height:33.6pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;margin-right:4.7%;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net sales above [ * ] up to and including [ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]%</p></td>
</tr>
<tr style="height:33.6pt;">
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net sales above [ * ]</p></td>
<td valign="middle"  style="padding-left:5.4pt;padding-Right:5.4pt; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000; border-left:solid 0.75pt #000000; border-right:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:3pt;margin-top:3pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]%</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Each Royalty Rate set forth in the table above will apply only to that portion of the Net Sales of a given Product in the Territory during a given Pfizer Year that falls within the indicated range. An example calculation of royalties under this Section 5.3(a) is set forth below.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By way of example only, if (i) Pfizer, its Affiliates or its Sublicensees sell two Products in the Territory during a given Pfizer Year, (ii) Net Sales of the first Product in the Territory during such Pfizer Year are $[ * ] and (iii) Net Sales of the second Product in the Territory during such Pfizer Year are $[ * ], then the royalties payable by Pfizer under this Section 5.3(a) during such Pfizer Year would be calculated as follows:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty for first Product <br /> [ * ]</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty for second Product <br /> [ * ]</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:12pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total royalty payable for applicable Pfizer Year <br /> [ * ]</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">35</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU37"></a><a name="DocXTextRef64"></a><a name="Elot31O"></a><a name="El2341O"></a><a name="Elk441O"></a><a name="El2u31O"></a><a name="El2v31O"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="color:#auto;"><strike Style="text-decoration:none;">Royalty Term</strike></font><font style="color:#auto;font-weight:normal;"><strike Style="text-decoration:none;">.&nbsp;&nbsp;Pfizer&#8217;s royalty payment obligations under Section 5.3(a) shall expire, on a Product-by-Product and country-by-country basis, </strike></font><font style="font-weight:normal;"><a name="DocXTextRef64"></a><a name="Elot31O"></a>upon the latest of: </font><font style="font-weight:normal;"> </font><font style="color:#000000;font-weight:normal;">(</font><font style="color:#000000;font-weight:normal;">i)</font><font style="font-weight:normal;"> the expiration of the period during which</font><font style="color:#000000;font-weight:normal;"><a name="El2341O"></a><a name="Elk441O"></a> the</font><font style="color:#000000;font-weight:normal;"> use for approved Indications, sale, offer for sale or importation of such Product in such country would </font><font style="font-weight:normal;">absent a license or ownership interest, infringe a Valid Claim in the Licensed Technology in such count</font><font style="font-weight:normal;">ry (considering Valid Claims of pending patent applications to be issued with the then-pending claims)</font><font style="color:#000000;font-weight:normal;">; (ii) the expiration of all Regulatory Exclusivity for such Product in such country; and (iii) </font><font style="color:#000000;font-weight:normal;">[ * ] </font><font style="font-weight:normal;"><a name="El2u31O"></a>years after </font><font style="font-weight:normal;">the </font><font style="color:#000000;font-weight:normal;">First Commercial Sale </font><font style="font-weight:normal;"><a name="El2v31O"></a>of such </font><font style="color:#000000;font-weight:normal;">Produc</font><font style="color:#000000;font-weight:normal;">t </font><font style="font-weight:normal;">in any Major Market Country (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Royalty Term</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;For the avoidance of doubt, the Royalty Term for a given Product in a given country in the Territory (A) will not begin until the First Commercial Sale of such Product in such country and (B) if not prev</font><font style="font-weight:normal;">iously expired, will expire immediately upon termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Fully Paid-Up, Royalty Free License<font style="font-weight:normal;">. Following expiration of the Royalty Term for any Product in a given country, no further royalties will be payable in respect of sales of such Product in such country and, thereafter the license granted to Pfizer under Section 2.1(a)(i) with respect to such Product in such country will automatically become fully paid-up, perpetual, irrevocable and royalty-free.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;color:#auto;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><strike Style="text-decoration:none;">(d)</strike><font style="margin-left:36pt;"><strike Style="text-decoration:none;"></strike></font><strike Style="text-decoration:none;">Royalty Reductions.</strike><font style="font-weight:normal;color:#000000;"> The following adjustments will be made, on a Product-by-Product and country-by-country basis, to the royalties payable pursuant to Section 5.3(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Biosimilar Entry.&nbsp;&nbsp;</font>For any Pfizer Quarter in the applicable Royalty Term for a Product in a country in the Territory during which (1) a Biosimilar Product with respect to such Product is being sold in such country; and (2) the unit volume of such Biosimilar Product sold in such country in such Pfizer Quarter exceeds [ * ] of the combined unit volume of such Product and such Biosimilar Product sold in such country in such Pfizer Quarter, subject to Section 5.3(d)(vi), the royalties payable on Net Sales of such Product in such country in such Pfizer Quarter would be reduced by [ * ] of the amounts of royalties otherwise payable on such Net Sales pursuant to Section 5.3(a) for the remainder of the applicable Royalty Term<font style="color:#000000;">, such reduction to be prorated appropriately in aggregate for the then-current Pfizer Quarter</font>.&nbsp;&nbsp;The unit volume of the Product and Biosimilar Product shall be calculated using a mutually acceptable method and using market share data provided by a reputable and mutually agreed upon provider, such as IQVIA (f/k/a QuintilesIMS Health). </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref480127558"></a>(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;color:#auto;"><strike Style="text-decoration:none;">Third Party P</strike><strike Style="text-decoration:none;">atents.&nbsp;&nbsp;</strike></font><font style="color:#auto;"><strike Style="text-decoration:none;">I</strike></font><font style="color:#000000;">f Pfizer obtains a license from a Third Party to any Patent Right (other than a Specified Patent) owned by such Third Party in order to Manufacture or Commercialize any Product in a country in the Territory without infringing such Patent Right, whether directly or through any Pfizer Affiliate or Sublicensee, then, </font>subject to Section 5.3(d)(vi),<font style="color:#000000;"> Pfizer shall have the right to deduct, from the royalty payment that would otherwise have been due pursuant to Section 5.3(a) with respect to Net Sales of such Product in such country in a particular Pfizer Quarter, an amount equal to [ * ] of the royalties paid by Pfizer to such Third Party pursuant to such license on account of the sale of such Product in such country during such Pfizer Quarter, such reduction to continue with any amounts not deducted carried over to future Pfizer Quarters until all such amounts have been expended.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">36</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref265016440"></a><a name="_AEIOULastRenderedPageBreakAEIOU38"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Expiry of Certain Valid Claim Coverage</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;If with respect to any particular Product in any particular country in the Territory</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">, the Royalty Term for such Product in such country extends beyond the date on which there is no Valid Claim Covering such Product with respect to its </font><font style="color:#000000;">sale, offer for sale or importation </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in such country, then, subject to Section 5.3(d)(vi), the royalties p</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ayable on Net Sales of such Product in such country shall be reduced by [ * ] for each Pfizer Quarter for the remainder of the applicable Royalty Term.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iv)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">No Adjustment for Certain Sangamo Third Party Agreements</font>. Except as set forth in Schedule 2.1(d), Sangamo will be solely responsible for (i) all obligations (including any royalty or other obligations that relate to the Licensed Technology) under the Current Licenses and under the Exclusive Upstream Licenses and (ii) all payments to inventors of Licensed Technology, including payments under inventorship compensation Laws.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref135585213"></a>(v)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Existing Pfizer Third Party Agreements</font>. Pfizer will be solely responsible for all obligations (including royalty obligations) that relate to Products under its agreements with Third Parties that are in effect on or prior to the Effective Date.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font>Notwithstanding the foregoing, during any Pfizer Quarter in the Royalty Term for a Product in a country in the Territory, the operation of Sections 5.3(d)(i), (ii) or (iii) individually or in combination shall not reduce by more than [ * ] the royalties that would otherwise have been due under Section 5.3(a) with respect to Net Sales of such Product in such country during such Pfizer Quarter.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref172971009"></a>(e)<font style="margin-left:36pt;"></font>Reports and Payment<font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Cumulative Royalties</font>. The obligation to pay royalties under this Agreement will be imposed only once with respect to any sale of any Product.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Royalty Statements and Payments.</font> Within [ * ] after the end of each Pfizer Quarter during the Royalty Term, Pfizer shall provide Sangamo with a report that contains the following information for the applicable Pfizer Quarter, on a Product-by-Product and country-by-country basis: (1) the amount of gross sales of each Product, (2) an itemized calculation of Net Sales showing deductions provided for in the definition of &#8220;Net Sales,&#8221; (3) a calculation of the royalty due on such sales, including any reduction made in accordance with Section 5.3(d), and (4) the exchange rate for such country.&nbsp;&nbsp;No such reports will be due for any Product (A) before the First Commercial Sale of such Product or (B) after the Royalty Term for such Product has expired in all countries in the Territory.&nbsp;&nbsp;Pfizer shall pay in Dollars all royalty payments due to Sangamo for such Pfizer Quarter concurrently with the delivery of the royalty report or within [ * ] after the end of each Pfizer Quarter, whichever is sooner, provided that to the extent any royalties are payable by Pfizer hereunder on Net Sales of a Product in a country [ * ] that is [ * ], such royalties payable by Pfizer shall be [ * ] and [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU39"></a>5.4<font style="margin-left:36pt;"></font>Currency; Late Payments<font style="font-weight:normal;">.&nbsp;&nbsp;All amounts payable and calculations under this Agreement will be in Dollars. As applicable, Net Sales and any royalty deductions in local currencies will be translated into Dollars in a manner consistent with Pfizer&#8217;s normal practices </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">used to prepared its audited financial statements for public financial accounting purposes.&nbsp;&nbsp; If Sangamo does </font><font style="font-weight:normal;">not receive payment of any sum due to it on the date due until [ * ] past such date, interest shall accrue on the sum due from the due date until the date of payment at the rate equal to the [ * ] rate effective for the date that payment was due, as report</font><font style="font-weight:normal;">ed by the Wall Street Journal (New York Edition).&nbsp;&nbsp;Such interest shall be computed on the basis of a year of [ * ] for the actual number of days payment is delinquent.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.5<font style="margin-left:36pt;"></font>Invoicing; Method of Payment.&nbsp;&nbsp;<font style="font-weight:normal;">Invoices must include the appropriate Pfizer Purchase Order (PO) number (provided that such PO number is provided to Sangamo by Pfizer within [ * ] after the Effective Date or within [ * ] before any payment is due), reference to the Agreement and type of payment due, itemized description of work completed (if applicable), amount owed and name and address to which the payment is to be sent.&nbsp;&nbsp;All invoices shall be clearly marked &#8220;INVOICE&#8221; and delivered by email to [ * ].&nbsp;&nbsp;Should Pfizer dispute in good faith the nature or basis of any charges contained in any invoice submitted by Sangamo hereunder, Pfizer shall promptly provide written notice to Sangamo setting forth the reason for the dispute, which the Parties shall attempt to resolve in good faith in accordance with Section 12.6.&nbsp;&nbsp;Payment by Pfizer shall not result in a waiver of any of its rights under this Agreement. Each payment hereunder shall be made by electronic transfer in immediately available funds via either back wire transfer, an ACH (automated clearing house) mechanism or any other means of electronic funds transfer, at Pfizer&#8217;s election, to the bank account as set forth below or as designated by Sangamo in writing to Pfizer at least [ * ] before the payment is due:</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Bank Name:<font style="margin-left:288pt;">[ * ]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficiary Account Number: <font style="margin-left:288pt;">[ * ]</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beneficiary Account Name: <font style="margin-left:288pt;">Sangamo </font>Therapeutics, Inc.</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:7.69%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">International SWIFT BIC: <font style="margin-left:288pt;">[ * ]</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ABA/Routing Number: <font style="margin-left:288pt;">[ * ]</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.6<font style="margin-left:36pt;"></font>VAT; Withholding Taxes; Tax Cooperation.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>VAT<font style="font-weight:normal;">.&nbsp;&nbsp;It is understood and agreed between the Parties that any payments made under this Agreement are exclusive of any value added or similar tax (VAT), which shall be added thereon as applicable.&nbsp;&nbsp;Where VAT is properly added to a payment made under this Agreement, the Party making the payment will pay the amount of VAT only on receipt of a valid tax invoice issued in accordance with the laws and regulations of the country in which the VAT tax is chargeable.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Withholding Taxes<font style="font-weight:normal;">.&nbsp;&nbsp;Subject to Section 5.6(d) below, in the event any payments made pursuant to this Agreement become subject to withholding taxes under the laws or regulation of any jurisdiction, the Party making such payment shall deduct and withhold the amount of such taxes for the account of the payee to the extent required by applicable laws or regulations and such amounts payable to the payee shall be reduced by the amount of taxes deducted and withheld. Any such withholding taxes required under applicable laws or regulations to be paid or withheld shall be an expense of, and borne solely by, the payee.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU40"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Tax Cooperation</font><font style="font-weight:normal;">.&nbsp;&nbsp;To the extent that the Party making a payment is required to deduct and withhold taxes on any payments under this Agreement, the Party making such p</font><font style="font-weight:normal;">ayment shall pay the amounts of such taxes to the proper Governmental Authority in a timely manner and promptly transmit to the payee an official tax certificate or other evidence of such withholding sufficient to enable the payee to claim such payments of</font><font style="font-weight:normal;"> taxes.&nbsp;&nbsp;The payee shall provide any tax forms to the Party making such payment that may be reasonably necessary in order for such Party not to withhold tax or to withhold tax at a reduced rate under an applicable bilateral income tax treaty.&nbsp;&nbsp;The payee sh</font><font style="font-weight:normal;">all use reasonable efforts to provide any such tax forms to the Party making the payment at least [ * ] prior to the due date for any payments for which the payee desires that the Party making the payment apply a reduced withholding rate.&nbsp;&nbsp;Each Party shall</font><font style="font-weight:normal;"> provide the other with reasonable assistance to enable the recovery, as permitted by Law, of withholding taxes, VAT, or similar obligations resulting from payments made under this Agreement, such recovery to be for the benefit of the Party bearing such wi</font><font style="font-weight:normal;">thholding tax or VAT.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Notwithstanding anything in this Agreement to the contrary, (i) if an action (including but not limited to any assignment (including pursuant to Section 12.2), any direction by Pfizer to Sangamo to grant a license or sublicense to any Affiliate of Pfizer pursuant to Section 2.6 (or otherwise), any sublicense of its rights or obligations under this Agreement, any transfer of payment obligations hereunder, or any failure to comply with applicable Laws or filing or record retention requirements) by a Party leads to the imposition of&nbsp;&nbsp;withholding tax liability or VAT on the other Party that would not have been imposed in the absence of such action or in an increase in such liability above the liability that would have been imposed in the absence of such action, then the sum payable by that Party (in respect of which such deduction or withholding is required to be made) shall be increased to the extent necessary to ensure that the other Party receives a sum equal to the sum which it would have received had no such action occurred, (ii) otherwise, the sum payable by that Party (in respect of which such deduction or withholding is required to be made) shall be made to the other Party after deduction of the amount required to be so deducted or withheld, which deducted or withheld amount shall be remitted in accordance with applicable law.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU41"></a>5.7<font style="margin-left:36pt;"></font>Financial Records and Audit<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party shall maintain complete and accurate records in sufficient detail to permit the other Party to confirm the accuracy of the amount of Development and Manufacture costs to be reimbursed, royalty payments and other amounts payable under this Agreement.&nbsp;&nbsp;Upon reasonable prior notice, such records shall be open during regular business hours for a period of [ * ] from the creation of individual records for examination by an independent certified public accountant selected by the auditing Party and reasonably acceptable to the audited Party for the sole purpose of verifying for the auditing Party the accuracy of the financial reports furnished by the audited Party pursuant to this Agreement or of any payments made, or required to be made, by or to the audited Party pursuant to this Agreement.&nbsp;&nbsp;Such audits may occur no more often than [ * ].&nbsp;&nbsp;Such auditor shall not disclose the audited Party&#8217;s Confidential Information to the auditing Party, except to the extent such disclosure is necessary to verify the accuracy of the financial reports furnished by the audited Party or the amount of payments to or by the audited Party under this Agreement.&nbsp;&nbsp;Any amounts shown to be owed but unpaid, or overpaid and in need of refund, shall be paid or refunded (as the </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">case may be) within [ * ] after the accountant&#8217;s report, plus interest (as set forth in Section 5.4) from the original due date (unl</font><font style="font-weight:normal;">ess challenged in good faith by the audited Party).&nbsp;&nbsp;The auditing Party shall bear the full cost of such audit unless such audit reveals an overpayment to, or an underpayment by, the audited Party that resulted from a discrepancy in the financial report pr</font><font style="font-weight:normal;">ovided by the audited Party for the audited period, which underpayment or overpayment is more than [ * ] of the amount set forth in such report, in which case the audited Party shall reimburse the auditing Party for the costs for such audit.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.8<font style="margin-left:36pt;"></font>Confidentiality. <font style="font-weight:normal;">Notwithstanding any provision of this Agreement to the contrary all reports and financial information of Pfizer, its Affiliates or its Sublicensees which are provided to or subject to review by Sangamo under this Article 5 will be deemed to be Pfizer&#8217;s Confidential Information and subject to the provisions of Article 7.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">5.9<font style="margin-left:36pt;"></font>No Guarantee of Success<font style="font-weight:normal;">. Pfizer and Sangamo acknowledge and agree that payments to Sangamo pursuant to Section 5.2(a) and Section 5.3(a): (a) have been included in this Agreement on the basis that they are only payable or otherwise relevant if the applicable Milestone Event is achieved or Net Sales are made; (b) are solely intended to allocate amounts that may be achieved upon successful Development or Commercialization of such Product as applicable, between Pfizer (who will receive all Product sales revenues) and Sangamo; and (c) are not intended to be used and will not be used as a measure of damages if this Agreement is terminated for any reason, including pursuant to Pfizer&#8217;s right to terminate for convenience, before any such success is achieved and such amounts become due; and (d) will only be triggered in accordance with the terms and conditions of such provisions.&nbsp;&nbsp;Pfizer and Sangamo further acknowledge and agree that nothing in this Agreement, or in any document or presentation provided by Pfizer to Sangamo or Sangamo to Pfizer prior to the Effective Date will be construed as representing any estimate or projection of (i) the successful Development or Commercialization of any Product under this Agreement, (ii) the number of Products that will or may be successfully Developed or Commercialized under this Agreement, (iii) anticipated sales or the actual value of any Products that may be successfully Developed or Commercialized under this Agreement or (iv) the damages, if any, that may be payable if this Agreement is terminated for any reason.&nbsp;&nbsp;Neither Pfizer nor Sangamo makes any representation, warranty or covenant, either express or implied, that (A) it will successfully Develop, Manufacture, Commercialize or continue to Develop, Manufacture or Commercialize any Product in any country, (B) if Commercialized, that any Product will achieve any particular sales level, whether in any individual country or cumulatively throughout the Territory or (C) Pfizer will devote, or cause to be devoted, any level of diligence or resources to Developing or Commercializing any Product in any country, or in the Territory in general, other than is expressly required by the Pfizer Diligence Obligations or the other provisions of this Agreement.</font></p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 6<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">INTELLECTUAL PROPERTY RIGHTS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.1<font style="margin-left:36pt;"></font>Ownership of Intellectual Property<font style="font-weight:normal;">. Except as otherwise set forth in this Agreement, each Party will solely own all right, title and interest in and to: </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU42"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">any and all Know-How made solely by or on behalf of such Party or its Representatives in connection with their activities under this Agreement, </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">any and all Patent Rights claiming any such Know-How described in clause (a) of this Section 6.1; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">any and all Know-How, Patent Rights or other Intellectual Property Rights that such Party owns as of the Effective Date or otherwise acquires during the Term independent of this Agreement.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For the purposes of determining ownership under this Agreement, as applicable, inventorship will be determined in accordance with United States patent laws. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Notwithstanding the provisions of this Section 6.1, Sangamo will solely own all right, title and interest in and to Zinc Finger Protein Research Technology.&nbsp;&nbsp;Pfizer agrees to assign and hereby assigns, and will cause its Representatives to assign, to Sangamo, all right, title and interest throughout the world in and to any and all Zinc Finger Protein Research Program Technology made by Pfizer or its Representatives, subject to a retained right by Pfizer and its Affiliates to practice such assigned Zinc Finger Protein Research Program Technology (x) for [ * ], and (y) for [ * ].&nbsp;&nbsp;Further, Pfizer will, and will cause its Representatives to, execute any and all assignments, applications for domestic and foreign patents and other documents and to do such other acts reasonably requested by Sangamo to assign such Zinc Finger Protein Research Program Technology to Sangamo.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To the extent that Pfizer files Patent Rights claiming any Research Program Know-How solely owned by Pfizer that is both [ * ] and [ * ], Pfizer shall and hereby does grant to Sangamo a non-exclusive, royalty-free, perpetual, irrevocable, and worldwide license under such Research Program Patent Right; Sangamo may grant sublicenses under such license to its Affiliates and to Third Parties solely for use in connection with products researched or developed by or on behalf of Sangamo.&nbsp;&nbsp;For avoidance of doubt, the non-exclusive license to Sangamo to such improvement [ * ] (other than the applicable Research Program Patent Right) [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Parties will jointly own any Joint Technology. Subject to (xx) the grant of licenses or sublicenses to Pfizer under Section 2.1, (yy) Sangamo&#8217;s covenants under Section 9.4 and (zz) the Parties&#8217; other rights and obligations under this Agreement, each Party will be free to exploit, either itself or through the grant of licenses to Third Parties (which Third Party licenses may be further sublicensed), Joint Patent Rights and Joint Know-How throughout the world without restriction, without the need to obtain further consent from or provide notice to the other Party, and without any duty to account or otherwise make any payment of any compensation to the other Party.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.2<font style="margin-left:36pt;"></font>Patent Rights<font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Filing, Prosecution and Maintenance of Patent Rights. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU43"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;">Research Program Patent Rights</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.&nbsp;&nbsp;The Parties shall reasonably cooperate with each other with respect to the filing of Research Program Patent Rights.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Licensed Zinc Finger Protein Research Program Patent Rights</font>.&nbsp;&nbsp;Subject to Pfizer&#8217;s rights with respect to Research Program Clinical Candidate Patent Rights pursuant to Section 6.2(a)(iii), Sangamo will have the first right to file, prosecute and maintain the Research Program Patent Rights that are Licensed Patents (the &#8220;<font style="text-decoration:underline;">Licensed Zinc Finger Protein Research Program Patent Rights</font>&#8221;) in the Territory at Sangamo&#8217;s sole expense using counsel of its own choice reasonably acceptable to Pfizer.&nbsp;&nbsp;Sangamo will keep Pfizer advised on the status of the preparation, filing, prosecution, and maintenance within the [ * ], and upon Pfizer&#8217;s written request any other country, of patent applications included within such Licensed Zinc Finger Protein Research Program Patent Rights and the maintenance of any issued patents included within such Licensed Zinc Finger Protein Research Program Patent Rights. Further, Sangamo will consult and reasonably cooperate with Pfizer with respect to the preparation, filing, prosecution and maintenance of such Licensed Zinc Finger Protein Research Program Patent Rights, including: (1) allowing Pfizer a reasonable opportunity and reasonable time to review and comment regarding relevant substantive communications to Sangamo and drafts of any responses or other proposed substantive filings by Sangamo before any applicable filings are submitted to any relevant patent office or Governmental Authority and (2) reflecting any reasonable and timely comments offered by Pfizer in any final filings submitted by Sangamo to any relevant patent office or Governmental Authority. If Sangamo elects to cease the prosecution or maintenance of any Licensed Zinc Finger Protein Research Program Patent Rights, Sangamo will provide Pfizer with written notice not less than [ * ] before any action is required, upon the decision to not continue the prosecution of such patent application or maintenance of such patent. In such event, Sangamo will permit Pfizer to continue prosecution or maintenance of any such Licensed Zinc Finger Protein Research Program Patent Rights in such country at Pfizer&#8217;s expense. If Pfizer elects to continue such prosecution or maintenance, (i) Pfizer will promptly identify and engage the attorneys and agents who will conduct further activities on Pfizer&#8217;s behalf and Sangamo will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer, (ii) except as set forth in (i), Sangamo will have no responsibility with respect to the filing, prosecution or maintenance of, or any expenses incurred in connection with, any such Licensed Zinc Finger Protein Research Program Patent Rights following Sangamo&#8217;s notice, (iii) Pfizer will keep Sangamo advised on the status of the preparation, filing, prosecution, and maintenance of all such Licensed Zinc Finger Protein Research Program Patent Rights and will reasonably consider any comments made by Sangamo in connection therewith, and (iv) Pfizer will promptly, and no later than [ * ] after written request by Sangamo, by written notice to Sangamo provide a status report of all such Licensed Zinc Finger Protein Research Program Patent Rights.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU44"></a>(iii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Research Program Clinical Candidate Patent Rights</font>.&nbsp;&nbsp;Pfizer will have the first right to file, prosecute and maintain Research Program Clinical Candidate Patent Rights in the Territory using counsel of its own choice reasonably acceptable to Sangamo. For clarity, it is agreed that Pfizer may use internal patent counsel and agents, filing clerks, and paralegals employed by Pfizer, for coordinating worldwide filings of such Patent Rights, for prosecution before the European and Japanese Patent Offices, and for directly instructing any US </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">42</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and ex-US outside counsel and patent agents, including by providing draft applications and responses, and that Pfizer may employ its preferred outside coun</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">sel and patent agents to conduct such activities as required for US and ex-US prosecution. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At Pfizer&#8217;s request and expense (subject to the next sentence), Sangamo will cooperate and assist Pfizer and outside counsel and agents in the preparation and prosecution of such Research Program Clinical Candidate Patent Rights. Sangamo will be responsible for [ * ] for preparation, prosecution and maintenance of Research Program Clinical Candidate&nbsp;&nbsp;Patent Rights in [ * ] and [ * ] for preparation, prosecution and maintenance of Research Program Clinical Candidate Patent Rights in [ * ].&nbsp;&nbsp;Pfizer will keep Sangamo advised on the status of the preparation, filing, prosecution, and maintenance of all patent applications and issued patents included within the&nbsp;&nbsp;Research Program Clinical Candidate Patent Rights that Pfizer is prosecuting and maintaining. Further, Pfizer will (i) allow Sangamo a reasonable opportunity and reasonable time to review and provide comment to Pfizer&#8217;s in-house or outside counsel regarding relevant substantive communications to Pfizer and drafts of any responses or other proposed substantive filings by Pfizer before any applicable filings are submitted to any relevant patent office (or Governmental Authority) in [ * ], and upon Sangamo&#8217;s written request [ * ], and (ii) reflect any reasonable and timely comments offered by Sangamo in any final filings submitted by Pfizer to any relevant patent office (or Governmental Authority) in [ * ] (or [ * ]).&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If Pfizer elects to cease the prosecution or maintenance of any patent applications or patents of a particular Research Program Clinical Candidate Patent Rights in any country, Pfizer will provide Sangamo with written notice of its decision not less than [ * ] before any action is required. If Sangamo elects to continue such prosecution or maintenance, (i) Sangamo will promptly identify and engage the attorneys and agents who will conduct further activities on Sangamo&#8217;s behalf and Pfizer will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer, (ii) except as set forth in (i), Pfizer will have no responsibility with respect to the filing, prosecution or maintenance of, or any expenses incurred in connection with, any such Research Program Clinical Candidate Patent Rights following Pfizer&#8217;s notice, (iii) Sangamo will not disclose any Pfizer Confidential Information in connection with such filing, prosecution or maintenance without Pfizer&#8217;s prior written approval, not to be unreasonably withheld, (iv) Sangamo will keep Pfizer advised on the status of the preparation, filing, prosecution, and maintenance of all such Research Program Clinical Candidate Patent Rights and will reasonably consider any comments made by Pfizer in connection therewith, and (v) Sangamo will promptly, and no later than [ * ] after written request by Pfizer, by written notice to Pfizer provide a status report of all such&nbsp;&nbsp;Research Program Clinical Candidate Patent Rights. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU45"></a><a name="_cp_text_1_209"></a>The Parties will reasonably cooperate to avoid including in Research Program Clinical Candidate Patent Rights any inventions also relevant to zinc finger proteins active against targets other than C9ORF72.&nbsp;&nbsp;In the event that the Parties agree such invention that is relevant to other zinc finger proteins should be disclosed in the same initial filing with an invention that is directed to Compounds, and such invention relevant to other zinc finger proteins is, [ * ], significant with respect to Sangamo&#8217;s business, the Parties shall cooperate in each relevant country to (A) [ * ], which for avoidance of doubt may [ * ], (B) [ * ] which [ * ], or (C) take such other action as the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">43</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Parties mutually agree [ * ].&nbsp;&nbsp;All patent applications and patents which (a) issue directly or indirectly from such patent application a</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">nd (b) solely contain claims that recite at least one zinc finger protein intended to specifically bind C9ORF72 shall be considered Research Program Clinical Candidate Patent Rights and not Licensed Zinc Finger Protein Research Program Rights.&nbsp;&nbsp; The remain</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ing Patent Rights in the relevant patent family shall in all cases be considered Licensed Zinc Finger Protein Research Program Patent Rights for all purposes in the Agreement, including for avoidance of doubt with respect to all prosecution, enforcement, e</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_209"></a>xtension and other related provisions.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_218"></a>(iv)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Sangamo Patent Rights</font>.&nbsp;&nbsp;Sangamo will have the sole right to file, prosecute and maintain the Sangamo Patent Rights in the Territory at Sangamo&#8217;s sole expense.&nbsp;&nbsp;Sangamo will keep Pfizer advised on the status of the preparation, filing, prosecution, and maintenance of all patent applications included within such Sangamo Patent Rights and the maintenance of any issued patents included within such Sangamo Patent Rights. Further,&nbsp;&nbsp;with respect to the Patent Rights listed in <font style="font-weight:bold;">Exhibit E</font> (the &#8220;<font style="text-decoration:underline;">Specified Sangamo Patent Rights</font>&#8221;), as updated by mutual agreement of the Parties on a time-to-time basis, Sangamo will consult and reasonably cooperate with Pfizer with respect to the preparation, filing, prosecution and maintenance of such Specified Sangamo Patent Rights, including: (i) allowing Pfizer a reasonable opportunity and reasonable time to review and comment regarding relevant substantive communications to Sangamo and drafts of any responses or other proposed substantive filin<a name="_cp_text_1_218"></a>gs by Sangamo before any applicable filings are submitted to any relevant patent office or Governmental Authority, including for avoidance of doubt the addition of any Zinc Finger Research Program Know-How to the specification in any refiling, conversion or new filing of a Specified Sangamo Patent Right ([ * ]), and (ii) reflecting any reasonable comments offered by Pfizer in any final filings submitted by Sangamo to any relevant patent office or Governmental Authority.&nbsp;&nbsp;If Sangamo elects to cease the prosecution or maintenance of any Specified Sangamo Patent Right, Sangamo will provide Pfizer with written notice immediately, but not less than [ * ] before any action is required, upon the decision to not continue the prosecution of such patent application or maintenance of such patent. In such event, Sangamo will permit Pfizer to file or continue prosecution or maintenance of any such Specified Sangamo Patent Right in such country at Pfizer&#8217;s expense. If Pfizer elects to continue such prosecution or maintenance, (i) Pfizer will promptly identify and engage the attorneys and agents who will conduct further activities on Pfizer&#8217;s behalf and Sangamo will reasonably cooperate to promptly transfer the necessary files and execute the necessary forms regarding such transfer, (ii) except as set forth in (i), Sangamo will have no responsibility with respect to the filing, prosecution or maintenance of, or any expenses incurred in connection with, any such Specified Sangamo Patent Right following Sangamo&#8217;s notice, (iii) Pfizer will keep Sangamo advised on the status of the preparation, filing, prosecution, and maintenance of all such Specified Sangamo Patent Right and will reasonably consider any comments made by Sangamo in connection therewith, and (iv) Pfizer will promptly, and no later than [ * ] after written request by Sangamo, by written notice to Sangamo provide a status report of all such Specified Sangamo Patent Rights.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU46"></a>(v)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Pfizer Patent Rights</font>.&nbsp;&nbsp;Subject to the obligation to coordinate with respect to the filing of Research Program Patent Rights, Pfizer will have the sole right, but no </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">44</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">obligation, to file, prosecute and maintain the Patent Rights that it solely owns under this Agreement, in its sole discretion.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vi)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Joint Patent Rights</font>.&nbsp;&nbsp;In the event the Parties make any Joint Know-How that is not Licensed Know-How, the Parties will promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon. Neither Party will file any Joint Patent Right that is not a Licensed Patent without mutual consent. If the Parties decide to seek patent protection for any Joint Know-How that is not Licensed Know-How, they will mutually agree based on each Party&#8217;s interests who shall have the right to prepare, file, prosecute, maintain and enforce any such Joint Patent Right throughout the world, as to any sharing of costs, recoveries and royalties therefrom, and as to any further licenses required.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(vii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Patent Term Restoration and Extension</font>. [ * ] right, but not the obligation, to seek, [ * ] if so required, patent term extensions, and supplemental protection certificates and the like available under Law, including 35 U.S.C. &#167; 156 and applicable foreign counterparts, in any country in the Territory in relation to the Licensed Patents. Sangamo and Pfizer will cooperate in connection with all such activities. [ * ], its agents and attorneys will give due consideration to all suggestions and comments of [ * ] regarding any such activities, but in the event of a disagreement between the Parties, [ * ] will have the final decision-making authority; provided, however, that (1) [ * ] will seek [ * ] to extend any Licensed Patent [ * ], including through the use of supplemental protection certificates and the like, [ * ] and (2) without [ * ]&#8217;s prior written consent, [ * ] shall not have the right to seek, with respect to any Product and country, any such extension of a Licensed Patent that [ * ] if (A) [ * ] with respect to such Product and country and (B) [ * ], unless [ * ]. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(viii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Clarifications</font>.&nbsp;&nbsp;For clarity, (i) prosecution under this Section 6.2 includes opposition, revocation, post-grant review or other patent office proceedings, unless such proceedings are concurrent with Third Party litigation under Section 6.4(a), in which case the provisions of Section 6.4(a) shall govern the Parties&#8217; rights and obligations with respect to such proceedings, and (ii) Third Party declaratory judgment actions or other court actions relating to Patent Rights shall be governed by 6.4(a), and by 6.4(b) if applicable. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ix)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Liability</font>. To the extent that a Party is obtaining, prosecuting or maintaining a Patent Right or otherwise exercising its rights under this Section 6.2, such Party, and its Affiliates, employees, agents or representatives, will not be liable to the other Party in respect of any act, omission, default or neglect on the part of any such Party, or its Affiliates, employees, agents or representatives, in connection with such activities undertaken in good faith. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(x)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Recordation.&nbsp;&nbsp;</font>If Pfizer deems it necessary or desirable to register or record this Agreement or evidence of this Agreement with any patent office or other appropriate Governmental Authority(ies) in one or more jurisdictions in the Territory, Sangamo will reasonably cooperate to execute and deliver to Pfizer any documents accurately reflecting or evidencing this Agreement that are necessary or desirable, in Pfizer&#8217;s reasonable judgment, to complete such registration or recordation. </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU47"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.3</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Joint Research Agreement. </font><font style="font-weight:normal;">This Agreement shall be understood to be a joint research</font><font style="font-weight:normal;"> agreement under 35 U.S.C. &#167; 103(c)(3) entered into for the purpose of researching, identifying and Developing Pfizer Licensed Products.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.4<font style="margin-left:36pt;"></font>Enforcement and Defense of Patent Rights<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Enforcement of Sangamo Patent Rights and Licensed Research Program Patent Rights<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>Each Party will promptly notify the other in the event of any actual, potential or suspected infringement of a patent under the Sangamo Patent Rights or the Licensed Research Program Patent Rights by any Third Party. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>As between Pfizer and Sangamo, Pfizer will have the first right, but not the obligation, to institute litigation or take other steps to remedy infringement in connection with the Research Program Clinical Candidate Patent Rights in the Territory with respect to activities competitive or relevant to those of Pfizer under this Agreement (an &#8220;<font style="text-decoration:underline;">RPCCPR Infringement</font>&#8221;), and any such litigation or steps will be at Pfizer&#8217;s expense; provided that any infringement recoveries resulting from such litigation or steps relating to a claim of RPCCPR Infringement, after deducting Pfizer&#8217;s out of pocket expenses (including counsel fees and expenses) in pursuing such claim, will be [ * ]. Pfizer will not, without the prior written consent of Sangamo, enter into any compromise or settlement relating to such litigation that (i) admits the invalidity or unenforceability of any Sangamo Patent Right or Research Program Patent Right or (ii) requires Pfizer or Sangamo to abandon any Sangamo Patent Right or Research Program Patent Right. Sangamo, upon request of Pfizer, agrees to timely commence or to join in any such litigation, at Pfizer&#8217;s expense, and in any event to cooperate with Pfizer in such litigation or steps at Pfizer&#8217;s expense. Sangamo will have the right to consult with Pfizer about such litigation and to participate in and be represented by independent counsel in such litigation at Sangamo&#8217;s own expense.&nbsp;&nbsp;If Pfizer fails to institute and prosecute an action or proceeding to abate any RPCCPR Infringement within a period of [ * ] after the first notice of such RPCCPR Infringement under Section 6.4(a)(i) (or such shorter period as may be necessary to bring or defend and maintain such action without loss of rights), then upon <font style="color:#000000;">Pfizer</font>&#8217;s written consent (not to be unreasonably withheld), Sangamo shall have the second right, but not the obligation, to commence a suit or take other action to enforce the applicable Research Program Clinical Candidate Patent Right against such RPCCPR Infringement at its own cost and expense.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_220"></a><a name="_cp_text_1_221"></a><a name="_AEIOULastRenderedPageBreakAEIOU48"></a><a name="_cp_text_1_222"></a><a name="_cp_text_1_223"></a><a name="_cp_text_1_225"></a><a name="_cp_text_1_227"></a><a name="_cp_text_4_228"></a><a name="_cp_text_1_229"></a>(iii)<font style="margin-left:36pt;"></font>As between Pfizer and Sangamo, Sangamo wi<a name="_cp_text_1_220"></a>ll have the first right, but not the obligation, to institute litigation or take other steps to remedy infringement in connection with the Licensed Research Program Patent Rights or Sangamo Patent Rights in the Territory with respect to a Third Party&#8217;s Man<a name="_cp_text_1_221"></a>ufacture, use, importation, offer for sale or sale, or other exploitation, of any gene therapy product that is directed to C9ORF72 other than an RPCCPR Infringement (an &#8220;<font style="text-decoration:underline;">C9ORF72 Infringement</font>&#8221;), and any such litigation or steps will be at Sangamo&#8217;s expense. Pfizer, upon request of Sangamo, agrees to timely join in any such litigation, at Sangamo&#8217;s expense, and in any event to cooperate with Sangamo in such litigation or steps at Sangamo&#8217;s expense. Pfizer will have the right to consult with Sangamo about such </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">46</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">litigation and to be represented by independent counsel in such litigation at Pfizer&#8217;s own expense. If Sangamo fails to institute and prosecute an action or proceeding to abate any C9ORF72 Infringement within a period of [ * ] after the first notice of su</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ch C9ORF72 Infringement under Section 6.4(a)(i) (or such shorter period as may be necessary to bring or defend and maintain such action without loss of rights), then upon </font><font style="color:#000000;">Sangamo</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217;s written consent (not to be unreasonably withheld), Pfizer shall have the se</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_222"></a>cond right, but not the obligation, to commence a suit or take other action to enforce the applicable Licensed Research Program Patent Right </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">or Sangamo Patent Right </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">against such C9ORF72 Infringement at its own cost and expense; provided that any infringeme</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_223"></a>nt recoveries resulting from such litigation or steps relating to a claim of C9ORF72 Infringement, after deducting Pfizer&#8217;s out of pocket expenses (including counsel fees and expenses) in pursuing such claim, will be deemed </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1) </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_225"></a>[ * ] </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in the case of assertio</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">n of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_227"></a>Licensed Research Program Patent Rights </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_4_228"></a>and 2) [ * ] in the case of Sangamo Patent Rights.&nbsp;&nbsp;For avoidance of doubt, Pfizer shall have no second right to remedy </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_229"></a>infringement of Licensed Research Program Patent Rights or Sangamo Patent Rights </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">in each ca</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">se other than with respect to a gene therapy product directed to C9ORF72.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_blt_2_232"></a>(b)<font style="margin-left:36pt;"></font>Enforcement of Pfizer Patent Rights. <font style="font-weight:normal;">Pfizer will have the sole right, but no obligation, to take action to obtain a discontinuance of infringement or bring suit against a Third Party infringing or challenging the validity or enforceability of any Pfizer Patent Right.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Biosimilar Notices<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Sangamo Cooperation</font>. Upon Pfizer&#8217;s request, Sangamo will use Commercially Reasonable Efforts to assist and cooperate with Pfizer in (A) establishing a strategy for responding to requests for information from Regulatory Authorities and Third Party requestors and (B) preparing submissions responsive to any Biosimilar Notices received by Pfizer; provided that Pfizer will make the final decisions with respect to such strategy and any such responses.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU49"></a>(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Compliance with Biosimilar Notices</font>. Pfizer will have the sole right in its discretion to comply with the applicable provisions of 42 U.S.C. &#167; 262(l) (or any amendment or successor statute thereto), any similar statutory or regulatory requirement enacted in the future regarding biologic products in the United States, or any similar statutory or regulatory requirement in any non-U.S. country or other regulatory jurisdiction, in each case, with respect to any Biosimilar Notice received by Pfizer from any Third Party regarding any Product that is being Commercialized in the applicable jurisdiction, and the exchange of information between any Third Party and Pfizer pursuant to such requirements; provided that, prior to any submission of information by Pfizer to a Third Party, Sangamo will have the right to review the patent information included in such proposed submission, solely with respect to Sangamo Patent Rights and Research Program Patent Rights, and to make suggestions as to any changes to such patent information that Sangamo reasonably believes to be necessary; provided further that Pfizer will determine the final content of any such submission<font style="font-size:10pt;font-family:Arial;"> </font>to the extent it is related to Research Program Clinical Candidate Patent Rights or Patent Rights that are owned by Pfizer. In the case of a Product approved in the United States under the PHS Act (or, in the case of a country in the Territory other than the United States, any similar Law), to the extent </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">permitted by app</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">licable Law, Pfizer, as the sponsor of the application for the Product, will be the &#8220;reference product sponsor&#8221; under the PHS Act. Pfizer will give written notice to Sangamo of receipt of a Biosimilar Notice received by Pfizer with respect to a Product, an</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">d Pfizer will consult with Sangamo with respect to the selection of any Sangamo Patent Rights or Research Program Patent Rights to be submitted pursuant to 42 U.S.C. &#167; 262(l) (or any similar law in any country of the Territory outside the United States); p</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">rovided that (1) [ * ] pursuant to 42 U.S.C. &#167; 262(l)(3)(A) and (2) [ * ], (A) agree pursuant to 42 U.S.C. &#167; 262(l)(4) that [ * ] or (B) or [ * ] pursuant to 42 U.S.C. &#167; 262(l)(5). Sangamo agrees to be bound and will cause its Affiliates and all Third Part</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">y Licensors to be bound by the confidentiality provisions of 42 U.S.C. &#167; 262(l)(1)(B)(iii). Solely to the extent any Sangamo Patent Rights or Research Program Patent Rights are involved in any such action</font><font style="font-size:10pt;font-family:Arial;"> </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">brought pursuant to 42 U.S.C. &#167; 262(l), the Parties</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8217; rights and responsibilities regarding any action will be determined in accordance with Section 6.4(a).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Other Actions by Third Parties<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party will promptly notify the other Party in the event of any legal or administrative action by any Third Party involving any Sangamo Patent Right or Licensed Research Program Patent Right of which it becomes aware, including any nullity, revocation, interference, reexamination or compulsory license proceeding. Sangamo will have the sole right, but no obligation, to defend against any such action involving any Sangamo Patent Right, in its own name (to the extent permitted by applicable Law), and any such defense will be at Sangamo&#8217;s expense. Sangamo will have the first right, but no obligation, to defend against any such action involving any Licensed Research Program Patent Right other than a Research Program Clinical Candidate Patent Right, in its own name (to the extent permitted by applicable Law), and any such defense will be at Sangamo&#8217;s expense. Pfizer, upon Sangamo&#8217;s request, agrees to join in any such action at Sangamo&#8217;s expense and in any event to cooperate with Sangamo at Sangamo&#8217;s expense. If Sangamo fails to defend against any such action involving a Licensed Research Program Patent Right, then Pfizer will have the right to defend such action, in its own name, and any such defense will be at Pfizer&#8217;s expense. Pfizer will have the first right, but no obligation, to defend against any such action involving any Research Program Clinical Candidate Patent Right, in its own name (to the extent permitted by applicable Law), and any such defense will be at Pfizer&#8217;s expense. Sangamo, upon Pfizer&#8217;s request, agrees to join in any such action at Pfizer&#8217;s expense and in any event to cooperate with Pfizer at Pfizer&#8217;s expense. If Pfizer fails to defend against any such action involving a Research Program Clinical Candidate Patent Right, then Sangamo will have the right to defend such action, in its own name, and any such defense will be at Sangamo&#8217;s expense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>Purple Book Listings<font style="font-weight:normal;">.&nbsp;&nbsp;To the extent of any Sangamo Patent Rights or Licensed Research Program Patent Rights Covering a Product, the Parties shall cooperate with each other to enable Pfizer to make filings with Regulatory Authorities, as required or allowed in connection with (i) in the United States, the FDA&#8217;s Purple Book and the Biologics Price Competition and Innovation Act and (ii) outside the United States, under the national implementations of Article 10.1(a)(iii) of Directive 2001/EC/83 or other international equivalents thereof.&nbsp;&nbsp;Pfizer shall consider Sangamo&#8217;s reasonable requests in connection therewith, including meeting any submission deadlines, in each case, to the extent required or permitted by Applicable Law. </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">48</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU50"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Allegations of Infringement and Right to Seek Thi</font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">rd Party Licenses</font><font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Notice</font>. If the Development, Manufacture, Commercialization or use of any Compound or Product (collectively, the &#8220;<font style="text-decoration:underline;">Licensed Activities</font>&#8221;) by Pfizer or any of its Affiliates or Sublicensees is alleged by a Third Party to infringe, misappropriate or otherwise violate such Third Party&#8217;s Patent Rights or other Intellectual Property Rights or Sangamo otherwise identifies any Third Party Patent Rights or other Intellectual Property Rights that may be infringed, misappropriated or otherwise violated by&nbsp;&nbsp;such activities, Sangamo will, promptly upon becoming aware of such allegation or identification, notify Pfizer in writing. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Pfizer Option to Negotiate</font>. If Pfizer determines, in its sole discretion, that, in order for Pfizer, its Affiliates or Sublicensees to engage in the Licensed Activities, it is necessary or desirable to obtain a license under one or more Patent Rights or other Intellectual Property Rights Controlled by a Third Party (collectively, &#8220;<font style="text-decoration:underline;">Third Party IP Rights</font>&#8221;), then Pfizer will have the right, but not the obligation, to negotiate and enter into a license or other agreement with such Third Party. All amounts payable under any such license or agreement with a Third Party [ * ].</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font>Third Party Infringement Suits<font style="font-weight:normal;">. Each of the Parties will promptly notify the other in the event that any Third Party files any suit or brings any other action alleging patent infringement by Pfizer or Sangamo or any of their respective Affiliates or Sublicensees with respect to the Development, Manufacture, Commercialization or use of any Compound or Product (any such suit or other action referred to herein as an &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Infringement Claim</font><font style="font-weight:normal;">&#8221;). In the case of any Infringement Claim for which a Party has an obligation to indemnify the other Party pursuant to Section 10.1 or 10.2, the Parties shall comply with the terms of Sections 10.1, 10.2 and 10.3, as applicable.&#160; With respect to any other Infringement Claim (a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Non-Indemnified Infringement Claim</font><font style="font-weight:normal;">&#8221;) against Pfizer (including its Affiliates or Sublicensees) alone, Pfizer will have the right, but not the obligation, to control the defense of such Non-Indemnified Infringement Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. Sangamo, upon request of Pfizer, agrees to cooperate with Pfizer at Pfizer&#8217;s expense. Sangamo will have the right to consult with Pfizer concerning any Non-Indemnified Infringement Claim. In the case of any Non-Indemnified Infringement Claim against Sangamo alone, Sangamo will have the right, but not the obligation, to control the defense of such Infringement Claim, including control over any related litigation, settlement, appeal or other disposition arising in connection therewith. Pfizer will have the right to consult with Sangamo concerning such Infringement Claim and Pfizer, upon request of Sangamo, will reasonably cooperate with Sangamo at Sangamo&#8217;s expense.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">6.5<font style="margin-left:36pt;"></font>Patents Licensed From Third Parties<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party&#8217;s rights under Sections 6.2 and 6.4 with respect to any Licensed Patent that is licensed by Sangamo from a Third Party shall be subject to the rights retained by such Third Party.&nbsp;&nbsp;</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">49</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref102466031"></a><a name="_AEIOULastRenderedPageBreakAEIOU51"></a><a name="_Ref104969498"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 7</font><font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;"><a name="_Ref104969498"></a>CONFIDENTIALITY; PUBLICATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.1<font style="margin-left:36pt;"></font>Duty of Confidence<font style="font-weight:normal;">.&nbsp;&nbsp;Subject to the other provisions of this Article 7:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">during the Term and for [ * ] thereafter, all Confidential Information of a Party (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Disclosing Party</font><font style="font-weight:normal;">&#8221;) shall be maintained in confidence and otherwise safeguarded by the other Party (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Receiving Party</font><font style="font-weight:normal;">&#8221;) and its Affiliates, in the same manner and with the same protections as the Receiving Party maintains its own confidential information, but in any event no less than reasonable efforts;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the Receiving Party may only use any such Confidential Information for the purposes of performing its obligations or exercising its rights under this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the Receiving Party may only disclose Confidential Information of the other Party to: (i) its Affiliates, licensees and Sublicensees; and (ii) employees, directors, agents, contractors, consultants and advisers of the Receiving Party and its Affiliates and Sublicensees, in each case to the extent reasonably necessary for the purposes of performing its obligations or exercising its rights under this Agreement; provided that such Persons are bound by legally enforceable obligations to maintain the confidentiality of the Confidential Information in a manner consistent with the confidentiality provisions of this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the terms and conditions of this Agreement will be considered Confidential Information of both Parties.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.2<font style="margin-left:36pt;"></font>Exceptions<font style="font-weight:normal;">.&nbsp;&nbsp;The foregoing obligations as to particular Confidential Information of a Disclosing Party shall not apply to the extent that the Receiving Party can demonstrate that such Confidential Information:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref172969313"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">is known by the Receiving Party at the time of its receipt without an obl<a name="_Ref172969313"></a>igation of confidentiality, and not through a prior disclosure by the Disclosing Party, as documented by the Receiving Party&#8217;s business records;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">is in the public domain before its receipt from the Disclosing Party, or thereafter enters the public domain through no fault of the Receiving Party;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">is subsequently disclosed to the Receiving Party by a Third Party who may lawfully do so and is not under an obligation of confidentiality to the Disclosing Party; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">is discovered or developed by the Receiving Party independently and without use of or reference to any Confidential Information received from the Disclosing Party, as documented by the Receiving Party&#8217;s business records. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU52"></a>Any combination of features or disclosures shall not be deemed to fall within the foregoing exclusions merely because individual features are published or available to the general public or in the rightful possession of the Receiving Party unless the combination itself and principle of </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">50</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">operation are published or available to the general p</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ublic or in the rightful possession of the Receiving Party. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.3<font style="margin-left:36pt;"></font>Authorized Disclosures<font style="font-weight:normal;">.&nbsp;&nbsp;Notwithstanding the obligations set forth in Sections 7.1 and 7.6, a Party may disclose the other Party&#8217;s Confidential Information (including this Agreement and the terms herein) to the extent:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such disclosure is reasonably necessary: (i) to such Party&#8217;s directors, attorneys, independent accountants or financial advisors for the sole purpose of enabling such directors, attorneys, independent accountants or financial advisors to provide advice to such Party, provided that in each such case such recipients are bound by confidentiality and non-use obligations that are at least as restrictive as those contained in this Agreement; and provided further that the term of confidentiality for recipients may be shorter as long as it is no less than five (5) years; or (ii) to actual or potential investors, acquirors, licensees and other financial or commercial partners solely for the purpose of evaluating or carrying out an actual or potential investment, acquisition or collaboration, provided that in each such case such recipients are bound by confidentiality and non-use obligations at least as restrictive as those contained in the Agreement; and provided further that the term of confidentiality for recipients may be shorter as long as it is no less than [ * ];&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such disclosure is to a Governmental Authority and necessary or desirable (i) to obtain or maintain INDs, Marketing Approvals or Pricing Approval for any Product within the Territory, or (ii) in order to respond to inquiries, requests or investigations by such Governmental Authority relating to Products or this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such disclosure is required by Law, judicial or administrative process, provided that except for disclosures governed by the last two sentences of Section 7.4, in such event such Party shall promptly inform the other Party of such required disclosure and provide the other Party an opportunity to challenge or limit the disclosure obligations, provided that Confidential Information that is disclosed pursuant to Section 7.3(b) or this Section 7.3(c) shall remain otherwise subject to the confidentiality and non-use provisions of this Article 7 (provided that such disclosure is not a public disclosure), and the Party disclosing Confidential Information to a Governmental Authority or pursuant to Law or court order shall cooperate with and reasonably assist the other Party (at the other Party&#8217;s cost) if the other Party seeks a protective order or other remedy in respect of any such disclosure and furnish only that portion of the Confidential Information which, in the opinion of Party&#8217;s legal counsel, is responsive to such requirement or request; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">necessary in order to enforce its rights under the Agreement; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such disclosure is by Sangamo and is required pursuant to the terms of any Sangamo Third Party Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref309026276"></a><a name="_Ref372011661"></a><a name="_AEIOULastRenderedPageBreakAEIOU53"></a>7.4<font style="margin-left:36pt;"></font>SEC Filings and Other Disclosures. <font style="font-weight:normal;">Either Party may disclose the terms of this Agreement and make any other public written disclosure regarding the existence of, or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">51</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">performance under, this Agreement, to the extent required, in the reasonable opinion of such Party&#8217;s legal counsel, to comply with (a) applicable Law, including the rules and regulations promulgated by the United States Securities and Exchange Commissi</font><font style="font-weight:normal;">on or (b) any equivalent Governmental Authority, securities exchange or securities regulator in any country in the Territory.&nbsp;&nbsp;Before disclosing this Agreement or any of the terms hereof pursuant to this Section 7.4, the Parties will consult with one anoth</font><font style="font-weight:normal;">er on the terms of this Agreement to be redacted in making any such disclosure, with the disclosing Party providing as much advance notice as is feasible under the circumstances, and giving consideration to the timely comments of the other Party. Further, </font><font style="font-weight:normal;">if a Party discloses this Agreement or any of the terms hereof in accordance with this Section 7.4, such Party will, at its own expense, seek such confidential treatment of confidential portions of this Agreement and such other terms as it reasonably deter</font><font style="font-weight:normal;">mines, giving consideration to the comments of the other Party pursuant to the preceding sentence.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.5<font style="margin-left:36pt;"></font>Technical Publication<font style="font-weight:normal;">.&nbsp;&nbsp;Neither Party may publish peer reviewed manuscripts, or give other forms of public disclosure such as abstracts and presentations, of results of studies carried out under this Agreement, without the opportunity for prior review by the other Party, except to the extent required by applicable Laws.&nbsp;&nbsp;A Party seeking publication shall provide the other Party the opportunity to review and comment on any proposed publication which relates to the Product at least [ * ] prior to its intended submission for publication.&nbsp;&nbsp;The other Party shall provide the Party seeking publication with its comments in writing, if any, within [ * ] after receipt of such proposed publication.&nbsp;&nbsp;The Party seeking publication shall consider in good faith any comments thereto provided by the other Party and shall comply with the other Party&#8217;s request to remove any and all of such other Party&#8217;s Confidential Information from the proposed publication.&nbsp;&nbsp;In addition, the Party seeking publication shall delay the submission for a period up to [ * ] in the event that the other Party can demonstrate reasonable need for such delay, including without limitation, the preparation and filing of a patent application.&nbsp;&nbsp;If the other Party fails to provide its comments to the Party seeking publication within such fourteen [ * ] period, such other Party shall be deemed to not have any comments, and the Party seeking publication shall be free to publish in accordance with this Section 7.5 after the [ * ] period has elapsed.&nbsp;&nbsp;The Party seeking publication shall provide the other Party a copy of the manuscript at the time of the submission.&nbsp;&nbsp;Each Party agrees to acknowledge the contributions of the other Party and its employees in all publications as scientifically appropriate.&nbsp;&nbsp;Notwithstanding anything in this Agreement to the contrary, nothing will prevent Pfizer from making any scientific publication or public announcement with respect to any approved Product(s) under this Agreement; </font><font style="font-style:italic;font-weight:normal;">provided, however</font><font style="font-weight:normal;">, that Pfizer will comply with this Section 7.5 and, except as permitted under Sections 7.2 and 7.3, Pfizer will not disclose any of Sangamo&#8217;s Confidential Information in any such publication or announcement without obtaining Sangamo&#8217;s prior written consent to do so (such consent not to be unreasonably withheld).&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.6<font style="margin-left:36pt;"></font>Publicity<font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo and Pfizer shall issue a joint press release announcing this Agreement, which joint press release shall be substantially in the form attached hereto as </font><font style="text-decoration:underline;">Exhibit&#160;D</font><font style="font-weight:normal;"> and finalized and issued by the Parties promptly after the Effective Date.&nbsp;&nbsp;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">52</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU54"></a><a name="_cp_text_1_235"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)</font><font style="margin-left:36pt;"></font><font style="font-weight:normal;">Other than the joint press release pursuant to Section 7.6(a) and disclosures under Section 7.4, the Parties agree that any other news release or other public announcement relating to this Agreement or the performance hereunder that would disclose informat</font><font style="font-weight:normal;">ion other than that already in the public domain shall first be reviewed and approved by both Parties (with such approval not to be unreasonably withheld or delayed); provided, however, that notwithstanding the foregoing, Sangamo shall have the right to di</font><font style="font-weight:normal;">sclose publicly (including in its securities filings and earning calls) [ * ]; provided further that Pfizer will have at least [ * ] to review and provide edits and comments to any public disclosure proposed by Sangamo under this sentence and Sangamo will </font><font style="font-weight:normal;"><a name="_cp_text_1_235"></a>reasonably incorporate any edits and address any comments provided by Pfizer in such proposed public disclosure. </font><font style="font-weight:normal;">&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">The Parties agree that after a press release (including the initial press release) or other public announcement has been reviewed and approved by the other Party under this Section 7.6, the disclosing Party may reissue the public disclosures without having to obtain the other Party&#8217;s prior consent and approval.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Each Party agrees that the other Party shall have the right to use such first Party&#8217;s name in presentations, the company&#8217;s website, collateral materials and corporate overviews to describe the collaboration relationship, as well as in taglines of press releases issued pursuant to this Section 7.6. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Subject to Section 7.6(d), neither Party shall use the name, trade name, service marks, trademarks, trade, dress or logos of the other Party (or any of its Affiliates) in publicity releases, advertising or any other publication, without the other Party&#8217;s prior written consent in each instance.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">7.7<font style="margin-left:36pt;"></font>Obligations in Connection with Change of Control<font style="font-weight:normal;">. If Sangamo is subject to a Change of Control, Sangamo will, and it will cause its Representatives to, ensure that no Confidential Information of Pfizer is released to (a) any Affiliate of Sangamo that becomes an Affiliate as a result of the Change of Control or (b) any other Representatives of Sangamo (or of the relevant surviving entity of such Change of Control) who become Representatives of Sangamo as a result of the Change of Control, unless such Affiliate or other Representatives, as applicable, have signed individual confidentiality agreements which include equivalent obligations to those set out in this Article 7. If any Change of Control of Sangamo occurs, Sangamo will promptly notify Pfizer, share with Pfizer the policies and procedures it plans to implement in order to protect the confidentiality of Pfizer&#8217;s Confidential Information prior to such implementation and make any adjustments to such policies and procedures that are reasonably requested by Pfizer.</font></p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 8<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">TERM AND TERMINATION</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU55"></a>8.1<font style="margin-left:36pt;"></font>Term<font style="font-weight:normal;">.&nbsp;&nbsp;The term of this Agreement shall commence upon the Effective Date and continue in full force and effect, on a Product-by-Product and country-by-country basis, until the expiration of the Royalty Term for such Product in such country, unless earlier terminated as set </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">forth in Section 8.2 below (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Term</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;Notwithstanding any provision of this Agreement to the contrary, upon expiration of this Agreement, Pfizer will retain the fully paid-up, perpetual, irrevocable roy</font><font style="font-weight:normal;">alty-free license to each Product as set forth in Section 5.3(c), except with respect to those Products and countries for which the Agreement was previously terminated.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref480215450"></a>8.2<font style="margin-left:36pt;"></font>Termination.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref107234267"></a><a name="_Ref108412246"></a>(a)<font style="margin-left:36pt;"></font>Termination by Pfizer for Convenience<font style="font-weight:normal;"><a name="_Ref107234267"></a><a name="_Ref108412246"></a>.&nbsp;&nbsp;Pfizer may terminate this Agreement on a Product-by-Product or country-by-country basis, or in its entirety, without cause, for any or no reason, by providing written notice of termination to Sangamo, which notice includes an effective date of termination at least [ * ] prior written notice to Sangamo during the Research Term, [ * ] prior written notice to Sangamo after the Research Term but prior to Commercialization of a Product, and [ * ] prior written notice to Sangamo after the commencement of the Commercialization of a Product.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Termination for Material Breach<font style="font-weight:normal;">.&nbsp;&nbsp;If either Party believes that the other is in breach of its material obligations hereunder, then the non-breaching Party may deliver notice of such breach (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Breach Notice</font><font style="font-weight:normal;">&#8221;) to the other Party.&nbsp;&nbsp;If the Party receiving notice of breach fails to cure such material breach within the applicable period set forth below, then the Party originally delivering the notice of breach may terminate this Agreement effective on written notice of termination to the other Party.&nbsp;&nbsp;For all breaches other than a failure to make a payment as set forth in this Agreement, the allegedly breaching Party shall have [ * ] from such Breach Notice to cure such breach, provided, however, that if any breach is not reasonably curable within [ * ] and the allegedly breaching Party is making a bona fide effort to cure such breach, such termination will be delayed for a time period to be agreed by both Parties in order to permit the allegedly breaching Party a reasonable period of time to cure such breach, not to exceed an additional [ * ].&nbsp;&nbsp;For any breach arising from a failure to make a payment set forth in this Agreement, the cure period will be [ * ] and such cure period will be tolled pending resolution of any bona fide dispute between the Parties as to whether such payment is due.&nbsp;&nbsp;In the event Sangamo believes Pfizer has failed to make a payment, Sangamo will provide Pfizer with written notice and both Parties will use reasonable efforts to convene their finance personnel to resolve such dispute within [ * ] of receipt of the written notice.&nbsp;&nbsp;If the Parties agree to a resolution for such bona fide dispute or such dispute is resolved pursuant to Section 12.6, any amounts due as part of such resolution shall be paid within [ * ] thereafter. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Termination for a Bankruptcy Event<font style="font-weight:normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Termination Right.</font> Each Party shall have the right to terminate this Agreement in the event of a Bankruptcy Event with respect to the other Party. </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU56"></a>(ii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">Rights to Intellectual Property.</font> All rights and licenses granted under or pursuant to this Agreement by a Party are, and shall otherwise be deemed to be, for purposes of Section 365(n) of the U.S. Bankruptcy Code, licenses of rights to &#8220;intellectual property&#8221; as defined under Section 101 of the U.S. Bankruptcy Code. The Parties agree that each Party, as licensee of intellectual property under this Agreement, shall retain and may fully </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">exercise all of its rights and elections under the U.S. Bankruptcy Code. The Parties further agree that in the event of a rejection of this Agreement by a Party in any</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> bankruptcy proceeding by or against such Party under the U.S. Bankruptcy Code, (a) the other Party shall be entitled to a complete duplicate of (or complete access to, as appropriate) any such intellectual property and all embodiments of such intellectual</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> property that are necessary for the other Party to practice its license to such intellectual property, which, if not already in such other Party&#8217;s possession, shall be promptly delivered to it upon its written request therefor, and (b) such Party shall no</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">t interfere with the other Party&#8217;s rights to such intellectual property, and shall assist and not interfere with such other Party in obtaining such intellectual property and such embodiments of such intellectual property from another entity. The term &#8220;embo</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">diments&#8221; of intellectual property means all tangible embodiments of the intellectual property licensed hereunder to the extent of the license scope, and shall exclude, without limitation, all inventory of Products and filings with Regulatory Authorities.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font><font style="font-weight:bold;">No Limitation of Rights</font>.<font style="font-weight:bold;"> </font>All rights, powers and remedies provided in this Section 8.2(c) are in addition to and not in substitution for any and all other rights, powers and remedies now or hereafter existing at Law or in equity (including the Bankruptcy Code) in the event of the commencement of a case under the Bankruptcy Code.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref228616381"></a>8.3<font style="margin-left:36pt;"></font>Effects of Termination<font style="font-weight:normal;"><a name="_Ref228616381"></a>.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Termination by Sangamo for Cause or Bankruptcy; Termination by Pfizer for Convenience<font style="font-weight:normal;">.&nbsp;&nbsp;In the event that Sangamo terminates this Agreement, pursuant to Section 8.2(b) or 8.2(c) or Pfizer terminates this Agreement,&nbsp;&nbsp;pursuant to Section 8.2(a), the following will apply:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;">Except as otherwise expressly provided herein, all rights and obligations of each Party hereunder will cease (including all rights and l</font>icenses and sublicenses granted by either Party to the other Party hereunder), except as otherwise expressly provided herein; provided that if such termination is on a Product-by-Product or country-by-country basis then such rights and obligations shall cease with respect to the terminated Product(s) and country(ies) only.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;">On Sangamo&#8217;s written notice to Pfizer, which notice may only be delivered within [ * ] following the effective date of termination, the Parties will negotiate in good faith for a per</font>iod not to exceed [ * ] regarding:</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(A)<font style="margin-left:36pt;">an agreement under which Pfizer would grant to Sangamo a royalty-bearing, non-exclusive license under the Reversion Technology permitting Sangamo to continue to Develop, Commercialize and Manufacture [ * ] (a &#8220;</font><font style="text-decoration:underline;">Continuation Product</font>&#8221;), provided, however, that any such Agreement will include [ * ] with respect to [ * ]; </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(B)<font style="margin-left:36pt;">the related transfer to Sangamo of development data and regulatory filings specifically relating to such Continuation Product or the granting </font>to Sangamo of rights of reference with respect to such data and filings; and</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">55</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU57"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(C)</font><font style="margin-left:36pt;">the provision by Pfizer to Sangamo of transitional supplies of such Continuation Product at a commercially reasonable supply price for a commercially reasonable period of time</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:23.08%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;">Neither Party will be obligated to enter into any transaction described in Section 8.3(a)(ii).&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Termination by Pfizer for Bankruptcy<font style="font-weight:normal;">.&nbsp;&nbsp;In the event that Pfizer terminates this Agreement pursuant to Section 8.2(c), all rights and obligations of each Party hereunder shall cease (including all non-perpetual, revocable rights and licenses granted by either Party to the other Party hereunder), except as otherwise expressly provided herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font>Termination by Pfizer for Cause<font style="font-weight:normal;">.&nbsp;&nbsp;In the event that Pfizer terminates this Agreement pursuant to Section 8.2(b), all rights and obligations of each Party hereunder shall cease (including all non-perpetual, revocable rights and licenses granted by either Party to the other Party hereunder), except as otherwise expressly provided herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font>Pfizer Remedies for Sangamo Material Breach. <font style="font-weight:normal;">In the event that Pfizer has the right, but elects (after notice to Sangamo and failure of Sangamo to cure within the applicable cure period) not, to terminate this Agreement pursuant to Section 8.2(b), Pfizer shall notify Sangamo promptly upon the end of such cure period and: (i) [ * ] and, [ * ] (1) [ * ]; or (2) [ * ] the uncured material breach [ * ]. [ * ].&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>Termination by the Parties Because No Compound or Lead Development Compound Identified<font style="font-weight:normal;">.&nbsp;&nbsp;In the event that the Parties terminate this Agreement as contemplated in Section 1.42 or Section 5.1, all rights and obligations of each Party hereunder shall cease (including all non-perpetual, revocable rights and licenses granted by either Party to the other Party hereunder), except as otherwise expressly provided herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.4<font style="margin-left:36pt;"></font>Sangamo&#8217;s Right to Receive All Payments Accrued<font style="font-weight:normal;">. Expiration or termination of this Agreement for any reason (x) shall be without prejudice to Sangamo&#8217;s right to receive all Milestone Payments accrued under Section 5.2(a) and Section 5.2(b) and all royalties accrued under Section 5.3(a) prior to the effective date of such termination and to any other remedies that either Party may otherwise have and (y) shall not release a Party hereto from any indebtedness, liability or other obligation incurred hereunder by such Party prior to the date of termination or expiration, provided that Pfizer will not be liable for any Milestone Payment that accrues between a notice of termination by Pfizer of the Agreement in its entirety and the date of termination of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.5<font style="margin-left:36pt;"></font>Survival<font style="font-weight:normal;">.&nbsp;&nbsp;Expiration or termination of this Agreement shall not relieve the Parties of any obligation accruing prior to such expiration or termination.&nbsp;&nbsp;Without limiting the foregoing, the provisions of Sections [ * ] shall survive the expiration or termination of this Agreement. </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU58"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">8.6</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Termination Not Sole Remedy</font><font style="font-weight:normal;">.&nbsp;&nbsp;Termination is not the sole remedy under this Agreement and, whether or not termination is effected and notwiths</font><font style="font-weight:normal;">tanding anything contained in this Agreement to the contrary, all other remedies shall remain available except as agreed to otherwise herein.</font></p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_Ref128913346"></a><a name="_Ref172970284"></a>Article 9<font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;"><a name="_Ref172970284"></a>REPRESENTATIONS AND WARRANTIES </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.1<font style="margin-left:36pt;"></font>Mutual Representations and Warranties<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party represents and warrants to the other Party as of the Effective Date that: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such Party is duly organized, validly existing and in good standing under the laws of the jurisdiction in which it is organized;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">such Party: (i) has the requisite power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder, and (ii) has taken all requisite action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">this Agreement has been duly executed on behalf of such Party and is a legal, valid and binding obligation on such Party, enforceable against such Party in accordance with its terms;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">all necessary consents, approvals and authorizations of all Governmental Authorities and other persons or entities required to be obtained by such Party in connection with the execution and delivery of this Agreement have been obtained; and </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the execution and delivery of this Agreement and the performance of such Party&#8217;s obligations hereunder: (i) do not conflict with or violate any requirement of applicable Laws, regulations or orders of Governmental Authorities, (ii) do not conflict with, or constitute a breach or default under, any contractual obligation of such Party, and (iii) do not conflict with or result in a breach of any provision of the organizational documents of such Party.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.2<font style="margin-left:36pt;"></font>Representations and Warranties by Sangamo<font style="font-weight:normal;">.&nbsp;&nbsp;Sangamo represents and warrants to Pfizer that:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="OLE_LINK1"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, except with respect to Licensed Patents Controlled by Sangamo pursuant to a Current License, Sangamo or its Affiliate is the sole and exclusive owner of the Licensed Patents listed on </font><font style="text-decoration:underline;">Exhibit A</font><font style="font-weight:normal;">, all of which are free and clear of any claims, liens, charges or encumbrances;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, Sangamo has the full right, power and authority to (i) grant the licenses and other rights (including the right to sublicense) granted&nbsp;&nbsp;to Pfizer under this Agreement and (ii) perform its obligations under this Agreement;</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref468632504"></a><a name="_Ref468632549"></a><a name="_AEIOULastRenderedPageBreakAEIOU59"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)</font><font style="margin-left:36pt;"></font><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:normal;"> sets forth a true and complete list </font><font style="font-weight:normal;">of all Compounds discovered or developed by Sangamo or its Affiliates on or prior to the Effective Date;</font><font style="font-weight:normal;"> </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">(A) </font><font style="text-decoration:underline;">Exhibit A</font><font style="font-weight:normal;"> sets forth a true and complete list of all Licensed Patents (i) owned or otherwise Controlled by Sangamo or its Affiliates as of the Effective Date or (ii) to which Sangamo or its Affiliates have as of the Effective Date been granted or otherwise transferred any right to practice under, in each case that are necessary for the Development, Manufacture, or Commercialization of Compounds, (B) except for expired provisional patent applications, each such Patent Right, remains in full force and effect as of the Effective Date and (C) Sangamo or its Affiliates have timely paid, or caused the appropriate Third Parties to pay, all filing and renewal fees payable as of the Effective Date with respect to such Patent Rights; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">to Sangamo&#8217;s knowledge</font> <font style="font-weight:normal;">as of the Effective Date, no Third Party (i) is infringing any Licensed Patents in the Field or (ii) has challenged or threatened to challenge the inventorship, ownership, Sangamo&#8217;s right to use, scope, validity or enforceability of, or Sangamo&#8217;s or any Current Licensor&#8217;s rights in or to, any Licensed Patents (including, by way of example, through the institution or written threat of institution of interference, derivation, post-grant review, opposition, nullity or similar invalidity proceedings before the United States Patent and Trademark Office or any analogous foreign Governmental Authority);</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, Sangamo has complied with all applicable Laws, including any disclosure requirements, in connection with the filing, prosecution and maintenance of the Licensed Patents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">except with respect to Licensed Patents Controlled by Sangamo pursuant to a Current License, Sangamo has obtained from all inventors of the Licensed Patents existing as of the Effective Date, valid and enforceable agreements assigning to Sangamo each such inventor&#8217;s entire right, title and interest in and to all such Licensed Patents;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">except with respect to Licensed Technology Controlled by Sangamo pursuant to a Current License, no Licensed Technology existing as of the Effective Date is subject to any funding agreement with any government or Governmental Authority;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">except as expressly disclosed in </font><font style="text-decoration:underline;">Exhibit E</font><font style="font-weight:normal;">, as of the Effective Date, neither Sangamo nor any of its Affiliates are party to or otherwise subject to any agreement or arrangement which limits the licensed or sublicensed rights of Pfizer with respect to, or limits the ability of Pfizer to grant a sublicense to, or provide access or other rights in, to, or under any Licensed Technology (including any Patent Right or Know-How included therein), in each case, that would, but for such agreement or arrangement, be included in the rights licensed to Pfizer pursuant to this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU60"></a>(j)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, (i) there are no Sangamo Third Party Agreements other than the Current Licenses set forth on </font><font style="text-decoration:underline;">Exhibit F</font><font style="font-weight:normal;">, (ii) true and complete copies of each Current License (other than financial terms redacted therefrom) have been provided to Pfizer, (iii) except as provided in the Current Licenses, no Third Party has any right, title or interest in or </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">to, or any license under, any Licensed Technology that conflicts with the rights granted to Pfizer hereunder, (iv) no rights granted by or</font><font style="font-weight:normal;"> to Sangamo or its Affiliates under any Current License conflict with any right or license granted to Pfizer hereunder and (iv) Sangamo and its Affiliates are in compliance in all material respects with all Current Licenses;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(k)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, except as expressly disclosed in </font><font style="text-decoration:underline;">Exhibit E</font><font style="font-weight:normal;">, there is no (i) claim, demand, suit, proceeding, arbitration, inquiry, investigation or other legal action of any nature, civil, criminal, regulatory or otherwise, pending or, to the knowledge of Sangamo, threatened against Sangamo or any of its Affiliates or (ii) judgment or settlement against or owed by Sangamo or any of its Affiliates, in each case in connection with the Licensed Technology or relating to the transactions contemplated by this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(l)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, Sangamo has valid and enforceable agreements with all persons employed by Sangamo or its Affiliates who will conduct activities under this Agreement which require such persons to assign to Sangamo their entire right, title and interest in and to all Licensed Technology; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(m)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">as of the Effective Date, Sangamo has no knowledge of (i) any prior art or other facts that Sangamo reasonably believes would result in the invalidity or unenforceability of any issued or pending claims included in the Licensed Patents, (ii) any inequitable conduct or fraud on any patent office with respect to any of the Licensed Patents or (iii) any Person (other than Persons identified in the applicable patent applications or patents, as inventors of inventions claimed in the Licensed Patents) who claims to be an inventor of an invention claimed in the Licensed Patents.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.3<font style="margin-left:36pt;"></font>Accuracy of Representations and Warranties<font style="font-weight:normal;">. </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo will promptly notify Pfizer of any lawsuits, claims, administrative actions or other proceedings asserted or commenced against Sangamo or its Representatives involving in any material way the ability of Sangamo to deliver the rights, licenses and sublicenses granted to Pfizer herein.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo will promptly notify Pfizer in writing of any facts or circumstances arising after the Effective Date which come to Sangamo&#8217;s attention at any time during the Term and which would cause, or through the passage of time would cause, any of the representations and warranties contained in Section 9.1 or Section 9.2, if made at the time of such fact or circumstance becomes known to Sangamo, to be inaccurate or untrue in any material respect.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.4<font style="margin-left:36pt;"></font>Sangamo Covenants<font style="font-weight:normal;">. In addition to the covenants made by Sangamo elsewhere in this Agreement, Sangamo hereby covenants to Pfizer that, from the Effective Date until expiration or termination of this Agreement:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref265016671"></a><a name="_Ref276051242"></a><a name="_AEIOULastRenderedPageBreakAEIOU61"></a>(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo will not, and will cause its Affiliates not to (i) license, sell, or assign (other than in a connection with a permitted assignment of this Agreement by Sangamo </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">pursuant to</font><font style="font-weight:normal;"> Section 12.2) or otherwise transfer to any Person (other than Pfizer or its Affiliates or Sublicensees pursuant to the terms of this Agreement) any Licensed Technology (or agree to do any of the foregoing) in a manner that is inconsistent with the license</font><font style="font-weight:normal;">s and other rights granted to Pfizer under this Agreement or (ii) incur or permit to exist, with respect to any Licensed Technology, any lien, encumbrance, charge, security interest, mortgage, liability, assignment, grant of license or other Binding Obliga</font><font style="font-weight:normal;">tion in each case that is inconsistent with the licenses and other rights granted to Pfizer under this Agreement;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo will not (i) take any action with respect to any Sangamo Third Party Agreement that diminishes the rights under the Licensed Technology granted to Pfizer under this Agreement or (ii) fail to take any action with respect to a Sangamo Third Party Agreement that is reasonably necessary to avoid diminishing the rights under the Licensed Technology granted to Pfizer under this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo will (i) not enter into any Sangamo Third Party Agreement that adversely affects (1) the rights granted to Pfizer, Pfizer&#8217;s Affiliates or Sublicensees hereunder or (2) Sangamo&#8217;s ability to fully perform its obligations hereunder; and (ii) promptly furnish Pfizer with true and complete copies of all (1) amendments to the Current Licenses and (2) Sangamo Third Party Agreements executed following the Effective Date, in each case redacted of financial terms, except in the case of Non-Exclusive Upstream Licenses;.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">Sangamo has made or will make any payments owing by Sangamo to any inventor of any Licensed Technology owned by Sangamo that is required in connection with the creation or exploitation of or transfer of rights to such Licensed Technology; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref441668734"></a>(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">during the Term, Sangamo will promptly notify Pfizer in the event that it learns of:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(i)<font style="margin-left:36pt;"></font>any prior art or other facts that Sangamo believes would result in the invalidity or unenforceability of any of the claims included in any of the Licensed Patents;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(ii)<font style="margin-left:36pt;"></font>any inequitable conduct or fraud on the patent office with respect to any of the Licensed Patents; or </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:30.77%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(iii)<font style="margin-left:36pt;"></font>any Person (other than Persons identified as inventors of inventions claimed in the Sangamo Patent Rights) who claims to be an inventor of an invention claimed in Licensed Patents.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.5<font style="margin-left:36pt;"></font>Mutual Covenants.</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU62"></a>(a)<font style="margin-left:36pt;"></font>No Debarment<font style="font-weight:normal;">.&nbsp;&nbsp;In the course of the research, development, Manufacture and commercialization of the Products, neither Party nor its Affiliates or Sublicensees shall use any employee or consultant who has been debarred by any Regulatory Authority, or, to such Party&#8217;s or its Affiliates&#8217; knowledge, is the subject of debarment proceedings by a Regulatory Authority.&nbsp;&nbsp;Each Party shall notify the other Party promptly upon becoming aware that any of its </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">60</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">or its Affiliates&#8217; or Sublicensees&#8217; employees or consultants has been deba</font><font style="font-weight:normal;">rred or is the subject of debarment proceedings by any Regulatory Authority.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Compliance<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party and its Affiliates shall comply in all material respects with all applicable Laws (including all anti-bribery laws) in the Development, Manufacture and Commercialization of the Products and performance of its obligations under this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.6<font style="margin-left:36pt;"></font>Compliance with Law and Ethical Business Practices.<font style="font-weight:normal;"> In addition to the other representations, warranties and covenants made by each Party elsewhere in this Agreement, each Party (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Compliant Party</font><font style="font-weight:normal;">&#8221;) represents and warrants or covenants, as applicable, to the other Party that during the Term:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">it is licensed, registered, or qualified under applicable Law to do business, and has obtained such licenses, consents, authorizations or completed such registrations or made such notifications as may be necessary or required by applicable Law to provide the goods or services encompassed within this Agreement, and providing such goods or services is not inconsistent with any other obligation of the Compliant Party;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">in conducting its activities hereunder, it will and will cause its Affiliates and its other Representatives to comply in all material respects with applicable Law and accepted pharmaceutical industry business practices, including, to the extent applicable to each Compliant Party and each such Affiliate and other Representative, the United States Federal Food, Drug, and Cosmetic Act (21 U.S.C. &#167; 301, et seq.), the Anti-Kickback Statute (42 U.S.C. &#167; 1320a-7b), Civil Monetary Penalty Statute (42 U.S.C. &#167; 1320a-7a), the False Claims Act (31 U.S.C. &#167; 3729 et seq.), comparable state statutes, the regulations promulgated under all such statutes, and the regulations issued by the FDA, consistent with the &#8216;Compliance Program Guidance for Pharmaceutical Manufacturers&#8217; published by the Office of Inspector General, U.S. Department of Health and Human Services;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">with respect to any Products, payments or services provided under this Agreement, it has not taken and will not during the Term take any action directly or indirectly to unlawfully offer, promise or pay, or authorize the offer or payment of, any money or anything of value in order to improperly or corruptly seek to influence any Government Official or any other person in order to gain an improper advantage, and has not accepted, and will not accept in the future any such unlawful payment;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d)<font style="margin-left:342pt;"></font><font style="font-weight:normal;">it complies with the applicable laws and regulations of the countries where it operates, including anti-bribery and anti-corruption laws, accounting and record keeping laws, and laws relating to interactions with healthcare professionals or healthcare providers (collectively, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">HCPs</font><font style="font-weight:normal;">&#8221;) and Government Officials;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU63"></a>(e)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">commencing promptly after the Effective Date, it will take steps toward adopting and implementing policies and procedures, and will adopt and implement such policies and procedures within six (6) months after the Effective Date, setting out rules governing </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">61</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">interactions with HCPs and Government Officials, engagement of Third Parties, including, w</font><font style="font-weight:normal;">here appropriate, due diligence (&#8220;</font><font style="text-decoration:underline;font-weight:normal;">Policies</font><font style="font-weight:normal;">&#8221;), and its Policies will mandate a robust set of internal controls, including accounting controls, designed to ensure the making and keeping of fair and accurate books, records and accounts, on its operations arou</font><font style="font-weight:normal;">nd the world and apply worldwide to all its employees, subsidiaries, and Third Parties acting on its behalf, and which Policies will include (i) providing training to its officers, directors, employees and where appropriate, its other Representatives on su</font><font style="font-weight:normal;">ch Policies, (ii) regular monitoring and auditing of activities to confirm compliance with such Policies and the adequacy of internal controls, and remediation of identified issues, and (iii) requirements for regular review as part of its internal processe</font><font style="font-weight:normal;">s of improvement, and, from time to time, benchmarking against the standards of the industry with the assistance of external counsel;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">to its knowledge, it and each of its Affiliates has been and will, for the Term, be in compliance with all applicable Global Trade Control Laws (as defined in Section 12.8 below), including those related to, import controls, export controls, or economic sanctions, and it will cause each of its Affiliates to remain in compliance with the same during the Term;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(g)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">to its knowledge, except to the extent permissible under United States law, neither it nor any of its Affiliates has, on its own behalf or in acting on behalf of any other Person, directly or indirectly engaged with, and will not for the Term, without any required government authorization, directly or indirectly engage in any transactions, or otherwise deal with, any country or Person targeted by United States, European Union, United Kingdom or other relevant economic sanctions laws in connection with any activities related to the Party&#8217;s interaction with the other Party, including those contemplated under this Agreement; and</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(h)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">it is, as between the Parties, solely responsible to ensure Compliance by it and its Affiliates.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.7<font style="margin-left:36pt;"></font>Representation by Legal Counsel<font style="font-weight:normal;">. Each Party hereto represents that it has been represented by legal counsel in connection with this Agreement and acknowledges that it has participated in the drafting hereof. In interpreting and applying the terms and provisions of this Agreement, the Parties agree that no presumption will exist or be implied against the Party which drafted such terms and provisions.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">9.8<font style="margin-left:36pt;"></font>No Other Warranties<font style="font-weight:normal;">.&nbsp;&nbsp;EXCEPT AS EXPRESSLY STATED IN THIS ARTICLE 9 AND IN SECTION 12.10, (A) NO REPRESENTATION, CONDITION OR WARRANTY WHATSOEVER IS MADE OR GIVEN BY OR ON BEHALF OF </font><font style="text-transform:uppercase;font-weight:normal;">PFIZER </font><font style="font-weight:normal;">OR SANGAMO; AND (B) ALL OTHER CONDITIONS AND WARRANTIES WHETHER ARISING BY OPERATION OF LAW OR OTHERWISE ARE HEREBY EXPRESSLY EXCLUDED, INCLUDING ANY CONDITIONS AND WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR NON-INFRINGEMENT.&nbsp;&nbsp;Both Parties understand that the Products are the subject of ongoing research and development and that neither Party can assure the safety, effectiveness, Marketing Approval, Pricing Approval or commercial success of any Product.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU64"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 10</font><font style="font-weight:normal;text-transform:none;"><br /></font><font style="text-transform:none;">INDEM</font><font style="text-transform:none;">NIFICATION; LIABILITY; INSURANCE</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref102214836"></a>10.1<font style="margin-left:36pt;"></font>Indemnification by Sangamo<font style="font-weight:normal;">.&nbsp;&nbsp;Sangamo shall indemnify, defend and hold harmless Pfizer and its Affiliates and Sublicensees, and each of their respective directors, officers, employees and agents (collectively &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Pfizer Indemnitees</font><font style="font-weight:normal;">&#8221;), from and against all losses, liabilities, damages and expenses, including reasonable attorneys&#8217; fees and costs (collectively, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Liabilities</font><font style="font-weight:normal;">&#8221;), to the extent resulting from any claims, demands, actions or other proceedings by any Third Party arising out of: </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the material breach of any representation, warranty or covenant by Sangamo under this Agreement; or</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the recklessness, negligence or intentional misconduct of any Sangamo Indemnitees;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">except, in each case, to the extent caused by the negligence or intentional misconduct of any Pfizer Indemnitees or a material breach by Pfizer of any of its representations, warranties or covenants set forth in this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref102214816"></a>10.2<font style="margin-left:36pt;"></font>Indemnification by Pfizer<font style="font-weight:normal;">. </font><font style="text-transform:uppercase;font-weight:normal;"> </font><font style="font-weight:normal;">Pfizer shall indemnify, defend and hold harmless Sangamo and its Affiliates, Upstream Licensors and each of their respective directors, officers, employees and agents (collectively &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Sangamo Indemnitees</font><font style="font-weight:normal;">&#8221;), from and against all Liabilities to the extent resulting from any claims, demands, actions or other proceedings by any Third Party arising out of:</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the material breach of any representation, warranty or covenant by Pfizer under this Agreement; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the recklessness, negligence or intentional misconduct of any Pfizer Indemnitees; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(c)<font style="margin-left:36pt;"></font><font style="font-weight:normal;">the research, Development, Manufacture, and Commercialization of the Products and Companion Diagnostic Assays by or on behalf of Pfizer or its Affiliates or Sublicensees; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">except, in each case, to the extent caused by the negligence or intentional misconduct of any Sangamo Indemnitees or a material breach by Sangamo of any of its representations, warranties or covenants set forth in this Agreement.&nbsp;&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.3<font style="margin-left:36pt;"></font>Indemnification Procedure<font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU65"></a>(a)<font style="margin-left:36pt;"></font>Notice.&nbsp;&nbsp;<font style="font-weight:normal;">If either Party is seeking indemnification under Section 10.1 or 10.2 (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnified Party</font><font style="font-weight:normal;">&#8221;), it shall promptly inform the other Party (the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Indemnifying Party</font><font style="font-weight:normal;">&#8221;) of the claim giving rise to the obligation to indemnify pursuant to such Section as soon as reasonably practicable after receiving notice of the claim, provided, however, that no delay on </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">the part of the Indemnified Party in notifying the Indemnifying Party will relieve the Indemnifying Party from any obligation hereunder unless (and then only to the extent that) the Indemnifying Party is prejudiced thereby.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Control.&nbsp;&nbsp;<font style="font-weight:normal;">The Indemnifying Party shall have the right, exercisable by notice to the Indemnified Party within [ * ] after receipt of notice from the Indemnified Party of the commencement of or assertion of any Third Party Claim, to assume the direction and control of the defense, litigation, settlement, appeal or other disposition of any such claim for which it is obligated to indemnify the Indemnified Party (including the right to settle the claim solely for monetary consideration) with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party; provided that (a) the Indemnifying Party has sufficient financial resources, to satisfy the amount of any adverse monetary judgment that is sought, (b) the claim seeks solely monetary damages and (c) the Indemnifying Party expressly agrees in writing that as between the Indemnifying Party and the Indemnified Party, the Indemnifying Party will be solely obligated to satisfy and discharge the claim in full (the conditions set forth in clauses (a), (b) and (c) above are collectively referred to as the &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Litigation Conditions</font><font style="font-weight:normal;">&#8221;). The Indemnifying Party will be entitled, at its sole cost and expense, to assume direction and control of such defense, with counsel selected by the Indemnifying Party and reasonably acceptable to the Indemnified Party. During such time as the Indemnifying Party is controlling the defense of such Third Party Claim, the Indemnified Party shall cooperate with the Indemnifying Party, and will cause its Affiliates and agents to cooperate upon request of the Indemnifying Party, in the defense or prosecution of the claim, including by furnishing such records, information and testimony and attending such conferences, discovery proceedings, hearings, trials or appeals as may reasonably be requested by the Indemnifying Party.&nbsp;&nbsp;In the event that the Indemnifying Party does not satisfy the Litigation Conditions or does not notify the Indemnified Party of the Indemnifying Party&#8217;s intent to defend any Third Party Claim within [ * ] after notice thereof, the Indemnified Party may (without further notice to the Indemnifying Party) undertake the defense thereof with counsel of its choice and at the Indemnifying Party&#8217;s expense (including reasonable, out-of-pocket attorneys&#8217; fees and costs and expenses of enforcement or defense). The Indemnifying Party or the Indemnified Party, as the case may be, shall have the right to participate (including the right to conduct discovery, interview and examine witnesses and participate in all settlement conferences), but not control, at its own expense and with counsel of its choice, in the defense of any claim that has been assumed by the other Party.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M1548"></a><a name="_AEIOULastRenderedPageBreakAEIOU66"></a>(c)<font style="margin-left:36pt;"></font>Settlement.&nbsp;&nbsp;<font style="font-weight:normal;">The Indemnifying Party will not, without the prior written consent of the Indemnified Party, enter into any compromise or settlement that commits the Indemnified Party to take, or to forbear to take, any action. The Indemnified Party will have the sole and exclusive right to settle any claim, on such terms and conditions as it deems reasonably appropriate, to the extent such claim involves equitable or other non-monetary relief, but will not have the right to settle such claim to the extent such claim involves monetary damages without the prior written consent of the Indemnifying Party. Neither the Indemnifying Party nor the Indemnified Party will make any admission of liability in respect of any claim without the prior written consent of the other party, and the Indemnified Party will use reasonable efforts to mitigate Liabilities arising from<a name="_DV_M1548"></a> such claim.&nbsp;&nbsp;If the Parties cannot agree as to the application of Section 10.1 or 10.2 as to any claim, pending resolution of such dispute, the Parties may conduct </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">64</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">separate defenses of such claims, with each Party retaining the right to claim indemnificat</font><font style="font-weight:normal;">ion from the other Party in accordance with Section 10.1 or 10.2 upon resolution of the underlying claim.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.4<font style="margin-left:36pt;"></font>Mitigation of Loss<font style="font-weight:normal;">.&nbsp;&nbsp;Each Indemnified Party shall take and shall procure that its Affiliates take all such reasonable steps and action as are reasonably necessary or as the Indemnifying Party may reasonably require in order to mitigate any claims (or potential losses or damages) under this Article 10.&nbsp;&nbsp;Nothing in this Agreement shall or shall be deemed to relieve any Party of any common law or other duty to mitigate any losses incurred by it.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_DV_M1553"></a>10.5<font style="margin-left:36pt;"></font>Limitation of Liability<font style="font-weight:normal;">.&nbsp;&nbsp;NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL, PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH DAMAGES.&nbsp;&nbsp;NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS SECTION 10.5 IS INTENDED TO OR SHALL LIMIT OR RESTRICT THE INDEMNIFICATION RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER SECTION 10.1 OR 10.2, OR DAMAGES AVAILABLE FOR A PARTY&#8217;S BREACH OF ITS </font><font style="text-transform:uppercase;font-weight:normal;">CONFIDENTIALITY </font><font style="font-weight:normal;">OBLIGATIONS</font><font style="text-transform:uppercase;font-weight:normal;"> IN ARTICLE 7</font><font style="font-weight:normal;"><a name="_DV_M1553"></a>.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">10.6<font style="margin-left:36pt;"></font>Insurance<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party shall procure and maintain, during the Term, commercial general liability insurance, including product liability insurance, with minimum &#8220;A-&#8221; Best rated insurance carriers to cover its indemnification obligations under Section 10.1 or Section 10.2, as applicable, in each case with limits of not less than [ * ] per occurrence and in the aggregate. All deductibles and retentions will be the responsibility of the named insured. Pfizer and its Affiliates will be an additional insured on Sangamo&#8217;s commercial general liability and products liability policies, and be provided with a waiver of subrogation. To the extent of its culpability, all coverages of Sangamo will be primary and non-contributing with any similar insurance, carried by Pfizer.&nbsp;&nbsp;Each Party shall provide the other Party with evidence of such insurance by furnishing a certificate of insurance</font><font style="color:#1F497D;"> </font><font style="font-weight:normal;">upon request and shall provide the other Party with written notice at least [ * ] prior to the cancellation, non-renewal or material changes in such insurance.&nbsp;&nbsp;It is understood that such insurance shall not be construed to create a limit of either Party&#8217;s liability with respect to its indemnification obligations under this Article 10.&nbsp;&nbsp;Notwithstanding any provision of this Section 10.6 to the contrary, Pfizer may meet its obligations under this Section 10.6 through self-insurance. Neither Party&#8217;s insurance will be construed to create a limit of liability with respect to its indemnification obligations under this Article 10.</font></p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 11<font style="text-transform:none;"><br />ANTITRUST</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">11.1<font style="margin-left:36pt;"></font><font style="font-weight:normal;"> </font>Approvals<font style="font-weight:normal;">. Each of Sangamo and Pfizer will cooperate with the other Party and use Commercially Reasonable Efforts to make all registrations, filings and applications, to give all notices and to obtain as soon as practicable all governmental or other consents, transfers, approvals, orders, qualifications authorizations, permits and waivers, if any, and to do all other things necessary or desirable for the consummation of the transactions as contemplated hereby. </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">65</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:18pt;text-align:center;margin-bottom:12pt;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU67"></a><font style="font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">Article 12</font><font style="text-transform:none;"><br />GENERAL PROVISIONS</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref172971557"></a>12.1<font style="margin-left:36pt;"></font>Force Majeure<font style="font-weight:normal;">.&nbsp;&nbsp;Neither Party shall be held liable to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in performing any obligation under this Agreement to the extent such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, potentially including embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, strikes, lockouts or other labor disturbances, fire, floods, earthquakes or other acts of God, or acts, generally applicable action or inaction by any governmental authority (but excluding any government action or inaction that is specific to such Party, its Affiliates or Sublicensees, such as revocation or non-renewal of such Party&#8217;s license to conduct business), or omissions or delays in acting by the other Party.&nbsp;&nbsp;The affected Party shall notify the other Party in writing of such force majeure circumstances as soon as reasonably practical, and shall promptly undertake and continue diligently all Commercially Reasonable Efforts necessary to cure such force majeure circumstances or to perform its obligations in spite of the ongoing circumstances.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref172971533"></a><a name="_DV_M1578"></a>12.2<font style="margin-left:36pt;"></font>Assignment<font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement may not be assigned or otherwise transferred, nor may any right or obligation hereunder be assigned or transferred, by either Party without the prior written consent of the other Party.&nbsp;&nbsp;Notwithstanding the foregoing, subject to the provisions of Section 12.3, as applicable, either Party may, without consent of the other Party, assign this Agreement and its rights and obligations hereunder in whole or in part to an Affiliate of such Party, or in whole to its successor in interest in connection with the sale of all or substantially all of its stock or its assets to which this Agreement relates, or in connection with a merger, acquisition or similar transaction </font><font style="font-style:italic;font-weight:normal;">provided that</font><font style="font-weight:normal;"><a name="_DV_M1578"></a> such sale is not primarily for the benefit of its creditors.&nbsp;&nbsp;In addition, Pfizer may assign its rights and obligations under this Agreement to a Third Party where Pfizer or its Affiliate is required, or makes a good faith determination based on advice of counsel, to divest a Product in order to comply with Law or the order of any Governmental Authority as a result of a merger or acquisition.&nbsp;&nbsp;Each Party will promptly notify the other Party of any assignment or transfer under the provisions of this Section 12.2. Any attempted assignment not in accordance with the foregoing shall be null and void and of no legal effect.&nbsp;&nbsp;Any permitted assignee shall assume all assigned obligations of its assignor under this Agreement.&nbsp;&nbsp;The terms and conditions of this Agreement shall be binding upon, and shall inure to the benefit of, the Parties and their respected successors and permitted assigns.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref480277249"></a>12.3<font style="margin-left:36pt;"></font>Notification of a Change of Control of Sangamo<font style="font-weight:normal;">. Sangamo will notify Pfizer in writing promptly (and in any event prior to the public disclosure thereof) following the entering into of a definitive agreement with respect to a Change of Control of Sangamo.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU68"></a>12.4<font style="margin-left:36pt;"></font>Severability<font style="font-weight:normal;">.&nbsp;&nbsp;If any one or more of the provisions contained in this Agreement is held invalid, illegal or unenforceable in any respect, the validity, legality and enforceability of the remaining provisions contained herein shall not in any way be affected or impaired thereby, unless the absence of the invalidated provision(s) adversely affects the substantive rights of the Parties.&nbsp;&nbsp;The Parties shall in such an instance use their best efforts to replace the invalid, illegal </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">66</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">or unenforceable provision(s) with valid, l</font><font style="font-weight:normal;">egal and enforceable provision(s) which, insofar as practical, implement the purposes of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.5<font style="margin-left:36pt;"></font>Notices<font style="font-weight:normal;">.&nbsp;&nbsp;All notices which are required or permitted hereunder shall be in writing and sufficient if delivered personally, sent by facsimile (and promptly confirmed by personal delivery, registered or certified mail or overnight courier), sent by nationally-recognized overnight courier or sent by registered or certified mail, postage prepaid, return receipt requested, addressed as follows:</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:25%;text-indent:-5.84%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Sangamo:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc.<br />501 Canal Blvd.<br />Richmond, CA 94804<br />Attn:<font style="margin-left:36pt;">Chief Executive Officer</font><br />Fax:<font style="margin-left:36pt;">[ * ]</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:25%;text-indent:-5.84%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cooley LLP<br />3175 Hanover Street<br />Palo Alto, CA 94304<br />Attn:<font style="margin-left:36pt;">Marya Postner, Ph.D.</font><br />Fax:<font style="margin-left:36pt;">[ * ]</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:25%;text-indent:-5.84%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If to Pfizer:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc.<br />R&amp;D Business Development<br />235 East 42nd Street<br />New York, New York 10017-5755<br />Attn:<font style="margin-left:36pt;">R&amp;D BD Contract Notice</font><br /></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:25%;text-indent:-5.84%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">with a copy to:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc.<br />Notices: Pfizer Legal Division<br />235 East 42nd Street<br />New York, New York 10017-5755<br />Attn:<font style="margin-left:36pt;">Chief Counsel, R&amp;D</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Fax:<font style="margin-left:36pt;">[ * ]</font></p>
<p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;margin-left:25%;text-indent:-5.84%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">and an electronic copy to:</p>
<p style="margin-top:0pt;margin-bottom:0pt;margin-left:34.62%;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU69"></a>or to such other address(es) as the Party to whom notice is to be given may have furnished to the other Party in writing in accordance herewith.&nbsp;&nbsp;Any such notice shall be deemed to have been given: (a) when delivered if personally delivered or sent by facsimile on a Business Day (or if </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:12pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">delivered or sent on a non-Business Day, then on the next Business Day); (b) on the Business Day after dispatch if sent by nationally-recognized overnight courier; or (c) on the [ * ] following the date of mai</font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ling, if sent by mail.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref172970866"></a>12.6<font style="margin-left:36pt;"></font>Dispute Resolution<font style="font-weight:normal;">.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(a)<font style="margin-left:36pt;"></font>Informal Dispute Resolution; Arbitration.&nbsp;&nbsp;<font style="font-weight:normal;">The Parties recognize that disputes as to certain matters may from time to time arise that relate to either Party&#8217;s rights and/or obligations hereunder, including the interpretation, alleged breach, enforcement, termination or validity of this Agreement (a &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Dispute</font><font style="font-weight:normal;">&#8221;).&nbsp;&nbsp;For clarity, Dispute shall not include matters within the JRC&#8217;s authority, which shall be resolved in accordance with Section 3.3.&nbsp;&nbsp;It is the objective of the Parties to establish procedures to facilitate the resolution of such Disputes arising under this Agreement in an expedient manner by mutual cooperation.&nbsp;&nbsp;To accomplish this objective, the Parties agree that if a Dispute arises under this Agreement, and the Parties are unable to resolve such Dispute within [ * ] after such Dispute is first identified by either Party in writing to the other, the Parties shall refer such Dispute to the Executive Officers of the Parties for attempted resolution by good faith negotiations within [ * ] after such notice is received.&nbsp;&nbsp;If the Executive Officers are not able to resolve such Dispute within [ * ], then such Dispute (other than Excluded Claim as defined in Section 12.6(f) below) shall be finally resolved by binding arbitration administered by [ * ] pursuant to [ * ], and judgment on the arbitration award may be entered in any court having jurisdiction thereof.&nbsp;&nbsp; </font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(b)<font style="margin-left:36pt;"></font>Number of Arbitrators; Arbitral Seat.&nbsp;&nbsp;<font style="font-weight:normal;">The arbitration shall be conducted by a panel of three arbitrators experienced in the pharmaceutical business: within [ * ] after initiation of arbitration, each Party shall select one person to act as arbitrator; provided that if a Party fails to appoint an arbitrator within [ * ] of the arbitration being initiated, such appointment shall be made by [ * ].&nbsp;&nbsp;The two arbitrators appointed in accordance with the preceding sentence shall appoint the third arbitrator, who shall be the chairman of the tribunal. If the arbitrators selected pursuant to the first sentence of this Section 12.6(b) are unable or fail to agree upon the third arbitrator within [ * ] of the appointment of the second arbitrator, the third arbitrator shall be appointed by [ * ].&nbsp;&nbsp;The place of arbitration shall be [ * ]; all proceedings and communications shall be in English.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU70"></a>(c)<font style="margin-left:36pt;"></font>Powers of the Arbitrators.&nbsp;&nbsp;<font style="font-weight:normal;">The arbitrators shall have the discretion to hear and determine at any stage of the arbitration any issue asserted by any Party to be dispositive of any claim or counterclaim, in whole or part, in accordance with such procedure as the arbitrators may deem appropriate, and the arbitrators may render an award on such issue.</font><font style="font-style:italic;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">In addition to the authority conferred on the arbitrators by the [ * ] rules, and without prejudice to any provisional measures that may be available from a court of competent jurisdiction, the arbitrators shall have the power to grant any provisional measures that the arbitrators deem appropriate, including but not limited to provisional injunctive relief until the arbitration award is rendered or the controversy is otherwise resolved and any provisional measures ordered by the arbitrators may, to the extent permitted by applicable Law, be deemed to be a final award on the subject matter of the measures and shall be enforceable as such.&nbsp;&nbsp;Either Party also may, without waiving any remedy under this Agreement, seek from any court having jurisdiction any </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">68</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">injunctive or provisional relief necessary to protect the rights or property of that Party pending the arbitration award.&nbsp;&nbsp;The arbitrators a</font><font style="font-weight:normal;">re authorized to award to the prevailing Party, if any, as determined by the arbitrators, their costs and expenses.</font><font style="font-style:italic;font-weight:normal;">&nbsp;&nbsp;</font><font style="font-weight:normal;">The arbitrators shall have no authority to award punitive or any other type of damages not measured by a Party&#8217;s compensatory damages.&nbsp;&nbsp;Eac</font><font style="font-weight:normal;">h Party shall bear its own costs and expenses and attorneys&#8217; fees and an equal share of the arbitrators&#8217; fees and any administrative fees of arbitration, except as provided above.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_238"></a>(d)<font style="margin-left:36pt;"></font>Statute of Limitations.&nbsp;&nbsp;<font style="font-weight:normal;">In no event shall an arbitration be initiated aft<a name="_cp_text_1_238"></a>er the date when commencement of a legal or equitable proceeding based on the dispute, controversy or claim would be barred by the applicable New York statute of limitations.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(e)<font style="margin-left:36pt;"></font>Confidentiality<font style="font-weight:normal;">. No information concerning an arbitration, beyond the names of the Parties and the relief requested, may be unilaterally disclosed to a Third Party by any Party unless required by Law.&nbsp;&nbsp;Except to the extent necessary to confirm an award or as may be required by law, neither a Party nor an arbitrator may disclose the existence, content, or results of an arbitration without the prior written consent of both Parties.&nbsp;&nbsp;Any documentary or other evidence given by a Party or witness in the arbitration shall be treated as confidential by any Party whose access to such evidence arises exclusively as a result of its participation in the arbitration, and shall not be disclosed to any Third Party (other than a witness or expert), except as may be required by Law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:15.38%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(f)<font style="margin-left:36pt;"></font>Excluded Claims.&nbsp;&nbsp;<font style="font-weight:normal;">As used in this Section, the term &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Excluded Claim</font><font style="font-weight:normal;">&#8221; shall mean a dispute, controversy or claim that concerns (i) the scope, validity, enforceability, inventorship or infringement of a patent, patent application, trademark or copyright; or (ii) any antitrust, anti-monopoly or competition law or regulation, whether or not statutory.</font> </p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.7<font style="margin-left:36pt;"></font>Governing Law<font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement shall be governed by and construed in accordance with the laws of the State of New York without reference to any rules of conflict of laws; provided that the United Nations Convention on Contracts for International Sale of Goods shall not apply.&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.8<font style="margin-left:36pt;"></font>Global Trade Control Laws.&nbsp;&nbsp;<font style="font-weight:normal;">Parties will perform all activities under this Agreement in full compliance with all applicable economic sanctions, import, and export control laws, regulations, and orders (collectively, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Global Trade Control Laws</font><font style="font-weight:normal;">&#8221;).</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.9<font style="margin-left:36pt;"></font>Export Control.&nbsp;&nbsp;<font style="font-weight:normal;">This Agreement is made subject to any restrictions concerning the export of products or technical information from the United States of America or other countries which may be imposed upon or related to Sangamo or Pfizer from time to time. Neither Party will knowingly transfer to the other Party any goods, software, technology, or services that are (i) controlled at a level other than EAR99, or for reasons other than anti-terrorism, under the U.S. Export Administration Regulations; (ii) controlled under the U.S. International Traffic in Arms Regulations; (iii) specifically identified as an E.U. Dual Use Item; or (iv) on an applicable export control list of a foreign country.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">69</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU71"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.10</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Restricted Markets; Restricted Parties.&nbsp;&nbsp;</font><font style="font-weight:normal;">The Parties agree that the activities under the Agreement will not (i) be in a Restricted Market; (ii) involve individuals ordinarily resident in a Restricted Market; or (iii) include companies, organizations, or Go</font><font style="font-weight:normal;">vernmental Authorities from or located in a Restricted Market.&nbsp;&nbsp;Each Party represents and warrants that neither such Party, nor any other Person, directly or indirectly, performing activities under this Agreement on such Party&#8217;s behalf, are on any applicab</font><font style="font-weight:normal;">le Restricted Party Lists, and that such individuals are not employed by any Person on any of the applicable Restricted Party Lists.&nbsp;&nbsp;In the event that any of the Persons noted above, or any Third Party directly or indirectly engaged by such a Person, beco</font><font style="font-weight:normal;">mes listed on a Restricted Party List during the Term of this Agreement, the Party responsible for such Person will cease the activities that involve such Person and immediately notify the other Party. Each Party shall conduct Restricted Party Screening of</font><font style="font-weight:normal;"> the names and addresses of all employees and subcontractors invited to participate in activities under this Agreement by that Party, and shall require its subcontractors to conduct such screening of its employees and subcontractors or represent that no su</font><font style="font-weight:normal;">ch subcontractor or employee is on an applicable Restricted Party List.&nbsp;&nbsp;Notwithstanding any cure periods set forth herein, both Parties acknowledge that listing of the other Party on a Restricted Party List, shall be grounds for immediate termination of t</font><font style="font-weight:normal;">his Agreement, for cause, with no cure period.&nbsp;&nbsp;For purposes of this Agreement, &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Restricted Markets</font><font style="font-weight:normal;">&#8221; means the Crimea region of Ukraine, Cuba, Iran, North Korea, Sudan, and Syria, and any other country that, during the Term of this Agreement, is or becomes</font><font style="font-weight:normal;"> subject to comprehensive trade sanctions by the United States and/or designated as a state sponsor of terrorism pursuant to section 6(j) of the</font><font style="Background-color:#FFFFFF;font-weight:normal;"> Export Administration Act, section 40 of the Arms Export Control Act, and section 620A of the Foreign Assistanc</font><font style="Background-color:#FFFFFF;font-weight:normal;">e Act</font><font style="font-weight:normal;">; &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Restricted Party Lists</font><font style="font-weight:normal;">&#8221; include, but are not limited to, the list of sanctioned entities maintained by the United Nations; the Specially Designated Nationals and Blocked Persons List, Foreign Sanctions Evaders List, and the Sectoral Sanctions Ident</font><font style="font-weight:normal;">ifications List, as administered by the U.S. Department of the Treasury Office of Foreign Assets Control; the U.S. Denied Persons List, the U.S. Entity List, and the U.S. Unverified List, all administered by the U.S. Department of Commerce; the entities su</font><font style="font-weight:normal;">bject to restrictive measures and the Consolidated List of Persons, Groups and Entities Subject to E.U. Financial Sanctions, as implemented by the E.U. Common Foreign &amp; Security Policy; the List of Excluded Individuals / Entities, as published by the U.S. </font><font style="font-weight:normal;">Health and Human Services &#8211; Office of Inspector General; any lists of prohibited or debarred parties established under the U.S. Federal Food Drug and Cosmetic Act; the list of persons and entities suspended or debarred from contracting with the U.S. govern</font><font style="font-weight:normal;">ment; and similar applicable lists of restricted parties maintained by the Governmental Authorities of the jurisdictions of import and export; and &#8220;</font><font style="text-decoration:underline;font-weight:normal;">Restricted Party Screening</font><font style="font-weight:normal;">&#8221; includes, but is not limited to, the comparison of any individual or entity dire</font><font style="font-weight:normal;">ctly or indirectly involved in activities under this Agreement, against the applicable Restricted Party Lists.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU72"></a>12.11<font style="margin-left:36pt;"></font>Termination and Blocked Payment<font style="font-weight:normal;">.&nbsp;&nbsp;If this Agreement is terminated for inclusion of a Person on a Restricted Party List, Restricted Market, or Restricted Market national in activities under this Agreement without a license or other authorization required by Global Trade Control Laws or any other violation of Global Trade Control Laws, the terminating Party shall not be responsible for any payments due to the other Party, even if activities have already occurred. Further, the other Party shall be responsible for reimbursing the terminating Party for </font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">70</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:normal;">any payments due to the terminating Party under this Agreement that are blocked due to inclusion of a P</font><font style="font-weight:normal;">erson on a Restricted Party List, Restricted Market, or Restricted Market national in activities under this Agreement without a license or other authorization required by Global Trade Control Laws or any other violation of Global Trade Control Laws.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_cp_text_1_239"></a>12.12<font style="margin-left:36pt;"></font>Entire Agreement; Amendments<font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement, together with the Exhibits hereto, contains the entire understanding of the Parties with respect to the subject matter hereof.&nbsp;&nbsp;Any other express or implied agreements and understandings, negotiations, writings and commitments, either oral or written, with respect to the subject matter hereof are superseded by the terms of this Agreement.&nbsp;&nbsp;The Exhibits to this Agreement are incorporated herein by reference and shall be deemed a part of this Agreement.&nbsp;&nbsp;This Agreement may be amended, or any term hereof modified, only by a written instrument duly executed by authorized representative(s) of both Parties hereto.&nbsp;&nbsp;The Parties agree that the Confidentiality Agreement between the Parties dated as of September 20, 2017, as am<a name="_cp_text_1_239"></a>ended, is hereby terminated, but each Party&#8217;s information that was the subject of confidentiality obligations under such Confidentiality Agreement (including any information that was orally disclosed within the thirty (30) day period prior to the Effective Date and was declared confidential at the time of disclosure by the disclosing Party, even if the disclosing Party did not provide a written confirmation of such disclosure as of the Effective Date) shall be deemed to be Confidential Information of such Party under this Agreement.&nbsp;&nbsp;&nbsp;&nbsp;</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.13<font style="margin-left:36pt;"></font>Headings<font style="font-weight:normal;">.&nbsp;&nbsp;The captions to the several Articles, Sections (and subsections) and Exhibits hereof are not a part of this Agreement, but are merely for convenience to assist in locating and reading the several Articles, Sections and Exhibits hereof.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.14<font style="margin-left:36pt;"></font>Independent Contractors<font style="font-weight:normal;">.&nbsp;&nbsp;It is expressly agreed that Sangamo and Pfizer shall be independent contractors and that the relationship between the two Parties shall not constitute a partnership, joint venture or agency.&nbsp;&nbsp;Neither Sangamo nor Pfizer shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.&nbsp;&nbsp;Neither Party shall report this Agreement or the relationship between the Parties as a partnership for tax purposes unless required by law.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.15<font style="margin-left:36pt;"></font>Waiver<font style="font-weight:normal;">.&nbsp;&nbsp;No provision of this Agreement will be waived by any act, omission or knowledge of a Party or its agents or employees except by an instrument in writing expressly waiving such provision and signed by a duly authorized officer of the waiving Party.&nbsp;&nbsp;The waiver by either Party hereto of any right hereunder, or of any failure of the other Party to perform, or of any breach by the other Party, shall not be deemed a waiver of any other right hereunder or of any other breach by or failure of such other Party whether of a similar nature or otherwise.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.16<font style="margin-left:36pt;"></font>Cumulative Remedies<font style="font-weight:normal;">.&nbsp;&nbsp;No remedy referred to in this Agreement is intended to be exclusive, but each shall be cumulative and in addition to any other remedy referred to in this Agreement or otherwise available under law.</font></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU73"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.17</font><font style="margin-left:36pt;"></font><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Waiver of Rule of Construction</font><font style="font-weight:normal;">.&nbsp;&nbsp;Each Party has had the opportunity to consult with counsel in connection with the review, drafting and </font><font style="font-weight:normal;">negotiation of this Agreement.&nbsp;&nbsp;Accordingly, the rule of construction that any ambiguity in this Agreement shall be construed against the drafting Party shall not apply.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.18<font style="margin-left:36pt;"></font>Business Day Requirements<font style="font-weight:normal;">.&nbsp;&nbsp;In the event that any notice or other action or omission is required to be taken by a Party under this Agreement on a day that is not a Business Day then such notice or other action or omission shall be deemed to be required to be taken on the next occurring Business Day.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.19<font style="margin-left:36pt;"></font>Further Actions<font style="font-weight:normal;">.&nbsp;&nbsp;Each Party agrees to execute, acknowledge and deliver such further instruments, and to do all such other acts, as necessary or appropriate in order to carry out the purposes and intent of this Agreement.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">12.20<font style="margin-left:36pt;"></font>No Third Party Rights or Obligations<font style="font-weight:normal;">. No provision of this Agreement will be deemed or construed in any way to result in the creation of any rights or obligation in any Person not a Party to this Agreement. However, Pfizer may decide, in its sole discretion, to use one or more of its Affiliates to perform its obligations and duties hereunder, </font><font style="font-style:italic;font-weight:normal;">provided that</font><font style="font-weight:normal;"> Pfizer will remain liable hereunder for the performance by any such Affiliates of any such obligations.</font></p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:55.77%;text-indent:7.69%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_Ref164228225"></a>12.21<font style="margin-left:36pt;"></font>Counterparts<font style="font-weight:normal;">.&nbsp;&nbsp;This Agreement may be executed in two or more counterparts by original signature, facsimile or PDF files, eac<a name="_Ref164228225"></a>h of which shall be deemed an original, but all of which together shall constitute one and the same instrument.</font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;margin-left:15.38%;text-indent:0%;font-weight:bold;text-transform:uppercase;font-size:12pt;font-family:Times New Roman;font-style:normal;font-variant: normal;">&lt;REMAINDER OF PAGE INTENTIONALLY LEFT BLANK&gt;</p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">72</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:12pt;margin-top:0pt;text-indent:7.69%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU74"></a><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">IN WITNESS WHEREOF, the Parties </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">intending to be bound have caused this Research Collaboration and License Agreement to be executed by their duly authorized representatives as of the Effective Date.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse;  margin-left:1.15%;width:474.9pt;;">
<tr>
<td style="width:235.8pt;"></td>
<td style="width:239.1pt;"></td>
</tr>
<tr>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="text-align:justify;margin-bottom:24pt;margin-top:24pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Alexander Macrae</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;">Alexander Macrae</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;">CEO</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top"  style="padding-left:5.4pt;padding-Right:5.4pt;">
<p style="text-align:justify;margin-bottom:24pt;margin-top:24pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pfizer Inc.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:<font style="text-decoration:underline;">/s/ Gregory LaRosa</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Name:<font style="text-decoration:underline;">Gregory LaRosa</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:30.6pt;;text-indent:-30.6pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:44.1pt;;text-indent:-44.1pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Title:<font style="text-decoration:underline;">SVP and CSO RDRU</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:35.1pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="margin-top:12pt; clear:both;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_cp_text_1_240"></a><font style="text-decoration:underline;">Exhibit A</font>:<font style="margin-left:36pt;"><a name="_cp_text_1_240"></a>Licensed Patents</font> </p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{<font style="font-weight:normal;">Redacted content comprises approximately 11 pages}</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ]</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.69%;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">74</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU75"></a><font style="text-decoration:underline;">Exhibit B</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">:</font><font style="margin-left:36pt;">Research Plan</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{<font style="font-weight:normal;">Redacted content comprises approximately 9 pages}<br /></font></p>
<p style="margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"> [ * ]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU76"></a><font style="text-decoration:underline;">Exhibit C</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">:</font><font style="margin-left:36pt;">Compounds</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><font style="text-decoration:underline;">Exhibit D</font>:<font style="margin-left:36pt;">Joint Press Release</font></p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;"><br />
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g2018030121531033832030.jpg" title="" alt="" style="width:161px;height:100px;"></p>
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p><img src="g2018030121531034432031.jpg" title="" alt="" style="width:259px;height:93px;"></p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-right:5.34%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:3pt;margin-bottom:0pt;margin-right:5.34%;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:5.5pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:1.1%;text-indent:0%;font-size:5pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:16pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sangamo and Pfizer announce collaboration for development of zinc finger protein gene therapy for ALS</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Richmond,<font style="letter-spacing:0.95pt;"> </font>California and New York, New York,<font style="letter-spacing:0.95pt;"> </font>January 3,<font style="letter-spacing:0.8pt;"> </font>2018<font style="letter-spacing:0.95pt;"> </font>&#8211;<font style="letter-spacing:-0.1pt;font-weight:normal;">&#160;</font><font style="font-weight:normal;">Sangamo Therapeutics, Inc. (Nasdaq: SGMO) and Pfizer Inc. (NYSE: PFE) today announced a collaboration for the development of a potential gene therapy using zinc finger protein transcription factors (ZFP-TFs) to treat amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration (FTLD) linked to mutations of the C9ORF72 gene. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">ALS and FTLD are part of a spectrum of neurodegenerative disorders caused by mutations in the C9ORF72 gene that involve hundreds of additional repetitions of a six base pair sequence of DNA. This ultimately leads to the deterioration of motor neurons, in the case of ALS, or neurons in the frontal and temporal lobes, in the case of FTLD. Currently, there are no cures to halt or reverse the progression of ALS or FTLD. The C9ORF72 mutation is linked to approximately one-third of cases of familial ALS.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We are excited to continue our collaborative relationship with Pfizer with this new program using Sangamo&#8217;s zinc finger protein technology to develop a potential gene therapy for patients with certain forms of ALS and FTLD, devastating diseases with very limited treatment options,&#8221; said Dr. Sandy Macrae, Chief Executive Officer of Sangamo. &#8220;The precision and flexibility of zinc finger proteins enables targeting of virtually any genetic mutation. Collaboration with the right partner for a given therapeutic application is a key component of our corporate strategy and enables us to pursue the vast opportunity set of our platform.&#8221;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We look forward to working with Sangamo on potential treatments for devastating diseases related to genetic mutations of the C9ORF72 gene,&#8221; said Greg LaRosa, Senior Vice President and Chief Scientific Officer, Pfizer Rare Disease. &#8220;Pfizer is proud of the progress we have made in the area of gene therapy, which offers tremendous promise to patients and their families.&#8221; </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU77"></a>Gene therapies are a potentially transformational technology for patients, focused on highly specialized, one-time treatments that address the root cause of diseases caused by genetic mutation. Sangamo&#8217;s ZFP-TF technology involves introducing an engineered zinc finger protein (ZFP) which is designed to identify and bind to a precise sequence of DNA. Once bound to the target sequence of DNA, a transcriptional repressor domain attached to the ZFP suppresses </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">77</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">expression of the gene. Under this collaboration, Sangamo and Pfizer will investigate allele-specific ZFP-TFs with the potential to differentiate the mutant C9ORF72 allele from the wild type allele and to specifically down-regulate expression of </font><font style="font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">the mutant form of the gene. </font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the collaboration agreement, Sangamo will receive a $12 million upfront payment from Pfizer. Sangamo will be responsible for the development of ZFP-TF candidates. Pfizer will be operationally and financially responsible for subsequent research, development, manufacturing and commercialization for the C9ORF72 ZFP-TF program and any resulting products. Sangamo is eligible to receive potential development and commercial milestone payments of up to $150 million, as well as tiered royalties on net sales. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2017, Sangamo and Pfizer entered into an exclusive, global collaboration and license agreement for the development and commercialization of potential gene therapy products for Hemophilia A, including SB-525, which entered the clinic in August 2017. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Sangamo&#8217;s ZFP-TF Gene Regulation Platform</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s zinc finger protein transcription factor (ZFP-TF)-mediated gene regulation approach is designed to either selectively repress (down-regulate) or activate (up-regulate) the expression of a specific gene or DNA sequence with a single administration.&nbsp;&nbsp;This technology enables targeting of a broad range of diseases requiring regulation of endogenous gene expression and differs from other approaches such as gene therapy or zinc finger nuclease-mediated genome editing, which are designed to replace or correct a missing or mutated gene or DNA sequence. Sangamo is developing ZFP-TFs as a novel therapeutic approach for diseases of the central nervous system (CNS). In keeping with the company&#8217;s strategy to externalize development of ZFP-TFs for CNS diseases, Sangamo has established collaborations with Pfizer for ALS and FTLD and with Shire for Huntington&#8217;s disease. Sangamo is also developing ZFP-TFs to down-regulate the expression of tau, a protein associated with Alzheimer&#8217;s disease and frontotemporal dementia (FTD). The company&#8217;s strategy for the tau program is to seek a development and commercialization partner upon completion of preclinical studies. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Sangamo Therapeutics&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc. is focused on translating ground-breaking science into genomic therapies that transform patients' lives using the company's industry leading platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company is conducting Phase 1/2 clinical trials in Hemophilia A and Hemophilia B, and in lysosomal storage disorders MPS I and MPS II. Sangamo has an exclusive, global collaboration and license agreement with Pfizer Inc. for gene therapy programs for Hemophilia A, ALS and FTLD, with Bioverativ Inc. for hemoglobinopathies, including beta thalassemia and sickle cell disease, and with Shire International GmbH to develop therapeutics for Huntington's disease. In addition, Sangamo has established strategic partnerships with companies in non-therapeutic applications of its technology, including Sigma-Aldrich Corporation and Dow AgroSciences. For more information about Sangamo, visit the Company's website at www.sangamo.com.</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">78</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU78"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">About Pfizer Inc.: Working together for a healthier world&#174;</font></p>
<p style="margin-bottom:8pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives. We strive to set the standard for quality, safety and value in the discovery, development and manufacture of health care products. Our global portfolio includes medicines and vaccines as well as many of the world&#8217;s best-known consumer health care products. Every day, Pfizer colleagues work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world&#8217;s premier innovative biopharmaceutical companies, we collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, we have worked to make a difference for all who rely on us. We routinely post information that may be important to investors on our website at www.pfizer.com. In addition, to learn more, please visit us on www.pfizer.com and follow us on Twitter at @Pfizer and @Pfizer_News, LinkedIn, YouTube and like us on Facebook at Facebook.com/Pfizer.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Forward Looking Statements<font style="font-weight:normal;"><br /></font><font style="font-style:italic;font-weight:normal;"><br />This press release contains forward-looking statements based on Sangamo's current expectations. These forward-looking statements include, without limitation references relating to research and development of therapeutic applications of Sangamo's gene therapy and ZFP technology platforms, the potential of Sangamo's ZFP technology to treat ALS and FTLD, the potential success and benefits of Sangamo&#8217;s corporate strategy to partner with other pharmaceutical companies, and anticipated milestones and royalties. Actual results may differ materially from these forward-looking statements due to a number of factors, including uncertainties relating to the ability of Sangamo&#8217;s ZFP-TF technology to treat successfully diseases like ALS and FTLD, the inability to execute on Sangamo&#8217;s corporate strategy to partner with other pharmaceutical compnaies or collaborate successfully, the inability to achieve anticipated milestones and the inability to develop commercially viable products. For a more detailed discussion of these and other risks, please see Sangamo's SEC filings, including the risk factors described in its most recent Quarterly Report on Form 10-Q. Sangamo assumes no obligation to update the forward-looking information contained in this press release.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:12pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Pfizer Disclosure Notice:</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">The information contained in this release is as of January 3, 2018. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU79"></a>This release contains forward-looking information about ZFP-TFs, a collaboration for the development of a potential gene therapy using ZFP-TFs for the treatment of ALS and FTLD and the potential of gene therapy, including their potential benefits, that involves substantial risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. Risks and uncertainties include, among other things, the </p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">79</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">uncertainties inherent in research and development, including the ability to meet anticipated clinical study commencement and completion dates as well as the possibility of unfavorable study results, including unfa</font><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">vorable new clinical data and additional analyses of existing clinical data; risks associated with initial data;&#160; the risk that clinical trial data are subject to differing interpretations, and, even when we view data as sufficient to support the safety an</font><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">d/or effectiveness of a product candidate, regulatory authorities may not share our views and may require additional data or may deny approval altogether; whether regulatory authorities will be satisfied with the design of and results from our clinical stu</font><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">dies; whether and when any applications may be filed with regulatory authorities for any potential gene therapies; whether and when regulatory authorities may approve any such applications, which will depend on the assessment by such regulatory authorities</font><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"> of the benefit-risk profile suggested by the totality of the efficacy and safety information submitted,&nbsp;&nbsp;and, if approved, whether any such gene therapies will be commercially successful; decisions by regulatory authorities regarding labeling and other ma</font><font style="font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">tters that could affect the availability or commercial potential of any such gene therapies; and competitive developments.</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">A further description of risks and uncertainties can be found in Pfizer's Annual Report on Form 10-K for the fiscal year ended December 31, 2016 and in its subsequent reports on Form 10-Q, including in the sections thereof captioned "Risk Factors" and "Forward-Looking Information and Factors That May Affect Future Results", as well as in its subsequent reports on Form 8-K, all of which are filed with the U.S. Securities and Exchange Commission and available at www.sec.gov and www.pfizer.com.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Contacts</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">McDavid Stilwell</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510-970-6000, x219</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">mstilwell@sangamo.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Varant Shirvanian</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">510-970-6000, x205</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">vshirvanian@sangamo.com</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-style:italic;font-size:12pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">###</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU80"></a><font style="text-decoration:underline;">Exhibit E</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">:</font><font style="margin-left:36pt;">Specified Sangamo Patent Rights</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">[ * ]</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_AEIOULastRenderedPageBreakAEIOU81"></a><font style="text-decoration:underline;">Exhibit F</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">:</font><font style="margin-left:36pt;">Current Licen</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">ses</font></p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;margin-left:7.69%;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><br /></p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">82</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;"><a name="_cp_text_1_245"></a><a name="_AEIOULastRenderedPageBreakAEIOU82"></a><font style="text-decoration:underline;">Schedule 2.1</font><font style="font-weight:bold;font-variant: small-caps;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;">:</font><font style="margin-left:36pt;"></font><font style="font-family:Times New Roman Bold;">Pfizer Obligations under Current Licenses</font><font style="font-variant: normal;"> </font></p>
<p style="margin-bottom:6pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">{<font style="font-weight:normal;">Redacted content comprises approximately 2&#189; pages}</font></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">[ * ]</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:0pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">83</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[ * ] = Certain confidential information contained in this document, marked by brackets, has been omitted and filed separately with the Securities and Exchange Commission pursuant to Rule 24b-2 of the Securities Exchange Act of 1934, as amended.</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>7
<FILENAME>sgmo-ex211_12.htm
<DESCRIPTION>EX-21.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex211_12.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 21.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Subsidiaries of the Company </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Gendaq Limited (U.K.) </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ceregene Inc. (Delaware) </p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>8
<FILENAME>sgmo-ex231_11.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex231_11.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 23.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We consent to the incorporation by reference in the following Registration Statements:</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Registration Statements (Forms S-8 No.&#160;333-189621, 333-206173, and 333-221827) pertaining to the Amended and Restated 2013 Stock Incentive Plan and 2010 Employee Stock Purchase Plan of Sangamo Therapeutics, Inc.,<font style="font-family:EYInterstate Light;"> </font>and</p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Registration Statement (Form S-3 No.&#160;333-218294) and related prospectus of Sangamo Therapeutics, Inc.; </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">of our reports dated March 1, 2018, with respect to the consolidated financial statements of Sangamo Therapeutics, Inc. and the effectiveness of internal control over financial reporting of Sangamo Therapeutics, Inc. included in this Annual Report (Form 10-K) of Sangamo Therapeutics, Inc. for the year ended December&#160;31, 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.5%;text-indent:-2.27%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_GoBack_1"></a>/s/&#160;Ernst&#160;&amp; Young LLP&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Redwood City, California </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>9
<FILENAME>sgmo-ex311_10.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex311_10.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CHIEF EXECUTIVE OFFICER CERTIFICATE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Alexander Macrae, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc. (the &#8220;registrant&#8221;); </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &#8211; 15(f) and 15d &#8211; 15 (f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2018</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Alexander Macrae</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Alexander Macrae</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>10
<FILENAME>sgmo-ex312_9.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex312_9.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 31.2 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">PRINCIPAL FINANCIAL OFFICER CERTIFICATE </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">I, Kathy Y. Yi, certify that: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">I have reviewed this annual report on Form 10-K of Sangamo Therapeutics, Inc. (the &#8220;registrant&#8221;) </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a &#8211; 15(f) and 15d &#8211; 15 (f)) for the registrant and have: </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(c)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(d)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions): </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(a)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(b)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date: March 1, 2018 </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kathy Y. Yi</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kathy Y. Yi</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Executive&#160;Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>11
<FILENAME>sgmo-ex321_8.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
sgmo-ex321_8.htm
</title>
</head>
<!-- NG Converter v4.0.8.21 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit 32.1 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certification Pursuant to 18 U.S.C. &#167;1350, as Adopted Pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002 </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to the requirement set forth in Rule 13a-14(b) of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), 18 U.S.C. &#167;1350, as adopted pursuant to &#167;906 of the Sarbanes-Oxley Act of 2002, Alexander Macrae, Chief Executive Officer of Sangamo Therapeutics, Inc. (the &#8220;Company&#8221;), and Kathy Y. Yi, Chief Financial Officer of the Company, each hereby certifies in his or her capacity, that, to the best of his or her knowledge: </p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2017 (the &#8220;Report&#8221;), to which this Certification is attached as Exhibit 32.1, fully complies with the requirements of Section&#160;13(a) or 15(d) of the Exchange Act; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2)</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:40%;">
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Alexander Macrae</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Executive Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
<tr style="height:12pt;">
<td valign="middle"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom"  style="width:auto; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12.25pt;;text-indent:-12.25pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">/s/ Kathy Y. Yi</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kathy Y. Yi</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Senior Vice&#160;President&#160;and&#160;Chief&#160;Financial&#160;Officer</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Principal Financial and Accounting Officer)</p></td>
</tr>
<tr>
<td valign="top"  style="width:auto;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:12pt;;text-indent:-12pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">March 1, 2018</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:inherit;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /><font style="font-style:italic;">This certification accompanies the Annual Report on Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of Sangamo Therapeutics, Inc. under the Securities Act of 1933, as amended, or the Exchange Act (whether made before or after the date of the Form&#160;10-K), irrespective of any general incorporation language contained in such filing. A signed original of this written statement required by Section&#160;906 of the Sarbanes-Oxley Act of 2002 has been provided to Sangamo Therapeutics, Inc. and will be retained by Sangamo Therapeutics, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>g2018030121531709731131.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531709731131.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -# GP# 2(  A$! Q$!_\0
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M **** "BBB@ KF]<%K=32QW%K,MQ&N8)HP?F/U^M=)3&DC618V90[?=4GDT
M8=Q97=SX8B%P";Z%1(OKN%6M,1K/3FNKH-YTQ\R4 9(]JO\ VJ '!E3._9C/
M\7I4I(523T R: .&CAAELKL-:W'VQIBUN54_A71.EY+IUK9S#,[J/-?L*U8I
M4GB66,@HPR#2LRHA9B H&2::=A-75C+NXH+'35@DMVN+=FVR<9P#WK$-H8[/
M4!#%.UB0OD1N"3NSS@>E=,VI6B(CO,%#KN&?3UI6U"T4X:=!2&E8RI/WFH1$
MPRE19E3\G&2.E9]E&T$5G]LLI'MO*:/9LSM;/<>]=-)?VT<OE-*-^ <>QZ58
MR",YH YIHTAN9A<V4ABEA"VZ[=VSC[OL:BM[!_M*K>6[2,MD5)9<C/8?6NJR
M/45 U[;JTP:4+Y.-^>,9Z4 4=-@%UX=CMID90T91E<8(K-@M;J#3;B:[A>5X
M5\F-%."5!ZUT=O<17,?F1-N7..E2T <?&)DTW4(3;R@R2(Z*L9 QD=!5V]6>
M>]G^S1R"3[($5MN 3W&?7%='10!SEM86=[97*K%.C-$%8R)M (]/>K6APF6$
M:A.@$S($7CHHX_6M&\MWNK9H4F:'<>64<X]*EBC6&)8T&%48 H Y>6*.>747
M>SG=Y7!@(0CD#K^=,U&*ZDB6*:U,ERD*EI0A;//;TKKJ* .8NH([NYOW:TD9
MC:C9N3OCM[U6O+:YN9H%C65-MF-V4X8C^$UV%% %/2Y$DL(REN;? P8RN,&K
ME%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110!0U'2H-3,)F:16A8LA1L$&ECTJ%+*6U
M:29TDZEW)(^AJ]10!G6&C6M@)M@9VF&'9SDD>E)8Z):Z?.98C(3MVH&;(0>@
MK2HH J6>G6]E#+%$IV2N78,<Y)ZU6L]!L[&Z$\>]BN1&K-D1YZX%:E17+M':
MRNOWE0D?7% &5>Z)I5U+<W$Y :=1&[;\8Q_6M6W2&""*&(J$50$ /85P\L4,
MFF:6SW")(RO(1.#Y;DGG)]:FM+QDM[&2"+RRD4Q7<=V,=P3VH ZF32+2>_:[
MGC$LC($ <9 'L*I76B1Q:'+8VNW:S[U$IX!SV]*R&UG5;5)5>=96:V28-Y?^
MKR<'ZXJO=ZC<7=G>P278N8H9(=DBKMSD\]* -W1=%ELXKS[4P+7/! 8G QCK
M5[^S[*+2QIKD>1LV89N<5S]GKNH2Z\D#8$1E,9A('"@=?6I-96P;Q1$-18"#
M[,2-QP,YH VM/T:VL(I%1GD$HVL7.>/2FZ=H=KID[2PLYR,*K'A1Z"N376-2
ML-.MH8V=(F,C1RR 990?E'-7+G7;\32'[9' R0QR+#L!\QCU% '0)H=K'Y.T
MO^YE:5>?XFZTJZ)9KI<FGE6,#L6.3R"3G-8$^O7ZS32>>L<D<J(EF4R7!ZGU
MI$UN^_MAX)YU,3,R!$4$#CH>] '0V.E6UI:2PQR/()@0S,V2>,46^C6UJ]HR
M%\VJ%$R>QZYKD].N[F*YLY%F"J+>1EA X<@]![U:AUZ^$:N+M+AI;=Y'14 \
M@CIG_P"O0!TL&FP6VI3W<<C!YQ\Z9X..^*O5R:R7@71K^>?SKB:4#"KM 1AR
M*ZR@ HHHH **** *UY<R6L:M':37))P5BQD>_)%8-S)?7&IQ7?\ 9=\OE$;
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M?FG_ ,51_:UU_P! :^_-/_BJU:* ,K^UKK_H#7WYI_\ %4?VM=?] :^_-/\
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MG_Q5']K77_0%OO\ QS_XJM6B@#*_M:Z_Z M]_P".?_%4?VM=?] 6^_\ '/\
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M/_BJ0ZK<D8.C7Q!_W/\ XJM:B@#G;8_9[3[+_85[)#O+!9/+.,\_WJL_;Y,
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M_$LUVJM&0C8(/"[FQA<]MQ%5/#?CC3-?D6S+B#4B9,VQ5B,(Y7AL;3V. >]
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MU1]-MKHR748.X+$^SCKA\;3U]:9J/BW0])U!;&^OA%<MCY/+=L9Z$D @#W-
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M\VNE;-,GB2&RCA$-M]G9[61?O,K.>"3\V5KU&X\3:-:VIN9[^-(1 MSN(/\
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M6%NT$(*]"RALD\]015S0? \NDW%K<23VJRPRS2/Y"28D+HJ@DN['(QZUVM%
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M^F*UF\*7D6LG4;6_B5FOWNBCQ$C:T:J5X/7Y<YKJZ* (X!,($%PR-*!\S(,
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M6**%+ERO(S\Y\L%?P4T >BT5Q%EX[O=6^PQ:9HZ37,ZR&19+@QHFQ@"5)7+
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M!6.2,L3GD4T>%]&(OMMHO^FS+-<8<_,ZXQWXQCH*YK7K2;2/A5!!:7ZVC0I
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MCNA,\DA  .0!M Q^.:PM-\$ZQ;Z5J4-SILTDDL$<4<8O(%20JV=V%C R.OS
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M*ZP12;EC#=%S[4 <O>/H?BV_LKB]TG7K"TN0+=)RD:6\X8Y"L,L?F/< =:]
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M0 4444 %(  ,  ?2EHH **** "BBB@ HHHH ,9ZT444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%(K*XRK CU!H 6BBD) &20/K0 M%%% !1110 4
M44@8$X!&1U% "T444 %%%% !112;AC.1CUS0 M%-61&SM=3CK@TH((R""#W%
M "T444 %%("#G!!QUI: "BBB@ HHI"0HR2 /4T +1110 444=\4 %%!.!DTP
M2QDX$B$^S"@!]%%% !13!+&S;1(I/H#3Z "BBB@ HHI"0.IZT +1110 444F
M0,9(YZ4 +1110 444F0>AZ4 +1129&<9&?2@!:**.G6@ HHI 01D'- "T4F0
M" 2.>E+0 4444 %% (/0T4 %%)N&<9&?K2T %%%% !12 @]"#2T %%%% !11
M2;AG&1GZT +1110 4444 %%&1Z]:* "BBB@ HHHH Y_QR^SP1K!+W" VK@M;
M#+J".2*Y#X97.GV$NKH+BTAA_P!&Q]FFS:;F3@(Q.3(?XAZXKTYE5U*L RD8
M((X(JNFGV44/DQV=ND6[?L6)0N[UQCK0!9KA_BJQ7PE 0Q7_ (F5KR#C_EH*
M[BLS6M'_ +9MXX?[0O;((^_=:LJEO8[E/UH \[A\9>(4U%;J6_A:Q&OG2S:"
MV&3'MX._.<BFKXLUVYU+7-%N]347+VUTUJ;..*6.()T)*L7#8XPP'.:ZW_A!
MV_Z&C7_O;_\ 7Q?>]?\ 5]?>H)/!4&GQS7;>)]<@4#=+*LL0)'N1'DT <EX-
MU[7KV;P_I%IK\$UN-&%Y,XMT=G<-CRR<\8Z$]:DTSXDZM=)H*+-:W=[-9W4U
M[:1(-_F1YV+@<J>.G>NLM_!""-9+;Q/KJ(RY4QRQ+D'GM'5&[\.Z7I-YMN/%
M^L6URZ&7/FQ!BN0I.1'ZD#\: .4U/Q/K.I>!-8D7Q/:SSBRANF6UM]LEJ2^&
MC8CC\^>#Q5N;Q5?Z7_;#V5Q93,GV*$ZDL PBN &E?!P0OY5UT?@-%1O*\2:X
MJ2\N%DB ?Z_N^?QIP\" 1M&/$NNA&&&02Q8(]"/+Y% ')OXS\0L]OI]IJUK<
M"35ELDU9+92DR,A8[5!QE3QP:6?QIXC_ .$4-TE_:K-::M-97-P4B1Y(T'WD
M1V"YZ9&:Z >%K."46B>+-<1HY HCCDCPCD9' CP"1WJU)X!25=LOB/7)%W;M
MKR1$9]<&/K[T +=>*8X_ARFO-=SVYD@4K.]NI<,> 2A.WD^^.:XG3_'WB34;
M&"V2^ACNGUD6!N6@C8^6R;@=JDJ2/8\UW#>!W:/RV\4^(&C(QL,\97'ICR\4
MU/ 8C4+'XEUU%!R DL0 /KQ'UH Y>#QMK<UO9V=QJEM9M_:UQ93ZI);J$VQ@
M[1M)VAF^M1^'I6?X%:I(TQD)^U$R _>_>'D>@KK'\!B1"DGB7770MN*M+$06
M]<>7U]ZB/A*.&>.Q_P"$K\0*TJ,R1++'M('7I'CO0!QM@FD6=]X:E\*-:M<2
M6$IU5+63>A00@@R@' .[IGG-3^&_$^O7;:?:V4UM!;0:#_:+6T-J#YSAL;%Y
M^4'VKKX? *6Y8P>(]<A+?>\J2)<_7$?-,'A&*.]6U7Q;KJ7/E;U19X@WE@XX
M_=],D4 <AHOQ!\4SZ#JVHR0178BM!-'@Q;K>3=@J41BQ !SE@#\M1Z[KVJ7?
MAU-GBZTND@U6T62\M;<*%1\95SG;P>>#T/-=M'X"6$N8O$FN1E_OE)8EW?7$
M?-)_P@<<5NT8\2:VD'WF020A/J1Y>* .3'BN_MKFXMK>\L;"&XUA[>75O(79
M&H3(9@3M)8\9)J2#QAXEU.71+&WU""W:Z^UJUZ+4.)UBQME12< -S700>%+.
M_000^*]<FCDC$P7S(RC*>C?ZK!JXO@=D";?%&OKL&$Q/$-H]!^[X_"@#CKOQ
M]KW_  BOA_61>6]O!<1S&\\M8C*S(^T;4D8#!P?NY-;GQ(O;M_!NE7]GJ3Z?
M')>VIED>,<(S#[V>@'4C\*T7\ 1R! _B+6W"?<#20D+]/W?%22>"'E0I+XI\
M02(>JO/&P/X&.@#EG\<:RFM3;-1M7,&I)91Z0(5\VYB.!YP;.<');@8P*M?%
M":35[[2?"MM:W-Z9R]W=6]K(J/Y2# Y8@ ;F_2M=?!L!U H/$^O?:XTSNWQ[
ME7IPWE_IFK/_  A,F_?_ ,)5XAWXQO\ M$>['IGR\XH X[2O%^J1>$- L/M:
M:7/'=2:??WERJR?93$/E#9.,L,<DUGS?$7Q.VC:<8[F 2W%S=QM>+%$J-Y;8
M1?WC!1GKUSQ7:WGPTM-0>%[OQ!KLQAD\U T\> ^,;B-F"<>N:KKX!TG2A;Z6
M/$>LQK=2N\-N\T;AY,%F(!C/.,F@##U3QEXJ6YOBEU;V'V#1X-0EM_)6;>[$
MAEW9Q@XZBKWA_6)C\1M0N]3UR*&VETNWG2VF"H K#/RDGH"3S[UT'_"#'!'_
M  D^O\KM/[Z+E?3_ %?3VJWI_A&*SO1<W&JZCJ($9C\J]:-TP?H@/ZT ;TL4
M5U;O%*JR0R*593R&!KS1_#&A:?;^+KFSTNWAGM('$+H"#'F-LX]*]/' P*88
MHR'!C0A_O_+][Z^M 'E@\1>(_#^@&%KQ+]AI]K+%(L"(;<.""3D[6 P.6(KI
M?"&MZAK7AW4'U!XY6A+)'.DD1,@VYR1&Q52,XZ]JZQK:W=&1X(F5EV,"@(*^
MGT]J;;V=K:1M';6T,*,<E8HPH/X"@#R'X?1:?'%IMV%\()<K S+(MZQN]VT\
MLI[^O/K6EI_C75WT_4Q/J4;SQE,7'EPM%;*206S&QR/]['\Z]&31],CD\Q-.
MM%?^\L"@_GBGQ:;801R1PV5M''+Q(J1* _U&.: .%M=?UJ[U.VL+37[2]CC\
MV1[J"U!^T!1D(.=H/.,J3T]:J67B[7+BQ>>#5K2^N7LS>26T4"AK(KR8VP<G
M/*_-@UZ3#:V]NJ+#;Q1J@(0(@ 7/7&.E)%96D#R/%:PQO+_K&2, O]?6@#SK
MP]XYU?6_$45@&B\J[D6\MF6+_ESVD,,^H? S[U)XVO=2O]<6+2-.NKT:0GG&
M2VF15CN#T#AB,X7G _O5Z'';6\14QP1(478I5 ,+Z#VIRQ1H7*1JI<Y<A<;C
MZGUH \WU/QO=SM)>6&KVMA"L,+VUG<1*SW>\ D@DY!4G;@=QS44?C;7I/&4U
MHR)';Q7+0?99&A3<@'$@W-YA)ZX QZ5T^L>#M&NK_P#M:[FFMXX@KS1(RB)P
MG.6!4D>^"*U#+HDM\C/';-=;E1'>'YB2I*@,1SP#TH \^FUOQ+<:/OGUF+9J
M5C=S(([55-L8F &#GY@03G-=#>WS6WA/PS*)[:\,EW:(9W0%3G^(8. ?>NP^
MS0;0ODQX *@;!P#U'XT"V@$2Q"",1I]U-@POT% '$>"?$VHZIK=Y8ZC>I<NL
M9D7R!$T2X;'#(Q/_ 'U@UER^.-87QTNG17$,MM)=O:B!5C^0",D,>?,W9 ZK
MMYZUZ1;6-G9EC:VD$!;[QBC"Y^N*0:?9+=&Z%G;BX/)E$0WG\<9H \XU;Q;=
M:IX=:UM-5MUO/[.FENS %9HG7'!Y^4]>*IZ7?:Q9:CJ&HV>M0SVZSV$<R^0K
M+<[T4%@V?DX/:O4TT^RB:1H[.W0R9WE8E&[/7/'--E73[&%0\<$,;.J*-@ +
M9PHQ0!P,?B_51?L_]J6TKRO/&^E")?,L@B,P=B#D\J.HQ\U5YM?OK"UM=0U;
M7+:%IM/:Y^V?8EW0@[<(HS\W/K7I0L;1;AYUM8!-(,/((QN8>A/4T265K,@2
M6VAD4# 5HP0!0!Y7-XR\16FAV3-K%I>374[F2ZM5@Q;*%RL;[F";SWY^F:DU
M?Q1JM_H4@O-4LM*SIV\PMLD^W,PYV.#V_P!G/)KT )H0;^SUMK0B24J85MP5
M+@9YP,9QZU=;3;!TB1K*V98AB,&)<)]..* (-.FC;1(%1U9X[9-RYR5^0=:\
MX3Q%KYM9_P"SKZTLH;&Q:\:);4,)3YK+MY/RC ZCUKU**TMX))9(H41Y2"Y
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M1X\T(Q(ZRW+,\S0"-;:0N'4 D%<9& PH S_&<&H-X1LK>U@O';,8F6V1V(
MX94(;'T(KDH=(\07.GVGVG3[QY(K::$%XV! \]"H^8EON@GDD\5Z+;>+]&NK
MZ:U6X=&B#'S)8F2-POWMKD8;'L:@3QUH1T^YO7EN(8;?9O\ .MG1F#':I52,
ML"2!D4 5?$.CSZOJ>CVTBWOV%8)O/^SS-& VU=N2I!ZYKF;ZRU=4LA?V>N7*
M1V8CL_L;/F.<.?FEP?[NWELBNPM/'6A7E[#:1RW"RRR&+]Y;.@1P,[&)&%;
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MJ$SHAB21?*(6098#@D$=_2J^G>,S?>+9M#DLX[8H7"F2X_>MM[^7MZ'J.>E
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M:ND<=[,D*03J0R(HX/&??ZF@#<\<Z9?ZMHEK;Z:#]H74+:7?@'RU60$M@]<
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M_+C1U?>&*;R&Y'3BEO?AQ)J=JS:AJJ7.H&X\\3O:_NQD8(\L,./QJ>+X@-'
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M-/2(VP8H#&&W9SR1Z=ZSM0\<>(+>QL85F43;IEEO1%$JRLCD 8D8*O '0DT
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M<@L%!.%!([5I+H5@FLP:JB2+=PVWV52)"%,><X*YP>>YKS_3O'?B"YUZX5H
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MI"9-BL#)@CRSG(X(R>_055;P7KR:%I=J=+\ZZMFD(<S6[(@9LA2KJ5X_V0*
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M95;3]O#%01DYZ_+CI5>;P3=)8SSG3K2^N_[5^U21R,H-Y"$VA68].><'(XH
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M(3&6\BT,<C;1@_,'Q@G/4' XH T/^$YT'S;N-KJ1?LH)=V@<*X!P=C8P_/\
M=S0/'.AF6VC,UPK3JK#=;2 1ACA2YQ\F>V[%4/\ A"KY[233Y=;+:;'D6D"V
MP#1C=G#MGY^..U3ZGX1N[R_GDM=6^SVMXD2WD+6X=I/+Z;6S\N?H: +L?C+0
M9+BW@6^ EN/-\M2C#/E_?[<=./7M5FYUVVB\-MK4.9(6@\V)2"IDR/E&#SD\
M5RVJ?#&'4;O4)X]5EMA<RPR1*D8_T<)]X*<]&[UT6M^&K?7+.STZX9?[,B<-
M-;%?]<%'RC(((P0#0!7L_%L"^'1J.K1FVG27R)K>)6D82_W5 &6Z]A2MXXT)
M;%+M;B:1'=D"1V[M)E?O90#( SR<<5SVL>#)= B:\\,12 +<1SI:QKYGE. 5
M9U#,-V0W()'KVJI!\/KO7M(MKW4Y$@U7SI9&%Q;[EVOC(9%<8/RCHQH ZR_\
M<Z!ITD*3W4A\V(3;HX'=40]&8@84>YJ?1/$D.MZGJEG##*GV"41[GC8!^.H)
MX-9:^!$%A=VPNXXQ<Z<+$B&#:B8).X D^O3-;&DZ--I>HZA.;P2P73(RQ&/!
MC(&#\V><T 9UEXXTV6"R6:5IKBY&[_0[>61%&\J"3M^4<'KCH:U]9UZPT*&.
M2]>3,K%8XXHFD=L#)PJ@DX'6N/?X:2M;Z;;+JD'DV:X\PVA\X_O"YPX<8ZXP
M0<?C6[XN\*R^)K>SBCO8X!;LQ99H?-63(QSAE((]C0!<3Q3H\ENTZW68TM#>
ML=AXB'4GCK[=:Y^[^(]M!?2Q):S&&&[C@=S"^2K*6W*,?,>!@"HI/AW=QZ7'
M8Z?K:VH-D]C.QM0Y>-CGY?F^4C\:TQX.E&J1W/\ :6;>.XAN%A,(SN1"OWL]
M^O3B@"Q)XXT./3K>],\[)<,RI&ML[2Y7[V4 W#'?(J/4_&^DVD$P@NE:=;4W
M*L8G:)5QD%V4' _6H+KP=="Z-]INK"UO3)*3));B12CXRNW(Y&.M)_P@D:Z3
MJ5@E^X%]8BT+F,$J<8+=>?I0!;'C?1EU:/2YI+B.[<$@M:R+&0!DD.1C:!WS
M3X/&NB3VUU<">:..V4.QE@="RGH4!'SCZ9K-3P=JS7]VUSKT4]E=1&!X39 2
M+$5V[$?=\OKTJAIGPQCT^*>/[7:@F();S16I62/!RN27(;H,C S0!T?ASQ)!
MXCNM2-O"4BM)%C5I(V20Y4,=RL 5Y-3:KXAM='OUCO)XHX!;M,V58OP0,C Q
MCGZU2TK0=8TN6ZNI-4@O+R]NHI+ES;^4HC50I"J"><#KGK4FO^%1KMZMR;LP
MXMS!M";NK!L]?:@"[HOB'3]?CF:Q>7,) =)H6C89Y!PP!P?6N?M/B#I_VYX+
MD *EM)<27,,+F/"N5QDC.>/SZ5T5EI L]7O+_P \N;F**/9MQMV C.??-<Y%
MX$N;6+R[;58BKVTMO*EQ:"17#R,X.-PZ%L>] '3:7K-IJ]FUU;B=(U)!^T0M
M$P_!@#BL^V\::+<V5U>++.EM;#+RRVSHK<X&TD?-D\<9IGA;PO)X<L+N WB3
M/</N 2(K''QCA2S?4\\UB6WPW9$O?.U*)7G ,?V6V,:(X<.&92[!B"!Z<$T
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M3:S)=KLBN(HK9RTI7*H<H,YZYH P8?B983^))-,2W!A29[<2B;,GF+P08]O
MR",YJK-\0=5N-$N)[?03;RS6375DSW2L'4,%);CY2,YP<UTW_"(Z8NJO?Q/=
MQ,[%VABN76%B>I* XY[TX^$='-E':?9W$,5JUH@$C9$;')&?7WH +G7&TGPD
MFK7T#-*L*%H48$L[8 &>G)/6LJ;QI?VX6UFT!EU9ITB%H+M2I#=&\S&,?A70
MR:+93:'_ &//&TUGY0B*R.68@=.>N1@<UF1>&=#T6U^TS/+M@F%RUS=W+.P8
M# +,QS@>E %S6=9GTNRMVBL3<WURZQPVHE"!G/4%R,  9YQVKBS\1Y](AN$U
M*V5KZ74+A(K>6<1K%'&%R-X4Y(+<<<YKNM2T^PUZS>TG8LJL#NAD*O&W4$,.
M5-8Q\&^'E1-.66XCN/,>Y5TNW6<[L!COSNP>,_A0!"GCF2\\A]+T::]A\A)[
MEEE"-$K$CY5(^<\'TJE>?$H6=M/<2Z4L<7VV2RM7ENPHG=&(<GY3L  )YSFM
MRX\%Z1=26SS"Z=H$$9)N7_?*#D"3GYQGUI!X8T&^TJ2SM]WDBZDF\RWG(>.4
ML2^U@<J<Y!'X4 <[<_%BPAL;*6.T1[B='=XGN-BJ$(#;6V_.<D8X&:ZN[\0)
M#X7&NV]K)<1F-9!$#M;!(!Z^F?TJK-X*TN>UMX7FU /!N"7"WCB;!Y*E\Y(S
MVK:%E"-.^PMODA\ORSO8LQ&,<GKGWH XZ/XC6MZ]U;V]G,)%N'A@(D ,T:#Y
MY5XZ*>U8K>,_$;S7:V]J6AB>R$!,R;Y/,&=K<8&[KGM78V7@7P_I\UO-;V16
M2WM6M(V,C$B-CEN_4^O6B+PCH(U%I8ED\^-(5>,3M@>7_JR5SU [T 6]!UJ7
M6;*Y>:Q-I=VL[V\T!E#@.H!X8#D<CFN;/Q/LDNEAET^:,?9I9G<R#".CE/+Z
M?>)'%=E9:=;:>UTUNA4W4YN)<DG+D $^W05C3^!?#]S<RW$MD6DENENVS(<>
M8O3CT]NE &)H_B[5_M5PFH::S6;W\ENMT)US"?X4V8R0.F:GTOQC>W-I9I8Z
M3<:AB%);R62X17B5V(4XQAS@$\8Z5O)HNCL\UJ@!=;C[7(@D.5D;G)] :JMX
M'T0_8PL=Q&MJH15CN'42*#D!P#\X!]: ,CPSXLU2XGA@U"P9[6XN9HH;[S5R
M2K'"F,#(&.,YJQXY\0WVAPS'3D=[H6<DJ*758QCN<C)(K=MO#NF6D5O'! 42
MVF::)0Q^5F.3_/I2ZKX?T[6=_P!MA9]\#VYPY'R-UZ=_>@"IJFJ3VGA)+^X2
M2"<B+>L+J2I9E! )&._I5+2?&G]I>)YM&>SCMS'NP7N1YK8QUCV\#GUK8NM+
MTX:!]@O&8V,"*6:64Y 0@@ECSVJEIWAO28M6_M."ZNKJ< E1+=M*B;L'(4G
MXZ4 4_&'CA/"<T,;60GWQF1GDG$2@ XPO!W-[<51USQG?LA_LJPD%HDUNDU\
M9%RF]EX$9&2,'!.>];7B'PUHNJ3#4=4EF@\N+RG=+EHE9,YVM@@$9/>FW/@?
M0[RY@GDCG B\L^6EPZQR%.5+J#AB,#DT 9]_XV M3 EI,EXOFBX2.5=UN(R
M3DC!^\OYTV#Q]&-;DTVYM%ABABWF66X E?Y V1'M]_6M2]TCP[!?WT]VT45Q
MJ,0$V^;;N1<9(&>.HR1[41>#])^W)?,]W<8&4BFN7DB'& 0A..E &!IOQ3L]
M1BN"ED"XC#VR1S[_ #2QVJK': A)(ZYQ6UX;U;5-1UG6(=3MC:-;B#;;>8)
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MRTIV?[7/IX8RJ=OR#Y02 3Z"N5U"]\7&VM8;6XU$/?VIFBE"',9BY"MQ\ID
MYKU1[NVCE6*2XB61CA49P"3Z 4OVJW^T&W\^+S@,F/>-V/IUH \PA?Q#K[:;
M-/>ZSI\5[:W=XT4#&-HF78$C)QQSN('?-=+J%UJB_#ZUG,MTDYCC%W-$I\](
M_P"-U'7=CGI6Y)X@TJ/4X-.-] ;F=69$$B_PXSGGW%:(D0OL#J6QNV@\X]:
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M-02>[F2?R[@/;9F?H#L,8V;%(X/#'->A>''2SL[73[F_N[F_GA-TWVIBSXR
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M;2.<*H))]A0!Y9XA\!:B^K0OIUHQL?)C1([1H(S;,#EBID!()/.5Q4D_A3Q
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M7%S"ETR_9U9V>6)D1E7[Q5B & ]B:AT3Q9:Z_JT]K9*YABA$A>2-HVR3_=8
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M=*[.B@#F? NC7.D>'5^W>9]MN9&GF$ARR9/"Y]A@54U7P'%J>D3V3W8WM?\
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M+>YG:STW-VS^8<DRCY(V]0!N//M1KVGZU=>)M2N+%[Q3;Z<C60$K+"TVY\Y
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M..,_A7)>)_"NJ:GK=]+:Z?IT\-];+;_:;B0B2VP?O*,'/X$?6J1\#:O%XO\
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M,0N3;SRK<+)'"=NY3N YST]C6?=_%:SM9;>-[#8SQK-(L]PL;I&S$*0N/F)
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M3M:OH;R[\_S8HFA'ERE R,02& Z\@4 8,?C"[>"&&_T^YL+Q9K<%(Y4D\Q)
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M6)OM+N]3L1<PWD, U-K?9'$KQA\NF['^R.:KZ;K6JZEXNT43:M;"!#=0.4C
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M(VX[<5Z%>:=8ZBJ+?65O=*ARHGB5PI]1D<4\VEL3(3;PDR;=YV#YL=,^N.U
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M:DP>S^RSE2+D,B X+9 <''4X//6@#'\6ZW>Z??Z?8VE_:::MPDLCWEVFY!L
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M7;WWV29S&^1\I)( 'S<C&!6F?&6E$6]RE[ +"2WDG9W#B0!" ?EQZGH>>G%
M''V<]]9P07=HOB5K6">![Y+I7=F?/[P(I^8C&,X^7TJM>0ZCJ M=7DMM<6;S
M]0%L ) R*<F+<HZ#TS]*].TO5[/6+0W-FTAB#%3YL+QG/T8 UF:3XG&HZSJ%
MG+;^1!#N:WG+<3(AVNWMAOS'- '*)IVMN)M3DFU<7EM-;B"+S7$;*2 ^4Z,,
M9SZ55T359'\4V+-?:J]U)-=&\W.QM71&.WR_X> !POXUV4?CWPW)#/*-0*I
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M5Z3//%:V\D\[A(HU+.QZ "L"/QWX=DT][X7["%)%C.^"16W-]W"E=Q!['&*
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MHFH7BZ==V=]!!JUD"HFDA+QL& #_ "9'7 QSQ46B>%6TB_@NS>>:RV[I*-F
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M"STB74(S>6;(\-RL.%W(<KE,\CCGFF:?X2NH=2M]3OM0CGO5G>:8QP[$;(P
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M7OFNEHH @M;5+1'1'D96<N [[MN>P] .PJ>BB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "F&6,*S&10JG#$G@?6H[R&6XLIH8+AK
M:5T*I,JABA/< \5XOIT;0>!+R"XF>:P3Q2R:A).V0\(V[BY]"=N: /;E974,
MC!E/0@Y!H9U099@HZ9)Q7#_#J\A@T9[=IXDMI[ZX&F)NQYD(;^ =P.>G:E^*
MO_(I6_7_ )"5KT_ZZ"@#N*0LJD L 3T!/6O)X_%WB2.^%X^HK):+KYTS[$+5
M1NCV\'?UR#68?$.HZMXE\/W%WJ*3WB7]QG24B"M:[ P4$CD[@!][\* /;**\
M1LOB'XNF\.:MJ+RV^Z*S,NUC"7M9=V,>6OS%<<?-SFK=UXL\6:;+J9DUI+A-
M.DL6*FR1?-6;&Y3CIC/!'- 'L=-61&&5=2,XX/?TKRI_%_B--3N+TZ@GV&'7
MTTX67V9?FB8 \OUR*RY+^_FU+2)?[433+?\ MV[A;RK=%C+#[I;/!)Z<T >U
MT5YYX0\4:]KGB9](NF4?V1')'J<GD@":;=A-OH"OS<5>^(OB2;0-.MEL[Z2U
MO9W;RML<95\*3@F3Y1V]SVH [6D9@JEF( '4DUX]'XU\3ZK!:/;ZFEGC0VU"
M7;:HY>5&8$<] <=JJ^*_%VI:MX:N8[K4XM-AGT*.Y2 Q*3>.X^8*3R,=/EH
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MXYOM[)%$L#EP#%_=W$9(W4 >GEU#;2P#$9P32]1D5XY>^(;_ %;28R+TK/\
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M"]EXAT9].D5(1O$B,(PP##H2O&?I6;H?@:/1I;2874)DMI)7'V>T6%7WJ%Y
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MA6TEOI\31I+(97WR,Y9R "26)/84 <_J_C:;2;S5M^G(UAIH59+@SX8NZ@J
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M+DKU[]N,_A3K:_T^Z'FVEW:S!VV[XI%;<1VR.] 'F$/C[63XFN;87D$T!%R
MBB,K$8P=O ._.1@[@!Z5KV^K^);="9M4CNR]@NI8-JJ;$5P'08Z_+G!ZUV,L
MNB61^T32:? 9F*^8Y1=Y[C)ZFH=732KZ!](N-12UFN4\L+#.L<Q4]E[X/TH
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M^E32SV,-L\V82B$MA<'++Z>_% '(^%K^\L_AM<7B7?\ :M[;I,P^4 EUS\A
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M@^] ',2^&=?MA-I]O:6]U;W?D--=R7&TH4P&79C)Z=<UT/A/1Y]&&J0S65O
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M0!PMYI&L:K%<_P!KZ)KE[-+'"D;&&V18_*9F4E1)\W+<C-26.G:SI=K&=/\
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MU<G&W.><YSWQVK7TCQ%<ZOXL6-=T5J+>93#D$%XYBF[/N!0!U]%%% !1110
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M97E9GVRLQ\Q5X^5<8^7M4EK'KEC#;ZB+O699[A;H3Q2,9%3:I*%4/ .0,>M
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MHH **** "BBB@ HHHH *RK'PUH^FZE-J%G81Q74Q)>0$GJ<G )P,GTQ6K10
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MOAC5+K3;JRO?$\]VLX4 RV4!" 'GY=N#GIS0 Z;QM9Q6-M<C3M3EDN-Q%M#
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M_P!O7M_KVG2W6K6VX7DA.E! LEKL#8+$'<00,\COQ7:Z)XGT'6[B6#2;I99
M/-<+"Z9]\E1FM,6%F+EKD6D G;[TOEC<?J>M 'D]A\0M>DAU-_M5O<$6?GVY
M*Q[$;=T&QB2,?W@#[5LOK7B73KR476L07,-E=6L,@6T53<"?'7GY-N>,=:[R
M+3-/AW>58VT>_P"]LA4;OKQ4YMX6SNAC.2"<J.2.GY4 >76WCW66\2W$2S17
M5LPF6.%%CPA7[O0^9G@\,HIK>-]:M;:^\G5K362ME#/OMH44VKNQ!#<[?E _
MB(]Z])ET?3I5G'V.!'G4J\B1A7.1@G<.<U@:1X?\/>%M16S:[>:]U&+R8TNR
MI+QISM "@$#/?DYH Y8>,?$+^&S/_:%K'(EWY?V@R6IDD0KGA=^P$'C[V<<U
MU5QXCNE^'::W; R7#Q(=\D8&W+!2Y4<8&2>..*WO[%TKRO*_LRS\O=NV>0N,
M^N,=:MB&(0^2(T\K;MV;1MQZ8]* /.?^$DUJ0PZ;9:]:7IDOHX!JL5NI7##)
M4*#M+#'KWK6\7ZE<Z5J.AF/R))O*NV\V2/)#+"3E?3)Z^U=,\6FZ79ES#;VU
MO$V_Y8PJJ>F< =:M20Q2E3)&CE<X+*#C/6@#RKQ!J?B%?#\T=WKT0\Z"WNUG
M2V5/(!E4$'GD<YR?2K%MXUUV3Q9]E)C-LLIA,+M"FY F?-7YMY)/(&,8->E2
M6MO*A22WB="NTJR @CT^E1G3;!KA;@V5L9U "R&)=PQP,'&: /,]1\6^)K+2
M=.N#?(W]H/(WG)!$BP!>B9D8*<^I.?2I[KQGK45SHLDUW;V\<\49G@MG@E9F
M+ '.7S@]M@->D36-I<0"":U@EA!R(WC!4'Z&HO[)TWS(Y/[/M-\6/+;R5RF.
MF..* .3\(RWDFA>(/,U83W2W<^&\L!H3CC(S].OI7+:-J-]H.E6]HFMV>G*;
M<WIFFME'VV1G(*#)Z\#D<\]*]=2WAB,ACAC0R'+E5 W'U/K5"_?1H_DO8K9C
M;()0C0AS&I.-P&#CGTH Q?#6J:OK.MZA+=7"0V=L(T6R$(W!F0,27Z\9Z5PT
M5MI\_B_6I+J+PJ\BZLXW:G>M'<@?+]U<8QZ5[(J(K,RHH9^6(&"?K5672-,G
MG,\NG6DDI.3(\"EB?KB@#A9?%NIV?C&XM&NXY[0$I;VUN(G'W,C<0WF#D'/R
MXJI_PEFM'3[<6WB+3[NXO9K1-\=L";-I9-K(P!P<#U(;(Z5Z1'IUC%<FYCL[
M=)SP95B4,?QQFHK.'3)(Y&LX+;9YIWF., >8IY)XZ@]Z .(E\2:Q;ZN\+ZS:
MF>"Z6S&EM HEN >//'.0.=V ,86LD_$37XM0\B186&S[$%6+YC?;\8^FSG%>
MJ&RM&NQ=M:PFY48$QC&\#Z]:7[);;MWV>+=O\S.P9W?WOK[T <OXXO+E=)M]
M&MK>2]O-0;RY(H'5)#"!^\922 #CI6!:^)=0@TJQT>2\70KB"=K>XN+X)*T*
M*A:/=D[<N .2:[V#4],O-8N+&&6.2_LU'FJ$.8PW(&[&.?3-5-?\+V/B!(_.
M>:WFC?>LUOM#$XQSN!!X]10!YY=>/_$1T_3'CDA1I8&E-P@B6.X8-@#,K+@<
M=1D\UMS>(/$,L]U>QWUO;6]F8/,L_(63?O52P\S/8G@BNOL_#NE6>DVNFBSB
MFMK9=L0G0/CU/([U:8V,,\=HRPK)."4CVCYPN,\>V10!P/A_[3_8VNZC)JT-
MQJ-A>W:P&8JBVY). _.,'J,UK^!->O-<L;Z.[NVGN;=E!E\N(*-P)&#&Q4]/
M7-=5]CM=LR_9H=LQS*/+&'_WO7\:6VM+:SC\NUMXH$)SMB0*,_04 >,0ZSJ?
MAC05FMM2@^TWUS<S2RF&-9'V-@#YV"D>N#GI@5K-K=QJUWIES)'%',\EG,?+
M7!+$9P3W&>U>D7UMI:6GFW]M:_9X?FS+&I5,GKR..:LK;6WRE8(AC!!"#C'2
M@#S>/Q[?RZ/:^5>VCZB--:>Z15!\N4,!A@#\OT-5]4\7>)]+UBWT\W4<QCAA
ME,K)!"ET7Y(^=@1CI\N?>O34TZQC>1X[.W5I/OE8E!;Z\<U5U)M&5@=0BMI&
MA4,!)"'* D 8&"1SB@#,\5:O=V%A8>1>0Z;]JE5);V95=+<8SSDXYZ<G%8FC
M:_KFLZOI]E'J<"PJ)FDN$MPPNUCEVAEY^4,.XR/2NS2?3=4L9"#!<VJ,R.&4
M,H*G!!!]"*;876EW$@BL6@+11*0L:8VHW*XXX!H Y[7M8UFWUZZCL)T%O96)
MNFMQ"':=N<+GL/I7$7?B+7?$7@G6[>ZO(TC,,3F4>064,X#1E8W) ]S@]:]F
M\M-Y?8N\C!;'./2J@T_3;2.:1;*UB1AF4K"HW <\X'- '%V?B232H+?1FO;%
M;V"_6U$ 4(?)'0[,_*,=ZR[3QSJT5CK)NM1@ENH(@\3A8C#'EPO#(Q]1C?CW
MXS7H5H^CZG-]JMHK>>5XU?SA#RRD94[B.>*L1Z7I\4<D<=A:HDO^L585 ?ZC
M'- 'F>C^([_7+K25OY_-DM]7"K*-BEU*'J(R5_(UI>)M5U'2/'%U/!J"A1H^
M^.U>,$9\P@OZG;]XX[5WL-A9VZJL%I!$JG*A(PN#^%/DMK>602201/(%*AF0
M$@'J,^AH YOPCK%UJ%QJ%I-JEOJT=J8RE_;QJBON7)7"DC(]C]:YUO&&JQ+=
MW8U6TGF.]?['$(\VTPP&YB.2 .3N %>BV]K;V<?EVUO%!'G.V) HS]!35L;1
M9Y)UM8!-*,22",;G'H3WH \Z;Q3K*I%86>OV6I//>VL*ZG%;KL3S20R;0<%@
M%SU_BI;?Q-XBMIX);O4H)XI)[RT\I;8+EH0V),YZDKRO2O0X=/LK>,1P6=O$
M@?>%2(* WK@#K[T7.GVUU;20/$H5PP)50"-W4CT- 'E%YXEO]3T*6&YU6VU"
M.>*"Y?[/&$-HXGC'ED@]\GK@\5V&D:[JUWXE_L25D9[ R&^E\K;YBM@Q;1V&
M"0?I6YI>G:3902:?9PP'R0JS#8,D]06XY-1Z'I]E ]Y?6UQ/<R7<Q:2:<_,,
M<!!P,*.<#WH Y#Q7XPUK0->EL8Y(3&"+X%HLXM$7]XOU+9P:P]<U[4]1TM;\
M7L5C]IMHKN.?R 'CA:X0*K$GH!R<]:]>DMX)6+20QNQ782R@G;Z?2D>SMI$*
M26T+(5V%60$;?3Z>U 'G&C7>KV.L7-S#JD4FGW'B!K5[<P@[]T8)D#YR.@(
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M@\5Z8U]H\6EG56>W6RC&?/V<+M.!V['BK*Z?8;)0MG;[9^9 (E_>?[W'/XT
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MU.+2WU*:3R)XYFN"I V$A&#XZ]3]:T'T?7[^R>::357F@TN+[,Z"2#,PE;^
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M?PH \\U#PI>1:)-;BVU>XA>RM+B6+SY)'-P&._;DYS@\J.*[+Q'IT^IIHMK
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MP^)M*N-<CTB"[BDN9+?[2@1P0R9ZCUH Y"ST+55O1J7_ !,EO6U*X0[YG*"
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MTJZF\8:-J-G;74DR6US$DT18I%(5&PN < 'GDUTTWB'1;>UM[J;5;*.WN/\
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M6M";6--M[^.PFU"VCO)?]7 \JAV^BYR: /-[6U\4)X]6>]:[7-SE9$MII(C
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M0M#'-]M+[P3GF/8 /S->@T4 <5?>&=3EUR[\JWTV6SO)!*UY<9,]N<8PBXY
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M?F[<CI7>T4 >877PTOW338HKBU:.WM@T^_/[RYC!$1Q_=!/UXKI-/T'5M/\
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MA#'Y9;C(QRP R?6LRY\4ZC;+J4RW\>[[)9JE\+41%]SR9;<PP,@#ELJ,].:
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M_=.XG/'UJV- TF.T2W^QQB"(LRJ2<*6SN/7ODUYSH_B?7]5M;6R7571Y=36
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M^';K5KR[-BDNH2J_V>P1EAB"KC@'G)ZF@"/4O&6LV'BN#08_#(GDN0[V\O\
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MATF:QF6*(J7D< !SCL,?6F>#/!>I>&IK,3:=X;"P1>4]W:Q2"X?C&<D8Y[T
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M@#,NM=\4W.H>*9K'4[2"WT1UV6SVF[SAY8<@OG([CI7<:3J8U70;74E39Y\
MEVGL2.E<YJ/@;3WO-2OI-;U"TM=196O($F18I> N"2N0"..#730/I]OID:03
M0)91IY:,KC8 .,9Z4 >5Z)\0-;O)--FDUB":6XOS;S6!TYHD2/>RY$Y.TD
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M?#UQ:6\)M;1(7 2TCP4!!SM4=^<UX9');P^$/$-A9I8W=NNEQ,=0LU=1)\^
MLZ'@28Y)'->_6-[;ZE807MI)YEO.@DC?&-RD9!YK+UGQ%H'AN6UM]3N(K9KV
M3RXE\LG>WO@<?4T >82RZ:_@?7DMF\*M/]@&1H\3+)MRN=^>HZ5$9M/;P%K:
M6I\*O=?V:-JZ3$RS'!7.\GMTS7K$FL:'::[!HKRP1ZA=1&2*'9@R(.N#C!^E
M5;+Q1X:NY[&*UGAW:@)/LQ\DJ)=APP!(QD$=* .(\#QW.E^.?*\4B.YUB_LD
METV]4'8D(7#0(#]TCOZYJ2_T2XUCXLZSY-AHMTL=I;;_ .U+=I,#'\&.AKT/
M2=7TW7H'NM.D$\44C1>9L(&Y3@X)'(SW%9^N>--!\-WBP:G+-#+)M"LMK(X8
MGH RJ03[4 >7>)=.O&U?QE=VVC:5?16XA27[1 S3PH4(+0GI\HYQ["M>/_A'
MH/$5LWB:XCN]%_LB%=+N+]<Q/C[YYXWXQGO7H=IXET>]F>**8B;[,+IXY(61
MA$<C)!&>QXZUG77C?PO%#8EYFF6[C,MND5H\I90<$X53B@#R#5+6]FM-!N(H
M[@P6=W=WVFHX._[/&=\8^A &/:NB^%GFW/Q U36)T=)=6L$O6##[NYNGZ5Z-
M<>+]!M=/M;R>61%N"5@B-J_FMCKB/;NP/I3)/&OARVTB/53=XMWF%LNR!S()
M/[A0#<#QT(H \RADL(O&WB3[8WA56.J9 UB%FGQM7[AZ8]/>M#XC-96OBG^T
M ;6\N4M8A'IUVCJ\@W@AK:1>C^HKMAXV\*2V\MW),$6*5(I3/:.C(S_=+!ER
M ?4\5KP:MI5_K5SID,B37MFBO*!&2(PWW?FQC/MG- 'G+-X<&L^(QXUC7[5)
M,K60N%)D,.WY! >N<\?+SFLCQ!I]W<>)/%%UI^BZ?J*VVFVI,6IPL\RH5;F,
M]F Y.><BO8-5U+3-,-J^HNB&>98(2R;B7/0=.*SX?&?AR>SEO8K^-HDN_L,C
M!#D39QM(QG\>E 'GMG_8,.J:"WB&Y6\\/#1$73Y[Y<PF;/SY!X#[<=>:Q=2N
M;S1-"A\3:3;S/:P:G<0:8K _\>\J%4VY_@W$8]J]X>&$Q;7B0HO(4J"!^%<S
M:>/O#=_J2Z3 ]RUT"H\EK&4;,]"<KA1[F@#S7P[H=QI_C?2O!TOF/;6THUQB
M?NY9<8_!C70_$N*Z\3^(K/PU9:?)J$=M;/=W,23+$ S?+$=S<<$$XZ\UUR^.
MO#3:I]D6]S+YOV?S_)?R=_\ =\W&WVZ]:9>_$#PUIVH7=M/<S":U<1W+I:2,
ML9X.&<+@=1WH X5-634]*\)77B1/^)1;^;:ZBDPS$ET@VJ9?49'&>,UAW]Y!
M<^%=;AM[32HM/@U:U*3VPD^QRDG+?*>BCC.WBO5-1\=^&=.OAIMW+-YTIRD:
M64CB7C.5(4AO7BMK3M0TS4UN(;,HWV>39+&8]I1L9Y!% 'D'B"WL-6\#W5C9
MS>'5DEOK96?08BNS).TOGWK2\%1W&L>+?$FF^)[".>YM+6""<3)O2?;]V3!]
M1@_C7K2V\" A(8USUPH%9$7BC0I?%$OA^.\C.K(FYX0ASC&>N,$X[9H YGX/
MZ98VO@N&Z@LH(;F2217E6,*[ .< GKBN/O[F%?#.M>'"Q&LS^( \5E@^8ZET
M(8#N, \^U>I#QCX>CBU-A?(JZ9.+>[ 1OW3DX QCGD]139O%GAV'^T[B:ZC1
MM+"FZ+Q$,@;[I'&2#VQF@#QWQA'JEAJWC[5;-'GLKAUL;R  _*&C3;(/H<Y^
MM;\K>%4\7WX\4"Q\LZ-;"+[6H)^YSLSW^G->O0/#=6J3QKF.= XW)@D$9&0>
M?SK%U3Q/X=TW5HM.U">-;I]HYA+*FXX7<P&%R>F2* /'D$L&H^'_ .W?['28
M:0P']OQLZ8\SY1Q_%MQU[5L:G8R:EXCTY]'TWP[J7E:,[QP/"QM7(<Y$6.AS
MZUWU[X[\*P:A<65U.QDM9A!,YM)&CB<D##/MVCJ._>GR^./#EIJ4^GJ\[W%L
MPCD%O92R*A(!QN52.A!H R?!&I6>C?"I=2,KE+>.6:>(J08'R2T0'HI^4?2N
M-\%+JN@>)]-OM3TV2VC\0PRI/<-.KB68_.C;1RORC&#ZUZ;J7C+P[I-RUG=W
M.U@ TH2!W6('IYA4$+_P+%7$\0Z--/>P+=1,VGQ+//\ +Q&C*2&ST/ /2@#P
MG08]4TY?"]K,CS:5J6M?:X7(.()%=U:,CT(P1^-=Q'X6C'Q/;0C,3H"*-96Q
M*_()RVW'^[D;L>IKMM.\6^'M4T";6K.\CDTZV)\R3RR-A'7@C/?TK9MIH+NW
MBNX"&CF0.CXZJ1D4 <)\7]+L+KP3-=36,$US%- D<K1AG13*N0#U -4=2L+K
M3_B'X=@\-6VG6KC2YSLFB81 %DSPF.:].9588901Z$5ST/C;PW//8(FH1F2^
MED@MB48;W3AER1Q0!X\VU/#GA0WO]EC&K7_F'48V-MNW'J.N,],UT5W)ICP^
M'9+W^QW\-I>2_P!H?V3&1:!]O[KS!Z;L=>,UW=YXR\,VUH)9YP\?VEK552V=
MR91U4*%)S2P>+_#,NF"Y2X1;=KI;1D>!E996/RJR$9!/N* /+?$"VUSIOB;_
M (1Z.,^'7FLDB"H?L[7'F#?L [=-V*W= \/P7?B[7]$US3].T^2:Q2);73HC
M'!<Q9)$HS_$"<>V*ZUO'_A6&>2T-PZK%/Y$CBTD\I),@8+[=HY([U-/XZ\/0
M:K<6)DN9;JV<12^392R!&(!P652.X[T <[\,M*EFN+[5]5N6O;ZRD?2K:61<
M&."(X_-CR35.]?P]#XL\2'QJD)=@OV#[6NX&':<B'/?/ISG%=IJ7C/P_HMV;
M6ZNF215$DOEP.XB![N5!">O.*J:GX\\+V5_'9WDLKW#_ .I"V4D@DXS\A"D-
MQSQ0!YQI^DZQJFK^&X+JST^YNQI4K;-9A:10GF?+D#^+;CK7>?$&W^R_"?4X
M/*AC\NT 9+=-L:D$9VCL*[.)HYHXYT7AU!4E<'!^O(JEK&L:=HMEY^I3!(F8
M(J["[.Q[*H!+'V H \]\8:YI6LZ!X?&FW\%WY&JV8E\EMVSYAU]*YFZN]1?Q
M/-X_BTR66R@U581>^< !:*?+*^7][[S9STXKU:W\5^&I-'N-3CN8H[:WDV3!
MX2CH_92A ;)[#'/:EMO&/AZZT^]G2X,<-G'YMQ'-;O&R)_>V, 2/<"@#Q[7&
ML7U?QD)9- #O>;HS=QM]L(V(1Y+=![>]7];DS)XQN)8YH@8=+=A/RZ_*N=Q]
M1WKUBVU_P_J%SIR6\\$TFHP-<6I$>?,1<9.<<8SWJ&#QAX<O=0NK*.[1YHE<
MR9B8*X3[VUB,/CO@F@#DO%^KZ5KT?A3^S;R"^CCUF%)?);<!F-^#2^'O#>B'
MXJ>*(SH]F(XK>V:(>0,(6#[BO'!/?%=/H_C'P[J\\4.G"9A+EDD^PR)&<#KO
M*A?QS3[;QQX<NM26UAO#YDDGE),8'6*1Q_")"-I/7H: .0\*^&53X@7NGW$[
M3Z9X?82:9;N.(GE&XG/?:#@>E6?&):Y\4ZO#.?W=MX:NI;=/5SP6^N.*Z]O%
M.AQ6=Y?-=J(;6?[//)L/RR9QCIS6/JOB/PK'XG1[A[N34]/38WV:UED"JXSM
M;:I!!ZXH \G$>J6=RVN::CS?8O#=O'<VH!_>Q.K@X]U.#^!KH])&FQ#PJWB9
M8SH(T-5@-TN8!<9^;(/&[;C&:]*_X2SP^MQJ-N;R-9M/@6:ZC,9#)&1D'&.>
M/3I5'4/'OA>QEM[:[EF_?JK0 64KK)N 8;<*03@]!0!R6I7GA_39O!%Y8R/:
MZ+%J%P4DN"P508SR"W1#V[8Z5I:GKNE0?$31=?EOH5TB339X5O=W[HON4[=W
MK@&NJA\2Z#>07I$R>7I\2RW*RQ%?)4KN&01Z=JBM/%7AO4/#,FMV]S%)I4#$
M/)Y1 0@@?=(SW';O0!Y9:QZ;!IG@F37XH$T^2]OI3]L3Y"K-E20?4'(S3RD0
MO[5M,0#06\2Q-I_EC]WC;\Y3_9W9]J]L46]U;QN$22)E#)E>,$<54U74],T+
M3_M5_)'! C *-N26/0*HY)]A0!X%8)J>D)I4+H\^CZIKHEC;G-O,LG*_1AS^
M%;^N7&F6=MXD.N0:=+XA2]=XUU)7WRV^,QB K\PYX&WOFO2X_&?AR32[N^-S
MY<%CAITE@='CST.PC=SV.*=I7BK0/$&H?9;9F:Z$?F*EQ:O$S)ZKO49'TH Y
M_P 9_:)_A99ZPUJR7FGQV^H^422R,@#$9/)[]:\X^RZB\ED'25O^$WD2XGX_
MU9$JMM/MY>:]\U;4K+1]*N-0U&016<";I7*E@!]!UK$@\>>&9X+B;[4T2V<'
MVAQ/;/&RQ_WE#*"1]* /-=0TBPF\#^/7FL8II+34W6W=XMS1C,8^4]1P.U;N
MIZ=+I_B#P-%X=M=/M9V@G?;+$1$28TR2$P<UWL_B'1K>:.WEN$5Y[5[U5\L_
M-$H!9NGN/>HK;Q9H%[%I<]O>QR)J*R-9L$/SA!E^W&!ZXH \KMUE&E(VL -I
MR^*;DZOY*MY)&?E+ \^7OQU_&I]9AM+V'Q.?"D(?0Q8Q-*+1/W)F616)0#C(
M4'.*[NX^(WA.WM(9Y+J0VUT<1NMG(R.2<8R%QG/:IV\=>&+1"DET;<!$D9'M
MG0JKG:I8;>,GUH YO2I]+\5>/5DM?)U'3DT9(KAMN^,,6/R-GC/'2I?A5I&G
M6T>N7,.GV\4Z:M<Q)(L0#! YPH/I[5U.I>*?#_A^:6"[NHX'CM_M4BI&3B/.
M-QVCUI^B^)M+UN9XM/6Z#*N\F6TDB!'U90#0!MT444 %%%% !7+?$*QO-1\&
MW5O86LES<;XV6*/&Y@'!.,^U=36)XK\0_P#",:$VI"S:[;S8XEA60(69V"CD
M\#K0!RNO_P!I^)K#11;:#J5LUEJ<#RK=(JG8%.6&&.0*\_?X>>)WB>U&FR"P
MO/-N;F$E<F:-Y#'W_B##\J]=TSQ?)+J=WINM:6VE7=O;?:PIG699(1]Y@R@=
M#U'O6?HGQ'@UG3-6NSI=Q;/81>>L4C@F>(YVN#V!P: ,WP=H&KZ?K$TUW8RP
MH= MK8,Q'^M5?F7KU%41H'B)OA+H_AF.QEAN[F8173. PMXPY8EAGD'&,#UJ
MV_QDL5\.Z-JJZ1<,^I7+6YM_-&Z'!QN)QR#6YJ?C^VTWQ;:Z&;":5)&C2>[5
MQLMV<90,/>@"AX2T/7?#^J^(M/O%2>SNT6ZM[BWB$40D*[60+DX^ZM8[>&M;
M/PIT72SI\WVZ#4XY9(<C<B"9F+=?0YKK]2\77,>JW6GZ-HSZG)9*&NW^TK"L
M9/106'S-[55OO'-S#=Z99V6@R375];-<>7<720>4!P02<Y/TH YX6.MZ1X>U
M[PJOAZXOIM0GG\B]3;]G99CPTA)R"N>>#TK&UKX>^(/M>J7NG+(=0L]-M[>T
MF)&VZ&QEECZ^_?T%>@ZMXQN-&TG3I[K2 +^_N/L\5J+M-@;D\RXVC@?TK=TK
M46U'2(;Z>UELF=2SPS8W1XZY(X_&@"MX4M9K'PEI-I<Q-%-#:QHZ-U4A1D5P
MGBOPCX@\7>)M9GC,5E:P60M+1KB 2><3\[,GS#:=W&:Z#PS\0H/$=[?VXTV>
MU6WB:>WDD8$7,09EW+Z<J:IZ9\2+B]33+JXT V]AJ$PABF6]25PQR!F,#(''
MX4 <[J/A3Q#XEU#2]3EM)['4[+1289F(PEVKCY3@\[E!_.ISX2U6[^"5O87.
MG2IKUNYFBB0@21R&0Y*G/'RL>]=(?B+!_P (U%JRZ<^^:_-A% \RJ"X;&6<\
M*..]2MX[,,NF076C7-O<7L%Q*T;R+^[,0R1G^('L10!TFD:?!I6D6EA;1"*&
M")45!VP/YUSOC[3+_4[71UL+=YC#J<$T@0CY45N6_"J>A_%'3M=M-#N+>TD4
M:G-+#(K2#-LT:[CN]<BK-KXXN[TQ7EKX>N)M&FE\N.\6=-[C.-XB/)7/?/3F
M@#.USPMJ>J^.]2O8KG4;*U;2UB26SD51*X+?(<@^U<W'X?UO3QX9DELM>C6U
ML)(9VTHQ^<K%L@'<<8KTS7_$<>@W&E1/;/-_:-T+92K ;"03D^O2N:T_XK:=
MJ-F\L5C*)X]5739(#(,J68@29[KQ0! UOJ5IKNB>)8]*U>^@@LY;.:&Y"&\0
MELA\ A3G&.".#67>^%]<U5WU(6=W8&_UN&Y\J%U6:WB56!D/4!CWZ]J[_P 0
M^(_[%DLK2WLWOM2OI"EM:HX3?@98ECPH R<UG7'C6;3]):?4M!O+;4&NA:06
M6X-Y\C=-CC@KC))[8- &1X?\+WL,_BC3M?AGU(W0 BU*<@_:(<?)&0.C*<]N
M]:OPVT"7P_X1A@NX)8[Z5V>X:9MTCG)QN/?C 'M4-UX^ETNUU,:OHDMG?65H
M;Q+9;A9!/&#@[7 QD'M1I_Q'L-5BL)K.UDDCN["2\SO'[LQ\-&1ZY&,T 6/'
M>F7VIIH8LK9Y_(U2&:7;CY$&<DYKS7_A /$=DUM?6%G*!>:MNU*T)'*K(Q28
M<^A.?PKO="^)VGZ_!H<EK9RAM3GE@=&<9MV12QW>H..,5-X?\;:CX@6WN8_#
MZ0Z=*[ W#ZC&755)!8QXSVZ4 =I7&V>D7_\ PLCQ#>O#)'975A#%#<9&"P'.
M._%/L_&E[J,D=S9^'+N?1Y)S"E['*I8X.-WE8SMR#SGIS45MXSUF?Q:_A\^%
MRDT2+-++]O0JL1;&[&.3[4 <NFEZ[_P@<?@3_A'K@72RB(Z@=OV78)-_F[LY
MS@=,=:AU/P5XDDB\3SVL^H*KWRN+$.HCU" (H<>H8X(SD=*ZBT^) U.RL/[,
MT::YU&^DF$=GYRIM2-MK.SD8 Z<>]1ZG\4+;1=%N+W4-+GANK.\2TO+02!C%
MOY#AL89<8/% %C4M,O;GQ9X-O+33Y8K*T67SE) ^SAH\!3S^'%5+75$TGQQX
MMU-HYI;(-96["!0Q,I!4\9[9&:Z32/$]MK6MZCIUM$2EG'#(MP&!659$W# [
M8KE+_P")&E:=8B270CYTFKO9S6X*95E.#,W'(Z>] 'HLKLD+NJ%V520HZL?2
MO';+PIXMMI]/\4M$ANSJINY]/$ $ZQR'8RF3=@@)CBNLD^)$/]M?V?;:7+.K
M:@-/CG$RA7<INS].U+IWCK5;W5-3LIO##6_]F &[?[>C[<KN& !SQ0!P>N>
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M:)+52-TBD8.W/!8=176T4 >4>(-'UKQ/)KFKP:/=62RV"6<%O+M6>9O,5BQ
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MRO9%:VC.=\* <(2>PZ#VJA+\,VG\8:]J\MW&UKJ%J\=O#SF&5P-S^G:O1**
M/-](^&]_IVE^&H);^WEN=-U'[;=RX;]]P5 7WQCKZ5NVGA6ZMM8\47K7,)36
M ODJ <QXCV_-^/I75T4 >=:3\,8M)?PK<6Z6$=[I;$WL\<9#7&4*\'ZG/-='
MXR\/7'B32[6UMIXH7AO(K@M("00AR1QWKHJ* .0UCP-;:[XR_MC48+.ZM%T_
M[*D$Z%BLF\MN],8.*H:!X"OM'O/#<SWELR:3;3PR*BM\Q<G&W/8>]=]10!P6
MC>"-3M/&<>NWLNFHT4<J-)8Q-')=[R,&5?NY ':G:Q\/6\2>)-3U'5K^46TM
MJMK:16LSQE%Y+;\?>R3T]J[NB@#SZ#P5KMC!I-U;WMA<:E9V+:=<)<J_DW,&
M<C.!N##CZU1M?A=<&QM8+]M-:,:P=0GM(XV\@1[2HC0'GOWKT^B@#S*?X97<
M/A[5M!TV:P&FSWR7EI%.K';_ 'T<CJO Q3KSP!JE[X:O-+6P\-V!EFAF5;1)
M/+DV-DB3(SC'I7I=% 'G#^ =1NM&DTYK'P]IR-=03G[ DF'"."0V1Z=*I:-\
M*+[2M5MKPZG!*(+N60;@V[R65@B#W!8^U>J44 >;>&/ 6J:#) CZ?X:;9O#W
ML:2BX(;//(QGFJMG\)KBRU#PYJ$-_ EQI[YO@H;9<@?=(']X=.:]3HH YNU\
M.W-OX\U/Q!Y\)AN[.*W2+!W*R9Y/;'-;EE]L^R)]O$ N>=_D$E.O&,\],58H
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
LH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>g2018030121531720831135.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531720831135.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &. H\# 2(  A$! Q$!_\0
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M?B%F1L':#S@T :%%1"5C;>;Y9#;=VP]:R?[:G^QV,_D+BXDV/S]V@#;HHHH
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ML<NPP2/0=J9&R-I&E+N7)N,CGZUT2Z?9KC;;1C&<87UI?L-KA1Y"80Y48Z4
M8=G)/>7?G-?")Q,RM"7YV],;?ZTENEU+>/IKW$Q:&;S&DW<F,]!6\;2W$YN%
M@C\_'WL<U7TZWF1YKFZ55N)CR%.0 .E %'6MC:EIJ>?Y9#MEMW(XJC#<+;0W
MUL9W\OS@!<IC=(3U&?7WKI9+2WF??)"CMC&2*#:6[0^284\O.=NWC- ',1W4
MAT>2/[7(C+=A 3)E@OIFENC]GM=8MC</)'&$*^8V2":Z0V%HP(-O'@G)^7O2
MO9VTF_? AW_>R.M &)HD[RWKK>3.EP%4I"'^0KC@CUKHJA%I;K(L@A0.HPK
M<BIJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ JM?VQO-/GME;:94*@^F:LT4 8FE:3
M>6#Q"2:V>-%VG9%AC^-02>&Y)-8%X+A$02"3*+AS['VKHJ* ,:^TBZDU%[NS
MNQ"TR".7*Y.!W'O4USI33ZC877F\6H(((Y;(K3HH QM2TBXN+[[99W"Q2M$8
M9-Z[@5/I[TVY\/K+X?CTV*7:T>"DA['UK;K&O[N<ZW!:0R;%6%YG]#CIGVH
MATKPVNFZDUR)=\8C"QI_=/<_C6Q>12S6<T4+A)'4JK'M7)Z;?ZA%?QK?74Z/
M*K'8Z@H_IL-6X?$5Q%9Q!;9[E_*:5W9P, &@"2#PHMG+93VMPZS0'YRQR&'<
M =JHZ[:WG]HWB6D4Q2[10_R AB/0]JOS>*2(Y);>R:6&*)9)6+XVYZ"H9/$,
MEG?7LLI+Q".,Q1>A;WH TY=*>>;2YBZK]D'S*1UXQ4&MZ#+J-W%<P2HKJAC9
M7'!!JSI>KC5+&:4)Y<D1*L <C..H-<_;W^IP:;;:J]^TRO/L>!@,8SCB@#7O
MO#YN-,L[>&55DM3E"1\I]:/[!?\ X1\Z=YJ"1G#LP'&<@FH8?%D4U\\*P'RP
M6"ONY)7U':B'Q2=BRW5FT,4D321,'SNQVH ?>>'9+K[=B9%^T-&5^7[H6GZS
MH4FH26\\$JK+$A0A_ND&H_\ A)98@1<V#([0>?$JONW+_2JLGB22[TN29%,#
MI*B_NW!."?I0!HW.AM-HEM8)(H,3JQ;'!P<GBK%MIC07E_,SJ5NL8 '3 Q63
M;^([I$O'N;;?MG$,*J>K'M_]>IIO$SV\<B2V+"[CE6-H0_\ >Z$&@#0T2PGT
MVR-M-(CA6)0J.Q/>M*L6SOKK^W&MKH%1-")4CSG81U&:VJ "BBB@ HHHH @N
M+VTM"HN;F&$M]T2.%S^=88UJ)M<,@OK;[* 8ROG#Z[JWY;>"8@RPQR$=-Z@X
MJ/[#9_\ /I!_W[% '*OJTD)4I?P/LD9U_?KR#Z\]J?+KURZ$?;;)D88($B@]
M*Z?[#9_\^D'_ '[%'V&S_P"?6#_OV* .63Q!<6\*0+=69"1\.TJDL?2K-UKK
M[4BCOK1MT6682J.3U^E=!]AL_P#GU@_[]BC[#9_\^D'_ '[% ',W%Y:,;")+
MZ';Y6V0"=0!GJ>O6HYKM#9@G481<%]ORW"GY1T/7O75?8;/_ )](/^_8H^P6
M?_/I!_W[% '.3WEO-,C'4;8;;4 _OP07';K48\0W$98"ZM63/RCS$X'YUT_V
M"S_Y](/^_8H^PV?_ #ZP?]^Q0!S(UZ[PP:_M/52)$Y]CS0FJ&ZGFF:]M89#"
MR(3,H],=_K73?8;/_GT@_P"_8H^PV?\ SZ0?]^Q0!SMEJD$#,(KFV0;1N9[@
M$LW?O5L^((=C'[;:=/E_>KQ6O]AL_P#GT@_[]BC[#9_\^D'_ '[% %"QUNS>
MW#7.H6@<]/WJCC\ZL_VSIG_01M?^_P O^-3?8+/_ )](/^_8H^P6?_/I!_W[
M% $/]LZ9_P!!&U_[_+_C1_;.F?\ 01M?^_R_XU-]@L_^?2#_ +]BC[!9_P#/
MI!_W[% $/]LZ7_T$;7_O\O\ C1_;.F?]!&U_[_+_ (U-]@L_^?2#_OV*/L%G
M_P ^D'_?L4 0_P!LZ9_T$;7_ +_+_C1_;.F?]!&U_P"_R_XU-]@L_P#GT@_[
M]BC[!9_\^D'_ '[% $/]LZ9_T$;7_O\ +_C2_P!L:9_T$;7_ +_+_C4OV"S_
M .?2#_OV*/L%G_SZ0?\ ?L4 1?VQIG_01M?^_P O^-']L:9_T$;7_O\ +_C4
MOV"S_P"?2#_OV*/L%G_SZ0?]^Q0!%_;&F?\ 01M?^_R_XT?VQIG_ $$;7_O\
MO^-2_8+/_GT@_P"_8H^P6?\ SZ0?]^Q0!%_;&F?]!&U_[_+_ (T?VQIG_01M
M?^_R_P"-2_8+/_GT@_[]BC[!9_\ /I!_W[% $7]L:9_T$;7_ +_+_C1_;&F?
M]!&U_P"_R_XU+]@L_P#GT@_[]BC[!9_\^D'_ '[% $7]L:9_T$;7_O\ +_C1
M_;&F?]!&U_[_ "_XU+]@L_\ GT@_[]BC[!9_\^D'_?L4 1?VQIG_ $$;7_O\
MO^-']L:9_P!!&U_[_+_C4OV"S_Y](/\ OV*/L%G_ ,^D'_?L4 1?VQIG_01M
M?^_R_P"-']L:9_T$;7_O\O\ C4OV"S_Y](/^_8H^P6?_ #Z0?]^Q0!%_;&F?
M]!&U_P"_R_XT?VQIG_01M?\ O\O^-2_8+/\ Y](/^_8H^P6?_/I!_P!^Q0!%
M_;&F?]!&U_[_ "_XT?VQIG_01M?^_P O^-2_8+/_ )](/^_8H^P6?_/I!_W[
M% $7]L:9_P!!&U_[_+_C1_;&F?\ 01M?^_R_XU+]@L_^?2#_ +]BC[!9_P#/
MI!_W[% $7]L:9_T$;7_O\O\ C1_;&F?]!&U_[_+_ (U+]@L_^?2#_OV*/L%G
M_P ^D'_?L4 1?VQIG_01M?\ O\O^-']L:9_T$;7_ +_+_C4OV"S_ .?2#_OV
M*/L%G_SZ0?\ ?L4 1?VQIG_01M?^_P O^-']L:9_T$;7_O\ +_C4OV"S_P"?
M2#_OV*/L%G_SZ0?]^Q0!%_;&F?\ 01M?^_R_XT?VQIG_ $$;7_O\O^-2_8+/
M_GT@_P"_8H^P6?\ SZ0?]^Q0!%_;&F?]!&U_[_+_ (T?VQIG_01M?^_R_P"-
M2_8+/_GT@_[]BC[!9_\ /I!_W[% $7]L:9_T$;7_ +_+_C1_;&F?]!&U_P"_
MR_XU+]@L_P#GT@_[]BC[!9_\^D'_ '[% $7]L:9_T$;7_O\ +_C2?VSIG_00
MM?\ O\O^-3?8+/\ Y](/^_8H^P6?_/I!_P!^Q0!#_;.F?]!"U_[_ "T?VSIG
M_00M?^_RU-]@L_\ GT@_[]BC[!9_\^D'_?L4 0_VSIG_ $$+7_O\M']LZ9_T
M$+7_ +_+4WV"S_Y](/\ OV*/L%G_ ,^D'_?L4 0_VSIG_00M?^_RUF7D^GS:
MM;7B:C9E%1HIE,R_,I_&MG[!9_\ /I!_W[%'V"S_ .?2#_OV* ,&WL_#]O,)
M!J<3A,^6CW(*QYZXYJ9(] 2/8+^WVF(P_P#'POW3^-;'V"S_ .?2#_OV*/L%
MG_SZ0?\ ?L4 <=J5C9SR&.UO[%8&C6/<;G! 'J.]:KVWA^6.02W]NSR(JLPG
M7@KT(YK<^P6?_/I!_P!^Q1]@L_\ GT@_[]B@#-L9M&T^V:"+4;=@Y)9GG4DG
M\ZIVUCX<MI4<:A$X1MR(]R"H/KC-;WV"S_Y](/\ OV*/L%G_ ,^D'_?L4 8)
MMM!CGFN(=0MQ(X8JAN!M#'J<9J'3++1+:V3[5J-O++Y90J;@%5SUQS72?8+/
M_GT@_P"_8H^P6?\ SZ0?]^Q0!A06GA^$29U.*0LGEAGN02B^@YIB6'AY871M
M2A=G927:X7/'0=:Z#[!9_P#/I!_W[%'V"S_Y](/^_8H PGM?#\AN,ZE#MG8/
MM%P/E8?Q#GK2+:: (@K:G$[^:)6D:X4LQ'3//2M[[!9_\^D'_?L4?8+/_GT@
M_P"_8H R(KJQ.N37TVH6>T1B.$"9<X[GK6E_;&F?]!&U_P"_R_XU+]@L_P#G
MT@_[]BC[!9_\^D'_ '[% $7]L:9_T$;7_O\ +_C3X=2L;B410WEO)(>BI("3
M^%.^P6?_ #Z0?]^Q3DM+:)P\=O$C#HRH : )J*** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\-V>J?VG;Z-:QWN]I/.5>=S=6^ISUI[>%_#\ODQ'3;4FUF-Q&H',;MR6]B:
M.,\=K>7?CW2;&"VO;V)[.1VM;;4#:Y(/WBV1G%;?PVNII="O+:YGFDGM+Z6%
MHIG+M;@'B,O_ !X_O=ZVM8\+:'X@FBEU738+J2(;4=P<J/0$5<TS2;#1;);/
M3;6.VMU)(2,<9/4T 7**BDNK>$$RSQ( P4EG Y/0?6I: "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MPQ0)CR4&!O)YP2"<CGFMG1/'<&K^*9_#\EBUM=Q1-*#]HCE!"L <["<'GH:
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MM;F=-4BO$\I8$7R/+4E2A R3QWKN?!SB3PCIC+>_;081^_P/F_+B@#<HHHH
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MK>DQWGV-]4LENMVWR6N$#Y]-N<YJ_7A.I-"VL^)K3[1HB7$NKL4@GM&-X_\
MJ_\ 5R \ XX_&MW4?%^K6_CR&WAO6$1NX8&LBZC8K8#9CV[B?]H-B@#UAF5$
M9W8*JC)). !21R)+&LD;JZ, RLIR"#W!KS&"XUB33$O+S5[NYBO[>[BEM9(E
M"( K8(P,YX[UH_#6]OI;&VM=4E>"XBTZW\FQ&#'Y.T;90<9R>A&>,4 =_111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MABC+;BB[O7'-+Y:;MVQ=WKCFG44 )M&,8'Y4;0#D 9QCI2T4 %%%% !1110
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M K?\)AX9_P"AATK_ ,#(_P#&C_A,/#/_ $,.E?\ @9'_ (U9_L#1O^@18?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH Y_P 8ZE-8:!+%9Q^=J%X?L]K"'VF1FZX)
MZ$+D_A7$V&J:IX<TB[T.6VDT9HY(I(Y9)$G^SVSG:\N1\I*L"2#_ 'J]49$8
MJ6525.5)'0TCQ1R9WQJV1M.X9R/2@#R:TUF>%[LQ>)52TN+U4FUL1(1M$9*]
M1L&3@9Z>E2^'=0U>6VTBUL=3*1NEU<2-%"";DHWRCYAP&]OPKU'[);>28?L\
M7E'JFP8_*GK#$FW9&B[1@84#% 'DGA[QGXAODO&N[^VAD>T=V2XN8!]DDQP
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MRA7V/!%3"*-6#*BA@NT$#D#T^E #Z*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** .7\8W+06RHMMJ*F92@O=/MA/+%ZKMP2
M 1WKE;;[?HUK>VUYI%\TNJ:?;PP):6[21PLJLI#$?=Y8'GWKN-<\11Z++:VZ
M6-U?7=SN\JWM@NXA1DGYB!@?6I;/Q!97&EK?73'3U+F-X[TB)D<=5.3@GZ$T
M <+##?6<;>'9-.OY;M[V&072VY,.T*N6,G08P:T5>ZO/&U@L.G7T$=I(XE@F
MM@MM$-IS+'(!\S$X&/<UV<VJZ=;&,3W]K$90&C#S*N\'H1D\U5B\1:7+J&HV
M7VR%)-/"&X+R !-PR.<T 5/%5M/<KHWD0O)Y>JV\DFP9VH"<L?85Q?CV/6IO
M%2FQ@U ^2L1@:..8QDYRV#&0O;D/G\J]/ANK>XMQ<03QRP$9$D;!E(^HKG(O
M&T$MY"JZ7J/]GS2>7'J(B!A8G@'@[L$\9Q0!RD2ZHOC:>X@M]1N#*K;FFBGC
M$0,?.#GRC@XP ,\U4M?"^IMI,?G-K7FMH)NI%-Q(";T?='7@_P"STKTBT\1Z
M;<V?VJ2X2UC\UH1]I=4W,IP<9/-7FO[-)Q ]W LQ&X1F0!B,9SCZ<T >3:W_
M ,)$^NV=S#;ZD+B&*WP!%,R]M^"IV=SD.":V]+T;48M2AU5QJ0NSJMPKAY7*
M>020/D)QMQT.*[^UO;2^C,EI=0W" X+0R!P#Z9%4]9UN'1H8RT,US<3-L@MH
M%!DE/4@9P.!SR: ,#7[Y](\:V&H2:?J-S;?8Y(RUG;--M8LN <=.E8\&C7VI
MZSITL]K>VFF7M[/<R01NT111'\ADVD;26YQZ]:Z_3/$D5_9W<T]E=V$UIDS6
M]T@5P,9!&"00?8U9T'6[7Q%I$.I68D6&3(VR+M92#@@B@#@H[3Q)!I=@D*WY
MEU)3:7+2,Q-N0_RN?[HV;@3[BJ?V3Q#:^/(P\MTBI=1K%,+>XE1H.!M8@^6,
MCJ2,BN[C\66\FL-9"RNQ;K*8/MQ5?),H_@SG.?PQ5&Q^(&GWYU&1+.Z6TL%D
M:6Y8QE3L)!PH8MU!QD"@#KJ*Y,>/+:'3[^[U#2]0L!:1++Y=PJ!I58X!7#$=
M2.N.M7].\3VUYH<^KW-O+8VT.2QF9&R ,Y&QF!H W:*S]#U>#7]$M-5M4D2"
MZC\Q%E7# >XK0H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
@ !1110 4444 %%%% !1110 4444 %%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>g2018030121531014931432.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531014931432.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %3 G0# 2(  A$! Q$!_\0
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M*,UY7>:CXE\4^+O%-CIGB%M$M- 1%B2*%',TC*6W.6'W>,<5CQ>-_%'B*V\
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MH XQOA?X9;2)],\BX6VEO#?)MG8-;S'^*,CE?I5NW\ Z-%HE_I-U)?:C;WX
MN&O[IYG;'W<$GY<>U=110!QMG\,?#EKI%]IDJ7E[;WJ)'+]LN6D8*AR@4_P[
M2<C%00_#;3M'LM3ETF2>?5KFR>U@NM2F-QY2D$!1GHO3BNYHH \7\)?#_P 2
M:5JN@,MD=(CTYO\ 3K@:L\ZWJ@8VK%T4']*[QOAWH#^&;W0&CN/L%[=&[F7S
MCN,A8-D'L,J*ZRB@#$B\*Z7%X@N=;6-S>7-H+.3<^4,0[8]>.M8=O\*O#=KI
M,NEI]N-D]S'<K"]TQ6-D)(">@R3GUKMZ* ./U[X:Z!X@U:;4[@WMM=7$8BN6
ML[EH1<(.,.!U&.*O?\(3H:W>AW,5LT+:(KK9)&Y"H&&#D=_QKHJ* ,C2/#>G
MZ)>:G=V2R++J=Q]IN2SE@7]O05BZY\,_#_B'6YM7O?MRW<T:Q2&"Z>(,J\ $
M+78T4 <Y_P ()X;'A5_#*Z9$FDR#YH5)R6SG=NSG=D#G-5]!^'FA^'[R:\@-
MY=7DD/V?[1>W#3.D?]Q2?NCZ5U=% ')Q_#KP_%H.EZ,L=Q]CTR[%Y; S'<)
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MMJD;>:TX4^7'%O\ FQRV0..G>O7 <TM 'F9\,+?ZEJDE_H_VC'ANV@MVFAW
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M?^@I76UR7@?_ %OBC_L.W'_H*4 =;1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% ')_#MW?PS.7=F/\ :5Z,L<\?:)*ZRN1^''_(L3_]A.^_]*)*ZZ@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N2\#_ .M\4?\ 8=N/
M_04KK:Y+P/\ ZWQ1_P!AVX_]!2@#K:*** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKE_B)_::> M6N-'NYK6^MX?/CDA/S?(=Q'X@&NHJ.>%+BWD@D7='(I1AZ@C!
MH \(_9^U#7M7OM6FO=2N9=.ME^6%F^0S2N79OKPQ_P"!5[W7 ?"3PF_A+PK<
MVT\92>:^F=LC!*JVQ#]"%S^-=_0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7)>!_];XH_P"P[<?^@I75NZ1H7D944=68X KD/ UQ";CQ
M*HFC+/KEP54.,D;4H [&BBB@ HHHH **** "BFF1 X0NH<C(7/)I00>E "T4
M44 %%%% !1110 4444 %%-\Q"Y0.NX#)7/(%.H **** "BBB@ HHHH ****
M"BFB1&9E5U++U /(IU !1110 4444 %%%% !1110 44Q98W!*.K8.#@YQ3Z
M"BBB@ HHHH **** "BBB@ HIBRQNNY'5AG&5.>:?0 4444 %%%% !1110 44
M4A( R3@4 +135D1U#*ZLIZ$'(IU !1110 4444 %%%% !1110 4444 %%%%
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M"#/FQ#I*!_?3]5R.PH [6BHX)HY[>.:%UDBD4.CJ<AE(R"/PI^<4 +129I:
M"BBB@ K,US6(-$TN2]G5G((2*&/EYI"<+&H[DGBM(G%>=?VU'KWC(WP8/I^F
M.T%D/X9)>DDWX<HI_P!X]Z (-,\'ZCX6MWU;2ML>K7$K7-W8I(?LTP8Y,*@_
M=*CA7]>O!P.\T36;77M-COK0ML;*O&XP\3CAD<=F!X(JW&R7-N&ZJPKC]61_
M"6L-X@@5CI\^%U6%1D;1P+@#^\O1O5?]V@#MJ*;&ZR1JZ,&1AE6!R"#WIV:
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M@.#/%U:/(YSW7T(]ZJ?#_P"(IU"UL;;5IO,CN3Y=I?OP6?IY,W82>AZ-['J
M>H-@<GIW-?-7B[PS?>/FO?$6FQM)J"J]T8Q_%;AMD: ?WMJDCUP:^C;Q7EL;
MA(_OM$P7ZXXKSKX/NK:6P)PYL;;Z_*9%/Z@T >,^ 5O?$FI6NC63M'<3'$DH
M'^IB'WG^H' ]R*[?Q_\ #^VT]%2R@"1PH!$P^\ .^>N?>NSG\/V/@#QU<>*K
M: 1Z5JD?DWI1/EM)"P82''1&(P?0X/0\=5X@M8-8T3SH7250-RNC @CZB@#Y
MOTK5M4UZSD\+:]>3/!:$75IJ,H+FQ(.W,AZF([L'^[D'H#6K?>&_%&DRBUUE
M MC'M>:6R?S7: GYI(UXW8[]QD<5Z)\-?"\+OK&OO$K0W@-I;!ER'B4G>WN&
M;CZ+[UK06D.EW,7AG4R[:5<.?[(N]_SVLO\ SPW=B.=A[C*G.,$ [+19M.GT
M2RDTF:.;3_)46[QMD% ,"KKHKHRNH96&"".HKR*&ZU/X>>-;?3X+&>[L-3\V
M6>WM4^0[0"9XE_A;GYXQ]1U%>F:3K^F:Y$TFFWD<^SB1 </&?1D.&4_44 >8
M>!M:'AOXB7?@J]B^SK%&T5K*S\3+O+Q#V^1F ]<8KV$=*\R^+O@Z34].A\1Z
M7"7U32QN=4)#S0=2 1SN4_,I^M2^ ?B'_:MO96FJ3*YNABRO^@G(ZQR#HLH_
M)NWI0!Z-*ZQ1M(YPB LQ]A7RYXQ\,WWB6&\\8:?"SW 3[;>1IVB9B(]H]0JY
M/L,U]+:VDDN@ZC'%_K'M953ZE3BN'^$[1RZ)*" =]K:$@C^'RMN/S5J /(OA
MU97'C+4H=)A=XX-OF7TJG!2$=0#ZM]T?4GM6Y\0?!"V%RTEG$(&B_P!4T0VE
M0.F".:[S2]%L/ACXMU"XCC6#0M;*%9B,):3 G]VQ_A1MWRD\ \>E=)XPL(+_
M $@W.Y"B*27R,;>N<T ?/^DZAJWC6R71]:O66]TR0?8=4N,E5,GR^3,W7:Q
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M?AYKZ19W_89",>PR?T%5/AW(DFCWA4CFZW_@T49'Z4 =A1110 4444 %%%%
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M;;3;<EDA7YG(P9'/+,?<DDT <+\:O!=_XL\-07&FN[W6FLTHM0>)E(P<#^\
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MUJW?P6NL:=-:7*!X9D*.OMZCW'4'VKQ'PCXE:<O--,TEQ/(99Y7.6D<]2?\
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M1)&55%4*JKP !VKOK;546W>5V&V-"YR>P&: .XTK48M8TBSU&#(BNH4F4'J
MPSBJVH^&-"U:7SM0TBRN91_RTEA4M^?6L?X>WUN_@'0S%YDB_8T^=8R1GN/P
M.173&]B])?\ OTW^% 'GFMZ9;^'_ !A;+IUO%;6FHV1*1PH%5;BV/F(0!W*E
MA[UZ1%(LL*2H<JZAE^AKCO&,\.;.^D1T6P:22,N-K32O&T:1H#RQ);T[5U6F
MPR6^EVD$O^LCA1'^H4 T 6J*** "BBB@ HHHH **** "BBB@!"H/6O/M:^'T
ML$TEYX9>* .2\FFS<0,3U,9',9/IRI]!7H5% 'AUUJ$FE2>5K%G=:9)ZW,9\
ML_21<J?SI\>KVDBYCO+=QZK*I_K7MCHKJ5<!E/4$9!K*F\+>'[A]\VA:9(Q.
M2S6B$_RIW \AGUW3X3A[ZW#'HJR!F/T R:T-.TC7]?(_L_3WM+<];S4$,:@>
MJQ_>?]![UZQ::/IFGG-EIUI;'UA@5/Y"KM%P.>\,^$K#PW'+)&SW-_. +B\F
M^_)CL.RKZ*./K70]!BBBD 4444 %%%% !574=.M-6T^XL+Z!)[6X0QRQN.&!
MJU10!\A>/O U_P##GQ$&CWRZ7.Q-K<>H_N-Z,/UZUK^'_%$26OFRR;40?-W/
MT^OM7TGKN@Z?XDT>XTO5(!/:SC# ]5/9E/8CL:\_\#_!33?"FKR:E>WAU.:*
M0FS5X]JQ#LQ'=_?H.U ''VVG77B!8=1&CZG>7LMS%(L2V\D21P*=OE&4[<95
MF)(/4UZL/ASH(YC;4XAZ)J4X'_H5=92T <M'\/= !_?)?7(_NW%_,X_+=@UT
M-G8VNG6T=M9V\=O!&,)%$H51^ JQ10 4444 %97B/P]I_BC1+C2=3A\RWF7K
MW1NS*>Q%:M% 'QIXE\-ZI\._$[6-YEH2=UO.!\LT?J/<=QV-=9H_BJ."S\]M
MTF!A8T&6=NR@>IKW_P 7^#],\::')IFIQ\9W0S*/GA?LRG^8[US/P[^$UCX'
M9KVXN1J&J'(2<Q[5A4]D7)P2.I_#Z@'&:-X=DU75]+N9])U&[EGN&;4)A%+;
MQ!)%P0)"5)"83&.N#ZUZ8/ASH:_ZN75(QZ)J4P'_ *%76T4 <O'\/O#JD&>W
MN;O':ZNY95_)FP?RKI(8(K>)(H8UCB1=J(@P%'H!V%244 %%%% !7/>,O".G
M>,] ETO4$P3\T,ZCYH9.S#^H[BNAHH ^+=1TO5? ?B6;3-3C*21G(9?NR)V=
M3W!KN=-\5>19H\8,TS_+%$H+%V^@YP._M7MOCOP%IOCK1C:7?[JZBRUM=*N6
MB;^JGN*I?#[X::?X%LRXE^V:I(N);MEQ@?W4'\*_J: .(\-^$UOO$-AY^EZK
M<6\D4JW]Y(DMJK.3O$@.5+?,2H&#PWM7H:_#K1%'R3:J@]%U*;'_ *%76T4
M<S!X \.1.KRV<MVRG(^V7,DPS_NLQ'Z5TBHJ !0  , #H!3J* "BBB@ KB_B
M+X LO'6AFW;;#J, +6ER1]P_W6]5/?\ .NTHH ^*8&U#PMK<VF:E"]O<0OLD
M1NQ_J#V->AV?B65H([:T9FO+@;(RD;/Y8/!D(4$X'ZG KU?XC?#&P\>6B2"1
M;/58>(KL)G*_W7'<>GI6GX(\"Z;X'TG[+9%IKF3!N+N0?/*1_)1V% '!^$?!
MEK=ZW+%-HVJQZ6;- MQ,9+4B5#C( 8%MRG)..J^]=P/AWH@'$^K*/0:E-_\
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M:R]0_P"/^;Z_TKEUMEUO7]5@NY+CRK+RHX(HIFCQN3<9/E(R2>!GIB@9W?\
MPEFI_P#3#_OC_P"O1_PEFI_],/\ OC_Z]82+LC5-S-M &6.2<>I[FEH W/\
MA+-3_P"F'_?'_P!>E/BO5!U$(_[9G_&N+U^>94T^TBG>W2]O4MY9D.&1""2
M>Q.,9]ZCT@6]KJUY8Q6=]:R)&LA6XN/-1UW$!URQP3@^E ';_P#"6:G_ -,/
M^^/_ *]'_"6:G_TP_P"^/_KUAT4 ;O\ PE>IXS^XQ_US_P#KTG_"6:GZP?\
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MQ#C_ *YG_&N7UBZEL=(U"[@4/-!#)(BD9!(!(K$MHK?3[[27==2GEO-H%_\
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MOXRMQITC6H;G;(@/R,I/4;2!^% &[BC I:BN9_LMK-<^6\GDQM((T7+.0,X
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M;)=.EQ;-$Y/F($8;@,J0S=*S[_PMK_B:XU6;5Q86(O-';3XTMY6EV/OW;F)
MR">PZ"M+2=,\0S>++76M9@L+:.#3I+,16TS2$N71MV2!P=O [>IH [&BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
,* "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>g2018030121525133431431.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121525133431431.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #' PX# 2(  A$! Q$!_\0
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MW(C;[I"2H0#\I4X(^7:*YJV#P>(TJTXR]4F;T\5B:/\ #FUZ-H_73]FW_@Z
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MR\GYA1117(=(4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,/\ A_!_P2F_Z.H_\L?7/_D*NL^&'_!7K_@FI\7;BZMO"G[8'A.U:SC5YO\
MA*)9M#5@20-C:C' )#QR$+$=P,U_-'179+@G+>7W:DT_-Q?_ +:OS.:/%6.Y
MO>A&WHU^K/ZW/"OBSPMXZ\/6OBWP3XDL-8TJ^B\VQU/2[Q+BWN$_O)(A*N/<
M$BM"OY/?A%\<_C/\ ?$I\8?!'XJ>(/">I.JI-=^']6EM6GC5PXCD\M@)8]R@
ME'!4XY!K]*OV$_\ @Y'^(F@:O8?#[]O'0[?7-)FG2)OB!H5@MO?689Y"TMU:
M0J(KB-=T8_<)$Z1QL=D[L ?!S#@W'8>+GAY*HNVTONU3^^_9'KX/B;"UY*-9
M<C[[K_-?=\S]F**Y_P"%?Q6^''QO^'VE_%7X2>,K#Q!X=UJW\[3=6TV8213*
M&*L,]5975D9& 9'5E8!E('05\C*,HR<9*S1]+&2E&Z"BBBI&%%%<-^T-^TK\
M#/V4OAU-\5_V@_B3I_AC0HKA8%N[[>S3S,"1##%&K23R%59O+C5FVHS8VJQ%
M4Z=2I-0@FV]DM6R92C3BY2=DNK.YK(\=>/\ P)\,/#%SXV^)7C32?#VC6>TW
MFK:YJ,5I:P9(4;Y965%R2 ,D9)Q7XM?MH?\ !R/\?OB7?77A/]C;PRG@#0.%
M3Q#K-K#>:U<#N0C;[>U5@=I4"9QM#+*I.!^=GQ%^*'Q,^,'B5O&?Q:^(FN>*
M-8>%8GU;Q%JTU[<M&OW4,LS,VT=AG [5]A@>#,;7BI8B2@NV[_R7WOT/F<7Q
M1A:,G&A%S\]E_F_N7J?T>_$W_@K[_P $T_A)>VVG^*OVO_"MU)=1EXF\,M-K
M:  XP[Z='.L9_P!ER"1SC'-<_H__  7+_P""5^N:C#I=E^U;:QR7$JQQM>>%
M=7MXP2<9:26T5$7GEF( ')(%?SBT5[D>"<MY?>J3OZQ_+E?YGE/BK'<VD(V]
M'_F?U:?"_P#::_9O^-^J7&A_!?\ : \$^+KVUA\ZZL_#'BJSOY88\@;V6"1B
MJY(&2 ,D"NXK^1,$JP93@J<@^E?5O[+/_!:/]O\ _97GCLM+^,-QXRT-3\WA
M_P ?M)J<('EB-1',SBYA5%4;8XY5C!Y*-D@^9B^":T8WPU52\I*WXJ_Y+U._
M#\54Y2M7IV\T[_AI^;/Z/Z\X\=?MB_LC_"_Q1<>"/B9^U+\.?#NM6>W[7I.N
M^-K"SNH<J&&^*6577(((R.00:_/?X[?\%\OA;^T#_P $Z/B)?_!KQ+>?#3XQ
M1:;;6UKX>O+W=<>5/?6MO<3Z=>*J"5UMYY64J([B,QO((PL8DK\8LDG)/U/K
M7)E7"5;&*;Q3=/E=K6U>B=[[6UTM>_R.C,.(Z6'<5ATIW5[WT[6[WT^1_51\
M/_VO/V3OBQXHA\$?"S]I[X>^)M:N59K?2/#_ (TL;RZE"J68K%#*SL JEC@<
M $]J]$K^16">>UGCNK:9XY(W#QR1L596!R"".A!K^EW_ ())_&_X@?M%?\$[
M?AC\5_BCJ7V[7+K2KFQOK]G=Y+O[%>W%DD\K2,S/-(ENCR.3\TC.P ! '/GW
M#JR>C&M"?-%NVJLT[-_HS;)\[EF565.<+-*^FUM%^I]&T445\N?0!16?XI\5
M>&/ _AV\\7^-/$5CI&DZ;;M<:AJFIW:06]K"HRTDDCD*B@<EF( '6ORM_;D_
MX.4M$\/W]QX"_8/\&VVM-&=LWCOQ59RI:L"C9^RV9,<C$%D(EF*@,C*874AZ
M]#+\KQN9U.3#QO;=[)>K_3?R./&8_"X&'-6E;LNK]%_2/UB)"C)KQ#XB?\%*
MOV ?A9I=YJOC']L+X>K_ &>^R[LM-\36]_>(V<;?LMJTDS$'J A([XK^<_\
M:&_;,_:H_:MU.34OVA/CMXB\3(]PMPFFWE\8]/@E"!-\-G%MMX3M')CC7.23
MDDD^9  # K[+#<#QY4\16U[17ZO_ "/F*W%DKVHTOFW^B_S/Z,F_X+O?\$ID
M.UOVJ1^'@G7#_P"V5=Y\-?\ @JC_ ,$Z?BOI#:UX4_;'\"6\*S>5Y?B+6DT>
M=F]H;_R9&'^T%(]Z_F1HKLGP3ESC[E2:?G9_HOS.:/%6.YO>A%KYK]6?URZ9
MJ>FZWIMOK.C:A#=V=W"LUK=6THDCFC8!E=67(92"""#@@\5/7\I?P-_:8_:"
M_9G\0_\ "3_ +XQ^(/"=TTT4MPNCZD\<-VT9R@N(<^5<(#_!*KJ02"""17Z;
M_L+_ /!RE?17%E\/?V]?!ZR0E8X(_B%X5L<,IS$GF7MDO!&#+(\EM@C"HELV
M<CY_,.#\PPL7.@U479*TONUO\G?R/8P?$V#Q$N6JN1_>OO\ ^!\S]:?&?C?P
M9\./#-UXT^(7BW3-!T>Q56OM6UB^CM;:W4L%!>60JB L0,DCD@=37FO_  \$
M_8+_ .CV_A%_X<G2_P#X_7XA_P#!=/\ ;"U#]I_]M*^\/>$OB;8Z_P##WPKI
M>GQ^#SH6H&:QF^T64-U/<G:[1M.99WA9@%(6"-",H2?BVN[+^#8XC"0JUJC3
MDD[);)]'?KW^XY<9Q/*CB94Z4$U%VNWO;TZ']97PS^+WPH^-&@R>*O@[\3O#
MWBS2X[@V\FI>&M:@OK=90H8QF2!V4, RG;G.&![BNBK^9+_@EU\;?B/\"_V\
MOACK7PY\376G_P!N>,M-T/7+>&0^7?Z?=W<4,\$J?==2K;EW [9$C<89%(_I
ML8D+D5\_GN3_ -CXB,%+F4E=:6?H>QE.9_VI1<G&S3L^IS'Q-^.'P7^"EK:W
MWQD^+OACPG!?2,EE-XFUZWL$N&4 LJ&=U#D C(&<9%<SX?\ VU_V-_%FN6?A
MCPM^UE\--2U+4+E+>PT_3_'>GS3W,SG:D<<:3%G9B0 H!))P*_F=_:7_ &C/
MB;^U?\;->^.WQ:UAKK5M<O7E\D2.T-C#N/EVL 8DI#&IVJN2<#))))/!U]-1
MX'INBO:5GS6ULE9/]?U\CP:G%D_:/DIKEZ7>I_79GC-> _'C_@J7_P $_?V:
M]:/AGXM_M1^'+75([N>UNM*T<S:K=6<\) DCN(;&.9[9@3C$H3)# 9*MC^?[
M7?\ @HQ^VAX@_9KT?]DJ]^/>MQ^!]'@DMHM/M;CRIKFT9&1;.>X7$L]JB.R+
M;NQC";5VE8X@GB0XX%3A."%S-XFKI?11[='=WMZ6?J5B.*WRI4*>O][_ "7Y
MW7H?T":A_P '$W_!-BR\0?V-;>+?%=Y;;]O]K6WA.86^,CYL2%9L<D_ZO/RG
MCIGTWX7_ /!9/_@F7\7=<;P[X6_:W\/V=REN9F;Q-:W6BP;05&!/J$,,3/EA
MA Y8C) (!(_FNHKT*G!>5RC:,YI^J?Z?Y'%'BG,(R]Z,7\G_ )_YG]=%E>VF
MHV<6H:?=1SV\\:R0S0N&612,A@1P01R".M25_,7^QC_P4D_:R_82UM+GX)?$
M*270VE>2\\&ZXSW.D73/C<Y@W*8I"54^;"T<AV@%BN5/[Z?\$^O^"B_P/_X*
M&?"O_A-?AQ(VEZ_IL<2>*O"%].'NM)N&'9@!YT#$-Y<X"AP/F6-PT:_'YQP[
MC,I7M&^>'\RZ>JZ?BO,^ERW.\+F+Y/AGV?7T?7\SZ K)\<^/? _PQ\+7?CGX
MD>,=+\/Z+8*K7VL:WJ$=K:VRLP13)+*RH@+,JC)&2P'4BOCK_@J7_P %G?AC
M^P)*_P (_A[HUKXP^)]Q8F4Z2]T5L]"5XR89;YD^8LQ*NMLA5WC^9GA5XG?\
M,?VC_P!J[]HC]KGQJ?'W[1'Q6U3Q-?J6^QQW<@2VL5*HK+;V\86&W5A&A81H
MNYAN;+$L>C)^%\7F455J/DIO9VNWZ+MYOY)F>99_A\#)TX+FGVZ+U??R_(_?
M'X@_\%SO^"8/P]O]2T:?]I2/5[[39I(I+?P_X>U"\CN'0X(AN$@^SRJ3T=92
MC#D,1S7,^#?^#A7_ ()E^)YY8M<^)?B'PZL>=DFL>#[N02\D?+]D6<]!GY@.
M".^17\^-%?4QX+RI1LY3OWNO_D3YV7%.8<UU&/W/_,_J4_9[_;J_9 _:KCMT
M^ /[0OAGQ%>7,4LL>BPWP@U(1QMM=WLIPES&H/\ $T8!!!!(()]8K^1:WN+B
MSN8[RTGDAFAD#Q2Q.59&!R&!'((/>OT5_P""<W_!P%\<?@+K-E\-/VP]6U'Q
M]X'?>BZ_-^^U[2V8@JYF=A]MA!W;EE)E ?*R$1K"_C9EP96HP<\)+GM]E[_)
M[-^5E^AZN!XHI59*&)CR^:V^:W7XG[J45@_##XG_  ^^-'@#2_BE\*_%MGKO
MA_6K47&F:II\N^*>,G'U# @JRD!E965@&! WJ^)E&49.,E9H^JC)2C=!1114
MC"BBOC3_ (*/_P#!:+]GK]@N:Z^&6B6K>-OB4+5)(_#.GW(2WTW>1M:_N,'R
M24W2+"JO*P";A&DJ2UT87"8G'5E2H1<I/M^O9>;,<1B*&%INI5E9?U]Y]DS3
M16\+7$\BI'&I9W9L!0.I)]*^4_C[_P %K_\ @G!\ $NK._\ VA+'Q5JEO9BX
MBTGP+"VJM<Y) C2YB_T19.#E))T(&,XR,_AG^UY_P4;_ &O?VW]5FF^.OQ7N
MI-&:?S+7PCHY:TTBUP[,@%NAQ*R;V"RS&27'!<@"O#:^ZP/!,.52Q=37M'_-
MK7Y)>I\CB^*I7MAH?.7^2_S?H?M-\2O^#HOX!Z7'&?@]^R[XPUUC_KE\3:M:
M:2%^A@^V;N_4#_#D[/\ X.H[1[R)-0_88DBMVD FDA^)0D=%SR54Z<H8X[%A
MGU%?D+17N1X4R.,;.FWY\TOT:7X'E2XBS:4KJ=ODOU1^\WPR_P"#D[]@'QKK
MEKHGC;0/'W@Z.:-C<:MK&@0W-G;L%)"G['/-.V3P"(>IYP,D?7W[/O[8/[,'
M[56E+JW[/7QQ\.^*O]%6YGL=.OU^VVL18J&GM7VSV^6! \U%)K^5NKOASQ)X
MB\'Z_9^*_".O7NEZIIMREQI^I:;=/!<6LR'*21R(0R.I (92"#TKS\5P7E]2
M/[B<HOSU7W:/\?D=F'XIQE.7[V*DON?^7X'];]%?AC^P7_P<1?'SX(7%GX _
M:_M;KXB^$XX_+CUVW2-=?L55(U3,C,D=ZHV,3YQ69FF9VG;:$/[0_!'X[?"'
M]I#X<V'Q9^!_C_3_ !)X?U% ;?4-.D)"MM!,<B, \4J[ANBD570\,H/%?#YI
MDV.RF=JT?=>TEJG_ )/R9];@,TPN8QO2>JW3W7^?JCK:***\D] XW]HOX20?
M'WX >-O@=<Z@EFOB_P )ZAHRWLEN)1:M<V[Q+-L)&XH7#@9'*CD=:_E2\2^&
M_$'@WQ'J'A#Q9HUUINJ:3?2V>I:?>PF.:UN(G*212(W*NK*5*GD$$5_6_7XD
M_P#!PQ_P3FUCX7?%:;]N'X2>%))/"?BR9!XZCL+2-8M'U8[4%TRQJI6*Z."T
MC!LW.\N^ZXC4_:<&YC##XJ6%J.RG:W^)=/FORMU/EN)\%*M0C7@O@W]'U^7Z
MGYDT445^F'PAZ9^RS^V#^T-^QE\1(_B3^S[\1+K1KHR1_P!I:>S&2QU2-=P$
M5U;D[)EP[@$C<A<LC(V&'ZB?LY_\'/WP_P!0T^/2_P!J_P#9[U33+Y88U;6?
M <\=U;7$I<[F-K<R1O;QJN#@33L<'V%?C?17EYADN6YE[U>'O=UH_O6_SN>A
M@\TQV!TI3T[/5?\  ^1_2E\*O^"Q_P#P31^,%])IGAS]K/P[I]Q#;K+(OBJ.
MXT6, _PB6_BAC=AW",Q'7IS7MWPO^//P.^-]G=:C\%OC)X5\86]C(L=[<>%_
M$%MJ"6[D9"NT#L%)'(!P<5_)_1CVKYNMP/A9?PJTEZI/\N4]RGQ9B(_Q*:?H
MVO\ ,_KL5@PRIHK^4SX9_M/_ +2OP5TN70_@[^T-XX\)V,\PEGLO#?BR\L89
M) ,!F2&158XXR1TKZ0^$7_!>S_@IA\*KRR.H_&6P\8:?8V_DKI/B_P /V\R2
MC'#23P+#=2,/[QFY[YKS*_!..AK2J1EZW7^?YG=1XJPLOXD&O2S_ ,C^B.BO
MR7^ /_!T1X8GC@TW]J7]F>_M'CLB;C6O .H)<+/<[A@+97;1F&,KN.XW,C @
M#!R2OZ(?LS_MR_LF?MA64UU^SE\<M%\236RL]UID;26U_#&K*IE>TN%CN$CW
M,H$AC"$D $U\[C<GS++]:]-I=UJOO5U]Y[>%S/ XS2E--]MG]S/6****\P[P
MHHK#^)7Q&\&?"'X?:U\4OB+KL>F:#X>TN?4-7U"2-W$%O#&7=]J!F<A5.%4%
MF. H)(%.,92DDE=L3DHJ[/(_^"@?_!0'X-_\$]O@Q)\2_B5-]OUC4/,@\(^$
MK6X5+K6[M0"54D'RH$W*TLY4K&K* 'D>**3^=7]JS]K;XZ?MG_%J^^,7QX\8
MRZC?W$C?8=/A9DL=)@)&VVM(2Q$,2@ =2[D%Y&=V9VW/V]?VS_'W[>/[26L?
M'GQO +.VEQ9^&]%1BRZ7ID;,88,Y^9_F:21N TDDA4*I5%\9K]=X?R*EE5!3
MFKU9+5]O)?J^K\K'YQG.;5,PK.$':FMEW\W^G8***]D_9&_8#_:M_;?\0KI/
M[/OPJO-0T^*Z$.I>*+W_ $;2=/.Z(/YMR_RLZ+,DA@CWSE,LD;X->]6K4</3
M<ZLE%+JW9'CTZ=2M-0@FV^BU/&Z*_6CX2?\ !K=XBN]*L=2^.G[6MG97K,W]
MI:/X3\,O<1JNX[1'>7$L9)*X)W6XP21\P&3ZQXA_X-@_V/KG0VM_"GQX^)5G
MJ7EXCN]0N=/N8 V.IB2TB8CV\P?6O!J<59)3ER^T;\TG;\ORN>O3X=S6<;\E
MO5K_ #_,_#^BOT_^.G_!L+\??"6B?VO\ /VB?#_C*XBAN);C2=<T>31YGVJ#
M%% ZR7,<DCG*_O6@13M);!)7\]OCW^SC\=/V7?'LGPR_:!^&&J>%M:C3S$M=
M2A&RXCW%?-@E0M'<1[E9?,C9D)4C.00/2P>;9?F&F'J*3[;/[G9_@<&*R_&X
M/6M!I=]U]ZT.)HHHKT#C"ON+_@WB_P"4EVA?]BOJW_HBOAVON+_@WB_Y27:%
M_P!BOJW_ *(KR\Z_Y%%?_!+\CORO_D94?\2_,_4__@N__P HI?BI_P!P/_T^
MZ?7\YU?T8_\ !=__ )12_%3_ +@?_I]T^OYSJ\/@G_D53_QO_P!)B>OQ5_R,
M(_X%^<@HHHK[ ^9"BND^$GPA^)WQX^(.F_"KX.^"-0\1>(=6F$5CI>FP%Y'/
M=F/2.-1EFD<A$4%F*J"1^CGP _X-B?COXPT*/7/VBOV@=#\%SS0V\T6B:#I;
MZQ<1[TW2PW$AD@BBEC.%S$UPC'<0Q !;S\;FF7Y<E]8J*-^F[^Y79V87+\9C
M?X,&_P %][LC\OZ*_<B#_@V'_8H&D"&X^-?Q2:_\G!N$U+35A\S'WO+^PEMN
M?X=^?<5XK\7?^#6_Q[8:9-?_  '_ &L-)U2\-THM]*\6^'9;&-8>=Q:ZMY+@
MLXXP! H.3RN.?-I<59)4E9U&O5/_ "?XG?4X>S6G&_)?T:/RAHKT3]I']DS]
MHS]D/QDO@3]HSX3:IX8OIEW6<ETJR6UZH5&8V]S$S0SA1(@;RW;8S;6VL"!Y
MW7OTZE.M!3@TT]FG=/YGC3A.G)QFFFNCT9]4?\$O?^"HGQ/_ ."=WQ+^SR&[
MUSX;ZY?1OXM\)HP9E; 3[;9[R%CNE4 $95)U14D(VQ21?T2?"OXI> /C;\.M
M'^+'PL\46^M>'M?L([S2M3M=VV:)QD<, R,#E61@&1@RL P('\F=?K%_P;8_
MMT:AI_BC5/V#OB#KLDEC?PSZQ\/_ +5=,WV>X3Y[RQB5LX5TW72HNU5:*Y8Y
M:6OC.+,EIUL.\;25IQ^+S7?U7?MZ(^HX=S2=*LL+4?NRV\GV]'^?S/V*HHK+
M\:^,O#/PZ\':M\0/&NKQZ?HVAZ;/J&K:A-G9;6T,9DEE; )PJ*S' S@5^:I.
M3LC[K;5GD/[?O[>OPA_X)^?!"X^*_P 29/MVI73/;^%?"]O<!+G6;P+D1J2#
MY<2Y#2S$$1J> [M'&_\ .O\ M;?ME?'_ /;9^*%Q\4OCUXTEOYC-(=*T>W9D
MT_1X7(_<6L)8B),*@)R7?8&D9VRQZK_@H[^WAX]_X* ?M'ZE\5]?O+NW\-V,
MDEGX'\/SHL8TS30WR;D1F7[1)Q),^YB7.T-Y<<:KX'7ZYP_D5/*\.JE17JO=
M]O)?KW?E8_-\ZS:IF%9P@_W:V7?S?Z!117L?[*7[ ?[6_P"VKJ4EO^SS\&]1
MU?3[>8Q7WB&X*VNF6K@Q;T>ZF*QM(JS1N84+3%#N5& KZ"M6HT*;G4DHI=6[
M+\3QZ=.I6ERPBV^R5SQRBOU-^%W_  :X?&K6--N)?C/^U?X7\/W:S 6L'ACP
M[<ZO'(F.69YY+,H<_P (1@>N1T/0ZK_P:O:M%IEQ+HG[<5O<7BPL;6"Z^'+0
MQ228^56==0<HI/5@C$#G!Q@^++B;(XRY76_"3_&UCTXY#FTHW]E^,?\ ,_)&
MBOL7]I;_ ((3_P#!0_\ 9OTI_$D'PUL_'VDPVZRW5[\/+J2^D@+2; AM9(XK
MJ1AD,QBBD15.XL K8^.J];"XS"XR'/0FI+R=_O[?,\ZOAL1A9<M6+B_-!111
M708A7]&/_!"#_E%/\*_^XY_Z?+^OYSJ_HQ_X(0?\HI_A7_W'/_3Y?U\?QM_R
M*X?XU_Z3(^FX5_Y&$_\  _\ TJ)]=US/QC^,7PU^ 'PRUCXQ?%_Q;:Z'X<T&
MS-SJFIWC$)&F0H4  L[LS*B1J"[NZHH9F /3$@#)-?@7_P %X_\ @HM=?M7_
M +0$W[/'PYU:-_A]\.=4DACGM+F1DUK5@GESW3 A5VPL9;>+ 8$>;(LC+.%3
MX7)<JJ9MC%26D5K)]E_F]E]_0^LS3,(9;A74>LGHEW?^2Z_\$\U_X*A_\%4O
MBK_P4.^(C:=8R7WA_P"&FCW#?\(SX1^T;6N"#C[=?;"5EN6'W5RR0*2D98M+
M+-\HT45^Q87"T,'0C1HQM%=/ZZ]V?F>(Q%;%574JN[845UWP0^ GQG_:2\?6
M_P +_@1\-=6\4:[<[6%CI-J7\F,R)'YTS\)!"'D16FD98TWC<P'-?H=\!O\
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MH8XU*_>(92WRX"#T->GA\5A\73YZ,U)=T[G#6P];#RY:L7%^:L%>Z_L!?\%
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M +RUNH2$NM,NU4B*\MI"#Y4T>YL'!5E9T=7C=T;^9?\ :?\ V>O''[*/Q_\
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M7?\ ^44OQ4_[@?\ Z?=/K^<ZOZ,?^"[_ /RBE^*G_<#_ /3[I]?SG5X?!/\
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M]/"X>-&FO=BDE\C\LK5JF(K2JSWD[LDM;.[U&ZCT^PM9)IYY%CAAAC+/(['
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M!TD1AE65AP00001P0:FK\C/T<**** "H-3U+3]&TVXU?5KZ&UM;6!YKJZN)
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M^T%_P06_9$^*]]?>(OA9JNM?#W4KI=T5OI<BW6F)*92[R&UF&\9!*B.*:*-
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MRZ)\1=(72_%5G8M%X9\<6%N&O=,?)9%897[1;[B=T#D AW*-$Y$B_A?^W/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M5 '.U^QY3EZRS 0P][M;ONWJ_P#)>1^8YEC'C\9*M:R>R\EM_P 'S"OZ"O\
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MJGCJ.&Y<3@(4KNZG!22]%+FE"2^]];G14445)\J%%%% !1110 4444 %%%%
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MS,C-^\Z_*N.^H/7S7,*..IX:--->SI*#O;5J4G=6;TM);V>^@5\%_ $#_B(
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MQLO_ ([6=^TI^Q=^S7^UZ=%_X:'^''_"0?\ "._:?['_ .)Q>6GD>?Y7F_\
M'M-'NW>3'][.-O&,G/EW_#E__@FM_P!&X?\ EX:S_P#)E5I8^E6-R#%Y5AL/
MBY58SI*2]V,&GS3<MW-/9]CW/PE^T!\!?'NNQ^&O OQK\):UJ4ZL8=/TGQ%;
M7$\@52S$)&Y8X )/' &:["O!/@Q_P3%_8@_9[^)NE_&+X/\ P4_L?Q%H_G?V
M?J'_  DFIW'E>;"\$G[N:Y>-LQR.OS*<;LC! (][J3P<='+XUE]3E-QMKSI)
MWUZ1E)6M;K??0_.3]G_XL>#?^"??_!4[XW?"OX_ZY:Z)H?Q<OX_$GA_Q9JLG
MV:TW//<W"Q%F^54W7=S"9695$EIC^,8^WOB9^U%^SK\'? J_$GXD_&CP[I>B
MSVK7%C?3:I&WVY!'YF+94):Y8IRJ1!V;C:#D4W]H']EK]G[]J;PW#X5^/OPM
MTWQ':VK$V4MR'CN+0ED9O)N(F2:'<8TW^6Z[PH5LCBO%M!_X(N?\$Z= UE-:
M7X%R7C13K+#;W_B34)8496W %#/B1>Q5]RD<$')JO=>Y[V(QV09M*GB,:ZD*
MJC&,U",9*?+%133<H\K:2NK-=CS;_@BGH_BCQSXC^._[8,_AV?2_#?Q6^(+W
M?AFWOE99WCBN;Z:1_N['C#7JQ!T9@9()E."G/WC530= T/PKHEGX:\,:-:Z=
MINGVL=KI^GV-NL,%M!&H5(HT4!415 4*     ,5;I-W9Y&<9A_:N93Q*CRIV
M26]E%*,5?J[)7?5B/]VO@[_@WD_Y,I\1?]E,OO\ TWZ=7WBZ[UVYK@_V=_V8
M_@C^RCX*N/AW\ _!7]@Z/=ZF^H7%G_:5S=;KEXXXV?=<22.,I%&-H(7Y>F22
M7?W;%X7'T:.3XG"23YJDJ;3TM[G->^M_M*UD^NQWM>6_MQ_\F5_%[_LE_B#_
M --L]>I5E>.O!7AKXE>"=8^'?C/3OMFCZ]I=QIVK6?G/'Y]K/&T4L>]"K+N1
MF&Y2&&<@@\U)PX6K&CBJ=26T9)OY-,^>O^".?_*-SX:?]>^I_P#IUO*Z?_@I
M'^SOXA_:B_8R\:?"7P9!#)KTUG#>Z''+@>;<VT\<XA4LRJK2K&T(9B%4RY/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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# __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>g2018030121532351331435.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121532351331435.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" )- L4# 2(  A$! Q$!_\0
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MD\:!-T1(96(<X/''7.16AKGCG3-!UIM*GM[R:X33Y=2D,"H52&,$G)+#!.W
M]R.10!T]%>=6WQ=M[VVCN;3P5XTGMY5W1RQ:4&5QZ@A\$5V&OZW_ &#I1O\
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M010!UM%>:0_&O1YM&GU@>'/$RZ;"NXW;62"(_.$P'\S;G)Z9[&NL\1>+M/\
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MIN3N\S=C ZXQQTP>^:]YM=/LK%[A[2SM[=[B0RSM%$J&5SU9L#D^YJH/#>A
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MJNY>I!:0#(Z<9XR0 >=/KKW4%K-J/B*_M;Q_#-K/:117+1^=?%I!]T8$DA8
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MY>*26YRW[LQ[OWKC$ $3;A\Y&.3BWJ\5W-<:U>-JFIV]Q:WME#$L%XRQQ!Q
M),)G8V=Y^\& Z@ DD]KIVL6&K!S87 G5%C9F56VX=0Z\D8R5(..H!&<9%7J
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M<9VY^7%274ERNI:IJ*ZCJ EM=?L;2&(73B%8I!;!U,8.TY\Q^H..HP:](HH
M\PFN;:;Q7I@O-3N/[<&O2*^GFY<HD 641,(<[44H(SO R2QY.2*H:#JU]-;:
M@VH:OY4OV"5M02VU6>XN(;KS $Q$R!+=PQ91$&P_ PP7->O44 <_X-GNKC0V
M;49F?5!/(+Z,L2(9LY**"3M0*5VCNI!ZDD]!110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M4E561V"CY$Z ?=% &W1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MB+L<86-%&3^  K&\)^(Y/$%K/]JMX[:ZB8/Y2/O_ '3Y,9SZC#(P[/&XZ8H
MZ&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;JNFZY!K3W/A>RM+:20A[F6ZN2L%R>^8E5CO_P!L%3Z[@ *ZU55$5$4*JC
M& !2T <U9W5YK5A_9E[J$VDZW%\]REI&BL4R0#'Y@D#(>/G&>1CY3D#1TS0X
M-,EDF%WJ%U-(-K/=WDDHQ[(3L7\%%3:EI5MJD48F#I-$V^"XB.V2%O[RGM[@
MY!'!!!(JI9:I<6MW'IFL[%NGXM[E!B.ZP,\?W7P"2GID@D X +.GZ%H^D_\
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M5E=%=&#*PR"#D$50T_\ X_M6_P"OM>W_ $QBH T**** "BBB@ HHHH ****
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MR:NT 8D'A72DO1?744FH7BMN2>^D,QC.<_(&^6/_ ( !6W110 4444 %%%%
M!4%[96^H6DEK=Q"2&3&Y22.AR"".000"".00"*GHH P[:]N=(N8]/U64RPR-
MLM;\C&\GI')CH_HW1O8\'<J*YMH+RVDMKF%)H)5*O&ZY5@>Q%8\,\V@3I:7\
MSS:=(P2VNY#EHF/ BE)ZYZ*YZ_=;YL%@#=HHHH **** "BBB@ HHHH ****
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M$\B22"Z&YD0HO^ICZ D_SK3JAI__ !^ZM_U]+_Z)BH OT444 %%%% !1110
M5#=W=O8VDMU=2K%!$I9W8\ 5))(D4;22.J1H"S,QP% ZDGTK"LT?Q!=1:G<H
MRZ="V^QMW&/,/:=Q_P"@*>GWCR1M )+*UN-4NX]5U*)HEC):SLV_Y9 \>8X_
MYZ$9_P!T''7).W110 4444 %%%% !15'5-4BTFU6:2&YG9W$<<-M"TCNQ!.
M!TX!Y. .Y%5K-=4U6RNDU>V6PBG&V*&WN6,R+WW2+@!C_L'C^\: +7]KV!U7
M^RUNHWOMF]H$^9D7U;'W0>V<9[5FC3=;U&\$VI:DMG:QR;H[/3B<N >/,E8!
MCG^ZH7TRPK4T[2[#2+7[-I]I%;1%BS"-<;F/5F/5F/<G)/>K= "8 S@=>M+1
M10 4444 %%%% !1110 4444 %%%% !3)H8KF"2">-)89%*.CC*LI&"".X(I]
M% &%#/)X?GCL[R1Y-,D8);74C$F%B<"*1CR<]%<]?NMS@MNTR:&.X@DAFC62
M*12CHXR&4C!!'<5BPS2^'YX[.\E>739&"6UU(<F%B<"*0GDYZ*YZ_=/."P!N
MT444 %%%% !1110 4444 %%%% !1110!'/!%<V\EO/&LD,J%)$<9#*1@@CN"
M*Q[#PZVDWD3:?JM['8+G=83.)H\8.-K/ETP>P;&.,5N44 8=UKE_I]U*MWH%
MX]H&.RYLF6X!';=&,2 ^P5A[U-JOB71]#L!=ZE?PVJM"TT<<S".215 )"HV&
M)Y'&,Y(%:U4]4FTV#3IGU:6UCL0O[UKME6,*>/F+<8YQSZT 8%OX@U>**UU&
M_336TZZGA@,=I(S26S2LJ)EONR?,Z@X"XSGG%=4652H9@"QP,GJ:\;TZ.PBU
MNXMH-.N=6\.23FWL[(VT:0R3 85GE95693^^QN=R-BGYF=<=Q#X*LX[J6:RT
MC1-&=)$-M<V%A$;A5P=V2R;5).,8!Q@]<\ &Q?\ B;0=*E:+4-:TZTE7K'/=
M(C>W!.:SY_%QEL[>ZT;1M1U2&:<PEXX3$   =X\S;N4YP#PI(/S"M*#P_IEO
M>37?V82W,L_V@RSL965\8!7<3L ' "X&*TZ .4TJPUS5H6E\1PK#*D;I'$)O
MW,F\$$2VZ,58 $#!D?/)X.#5S3_#<UO);RWFLWD_V?'EV]OBUMTQT CCP2/9
MF85OT4 ,2*.-Y'2-%:0[G*K@L<8R?7@ 4^BB@ KGG_XF_C%(\;K71D\QO0W4
MBD*/JD9)_P"VRFM?4]0@TK3+K4+DD0V\;2-M&2<#H!W)Z =R:I^'-/FT_1T^
MV!?M]RS7-X0<CSG.6 /<+PH]E% &M1110 4444 %%%% !1110 4444 %%%%
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M2;EL_P 3E3M3C^$9/<D'BH;*2TT/]U=:K>:C?7-PL<C'=*1(1P!&@(B4#GH
M!R3WJU'<:O=O"R64=A")F$RW3!Y&08P4$;%1GGJ>,#CG  +EI9V6E6*V]I!#
M:VL0)"(H55'4G^I-4O\ A(+6XVC3$EU(R0O+'):C="^TD;?.^X&+ C&<\<TM
MOH4(:WEO[FXU&Y@#A9KE@!\_7Y$"ITX!VYQWZUJ*JHBHBA548  P * ,D0ZU
M?*WGW,.G0R08*6R^9/%*3U$C?)@#C'EGKUXYGM]%LK><W)C:>Y:-(GGG<NS!
M,8Z\#D \ <\]:T** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M[D]2>Y-6J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MVD8./UYJ0>--$.F)J)DO5MY7"1;].N%>8E2P\M#'N<;03E01@$T =!5#3_\
MC]U;_KZ7_P!$Q58L[NWO[.&\M)DFMYT$D4B'(=2,@BJ^G_\ '[JW_7TO_HF*
M@"_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** /(4\*Z__;WBB"RTBZL=)OK*X2>T^WH8;F5RVUH'
M96,98,Y(*@ M@CH:LP>'?$MO?6>JQZ?J4EGI]\7M=*NM02:X6-K5HG/F-(5Q
MO((4OP-V,9Q7JM% &#X/T:YT'P5I6D74@^TVUJL<C1G(5L<X)'(';([5;TB-
MH9]41YGF870S(X4,W[F/KM 'Z5IUGZ?_ ,?VK?\ 7VO;_IC%0!H4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !63J'AR
MPO[DWB>=9W^-OVRSD\J4CL&QPX'8.&'M6M10!SWV;Q9:<0ZEIFH1CH+NW:&3
M\70E3^""L_7--\8Z[X?U+3"^A68O+26WR#--]Y"O7Y-N<]<''7#=*[&B@#SQ
M_"WB74)K.35;;3[BXBO;:X-Y+JLDIA6.9)&$4(MD120I7/!(."QKT.BB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ JAI_\ Q^ZM_P!?2_\ HF*K]9^G
M_P#']JW3_C[7_P!$Q4 :%%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M16?YVL?\^-C_ .!K_P#QJCSM8_Y\;'_P-?\ ^-4 :%%9_G:Q_P ^-C_X&O\
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M#0HK/\[6/^?&Q_\  U__ (U1YVL?\^-C_P"!K_\ QJ@#0HK/\[6/^?&Q_P#
MU_\ XU1YVL?\^-C_ .!K_P#QJ@#0HK/\[6/^?&Q_\#7_ /C53V$=S':XNV5I
MC([':Q8 %R5 ) S@$#IVH LT444 %%%% !1110 4444 %%%% !1110 4444
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M[/&;"^%Q<,^0\B".10!@')!?H<=30 L/C&T?6WTRXL-0LGV3R0S742HEPL)
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MA!ZUP#^%/%%IX1N-'TVYL5DN]3N)[F3[3)$WV:21GV1N(V*N00"<'&3C)P0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZ*/82B3)E>(<2H5P#D,  WR\\]<WA;16L]6M'L@T.KNTE\K2.3*S*%/).5X
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M[F;S%D9AM&#O!&!CIBL(_#(2>%;O09=3B>+4=0%[J$IMG9I,,AVQEY6*L1&
M6<R$Y)/6@#K/#=Y?ZCX9TV^U.***]N;9)IHX@0J%AG !)/&<=:U*0 *H50 H
M& !VI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?Q#
MH;:[;V\2WDEL89A+E"XW8[?*RD<XYSD=B#S6Q7/^*_$O_"-V]C)C3Q]JN/(\
MS4+[[+"GR.^2^QO[F ,=30!QWAE=,C^(6IV^GS07-S<"?S+N$-'=VOS$L)E.
M=_S8 9PN-JX!!J3R-+MO#VFPZP8VT*/7K];LWSF2,@27(C,S.3D;]O+$_-M[
MXKJ$\5V-JZF^%N+B>&&0+IHEO6EWB0KMV1 NNV-B& Z9R ,$VKCQ=H=JMJTE
MXS1W,23I)'!)(B1N<*\C*I$:DYPSE1P?0X //5$6-)_M '^V/L6F_P!CB<-Y
MP_?'S-F>=VW;YF.=N-W%=5XOO;RVU[3(;*X%M)/%Y1G6&-Y$#W5LAVEE/\+M
MQTS@D' K1OO&.FVT.HBW\V>YLK>:?RVADC241$!PDI7:V&(!VDX)YK5GU>QM
M;HVUS<+%*+9KHAP0/*4@,V<8XR,]QD>M ''MKVLZ?I\3/=R7;RW5UI43R0QA
MC<>:1!(^T 8PI5L  G!P*KMK^NQ>.SIKZG:I%#*(A9RMF6XB\G<9A"D!8_-N
M^82A/EVX!Z];'XGTF6]AM$GE\R8 JQMI1&"5WA6D*[5?;SL)#<CCFH%\::$U
MM<7'VJ=8X/*W%[.92PE8K&4!3,BLP(!7(/K0!YW#XBO]4TFZ@U/Q"Y%K>:?+
M)>6\EM)#'F9=WS^6I3DC]W+&&4H?F8$@:,?BOQ(=1UK%]9M+;QW9&G!_-EMA
M&V$D,2P!E^7#?-*P?=\O4 =Y>^)--TZUM[BY:Y59X_-1%LYGD5  2SHJED R
M,E@,$@'!IJ>*-(?5AIB7,C7!?RPPMY/*W^7YFWS=NS=L^;&[..: .0TC4GAT
M[QKJ6D:N-:FB"/#>;$?>RVZ_\\@%?!_N@=,=0:EM-5U'4;BWL;'Q/-<V4VI>
M1%JL,5NSRH+5I&56">4V'7&0O'*GD9K7B\>:?=:B]O:*7@6.WD%Q,DL0?S93
M&NT&/+*>"KCY6SU R:NV_C+0KJRN+R.ZF\BWCCE8O:3(720D1L@909 Q!"E
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M3RWB>)=,M+_7[IX[/6Q''-*L"-)OLRX1L1A<[BRC !P_J :]$HH X@ZY?_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
)110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>g2018030121531680431126.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531680431126.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" +5 G # 2(  A$! Q$!_\0
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M205V^F #GWJMJ$\^G60?3]/%VX< 0)($X)Y.2/QH G^WV@U :<;B(7WE^:(
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M]#TYJ;3YKJ;SFN[46X65TB&_<9$!X8C'&<9QSUJ:6619852'?&[$.P. H]:
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M8/-SYMXX)4NP 7..1D@"ME?G"ET&XCICI[57L9Y[A)#<6C0%92JACG<!T84
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MF0<%<D>O<>E,AGAU>"\MIK2:.!7:!XYTV[QW(P>5]ZNPP1V\"Q1HJQJ,!0.
M/2@!K3*\S6PE59@F\JI^8 DC/TR/TJOI=I>6EH$O;]KV?<Q,SHJ\9X&% ' X
MJ5;2W&H-?>6/M+1"$R#.=H)./3J35@X4<C'':@"H(;E=2EF-SNM3$ EOM'RO
MDY;/7D$#\*)F:]M)ELKE8Y =HE7YMK=P1Z_XTY+U)-0ELPL@DB57+%?E().,
M'UX-4KA[#PUIUY>I;/Y32^?,MNI=W=BJD@9Z_=X]J -)I!"B^<P[+D]S3]X5
M-[D* .2?:J-QI]GJ/V6>ZM@[Q$21"0D,C''OUX_G3_/M[Z:ZL"I=5C"RC&%*
MOGC/K@'- $5^E_</93:==V\4:RAI_,3=YD6.54]C[U=$R&3R@5# 9V@\X^E4
MX5LM#MK2PMX3%#D0P1Q*2%XS^ ZT#3-.M-3N=8%LHOI85CFG&2S(N2!C/;F@
M#2JJZS_;E*M%]GV?,I!W[\\'TQC/'KCFH],U:RUFS6ZL)C+"6*ABA7E3@C!
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MIH]J\%G$8UDF>9P26+2.<LQ^IH NNH8;3GD$56TRPBTO3;:Q@XAMXUBCX X
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MU:\UVWL5&IW*!9IDSOE   7DX_A _"DDLK/Q#:6=S?6$B>3*+B&*X&UXI%R
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M][,(7G9O,N7WE2[9V@@<#)XS["K$FG*^IQ7XGG5D1D\I9/W;@@=5[D8X^IH
MOYP <D4H[U6$L-];2+#<Y^]&7A<90C(//8C%1^?;Z5:PI=7I^:01(\[@L[-T
M7W/7\J );R26.U<V\0EF"GRX]V-Q],]*JZ+/J-SI%O+JUFMI>OGS8 XD"')Q
MR.O !_&K/V=A>F=IY2IB$8AR"F022V/4YQ]!6==(GB33$;3]6GMT\W>ES9N
M258@J<@Y'!R/\* )9+O4!XCAM$TXMIK0&1[[SU^5\\1[/O>^>G(K40#G: ,G
ML*@BNH))I(%FC:>+&^($$KGD9'4"FQA+%;B6XNR8WE+@S. L8.!M!],_SH H
M^)]%DU[19+"&]:RF:2.2.X09:,HZN/KR,?C7)V_A?QO-+=!_'=_"D;[(B;2
M[^/O?<Z9Q^1KNI[:2>>"9+J:..(EBB$8DSTS_/\ &B>1)TN+."Y6.Z\K&$8%
MXMP(5L=NAQZXH X6?P]XBM+26TU76[SQ%;WK);[(UCMFLP2,SAE')7J!7,SZ
M'X1,5[]H\5^($-E(4NM34L5D<_($\PQE?DW8 7IN/U'K=O(FF6=G;:AJ*/<,
M%B$L[*C3/CL,]3UP*Y^Y^'^@R3:A->":6QO"TLUE)+B!9"0S2 #H3M'.: ,&
M1/"=SNU?6O/<Q6JVWV20F=I(<[%D\I5W9)P=P&02.:ATKPS;?VK/:^&-4U:T
M>R9Y(S<QM]FCN&P'RI53(Q4GJQ KH9?AUX>N[-1;FXAD#!TNK:?$@ & N['*
M@=JV-%\/:3X:22&SW*URX9O-DW,["@#D+C1/B+I*W6JP^*;'4?)B=TTS^S0D
M<S;>!E6#9)]^OK3W;Q7'XKT:RO5T'5D>0W,S+:>7+:0@X+)ND)X) X!-=AI]
MK?V5S?7&I:N+J*60O"AA$2VZ?W<Y.[_>X^E8#V>J:IXRN;ZRUB*UL[$1Q;1
M)?/5AEU))&T;@.F<T ;]KJK3ZW>:7]BFC2V1&%PRG9+NYPIQ@D<YP34TIAT>
MQ46EF!$KA1#;Q[0H)ZX _I3KM3>65Q;VEXL%PZ%4D7#F)CT.W/45);"6&SC%
M]-&TX0"1PNQ6;N0/3)H =]EMXKE[M((A<.FUY0@#LHZ MU(&3P?6JT#6VM:>
MCW-FK1L_,5Q%GD'@[6'MD4_RKS^UO/-VHLO) -L8LG?DG?OSZ8&,=NM.OUO)
M+"1=.FBCNC@1R2KN4'(!R,CMGOUH E\^..X2W(82.I8;4)&!UYQBF""UL!<7
M*6Z1M(3)*\<?S.0#R<<L<4\%A$@>1?,9>"> 3ZX_'I5+38=5A:Z_M:\MYXS(
M/L[0Q>5A,=&Y/.?>@"T8;6^2WNI;:.39B6$S1#=&<<$9Y4X_'FAKB"6Y>R:-
MV/E[F!B)0J>V<;3],TCI=&]@=9HTM%5O.B*99R<;2#G@#YL\<Y'I5G*^F>_2
M@"$>1801QQQ+'$HVHD,> OL .@J<$'!&<$9'%,A\T1KY[#S#UV].I_I44$*0
MF9DD>3S)"Q#/G:3U ]/I0!RWC77/$ND*S:+96;QK'E9KILAI?X8@H8'<Q(4'
MU-;/A?5GUC0;:\N/+6[*;;F./.V.4??7GT-8K6">+?$T]Y))+]@T[,%H\+X'
MG$'>XZ@E?DVG'!!]*Z&XT<7%S!,E[>VHB#;H[>0*DI(ZN,<GN#Q0!I%@.N?R
MH#9(P#@]ZJRV9DLU@%S<(1C]ZC@2''OCO_6HK?3C;S22&]O)=TS3;99=P7/&
MP<?='8?2@#0HHHH #TKB-=AQ\3=!N/,?F!D\O/R]2<_6NW[5QNN_\E"T#_<;
M^M '94444 %<IJFE>)YM7>;3]=BM[%F'[ETR4X XX]<FNK/-,W#T//\ DT <
M(-"^(#VQ\WQ19K,.ACB^7.3G.5SC&/Q%=1H&CKHM@;?SY[B61C+--.^YG=N2
M<X&!GH.U:>_V..G2E#>Q- #ATHI 23R,<9I: "BBB@!#T/./K5:^N+BVMVDM
M[-[N0=(HW52?Q8@5:IN>2,XXZYH SQ?WIN6B_LN;RU/$OF)A^0#@9R.,GGTH
MEU&\BD(_LJ9XP3F19$X'KC.3FM#<#_7-&1GIC'- &,NM7S;2=!O &[[TZ9QZ
M^]4HK.35O"E]:VEY);RRW%TB3P,,J?.;OS73;AFN9M]0&B>&[BZAL+F[V7EQ
M^XM54NV9FR1N(S^= &U;L+.VM;>XNQ+<[0F^1ANE('7H,G/TJWGY20>E4Y+6
MUU#[+=36ZM)$1+#Y@^:-L'GZX)IJ31:A]KLIK:0*A\MUD&%<$9R#W'- #=0M
M[F]:U:TO7MT64-*8B,R)@_+R#WQ^M7)0S0D*VTX.TCL<<'\*JW5U!H]I"$MY
M&C#+"D<";B,\#\!3S86D=Z=3\A!="+RC,!\WECG'TZ_G0!4T.VO],TM8=7U!
M;R=&R;A@%R.W8<\'MWJR\5V^IQ3I.!9>4P>'')8GANGUK*@N]+\<:/=VLUC=
M?8V?RY([J)X3)M8-P#@D<?S%:L=U;VUW'I@C=6$7F1@(=@4<8W=,C'0G/UQ0
M!/=I,UI*MNZI<,C+&S=%8@X/YXJ#2XKVVTFWCU&Y6XO(U_?2J-JNWJ!Z<U:N
M9EMX'F<,40;F"J6/'/ %4KO3;?4C:7,CSKY#":-4<KD\8W>M #;2+48]6U"2
MYN(Y;-S']DB52&BP#O#'ODXQBFZ_!J\^F-'H=S!;7RNA66Y!9-H(+ @<\BI?
M[0MKC4I]*VN\T<8:7=&P0!N@W8P3[ YJ%Y=,\):'&)&DBL82L:X1Y6&YN. "
MQY/IQ0!I\E1G)8=0.>:HZ7'J:1W#:K/:R2&X9H3;JRA8?X0<]3UR12S:5;W.
MJ6NJ/O\ M%NC+%AR!AL9!'>I-*U2UUBR6\LS(8F9E&^-D((.#PP% !.E\=0M
MWBEB6T56\Y2I+L<<8/3%27"3BUE^Q>2EPZDQLX^3?C@L!R1_A2W%[#:W-M!*
MS![EBD6%)!(4L<D#C@'DX%5X=.@M-0N]3W2&:Y50X)^50HXP.U $FG?;/[,M
MO[1,0OA$IG\@$1[\<[0><9SC-0,VJ_V_S]E_L@6PY(/FF;)R,]-N,=NM03VU
MGXFT^PNHKFX6W2:.[B:-C'OVL&&X$<J?0U:CU>R?5Y-+1B;V*-977RV VD\'
M=C!YST- #=9&J'3)/[&DM$O\9C-XK-'[@[3GM5JV6<V< NBGVCRU$QC!"[L<
MX![9K*CCL?"EK<W%U>7#P7-WOS+E]CR-PJ@=!DX'H,5N!LJ& X/3M0!3L1?E
MK@WXB&)2(#'_ '.V>O-07_\ :GV^Q^P?939[V^VB4'>4QQLP>N?6I7F@U6&]
MM;:Y9716A=X^&C8CJ,]QD&F64<.B6%E87%Z\K?+!'+</EY6QW]3Q^E %SRPI
M:50HE;AFP.?3/KBJFE?VC)9L^J)#'/YC86+. @/&<D\GK5'3O#9T_P 37NM?
MVM?S+=IM-I+)NB0_+RH_X#^M4?%_B>RTZQFM(Y+J2_,:R*EC\SHH8?.6'"KU
MR3U&[&<&@"SXBUZ73S#8:>89M9O%9+2U9ANW8_UC<@[%&2>_8<G!BMM N]/T
M>XN+>Z-SX@FA&Z]G.[<P.=H&!M3.1@ =>>F:H67@R#4-&OGO[\W5_J+"<:A"
M^XPX.Z+RF_NH2"/4=:OZ3KEY;WZZ3KT,<-TQVVMPC[DO !U&0,/QDK^(SS0!
M8\/:[/>6T-IJML;'6% 6:!EPKD=6C.2&7Z$X[UIC5[/[+)=/.L4$;%7DF^10
M1UY../>J^K:=]I":A;6MO)JUHK&S><$!&(P1D=CR#]:BTUM5N[B3[?8PVUHL
M841,0[N_\1[@+Z>O?% #+_2+?Q"(A=EY--V FVR/+G)&06XS\N 1@CD=ZQ-.
MN9O"5V+/7,367G>5I^JNH)6-N%CE?'!SQG@'UZUU>IWB6&G37;12R)!&SF.)
M=SMC^%1W/'\JXRR\&R>([K^W?&4?FW,B,MOIF\F&UC/0$?Q/ZMZXH [:#?=P
M2"\ME3]XR^6^UMR@_*W?J,'!YI);B2*\M[<6SO%*K^9,"H$6T# ()R=V3C [
M5RNBZB?"U]%X8U6^6XA)V:?=.V7*D<1R^C < G[PQWXKKY+NWCFBBEFC260X
M1'< L?8=30!#<XT_3YY[:S,LBAI!!"%4RO[9P,GU-%M&UY9V\NH6L:SJWF&-
MMK;&!.".HSTY%06*7.EVES+JFH1S+YTDB2.HB$<9)*J3G& .,G%33//<K;2Z
M?<0&(RJ9'QO#Q\Y"D=^GZT 7>PR3CU]:J2(NGV;?8[,-M.5MX0J9)/)'09Y)
M_.IDN8IY7CCD5FB.)%5@2N1D ^G!S45A'=QVR+?21R7 R&:-2%/S';@?3&:
M)5MH5G>X$:"9\*T@0 L!TR<9/>JL#?VQ:S)?:<\,8E*>5/M82 $$-QG@G^5:
M'L*H:@;JYL9TTRXACO%X5I1O53D<,/I_2@!M[J$UE=V5NEE/,EPS*TL8&V'
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M0!";VUL+JQTHF3?,C+!\K-P@&<MT!Y'7K@TX:=:6U_=:B-XFG11*2Y((4'&
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MM@(KI K)MW+D8;Z$=#QB@"75I-8'V5])ALY5\T"X2X9@=G<I@XR/?K6ENRA
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M8'%4-7T:TU>R^S7<>Y0=R.IPT;#HRGL1ZUYKI?B[4O"'B5_#^LYNK.)LRW6
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M?#1Q,6!5CNP2H4-COTS60^E^.DT74)AK.HO>" 3PVXC3>"6(,>>A.!D'MD4
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MJ*** "HS.@#'</E.&Y'R_6I*J-IEC(MTKV<#+>'-RI0$3<!?F_O?* .>P H
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M:(:>FGW8L[.V(#V\<:%9(P/NY(R!]/2K=SYLMG<0V\ZQS[,*QP=A[$C_ !H
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MG7\<P>*]/ELASUVO@_=)SD$C-=Y,]O<M)9N^',9W+G'RGC^M %+6?[6FL?\
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M;Q3:>)=.6:$HMPJJT\08X0D9!!(!*D=_SK8U"]AT^QFO+@N(84+N54L0!UX
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MRRQ'JKCYN!UR: -&VNC\+I%L=0DGG\+S3!+"<*&>SD=N8WYR4R<@]N1VK?\
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M=5.1C@#<.1GMQ7,3_&6[MM5MK)] C_>W$EN1]K._*!2=J[/F)+849Y([5/\
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MGN10!>FNKS7-<EMM"OFMM-LG6.[N(D#>:1\QCA(X# C:V0<9QBN6T73-2N=
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MX=0.A.!T8@ $$D9&9/#7@N6RU.XUO6+F6ZUB\W"W+DL+1".0&' ?U/Y4 6O
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M,X'IFM"X&ZVE^;;\C#)[<55T8!-$L4#APMM&NX9P<*.: /,/%FA:AX3\5_\
M"7Z-"!IL<6Z[BA(W*,_,,'JIZD>H'2O2-!U_3_$&F0WVG3>9#)V(^=3Z,.H-
M/N]+%SJ$%VUQ<JL0*&%)2(Y ?[R]SVKRJ[@L_#&NWVI^"[F.7^SMJZEIJD_N
M8B[,2/49)XZK_#WH [?PA\WB'Q,<G_CY'/\ P)ZYCQ9XRUO4]8FT#PS<6VE_
M9Y3;W=[J!$?S,%VB+/.X=?RKH/ 5TM[J6NWB !)Y5D7:X<88N?O+D'Z@X-2:
MWHA_X2^QO$TY+W3]00VFIPNH91M):*0@]<%F!/ICTH L:!I=OX.T&:6]UBZO
M&$0DO+BYF\Q=X7YBN>0">WTIVF_$#P]J6HQZ='>-'>2,%2&92IW%0P7GN0<X
MKFO%7AW1_"VF^?I.DZDK3.V^VT]G$&#R6E4?*%! /X =*Q=%UB"QF%^]O#>6
MEK\MI)93QI#+*RI^\"D@>8Q#+@=T8CJ: /91(A/RD?G^?XT-M*'*Y'0@C./6
MO)-.NKNQT^3P_I&KW$NJS:E+.S7$)2?:5SC#X& VP%EXQGIFMW3_ !7JNDVV
MNMXEN=/NCI%HDK"Q.W=+AV:/YL?-@+@>XH YRXU'Q1!XRO+BVU6_ETN#4&B\
MA+<K!&@8#R]YX+%BH]@&]:T/%FI>+XI-2_L>'4,P7$;KMY$L?&Y(_0J <GG.
MX<5U=CXTT2\^26Z6RE6;[,8KL>7NFXS&C-Q(PXSMS72C9C!QGGG'YT <)X+U
M#QA=:^T/B"VD6T2&YVW/E>6DSB5-F$/*#;NP#G(Y[5W_ 'I JAL@<\\TV601
M1/(<[4&3MY- '*^/8(GTB*2*[^Q:JD@_L^X49(E[+CN&Z$>]96BZ_:>+=!ET
MWQ!$(=2MI$6=#T60M^[D0C\#[&NMLKK2_%.A)<1E+O3;V+@2+PZG@AE(X],&
ML7Q?I 5++5M.D-MJE@Q-NP&(Y5P 8I2.D9 ')Z4 <I/%J"W=M;R6^=7T^.(S
MRB/:M]$H!=$.<')&X'^$XSG%:MQ'/XF\!7*H8WUZ+S!;9D\MX7#;D4YZ$(5&
M>^<]#6_I%W9^+;#[5<VT+F)C&UNZYDM90I61&XZYR,CM6)K^D:;H4T=_;36%
MG>P(956Z4F*>.,[CD=F7=]X<C(H P+BXN+6XANVMI[>2[<WMM/;?+M1CN"[>
MWR?(_IR_2NTFDL/&.B3QP;(=01 #W>%CR!G^)2.AZ$$'N*B\(26^H:;?Z?*K
M*UI=$N@3;Y?F?O%1<<$*& ##AL BLW5]'3PQJ-OJMI,JV_F$>0(U$H8\D1'O
MGDF/IP2!G- '+7&HG1K)5U&RU".Y2Z%ON@7[K/&55&;'!!8 ?WDP>^:[6V:+
MQ?X:6UB22PU:R5?*$BD/;RIE5<>JDAAZ=1U%1>.=3M;CX9W.HR+BS>6VE)^^
MIB%Q&=V1P05&1[&L?0O$VGV>G)*LJW[1++):R180,LDK%(CGL  3V'0]J +]
MAKFM^';F>Y\33326$J*@7R#NCF"_,$/\:N<D8Z# -96AZ?-XPU2^UW5!%J<=
MK,6M;7S-J[@!L1NQ"<G/3+MZ4:#8W_CC5Y=3U:_MY+2UP4L8Y 90S _*X'^K
M4C([%@>>IK8O]*U'Q#=326B3^'I+.-H)YT4!;L8!501P8U&1N[;N.AH KZ\T
M?BII/[!(&I6:A-3$#_>A!_>6I..=P#8]UJI=3VWB"[@NO#5I-_9]E&8=57F!
M9(1C$0)ZLO)..W!^\*:D\OBMC;Z3';Z;=Z9;"*],TBNT\6,>5O!.8V 8[SR"
M!ZTBZDOCJ&6]\/RI;VUA!Y5]#YH+3L/^6#<_<VA_G[Y&"?FH TC;/XB72[+P
MSY%KX949OFMR$:39P( !R/1C^M8^DZ=<?V7-?6%N9]--Q<6^KZ>@R\Z@C!49
M^8A0PP.3NK1\. :XRWGA(1:-9VP2&YA2-#Y[J06B_P!G:N5WCDYR.*R?"FG:
MM?:;J<EDT:V$>L7)N[3?B2[QMZ,3A< 8P3@YYH V;MX=2OH]0T2*.7PZJE=7
M\EMBW  P ,]=G\0'/!7K5*\M;NZU&74]&BDN/!TI$EY;09S<G^)XE[KC'3KV
MJY9W<?B*-M=\.Q0QZ"PQ>13+Y8OMOW^N-NWD9. V,'@U!:6MQK&E7VH^'D5/
M#MU('%A'*8FN H(<J<@1;N../N\T 0>)()->FAUSPM]BAL-.C!DOXT!-PJGE
M8B.OEC)!Q]X8YZ5TW@KQB-:M(+34G1-:6(&=$(V.1U*GIZ97MD5S$2V]W8MK
MMC9*G@</]HEM"Q3S%7[TX0XQ&,$F/'S=<$FKNIZ1<^+_ #=9\//;VJ",/:74
M#@O>$=-W9=O\)ZC)Z4 :?A'[3H_BOQ%HT]E.D-Q=&_M;A8\QNL@!;+?WMY/6
MNY5P?S_*N&TCQ-#X@AD\.7MS)9:Q-#(JO$VUG52RLZ$<!U8$$#HRG'%,M/#7
MC72D\G3_ !='?P%AG^T[8,X'?YEY/L#Q0!WN1G%-^5OE)!R>E<_H]KXIAAU#
M^U]0L;F5W_T/R8BBQKC&&XR>>>_Y5DG3?B.DDC1ZYHKJ4 1)+8@ Y/H,XP1^
M5 '6V>F66G^;]DM((/.<R2>4@7<WJ<5;^5!CIQ7-RP^+/^$:AAAO=,&OA_WD
MS1MY!7<> ,9SMQ7&ZUKGBS0&B@UWQEX8TP3]"D#-+M[E588/X\4 =+\2+R?_
M (1*ZTRRBNGO-24VD30Q%U4N0IWD=!AJZBQ@^RZ;;0$+NBB5"%Z9 [?E7G^A
M_$3PCI6FQVM]XT34YE8L;B=0KG))P<>F3]*U9_%]MXDT*^7P7J$%[J4/E$(K
M 84N-W7C.W=CWQ0!V>_C.#C&:"V#@BO./#>A^*+66X2[N;Y0\4K%I[TSAR2?
M+V#.4P",],X-5K?0_'\'V47-_-//'/)Y=PEPHB0%DPTB$YD7;NP""P/7M0!Z
M>) <  Y-*,-R/SQ7F,7ASQ==73PB^U#3+-F)E>XU 32-(&RLD>"=J$<;./<5
MZ7%\D85FR>F?4T 248XYP?6@,#T-&X=/7VH ,>N/RHQV[4M% "8XZ5@^,>/"
M.J 8'[H ?F*WZPO&/_(IZGQG$//YB@#0TL@:18].;>/_ -!%<UXS\:66AQ#3
M;:;S-8N$Q#!"NYD!.-Q]!V'OBL[7?%LVGZ98Z)HR_:-:FMX5$:X/E!QA20>Y
MP>O [XXJUX<\$1:1-)KFI1+J.O",@2'J#CH';DL>!N//2@!W@GPZ-&L9-3U-
M2NIW()D::3<\<>20N?J=Q]"V.PKH--%M>ROJ]I<M<P72*L>V0-%M7/*#MG//
MT'I7)ZWXT\)7,L%I<$WVJQJ2EG8 SW$,G\2*8\A2",$YQQ5^#7]::U\K3O V
MH+:KE$9KF"$X]0K,"/Q% &S:W^F:AJ),5ZLLR@A(3("I (W.!['C/M6RO('M
MS7$7-]K]R%+^ [SSDC:%)QJ5LLJ(V-VU@^5)P.GI4FGZ[XJ@U$6U[X3O!9.4
M6*8W<#NG9S)M;D XQC)ZT :NK^'K&YGCOHHTM]2M]SP3QG9AB!U[$' !SVJ+
MP]JFIE(M/UJTN!J$-JDD]VL?^C2L>H1QQD''%<YXIT<^-HH+S3M3T^2P5MD8
MG!9#*K\JP[AB ".O%96JW_A^ZT*/29/&$-@=(NUFNDAE+,@!P(U/<*2,'L0*
M /5Q<1;-RNI4<$[A3UE5CA3GZ5X@MKH-H+D/K/AAI7,>^UF9_L]P"^5DN>XD
MR>/S-=7X2ET3119WDOB&UN&U%$L[;RY\PET^\D8/8$8'Y4 >CT5S2>//#$LM
MY&FNV1-FF^9A,NU!V.>A^E:5EX@TC4I8HK+4[6>26/S4CCF5F*?W@!SCF@#3
M[<5RFYC\5F3/R_V&#CW\\UU0(9>I(-<C)(4^+:@([;M$ RHSM_?GK0!U]%%%
M !69<:[I=G<-!<WT$4J?>5VP:TZB>"-VW,B%L8R5SQW% &7_ ,)3H>,_VK:<
M=_,H/BK0>O\ :UIQ_P!-/\^GZ5:&C::%*C3[4*<Y'E+SGKV]A^0I#H6C]3I=
MEQ_T[K_A0 LMZT^F-=::L=XSH3 OF;5D/;GL/>N+T3QIK4OB>'3-<LM/@CN9
MGMX#:NTA\U$#ON/0C# 9&.<UN>))Y+33XM&T<+;ZA?'RK81J (E_CDXZ;03@
M_P!XBM71M'MM&TBST^W'F1VRX61^69CRSD_WF))/N: -*BD I: "L34/"]AJ
M6HM>W!D+LH4J#\O'^?UK;I,\X&.GK0!S^H^$;/44*-<7$2[MP$3  <8QTZ4Y
M?"T,>G_8H;^\BCR"2CC)([]*UX;ZVN9I88)XY)(CAT5LE?J.U6.: .*F^'=L
MSW-Q)K.JR.Z#:&D4A,+CY1COUKIM&C:/1;%'D9V6VC!=OO$[1DFI;V>.."1&
M8*[HP4%NI )X_"H=#?S/#^FR [M]K$V[/7*#F@!]]=36S6XBM)+@2SB-RAP(
ME(/SGV&,?C5>XM;>PM[R]M;!9;EU+M'$ KS-C[I/Z5<DO+9+E+62:,7#C<D9
M8!F /4 U1L[&^M]8U&]N-4::QN"K06Q0 0$* <-U.<=* /.[C0]7\(-%K>C+
M]EL'!FET^125@W89D<KCY1EL,/NXYSFO1=!UVU\06"7=K(", 2(&Y1L X/J"
M""#W!![T:E;76KVMJVFZG]D7S5D>5(UE$D>#E0&XP<CG':N!US3I? NO+K^D
M@C3RW^E6<9X"'.2V?NKGD'HI)SUH ]0DC62-HW 96&&![CO7$ZU\*?#>JQW"
M16_V(30&,K;J H?=N60#^\N6 /\ M&NET?7[#6(6-FYW1$"6)UVO'GU4\COS
M[&M3)(R/R- 'C>K_  ^U[3M-FL]/E-Y:+%%*K*?WWF1G) '4AER.O7%9T%IJ
M5AX<FCUNUTLA9=IT[4Y<_;I^7+!AC#A&C09SC!S7NNT>G2JE[IECJ.T7MI;W
M00[E$T8?:?49Z4 >*7.H>'S<1S/+8);PS20&WU.,SQ%I&5V$3(5V[2@&XYQN
MYJ[97.M>&Q#-IEY<ZM86D3*MM"?,@D499BSC_EIA@%&.=HKM9OAKICZ]::C'
M/-%;P)+&UBH!BE$HPY;/.3P3SU ]*O/X \.;8C!ID=G+$FQ)K-C;R@?[Z8)H
M H:3X\\S1+'4]7TV>PM+F*2;[64S#&B_=+G^ L.0/P[UMCQ-I-Q>PV$%Y'/<
MS*SI%'\S85=Q^G!'YUR6H^#/$'V.>SO;JW\4Z6P8K:WX$4X8@CY9!@9Y."W0
MX(Y%:>E:FNVXMK#PU=Z9K$L3-NNK-_)=U7@R3J-K=!SG- $]Y#)X7OY]3LH3
M)IUXZM>0QIDP/_SU51U![CUYK5T_7-,UU6AM[BWG)3>T:MNRO3TYY!'X&HM&
M\0P:JO,:V\JD(\9E5BLF,E1CJ,9(;HPY%8'BKP\UE?CQ):SS010KNNHK91O&
MW_EHH'+-MPK+_$%% #M2T:?1O%!UO1(KISY#-=6T0'EW(Z  =3(HY'/(7'7F
MH;[XB^&KFW>W6:[N+I0%DBL[0R2P/W!'8@@Y!S5#PU'=^*_$DGB35-0FMXHH
M@UKH4<Y)A1A@/*HX+,#G'OBM;Q+8WVD^=J>C1SK:W,6R_BM%_?(0/EF1#P6
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MW8!/&\@@\\#()XJC::/8^#X[>_U9;R]OII5C4P1/.$=N 3G+,W!^=LD=C@T
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M,(Y]',:/*Q7<"VX<*"=HZ XYZTBGQK'?YE36P0S>>\1A:/ /R^6I7DD?AC-
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M4M3.YB51<6^R-968*RNP4YV'.>V 3[5['C\\=136B1HS&R*T; @J5X(/7(H
MX30-0T?Q+/-I%QH,$<2IOAE\O,=S@CS3'D A58H/?=TXKM[6U@L[=8+:*.*)
M?NI&@51^ J78,YP,]N.E95]!K4EP_P!BO+:&(X*K)$S,..>0<4 1>*=5DTK1
MV>UC>:]N"(+5$ZF1N ?H/O'V!J7PYITVFZ+;QW1#7DF9KI@<YE<[F^HR3CVK
MGH8-8U7Q-<2?VC8RMI4/DQ#R7V"=^KG#=54%>/[QS6Q%;>*D(#WVDNH4*0;9
M^?4\-Z=* -NX.+:8[@N$//IQUJKICXTBU<R"7_1T)?IN^4<_CS67<Q^*Q'*5
MN]%\L1<AK:7.<?-SYF,>E:6AEVT#3F?:6-K$6P, G:.W84 ,A\0Z9/)91Q72
MN]]%YULNUOWB>HXZ=.M7;FZCM+>2XG=4AC4L[GL!3RB9X4!@-O'&!FLRV&JG
M5[M+X6C:68U:W:.,A\Y.Y7))!_ #K0!;CN4U#35N;-P8YXM\,N,9##*M^M>4
MIHNOPW]N E[-J, \Q8QJ!"6S,S@RLI7YE8*,#/KP._HVN2ZW =.30K>U=9+@
M)<FX1CY46"2XPP/&,8_VAVK4E^57DBC!F"87 Y.,X7Z9H \QU+3_ !9JWV9K
MEWT2&"**.2Z^T&0JRGYVVC&03M'X^U79[7QR=-E@F@MKB%;>=(FAN2DK$L"A
M/')QT QC!ZYKJ/#%]K6I:,)O$>DIIMZ)2#!YBN"HP0V03W)XSVJS/<ZFGB.S
MM8; '2VAD>XNBPRL@QL4#.>?FSQV% 'FS0:N9+U]3UXVVGV-PLWE6]P1]E+.
MBI#(2I+A@6[YR!SS7IFGW>EZ_9QW4$:3Q$LH\V,$H0<$8/2C6HY$T2^-CIT5
MY<O$Q6V8*%F;' ;/]:\QSK7@B&VUR2![&.[@=[NQD=IUCF3[L6_)QN&=KDX4
M [C@** /5WTK3Y(S&]C:LA[&%2/Y5SNJ?#?PYJB3%;::QFE4+YUC<O"5QTPH
M.W]*WM*U2VU73X[NUE$B/QW!!XR#GH15\\\8/I0!YW<>"]>T>%Y=.\8W36L2
MYV7]LL\BJ&!8!UVG! P<YX)QSC$MIXM\1I=_V?-HFG7UVHW2"RU'#(N.#L9.
M>G9JM>']>-OK5]H]_=N889S%;2W6(V)'\'.,YZJ<<@'DULZQX:L-92.7#VUU
M!E[>Y@.UX7/4J.F?4'@]\T >=^(=0TP70UFYL-9T"^E3:ZR6WS2,OS*T14D>
M8I 'S##CY3UR+>A>)(-7\=:;)+>VET5TE]TT:F(NQD;CRW/!QCZ_2NJ\):]<
M7EG]DOT2WO;?]V\.2[, <+)NSRK#'?@\'FN4^(6F1?\ "7Z?=1Z-%?M/I]Q#
M'&T8Q),GS*-P^96.>&R/K0!N>)-)L=.B&OI=HHAD.XR2D1SH_ C)4\G)PK<$
M<9)'7E+6V\40V*^(=/\ %$[RW]^D5K9W* VS1= C=6 7##<#R /K4>H:98R:
M/8VFEM$)]>5K*2.2>5X+1&& S0,W#J<("  &QP.E4-(\,:E80-H]_-?65S J
M65L_GM*&,TCK]H0 GR\JBJ%XVXSWH [/PW9G7[_7M46.&W^THT$$JKE6W+A)
MDYP,H5R!SG-9_ARYU?1(6T[3M$TR\U&TC OK=IS!=,!E5?+*V\-MR,' SBNW
M\'65O9>&;,6L92&53<)'DD)YAW[1GG W<>U5_%6@_:8EUC3T9=:L%+VLR'#.
M!R8F[,A]#_\ K .;_P"$OAL?'1;5-(U"SO!I;2S($\U=H=1E2#R!TZ#G-<_+
MJWAP>.=(U/3=55]*EN#/<6LD;*+6;:!YHW8V@[@#Z'GO76:-K%EK7BJTUY3!
M"5T9HYU<X>V?S5WQL3@##<<CMZ5S>M:K8_$'XAZ3H/\ 9ZW.CQK+(]W@J;@#
M 8*>#Y>=N>Q]>* /8$<,@VC.1D8Z5@>)M9U/2_)32])%ZTBNTD\L_EPV^T9&
MXX)R2<  5NP1)#!%%$@CC10JHO10!P!["N9\;7<D=E8V%O"9Y-1O8[8HKD%%
MY<OP>VWGZXH F\(>(KS7+6=-3TV73]0MRAFB894JX)4JW?.#]*W;RS@O[22U
MN8EEAD&UT<9!%3;1GH.*"0HY!ZT >3S6^I?#77DFMD,V@7=SL*HI8JK'@-D\
M.OW0W\0)W<\C,TZ_U6>UF\/:'I\HDN;V>XO)"WE%E;:",Y)4<C+CN!@'DCVB
M:.*:*2*6))$==KHRA@P]"._TK.TG0M+T-9/L%MM,A :1W:1V Z#<Q)P,\#/'
M84 4O"7A?_A&[243W?VR\G;?--Y811_LHH^ZH],FNBQ3?, Z]J<#D9H 6BBB
M@!,8I:** "N9\<:.=7\.2(D?F2PN)D7=MW8[9].A/KMKIJCE19(S&XRKY5E)
MZ@\&@#,\-ZDNJ>'[.Z63S"Z;6D X=E^5B/8D$U-?Z'I>J(ZWVG6MQNZF2(9_
M/J#TYKF_!6VPU'5=',@WQR?:/)52!#'DHB ?[J*W7J3ZUVM '$7OPPT>1O.T
MNZU'2;E!^[>VNW*H?78Q(YZ'BBVT_P >:.@A75-.UN,9(DNHC!-Z@$J2#Z=!
M^-=O28YZ9YH Y#_A+=7L98TU;PEJ" C]Y/9.MQ&G..3\IQWZ5@>#_$NBVFN7
MLMU?I;F[LK)(TF4J<KYO!)XSR.]>G <]*\^\+6MKJ>L:Q:ZE!#>6JV%@PBN$
M$B GSL_*<CL* .ZAO+>Y_P!1-'*/6.0'^1KD?'OB[^QK(:=IP:?6KX&&WBAY
M=,C&[\,]^^*YCQO_ ,(SX5O;&#3=*==1D<LT>GW+P?9X^K2&-" WLI!SZ&K_
M (=\&ZS;VL>N07YCU:Y_?&/5(!+Y ;DKE<-G&<D$>GK0!;\">"KRP/\ ;.N2
M++JDRAEB;GR25PS,QR3(W.1G:,D #%:OB;QM:Z/,VGVJ?:+[;DC=\L>>!D\\
MY[#T[5QVJ?$+QCH]S)IFJ:!#')+/Y,5]92@_*7QY@B)9@2N-H8=?7I5[PCJ?
MA"P,=U?ZK -8G(5A?!HC QY*KY@!ZCECDD]30!K^%O#MU96TNO7\!GU>>,M%
M%(2&4<M\V<[78DD_W0=N2!FNNM3+=V,#7UI'#<%0\D&?,$;=P&P,]^<51LEL
M+62_U6._:2&=A)(3<>9''@ ?+R=HXR0/6KMS:K=FW8O+&(91,!&<;L9 !]0<
M_I0 L,UQ)>SPR6VRW0*8Y2V=^>HQCC%0ZI<2:;ICR65B;F1<!+>/ +$G' X'
M&<GV!J_D9QT(Y(%5+Y756N ^8X8W;RBOWF X.>O&#T]: (=)L9=/L'2YN$N+
MJ5V>6?8%,C$\#C^Z,*,\X453CTBZ2QUDS"*:\OBY4*[*-NW"+G/&#GD>M<I<
M>+=<C@-U,=%EA@V,1'OW,S#<,?.>%! ;.<G.,56\._$;7-?N[U8[*R$-G;B5
M@J/NERKD..<1C,>-K#/S>E %,?#WQ%/#-'.MO%'*@CLUCU!R=)(4!WC;;F3?
MC)!VXQWJK=^"?%EC:2P27!GBCR'OH+J1KFXW,OSF/("  =B<<GGH=*W^,(^Q
MF[N=+*Q PIM#$,"V3*0".0GR9."/F'-69/BA-%J-R!807=DE]]FCGM9@^U"N
M5=L$C!/';'>@"PB^+;_RY/#NKZ?=Z'( N^X#&51@(ZK@#)4H6#'J7/'%5=6\
M)^*YM/TDV$L3WD5A-%*TEY)#LN'(Q* ,AN PP>!NXK+L/C7'<:5J%PVD+;SV
MTAVKO)2Z"YWA#_> V]2?O@UT&G>.=5EL(S?6-HMTNI1V5Q)#<*8E5^0X^8\Y
MPNW).2* ,R?PKXNDLV6]CBU#43D6M^FH/"+5]BA9#&HP^6&<'CY?<BIK;PSX
MDL]$U:RALM^H2S)+;7<VI.PVYRJ'C^#&#Q\V2:KGXM7XUJ_0Z-#_ &;;)<K%
M+]H'FS2PJ6VA,YY)4=.]:,7Q8TFXA9K81RD&[* 2@96!2P)_N;L<;L4 9$WA
M3Q7/<L;2*>TO=YDN+\ZDS)-)C]VRIC 5&^8K@9Y%>E^&X;NW\.V$%]"8KJ*%
M4E7S/,^8=?F/7ZUQ.A^/]=U*[LK.?08(+J6_$,\/VI"8H/+5C+UP<;N@]*])
M4?+^/7UH 7ZTM%% !VXKE!_R5IO^P$/_ $>:ZHXP<]*Y4?\ )6F_[ 0_]'F@
M#JZ*** $-9LV@Z7<:@;^2S1KLX)ER0W'3G/:M.L#4/%'V"\EM_[)U&X\O_EK
M##N0\9X- $\WA?1;DJT^GI(5X4NS''ZU&_@_P_(29-+B=CU+%CGZ\U/%KT$L
M,CK;W>Z/DHUNZD_3(J*U\20W,SQBROH\)N!DMV 8^@..O^- &M#"D$:QQKM1
M1A1GH*DIJL656*XR,X/44Z@ HHHH 0]#G'XUC^)]-35M"N;0RI%,5W02.Y4)
M*#E"<$<;@#C/.*V:CEBCF79(BNH.[#*",CIUH YCP5I^O6%K/_;)T_?+(9#]
MC!8O(3EG9C@<^F*Z1[F&+<KS1H54L=S@8'K]/>GI&D:[45%&>BK@54N-(L;L
M72SVZ2"[79-N!.Y<8*Y[#'I0!%JFJP6FE7-R&\Y47&V'#'G@=.W(Y]*Y3P[X
MVFNI=+T]M%>UM9 ($N/-#J2L2M\G'S#)(STXS71:3X0T71!,-.M/)6>,12CS
M7;<H&.[<<=ZG@\.:9;#3!#;(O]EQ-#9X)_=(5"D=>>!CF@#@;OXA_;]1LHX]
M*U%H[>6>YE-I+\JQPL4!?*_,K @X'/(I#\5;?48KFR-A?6GF8BBN+9@65VB1
MUYVG:3OQR#]WGKBO2I(+:UMG98(TC12Q5$ [9/:N!M_&NGGP;<:UI>FVT=U]
MH)GL_LVV0J9"@9E'))4 YYH M?\ "9W6F:1H9?3I+A[^1H<272^:57C>2% 8
ME<L>@&/I35\<Z5:-K^J+>WEQ#:R1P1V>0X=L?*85"CEN?XCTS@5SG_"Q[=Y=
M56^\-V]Y!ILCPH]O;JX*,2.,G[O"DXZXR,U>O/'5GHVI-;'1K;['!%%(JVML
M PD**PE SCRP'P&XY! H U=8\?6-PL6F6(OC=7MM'<P2VA5>&5GV[F!"MA&X
M8=,]*JQ_%O2[;3X[B]MYHHR' 9&\XKM"_P"LV_=SN'.,<=JIP^.XKC0M0O+7
M0+>WF34'MX5N;4('"H[[F&0<[$8=N6Q4=MXPM;7P?J6KQ^&],ED<1!(]/2(K
M)'(N0),-R058%<Y^[Q0!<MOBIH=G?WLEU+J30O.D<<3QC$0(X9<?PD98DGHI
MKL]3TVXU=[*:WU*2"T4EYHD0.EU&<':V>V 1QV:O.;[XB16]K?2S>$XHY;2$
MI*L\,7R-OC0*QW8"D2D?C]:Z/Q%X<L-6_LR\N!K(:XBBMQ#IEVR10J1]Y@I"
M[1DY(SP!0!GW.FZAX)U,W6AR37>E,ZF2S#AQ&,8"D]5'.5;DY 4\'<O?Z7JU
MKJUBMY:RAHB2I!X*L.JD=B*XP_"?0;=)YEO]:&Y/WFR_DS(H'0X/S<$\'UQ7
M)V\.I>"K:?6-%N;X:7>,FV/6!\B,"5(E& ^XY&TCK@;C@"@#TSQ+X9@UJ'SH
MXXEOXB&CDD&0=I# 'TY'#=5/J.#5T/Q"RZ;);:K,+>]MY/)8S_>Y("E@/<]1
MQC!S6)I_BOQ@+4W]UI^E:G8QNWFS:5,(Q&J@EMWG.,$=\U4\1:KX>UV: :OH
M>L6DT2B1;I+221=O4(SPA@Z'D8Y&/2@#J]6T*/5RMU:3R6UW$Q1'5<J>,8*Y
M&4.3G!'L0>:R=-U75Q97%E'"EQJZ1M+;_;+G>LW)&$81K\O&"",CG.1@F7PI
MXOT!;0:=+X@AEF21EB%PWDN4Z@ ,%) '&<?G6GJFFV.MQO)9Z@5NH7%S'):N
M'9)!PI[X!  (Z'!R* ..@M[;Q#=P>)=$6VL_$$/[F_TB\( E=6W;2,_*P<!@
MX!!ZXK/U,7>MF2TG,<&I:M<O;S1I.=MC*JIY8W8!.<;L8_BZ]JUHI+"?QA8Z
MCJ&B_9_$]L(XIKAV 5@<(WR[OF7!)5@,= 3GBLW7UU9/'5E<#0+2]L8;R.:U
M>UN%%Q-C/WM\@#$-G'H."<4 =/-XW_LR9O(TN$Z)!="P29+G]]Y@.P@0[<[0
M_&=W3G&.O=$9&">?I7EC7$!UY_$[?#?63>G&9O,B+$%-N?+\W&?^ Y_&KS^*
MO'MZ'?3/!CPQ,V(GOI(TV#/5@),]/0&@"[XI\->#X;N77-:?[.C)_I$*R[([
MO'(W(.6/ Z$9('6M3PA=RZSI2ZC<:0FG(Q*V494"1;?C;NX^4D@G;]*+OP5I
M&J^([;7K^-KB[MU 2.1BT2GUV'C/)[>A[5TBC!S_ $H 7MWKDM=O;RR\765R
MFA:M?6T%M(-]F(V4NY7J&8'("GI_>KKJ3. ?84 <K_PF=SG'_"'>)@2/^?>'
M^?FXK1M]5DU'1[BXDL[K3&PZB.^"HPXX;AB "2.<]JMW.L:?8S>3>W]I;2;#
M)MEG5#M'4X)'%>2W7AFZ@TUKZ7Q987]K*6:".ZO1Y$CN^95[ IA8\#)P=WK0
M!=EB\8WBO';7KI)%;M&\(U*(O< \(T>$.SL3G/' ]:>^G_$3[%I9M[N=)$N,
M7)-TC&2+'WW&S@]1@'GCI5"/P]<VES9WEQ<>'+*RMV5QJ\=SLDA#\B.-B=K!
M?X1(&X]35N?1O$,5NZS>(].,<T3Z<\<MR$+1Y!60$8Q-@G/;!&!0!9N(O'4.
MNFYU"^MIK1&C2U2UNEB&5/SM(&!^\H(*@\9Z]Z]&O+];#2YKQXY9?)C+M'"
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MR: -ND*!CDA2?<4[M10 W:!G  S[4ZD)P#[#-(751N)P.F>U "Y]N]<WXO\
M$J^'-.WQ1+->S,(X(2P ).?F;OM&.?I7/^+?B=9Z/J/]B:6#>ZQ)GY%4LD?K
MT^\W8 =Z=X?\"7$]_P#VSXID-_>+@0Q3N&"@<[G ^4GG@ 8'4#))( >"-'NM
M0G;Q%JSB>=V8P.5(5V.1YJ@]%(P$[[0IX)(JQXT\7-IY31M*8R:G<'8SH QM
ME/&['=CT ]LG%,\:^-?[/NUT31BTNIRA=XA(,B[^%5 ?XSC//"C!/%1Z3X4O
MM)BM=6>U34=8:12T,TY$=L&^^Z[NLF,9;J>@.,"@"SX)\-P:#)OO;E+C7+B)
M3(",&.(= !ZDY9CW8FM[2-)M/"NFW*&]GE@DN&F9[F3<4+X&T$]L]/K6IY4)
MF\PQIYVW8'V<[<]/I4-MY]W;R+J5K$A+D"+(<,H/!H I7_AZ*_UJQU62ZNXY
M;,$)%%,5C;/]X?Q4M[!8^)M+O-/2]8*Q\N5[64J\; @\,.A!_.K-Y-?QWUBE
MK9"XMI&87$QF"^4 ,J0O\63QQ3W@6TM+IK"UB%PX:0* %\R3&1N/J>.30!#;
M?9M$M+.QENB6($433/EY6 R>>Y/)ISV"Q:N=5>ZN"$@,7DF0^4!D$MM]>.ON
M:6WA-]:6DVJ6$*72;9/+<K)Y,G^RWK[BF17%[+K%Y9W%ABP2)#'<EP1(S9W+
MM]N/SH I:QIL/BO1_L]KJ]S:Q.W-Q83;6([@D>_:M-O):-M/\[]XT)7:K .%
MQMW>WUJC<+'X>LHAI.BHT<ERB-!9(L87>P#2$ =!G)]@:NFSMH[B6^CLHFOO
M+V&0(HD91T0MCIG\* (;*%="TL1WFHM+'&QQ/.0NU2> 3[# S[5#?Z/=7VL:
M??IJ]U:VUKEWM(>$G;/&\]QC/'X]J98&XURWOH=>T2*&V\XQ107#)/YR#^)E
MZ8SG'M46KZ]?:9K>FZ;;:!>WT-W]^[@&([;''SG'% %K4M=TW3;*Z:XOXHC
M1'(=W*.P!48]2&'YUSGASPE<7%U8Z[K\\]S>VUNL-K#.<F(8^_)GK*3R<< G
M@XJYIFA/>:LWB#6+>VCNF8-# D0#1@#"M(W5I N!Z#MTJ&YURX\1:G<Z'X>E
M:*&$A;W5(@&6%N"8TZ@OV]!]<4 =F.N,#..:=44,:Q11QJS%54 %FR3CO4M
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M$)!#1-JDX#?^/5OZ-X=TGP_&T6E:;:V:O@R&&,*7([D]S]:U>/?I0&!X'TH
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M#_T>: .LHHHH **** "BBB@ HHHH *R?$&DMK.D2V,=V]I*Y5HYT&2CJP8'
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M0!T&AB./4=16&8RQ@6X61VRS#RA@D]SBLCQ+XZAL;B;2M-4SZ@,(67!6)F'
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M\2_RK<'04M% !VKE!_R5IO\ L!#_ -'FNK[<5R@_Y*TW_8"'_H\T =71110
M5E:7_P A;6O^OE/_ $4E:AK+TO\ Y"VM?]?*?^BDH U:RM*_Y".L_P#7VO\
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MKNV!NK:20+)'<#"AMW0X3(.#R:Y/Q3X>U77]?CU+5H(]*M9;.;39FFG5@N_
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M2Z3X@LY7O-)U87+3LKR6VH$^6O(W"/ )3(/ QUKH+B<PW-K$HCVRNRDLX!&
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M_5%^;:29[<@#CYN).G/;WJHNNZBGB6\*^%]3>1;2+($T&-N]\$?O.O7BNQ/
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M^>U &D>E9<7_ "-=W_UY0_\ H<E:AZ<UGI;RKX@N+HK^Z>UBC4^I#.3_ #%
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MO81-;2I)&1G<AR,58(XQV/6N>G\)69OX[ZRNKK3YD;+?9I2$8;LD%&RN#T.
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M@G0AGCG_ %YH ZB&)HVE8R%P[94$8VCT]^<G/O4M1HJJ[E>2QRW-24 %%%%
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MSTH [6%65Y=R*H+?*1U88')J6D_K2T %%%)D4 +12 YHW#_(H 6BDS03CK0
MM%%)GGH: $9 PP0".N"*0QJRLK*I!Y((Z_YXIP.0#TSZT;A_^N@"*&UAMT$<
M,,4: [@L:!0#ZX%2%@H_^O3JH:O9C4M'O+%9VA,\+)YJ'E,CJ/I0!B:X]MJ_
MB.QT!U::)0;J\C7! 1?N!NX^?:P]<5U(SR37"^%-'\46>L7%YJMKH]O]K8-=
M26SO)),0I"@$X"A>.,'O7=%@.M "T44F1C- "T44FX4 +1132P'4'I0 ZBBD
MR* %HHI"0,YZ 9S0 M%':DSSB@!:*3.?_P!5+0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 (3BN2U;Q;?6&JW>GV7AZ[U">!HAF.54$BNI8LN[J%/!QZCUKKJY[Q/I%
MQ>VZ7^F\:M8Y>T8/M# D%D/!&& QTZXH S;?XD:,#C4EN=-/F^4GVF"3#'O\
MVW&!ZDXK<M_$VBW;!8=4LV)) 'GJ"<=< GD=.165X?\ %FC>,$N;58F2^M<K
M=6-W&"\!Z'.>",Y&1U[TYO!FA[)I-6@BO<%BD]RB(T,;#&Q2H7 ')]>: +]B
MPG\2ZA<Q@F)88K<N#E2P+,<?@ZUL[O7C'6N(;X:Z,(@-'OM3TFWD!\P6%T<2
M@X Y?=P,9X]:FDT?Q!'/<0Z9XR!D+JZQ7ENLS1H.@PI4X/J: .RX_+CZ4M<.
M+OQ_9#_2X?#]S&N&,PN'MPPSRN"&QQ_%D_2NB\/ZW!X@TF&_MO\ 529 ()*D
M@\E6P-R^^.: -:BBB@ KF-<\37NC:M# /#]Y=6#_ .LOX9%*QG!."@RQZ>G>
MNF) '/\ .DX/K0!ST?CGP\\QB:]>%E +&>VEB5<]/F=0/UK9M;^TOH_,M+J"
MX0]&AE#@_B*EGMXKE"D\4<J$<HZ @_G6%=>!O#=WMWZ4D>PY7[.[P@'&.B$=
MJ -XO\O ([^]>8>"KR\U/XFZMJ5W@--9311@+@JD5V\8!'K\M;NI: OAC1[O
M4+/7]3MK>W!F:&:97A/&"#E2V/H:BT6U6S^(%M:H@3R_#JJP#9.[SSG+ <G.
M<GJ3DF@#L;1YFFNA)C8DNV(!<87:O]<U:JG9S>;<7B^:)/*FV;=N-GRJ<9[]
M<Y]\=JN4 %9?B.>6V\-:E/"Y26.W=D<=B <5J5D>*/\ D5=5_P"O9^WM[T :
M%D6:PMV8DL8E))]<5#JLCQ:1>R1-ATMG96ZD':<?R%26'_(.MO\ KDG\A4.L
MX_L34 ?^?63/_?)]>* )[-BUI S?>,2DYZ].:JZW-+!8*\3%&^T0+D'J#(H/
MZ$U9L>+*V!_YXK_(53\0?\@V/_KZ@_\ 1JT :@X.!Z=*R-=NI[:*S:%ROF7D
M<;D 'Y2P!']/QK8K(UR-9(K/=-(JK=1$HF )#N&,D]@>?PH UL<$#_"LW6)Y
M[>*W>%MI:ZAC8_[+. ?ZBM(<CGG/K67KX_T*V_Z_;?\ ]&K0!J&LB_>Y&O:,
ML5R4A=YO.B"@B4!#MR3R,'GBMBL#5 S>)_#["X$81[@M$3CS/W1Z>N.M &\.
ME9UY<31ZQID"R8CF\WS!C[V%R*T1_6LF_P _V_H_MYW;_8H UAR :S7FN?[?
MBAC>(V_D%W0M\^<G!QCI6G6-(BMXLB?]X2MJ>5/R\L>H]>/YT ;-9MU<31ZW
MIUNCE8I8Y2Z@<$J%Q_,UI5E7I_XJ/2A_TSG_ ))0!J"L>^N98_%&D6BS!89X
M;AGC(R7*^7@Y[8R?SK9[<5E7DI'B'38@?DDAG8X7/39W_'IWH U.P['VK)US
M47L%L?+'S3W<<+8S]TG!YQ6O6#XHYATOC_F)P?\ H1H W1^'7M69K=^^G06L
MB;2TMW! 0QQP[A3CWY_2M,5EZX3]FMB(%E'VJ'AQP/G'S=1R.M &IQC\:R]7
MOKFSDL1#"'CFN4AF<G&P,<#ZYS6I_#G/XFL?7XT8:?*P):._AVD'IE@#W]#B
M@#8[]3U]*HS7TD.K6=IL5H[E9,MNY4J ?Z_I5WN?K61>[/\ A)-(.?G*S\9[
M;1VS0!L-]T\XXK/6]G.LS6>(A"ENDH;<=^XLP((Q@+P.<YZ\="='M6)%$/\
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MQ]FU*<:@9[)U7;I\-FKR%0 &4,TBABW/7% '26)'V"W_ .N2\?@*KZP<:)J
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M: "BBB@ [5'+*D:,SMA5!+'T&*>?J17)>)KM]4O8?#L#&-;@;[R=7 \N(<E
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M.Z-(6GVN/E& =H. > ,NIYQ56XU"7P[-9ZU+JEQJ5S>J%:VA8JBH6^1,;<;
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MD22=[>66<*%^8*1B,(J8QC)SFM'_ (1[XC)M5?&NG, !\S:0N>O^]Z4)X?\
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M@8+<@  ?=_=H<?K6C6;IDBO>:H @4K<A6.<[CY:<_P!/PK2H **** "DQ_\
M7I:* #%)BEHH 3'UHQ^?K2T4 )BC I:* $I:** "BBB@ I,4M% !1110 F*6
MBB@ Q1110 F*,4M% !^-)BEHH *,444 %)CZ\>]+10 4F/TI:* "BBB@!,?C
M2T44 %%%% "8I",XSG_"G44 )SUYJ,0J"[*H#.!N..6QQR:EHH YN\\">&K[
M3IM.FTN(6DTHGFBB)C$KC^)MI&[IWJGJ^G1Z?K,%]:SWKW=ZR6R6YNG,,2CA
MI/+!QQQD^]=>>AZ].M<AHI'B'Q1<:XBLVGVRFWL92^0S'B5E&/NG"X(/.* .
MN7HI]L=*=2#IW_&EH *0_6EHH BDDV+DAF&<?*,GK5/2[66QL5CNKD7$^]FE
MGV!-Y)."0..!@9[X%8GBVUFUBZT_0HK^[LEO/->::U;:RJH&5)!XSDC.#TK%
MM/!GB?09I3%K0\16#+L73]5=EPH((S)\PR,#G;V[4 0^(K+4KO4$L;C2[R=H
M&=[+4HI<.BL,DH5QM89*D=2JCN<U#]AUK^T8X[C3-MCY7DW$DEV?+7Y&VE%S
MMY8@$8[G=P:Z2]UJXDLA8ZSX:U!$O(&6X:U"S0Q!BR$,V0>G.0O1A7FVC^'C
M!X@EO/#/CIWL?GD?3IW>%D&WCK]_!&3A>@QQUH Z+1;"XTZY@VV7APDS0QO<
MPJSSJP8;HVD+'D ' ' P !@5+=ZZC:E*&F-ZE]OA6QBN/M/D3Y#(65,9C.W/
M;:,YZT7.C:R+"&WM='A\Z]B*F]M)]D4&]2K$*5R@(8MU/S<^U=;H%AH5F+K3
M-,L;>UFMT5;M;>'9\S#UV@,>.HH FTG2KK3K0R/?-=7<S*TKRH JX RJA0.@
MX&<_6M28G:RQLHDV_+N/3T)'7%4;B^TWPU9P+>77DPR2B&-I,L6=N@X%6A8V
MKZBFI^2@NEB,*R8YV$@D?F!0!7TN/5(HK@ZQ=6TS/*3$((S&D:=AR<D]SS45
MXNO-JT#VD^G+IF/WRSQN93S_  E6"_I4<SZ)XST[4-,\S[3;QR&WNE"D!74\
MKR,''MFI[OQ!I&F:K9Z/<WB17UT,6T!4DR8],# _'% #->TV/5]+GM5BMYKA
M1N@,^[$<H^ZVY2&4Y/5<'T-<_#H/B7P]$G]D:K#>P*-QL+Y>/]R.3JH&, MN
MK;6VTKPT=3U::;R5NYEFN97YY"A1T&<<5I7-C%>R6\K@[[>02HP]<'CZ<^U
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M*QV/I.H:EII1BV8[II$]QLD+*!U[5/X361K2\GEOY[QGN'0SSQ+&S;"5R-H
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M2EH \Z?XCZX"-OPY\1-D<_*!@^E-3XCZ\0?,^&_B!3@X 4'\.E>CT4 ><_\
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M-B+32]9 7">4S6KC /WMQ8'G'3%=A2'M0!P.A_$O0M5;['K*-I.IPGY[>^4
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M'B\9?\(](FG^+F6SF+!(M0 Q;7?'4'DJW7*_KS7:5!<VEM=Q>5<012H1C:Z
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MMZ8]JMT %%%% !1110 4444 %)@4M% !1110 4444 %%%% !1C%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% #'19 595//(*\&F?9H
M0<B.,9/90,_Y_I4U% $9A1EP1E3CJ.OUI60.NUE!7/0BGT4 0S6\<T6R105!
M#=^QS5"Y\.:5>21R7%H)&C<NAWL,,2"3P>^!^5:M% #57'3@>E.HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ,4GK2T4 90\.Z0NL+
MJZ:= FH*A43J-K8)S@XX-:O:BB@ HHHH *3I2T4 4M1TJRU:U>VU"VCN(7ZH
MXXXP1CTZ58@@CMX_+B4*@Z 5+10!2@TFRMM0EU".W1;R90DLW)+#.<?3/-7:
M** "D/IZTM% %.ZTVTO9[>>Y@622V?S(2W\#8QD=LTY=/MDOI+U8D%S*FQY<
M?,5'09]*M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
E10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>g2018030121531685831128.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531685831128.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -# H4# 2(  A$! Q$!_\0
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M=:RF*XO[6&0=4DF52/P)H MT50&MZ2>FJ61_[>$_QI1K6E'.-3L^.O[]?\:
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M/UJQ-K%C%HTVK1SK<6<4;2^9;L) P7KM(.#TH X72M+\.0Z-XDN="TS39+&
M;[61;=9%#B$%MI(.0#@X]<U!?^!_#^F:9I^NQ64+1I+:RS_N$,:Q$P[W(QT
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M,<C$]H\E[I OVLM,@$5K$9@NF1L S2LCR'*Y^4+G  'J,5Z[4%Y:0W]I):W
M<Q2##!)&0_FI!'X&@#R9[FT%J_[W25MXY+@0ZA_9L.+ET">7#C;C+;F.5Y.W
MBMWQ%!8V=EI3R66F:.MQ \LUP]A$X68*I6'##'S9;W^3 KN=/TZTTNT6ULX?
M+A!+8W%B2>22222?<FK5 'F%I!)+JMG<7&F:;#!+=PVTEA_9L?R;X2[$MC=D
M-_\ 7JIJ7AZVD^(;6ELUG QDWI&-/A;RD^SMR 5Y!([UZU10!Y%:W4ESKVEQ
M/I>A012I;YMY+9 ]R''SNJB,MP<C(8 ;>>*]*_X1S0_^@+IW_@*G^%:=% &9
M_P (YH?_ $!=._\  5/\*H^#(HX=#GBBC2.--1O0J(H"J/M,G  Z5T-8'A#_
M )!%U_V$KW_TIDH WZ*** "L#0/^0[XG_P"PA'_Z30UOUQUEJ5[9^)/$L=MH
MEY?H;Z,F2"6%0#]FAX^=U.?P[T -N?">I2ZR9(Y;#[)]M>]$SH6G!:)DV8QC
M:"P/7H,8K*LO &JP12&2:Q65VMR5661U!CW!F!8?+D-D*  " !Q74_V[JW_0
MIZI_W_M?_CM']NZM_P!"GJG_ '_M?_CM %'PAX4G\/O.;D6Y)A2!6CGFE,@7
M/S-YAPN?[JCCGFJ.E^!KRUT^.*X>Q%Q'<VCK)"#_ *N%P3R1D,1GVR:W/[=U
M;_H4]4_[_P!K_P#':/[=U;_H4]4_[_VO_P =H S?"G@^?0-0FFG:!U$31)(D
M\SO("Q;+*YVIVX4'G/-6+/1_$%F(]-CO+)-*BD9A*H)G=#DB,J1M')QN!S@=
M!FK7]NZM_P!"GJG_ '_M?_CM']NZM_T*>J?]_P"U_P#CM '.S_#ZX9M-"&T=
M(;.&UF5I9HU3RV+;T1" Y.3PV.@I]UX(U2Y\ZW\W3Q L-U'#-AO.D\YE;,G&
M.,8X)SQTK?\ [=U;_H4]4_[_ -K_ /':/[=U;_H4]4_[_P!K_P#': *Q\-W;
MZ9?61>U43:DEW$RY^X)$<AAC[WRD<>U,\,>&;W1-8U"YEEMQ:S9$4,3,W\1.
M[+#*<?P!BN2<8JY_;NK?]"GJG_?^U_\ CM']NZM_T*>J?]_[7_X[0!A/X(U$
M:EIMS!<6B&WD#2R MN*B5G VD%7^_P 9 *D9!I5\$:CY^N!;BUAM[V"2.)%+
M.-S-N#$,,H/4*Q!SG K<_MW5O^A3U3_O_:__ !VC^W=6_P"A3U3_ +_VO_QV
M@#GM1\%:QJC->W36#79N7E^S)<31Q;6C"??3#$C;GI@YQ[U./!>H0WMHD$E@
MUG'=VMV\D@?SE,2JI1,Y^4A01ELY9O7-;7]NZM_T*>J?]_[7_P".T?V[JW_0
MIZI_W_M?_CM %77-*U/Q%HVGGR;>"XCE,DT$LK)QM9>)%&Y3R#QC(R,X-9&F
M^!-2L-4T>Y%S:8LXT2>16<M)M# #8P*G@C#?*PR1DUT/]NZM_P!"GJG_ '_M
M?_CM']NZM_T*>J?]_P"U_P#CM ":OX>EU/Q%IE\)T6T@S]J@8',N.8\?1LYS
MV-<K)\-[X6\/^E6]W,OG1.)9YH5\MBH0YC(+,JQJ"#P?45U?]NZM_P!"GJG_
M '_M?_CM']NZM_T*>J?]_P"U_P#CM &3<^"KJ668B:U>-HKE%1]X!\Q8@N2#
MD?ZHY(.1D=:M:?X9OH?!5_HMU<PO/="4(<EE0,, %L O_O$9.>_6KG]NZM_T
M*>J?]_[7_P".T?V[JW_0IZI_W_M?_CM &3K?@:.;3[2TT6TT^UC1F,Z -"&)
M3;N#1C=D>F1GH3BJ<OAB[T32&N"D=[=12VKHD4#2>9Y480A@!G!()[XXKHO[
M=U;_ *%/5/\ O_:__':/[=U;_H4]4_[_ -K_ /': .6L/"&K7.D1LT-E;/>0
MR0W$4JD-;*TK/NB !^;#=#CD ^U;?B?PM>ZQJ>GW5G+;Q& *KR2%MP 8-]W!
M5P<=& P<$$5>_MW5O^A3U3_O_:__ !VC^W=6_P"A3U3_ +_VO_QV@#,N_!US
M-YCP36L<[75W/O:/=D2HRJ#D<XR,YXXK.L/ .HV_VAGGM4\^7S-BRR2[?]':
M+&YAD\D'L!T KI/[=U;_ *%/5/\ O_:__':/[=U;_H4]4_[_ -K_ /': *>M
M>&[^[MK$6;6,DL%H]I(EVK%,.H!=< \C'3N.XK,M_ -S!K,=P\EO+#^[D:1I
MIMR,L0CVK&#L(X!R>>2,&M_^W=6_Z%/5/^_]K_\ ':/[=U;_ *%/5/\ O_:_
M_': .:LO %_#J-O<3M9,!Y3.RW$X\MHTV@*@(5@< Y;ID\&KC> W:!8V-D=N
MG0VG,?&Y)O,8].A'ZUL_V[JW_0IZI_W_ +7_ ..T?V[JW_0IZI_W_M?_ ([0
M!DW_ (*N+IIPDMJL4DMTX0J<!9410,?\!.?K4.L>!;F\NIKBV:U(:X$B6[2R
MP(1Y"Q'+1X((*Y]"#BMS^W=6_P"A3U3_ +_VO_QVC^W=6_Z%/5/^_P#:_P#Q
MV@"MJ7A::[T73;"*6%/LD3QMN#%3NB9.,DG&6[GI3[3PS):KK21O B7]I%!&
MJ*0$*QE"3[<BIO[=U;_H4]4_[_VO_P =H_MW5O\ H4]4_P"_]K_\=H YK4_
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M16!_;NK?]"GJG_?^U_\ CM']NZM_T*>J?]_[7_X[0!OU@>$/^01=?]A*]_\
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M=9#HUG%H$>C,F^T6 0%3_$N,?G6=;>#[&WN(;F2ZO;JYAG299KB4,WRHR*O
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M6XNUVJB@'<K[?F)W  8'.<XK2F\(V-S%;K<W%[.\,>SS9)LN^75R6..N5'3
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MMH[EM[.FY1\AQG@UWK^$-/EO(KN1I&N(E*1R'&5!Z@5./#EN.EQ,/IC_  H
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MZ_G6U0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'0?XT?VWXA_Z%*?_ ,#H/\: .BHKG?[;\0_]"E/_ .!T'^-']M^(?^A2G_\
M Z#_ !H Z*BN=_MOQ#_T*4__ ('0?XT?VWXA_P"A2G_\#H/\: .BHKG?[;\0
M_P#0I3_^!T'^-']M^(?^A2G_ / Z#_&@#HJ*YW^V_$/_ $*4_P#X'0?XT?VW
MXA_Z%*?_ ,#H/\: .BHKG?[;\0_]"E/_ .!T'^-']M^(?^A2G_\  Z#_ !H
MZ*BN=_MOQ#_T*4__ ('0?XT?VWXA_P"A2G_\#H/\: .BHKG?[;\0_P#0I3_^
M!T'^-']M^(?^A2G_ / Z#_&@#HJ*YW^V_$/_ $*4_P#X'0?XT?VWXA_Z%*?_
M ,#H/\: .BHKG?[;\0_]"E/_ .!T'^-']M^(?^A2G_\  Z#_ !H Z*BN=_MO
MQ#_T*4__ ('0?XT?VWXA_P"A2G_\#H/\: .BHKG?[;\0_P#0I3_^!T'^-']M
M^(?^A2G_ / Z#_&@#HJ*YW^V_$/_ $*4_P#X'0?XT?VWXA_Z%*?_ ,#H/\:
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MD9'!QZB@#HJ*** "L#0/^0[XG_["$?\ Z30UOU@:!_R'?$__ &$(_P#TFAH
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M=]-745@^924\T18_/;C\*9;ZQX;NY8H;;4-+FDD8)&D<L;%B@#   \D<$>E
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MWX>6DUAX12SN+N2\F@O+N.2YD^],PN) 6/)Y/7K0!U-%%% !6!H'_(=\3_\
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MG#W,QCD3SQ^[&0 >1WS_ !!>01Z9 .:_X5IK)T-;'[39+(- DTTD,V/-:82
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M36LOAZWU>*WN'%RPCAMP )'DW%=HR<=0><XP,YQ5'3?$UYK/B1+*VL3;V=O
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M7!N95 639G=M&<X&.N*Q;[QW+!!NBT6Z211YLBS/'\D!1F$APQX^7&.OMR*
M.F;1M-.TK8VZ.BD1NL2Y3)!XXXY /U J:QLHM/M$MH=Q5<DLQRS,3DL3W)))
M-<?_ ,+(MK*U@CU;3[FWU+ \^V&P[?E!9A\QR,G 7.[MBMZR\1PWECJ%_P#9
M+F*RLS(//D"@2^66#E1G. 5/)QF@#:HKE;WQQ;VTHA@TN^NYA'YKQQ>6#&OE
M^82Q9@!A2OXL *JZA\0K>T%O<BSG33W<YN90H$@"XP@W9SO:-<D8Y/- ':45
MQ3_$%+BQ9]+TB\N;KR6?82@1&W;%#,6 .6(^Z3D5!?\ Q,LK7[5"T0MY[;;Y
MCRNKH/G".,(Q;()(Z<D4 =Y17*3^-!'-"L>F7<SS*ABMT$>]]Y<JVXO@#9&S
M$'D CZ4G_"<030PR06%VL4Y\K[0ZILBF*EMK#<"V "3MR/>@#K**Y6?6+\>%
M]#OKE$6ZNY[?S5C+(H#\],YZ8X)-0>%/$FKZI=6,>IK9%;_3C?1"VC93'AU7
M:2S'=D.#GCH: .QHKS>\UG6;#QAKVW5(F"/'';6IMIIR$\H.=L2.-QY&6XQ^
M.*9/\1M231[0I9VG]I7DEL84;=Y8AEPK2'G)"L>>G44 >ET5Q=KX@UV7Q0F@
M2-IQEB9FN+E8GPZ!58!5W_*WS$')/8]\5>U_6]2M+Z>WT[[&HL[+[;,;E6/F
M+N(V*01M^Z?F.<9'% '345QGA:XU"[A\1:C=WSREKEU@C^91"@0$ *6(!^;G
M&.:9_:-[_P _<W_?5 ';45Q/]HWO_/W-_P!]4?VC>_\ /W-_WU0!VU%8.@7-
MQ<33B:9Y %&-QSCK7&Z/K_B&W_MV5[VUN3932W$_V@28=!(ZA(QOPF AYYY(
MX[T >H45@>%M5O\ 6=/GU"\^S) \KK!%&C!D56(^=B3DG&> ,>]<I=>/=8BN
MF@MOL%P9U4VTOV:9(ES/''PY/[T8DZJ!R* /2JP/"'_((NO^PE>_^E,E2^'-
M3O=0CU"&_P#(-S8WC6K20(520!58,%))'#8QD]*B\(?\@BZ_["5[_P"E,E &
M_1110 5@:!_R'?$__80C_P#2:&M^L#0/^0[XG_["$?\ Z30T 6EO]"L=8GM1
M>64.I7)$DL)E42287J5SGA5_(5CS_P#""ZHJ)+=:3,'N,KMN5^:5\<<-SNXX
M[UE:]X=\1ZGK;&.*+[&MVLZ%)DC1EVX^9=I8R#)^;<!@8I?^$+OUTV.%+>U6
M5=(M+/(8#]Y&X9N<=.#@T :TFF^!WU6ZED72S>6Q#SJTJ_N3PH)7.%Z@=!UH
MNK/P3I5A-IEY)IUK TH:2.:YVL' !');<" 1CGH?>L*]\'ZS?6*Z:;:VB2R2
MX,5R)O\ C[:1MP!&,KZDG/(JW:^&]7N_%5UK5_8VT"SB3;%YPD*$P1QCG'JK
M=.U '0:)J&A737NA:5Y)CL L<L49!7#KD8P>0<\GUS5?4[3P?%=:?9ZF=.BG
M@5([6&:8(VW("J%S\PR!@'(J#P;H>H:%)=17D,0CDAM]DD<F?F2,(RXQVQUI
MNO>&[K4;[5[B*&!C<V,4$3.>=RN6(/' Z&@"CK=OX(L+^\U:XEM/.LHY/MUM
M%(K%UD 4AD)XY(/&,GK6Y'X2\-3Z>$CTZ%K:5EG#*[98[=H;=G)^7 Z]*Y:^
M\(:W=::-,6UMD%FERT5SYW-TTF<*1C*_>R2<\J*[RXMY;_1);9A]FFGMS&<-
MN\LE<=1UQ0!D:?;>$)-32\TYM-:[C?R%,$H.UPO0*#C=M![9Q5W3Y] TJ&ST
MVQN;.".?<;6!9A\_/S;!GG!]*XJR\$ZQ);M:W8DB+016ANGO%D,:(=VZ-51<
M=,#)R,FMRUTC5;76+:<Z78RPR000R R#;:>2S?,@QD[@P(Z8P,T 7;6Q\)PM
M>Z;;#3PT4+)=0+*"8XR2Q##/RKDD^V:CB?P;:/\ \)'#<:8N]C$+M9UV%\<@
M<[=Q [<URLW@#6+F*YL7GGV1BX:WN'NU\MC(2<>6$W#.>=Q(R,\U:M/#.NVF
MH'6C9&ZN9/,BDM;R^5RP9%42;E0*"-N, 9(/6@#5O-0\'>(K.UU+5V@AC"X@
MDNK@0MAE#$#:^>F,@U:N[7P8\VFV=TVF"2.-39Q-, 60],#/S*2.^0:Q/#G@
MS4]/OM'EO8+7R[1F:0*^X+FW6,;1CU!_"L*UTO4=+6T\-/91W5S+/9S22J&(
MM_+"@J#MP0 N00W&X\4 =[J__"-:,MA;ZA;6Z)=3O# C*,;Y 2W!/0]/Q%9^
MDIX&O]*F%LEB(8E:6YBFE!>($;29,L2.!CD]*V/$=A=W@TV2SA29[6\69T9]
MF5VLIP<=1NS^%<E>>!M3ETC3K> 0PRVMLP<12!=[B99 H.".<'D@X..* .LM
M-(\.:D;C5+."TN5OHS'+/$V]9%Z$<'';!QZ5FS6/@274KMYFTIKN %[A6N!F
M+& 6*YPO4 G Z\U>\):5=:9973WJ2I<75P9G$MP)F^ZJY)557)V]A^M<9JGA
M#Q/JUP1/!;^6@F0+YR+"0Y!!2,)E> -VXDDG- '66<GA^Y\16EY;ZU9SR);-
M;V-K'+&=B@C>5QR?N@'TV_6KLUYX=U^$6\EY8WB)<JH59P=LPR5 P?O<$X]C
M6#J'A"\NKB[,*P0B?5!<^8IP0GV=H\].N2./2J3>&M=DN[#4_P"S;6&;2UMX
MH[6.X&VY";@6!QA>&X!]Z .@@E\'Z3J[W$-UIEO?W3%#_I"AF.X@@ GCY@<X
M[CUI+2#PSXQM;JZCMHKA3<E)GSAC)&-F<J<]/?D5S=MX*U<Z?K7VBVM%N;V(
MK$!)NVDW,LN,XZ8=?QKK_#%C>:;975M=PHA^V2R1NK[A(C-N!Z<=<8]J *HM
MO![:HTZMIOVS34 ?;, 8%7@%USCCU(XJLEKX#2SNM35])^RW#M%-<&=2FYCN
M*YSA23S@8]:Y[5_#6L06.N"*U"6+VUP%@\T3K(TC CRUV[T!.2P)(.>*EO?"
MVOWFJ+KL=N;.9=L0L+6[13M",N\.R%<G=C&.@ZT =A8_\(_I*_V1926<;/&U
MQ]F$H+R*<Y8Y.6!]37-:;+X('B:WTJRTV+[>\:SAO,1A%CYU7ER3C:#A00*D
MT#PSJ>B%K(V-K/;RJ)!=23[WMV\@1^6N5R>1][@88\52;P-JTTMDK-#"J6BP
M22*^2A\F5"1QSRZT ;EY:^!]4LKB[NGTN:UCE?SY?/&T.^ P8@]\#@^E:5L=
M'\5>'U_T=9M.9V1%<8_U;%<@@\<KP0:XZP\)Z[:7=MJCVK3W-CY<:V]Q?*RS
M*H897:BA<;N,Y.,CBNK\-Z7?:;X3-E/#;0W9:X<1(=T2%Y'91[C#"@#&N/\
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M?7M^498/-2,@#+J$12,9WD\=0:O6]EX*U37&TZUM+6YN+>V^;R7W1QJ,Q[2
M<!L$CIG&:P].\":O%X<DLIUMXKN2[LI#)')DJD2H'(..VUL#W[9K;\,:+JME
MK,$U]8VUO#:Z8E@LD4V]IF5L[L8X!'.#SDF@"[JEEX0?56?4VL!>I#O=)9PI
M$8!&XKG& "><5%))X2N;HNZ6DD<EH]RUUO'DF,!8FRV<= H_"J6O^%-0U&\U
M>YMV"--)9RPE) KR>3N++D@A>O!((]JSH/"FO6HN;R"&,W,\;%DNKA9GW&5"
M>=@0,54D'& ?6@#3B/@BXO\ 2]+MI(+B299I[5XKHL/D*[QN#Y/TY'RGTK2U
M&?PCK5FNH7UWIUQ:VLFWSS<#8C?W20<<^AKD[7P7K[O=?: $-]%>PO,URKR0
M^<D85R0H#$%"#@#J*GL?"^NV=_;ZRUFT]U;%4-K<WR-YJA2H(*HJKMSQD$XS
MTH Z[3[_ $B3PN]];Q+'I>R5V5E !7+;CUQ@G)_&L:QM_ LVG::T:V$<5_E[
M6.68!I2P"D8+?-V&.:T_#^D75CX-33+F."&Y,<JE(3F-"S,0![<BN:;PSKC:
M4;+^S[;=>V,-E+*UP";3RRWSCCY@0VX 8((H Z?5-%T*,"[NK'+^<9-\3,K%
MVQDD@C/04U=2T=-/:P6U<6C(R-%L&TJV<CKWR?SI?%M[;Z=HBRW3LL?FJN5C
M9SG![*":X?\ X2G1_P#GXF_\ YO_ (B@#J+.V\*V$<D=KI?EK(K*_P I)8,%
M!!).>B*/P%-:T\*/<7$[:5^]N%*R-M/0D$XY^7E5/&.0*YG_ (2G1_\ GXF_
M\ YO_B*/^$IT?_GXF_\  .;_ .(H [VTT+19]+:.*Q'V>=5#!V8LP5LKDDYX
M//6HM/T'PS<RG5+"VM9V>0N)XW\Q=P;)QR0/F[#O3(]2V^ I=1LA)*RVDCPA
M8VW,P!Q\I&>OM7)R:-KVG0S2:>+A(/L4=K9F*Y;!)55'R8^3')R1P1G)SB@#
MNXO#^DP>68K&)3']PX/R_(4X_P" DC\:YK5OA_87%Y)>MJ3V4?E?9XQ%&BB-
M6 3J>IQ\H)Y&:RYO"_BPRV@M[J>WM-Y<0"\,KVS9'S%V(WY )QR!DC'2M6QT
M/7EF:659(Y'N0;AFU!Y!,JEFW*O1 3L7:,<9S0!TZKI>JP^2C6]U':3 %58,
M(I$[''0CTI]KI&GV3V[VUI'$UO ;:$J/N1D@[1[94?E7&>%="N[/4ET]))X[
M"TCBENQYLF'N\,65"W5,MN)'!X]ZU=4TG6;OQ$\\&Y8TC!MKD7C(L1 .5,0X
M?+<DGMZ8H U+_P ,:+J<TDUYI\4LLCAW?)#,0H7D@^@ Q[4B>'=!)\E-/M28
M;<VNT*,I$QW%/8$\UR,7A/7;E<7!N+>V6*1_LXU65F>X"!5=G!!P26.T8 VC
MBI8/".K)=W=P6E241R/&WVYR+B;:JQEP#T 4G'J30!U]AX?TK2S&;*RCB:+=
MM89+?-C=R>3G Z^E)J.BZ1K<R&^M8;F2V; R>5S@X..HZ'!XKA].\,^*4@6*
M^#20/.S+$NHR1M <(!(6!);&'^4''3CK74:9I%W8:/JXBC,=_=SSR*S7!?<3
MD(V3]WC' ]* -273(TL+Z&Q"VTMUO<R*H/[QAC<0>">GY5Q__"&>)/\ H91_
MX!Q?_$U$/#?B71@5TIY;M#'L"W&HN3YAA"^82V<_/N.![&E?P7J\J/))>79G
M9),E=2E52<JL8P#P H+<=SSF@!4\(^()2XC\4HY1MK;;6$[3Z'CKR*?_ ,(9
MXD_Z&4?^ <7_ ,34=MX:\210ZQ);NUG>W"2E93=F19G=PRD+T3:H*YZDFKGA
MGPWJ\-U;2ZO<70AM49HH/M9(\QG_ (L$[@ H(R3]XT :GAK0]4TB>X?4-4%Z
MLB@(/)1-I!/]T#-7)_"VAW,D4DNFP,T4C2J<'[S-N)/KEN<'C-8VO:3KUWKX
MGL]QC41M;S+=M&L&TY=6C'#E\;<GH#[5I6&C7>F>%&L;>[FDU)X#NN)YFD)F
M*X)R<X&>F!@>E &G'%8Z9;F-1#;PLSN02 "3EF//XDUEV_@_PT&2Z@TRV8L1
M(D@);^)7&.>FY5.!QQ7)3^#=9O[81O;R0(0_E+)J;RM;.55#(6/WMPW_ "]!
MQZFG7/A+Q+;W<$6GW4J:;%.S11I=,S0C<-K$NW/R@?*<@<\4 >AV]G;6C3M;
MPK&UQ*9I2H^^Y &3[X _*L?PA_R"+K_L)7O_ *4R5/X<TF;2]/8W<\TU[<.T
ML[23M( 220JYX  .. .E0>$/^01=?]A*]_\ 2F2@#?HHHH *P- _Y#OB?_L(
M1_\ I-#6_6!H'_(=\3_]A"/_ -)H: ,G5_'S:5J5]$+!+BWM&*$13YG<B/>2
M(\<*#A2Q..15:+Q[J5U9NT&E6HFB@FN)GEN2L:QIT(^7<<GCH.E._P"$CT;2
M-5U&W&C3EO[2%I/,87=I3*AD.WY26&1C8,]C6K!XB\+1VT*VZQK;W"_,([-@
ML:EMO[W"XC^8$?-CD4 8J>,M8MU,9@LKJ>*)GG=KDK%MC$89DPF22\FW!X^6
ME3XBW=U=S6]EHVYS*L$ FE*?.75/G^4X')(QGA><5UM]>:1I:JMVL,2M%(X'
ME9!5!O;H/09Q[5EGQ)X7A>.[B19)[F)+E6M[-GD=&!(;Y5SP!D^G&>HH C\.
M^(-2UO5&,J645G%;9E2.8L_F;V (RH^4A3SQ67<_$.]MS;_\2=6^U-(]N%F+
M;X5?;G.W 9N"!G&#R16TOBSPW'+*;9C(RJBEK:T=]^[YE0%5^9B#NVCG&3ZU
MFP>,] O[,3WUG&D$4PB@C,#2R;S(R+A G!.SH.1T- &5;>/=3M]<N([FV-Q#
M/-NAC5L+% '9 5.T98[&8Y.,8P1FKDGQ#OH)+-)M%4/=*)U1)BQ,)8J,';C>
M<$XSC&,GFM2Z\4^$Q!;W-P@=$5F#&Q=C; -L.\;<Q_,"/FQR#Z5=U[4-/T^3
M1Q<:9]K^U72V\+"#?Y.03N^Z<=!Z?I0!A1^.]1RHN=/T^V%RBR6LLMZ1&%+,
M 96V_+E5W#&>N*4>/Y)-46P;3VC00AKF>-\^63'O+ID890,<G!]JWK35M UJ
MYDTZ)(YB%RJRVQ$<JH<$H6&UPIXXSBLG5=3\/ZEK%_HVJ6\D,L;1P&[C1AD.
MN0K2J/W8/(P3SS0!6UC[=-\/]&EU#4Y8[EKJS>>Y4(I.95Y/R[0 ".PZ4_3=
M>OIO$-JK:F)GN+N>";3-B?Z/&@;:_ W?PKDDX._C%=!IVKZ/K*M8VX\R-(PR
MQS0,JR1@X#)N&'7/<9'2HIO$'AZR#:C))%&SM)"9A"=S&/[RYQDXQQZ]J .<
M\4^)-9L?$TMI:2""*WAADAWRPQQSLS'<'\SYF   _=\@GGM5;4/$VK0:+K$R
M:LJ_9(@+.Y\I2+E3( TV,8.SE>.#][N*ZF?Q!H4T$%Y/!-+,LK1Q1-8R-<*X
M +8CV[Q@8)..F*S=?U_PW/IT%CY'VV&Y,*)Y",L:J[#:#(!A<XSM)!.* .;U
M;Q)J=G=7:6NJI>"T@N#;:@T4;%CLA)&5 4[2Q''L#R*OIKVO6WBK^SFNWD6W
MO([;%S+;H)XR 2Y4 2%N3@J-OR].IK<U;Q#INAZW;:.^EJ+8P--)*(&VH"P
M5%5"&9F(&,CG'4\5;M_$6@7^JVJPHTFH2JP3-F_FQ!3M8/E<I@]=V.OO0!7\
M0DC4A@D?NQT/N:RMS?WF_.I=?MM)UGQ')$VLZK;3PJ(I%MC*L*L%W[2R_+OV
MG.,YQBLF;0]#@@BF?Q/K966%9HPD\S,ZLP5=JCDDD@8ZT :.YO[S?G4MJS?;
M(/F;_6+W]ZYJYM-&L[^**;7M>^RRV0O%N4GG?:NXJ=RCE0,<DXQ6Y<^&]-T"
MXLKBZU_6I&>0-%$DTLQDV_,?E7)*@=3TQ0!T7BG4IK)+&&WNC;//,6>0!?\
M5QH7898$#(7&<<9K!7XA7+6%N_V.P2XE,K'S+W;&JQA<\[<EB6"A0.3STYK7
M_MGPWK!M-9%X[I;E8D;#JA\Y1@,N.001UZ53_MOP?#<FX:W>-X$188VL9%#!
MG(5HDV_,2W&Y0>WM0!2@^),EU<3K'I1AA!V1R74GE"-]P7]Z2,*N2>1GI[BE
MU#Q-K%]%';::]O#?2F&$M%,)(@9'8[T)0Y^2,D9'\7(K4G\2>%(Y;EKJ 1;X
MV>66:P=5E"8+#<5PY'&1R>/:HG\6Z/=7ECI]O;72_;'>!Y/LTD#VVV/<&.5!
M7Y3P>,#GM0!:TKQ4+[1+C5'@V6EM "\C,26E ^=< = <#/KD8XKGH/B1J5W:
M7$EMI-HTEJLLMP7N711&BJ?E^3)8EB,8QQUKH+#Q!X<LM)%I;-*MM"BI'$]O
M)NG5C@% 1F7<>ZYR35ZVO="70Y-0A2W@L(U;S<P^7Y>/O*RD @@]01G- &?X
ML\72>'([)8[$SSW6XX9B%0* 2"0#R<X']*KW'C=X;?4)5LH6-HJD(;D RER
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MXT@C6RC5]SQS-&IP^0/XG6K6I^*]!^U66GR01W4,DXC,DD)\B+$;/D.5VD@
M< Y&:E_X2OPY';EMLBF65$$'V&022L1E"$V[F!"\'&.* ,0?$66.6]B-@62U
M#1+-(2I:56"_, O 9LXQGMQ4EC\0Y;PZ;_H5LHNBXES<$%<,0" 5S@@9YQGD
M#D5:MO%/AVYTH:I>:8\+72R&938.["-&P7DPF=G Y/'Y5/!X@T9H9YQ8VZ2V
M;3QPX3<!''U?<JG8IS^N.: $;6=:C^'C:N7L&U Q&5'0EXRI)VXP!DX(&..>
M]51JNJCQM:V3ZE'+:)L@>W@DC\UI/++.[IL)"YV]&7J.M:<7BSP\)SIQD$0B
M?RFS;NL".$W[-Y4+G:,XSVJSH^M:+K-_.UE&PO8XU:0RVK12>6WW3\R@E3CB
M@#F]4\=W,&HD0"S%O%+,IC\XM,VSY/WB!3L4R$8.2<5+:?$)[C3X9GL(TFG1
MVA!F(1O+<B1B2N555 ;)'?%7O%6N:9X<BO9I-*ANI6M?.>-(R7F^=4 ;"'Y<
ML,D]/2I9;C1]$>+4;RVGCN)[7'D00R3+!$,%\*J_(N2-QP,\9H BLO&$LWA&
M_P!:N+2!9+4LJQ17&Y7?@!2Q Q\Q SCOGFL\^.[Z1;A$L+3%O'(\]Q'=[HP!
MM";#M^8EFV],95JT;W5_"G]BVZ,5:QFNUCB@M8'/F3 AP B#)Z ],'CUJ-O%
M6D)$L5C9QR1X5&@:,PO&?.$9#(R<88YP>?;G- %.;QU=VS-%'96US(28((OM
M0$[2AE3]XNW"*S' /7IQSQ?\0^(=2T:33!Y=B&=7DN4,Y ZJB@$K]W<X)8XP
M%-1ZAXP\/:<+FY2UW3AE9F:U:/SP'"ET<KB3:6'3/;UJ>7Q9HMS>1I+ &A^S
MSF:2YB*/#L* HT;+N^;>.._OF@"*3Q-?W'A>XN[=;".^6[%I$YN"UO(2RC<K
M[>1R1TZJ:Q(OB!JEA8A[ZRAN'NL36K1R'Y8W=]GF +\HVJ<$9)QZUVNF7.EZ
MK8F*U@40P/M:VEMS&8F'(!C8 KV(XJ/Q!/9Z;H\MS/I\5U&&C1HB@PPW #L>
MF<@4 9][KUQ-H>D3M(-(_M&0+--*5)MQL9N"?EW': ">.>G:LIO&-SI<-QY6
M_6+.TC,TM[(!&Y!?8BJJKA\GG< !@$_6RWBVUD\(:EJ<^A.;"TN#;Q6QB8F5
M58+DH4^7GTR!CK5FR\7:+<7EYIUS;_9/*G:TS+"?*<+&'P6VA5.TGY"<X!H
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MVE;(\S>9Q(K9&XD'/W2,8.:S4U_4+_3-&,^M_P!HM=RPRW,01%^RLMS&%^Z
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MUZ@]0>*YZPFG?0BL<VKOJ+7=K]O64R;4D,N) A/3CJ%^4#;4.@6EWIEQ::5
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MI\6NM!9OID@,CVB*1/%%S\^\MM8\9*[1UX/',7_"Q+!!$UQ8W-NI2.68R21
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M4)'"I:1R1,2"I8,6#[0, ]3D'BJ5IX.T76[.-+77)+W1$D<BUA9&C+M&R/\
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M''%'"F!'N7:VQ06(W8)// J1_A[8F[%S%=.DCN6F+012%P7+8!93LQN(RO-
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MP4*NX$#DY/!_"L6\\6:GX?-S;7:VFH+8PB26[$NQGW.R("H4@-P"W0=<#H*
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M0G*(,QC@GY2>#C-+'X]O96G:QT>TDDAM9[J[E:9T218MO^K)3+9#<$@8((H
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M<&VWJ]NPE"MD [<C![XR/J*HPZS=Z9HL][]HOYG,B(/[>1;54X))4)'N;/3
M!YQTYH YNS&J6FIZ:SG4KF1)5BBMY3.K!!,P+*X^1AL.6\WG"\'D5WOC 79\
M+7ALC,)T,;CR,[]JR*6QCD_*#P.M<Y9_$#4-1@22UTJV/RQH=]RP#2R2&-0O
MR?=R-Q)P<=L\5:A\7ZS<75WIT6D6AU*SDD\U#=,(S&BH<JVS.27  ('N: ,*
M6*Z\1>)-2FW:P-,*SR6P5IH%8B"$+@<'[VX@>N:J%=1N5L6N8]4?Q$MW$\&4
MD\H0B/Y6;^ <]2?FW>U>A?\ "0K(-!D@MRT6JMP6;!C'EE_QZ8KG8O'NHSQ2
M7B:3;+8VRQO=.UR=X5Y"GR+MY( SR10!SFDVVL7DME;SS7WD27%NM]'%]J4[
M\/O+.Y&,]"$^7ICM7?>+5DCT:V2/[2+-;F(7GV<N9/(_BP5^;TSCG&:YS4/'
M>IV5Q9:A/:PPZ7<P3-;H)-S2-O1$\SY<I][/RYX/<\5H:/XUO=9U.VL+>PMB
MY+F>?S7$6Q=O,>4!;.['(&"#]: *OA>SN;KQ"LLYU(Z=!#(]@)Y)%&WS2%+
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M<DH6/5@3@@=O:H_B#I.IZM/Y-GI"W*M:,L=P(HY&60D_+^\8>6,8.]06S]*
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MY7.6$8;;*03]YR,CW%6%\#WTMCJ+S:9)-,UI MF9Q&KQ$7$KE%"G$>%9> >
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M)[=*:?!'AVT61IO.6"4L6CFNW\O>R;-P!.-VWC/6N.TGPOK-G)IKOI$@NTE
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M.?8BJ<>AWCZE;E-#DAN7NK6XAOSY8^RP(J[XC@Y4X5UVKE3NSGDT ="X\/\
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M#[/E''# \U%JWBW6[;4$M;.!+AK>TBN)VMX/,BG+DY <N/+7Y3@\]:O76O\
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M-Y<KO#'>B[H78K@$!^>G.. :K-?_  X>S2T;^RC;H_F+&8> V,9Z=<<5;O\
MQ'X&U2U2UOKNPN((SE(Y(R54XQP,<<4 8$?CO7I[EXX+42_866.=H[;,5P3(
MR%MY<>6,)D?>YXK7?Q7J8LKI@+99[*-8+DLIV+</+L!SG[JA22.^Y>:<^K_#
MV1[-WDTQFLU"6Y,/^J4= .. *2QUWP;:6M[#+K,-W]NE:6Y:X7)E) &" H&
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M *#-O_X]_A1_PG?AC_H,V_\ X]_A0!T5(0",$ CWKGO^$[\,?]!FW_\ 'O\
M"C_A._#'_09M_P#Q[_"@#HJP/"'_ ""+K_L)7O\ Z4R4S_A._#'_ $&;?_Q[
M_"D\$SQ76@2W$$@DAEU"\=''1E-Q)@T ='1110 5@:#_ ,ASQ./^HA'_ .DT
M-;]8&@?\AWQ/_P!A"/\ ])H: ,;4KC7H_B'8:1!KSQV5Y;S7)3[+$2FQE 4$
MC.#D\GFJX^),[:.VI?V(BQ-=26T"/>_/*8RP8A0A8]. H8]<X S77S:):3^(
M+76G\S[7:PO!'AOEVN03D>O K%?X?:,UC:6L<E[#]DGFGAFBGQ(IESY@SCH0
MQ% &3=_% 1:?;WMMHSSQ/I']K2[K@(8XPP5E^Z<L,^V?:H-;^+=OH^IWMHND
MF46L*R_/=+$\@:/>"BL,,.<'!)]L5N?\*ZT+^SQ9?Z481IK:7S-SY);<>WWL
MCK46L_#30M>"QZA-J$ENI#);_:3L1PFP,N1E3CT.,\XH I)\1[A-2^RW>@^2
MB7MM9S2)=A]C3C,9 VC/49Z8]ZI3?%#^R],M9KBS>=KF\NH!+<3+#&GE.0 7
M"[03VW8]S73S>!]'GN99W^T;Y;NWO&Q+QYD  3\..1WJ"?X?:1-IIT\7&H16
M[O,TBQW'$@E;<ZL""",].,CL: .8OOBR));NVM["2V>WNHX"?M$?G<RHG,;+
M]TAC\R[NG45O/\08TNV8Z:_]F-?2:=%>><,O<(I)&S'"DJP#9[=.:9<?"OPY
M=26QF-\\=H0;2-KDL+;#!L(2-V/EZ$D8)QBM(^!M'.IR7A-R4>9[D6OF_N4F
M==K2JO9B">^.3Q0!5\)^.&\2WD-O-I9LOM%@E_ ?M DW1LQ7!&!@@CWXIEQX
M^6+4)ECTTOI\6H#2VNS.%/VDC@;,9V9(!;/?H<5IZ-X0TO0KFUN+/S]]K8BP
MCWR;AY0;<,^^>],?P7I+ZR=1;[1@W(O&M?-_<-.!@2E/[V,=\<9Q0!SFA^+]
M:C^%^H>*M6$4]RIE>")<!  VU5. #C(YSD]ZO:EJVN^$-"EUS4;U=9A\N(&T
M2!86$KNJ_(X_A^;HP)X'-;]AX8TO3_#9T!86FTYE=6CG;=N#DD@G\369+\/]
M,N;1[6[O]5NH2L:1I-=DB)4<. H  ZJ.3DX'6@#//Q*B@\2#1;RPCCGCN(K6
MX\NZ#LDL@R-J;07097+<8STXK/N/B!J5UJVGR6EJ+?2)UU +)O5WG^SHW."/
MD^9>.N>]=<WA2P.O/J\<UY#+*Z2S0Q3E8IG085F ZD#WP<#(-4%^'FBK?"Y$
ME[M3[1Y5OY_[J'SP1+M7'&<D^QH Q-%\;^(=1OC';Z0E]$-)MKR./[0L<LC2
M'!).T*.,\#'3WKT2.590Q4,,,5.Y2O3Z_P ZY;_A7VDHB+;W6I6VVRBL2;>Z
M*%XXSE,D#.1ZC'!KJ8HS&&!D=\L6RYZ9[?2@#SO2_$.O7D\4T-[=W+&\FCFM
MWTW9;QPJ[KN$VT D!1_$<GC%367Q)A1;*WNUAEG,< N2)U27?( 1LBQ\P 92
M3D8SWQ7:6.EVVG::;"#?Y):1OF;)^=BS<_5C65%X,TZ!HA!<7T,*HB2PQS[4
MGV#"E\#).,#@C.!F@#&N/B,;6YN[:;3K?SH%#8BOQ(L8+A#YQ53Y6,@G[PI]
M]\1[:RM;-S!:&:>![EU:_0)L5BO[MP")&)' X]\5>M_ 6G6K*\-_JB211>3
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M4$'MWK5_X1'3?LL-NKW2B!Y)(W28JX9^IR/THM?"&GVUQ%<M+=3W2/([3S2
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MXOU)GN+9=*%QJ$<\WF0?:E5(HXPN=K[/FR6X!'KDBK\G@?2IFD$LEX\)W>5
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M9_=JY#8Q_%L QVS[5>F\%Z9+:6MLDUY#'!!]E/E38,T.<F-^.0?P/)YJM?>
M].G$SQ&5P3))#9S2G[,DCH5)V@9&<D]>O2@"C/XOU\Z[;Z9'HL,=VLFV6 W8
M*2*8BX/F;,KC']T\\>];H\1-+X4BUN&T7=)&&,4UPL:QG.&W.>@&#R ?I6=X
M>\&RV%Z^IZM?27>H&3<K"0L% 39@DC)X]A6G/X7L)M#M])#W$<-M(LL,B/\
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M\-VNHQ6"_:;RVDL,_9YK:7:ZY7:>Q!XXY% &?IWC--0$*+82)<2W"PB(R D
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MGN>IQBI+CP7ILR%4GO8-YD\TPS;3*DC;F1N/NY)Z8(SUH RQ\1[4R0K]A?\
M>6T\S'S1\K(?D3I]YQR/2H8/'E\+1)!HS7"QP?:+J1[E4,:F5DP %^8C&>W
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MF\J>28S6DRE62.(MM)0D$;R@Z]\'FK$WBK6-.M[NRCA@>[TV-9KDOD(J.@V
ML2<?,6)8GA4.>M %32_!]VOV6Y&GW5G,CVX1?M/,3%S).YPYR">._!Z5K>#=
M(UFUUB[O=4DO1(Z%9A-Y8CDD+9R@4DD ="=O!Z53M/%/B&XL80DEE+*#<2R2
MPJ)=T4:@X4*VTL6.W@D?CQ4>G>,M:N;-VN;O2H%GFCC2\$BR16VX$D-M;!.
M ,D')YQQ0!%?V.HZ3ISZO>27EN\L;M>DW.23),H$:G=M7";@#P!NR2,57L=$
MEUW2I+NVM+S[ #=3VEN]T?F(54A7=NSC(9N#CGK78^"KN2_T 7-S>+=374LE
MP#G_ )9LY"X4\A<#@5T@  P!@4 >8:GX<U+==NFEW\]T\Z#S4N $N%2%57?^
M\4@;MYW+@@@<&MSQ+INH71M(5L;R\C6V*0B*[V"*XX >5L@D =#SWXYKLZ*
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MKG&]\+P>GI39?#FK3V=I87VFWMR3' D;K= 16R&0^:&RV6;:<<AL@#FO3J*
M/.M,TZ[L/[3OM3CETJ-X;C[;=3W0V2O(WR% &(4*N.>#DXYKI?"4-^^EKJ6J
M*\=]>(C-"S'$* 85<>O))/7)]JWR 1@C(]Z6@ HHHH *P/"'_((NO^PE>_\
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MLK+0XK.:>206RNX=)=JJ,<'*Y]\@]!C/5>'FT#Q)IWVVVT*&&/=M'G6L?S#
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M*TIO&OAAM'O+VT\*L[16,U[ LUK"BS)$VU\')Q@]<CITS756,&E3>&8-7N=
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M'N4 YP"RGG:<$&JU_P"(_#\-E/+:>%Q+)ETMB]I$JSNL@C.W)S@,1SP".AH
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M37$L5K=?9$$<GEJ"PSUR#NYQCC&<YH S?^%[> ?^@I/_ . DG^%'_"]O /\
MT%)__ 23_"M.?6?"\%M8R_\ "/[VO4C>*)+*,O\ .X501ZDDGZ U'%KWA=HK
MZ6?P]]FBL]PD>2SB(+@A2GRDD-D@ -C/;- %#_A>W@'_ *"D_P#X"2?X5T'@
M"_M]5\*_VC9N7MKJ]NYHF*D$JUQ(0<'I4NC+H&LQS^7HEM!-;R>7-#+!$60X
MR.5+*<@]C3_!J)%HEQ'&BHBZC>A548 'VF3@#M0!T%%%% !6!H'_ "'?$_\
MV$(__2:&M^L#0/\ D.^)_P#L(1_^DT- '-:UX-\-7;>*KS5=4F^U2@2SW!D9
M/L:! 8_E!"L%QN&0>:I:5X0:YOYXM1UI9XKB].KVUM&H_?@(%25FQE,DY*^M
M:NLZ'J&J^)]5MFM&_LB:VCGDD)&)Y4!"1@=P#AC]%]:QIM"UV3PQH]Q>6T@D
MD,?VZT%M]I*HD>V.,QAEW+NRQYZD9!Q0!'9^ H8] MM(\1ZXPO!ISV4,4488
M0"9P&(;'SDD #.,#\ZZ:;X?V[SSW4.I3Q7AO(+R"4(K"&2.,1XQ_$"N<@^M8
MNGZ%K5N;?S;*>X> J424K&H\I))$4$$A1ND"#!.-GM6UX!TQK!;YQI]Q:1.4
M"FYC\N5S@EMP!PQ!.-^ 3WSC- '.:QX:TI]<F@O?%&I2ZC*EL+S&GF8L4?S$
M^94(C!_N^@%=1_P@EL=36]^WS;EU?^U=FU<;O+V;/IWSUIUCHNI->ZGJAU"_
MMY9;MGCLT,:QRH@ 0,60L,XYP1P>U<9I^@:OJ.H[+G2[BWMKM85O&2V^SEF\
MW?)N;>QDQM #<9W'% '<Z1X1&D^$I_#L>IS/ QD\F7RTWQ*Y+8Y!#<D]1R#B
MG^%?"<'A>UOH[>XWR7DQFD*1+'&K8 ^2,<+TSQWKSN2R^UW+:?HMH\>LVS74
MUQ/;.H62,$K'&C*?1EV@XVD>M=]X0T\6L^H7%KITNF:;,8Q;VDJ[&RJX9RN?
MER?Q.,GK0!EP_"S2[:SL?*O+G^T;:Z-U)>,Y)G9BWF!DSM 8,02!FN3TSP;=
M7D$UGKNJ16]K'IB:=!Y)WNBO*'CXV@CA<?-SZXJWJ&@>)'L'@MK&Z$DPO; ,
M&'[N%G+A^O.XG [XK7M?"R2WDEI+I4\<,FI+)/*$V[XH85$8W Y92P_4B@#8
MN_ -G<^)?[:2X"/((?/5K:.0N8N%VNP)3(P#CKBH;7X=6%GJ5]<0706*Z,["
M,6T>]7E&&/F8W$#)P,C&>]306.HVWPUDLX;5X[^6!U2V4@>47)^48X 4'\,5
MRY\):C8>)I$T^T=1#-'):2+:C"Q(HROGE_E+D,&^4D[L\T ;4_PPLY]/GM#J
MEP%ETF#2RP1<A8GW!_J?2KUCX"LM.\22ZM!<*$EG:Y,1MHRWF,N#^](W;>^T
M$<FN.CLS:1"WDT?4$@OKN(RPF/;<S*H:253M/[T!MOSX!()'-.N_#6LRSQJM
MC+%I\RR-86:V8F%FSR$Y.741,!M(/./F ]P#H?\ A6NGPZ6EK-J=QY,.G75D
MS%5!V3-N9O8CM6M=:;8W?P[_ ++OM5+6=Q9K;B]50A8-A4( XYRO'?\ &N6E
MT>X?2M52ZT"]N]<$$ZR7[J,3!AM55Y^<%?X>@(KH]=T:VET30=,ATDS:<E[!
MYD @!\J, D$KV ;:#Z9- &?#\-(A'<"XUB::2>\M+MF6!(PIM\!5"C@ @ ?A
M4-WX-TRVNYGBUZ:UO3<SF1Q$K_+>''EXQZ@8/48]ZDT#2;S_ (22UNGTV>VO
M('N&U.]DX%UNR$53GYU'RD=E"@=:1_#PO]>O6GTF94N=5$US+L"AXHH?W8#
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MYISMJNI?Z?.9DO";9)!N<]4WC"L %&Y?3CI63I'A^\EU2W:\T24Z>+J!BO\
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M=)T32;<QW<#KJ<P6.2*V6!97*G"JJ 8X4]?0\UF67VVQTE?#C^'Y[RX29O\
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M^'#I=X97U0W'VK:/(\LS^;NWYZXXQUS6?;^'M<M-*T22=M0O;95D$NFL(_\
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M:-D\M/[P);)(X^4>HK%_L7Q!<VEK?S63?;[^Y:TOD.,I;$!"Q_V?D9A_UT%
M'8:M9Z?>PG5;VZ*V"6,R/Q@;) ,OGJ#M!'XURD6B>']$L=/NI-5!2X.;5K33
ME!E41,!E8T+,1OW$GNHZ5U/B2QOM0M;/2]/*PQR2AIIGB\R-(TYVE<C.X@#&
M?6N9L_#^MI?:?I<T]U#%874[1ZA9QHBF)X\@ -O PQ*XYZ"@"29O#<5O':-J
M5[F2RMX41;&5G6&)\\@)D;B#G.*B:'0[-GAOO$%W<A3<P6T4=HYD@DE7=*WR
M*23B08R, -6R=!U"7Q:\PU/4H($L8H_M$?E9G8.Q(;*$9P>P'6LG_A'M7N?%
M-U+%->Z:C7ES(EW"J'AH80I(8$$$J>W:@"70-/TJ?5K"4^)'O[LQAX8C$(@8
MX@\>T+CY2K.21UR*J7.CZ$;74!?^()+XHZ6:$VOG21O&_FJKA03,0<9R",9'
M<U2@TC7;/9J$.DW#:MIL4C,SD$7<YE.]E/ PZL2.!C..U68_#]UI4;>98ZD1
M'>&5;O3G_?QL8URRJ00Z,VY2"/3CT .P\)6-C9Z(KV%Q#<1W#&0RPVZ0J3TP
M$4#;C&,'D'.:;X0_Y!%U_P!A*]_]*9*?X4BO8M%Q?1E)&FD="\2QR,A;*M(J
M\!SWQ3/"'_((NO\ L)7O_I3)0!OT444 %8&@?\AWQ/\ ]A"/_P!)H:WZP- _
MY#OB?_L(1_\ I-#0!FZO_;47BRVM+?Q#=0VUS:W%SY0MX#L,9C 4$IG'SG.<
MGIS5&Q\;W%U8>&2ZWD4MTZ?;)Y[%XXG7RF9L.1MZ@'@UH:IK>F)X@EFGTW4Y
M#IJFUFO(E4PQ+-L9LC=N. %.0IQS5:Z/AVYT.#2Y8+\#2[Q+2.S#8F9\%5'7
MYE9"3G/*Y]* &^&/%$OB>?4K!-819G5;NTDMXUWPPL<>60P(++A<D@_?K5\&
MR:E<Z4;W4=6FO6D=T"O#&@3:Y&1L4'D =:UKG3+:6\M-0,;_ &BR5Q$(VQD,
M,%2.A' X/<"N:TSQ18Z4LFFIH>LVT5O.L<KS+$PC>4@KDB0GG<.@/6@".Y\0
MZV^@66K6;VZ076I11L)%RT<)G6/:HQ@DC)+$\9X'IT.GW\[ZYJ>FW#!_(\N:
M%\ ?(^?E./0J>?<5SU_)INC1-X?N8+R\5;B&\M8+5 &&Z8LBY+ '#H?3BMOP
M_'-->:EJ5U9W5M<7,BJ$N%1<1J/E VNWJV3GJ: .52757@M[RSU9K%KK69;&
M1+>S@P46:10<E"=V .IKIO$.JW.@VNDL))Y]]XD,YC@\R252C$X51UR!T%<]
M<:SI.F^=:3>'M=1=.G_M1SB(A3)(Y#?ZSD%M_%;&HZS!-9I?:EH6KVZV$\<T
M*N(MTDA.Q0 LAS][O@4 8]YXWF']NA;E[!1-;6UD][:F,PNZ$LS*PR0 "1D8
MXQ4K>)M1U70]&O;&6Y6"9&6]GTV!)Y8Y%^4XC8$E-P/(4GITS2MKF@Z=XAEU
M74;#5+#496AC,=R%( <%%D 5F 'RD$]O2EUI/#%GKEXKW-]9WZ0-J,L]I(5*
M(Q5"H/\ MD+\O3(SQ0!O:;JLUWX._M'[3!/<"W=O-B0JI90>JMRIR.0>AR*Y
M73M?U=_"T6J'5-4EN72T++=Z:D,69)(PVP^6N[ACCD\'-=+H,MA<6$^B)I][
M8-''^\@NP!(Z/G]YN5F!R=V3G.0:J:A>Z3;:;)X=&FZC?65G;I%</;(&%NJJ
M-N6+ E@ #\N3QZT ,U_6;^R\5V=I!(@@98,@Q@G+RE6P3R,@5LB^N#XP;3]X
M^S"Q$VW:,[]^,Y^E<E]GTF\FFM+2#Q%J<A-O,=3BN$+(,;H]KLZG !)P!WJW
MK^D6VB6Z:G)<>)KEHHV22>TNE+K'G=\VXC(STQF@"S;ZCKS:ZWAR64^?%+]J
M;4!$N'M"?E&,8WELH>.BD^E2^,-4O+"[TF"VN[VVCN'E$K65H+B4A4R,*5;C
MU.*FTB_LK[5+N^-CJ%K?6]G''*MUMR8LLRGY6()/-4W\3Z-J=S87L-I?W-Y"
M?]&@B50[^9&&/!8 X4C.30!A0>)M7NH]-_XFFI_8[HW#P7-KIJR3SQ*5V,\>
MP[.2P^Z.@]:T?$GBN;0M'TU(M3*WDBM<NVH0"-Y8DZH5"@*S$@#@'J>U7;#P
MUI&K1#4M/N-5T]FFE9HXIS$T,C'$B;>0/F7) XSR.M3Z;>Z18:CK$ GOKF[L
M+93<37)WEXQN;"GO@E@?<B@" W>I:YK5T-,UR6SM$LH;B 1P1.'+ACEMRDXX
M' (K3M_$4:^#$U^^"(%MO.E"'Y2PZA<]B>GU%<6AT&"T^U&'Q-I5LU@\\:>>
MJK<0H"Y4!7;D!^ <<'%;UQKVD)8165_I&I:?!:"&:&WD1 '4.J+C:Y! 9ER#
MCL: ,:/QEK%UX5F73]1L[O6[?4(8/-5 (Y4D8,HQVR"4SZJ34\OBO4=9URSM
M-/OY+"&X:!)%$*-+ Y6?S$.X$9!C4<CM[UN>(8] AUF&ZU0SQS)!YYD1B$*P
MNK+N ZD,W QW([UE#3- U36;V[EL]7T74I52]9V<1,ZQADWKM+ <.00<'D9%
M '0:#>7IU'5=*OKK[7)8O&4N"BHSJZ[@&"@#(P>@'&*PK;QRDGC2ZLOML,UF
M5EBAMD7]XLL/+$G_ &OF '^QQUJSIFKZ9I_A)M8T^RU:\AGWR7,AVFY!4<M)
MO8<@#H/;BH!K&ARZ3:V5SINJ6GV(P3VD4BKYTCDXCV;&.6)SG/OGB@!%UC5K
M5-)U.\U64I?NC/;)8[K9$<@!?,52RMR,%FP3VQ6-I7BO6;@6134[Z>]E266:
MWN-/2*!8E#9=)-@W8;9T8YST[BU/)X8TF![K4HM:L[:RN(G_ ++N'S'$9'PD
MBHK$%0V3PQQCITK?31]!OC;:'&L^=,1;F&9),';)N& XZAAD$=",4 85AKVJ
MGPE>:L=5U>6ZCTE[D+=Z8L, D\O<"K>6-V#T&3D>M%[JE_\ \(KJ-S_:.JSR
M"*+:-2TE(HU+2*-RYC4,<$\'(J_#I6C6VIMX4?4M9G6>P>+R)K@M"(RNW:#V
M8+R/;FJ5O)X>U#P_?;]5URZM#<C3IH9[C+Q2!Q@@=N0"#Z4 =#I9O=)U^/1;
MB^-[;RVC3PLT,<;1%&52N$"KM.\8XSP:H:Q-J]CXC(37;H68LY;TVXMX/X"/
MD#%,X(S[^],\,:AIR7L,QMM;$FHKY=O?:HRN) ,L(U*L=N?F8 @9Y[X%:&OZ
MA:Z5K-K=S:-J=Y*Z?98Y+81F,[S]TAG'/'IB@"JMWK=A!I>J76J)=17TT236
MGD*J1B3IY; ;B1Q]XG(STKIM3O1IVEW5ZR[A!$TFWUP,XKCK.WT*UTR766CU
M5+?3YS''97,FX6LF0OR("0,;L#DX&<5HZ7JYU?34TZ32]6N+>5&MI+^18E1\
M95F^_NQD'^&@""6?7(3I4YU@2SW<D(_L];9-K(V/-8MC=\JEB",#@ @YYT=-
MU":?1]3CFV-<:=-+"7" !BHW*VWH."/Q%<_J.FQ>&+B#5KC^W[JXV10R2V$J
M^40K!44H[ C/&<<$\FK.BZLRP7UBV@ZS/<2SN;V18X459' X_P!;T"[>F>E
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M$VD _)@<XQTJ'PA<WK>(-/MW75+1CI_VB==0U W"W08* T8WM@@Y)Z8W =Z
M-6#PSJ.GV_B*PANI+RUU&W:2*6YD7>L[*58':H&#\ISCUJ*\\-:J=2MM1ME@
M,UG;V_EQN_$KIN#H3CC(;AO6M/Q#)+<:UH^DFZFM;2\\YI7@D,;N4"E8PXY&
M<D\$$[?K7*:I-?Q:]#H=M/JFH6D-X0JP:@8I6S"S&-I=P)VD _,<_,/:@#7U
M#0]8\0745_>V,%MY<]LJVIF$F8EE#R%B!@Y   'OZU;\,^'+[0M=U+S)$DTS
MR8HK#YOG2,%CL;V7=@'T^E;^D0FWTN"-H[F)MN3'<W!FD4GG!<DY_,UP=WK%
M_9W4<1U&X":!(\^H;Y#F:!I0%+^H\OS& /H#0!I3^$]5>3^VDU"?^U5O1=+9
MF5?L^ =NW.W=_J_?&:HW'@C4Q:6$MF(([HW9-_$7^66+S6=&SC[Z[OR)%0RR
MZG?ZEI_R:K?1W5M/=^39:B;;:K2CRR3O7(V8XSW-=+HLES'XDFLW-TD,>FP.
M(+B<RF-RSYRV3EN,9R>E %#2-,UR2UT?3+_3X[.VTV197G%RLAF* [0H XR2
M#D]ABM_7;"XU!=/%N%/D7T4[[CCY5SG'O6);WE])X&U28:DMM=">YCBNKESM
MC_>,JY/. .!GM2^%9KFWUFZTV[74+:;[,D_V2\N?M0'S%2Z2[B<$C&TXZ9QS
M0!2OO KW6GZM)L?^T+B_,\.+V58]N]2,H&VYP#VIWAS0[_2M0C\_0Y]PGD9K
MM=68QX9B<^3G'0],5)XH-Y/XOL;2"#4[J$V,DC06.H?9<,'4!B=Z[N"1C/>J
MGB/7;O3-3LUM%U;[/I*1R70C1IDDW8W++)D\K'ELG/+ T =9XDT^XU/1FM;8
M*93-"_S-@8616/Z US4^A7\/BC4+[^Q)KQ)[A)8IHM6:  !5',8(!Y'?.:Q=
M5O[XWVI3Q-JJ[]12WM-034BMK;E@NPO%O^YD\_*0<@=ZOZA=71T34]?ENM4:
MZM)Y@Z6MXL:6:1DXS$S!7R "0V2=WTH GNO!-UF;4H4,E^NJ-=BUDNW\BXB+
M?=9,[0<<@XX(&<U5?P5K+VQ@'D"WFAFDFB,G6X!81'..F'R3V,:U8$TVH^'M
M6\22:O>V][:O-Y,27!2*$1D[%:/.UBP )W D[QCM757^HW<'A*;4HX<7:V?G
M",C.U]N<8]C0!R][X:U9]0+V]A%%=L8O*U6VNVA,:KCB6,<2D889(.01TKIM
M?L+RZ2RN[ 1R75C.)EBD.U91@AESV.#P?6N;OQ)HEEIEY9:W>W4U_N2437)D
M6<&)W+HI.$VD _)@8X]*H^$KJ^;7M&@<:I:M)8?:9_[0U$W"7BE0 8UWM@AC
MD], ^] &AJOAS5O$MS#>7]I':@7%LIMDN3O6)'+.Q=<?,<C &.G7FNRL+"#3
M;1;:V\WRE)(\V9Y&Y_VF)/ZUB^,]1DM-'6TMVO%N;^3R$>RC+S1C!+.H'=5!
M-<D/$6N7K>&[FQ>X^TV<=V-0L) 5-P8C$K*P/\>UBR^Y]Z -[5O#%[J']LIM
M0QWM[:2KB4H2D93?R.0< XQ67KO@6X%_YVEVDEQ;"2WD>*349!(^QG+ .S$K
MPPZ$5!:ZUJ;P-K^DW\E[;WE_)9+%/*3&@=AY4B@]-I)R!R1QU%>B:?:&QT^"
MU:XFN&C0!IIG+.Y[DD^] &?X;MYK6PDBETV:PQ)E4EOC=%N!SN))'TKGK?P[
MJL?B".>.QBLY1=^=/?VMTR17$?/RM;YQN*X!/J,YJI]INSX0/BS^T[S^UM^_
M[-]H/DAMVWR/*^[_ +/3=GG.:AUZTET^Y\12VNI:QNL[.*>!/[2F(#L6SP6Q
MSQP>* -^^T#4;I]:@1Q%!JD\2M+'( Z0A,.1D=3C&/>LZ;P;J$6H?9TG;4-+
MGO(+R9KR1=ZLH*.,!0""FSM_"?6L[Q5KFN27@A-EJ.F@VZ;88[Q TQ,\:G:R
M-\IP2,DCK5G58[^RT6W6.RURVDN-2@B:&35R\LRG.0LGF'8#WY&: (X?"WB#
M1]<CN[>"+4;:SNU-JIN!'(8/(DC"L2,94N![@4[4?#&L7NMPZY<Z7Y[RM)YM
MG!J!@:)=B*G[Q<;C\K9QQR*V? UQ<7(U8N;N*".Z$26E[<F>>!E4;MS$G@GD
M#)X.>]4/&?B&\LM8A^PIJ31Z6JW-R+2%GCD#'!20CH!'N8>^* )CX1N9_"&F
MZ;<PQO-;WHN CREO*C\TMLW]6PIVG/WJZ;7+.6^T"^L[95,LL#I&"<#)''TK
ME+J:;5_[;O5NM0E:SF$=M!8WPMQ'$8U<2G+*K9W$_-D8&!WKFKO7+R[AU#4S
M_;4D)6U6&[AU'R(;9GA3#21J^-NX[F(!'- '1:GIVNZO9:3'<^'BJZ?,&:./
M4Q&TH\IDX=,$8)!Z\BM&YT>^OO!4NFQ:>UG.9XF6&>],YVK*CD^823T!XK*T
M:/4;W7;U[JWUB[$6HF(W4.J&*! H7/[KS!\H.3C:<^]2>'$OKS4Y+F>TUJ9!
M?S@77]JD0!5D8#]SYG08QC;0!T.JZ5=7>NP7<(3RDL;B DM@[GV[>/3@US&F
M>&]2@T2?3CH<UO-)8O;FX?5VFC+%<<(3@9/H.*Q1XFU?_A!18?VE.=4VI=FY
MW?O/LQ(.2?=@R9^E=!I*7U[XAOY9;36KB*/5)(UN$U4I B*PP/*\P9 ]-O/O
M0!?T?PK-H/B.VN[9&GM);/R9Q<73RM:N,<Q[R?E;H0,= ?:I)+/7]-FU2UTZ
MRMKJWU"9IH[B2;9]G9U (=<98 C(Q]*Y(:[J]IISVM]J%PT>HZL@L;E9"KJ/
MM2K) 6'/W<D>Q([5UGAS35A\1ZSF^U*9;29$A2>_EE10T8)^5F(/)[T ,T#P
M7%INJ7EU<F5BLD/V9TNI%#*D,:$L@8*?F5NH/&*TM7M=1M]8MM7TVU2\986M
MYK9I1&2I(8,K'C@@Y!ZY]JH>*EO[G5[*WM&FN(5AD>:RL[\VMP>0%E!R RCD
M$$@?,#S7.PZ_>7<]M&NKW2VMS96<<MRX$;1EIYE=L9(5SM";A[$=J -2X\(Z
MGK^K27NLS&U>33VAB?3[F2-K=S(64?*1OP,9)X)SQ6;;^&-8M[[[1=>'1-FS
M@MU6QU9[9%:,N"< C(.X$9R1DBH]<EU&POKG1-.O]5L9I3 ]O)<W8N!_K0N\
M$N7"GH4. 1FH-0\0ZEJNK_9E^WK,DEK!=Z?:W9A99<R[U5LC .%.<C(Q0!T<
MECXA@U'74M=*B:'51'LN'NQB#]PL9W+C+8()XZTRV\)7]IX=GTV,1L1J\%S$
M6?K#&\1R?]K"'BFM8S/<:'83?VS81W%S.98I-4=Y&VQ$C]XKD[<C.,UM^&)9
M0=4L6NIKJ&SNS%#-,Q=\8!*ECRVTG&3SZT 2>(-*NM9:RM8[F6UM5E\Z::!P
M) 5Y0#((QGDY':L&V\.ZUHDRO9[=0CLYI?(6XG"R2PS ,XW  *RN#CC&..*Q
MM2O=3AU37+]?[7\NSU6)%NX[[]Q#'MAW*8"_S#YF_A/WO:MZWBU;_A)&\/O>
MSM81/_:"W7G'S6B)^6 G.<!\\GJN!0!1MO!FH7FH0SZA'+!8M=M-]E&I3/)
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M\AWQ/_V$(_\ TFAH Y?7;G2X]?U:_E\-:?<'3GC:XGDOMDLN$5@5BVD,0"
M3SC%= ==M3:ZMK9T[_2-+E>S!+?,ZC:3SC@$MT]JL6WA:Q77M1U6\M;.YFN9
MDEA>2W5GAVHJX#'GJ,\51NO#&IM/J-I;7MHFE:C<BYGWQL9D)V[E4YVX.T=1
MQDT 4W\5MJUIY=]HMG)I-U=M8NOV[?*?WACR8M@[C.-V<53T"XT<2_;;#P[
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M) ==K8&X?/P< @Y%$%UIVG7\FE:/X?A:^L[QHK9?-V EH5D>1GP2HP^WHQ/
M^FEJ>@W<=UI=QH"Z=:BQ$JB"6(B/#CG 3&.>?QJFGAC5HKR?5XKRS75I+@3
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MMR3DK@<UZ?%XHL((A'#H^M1QCHJ:1, /P"TA\3Z>T:QMHNLF->BG2)L#\-M
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MO_0+UW_P53__ !- '045S_\ PEUK_P! O7?_  53_P#Q-'_"76O_ $"]=_\
M!5/_ /$T =!17/\ _"76O_0+UW_P53__ !-'_"76O_0+UW_P53__ !- '045
MS_\ PEUK_P! O7?_  53_P#Q-'_"76O_ $"]=_\ !5/_ /$T =!17/\ _"76
MO_0+UW_P53__ !-'_"76O_0+UW_P53__ !- '045S_\ PEUK_P! O7?_  53
M_P#Q-'_"76O_ $"]=_\ !5/_ /$T =!17/\ _"76O_0+UW_P53__ !-'_"76
MO_0+UW_P53__ !- '045S_\ PEUK_P! O7?_  53_P#Q-'_"76O_ $"]=_\
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M4-)6W%NLD @";!$%^4+C&,8QC':LZZM= N[_ $NZDG 73"6M;=/EB1MNT-M
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MO0 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\5_\ (G:Y_P!@^?\
M]%M6O61XK_Y$[7/^P?/_ .BVH KZO?W&E^ [F_M65;BWL/,C++D!@G'%<SI'
MBCQ/:WUA:ZE8272:I(J6CW+16[J1&7D)$>X%<#COUKMH!;MH4*W2H]N;=1(L
MBY4C:,Y'<5&U[H[/"[-;EH/]2Q3F/C'R\<<<<4 <:/B4]L9E;3GN8X"\D\SS
MJA2,7'D\*%^8@\]N.^:U+#Q?=+H'B#5]3M(Q'IMW-''';R;BR)@ '@8/O[UK
MG_A'"'!@L<.,/^X7YANW8/'/S<_7FI$N-"C^T>6MHGVDYGVQ >:<8^;CYN..
M: .?@\>W$^JVFDKHZG4)KEH)%6\!B0"(2[@^WYOE/3 YJ;Q'<:U!XMT.SLM9
M-M:ZB\B/']FC<KL3=D$\\UO:=9:,L41TZRLXXX'8Q^3 JB-B/F*X'!(/..M7
M9+>"6:*:2&-Y(B3&[*"4R,'![9% '#77Q+$!N8DT=WN+29;>Y1KE56*1Y?+0
M%L?Q##Y["F_\+/7[=;62Z)<RW#22)<+ QE$>R7RR4*KAQGGG;Q[UMR^!M'N(
M+Z*X$\QOKQ+RX>1P6D9,;5/&-H  QCI6M_8>D;+9/[*L=MJ2;=?LZ8AR<G9Q
M\O//% ''^._&&J>&-<LQ;1K)IWV&>XO,)N>, JJR#U 9AD>F:SX?BS]GLH5N
M+!+N?["DYE@GPLDG[L,IRN%.9.@+8QS7I$UG:W#EYK:&1C&T19XP24;JO/8X
M&1[53'AW0U<NNC:>&88+"U3)''M[#\A0!S%G\1B]Q/%?:0UMY,=T28[D2EGM
MP"Z@;1Q@C!_2M7PWXO&O:)=ZE-IMS9I;#?AE8B1=@?*$JN?3IU'?K6VNFV"2
M^8ME;+)ECN$2@Y;[W.._?UI;+3K'386AL;.WM8F;<R01*@)]2 .O H \\U'X
MA:I>:7;IIEC%:7MU-9F)S<+*HAG?:"?EP'X(*G.,YYK=UG5=2;Q'-I=OJMOI
M45K8"[,\T2N)CN(.=V $&.<<\]170PZ+I5LC)!IEE$K2B8JD"J#(.C\#[P]>
MM/O=+T_4C&;ZQM;HQ'='Y\*OL/J,CB@#FH_'2?VP+)[,/;"X%FUU%)EFF\H2
M96( DI@_>S^%8WBOX@W-AJ]C_99E%C;QI<ZBKV,A;RVD"A3E08OE$C9;&<"N
M_P#[,L/[0_M#[#;?;=NS[1Y2^9M]-V,XIS6-F[7#-:0,URH6<F,'S0!@!O[P
MQQS0!Q5S\2TMKG4 VE;K:VDN88Y$NE+2/#%YGW,?*I'1LFJEQ\0[R<0".V2S
MD20&=5E6</&]N\J;6P &^7D8_,&NF3P3H4=OJD26BJVI"433!5\Q5D7:RHV,
MJN!P*OV?A_2+"RCM+?3;188^0/)7EMNTL>.6(X)[T <M8_$5)K9I9+6-+>*/
M:;FYNTC+2B)9""F,[2&QN4'GMBJ:?%?S+5YDT-BT$4\URK7.WRTB<(V,H"2=
MP(! KN&T+1W=W?2K%G>+R68VZ$M'C&P\<K@=.E$>A:1%&T<>E6*(RE&5;= "
MIY((QT.!D>U &-X=\0ZGJU[JL<UI;+#:ZDUJA6X^81A P8C;R>1Q[^W/4U47
M2].6Y:Y6PM1.SB0RB%=Q8# ;.,Y XSZ5;H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ K \(?\@BZ_["5[_P"E,E;]8'A#_D$77_82O?\ TIDH
M WZ*** "L#0/^0[XG_["$?\ Z30UOUQUE<:U#XD\2KINFV=S";Z,L\]ZT)#?
M9H>,"-N.G.: *'Q$%S+J&F6]JQD9\E[2.Y,$LZCKL<8Y&<XR,UQ5QJ5U+H46
MGVLFJ&\,TJNT<?F3P",\*Q4G<-Q4;NXS7=Z_H_B#Q#Y:WF@:.\:#A7U*0X/J
M"(015*U\+^(++'V71-%AVIY8V7[_ '<YQ_JO7F@#D_[=O9M4T_58&D-G'8^9
M?6?MO"N0/[Z'/X BF:'-/KMM)YMS>7/DQ!X(;>[,+3!F/S[LC([#)P,5U\/A
M?7[>>2:'0]%CEDSO9;]\MDY.?W/<\U5D\#:G+;PV[^&M!,,((B07\@V \D#$
M73VH Y6?7KVXTFP-E_:4\ULAN)FAB#F0HY4)(4)&" V3WX-66\0R6VLW]VER
MTMC<PQ+:HQRJRLF4QZ;L@8KK;?PWXBM PMM%T6$-@,$OW .!@?\ +'TJ"/P=
MK$2!(_#VA*HD60 7SX#+G:?]3U&3CZT <SH(N]6DBT_4;Z[/DQ/)^ZG:-YG\
MUU.67!(4 < XYY[5MZ-NU'2[BVN+B6:..YDMTN$D*/(BM@'<N.>V1UQ4=SHE
MU<P)!<:)HCQQNS(IO91M8GD@B'/)JY##K-O$D,&GZ1''&,*B7L@"CZ>30!RU
MBUU9-IMQ;MJ%[++>7$+PO>L0Z+G;]]MO%1?:M3U#Q)<6\EIJ3 3R?Z%!?B(Q
M@1Q$?,K $<DX![UU"6.HQ^6R:7HR^4[.A%[)\K-]XC]SU-5KK0IKV0RW.B:'
M([.7+F^E!+$ $Y$7H /PH RM3,]M?01M8ZQ+##8--);0:B5D0ANI;?\ .<>Y
MJO/JVHII.F>1+>W<EM +R:2T0RK("WRQNP_V,Y)[X/:NDM=/O['8;;2]&B*)
ML4B^ER%)SC)AZ9HL]/O]/CECLM*T6!)6+R+'>R ,3U)_<T 85R;S5M4U-M/6
M^F!CA-K/#?\ E10EDR&*;AN'0G@YZ5/8P7MWJ]Z9K74[I8KL1^?#J!BB0!5S
M^[WCC.3T[UKVEEJ%@K+::9HL ;&0E[(,XZ?\L>U59/#\D]XUU)HFB-<.V]I/
MM\P+-Z\1=>* *[W=R?#-^_VF03#4WA5]Y# >< %![<'&*H7=LUE-KKPWVHYL
MYK18 ][*P4.5W#!;G/O6X^CW1U+^T'T;1/MF=WG&]ESG&,_ZG&?>I9+'4)?/
M,FF:*WGE&ES>R?.5^Z3^Y[8XH S[7$FGQZU=:O/;3&X*N6D)A7#E?*\O.WIQ
MZYYJOI$EY;ZCI[7DMRWVQI%%RESY]O=\%AM4G,9P,\ #@BM/^R+D:A]O_L?0
M_M>=WF_;9<YQC./)QGWID>ASPRS30:/HD,TR,C2)?2YPW7'[G _"@"SXCFEM
M](#PR/&_VJW7<IP<&9 1^()%<G%K6IV>F0Q7-Q+*]S>-+9R[CEU61@T)/M@8
M]0?:NL^R:HUE%:2V.D311! !)?2')3&T_P"IZY -,.G7Q@AA.DZ(8H9/.B4W
MLF$?).X?N>N2?SH K:=$BPZ7J3ZQ/Y]X1N624M'<%ADHJ9PI';;TQS7JVF?\
M@NV_ZYBO+H]#N$N);F+1-#$TH8.ZWLO.[[W_ "QXS[8KJ+/7M9L[*&V72M**
MQ($&-2DZ ?\ 7"@#M**Y+_A)]:_Z!6E_^#*3_P",4G_"3ZU_T"M+_P#!E)_\
M8H ZZBN1_P"$GUK_ *!6E_\ @RD_^,4?\)/K7_0*TO\ \&4G_P 8H ZZBN2'
MB;6STTG2S_W$I/\ XQ2?\)/K7_0*TO\ \&4G_P 8H ZZBN2_X2;6_P#H$Z7_
M .#*3_XQ2?\ "3ZU_P! K2__  92?_&* .NHKD?^$GUK_H%:7_X,I/\ XQ1_
MPD^M?] K2_\ P92?_&* .NHKDO\ A)M;QG^R=+Q_V$I/_C%'_"3:W_T"=+_\
M&4G_ ,8H ZVBN2_X277,X_LG3./^HE)_\8IT?B+7I75$TC2RS' _XF4G)_[\
M4 =761XK_P"1.US_ +!\_P#Z+:J_VWQ5_P! +2__  :/_P#&*R_$UYXF;PIK
M ET734C-C,'9=2=B!L.2!Y(S],B@#>?_ )%=?^O5?_017*UIQ3>*;C1(H%T7
M2PKP*H8ZF_H.<>369_8_BO\ Z!ND_P#@Q?\ ^,T %%']C^*_^@;I/_@Q?_XS
M1_8_BO\ Z!ND_P#@Q?\ ^,T =/X<_P"/"3_KJ?Y"MBN4TT>*]/MVB.C:4^YM
MV1J;CM_UQJY]M\5?] +2_P#P:/\ _&* -^BN6N-?U^UE\N;2-+5\9Q_:<A_]
MH5%_PD^M?] K2_\ P92?_&* .NHKD?\ A)]:_P"@5I?_ (,I/_C%'_"3ZU_T
M"M+_ /!E)_\ &* .NHK ^V^*O^@'I?\ X-'_ /C%'VWQ5_T M+_\&C__ !B@
M#?HK ^V^*O\ H!:7_P"#1_\ XQ1]M\5?] +2_P#P:/\ _&* -^BL#[;XJ_Z
M6E_^#1__ (Q1]M\5?] +2_\ P:/_ /&* -^BL#[;XJ_Z 6E_^#1__C%'VWQ5
M_P! +2__  :/_P#&* -^BL#[;XJ_Z 6E_P#@T?\ ^,4?;?%7_0"TO_P:/_\
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M^]>A_P#"#:9]LCN_+A^TQJ%2;[.N]0!@ 'J,#BI)?!UG/O\ .9)-X"MOA!W
M'(!^AYH \G@U74K'3KE#?R?;O.GF=1 )G(4*?XB%5 6&><],4Y/$&J7=O;7\
MDT C^U+&D*Q< F!WSNSD\]NF*]1G\"Z7=$&XC@E(<N-]NI^8]3SWIR^"=.6,
M1JL00-O"B!<!L8S]<$C\: /-(]<U:)88+G4(WGNK>&>)HK,%P7ZQHN<$^A8@
M<&GSZK=:E\-+^^D<BX"R1[T_=D[9=F?E)VD@<X/&:]&G\#:9<Q^7/'#+&%"A
M7MU(P.@^@IX\%6 M'M (Q;29WP^0NQL\G(Z<T >81W-UH^H75K# +!ITMQ&K
M71NHXB\C(9,MT/0;>AP/>IAXBU"&758)KBWD^PVL[)/Y842NAX..G0@$"O18
M? 6DV]M+;0PV\<$PQ+&ENH5_J.](W@'2'@A@>"W:*#/E(;92J9ZX':@#RV'7
M]513!:^:TC&XN6D6-9,[2 $^=@%7G)(.0*LS^*-0+PV/FQVUZT@>3; )BT3
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M(VM@5F&5SO' 4AQNQR5XZUWEO:V]YH=O;W4$<\+P('CD4,K<#J#3KO2--O\
M?]LT^UN/,18W\V%6W*IW '(Z \@>M 'G+?$C5/\ A&!(EM$VH"-IYIBP"0I]
MI,2@+_&>,'!'K[5L7'Q'-MI\UTVC2L!J+Z?;A9=QF="P9B%4E1\O'!SFNH?P
MYH<D=O&^CV#);Y\E3;(1'DY.WCCGGBI9M%TNXM'M)M.M)+9Y#*T30J59R<EB
M,8SGG- &$_C94U/1[:33+BW@U**-UN+G=&$=R0(\;3\_ X)7J*DTSQ;+J=_J
ME@NF&"\LP6CMYY2C2KN*[ONX"G'4%NM;+:-I;W5O=/IUJUQ;*$@E,*EHU'0*
M<< 9/2FIH6D1?:O+TNS7[5_Q\;8%'F]_FXYZGK0!B>(/^0G_ -LU_K6775W^
MBK?7/G&=D^4+@+GI57_A&4_Y^F_[X% '/4=ZZ'_A&4_Y^F_[X%'_  C*?\_3
M?]\"@#='04M':B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *P/"'_((NO^PE>_^E,E;]8'A#_D$77_ &$K
MW_TIDH WZ*** "L#0/\ D.^)_P#L(1_^DT-;]8&@?\AWQ/\ ]A"/_P!)H: -
M^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "LCQ7_R)VN?]@^?_ -%M6O61
MXK_Y$[7/^P?/_P"BVH O:=_R#+3_ *XI_P"@BK-5M._Y!EI_UQ3_ -!%6: "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "L#PA_P @BZ_["5[_ .E,E;]8
M'A#_ )!%U_V$KW_TIDH WZ*** "N,M+[5[7Q)XD33]%6]B-]&6D-VL6#]FAX
MP0?S]Z[.L#0/^0[XG_["$?\ Z30T ,_M?Q-_T*R?^#)/_B:/[7\3?]"LG_@R
M3_XFN4U'6-?'Q .IP0Z@VAV5Y%I\JJ^(B&!#N8^K$.Z88#&%/-4]0\;>)+_3
M+JVME%K>06DLER\=I(6B=;D(%&3WC^;C/J* .W_M?Q-_T*R?^#)/_B:/[7\3
M?]"LG_@R3_XFN3M?$?B2PU&\>)'U.UN+VX2&)H'#?);)(A5B<*A;(QCJ3SFI
M;/Q?XDOOL,-N+:07%]# ][]AD"(&B9W386SE64#=G'S>M '3_P!K^)O^A63_
M ,&2?_$T?VOXF_Z%9/\ P9)_\37*'Q=K-KKEGIZ-% MQJMQ',;JVF=1 CX!5
M]WRLW15QCOP!3K'QQXFN-+UNYFTV".2T8"--A+09EV-O0$E@J_-D8S@\<T =
M3_:_B;_H5D_\&2?_ !-']K^)O^A63_P9)_\ $UF>%;_4+[PQKMQ<WMQ+)]KN
M1!<I P.S VM'&V3CN%YKC].\4ZWI5@TL<=Q?K;1SN+F:>9HI2(8SD;]I'S%L
MJV<'(4B@#T/^U_$W_0K)_P"#)/\ XFC^U_$W_0K)_P"#)/\ XFN1C\;>([N5
MK:QELK@)<3Q_:UL9-K(D"R*=F_@EB5ZU'J'COQ#=7$=GI]L\3W&G&23-FVZ"
M4P&0%3N^8;L#D8SQG(H [+^U_$W_ $*R?^#)/_B:/[7\3?\ 0K)_X,D_^)KD
M[3QQK,"Z?92!+F:?["(Y#:R RHX(F8\X!4C'/2FW7C7Q9:^'-&OS:6IFU RL
MY>W:-(=O"1MEL@MS\WMP#0!UW]K^)O\ H5D_\&2?_$T?VOXF_P"A63_P9)_\
M34&OZC=P:YX<A9Y(()C/-<+$22S1Q;@G'WADGCOBN2T[QYXGU286]O;Q('N"
MJW,MB^/+\EW&5#\'<NWKW]: .T_M?Q-_T*R?^#)/_B:/[7\3?]"LG_@R3_XF
MN-N?%VO:E>Z%$RO8":XT^1H([>3?,KL#*=^<*@/RE2/J:Z+7-/DE^(&A!+G4
MTMIXYVN$ANYDB)0*4R%;:.<_7WH T/[7\3?]"LG_ (,D_P#B:/[7\3?]"LG_
M (,D_P#B:\^EUOQ))!<!KNZMU>V1H((XI=^1>%6(<DG.T#.>QXP*ZCPUXRU.
M\OM7;7;>WL;*S)Y/RO"1(5 ;D[@1@[L#ITYH V?[7\3?]"LG_@R3_P")H_M?
MQ-_T*R?^#)/_ (FN<^(=]K:7QLM*DGMUDMH"T\*R$C=<*K ;6 !P<D]<9Y]+
MGB[Q3J/AS4=*L=/B:X+^7YZO;,X9#(J$A]WW@"3C#>IH U_[7\3?]"LG_@R3
M_P")H_M?Q-_T*R?^#)/_ (FN$7XE:\=&O;Y%LYC'"[MBTD5;5A.(U#$M\^Y2
M6XQTIVJ^)O$%S%%<Q^=-'"+V-)+:*:&.Z"M#L<J#N!&6 Y['% '<_P!K^)O^
MA63_ ,&2?_$T?VOXF_Z%9/\ P9)_\37-3^.-6@&K&8)') [)';I82.UOB7:I
M=]P1@R\YR,>]8NG^-/$DNMPWCJXDN;6U7^SGMI"DKF>1)/+.<1D* Q)SP!0!
MW_\ :_B;_H5D_P#!DG_Q-']K^)O^A63_ ,&2?_$UQND^*_$UMJFFZ6UJ989I
MFW37F0TH,[J0K$\%5"X&#G(Z"NG\+ZE<S7-Y:SWI9(M3NH(1*I=Y44@@!L\;
M<D<YS0!;_M?Q-_T*R?\ @R3_ .)H_M?Q-_T*R?\ @R3_ .)KHJ* .=_M?Q-_
MT*R?^#)/_B:/[7\3?]"LG_@R3_XFNBHH YW^U_$W_0K)_P"#)/\ XFC^U_$W
M_0K)_P"#)/\ XFNBHH YW^U_$W_0K)_X,D_^)H_M?Q-_T*R?^#)/_B:Z*B@#
MG?[7\3?]"LG_ (,D_P#B:/[7\3?]"LG_ (,D_P#B:Z*B@#G?[7\3?]"LG_@R
M3_XFLOQ+JOB)_"NL++X92.-K*8,_]H(=HV')QMYKMJR/%?\ R)VN?]@^?_T6
MU &98ZMXD&GVP7PNA41* ?[13D8'^S5C^U_$W_0K)_X,D_\ B:GOM2;2/!DE
M^D;R20689$1"Q9MHVC Z\XK@]$U[Q-X:MI+36H;MF6ZM9I9[QC/MMY?EE(9"
M?NN#@=@1D4 =K_:_B;_H5D_\&2?_ !-']K^)O^A63_P9)_\ $UP-_P")_$VH
M6@NA<RVJ7.ESO##!;2(3*MQM!!SD-L //8FM6[\9>)+&&2"=($:"ZG@:^-C(
M4EV1J\:A V07+$9R1Q0!U/\ :_B;_H5D_P#!DG_Q-']K^)O^A63_ ,&2?_$U
MSMQXB\275MJTTUF+>.U:T2.U6*02%I!&SGS%89 W,, ?6J$OC[Q (=;EMTMY
MX[:^CMH,V;QND>XAY74M@KG"CD>IQTH ['^U_$W_ $*R?^#)/_B:/[7\3?\
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M4/$GB62/6M2LE6^C7R[5HPI_T:'GYD8Y_'M795@:!_R'?$__ &$(_P#TFAH
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MD\TL<,>YX8U<8"'(!('3MQZ5R=UX%\26ND7+Q7N!%;SK!96MQ)*4W1(H5&<
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M&U00,$\'MTK>N/AUK$UKLANK*U^:Z,<$<DAC@$IB*JC8SC]VQ/ Y;B@#KO\
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M#_XU7044 <__ ,(U=_\ 0TZY_P!]0?\ QJC_ (1J[_Z&G7/^^H/_ (U7044
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M ,_0"NBK \(?\@BZ_P"PE>_^E,E &_1110 5@:!_R'?$_P#V$(__ $FAK?K
MT'_D.^)_^PA'_P"DT- &_1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !61X
MK_Y$[7/^P?/_ .BVK7K(\5_\B=KG_8/G_P#1;4 7M._Y!EI_UQ3_ -!%6:K:
M=_R#+3_KBG_H(JS0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5@>$/\
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M--_Y^=7_ /!M<_\ QRC_ (1#3?\ GYU?_P &US_\<K>HH P?^$0TW_GYU?\
M\&US_P#'*/\ A$--_P"?G5__  ;7/_QRMZB@#!_X1#3?^?G5_P#P;7/_ ,<H
M_P"$0TW_ )^=7_\ !M<__'*WJ* ,'_A$--_Y^=7_ /!M<_\ QRC_ (1#3?\
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MQM/_ .?8?]]'_&@:/8*P86X!!R/F/^- %ZBBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *R/%?_(G:Y_V#Y__ $6U:]9'BO\
MY$[7/^P?/_Z+:@!S_P#(KK_UZK_Z"*Y6NSLXDFT>VBD7<C0(&'K\HIG]C:?_
M ,^R_P#?1_QH X^BNP_L;3_^?9?^^C_C1_8VG_\ /LO_ 'T?\: *WAS_ (\)
M/^NI_D*V*AM[6&T0I!&$4G) />IJ "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K \(?
M\@BZ_P"PE>_^E,E;]8/A'_D$77_82O?_ $IDH WJ*** "N-L_#FC:QXD\2SZ
MCIEM=3+?1H'E0,0OV:'C]3795@:!_P AWQ/_ -A"/_TFAH XC4QH6FSZO.W@
MW2GTS2[E+>>4/B4[PI#!-F, N/XL]:I-?Z!9:7:WFI^#-'A.H62W-BL4VX.Q
M*@1N60;3\X.1D=:]!N?!.D7FH7-W.;MUNI1-/;?:&\F1P  Q3ID8'X@54A^'
M'A^-[$S)=W@L=OV9+NY:58U P% /&WV/H* .? \)?\*\D\4GPK8NT43&2VB4
M2;9%8JR[@.@8=<=.:EMO^$#V*E[H-K;SJG[XBT8Q)*(_,:(.5&7"\[>O'2NM
M_P"$2T<:1J.E);M'8ZA(TDT*.5 +8SMQ]T<=!4$W@G19[R:XDCG(FW,T/GMY
M0<IY9D"] ^WC- '-:I;^$+3P3)XEM/#%I)#^[,:W4!@W*[JH8Y4D+AL].:@L
M)O 4EQ:V=]I>C+>7+ (+1&DB&XD)EF1<$D$8Q7=SZ#87&@PZ-(CFRA6)44.0
M0(RI3GKU45#=^%]+O-?AUN2)A>Q*J;E;API) 8=\$F@#DHY?AI*NI,NG6173
MD:2;_13RBMM++Q\P##''J*UK'P]X.U&WM9[?PY 8[G=M)M,;<?WO[OXUH67@
MW2=.74%LQ-"M\&$@23[FXDG9Z<FK.D>'+'0[6"VL#/%%%(\I7S3B1G^\6]>>
M: .&N?"^@K=3*ND6H D8 !.G-1?\(QH7_0)M?^^:ZJXT>_>YE=8,JSL0=PZ9
M^M1?V+J'_/O_ ./C_&@#FO\ A&-"_P"@3:_]\UIZ'X2\/3W[)+HUFZ^63AH\
M]Q6E_8NH?\^__CX_QK1T;3KNUOC)-%M381G<#SD4 )_P@WA;_H V'_?D4?\
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M*C_\>H Z"BN?_L[Q3_T,5A_X*C_\>H_L[Q3_ -#%8?\ @J/_ ,>H Z"BN?\
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MO%/_ $,5A_X*C_\ 'J/[.\4_]#%8?^"H_P#QZ@#H**Y_^SO%/_0Q6'_@J/\
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MN_\ @TF_^*K=HH^LUOYG]X61A?\ "+0_]!?7?_!I-_\ %4?\(M#_ -!?7?\
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M (JC_A%H?^@OKO\ X-)O_BJW:*/K-;^9_>%D87_"+0_]!?7?_!I-_P#%4?\
M"+0_]!?7?_!I-_\ %5NT4?6:W\S^\+(PO^$6A_Z"^N_^#2;_ .*K?TZU6RL(
M[=9IY@F?GGE,CG)SRQY--JS%_JQ7?E]:I.JU*3>G^1,TK#Z***]@S"H)_OCZ
M5/69?:KIUK<>5<7]K#( ,I),JD?@37#F";H:%0W)Z*S_ .W='_Z"MC_X$I_C
M1_;NC_\ 05L?_ E/\:\+DEV-30HK/_MW1_\ H*V/_@2G^-']NZ/_ -!6Q_\
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MJ,@"1P['C'.0!]!2E3IVTN%V:%QXJLK?Q9:^'MDCW$T32/*,;(L#(5C_ 'B
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MQH_MW1_^@K8_^!*?XT<DNP&A16?_ &[H_P#T%;'_ ,"4_P :/[=T?_H*V/\
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MR>*O_P!GV1OOMIL[?[65V&?RE\S;Z;L9Q[4>U2>@6/,M$N6247&L:;ITEO\
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M?]!JT_[ZKMIXRO""@H;>I+BF16EC=)>0NT#A5<$GTKI*P/\ A-_#'_0:M/\
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MV548*P&,[7QM) 8' )ZU!=>!M(O+);:02 (R,KA8R5*H$X4J5&0/3\J+;P?
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MEQ<0F\.ZW&9"(G*] V V,,<,IP"3S1#XKT:XE,27;!@P7YX9$!)8+P2HSAB
M?[I/.*HV_@RU6\OI9YYFAFEW00(^$A78B\#&=QV>N,=JFN/!NG72WR2S7ACN
MXY(]@EP(!(P9S'QP2P!YSC'&*5J7=AJ._P"$QT=87G>X)@$GEHT<4CECMW'*
MA<@#GGI@9S5Z#7M-N=4;3H;@M<@$X\MMIP 3AL;3C(Z'O56/PKIL491/."E<
M??\ ^F?E_P OUJGIGAF[LO$\NH27@:Q0/]FMP3\A8*#D8_V>N><]!1:FT[,-
M223Q3+ [7$NF.-+\UX8[E9=SLZY'^K R 2I .3VXYJIHWCJ+4WF-S9FQAA0.
MTDKOGE-YP"@Z C\_IG3/A>R:Y>1I[LP,S2+:^9^ZC=LY=1C.>2>N 3TI'\*:
M9(DJ.)F65=K R?\ 3-8__05'XT[TK!J/C\5Z-+/! MVPEG)"J\+KM([/D?(?
M0-@GM3;?Q5I\[P$><(;H@6LGDN?.'<XVY5>1R< U6_X0G3FO[>^EGNIKJ$Y:
M:8H[2\\;B5XQVV[:L7?A2PO+72[622<0:<$\E 5YVXQDE2<\#D$4OW7F&I6/
MBU1XEN])9+)$M6Q(\E\!,1Y8D++%MR0 ?7L:M6?BW1M0<I:W,KL(S(1]FD'
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M*906"-G+E]OS*2 "3C!!YZU3]EYAJ:MSJD%K,8I ^X '@5%_;EKZ2_\ ?/\
M]>H-1TVYN;QI8PNTJ!RV*J_V+>>D?_?5=M*CA'!.4M?4EN5S4BU>VFF2)1)N
M<X&5J_6%:Z5=0W<4CA-JMDX:MVN7%0I0DE2=T5&_4****Y1A1110 5E^#O\
MD"W'_81O?_2F2M2LOP=_R!;C_L(WO_I3)7J97\<O0B9T%%%%>R9A7#V^B6VI
M>)O$LTUQ?QLM[&H%O>RPKC[-#V1@,^]=Q7,Z/_R,'B;_ *_X_P#TFAKBQ[:H
MW14=SD9F7^T[ZTL[+5YTM)O):1]?G3<< ]-WO6GX<L+'7["2X9M:MI(IFA>,
MZS<-@J>QWUGW=EK5GKNJ26:V4D-Q<^:/-WAAP!CCZ5O>"+&XL-,N8[HQF:2X
M:5O+SM&[G S7-7HPAA^>.^G4I/6QD7DN@6%Y-;W3^*H_)(\R8W5WY:@MM#;M
M^-N>]; T/1&$)76-0(G)$.-:G_>$==O[SG\*LZWX<&L"\5IU1;F&.(JT>X *
M^XYYYSTK#NOAX'U:.\MKU(HQ*SF *ZJ@,A<;-C#!Y()[X'%<*E%KXFBB;4K3
M0]+N/)FNO$4K*H>4V]]=R"%3_$^U_E'7\C5P:+H3!"-:U AWV+C6Y_F;^Z/W
MG7VJU?:1J1U"YN=*U&&U%XBI<>; 9&4@8#QG<,-CU!' XK!N?AR)(]-$-\BO
M:H4ES&R++EPV_",N&XZ\T*46E>0%F\M_#=C,\4VKZKNC4O*5U>X(C (!W'S.
M,$CK5O\ L;0Q9PW;ZOJ4=O. 8Y)-9G4-D9&"9*R;CX=-<@QO>6@A4!4(M/GD
M&\-F4[OG;CK@5>UWP?>:QHNFZ?'J,-O]EB\N39"=C' &Y5#<8P>#D<T[QT]X
M"Y_PCVC^:T7]JZGYBC+)_;,^0/4CS*:NAZ(XA*ZQJ+"<D18UJ<^81UV_O.?P
MKFW\"ZE<6A:5+99KBX8NH0;@I<9,K;OG7;&@VK@_,>>]7#\.Y3J,-V=111PT
MD,<;1QQMN+?NE5L*.1USG:,]31[JWF!K+HNA,DCKK5^5C.UV&MSX4^A_><&G
M?V%HODSS?VOJ1CMP3,PUF<B/ R=W[SCBLK3/AX;?4/M.H7T5VGFK*8C"<,RJ
MX4G<QZ&0MZ9 K2T?PD=.M]4BGEMI#?*R?NH"H"G/4$G/))QP.M*3BMI@%KHV
MAWJPFWU?4W::(3(@UF?<4/0X\S.*D&@Z,9I(1JVI&6+'F(-:GW)GID>9Q572
MO!LVGW]K,]S:-'"5D)CMBDI8($VAMQQ'QG;CKWIDG@NY>^U:X2]MXEO"6CC6
M%B ^\.&?+<\CG&.II75_B NMH&C),L3:MJ2R.=JH=:G!)] /,IAT70A%)*=:
MOQ'&0KN=;GPI/8GS.#6+_P (3J<FMW,T\MD\<T0>2X%O\V\S22%8LME" 5^8
MYSGVIVG>!KY+*VFFDTZ.ZA156W:TW0L!NR95#?._S<,",8JO=_G T[K3?#UE
M-##<:UJ*2S2+$B?VS/N+-T&/,[U9?P_H\<_D/JNIK-MW^6VLSAMOKCS,X]ZH
MVW@1+6WB"7%O)<1WT-T)I;8,2J(J%.N>=I(YXXXIFM>!IM7\0S:D-0BBCD7&
MSRF+?<V$$[L$=3TI7C?XP-&+P_H\\#3PZKJ<D*YW2)K,Y48Z\B3%5!8^'3?P
MV0UG4S+-%YL1&L7&UUW;?E;S,$Y["K@\*Q1Z9J=E!+'#'>!-JI$ J%45>5'4
M$KDCC(.*R#X"N&NEN&N]/#2!EF1;(A8P75OW(W?(?EZG/))HC*/60%JSL?#]
M["LJ:KJT:L^Q/.U:X0N< _*"_/6GW.G>'K,'SM:U%2)5A*_VU.2'8X"D>9P3
M_0US-_X#U2RG,5C%!J$=VP\R6:-?W&#'R,L"#A#\P#>F*TT^'4ZWL]RVH6KL
M\JR(KVQ*\2;N06QG!(XQUJWR;\XC8CT719!_R%=41Q&)&C?6)PRKZD>9P*CN
M-+T"UT_[?+K.I"U+!1*-9G*DDX !$GK6?'\.W6%K9KZW: DOO-M^^9B "I;=
MS'Q]W'ISQ6Q<>%8WT:^T^!K>-9[M;J)6@!CCP4.W;D?W3TQUJ'*-_B8PB\.Z
M1.TJQ:IJ<C1'$@369R4/OB3BHAH^@DX&MWY/(Q_;D_89/_+3L.:=HWA632Y+
M@O<P,K0-;QF*#8S G.Z4Y.]NG/'?UK+O_AQ#<:2;6VFM8)L0 3?9<_<!#="#
M\V>2#GZTE*-[.3 O)IF@R7:VR:MJC,T0E5AJ]P492VT8;?@G/&*LP^'M(N(F
ME@U74Y8U)#.FLSL 1UR1)6%;?#:2+#OJV9%5T7;&=H#MEN"QR0,[3V.#6CI'
M@R;3-!U/3FO8W>\0(L@5R%P,9*LQY^F*<G'I,">+PQH+[M1BU&_8,@1KE-8G
M(*J3@%O,Z D_F:0Z3X?$9D.N7P0 $M_;DV #T/\ K.]1Z=X,:T\-W6D3W<<H
MN+A9B1&=H *DK@L2?N^O>J]WX!4WMK=V,EA&]N\[>3/9!XI!(> R@C[O;TS1
MS*^LV!H'0=%$[0'5]1$R+N:/^VI]RCU(\SI5?^S_  X;A(!KFH%WA:=2-:G(
M,:D!FSYF, G^?I5/_A7$/]GRVWV[$KL3]I$6)=OE)&%+9SC*9/L<>]0+\.KA
M;;:M]:>:T<D;LT#MD,R,-I+Y7[AS@]STIIP_G8&T-#T0F(#6-1)E&8P-:G^<
M9QQ^\YY]*D?PYI,432R:GJB1J2&=M8N !CU/F5CP>")-*T>^*L+^]:W\NW,<
M85XW#LRE6=N,%@>O\-:&H>'+G_A%+'2[58);B.>.65I4W1LV[<[,I(R"23CW
MJ6U?20$IT/1 8P=8U',J;XQ_;4_SKZC]YR/>EDT#1H1F75M2C&0,OK4XY/3_
M ):=ZQ6^'LIU&SNY+R!XH"))8(X"N\[G8HOSX"?/@ @X'>K%AX+-SI-O_:>T
MW),KRK,BR$;DV(#@XRB[1QZ4VX[\X&@NB:&[HBZSJ#.[%54:W.2Q'4#]YR14
M+Z=X=1X4_MO4&::40H$UJ=LN1G'$GH*RY/AKC7O[1M[^-(F$ : 1NH!C ^9=
MK#DD9.<^^:T;7P/'92Z7)!+:AK(0A\VPQ(44@MP>&.>O./>FW'^=@6WT#1HY
MFA?5M2655WLC:S.&"^I'F=/>JUUI_AVSL&O9=:U'R &(9-9G;=MZA<2<D>@J
MIK'@&;5M?NM0.H11Q3 @1^2Q/*!"&^;!''IZ5)J?@,7370M)K*&.Y#*4DM-P
MA!QS& 1M;(Y/>DG'2\P-&3P]I$,Z02:IJ:32#*1MK-P&;Z#S,FJEG8^'+[3(
M]0AUO4?LKHK;WUJ==NX9 ;,GRGV-7-3\-SW_ (FL]5BN8H%@ # 1L7<#/&=V
MW'/I68G@$6MK9K:2V7G6T$416>TW0S,BLI=T##<3NR.>#ZTE*-M9,"Y?:-HN
MG64UW<:EJXBA&7VZM<,>F>@?DXYI8M&T2>_>RAU35I)XTWNJ:O<':,XP</P?
M:LZ3P#=-;_8DU6,6?+_- 3*9##Y6=V[&.^,9]ZT=%\)RZ1>W,XN;<A[<V\1C
MM]CD%BVZ0Y^9N?04VXI?%J J:+H4L@CCUJ_=RVP*NMSDEO3'F=?:@:+H1B\T
M:U?F,/Y9?^VY\;O[N?,Z^U9Z?#FUCB18YXHI%2%/.CMP'&R-U+ _WBS[L^U,
MF\ W$]NJM<Z<C[TW)%9%8@J@@$+OSN(9LDD@@].!1>/\[ N36'A^&'496U;5
MBNG?\?6W5KEC&=H;& _7!I5T[0S>R6C:CK,<L:[V\S5+E5V[MN<E\<GBKJ^&
MB-.N[3S8 +B\$[,L."T8<'8W/)P-N?TK/B\#!=1MKZ74&ED@ZHR?NW!9V;<N
M<$Y<$'MM%)2C_,P);C3-!ML!]6U1B9UMRJ:O<,5D;H#A^.AZ^E.O='T33X/.
MN=4U98]R*3_:]P<;SA2?GX!/>LS3? DFC$7$LYU$0Y80KNWSX4@9+OMW9.<\
M5=M?"5P?"B6=U/"VI22133RRQ;T.Q@5C(!&5  7KZGO3;BMI 6ET+16>%%U?
M42TXS$!K4^9!ZK^\Y_"H[W1]$T^&>2YU755,$+7#QC5[@OL4$DA=^3TK.C^'
MTJ:M:7YOX_DE666%$=$4A]V(@K_*OL<UHZOX2EU.^OI5N;5([N%D+O;;YD8Q
ME/E?/"\YQC\>:+QO\8#AHVA%)'_MG40(U#2;M:G!C!Z;OWG'XTIT31 R*-6U
M)GD3S(T769RSKURH\SD<'I6(?AS<_:+N;^T+5_.4JBM#( /G#[CAQ\PQVP.3
MQ5Z/P5=K>64QU&+]Q:_9Y'$3;Y/E8?WL8^;TS@=>]-N/\X#;"+P[J3S"WU'6
MRD#E)9&U2X"(P4,06WXX!YJS<Z;X?M+>.>36-3*2X\O9K%PQ?)"_*!)SR1TK
M-;X:*=#CTY-06(I-YWF10[-QVH #@],IS[&I(/ ,\,,,8O+1OF1I6DMVD9=L
MF\>46<E,]^M-N'2;#4UW\/:1'<+;OJFIK,REEC;69PQ ZD#S,XXH@\/:1<PF
M:WU34Y8AG+QZS.RC'7D253UOP;/JWB1-56]A1$V?NFB8DX!!!(8 @Y/;-3Z9
MX4N+'PMJ&CO>Q.;I65"(CLB!7;C!8DCOUJ.96OS:@#Z-HB:;-J']K:F]I"C2
M/*FL7#*%49/(?VK&>]\++)#&NHZ_++,7"1QZC<ECLQN.-_ !./J".U=#X7\-
MMH.EW-G<SQW0GF:5@$(49 &,,3QQ5+7_  1#K5W<SQRP6_FV)M$ MP=A:0,S
M]1R0,?C3C./-9R=@)DT316F2#^UM36X=0PA;69Q)R,_=\S- T;03#),-:OS%
M&=KN-;GVJ?0GS.#56;P(DFMOJBW423F\%RKBW!=56#RD3=GH#\WOTQ6?IOPV
MEMXF74-2AO&DO+>YE!MSM=8E.%(+'JQW?IBB\;7YP-S^PM$V0O\ VQJ.V<XB
M;^VI\2'T7]YS^%11Z1HCQ1.^J:K!YK,L:S:Q.A<@XX!DY_"LR'X<M!]A1;VU
MDBAB,<BS6F\ F4REHQNPA)."<'@#&*CO/AO<7-AHNGC5T6SL(D26,P']ZP<.
MS AN,XQSG%.\?YP-BQT?1M1DO([;4-:8VDY@F)U2Y #@ D#Y^>M4KO3O"=E+
M;7TNK7V^YD^QQW*:O.W."VTL).!P3S6K'X8(\/ZSIC7KA]3FN)6GC7:4\TG&
M.>PP/PKG_P#A7-R)(KA;S3!,D_F^0;#_ $;B+RU CW]0"222<G'I1&4;N\F!
MH26>@I=7%LNH:W+-!%%*XCU.Y;Y9"0F#OP<X/X5=.@:,)GA.K:D)4&73^VI]
MRC&>1YG'%9EI\/$LK9;9-1+Q":S?YX\DI;C[O7N23[5CVO@S6;KQ#J,^P6$1
M2[,%[-#&TS23L/O;7;>JJ"!G;@$"G[KVF!T-S9>&[2W@GEUS4/*GF6")EUJ<
MAW)P ,25+%H^BR0P2-J>K0^>2(EFU>X1G.<< R<_A659_#N>UL[.-K^UEE@O
MY;QS):EE8NA0  MD%0<YR><4LWPX$D.GVZWT7DP64%I*7M]S@1L&+1'.(RQ'
M/!I7A_.!J2Z3H,*W!;6-2+6R,\J+K,Y90O7($F:;I>DZ/K$#S6MYKNQ&VGS-
M2NEYP#W?WIFC^!H-+UB+4'FAF=1=&7$ 4RO-('RQSSA1MP?K74I&8Y,1B-(2
M,E57!W9Z^GZ5$II:1;8&/_PB=C_S^:Q_X-KC_P"+H_X1.Q_Y_-8_\&UQ_P#%
MUNT5G[2?<=C"_P"$3L?^?S6/_!M<?_%T?\(G8_\ /YK'_@VN/_BZW:*/:3[A
M8PO^$3L?^?S6/_!M<?\ Q=2^!X5M_#LD*%V6._O%!D<NQ N).K'DGW-;%9?@
M[_D"W'_81O?_ $IDKTLMDW.5WT(F=!1117L&85S.C_\ (P>)O^O^/_TFAKIJ
MYG1_^0_XF_Z_X_\ TFAKAS#^ 5#<Q5UG6+C5]5A2]CBAMKKR8U%N&.-H/))]
MZT_"&JWNK:?=27TB220W4D(9$VY /'%9M_X,>XU6\O(;B[A^T2>8PBN=H)QC
M.,>U;/AK1/["L9+4;BK2&3<[[V)/4DUR5_8?5_<MS:>I2O<Q+KQ)XATR^9;N
MUL+F!+R*V,=FLGG/Y@R-NXXR/<U>M/'NB7FJ6NGQO*L]PJX#A5V,PR$8;MV<
M>@(YZUMRZ38S3>=);AI/.2?=N/WU&%/7L*J0^&-)MKV*[@MGBFB "^7/(JG'
M3<H;#?B#7%S4VM5J5J4[K6M3%Q=W%I!9G3K&3RYQ,[+*^ "Q7L, \9ZX[9JN
MWQ"T6*XM8;D3VSW$:RXF"*8T;.TL-V<-@XP#[XK4O_"^CZG<R7%W:&1I0!*O
MFNJ2XZ;T!"L1ZD'H/2ED\-:3+<03M;,LD$:QKLF=057H& .' _VL]:2=.VJ#
M4YK4_B&]D[E-)NMNV,QQ2QXDEW"0Y'S8"X0'/N1BMW7O%NG>'3:B_68&X(P$
MV97) Y!8$\G^$&D;P5H#HZO8NX?@E[B0D### );( #-C'3/%3ZAX6T?5;VWO
M+VT,L]NJK&_G..%;<N0#AL-SSGFFW2NM&&I0F\=:3;ZA=6LL5VD=N\L;7)C'
ME,\:;W4'.20/;&:JS?$G1;6S::[AO;:4.B+;S1JDC;T+@C+8QM!/)%(WPZTY
M],O('FD:]NWE:2[;)QYCY?:F=JDK\N1SBM,>"] %H+?[$^!+YPD^T2>:'V[<
M^9NW?=XQG&*?[A=PU*T7C_1)]1CLXVF8RV[7"2 *5*A-YR VX<>H ]ZB'Q!T
MPQ:=(UCJ*#4!NMA)&B%U^7##<X_O#CK[5?3P7H$=W-=+8GSIT>.1C/(00X ?
M@M@$@#)'-27/A+0[N:UEFL0S6L:1Q 2.%VH04# '# $ C=FE>CV8:E:Z\::=
M9ZZ=*E@O-RS) ]PL8\E'=2RJ3G/0$\#BJ%W\1+*/3)[FTTZ_GE"1R6T31A/M
M*.^Q74D_=SZX/(XK?;P_I3WANVLU:<S_ &DL6;F39LW8SC[O&.E4D\$^'H[=
MX%L"$9HV_P!?(67RSE K;LJJGD*"![4)TNJ8:C+OQ5]AU<V$^G7;'[)%,IC5
M27D=RHC W=>/IP>>*EO?%NGV&B0:K+'<&&:3R@F%5D89!#;F"C!!'7Z9JW?>
M']-U*X-Q=0.TWE"+>LSH0H;<,;2,$'D'J,GGFDE\.Z;-I<6FM%,MK$<JD=Q(
MA)YSEE8%LY/4FIO3TT#4KW'BO3;:WGGD$Y2&7RF*IGYO+63CGD8855_X3>Q$
M@A-AJ0G4,TT/DC= @VY9_FQC#J>"3@]*FU#P;I%['+MA:&5X_+5ED?:GRA<A
M,[<[0!G&<5#_ ,(+I'VRWF(G,<,3HR&>0F5F*'+MNRPP@&TY&/I5+V5M;AJ*
M?&VG$!DM;Z19&VVK)$"+KYMI\OYN0#CKCK4D'BN/^P;S5[RRN;:*VG>+RV"[
MFVMMSUQU]2!5J+PQH\%T;B.T(DWB1<RN50AMWR*3A!GG"@ ]ZDD\/Z;+97%F
MT#^1<3&>15F<'>3DD$'*\^F*3=/H@U,NT\=:7?36Z6T%Y(DVS=,L:E(B[LBA
MB&_O(PXR*GU;Q7;Z;+=P+;SR/;KAIMG[E9"NY8R<YR1CH.XYJU:>&-'L4*6]
MGM!*,29'8DJS.I))SPSL?QI;OPYI5]>M=W-J7E==KCS7"-QMR5!VD@' )&1Z
MT7I<VSL&IS]Q\08;>2S\^VDM%92UV+F,[XAA&! !/!#'GVZ5:O/'^F:=:O-?
M6E_:E'"O'-&JLN5+9.6QC ['/M5N3P5H4EL8OLAW8;;(\KR,I( ZL3D# P#D
M#%4;#X?Z='8R0:I--J$DC[C)YLL?&W;M^^21CL21["KO1?1AJ)!XZBDNVB>P
MN@S22QV\*1@R7&QE&Y?FQC#9(..GM5VS\9:??ZA%:06]Z1(RH9S$!&CLI8(Q
MSD' /;&>]3OX0T-V9S9LKL20R3R*RDE2=I#97E5Z8_4U8M?#VE66W[-9K'M=
M)!AF^\J[5/7KC\^_-0W2MHF&IEOXSB@O+^WGTZ])M9F0&)%;<BJ&:3K]T9^O
MH#5K5O%=AI$L*2PW4PEA\_=!'N"1Y"[CR.[ <>M27?A71[V>::>U<R3/OD*S
MR)N.-IZ,."  1T/>K5UHNGWC;KBV5SY/D=2/DW!L<'U4'\*+T[K1AJ<W-\2-
M,!GMXH+B.]B61?*N JA9$!)0X8GL>0"/?-3)\1-#:2R1GD'VS:8Y/E",I;:&
M&6R5+9' )XZ8J\W@K0&O+B[-BQEN)&FE_P!(DVL[##-MW;<D=\5,?"FC?:UN
MEM7BF5MX,4\B#/N%8 CVZ=?6J;H]F&HV]\5:=8>(;;1)_-%U<%0C8&W+9P.3
MD]#T! [XJ"^\86=CJ%Q9&QU">2%_++0P@JS^6)2H)8<A#G\*O7'AW2[K5X]4
MFMW:[C*LK><X7*YP=H.TD9/.*EDT73Y9Y)GM@9))#*[;CRQC\HGK_<&/_KU"
M=/31_P#!#4QH?'>FW%M#/!::A(ER%-IB$9N0>Z9;I]<=:@N/B/HL3>3&)WN3
M"9!$0H8. Q\L@MG=\I' (]ZU;'PEHFFM&;6R*>45,2F5V6/;T"@DA1ST& :7
M_A%-&\\3+:,C;2I"3R*K@YSN4-AOO'KFJO1OLPU,I?B%I<;K!=07<-S]G$S1
M%%SG:&*@;LYP>N,>]:]IXBM;J\BLO(N8;MR0T$J -& H;+8)&,,HR,\D"JZ^
M"= $OF?8I&;;MP]S*P' '0MC. !GK5R#1TB\076KO('EE@2WC4)CRT4DD9SR
M23U]@.U*7LFM$&I0F\9Z=!->I)!>+':-(C3>4-CN@!9%.>N#WP.O/%)8^-M)
MU"&)X?/#2N$C0JI+,6VX!!(..IP>E+%X+TOS]0FNEEN7O)Y)CF5U$>['"@-@
M$;1\PP:?!X3L;74[&Y@RD-GYCQPL6<F5P 7+L23P.GKS3?LO,-2A+\1=(M[0
MWD]KJ,5HJH[3O  BHY*JQ^;H6!'_ -;FGQ?$#29[=9H+>]F #-,(D1_(52 6
M<AB,<CH3UK4E\+:+-8?89;!'MBD<?EEFQM0ED'7L231#X8TF""2%;>1TDC:)
MO-N))"4;&1EF)QP*+TK;,-2G#XMA'AB36[VSGMXTG>'R_ER<2% 02< ''4D5
M#%X^TB7RG6.[^SNBLUQY0,<98,0K$'K\K= 1QUK4?PYI<FG-8&W<6S3&XVK.
MZE7)))5@<KR3P"!S38?"^C00>3'8KY>Y6*L[-DKNQG)Y^\WYTKTM=&&I5L_%
M23VVJ7<]E<V]O8HLFR2/]ZRE=V< D=.G/UQ5,^.K<O:SQV5Q)930/*\D>QVA
MVL%);:Q7:,]B3[5LVOAW3;*TN;:WBF2.Y $I^TR%R ,##EMPP.!@C%-@\,Z1
M;V[01VAV/&\;;Y78LK'+9).3D]Z+T[[!J5H?%^GS74<'DW:>=,(H)&C 28[B
MI*G/0$=\50G\<Q1RW\<-E/<-!$9(UB3+8 ;<S\\*" .,GGI6H?">BDS'[*X,
MQR2L\@V'=N^3#?)SS\N*8W@W06A$7V)E7&TE)Y%9ASP2&R0<G(/!IITNS#49
MJ'BRVTJ"T:XM+N9Y[?[0XM8MXC7Y02>1QE@!C)/I4:>-+%\?Z%J*E7V3AH1_
MH_S;07^;H3TQD^U:TNC:?,RM);!BJ)&OS'A4;<HZ]C55_"VC//',UF2R-NQY
MK[6.[=EESA\-R-P..U2G3MJ@U*/_  F,4X(LM/O9I%O5M""BCJ3EOO= !G!P
M>G%-U7Q6=.N;^,)%LM3@,^<$B(R-D]@!M&?4UHVGAC2;&1)+>WD5TE$JDW$C
M$, 0.K= "?EZ>U27/AW2KLS&XLQ)YP829=OFW;=W?OM7\J=Z=]M U,5_B'HU
MO96MQ<,^+@91D*[9% &YTW,"4!./4XX!JU:^+;:0R":-LM*RVPA7<9E#^6,9
M_BW!N/09JW-X6TB=T<VSHT;LZF*>2/!8Y(^5AQGG'3VIL'AJU@UJ&_&TQVL3
M1VL 3_5%SEV+9^8D_ESZT[TK;!J4)?&UKI]SJ2ZG;SV]O:3-&ER$S&^$5MN<
MYW<^F/>K=KXMTZ\T)M5@$TD8E$'DH%:0R%@H088J221WQSUJ:;PKHUS=W%S/
M9^9)<9\P-*Y0D@ L%SM#8 &X#/'6I4\/Z<FEMIOE2M;,V\A[B1F#9R"'+;@0
M0""#Q2;I6V8:F+>>.[737DDO;2XB@"(51E"R!CNR&#$*,;?7GMFK'_"<:27O
MPJW#+9PB9V 7YU(4_*N[=_$.2 />K,O@_0YEC#V;Y1=H9;B16(]V#9.>^>O>
MG+X3T=&=EAN 6C\H'[7+E%X&%^;Y> .F*=Z79AJ9%UXU>2;2H]+M#,;]E W@
M-Y:[B&)*MCL>A-):_$C0Y&$,TS>:$8ED48+*"=@7=NS@'MCWK<MO#.D6CV[P
MVF'MSF-VD=F!R3DDGDY)Y.:AC\'Z%$^8[(JI0HT8FD",""#E-VTGD\D9HYJ6
MUF&I%;>*4.EZGJ-Y9W%M%8S>6T3H/,Z+U&<?Q=<XQSGK4-EX[TF_N;"W@6<M
M>$JA)C 4ABI!.[YN0?N[NU:*>&M*CTN?3A!(;>X?S)=UQ(SLW'.\MNSP._:H
MH?".C6\MO)';S9MVWQJUU*R[LYW%2V&.3G)!I7I:Z,-0O?%.G:?X@M=%G\T7
M-SM"-A=N6S@<G)SCL"!WQ3-3UC4=/U)LZ?\ \2J*,2379(^50K,QQGL !TZF
MK5SX=TR[U2/4I[=VND9&5A,X7*_=)4':2/4BI-=TH:WH=YI;3- MU&8G=5R0
MIZ_F,C\:2<+K3U YZ3XEZ);VAFNH;VVDW1JEO/&J2/O4NI&6QC:">2.E07_Q
M(M3HM[>Z+I]Y?M (U1_+"Q%Y I4$[L_QCH*V1X+T 6GV86+;?-$V_P ^3S P
M7:"'W;@ .,9QBK2^&])2U:V%IF)KA;I@TC$M*N,,23D_='Y5=Z*Z,-3&3Q]8
M6T3C48[A'@2433QPXA:2)=TD:Y))*@'VR#S1-\0M.MWB673-64R(DN/LX)5'
M8(C$;N-Q/ Z^PK1F\&Z!<3W,TVGAVN0XD!E?;\^-Y5<X4M@9*@$U:G\/Z7<W
M?VJ:T5ILQ'=N;_EF24XSV)-*]+LPU,67XAZ-!:V-Q+%=QK=RM$JLJ!T99/+.
M5W9/S?W<U(?'VD)?7-O/'>01VYG!N9(@(G,) DVG.3@D=JM-X*\//-;2G3_G
MMB#'B:0 $.7&1NPWS$GG/6IV\*:(Z,C:>C*R3(0S,<B5@\G?NP!S^5%Z/9AJ
M8UY\2=%TU8Q?P7]I,^3Y$\(1U08^?EL$?,/NDGVXK3U?Q=IVC7@MIH[F5EC6
M69X8PRP(S;59R2."?3)X/% \&Z$!#MM)%>%F995N91(2Q!.Y]VYLD#J35J_\
M.:3J=]'>WEH)9XPH!WL%8*=P#*#A@#R-P.*+TKK1AJ<P_P 1EBM=6:33Y4DM
MWNA92,/W-R(3@_-G.<]>*U/^$OBM_M'VJ&226*XAM%M[:(L[SO&'*KDX( ).
M>, &K'_"$^'OWX.G;A.&#JTTA W,&;:"V%R0"<8SWJ+7?"$&J6<D-I)'9R2W
M/VJ24H[L9-NW<I#J5...#TXQ3O1;M8-2!?B#HS#2VV7(74F"P[E4,"7*#*[M
MW4=@:BL_',=SJ<T,]K)96T,MR#+.F0\< P[@J>,-D8([5;L? FA60TYS;-+<
M6$<:1S-*XR4SM8J#M)Y/4=ZN6_A31;621XK$9=9E8/([C;*=T@P20 QYQ0W1
M6R8:F8/B#IIC7%AJ?VB1XECMC !)()%9D8#=C:0C=2,8YJQ;Z_J&KQZ?>:-8
M!]/NHTD:6X^5ER^&& >H4$_4CUXL6W@_0K0H8K'YD?S%=YG=L[#&/F8DX"D@
M#H,\5J6EC;V%A%8VL7E6T2".-%)^51VSUJ9.FOA0:EBLOP=_R!;C_L(WO_I3
M)6E&@BC2-<[5 4;B2>/<\FLWP=_R!;C_ +"-[_Z4R5W99\<O0F>QT%%%%>R9
MA7#0^'='U?Q/XDGU#3H+F5;V- \BY('V:'C]37<US.C_ /(P>)O^O^/_ -)H
M:XL>VJ-T5'<X&?28I]9U*WL=$T-+>UN/)7SHF+'@'/'UK9\(Z!HNM:;/-?Z%
MIRS17#PGRHSM.WOS2WF@ZU%K6HW%A=A(;F?S=KVN_!P!U_"MSP?I=QI.FSP7
M+F262=I6<Q[ 2W/ K'$."PUX[Z#6YS$X\+6-PR:EX-^Q6Z3I!)<RM"R(S#*Y
MVN3@_2MF'1O =S<V]O!::9)+<1B6%5YWJ1D$?D:V;G0(+F[^T/-(&^UQ7> !
MC=&, ?2LBT\ 6-EK-OJ,-S(6B979)$#!V48#?[)QCIZ5Y_M(M;M,NQGW5EX1
MM-5FLY/#,?E0#,UP F%^7<3LW;R .X4C\C4MK:?#V[A@=;734,UN+D(XP0A&
M<GTXK8U#PJNI:J+N>_D,(.1%Y,99?99<;U&>< XZCH366_PY@FEC>?5;F3RX
M1$,QH"0$V=AZ>U"G%K63 @FA^'45@MXMOIDL;L40)C+L,<#WY'YBG:99^ =4
M8QQ:?81SJ_EM!( '!S@<9[UIWW@V*ZN;BXBU">WDN1LF*HC;X]D:E>1Q_JE.
M>O6JE[X+G73[B.TOGGE\MX[19ML:VQ=U9GRJY8@JI&?3WH4XM?$P'3Z%X-B2
MQ=-&M)X[VY^S1O$H(W88Y//3Y"*CU'3/ 6EFX2ZL=/66WA,[Q!<L% ST]:V;
M[PZMQI>G65I>2V;:?(DD$J(KD%5*\AA@Y#&LF;P!;W.HS7T^H2R33I^^8Q+\
MTFS9O'93@#@#M[THS763 I6:?#F]1FCM=/4"80C>N,O@' _/K6C%H/@:>*ZE
MBL=->.T)%PX'$9')R:ANOA[;WDJ33:E/)*I/+Q*05(4,".!R4!]JVT\/6Z>'
MY='$LGE.6(DXW*2VX$=N#1*<>DF!S<%IX$O-7LM.LM*LKI[J-Y0\0&U57@YR
M<YSV%.ETSPK'=2#_ (14-8Q2&*6_5%\J-A][(W;L \%L8'//%;^E>'5T[4&O
MY+V:YNY%<2NZJH<L5YPHP,! .*KWOA1KS[5 FL7EOI]R[2R6L04?.W)PV,@$
M\E>AR?6CVBONPL9\.E_#^YDBCAMM+=I4\Q .Z\\_H:RY;CX=1,6_LZR>#S$C
M$R@%69MN,#.3C=SQQ6U>^ -.O=6:]DFDVR(BS1%0=Q5-@8'^$X Z4DG@;[1.
M;JXUFZDO-RN)O*C7!4ICY0,?P#\ZI3A_,P$NM$\"65R]O<V>FQ3)%YS(PY">
MOTX-1-IWP]5K=6@TH&Y7=""<;Q_D&M?5O"UKJXU#SIY5-XD*G;CY#$6*D>O+
M=/:LC_A S;6D4-G?G:TL;W49B55G"R%\YP2I&YNG7O4QG%K63 DN-&\!VL G
MGM-,2,JK!CW#9P?H<'\JKWEE\/[&&\>2ST]C:1>=*B+N(7C'YY'YBI;GX?0W
M<:B?5+B22(*ENQC0")!D;< #/#=34L7@2".29EU"5$DM3;+'#$L:J-H7<0."
M1@=::E'K)@0C3?A_B8FVTP>1&)9<_P "G')_,4EMIG@6XTJ74SIEE%9QS/#Y
MLB\,5;;D<]">E21_#VUBOIKM+^82NS2HQC4F.4G<7&?]K)QC'.*O2^$A-H$F
MF/J,Q>2Y:Z>X,:99V;<?EQC&3VH<X]),#(MK7P!=:M)IJ6%@)@B/&6 VS*RE
M@5.>> ?RJ>VTOX?WENT]O;Z7)$BL[,.P498_0 BEMOA[:P0"T?4;F2Q:-4FM
MRB#S"H8 [@-P^]V/:K1\%Q3Q#[;J5Q<W'FQLTVQ$+1IP(\*,8/.3U-#G'I)@
M1V_A_P $7=[)9V]AITMQ&NYXU&2!_DBH++2/ U]<K:1:=IQNR"?)&&8 'V)'
M:M#3?!]II?B*?5H)F/FO)((G0'8TARV&ZX)SQ4>F^#(M-UF+4([^9A%N(B"*
MN[.?O$?>'S=_0>E+G6OO,")?#_@AM4.FK8:<;T+N, 'S8_R13$T7P)+<RVZ6
M6FM-%((G4#[KDX"_7/%7$\(PIXL.O&]F9]Q=82J[02H4\]3P*IWO@^4)K$]K
M=-+<7Z%$C)$*1$L&W_*#E@><XY_&A27\S C;3/A\EW#:M!I0GG.(DR,MR1Q^
M((_"JB0_#^6YDCBL-/>*($R3Y4(N 2>IR>G:MW_A$;,VYA:638T%O"ZJ  1$
M[/G\2QS5$^ H9 OG:I=2-"$6!O+0>6$!$?0?-MX//7'--3CUDP(O[.^'ICMI
M/(TK9<Y\D_W\'!_7BHM/M/A]J45J\%GIX-UN\I'7#'!(/';D&K=_X%75);66
M\U:XDDA</(WE(OF$.'[#Y>5'2HF^'5E)=0S2WLTH5=DBNBG>H+%1[$!B,CGO
M1SPM\3 KI:^ 9;?4+F+3K*6VL(_,FF1,KCG@>_%.6U^'36[S&#2U6,)YF1RA
M89 /OCM6Q9>%A:V=];RZA/<?:H%MP[(BF-%4JH&!R0#U-5KCP3'<:7)9MJ4^
MZ2Z^U/*8U^9M@4C&..G:CGC?XF!4.G_#P7+VQATGSDC\QDR.%VAL_D0?H:<=
M,^'ZP6\S6VF+'<L5A9AC>0<']:LP>!K6VTK[#%>2D!]X>2-&Y\E8>A&#PF?J
M:J7/P[@NM/M;.35;HI"7W'8IW!F#8']WI1SQ_F8$-Y;?#RR\P/::<[QSI;NB
M#)5V. #^1_(T^*R^'TB$M;:5&ZPB>1"RG8I Y)!QW'0]ZT_^$1Q$\2ZI<K&L
MHDMU\M/W/SER,XRV23UJI#\/[:*U2S_M*Z:SCPR0E$XDPH+[L9.0O3IS0IQM
M\3 6/1/ DVEMJ<=GIK6*YW3@?*,'!_'-0KI_P]::VA$.E&2Z ,*YY<$X'Z\5
MMWWAV*]TR^LA<R1_:Y_/9PH.T\<8/4<5GV/@6RLK&6U-W/(DK1,^0!G9*9 /
MQ)Q4J:MK)@5M-TCP/J]S<PV&F6,XMP-\B+E<G/&<^U1VNG>!I["XO9=)M+6W
M@E,3/<)M#?W6'/*L""#WK5L/"IL;2\@_M2Y<W$"VR2;$5HHU!"@8') /4U2N
MO UO;0>7H+?8 [PETSN4>6V0XW9Y R,=*?/&]N9@5WLOAZHC"VVER231&6*-
M<;I%P3Q^1J/3[3P#?K:C^S]/@FNL^3#(5WMQGL3@^QJQ'X'E^WW1EU.4VERL
M;3@(FZXE#.Y8\?)\S9PM6=-\$1Z40MKJETL#L&GC*(?-*_=YQE<8[=:;G%+X
MF!1:T^'*6[SM'I(B1_+9L\;L9Q^51/;> _[/U6]BTFUFBTQPD_EIZA3D<\CY
MOT-7]&\!6VD7:W(OYYI!ZHJC&TJ. /0GI5N'PC!%I&H:7]MG:VO"A(*KF,JJ
MJ<''.=@ZT.<4_B8&:NG_  ]>.WD6#2BMPYCB/]Y@<$?GQ5JR\.^"=2:9;+3M
M/G,#;)-BYVGT_2DUGP);ZQ=-,U_/$'=G9513R2#P<>P]:T-&\-II%U>S_:Y)
MOM1YCVA$7DGA1QGGK4N:Y;J3N!BFQ^'8M9KKRM)\B&01R.#PK'H*BOX/AWIR
M7'FVVF/+!"9FA3!8KC/'/I6I%X0D@@MQ#K-RMQ: ):3>3&3#&%*A,8PW!(R>
M:$\$6,>GBRCN;A8ED:0="06A\H]O3FJYX_S,#*@MO 31*]UIVG6C,GF>7*RD
MA=NXD[2<8%/%O\-VSA-(.%+8!YP#@UK7/@^UN9=4D:ZG!U&U:VDP%^52H&1Q
MUX[U6UKP%8ZTP>2[GC=+Q[U"@&!(R*G/J %_6A3BWK)@4[BQ\!0W-E;+I]A-
M/>-&(HXP"2KG ;KTX-59_P#A7EKJ<UC/I]E$T,IBDD=,*K!5;&?^!?H:V+/P
M3%9-9B'4)5@@F2X>%8D"RR)G#9QD=>0#5Q_#$4FK75^UW,1.'Q%M7"%HU0D'
M&>BBCVD5]IA8P]0MOAYIJW!GM=-W6^WS$0989( _]"%1ZK#X!T;4([*[TNT6
M5@C$B/A%<D!CSTX-6?\ A75O]NDNEU2Y60Q[(\1I\G*'/3G_ %:]:V[_ ,.I
M?ZQ:Z@]W*OD&-C$JKM<HQ8$\9'7M1SQ5O>8&3#H_@*XGMH(;33))+F,20JHS
MO4]"/R-4;NR\(VFK36+>&8V2#'G3@)A,KNSL+;V&.I"D#GT-:,7@*Q@UN#4H
M[B0M&ZR/&Z!@[*3@_P"R?IZ5=U#PNNHZLMY-?2>4K!A%Y,992.<+)C>HSU .
M#SZFESQ3^)@8MG;?#N]MX)4MM-7SK<7(5Q@A",Y/I@9_*FRP_#J/3Q>K;Z9+
M$S%$"=78#)4>_(_,5(WPUMI?)$VJW,@B@$ S&@)41F,=!C[I].U:=_X/BO+J
M>YBU">WEN%\N8JB-OC*H"O(X_P!6ISUIN<+_ !,#*TRT\ :HQCBL+".X63RV
M@D #ALX'&>Y_F*MR:#X-2*SECT>TGBN[@6\;Q*"-WS<]>GRD5'>^"YUT^XBM
M;Y[B3RWCM%EVQBV\QU9W#*N6(*@C/I^-;5[H GTFQL;2\DLVLG1X9E17(*@C
MD,,'.32<U?23 Q-2TSP'I/VA;JPL%F@@:=X@N7V@$\#UXZ54LU^'%[$TL5MI
MPC$P@!=<;F*@\?GBKUQX @O+^2\N=1EEEGC*SDQ*-[%"F\=E.#V';WIMW\/8
M+TQO/J<\DR$X9XEP5*H&!48')13[52G"VLF!-%H'@>9+MX['362S)%PPZ1D#
M)R:H16O@2ZU6PL++2K*Z>\1W5X@-J*O4G)SUXP*Z-/#ELGA^XT?S9##-O)88
M!4L<\=N#3=,\.BPO_M\U]-=7;!_,D=%4/NQV48& HJ%46OO,+&!+I?A:.[D4
M>%-]E#(8IKY8U\N-@.<C=NVCNP&!SSP:GATSX?W,D,<-OI;M.ADC _B49Y_0
M_E6AJ'A1[X7MNNL7EOI]YN:6UB"_>88)#$;@#U(Z=?6JUYX!L+S55OGGDP4C
M66,J"'*+M# _PG '3TJE.+6LF!ARW7PYB\Q_[.LFMXY%B\]0"K,VW&!G)QO&
M>.*U[[2/ 6FW*V][:Z9!,PW!'X)'/^!I7\!K+(\\VLW4ET75UF\J,;=OE[?E
M P<>6/KDUM7.@P76HO>/*X=S"2H Q^[8D?J:)5(]),+&!!IWP]N=YA@TIPD7
MG,5Z!.N?U%5VB^'*7"Q-;:< T'GA]OR[=VW\\\8IR?"[2TDNLW<SQ7#22;64
M%D=SDL&^O;\*LKX CCM#!%J3IN4K(?LZ$.=^X-@]&![@T^:'\S#49J>F>!M*
MLK2[N-+M##=R".!ECSO)!(_E4-M;_#NYTY;Y;;3%B)56W=48C.TCUK=G\,I-
MH=AIHO[A39R+(LYPS-@,"#GC!#$>W%9VI?#ZPU$0L;F6.2&&*%&V@@*BLO([
MY#?I4QG'K)@7U\%>%V4,NBV94C((3K2_\(1X8_Z EI_WQ6S:VZVEG#;)C;$@
M08&. ,=*FK'VD^X[&!_PA'AC_H"6G_?%3^!X(K7P[);P1K'#%?WB(B]% N),
M 5L5E^#O^0+<?]A&]_\ 2F2O2RV4I3E=]")G04445[!F%<SH_P#R,'B;_K_C
M_P#2:&NFKF='_P"1@\3?]?\ '_Z30UPYC_ *AN;5%%%> :GG5IXJ\423WR/9
M+Y\;$Q6OD,26#$>7NP!C'.[/;WITGB76);R2UAF^TLL4?[@6$B&4-'N9RV?W
M94\[3R>E=9_PE.A_+C4H3NE,2XR<L,9'3W'/2HQXC\.PW%XRW]JLR'_2"OWB
M1A?3YNH'&:Z>;^X(Y*]\1^*;'0K6Y1,SSNX6'[$^4" 84GG[Q[G'M4::SX@M
MKV5I)9@CR2>;<O8R/]E0NNT!!PXQ@=/ZUVA\5:$%+?VG!@0B8X).$)P#^9Z=
M:I1>.M":'SY[V.WA8D1M(W+X+ D <@?+GGM34G_(!2TK5O$=W>03W*B.U,T<
M+P?9&4LK1@^9N)RO/;'M5+6=;UN'6IS&TH^RM,4MELY&4*(SL<N.'#'G;VKK
MH->TJYU)M.AOH9+M1DQ*>>F>.QXK)MO'NA7.HFR^T&-BQ1'D&%=M[)M'IRO?
MU%2F[WY0.3C\3>*WC^W;)BPAEC6+[(P5P'7][TZ@$\8YQ730ZMKMWX8TN:/R
MX[ZYO%@EE$#.%CW,"^TXP< 9SP":VM.\0:=J<_V>WN4>Y"[FC0[MO_ AQG\:
MK6_B_0[BZEMOMR1S1RR1%'!!)CQO/T&>M.4F_L; <K;^*?$TD]['=0BT1) '
M<6K2-;*'P2% _> C'.>*=:>+M8NM*020F6XN45H3%:2!73#AR2/N\J."01FN
MI/C#P^L4,K:K J3,53.021C/&,C[R]?44^'7="MK>Y6"Z@CALSB4(I"H2QZ8
M&"2<],\T.6GP <A=>(?%=EHMK=+$O[Z5T(:U8>2%'R@]2=WKCC%6Y]7\6FWN
M;N$1C:D\D=L+-F),; *@;(SO!ZX[9%=*WBG0T\K.I0_OHC+& 22RC.?QX/'7
M@U6L_&FB74$,S7D<*SE1$';YFRH/('W?O#K1=_R <OI/B3Q;JP6!D2TDDE^>
M1K1G, \N1BA4X!&54;L]_I47_"1>)+5S(\LK22SHSVWV%]P4QJ=J$C&"<]P:
M[NT\0:5?3W$%K?132VZEI53)V@=3[].U5M.\6Z+J8LQ#>H)+M=T,;Y#$9/Y9
MP>M/GU?N 4O$>LZEI^LZ5#: M;SL!-$D!=SE@.N,  9[YKFF\0>*+R[>*<-9
MI#?P^8([=G:-/-VE>!\RD$$G/;T-=1=^.M$L=4>QN9VC,4QAED93M1@F_GVQ
MZ>E:]OK.G7=^]C;WD<ERB[F13VX[]#U%2FXI7B!S&J2:K9:]JU_'<S+"J6\,
M;?9VD6!&.7<(#\Y'TSS[5GSZKXGOK"YF,\EI#;FU*M'8,6G5I3N?&<@%0I*@
M<9YKHT\7VC75E;O;3QM<K(6+;?W)3=P_/?8V/I3)/&^E)I3WJEY)(XT>2W7&
M]-W;T)&><'BFG+^4"GX?FUN*RDBOI7N(WLWFBWP,K1L&("DYRQ((/8T>%]0U
M^XN+=M0 6UD::'R#;,ACV8VL7)).1GKUK?TS7=/U9VCM+@/*BAI$ /R9[$],
M@\'!K)LO&UI<R3M/ +:TA+ SO<Q,<AMH'EJQ<9/J*7O._N@<]/>W^GZOJ5QI
MT-W>7BK(=DGGJR^[*V8BH[;.3Q[U8L?$WB&X2R\XK%O=E#K8R2?:#N4;3@#R
MS@DYZ<=>M=2WBK0D#DZG!\D2S-@DX1ONG\?3K3X?$VBSSV\$6I0/)<@F)0WW
ML$C\.01SZ&FY-K6('"VVM^(;/<LL\^WRU\R]DT^1R'#SXCV XYPHW#U'J*Z/
M1-2\0W6J))J"+%:RRRQ&V^S%3%M"E6WYYSR.E7KKQ1':ZXVG&TD98\>9-YB#
M&1G(0G<P /)4''/H:L77B;1+2'S;C48$C(7G).=R[EX'JO/THDVU\.X&M6+X
MFOKNPT^.2UD,(:4++<"W,_DKZ[!R><#VS7/7B^ HKQ8%TO2[FXD'F-MC3 !
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MDD=Y#JDBRR0RJ(YE@\K>K1H_3)Z%B./2MFBBL).[N,*R_!W_ "!;C_L(WO\
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M4CCG!8\'/2BU\#6]FEO'!?W$<231SS1I%&JSNC[U)^7CGKMQFK7_  A.@?\
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M_P"-4N5=_P P-VBL+^P]5_Z&O4_^_%M_\:H_L/5?^AKU/_OQ;?\ QJCE7?\
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M=XH(4 G) Y/K2T5R3FY[E&#XR_Y%MO\ KZM/_2B.MUU#HR,,JPP1[5A>,O\
MD6V_Z^K3_P!*(ZU[V:6VLYIH+=KF2-2RPJP!?'89[T_L+U_R YT_#[0S$4Q=
M[F:1GD^TMODWA0=Q[\(O7T%26O@/0;141+>5E0 !7E8@C8R<_P# 6:J]YXX$
M.FV]_;:7//!=3F*W+$J7 4L6VA20,@CIVS5^Q\2&[UPZ;)9& ^6'#/,-Q. >
M$."5Y^\,].<5H_;6U8M"H?A_HCQ1)*;V;RY_/W2W+,S-A0-Q/7&Q?RJS'X,T
M:*6WD2.8>0H4+YS;7P6*EAW*EV(/;-<U#=:YJ%U?R#7KF!([R6)(XX4(55;
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M";:Y>9XK2$QQX9E;"#=\I^7'?@FNUU?_ ) M_P#]>\G_ *":N53U;_D"W_\
MU[R?^@FAU)3:YA6*6B1&X\%Z="&VF33HD!QTS&!7-V?PYDL;>:U@U41V\T=L
MA3[.'V^4#D ,2-K,=V"..:Z70W,?@W3'7[RZ?$1G_KF*J?VU>>L?_?-=5&C6
MJ.7L^XFTMS'TGP)J6BPJUMK,-Q=_OHFEN[;<&AD*GE0P^<;!ST//%=S&OEQ(
MF<[5 SC'Z5SW]M7GK'_WS6KI=U+=P.\NW(; P,=J,1AJT8\]2P)KH7J***X2
M@HHHH *R_!W_ "!;C_L(WO\ Z4R5J5E^#O\ D"W'_81O?_2F2O3ROXY>A$SH
M****]HS"N9T?_D8/$W_7_'_Z30UTU<B#JVEZ]K<D>@WEY!=W*312P30 $"&-
M""'=2#E#VKDQM.4Z7+%79479D[>)(UU2XTXV5P+BW5Y9>FT1 95\YP0QX ZY
M!STK)M_'\5SI:7RZ9,$>41J#/& /EW9+$A0<= 3R>E7I+F_EGFF?PCJN^6$0
M.?M-MR@)./\ 6_[1YK(?1II+'['+X<\32Q=O,U2%B%Q@KDS?=/''L*\R.%EU
M@R^8VO%FJ7>G^'/M5A((9I)8D5V0-M#, >/7!KGYM6U[3K_3S)JRW,4UTL+Q
MM;*N0<]Q5_7(]2U?1/[-7PKJL* H49+FV!7:01C][[5A)X?U_P"UVT\^D:[<
M""42JDEY:[=P_P"VE=N$PL53?M(ZDREKH>G5E:MKUMHUU8PW,<FR[=D$J@;8
MR%S\WH#TSZD5%_;&K_\ 0IZI_P!_[7_X[5+4'N]44+>>#=3E4(\>TW%M@JXP
MW_+7TKS8X2K?WHLOF1-%XI69XI(].N39'8LUSN7$+. 0"N<GAER1P,UT-<7'
MIKQ3VTD?A'6U2W5%6$7T'EL4&%9E\[#,,#D^@]*VO[8U?_H4]4_[_P!K_P#'
M:<\)5^S%BYD1^,O^1;;_ *^K3_THCK>KDM?GUS5=):TA\*ZBKF>"3+W%L!A)
M4<_\M?136G_;&K_]"GJG_?\ M?\ X[0\)6Y$N7^M YD3W&@6%S:6MJ5GBCM3
MF$P7,D3)P1]Y6!Z$]Z2W\/:=:ZB+^..4W"J0"\[N 3@%MI)&XXY;&34/]L:O
M_P!"GJG_ '_M?_CM']L:O_T*>J?]_P"U_P#CM'U;$[68[HQYO A:[N9H=3NX
M%GF:8I',0 6.3QBMG1_#MMI>DPV##S4@E,B%F).?4^O4TG]L:O\ ]"GJG_?^
MU_\ CM']L:O_ -"GJG_?^U_^.UM46,J0Y)+0E<J&CPAH:P6\$=HT<,"E5CCF
M=59=V[:P!^=<D\-D<FI_$&BIKVFK9O(\>V595=&VE2O3!J+^V-7_ .A3U3_O
M_:__ !VC^V-7_P"A3U3_ +_VO_QVLHT,3&2E9W0[HR+;P,8=0M;N74;F=K:3
MS$668LH/KC%=C6+_ &QJ_P#T*>J?]_[7_P".T?VQJ_\ T*>J?]_[7_X[5UJ>
M*K-.<=@3BC:K \:?\BO-_P!?%M_Z/CJ7^V-7_P"A3U3_ +_VO_QVLSQ!-KFK
M:/)9P>%=161I87!>XM@,)(KG_EKZ*:SIX2LI)N(.2.FO(VFLY8T&692!6#_8
M][_<7_OL5;_MC5_^A3U3_O\ VO\ \=H_MC5_^A3U3_O_ &O_ ,=K>@L51348
MB?*RI_8][_<7_OL5L:7;RVMH8Y0 V\G@YJE_;&K_ /0IZI_W_M?_ ([1_;&K
M_P#0IZI_W_M?_CM.L\76CRR@"Y4;5%8O]L:O_P!"GJG_ '_M?_CM']L:O_T*
M>J?]_P"U_P#CM<GU.O\ RE<R-JBL7^V-7_Z%/5/^_P#:_P#QVC^V-7_Z%/5/
M^_\ :_\ QVCZG7_E#F1M45B_VQJ__0IZI_W_ +7_ ..T?VQJ_P#T*>J?]_[7
M_P".T?4Z_P#*',C:HK%_MC5_^A3U3_O_ &O_ ,=H_MC5_P#H4]4_[_VO_P =
MH^IU_P"4.9&U16+_ &QJ_P#T*>J?]_[7_P".T?VQJ_\ T*>J?]_[7_X[1]3K
M_P H<R(=9_Y&KPS_ -=;C_T2U:6J6TMU;*D0!8/DY..QKG]0FUR[UK2+U/"N
MHB.R>5I UQ;9.Z,J,?O?4UJ?VQJ__0IZI_W_ +7_ ..UO&A7@XRC'5"NF5/[
M'O?[B_\ ?8H_L>]_N+_WV*M_VQJ__0IZI_W_ +7_ ..T?VQJ_P#T*>J?]_[7
M_P".UU>WQO\ )_7WDVB:MLC16L4;_>5 #4M8O]L:O_T*>J?]_P"U_P#CM']L
M:O\ ]"GJG_?^U_\ CM<$L+7D[N)?,C:HK%_MC5_^A3U3_O\ VO\ \=H_MC5_
M^A3U3_O_ &O_ ,=J?J=?^4.9&U6'XR_Y$G7/^O&;_P! -._MC5_^A3U3_O\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
EBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>g2018030121531715831133.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531715831133.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -  G@# 2(  A$! Q$!_\0
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M6/!S_P >R5NT4 97]GZJ!@:TW_@*E'V#5?\ H-M_X#)6K10!E?8-5_Z#;?\
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M$]Y>SR6_V5%3?#)'C<KY; P#G@FNCU?5#I.DR7YM9)A& 6C5T4@>Y8A1CZT
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MTN[:$J79;F0N%;*D'&WYL8QS@T =GI/P\T?1[FQGMY;MGLIIIHM\@P6E!#9
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M% %272]/FGFGELH'EGB\F5VC!+I_=)[CGI5*W\)^'K6&6&WT2PBCEV^8J0*
MVTY7/'.#TK8HH S[W0M)U&X^T7NG6MQ-Y9B\R6(,VP]5R>WM2RZ'I4_G>;IU
MJ_GQK%+NB!WHO13Z@5?HH S;;P_H]G%;Q6VF6D4=O(9852( 1N>"R^A]ZTJ*
M* "BBB@ HHHH **** "BBB@ HHHH AN;2VO(_+NK>*>/.=LJ!AGZ&I(XTBC6
M.-%1%&%51@ >PIU% !1110 4444 %%%% !1110!7CL;.&X:XBM($G?[TJQ@,
MWU/6K%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !5>XL;.[='N;2"9T^XTD88K],]*L44 %%%% !1110!$MM D
M[SI#&LSC#R! &8>Y[U+110 4444 %%%% !1110 4444 %5X["SBN6N8[2!)W
M^]*L8#'ZGK5BB@ HHHH :L:(6*(JECEL#&3ZFG444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% &-XKUB7P_X6U'5H(DEEM83(J.2%8CL<5Q4_Q5EM-;
MU'3;FRA3RM,6[M9=QVO*8]_EMZ9YQCT-=WXBT9/$/AZ^TAYV@6[B,9D502N>
M^#7*ZG\+=.U:PU:UNKR1OM\=NJ/Y8S T*E0R^N<\B@#1U;Q5>:?X'L/$*6L+
M&46\EPC$[423&XCZ9'6N9G^*]REUX@CBTZ%XK0!=,DW-B[??L8'Z$'I7;7WA
MF"_\%OX:FF<PO:"U,H4;N  &QZ\9KG5^%>FI9>&;5;R4)H<OF_<'^DG.[YO3
MG)_&@"K<^./$?]D>(;ZVL]*4Z),5E29I#YBA<\8Z'--U3XAZQX;A\/3ZQ9V$
ML&IR S/:;_W$9 (;YO3/-;S^!H7TWQ+9_;Y0NNR-([>6,PY&,#U_&I[OP;:W
MTNCFXG:2+3H6A,3(")E9-ISZ4 <S??$F]BTG[7!'ID2OK!T])[F1O)6/;N$C
M$<UI/XRU"V\$ZEK?FZ1JDMLV$.FL[1*.,E\\\9R<=JJVOPJAT[P_;Z78:Q+$
M;74CJ$$KVZR;3C 0J3@@"M]/#VK-HES8S^(6^T2,&BNK>T2$QX[%0<,/4&@#
M(7QO?IX$O]<,.GWL]JY ?3YC)"RY^^1]X  Y(Z\&MCPMKMYKNB7%U(VFS31N
MR1R6,^^&3 X/JON#S5.P\#R:?I&IP1:S/'J&H3BXEO((5C <8QB,?+CCD=ZO
M^%O#"^&X[YWN_M5U?7!N+B41")2V,<(.!0!QL7Q7N7FT!'L( +EG&JE6;_1,
M,57'UP>M6=.^)[/J-B-7CL=/TZ\-SY<\DA4XC;:O7C)Q5G_A5&F?9?$T*WDH
M.NL"7V#-O@Y 7UYK5L? UI8W>BSBY:4:7:/;!'C!$I;&7/H<\_C0!S,OQ/OI
M-&TB]@&D6ZZA?W-M]HNY'\A$B)VMD<Y;%6-2\?ZE86&D2+?>&Y/[0N9(6O1+
M)]EC"J6Y.<Y[?C5UOAN8K+38K+66@FL+RXNXY'M4D4F4G*E#Q@9XK0'@V>YN
M])N=4U5;R33II)55;-(TD#H5P5&1QG.: .;F^)6J1>'#>F/2-_\ :RV"WN]_
ML;H5+>8IZX!&*T1XWU!=*A,,VB:IJ%Y>+9VGV"1_)5B,DR$G/'7BI)?ALJZ5
M_9UCJ\EM;0ZF-1LXVMDD6W.#F, _>7))YJY/X,O+_35AO]<\R\@G6XL[J"S2
M$P2+WV@X8>H- &7JWCG6O#D&K6VK6=@^I6ME]NMFMV?R94W;2#GY@0<UN>$-
M>O-=CGDN-0T.[1 N/[,=V*$]FW5G77P]?5+;56U?6YKS4+^V%J+H0*@AB!SA
M4!QR>2:W]3M;ZTTB.+1!''="2)2WE+@H" V1QVS0!3\4>+4\-W^BVK6=Q.VI
M70@W11E@@QR>._3CZ^E9GAKXC6FJR&VU*-K2Z:XN(HV$3>2PC8C[YXW8&2*W
M/$7AUM=;3)8[Y[2XT^[6ZCD6,.&(!!4@^H-8D7PWMDM]/@DU&:1+2\N+LCRP
M/,\W.5]L9ZT ;.A^,-'\0W3VUA++YBQ^:HEB9/,CSC>F?O+GN*J7_P 0-!T[
M5KC3KA[H26TD<=Q(ML[1PE_N[G P ?6JW@[X?VOA"Y>2&6WG C\J)A:+'*JY
MZ%P26K(F\#:MJ_BCQ*;B]>QTC4)K9F1$5S=(@R1G.4YXS0!U+^,M*BUQ=)F%
MW%</N\MY+=A'+A=QVOC!X]*P;OXJ:9C27TZRU"Z@O[P6PF^R.%(YR5./F.1T
M'OZ4S_A5\9\31:T^LRR-#.TL2O I=59"FPOG)4 \<5?'@%8O#FAZ7;:K+%+H
M]S]IAN3"K;CEC@KT_BH 5/B#I=M9"6]G\Z1[F>%$LK>1CB,G<2IYXQR>E:$O
MC71UO[.RA>XNIKJ)9H_LT#2*$8X#,1P!]:YN[^$UG<Q6^-0!GAN)YM\]JLJ,
M)225*$@<$\&KNL?#B#5?[,C2[@M(+&-(U$%DH?"L#A'SE <=!F@#3\7>*)/#
M+Z.5MO/CO;T6\H569U7:3E5'4\=*C?X@Z NFVMZ);AUN6D5(4MV,HV??RF,C
M'?-:&L>'H]7NM'F:Y>+^S+L7*@*#YA"E<'\^M<G=?"6RN+>$#4-T\5S/.KSV
MRRH1*<E2F0#CL: .@_X3O06U&"RBGFF>:W6Z#Q0LT:1-T=F PH^M9E_\3M(B
M\.ZAJ=C%=7$EK$)4A:!D,BL<*XSU3/<5<L_ =C:7]Q<>=^ZN-,73GMXHA&@
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M5FG6:R5BSA<$JV?DSC/'2GVGPZ-IJEC,NM3-86%Y)=VUF8%^5GR2"^<D<G%
M%CQ!XY&B^(GT9+">64:=+>"7RV*909 )';U/:H-.^(MGJ'A^6Y;-I?PV:W4B
M3P2"/:?XE[NN>XK1U_PBVM:S'J,6IO:,+&:QE01!P\<G7KT(-9\WPX@FC1#J
M<P":5_9@_=C[N0=_UXZ4 :MOXQTV;5+?2E^T3WDD<;N8+=S''O&1N;^$?6F^
M,_$5UX?TRW_LVVBN=2O+A+>VAF8JA)ZDD= !S6;??#Q+_6--OGU%8TL1" ([
M55E<1C@&4'.#Z8K2U_P;9>)=;T^]U1_/L[)'"V+H#&[L,;R>N0.E %;3O'EC
M+X1T[6K]6CFNV\G[-;HTKF89W(JCDXP?PH7XD>'I$M#$]W*]W,\$4<=J[.73
M&X$8R,9KG]8\!WNAZ= ?#"M*;?53?6\*A0;574JP0,0KCGHQ%6/"'@:\@;3M
M6U2:2"\M[JYN/LY"L6\W'WB#@'CMZT =!;>/- NK^2T2Z=2@<^;)$RQOL^^%
M8\$CN!5=/B1X;;3;F_:>XCAMU1V$ENRLR.<*ZKC+*3W%9MA\*M,L=1O)O-BE
MM;@RD1O:KYL9DZXESGJ3VJO:?"2SMM%GTW[=%^\$2I<162I*%1L@,<_-G'>@
M#:M?B/X?N[N*V5KR.1YA WFVCH(Y#]U7)'RD]L]:LP>.M"N-1N+*.>7? LC>
M886$<GE_?"-T8CT%9]S\/(;BYNYCJ<RFYU.#42!&.#%C"_0XZU6T[X7V&FZG
M>W,4\+1S^<8PUHIEA,@()$F<G&3VH L-\3M#ETVZNK-+R9HK5KJ)&MG7ST'=
M"1R >N.E;6E>(DO_  C;:]):W*K);B5X5A8OG'(5>I]O45AP_#BVBBT^-M2G
M9;/2YM- V ;UDZM[$8Z5H2>%+F;P.GAR36IO,2(0B\2%5)1> "H.",8!]: $
M'C_0CI#ZD7N1&ER+5H3;MYOFG^'9C.:VXM5MI-'_ +4D\RWMA&96-PAC9%'7
M<#R*XVQ^&4=AH.H:9'J$#B]N%N',M@C1J0.@3.!SSUXK<TSPA:V/@M_#4UQ+
M<V\D3QR2-\I.[.<#L.>!0!EZA\3-*AT#4;^SBNGGM8!.D,ULZ>:I. XR.4]Q
M3[[QK<Z1\.H?$=]9&6ZE13Y,$3A06/&0W(%5V^&[7-A<V^H:Y-<R-8C3[:46
MZI]GAR#C /S$X')]*W]9\,QZQX2;06NI(AY21K.J@D%<8..AZ=* ,&V^)-HN
MNW]EJ-M/;VT4MM'!,+=^#*H(\WLAR<<UM6OC71+O7#I,,\AN/,:%7,1$;R*,
MLBOT+ =JR;KX>?;K35([O6)7GU*:UFFF6!5^:''1<X^;'X4FE?#:QTCQ,^K1
M2P2QF=KA8Y;16D1V&/EESD#\* -;Q-XOL?#B-$ZS37IMY)HX8H6DP%'5]OW5
MSW-4;/Q_9)I.CW.JP7%O+J$,3[XH':%6?HN_H.?6I_$/@^36=2-_9ZK)I\\E
MH]G.5A6021-VY^Z1SR/6N>O?A''>K9QOKLQBM(8HH@]NK%/+Z%#GY<]Q0!UD
M7C'1IY884GD,TUV]DD?E-N\U/O CL .<]*?K_BFP\-+')J$=WY+@L98;=I$0
M#'WB!QU[USNB^%KEOB;JOB*YM9+6S11':Q.ZG?)C:TP )P"..>>:L^-/A^/&
M5PK2ZK)!!Y#0F PB103_ !KDC:WO0!:O/B'X?LK^2SEEN2T)B\V1+=VCB\S[
MA9@, '-4O$'Q$M=.O(K+3H7NKC^T(;.9VB80IOZ@.."P':DG^'$,]IJ\#:I,
M/[22V1F$2_)Y.,8]<XIMS\.#-=L(M:FAT\ZA'J)M/(5OWJXS\^<X..E '3WV
MOZ=INHPV%W,8IIHGFCRIVE4&6YZ9 YQ60_Q$\/)]DS-<%;F-)0PMVQ&C'"F3
MCY 3ZUG_ !)\.7GBFUTW3K*VE#FX'F7B2!1!$>) ><G<N1Q2ZQ\,M/U/78=3
MCD@3;#'!)!/:+,C(GW<9(V\<4 ;4_C#2[77(-)N%NXI[A]D,C6["*1L;L!\8
M/ J30/%6F^)$GETX7)AA8JTTL#(C$$@[21@X(/2N<NOADEUXI36I-8E)BNA<
M0QM I:-0NWRP^<[/08KI/#7AV+PYX?725N'N(P\C%W4*3O8L1Q]: *,/C_0K
MBXEAADN6*"3RW^SMLG,?WA&V,.1CH*S_  UXYNM4\"7GBB_L=D<0DDC@@B?<
M57/][K]1Q3M/^'BV5W:^;J\UQ86+RR6-J857R6DSG+CEL9.,UK:1X5BTKP9_
MPC?VJ2:+R)(#,5 8A\Y./QH YJW^*</VBSDO;"XBLI]/^UNR6[M)&<\Y4?P
M?Q5T-SXZT&UU""S>YD9IDCD\U(F,<8D^YO;HN?>LNW^'9CMI(KC6I9V;2VTQ
M7$"IMC/0X!Y(JJWPIT_^U+6\%Q#*(X(89H[FT67S3&,!@2?E)&.GI0!T>O:_
M/I.LZ%9101R)J-PT,C,3E %SD>]01>/-$>34(Y6NK5["W:ZG6YMGC/E@X+#(
MYY]*MZ]X<37+W3+DW<MNUA*\B^6!EBR[>O;'6N9T;X8#2+VYO#K'VFXN+)[-
MVEM%Q(&.=SC/SGU]: +FK_$6TL?#\&J6NGW\JW%RD$8DM77[Q^]CKC'3U-=G
M&XDC5P& 8 @,,$9]17 V_P ,$MM%NK*/5WCGFNH[E)8K95CB9.@6/.,>O-=[
M$KK"BR/O<* SXQN/<X[4 /HHHH IZM>2:=I%Y>PVLEU+!"TB01_>D(&0!]:X
M1/'KZIHT$[HL-T+^""2"TN6#1[^F_>@/X8Y]:]"N;>.[M9;>8,8Y5*MM8J<'
MT(Y'X5B6_@GP_;0-"EAN5ITN&:25W9G3[I+,23CZT <\OQ&O'O[-DT>,Z7>W
M\EC!<&YQ)E VXE-O RI[TNA?$6[U2[TY;S2H+.VU*&>2UE-UN(,7WMXVC:#Z
MY-0VWPQEC\6KJEQJ,<MJEXUXJ"-A(6((VGYMH')Z*":Z@>"_#RP6L(TR/R[6
M.2*%2S$(LGWQU[T <)>_$[5+W0]=CT^TM([ZRCC=94G9D*.<9!9%.1],5LR?
M$*[L-/UHW>E*;C2#:1R!9\B0S8YSCC&?QK;M_ 'AFUM[F"/3<QW,(@E#S2.6
MC!R%R6) ';'2F7'P\\+W<D;SZ:79$CCYGD^81_<W?-\Q'J<F@##N_B5=6D.O
M7LFCQ_8-*F%L)/M!WR2G;M&W;POS<G/;I6[X7\4R>)-*OII+-K6>U=HS@-L?
MY<AD+*I(_#J*O'PKHC6>H6AL(S!J$GFW2EC^\; &>O!X'3TJUINC66DV;6EH
MLODL22)9GE//NQ)H \V\*?$/4[+0=,F\0V_GVUVEP8KU)MTCF++$,F!C@8&#
M27'Q+O=:\*:I+;6[Z?<Q1PS03P[V4JTB@@LR ;L'H,]:[73/ /AC1[@3V6EH
MC!650TCNJAOO85B0,]\"I(/!.@6^G7&GI9N;.XV^9"]Q(Z_*<C +';SZ8H P
M7^(5Q#<32#35DTBRNH[*ZNVFQ*)6 Y6/'(RR]QUJE+\7;>SU%+*]TUH9(_.%
MVWFY6!E8K&#QSOQ^M=;+X,T";6$U5]/4W:LKY#L%+*,!BF=I('<BDO/!/AO4
M)+^2ZTJ&1[^2.2Z))_>,GW2>>WM0!HZ/>3ZCHUG>75M]FFGB61X=V[82,XSW
MJ]2 !5"@8 & !2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%5M1U"VTK3KB_O9/+MK=#)*^"=JCJ<"LG1_&6BZY>"TLYYA
M<-'YJ)/;O$73U7<!N'(Z4 ;]%%% !115*[U6TL9FCN6>,)"T[2&-MBHO7+8P
M#[=: +M%16]Q%=6T5Q X>*5 Z,.X(R#4M !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M45G:UK=AX?TYK_4I6BMPP3<J%R2>@  )-5]&\4:5KUQ-;V4LHN(5#O#/ \3A
M3T.UP"1[T ;-%%% !161J?B73-(U"VL+J24W5RI:.**%Y"0.I.T' ^M:=O,E
MS;QSQA@DBAE#J5.#Z@\B@"2BJ]K>Q7C3B(2@PRF)]\;+DCTR.1[CBK% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%<[XV\13^%_#K:C;Q022><D0^T.41=QQDD=A6-I'Q S<7ZZQ
M)IKVMK'&YO\ 2Y6F@!=MH1CC(;O]* .[HK('B73'N+F"*26:2VFCAF$4+-M9
MQD=!^9[=ZUZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,WQ!I(U[P_?Z
M4TQA%W"T1D"Y*Y'7'>N6L? US87=M?:A?Q7R6%NZ16UI8K;M+E<88AOFX'0\
M9-=W10!Y]\/_  GJFC>'M0FFD-GJE].S0^>HE:VA!^1" <' ST/>N@\2//"N
MG.--O=26*;S&CM$3.]1\K'<PP,^F:Z&B@#R"#3M335;J]F\/ZQBY)\R.WM(8
M_,4ME@_[X@Y'' 'K6_K=]<:Y96UG/X.UU88)DEV;("&V] ?WE>@44 >4ZO;Z
MEJ%O<6MIX>URTLYIEG-LUM!(@<9SQYHPIXX&.15.RTG4;"VLHH-"UU/L[3^9
MMMH-LBRKA@ 9?E^N37L5% 'ETZWS6[*GA;7V8:4=.12L"]\A\^9P016GX=U?
M4=#T*UL'\(:[)-&O[V3$/[Q^[']YR37?44 >=Q7EY$FMJ/"NOYU5F9SY<'[O
M*;?^>G-7M)U_4-*T>QTY?".O2"UMXX Y6$%MJA<X\SOBNVHH Y7_ (2[4?\
MH3=>_*'_ ..4?\)=J/\ T)NO?E#_ /'*ZJB@#E?^$NU'_H3=>_*'_P".4?\
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M $)NO?E#_P#'*ZJB@#E?^$NU'_H3=>_*'_XY1_PEVH_]";KWY0__ !RNJHH
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M_P#QRC_A+M1_Z$W7ORA_^.5U5% '*_\ "7:C_P!";KWY0_\ QRC_ (2[4?\
MH3=>_*'_ ..5U5% '*_\)=J/_0FZ]^4/_P <H_X2[4?^A-U[\H?_ (Y7544
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MM;>=U>:"*1D^Z70$CZ9J6B@!J1I$NV-%1?11@4WR(?+,?E)L)R5VC!_"I**
M(C;6[2&0P1%SC+%!DXZ4@M+83-,+>(2MU<(-Q_&IJ* &HB1($C144=%48 K!
MU'PK_:%_+=C7M;M?,QF*UN@B# QP-M=!10!R/_" P;@W_"0:]N48#?:ER/H=
ME/'@5%)9?$OB(,3DD7H!/_CM=710!Q[_  ]MY+F&X?Q%XB,T((C?[=RF>N/E
M[XJ8^",C!\3^)"#U!O@1_P"@UU5% '(S^ HKF%X9_$GB.2-U*LK7PY!ZC[M/
M_P"$&&S9_P )/XDVXQM-\,8_[YKJZ* .23P%%&I2/Q%X@13R56[4 _@$I_\
MPA'_ %-'B7_P/'_Q-=510!R4?@.*$$0^(O$$0/41WBKG\DI__"$G_H:?$O\
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M_P #_P#[&NJHH Y7_A"3_P!#3XE_\#__ +&C_A"3_P!#3XE_\#__ +&NJHH
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M6C/$A,>/G4;3L7Z5J>'O!.MV7CB74;Y+@(+B643Q&';-&RC$;G._ X&.GRT
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M*%J/% T.;3V21;A+65EF#,DK+G[H'*C.-V:LZ5\0DU+4=3M&TXPR6?G;(3<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\
MP@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\
MP:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#I
MW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_
M !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\
MP@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\
MP:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#I
MW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_
M !5 '545RO\ P@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\
MP@.G?]!+7?\ P:S?_%4?\(#IW_02UW_P:S?_ !5 '545RO\ P@.G?]!+7?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M3?\ ZE?Q+_X+_P#[*C_A-_\ J5_$O_@O_P#LJZJB@#E?^$W_ .I7\2_^"_\
M^RH_X3?_ *E?Q+_X+_\ [*NJHH Y7_A-_P#J5_$O_@O_ /LJ/^$W_P"I7\2_
M^"__ .RKJJ* .5_X3?\ ZE?Q+_X+_P#[*C_A-_\ J5_$O_@O_P#LJZJB@#E?
M^$W_ .I7\2_^"_\ ^RH_X3?_ *E?Q+_X+_\ [*NJHH Y7_A-_P#J5_$O_@O_
M /LJ/^$W_P"I7\2_^"__ .RKJJ* .5_X3?\ ZE?Q+_X+_P#[*M[2]0_M.Q6Z
M^QW=IN)'E7<7ER#'J,U<HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M(+VZ^Q64USY$\_EKN\J!-SM[*.YKG/\ A-_^I7\2_P#@O_\ LJZJB@#E?^$W
M_P"I7\2_^"__ .RH_P"$W_ZE?Q+_ ."__P"RKJJ* .5_X3?_ *E?Q+_X+_\
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M_P"I7\2_^"__ .RH_P"$W_ZE?Q+_ ."__P"RKJJ* .5_X3?_ *E?Q+_X+_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M#30H'ED7:S;_ %^Z.,?UH UJ*** "BBB@ HHHH **** "BBB@ HHHH ****
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M1_;OBW_H3!_X-8O\* .JHKE?[=\6_P#0F#_P:Q?X4?V[XM_Z$P?^#6+_  H
MZJBN5_MWQ;_T)@_\&L7^%']N^+?^A,'_ (-8O\* .JHKE?[=\6_]"8/_  :Q
M?X4?V[XM_P"A,'_@UB_PH ZJBJ>F7%[=6*2ZA8?8;@D[H/.$NWGCYAQS5R@
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M9W'_ ,70!U5%<K_PKS0?74O_  9W'_Q='_"O-!]=2_\ !G<?_%T =517*_\
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M$25\BYDAZ^NPC/3O61_PKS0?74O_  9W'_Q= '545RO_  KS0?74O_!G<?\
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M_P +'\*?]!1O_ 6;_P"(KJJ* .5_X6/X4_Z"C?\ @+-_\11_PL?PI_T%&_\
M 6;_ .(KJJ* .5_X6/X4_P"@HW_@+-_\11_PL?PI_P!!1O\ P%F_^(KJJ* .
M5_X6/X4_Z"C?^ LW_P 11_PL?PI_T%&_\!9O_B*ZJB@#E?\ A8_A3_H*-_X"
MS?\ Q%'_  L?PI_T%&_\!9O_ (BNJHH Y7_A8_A3_H*-_P" LW_Q%'_"Q_"G
M_04;_P !9O\ XBNJHH Y7_A8_A3_ *"C?^ LW_Q%'_"Q_"G_ $%&_P# 6;_X
MBNJHH Y7_A8_A3_H*-_X"S?_ !%;VEZK9:S8K>V$QEMV) <HR\CKPP!JY10
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'^S[J_ET^&,.WVA9%R S#IMR.0.0*Q_^%QW:S&*32X4*0"&1MS8%\S$+"/;
MR>]>D1>&]%@UAM6BTRV34')+7"H-Q)ZG-#>&M$=F9M*M"7N?M;$Q#F;^_P#[
MWO0!S?Q!UN]T_P &6MNKRP:KJ<D5L!9JS2(3S(8P.20 <5@>'?&M]I_A22P
MGN-3M]673HGU0,C!9#F-Y1][ 4BNRN-=\+7EK-KMS)#(NBSO&TTD1W6\G (
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MWVDXR0!P/<B@"[138W62-9$.58!@?8TZ@ HHHH **** "BBB@ HHHH ****
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M/^%B^&/^?VX_\ 9__B*ZFB@#F8?B!X;N)XX8[R<R2,$4&RG&23@<E*Z:BB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:SNKC4X+B]CADAN#/;$12ASDX1&7 ]B3[T =:WBO15UF/25NVDO9$1PD4+N
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M]P@UZ-IV@Z-ILDT^G:;:6[W S(\,04R \\D=>M/@T+2;5K=H--M8FMBQ@*1
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML:R1NKHPRK*<@BG4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110!4U(WPTVX.F+"UZ$)A6?.QF[ XKSQ?"?B&6WGOVLH()H]1AO[?3?M
M(?<Z@B3,V/XLY&<XQ7IDA<1.8P"X4[0>A/:O-_"GBS6FOKRVURY9K^.U>X;3
MI[46^PJV,QR_==,8Y/- %1? VO6,-MJ-M;P3:A*+Q;FU:<*L?G\ AL<[<<^M
M7+_PMXCBT+2?#]C;VDT%I!"(KYIMIMYE/S,T9R)%QT%3P_%>TGTN6ZCTN62>
M._BL?(AN(Y S2#*L'!P14=_\0]2D33ET_1G2X;5EL+R"29"4/4J#T.1W[4 =
M/XRTF[UKP7J>EV81KJXMS&F]MJEO<]JYKQMX:\0:OH6F:786=I-"EJ8KAG,>
M]'V!1M+J1MZYQ@\#!K6L_'D%QXT/AF:S$5P0^QUN8Y,[>3E5.5./6HK_ %#6
MM8\9WN@:7J8TN.QM8YWF$"RM*SYP,-P ,'WH YF^\$>(,:%+:6D9U.TLX;:6
M[DFB>)0C?W'4GIW4@\^U*_PVOIM4:[GL+&1I/$ O)79@2UKMP5Y&<$_PUT$F
MO:[IWBC2],O9K:?.EW%Q<K"H199$*X(9ONC!Y[53B^+-I+I=U<II4LL\%[%9
M^1#<1R!VD&5(<';CM0!C7?@?Q,/"T>BPV5B\!O+J0J&C+1(Y.S:74@#!Y  /
MH:3_ (5QK%U8R_;K2SFN?^$?2RB:20-LN03R#CC_ 'A74ZG\01HVLZ=IVI:6
M8'O7BCXO(F:-G.,% <D ]QQ74ZM>_P!F:/?7^S?]EMY)MG][:I./TH Y?Q+H
M.KW_ ($TVPM8HY]0M6MGD1Y=H8H!N^;%87B/PCXA\6Q:Q?W-A;V5W-91V-M9
MFY$@($F]F9P,=R,8[5O>&O\ A*;^WTO6Y];MI;6\3S9[%K956-6&0(W'S$CC
M[WO7-:3\1[N\^(XLY=3LVTFZNY;*"S55\V-D PY/7#-N% &I?> )+G5]1\BV
MM;:QFT=+:#RP!LN%?>&V@=C@YK(O/A]XAN?#=I-.\4VM/J!O=0B1UVR_*550
M7!4A1@C(-=+X^U;7=,>S.FR7-M9%)&GN;6S%RX8+E5*$<*>[5SE]XT\2WEGH
MNL6L=S::.^G+=:A-;PQOL9G _P"6G4 9) YH [SP=H\FA>%[33Y?/#Q@DI-*
MLC)DDXW* "/H*W:\P;QKJW]N"]2Z5M+75X]*^R"!<NK1[O-W==WMTIWA_P 6
MZU!KLS>*Y[FRMIEN9;.&2&)8VBC;&21\X.,=>N: /3:*XKP'XEU7Q#J/B)=3
M1(DM;I%MH H!CC9-P#'N?6NUH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** &R(LL;1NH9&!# ]Q7)1_#;0E@N(9'OYUE@-NGG73,8(RV[;&?
MX1D#\JZ^B@#D+?X;Z#;H1NO96-S%=,\DY+-)'G:3^=6+CP%HUQ%<*#=Q/-?"
M_,L4Y5TF QE3V&.U=/10!RFF_#[1=*UJ#5;=[UIX'D>)9)RR(7&&X]#FKVL>
M$[#6+U;TSWME>"/RFN+*<Q.Z?W6(ZBMVB@#F+KP!H-W;PP/#,L<5F]DH28C]
MVY#,<_WLC.:KP?#;08$8%KV5GN(KEI)+@EF>/[A)]NE=?10!RFH?#W1-2UF7
M5)VO!-+/%</&DY$9DCQM;'X5K:3IMQ;65U;ZA<O>">>1P)6+[8VZ)D]@*U:*
M .6M/ 6DV=Q')'<:@T,.[[/;/=,8;<MD91>Q&3CTS4B^!-"31+'2D@D6&QF6
M>&4/B4.I+ E^IY)S72T4 8GB#PM8^(O(:YGO;>2$,JR6EP8F*L,,I(Z@CM5/
M4/ 6B:@]L2+FWCAB6 PV\Y2.6-2"$=>C#C]373T4 <ZW@G1FUU=5V3!U<2"W
M$A\GS NT/LZ;L<9JO;_#SP_#-*\L,]W$Z.B6]U,9(X5<Y8(I^Z":ZJB@# T#
MP7H/AB^O;S2+(6\MX1YN&)  [ 'H*WZ** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MT?\ "#Q_]#'XE_\ !F]=310!RW_"#Q_]#'XE_P#!F]:>CZ$NC-,RZGJ=YY@
MQ>W1F"X_NYZ=:UJ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M<K-;6DUK$Q53CS'W[L8Z@_A6EKWAJ#Q'X;;1]1G>0,%)FV@-N4@AL=.HZ=*
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..1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>g2018030121531683131127.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531683131127.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,6 F$# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** //OB[-+#X;LVAEDC8W@!*.5/W&]*\=^WWO\ S^W7_?\
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M_P '_/S.3&JV&G\OS/7****]<^9"BBB@ HHK&\5WMQIWA?4+RTD\NXBCW(^
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MF&(&X _*2!G![$4 ;E%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7FFBVWR.';]W)Y1^^!_6M77;25_!FGKI?@6ZL=-DU5Y9+5K8W,T*$'$JV^[
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M(&UN>*\E_P"$7\0?] /4?_ 9O\*^E:*RE24G<]'#9C*A3Y%&Y\U?\(OX@_Z
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MO;>9YA4-(&^5'V,V5R, ]?3O7'6/PSU^T(2;6[>Z2:]M;R>6=6:4&%B=@/\
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MYJRZ[I=W)J%I-!8SVTJ%P^^-8XMC1H/N@,?FSU[5Z10 4444 %%%% !1110
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M7]MM/M)MOM4/G@9,7F#</PZU,CK(BNC!E89#*<@B@#R[_A??A/\ Y\M;_P#
M,?\ Q5'_  OOPG_SY:W_ . 8_P#BJ]2HH \M_P"%]^$_^?+6_P#P#'_Q5'_"
M^_"?_/EK?_@&/_BJ]1W L5!&1U&>E+0!Y;_POOPG_P ^6M_^ 8_^*H_X7WX3
M_P"?+6__  #'_P 57J5-:1$V[W5=QVKDXR?2@#R__A??A/\ Y\M;_P# ,?\
MQ5'_  OOPG_SY:W_ . 8_P#BJ]2HH \M_P"%]^$_^?+6_P#P#'_Q5'_"^_"?
M_/EK?_@&/_BJ]/CECF3?$ZNN<;E.1213PSAC#*D@5BK%&!P1V..] 'F/_"^_
M"?\ SY:W_P" 8_\ BJ/^%]^$_P#GRUO_ , Q_P#%5ZE10!Y;_P +[\)_\^6M
M_P#@&/\ XJC_ (7WX3_Y\M;_ / ,?_%5Z>\T47^LD1.0/F8#KP/SI] 'EO\
MPOOPG_SY:W_X!C_XJC_A??A/_GRUO_P#'_Q5>H/)''MWNJ[VVKN.,GT'O3B<
M#)H \M_X7WX3_P"?+6__  #'_P 51_POOPG_ ,^6M_\ @&/_ (JO3UEC=BJ.
MK, "0#G&>E.) !)( '4F@#R[_A??A/\ Y\M;_P# ,?\ Q5'_  OOPG_SY:W_
M . 8_P#BJ]15U=%=&#*PR&!R"*6@#RW_ (7WX3_Y\M;_ / ,?_%4?\+[\)_\
M^6M_^ 8_^*KU*FF1%=49U#-G:I/)QUQ0!Y?_ ,+[\)_\^6M_^ 8_^*H_X7WX
M3_Y\M;_\ Q_\57J+,J(7=@JJ,DDX % (900001D$=Z /+O\ A??A/_GRUO\
M\ Q_\51_POOPG_SY:W_X!C_XJO4J1F"J68@*!DDG@4 >7?\ "^_"?_/EK?\
MX!C_ .*H_P"%]>$_^?+6O_ ,?_%5Z@CK(BNC!E89#*<@BE)"J68@ #))[4 >
M7?\ "^?"7_/CK7_@&/\ XJC_ (7UX3_Y\M:_\ Q_\57I\4T4P)BE23:<'8P.
M.,_RIQ(5220 !DD]J /+O^%]^$_^?+6__ ,?_%4?\+[\)_\ /EK?_@&/_BJ]
M/66-V94=69#A@#DK]:?0!Y;_ ,+[\)_\^6M_^ 8_^*H_X7WX3_Y\M;_\ Q_\
M57J)( ))P!U)I%D1V94=6*XW '.,\C- 'E__  OOPG_SY:W_ . 8_P#BJ/\
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M >6_\+[\)_\ /EK?_@&/_BJ/^%]^$_\ GRUO_P  Q_\ %5ZE2;ANVY&[&<4
M>7?\+[\)_P#/EK?_ (!C_P"*H_X7WX3_ .?+6_\ P#'_ ,57J5% 'EO_  OO
MPG_SY:W_ . 8_P#BJ/\ A??A/_GRUO\ \ Q_\57J#R)&NZ1U0$@98XY/2G4
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M,G_0N:[_ . R?_%T?\)3)_T+FN_^ R?_ != '045S_\ PE,G_0N:[_X#)_\
M%T?\)1)_T+FN_P#@.G_Q= '04=JY_P#X2B3_ *%S7?\ P&3_ .+H_P"$ID_Z
M%S7?_ 9/_BZ .!;P;K=SH5YK4T034;BZN+J.TCM0MR'ES$@>7<?E5&SM '3V
MHLH/&VDI?6T4%VRVT,EO'&A?RS'N18FB&W:"J9.%.6YZ&N^_X2F3_H7-=_\
M 9/_ (ND_P"$ID_Z%S7?_ 9?_BZ //WC\=-I-C 'UOS3=3L"H*EHS(%0,^YB
MA"Y8;PRD'!Z5T6@#Q6WCJY.IO<)9K)."&W&&2+Y1%L&W:K#&20<G)S6]_P )
M3)_T+FN_^ R__%T?\)3)_P!"YKO_ (#+_P#%T >;WDGB'1]6?^SYKV/6-8UB
MYMQ;W,A(,++MCF"DG*(%W9 QSBI8I_%U\^H2>'KS5KB>WNIXH)KEP;5H8HC'
MWX:1I1GV(/:O03XD!E$I\,ZV9 ,!_LJ9 ],[Z5/$QC7:GAK7%&<X%J@_]GH
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M<!C&N. <CG%=]_PEI_Z%[7?_  &7_P"+H_X2T_\ 0O:[_P" R_\ Q='MJ?\
M,OO"S.(E3QM*FD0QOJXQ,Q.W<O[MI>-\AYW(HQ^\7# GO6AXWLM<O_%UN^FV
MNI*UK8[+*[MCMC%Q)(-V\_W0B\YXYQ73_P#"6G_H7M=_\!E_^+H_X2T_]"]K
MO_@,O_Q='MJ?\R^\+,X0V?C;4;;5+'4$NF:\'V29"6,6'FQYB9 55$600I.>
M">:4)X[M[1I[.'4S=6JAKBWD8"*603C8D*]-@C#9(X(([UW7_"6G_H7M=_\
M 9?_ (NC_A+3_P!"]KO_ (#+_P#%T>VI_P R^\+,P_"0\5V,TDGB$7UWLN?L
M,*H00REB[7#<_=&0B]\+TYK3\<6^K:Q:0:!I=J6CO23>7$CF.-8%^]'N )#/
M]W@=,U9_X2T_]"]KO_@,O_Q='_"6G_H7M=_\!E_^+H]M3_F7WA9GG$,OB**S
MT_P];IJUO=Z=I+H(+)]JI.92D#2-_P \PB9YZC.:;;S>+?$.E37%J^J7*WQN
M8;AG/^C&)W$<9A'L-S$CH,YKT?\ X2E0[./#>M[F&"?LJ9/_ (]2IXJ$:A4\
M.:VJCH!:J /_ !ZCVU/^9?>%F<=HUCXCM]0BCNH-9@MG??:1V11%C D(Q,3Q
M@1I& #GACCFLZZMO&.KV6LI?P:PEI=+ &MTW;D+3_O0GS?,!&,?+M!W#BO0_
M^$M/_0O:[_X#+_\ %T?\):?^A>UW_P !E_\ BZ/;4_YE]X69P\EKXQ6>X>--
M607#2-IXB8 I() B?:&[J(U#8;(.YN]%S#XX;9<^?K43W*74DXA576W5I%6)
M%CR#D*"W!W8/%=Q_PEI_Z%[7?_ 9?_BZ/^$M/_0O:[_X#+_\71[:G_,OO"S.
M8O+#Q!>_"D6=['J;7UQ<HLRQRLTJPF4;L'AL;,G!RV#@DUD2:9XLTZ>34=+@
MU0->S7,MS$7^Y$"L,((ZLX0!^N< X(KOO^$M/_0O:[_X#+_\71_PEI_Z%[7?
M_ 9?_BZ/;4_YE]X69Q^@:9XAN==\.RZY_:S16TM[*KL6 7Y@L0D&XG[NX\D_
M>QFF7TWCF37]6GMK?48H_L]S'#"N3&&W(D+*2V"<9?( QR"379_\):?^A>UW
M_P !E_\ BZ/^$M/_ $+VN_\ @,O_ ,71[:G_ #+[PLSF&T_Q7I_B^SLXKS4)
MM.C-N4N9)7D5QSYPD 4@DGIDC;QBJOC2P\1:IKEXUOIUS-:PNOV<!1M/EQ,P
M([\RR+_W[KL?^$M/_0O:[_X#+_\ %T?\):?^A>UW_P !E_\ BZ/;4_YE]X69
MYXD/C3P[::A!%+);QV%M)% 78^0\8"+%LR @<<G.[))(-5)9?$FNQ:J^C'6+
M[24$L-L+E@[,PC6/.3WW2.W_  &O3)?%"31F.7PUK4B'JKVB$'\-U$?BA(8Q
M'%X;UM$7HJVJ #\-U'MJ?\R^\+,\ZN='\6^1"NEVNI"RTYGFT\7A_?(@2.+:
M.I#8,K*.<#&*ZQ$\32> /LT<MZNHW5Z(HI?F\ZU@:4<L7 )*KGDCGBMO_A+3
M_P!"]KO_ (#+_P#%T?\ "6G_ *%[7?\ P&7_ .+H]M3_ )E]X69Q:VWC2R26
MXA?6;C,%T1%/+NVAI@D0QU+J@:3CDYQD50;4/&-G!H^F)?70U34KN[MTBN&/
MF16[;=D[*2Q^0*Q&2<%L5Z'_ ,):?^A>UW_P&7_XNF_\)0GF^;_PC6M>8!MW
M_9$SCTSNH]M3_F7WA9G-^.=/U>74M)@L8-7G%C93&WO+9OF^UN D9D;T W$G
MIS[U/X47QA_PEDIUN2<1*)5E!W&&0?+Y9C&W:I '.#DY.:W_ /A+3_T+VN_^
M R__ !='_"6G_H7M=_\  9?_ (NCVU/^9?>%F<=J-IXQ&G1:@DFJEKV^N&N;
M99V#6\.6$*J$!*C@$X'/0\5!]E\36FNOJ-Q%K,LSR6$4\MLK%7@2,O(57(QN
MD&TC&1N/K7<?\):?^A>UW_P&7_XNC_A+3_T+VN_^ R__ !='MJ?\R^\+,XN&
MT\;W6F:G>W$NKPWPMU2SMEEPHEE=BS$#@B-64>GRFJ^H6GCRWO;B*VN=6?3_
M #Y4MY'D8R+(J(JR'8I)C+;VV\"N\_X2T_\ 0O:[_P" R_\ Q='_  EI_P"A
M>UW_ ,!E_P#BZ/;4_P"9?>%F</J<'B2]UZU?4-.UB[6TU-KF:&$#[,\,:_N0
M@) +%L-Z]<]!7K=<Y_PEI_Z%[7?_  &7_P"+H_X2T_\ 0O:[_P" R_\ Q='M
MJ?\ ,OO"S.CHKG/^$M/_ $+VN_\ @,O_ ,71_P ):?\ H7M=_P# 9?\ XNCV
MU/\ F7WA9G1T5SG_  EI_P"A>UW_ ,!E_P#BZ/\ A+3_ -"]KO\ X#+_ /%T
M>VI_S+[PLSHZ*YS_ (2T_P#0O:[_ . R_P#Q='_"6G_H7M=_\!E_^+H]M3_F
M7WA9G1T5SG_"6G_H7M=_\!E_^+H_X2T_]"]KO_@,O_Q='MJ?\R^\+,Z.BLC2
M?$$.K7EQ:"RO;2X@C25DNH@A*L6 (P3GE&K7JTTU=""BBBF 5@>+/^/+3O\
ML*V?_HY:WZP/%G_'EIW_ &%;/_T<M '.?%KR?[-\/_:@IM1K-OY^\?)LYSN[
M8]<UYYJ_B74M"O==B\-WDMCH<DLMQILB*! S(BB18\J<YD)PJX4\G/%?0M%
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M&\CU#3[:]@W>5<1+*FX8.U@"/YU/5.QTJSTV6YDM(C&;EP\@W$C(4*, G"C
M' P*N5SNU]!A1112 **** ,JQ_Y'G4?^P;;?^C)ZZ&N>L?\ D>=1_P"P;;?^
MC)ZZ&OI,'_ B8RW"BBBND05@>+/^/+3O^PK9_P#HY:WZP/%G_'EIW_85L_\
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M.REX??Q!I&AVMC-X7NGDB# LEW!@Y8GN_O6E_:FN?]"K>?\ @7;_ /Q=0?\
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MQ#2+YQ.WYCQN08]#GWJYX@W>(/[,BTW1-6M%6^M5NYQ;M;,8 6W1YX<J._\
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M<CDU(VCZ_:_$%([=[Z*PBN(#:.JRS)Y 0^8K,7V#)W9W MDC% '2:WH6C?\
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M_C4W]CZ9_P! ZT_[\+_A1_8^F?\ 0.M/^_"_X4 0_P#"2:%_T&M._P# I/\
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MW<JL<0-NKR&-0<]3N!Z=AF@#N/\ A)-"_P"@UIW_ (%)_C1_PDFA?]!K3O\
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MUI AE#*001D$=ZP?$.DZ:OAK5673[0$6<Q!$"\?(?:M'1O\ D!:?_P!>T?\
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M)17,)XULGMY[CR]L,#,LKL^ I7KU':IM!\766OWLEI!%-#*D?F[9T9&9<X#
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M3/ON?)F0J]L),1DE A;@9SM '7'?&:@N/")>*%$U2^D;#13RW$N]GA;&Y0,
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M:G.%8\CZ"J=MI&I:7JDEXL3Z@T4K[99+@>;<1NJCDMP&3:!S@$'UKVCRH_\
MGFOY4>5'_P \U_*@#QH:)>7FM+J%R9K-99'=TM[G:\8\M44%EZD[<G'%)=Z-
M+::I$]E;:A):K:^7FTOEA<N7W$N6(+9Y.?6O9O*C_P">:_E1Y4?_ #S7\J /
M%K[0+Z\&IW,<ES')-Y+):M=8CG55PT<F#CGIG^E;,-F[Z[<74T*K:SV$4!0L
M#R&<LI'IAA[5ZAY4?_/-?RH\J/\ YYK^5 'D^C6IT+2(H9(7:62YVMA]YPS8
M4D^@4 >P&*DU!;R'7;2^MK%[N-+>2)UCE1"I+ C[Q&1Q7JGEQ_W%_*CRH_\
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MT-N"0#M)(\G( /!)QCO3OM]I]DAN?^$YU/RIG:-#]G@SN4X.1Y&5P>I. ,T
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M$>NK>W%[&I^R7;#RY6;!S%M&5"Y)QSQ^= &1<>'W>^MYT\'7G]BJEPJ:8+A
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M]A18F@8Q3*&DC9MQ5C]?3!K13PWJ36,UI<1O(L@= 0R@JAX _ 5WE% 'FB^
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M]"MK/YVW_P >H_X2"^_Z%;6?SMO_ (]0!NT5A?\ "07W_0K:S^=M_P#'J/\
MA(+[_H5M9_.V_P#CU &[16%_PD%]_P!"MK/YVW_QZC_A(+[_ *%;6?SMO_CU
M &[16%_PD%]_T*VL_G;?_'J/^$@OO^A6UG\[;_X]0!NT5A?\)!??]"MK/YVW
M_P >H_X2"^_Z%;6?SMO_ (]0!NT5A?\ "07W_0K:S^=M_P#'J/\ A(+[_H5M
M9_.V_P#CU &[16%_PD%]_P!"MK/YVW_QZC_A(+[_ *%;6?SMO_CU &[16%_P
MD%]_T*VL_G;?_'J/^$@OO^A6UG\[;_X]0!NT5A?\)!??]"MK/YVW_P >H_X2
M"^_Z%;6?SMO_ (]0!NT5A?\ "07W_0K:S^=M_P#'J/\ A(+[_H5M9_.V_P#C
MU &[16%_PD%]_P!"MK/YVW_QZC_A(+[_ *%;6?SMO_CU &[16%_PD%]_T*VL
M_G;?_'J/^$@OO^A6UG\[;_X]0!NT5A?\)!??]"MK/YVW_P >H_X2"^_Z%;6?
MSMO_ (]0!NT5A?\ "07W_0K:S^=M_P#'J/\ A(+[_H5M9_.V_P#CU &[39/]
M6WT-8G_"07W_ $*VL_G;?_'J1M?OF1@/"^L\C'6V_P#CU #_  ?_ ,B5H?\
MUX0?^@"MNN1T#4=3TOP[IMA/X7U8S6UK'"Y1K<KN50#@^;TXK1_X2"^_Z%;6
M?SMO_CU &[16%_PD%]_T*VL_G;?_ !ZC_A(+[_H5M9_.V_\ CU &[16%_P )
M!??]"MK/YVW_ ,>H_P"$@OO^A6UG\[;_ ./4 ;M%87_"07W_ $*VL_G;?_'J
M/^$@OO\ H5M9_.V_^/4 ;M%87_"07W_0K:S^=M_\>H_X2"^_Z%;6?SMO_CU
M&[16%_PD%]_T*VL_G;?_ !ZC_A(+[_H5M9_.V_\ CU &[16%_P )!??]"MK/
MYVW_ ,>H_P"$@OO^A6UG\[;_ ./4 ;M%87_"07W_ $*VL_G;?_'J/^$@OO\
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MMMOVA/,3%R0Q;+_+P<G'RXXH AUGQ1K=G<SQV=S'MM+?[3.)E)+J6QA<$8.
MW)SVK-D\=ZZB6LPFA,6H%ULUVMN0A@ 7.>1@YX ]*W)_ NIWRQO=7DBS&(Q7
M!A9 LZ;MV#E>/3(P>343_#>9PRM<3^6I8V\?F)BW+,&)0[<]1QG/'% $(\6:
MQ#I6J2W$ZO=V$S0_N\K'(<*5.#D@?,,\]JIOXO\ $HU&ZTI;JU-[:QM.\IC;
MRW0(K !=V03NQG)Z=*VU\"W?V&ZM99Y9A=[S.[.@9F; W<*,$ #&..*KM\.[
MUW>8W]T+N3<LER'CWNA4*5(VXQA1T&>* .XT"];4O#^GWKYW7%NDC9[$@$UH
MU3TJS&GZ3:684*((EC SG  Q5R@ HHHH Q?$.M/I,*+;HCSLKRMO!(2*,;G;
M ()/0 9'+"J]GXKBN-1BL7L[H%I!";DH%C,GEB3:!N+'@X)P0",$U/K'A]=7
MU"&9YF2,6TEM*%.&VLR-Q^,8!]B:F@\/VEO=6]PKRL\$L\R;F&-TI);/';.!
MZ"@"I=>+]-LKTVMP)4*SR0NY VILB\TL3GA<9 ]Q5"#X@VLMG;W$ND:G ;M8
MWLXG1"]PKN%!4!CC!8$[L<'-7-0\%Z7J=Y<W-T]PWVF6.21 X"D(I&SI]U@3
MN'>BQ\&V=G<VD[7=Y<O9[5MA,RXCC52%C "C@;LY/)*C).* ,NX^()C>UF31
M[L6+QS3/,P5MZ1C!V;6/\949.!C)''-:T/B22XN-.$=DZI>1SE8F9=^^, C#
M!BA4CH0<=.:J)X"M$:)EU34@ULNVS(D3_1AO#_+\OS<@#YMV1P:LZ=X7^PSH
MPNG5;9"EJRA2P+MOE=AMV[F/& , =.O !G>.]7UG2;.*[TR>"';'NDCFC+9R
M0.JL,8S[US47CG5K.>[@U0RNMO.8?M5L@6,D)O VLQ;. >>E=OXHT*7781;@
M?NF7#$, 1R#_ $KG[KP%+>)<+)N GG\]ML@X;;MXXZ8H RA\1MK(+F2ZMEPA
MD,LD>8MXRF5#9.00> <9YQ5W2?&CZQ-)##<3)(L8E56D1MT9. WRDXY['!]J
M>_PZ9KE9L$#8B2H"A\T(NT98KN'  .TC.*L:5X&N=(+^2Q=2H158H BCM\JC
M/U.30!SP^(6K?V%]I)'V[[3Y(B#?+LSP_KC'ZTYO'VJ_:S&DN8P4!8J0>9'0
M\9[!!6I_PK4;@V)-P@,&?-'3?NSTZ]L^E*/ANPD9\R9)!_UJ]G9_3U<_I0!5
M7Q[.($F=KQH0B>=<(%"1NR[@I!.>F/4#(YJWI/BZ\U5G3%[:N(DF59]N61\X
M/RDXZ=#S2'X;R&,0B686Q5/,@$J[9&5=JL>,YQC@'!P.*OVG@VYLY_.C&6^S
MI;_-(,;4S@].O- ',V'CK5KFS:ZDU:T?;@-;0V[[TRX498M@]:MW7Q$^S36D
M DNI)[E)'6/?&FP(VU@Q8@ Y!QSSBMG_ (0JY.C)I9+>0A4@^:-W#;AV]:H3
M_#3SKRXO%!CN9I?-\S<CA,C!"JRD8/7D=>: &W?C66#3]-U!+\_8KR55,KY^
M52#SQWR*@L_'TMW?7T*74DL, 9XY(Q]Y516;.>^6Q6W_ ,(?=>58QX(%FZO&
M?,&20".>/>J=Y\/KF[NY[H7$\$TY;S&CE7E60(5Y!P,*.>N>] &<OQ$?:99%
MOXK;+(L[!-K.%#;0 <YP?3&:C3X@:BFHW5K>6]Y"8FR%RF401J[,QSC'S<8_
MG6D?AONL5LW#M"LK2C,HSEDV]<=AR/>B'X=3+=S7-S//=RS*RR&:5?F#(J$?
M*!CA1TH IV_Q!>[D6" W<MV^TI;1R1LS(03NR&VCA3P2#D8Q3X_%&OW?A&'5
MX+F*&X-N9W25&9> 3M&""#QZU/#\.;BW$;174R3Q,#%,AC5D 4KMP%P<@G)(
M)]^*OVW@NYMM#725RT"PF'>T@+D$$9SCKS0!SUOXYUNVN9(]38RPK';R&XM4
MVK$)>!N#,2><=*NQ^.YFEMT?[;&+ED%N[;<2JS;0PP>!D@X.#@CBKLG@&26.
M9&#;9D@1OW@Z1'*]N_>H/^%<SE5!N;C,(46K>:G^CA6W +\O/('WL\ "@"O'
MX]DFU06$;79D\PQL2R#&&*Y )RPR/X0<=Z9<_$">UNI+:2*_\X?ZN-6C+2?,
M%Z;LKR0?FQQ5I/AO,IBWW$\J),9V21T.]RV[.=N5Y_ND9J*'X7M%<QS>=,QC
M.4!=.F[=@D+EN1U))]Z *M[\0;^/3[J2UAO'NK9&::)RN("&V_-@\YZ_+GCF
MM#4-?UX:O96%C>PQF>&65Y)XV?&PH,  C^]^E)=?#:6Y-T5N+B#[66^T"*5?
MW@)S@Y!Q@^G/:KM]X-U"\O+>[BNI+2>!'C5H60Y5MN00RD?PB@#'MO'EX59;
MD7.ZW?R[V6$J8X#OV9YY()YX!P.M0Z9X\U:YL9+B=7<JD3;8750-^[)+.0H'
M ZGO6F/AS(H"I),L3!?M$8E4BYPV[+DC.<DYP14(^&++#'''+*AC*[6+HWW0
M1R&4@\,>H^E %0?$AW@$\:7SPGRU,A:-%#N"54EF '0\]/?D5Z3H5VU_H=G=
MN'#31AR'QN&?7''Y5PUM\.9K*PDM+:>9%=D)8NC'Y<@ @J01ST(/:NV\/:4F
MB:!9Z:@(6!-O)SSDD_S[4 :=%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110!F>(O\ D6-6_P"O.;_T U+HW_("T_\ Z]H__0147B+_ )%C5O\ KSF_
M] -2Z-_R M/_ .O:/_T$4 7J*** "L*\_P"1XTG_ *\+O_T."MVL*\_Y'C2?
M^O"[_P#0X* +FJ:[INC&%;ZX*239\N-(VD=\<DA5!.!W.,"K-I?6M_:17=K.
MDMO*H9'4\$&N=U:SU"R\:VWB"VL9=0M_L#V4D$+H)(V+APX#D @XP><].M<M
MKN@^(]0U2\N$T5E_M%M/D(2YC*P>3(2X8D@DXP> 0>>: /4#+&,YD7CKS3MZ
M\_,/EZ\]*\IT[P!="\T*2\TB%@FKWMS?,Y1LQL)/*+<_,,E<#G'I5&W\#>(X
M]"\06[P3M?3:;/;!@T2QW4CR%D;(.YB!_$^W&[% 'L?F)M+;UVCJ<\4NY?[P
M_.O*I/!VJ6UZ^W1Q/H\>IP7+Z?&T>)T%L$8A20I(DP2&QG&>:9I^B2/\0K'3
MH;,6NG+'%J=[9B8R_9IXU*1H6Z'(93C_ &* /4[B[MK10US<10JV<&1PN<#)
MZ^P)J:N4U:"[O/$,T<*L7CBM_*PV-L9ES*1[D*%X]J7P[I.JV>J&ZOI+EC+;
M%I3+<;U,C2$A N< (H R!SGJ: .D%W;%587$6&D\L'>.7_N_7@\5437]&DCN
M)$U:Q9+;_7LMPA$7;YCGC\:YG3]-UAK:RM9=-,;:<)II&GE79=3L&"[=I)VY
M8G) (XXJA_9NJI%#&FAWLNGQS0CR)_LYG1%;>41@^&CW*F-Q!XZ4 =]9WUIJ
M-N+BRNH;F D@20R!U)'7D58KE9++5/[#UNZMK1[:]OSNBMXW7S(QM"YSG;OQ
MD]<=.:RKC2=>U.*ZGE@O[=769XK5;S:V["I""5;C #.<'&2.M '>)-%)))&D
MB,\9 =0P)4D9 /IP0:?7F]_X=\22WD926[199W=FMY$'S JB22$L#]Q<\!NI
MRM/O=*UZ6[U=UM=4V384.MVNX_,/N+Y@4KA0?^6;?,1DT >BU$]S!'*L3S1K
M(V,(S $YSCC\#^5<E=V&ICPYI,#V5[<(JL;JT@O2LNXJ2BF0L"54GGYL\#[V
M#G(E\):G>7\DMY;W+3QP!A.EV561T@V(H(8'[SN2<#[N>] 'I-%>=G1?%":N
M]QY]\\D-L%A/F((6Q"%"_>R27R3E??=VJ5M!\1V-S'%I\MTT$;0R&66[+F21
ME9)6(8\A>'V\ G&!0!WD<L<I<1R*^QMK;3G:?0^]/KSA="\117.FQQ)?%H8W
MQ,]W^[0EF8%OGR6 VI@JX(/;K6IX4TS6=.TG4'O'U"2>5!LBN94#EPOS,""P
M4D^^.,X% '9T5Y3%INN,!IC6VL%A%)(G^G;&\QMJ1RR_O#@ AR55B,@';SBM
M+^QO%8U34+DW5\TRQ.J,KQK%(N %"?,3NQDY95PW<B@#OKB[MK12US<10J$9
MR9'"@*HRQY[ =31:W=O>VZW%I/%/"_W9(G#*?H17!W7AS4-0M&M5T^]@T]PF
M+:XOC(XS*"^3O/55QC)^]U[5%;Z!XF35+$B>]B2"&-HCYJM$AP6=')8L3N.W
MHW'0B@#T&2ZMX94BEGB223[B,X!;D#@=^2!^(JIJVLV^CBV^T9)N9?)C [M@
MG'Y UPUOI5Z;LI<V=Y#=W<=O$IN+@2L763?/+PQ"+P@ &,\<"M3QI;3/IFE7
M5M:3,\%^+I[9G'F$$,& ).,_-G&<4 6[CX@:3:NZ2B7S$;8R(A=@<9/"@G&"
M.>G-13?$?18&0.96WQ"8&.-I!Y9SAB5! '!Z^E<'+I]Y)>OJ3Z=>QM+.SI]D
MN$2YA&T*,Y.PJV#D9..*=I\6K:7<B6;3);IY-/2$FW,:J'$DC88$CLRY(!&<
MT >QV=U'?64-U$08YD#J0<@@].:GK&\*6<FG^%-,M)6#216ZAB.F?;VK9H *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH S/$7_ "+&
MK?\ 7G-_Z :ET;_D!:?_ ->T?_H(J+Q%_P BQJW_ %YS?^@&I=&_Y 6G_P#7
MM'_Z"* +U%%% !7,:Y=7%IXQT>2VT^>^<V5V#'"Z*0-\'.791C\>]=/6%>?\
MCQI/_7A=_P#H<% !_;>K?]"IJ/\ X$6W_P =H_MO5O\ H5-1_P# BV_^.UF^
M._%=[X;MK--*M8KN^F9Y6ADS_J(EW2L,$<XP![D4^3Q]IZ7BVJ6UQ++*]J+<
M)M_?I."0Z\_=4*V?I0!?_MO5O^A4U'_P(MO_ ([1_;>K?]"IJ/\ X$6W_P =
MKG9?B=9RZ=J\D%O-#-IZP2'<$E#I))L!&U@,YSD9X]^E.F^(C:9::M<W]GYJ
MVFIS6D:P,%/EQJ#D[CRW.,#]!0!T']MZM_T*FH_^!%M_\=H_MO5O^A4U'_P(
MMO\ X[7/GXB/#K%\9+!Y-&@M[.<7$> \2SYY<$\C..%&1S5:3XAW2SIY<<9M
MOLVIS2.8?G!MB NT;\$'GJ1GVH ZG^V]6_Z%34?_  (MO_CM']MZM_T*FH_^
M!%M_\=KG;#XC2/KCV>H:8T-CNMXUO5=<!Y83(-ZYR <8&,X/4UUF@ZRFO:3;
MZA':W%O'/&LJ+, "5/3H?3!_&@"K_;>K?]"IJ/\ X$6W_P =H_MO5O\ H5-1
M_P# BV_^.U-=:T;:]U*W\@-]CL5NPV[&_)D^7IQ]SK[UG+XWLFA8?9KD3K%N
M.8SY7F&+S1'YF,9*F@"W_;>K?]"IJ/\ X$6W_P =H_MO5O\ H5-1_P# BV_^
M.U3'C_05N9+6>Y\N>& RR@<A2$#LH[DA3GI4K^-](33K2](NMEW*88D$)WEA
MUX[CZ9SVH G_ +;U;_H5-1_\"+;_ ..T?VWJW_0J:C_X$6W_ ,=J[J>KV^EP
M1221SS/,VR*&",O)(<9X7V )/L*YY_']O_:RVMOIM[<V[I&Z30Q%C('1F^5>
MY&W^?I0!J?VWJW_0J:C_ .!%M_\ ':/[;U;_ *%34?\ P(MO_CM0+X[\/M?P
M6:WF7GB65&QQADWJ/7)7G&*;#X[T26.!Y&N;?SY%CC6>!D+!D+JW^Z0.OKQU
MH L_VWJW_0J:C_X$6W_QVC^V]6_Z%34?_ BV_P#CM5O^$XTI)H8Y#*6N)-D*
MI$Q;&%.2,?[:],]?K5N#Q9H]SXBDT.*Y!O4+#'&"RC+*/<"@!O\ ;>K?]"IJ
M/_@1;?\ QVC^V]6_Z%34?_ BV_\ CM//BG3!JUYINZ8S6<9DF81DJH #$9]<
M'\>U4)?'^AP6/VF=KF EE589H3'(X92P8!L9! )S[>M %S^V]6_Z%34?_ BV
M_P#CM']MZM_T*FH_^!%M_P#':8?&&F2";[*TDRQVWVCSA$QAQM#!2X!^;:0<
M>AK,A\?P+>:D-0MFL[2U!,3.&#S895R 0%Y9@!SF@#6_MO5O^A4U'_P(MO\
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M -PS6?>^/M#L%=YGG"+*8D?R\+*P&6V$X! ')^M %O\ MO5O^A4U'_P(MO\
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M[W58-7\'ZS-!'-&8[>>*2.>,HZ,$.00?\\UIZ-_R M/_ .O:/_T$4 7J***
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MX-TZ>6=I)[LPREV6#S!LB=_O,G&03SU)')P!5J\T6P:RU&WFN)(4U*8-(_F
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MZUFKX-T:.&"*&&:!(2_$-PZ;PS;V5R#\RY[&@#,D\<&R6ZFO;4-!#D?N.O\
MK6C!)8@ 8&2216W>ZR8_"=SK5K'DI9M<QI*.X4L <'^1ILWA;2IED'ES1M(2
M2\4[HPRQ;@@\<D_GBK2:-81Z'_8R0;;'R3!Y88CY",$9ZT <P?&\VDZ0+_68
M)9!(V$6*Q>U*@+DY$S_-[8K1/C*)Y9$M=+OKG#[(RGECS2$#MC<PP I'7'7
MR:T-4\/:?K"VXNEF_<*R*8IFC)1@ RDJ1D$ 9%9^I^$(KC3%M--G^PN)?,\X
M^8[CY-AVD.I&5 !YP?2@!J^,[>X\K[-971279&)W50B32+N2-ANSDY7H,#(R
M15BS\413>(?[ GMY4OTB#R, H3.T,<#.XCG&<8SQFELO".EV3V<@65Y+5(P
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M ,E__CM'_"0WG_0KZU_Y+_\ QV@#G9?!5W;V]XFFQ0P&:WO85VRD?*Y4PK[
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M*MAKIT"-M+?>&T$Y_P!OUK8_X2&\_P"A7UK_ ,E__CM'_"0WG_0KZU_Y+_\
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M,S&-QDA3LR$9<D$<#L:U=-T?4K/2O#^G3QA9X+\SDH.(XANX8CY<G<.!@<\
M8K;_ .$AO/\ H5]:_P#)?_X[1_PD-Y_T*^M?^2__ ,=H YG5?"6K7FIZA)':
M6Y>47&V^-P0[K)'M2,KCC:?P[CO277@F\D\3Q2V]K';V$>(P\4P4"$Q,K+MP
M6W;FSP0O'3/-=/\ \)#>?]"OK7_DO_\ ':/^$AO/^A7UK_R7_P#CM '%IX'\
M23V]\E]+!(+J,RE?M#$^>65#SC[ODI^;'ZUTEQX=NX/"VK:7800A9KDO;P+)
MM41$J2H[ GYN#D9/((R*T/\ A(;S_H5]:_\ )?\ ^.T?\)#>?]"OK7_DO_\
M': ,'PMX5OM)U"UN+JSB/EQW$:2&96>%'<,H^50/4': !^-5]+\*:S9V]Y$%
MCMXWOH)T/G;G.U\NQ*@;AC&,C=V)-=-_PD-Y_P!"OK7_ )+_ /QVC_A(;S_H
M5]:_\E__ ([0!PVD:!)K%VT0TE8K2&2U^U-(7"7;([EWPR@DD%21COUKHM%\
M+7FFW-V1###)+IWV6*[1\M$0S[5QUP RX_W<5K_\)#>?]"OK7_DO_P#':/\
MA(;S_H5]:_\ )?\ ^.T <W:>"[F?R8[S3;:"Q$R-+9"<NDA6)U,A[$LS+Q[9
M/-3ZYX3OM0\-:':?98+F[L@4<R2XV Q,FY6(YP=I_"MW_A(;S_H5]:_\E_\
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M&5R.<>8"<#'KUK)M? >L)9L@MHXI#*7@+3J6MV:%D9P54 '=M/'..^17;_\
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M/^$AO/\ H5]:_P#)?_X[0!NT5A?\)#>?]"OK7_DO_P#':/\ A(;S_H5]:_\
M)?\ ^.T ;M%87_"0WG_0KZU_Y+__ !VC_A(;S_H5]:_\E_\ X[0!NT5A?\)#
M>?\ 0KZU_P"2_P#\=H_X2&\_Z%?6O_)?_P".T ;M%87_  D-Y_T*^M?^2_\
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M/):1R70N[C*XC2W #L!G)^9E'YUL?\(AX>_TO_B3VG^F?\?'[O\ UGS;^?\
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ML\6D&>*ZCA^RP1LQ<.R.S[MJ$X 0] >W YQU*^%-!6P:Q&EVXMFD$I3'5P,
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MKQ6KX*\3ZKK6H7]IJEO'&8D26$JNUBC?WESP3UQVH I77A#4I8;^5X8;BZ:
MQV[/*<\S.S8[ E"/;L<BJ-GX(U>W%F?LL(DB=@DC3KO@C,\<H'RJ > XPH S
M[&NZUS6X]$MH96@DG:64((X\;@O5F^BJ"Q]A5=_&&A1W%Q"]Z5:W5VD8POL^
M0!F ;&&(!!P"3B@#F8?!VH32/%<VL*0-)$+HBX+?;]LV]I&';*Y&#R<XZ5IR
M:'J-IX8M+2TMHY9K/4%N(X/.VCREEW!0Q''R]JU[;Q1I%TH,=RZG$C%)8'C8
M",*6RK*",!E/OGBJ]SXRT>!YH8YVEN8X6E6,1LH?"[B Q&W..<9S0!S'B#PM
MKFN6\\S6,,4EY,7>W6X7,6(@B,6(*L<C)XSC !!&:J:AX&UB>9Y!:JWF%'E\
MFZ1&ED\E4W$LC?=96YQGYLBNVM?%6GS+<F=C;M Y4JP+$J&"[A@>I Q[U/<>
M)-*M;^2RFN2LT8)<^4Y0$+NV[\;=VWG;G..U &!XG\,WNI3Z3-;V\5Q+;6\D
M,TDDNUB#L)7.,D,%92?]O-(WAR_D\&76G?8X4:6[$T5CYYV11[U;R]XZ< ].
M.:V1XLTN;1K_ %*U>:>.RC\R2/R'1R-NX85@"01T.,&JNG>.-)OFN5F,MFT#
M2 F>)U4J@!)W$8S@@[<Y]J .9N/!>M3/92",Q0)([0VD-VJK99D# ABC9X_N
M8QT'%:GC#PYJVL:S97%E&I6W$;1R^<%,;+(&;.03@J,#;@^IQ71VWB32;O2Y
M]2BNQ]EMR1,SHRLAX."I&[)R,#'.1CK6<GCK1A!<3W3S6T45PT ,D$F3M16+
M,NW* ;L'<!TH Y^Y\+:U>V[VMU86TT%N7,6^XSYY-R)1P1\N%R.>_M3X/!VI
M/F*>U@BC,T7VIA<%OMP$X<NW<84$8/7..E=G%K>G3.J1W(9F\S^$\>7C=GCC
M&1UZYXK/3QKH,ENTT=W*X658=BVTI<NP+ !-NXY /(&.* .>/@R_L["YCL+>
M%7FM)8743$;_ -\K1C/H(]P'89QTJC9^!]6@6S/V2(/%.QC=IUWP1F6.3'RJ
M!T#C"@#\ZZZX\9:4DUA%;.]RU[+$B&-&VJ)#P6;& >"=I(/M4][XKT?3[Y[*
MXN)?M"$*4CMY'^8C<%!52"Q'( YX/I0!REQX4U231Y[/^S(2TEX'G9+O+70
M?][AP44DE>"#^8!"VGA'4HK>V_M,IY4,06=T<NV%MY(\@ 9)R5P!76?\)1HY
MFM8UO-WVE$>-UC<IA_N;F PN[L&(S6?<^/=&CM?/MC<77[Z*/:EO("1(^P.,
MK\RY!Y&>1B@#(ET+6-9\%1-,)/MMU<K=74!=8VD0<!/F5@#M"G!';FJ>H>"]
M7N=+BA^S13QQVHBDM)KK<)WZJ[-M S']T<8.3Z"NRT3Q+I^N6S20,\<B1K+)
M'(C+M4YPP) #+\K?,,C@U OC;0'A>1;N5MDJ1>6+:4N6;)7";=QSM;D#'!H
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MMO;>8EIM/[F7S-[9<EV;G))_PJSJGPT?4#=F/6 @N;NZN&CEMO,C'G(%^[N
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M>%7*KN. %0 <D\DYYJ/1? 5GHVM"]B,#11N\D2^1^]#/UW.6((&3C"@X/)-
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MAHH Y_\ X0G0/^?2;_P,F_\ BZ3_ (0C0/\ GTF_\"YO_BZZ&B@#GO\ A"-
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M1J8YF@<!68AU +< = ",GH,\FLCQCX"B\7:KIMU-<B*&W22.YBVY\]2,H/\
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MCO*"&P @!< XP2H.2 21Z5QW_"K+B.QN;>+58BT]I!"S-"?]8ESY[-@'H<D
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MX>ISBJ#:1XTL[^WM[*[G;3XI6\EI)$=E7=QYGS+E<#H <9/>O1** /-(]/\
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M_("T_P#Z]H__ $$4 7J*** "L*\_Y'C2?^O"[_\ 0X*W:PKS_D>-)_Z\+O\
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M*GO_ !M;Z9;M/>+#"@!(WRX+8&<*#U/M7G7_  CNI+9O;BULW,T$EJ6>7_5
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MA%9QB2Z6W@0G:&EF"@GTR>]>=GPY>7-[?WL]K:0M=6\T:P*^X1LP4#G'?')
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M-WDUI,KI!!/*]L0RON*"-<-@X_*K7AC1;K2;@RW><I!';J?/#[@I/( 5=H]
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M0/MW,C$MCCT/6O4O#9_T:?\ ZZ?TH L>(O\ D6-6_P"O.;_T U+HW_("T_\
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MP-2*:K-#;YPA6>XP@.1E<Y."?K0!S]QXAUB#1KBY>2()/<2PPE<^="P7</;
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M:M_UYS?^@&I=&_Y 6G_]>T?_ *"*B\1?\BQJW_7G-_Z :ET;_D!:?_U[1_\
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M17*J GV89<,?)VYX4]#Z^O%=;IVJIJ,NR.%UVQ+(Y8_=8DC9]1@_I62GBN5
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MMN$FM+YKQ2JV$P)VP(';<'.<#(]<Y!% '5-X;T_RYD:.8+,H5_WAY <R#'_
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M#_WP*:=,L&*EK*W)7D$Q@X^E6Z* *W]G67_/K#_WP*/[.LO^?6'_ +X%6:*
M*W]G67_/K#_WP*/[.LO^?6'_ +X%6:* *W]G67_/K#_WP*/[.LO^?6'_ +X%
M6:* *W]G67_/K#_WP*/[.LO^?6'_ +X%6:* *W]G67_/K#_WP*/[.LO^?6'_
M +X%6:* *W]G67_/K#_WP*/[.LO^?6'_ +X%6:* *W]G67_/K#_WP*/[.LO^
M?6'_ +X%6:* *W]G67_/K#_WP*/[.LO^?6'_ +X%6:* *W]G67_/K#_WP*FB
MAB@39%&J+G.%&*?10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!F>(O\ D6-6_P"O.;_T U+HW_("T_\ Z]H__0147B+_ )%C5O\
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M$#SR#M'3/6@#TK3]=TO59GAL+Z*XD2))F"'/R/G:WT.#^5/U#6=-TH@7UY%
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MCW6EC?S.K?O8T1"8TXPY^;!'/123UXXJY;^#]$@N9)VLHY69=B"101''L"[
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M=V#.L:6&HO+*V+>,1+FX&7&5^;@?NV.6QQSTK=GTNSN(KM'@3_2U"S-CEL#
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M*** "N8UR*^F\8:.NGW<-K-]BNR7FMS*"-\'& R_GFNGK"O/^1XTG_KPN_\
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M-E8W1F'F1X8'< 0R=.AR* .TN5UVRMC<W?B?28(%QF673RJC/3DS8J!KS4D
M+^,="4-'YH)LP,IUW?Z_I[]*EU?3-7D\.:;:VZVTUW 8_/955.B$%HMRLJ'/
MJ#QD5R]EX"U>#0Y8I/(6]5H'0QR#+^7*[E=Q3 SN&/E(SVH ZG_B=_8A>_\
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M9:;!8EV! E=<LS#/4<]?4F@"U]A\3_\ 0>T__P %;?\ QZC[#XG_ .@]I_\
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M]%+/>LJCJS0N /TJE\0&5-)TUF8*!J4.23@#K7,Z]=0'0-0 N8B3 W D'^-
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MK$L1A6++.Y4,.2=B+G/<@#&:[&WU/R/#TES)</>7$%K]HD_=;7.06 V@<=,
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MSG%>E4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN$;:"BKO)6,*2-O0#H>O% 'H2WEJUU):K<PFXC4.\(<;U4]"1U J.WU33[Q
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MPEFI3K$R6%JQ6V#1%!YLF#*5R.1D#YAP=Y]* .JHHHH **** "BBB@ HHHH
M**** ,SQ%_R+&K?]><W_ * :ET;_ ) 6G_\ 7M'_ .@BHO$7_(L:M_UYS?\
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MLCK]D7'G>2GS<[CG ([=*M:AJ%Q;ZI;6\3QJ'Q\C+DR9.#@YXP.>] ')W_\
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M]X9%4_NLX#$]""0<$D5?GU7PS<:]%JS:C?B2/;B);2782H8 G]WGHY[UVU%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
D"BBB@ HHHH **** $P/04N!Z444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>g2018030121531033832030.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531033832030.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0-&17AI9@  34T *@    @ !%$   0
M   !     %$!  ,    !  $  %$"  $   ,     /E$#  $    !
M    =L0 E.  H>@ <<  9;5-E<QOJ]CJ]?L 7:T F^3S^OT ?LU<N.D J^P
M<+\ ><< @M  @,Y.H]D >,:EV_4 E^( D-P ?,J%M]T G>8 AM0 INI7Q/%)
MMNL A=( G.4 D=ZVY/ALM^.6V/7B]/P J.N6R>D8J.DGJ^G:\?P B-8 H^BX
MU>N*U?0 H.< <\+L^/W\_O^CR>4 6JHWL^PEL^UGRO( 8+#Y_/X B]@ 8[(;
MD]BUV_( CMN)PN8 C-C+X_, :+?"V^XHF-EWRO'*[/JITNQ)JN$TBLG3[?HE
M<[BIX/< G.8XFM8VK.<GALD 7Z]YP.G1Y?/;ZO;A[O< C=H D>%EPN[#Z?H;
MC=)YT?09@\H9?,0;L>T-JNK:[OG!X?.%SO$+G.0 ;;P 7;$ ;K\ 9[8 5:D
MCMH :[H7=+T.I>@7GN,8;+8VN^\ D-\ 9;@ ;L+3Z?9AG]$-DMLH?L'P]_L
MI.H 4::_YOD :;TWH=X 3*, 8;8 <<0 =<@[D,TKC]$ 6*T ><P ?=!(ON_V
M^_T ;+L D^(.H>8 BM< E^0 9+0-><00@<H*;+D @<]:KN FG^$-?<BQS^<
M@M,&I>D.B=, AM>6P.  @]'+Y_< 8;$,9+$ G^<.:K4%C=D-<[\ AM((J>L&
MG^8 CM\.E]\ 7[, BML&HN@-AM 'F.( :[_D\/D-CM@ 9[J:S^XU?[_8Y_,$
M=<(&BM8%:+@%EN$'K>P'@LX"J^P$J>L.7ZT&DMT'FN,0K^T#H^CI\OD%<K\J
MN>\"E.(#F.,'7JX'D^  D]\#I^L"8++0XO &AM("EN,';KP"E. #AM( F>,#
MG^8$9K4&7*H#FN0#DM\$D-L'C]P F., F.(%>,4#IND#G.4%8[("D=P%B]D
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M,C(R,C(R,C+_P  1" %H CX# 2(  A$! Q$!_\0 'P   04! 0$! 0$
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_I6V%I^TK1CYG-CJWL<-.?E_P#S&BBDS7UY^?6%HI,TE,+#LTF:2B@84444
M%%%3V5LU[?V]JN<S2*G'N:3:2NRHIR=D>Q^"[+[#X5LU(PTJF5O^!<_RK?ID
M4:PPI$HPJ*% ^E/KXNK-U)N;ZGZ)1IJE3C!=%8*ANYUM;2:X<X6-"Y/T%35S
M/CV^^Q^%;A0V'N"(1[@]?TS3HT_:5(P[L6(JJE2E4?1'CT\S7-Q+._WI7+M]
M2<U'125]HE;0_/&VW=A77?#FQ^U>)A<$?+:Q,^?]H_*/YG\JY&O4_AE8>3HU
MS>L/FN)=H/\ LK_]<M7%F%3V>'EYZ?>>CE5'VN+CY:_=_P $[FBBBOE#[@*\
ME^)=]]H\016JGY;>(9'^TW/\L5ZR2%4L3@ 9)KY_UR^.HZW>W1Z22L1].@KU
M<HI\U9S[+\SQ,\J\M!0[O\B@3244<D@ 9)Z 5]&?*(DM[>:[N([>WC:261MJ
MJHY)KVCPCX4A\.V>^4+)?R#]Y(/X1_='M_.J?@?PBNBVHOKV,'4)5X!_Y9+Z
M?4]_RKL:^=S#'>T?LJ?P_F?5Y7EWL5[:JO>>WE_P0HHK.UK6;30M-DO;ML*O
M"H#R[=@*\J,7)\L=SV924(N4G9(-;UNST'3WO+Q\ <(@^\[>@KP[Q!XAO?$-
M^;BZ?"+D11#[L8]O?WI-?U^\\0:@UU=-A1Q'$#\L:^@_QK)KZ;!8%4%S2UE^
M1\GF&82Q,N6.D?S"DHI*[SS0->S?"^U6'PGYV,-/.['\.!_*O&*]U^'W_(E6
M'T;_ -"->9FS:H)>9[&313Q#?9'3T445\X?4!2,P498@ =R:Q/&+%?!VK$$@
M_9G''TKY[+-_>/YUWX3 _6(N7-:WD>=C<P^K24>6]_,^EY=1L8/]=>V\?^_*
MH_F:S+KQEX<LQF76+4X_YYMYG_H.:^>22>])7='*(?:DS@EG,W\,4>R:A\6=
M'MP5LK:YNW'0G$:G\3D_I7&:O\3M>U%6CMFCL8CQ^Y'SX_WCW^F*XRFUUTL!
M0IZI7]3DJYAB*FCE9>0Z262:1I)79W8Y9F.2:;12&NPXQ#7J7P=TTF34=38<
M#; A_4_TKRROH#X=Z=_9W@NR##$DX,[>OS=/TQ7G9G4Y:%NYZ65T^:O?L=51
M117SA]*%?/OQ)U/^T?&MV%;,=J%@3!XX&3^I/Y5[U?726.GW%W*=L<,;2,?0
M 9KY<NKA[N[FN9?]9-(TC?4G)_G7K953O.4^QY.:U+0C#N0FDI:2O</$0E(:
M6FT#04T]:=3:0RWIFFW.KZG;Z?:)NGG<(OH/<^PKZ;T'1[?0-%MM-MA\D*8+
M=V;N3]37$_"SP=_95A_;5]'B]N5_<JPYBC/]3_*O1Z\#,<3[2?)'9?F>_@,/
M[.'/+=A1117FGH'*_$*0IX3E4?\ +25%/YY_I7D%>L?$K/\ PC477_CY7/Y-
M7D]?2Y2K8?YL^-SUWQ7R04445Z9XP9HR:** %S7=?#.Q\W4KN^8?+#&$7ZM_
M]8&N$KV#X?V7V3PO'*1\UP[2=.<=!_+]:\_,ZG)AVN^AZN34?:8M/^74ZFBB
MBOES[8*\@^(-]]K\3R1 Y2VC6(<]^I_4X_"O7)9%AA>5SA$4LQ] *\!OKI[V
M_N+I_O32,Y_$YKU\HIWJ2GV7YG@9_6Y:,::ZO\BO1117T)\F%%%% !1110 4
M4E% Q:ZCX?V1N_%,4I'RVR&0GWZ#^=<K7IOPPLMEA>7S#F5Q&I]E_P#KFN/'
MU/9X>3[Z?>>AE='VN*@NVOW'?4445\F?=!7FGQ0OMUS8V"M]Q3*X]SP/ZUZ7
M7B'C&^^W^*KZ0'*1OY2_1>#^N:]/*J?-7YNR/'SNKR8;E_F?_!,*DHHKZ4^.
M"O>O#UC_ &;X?L;3&&2(;O\ >/)_4FO%_#MB=2\0V-KC*O*"P_V1R?T%>]]!
MBO#SBI\-/YGTN04?CJOT_P _T"BBBO#/I#'\4W_]F^&KZX!PWEE$^IXKP:O4
MOBE?^7IMG8J>9I#(P]E_^N:\L)KZ3*J?+0YN[/DL[J\^(Y/Y4!-=_P##GPP+
MN;^VKM,PQ-BW4C[SCJWT'\_I7&Z1ILNL:M;6$60TSX+8^ZO4G\!FO?[2UAL;
M.&UMT"0Q($11V I9GBG3A[..[_(K)\&JM3VL]H_G_P  FHHHKYP^K(KBXBM+
M:2XG<)%&I9V/8"O"O%7B2?Q'JC3$LMK&2L$1_A'J?<U[/KVBIKVG&QEN)88F
M8%_+ZMCM]*Y7_A56E?\ /[=?I7IX"MAZ-YU/B/)S*AB<1:G37N^NYY)25ZY_
MPJG2?^?RZ_2C_A5.D_\ /Y=?I7I_VIA^_P"!Y']D8KLOO/(:2O7O^%4:3_S^
MW7Z?X4?\*HTG_G]N_P!/\*/[4P_?\!_V1BNR^\\@)KVKX8W:W'A%(MV7@E=&
M'ISD?H:\]\;>'K#PU?6UK:3RRO)&7D\PCY>>/ZUI?"_6UL=:DTZ9]L5X/DR>
M!(.GYC^53C;8C"\\/4O 7PV+Y)^A['1117S9]24M7L1J>CWEB3CSX6CSZ9%?
M-UQ!+:W$MO.A2:)BCJ>Q'!KZ>KB/&G@&+Q QOK!D@U #YMWW9?KZ'WKTLNQ<
M:,G&>S/+S/!RKQ4X;H\3IIK9O_"VN:;(4N=,N!CC<B[E/T(JM;:'JUXP6VTV
MZD)](C7OJI!JZ:L?.^RJ)V:=S.-36=G<ZA=1VMI"\TTAPJ(,DUV^B_"K5[UE
MDU*1+&'KC[TA_#H/QKU+0O#.E^';?R["W"NPP\S<N_U/]!7%B,QI4U:&K/0P
MV65:CO/W5^)PEM\+5M_"EZUT1+J\D6Z(*?EB(Y"CU)Q@G\J\GKZJKYU\;:8F
MD^+K^WB*F)G\U #G:&YQ[8.:QR[%3JSE&;UW-\QPD*4(RIK38R-/M&U#4K:S
M0$M/*L>![FOIV"%;>WCA3[L:A1] ,5X7\,-.-]XQBF*YCM(S*3Z'H/YU[Q7-
MFU2]10['3E-.U-S[A1117E'K'&?%#4OL'@JXC5L27;K ON#RW_CH->!&O3OC
M)J7F:II^FJW$,1F<>[' _13^=>85])EU/DH)]]3YS,:G/7:[:"4E+25W'"(:
M2@T4%"&N_P#AIX*.NWXU2^C/]G6S?*I'$SCM]!WK%\&>$+KQ7JHC :.QB(-Q
M/C@#^Z/]HU]%65G;Z=90V=I$L4$*A$1>@%>9C\7[->SAN_P/2P.$]H_:3V7X
MD_2BBBO /="BBB@#E?B'&7\)RM_SSE1C^>/ZUY!7N/BJU^V>%]1B R?)+@>I
M7D?RKPVOH\HE>BUV9\CG\+8B,NZ%HI**]4\,6BDHH DBC::9(D!+.P4 =R:]
M_LK9;.QM[5/NPQJ@_ 8KP[0;JULM<M+J]#F"%]Y"+DY'(X^N*])_X63H7]V[
M_P"_0_QKQLTIU:KC&$6TCZ#)*M"C&<ZDDFSKZ*Y#_A9.A?W;O_OT/\:/^%DZ
M%_=N_P#OT/\ &O*^I8C^1GO?VCA?^?B+_C6^^P^%;M@</,!"O_ NOZ9KQ:NQ
M\:>*[37[:UM[$3".-R\GF+C)Q@=_K7&U[V6T)4J/O*S;/ELXQ,:^(]QW20M%
M)17H'E"YI*2B@!:*2B@ HHHH *]Q\)V/]G^&+&$KAS'O?ZMS7C.E6C7^KVEH
MHR9954_3//Z5[^JA$5%&%48 KQ<XJ:1I_,^DX?H^].J_06BBBO!/IBMJ-TMC
MIMS=O]V&)G/X#-?/KNTLC2.<NY+,?4FO7_B)??9/"SP@X>YD6,?3J?T&/QKQ
MVOH<HIVIN?=_D?*9]5YJT::Z+\Q:2BDKUSPCNOAC8^=K-S>L/E@BVKG^\Q_P
M'ZUZK7E?@SQ7H_A[29(;K[0;B64N^R,$ =!SGV_6NC_X69H']V\_[]#_ !KY
MS'T*]6NY*+L?6Y;B,-0PT8RFD]V=C17&_P#"S= _NWG_ 'Z'^-)_PLW0,?=O
M/^_0_P :X_J6(_D9W_7\+_.CC/B+?_:_%4D(.5MD$>/?J?YBN2JQ?W37VH7-
MV^<S2,_/N>*K5]30I^SIQAV1\;B*GM:TJG=GHWPKTT//>ZFX^X!!&?KRW]*]
M.KRKP;XRT?P_H?V6Z6Y\]I6=C'&"/;G/H*Z'_A9_A_\ NWG_ 'Y'^->#C:%>
MK7E)1=CZ;+\3AJ.'C%S2?4[2BN+_ .%G^'_[MY_WY'^-'_"T/#_]V\_[\C_&
MN3ZGB/Y&=OU_#?SH[2BN+_X6AX?_ +MY_P!^1_C2?\+1\/?W;W_OR/\ &CZG
MB/Y&'U[#?SH[6BN*_P"%I>'O[M[_ -^1_C1_PM+P]_=O?^_(_P :/J>(_D8_
MKV&_G1VM%<3_ ,+3\/?W;W_OR/\ &F3?%/0?(D$2WGF;3MS$.N..]'U/$?R,
M/KV'_G1YUXXU#^T?%]_(&RD;>2GT7C^>:P$D>*19(V*NC!E8=01T-#R-+(\C
MG+NQ9CZD\FF$U]33@H04.Q\A4FYU'/NSW+P5XR@\16:VUPP34HE^=3QYH'\2
M_P!1775\PPSRVTZ302/%*AW*Z'!4UZ1X?^*KPQK;ZY TN!@7$(^;\5[_ (5X
MN+RV2?/1V['OX+-(N*A6T?<]6HK'L/%6A:FH-KJ=NQ/\+OL;\CBM=65U#*P8
M'H0:\F4)1=I*Q[$9QFKQ=Q:*"0!D\5GW>NZ38J3=:C:Q8ZAI1G\NM)1<M$AN
M2CJV:%(2 "2< =2:X75?BKH=D&6R66^D'38-J?F?\*\X\0>/=;U\-$\PMK4_
M\L(. ?J>IKMHY?6J/567F<-;,:--:.[\CO/&7Q*@T]9+#1)$GN_NO<#E(OI_
M>/Z5X[-+)/,\LSM)([%G=CDL3W--IIKWL/AH4(VB>#B,34Q$KR^X]A^#VG>5
MI5]J3*-T\HB4^RCG]37I=>6^&/B'X<T'PY9Z<XO#)$G[PK",%B<GO6O_ ,+;
M\-?W;[_OP/\ &O#Q-"O5K2GRL]W"UZ%*C&',CNZ*X3_A;GAK^[??]^!_C5>\
M^+F@_8;C[*MX;CRV\H-" -^.,G/3-8+!U[_"S=XNA_,CR_QKJ7]J^,-2N0V4
M$QC3TVI\H_/&?QK I223DG)/4TE?3PBH145T/F9R<Y.3ZB4AI:;5"05M>&/#
M%]XIU1;2T7;$N#-.1\L:_P"/H*?X7\*W_BK4?LUH-D*8,UPP^6,?U/M7T+H.
M@V/AW2X["PCVHO+.?O.W<D^M<&,QJHKEC\7Y'?@\&ZSYI?"/T71K+0-+BT^P
MBV0Q]3W8]V)[DUH445\ZVY.[/H$DE9!1112&%%%% #7021LC $,""#7@&HV;
M:?J5S9MG,,C(,]P#P?RKZ!KRKXDZ4;;6(M11?W=TNUS_ +:_XC'Y5ZV4U>6J
MX/K^AX>>T'.BJB^R_P &<3124M?1'R(4444 %%%% !1110 4444 %%)10,6B
MDHH 6DHHH **2B@#K_AS8_:O$OGD96VB+_B>!_6O7JX;X96/DZ-<7C#YIY=H
M/LO_ -<UW-?+9E4Y\0_+0^VRBE[/"Q\]0HHHK@/3/+OBA?>9J=G8J>(8S(WU
M8_X+^M<#6QXJOO[1\3ZA.#E?-*+]%^4?RS6-FOL,)3]G0C'R/@L=5]MB9S\_
MRT%I,TE%=!S!1FDS24AA113:!BTE%-H&!-%%)0,#244E(84E%)04%-I2:2@8
M4E%!-(8A-)124%!244&D,0G!XZT];F>,Y2>52.F'(J.FT6*5T3/=W,AR]Q*Q
M/JY-0DDG).3[T4A-*R'=L0FDHI*8PI**2D4%-I324#"FTII*0Q*2BB@8AKJ/
M!_@>_P#%=SO&ZWT]&Q+<$=?55]3_ "K=\%?#*XU<QZAK2O;V/WD@/#S?_$K^
MI_6O:K:V@L[:.VMHDBAC7:B(,!17EXS,%#W*>K_(]3"8!S]^IL5M)TBRT/3H
M['3X%B@C' '4GU)[FKU%%>$VV[L]Q))604444AA1110 4444 %8WBC1AKFA3
MVH \X#?"?1QT_/I^-;-%5";A)2CNB*E.-2#A+9GSHRLCLCJ593AE(Y!]*2NW
M^(?AXV5]_:MLG^CW!Q* .%?U_'^=</7V%"M&M34X]3X'%8>6'JNG+H+1245L
M<XM%)10 M%)10 M%)10 M%)10 444E "T4E% Q:3DT5H:#9'4=>LK7G;)*N[
M'H.34RDHQ<GT*A!SDHKJ>U>'++^SO#MC;=UB!;ZGD_SK4HZ45\7.3E)R?4_0
MZ<%""@N@52UB]&G:->7F<&&%F7W..!^>*NUQGQ+OOLWAM;4'YKJ4*1_LKR?U
MVUIAZ?M*L8=V98JK[*A*?9'D1)8DDY)ZTE&:3-?8GP09I**3- "TF:2B@=@H
MS29I*"@HHIM Q:2BDI#"DHI*!A2$T9I*!A2444AA3:*2@84E%%(H*;12$T#
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M4E[BL%%%%8FP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
0B@ HHHH **** "BBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>g2018030121531689031129.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531689031129.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "R JX# 2(  A$! Q$!_\0
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M%O*8IKZVCD'57E4$?@30!:HJC_;.E?\ 02L_^_Z_XT?VSI7_ $$K/_O^O^-
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MO^- %ZBJ/]LZ5_T$K/\ [_K_ (TO]LZ6.NI6?_?]?\: +M%4?[9TK_H)6?\
MW_7_ !H_MG2O^@E9_P#?]?\ &@"]15'^V=*_Z"5G_P!_U_QH_MG2O^@E9_\
M?]?\: +U%4?[9TK_ *"5G_W_ %_QH_MG2O\ H)6?_?\ 7_&@"]15'^V=*_Z"
M5G_W_7_&C^V=*_Z"5G_W_7_&@"]15'^V=*_Z"5G_ -_U_P :/[9TK_H)6?\
MW_7_ !H O451_MG2O^@E9_\ ?]?\:/[9TK_H)6?_ '_7_&@"]15'^V=*_P"@
ME9_]_P!?\:/[9TK_ *"5G_W_ %_QH O451_MG2_^@E9_]_U_QI?[9TO_ *"5
MG_W_ %_QH NT51_MG2O^@E9_]_U_QH_MG2O^@E9_]_U_QH O451_MG2O^@E9
M_P#?]?\ &C^V=*_Z"5G_ -_U_P : +U%4?[9TK_H)6?_ '_7_&C^V=*_Z"5G
M_P!_U_QH O451_MG2O\ H)6?_?\ 7_&C^V=*_P"@E9_]_P!?\: +U%4O[9TL
MG U*S_[_ *_XTG]LZ7_T$K/_ +_K_C0!>HJC_;.E?]!*S_[_ *_XT?VSI7_0
M2L_^_P"O^- %ZBJ/]LZ5_P!!*S_[_K_C1_;.E?\ 02L_^_Z_XT 7J*H_VSI7
M_02L_P#O^O\ C2_VSI>,_P!I6?\ W_7_ !H NT51_MG2O^@E9_\ ?]?\:/[9
MTK_H)6?_ '_7_&@"]15'^V=*_P"@E9_]_P!?\:/[9TK_ *"5G_W_ %_QH O4
M52_MG2STU*S_ ._Z_P"-)_;.E?\ 02L_^_Z_XT 7J*H_VSI7_02L_P#O^O\
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M_P"_Z_XT 7J*H_VSI7_02L_^_P"O^-']LZ5_T$K/_O\ K_C0!>HJC_;.E?\
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M - +3/\ P$C_ ,*U:*.>7<#*_P"$8\/_ /0"TS_P$C_PH_X1CP__ - +3/\
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M@XQUY/YFNQK N?\ DH&F?]@RZ_\ 1D%7"<K[]Q%K_A&/#_\ T M,_P# 2/\
MPH_X1CP__P! +3/_  $C_P *U:*CGEW&97_",>'_ /H!:9_X"1_X4?\ ",>'
M_P#H!:9_X"1_X5JT4<\NX''>+?#NAPZ&CQ:-IR-]NLURMJ@.#<1@CIW'%;G_
M  C'A_\ Z 6F?^ D?^%5?&7_ " $_P"O^R_]*8JWZMSER+7O^@C*_P"$8\/_
M /0"TS_P$C_PH_X1CP__ - +3/\ P$C_ ,*U:*CGEW&97_",>'_^@%IG_@)'
M_A6!HWAW0W\4>)8VT;3F2.:W"*;5,+F%2<<<<UVE<[HG_(V>*/\ KO;_ /HA
M:N$Y6EKT_5"+O_",>'_^@%IG_@)'_A1_PC'A_P#Z 6F?^ D?^%:M%1SR[C,K
M_A&/#_\ T M,_P# 2/\ PH_X1CP__P! +3/_  $C_P *U:*.>7<#*_X1CP__
M - +3/\ P$C_ ,*/^$8\/_\ 0"TS_P !(_\ "M6BCGEW RO^$8\/_P#0"TS_
M ,!(_P#"C_A&/#__ $ M,_\  2/_  K5HHYY=P.-UKP[H:>(O#2)HVG*LEW,
M' M4 8"WD//'//-;O_",>'_^@%IG_@)'_A537/\ D9?"_P#U]S?^DTM=!5SG
M*T=>GZL1E?\ ",>'_P#H!:9_X"1_X4?\(QX?_P"@%IG_ ("1_P"%:M%1SR[C
M,K_A&/#_ /T M,_\!(_\*/\ A&/#_P#T M,_\!(_\*U:*.>7<#*_X1CP_P#]
M +3/_ 2/_"C_ (1CP_\ ] +3/_ 2/_"M6BCGEW RO^$8\/\ _0"TS_P$C_PH
M_P"$8\/_ /0"TS_P$C_PK5HHYY=P.<T;3[+3OB#J$=C9V]JC:5;LRP1*@)\V
M;D@"NOKF++_DHM]_V";?_P!'35T]?1X1WH1N8RW"N5\._P#(2\2_]A9O_1$-
M=57*^'?^0EXE_P"PLW_HB&L,Q_@?,<-S>HHHKP34**** "BBB@ HHHH *P(/
M^2@W_P#V"K;_ -&SUOU@0?\ )0;_ /[!5M_Z-GJX;/T WZ***@ HHHH ****
M "BBB@ HHHH *Y_PC_QXZE_V%KW_ -'-705S_A'_ (\=2_["U[_Z.:K7P/Y
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M?_K[F_\ 2:6N@KG]<_Y&7PO_ -?<W_I-+705<]H^GZL HHHJ "BBB@ HHHH
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MS_H:M<_.W_\ C5'_  C=Y_T-6N?G;_\ QJM^BCVD@L8'_"-WG_0U:Y^=O_\
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MWBNI$6VS1'BO1&-SB\.+8$RGR9,#!V\';ACDXP,UHV5];:E9QW=I*)8)/NL
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M?M6_[!UI_P"C)ZN&S]/U0&_1114 %%%% !1110 4444 %%%% !1110 4444
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MH=S?HK _MW5_^A2U/_P(M?\ X[1_;NK_ /0I:G_X$6O_ ,=H]F_+[T%S?HK
M_MW5_P#H4M3_ / BU_\ CM']NZO_ -"EJ?\ X$6O_P =H]F_+[T%S?HK _MW
M5_\ H4M3_P# BU_^.T?V[J__ $*6I_\ @1:__':/9OR^]!<WZ*YM_$VH1N5?
MPQ?JPZ@W5KG_ -&TW_A*KW_H6K[_ ,"K7_X[5JA4>R%='345S/\ PE5[_P!"
MU??^!5K_ /':?'XDU&4D1^%]0<CJ%NK4_P#M6DZ%1*[071T=%8']NZO_ -"E
MJ?\ X$6O_P =H_MW5_\ H4M3_P# BU_^.U/LWY?>AW-^L"Y_Y*!IG_8,NO\
MT9!1_;NK_P#0I:G_ .!%K_\ ':S9;S7)/$]GJ8\*:AY,-G-;LIN;;<6=XF!'
M[SIA#^8JH0:?3[T([&BL#^W=7_Z%+4__  (M?_CM']NZO_T*6I_^!%K_ /':
MGV;\OO0[F_16!_;NK_\ 0I:G_P"!%K_\=H_MW5_^A2U/_P "+7_X[1[-^7WH
M+F_16!_;NK_]"EJ?_@1:_P#QVC^W=7_Z%+4__ BU_P#CM'LWY?>@N;]%8']N
MZO\ ]"EJ?_@1:_\ QVC^W=7_ .A2U/\ \"+7_P".T>S?E]Z"YOT5@?V[J_\
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MI_\ @1:__':/[=U?_H4M3_\  BU_^.T>S?E]Z"YOT5@?V[J__0I:G_X$6O\
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M  *3_&CDEV K67_)1;[_ +!-O_Z.FKIZY'2+VUOOB#J$EI<PW"+I5NI:&0.
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M99)?1M&6MQY3 1N&PQ8+P<K@C'&5R<'-=C'H>EQ0I"FGVXC0EE78, E=I/\
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M; >%[1(7B#B<Q1GG )&-O0'*G!R".0*W[?PWHMI;-;6^F6T<+(\;*L8Y5_O
M^QP,_2I8-$TNUU*348+&".\D7:TRKAB./\!^5)U8VT_K\0L<.L:2^*+\MIPC
MTFTN-@,6E0-"R*BLVZ0_,#N+#@=A4XU?3_-AMV\&6@O+DQM;PCR23&P)WN=O
MR8 )(Y[]:[J*UMX8Y(XH41)&9W4+PQ/4GZU1L_#FBZ?M^R:9;0[69@4C ()&
MT_IQ1[:+W"QQ<.O6DBH[>!+58V59 VZ$_(TGE@XV]>X'<5TNBZ;IE[!=&?2-
M/+0W<L"L+5!N56P#TK3ET6Q:!HXK>*%MJJCK&,IM^X1GCY>U6+&SBT^RBM8
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MC_XY1_8GBC_H:+7_ ,%8_P#CE=/11]5H_P J#F9S']B>*/\ H:+7_P %8_\
MCE']B>*/^AHM?_!6/_CE=/11]5H_RH.9G,?V)XH_Z&BU_P#!6/\ XY1_8GBC
M_H:+7_P5C_XY73T4?5:/\J#F9S']B>*/^AHM?_!6/_CE']B>*/\ H:+7_P %
M8_\ CE=/11]5H_RH.9G,?V)XH_Z&BU_\%8_^.4?V)XH_Z&BU_P#!6/\ XY73
MT4?5:/\ *@YF<Q_8GBC_ *&BU_\ !6/_ (Y1_8GBC_H:+7_P5C_XY73T4?5:
M/\J#F9S']B>*/^AHM?\ P5C_ ..4?V)XH_Z&BU_\%8_^.5T]%'U6C_*@YF<Q
M_8GBC_H:+7_P5C_XY1_8GBC_ *&BU_\ !6/_ (Y73T4?5:/\J#F9S']B>*/^
MAHM?_!6/_CE']B>*/^AHM?\ P5C_ ..5T]%'U6C_ "H.9G,?V)XH_P"AHM?_
M  5C_P".4?V)XH_Z&BU_\%8_^.5T]%'U6C_*@YF<Q_8GBC_H:+7_ ,%8_P#C
ME']B>*/^AHM?_!6/_CE=/11]5H_RH.9G,?V)XH_Z&BU_\%8_^.4?V)XH_P"A
MHM?_  5C_P".5T]%'U6C_*@YF<Q_8GBC_H:+7_P5C_XY1_8GBC_H:+7_ ,%8
M_P#CE=/11]5H_P J#F9S']B>*/\ H:+7_P %8_\ CE']B>*/^AHM?_!6/_CE
M=/11]5H_RH.9G,?V)XH_Z&BU_P#!6/\ XY1_8GBC_H:+7_P5C_XY73T4?5:/
M\J#F9S']B>*/^AHM?_!6/_CE']B>*/\ H:+7_P %8_\ CE=/11]5H_RH.9G,
M?V)XH_Z&BU_\%8_^.4?V)XH_Z&BU_P#!6/\ XY73T4?5:/\ *@YF<Q_8GBC_
M *&BU_\ !6/_ (Y1_8GBC_H:+7_P5C_XY73T4?5:/\J#F9S']B>*/^AHM?\
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=** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>g2018030121531712731132.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531712731132.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -0 J4# 2(  A$! Q$!_\0
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M1BOM#N&MG=61@K @J1S6C;:C;RRBU1F:1% 8A3@<>M %ZBBB@ HHHH ****
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MH H65AAS<W(W3L<\_P -4=1BO+V.YM)=/27<<0RYX4>M:S7T"SB+=D["Y(Y
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M'-=110!R\J:G(BH-(GVJV>;A*T$U#4XXU0:),0HQDW"?XUL44 9']IZG_P!
M.7_P(3_&C^TM3_Z <O\ X$)_C6O10!D_VGJ?_0#E_P# A/\ &D_M/4_^@'+_
M .!"?XUKT4 9']I:G_T Y?\ P(3_ !H_M+4_^@'-_P"!"?XUKT4 9']I:G_T
M Y?_  (3_&E_M+4_^@'-_P"!"?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0
M#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F_P"_Z?XUK44 9/\ :6I_
M] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F
M_P"_Z?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_
M $ YO^_Z?XT?VEJ?_0#F_P"_Z?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0
M#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F_P"_Z?XUK44 9/\ :6I_
M] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F
M_P"_Z?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_
M $ YO^_Z?XT?VEJ?_0#F_P"_Z?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0
M#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F_P"_Z?XUK44 9/\ :6I_
M] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_ $ YO^_Z?XT?VEJ?_0#F
M_P"_Z?XUK44 9/\ :6I_] .;_O\ I_C1_:6I_P#0#F_[_I_C6M10!D_VEJ?_
M $ YO^_Z?XTG]I:G_P! 2;_O_'_C6O10!D?VEJ?_ $!)O^_\?^-']I:G_P!
M2;_O_'_C6O10!D?VEJ?_ $!)O^_\?^-']I:G_P! 2;_O_'_C6O10!D?VEJ?_
M $!)O^_\?^-07DM[?0>3/H4Y3(88N$R".G>MZB@#&^W:AE3_ &#*648#&>//
M\Z7^T-1_Z 4O_?\ C_QK8HH YV^-YJ"*DVB7*[6W I<HIS^=+8M=Z?!Y,&@S
M;2VXEKA"2?7K70T4 8XO]1#%AH,@8]2)X\G]:#J&HDY.@RD^\\?^-;%% &.V
MH:BXPV@RL/0SQ_XU7+W9OS>'09C,4V<W$>,?2N@HH QVO]18@MH,A(Y&9X^/
MUH-_J#,&;09"PZ$S1\?K6Q10!CF_U @@Z#(0>N9X^?UI/MVH;@W]@297H?.C
MX_6MFB@#"N+B^N;>6%]#F591ABMQ&"?UI\-[J%O"D,>A3!$4*H\].GYUM44
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MWU_"@":BH4N[:2Y>W2XB:=!EX@X++]1U%5Y-:TJ*<P2:G9I,#@QM.H;/IC-
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MF@"Y159M0LDMH[A[RW6"0@)*90%;/3!S@U)/<V]K 9[B>**$8S)(X51GW/%
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MK.Q]?2J(M7O;F."VALII'\43;$OD+PM\@^\!U%>I)XH\"7&I+ EYI<EXTNP
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M:7MK&EI<K TJC;G<GR@D'D5RL.CZM,^@2VJ3:='>:Y<7-GOM_,^S1,A*ED/
M!]#CK7H,GC+5++0[W6-3\+SVEG;6IN0WVR*0R8&0H"\@GWK(NOC!I=MH&B:H
M-/N7_M24Q" ,NZ$@@$M]"10!-\.H;N'6/$0UI7_MTW""XE6'RX98PH$;(!QT
MZ^]7/B);3&/1-0,#W%A8:@EQ>1HNX^6/XMO\6/2H+[XCRVL^KM%X>N9[#2)
MEW="XC7;P#D*>3P>U;VD^*K;6-=O-,MX)!]FMH;CSF(PZR D8'48Q0!R'B'Q
M+I]SH&N7GAW2;E[RYB2S6]6U9!*S_*!R V%!/.,5D^']#UOPWKMUHMSI]M%%
MJVDE(_L9=T,T:X)=B!AB*[/Q+\0K+PWX@M-)ELY[@RJ'GFC(VVZE@JEOJ31X
MH\:7WAJ_MH/^$<N+R&ZF6"">.YC4/(W08/(^M '%:-<_VHG@?1K>VN1?:7<F
M6]CD@91 JY!RQ&#UXP:D\4$V7C:[;2HYWO[FZMC-IUU8^;%<@'_61R?P%1FN
MOG\:ZFFL1:/;^%[B?4#:K<S1"\B41 DC&XG!/':EOO&FI6FJ6&DQ^&;B?4[J
MV:Y:W6[C B53@Y8\'\* .'T_4I-)\3>(1<:_)I*2:B9/(;1VN/-&!R'Q^%>S
M1,'A1@=P*@@XQG\*R?#7B*#Q)I\EPD$EM/#*T-Q;2_>B<'D''7US6;XQ\877
MA*%;HZ#/>V1*JT\5PB[68X VGG\: ./M+ZR\.6_BK2M<L+A]2OKJ:2'%NTGV
MM) 1& P!''3DC%0:5X>\0IXKT6U2\;3KF'05669[03@?O#B/YN 0,=ZZ^[\:
MZG:WFG:=_P (M</J=[')(+47<0\M4.,ENG-21>/[7_A&-5U>[L9K:;3)&BGM
M"ZLQD'10PX.<B@#JK:.2*VCCEE$LBJ SA NX^N!TKQ_QCI6M^,O%.N-IVGV\
MMOIEHMM"]X70B7_6%HP!AB",5V"_$:T/@6]\3OIUR@LG,<]FS#S$88R,].A%
M7M*\<:?K.JZ99V44CIJ%@;Z.;(PH!P5(ZYH X^VU4C6/#7BG6;6X6P_LMK9W
M:!F,%P"0V5 R-V,9Q6EX@:QU3X6^()](T>6WBG#M&IM]K3DD9D"]>?< \5KZ
M)XZ77-8:UM](N_L)FD@2^!#)O3[P91RGMGK3-.^(5EJ/C2?PZEE.H1I(TO"1
MY<KIC<H[Y&: .>\06-U,/ <=M;R+("066,CRV,) +8''/K60US;+\.9/!XTR
MY_X21G:(0"W;/FE\B7S,;<8(.<UW%UXZE^UWJZ5H%YJ=G82^5=7,#J-K#[P5
M#RY'M46M>.[_ $C5;&S3PO=7":@X2SE%S&GF':&.5/*XSWH \\\0:'KD'B'Q
M+KNGI++?6%E;V\D90[;J)XR) /4@@'CTKUCP)&\/@+0HY$9'6RC#*RX(..A%
M9K_$.TM9=6AU&PGM9M-CB:1-P<N\F<(N.IJ6U\:SK?Q66M:'<:5-<Q-):^9,
MD@F*C)7*_=;'8T <AXUTO5O&GC*]L;'3[>:VTVP:$->LZ)YLO5DP.6  JK"-
M>\0:AX*F@D?3]2BL+J&:::S\Q4D7:,$-P,XZUU>E_%/2]6TNPO+>TGW7.I+I
MSPEANA<GACZCZ5W;':I;T&: /#8+6]?3--%Y:SG6$\1AM2VP$)OYPR #&S;C
MD5I>)LV7CBX;2XIWO;J]MO-TZ\L?,AN,'_71R?P$#W'2NP'Q!M3X5BU[[!/Y
M4E]]B$6Y=P;S/+W?3/-"^,]3O-9U.PTKPQ/>IIUQ]GEG^UQ1@M@'@,<]Z /,
MM0\.W.MS2Z=)!<P"X\42GS1&WR?(<-G'3..:FL=.\2ZGH?C);ZQF.I1WEMYL
M:J0+N.( -@GKN4?K7HM[XXOHM8U'3K'PU<7KZ="DMTXNHXPFY2<#=UZ'I47_
M  L-[RXTJWT;0KC4)M0L?MH7STB\M0=I!+=2#0!BVNO?VM\0=#&C*+BT$;^=
M')IAC:R4*.!*0,DGC'M7?^([6ZOO#6I6MDQ%U-;2)$0<?,5..:Q9O&LECJ%E
MI^HZ-/;7=S;37&P3(X01C)!(X)-5-'^)VEZWI^B75K:S'^T[PV9C+#= X!/S
M>HX[4 <E)=V>J^#-!\+:7IES%KUO-;J\1MF3[,\3#S'+D8QPQX)SFH=5>2QT
MGQKX<N+:Y;5=5O=]FB0,PG#;,,& P.AZFO:ZYG6?&=OHVMOIDEG-*ZV$E[O5
M@ 0G5?J: ,+Q18RC7O :_92_DW8$K+'N"XC(Y/85Z$  , 8%<7I'Q*TS6K70
MKBUMY=NK.\?+#]PR DAOR[4^#QW-=R+<VGAZ^N-':?R%OXV4Y.<%O+^]MSWH
M P(-0LO"WB#Q6FOV<YFU"X,UK(+=I1/$5P$! .,'/!QUK&TSP_KT>M>$;6.:
M33;B/3[DF1[43B%&<%8SG@''O7J.E>(8M5UG5=-2WDC?3I%1W8C#Y&>*SW\;
MVR:?K]X;*;;HTIBD7<,R'U'_ ->@#H;*&:WLXHKBX%Q,JX>41A-Q]=HX%<#J
M%U;^&_B;?:MKEO*;&\LHXK2Y6!I51E)WIA02I.1VYK2G\=W;:J=/TOPY<ZA*
MEG'=R%;B./:KC@?-U-+%\1M.N9--6WM9Y!?6LUP#D#RS%]Y&'KF@#@CI.J7(
MT>XLHYM/AO?$,MS9[[?S/(B9&P[(> #Z'%==\/H+Z#Q#XA37=S:V)5#S)#Y<
M,L( V,H'&?7O5G1_BAI>MZ=HMY:VLV-3NS:%&89@< GYO;CM4[>.[B=[BXTS
MP[>ZAI=O*8I+V&11D@X;:A^9L'T]* *7Q;67_A'-,DB9XS%JT$C2I 9O* W?
M,4'4"N436;JWN/$>HVTD^LR2Z<L$6H1V+6Y61CM$8CQSUW;O:O:(W$L22 ,
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MHVH0::Y-K]H2XTVX,T8^;&UB0,'O6A<>)98?'=OX>%JK1RV;7)FW?,"#C&*
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M#VJ6&L:I8^9>"-8HK>%O)B"L"3S\Q)QZU0O?%/B'1M;BTN[GLKIFTFXO3+'
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M9(S\I[CWJS0 4444 %%%% !112$D*2.N* ,7PUX;A\-V=Q;QSM<>?=2W)=T
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M"N"K_P Z[&B@#@+OX:SSZ?-HT'B.X@T&:7S#8_9T9E!;<5$AY )_G6E/\/\
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M5/?'3-;/B'P_'X@\+W.AR7#PI/&J&55!(P0>A^E;-% $<$0@MXX0<B- N?7
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M*75]'.(W"07"W$<T@RO._P L!<@]..E $!^'^IMJ8U-O$-J;\$$7)T:'>".
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M0/I5BB@!AAB*LIC0AAA@5'(ILMM;SHJ3012*O170$#\ZEHH 1$6- B*%4#
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MD'C&\D#'7G@U%9^&-?AT:%KK28;SR+OS%TV>2$>8N,9+* F?J* /0_[5T[=
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MK^-=1;>'+"U?3FC\W-A$8H=SY^4C!SZUGV7@;3+&Z=X;B]-LX8?8FD4P -U
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MAL+HC3-<*KY8XRL>,L/<5KZ)X5L]#N6N([J^NI3&(D:[F\SRHQT5>!@54O?
MFFWVJ2WTEWJ"^;()7@28",N"#G&,]O6@"G;>.[FZU$Q)H$WV-KN:SCNOM"_/
M+'GC9C(!(QFM32?%5OK%]!:VT#EGMS/,=PQ#ABNT^IW C\*D@\+:?:1(L F)
MBNY+U TG_+5R2?PR>E5O"?A^;27U*^O(H8KN_N#*T43;EB7H%!P/K]30!#J?
MC*2PO[E8M)EN=/LF5;R\291Y18XP$/+8XZ5S<GC#Q,=5LA'I^Y7U>:V6!)T
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#J'?V )% %NBJJZA:EHXWGBCFD0.(7D4/@CTS533O$6FZDLWE7"(\+LC1R,
M_P O4XSG'O0!JT5DP^)-,N-"N-9CN%:R@5V>0,#PN<]_:K%OK&GW-I:7*7D
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MM=2:=:6JFX-TBI)YDG0(4;T'.:Z*QOK74K..[LIXY[>4922,Y!%<Q/XNU?\
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MNEM_%F@7:3O!J]K(L#!92)/NDG S^/%37WB+1],69KW4;> 0L$DWO]TD9 -
M'D/BV[91=P:QHT=SJ\UG"L>^9/,MB&(^3/+9QGY.:U[OPAK@\6_:6CO+B)IX
MI8[NW6 &)1CY=S_. .X'8UZ7 NEZO';ZE%';72D;H;C8&./4$C(JO_PE&AF]
MN+(:I;&ZMU9I8@_S*%Z\>U ')Z5X+DMC9W,NEVZWHU"YDGE&TL879L GN"#T
MJUX9T34-+^&TVD_V6EO?()5$:R@"8EB0VY>F01U]*/#/Q/TKQ%J1L?W-O*P>
M2+%P'W(I/)X&T\9QZ5T,'BK0;FRN+R'5;5[>W.)I _"'WH \MMO VN'1]4@?
M1F*2P1&.WF$";W1P2/W?&2H/)KNO&>EWNI^%+6VLM,9R&C+6J,F8P,< -\C8
MZ8/%=-;:C9WFGK?V]Q'):,F\3*?E*^N:S&\9^&TLS>-K-H+<2>49/,XWXSC\
MJ .)\/>"M0<6$6MZ8DMI%<73F&?RR%1PNSY%^4<@\#I3-3TJYTZ'1]*M3%#J
M%\7L7M]^?]$+;F.!V &,]LXKT&]\2Z+IIM1>:G;0&[&8-[X\SZ?F*;)K.@_\
M)!'I\EW:?VMMPD9QY@!&< _3F@#(\9>'S>:#I=O9:7'?"PNX'6W8J/W:'! +
M<=*P$\$7=WJB/J&F126JQW95)'5@KOM\OCUX//:NL7QGHT%BEQJ>H65F7+ +
M]H#C <KG(^GX'BIK;Q3IMWXHN/#\4RF\A@6?&?O*WI]./SH X7_A!=8CL$AL
M($LI9=#$5U,C*6DN0ZDAO[Q*@C)XYK9^'FAZAI,M\]Y:W=HLBJ!%(L"1DCJ0
ML7?W-=7JNO:3H@B.IZA!:><VV/S6QN/M64GC&UG\<+X9M4CF=;;SY9O. V9Z
M +CYN,'KWH Y2U\+7RZZZR>'XX2VIO=2:L9D): @@Q]=W(/3I6EX%LS<:Q?7
MAECFL]/W6.GR1'*&+=N./=<;:ZS5?$&CZ*\,6IZA!;-/D1K*V"_KC\Q43:YH
M&EWL.E&]L[:XFYCMU(4MGV'K0!YEXEEM?^$KU*REL([R_GOH3!=&15D@7"_(
MJGYF'!/R\<UM2^%]=MK&YN=/M8QJ$NHS*=T@&ZUEQN;Z\<"NGN-<T&V(U#5C
MIUM,LS0PRNZNQ([!L9!]JTM"U=-<T&TU58C"ES'Y@0MG:/K0!Q%QX&G&I&WC
ML8Y=,66W #L,.B( V1WY_.LO7["W\-W]N+[2[>?2VO;EK?3W=$B*F-<,-WR+
M@YX///%>CV?B?0]0U%]/M-4MIKM 2T*/EACK69J?B[PK-I&I7,EU9:A%IR[Y
MXN'VG.!P1UR* ,S0-,;4OA-]C%HK&Y@<I;R'(Y.0,G^=9MOX)DNK.\FN=!@A
MN!9PQVB.R,8I% R5(X!SWKK;3Q7I)T^2]>ZL[?38HXW283#&&'&1CY:LW'BO
M0;6RMKR?5K5+>Z_U,A?A_I0!Q]KX-O;CQ TNJ:=%/9/J,L[B5E<,IA102._S
M*:RKO29_#FF2?9=/M[#4VU.2.U5&7==P2<$*!R, YQ_LUZVCJ\:NC!D89!'0
MBL"X\4^&W2]N!>V=S+I:-+( 0S18]/0]N* -32=.CTG2;6PC.5@B5-W]X@<G
M\:NUB^%-?_X2?P];:N+=($N 61%F$F![D <^H[5M4 %%%% !1110 4CKO1ER
M1D8R*6B@#SN+PCKHU.QC,.EK9:>\[Q7.299C(" &7&!UYYYQ6?IW@Z_TBYGU
M#7?*738[.:*5!<O/P<$%5VC'/;FMF;XF6\-D;J32IHXY;A[>T::>.,7#(2'P
M2<*!@]>M+-\3+)=-L+JWLO.:Z9T=3=1(L3+C(+L=K'GL: ,K3_#>K7_@F"X>
M".[U:ZN!<&:6=K9T0 A"" <$+QC'<UVOA73[_2_#\%KJ4WFW*EBQW[\ DD#=
M@9^N*QYO&0M=4OX(X+J\N"ULEM9KL +21E\*_P! 22?3BFGQ^[K;0VV@7LVH
M3S20BT\Q%961=S98G& /SH Q7\#:[-XKBNV:".S2^-P62Z;#*5(_U6W ;GUJ
M]I?A#58[RQMK^WTX:?8P26RS1,3+.C#&6&, _B:L7WQ*M+/2]/O1ITI^UHSE
M)9DB\L*<$98@,<YX%5-0\<7ANKMHK:YBTQ8+:6&ZBV%CYKJ/NMZYQ]* &2>"
M-9/A^_A=[2XOI+B(6^YRHCMXR-BA\95N,YP>:30? VJVDEM)?M ^V_-VZO,9
MB 1C&XJ,G\*W8_&R/J!4Z9<+I9F:W34MZF-Y <;=OWOO C..U,T#QO\ VWJ%
MK VCW5I!>))):7$KJ5E"'!X!ROXT 9G_  B>LZ=,;NPM]-NY#-=+]FN6*Q+%
M*^X,, _,.F/0FLS4/AYK#:E)+"XG@NE0SQ1WK6J1D<;555.1QUR*[;QC?7>G
M>%[NYL9O(N045)=H;;N<#.#P>M8R7NJ>%M3L_P"U]=;4K&\CD9FEMTC:'8N[
M(V#D'WH Z75-*CU/09]-D4%9(M@!.1D=.?J!7 :/\.]:M=3L;F\N[5D?S;C4
M50D^=.<A.W*@5I6OQ4TV>VOI6M"&MX#<1QQW,<K3(" 3A3\O4<'UK0_X3GR8
M;@7FCW5M>+M-O:LZEKD-@ J0<#D]^E &?)X'O6LM%A4VBM9PWB3'^\95PN..
M>>M4KOP/K>H6TL,JV-MY^GQP.\$A#))&> #MZ'N>U;-UX_2RTQY[G2IX;V*<
M02VDLR)L)&03(3MQ@CO6;K_CF]MM):]TVWEDN'M4E$ >-HX\N 3O'WCVXXYH
M BTOP/JJCS+V*-93=QS2>;?-<AU48[J,&NPT/29=+N=6=_+$=U=F:)8^RE0.
M??(K,D\;>3>['TBZ%E&Z0W-X'4K#(V!M(SDX) )'%7] \12:])=,NF3V]K"[
M(EQ(ZD2L&(( '/:@#+OO"=S<IKA46WFWMQ'+"[=5"L"<G'!X[53A\)ZO'?\
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MC&U2Q+$ GH.PKD=.\4:E&(Y;BVN;B\"W3^0LY*@H/NX ^8>AH VK?X>6%OJ
MNSJ%])L+E$<IA=P((W;=QZ]R:T!X/TW[#9VCF9XK6V^S(&;DKZGWKDW\;:WJ
MFG63V":>MT=0BAFCCFD&$8$X.Y01T].U32^+]3OT2>2R%K:M=3V\$D-T0Y9
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MBF[MM9ACMGCME80P3&2/D]02 <^M &O<>'X+KPO+H4]Q,T,L)A:4;5?![\#
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M1=.@O)H8A/<^?-Y>U"<#;P<G@]<5GR^-;X3RWL6FPG0[:9(+B9IL3*[$*=J
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MU#3+35+9;>[C\R)760#)'*G(_6L^^\)Z3?K=":&17N9A.\D4K(X< #*L#E>
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MD@<<U9L_$^O:EJ6G:=;O8)(6D%S.49DD"==@SQG\<4 ;$W@31)EMHR+Q(;=
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M&-,;@.Q_.LR^\ :#/I=[:6-E#8/>*%DFACR2H8,1CWQ7#7/]KMHEZ?#XU/\
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M%-AL="UG29X(K:VN+">5C*FSY6?/)/OFN'UQ[I/B-"\'VR[(FC'E%+A$C'<
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MX[>VC&$BC&%7Z59K-T!KA] L6NY?-G,*[Y/+*;CCKM;D?C6E0 4444 %%%%
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M>VD^Y(T95^&RIP>/2O+(_#FKP7N@,FC74EY;V]JDTEQ!'+%&5 W;7+;DQSG
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0E[JT\=BTUQ/'!&H>0R)&VW=P,UQ5J5TT65U92Z@VH6=Y<3QF?1[CRBDW4$
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M"WS$?6@"%O&N@_:+VVCOA)<V:.\D8C;G;U .,,?H347AKQ4=9\)OK]U''%
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M X*^X([UI:EH,E]KD>H++&JI:26^UER<MW^E "P>,- N?M?E:E&1:())F*L
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MS6,JL &/3C=VK4B\)3101()X T>G&S!"'@GN/:@#3N/%>B6M_!937RK/,%*
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M3TJM_P (!E[I7U:5H)KB>XCC\E?W9E!##.>?6EUGPE(ND;[1WN;FUTQ+2&/
M4LT9RKC_ &L]NE &OHGBBSUVZN+6&VO;:XMT222*[A\M@&SC^59-[XZA_MFU
ML+*"X*/=FW>ZD@/DN0#N5&SRPQ^AJ'P+8:Y]OU+5M<\_SKB.*%!<1)&^$S_"
MA(QSZU97P3,NJPRC69?[,ANFNTL?(7[[9SF3.<<GB@"S=^,+/^RHKBT\PRW2
M3FVWQ\%H@2V[T'%)8^,;-]+2:[\Q;D-'&\2Q\L[_ '=H[@\\^U9T?@"<749E
MUV5[*W%P+:V%LJ^7YP(.6SEL9XS38?#$K^--/E-O*MEIMLJO/)@+<R#_ %9
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MRD9\MGSPW(XK$LOAI]CTZ[MDU*VCEF\LQSV^G)$R%&W#.#\P]C6C_P (5/\
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MIEJC3VK7=F()BVY R@A\C@_,.F15K7_&=UI,<BV]C%-/Y=N45Y"H+2N$ /'
M&<UI:?X+T+36N6M[1LW$;1/YDKOA#U5=Q.T?3%16O@/P]:0-#'9R,K/&Y,L[
MN24;<O).>"* .=OO$WB>26RM?LME;W46JI!<B.9BCIC(P<9YYSFC3_B;+?:K
M)$MBK6C>:(2B2[U**3F0E=@!VGD$]JZZ]\+Z1J!8W%L2S7"W)99&4^8O0Y!J
M!/!FC1ZA)>I%<*\N[=&+F01'<,'Y,[>A]* ,"V\7^)[V/38X-)TT76I0?:(
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M91V<NG6<EK'S'"T"E%^BXP* .<NM;UE_A\FI1M;VNI%5!:22,CK@D$G86(Y
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M/5]6GT:^N=2$36US=0M$T<?^DLB@J#M. Q_V<UZC/H^F732M<:=9S--CS#)
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M;W-K<V_VFUGAEA(R)(F#*?Q'%<_!XYT&>X@C2YA6&<R@3M(HC&P@')SQG/%
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M?PJU?:W;:;?>5=SV\, A,KN\F& SC[N.GO2Z/XATG7XI)-*OHKI8CA]F?E_
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M\'ZG_;5O-+)9&SM]7DU!,;M[*Z,,$8QD$BJ&I_#[4I/(N+*YC^T1R2YC%S)
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MG=?-CC,29QD[R,\AN!GI0!VU%<M)XVMS?I%9Z?>7MH!&9KR!04B$GW<C.3^
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MZT9S?6M]-*+:UEE\N'RTCP23@\[@2*FO?BLD%OIYBLH5GGMOM,T5Q*R[%R0
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M'<EU.#],5T6M:0VL:6;%+V2U4D;GCC1MP'8A@1C\*SO$^ISIX O]3LIC%/\
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MZN;"4W6G/:1SVJW=HT-S^]:/>J_-Q\IYZ<U;B\:Z@;P,^D1C2ENEM'N?M.9
MQZ'9CD?C0 ^Y^'EM=?98I=4NFM+=0@@,<9R <_?V[A^!%;VIZ!::O<V;WN98
M;5BZV[@-&[8(!8$<X!-8>E^,M0O]2L1+HZQ:=J#NMK<"?<V$.#O7'&>W)J?Q
MGXND\+Q6YBM8I6EW$M/*8T4 =,@,<_ACWH I>(O!KQ6MS<^'(1#<R21.+> I
M"JLI^^G& ^..>*3PGX0O+: 7FM33&_\ MTEV TBNV&  #E1M)X[8%07'Q"OI
M8XY-*T:.Y1-.&H7!EN/+VKD@A>#N/!]*ZVZU86WAY]6$#R!;<3")<;CD9Q0!
MA0_#ZPMM9DOH+ETMY)&=[3R(BK;L[AN*[^<^M0VWPWLK7[7$FH3BUN(9(?($
M$2[%<8X8+NX]S5+2_B5)J%E?'[! ]["T:PQ03EDD+] 691MQ]#4LOB3Q*WBG
MP_8RZ9#:^=/-'=Q?:0RN%CW!E..0 <\@<\4 ;L_A*SN(;J-IYP+FTCM&((X5
M.A''6L^;X?61UE=1M;R2V.Y'DB6")PY7N2RDC/L:C\876L#Q!H=E8L\=I([R
M3M%<>6[;1G;T.1[=ZQE^)$^K1:E9);K9W"VK30O%*6=,'&'!4 'Z$T =A;^%
MK.WMH($EFV0W3W*Y(^\Q)(^G-2:)X>70O#_]D6]]</&I?RI)-I:,,<X'&,#/
M&:XF'QIJ>DVM]-*HO0;Q8E>YD*1P+Y*MR54GDDXXZUW4&LB;PR-858Y ;<S;
M8GW*<#. <?TH Y^'X;V0AN%N=1N9Y)FC)E\N.,@(X?&$4 Y(')YJ_J_@RWU7
M[4POKFWDN)EE9D"L 0,8VL""..XJI=^.6M;6"7^S]S2Z:M_M\S&,NJ[>G^UU
MJ)O&^H6HDM+W1XX]6D:+[);QW&Y)%E;:I9\?+R#G@T 2VGPZTZULUM_MER^&
MF8MA5R9,;N  !]WC%:^K>'+?5O#@T9[B>&-?+V31$!U*$%3^8%8<_C35(8H;
M0:-$=9>Z%LUO]I_=*2,AM^.F!Z5O>&]:DUS2#=3VOV:>.:2"6(/N 9&*G![C
MCK0!CS_#ZTO+&2.]U&ZNKYY1*+Z949U(Z *5VXX]*V=&T)=(T=].-R]PKELR
M-&B'![80 ?I7.:-\0SJ?BQ-%EL8X?.,HBQ*6D79UWKM &>V":N^,UU)Y;06\
MVI"R4,T\6DNHNF/ 4C/\(YS^% "V/@2VMG5;G4KV^M8XGC@MYRNV'>,,1@ Y
MP2.?6F6_@4P+,3K^HRR/!]FC>01GRHNR@;<$?4&L]O%LV@^&+>0&>]F:=H2=
M1/E/!CG$I4,=W;('-4O^$_U2]DT[5;.QC.FFQFN)H_/P6=3@CIR!C@^] &Y9
M?#VPM(UW7EQ+*)"YDVHF[*E<;5  P">@JZW@S39-/M;&9I98;:T^RJ&(^9?4
M^]5=<\:-H^GSW*V'G-'9I<JGF8R68*%Z<<MUK-UCQ5X@^QZA!!I4,4ME&HO9
M8[K)A9AE=@V_-P03TH NVG@$66GW5I#K5PJW"JNX6L *J.W"8(/OFFGX>0C1
MTTZ/5[F-/-:65O(A(D8_[)3:,>P%4Y_B(]AKUKI,MFC1L\4!E>4B21F4'<JA
M<%<GN0>O%;6G^+3J&IVVFK:8NRTHN4W\0^60#VYR2,4 ;>EZ=#I.F6]C 6,<
M*! 6ZG'>K=%% !1110 4444 %'48-%!X&: .-3PWX07Q$?\ 34:^!?99-?9$
M9<?-MBSP2#Z59A\%VFDE[S2FFEU!(7CM_MMR[QKN[8[#Z5Q2/I5KK M[>72K
MS-Z7-K<0,NI!S)DX?/0'D?[-:[^,+B.>/33J2C5/[9$3V^!O6 J3@C'3WH W
M--\$6MMX4M-%EGN(3&YFD>RG:'=(<[N1SC)Z5JZ9H^GZ0+>TM99%:)6(1YRS
M/D\LV?O'/<UQ&FZEX@@M+#4SJMS?27UM,?LDD2[$9<E2N!G/'0UE6>N21W]U
M?1>(CJ-PND;Y)9(P?LDI;E/E   ]#DCO0![%61!X8TJVN-5GBMRLFJ?\?1W'
MYN,<>G7M7G'A_P 6:W-8ZM.^H2W46E^3=-B2.9ID.=Z;D &..G45W&C:AJD_
MA*ZU=_\ 2+B=9;FTAVXPA!,:?RH O6'AC2M-73EM8&0:<C);C>3M##!SZU0N
MO!.B?8[=?,NK*.T0J)8+IHCLSG#,#R <]>E<9#XHU%-+NI;#Q"^I7+V1FN59
M%/V"7^Z,#URN#GI72>([*[7X77D,VJW4T[6X=KEE7>V<9& ,8YH VK70M&NK
M>YFMW^TQWR1I+,L^_P P1C"G<#^M03^$](CU2/4?M-U:/O7$<5VT<;L.F5S@
MDX_&O/)==US1=9M=+AO$MX+98%@6:XA@2X4XW%E*Y)Z_=QS5V_U2XO=7M5O=
M8?[=_:D0.B%5Q$JGY6!QGG@Y)[T >A)X:TJ._P!1O!; RZBH6XW'*MCV[>]4
M(/ NDPV\UNTVH3P2[<QSW;NJ[6## )XY K@]#\8>([C4KAKJZ1)FBF,MG+=1
MY@(SC9$%WC&.A)I-;U_6]+T320?$5PUQ>6ANV9FBA;<0,*&92I )^[C=[T >
MLW45GJ$,^FW!CD$D6)8=PSL/'(ZXKG[#P1X?C2X$3W%T7=5E>6[:5@4Z+DGC
M'I65X1O)=1\7M>W 'GRZ+ 9"!U.]LUD:9_:NG:A>:C::E,(9?$4MNU@$7RW!
M7.<XSDD#G.* .ZU+PQI-\+Z:Y$D;W+)++/',49"@P&5A]W@8.*H1>#?#L]B+
M.VGF+1R&83PW9\X%A@G>#G!'YUR2:_>W+S1'6I+Z>ZAN4O\ 3&1<6"A&(Q@9
M&" .2<YIEKJ][;6"VXOCIUD$MUEO4B7= I [D=_4T >A:7HFFV<Z7%M++//;
MH;<RR3F1@,Y(8GO]:DU;P]8:U-;RW8EWV^[88Y2G##!!QU&*\I37KFP\.7'V
M'6F/VC6KEA>!DA-PH Y#L"G/'&.>U;,7BS7$\/Z==M.\LFI1FQB"J&,=QNP)
M"0,'"Y)[9% '=OX9TJ6"&&2VWQPP- BLQ(V-U%)HOARUT)I#;7-]+Y@ (N;E
MI0N/0'I5VRF4PBW-TL]Q;JJ3L",[L<DCMGK7F]OXDU0^*]3M4U5[QF6<01V\
M\3QQX7*YC"[UQZDF@#MKWPCI.H7UY=W$<IENXU24"4A?E^ZP'9AV/6H[7POI
M.G&V22ZNIG2<2P_:[MG;>/3<?TKD(?&]W>V\::?J N9HM&62\,: ^3-D!V/'
M# 9./:JC2RZQ<Z7:6/BJ?44^U@KJ*PKOB)494,!M)[XQQF@#T-/#.E0N)!$P
M*WSZCDN>)F!!;Z<GBLR?P?H5ZHLXKV[A!+SF*UOF3=O;+,0#R,FH]-FO[WP5
MK%O<WDLUQ;-<6RW.T!W"C@D 8S]*X2PUK4;30=/CT[5WF8Z;; 731*SJS7 5
MESCL.,4 >M7&BV-UHCZ/)$?L3Q>445B#M^M07GAK2[Y91/"Q,L2Q%@Y! 7I@
M]C[UQ+7>OV%Y)*^O7=Q'9:M':")HD_?HP!._ ]^,8JKH7BK7[KQQ';7-S''Y
MER\4UE-=Q#8@!QLC W[N!U/3- '<67A#3K(1?O;VX,,WG1M<W+2%6QC@GM[4
MQ/"^D2ZV^HV]S=+,DNZ6""[81;^^Y <9/<&N<\?Z]>Z1K=IY&K&& 1;FM(+B
M..5VW=<.I+ CC P:S[4ZC;ZOK.KV>I7%O$-80/9^6NR4,BYW9&<_0T =G;^#
M-&LM0FOU^T'<'(CDN&,46[[Q13POX5HV-MIB::-,M)(WMUBV[%DW'::\M;Q?
MJLWC-K+^T?/M;B>:"6 2)MCC$;'_ %>-ZD$ 9)Q6_P##\ :L_P N/^)?'V_V
MJ .CTOPOHEG%,EHTDH,7V60M<&0A0<[<YXQFFW'@K2IKJ*XCDO;5XU52+:Y:
M,/MZ;@/O?C7"Z?JD^G>(KU;+6G:\DU=U.CB,;6C(&7Z;L\?>SBI_"'BG7K_Q
M:D-[<Q@S-(MQ937D1,&#G"1A=X(QCDGB@#T76=%L]=TQM/O1(82RL#&Y1@RG
M(((Y!S56W\*:3;7@NXX9/.#2MN,A.3( '/XA17%^/_$NN:9XC2UM;@65LMN)
M(9'N8X4EDST8N#D>PP:L2>(-0DUE;3^V"EC,4^TW,<886DQ'^I5\8(/7GI^-
M '5Q^&=%>.!%A$B6T#6B#?N"J3R#[YI^B>&K309)7M;F_E\Q0NVYNFE50/0'
MI7DPUO5='TI+2UUBX:%[^Y^T7;SQ0M'(&^5"SJ1R/FQC/%=#_:?B#6O+0:W)
M8F+1OM9:RV2K)()"H.XC!R ,XH N>+?!%[J^MS7;7UM;Z9,L8F=IWC*;6SRH
M^1^WWJZF[\):1?6%Q9SP.T-Q.+B3$A!+YSD'M7F_BW6KF^TB[34=;>RD,$(@
MT\1C;=@L,MR,G\#Q5J?Q7X@3QS);F9(/+NA%'8S7D4:21= VPC>20<CGK0!W
MU]X<T6ZOHY[E LQ>$QCS-N3$=R8'L:R/%7A-[^-1I,L,-Y)<_:766=XB_&#M
M=/F7MP.*YO3]3FO_ !EHQN=;>YO#<SB?37C ^R 9"X &1D ?>)SFM+Q1<7FG
M^.OMEK>S-<#2Y#;61QL=@1DCC.<<_A0!U/A306\/>'H=/ED$LFYI)""2-S')
M&3R1SU/-4M/\(:!I.K1WL5Q<&>*1A"DUXS+&S\D*I/!.>E9W@K5Y;O59;6WU
MY]>L?LPFDNW5<PRY \OY0!R,G!YXKE9+6>;Q!JEC'KER+HZ_'U"EH%*##J,=
M>PSQQ0!ZK<Z-97>J0ZC-&QN88)($8,0 CXW#'X"LF\\#:+>I;HRW,2PQ^5B&
MX9!(G]U\'YA[&N%UGQ+XBT^TCL3J$QAAOKFWDU%I8X'/EXV!F92N3D]!SBNO
MBUG4G^&LNIM-#]N2V9EEAD$JDCHV1P3ZXH T9?!NC37INFAE#%HG\M96$>8_
MN';TXJ./P1HD=]/=&*:03;OW$DS-%&3U*(>%/TKB[S6?$FB6%]&FIW&HLVGV
MUUYDRHC0>8S!V!Q@  9Y!Q2:5XHUA]#FE354N;J"<&TB6>.Y>[R#E'\L# '4
M8YH [S1?#ECH%P_V:\O9&E3:([F[:4 #^Z">*K:QX;\/ZKK<37T[)>2)@VR7
M1C%PH.?FC!^<?A7*Z/<O<^-]#NY_$4\[3V<N8RJHK2[OFBQC(V^G7BH]?CNK
M'XA:YJD%Y*9(-)A*;HU80*\C!F'&?E S^/- 'H=K9:?HQG:-E@^U3&1M[X#.
M1VS].E<\_@NSU;Q'>ZQ=73RV\[1&*.VN&56"  AP.&&1TKDYM3EOU2V35GUJ
MPM[Z%H;]E&69HWW+E0 <<=N,TQ-:N;'38(7UM]'BAMGFM55%/VR7<?E.0<^F
M!SS0!Z _@[3&U7^T(I+RW?<&:*"Y9(F(XR4'!J5= T9#9V8 WVLYO(8C+\P;
MD;L=2.37GVK^+?$FFWP@:X=2B?VM,HB!Q;!1F+IQEL^])J'B375TAM22Z>*:
M\L/M,):%=\"R3(H7IV!/!H [F+P/HL5]-=".X8R!\1/.QCCW_>*+T4G)Z5?'
MA_38WMI/+8&UMVMXR7/",.?_ -=<3?7^K:.U_IMUXBN1:)<Q!]4EC0/;(R@X
MZ;>3QG%;7@[4[C5-%UII=1.I0PW<L5O<E0-\808Z>Y- &@/"NA7EK;E$\V&.
MU^S1,DQ(,>X-C(Z\@<U:7PUIBVY@$+>6;A;DC>?]8IR#_P#6KS+PIJUW::'9
MP:5KLE[.;&0RV.Q<68&2&'&>O'/6M.3QK+J$4RZ?KL"B'1899IBRJJ7!?##<
M1@.1QSP* +F@^";W2/%-O>ZA?VIAB:7[.B3O^\+G/$3?*F/]FNKUOPOI^O3P
MSW37,<T*E%>WG:(E3U4XZCCI7 Z;XFO[C2K1UNY9Y4NI5,\S1SY 4$;710.O
MIS2Q:UXFTRP^T)J,^J37>CM>B&6-5\I]ZCY2 , !B><]* .ZM_!^CVT<J1PR
M8EM3:/F0DF,DG'YD\U?N](L[[17TF=&:S>(1%0Q!VCW_  KRW3?%&LS>&]68
MZ];J(_*:.YFOX7D4D@,F54*N1T)!Y--N?%FHMX:L9H]<DA*SRI*9+R!99\8P
M4D*[&4>PS0!WD'@/18;6Z@;[9/\ :5"O)/<L[\<C#$Y!':BV\&Z%%+:^4\[7
M5C<&X$IN6:4N5P=[9RP*X&#VJOJFLWH^'T&I6KS0S2QQ%YG0,\2L0&<CID#)
M]*XM-<DL-,U^YL?$/VM6NX8TU)MJEP5&1OQL![ XQQ0!ZI>:39W]U!<7$9>2
M ,J?,0 &&#6'9_#W0[/=M^V2AHS$!-=.X1/[JY/ KD=(\8ZO%X8_MNZNI;BW
MM;Z6R904?S%8#9(64 '#<9'!S7H>ARW"Z=:VVI722ZH(5>X P"">O'IF@"A/
MX(TJ:-TCEO[822"1_LUV\98A0O.#Z 5L6>EVECI2:;!'BU2/RPI.<@]<FKE%
M '%7/PXTZ/3[N/3I)Q<SPBW5[JX>0)%O#%5ST'':K]OX%T>'2YK*07,QF*,T
MTMPS2J5^[L<\K@],=*Z:B@#"LO"&DV,=LL:3R/;SFX66:9G=GQC+,>3^-:.G
MZ9:Z9;RP6J%8Y97F8$YRSG+?J:N44 <WIO@?1]+U.._@:\:6(N8EEN6=(]WW
MMJDX&:NZUX;L-=:&2Y-Q%/""$GMIFBD"GJNY><'T]JUZ* .;N/ ^D7%A:VA:
M]C^S.9$FBNG64L002S@Y/7O2Q>!]$ACLXTBG"VJ.B#SF^8/]X-_>S[UT=% '
M+1?#_0X[6YMW%W.ERJI(9[EW;:K!@ 2> "!5K5_!VDZW>_:KH7*N5"R+#.T:
MR@=-X'#8]ZWZ* .8D\!Z++J9OC]K#&19?*%RPBWJ  VS.,\"ETKPW/#JFMZG
M>/#'=:CB-#:DXCC4$ \_Q'.3[BNFHH @L[<VEE!;&5YC%&J&20Y9\#&3[FIZ
M** "BBB@ HHHH **** (OLUOYWG>1%YO]_8-WYT?9H/-,ODQ^8>K[!G\ZEHH
M :(T&,(HV],#I3%M;= P6")=_P!["#YOK4M% &9J>A6FJ:;)8,9;:&0@N;5A
M&S =B0.A[UH11)!$D42A(T&U5'0"GT4 1+;0)OV01KO^]A -WU]:D*JR[2H*
M^A'%+10!%):V\K*TD$3LO0L@)%*;> R^:88S)_?VC/YU)10!%]EM_-,OD1>8
M>K[!D_C1);02A1)!&X7[NY <?2I:* &K&B'*HJG&.!VH\M/[B]=W3OZTZB@"
M);>!9&=88P[_ 'F"C+?6E,$+(4:)"K<$%1@U)10!";2V,8C-O$4!R%*# /TJ
MA<Z!9W6KV.HR--NL@WDP*V(@Q_B*X^]@XS6K10!%%;00R2R11*CRG=(P'+'W
MH2UMXY#(D$2N>K*@!/XU+10!$EM!'N\N"--_WMJ 9^M+';PQ*%CAC10<@*H
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M..:6B@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAJMQIEI<+I3JSZQ 94QO.T?7;CO6SJ<4NL:_X5_LB30KJ7[-=8D%H6M&8$9
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M\3+%>Z7>(UK8@1G&FODXXZ?-_>[4 >^44=1FB@ HHHH **** "BBB@ HHHH
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7 HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>g2018030121531718431134.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531718431134.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (; I,# 2(  A$! Q$!_\0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBL;Q2S)X=NF1BK8&"#CN* -FBN;\/0^29)#'&
MK^4,%;GS-WU':FZ-KMY=ZJ;:[\M0X8QJHST]Q0!TU%<_;:Q<W&IL&FMHX!.8
M!"WWSCN*F@O[ZY\17-HC1+;6V"V1EFR* -JBN8_X2"Z^U^9^Z\G[3]G^S_\
M+3_>I=6\07>FZA):B)')*O'Q_!_%^5 '345FZ+J,FJ6KW10+$SD18[KZUG^+
M+UHK2&RB=TEN&Y:,$LJCJ>* .BHKG+#7''A5[LJ7N+9=CJW7([FIM*U:YN;V
M:WF>"01P+*'B/&3VH W:*P=/U>\FTBYU*=(C&@8QQIUX]:CT37;F^>59XE*B
M+S59.WM0!T5%<WHOB"YU&_6.2-!%(K,,=4P>A]:B.N:F\P\M+<1O=-;)G.>.
M] '4T5SR:_,/#4NH/$K31N8R%Z$@XS4NEZQ<7-E>23QKOMQD,O1N,]* -RBN
M=TK6;VZN[-;A(A'=PM(H3JN*ET:ZO)]6U-)YD:**7:J]U_\ K4 ;M%%% !11
M10 4444 %%%% !1110 5AZK!>7?VBV>RCGC<?N9,@;/K6Y5>2]ABO(K5FQ+*
M"5'TH SKC297\.1V6_=<Q*"CY_B%6;>WDL-)$:1^;-C+C.-S'K2_VQ:A]A+
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MM6B@#*QK_P#>TW_OF3_&C&O_ -[3?^^9/\:U:* ,K&O_ -[3?^^9/\:,:_\
MWM-_[YD_QK5HH RL:_\ WM-_[YD_QHQK_P#>TW_OF3_&M6B@#*QK_P#>TW_O
MF3_&C;KW][3?^^9/\:U:* ,K;KW][3?^^9/\:-NO?WM-_P"^9/\ &M6B@#*V
MZ_\ WM-_[YD_QHVZ]_>TW_OF3_&M6B@#*QK_ />TW_OF3_&HTM]:BDDDC&EJ
M\ARY"R?,?SK9HH RL:__ 'M-_P"^9/\ &FO'KDB,C_V8RL,$%9,']:UZ* ,&
MUT[5+(L;:+2HRW4JC\_K5G&O_P![3?\ OF3_ !K5HH RL:__ 'M-_P"^9/\
M&C&O_P![3?\ OF3_ !K5HH QA;:TMPTX&EB5EVE]LF2/SJ3&O_WM-_[YD_QK
M5HH RL:__>TW_OF3_&C&O_WM-_[YD_QK5HH RL:__>TW_OF3_&HS;:R;E;@C
M2S,J[0^V3('YULT4 96-?_O:;_WS)_C1C7_[VF_]\R?XUJT4 9T UGST^T-8
M>3GYO+5]WX9-:-%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M6Y\H>9TQ][KTK0HH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MYH4GC)CRHP0V.?Q%<_J?PWU*]E^T_:K.26X1ENX=\MO#RV["K&1D<X^;D]:
M/0KG4;*REBCN;F.)Y@QC#MC=M&3CZ#FLZ;Q5I0M;:XM[ZUFCN%$D;><%#1YP
M6!QS]*J^*_#$OB#0(K*VG2WNHL!)F!8*I&U_?E216/IWP]GT][K%]$\1NX7M
M8]A A@C_ (/J3DT 6+/XG^'[H6TDEPMO;SB0"65L!75MNTC'7O70:WK:Z3I
MOHH?M1D94A17"JY;IECPH]S7-Z3X(OK.%H[JYLY!';7-K"R1MG;*Y8%L]QGG
M'I6W/H]^OA*TTNTN;87%O!%$WGQ;X9@J@%6'7:?;F@!MCXF/]G7%WK5HFEI
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MQCM99OLKR)E3@;2O$?7)W?6N^U30)=2M]%C$JQ_89EEDW#)8"-E('O\ -^E
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MV9&=3P"IPP_ UP.H_#.>X:'[)J,42PV/EKOC)/VH *LOL !TKHF\.72>"HM
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MVW_7Q<_^CY* .IHHHH **** "BBB@ HHJ"\O;73[9KF]N8;:!?O23.$4?B:
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M68@*.22>E "T5%%=6\\CQQ3QR/'@NJL"5R,C/U%2T %<M\._^1+MO^OBY_\
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M7V^S+RH+N#=%_K%\P93Z^E/^TP;BOGQ[@P0C>,ACT'U]J ..^'=_J%YI]_\
M;+PW,<<@\DNTCR+E>0S.B;N>F!QTKB8=1U_6(M>M9+G498KC3;G<A$@*R $J
MH4H A/3"LWUKV::\M;>1(Y[F&)Y#A%=PI;Z ]:/M=M]J^R_:(OM&,^5O&_'K
MCK0!P>KP"?X<:$T=WJ9BADMG>10WG, 0#N&W)P?;L*H:/::SIEG!>Z?=:C))
M<37*BSF'[D#)*MMQD$]<Y[UZ0NHV+Q2RI>6[1Q'$CB52$^ISQ4D=U;RHCQSQ
M.L@)0JX(8#J1ZT >??#G4]9O-0NHM1O'E7R5:2*5Y7:.7/."T:@#M@$UGG^T
M-.UG4DL[C4GF;4)G<2(655,65*G;C&?0^U>FOJ%E$Z))=VZ-)]Q6D +?3GFH
MK+5[+49KN*TF65[23RY=I!PWI0!Y\;77XK22<ZUK4C):1W@3.,S9P4^[]S'\
M/ZU%;ZSXE/CY8[NX:W5K@*MNS2^6\)48PHC*YSGDL.G2O1K?5[.>&V>25;>2
MX7<D$[JLA_#)S^&:O4 >9^/K*237;EUEU F?2S'%%$K-$S!QG@#KWZ]JBU@^
M(M#T^\M;*^U"ZMP\#R7%PYWQ(P^8(RJ2!] 2*]1HH YGP)>7M[X:22^N1<2"
M5U23YRQ4'@,7523[XYKIJ** "BBB@ KEO#__ "._B_\ Z[6O_HA:ZFN6\/\
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MCOXO_P"NUK_Z(6@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKEOAW_R)=M_U\7/_ */DKJ:Y;X=_\B7;?]?%S_Z/DH ZFBBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .6\9?\??A?\ [#47_HN2NIKEO&7_
M !]^%_\ L-1?^BY*ZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@#EOA[_P BJ?\ K^N__2B2K4GA&P?6_P"U8Y[V
MWE+B1XH)]L;L.[+WSWJK\/?^15/_ %_7?_I1)74T <PO@32_]+,]SJ-R]S&8
MV>>Z+,@)S\I['-(G@/24U%;WS]0=Q()MCW)*%P,;L>N!7444 <Q;> M'M3*
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M_'WX7_[#47_HN2NBO;VVT^SEN[N98;>)=SNW0"N=\9?\??A?_L-1?^BY*O\
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M=1M[KRYD6\M_.+69D7S<1L03CT./UJ[:>)]*N181O>007=["LL5K)(/,(89
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M ,BJ?^OZ[_\ 2B2L^7XA;?%C:5%8-+;1W"VSNBR&0.>^ FW:#U);I6A\/?\
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MQ/H4>F)J3ZO9+8NVQ+@S+L9O0'UIUWXDT2PCMI+O5;.%+H9@+R@"0?[/KU%
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M^\M[588XE@$]Q-=),9 B@'(,>[/&,A@.^*] LU9;<![>.W;)_=QG('Z"IZ*
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MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#EOA[_R*I_Z_KO\
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MLR)YUR_V?<8M['IE>,]!R:GO?&NKV-S813Z?:PQOA;F;=)*@;< P5HU(&/\
M;Q0!W=<M\._^1+MO^OBY_P#1\E=0I#*&'0C(KE_AW_R)=M_U\7/_ */DH ZF
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** .6\9?\??A?_L-
M1?\ HN2NAN[&UOD1+J!)E1PZJXR-PZ'%<]XR_P"/OPO_ -AJ+_T7)74T (
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M<6\T$EA$8IE5)% (R%^[TZ8]J;8^&M'TT1"TLE3R=WEDLS%=PPV"23R*U:*
M,G2O#.CZ'/)/IUDL,L@VL^]F)'7'S$XJ.Y\):#>?;/M&FQ/]LD66X.2"[@8#
M<'@X]*VJ* *UIIUG8Z>EA;6Z1VJ+L6(#C'I6=IOA+0=(GFGL--BAEF4H[ L3
MM/4#)X'TQ6U10!AZAX.\/ZIY'VW38Y3 @CC.Y@0H[9!&?QK4@L;:VDWP0K&V
MP)\O VCH,=*L44 %%%% '+?#W_D53_U_7?\ Z425OI;V5A+/<*D4+W,@,KDX
MWMT'X]JP/A[_ ,BJ?^OZ[_\ 2B2N6\07UQ<>(H[:ZU&Z6Y75;?R],$.8O*#
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M$G"[3D8.<\&G)HVE6EM$BVD,<,#,Z ]%+=3SZYKS.#Q1XD_X22_AFNQ%*!<
MV;S9V!4)0H@C^]P#RYZFDUQ-:_X1&Y%UK6ISI<:?;7DA,:YB;<-P7:O3GD<G
MB@#TG2_#>D:+<2SZ=9B"248<AV((SGH20/PI'\,:+)>37;Z="T\S%Y'.?F8C
M:3^7%6]/N[>ZMPL%P9_*"JSL,$G .3P.2#FK= &>VB:8\31-9Q%&B$)7'5!T
M7Z57;PMHK:JFI_8%%XF"LBNR]!@< X/'M6Q10!E:OX;T?7G@?4[&.X: DQEB
M1C.,]",]!UJ[!8VMM<2W$,"1RS8$C*,;L# _(58HH **** "BBB@ KEO#_\
MR._B_P#Z[6O_ *(6NIKEO#__ "._B_\ Z[6O_HA: -[4=,LM7LGL[^W2>W?[
MR-_CU%9B^#/#JZ6=-&EQ?9#)YI3<V=_KNSG]:WJ* ,FT\,Z+8[/LVGQ1^6KH
MIY) < ,.3WP*Y[5_AU;ZIK5K=)<QPV<"1Q_9_)RRJASA&W#;^(-=O10!B?\
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M_P!?%S_Z/DKJ:QO"ND3Z%X?AT^XDCDE269RT><8>1G'7V84 ;-%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%4=7O;C3]*
MN+NULI+V>),I;QD!G/H,U!HVK3W^@QZCJ5A)IDFPM+!.P)C ZDX[4 :M%<II
M/C2.?3+^]U6$68M<2[4)<F!B1&_'<X-:VC>(;'75G^R>>C0-MD2>%HF&1D'#
M '!]: -6BL"#QEHMQJ4EBMQ(DB;\221,L;[/O[7(PV.^*SH?B!ITU[-E)XK*
M*U$Q>:!TD9RX555",MG/&.M '845PY^(,1M[FZ6';##)(BQ/$XF?:A;&W'RG
MCOVJW9>.K*:T-Y<%HXVMX)4ME@D,^Z3=A=N/FSM. .<#- '6T5S-QX[T2WM;
M:=FNW-P&*PQVKM(NW[VY ,KCOFI9O&VB0S6D?G32+=1I(LL<+-&BO]TNP&%S
M[T =#17-6GBAY-!UK4Y[;C3KJYA5(06+K$2 ?J:I:/X]M9[&R.J*T=W<!6=8
M+>39"&/R;R1\N??K0!V5%8D7BS29M8_LQ))?-+^6LIB81,^,[0_W2WMGM2:S
MXMTG0KH6U]),)?+$I$<#.%0G&XD#@9[T ;E%<XOC?1FL[BY#70$$JQ&,VSB1
MV;IM7&6!SU%2P>,-&N+9KA;ATC6W>X?S(F4JJ'# @CA@?X>M &]17/:_XG31
MK+3;U86EM[N=8VPC%PK*3E5')/ XILOCC18K&"Z+W+"8MB)+=S*FW[V],97'
MO0!T=%4+K6;&ST?^U))LVFP.K(I8N#TV@<DGT%<W/\1+"*[M-L%T]M,DAD46
MLAGC93T,>,@=\D=* .SHKGKGQKHMK-:QM--(+A4<210LZ(KG"EV PN?>F3>.
M=%AFNHMUU(UM+Y#>5;.X>3^XA ^9@.<"@#I**YI_'>AK9172RW$BRLP"1V[L
MZ[?O$J!D =R:AUWQWI^F6S?9-]U<&))$*Q,8AN/ 9P,*2.<&@#JZ*P_$'B!-
M"^S/)AED65C&(V9WV)NPN._UJCI?B\?\(3!XAUQ%MUE(^2"&0GYFVH I&XDY
M% '545S\?C/2)-0AL@;E9)<#>UNX2-B.$=L85O8\\BH]1\8Z;;Z9'<07*B2=
M6:+S8G( 5PK%@!D8)Q0!TE%<Z?&&GS2WD%MYQDMD=FG>V?R,KU^?&#]!2Q^,
MM)^V064DSF:0)NE2%_)5F&0I?& 3V!YH Z&BN;M_'.AW,LR++<(L<;R>9);N
MJ.%^]M8C#$>@K1TC7;36K.2YM8KI(TZB>W:-CQG(##)H TZ*X[3_ (B:;<Z/
M%?7,%W$\LTL:P);.[X0X+8 SMZ9/2M37?$]OH_A^+5HHY+J*9XUC\E"^=QX.
M!SB@#=HKDM(\=V5]J$MC=QRV\PN9(8W,+B(A>F7(P&([5J:3XHTS6KN2VLWE
M\Q%WCS(F02+G&Y"1\P]Q0!LT5AW'BW2K;6UTF1YO/9@AD6%C$K'HK/C /'0F
MH$\<Z')>26PFF!0.5D:!Q'($^_L;&&QWQ0!T=%<O_P )_H?DP2YO,3+O4?9)
M-RH3@.PQPA[,>#5R3Q=I$>K)IQFD,CLJ^:L3&(,W12X^4$^F: -RBN4;XB:
MID :]?8I8;+.1MX!PVW ^;'?'2KD_C'1H+N"W::5C,J-YB0LR1AON[V PN?>
M@#?HKF9/'6CK=3VL?VIY8MX#?9G\MW4$E ^,%N.E6=*\3VE]X2C\0W"R6ML8
MC(XE0J5 ]CR?ZT ;M%<T/'>BFR:Y)NU*RB$P-:N)MY&0-F,\CI5BU\7:3>:J
M-.BDF\YB55VA98V8#)4,1C</2@#=HK'U#Q-INF:DEA<O*)F0R'9$S*B#^)F
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MW>:1G$@& 2Q;)X[$XJYHFF-I=BT<LBRW,TK3SR*NT-(QR2!V'M6E10 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>g2018030121531707031130.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531707031130.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,0 DP# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(Y&8T52 HSCFDMM=O&T2^NGC262W/R%>C9]1[5>OM6M=/G%D;6:0F,N5BC!
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MM_S\7W_@7)_C3H]&MXY5D$]X2I! :ZD(_$9YH T:*** "BBB@ HHHH ****
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MOI#VMUI^K3S&Q>VCD;19V\MV<L&!*YXSUX/% 'K0U.P-ZUD+ZV-VHRT'FKO
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MHH **@N[VUL+<W%Y<16\((!DE<*H)X')I3=VRW4=J;B(7$B%TB+C<RCJ0.I
MR* )J**C@N(;F+S8)4ECR1N1LC(."/P((H DHHK,O/$>B:?>K9WNKV-O=-C$
M,LZJYSTX)SS0!IT45'-<0VZ!YY4C4L%!=@ 2>@H DHHHH ***@-Y:K!-.UQ$
M(8-WFN7&V/ R=Q[8% $]%9VFZ_H^L/(FF:I9WCQC+K;S*Y4>IP:T: "BBB@
MHIL<B3('C=70]&4Y!IEQ<06EN\]S,D,*#+R2,%51[DT 2T5')<0PO&DLJ(TK
M;8U9@"QQG ]3574=9TS2%C;4M0M;-9#A#/*J;C[9- %ZBD5E=0RL&4C((.01
M2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'BJZ/KBWUU:#3M2?=KC74=N]B@MG7S<AS./F QS^E7$A\>_:]?,EQJ"S"&[\
MJ-4D*2<_NO*8G8K 8Q@#/.:]>HH \BO+/QQ:65_!8R:M+&UO8REYIF>3<?\
M7K&0=P/J%Q[4#P_XAO;KP]>WCZE<RVUM?XD(>,Q$K^Z5E8DEB>,GK@9KUVB@
M#RG2X_%D=_IO]I)KQD$%GY MG A'7SA<9^7/U&?2J&M?\)L-(%M:6>LB]^T7
M,D=Q#*X 'F_(A"D#[O(+9&*]EHH \NNX?$$-GXGUV\U'4[*2TE2:RCDN2D+1
MJB,ZA,XY(9?J:WO",E_=Z5I>I:LVI-=:A-)=B-&;RK=67Y4<=-H&,9[FNMNK
M2VOH#!=V\5Q"Q!,<J!U./8\5* %4*H  & !VH YGQ]8#5/##63;-LLR*Q=@H
M49ZY/IU_"N1@>[\[^UI9%COH=/GLX]MQ&S@)@(RY/5^3[X%>FWEA9ZC;^1?6
MD%U#D-Y<\8=<CO@\5G?\(CX:_P"A>TG_ , H_P#XF@#SO0;C6;I/LVH:K>0V
MC7L;;VO#'((]GS<LY8#=[_2IX/[5G$[SZS=PM;Q;K98]050\GVB0X8!OF_=[
M.#VQ7>_\(CX:_P"A>TG_ , H_P#XFC_A$?#7_0O:3_X!1_\ Q- '#V>K:O\
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M63S)")<KG<Q;.WL35^>/Q%]ON_LJ:X+PK-EWD/V8P>4WEA 3@2[O+[9SNYH
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M6^D7UM-!>NB^;\R;4D*;BH&[>P[;@N/>LRX^(D[^9)#I-[;67V!KM+J:-&R
MX4'8'R0<^QK=G\%:5<:R^J2/=F5Y/-,?GGRP^-N0O;@4MSX*TBZMH;=_M*Q1
M6IM-J3D;HR0<-ZX(R#0!33XC:))JUU8)YC- )0'5XSYC1_>4*&W@C!ZJ!QUK
M1T3Q$OB71YKO38O*D&519I$<;L<9\MF'X9S42>#=.AU"XO+:XO;9IRY:*&?:
M@9OO,!C@DY/U-6-(\,66BDM;37;2/)ODDEF+-)@$ -Z@9X% %[3!J(L@-4:W
M:ZWMDVX(3;D[>O?&,U<HHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD2Y^\0"3^@H LT50N]8L;*X^SSSA9=@?8!DX)P/UJ\"",@YH 6BBB@ HHHH
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M2%6RG,(S&6 ^Z#C^]SFNB>_U#1/#WAQUCO$A^SR)<)%;-(P<Q_N\J 2/F_\
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MR_\ ?F3_ .)KE=,U'7=1N)H],U75+J&W'F1-<P"-I'$>X(^4'REO89'2LO\
MMKQE_9"%+JY,(F/F3-'-YJ-M&T?\>^2I.[@(?]X4 =]_PL3PI_T%E_[\R?\
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ME+YMO+DHX!&<''0\]15FB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"*.WAADEDCC57E.YR!]X],FI:** *FI:78ZQ9FTU"UCN;<
MD,8Y!D9'0U/;V\5K;QV\$:QPQJ%1%& H'0"I** "BBB@"*&WA@,ABC5#*^]]
MH^\WJ??@5+110 4444 (Z+(C(ZAE88(/<4R""*VMX[>"-8X8D"(BC 50, #\
M*DHH **** *%SHFF7FI0:C<6,,EY!_JYF7YEJ_110 4444 %%%% !3)H8[B"
M2&9%>*12KJPR&!X(-/HH IZ9I-AHUI]ETZTCMH-Q;9&,#)[U<HHH **** (Y
MH(KF/9-&LB!@VUAD9'(J2BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** /+M/\6^*;W79EMS)<PPZK);26XTYEB6!6
M(+?:,XW =O6ML_$O3AIUK>FQN_+N;6YNE'RY"P-M8'GJ>U64U?2/#K3V>FZ7
MJ5V;BZFDD6TB,N9,YD/)' /%9.EZ#X%U!+JYB$R1@R6;+<W3JB&4!WC12V!G
M=T'?- %B7XDM$ #X;U N+#^TI$$L1*6^1\WWN3ST'-6F^(=@;TB&SN9=/CEB
MAGOP5"1/( 5!4G<>JY('&:IZAX.T+4?$CS76IQ"RMM,%B]E'=&-U4,#\[!@=
MN!@@UJ/X;\*3ZI;7P:$22LCQ11W1$4[(,*?+!VN0.^#TH I_\+*TU)=9%Q;2
M6ZZ6DC.))4\R380.(\[@"2,$@"M+PQXRL/$]A=W4*-";1L3(75P/EW AE)!X
M]#4-QX6\,OJEPU\YGN[R%X?+NKQG(1^6"*S?+T'3TJ]I,&BZ3:BQMM065)F(
M5;B\,S-C@@;B3QZ4 <MJ'Q.*^'[R\M-)N8I'L9;O3GG9-MPB'!? .1C*G!P2
M#4NM>(]=TWP%HE^9?+U&]GMXYG%J)642'G;&I.XX/ !JZ/"'A2V6:V$+R17M
MN\14W3,L,#98[,M^[0X_AXX]JLW*>&?$.D1V$UR%L[.X2."1;DQ?O$ *E'#9
M)'L: ,W_ (3&?P_H"WVJM>W[377DH9K$6'E_+GYO,( '!Y)K0/CB"34HK2ST
MVZO0(H9+J6V9'6W$IPN<'YNAR5S@#-277A[1(+#^SKW5;Y(YY-P$^JRAW.,8
M#%LX]JJ7/ASPC'K%E931FWGBAB$<?VAHXYE1OD5AN D(;D YH 8OQ$BE25HM
M%O7S?G3[8!XQ]HF!P0/F^4#KEL"H;SXI:786#7-U8WD;)',3%A2WFQ.J-$.<
M%LL",<$5?DT+PN]I/INT);I.VH/.ER5\F8MRP<-E#GZ57CTOPE<ZII_A^*S-
MS)8#^THI ^]59B?F=MV6+')YSG\J -&P\86>I:?JE];P3?9]/0%I#C#MLW,H
MP>J]#[UR4WCWQ##9QJ]C%YKZ(=3:=<%48G@;<Y('3U)KIM+B\*Z5IU]H5A)!
M#9KN>=C,"@:0D'+D]<]JJ6OA+0GL[&QU.^2ZO+6Q-KO2Y,;2V_4;E#<C&#G\
M: *H^)UM9:3-)JMA/;WUO]F4PM)&!*9AE6#;MJC )Y(QBMRS\12^(?"#:KH$
M&^Y;*I$[+PX;##.=IQSSG!JI>Z!X3N(992$F:[6%5:"Z^=O)X0QD-P1SR/>M
M2'4M$T/3T@_M.,QQLL8\VY\Q]S'@$DDY/O0!S'BK5?%FE>'_ .TTO(+*47BP
M>0]LLH9'D"JVX-QP<X]:UD\37-EK3>'I;:?4KVVM!<W-XOEP1[23C@MQZ5I:
ME%H_B"RBL-2*8D*W"V[RA'^1LAL YP"/TJ*71/#^MS:A=_NKEKRV^QW+Q3D@
MQC^'@\'WZT 8%K\4K*\MF:#3+B6Y^WQV"P131/N=UW*0X;;CMUJ2X^)MC;Z7
M8WK:?.IN9I8766:.-8'C.&#.S;<^F#S4::1X,TJ]TU+99;RXNKU)8&CNFF/F
MQ+@,Q+=%'']*LG0_!]]8W6EI>F.VBN91<0QW[QAI'P7#889'/3IS0!8O?'EC
MI_BBST6>#F[V^7,D\;#E=W* [@/?%9E]\1;D^&K_ %73]!NS&D7F6D\K)Y4Z
M[]F[(/'8[3@G-7O^$:\&?;X=76>!2DZ21E;XB+S5&!A=VW..*5?"G@^V74H&
MDCVR1%)XY+UB($9MQ"@M^[!8@\8[4 58_'<D%S/;365U<7[3P6\-BHC4^8\>
M\@/NP0 "23CTHF^)EJ$A%MI%[<3M!//-"K1J8/);;(K$L 2".W7M5N3PQX2-
MH ]P!]H9)X[C[>WFLT8VAD?=G('!(/UJ.PTKP?/917, 1;1+9K6.X>XPLJ3#
M<WS;N6;/)/.<T 6X+O7M5NK:]T^6)-(NA#+&7C4L(VC8MGG/WMGZ]JE\)Z]>
M:WH]G/<6NZ1O,2YFC8!$D1BN,$YYQVK3L?[/L;>/2+">!7M80D<!EW,B@8&1
MG..E8GAZRT[0;**UFU!O-L"8Y9WD\J*663YFXS@GGZB@#JZ*AN+NVM%5KFXB
MA5CA3(X4$^V:8U_"M_#9G=OFC+QMCY6QU /KCG'I0!9HJL=1L1/) ;VW$T2[
MI(S*NY .Y&>!2)J=A(T*I?6S&?\ U0$JGS/]WGG\* +5%4'UO2XVB4W]L6EF
M\A LH.9/[O7K[5.U]:).8&NH%F +&,R , .2<=: +%%0/>VL;*KW,*EB H:0
M#)/0?C5*3Q%I45U;0->PG[1O$<@D79E<97=G&>>E &I154ZG8"26,WUL)(1N
ME7S5R@]6&>/QI1J-B3 !>VY,_P#J<2K^\_W>>?PH LT5 ]]:1726LEU EPXR
MD32 .WT'4U&-4T]E9EO[4JK;21,N ?3KUH MT55_M*P\N:3[;;;(6VRMYJXC
M/HQSP?K0^I6$;!9+VV1BF\!I5!*]<]>GO0!:HJL-0LC(L8N[?S&3S%7S!DK_
M '@,]/>H!KFEM/;PIJ%M))<.R1*DJMO*C) P>W'YT :%%9MWKVFV6H06,]U&
M)YMW&X?NPJER7Y^48!Y-*->TDW$4"ZC:M)*C2(%E4Y5>IZ]!0!HT5G7FNZ98
MV*W<MY"T3C,>R129.<?+S\WX5')XBT^+7H]&D9UNY+4W:Y7Y2@.#SZ^U &K1
M7,Z3X\T/69A%:R3+NM&O0TD>T&)79"?S4_ABD_X3K3&TRQOK>VO[E;U-\$4,
M&9&&[;TSQS^E '3T5S$OC>S1+<1Z9JT]S,7!M8K;,L13&=ZYXZCOWJV/%>FM
M+IRCSBE\,I+Y?R1G. KG^$DY 'J* -RBN>B\9:5(UUN^T11P(TBRR1X2=%."
MT9_B&:T]+U2'5;8RQQ30NC;9(9TVR1M@'##L<$'\: +U%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110!P\7A&+5;F*'5(7:&RF
MGW R/&9-YRK!E(SD=>:SM<^'5Y=R2FP>%;?SV,=L)O*41F*-,EC&_P P,9YQ
MGGK7I-% 'F5QX"UJ?4IKF06$L9A:%4,VTN"@ +'RL[@1U8L#UQ31\/=:,VG2
MSW,4OE8$B)<"+R@'W (1#SQU(V9KT^B@#@-9\.7VL>-M0:*RM! T%G_ITX(D
MB*/(Q$7'.> >1@'O37\!7*_98(;;2S"T21S3D$2VY!RS187DMGDDC\:]!HH
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M^ J?X5OT4 8'_"#>%/\ H7-+_P# 5/\ "C_A!O"G_0N:7_X"I_A6_10!@?\
M"#^%/^A<TO\ \!4_PH_X0;PI_P!"YI?_ ("I_A6_10!@?\(-X4_Z%S2__ 5/
M\*/^$&\*?]"YI?\ X"I_A6_10!S_ /P@OA/_ *%O2O\ P$3_  I?^$&\*?\
M0N:7_P" J?X5OT4 8'_"#>%/^A<TO_P%3_"C_A!O"G_0N:7_ . J?X5OT4 8
M'_"#>%/^A<TO_P !4_PH_P"$&\*?]"YI?_@*G^%;]% &!_P@WA3_ *%S2_\
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MV\26KS*HC50"?W@!#=?3O7<W5K9ZOI[03JEQ:SJ,X;AAU!!'Y@BL2/PKX8:
M:="@!61IL1WL@FW=&)</O/8')]* *3^/H7U"SMH[-XX;RW6:.>>01M\REAM1
MA\Q&,?6JQ^(8L].DN9[":2W@BBWW,DJ)NDD.$7:!Q[GH*W7\,:%)?PM*DDEQ
M%& D4EY*PV@;02A;!X[D?K5@>&='%G/:"R40SJJR*';)V_=P<Y!'8CF@"/PW
MXAC\1Z4UY%"8F1VC>/=N&1Z-@9'O7.Z=XYU.32Q)/HAGNA)=/(L=PBA8(I63
M?SU/&,=\9[UV&FZ9:Z3:_9K02B/<6_>SO*<_5R3^M9<O@GP_/$8GL6V&:28A
M9Y%^9SE^C?=)Y*]/:@"SJ?B*STSPTVN2;C;")9%'0G=T!].HKF3\3(?[(%ZN
MF,66<PRYG B3Y0P/F;<'(/IU!':NTN+"UNK!K&:!6MF39Y?0 =.,=/PK);P9
MHK68M&CO#"'+X.H3Y)( .3OR1@=.E &'/X[N[*34IY]-5[2*2&.V9;A0K;TW
M$LV.![U%'X]O;B^MKRSTY[C3)--%U,@D56@/F%2V3]_@=!Z5T%WX0\/7$BF:
MU*2.4"&.YDC.44@;=K#!VDCCJ,YI)/ _AV0V^[3S_HZ[$Q/(/ESNVMAOF&><
M'- &&GC:XMY+R61)KM8A,\<42JH**R 9/48W=?K3'\=ZC+=6MS8Z<EY;/833
MSVT5RGR,DB@G>1SP3\OO70-H?AN\>ZV"+S(RPG:"Z9&C+89@2K K]T'MTJ6Q
M\/:#"K):01L5B>%SYS.VUR&8,2223@')YH C\3ZW<Z;X0GU?38!-,%1HT<A>
M&8#G/UK#LO&6IK=W=OJ&G2+";J:WAND=/D=8O,V;>^,-\W0FNON]*LK_ $J3
M2[F /9R1^6T6XCY?J#FJR>&])2%(A9C8DC2C+L3O9-A.2<DE3B@#%TWQJMSK
M=KI,EJ4\Z%'$\TJHSEESP@'/U!J;QSXD/A_2X%@NXK6\NI-L,DJ%E7:-QR #
MP<!?^!5H0>%='M[Z*\CMY/-AQY8:XD9$P, A"VT$>N*T38VS:@M^8@;E8S$L
MA)X4G) '3G _(4 <I=>/A'I<6H6.F2:A +(7EP\4JIY:=. W+'(/Y4:G\0%T
MP7,DNF,(8[D6L,KW"J)9<9(Z$J .YJ+Q!\.;?6+I#;70M+5@XGA"N2VY@6*D
M. .G1@P]JZ"70]%OH;FR:)'_ 'PEF$<S*Z2$<'*D%3CTQQ0!S%Q\5=.@CLV6
MT=C-%YLR,^UHEW8^48^<\'@8SCWJY)XZN6NY8+70)YU$TT$3FX1!(T0RW7[H
MQW/TK6E\(:--%;H\-S_HZE4=;R97P3G#,'RW/J35B/2-&CN_*2&(7(:2YV>8
M=V9/E=\9S@],T <VWQ-T\:C96JVKL)TA:4^9\\1DQ@!0/FQD9(Z<U#J?C_4(
M]!O[VUT5HMMK--:327",LAC.#E1R/7GK72'PEHOG6TJ6TD3VRJL?DW,D8PO3
M<%8!L?[6:EE\,Z/-8_8I+%&MO+DB\O<V-K_>'7OF@"IXFU74].\&7&H6EJ$U
M 1*1$9%(C9B >3P<9_&LRU\:7%O;*;W3YY((PT)O?,3,DZH69=B]!P1GI742
MZ79SZ6--EB,EH$5-CNQR!C&3G)Z#O5%_">B2:A+?/8@SR@A\ROMY7:2$SM!(
MXR!F@!UKJUY=>&Y-3;3S;S>4TD4#3*V1C*DD<#/IVKD-+\=:V9(9K[23);/9
M6<TPCE0>0979=W^WGY3@=*]"2UACM%M4C @5/+"=MN,8K%A\.^'-.@:R2"*)
M'2*(H\[$E58M&O+9X;./R[4 9^B^/[+6O$;:5#;L%+.L4P?<6*==RX^3H<9/
M.*O:YXFFTF_%I;Z7)>LML;J5EF5 D8)#'GJ1CIWJY:^'-,LM4?4;:&6.X<DD
M+<2>7D]?W>[8/RJKJWA*QUO6X;^_WR1Q0>4(5=DS\V<DJ1D=L'B@"&#QE;7$
M+RQVLOEB]-HI+ ;OW0D#?0@XQ6=#X\O;@1F+PY,WF6GVW!NHQB#=MW?7OMK9
MG\+Z E^VKSVJ)+&"[.TS+&N%P6VYV@[>,XZ5G7/A#0;W6+.665#;PV@M8+1)
MV7HV_.58%ACL<T /3QJLMT&BTR>337D\B.[1P2\NS?M$?7IQGUK-_P"%FVR:
M5+=S64<<PN%@C@^U Y)&?F./DP >H/2NBF\,:$-0;4I+4),>"WG.J D;,A<[
M0V#C<!GWJ"#PCX=>SFAAA>5)) 7D^V2O(&7L)"Y9<>@(H MZ1X@MM6\.KK(1
MXH=CM(K G;MR&QZC@X/>N6UCQOJW]B2FSTEK6\G2.6R9IXW\R%G52_/ /SK\
MI_O>QKM;2QM=-T\6D0;[.@/^NE:0X/)RS$D_B:YS3;#P.]Q+:6%U87$UPP)A
M6_\ -;Y6W@*-Y*@$9PN!Q0!+XKU'6=+\/67]G_-?3SPP/*2@*[C@G!&TG]*S
M[?XCVW]HW5A/92K+;Q2,A\Q2TA1@I!4#Y,EACD]:[&[L;:^2-+F(2+'(LJ D
M\,IR#63#X,T""XFF2Q8O,LBL'GD=0'.6"J6(7)] * ,'7/%^J6FG2%K*73-0
M6&5Q"S1S)PN5.X=?H*2'QI?+J4P-I)/86\=S)+(60/NCD*A0H[<=>O/-;\?@
MSP_':_9AIX:,A@3)*[L0PP06))/'J>.U.G\'Z#< B6P!!\S($KC.]MS9P>YY
M]NV* .77XB7>H_V<=/TY?WE[);W2BX5MJB%I 58C!/&?^ X[U=M/'KO/#$=+
MN);4-#%/>M(@*O(NX?(.HQUQ6G!X4\,NJP11"5HY1<?\?<CN&P5#$EB>A8<\
M'FKT7AK2($*Q6:H#)')PQ^\@PAY/84 4-)\53:EJT%G+I,MM%=0R3VT[3*PD
M1&49P.5)W X-0^)?'$'AK5+:SFM&D20!GE\T+M!8#Y1CYCSTXJ#0/!R>&]9N
M-7O-2CD!#1Q9#(%#OGG<Y&<[0-H4>U;6I^%M'UBZ^TWUJ\DI0(VV>1 X'0,%
M8!OQH QU\=%;B8SZ1-%8I)/$ESYRMO>)L$;.HSV-6O#>N:EJVLZK!J%D;);>
M&W>* NKD;PY)W+US@<=L5J#0-*6,1BS0H)))-I)(W2??/7OFHM%T+1M#GNDT
MR()-*$,^Z=I'P,[,[B2!][% &+J_CU='EOO-TU_L]M.EJD[3JHDF;D+C&0,?
MQ5&/B#Y^F"\L='FNO*MY+B[03*ODJN>A8?/G!Z5T5SX?TN\AN8IK4%;F02RE
M796+CHP(.5(]1BN<U[X>1:HMI#:7KV]M$CQR)*TLK,K$$X?>#GK][</:@#3/
MBN.2TDE2UD4BX6V4DC[S+N#?09K!TWXB[$T"UO[;S)[ZUMWFN X3YY%S\J8Y
M&?IC-= ?#WAR35H[AUC>^3" &Y;EE7^X&V[MO?&:5?!/AY)89$L60PJBHJSR
M!/D "Y7=@D  9(SQ0!DVWC6\O9(YX=*ECCDAFD@BDN(U698W"EF8C*=^*CE\
M=W-O81:C>Z1=VH:&61;3S$;S0I #;NP.>/:MN\\)^'+NTBTVYLXS$$=(XA,Z
MG:6#L!A@<;L&@>#M CM#"]HSPA2#Y]S)(0#C/+,3C@4 4$\97DC&T&@2_P!J
MK.T<EF+E,!%56+A^AX9>.N36BVORW'@N37;.T/FFV::.WD<#D \$]*S_ !'X
M1A\0VR2Z;=Q6SR3>>\N&=924VYRCJ>@'0X]0:W;'1[:RT&'2"#+;QP^2=W\0
MQ@T <CIOC/6%O)/[1TLM: VZR2I*G^CEXP>G5^3VZ5H^'/'EGXCUB:P@MV0!
M6:*3?NWA6P=PQ\I]B:UH/#FC6-H\,=JJPDH[[Y&;[@PI))[ 4NFZ#I5C=O?V
M"2*TP)^6YD:/!.?E0L5'X"@#6HHHH **** /+M8@\6PZ<EQ!<:JWGWLWVE09
M"T:#B+8L:E@I[X'/>K?F^(6NK)KA]::\\B+[,+6$K;.>=_GAQ\I_WL>W-:IU
M+Q3#K5Y;S7&C-:VL!N&"VTH=EYP,[\ \=<4RP^(UB^AI>ZC:7=I<?9X)C$\8
M03>8.#%EL$$AL9(Z4 <YILGC%GODNS>LY*EHV@F(#"4<HSKMQMSPN?7M5=3K
MFN:?J"13:[.'BN5NL@B+Y7'E" XY; .0,^]>G:)K=GX@TX7MDQ*;S&Z,1N1Q
MU4X)&?H37'/XKNK;Q1>:-:W>DV,$%RL20-I\\CON 8G<A"@DL?ZT :6N?;D\
M.Z.MN=76TRHO#:*QO GEG' &[._;G S5'PYI.I2^,+76-26_W+I7EJT_ !\P
MX##'#[<$CUK9B\;Z9+<:A$(KH"Q5F=RJX<@A<*-V[))P,@4#QK9@V\<NFZI#
M/,S P2VX5XE49+MSC;CG()H PWTO7[J[EEDU'6HEEFN4*12;56->8]O'!)[]
MQQ4"3>)3J5FTPUA;O$ A2-#]E*?\M#,<8W8SU[XQ70P>.],E6-Y;:^MHY2AB
M>>$*'C;.)!S]SCJ>>1Q5K0_%NF^()(TL1<;F1W(DCV[-C[2&YX.3D#TH Y&>
MS\30:89TGU>XN+J&7SH9/G6-ED79L7'RDKGZU#;3>+U\0:B+R:^A#).I\JWG
MEC"[?W9CPNP-PO0D]1UKKO%_B4^';2V,36GVF>3Y5NI0B^6HS(<Y&2!T'O3;
MKQOIML(66"\N8I(([B26WB#I"DGW"YSQGG&,]* *7@R36VT"_2ZCO/M"$_9Y
M;PR;I#M]) & !]1BN<LDUR":XOXT\02216]O]I:ZA8NSB0F5(AC++@\ <=<5
MUB?$#0Y-3GL5DDW1*Y#_ "[9"@RRJ-V[(]P*JS?$")HH/LND:EYTD\*>7-"%
M;RI,[9!\W*G:: .;UF\\7W0$]LFJP64EW<%!Y4PE7E?+RL:EMF-W!&*]%TR_
M>ZLVCDW->0(@G_=% 7*!N WU_#I4VIZG!I-B;RY60PJRJQ1<[<D#)]AGFN<F
M^(&ER6LC6C3"5)VA)> L%*LH)(!!P=PVGO0!R=G-XRFNM1BSK"Q2H"'>.161
MO/4?+N&!\A;[N1@5IZI::W9P2V<ESXAFTZ.:0)-;9DN'ROR@D#)3/M]:W_#/
MB:\UJ_E@N(((U2-G!CSG(E=.Y]%%:&J>);/2=1BLIX;EV>(SO)'&"D48."SG
M/ % &*\.J6WP\TB!8[Z&2.*!;Q;1?](1 OS! /XLXZ=LUS<,&NVUI=-;KK$$
M,J7+K*ULQF9C*FW<%&X,5SR.0,G%=7:?$+1[VUED@BNGG1D5+1%1I9=^=I4*
MQ'.UNI'W31+\0]%@N[>VF6YBED"&5955#;[C@>8&8'\@: .0\K6I([*[N8/$
M45PEK)%%+:K([N_F$H)"R[@O3A@*W?MWB.*[>QG@U)[J2[67S8H28$B\H94/
MT^^#QUYK7@\:6*P7CW1D/V>24!D@*APLQBVJ"3N8$#/KG/%2:7XWTC5M:;2[
M=I!,-P1W*;9&7AE7#%LCGJ!T- ''W,7B2RAT207.NW5Q(@DN;<B7&\MR"Z*0
MHQQM;  I!/XU76]6+F\60I<B)%BF>(K@^5L.WRPV-O0]<UV'C'7[[0;2R.GV
MC3S75TL);RC(L:]22 RG.!QS3KKQGI=II::@Z7+126ZW"*D66968(!C/7+#B
M@#F(=/\ $UG=1R+>ZU<"&>RV+*^5<2$>?OX^8+_X[67%)XX-OK"2/J*WCQD%
M8XIB _F@9A9EV ;2WW2<C'I7:?\ "<6;6VY--U,W7F/&]IY \V/:,EF&[&WI
MR">M1Z+XYMM1DTRRFMY1?75O%+(8PHB1G3=CYFW'CT!H R#I&IV_B/2_/GUN
MYM+34Y/+E9RYV-%P7('*[N,GIDBK?B-];'B-OLQU4,!%_9ZVJDVS'/S_ &@X
MP.?4CBNKU75(=(L3=31S2_,J)%"NYY&)P%4>M8FB^,HM0$XNK::WE22XVQ&/
M#*D1P0W/WOIQ0!DVWAVY@\!>([51J/VJ[EN74%_WK?,=NTXSR/SS5/2])U>V
MG_M*S?5XV-S;H()\A9(RH#M(I')'KVQ711?$#0YM5@T]'EWS;!YAVA4=U#JA
MRV[=@CH".>M;NJZG!H^F3W]R',4*EF"#+'V';\\"@#SJ-_$1TR]43>($N3;C
M[6TT#L%GW=+?:,[.O*YP,55OY_&9TO33$FI00JL@W@7$DID!&UG55WE<9X8#
MI]*ZS_A8NE/9V\\%EJ-Q),TJBW@B5Y%\L L3AL8P0>">M&H>.846 :=9W,_F
MRVR-.T7[F/S74;6.<A@ISC&.E %C78-5OH-'@AN+V 2$_:Y;/*,!L]2,KS7/
M&W\46=A(5N-8G>>TC:<L=SQD/AO*&.'*<X[]:[S4]2@TG3Y;RX#LD8X2-=S.
M>P4=R:YBU\<>9+=O=VTMI%!<R1"&2 ^:56%'.<-@'+'U'2@#,MK37M2$-O\
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M'-B.5XR"K.,<G@=^U=+10!4U+3H-5L)+2XWA''WD;#*>Q![$5BP>";&"-_\
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M JJ6C*$R[>A<LI)/N,5;L/"5CIVJ)?0W-Z5B+F&V:7,,._[VU<=R<\DUOT4
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MXC61)UV"/#+N'5@QX] :BO?%YTWQ-=:=<V-Q):1)"WVBWCW"+>2"9"3P,XZ
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M7<ZXBW<97"@Y '&2: -Y&WHK;2N1G:W4?6G4U%V(J[BVT8RQY/UIU !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 45AV'BS2]3\37F@V;O+<V<0DFD4?NQ\VW;GNP/6MR@ HJIJ>HV^D
MZ7=:A=L5M[:-I9".N ,UE:)XQTK6=";5F=M/@25H9%OBL31N#C!YQSU'- '0
M45F/XCT..SCO'UG3UMI"0DQND",1U .<&I)M<TFV6W:?5+*);D9@+W"KYO\
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M:317%RMJCPSJZB1AD D'C_ZXK1M]2L+NYFMK:]MIIX#B:*.56:,_[0!R/QH
MM4444 %%%% '-#P[=V_C._U^UEM@)]/6VCA92,2!RVYB.QS]:Z*+S?)3SMGF
M[1OV9VY[XSVI]% '(_$2UEU#P]'IX%Z;>XN8Q<_8[9YI#$#N91M^Z3C&37G&
MLZ7=)8:E;:5IOB*[AO+RUNUCO=/E=TDC/SLS-]Y2 ..M>N^)I;Z+17_LZ817
M+2(H(*[RI8;A'NX+D9V@\9Q7)_\ "17]CI<L<EYJ+72RNJK>PQ1S1_NBPW[
M589Y&,'UH XR6RU6'6[#4H-"O9I_ML]U/&^CRBUBWQ! %7[QZ9X[U(NA3V]C
M';6]GJLOF:?]AN#=:),1&"VXM"!T/) !]!7;:7XPU*:W%O;63:CJ+$,R37"P
MIM$,;,RD+ZN/E/J><5>_X3:0W(D&E_\ $M\\6IN/M WB8C[NP#!7/&[=[XH
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M8:UU>XGLKLSV]O<Z3/);A#&4V'(W'KD'UKT77-<OXM/T.YTJ*"47]U$C[I<
M(REC@XYZ>E<]I?Q!O[/0%N=:L-Y-LTT$Z2Y,Y$NP!E5?DY(Z;N* ,.TT^..:
M[>XTW6!]HTE=/'V;0Y$\E@6RR#LOS<#K54:7<36%PL]AJEO>+:06]G)9Z+,J
M(\+;DE<'JV0.G;-=@GC]YK:"[>PN(G1IEDA5B$DVJK##/&K$8;J ,'/6KOB3
M6-7C\$PWT44ME?3SP)Y=HRS2!7D484L I8@]QUH X_P?80^%M8-VUAXAN;>.
MW$=O$=(E!CD8YEDR>[']*BUS2UU^_P!:O[J'Q1'<W8C6S$&G3+'"L?*"1?X\
M/EOQKJX]>U/0M"EO)K76;QVG5-NJK'&8QCK^X1OE_ \^E7T\87$[QR6NF1SV
M21Q-=SB["^4S] JL!N'N2OTSQ0!YIJZ:S?:E>R+X<U62*>[L9WGDTU_-)CQY
MA3^ZO' //-.M_#QB@U:%[/7I/M4%Q#;S-I]R2HE;)WI]W\17?0>-]2NXH3!H
M,9DDA>[V/>A<6ZMM+9V?>S_#^M13_$VUM[J**2PD5'D97D:0#RP4WQ$\?Q]/
M8^M ''7FD&6.Z^S:;JJ,\=@(HWT27R]]N<L6QV8<<<U[#8&],+&]%N&W'RQ
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M%N!@]^?P]Z ,L^ +V9"\]S9B24R/+''&WEJ7D5L*/[N%[^M:$OA2[MM<75+
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M)8!*[A1$^PE62-MQ)' ('UJ^GC6[GU)XX-&S8K<K:?:)+C:_F-")1F/;P/F
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MG6*V5@X._&/O \#'^L/%='XOT.?4WLGBTJVU6WA#*UE<3>4JDCB0'!Y'3\:
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MBP&PC\G?O $SC<V,<G=D\>M<=+X&UF:WNHK:QM=-D^S>4\T4X<WK"5'9F!7
MWA2#G/7G(J_H'@J[BFTHZE:(;:TFFE\B62-EC9@-I1455Z\].* .CUB7PY'!
M'I>HK$8[4PR)!@_N\MMC(QTY&*L'2-$5(K+[!&8FMWA7:A*+&3EAN[9/-<UX
MG\&3ZQXEN+N*PM9(;FU@A>=Y-KC9+N92,<AEP.O;%0S^"[V&UNK6VM(S9M)=
MB*VBG$8$<@7:!D$ <'@C% '4VWA708;40PV$;0@L0&=GP6 #<DGJ *0?V!XK
MTNYL"D=W96\ODRQL"H#(01CIT(X(]*RO#VDZWH_@ZZLUMK>.\+-]FA1D0(#Q
MDE%"YZG@5A:CX5U3PYI%XZZC+J5C):HMTDD:(QV.&QA%&58&0,3DX.><4 =6
MO@OPRMF;9;%1 S[]HN).6QCKN]*LMX7\/R7-M<'3[=I;)!'$<GY%'0$9P<>^
M:X/P[X?_ .$@EM;Z+3+:VTN*]GD6WWEHT_=!$9,@9PV3T&.U1V7@#Q%%9:M;
M>>T,]Q#L-RLD(6Z82!LL%0-EAN&6)^\<YH [^\\,>'[^RMK>YL('M[;/DC<0
M%SU&0>GM3[SPWH%_+<37>G6LKS+&LS,.HC.4!^AKB],\!7DEM:6VI6:&TBEF
MD:UEEC9 6C(4JL:*OWL'IQUJ*]\ :M_9@@L1#%NM[9KJ-74_:YD+>9OW @D@
MKRP.<=* /2);:SDN;>ZE2,S0Y\ER?NY&#C\.*Y/Q!X3TSQ7=SQ6EW';W$$V;
MP"'S [,F!GD88#OGZBLB'P#=W6GPPZA:1RB#3KF&".XE1O)G=E,978H48P<$
M#C-=#X>T"YTJ]UN1K."-KS8ZW"2?-(VS!W8&1SWS0!=3PIH0^Q.UNKRV$4<,
M4OFL" GW=V" 3QWJ:XT70ETMH)K.W^Q+#)&4[;&R7 ^O->>:9X UU8;R*ZMH
M(X;KR1-%YR$2%9-S$E5!;()'S9)[GFM*Z\$7D,<L4&DV=[9BXN/LUF\_EI;A
MRI25>#@K@C ]>#0!V\%MI=YIUA*D2/;0JLEJ7S\@Q@'GV/>JMOX5\.V@F\G3
MK=!<2)*^23N9&WJ1D\8;G XK'\0^'M2O?!&G:7;V\<\\'E":,RJH(5<'[P*M
MSV8$5PNIZ7=:/8V&D:IIZ7U_+:&&U9G/^C.9#_JRJX)(900-OW1VH ]?U'3=
M.U01"_ABF\A_,3<<;&Z9_6HI-"T9[1;5[.#R?(%NB]/W8Z*/I[5Q6J^!;^YT
MZ\DMX83>3WQFD&4)GA_A1BZE>#S@@UGW7@/7Y$TI\RRK!#Y8A:: O:L)&;<K
M&,CD%0-H& H% 'H(T#3XM#NM%L?]'AG1U(#ERNX8)^8DUFZ?X:\*BPO='AM8
M)$BD078+-GS H(.<Y!P1T/&:S]#\-ZG8^.+C4S9QPVLVXRRR21R229  P0H8
M<C/)(JKJ'@^[_M;5[F+1;&\MKF^CN3 \P072^6%(?@X*MEAG(.: .EN/">DG
M0KO3;.".R2XLY+,2QC)1''.,]>3FFP^#_#D.D-I_V" VLK*TF6/SL. <YR.G
M8UA:UI5]9?#"+3IHQ<72SP_N4<D &X4A-W7 ! SZ#TK(U+P-K5W81>1906MN
M)Y'&DQ2QLD0(QN5G0KG// XS0!UFL:-X3TFQBO[^S1(-/55C5"YQ\WR@(I^8
MECZ$DFK2>&/#UQ)-=K8A)+J,^:/,=#M8<Y7/R_D*Y:[^'TNHZ7=B]LK>ZO7-
MF(9+IP[A$,?F MCJ0K=!S27/@S5I;V^$%E:PLZW -^)_GNE="J1LH' 4D=21
M\O% ';6&CZ3IEA)964$<5O-G>H<DOD8.23D\>]9L_AGPMIVAW9FLHDL%'GS.
M9&) 0'G=G(P,]#6'<_#Z-Y93#8VJ*L4"V^U]OEL&S*1Z;@3D]ZT9/"LI\%^(
M="CM[9([HW LH1_JT5E^0=.,-S[4 :.DV?AW^T0VGPI]KL(A;J^YB5C?Y]H)
M/S#G/>I[WPWH>J02V]U8PRH\_GN Q!\S&-V0<YQQ7(V_@6X%S%?K86MG>)<V
MK1F.7)@B2,*Z*0!QGG ZU-X&\*:MH&LW,U^&VO&4>99(MMRV[(=E5 Q;J<L3
MU- '37>C:#!87PN+* 6\D*"Y4 _,D8^7('/ Z5%N\/Z=9V$Z1(L,UP#;;$+$
MRN"<^N2 >M<U<>$=5DUB^D2SM@\TDTG]I>?^\E1UPL)7' 'UQQP*JVO@K51#
M&(=,L]-2.2#=;Q7&\2L@D#3$X'S'<HQUXZT =X+#2[W=</:ION3%*_F*59BA
MRA(/.0:S;W0/"]DM_J5W:PHKHWVIFD;:5)&<KG YQVK@)[*6V\1V.D3Z<EQJ
M8FM'2[+MOBC1MS*O&&0;3SD=>E6)? &NW,^LF6SMMMY!,I#3(5E<MN4DA=Q_
MX&210!W\NCZ'JNH+J,UH?M-NX1)6+QY(Y&.0&'/7FK$>@Z-!');QV4")*@1D
M'\2@Y _,UQ%SX.U1E\QM'LKN$O)LTZ2YVI 62,*X.,938PZ=^,5;'@B\.H"_
MF6&>]CN+-HKDN=XCCQYH!ZC(R,=Z .SAT^S6SN+/'FPS,YE1WW9WDDCZ<]*H
MV'A7P_IA*V=A#&P=9#\Q8AE^Z<DD\9X^M8?@GP[J6BZMJ,UQ916MM.!M!>.2
M1FW,<ED52>O5LFL.+P9KRZ[J5Y+9H8[F*>*3R[E%,P?[OS;-W8<.3^5 '<7?
MA7P_J:H;G3H)@DC2 Y/WF.6S@\Y/.#Q3M6M]"N5T^WU)(74W 2T5CTDVM@#'
M^R&K'\*Z%J6E>&+ZQN[6*/S"WDP0LB-@K@Y9%"Y)[X^N:YW3? VJ6]KIWFZ5
M8D66IQW"0NT88((V5F+1H 2"5/3/R]>E '<:EIWA^'3Y&OK>W%LD(MSG^%-V
M0HQR.>F.<U:L]'TRRTZ33+:!1:R*P>$N6R&'.<DGFO,K7X?:V3JANM/MI(IX
MAM@DG0B:02APQ(0'H",MD\U>L? ^NP>(+RX=R@G\[;=1R1#"ODK&P";R%X7[
MW;B@#I+'PKX0BNKO3[.P59%A43(LLF C'@ [L?P]O2I++P]X3U?1+46]C%+9
M*QEB!9@02>223N_.JG@KP]=Z/?ZC/-I=KIL,T,,:0V\WF!V3=N<\ #.1[\<U
MDK\/[V#0_)L!!9:A/920W-Q$W,CELJ"<<CM[4 =E<>']#N].>RELK<VDDOFE
M%^4;^F1CH<<<5%<:%H$5K!OTV*2.RB:&)$0N41QM90!SR.M<EH?@>]06<6HV
M:"UAO&G:VDDB9%^3 *K&BK][!QCJ,U2TSP'K]F;^.4[Y)4*F?SHU6<[\@L%0
M/G'=B: /1ETG2_[/M]-6UA^R6P3RH!]U-OW>/:J/B7PO;>(K1U++!=,JH)]F
M_P"4,&VD9&02/45B:-X0N=(U.VU1+2W-X)+QKF19,-,KOF($XYP/7I7;H6,:
MEUVL0,KG.#Z9H YBP\!:-;:+;Z==PBZ\F1Y?,RT?S.<MC:<@9[9-;46BZ;#G
MR[2,9F%P3ZR!0@;Z[0!^%7Z* ,M/#FD1Z,^D)8QC3W)8P G&2<G'.1SSQ54^
M"_#K6/V-M+B,'F^:5+-G?C;G.<] !UK>HH R/^$7T/\ M%;\Z9 ;E8_+#8XV
MXQC;TZ>U9MY\/]#N;2.UA@,$ N8[B5 [,)-F<+RWR]>HKJ:* ,27PAH$UO;V
M[Z;'Y=M&T<05F4JK$$C(.>2!5NRT/3=.TV33[6T2.UDW;X\EMV>N23DUH44
M9EMX=TBSMS;V]A$D1*,5Y.2@PO7T %%EX=TK3M1EO[2T$5S+G>RNV#DY/RYP
M/P%:=% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% 'EV@ZI8W'Q(N_[,UN5[2S\_\
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MO"FFV_V>VN_$6N,)I5BBB:Y5AN()'&SCH>:D_P"$.LVOG5]=U\36Z*1,]P
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M0%_#?7I$\%HT+17$4!B<Y99%&UCZD'K4;Z?IKK%#)9VC",?ND:)?E^@QQ^%
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MME87(M8;>Y1,0Q[)74M'N^9A)D<Y_@(Q@YYK2\<>([KP[I]J]FUNLUQ*4!F
M. %). 60$\=V'X]*Z!-/LH[@7$=G;I,!@2+$H;&,8SC/2I+BUM[N,1W,$4R
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M%KG7-3U59M1O9E@ALH7$<<6V*9VWAB2R!LX"G''/:@#M**** "BBB@ HHHH
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MB#PLVMZ@ER+I(U6)(RC1[L[7W9ZT 4[#PCX'U6Q%U865K<VI) DBF=ER.O\
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M6CW\3HT<<4,K&9W"(X8 AG*]OX0.M '40>+-+^QVL]]=VMDUT^R)'N$;<W'
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M7;/6=,U"[GM+.^@GN+<XECC<%D^HKG]0\)WU[K%[*M[:II]]+%).A@)F&Q0
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M&,C! T/F* K-ZN?E 'K6+_PL5)K2UGL='N+OS;1[N41S1@1(CA&Y)PW)[=:
M-C6[64ZCI5TK2>7&)8'\M22ID4 /^!'ZUS,?@O4A9NG]EZ,C1,A,:NVW4=K9
MS-\N!Z]&Y/7%:MUXNNIM4T^&PL9%L)=02U>]<J5?Y6+*%SN!R ,X[4SQ#XEU
M+2O%]I;+"PTQ+.2XE*["TS[E1$&3E?F8#(]1V!H SD\#:H40[K.#=N;R(G;9
M!NF+A$X' ' X'T%5K#X?ZO;7FHF2=6$T,J)/]H7]]N8,!(@B!(.,9+M@9QUK
MH%\:3F[@T\Z%<KJ<DYBDM?/C_=X02!B^=I!4YX^E,\6^)=3T;4X[6SM \+Z=
M=733D@[&CV8.WJ0-W3OD>AH QY? ^H3^5,FD:'9OLEB\B!FVPADP&4[>I/)
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M"6PF:!HI&M&2]_?EE,F[*\9QT]*R-0\/^)IO&MQ?6UM.L#M(IF\Y-K1F)E4
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'F&E>.#
MJ_Q86VCU5%TPV4JQV@;'SH^-SC'4CD>@KTX$, 000>015>;3[*YF,L]I!+(8
MS$7>,$E#U7)['TJ>.-(HUCC14C0!551@ #H * .5^(5_=Z;X>MIK.YDMY&U"
MUC+QG!*M( 1]".*P[/X@:U=7T48T^P\JZN;RSM0)'WF2'.-W&,-C'%=9XGM(
M+VRMHKC4Y+!6N8U1DBCDWR$X1<.K#.[&#CK68G@>>-HV3Q)?JT;M(A%K:@J[
M?>8?NN">Y[T 8,GQ1O)-'GU&TTM&B26WLU8[FQ<MGS5(')5.!QR2:LWWC[6K
M30M-U&71EM4E:07DD\<A$04\,$7YL-U!-:;>!)7LY;-O$5ZUK,Q>2 VEKL=B
M<DD>5@G/-59? -O*UOI\VN7<BP(7@B:PM2D8SSM_<X'/:@#'N?&_B&SU_4TB
M.FW,+W]I9V<<CNFQ94W;B.I]ZEM/B;J2)YVH:;:&(Q7FU+61B[26XRW4?=;M
MWK=D\!R37GVR7Q#>O= @^>UI:E\CISY6>.U*G@::-D9/$E^K(6*D6MJ"I;[V
M/W7?OZT 8-M\1]=GTJWE;1H([BZOK>UADE$D<++*#SS\Q*D?C3K7QCKNJZYX
M>A5K"VB>]N;:\0,V)&B!'RD]L'(![XK7M_AX+.,1VVNW<*"03!8[.T4"0=&P
M(OO#UI[> G?R]WB&]/ER^>F;2U^63^^/W7#>_6@ \5>+K[1]6;3[""RW0V+7
M\LE[(R!T#8V)CJWUJCX3U75-<\?:Q<SSLFGPVEN8+3S&&SS%#Y9.F[L3^57[
MWP)+J?E_;_$5]=^4=T?GVMJ^P^HS%Q4Z>$+^.>6>/Q7J:32X\R18+8,^.!D^
M5SB@#G= DUC4/%^M3RMJT]I9ZI-&DB:BJ01JH!"&'J1_C3!\4[O^RK2Z^P6A
MFETF>_DB$QRC1L%">P.>]=!9>&KEEF>R\8:D TK&4Q06PW2=R?W7)]ZKQ_#B
M**2:2/6KA'F!65ELK0&0'J#^YYS0!G#XA:O']HLKBRT]=1\RT6%UD?R%6<$@
MR$C(P!CCJ2*H6?C77]/T2ZO'2&] UB[BN)R7ECMHTZ! OS%>P]*Z:7P')<1S
M1S>(;V2.=5657M+4B0+]T-^ZY [>E0O\-XI+9+:36;AH(W,B1-96A56/4@>5
MU/K0!UNGWL.H6-O<PR*ZS1)*"O'# $'!Y'7O6#XWU6:RTR&RLS>BZO91&&L8
MC)-&@Y=E4<]!C/J16SI>EIIL !D-Q<D!9+IXT624#.W=M ' X'%6C;PFY6Y,
M,9G52BR%1N"GDC/7% 'FE_XKU"\L;&XANI[6;[,%N8<;"DRRA7!4\@]:ZGQC
MXAU'P_!;RV5K%+&Y8RR.COL &?NIS^/2MQM*T]Y'D:QMF>0Y=C$N6/OQS3-0
MT;2]6,9U'3K2\,6?+-Q"K[<]<9'% & _C+86'EP,?MJ6Z*'^9T9=Q8#KFL6?
MQ3KU];Z6T#:9'-=W,$END-PQ_=NKG9,.HQ@9QW%=RVC:6VH"_;3K0WB@ 7!A
M7S!CI\V,\46^BZ5:,[6VFV<+/+YS&.!5)?\ O' Z\GGWH QQK&I77@J_O0MM
M#J4$<J':6,0=<\COBL+0O%5[I^DK9WYBFNH;B" 223L[3"2(2%LMSP6(_"N^
M%M L+PB",1ODL@48;/7(]ZJOHFDR7D=V^F6;7,2A$F,"EU4=@<9 H X^+QQJ
M\<'FW=C8A;J!I;/RY&^7$JQ?O<CIEP21V!JJ_BW7[!+Z5DL[F1+L1RF(O+%$
MHC!R@7YN3^5=^=-L3'Y9L[<IY;1;?+&-C?>7Z'N.]4V\+^'VMTMVT/3C#&VY
M(S:IM4^H&.M %+6O$QTGP[9ZXL<<MDP62X?)&V-D)#+^.T<^M<W;>.[W5H8D
M>T2WF@FBAO%BF8>7,YRJ@_Q#;R1ZUZ#-:6US:FUGMXI;<@ Q.@*$#H,'CM48
MTRP!<BRMP9)!*^(E^9QT8\<GWH Y+X=ZG?:E92->WDMRPM;1LR-GEH5+'\3S
M6/I7CG5=-T#S[];>_#1SM 89&>8%92H\T>G(Z>E>D6UE:V:[;6VA@4@+B- O
M & ./0<57AT/2+9[EX-+LHFN5*SLD"@R@]0V!R/K0!D^%O$5[K&EW5Q?V+02
M6[8RL;(LHQGY0WS>W-<O=>.=5M)5U.>.WDMS9R2P6EI(SM\TD:)YJ]0R[N<>
MXKT'3]*T[28FBTZPMK.-SN9;>)4!/J0!4<>A:1%)<21Z79(]R&$[+ H,F[[V
M[CG/?- ''0^.-:N(+&W6PL[:]N9Y(_-O-\4)5$WY /S<@8J5/'=[.([N*UM(
M[.-(#<12R-Y\ADQS"!PRC(Y/H:W9_!?A^9[4?V7:);V[LXM4@01.S#&67&"1
MVK2DT?3);NWNY-.M'N;90L$S0J7B Z!3C('TH XBY\::CYU[:7EM';O'<1K"
MD32(S+YZIGS/NL,$' ]<52C\>:]8VUM;R6L-[>2F69WBCD==@D*A!C[K?7CI
M7?P>']%MGE>#2;&)IF#2%+= 7(.03QR<\_6DG\.Z)<Q>7/H]A+'YAEVO;H1O
M/5L$=3ZT <K/XHU2\US3%C%O:V#ZDELT1E(N2?*+$,O3;^O%3^(?$6IZ-XN9
M8VMWL(])DN/(=B&:02*H.?09Y]LUU']BZ7]O2^_LVT^V1J%2?R5WJ!P &QD"
MI9].LKJ=9[BS@FE1&C5Y(PS!6^\ 3V/<4 96@:O?:B+^VO%LS>6;A#):N6A?
M<H88SSQG!KA])\4>*1;+?22V%TL-G)/<HTC@;5F8?+_MX&.>, 5Z;8Z=9:7;
M_9["S@M8,D^7!&$7/K@5'#H^F6Z2I#IUI&LV?,5(5 ?)R<\<Y- '*:5XYO=3
M\5R:>FER"P6=[?S/*?<K+_$6^[M)].:I^+9]1E\8_9+=]2>%+))/*L]42S"L
M78$G=][.!TZ8KMO[%TK^T1J/]FVGVX# N?)7S!QC[V,]*9J&@:/JTJRZCI5E
M>2(-JO<6ZN0/0$B@#FYO%%]I6N66G2VZC3VCC43R%YI'=ATWK\H.<#GK56/Q
MKK4MM8LEOI#3:E)!]E5;ACY:R;N)!UW#;U''6NNC\/Z-%=Q7<>DV*7,2A8YE
MMU#H!P #C(%/@T72K5G:WTVSB9Y1,Q2!5)D'1C@?>Y/- '(R>--81Y'2RL)D
M<S106Z2-YWF1H6.\=E.T@=^5I="^(,FMZ\NF1VD2^=.YMW#D[[=%&Z3V^;@>
MN*Z^/2=-BU"74(]/M4O91MDN%A42./0MC)Z"EM]+T^S='MK&VA>./RD:.)5*
MIG.T8' SSB@#C_&GB2\L-6MH-/34'6R3[7=?8[=I5(S@))CH"OF'ZA:L7'C.
MX2_DF@2P?2XMBD-,5N)"ZY!0=".G'4\UURVT"/*Z0QJTQS*0HR_&.?7BJR:+
MI4=W%=IIMHMQ"GEQRK H9%] <9 Y/% ')+XPUCRH8&713>7;(T#I<L8HT8$_
MO.X;@].#4L'CJ1["YGEM[:-H;7S5S+\LD@<H0I[KD<?6NC7P[HBV<UFND6 M
M9G\R6$6Z;';U(Q@GWITV@Z/<?9_.TJRD^S+M@WVZGRAZ+QP/I0!R+>,-=G>]
M\NVT^.V,EW;6[[W,BR0@X9AC&#CMS74>%KNYOO"VEW-[+%+=2VL<DC1'()*@
MY_SWS5Y;"S7[MI /F9^(Q]YOO'ZGOZTRRTJPTTL;&TBM@55-L2[5 &<  <#J
M: .&NOB3=6FJ-82:?"9$>6V<B0_\?(YB0>SKW]:@L/$^NV]E=_;_ ")[62>_
M6*5)F693'*V!GH% X&.>!7H+:5I[S-,UC;-*TBS%S$NXNOW6SCJ.Q[4ITVQ*
M;#9VY7+-M\H8RQRQ_$]?6@#@=5\8ZFV@ZM) UI;6\=K-%$_V@BZ258-X?!X(
MS^/>NF\,ZKJEY)=6>K16JSVZQ,KVSL0RN@/.[O6FVB:4]Q)<-IEFTTL7DR2&
M!=S)C&TG'(QVJVEO#$[/'$BNP 9E4 D#@9^E 'G&K^,M9>UU:T*165U$Z&UV
M*X+ 3HIRY^4@AAG;_>JYJ7C76M-LVCEL[%]0CN7B?RO,=-H7<"%'S'T]JZV'
MP_HMN\SP:38QM.092EN@,A!S\W'///UI][H>DZDNV^TRSN5W[\30*_S=,\CK
M[T </IOB:]U;7=-N%N)8;>\:WD^S[^%#P[BOYU>UG7]5TKQ7?FWEM)+&WMH)
M9;>XE*N06;/E =6('?VKKX],L(F1H[*W1DQM*Q*"N!@8X[#BF7.CZ9>7<=W=
M:=:3W,1#1S20JSH1R""1D8H Y70_&]]K'B9['^RY$L2\D:R^4X9"O=B?E(/M
M2^*?&UWH&NPVD-G'-;#RO.;#,W[Q]O;A<=?FZ]JZA=&TM-2.I+IUHM\>MR(5
M\P_\"QFDNM$TF^O8[R[TRSGNHP DTL"LZ@<C!(R.IH S?$NL:GI]WIEEI4-H
M]Q>M*-]TS!$"(7/W>23C%8B^.K^6*"[2TLTMDBMVNHI)&\YVE('[H="!D<GT
M-=N]O!+)'))#&[Q9\MF4$KD8./3(XJLVBZ4]S;7+:;:-/:C;;R&!=T0]%../
MPH YC3/%^J32QSWUC UC.DYA2R#R3YBD*\KCG(!Z5%-XKU!]9EMM,M LUQ)"
MD:ZBSH(]T>[E,94^U=G%96L'E^5;0Q^7G9M0#;DY./3)H-E:-<?:#;0F;(;S
M"@W9 P#GZ4 ><R^.]8MI[B_E@MGMTLDQ:Q%V;SC,T98>JY&?7&*T;/QIK5VE
ME'_9D,4[O*9C,KH&C0;LHIYR1Z]ZZ]M&TMVR^G6C$QM%DPJ?D8Y9>G0GDBBS
MT;2].55L=.M+8(25$,*I@GKC [T </IOC_6=2TF\NX]&PRPI-;EHI%4!C]UL
M\LP'/R]:N:'XDU75_%6G1M+:+:2:?,\T(5T;S5D4<*W/&1U[$UT9\,: ?/SH
MFG?OSF;_ $5/WASGYN.>?6K,.D:9;-;-!I]K$;562 I"H\I6ZA<#@'OB@"[1
M110 4444 %%%% '-^-]*N-7T&.WM[-KS9=PS26ZRB,R(K@L Q(P<>XKBM3\)
M^))K.S^SVLZ6B-*8K!94EDM<L2IW-(H) ]VQ7K-% 'F3>'O$[>-;;4?(G*1L
M@:X>6,[D\O:PX?(^8G*A2.X--B\%ZQ#IMI D4H:2U47O^F'+R^9ECG=UV]Q7
MI]% 'D/BJS3PVHMKJWF?2C)<M96PO#'M;9'M8.S=0V_"DYYX!KJ-7TW5+_X>
MV%I;037%PR0F6/S '(X)SN90WN"17:LBN,,H;'J*6@#R^S\,Z\FG:9'J>F7%
M]Y(D2*-+U8C:-YI*N2&Y&S:, MC;BIW\-:XSZAMT^47TBMY^H?;ODO(R0?*5
M,_*2HVY(7&,YKTFB@#S>WT77+!K:^L='N8K:">7R])^VH717BV$ER^TC?\V,
MG%)_PA^KW$:W-S#)]O@@LQ;,MV?W;K)F;'./N^O6O2:* .9\(Z7-HD-W9-IC
M6\;W<THE$P97!;@XR2,CM73444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%>2>'WAT_P"(MW>-<)=R33WDE^TMJT;Z>BXV?,>2IZ>A[5ZQ%*D\
M*31,&C=0RL.A!Z&@!]%<9\48)KGP6T$$8D>2]M5V$-M(,R9#;>=OKBN)AN]:
M\)6WB3[)80V-]%=6\;6UHI,"0'_EY7?QD\@YX&.: /::*\GU'QAXFLO#.D:A
M+>6RF1IO-%L8GEN54C9L!&W/4$#G.,47/C;7QXJO;:WO1F"_MH(-+:S&^:.1
M07RW52,D^V* /6**\H'C/Q)Y]V5F$MTJ7AFTW[)@V"Q@^7(6ZMG"\'KNXZ5+
M;^)?%4>G:@DU_"UP=)M[^&XN+81)"[G#)Z'VS^- 'J5%>.WNOZCK6B:>[P33
M/);:E&]Q) N]BB@ QLG !Z9'7%5=/\1:N_AV&RCN%U>UAM].8O)98^S2-(JM
M&?[QQSD\C&: /;**\66354:>WM5EBEEN=89)S 7DC*C*[">F?UIMOXEUK3=&
M:XTXK=NFEV"M??9@KH"[J^2>#MQCGZF@#VNBO)]2\8>)K/PMI>HRWMM'O>;S
M3;F*26X1?N% 1MSV('X5Z1>WEU%H$][:6KR72VQEBMW&&+[<A2/7/% &A17B
MFKZ_K^M^$-3MUU-[R-K6WEGEBL]AMY7D"O;X[\$G/7Y?>O1=<LS8_#B]LX 2
M8=/9%$:;3PO8#I0!TU%>.^%;B*Q\/7MQI4OAR#5(].5EDA$N]3\N3+OX_P#K
MU93QOK4^C:>S:A+8PO<SQ7.JS6B2*"B90*%&TJQXSUX]: /6:*\S_P"$E\5R
MW.KW$!,D=AID$\5J+(KY\KIECEOF !YV]>QJFOC7Q%;:5=ZC!<_VS86!MYI;
MF.SV&4.")(@H[J=K9'..#0!ZQ17G_@;7O%.KZO/8ZY$(3I\1%TP@VK,[MF,J
M?3R\9]ZH?$N#5/$6L6NA:597%S]DMGO9/*F$(64_+"=QX."&)44 >GT5Y%JG
MCW6%TBQN(;U=,)T9KM5FMA(UQ<(VUHSGIC!/XU9T[QCXJN_&$=E(D*0?N_\
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MS"?QCK#>+(K'SD-M(%CDM@B@KNCR6Y^?J>".*T_AEYO]GR>;YN?LMG_K,_\
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M((STH VO^$-\/_O3]HU#]U_K/^)O<?)QGG]YQQS50:#X.-D;T:O,;16V&?\
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M!PK>+-0U+6+%$FL[6U-]%";82$7+YC#[NN"GS8QCMUJOKNKZ\GBJ^LK74;9
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M:%AKVMWGBG2[6[N;&%4ENH+B.(,!,R< KD^G8YKL(M'TN"1Y(=-LXWD;<[)
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M3! (91'*4.T[B<XQU [U9O/&%K:WTUJMG>2+&_DBZ5%\DS8R(\[L[NW3&>]
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M@^R&]U$J)!(C^<-R$ K@?+C&#W!J:/P-I4/V40RWL2P*$9$N"HF4,6"R8^\
M2?2NEHH R=.\.:?I?V3[,LH^RB41;G)_UC;FSZ\FJ\OA+3IM7.H/)=8:3S3:
MB8^09,8W[/[WO6]10!SUIX,TNTMY85>[D62"*W)DF+$)&[.@!]BQ_#%0_P#"
M":2+JZF1[J..Y5UDMTD C^88) QD'OUZUT]% %>&T6"0,DDNT1K&(RV5 '?'
MK[U8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^4[?;- 'O0(/0T5YC\,;UK:WN-.M6LKE/-0I% RK)%%C#22,JA7.<=.:].H
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M#D'N* %HHR,XSUIK.JE0S %C@ GK0 ZBBB@ HHSCK2!E;.T@X.#@T +1110
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MP7:P'+K(3G!_B1>:I:_KVI:3XNO@FHVL<)MH$B2=/EMPSD-,WS#*J>O3J.:
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M7":G\-M0+1O90VWE^9,7MHFCC +.&60%XW&X 8X (]: /4%6U1A HA5@N!&
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M>X%<W9_#_4DLFMKIK65$D,,"DDA;98]J Y'))Y(H ['2]2T2[D,5A]G!V1S
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M NAW!)\JXAW2.[""X=-V_&X'!Y7Y1QTH B'C>V>_DC2PNC8PR1QRWY*+&A=
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MM[RZ,BRG<VU226 &".@K'E\*W^K^%O%"7.C/'+>2&XLH;B5?.:7RPOSE6V$
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M@ _=1>W3)XKT&B@ HHHH **** "BBB@#/U?1[;6X(K>]!>V259'@(!27'(#
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M.\3LQ2)"?+<.N=J#/(Y)Y.>M=G10!@2>$[5O#UGH\5W=0I9RI+#.C+Y@96W
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MLIR\8RI^4G)]1G@UIW7A^WN+#3[2*:>W6PD1X6C(+?*,8.0<Y'6M>B@#F)?
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IHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>g2018030121531381231125.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531381231125.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" &Q E(# 2(  A$! Q$!_\0
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M+_PD\/?3]0_[\?\ UZ -RBL+_A*(.,Z?J/\ WX_^O2_\)/!WL-1_\!__ *]
M&Y16%_PE%O\ \^&H_P#@.:4>*+<_\N&I?^ __P!>@#<HK#_X2BWS_P >&I?^
M _\ ]>@>*+8_\N&HC_MV- &Y16'_ ,)1;?\ /AJ/_@,:3_A*;;_GPU+_ ,!C
M0!NT5A_\)1;?\^&H_P#@,:0>*;;_ )\-2'_;J: -VBL+_A*;7_GQU+_P%-'_
M  E5M_SX:E_X"F@#=HK"_P"$IMO^?#4O_ 4T?\)3;8_X\-2_\!30!NT5A?\
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M_P#A*K/_ )]-0_\  9J/^$IM ,FSU ?6V:@#<HK#_P"$IM/^?2__ / 8T?\
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M9_L;_L*0?UK>H **** "BBB@ HHHH **** "BBB@ HI 0>E+0 4444 %%%%
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MI3%<D_ZU0/H: #[!;8.(P,]2#0+&$;>#Q^OUI/)NN?WZ@]N*4QW?&)D]\J:
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M&3'4DL*EW^)!_P LK$\_WB*M_P!D_P#40O\ _O\ ?_6H_LGG_D(7_P#W^_\
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MT 2"XA/\8'UXJ0$,,J00>A%4[Z<QQ 06ZSR$85<9 QZUEF_U![=@^E ;1]T
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MS$%'63G /M4D?BC3'QN>6/)P/,B9?Z5'J6IZ+--IR7$ZNYO%\G:W209QGVH
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MJ'5F+J(;*XD##@XQ_.LRUAF^U;K2(3.NY&N)NA]"/6K[V5U)<1";47W$-E4
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MK_*H/I_GM6[9^&[6WN!<3RRW<RG*O,<X_"K(T>!!B-Y$'H&-._LJ/=GSIO\
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M/J?K70_V5:K!Y."(@/N8&!^&*O5R26,]Y<:A+)=W85+F11MDPJ@8P,?B?SH
MT+CPQH4Q&ZW2*0'AXI#&V?P(J@=*CTP@67B22''(2Z99A^O(J0>'H"(]\9,C
M@X+2'GI[]:E30;15FQ!&50MN#C)XQCK0!ES^,;K1;I8K](]1A=25EL$)((_O
M"F?\+%:4'[+HMW(?1_D_G6_'I5N)(3'%$C."P*(!M'&*F-HGESL024)7:!P2
M: .1M]3U2[@,VJW6J6TA+.8;2(*J+G^]WX[U>MIKS3K%M6TR2\OK925GMKJ7
M<Y([J?Z5TCV2$Q1Y8I("'YZ]_P LUY_<7E[9ZM-I;F2.U6Z) 5"5P>I)]NU
M$EMI^H:[>S:S?1JUTJDPHW*6Z=0,?WJM^'M5N++PMH %N)9+R292Q'*')P0:
MWUU/38=(N+:SE_>K S$,N">.2:P_"1FDT+PI"%_<.999#[J"5_4T =S:6ZVM
MLD0.2.6;U/<U-110 4444 %8'BO_ (];#_K^B_G6_7/^*SBVT_WOHOYT =!1
M1WS10 4444 %%%% &!XD_P"/W0_^O]/Y&M^L'Q%@W^ACO]N4C\C6]0 4444
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MKNE8Y_6I5\)Z& H.GQ,%^Z&YQ6S10!D_\(SHGS9TVW);J2G6FMX5T-@!_9L
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M=WDGEPI]YL9Q5NFNB2*5=%93U##(H P'\;Z!';07$EZ$CN-WE%EQOV]<4_\
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M>]5?!5PYL_#MOGY42X!P.#CI5R[)76&\P*&-DPRIX.35#P.H T8#H(IR.?\
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M=W,4"L< R.%!_.@"Q15)=9TQTWKJ%J5SC/G+C^=.CU.PE!,=[;OC.=L@.,4
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M+^TCN;:0212 %6%2NBR1LCJ&5A@@]Q7&3VLO@N^:]M [Z/,V9X1SY.?XA[4
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M$U75XVBL4.ZULVXSZ,P[^PHTW1[OQ!?QZSKJE(D):ULC]U >[ ]378 !1A0
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M(] 9"?\ &J>I*H3Q!O8AA;KCN<XJSX198I+=BA;;I\8&T9.22: .VJ.24(.
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M1:6C6^F:Q"+-3^Z2>'>RCTSZ5*UMXR4?+J-BY[9A KJ:* .5\OQJIXGTY_\
M@!%&[QJO1--?_>)%=55:^OK?3K22YN95CC0$DL: .6O+[QC;64LEQ9Z0L2J=
MS-.0 /7I6/H.G_\ "8_:;O6=&M[:S('[Z*9QYQ'\6#@?C6K!;W?C:X6YO$DM
M]%0YB@/#3^A/M3O&6IO:6MOX?TE-MW=_(%C'^KC[GCI0!#;^ /!^HPLUH/-3
M)!\N<D5+\-WD_LB^MVFDDBM[R2.(N<D*#P,U0M_!,VGHMUX<NY+.\B0;MQS'
M.<<Y':MCP!I%_I&AS)J<:QW4US)*ZKTY- '5<YZU7D8[R!=HF/X2!Q5FJTC
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M4)^8#M63XC8&?1,'.=1C_K0!OT444 %%%% !1110!AZQ_P C!H/'_+67_P!
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MX5^Q>'KJ>0G!8J8T_,GVZ57;>?\ 6Z9I]N,=7U$MC\ <XYH [^N+O<7/B[4
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MBLF0R#2H\.B@-^\!/7GM3+S488=2$<EY$I*'8.I7WXH UFN$2.9V.%B!+'T
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M61JVEV]QI4EO-$LSSG:SMZGO^%<O:W.M>%;<:=%#+J,$WRV4@'W&_NMCTZT
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M "'TSS56>0!66>,GNA7O_@:?*T3MY<N5Y^4DXKG?$&HM;[;59BSOE 1_AZT
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MK;PE, [7NNZA/(YRYC81!OJ!6YIVFVVEVWV>U5@A8L=S9))ZDD\F@"W1110
M4444 %8/B'_D(:(,?\OH_D:WJP/$/_(1T/\ Z_!_(T ;]%%% !1110 4444
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M_P"]=.?UH U:Y3SFB\2&5IGV_:'1AGC:%ST^M=77$7JR2ZO(D!*S"[8JV_:
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MQRQ/J36S110 4444 %%%% !1110 5@>(?^0CH?\ U^#^1K?K!\0<ZEH8[?;
M?T- &]1110 4444 %%%% &%J0SXLT3_=G/\ X[6[6'J//BO1N,X28_\ CH_^
MO6Y0 4444 ';BN;M6LV\<77D+(+A8 )B>AYXQ725S=C<6L_C2]2*+;-#%ME;
M^]DY% $6EF/[5J!5BK'49-Q!/3CI716VS:=C2$=]]<_I&_?,W7=?RE ">HP#
MFNDC\S!\S;GVH ?6)=:S<0:G-$(4^RV[QK*Y;YOGYR!Z"MNN?%JMY-KL9X+E
M0#C."%XH TY)\_:(S*BG *'-5_M\(E# EP5V.HZY]ZY2*+4-02-C(=G3.=N>
M>M7[#16M'>X=F8C&Y=QV_C[\T :K7OE*JDHK0-C)/)/I_*HS<22.R1K(^\;B
M%7 JREFR2NG[M"R;V '7MUI\=J'%K(QDDR23D]#_ (<4 9\IGEBZ ;@?G>3H
MW;(%84>GZO) B3S[)(B6 67;^/R^N>]=B++Y"/+SB7/)^\*G^RC,_ &\ *?3
MB@#C5\-74[ 2,@=AN9OF<_CDBID\--)&!)*6+@JNU53/'?@XKL%AP\;D\HNV
MD6W1411_ VX&@##M=*BL;1H88E,4;E06^8YS[U:-D1-("(=P3+L(P,UJ&",A
M@5R&.2/6G;%W,VT988)H RT@D)MP)<;P=F!]SY:@FTZ&9'DFCC<K)M)= Q)R
M.>>M;810% 'W>GM2A0.@ZG- '-VYL=$UR_:66.&-HD;E0N?ICK5SPQ)]HT<7
M 4J)I'< C'!/%:<UK;W!S-!&Y'0LH-2(B1H$10JJ,  <"@!U<S'IUQ)XCF,M
MLWV<R,Y<_=8$8Q7344 9OV$?(QCRPEY_W:#IZKY^V+)'^K/?WK2HH I+9J)@
MIC_=F,AOKZ5 EFL=BJK'M=\(P![ G K4HH Q$LYO[9N 0PM$B4Q 'JV<FK'V
M;8D4OS;V=<CJ%^@J&RN)7\2ZA"TC&..--JYX!-;- &<+0F9E$LBK$H&XG);O
MW[5''$_E0?O"5D/"GH,$FM7OFDP...G2@#/C2>.Y<F?.S:SDC[PQT]*IG3(B
MEJS6ULR%A\IA!).2>M;>Q>>.O6@QH552HPI!4>F* ./G@4:RMLL<<1DDC!6-
M<+E>?\*[*J7]EVG]H_;]A,^,9)X^N/6KM ",P52QZ 9->=-:++YB)N'GSAB
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MOH:V,@+D],9K-U73DO\ 1FAD&)$CW(P'*L!U'I3-,O'N_#JSR_ZP1D/CU H
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M:0(1CIR1_/\ .K=M:0Z:QCMX $894*/SYJ^I)4$C!/:@#._L:Q:1'N$6:5>
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M<9QFNFL8I8;1%F;=*?F;V)[4ZSLX;&U2W@7:B# ]ZGH **** "BBB@ HHHH
M**** "BBB@ HHHH *P==XUG0SC_EY/?_ &:WJPM=_P"0OHGJ+D_RH W:***
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M5KJ2Z];7]G9_:H5@:*1!*$.=V1UZBIO[4UT<#P_]/])6@#>J.:7RH]V"22
M.YK$_M;7L?\ (OG_ ,"5H_M77?\ H '_ ,"5H W4+% 7 #$<@4ZL ZMKO;P^
M?_ A:/[6US./^$?;_P "%H WZ*P/[7UOC_B0/_W_ %H_MC6L9_X1^3_O\M &
M_16!_;&LYQ_8$O\ W^6C^V=9_P"A?E_[^K0!OT5@?VQK.?\ D R?7S5H_MC6
M?^@!+_W]6@#?HK _MC6/^@!+_P!_5I?[8U?_ * ,W_?Q?\: -ZBL$ZQJ_P#T
M 9O^_B_XTG]LZMG_ ) $_P#WVO\ C0!OT5@?VSJX_P"8!.?I(M+_ &UJV?\
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MHK _M[4/^@!??D/\:/[?O_\ H 7WY#_&@#?HK _M^_\ ^@!??D/\:/[?O_\
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M_8%]P/0?XTO]O7^?^0!?'\!_C0!OUA:U_P AS0QG_ENW&?\ 9_S^5)_;U_\
M] &^_(?XU5::_P!4US37;2[FWBMW9WDEZ=,#CZT =11110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4=112,RJ 6(&3CF@!:*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "J&K?\ 'O#_ -=X
M_P"=%% %V/\ U:_04ZBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
..*** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>g2018030121531722631136.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531722631136.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" -2 H(# 2(  A$! Q$!_\0
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MV\L+_9S(N_\ B4]Z -H$, 000>A%+6-HVHI);VUK%'))LB7?(,;5..A]ZV:
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MBBB@!&57&&4,/0C-(J(OW549]!3J* &JB)G8BKGK@8S0$4,6"@,>I Y-.HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MN<XH [6BN>T6S\1VMXKZCK4&HV<L.2K6RQ21O_L[>"OUYKH: "BBB@ HHHH
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MVY?GYB.U$7BCQ7J;:? -0>Q#Z=<W)F2U1C/Y3$(^&& &4 X]^* /7Z*\?O\
MQSKD5IX;U*6_$<%W8QR3V=MY0GEE+ '"N"2I'9<&O7HVWQ*^"-P!P>HH =11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %<]XMUR\T.RMY;5;5/-EV27-X6$$ P3ERO(R
M< >YKH:R];TN[U*&,66IR6$R'[PC65&'<,C<'^E & OC"Z318+J5M-EFD$I1
MK9V>*X"@<H?X1S@AN>*F@\;VD=H\UX6DE\Q46WLX'DDR8U=N.^ <DCC&*:/
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M*&\R-02R?Q(<]F'6L?Q-\/XO$=Y!(;Y8+>*!81 ULL@4 YRI)RI[?@* '?\
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MNIHT"M.R!2_N0*LT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MP7<(ME\N\!%P,G]YQCGGTJO_ ,(QHOD10?V=#Y4-LUK&G.%B."5'/J!SUXH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MX1U*%8K*"/2WM)$C$]RZLMPFT[CM(!##.<9(QFNYHH XY? <=MXMM-:M=2U
M(DDDL\+W1*LS  8&.G'(^E=C110 4444 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M&IJY3PE"=.T;35U&&Y@NH[+:[SG"*-_W6YV[^G;.*Z+^T;'_ )_;?_OZO^-
M%FBJW]HV/_/[;_\ ?U?\:/[1L?\ G]M_^_J_XT 6:*K?VC8_\_MO_P!_5_QH
M_M&Q_P"?VW_[^K_C0!9HJM_:-C_S^V__ ']7_&C^T;'_ )_;?_OZO^- %FBJ
MW]HV/_/[;_\ ?U?\:/[1L?\ G]M_^_J_XT 6:*K?VC8_\_MO_P!_5_QH_M&Q
M_P"?VW_[^K_C0!9HJM_:-C_S^V__ ']7_&C^T;'_ )_;?_OZO^- %FBJW]HV
M/_/[;_\ ?U?\:/[1L?\ G]M_^_J_XT 6:*K?VC8_\_MO_P!_5_QH_M&Q_P"?
MVW_[^K_C0!9HJM_:-C_S^V__ ']7_&C^T;'_ )_;?_OZO^- %FBJW]HV/_/[
M;_\ ?U?\:/[1L?\ G]M_^_J_XT 6:*K?VC8_\_MO_P!_5_QJ:.6.9-\4B2+_
M 'E;(H ?1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8GB'7
MI]&>QAM-,DU"YO)3''$DJQXPI))+<=JVZY[Q-I>JWMSI=YI!LC<64S2%+MG5
M6!4KU4$YYH ?9>*;9K*ZFU:/^R9K-@MQ%<R+A,]"&'# ^HJS/XGT*ULX;N?5
MK..WG&8I&F 5_H>]<KJO@C5]:LWN[J^ACU9KE)PEO*Z0A4! 3?C=W)SBLQ?"
MVMZ=J.E06MI92W"PW'F-=2RS0C?U^<KD'VQ0!Z#/K^D6MY;6<^I6L=S= &")
MI0&D!Z;1WJ";Q-I*R7MO!?VLU[9Q/));"=59=HR<Y^[]3TKEAX%U2T@^PVEQ
M8S6MS!!#<SW 82P^6H4F$ 8Y SR1S3)? ^LS7FJ".XM;6TNX)XPB7$D@D+H5
M!9"N%Y()()Z4 =':>-=#N/MQ>^MX18[/M#/*-J%AD<^GOWJW-XAT+[+;O-J=
MF8+T%82THVS#N!ZUR[>"]6B?S+=].=H9H+F!9-P61TCV,LF!]WN",FKFD^$;
MVUU:UU.[:R:95G:2&)3Y:.^,!,C[O% '0Z/IND:=:'^QK2UM[>8[S]F0*KGI
MGCK6C6==ZFFCZ2+O4(V^7"NMI"\O)]%49Q^%8W_"P=$_YY:K_P""NX_^(H Z
MJBN5_P"%@Z)_SRU7_P %=Q_\11_PL'1/^>6J_P#@KN/_ (B@#JJ*Y7_A8.B?
M\\M5_P#!7<?_ !%'_"P=$_YY:K_X*[C_ .(H ZJBN5_X6#HG_/+5?_!7<?\
MQ%'_  L'1/\ GEJO_@KN/_B* .JHKE?^%@Z)_P \M5_\%=Q_\11_PL'1/^>6
MJ_\ @KN/_B* .AOM/L]3M'M+^VBN;=\%HI4#*<'(X-8__"">$_\ H7-+_P#
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MM;QG_P!"K8_^#7_[71_:WC/_ *%6Q_\ !K_]KH ZJBN5_M;QG_T*MC_X-?\
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M-!T^]^Q7FL6,%UD#R9)U5N>G!-:U !1145S<P6=M)<W,R0P1C<\DC851ZDT
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MJ\,6GPQ#RV5QL5 ..>F,4 <"=2U+Q%J=PMG<ZQ;Z;+>P1K(D;PL$\D[]NX9
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MRMP&;'8$Y)]JVVOK-+M;1[J!;EAE83( Y'LO6DBU&QGN&MXKRWDF09:-)5+
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M;^8=+NF=A%Y488;I"Q(<#_<VDGUH S]1^'U[=W<L=I)'867VR6>);=@H"F-
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MF##?1"0337*Q*,L5*KN^^00>GMZUT>JZ[!H]U;QW4;+!,DC>?D;4*C.#]>U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M ,&L_P#\57544 <K_P (#IO_ $$==_\ !K/_ /%4?\(#IO\ T$==_P#!K/\
M_%5U5% '*_\ " Z;_P!!'7?_  :S_P#Q5'_" Z;_ -!'7?\ P:S_ /Q5=510
M!RO_  @.F_\ 01UW_P &L_\ \51_P@.F_P#01UW_ ,&L_P#\57544 <K_P (
M#IO_ $$==_\ !K/_ /%4?\(#IO\ T$==_P#!K/\ _%5U5% '*_\ " Z;_P!!
M'7?_  :S_P#Q5'_" Z;_ -!'7?\ P:S_ /Q5=510!RO_  @.F_\ 01UW_P &
ML_\ \51_P@.F_P#01UW_ ,&L_P#\57544 <K_P (#IO_ $$==_\ !K/_ /%4
M?\(#IO\ T$==_P#!K/\ _%5U5% %>QLTT^RBM(GE=(EVAII"[GZL>35BBB@
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M'88HK<1J7SG< "<<<8K6HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH *KWUQ+:6,L\%K+=R(,K!$0&?V&X@?F:L44 <K_P )3K/_ $)6
MK_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_
M ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3
MK/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K
M_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_X
MY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K
M_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_
M $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\
M?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4
M?\)3K/\ T)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\
MT)6K_P#?Z#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?
MZ#_XY7544 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY754
M4 <K_P )3K/_ $)6K_\ ?Z#_ ..4?\)3K/\ T)6K_P#?Z#_XY7544 16TKSV
ML4LD+P.Z!FB<@LA(Z''&1[5+110 4444 %%%% !1110 4444 %%%% !1110
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MB'_H=K__ , [?_XB@#JJ*Y7_ (1KQ#_T.U__ . =O_\ $4?\(UXA_P"AVO\
M_P  [?\ ^(H ZJBN5_X1KQ#_ -#M?_\ @';_ /Q%'_"->(?^AVO_ /P#M_\
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MW,T<,*#+R2,%51[D\"@"6BLC_A*_#G_0?TK_ ,#(_P#&C_A*_#G_ $']*_\
M R/_ !H UZ*R/^$K\.?]!_2O_ R/_&C_ (2OPY_T']*_\#(_\: ->BLC_A*_
M#G_0?TK_ ,#(_P#&C_A*_#G_ $']*_\  R/_ !H UZ*R/^$K\.?]!_2O_ R/
M_&C_ (2OPY_T']*_\#(_\: ->BLC_A*_#G_0?TK_ ,#(_P#&C_A*_#G_ $']
M*_\  R/_ !H UZ*R/^$K\.?]!_2O_ R/_&C_ (2OPY_T']*_\#(_\: ->BLC
M_A*_#G_0?TK_ ,#(_P#&C_A*_#G_ $']*_\  R/_ !H UZ*R/^$K\.?]!_2O
M_ R/_&C_ (2OPY_T']*_\#(_\: ->BLC_A*_#G_0?TK_ ,#(_P#&C_A*_#G_
M $']*_\  R/_ !H UZ*R/^$K\.?]!_2O_ R/_&C_ (2OPY_T']*_\#(_\: -
M>BLC_A*_#G_0?TK_ ,#(_P#&C_A*_#G_ $']*_\  R/_ !H UZ*R/^$K\.?]
M!_2O_ R/_&C_ (2OPY_T']*_\#(_\: ->BLC_A*_#G_0?TK_ ,#(_P#&C_A*
M_#G_ $']*_\  R/_ !H UZ*R/^$K\.?]!_2O_ R/_&C_ (2OPY_T']*_\#(_
M\: ->BF12QSPI+#(DD;J&1T;(8'H01U%/H **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHKD_&_B6Y\.IIWV>ZL+074YC>
M>]1W1 %)Z*0<\4 =917#Z-X[4Z'/?ZG-;WD8N?(MI]-C;9=$C.U%8Y)'.>>U
M,U#X@K_:6B)81LEC=>;)>7$\!(A2/[RG!^5O7.0.* .[HKE(_B#H[V$UTT-]
M&8GC7R'@_>OO("E5!.02<9J5?'6DG4H;)X[N)I"J-))%M2)VZ(YSPV>,>I%
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M&4'^-=310!RW]O\ BG_H29?_  90?XT?V_XI_P"A)E_\&4'^-=310!RW]O\
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MC /3(P<=LUOUBZMX3T;7+L76H6TLDP0("MS+&,#V5@.]4/\ A77AC_GQG_\
M Z?_ .+H ZFBN6_X5UX8_P"?&?\ \#I__BZ/^%=>&/\ GQG_ / Z?_XN@#J:
M*Y;_ (5UX8_Y\9__  .G_P#BZ/\ A77AC_GQG_\  Z?_ .+H ZFBN6_X5UX8
M_P"?&?\ \#I__BZ/^%=>&/\ GQG_ / Z?_XN@#J:*Y;_ (5UX8_Y\9__  .G
M_P#BZ/\ A77AC_GQG_\  Z?_ .+H ZFBN6_X5UX8_P"?&?\ \#I__BZ/^%=>
M&/\ GQG_ / Z?_XN@#J:*Y;_ (5UX8_Y\9__  .G_P#BZ/\ A77AC_GQG_\
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M3<,9R,>N:7- !12;@.I'YU7LKZVU"$S6LHDC#LFX="5.#^M %FBBB@ HHHH
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M+O#7_0PZ3_X&Q_XT?\)=X:_Z&'2?_ V/_&K/]A:/_P! JQ_\!T_PH_L+1_\
MH%6/_@.G^% %;_A+O#7_ $,.D_\ @;'_ (T?\)=X:_Z&'2?_  -C_P :L_V%
MH_\ T"K'_P !T_PH_L+1_P#H%6/_ (#I_A0!6_X2[PU_T,.D_P#@;'_C1_PE
MWAK_ *&'2?\ P-C_ ,:L_P!A:/\ ] JQ_P# =/\ "C^PM'_Z!5C_ . Z?X4
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M#I/_ (&Q_P"-'_"7>&O^AATG_P #8_\ &K/]A:/_ - JQ_\  =/\*/["T?\
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MV=K.D"6YB#')16.7W<G+8X]*[&@ HHHH **** "BBB@ HHHH **** "BBB@
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M!3)*06? ZG'<U+110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC@MXAEY)#A5'N:GI&574JZAE/4$9!H YW_A/_"/_ $,>F_\ ?]:/^$_\(_\
M0QZ;_P!_UK<^QVO_ #[0_P#?L4?8[7_GVA_[]B@##_X3_P (_P#0QZ;_ -_U
MH_X3_P (_P#0QZ;_ -_UK<^QVO\ S[0_]^Q1]CM?^?:'_OV* ,/_ (3_ ,(_
M]#'IO_?]:/\ A/\ PC_T,>F_]_UK<^QVO_/M#_W[%'V.U_Y]H?\ OV* ,/\
MX3_PC_T,>F_]_P!:/^$_\(_]#'IO_?\ 6MS[':_\^T/_ '[%'V.U_P"?:'_O
MV* ,/_A/_"/_ $,>F_\ ?]:/^$_\(_\ 0QZ;_P!_UK<^QVO_ #[0_P#?L4?8
M[7_GVA_[]B@##_X3_P (_P#0QZ;_ -_UH_X3_P (_P#0QZ;_ -_UK<^QVO\
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M ,(_]#'IO_?]:/\ A/\ PC_T,>F_]_UK<^QVO_/M#_W[%'V.U_Y]H?\ OV*
M,/\ X3_PC_T,>F_]_P!:/^$_\(_]#'IO_?\ 6MS[':_\^T/_ '[%'V.U_P"?
M:'_OV* ,/_A/_"/_ $,>F_\ ?]:/^$_\(_\ 0QZ;_P!_UK<^QVO_ #[0_P#?
ML4?8[7_GVA_[]B@##_X3_P (_P#0QZ;_ -_UH_X3_P (_P#0QZ;_ -_UK<^Q
MVO\ S[0_]^Q1]CM?^?:'_OV* 'V]Q#=6\=Q;R+)#*H='4Y#*>014E( %4*H
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MI):N+Q2&WI/(@)'0E58 _B* .>LO'.H/''>7NDP1:?/%,T+Q7!>0M&V,,N
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M!U5%<K]A\<_]!S1O_!<__P <H^P^.?\ H.:-_P""Y_\ XY0!U5%<K]A\<_\
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M"Y__ (Y0!U5%16RSK:Q+<NDDX0"1T7:K-CD@9.!^-2T %%%% !1110 4444
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M(X_&DMTWVD2/,[+?Q11;2A0A59R^_:.. O85ZMTHH \\\'Z!=Z?X@AG?0Y;
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M>)G#QIL8*-H"Y1V4-]<\5W-% 'DDOAK7B^A.VESSWMI D323+$\28;CDN&3
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:/\ A/=._P"@9KW_ (*IO_B: .JHKE?^$]T[_H&:]_X*IO\ XFC_ (3W3O\
MH&:]_P""J;_XF@#JJ*Y7_A/=._Z!FO?^"J;_ .)H_P"$]T[_ *!FO?\ @JF_
M^)H ZJBN5_X3W3O^@9KW_@JF_P#B:/\ A/=._P"@9KW_ (*IO_B: .JHKE?^
M$]T[_H&:]_X*IO\ XFC_ (3W3O\ H&:]_P""J;_XF@#JJ*Y7_A/=._Z!FO?^
M"J;_ .)H_P"$]T[_ *!FO?\ @JF_^)H ZJBN5_X3W3O^@9KW_@JF_P#B:/\
MA/=._P"@9KW_ (*IO_B: .JHKE?^$]T[_H&:]_X*IO\ XFC_ (3W3O\ H&:]
M_P""J;_XF@#JJ*Y7_A/=._Z!FO?^"J;_ .)H_P"$]T[_ *!FO?\ @JF_^)H
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M=._Z!FO?^"J;_P")H ZJBN5_X3W3O^@9KW_@JF_^)H_X3W3O^@9KW_@JF_\
MB: .JHKE?^$]T[_H&:]_X*IO_B:/^$]T[_H&:]_X*IO_ (F@#JJ*Y7_A/=._
MZ!FO?^"J;_XFC_A/=._Z!FO?^"J;_P")H ZJBN5_X3W3O^@9KW_@JF_^)H_X
M3W3O^@9KW_@JF_\ B: .JHKE?^$]T[_H&:]_X*IO_B:/^$]T[_H&:]_X*IO_
M (F@#JJ*Y7_A/=._Z!FO?^"J;_XFC_A/=._Z!FO?^"J;_P")H ZJBN5_X3W3
MO^@9KW_@JF_^)H_X3W3O^@9KW_@JF_\ B: .JHKE?^$]T[_H&:]_X*IO_B:/
M^$]T[_H&:]_X*IO_ (F@#JJ*Y7_A/=._Z!FO?^"J;_XFC_A/=._Z!FO?^"J;
M_P")H ZJBN5_X3W3O^@9KW_@JF_^)H_X3W3O^@9KW_@JF_\ B: .JHKE?^$]
MT[_H&:]_X*IO_B:/^$]T[_H&:]_X*IO_ (F@#JJ*Y7_A/=._Z!FO?^"J;_XF
MC_A/=._Z!FO?^"J;_P")H ZJBN5_X3W3O^@9KW_@JF_^)H_X3W3O^@9KW_@J
MF_\ B: .JHKE?^$]T[_H&:]_X*IO_B:U]'UN#6XI9(+:]@$;!2+NV>$G/H&
MS0!IT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&9+55MI)$V^9&@R#C /OCWKG?^$:\0?]#MJ'_@);_P#Q% '545RO_"->(/\
MH=M0_P# 2W_^(H_X1KQ!_P!#MJ'_ ("6_P#\10!U5%<K_P (UX@_Z';4/_ 2
MW_\ B*/^$:\0?]#MJ'_@);__ !% '545RO\ PC7B#_H=M0_\!+?_ .(H_P"$
M:\0?]#MJ'_@);_\ Q% '545RO_"->(/^AVU#_P !+?\ ^(H_X1KQ!_T.VH?^
M EO_ /$4 =517*_\(UX@_P"AVU#_ ,!+?_XBC_A&O$'_ $.VH?\ @);_ /Q%
M '545RO_  C7B#_H=M0_\!+?_P"(H_X1KQ!_T.VH?^ EO_\ $4 =517*_P#"
M->(/^AVU#_P$M_\ XBC_ (1KQ!_T.VH?^ EO_P#$4 =517*_\(UX@_Z';4/_
M  $M_P#XBC_A&O$'_0[:A_X"6_\ \10!U5%<K_PC7B#_ *';4/\ P$M__B*/
M^$:\0?\ 0[:A_P" EO\ _$4 =517*_\ "->(/^AVU#_P$M__ (BC_A&O$'_0
M[:A_X"6__P 10!U5%<K_ ,(UX@_Z';4/_ 2W_P#B*/\ A&O$'_0[:A_X"6__
M ,10!U5%<K_PC7B#_H=M0_\  2W_ /B*T]'TK4M/EE:^UZYU)74!5FAC0(?4
M;%'ZT :]%%% !1110 5P5U=WMAX^U748YY'L[2"$75L6)41%22ZCL0>3Z@&N
M]J(6T EDE$,?F2@+(VT9<#H">] 'D=GXVU72?!NB/9,ER&M9+F9Y(S,[KYC8
MS\PVC'?GZ<5OMXM\0W5](;(:<EJ;Z&R1959FS)&KAB0<<9Z8YKKIO#>AW"0)
M-H]A(L"E80UNI$8/4+QP*MIIUE']RT@7YQ)Q&!\P& WU XS0!YU>>/==@MK6
MVC@ADOO-F2:>*U9XV\MB  I<$9QW)KH-=UJXD^'PNY(&L[R_B2%8VDVB*63Y
M1N<=!D\FMZZT+2+Z 07>F6<\(<R!)(59=QZM@CJ?6ISI]D=/_L\VD!L]GE_9
MS&-FWTV],4 <A\-KP+IEQI$\CM?VDFZX4.7B0M_#&Y)+*,=?>F2>%-(/CM%*
M7>&@-P5^VS;=^[KC=C\.E==9:/IFFX^PZ?:VV%VCR8E3 ZXX%6?)B\_S_+3S
M0NW?MYQZ9H \;N]:U6YL;QDOH;6T^Q2,L$;/OW"Y9=RL6SGCG^E=-I_C?6+[
MQ<]DNGL-/6Z>U*F##+MX\PR%^1GG&WI79/H>DR%"^F6;%%95S"IP&.2!QW/)
MH?0M)DU+^TGTRT:^'_+P85\SIC[V,]* +-F96LXC/+%+*5^9X1A&/J.3Q^-3
MU1N]/=]*-EIUR=-( $<D$:GRP#T"L"/;I6'_ ,(UX@_Z';4/_ 2W_P#B* .J
MHKE?^$:\0?\ 0[:A_P" EO\ _$4?\(UX@_Z';4/_  $M_P#XB@#JJ*Y7_A&O
M$'_0[:A_X"6__P 11_PC7B#_ *';4/\ P$M__B* .JHKE?\ A&O$'_0[:A_X
M"6__ ,11_P (UX@_Z';4/_ 2W_\ B* .JHKE?^$:\0?]#MJ'_@);_P#Q%'_"
M->(/^AVU#_P$M_\ XB@#JJ*Y7_A&O$'_ $.VH?\ @);_ /Q%'_"->(/^AVU#
M_P !+?\ ^(H ZJBN5_X1KQ!_T.VH?^ EO_\ $4?\(UX@_P"AVU#_ ,!+?_XB
M@#JJ*Y7_ (1KQ!_T.VH?^ EO_P#$4?\ "->(/^AVU#_P$M__ (B@#JJ*Y7_A
M&O$'_0[:A_X"6_\ \11_PC7B#_H=M0_\!+?_ .(H ZJBN5_X1KQ!_P!#MJ'_
M ("6_P#\11_PC7B#_H=M0_\  2W_ /B* .JHKE?^$:\0?]#MJ'_@);__ !%'
M_"->(/\ H=M0_P# 2W_^(H ZJBN5_P"$:\0?]#MJ'_@);_\ Q%'_  C7B#_H
M=M0_\!+?_P"(H ZJBN5_X1KQ!_T.VH?^ EO_ /$4?\(UX@_Z';4/_ 2W_P#B
M* .JHKE?^$:\0?\ 0[:A_P" EO\ _$5KZ/IU]I\4JWVL3ZDSL"K31(A0>@V
M?K0!IT444 %%%% !1167K7B'3/#\4,FI3O&)WV1A(GD9FQG "@GI0!J451TK
M6+#6[3[383^;&&VL"I5E/H58 @_45/)=P17<-J\H$\P8QIW8+U_G0!/1110
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MA?TK_P  H_\ "@"?^W]&_P"@O8?^!*?XT?V_HW_07L/_  )3_&H/^$2\-_\
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M  )3_&H/^$2\-_\ 0OZ5_P" 4?\ A1_PB7AO_H7]*_\  */_  H G_M_1O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
..**** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>g2018030121531380031124.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531380031124.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %= EX# 2(  A$! Q$!_\0
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M&EN)J,XM+4F)4\SCMTK/MM9N3O5B#\N5P.]+?7,5EJ-S"X++NV<C)JO&(O,
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MI97.U&4'UJ=5+XQTK&UMPN/$S$XQ45RV0@'!SS5M+9L@XJ"_P&4XYSBE%IR
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M(2YD2QE.#X&-N?>E44Y0V.!^E6 Y)%W F)3VP:C:XG:Y*>2@C'?%2!7 +."
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M2&-N+.66;9<R[]G4K]TFJ%Y:K$N<?Y]_:NA5<2;EY_K4%_ LB,Z#Y>A'I_\
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M,#J/&5O)/#IX2,N=N  /:L&^BC\-6&?E;49QP"/N"NXUK4$T[3893&7D*@*
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M3 5=_P!X=/H:4CRI=N?D;O4@M9G22-5P,<.>@I#.ML=5T\6,5NTJ(Y3 ]C7
MZC#=MK,LC2EP&PIZC'M51('_ 'B-<@L>,BKEC)<P'#D/&I!YYKGD]=#1(K7%
MM)<3$3R'9&N$7-,AMA P*$@YSFMS6DM+MXIK5#&X7Y_>LU4)Y/0"LI2=[#2.
M@T68S:7/N&,2@'\JM'IUJKH/E?V)<NIY,PX/TJT2"*Z*7PF<MR,D]!5O2T/V
MEC_L'^8JH:N:7_Q\M_N'^8K01>\1Q>;:Q@<?/UKFS;)G'F GZ5U6LD"V!()
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M-AM*GK@#!%+O"E\#[W!HL [Y%BC?RH^2<_+6:MT8]2E/E!(W.,"M-679L*9
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M0*: +!E J)G!.<4W:3UHVT !8'K2[QG_ !IF*,4@%.W?E5 ^E.W#C%,HH22
ME\P>E)A)#\T:L/0]JCHSQBAZ@7K=Q# 8EC7!(-6WO$=E;R%X'W?6L8$^IIPD
M<=Z8K%\7"JKB2(,2,*?[M2M<6\KQAD8I_$*S/-;N:42N,GCBBX6+I6$\,Q4
M$K]:L,(9$1%F4!R W^S63YS$\XI5?&3ZT7"Q=%D'N759U*)D@GO5J.)Q&L@'
M&."!TK)WD4HG=#PS#\:'J"N2NDJ%F'##+ XY%8\5Y(UVLMS/-(">036N+B4_
M><GVJ.20$\(G_?-1)-[%(U+K2)8;%+^&16A<9Z\BLO=DY/6E:>9H]A<[!_#G
MBHCPOUJE>VHF#MNZ4(0IR5R/2F@5(/E^8@$>],"1?(;JK+]#2K(2D@V*R(V
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MKF$\,O\ ,(KC;)_=<<'\:S<+#,( K%\K9-3*RJ<9)&,\5;NM-EL6V7,3#/\
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M#^''-7L!MK@*01SZTQYH85S*ZCUR:Y*?Q3<W+&.QM6(/0XJI_9>J:FY>ZF9
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M\ _^O1SL#43Q-=KR3'BM"#Q:6B82A W8YKFO[!YQ]IZ?['_UZ3^P=IS]I_\
M'/\ Z]/F Z9_%*QQYV!G^O%1P>+XS-MN$4(?0USG]A.P&;PE<]/+_P#KT_\
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MD9[I_P#7I@L6N%V2394?[/\ ]>ER1N*YS?\ 9/VE0652#4\&B) ,K]ZNA33
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M]+DC>X796EGDE)&0JDY('>D0;B >!6BND#_GM_X[_P#7I_\ 9F!N\[I_L_\
MUZ>B%N<S?2%[H1JW[M.ON:2&S%Q,'#?(G4>M:SZ&KNQ,W4_W/_KU:BT18%VI
M.<'D_+_]>N=1YI:FC=D5,YJOJ5ZMK8FWC91/-][V%:4^FE;>5UGPRJ2/D_\
MKUQL6CR2R^=)=EI">I3_ .O6E1Z61"(MFUN>IJU A<*/SS6C%I'F!-TX.!_<
M_P#KU>CT4*,B?_QS_P"O7&T[FB5RM:VRJ  ,CUJ2[@\H9!XZUHQ:6412+CK_
M +'_ ->HAIKS>86N?XL#Y.@_.BS-E:QC6D \XN1TJ](1#$9".>U:XT=8QQ+V
M_N__ %ZHZCI;-$BBXP,Y^Y_]>KBB6S!MXGFN3WYR36IM6/D] .!ZU;L=(\J
MD3Y)/)V?_7J2ZTG]]N$^,*,#9_\ 7IRN*-C/!5+;=T^:IM*N@;Z1\=8R/U%7
A9-' LA^^]_N__7J'2],99B?/!^4_P>X]ZS2=S1M6/__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>g2018030121531377131123.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531377131123.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" ,4 F$# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBFR2)$
MA>1U1%Y+,< 4 .J"\8)8W#-]U8F)_*F?VE8GI>VW_?U?\:@U&_M%TRZ8W$+*
M(26'F#H1@'\: +ELH2UB0=%0 ?E4M5/M]C#^[>\MU9."#*H(_6GB^LV (NH"
M"I8$2#H.I^E %BHKJ3RK2:3."J$C\JC;4+)#AKRW4X!P90.#T[U7O+RUFMTC
M2YB<2R+'\K@YY!/Z4 785*P(K'+!0"3ZUDV]O,8'U&R"_:979F1SA95W' )[
M' &#V^E6KW5K.UL99OMEN,1LZYE7G@]/QI;*YLH;&&);N B)5C)$H/.,?F:
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M(FT.W&]LM\\##TR?FI\>M+,HD-@^X';\KR=CC^[1_;F5\U+!RI!.3(X_]EH
M<DVCJ^5TJS4EF3<!#TQUZ]#_ /KJ%-0T5KR&TN-)MX/M*$*SB%E(0 X.TG\/
MI3O[7?85&FMM//\ KI/_ (FJ=[=B\2$S:;*C0MF.2*\E1E)XX(7/.<4 :US>
M>'M,M))2MDL<0WE8HU)_  <FH;;5?"UTXB1[!92"HAEB$<GN-C ']*R5CMO,
M5[E-5?\ >*1%)?32(S#YAE2,'D=/:K]U?6=]#]GO-):6,G(67<W([CY>/PH
MT6M_#LHV/;Z8?]EXT_D12_V%91GS+%4M6)+CRT!4L>IVGCGU&#[UFV3RR7)2
MVB9HP%S!<RL0BC@[21DGD'YLCW%,MKNW>1?[(,L,L3[KN%QL\I!U#H> Q['C
M/)R0* -%$M[>98;[3K56<[4G2(;)#Z>JGV/X$TNF11VNN:K;1HB1OY5PB*
M-R[#P/>.K%M?6NJH\#Q,,IN\N9<;T/1@/0_F.^*ST5K#Q#;K+\WFQ-#%,\F"
M5'S!"#]Y@<_@<^M '0T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJAEMVV1 ] V,EOKR!^=4D'^DS'/55]/>KNGWL.GV-U.ZNP-T$(1<DL0H']*
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MB:,,/]Y>#^A'Y43_ +B_AF_AE_<M]>J_J"/QI-1&R%;H9W0.'X[KT8?D3^5
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M;%]_QX7'_7)OY&G6X'V>(X&=@Y_"@"6BBB@ HHHH **** "BBB@!#7D.A?\
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M=C!&?O<#'#;A[52E(99 %++@1JG7?S@?^/5U&F6*:?816Z8^5?FP."3R?UH
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M)>Z?DHEU$4V;?O\ ;)J*34+&WG5UN(RB0_*-_4[P=H]Z[RJJQ>9>222-N$1
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M.'BMY@,B7 [@<JG;U8L>RUU!(522< #F@!:*J6E\ER[KC!!^4>HJW0 4444
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MZCGK$<]/X3P.#@0(ECH>G@O*EO;(0N^63A<G"J"3TYP!VZ"I ;%!-?W2ZAJ
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M?N5QCGY^?Y4 3T5$&GW',2 <X.__ .M1NFV_<7=GINH 8?-:Y/3RT7TY)_\
MU?SI;0LT19V4DNWW3D8W'%$$;QK(TA&YV+''0>WY4VQP;;*H4'F/P?\ ?//X
M]: +-%%% !1110 4AI:Y/QAXL.C)'INFHMSKEV/]'AZB)>AED]$'ZG@5<(2J
M2Y8B;L9?P^_Y"_B#C_F*WG/_ &UKT"N2\%>'9M$MWDGFEFFG9I999/O22,=S
M.1VR>U=;55Y1G4<H[ M@HHHK(84444 <EXM\)'5RFIZ;(EMK5LA$4K?<G3_G
ME)ZJ>QZJ>16=X9\6,]O-8W4+07EN?*EMISAX9/[I/=3U5NA%=Z1FN4\6>$SJ
MS)J>F.EOK5NI6.5Q\DR=?*E'=3V/53R*Z(3C./LZGR?;R]/R):ZH>H;+.[%Y
M&Y9C_+Z"L'7=),E]!JUO:R7]_"ODVMO+*%MX7.?W[ CJN>HR>P%,T7Q%]H#V
MUU"]M<V[^5<P2GY[=^P;U4]FZ$5T=8SA*$N66XT[E33(;RWTV"+4+M;N\5?W
MTZH$#MGJ%'05;HHJ1D-U=0V<!FF8A<A0 ,LS'HJCN3V%5K*R^T!M8UF1(+=!
MA$9AMC4\$9[D]V[]!QUGN-&N-7CCN8"L<EJ_F6S2 [96Q@JW^PPR">O<=.=C
M3M+N!+]MU*;S;MEPL2$^3;C@[4'<\<L>3[#B@ EO+CRMNG:;-+L8H Q6)2!W
M^;DJ?852L9;>ZEG@B,FDZG$?WML"&!ST<+]UE/9@!Z'!!%='@#H*SM5TK[;Y
M=Q;R>1?V^3!.!G&>JL/XD/<?B,$ T 8NJNL1L+6VBDGM+1?-F:+#,&Z(2.IY
MW-QGD9JM%=6TP)MYT;;R06^Z>P(ZCKWK8L734VF?,MAJD)"7,2-G![9!X=#U
M5L<CT.0([^S#'S=3M$?8.+VU)21!ZD9S@>Q(]J *(N%:158A3G.,YSGI_C3E
ME267:CA@HR<'\JFET?4;3=Y#KJ$!ZI*0DOY_=;\<5GQW,$S%"[V]PC'='(NU
ME]0!WP/3- %[<?,V@< 9)_E2&6-9!&7 <]!4'GF $SKM^4R2$?PCGGZ "LG[
M=>QMC$9AGE)E!'S)(@60\^BH F .6)Y% '044=#BB@ HHHH CA2^G@-Q%:+)
M"20 L@$G!QT/';IFH'N5A\SF19V&$AE4J=QX  /7GTS6KHDXAN+BS?C<WFQ>
MX/WA^!_G6V45L;E!P<C(Z&@"#3[465A#;#'R+@D=SW/YYJS1535+S^S]+N+K
M&YHT)1?[S?PC\3@?C0!@2W'VOQ-(77=:VJ%G$B @!#P5]S(3S_TQKH+*)H;,
M-)Q*^9),_P!X\G\NGX5@:)IT<%K# 0&EN7WRR"0.)$C/WLCLS'=CG[YK6UN9
MHM/\F-L23GRE.>1GJ?P&: ,A9C=S2WA&/.;Y/9!PO^/XT^D "@!1@#@#TI:
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MZ/9R+OPT2D;VW-T[GN:NT %4H26U:ZSQMCC ^GS&KM4U)&L2#G#6ZGVX9O\
M&@"Y1110!4U'!M1$?^6KK'^9Y_3-/O9Q;64TQ;;L0L#[XIESF2]M8P#A2TAY
M]!@?^A?I2:B08HHB,^;,BX_'<?T!H ELU1+2)(W#JJ !@<YXJ>LX8L;^./S
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M2MV,=Q;RC#HPZ@CU_0]16DZ<7'VE/;JNW_ [/Y"3Z,ZJBBBL!A1110 4444
M%<-K%O>#QQ)="&3[$NG2B28# 0[3@@YZ^]=S7 ZA&\GC^_VKF-;%BQ'\),1
M)&/PSG';;_%0 GA[5KO1]!T^.>"%IKVXDW)YH0IEE'RJ2<XSD@'L?45W]>9:
M0F^R\/P:G%,]PU[+\P5RR* &P=I.,D(<Y(QD=":]-H **** $)Q2T44 %%%%
M !534=1M=*L9[Z^G2"UA7=)(YP%'^>U/O;RWL+26ZNIDAMXD+R2N<*H'<FO-
MA:WOQ+U(WDTKV>AP-NL8'CYE8?\ +9U/4]=JGIP2.QUI4U+WINT5_5EYB;L4
M;6"_^(OBV/5DA:PLK-#%#(5 D"-SESW9AR$Z*#D]L^JZ=86VEV$-E:1^7!"@
M1%SG %,L=-@TNS2VLHPD:# 4GJ>I8GN2>2>]3))*)%28*"V<%#Q15JNHUT2T
M2[($K$]%%%9#*=_@O9I^Z^:<'#]3@$\>XQG\#6!J:^9JMTZNROL$:NJDA> >
M<=P:WKL%[^S4>65#.Y#?>&%QD?\ ?7ZUSETS?;[Y_.V9D[*<#'&?J1@?A0 ]
M9T"*#)\Q'!8$=.IYIED)_+=I[A)BS95D' 'H/\_C3WN$\ME2:,.%R-YX'H2.
M*98K<+;8NIEED+$[EZ8].@H LT444 1NCLV5E9.,8 !'UY%,#.9&C6=2X X9
M.GOP:>4D+$K*1G& 5!Q3$DD9FV21OM;!&PC'MUZT ;>A _V6A).6=VY'3YC6
MG5+2!C1[/DG,2G)//3-73TH R[:5/[2U2<B/]WLC+!LG"INP?3&_]:LVS>1I
M<;M_!$&.#N[9/UK.M)&:QU>5WBYN9E5L<  !>?Q%7]1<6^CW+8<!(6_U8R1Q
MVH Y^T&+.'IR@/RDXY&>,\XJ:D4;55<YP,9I: (;E/-MS%_SU98_^^F _K76
MUS"KOO+-,@9N%/(ZX!;^E=/0!CZXV7LXL]79_P E(_\ 9JH5;U=LZE"O]V%C
M^;#_  JI0 PKYEW91_WKE2?^ Y;_ -EKJJYRS3?K%H<'""1_IP!_6NCH ***
M* "BBB@!#7D.A?\ )P&N?]<'_P#08Z]>->0Z%_R<!KG_ %P?_P!!CK2GM+T,
M*V\?4].F[UG3=ZT9N]9TW>G$T,^7J:HS=*O2]35&;I6J,Y%*7H:I2]*NR]#5
M*7I6B,V4I*J25;DJI)6B,V14444R3W>HS-&'"%QN)QCOZU)60UG(?$*7N<QB
M/RP%0<=<DM^0Q[UYAZ([PW#);^'+&&4 .D>" P;N>XXK5K-T#9_85GY9A*;.
M# I5.O8'FM*@ JG:#-Y>ON!_>*N/3"#C]?UJY5+3R2UVQ &;A@".^ !_2@"[
M2'I2TC$*I)Z 9- %:P_X]V<_QR.W7/\ $<?I55;MA>72PPO+,9 H7;M4 *.K
M=,<GU/M5O3_^0=;G*G=&&RHP#GG-)8C]U(V,;IG/7.?F(_I0!%IVFI9F64J/
M/F;=(RG@^P] ,G^=7Z** "BBB@ J*YS]FDPVT[3@^E2U'< -;2*>A4@T 86A
M?O+&WQ:K$!<-N0H5V\-\P#<\GOUYKH:Y[1HA&+..2.1) \KA=X8#@ Y(X.<Y
M&.E=#0 A&17(>+/",VH7,>LZ)*MKKMN %D)PERH_@DQ^C=1]*["BKIU)4Y<T
M?Z\@:N<OX4\61:X)K.YB:TU:T;R[JTE&'5L=?<'L1P174 Y%<EXO\(/K#1:M
MI,PL]>M!^XGZ+*O7RY,=5/8]CS2>#O%ZZT)M/OXFL]9M&\NYM9>&!'<>H/4$
M<'K6DZ<91]I3VZKM_P #S^1-[:,ZZBBBL"@HHHH *JRZ=:32/))!&SN"&8J,
MD$8(SZ$<5:HH S(_#VDQ);K'91H+9R\.,_(QZD?D*TZ** "BBB@ HHHH *K7
MM[;V%G-=74Z0P0H7DDD.%51U)-/N;F&TMY+BXE2*&)2[R.V%51U)/I7G\4$_
MQ'U&.\N!)'X6MY-UM P*F\8?\M7!_AS]U?Q-:TJ:E>4G:*W_ ,EYB;&007GQ
M(U&.\NXY+?PQ;R![>U<;6NV'220'^'^ZOXFO0H;6*"W6&) J)]T#M3X84@B2
M.-0J*,  =JDHJ57-I)62V7;_ (/=@E88C,  _P![^=-E0M)&^,A#G'X8_K3I
M$$B%22,]QU%1B41NL4IY;[K'^+_Z]9#'I,CL5^8$>JD9^E25$ZDR1.N-HR3Q
M3HY5DSMSQUR"* *SJ6U>$[$*K"YWY^922O'T.#^5<TLVZ:5]X1C,XVE,\EL]
M?0CG\:Z3"_VQ(YC(*6X DSP06.1^@_.N6M5_T:%&D0L#SF/N.N#G]: )W\Y4
M)>2$*!DEL@#_ .M3K3!ME8,K!\N"IR.3GBH[E0UNZW*V[1]3OSC _K5A H1=
MOW<<4 4+S6K2QNIX+CS 8+)KYV"9 C5MIZ<DY[59L;R'4;"WO;<L8+B-98RR
ME3M(R,@]*K7.AV5UJ,U_()!<RV;63,KG C8Y.!TSSUJW:6Z6=G;VL99D@B6)
M2QY(4 #/OQ0 XK)G(D&/0K_]>H9)&^S3.9(B$1M[*#P0.W6IL2@C]XI7G.4Y
M/IWJO.TILY"CP GC<I( SQ0!UMHI2S@4D$B-02!@'BIJ11A% &,#IZ4M &);
MJ5T&X/D<RW,K%"0<[ICSQ['-7=8W_P!E7 C?8Y "GW)%4=+D7_A'()(U"AY^
M@_VIN?YFKFMQ>=I4J9Q\R-^3@_TH R._%%'4\<T8(ZT +;OC5[!/[SN3^"'_
M !%=-7.6*[M9MC_=21O_ $$?UKHZ .>U+#:U(>ZP1CZY+U#4EZQ;5[I?[JQC
M]#4= $VF8.M*.XMV/YLO^%=#7/:6!_;A/_3L?_0Q70T %%%% !1110 AKR'0
MO^3@-<_ZX/\ ^@QUZ\:\AT+_ ). US_K@_\ Z#'6E/:7H85MX^IZ=-WK.F[U
MHS=ZSIN].)H9\O4U1FZ5>EZFJ,W2M49R*4O0U2EZ5=EZ&J4O2M$9LI254DJW
M)522M$9LBHHHIDGN]8Z3;?$KP>:?FA#;,G&/7'3.?QK8K"Y/BC!+%?+&T;S@
M'!YV]#QQFO,/1+NB1M#H]O&Z%"H(P1C')K0JGI8 TZ(  8ST?<.I[U<H *IZ
M=_JI_P#KXE_]"-7*J:?_ *J;_KXD_P#0C0!;J*Y8K:S,"%(0D$]!Q4M5M1*#
M3;GS,[#&P;'H1B@"6 %;>-2 "% ..G2H=.&+&/Y-F<L5SW))_K5D<+]*KZ>C
MQZ=;I(<NL:ACGJ<4 6:*** "BBB@ J.<D0.1C(7/-25'. T#@D %3DD\4 96
ME7$EQ+&P5$BV/E%(QG*X/'X]/6MFL;2[26TFACNF1[C9(=R?=VY3C]!6S0 4
M444 %<IXK\'+K4\&JZ;.+'7+0?N+H#B1?^><@'53^8ZBNKHJZ=25.7-'<&KG
M*>%/%IU:2;2]4@-CKEF=MQ:N>OHRGNIZ@BNKKF/%GA,:Z(;^QG%EKEG\UI>
M?^./_>0_IU%,\*>*VU<S:9JD/V+7;3Y;FU8]?]I?53U!%:SIQG'VE/;JNW_
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M H'4D]A2RR+%$\CLJJ@+,S'  '<UP6)?B1>$^8T?A&!\;5^5M2D4^O7R@?\
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M@/\ B;6YQT23G\JZ&@ HHHH **** $->0Z%_R<!KG_7!_P#T&.O7C7D.A?\
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M863\"1592MQ:6HF)WN6B/UVL#S^!H TZ*KV4C2VJ,_WP-K?4<']:L4 %%%%
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MB_Y DO\ UTB_]&+0!F]Z*.]% $^G_P#(3A_W7_I705@:?G^TXO\ <?/Z5OT
M<U=_\AJ]^D7_ *":;2W?_(;OOI%_Z":2@!UN<:G8\XS*1]?D:NEKF8,?VG8?
M]=C_ .BWKIJ "BBB@ HHHH 0UY#H7_)P&N?]<'_]!CKUXUY#H7_)P&N?]<'_
M /08ZTI[2]#"MO'U/3IN]9TW>M&;O6=-WIQ-#/EZFJ,W2KTO4U1FZ5JC.12E
MZ&J4O2KLO0U2EZ5HC-E*2JDE6Y*J25HC-D5%%%,D]WHHI.]>8>B4M-+%;K<9
M3_I,@'F8SC=V]O2KU9.@HT::@&=&S?3,-K[L MT/H?:M:@ JGIL92V=F^_)*
M[MSZL?Z8JW4-G_Q[#_>;_P!"- "7-K'<A=Q9)$Y21#AE/L?Z=#5*^G-O9QP7
MDFXS.(C*J[5Y/?KCC-:A.!FLJ"\35GM)$C98?WC%9!RV/E_+YCU]* +MY<?9
M[2209R%."/7'%/M8?(MHX1TC4+^0Q5>XCCMX;:VA 16F554'L,L1^0-7J ((
M'3=+&J!-C\@$<YYS^.33;3Y3.F,;93CKWY[_ %H^5-1*@@%X]V,]<'&?U%.5
MRMTT9)(*AEXZ<G//Y4 9&J[O[1;!Q^Z7G'NU45)==RRY![[:NZKG^U&(; $*
M]L]VJB-TOS)< J?1010!(-V.3G\*7-"@@89MQ]<8HQ0!%<;F$2H1\TJYR<?*
M.3CUZ4V="^G:@ZKEEFMD!!YX=2?I]Z@['U!%():&,N#G@;CCI^!JS IFTG4%
M5X4=;H$/*V%XV,,G]* *LTJ.44'YA*A([CYL4K2H\D>TYVL<CN/E--D5W !U
M#1U<,K8^TGG!SCI39)&7:YOM&&T[O^/OKQC^[0!,9D.)1RJJ<X[=.*4RH#OW
M#;CJ.G7UJ(762I%K<@$?W!_C1+/Y0+")N$/484<]_:@!5E03R.3\K*F#_P!]
M4]ID1@S-A6 P?SJNC2B1V-]HGS*HVB\/&,_[/O5B)+B7+"YTINGW;DG_ -EH
M 3[EU-(1\I1!^K?XTGF*)GD&6 B!^7G/)J0Q3IND,]@PQ]U9B21[?+UJ(2XN
MVQ%)_JU_A]S0!)O7<7'("=OK095!W]5Z9'UQ^5('_>\1L/E[@#O2[R-Q\L\+
MTR/\: $\P>9O[&/^M*9%WAQR-A/'U%.AC,L<<YN+2-GC'R,YRN><'BI5MUWY
M>\M5XP &)H JF1?.,H^95C/3O\U!=3=*XR0(G/ ZX*U;-N@?>+VV)"X YJD)
M,W43>6PS"W 'NM #S,A='!R K=!GTJ16#D,IX.:C+YGCQ&X^5NHQZ5(#\ZC8
MPX]* (Q(LD\9&>%;((Y[59L2LNK6O (Q)D$>PJ"".2XCBG,UI$64G8\A##..
MO'M5NUC$.H02RW5KA W$<A.<C'I0!=OM*1E:>T18[@#)"C"R>Q']:RD<21JZ
MYPPR,]:Z-;J"1MJ2HS'H >M<U'GS+D$ !;F4*!V&XT /[T9I.M.Q0!&_FX_=
M[,_[0/\ 2FH9MX$C09Z@*#G]33_WF3@ICMP:C;S/-^7[/YF.Y.<4 5X8YW2R
MD4B.2*S\B19(R?FR#QR/SJR&<J?+:(GUP<?H::K3MG:T(VL5;(8]/QI8@Q3*
MM 1GG8"!G\Z )$W[?WA0MG^ ''ZT[-( <?-C/M3J $S3&GB1MK2HK>A;FGXI
MC311#YY8TYQ\S 4 ",AE\P39!ZC=Q6SH)8Z':;OO;,'\S6*LB.<B1&4\C!!_
M_76]I&1I5OE=N5R!G. 30!>HHHH R].4)HX "+B9S\K[A_K3W_SBCQ"I?19%
M4<^9%_Z,6H-&8_\ "/Y88(N9AS_UW:KFL_\ (,?_ 'X__0UH QZ*** )]/'_
M !,XO]U_Y"N@KGK XU2 >JO_ "%=#0!S-U_R&[[Z1?\ H)I*6Z_Y#=]](O\
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M<$DD'YNI.#G%;P.:K6HS<7;^LH'3'11^?>K.<HS0:C)>6\8OX@Z*[L3;9ST
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M.0.!@YY_"@"LT0^42N"N\%?EYSNR!_2AX\/"&(.6/./]DU).C.L849Q(K'Z
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M"Y.!GZFB-F:2967 1@%/]X8!S^N/PJQ;)FVU"3_;C0?A@_\ LW^<5H<1"[A
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M*?P_D^S_ $?7[RK?G_3+4QL"IM,C)X(W#GBH$4*ORJ@]EZ5/?+LN[5$Y M,
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M_4UYSIVO>+_#NGV-FT-@;28[8)[HRLD1(XAW#G@Y )^F:Z_XC3#^P+6Q!/\
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ML5Q-&@PJN0HST% #:*** (Y_^/>3_=-=4.E<G=X^Q7!/01-_(UU47^I3_=%
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M[5UV:J+NB*M-TY<K_P"'\S,MCM\0ZC"2OSPPRA0F#@[U))[_ '?PJWIY_P!
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M_P"GN/\ ]#%=%I>J6NKV$5[93++!*,JP_D1V([BN=\68_P"$@\/\<_:X\?\
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M8QW*D (S9],8%03@N")"L:LI4Y;(_ECO5EBP'RKN/UQ43E]N7$87([%L'UH
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M8XP3Z_Y]ZLU4CEB^VF#S7DG5<L3T'MQWJW6IQA36)'1"WX@4ZD8X&<$^PZT
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MYFM9&>%MI(P<C.:>^LPRC;>V,<H_O+U_7_&FU(6A8TJYTZ6[>&UL0FU"_F.
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M+Y@[1R(4D0X93V]_<>];6EW!FMMCD&2+Y&]_0_B*=?V*W:!EPLRCY7/\C[4
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ML>".!@D=*BMHY1;IM=BI+!MS<CYCTIZ0R^6JJ[XW-N.[G&3TK0XR03*J%F.
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M 'A5RJU]$T]N$4'/F1MQ[.#_ $H LT444 5;T;C;J5W9F4]>F,G/Z5+<1^=
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M6Z$<W4I2<54DJW)522MT<[(J***8CW>BBBO,/1"BBB@ HHHH **** "BBB@
MHHHH **** "D  Z"BB@!:*** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ I,#.:** %HHHH 0UY#H7_ "<!KG_7!_\ T&.B
MBM*>TO0PK;Q]3TZ;O6=-WHHIQ-#/EZFJ,W2BBM49R*4O0U2EZ445HC-E*2JD
,E%%:(S9%1113)/_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>g2018030121531016131433.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531016131433.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %N E # 2(  A$! Q$!_\0
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M*UN44 8?_"&^&O\ H!V'_?E:/^$-\-?] .P_[\K6Y10!A_\ "&^&O^@'8?\
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MX':@9TM%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K+U#P[HNJRB74-*L[F4<>9+ K-^>,UJ44 <__P (/X5_Z%_3O_ =:/\
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M ZUT%% '/_\ "#^%?^A?T[_P'6C_ (0?PK_T+^G?^ ZUT%% '/\ _"#^%?\
MH7]._P# =:/^$'\*_P#0OZ=_X#K7044 <_\ \(/X5_Z%_3O_  '6C_A!_"O_
M $+^G?\ @.M=!10!S_\ P@_A7_H7]._\!UH_X0?PK_T+^G?^ ZUT%% '/_\
M"#^%?^A?T[_P'6C_ (0?PK_T+^G?^ ZUT%% &58>&M#TN;SK#2+*VE_YZ1P*
M&_/&:U:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BN6UZU.H>*]%L
MWNKR"%K:[D86MR\)8J8<9*D9^\?SJS_PB-G_ -!+7/\ P;7'_P 70!T%%<__
M ,(C9_\ 02US_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C9_\
M02US_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C9_\ 02US_P &
MUQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C9_\ 02US_P &UQ_\71_P
MB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C9_\ 02US_P &UQ_\71_PB-G_ -!+
M7/\ P;7'_P 70!T%%<__ ,(C9_\ 02US_P &UQ_\71_PB-G_ -!+7/\ P;7'
M_P 70!T%%<__ ,(C9_\ 02US_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%
M%<__ ,(C9_\ 02US_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C
M9_\ 02US_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!T%%<__ ,(C9_\ 02US
M_P &UQ_\71_PB-G_ -!+7/\ P;7'_P 70!/XO_Y$K7O^P=<?^BVK3L_^/*W_
M .N:_P JP9O!FGW$,D,U[K,L4BE'1]4G*LIX((+\BGCPA9* !J.M@ 8 &K7'
M'_C] '0T5S__  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__
M  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\
M&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\&UQ_\71_PB-G
M_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7
M'_Q= '045S__  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__
M  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\
M&UQ_\71_PB-G_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\&UQ_\71_PB-G
M_P!!+7/_  ;7'_Q= '045S__  B-G_T$M<_\&UQ_\71_PB-G_P!!+7/_  ;7
M'_Q= '045S__  B-G_T$M<_\&UQ_\75;0;4Z?XKUJS2ZO)X5MK211=7+S%2Q
MFS@L3C[H_*@#J:*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@#G]0_Y'K0O^O*]_\ 0H*Z"N?U#_D>M"_Z
M\KW_ -"@KH* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "N?T_P#Y'K7?^O*R_P#0IZZ"N?T__D>M=_Z\K+_T*>@#H**** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@#SG5/B!X8A\:Z?))J15;*&[@N,V\OR2%HL+]WG[C=/2O0HW62-9%)*L,C
M(QQ7@_B?PMYWQLAL!'^XU">.Z*XZIUD_57KWR@ HHHH **** "BBB@ HHHH
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M^W]?_P"A;C_\&"__ !- '3T5S']OZ_\ ]"W'_P"#!?\ XFC^W]?_ .A;C_\
M!@O_ ,30!T]9%IH4%IXFU+6DQYM]%#&W'(*;@?S&W_OFL_\ M_7_ /H6X_\
MP8+_ /$T?V_K_P#T+<?_ (,%_P#B: .GHKF/[?U__H6X_P#P8+_\31_;^O\
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M-:WEQ(+F)%<Q)$S,5()R,>P.?2@#?HK#G\7:-!I5GJ/VEY8;P[;=8HF=Y#W
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M4\ 2ZCX,TS2UN8H]1L$VI/SL*MPZ^N"/Y4W6["3S/!7AD,))+>6.>9E'&V!
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MT>=XE_Z%Z'_P8+_\30!JT5E>=XE_Z%Z'_P &"_\ Q-'G>)?^A>A_\&"__$T
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MG;$<4+,??C@?4]*T?#MK+8^&-)M)UVS064,3KZ,J '^59%MX?U'4;Z"[U^6
M16[B2&PM26CWCHTC$ N1V& ,^M=72 **** "BBB@ HHHH **** "BBB@ HHH
MH **** ,OQ%:RWWAC5K2!=TT]E-$B^K,A _G6=H]Y#?Z-9W<#9CEA5A[<<CZ
MCI72URESX?U'3KZ>[T"6 Q7#F2:PNB5CWGJT; $H3W&",^E &I165Y_B7_H7
MH/PU!?\ XFCSO$O_ $+T/_@P7_XFF!JT5E>=XE_Z%Z'_ ,&"_P#Q-'G>)?\
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M@Q[MJ(P/KA*LZ7X?NO[175=:N8KB\C!%O# I$-L#P2N>68_WC^ %(#HZ***
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MB8MG/.W(7'Y^U2:AX8U*T\1:]Y^F:Q?6.IRF6(Z;?>4C!ARDJ[AZXR:]9HH
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M!50;C'$DK*&;^ZHP%]^V: .NHK-U76;?2(X/,CFGFN)/+@MX$W22M@D@#@<
M$DD@"J/_  EM@NEWU[/#=P-8NJ7-M+&!+&6QMXS@@[@<@XH Z"BLZYU:*"_-
MDL$\UR+<W CC ^90P7 R1SDU5\+:U/KV@VM_/9R6TDL2N<@;6R,Y7DG'UH V
MZ*** "BBB@ HHHH *YB70+QYG8&+#,2/F_\ K5T]% '+?\(]>^L7_?1_PIKZ
M#=1KN>2!5[DO@5U=5;^PM=4L9K*]@2>VF7;)&XX(_P ??M0!S/\ 94G_ #]6
MG_?T5\_>*T\KQ9JJ$JQ6Z<94Y'6MGQ[X"NO"%]YL6^?2YF_<SXY4_P!QO?\
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MW*L.&C;LRGL:U:* .$\#_#:S\(S37D\BWE^S,L4VW CC[8']XCJ?P^O=T44
M,DC26-HY%5XV!5E89# ]C7 V/PDT.R\5-JW,EHOSPV+KE$?/<]U'85Z#10 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45SWC
M'Q-_PB7A]]4^R?:MLBIY7F[/O=\X/\J\\_X7S_U+?_D]_P#:Z /9**\:_P"%
M\_\ 4M_^3W_VNC_A?/\ U+?_ )/?_:Z /9:*HZ1?_P!JZ+8:CY?E?:[>.?R]
MV[;N4-C/?K5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *Y3QMXVLO!VF[WVS7\P/V>VS][_:;T4?K1XV\
M;67@[3=[[9K^8'[/;9^]_M-Z*/UKYMU;5KW6]2FU#4)VFN)CEF/;T '8#TH
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MXUKUYUX?^)\.I^*1H%[!#%+AHA<Q2;HY9E)&%R/NL!Q[\5Z+0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117"3_\?$G^
M\?YT =W5/4I;V'3YGT^W2XNPO[J.1]BEO<^E<910!P&K?#+QUK>I3:AJ!MIK
MF8Y9C<#CT '8#TKS[4;"?2]2N;"Y"B>WD,<@4Y&X=>:^@*\+\3_\C1J?_7R_
M\Z ,FNUTWX6^)]3TZVU"TCMO)N$66,F< X/(KBJ]T\,?\BOIG_7LG\J .O\
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MV[@/F/;M[T =_1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 45EZ__ ,@QO]]:Y2@#OZ*X"B@#8\1>!=$\2-Y\
M\!M[Y2"EY;?)(".A)_B_&MZSCN(;.*.ZF$\Z*%>4+MWD?Q8[9KY5\3_\C1J?
M_7R_\ZR: /LBEKXVKN/AA_R&[S_KV_\ 9EH ^D:*X"B@#OZ*X"N[@_X]XO\
M<'\J )*8)$9V0.I9>H!Y%8GC2_N=,\&ZK>6C%+B. [''5">-WX9S^%)8^%=
MTE+>YMM/@2:V4L+I5_>OP<EF'+9R>N: -^BN'A\0:Y_9.G>(IIK0V-[/"IL5
MA(:..5PJD2;OF894GC'7I5W3M3UK4-5U>0W%K%I^FW4EN(A"6>8B,,"6W?+C
M<O8YYZ4 =717 Q>)=<@\(V6M7DUJ\VJ-!%;P0VCN(2_5B%):3C+;0!SQ4O\
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M]+^#=#M)_!>C2N9-SVD;'#?[-?-%?5/@;_D1=#_Z\H__ $&@"U_PCUEZR_\
M?0_PH_X1ZR]9?^^A_A6M10!D_P#"/67K+_WT/\*N6=E%8QLD6[#'/S'-6J*
M*FHV,>I:;<V,SR)%<1M$YC.&VL,'!JOJ&B6>HZ.NF2*\=NGE^68SAHRA!4@]
ML;16G10!B-X:MO[4FO8;N^MA/*LT\$$VV.5QCYB,9R0H!P1GO23>&;2:752;
MB[6'5(W2Y@60>62R!"X&.&V@#KCVK<HH QM4\-:?J\NG272R$V$@>+:V V"#
MAO5<JIQ["H=1\*VFHW=W.;J]MQ>Q"*ZCMY0JS  @9XST.."*WZ* ,=_#]N;Z
MPO(KBZ@ELXA"OE2 "6/(.UP1R,J.F*CM_#4-G=^9:7^H06YF,YM(Y1Y.XG<>
M,;@"<G:#CDUN44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% %>ZM8[R#RI=VW.>#5'_A'K+UE_[Z'^%:U% &
M3_PCUEZR_P#?0_PH_P"$>LO67_OH?X5K44 <!>_"'PU?WTUW,]^))G+MMF4#
M)_X#4/\ PI7PM_STU'_O^O\ \37HM% 'G7_"E?"W_/34?^_Z_P#Q-:6B_#/0
M= N9+BS>\+R)L/F2@C&<^GM79T4 9/\ PCUEZR_]]#_"C_A'K+UE_P"^A_A6
MM10!D_\ "/67K+_WT/\ "M1%"(JCHHP*=10!%<0175M+;SQK)#*A1T;HRD8(
MK&T[PQ!ILT#1ZCJDL-O_ *FWFNBT:<8 QU( /&2:WJ* .=MO!UA;2P 7%X]G
M;S>=!9/+F&)\Y! QG@] 20*T;/2+:Q_M#RBY^W3M<3;C_$RJIQ[845HT4 8Q
M\.6!\.V^B$3?9K=46%Q)B1"F"K!AT8$#FC_A'H)M/O+&_O+W4(;I0K_:9!\H
M'3;M P>^>O K9HH P_\ A&H'TR\L+N_U"\CNXQ&[W$^64#.-N  #SUQD\9S3
M+?0[B/7;6ZN+M[FVLK9XX&F;=*TKMEV;  X4*HQZM6_10!1L=+@L+B]GB+M+
M>S>=*[G)SM"@#V 48%9A\(:>+>**">[MF@N9+FWEAD :%I"2ZKQC:<G@@UT-
M% '/1^#]-32[NPWW;+<W(NVF:<F59@%PZMU!R@/_ -;BK.F>'[?3-0N+\7-W
9<75Q&D<LMQ)N+!2Q'   ^]VP/:MBB@#_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>g2018030121531049431434.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531049431434.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $_ L$# 2(  A$! Q$!_\0
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MLYO)NI[V"4 $I*S*<'H<&M2P\6S6/]FO]@CEGL%$<<AF=0R!F8 J#C.7//\
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MQ3=Z[%:QW%M"@A<2.%R5D?:JY([#"CCWZ],5M:UDZPUHJV,5I#:Q&**.-F?
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MV[A@C.1N7CKS6RMG:,H/V6$9&>8Q7'0>''D^R_;[^TE(U!KVX?S26/RJ @X
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MZW_Q-<^A]%@714'[6U_,H_\ "Q_%'_01'_?B/_XFC_A8_BC_ *"(_P"_$?\
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M6_\ B:V=?^'VLZG'I*P/:#[)81V\F^0CYE+9QQTYH,Y2PO-&UCF/^%C^*/\
MH(C_ +\1_P#Q-'_"Q_%'_01'_?B/_P")J]_PJGQ!_P ];'_OZW_Q-'_"J?$'
M_/6Q_P"_K?\ Q-!IS8/^[^!1_P"%C^*/^@B/^_$?_P 31_PL?Q1_T$1_WXC_
M /B:O?\ "J?$'_/6Q_[^M_\ $T?\*I\0?\];'_OZW_Q- <V#_N_@4?\ A8_B
MC_H(C_OQ'_\ $T?\+'\4?]!$?]^(_P#XFKW_  JGQ!_SUL?^_K?_ !-'_"J?
M$'_/6Q_[^M_\30'-@_[OX%'_ (6/XH_Z"(_[\1__ !-'_"Q_%'_01'_?B/\
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M/_T"I/\ OM/\: ]EA/+[S<_X6WK/_/C8?]\O_P#%4?\ "V]9_P"?&P_[Y?\
M^*K#_P"$!\3_ /0*D_[[3_&C_A ?$_\ T"I/^^T_QH#V6$\OO-S_ (6WK/\
MSXV'_?+_ /Q5;&N_$74]+CTMHK2T;[78QW+[U;AF)R!\W3BN+_X0'Q/_ - J
M3_OM/\:WO$OA'7KZ+15MM.>0V^FQ0RX=?E<%LCK[B@SE3PO-&UOO&_\ "V]9
M_P"?&P_[Y?\ ^*H_X6WK/_/C8?\ ?+__ !58?_" ^)_^@5)_WVG^-'_" ^)_
M^@5)_P!]I_C0:>RPGE]YN?\ "V]9_P"?&P_[Y?\ ^*H_X6WK/_/C8?\ ?+__
M !58?_" ^)_^@5)_WVG^-'_" ^)_^@5)_P!]I_C0'LL)Y?>;G_"V]9_Y\;#_
M +Y?_P"*H_X6WK/_ #XV'_?+_P#Q58?_  @/B?\ Z!4G_?:?XT?\(#XG_P"@
M5)_WVG^- >RPGE]YN?\ "V]9_P"?&P_[Y?\ ^*H_X6WK/_/C8?\ ?+__ !58
M?_" ^)_^@5)_WVG^-'_" ^)_^@5)_P!]I_C0'LL)Y?>;G_"V]9_Y\;#_ +Y?
M_P"*H_X6WK/_ #XV'_?+_P#Q58?_  @/B?\ Z!4G_?:?XT?\(#XG_P"@5)_W
MVG^- >RPGE]YN?\ "V]9_P"?&P_[Y?\ ^*K7\._$;4]8OIX)K2T18[:28%%8
M'*J2.K=*XS_A ?$__0*D_P"^T_QK>\*>$->T_4KB6ZTYXT>TFC4EU.6*D =?
M6@SJ4\*H/EM?U$/Q;UD$C[#8?]\O_P#%4G_"V]9_Y\;#_OE__BJQ#X"\3Y/_
M !*I/^^T_P :3_A ?$__ $"I/^^T_P :#3V6$\OO-S_A;>L_\^-A_P!\O_\
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M>.0=)"NYA^)R:V**T=>JURN3MZF:H4HRYE%7] HHHK(U"BBB@ HHHH ****
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MB#_H#7W_ (#M_A0=OU;"]E]__!.T_P"%OS_] >/_ +_G_"C_ (6_/_T!X_\
MO^?\*XO_ (1/Q!_T!K[_ ,!V_P */^$3\0?] :^_\!V_PH#ZMA>R^_\ X)VG
M_"WY_P#H#Q_]_P _X4?\+?G_ .@/'_W_ #_A7%_\(GX@_P"@-??^ [?X4?\
M")^(/^@-??\ @.W^% ?5L+V7W_\ !.T_X6_/_P! >/\ [_G_  H_X6_/_P!
M>/\ [_G_  KB_P#A$_$'_0&OO_ =O\*/^$3\0?\ 0&OO_ =O\* ^K87LOO\
M^"=I_P +?G_Z \?_ '_/^%'_  M^?_H#Q_\ ?\_X5Q?_  B?B#_H#7W_ (#M
M_A1_PB?B#_H#7W_@.W^% ?5L+V7W_P#!.T_X6_/_ - >/_O^?\*U=:^)$VE)
MIK+IL<GVRS2Y.92-I8GCI[5YM_PB?B#_ * U]_X#M_A71>*?#VL74.AB#3+N
M0PZ7%')LA8[6!;(/'!H,Y8?#<T4K??\ \$TO^%OS_P#0'C_[_G_"C_A;\_\
MT!X_^_Y_PKB_^$3\0?\ 0&OO_ =O\*/^$3\0?] :^_\  =O\*#3ZMA>R^_\
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MR-Q)#YRJ8XQ(S-PH!QCG\13O[3LO.,7VF/<$$A.[C:>AS6/_ ,(VH.Y;Q0P
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M]35<SM8CV<;W,GQ)/+;Z.)(9'C?[5;+N0X.#.@(_$$C\:UZP_%3K_88^8?\
M'Y:=_P#IXCK:WI_>7\ZDL=13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =
M13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=
MZ?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?W
ME_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.
MC>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G
M]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?
MSH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH =13=Z?WE_.C>G]Y?SH
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M$DX4.(XY8U98]S[N,CC'2I(M 6/6EU)[J21D+F-61=PW=5+XW,HSP">./04
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MW_,4>RPOE]X_K&8_WON_X!?_ .$OE_Y\+/\ []G_ !H_X2^7_GPL_P#OV?\
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MT'_/"/\ [X%2T4 1?9H/^>$?_? H^S0?\\(_^^!4M% $?D0_\\D_[Y%%244
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M\7_&C_A$]8_Y]1_W\7_&CEPOD'/F7][[F6?^$UU/^Y;_ /?!_P :/^$UU/\
MN6__ 'P?\:K?\(GK'_/J/^_B_P"-'_")ZQ_SZC_OXO\ C1RX7R#GS+^]]S+/
M_":ZG_<M_P#O@_XU=U+Q5?VGV7RUA/FVZ2-E3U(^M9/_  B>L?\ /J/^_B_X
MUH:IX<U.Y^Q^5;AO+MDC;YU&"!SWJ7'#<RV-(SS#DE?FOIT9!_PFNI_W+?\
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MBBBLSH"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M99  S%8_+10% &,')^GO6[0 4444 %%%% !1110 4444 %%%(Z[D9<XR,9H
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M_P#?)H_X1[5?^?*7_ODT>QPWE]X?6\Q[R^[_ (!M?\)S<?\ /I%^9_QJY?\
MBV:S^S8MXV\V!93DGC(KFO\ A'M5_P"?.7_ODUHZMHNHS_8_+M9&V6J(V%Z$
M#D5+I8?F6WWFL<5C^23;=].G_ +'_"<W'_/I%^9_QH_X3FX_Y](OS/\ C6+_
M ,(]JO\ SY2_]\FC_A'M5_Y\I?\ ODU7L<-Y?>9?6\Q[R^[_ (!M?\)S<?\
M/I%^9_QH_P"$YN/^?2+\S_C6+_PCVJ_\^4O_ 'R:/^$>U7_GRE_[Y-'L<-Y?
M>'UO,>\ON_X!M?\ "<W'_/I%^9_QK8T#Q!+K%Q)&\*($3=E<^H_QKC?^$>U7
M_GRE_P"^371^$=-O+&[G:Y@>-6CP"PQW%95Z5!4VXVOZG5@L3C98B,:E[==/
M^ ==1117E'TP4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1'6U2+"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MO_$__0+;_O\ 1_\ Q5=F!CAW!^UM>_4Y<QGB5./L;VMT+_\ PLS5O^?+3_\
MOA__ (NC_A9FK?\ /EI__?#_ /Q=4/\ A7_B?_H%M_W^C_\ BJ/^%?\ B?\
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MW0N'WS-<X<R'@#/&.   ,8XIE[HL%Y(DBS7%K(L9A+6S["T?]T\=/3'([$4
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MMC_WT_\ \377@9X>,'[6U[]3GS&&)E.+HWM;HS$_X3SQ-_T%9/\ OA/\*/\
MA//$W_05D_[X3_"MO_A4^L?\_MC_ -]/_P#$T?\ "I]8_P"?VQ_[Z?\ ^)KN
M]K@O+[CS_8X_^]]__!,3_A//$W_05D_[X3_"C_A//$W_ $%9/^^$_P *V_\
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M^$%\2_\ 0*E_[Z7_ !H]C@O+[_\ @A[?'_WON_X!O?\ "V=6_P"?&R_[Y?\
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M= %BBJ_VZU_Y[)^='VZU_P">R?G0!8HJO]NMO^>R?G1]NM?^>R?G0!8HJO\
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MK_;K7_GLGYT?;K;_ )[)^= %BBJ_VZU_Y[)^='VZU_Y[)^= %BBJ_P!NM?\
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M%&MSC<S B1@0S%22#G@Y52#VQ37\-Z8^"T<WF  >:+APYQN_BSGG>V?7/TH
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M>++'4+1KTP7%I8K'YOVJZV)&1G'9B?S%1-XWT1;.6\:=OL\9E&\ '=Y94$J
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M_P :M6VJ6%X\:6UW%*TD9E0(V24!VD_0'CZU;I<TD%HF5_PCFD_\^G_D1O\
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MT\""T^SQKJ3&W3[.9T,(S*T)RA#9^0=,CG\,UV%%'M9]P]G$Y[0_"RZ+>0W
MNS*8[5[?'E[<[I3)NZ^^*Z&BBHE)R=V4DDK(****0PHHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>g2018030121525117431123.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121525117431123.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "X 4H# 2(  A$! Q$!_\0
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MWSD[CV _$   #@# XKIO#W@_QUXPMEOK"SM+"QD&8I[QBH<=<@ %B.G.W!H
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MF4<\QKR^,<@A WY]NM?6D<:0QK&BJB* JJHP !T %?,GP]_Y+7X<YX\NX_\
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M'6?CQK.JW4UKX2TJ&*%3M^U7?S/C^]MR O?@[J />KB=+:VEGE)6.)"[D G
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M*3[?,DG%<]979T/QSX?UL3""..\C6>4-MPFX!LGT*%@?:O0_CU9QVOB?PQK
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MJOK7PXT*]E8O*;40N[$DLT9,9))Y))3)KYX\26'V+XA^+[!,#?=-*@'0;R6
MZ?[>*]C^ 5RDWPQBC7&8+N:-L'/)(;GTX84 =_K^C6?B'0;S2;^,/;7491@1
MG!ZAA[@@$>X%?*FE176GW6H:!?(HN-/F:%B#D'YB#C/49!P>X(KZ^KYS^+VD
MC0_BC9:K#&RP:O!B4Y&&E3Y6QZ<>4?J3ZT )\%-;;PYXXNO"T\KM::DGF6S,
M,#S57/ZJ&&>Y5:^C:^/M3N#I=WINMQ(OVBQO(ID).>%;=C'0\@5]<6MU!?6<
M-W;S*\$\:RQL/XE89!_(T ?/?QMT"Y\.^+X_%5G;N]GJ"".Y(^ZLRC'.!QN4
M*1[AJX^]T^#5[12K+O W13+V/^%?5FL:18Z]I5QIFI6PN;.==LD3$@, 01R.
M000"".017S;XJ^'7B/X?2W%S91'5/#ZG>)Q]^%>I#J.1CGY@"O0\$XH V_!W
MQJOO#@M]$\7P/=6\85(K^$YD5!P-R_QXXYX;CD,:]IT#QEX=\4)NT75[:Z;D
MF(-ME '&3&V& ]R*^8K'4=/U&/:DB,[ ;HI!@Y^AZ_A5:70Q'.EWI,\EC>0N
M&22)RI!]00<J?<4 ?8M5K6TM[&V6"T@BMX%)*QQ($4$DDX XY))^IKQ;X:_&
M"=KR'PUXN<_;"XBMK\C D)^Z)/<\ -CGC/.2?<J &LH92K %2,$'O7QTVG1V
M,_B+0"W_ !Z7DT._''RL5!SU/*5]CU\E:S&B_$/Q:(I%=?[2DR44@;B[DCGN
M#D'MGIQB@#V[X(ZJFI_"[3HQ*TDUE)):R[AC:0Q90/4!'2M_X@Z$?$G@/6-,
M2-I9WMR\"KC)E3YD ^K*!^->+?"7XE>'_ WA*\T[6&NENGU!Y1'%"6(4QHN3
MG '*$8ZUW$?[0O@QV=3!JL>TX!:W3#>XPY_7% 'A=J_]I^%VCD7<Z(5!(SRO
M3\>E?1GP9U0:K\,-++3>9-:;[63YLE=K':O4X^0IQZ8[8KYYL+B"ZN=3N;*)
MX[66^DDA#@ A"<@$ G! Q[>YKU;]GF\,%OXBT-G)-M<I.O'!# J3UP/N+^??
ML ;GQ\T%-3^'K:DJJ+C3)TE#;,L8W(1E![#)1C_N5Y#X%U<:1\2_#NJI*!%J
M#"VG!.!\X"<_0E3Z96OI[Q#I@UKPYJ>EG'^F6LD . <%E(!YXR"<U\8[Y#X=
MBF63$EM<#8P'*^G/X@T ?:6LZ3::]H]WI-\A>VNHS'( <'![@]B#R/I7R<UA
M/X;\0:CX7OB?.LYF$38X=#\P/ME2&'^]7UKI5\FJ:/9:A']RZMXYUXQPRAA_
M.O%?C_H+V\VE^+[2-F:)OLEUCIMY*$XZ=74D^JCZ@'G9< \J2,\@5U_P2E^S
M?%'5K41(5GLB^\L RX9#QZY)Z>V>U<@I5HXY4;<D@##Z=JWOA;<R6?QIL8]@
M*W=M+%N)Z 1L^?S3'XT =U^T;$I\"Z;-@;EU)5!QS@Q2'K_P$5Y+.FZUE0*/
MG5@ >Y(KVKX^IN^&3G#?+>1'Y5R.XY]!SU]<>M>,*6$42N26 &2>>: /9_@#
MJ,E]\,D@=%5;&\FMT*]6!Q+D^^92/H!7J=>$_!6TOI_ /BNUTNY-I?FY=+:9
M /DD\L;?O \9QGOCOGFO-+36/&C:G>:=?^*M?M;NT8I)$;Z4D,,@_P 6.#CZ
M_K0!]@T5\>7NN^,K*:U2#Q=KMQ<SRA(X?M<N6.1CC>0>2!CWKZ;\!Z9X@TKP
MO#!XEU0ZAJ#.9"Q )A4@?N]W\>#D[O? X H \A^-2JOQ4TA_,7<^F;-@!RN'
ME.3QC!R>ASP<XXSJ?L]N$E\5VX"*J7,3(F?F /F#\N!S]:R?C5*9?BGIL7FL
MR0:6'$>[(5FDD!X[$C;^0KSB:YL;/4;B6#5KRQN#\LOV9F7=[9 ]J /L'6+<
M7>BW]L<8FMY(SDX'*D5\A>'68Z1&C 8#-M^F?\2:K3:X]PKQ3>)]7DMW0H\<
MDLA#9X(/.",=L5>TZ.U2SC%I*TD66PS'G.><B@#TOX"G/B_Q1@D#RH>,^YKU
M7XA0?:/ASXC3.W&G3OG&?NH6Q^E>7_ "!GUGQ5>$J K0P!1WQOY_0?F?2O6O
M&9V^!O$!]--N3_Y":@#Y5T<A]'MFW?PD?D<5%J%Q+I=WI>KV[_OK"Y25!@?>
M!# \Y[J.QZT[2 #H]MQ_"3Q]:O/&CP;)$21#_"5X- &U\2KRTU'XPZA):%76
MWMHXWD1]RN^U<X(] V,>JFL575BP_6H1#'$28H8T+\L57!/UJ92<D\?XT >D
M_L^3*M]XMM!M&V:"11GD@^8#^6!^=>Y5\_? =Q_PG?B-3PS6J$*3R0&'/ZC\
MZ^@: /F'X@D?\+E\3#!)V6W0_P#3".N__9R_Y)[?_P#85D_]%15YSX]FAN?C
M#XD>)@ZCR$)'9EB16'X$$?A7HW[.7_)/;_\ ["LG_HJ*@#U^O%?VA;2-],\.
M7NUFFAOS$@![.H)'IU1:]JKQW]HF<Q^"-,5=RN=31U=<C&V.3OV//Z4 >3ZE
M"L^EW,;1*Y\MB@_V@#BM'2?C%J>EZ-8Z?':.4M;>.!3_ &D5R%4*..W3I55E
M#03;CA-IR3]*\W &/O?^.T ??=%%<'<_&+P#:W,EO)XBB9XV*L8H)I%)]F5"
MI'N"10!!XR^$'AOQ?YUT(3IVJ2'<;RW'WC@_?3.ULDY)X8X'S5X9XBT+Q)\.
M[H0ZU;"[L78)!>PME&XSC.,@XSPV#P<$CFOJG3]2LM6LH[VPN8;FTE!,<T3A
ME;!P<$>A!!]"*9J^EV6MZ5<:;J5LES9W";)(GZ,/Y@@X((Y! (Y% 'R??6=M
MK-JK;D+E?W4R_P"?K7L_P3\;7&OZ-/H6K2,VIZ7@!I'R\L62 3ZE3\I/^[WK
MROQ5X2N?AKXH2Q:9KC1]0):SG;[P(."K=MPR 2.""IXY =X'U,:)\7=!NB2J
M7C?9)57^(R HN?;<4/\ P&@#ZKKY$OF1_'WB]UVNK:K,5.<@CS9.:^MY94AB
M>60X1%+,<= .M?&VDW(N$U+4'0+YUP\K8 ''WL?3DT ==X"^'L_Q&L=0U!M?
MFL8[>[,21)"'XP#G<&'8XX_6NL_X9\O@Q*>.;@*>@-B3_P"U:W/V?K$VOPW:
MY9"IN[V64,0/F4!4X]LHWXYKU>@#Y0\2>';OP1XSCT*XU9M1CFM1<"1H/+P2
M6&,$G^Z>0<<^M=5\$99(?B=K5J&)CFT[S6 X&5>,#_T(_G47QH;=\6;'9\VS
M2$#X/W?WLO7\Q^8I_P %)=_Q6U5>NS2BO_D2(_UH ^AZ^*]6B']H^+479A;Q
ML;#\N!*W3VXK[4KXXU^X!\2^-Y@O$E_/@/QC=+)Z]^: /JGP5(TW@/P[+(<N
M^F6S,<=28ES2>,]$7Q'X-U?263<UQ;,(P.?W@^9#^#!32>!/^2?>&O\ L%6O
M_HI:Z"@#XRT*07&DQ+CE&*'T]?ZBNL^'2EOC=H(7Y@D,Q8@?=_<R]?S'YUR^
MG21F?4!"9#";R0QJV <$]P. <8Z5W?P;1;GXO7CLS9M],=EVM@$[HQSZC#G\
M?I0!V_[0 #?#5"S@$7T14%]NX[7X S\W&3CGIGM7CY&,;B<"O5OVAF9O!FDP
M"/S&DU1" 3@'$<@Q^.?6O(KF0Q6ES(V %C+<?0T >M_L[[Y?"FLW)3:DNIMC
MG/.Q"1^HKD?C'9PZ;\6;6[B)5M1LU:?.3EQE 1Z<(@_#/>O1?@58267POLY7
M(_TN>6=5Q@@;M@_/9GZ$5Y]\;Y5N?BCI5NN?]&T\.Y'J7<X_E^= &-X/MEO_
M (M^%[=U5T61YQN/&41G!^H* CWKZFKY7\&?\E9\,;=SMYLGRHA.!M;GCMUS
MZ8R:^J* /E_XE7#7GQIU16=62SMXHH\>GEH3GWW.U=C^SUI\-UH>NZK-;QNU
MS>B/+J&^ZN['_D3TKRK4;Y-1\5>*]61]\4UW,T,R'@IN8C!'7C;^E>[? :Q^
MR?"ZUGRI^V7,T_RC!&&\OGU/[O\ +% '?RZ=IHC9Y;&VVJI)/DC@8Y[5\>:&
MJ?8)?*+K'Y[E"W7;A>M?6_BV_.E^#M:OD*B2WL9Y$W="P0D#\\5\A6+FR\+S
M2L1F0-MY]>* /<?V=++;X1U747+&6YOS&2W\01%(/OR[?E77_%R[%G\+==<R
M!#)"L0SW+.JX'U!-)\(M,.E?"[1(FQOFB-RQ (SYC%UZ_P"R5'X5S7[0NK"S
M\"6VG* 9+^[4'*]$0%B0>QW;/P)H \8TY#'I-O&1@F,'@^O-6"6123P<5-H&
MB3>*/'&D^'8YY(X"/,N9(P>$523G!XR!CKU8549)+36]:TAI)IEL+V6)'F;<
M^T,5P>2/X.Q[F@ ENH+6+S9W"H#@$C.2?IUIEM=P7?FBW?>4(W J5QGZCVK0
M\(: WC+XC:=IBQ1R6=B_VJ[$F"IB5E+*03SN.U.,_>ST!JYXYD+_ !@\1XR!
MF,$<=1&@SP!_C]>M '2_ H@_$+Q 0(Q_H:]OF^\O0^GK^%?0E>"?L_QO)XD\
M57 V^6BPQGUR2^/_ $$U[O)(L432.=J("S'T H ^1]:N5N/B!XNN3M8#4)0I
M4\, [@<^X KV7]GVS:V^&K3,ZL+J_EF4#^$!43!_%"?QKP6*[6YCUK5%3RQ<
MSRRJC8X!RP&>_P![%?2/P5MOL_PGT7*[7E\Z1N<YS*^#^6* /0*\3_:%NHVM
M/#>F;0TL]XTN",C:H .?^^_T->V5\Y?&/5?[4^*5EIL1^72;7,A'4.XW'MTP
M8_S- '&ZI+Y.C73 E?W94'Z\?UKTSPU\&]-U3PMI&H2;=]U90SM]60-_6O,Y
M;"XUW7M(\/0.VZ_N$1V7^%,\G\!D_P# :^N888[>".")=L<:A%&>@ P* /,_
MCMKUUHG@ 064TD,NH72V[/&Q5A'AF;!'KM ([AC[UXI:Z1:VMBMM+$LBR8+Y
M&<M7N7QO\.3^(/A]++:(TEQITHN@B]60 JXQ[ [O^ U\^ZAJ/V_P]#=8D"?:
M%^T+$^&4#KS^6,@]10!Z1\"]1N-*\9:GX7BD>XL)83=#;@^3(I4$MZ9!"G'<
M+^'T+7 ?##PGX4T30DU?PP9KE-2C#&[NG#2[0?\ 5\ !<-D$ =1SG QW] 'C
MO[1,<;> =/E?/F)J2*A ]8Y,@\^WOT]Z\MT2V-U\3O"=M'@.E]'.3[*X8_HA
MKN/V@-374-3T/PO"_P"\7==SG;G:#\J<YZX$F1[K63\$]*&L?$R]UE@QATJ
MB-E;CS'!09]BOFG'KB@#V?XD:JNB_#K7KW=(C"T>)'C)#*\G[M2".F&<&OE?
M(L?!V,8:=??DL?\ #^5>X?M!ZZ;7PO8:%"Q$FIW&Z3'/[N/!P0.?OE#_ ,!-
M>3Z?I/\ ;GC#PUX>$"2QO.AER#DQ+R_X;58_@* /I;P!I:Z-X T&Q$1B9+*-
MY$/42,-[_P#CS-72T5%--';P232L%CC4NS'L ,DT ?,/C^^@U+XQ:O+;$E+6
M-;=R'#!W50&Z=,'(QSRO;H.F^ -OYGBOQ3>*!MC2*+/7EF8]?^ 5YM82-J&H
M:QJ\CEDO+J23>01N^8L3S_O5Z_\ LY:8EOX/U/4BN);J]\O/JD:#'ZN] 'LK
M,J*68@*!DDG@"OBB^N5N[+6KR/\ U%Y?L8020V2V[D?0C]:^N?&FK#0O!6LZ
ME_%!:2%.,_.1A?PW$5\FZ+:2W4OAS2@ZK_:&H1C)'"YD51GU^]F@#[$TJU%E
MH]E:",1""WCB$8.0FU0,?ABI;V\BT^PN+RX)6"WB:60@9(502>/H*LUROQ%O
M&L/AUX@F4*3]ADCPP!'S#;T/!^]T_0]* /E[PR/^)02V>9&.3^%>J_L^P"XU
M'Q5JAAPI>&&*4$E3]\L!Z_P'\17EVGN;/P[',VT>7"7'&.N2/\^]>]_ O3EL
M?A=:3*CH][/+</O[G=L!'MM1?3^M '+?M"3I-=^%]. 8R--+*V"?E7Y!TZ'O
M],>]>3Z])MTUH "TDSJB*.2><]/\]:[[XRW N_BW8VV1ML[!?E!S\Q+M^'!7
MCV]ZQ?!^DMXE^*VBV:@F'3V%[<$*"%"$, 0>Q81K_P #H ^D/"ND?V!X4TK2
M<*&M+6.*3;T+A1N/XMD_C7S3X@U;_A)OB9X@U0-NBAD^S6X#EEV)\@(ST#;"
MV/5C7T1X^\0#POX'U750^V:* I!SSYK_ "I^1(/T!KY@T2!K;1T,I"LV9&..
MQ]?PH [#X5V1U'XR6LB3!1IEE+.ZE?O;AY>!_P!_5/X5[]XGU#^RO"NKZ@)&
M0VUE-*K*<'(0D8]\XQ7DO[/-B]Q%X@\0R!0+B=+6, \KM&YOT=/RKHOCQJ36
M'PQGA#E3>W,5OQW&2Y'Y)[?TH ^=546W@\L/E>4G/N2V/Y"OK+X=Z<FE?#S0
M+5%V_P"A1R,-NWYG&]LCURQKYDCTN;5]7\/^'(U(2[GCCD"\$*, G/H 6/X5
M]@*JQJ$10JJ,  8 % 'E?Q\UHZ=\._L*MB;4;A(2H;!V+\['IR,JH[?>_"O!
M[C3GG;1]"@&&N[A(05R>20.F.Y;/X5Z%\;-3&J_$S3M(5P\.EVWF2*?X9'^8
M_P#CHBK.^&6G'6?C'9[E5H=+MWNG5N_RX4CW#2(?PH ^EK6WCM+6*VA4)%$B
MHB@  *!@#BO OCKJGV[QKH6B(RNMI";B4 @X9ST/<'" X/9AZU]"U\G?$/4S
MJ?Q(\67\( 2T'V1=S %60!#CU^9&/Y"@#M?V?-,%]?:[XEG0>9N2V@[[<_,_
M./3RQP?7(Z5POB@IIGC_ ,8MD@"]:7!4J26+-TR>[=>_7 Z5[S\'M"70OAII
M:X'FWR?;I2.YD *_^.;!^%?/_C2"?5OBWK6D192;4-52V1I) V,L%'3C&2IQ
MU &#S0!Z]\ /#S:=X2N-<N5'VC59<HQ)+>4A(&<],MO/N,&O,?&A27XM^)G5
M@P651QSSM4'^6*^GM*TVVT72K33;12MO:PI#&&Z[5& 3ZGCDU\C7%^MYXD\4
MZK&K+#/>S3IG/0N[8^N"* /7?V=()6T#7;YE79/>J@.<DLJ9(/\ WV/S->D>
M.[^73/ 6NW< 8RQV,NPJ0"I*D!N?3.?PKE/@-IZ67PMM;A>M[<S7#<YY#>7^
M'$8JM\?M:;3?AZMC&ZB34KI(67."8UR[$?BJ _[U 'SX8_LWA#<.3+@G(]6_
MPKZ]\':>VE^"=#L74"2"PA1P#D;]@W?KFOEFWT8ZMKWASP[EF2XN8XY0G9 0
M&;'LNX]NAK[#H S]7U2TT72;K4[Z416MK&99&)Z >GJ3T [D@5\E6=])JNIZ
MMXANPJ/?7+RD9.$!8L0,GIR /]VN^^-/C-O$6KIX,TF5&M;5]]],I/\ K5)&
MP]B%[]?F(Z%:X3^S[C7M3L?"FB1[IIB%?;TC0<DD^P!)_P#KT =Y\"]"GUGQ
M/>>+[N$+;VL9M[0M_P ]&^\5/?:F0<C_ ):>U?0U9'AW0;+PQX?M-'L$Q!;1
MA=Q',C?Q.?<G)/UK7H *^9?BA\/I? VHS:WID"S^'KY\2VX&/LS'HI_V2<[3
MCC[I[$_3507%O#=6TMO/%'-!*A22-U#*ZD8((/!!'&* /D_P!X^O/AWJ$3K*
MU]X?O6W7%L.&5A@%T!/#CCC.& P>@*_4VDZO8Z[IL.H:7>17-K,NY)8VR/H1
MU!'<'!!X-?._C[X1:CX1FGU/P[#+J&ARC,]L1OD@'?..64<D,.1WZ9/*^#O$
M^M^%KPW/AJ_A\J8_O[&YY1B!W'4X_O*0?UH T?&VIR7/Q0\5:A)M?[*QMTV\
MJNP! .O7Y.??->P_ G1/[)^',5Y)'B;49WN#E,-L'R*.F2,*6'^_[UX!JXO?
MLVKZE?-$;K4KCSIECX569RQQ^+'CMZU];^%;;[%X0T6UWEQ!801[BNW=MC49
MQVZ=* /#/C+>Q7_Q4T^R3:WV"Q!DPPRKL6;!_ H>QY^E'P>M#J7Q7NKLA_+T
MZQ;:R_=WL5 !^H9_^^:H?$ [OC1XBSC"Q6X&% _Y8QGKW_SZ5U/P!CC_ +6\
M7S?\M1+ O7HI\P]/P_2@#W*N7^(E_%IOPZ\07,DAC_T"6)6!P0[J43_QYA74
M5YK\=+H6_P *M0B)'^DS01#(/:0/Q_WQ0!X!M%KX2^4,#]GSSURW7]37TM\*
MM+&D?#'08 P;S;873,!U,I,G/T# ?A7S+K#'^P(XMKM)+Y<:A5ZMUZ?A7V)9
M6D.GV%O90 K#;Q+%&"<D*HP.?H* //OCEJ7]G_"^]B# ->S16ZYQ_>WG'X(?
M\\UX[X2L7N_B9X/L3A_)?S<D9!\M=Y//^Y7?_M$7#2:;X<TGS_+2ZO'D(V9&
M5 4-GKQYAX[Y]JY?X86XO/C-:2!'8V=C+(2!PI(*Y//3]YCOR1]0 ?2M>:_'
M2_M[3X5ZA!*Q#WDT$,( SEQ()"#Z?+&WY5Z57B/[1-R)M-\/:0H_>W5V\H;/
MW0JA>1_VT_0T >1:S*MKX:CB7D,B1*?PS_(5]8>$],.B^$M(TQD5'M;.*.0*
MNT%PHW''J6R3[FOF"TTQ-6\<^&--.766\7S5!^;R]RECQTX#<^U?56LZ@-)T
M+4-290RV=M)<$'N$4MV^E 'R_P"*+PZC\5O%-Z[ ^5<&VW 8 "80?I'U]J[O
M]GG2A.=>\32+AII1:1 -]T##N#Z_>CY]C7C4<S)HM]J-S*9)[]FR?5B6R>GN
MQKZI^%_A_P#X1OX>:39.FVXDB^T3Y'.^3YB#[@$+_P !H X/]HB\G.E^']&C
M8K'>W3R.0/[@51GV_>$X]O:O'=;NC#I\L:C&_"#!_/\ 05Z!\9KN:Z^*]E:E
MPT-E8J0B\[2Q8DGT)ROY"N7T?28]=^(GAS360%9+GS)EY^9%P[#CIE5(R* /
MH_X?:#_PC?@+1],>,QSQVX>=6QD2O\S@_1F(_"O+/V@[DW.M>&=)5P5'FW$D
M77.2H!(^BO\ K7O=?,OQ5G^V?&6[C,K2?8[.) K#'EY4-@>O^LS_ ,"- !\+
MM/&L?&"VD9E5=+M'N2I'WS@(!GMS*I_X#[U],,P52S$!0,DD\ 5X)\ K1+OQ
M1XFU<@,T,<5M&XS@JQ)('8_ZM?\ )KU;XA:DFD_#W7[MI3$5LI8XY%."LCKL
M3!['<RT ?--QK?\ PD/C/7M??<RW,^(6/'[L<*.?152O3_V=[!9-.U_Q Y'F
M75X+<+_<"+O/Y^8/^^:\AL%2U\,F3G_5,Y..YS_]:OHKX+6@M/A3HY,)B><R
MROE2"V96"M^*A<>V* .\GF2VMI9Y/N1(7;'7 &37Q3>32:C:ZCJ;KLDU.^+!
M0V%R6+8Y[9)ZGM[<_8/BZZELO!>NW<#;9H-/N)4/!PRQL1U]Q7R=X?M3=:CX
M1L%BC<7.HH6!7(/[U1S[8//'04 ?7^E6*Z7H]EIZ,62UMXX%8]2%4+D_E7A'
M@SPU)/\ M&:]<D[HM.N;F[9BA +2DA5Y[_O"<_[&17T)6'H_ANTT?6-:U2++
M7&K7"32LPY 5 JI] =Q_X%[4 :.H77V+3+J[) $$+RG/3Y03[>E?%Z7#)X8N
M)),.]Q*Q).!R3@]/IFOJ?XK:FNE?#'7ICUEMC; 9&3YI$??V8GZ U\OV%D;Z
M?PYHSH2MY>1HRAL9W.!CZ_/^% 'UGX)L5TWP-H5F(_+,5C"'4KM.\H"V1V)8
MDUX]\==234O&N@Z$I#+9PM<RX8')<\*1ZXC!^CU[^S*BEF(50,DDX %?(FJ:
ML/$OC[7]::19!)<%(&5< Q#Y4_\ '$7GO0!TWPR2WE^+L5Y=7$5O'IMA),7F
M;:.1LZYQTE)Y]#72?$OXOQW,<OAKP;/Y]U/F.XU",C8B8Y6)NY/]_H!]W)(*
M^8W.EV5Y*9KB!2P7EMY'YXJM;JTU\ND^&=/:[OYP5'D L5Z=^X'4G.!U/>@
M$#Z0(-*TNW:YU:\(5=B9)).!@=_8?B??Z'^%GPX@\#:1Y]SMEUF[1?M,G!$0
MZ^6I] >I[D#T&*OPQ^%=KX/@CU;556Z\02J2TI.X6X;JJ^K=BW7D@<$Y].H
M**** "BBB@ KR3QY\%;+Q#=OJ_AV>/2=6;YG7!6&9O7Y>4;U(!SW&237K=%
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MKB:4&-ZUC,(0BL7)V'A O.[^[COBOD33M7M;"P6W$$IG#'<F/O-_GC\*^L?
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MM$4NV5VL<-D?-SGO@G!!P044 <%I/[/OA"P97OI+[4F"$,DLWEQD^H" ,/\
MOHUW&B>"?#/AS8VDZ+9VLJ A9A&&E (P?WC9;]:** .AHHHH **** "BBB@
2HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>g2018030121531013631431.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531013631431.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %= F # 2(  A$! Q$!_\0
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M&ZNI+I)'2*&/YU$;!7W!B,%6.,=:KKX<O+2YAO+"]@6ZC>[R)H2R-'/-YI&
MP(8';S['CGBO=>$+B;1X[!+JU,F^69KR2W;SHYY'+-+$5<;>6.!],D]P#1N_
M%-C9W,Z/%<M!;2+%<721YBA8XX8YS_$N< XSS45WXQTZSN;J*:"],=I.MO/.
MD!:.-W"[>1R<[@. >?PJ"Z\+WDZ:A8QZA$--U&7S;A7A)FY"AU5MP7!V]UXR
M:M/X>9H=4C^TC_3K^.\!V?<"B+Y>O/\ JNOO0 Y?%%F;>=G@NXIX9D@-L\7[
MUG< H  2.0<]>.<XQ5[3=3BU..8QQRQ202>5-#,NUXVP&P>W1@>/6LK5O"XU
M2:YE,T19YX9XTFAWINC4C#KGY@03Z5HZ/IW]G6\J&"PB:23?MLK?R5Q@ 9Y.
MYN.O';CB@#3HHHH **** "BBB@ HHHH **** "BBB@ HHHH Y+Q++,WBGP[;
M00;G5YKAY&< ",)L88[G,BGCTK6K+\;Z=J,VGQZII-U';WNG)+*&>/>'0IED
MQ[E5J]:SK=6D-POW98U<?0C-,"+5;=[O2+VVB_UDUO)&F?4J0*M>%[U=1\+Z
M;=+&\:O H"OC/'R]OIFL3Q$E]?/9:/I]X;*6^=P]RL>\QHJ%C@>YVC\375V-
MI%I^GVUE ,16\2Q(/]E1@?RI 6**** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH ***Y[Q-XOTWPQ /M+&6[<?NK:,Y=OKZ#WH Z D*I). .I-<EK'Q%T#2F:)
M)VO9QU2V^8#ZMT_+-<V=(\8>.F\W59O[)TMN5MP#EA_N]3_P+\!72Z3\.O#N
MEJI>T-Y*.KW)W?\ COW?TH Y&X^*6L7TACTO38H\],AI7_3'\JK'6/B#>$8C
MU( ]-EGL'Y[:]?A@AMHQ'!$D2#HJ*%'Z5+0!XH]QXYC),G]M #J=DF/Y5&OB
M_P 3VC[7U"=6])8U/_H0KV^LO6]-GU?3VM(;I+97X=C#YA*^@R1@^] 'CT/B
M34XM;;5TE"W3X\S:N%<8 P1^%>L>'?$UIX@M-T9\NY0?O(&/(]QZBN=7X76H
MSOU.8_[L0']:O6/P]LK"ZCN8-1OXYH^59&4'_P!!Z>U/0#L:*P-4\9:#HNY+
MO48S(O!CC^=L^^.AKE+SXTZ#!D6]K=3$?WBJC^9I >E45XS/\='S^XT=!_O2
MEOZ"J3_'+5L_N],LA_O!C_[-0![G17A ^.6M_P#0.T__ +Y?_P"*J>'XZ:@I
MS/HUK(/]B1D_GF@#W"BN T#XN>'-9=8;II--G;C_ $DCRR?9Q_7%=\"& (((
M/0B@!:BFGBMHC+/+'%&.KNP4#\37F_CWXFKH<\FFZ4RM=)\LLN,[&_NCWKQK
M4_$NJZM,TMW>2R$G/S,3B@#Z*U'XA>&M,)$FHI,P[0#?^O3]:Y34/C;I<)(L
MM/FF_P!J1PGZ#/\ .O"F9G.68D^])0!ZZ?CI=A_ET: KZ>8P-;^A?&?1M1G2
M#4[:739';:)"WF1?BV 1^6/>O Z?!!+<SQP01O++(P5$09+$] !0,^PT=9$5
MT8,K#(8'((I]87@ZPO-+\(:797[%KJ& !P?X>X7_ (",#\*W:!!1110 4444
M %%%% !1110 44R21(HVED8+&@+,S'  '<URQ\1:GK()T*T2&S;[NH7H.'']
MZ.(?,P]"Q7\: -/Q%J]MI>F2"4&6XN%:*WMDY>=R/NJ/YGH!UJIH]I)8:'86
M<S!I+>VCB<CNRJ ?Y5#IVBPV4[7DTTEYJ$@Q)=W!RY']U>RK_LK@5ITP,;6)
MUTW5=)UB4?Z+;221W#@?ZM)%QO/L&"Y] <UUJ.LB*Z,&5AE6!R"*RF574JP#
M*PP0>AK&CTB]TAF.@7RV\).XV-RAD@S_ +/(:/\  X]J0'8U%--%;Q-+-*D4
M:#+.[;0/J37&P>-[R]N5TJWTV)=4=F197GS:-M^\5DQER/[@&>#5P>"H]1E6
MX\27T^K2J=RPM^ZMT/\ LQK_ #8F@"M??$G2TF:UT:VN]:NU_@LXB4'U;'3W
M -9TFH?$K5\FSTRTTB$_=:9E9_QSG_T&N^MK2WLH%@M;>*"%>B1(%4?@*GH
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M, :UZ^>?@S'=-XYWPAO)2VD^T$#C:<8!_P"!8_*OH:@04444 %%%% !1110
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MN,->W)#2N/X0/NH/]E<_F2>]>0>&OB_/IERUCK\W]IVJ<1WUNA#GZJP7</J
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MBI6N8\66I=KB->'_ -\=_KUKR/4/A-XNLI7$5@EW&IXD@F7D?[I(/Z5])44
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MZFL7V1!-_:!!_P!)_B\O_9Q^'3WK8TBU-AIS2W%PT]Q.QN+B9AC<[ 9P!T
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MXXSSUX)KLHY$EC5T8,K#(([UY[JJW,^L7 G$RM$?,C78N!\H!V[AC^(_-Z#
MKHO#>ZS:33\2>5S)%OV_+TW#Y>.K9 ^M '1T444 %%%% !1110 4444 <=H+
M+::9?"7$<5O?WF2>R^>[9/X&LXJ__"O+:WD4I<:_=Y*GJ%GD,C#\(L_E4%SN
MDTC5;/<56_UM[1FZ8228*WZ%A]36_JH6;Q?I-JH"Q65I-<8 Z,Q6-/I\OF4
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M!FF^&/#<.L:WI6NW=Y8VB/'-')TBQAC@8&X\#!'6@#E?B+I,Z_$"]5[![O\
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MVR)\X*M&QSSU&P\4#.J\/^#]'BO;K7+9I)K?5[>-VMI@&C.<-N/J2>?Q-=>
M%& , = !6/X3MKFR\):3:W<;1W$-I&CHQY4A0,5LT""BBB@ HHHH ***AN9U
MMK=YGSM09..] &=K5_Y,7V6)OWT@YP<%5JGH=B6N/M# ^7'PN><MC^G]?K6>
M@FN[G<_-Q,W3'']. /7TKK;>!;:!(4SM48R>I]Z )J*** *U[<BTLI;@A3Y:
MYY.!^)["N(FWQLB_N0844M(DY3S$YX_F>O\ .NMUQ@ND2LS*H#)\S=!\XZUQ
M\OR+)Y0V!I0K?9\%"0,_=_B..OM]*8!;VL^K3):6JOY$>UL3!6\L=CN!R".P
MSGBNOTW0[/3/WJH);I@-]PXR['&.O:N2\/:Q/:">UBAA$C3%V+C!(.0.%X_@
M/'XUO6_BE?E^UV<D:LRJ'B;S!R,\C@_SI ='144,\5S$LL,BO&V<,IR*EH *
M*** ,3Q%/IMG;+<WMK!-)G;&)$#?Y'^/;-8$?BDQ7,;-:I%!"0SI%;2CY2.7
M#;<8Y_\ '>M=!XDTQM2TY?+0O-"XD4+C+#NO/'-9%G8:K<SRR_/%N4(#+%MV
MCW4]\Y/'K0!UX8,H8$$'D$4ZJ.FJD,,MHF=MM)Y:Y.>,!@/P# ?A5Z@ HII(
M4$DX Y)-<_I?C70]:U^?1]/NO/N(8S(74?NVP0"%;N1F@#HJ*** "BBB@#S)
MKJP?PG/:W3JMQJMS>O;1Y(9I/-=UP>Q!V_CBM;3KS^T/$<-UO$GFZ':2A\==
M[RD_R%8&LZ;#IGBS^S[PM'87A<0S#K$LTBL&4]F2X"GZ2+Z5OV&EQZ)XEBT^
M-Y)%32(D61\9;9*^>!_O_P J .@KG?'<WD>!M7?IF#9_WT0O]:Z*N<\:VQU'
M1(M, S]NNHHL>H#;R/R2F(W;,AK&W93D&-2"/I4U9OA^<77AO2YQ_P M+2)O
MS05I4 <W'<I;>'?&TLQ?8+J50%ZDM;Q  >Y)_6J=EJMO<0Z%=VKAWTW48]/G
MPH"EG3RFV^V74@^U:%EID&L^'M>CN;B2WBDU224S18W*860 \Y!P8NX[5B^#
M-/75-86:&(PZ=:.EQY9_O",);H?5A'^\;_:=1VI#/4:*** "BBB@ KF?%H-N
M^C:D1^ZM+X"4_P!U9$:+/X,ZUTU9VN:<-6T.^T_.#<0LBM_=;'!_ X- $-%9
MVB:@=2TF&9U*7"CR[B,CF.5>'4_1@:T:8@HHHH *SM<U--(T>XO';;L0X/RY
MSCL"1G R<=\5HUQWQ*./"LFXG86^8;P,COQ@YXSTQ0!;\$Z4]II)U*Z'_$PU
M+_2)C_=4\H@]@#^9-=-34*&-3'C80-N.F*=0 4444 %%%% &/>:<[ZE)<M;)
M=1RHB<MAX@-VX+GLP;U'-9LEK;BX\Z_T?[.S-_K8[=6SN;^)EW%0, [CZD=*
MZJB@#"T.<O<,EO-+/9&%7W/DA'R?E!/MU&3C'O4\G^F>,=+M8X]_V))+N9B>
M$#*T:#ZDEO\ ODUK51\((+B/4M7/)OKQQ&W_ $RB_=K^&59O^!4AG2T444 %
M%%% 'G7QCLYYO"5M>PIO6RO$FE'^S@KG\R/SKE?!UA'XLC\=:78W)M[6_FBF
MAEV9"+YCL 1QU&!7M4\,5S;R03QK)%(I1T89# \$&OGJRU+5? WC?7H]!@,M
MG;3,9[1AG= K'!]?E#?>]\GC- 'I_P // MWX+EU87%W#<1W31^28P0=J;^6
M!Z'YN@STKAOB/X;2#QO/JES>1Z593QI)#=*,DS#:#\B_.3W+ <<?CZII7C#1
MM5\,G7EN5ALXQ^_,IP86[J??D=.N1BO$M3CU'XI>/[HZ6Q>W0 1-,=JPPC S
MCZG.!SS0!ZEXH\/+XV\*V,VE:K!<:A9,);>\B<;)' &X97[N2 ?8@5PWPTU*
M:?XJ7S7QAM[N>WDCFCC/RRS*5W$8XR=K,>W7%>L^%_#EKX5T&#3+5F<)EI)&
MZR.>K8[?3T%>2Z?X>\+:1XNT_37U2YU/4)KN:)GM-JK$"-NV3J<_>Y!]: .N
M\1Z7H/Q0G>RLM4,5_I$Q21A&3E6.& !QD97J/3WI^O>*]$^&%O'HNGZ3.&DA
M:>$*<Q[B2.69LGD<^@Q7 >(;&Z^$WC"UN=$NGEAG@+8N%!W+N^9&QUZ*<C%>
MJO/X;\;>$=,OM96!+.X=9(TGF\O$P)4H#D9YW+CO0!YKXHU[Q%XD^&"W&JZ;
M);"&^C)G\LHL\;*^" >P.T9Z'(K?\!2IXA^)FL:_8Q.FEP6JVT&5QV10/R1C
M^(KJOB)HNK:YX3.F:*L>^29!,KOL'E#)X_X$%_ &N:\$74_@#PYK4/B*WN(+
M.TO0()O*/[[=\OR^H^4'/3YJ )OB3X5OFOX_%.D)'++!"T-Y;R'"RQ$$'_QU
MBI]L8J?X>7FC^&?" AO/$UA(QS<M ;F,FV! RG#'/.?Q/2KO_";>$/&.GW&C
MB\5Y+I"BV]R&BWG^$;OKCH<UQ7A_X.WM]J NM?CATZT4_P#'G;2%V;VW%FVC
M\2?I0!V'A_XH6?B3Q<-'LK)EM61BES+*%9RHSPG_ -?/M7?URNC?#SPSH.H)
M?V.GE;J/[DCRN^WC' )QWKJJ "BBB@ HHHH *P_$4Q,$-JIYE;<0.>![?_6[
M5N5S&OG?JD<9Z"(8^N3]?Y4 2:' 'O'D(^6%< _[1X_/&?3K71UC^'^;:X)S
MN$VWG_=7_&MB@ HHHH S==_Y URW.4 <8'.00:XZ2%IE+HC!]V1BV9">.F01
MQ^-=;XBN(X-"N1*V%E7R<8SG=P1^6:X[2I0T364J S0\-&8^)/1L;MOYX_2F
M!Y!J.M:MI>K36X=(FA)3Y,D,,$9R?4$\^]=%X;\>/+=PV=Y'C?\ (&4G!)YQ
MZC<?3T%=3XA\%:?K\QN)&>.YX4RHP)ST"MQ@DD_@ /QRM.^&=G97D=Q-<R3>
M4Z-M.-K9.T?J,]>E 'H.F736.IVZ(V+>Y.PPB)D&X]&&>_!R!ZY[5U]</H]L
M;K6K;R@5CMP)G*K@=& 4^O/3OC-=Q2 **** (+JX2UMI)Y,[4&<#J?0"N%N]
M?GNHD>34_*C9U;RHTYVGN2.@]CVZ\].ZNK=+NW>%R0&P<CL0<@_F*X6TM)K7
M1YM+,2FYCW)*V0/^!?\ ?.",\8QS0!N^&-32Y6XMVDW.),H[!@7&T=0W.1CO
MVQ725R5M#.US:7C1JBVS LX5AN4_*1R/]K./;\^MH \S^,VO3Z9X<M].MG,;
M:B[+(P.#Y:XW#\=P_"N3^$/AN.?4X]=;6((98'*I9QNIDD!!!W ]%.>/Z5TG
MQOTN6YT'3]2C7*V4K+)[+)MY_-0/QK \!GP%J7AF&Q\00V$6HQ2.A>4F)I%)
MW [QCUQU[4 >YU5OKV+3[5II3P.%4=6/I7(6W@6Q53+X>\2ZK91GI';WGFPC
M_@)S_.M.\T'4KB")9;];IXEP'D786_+CF@#?M+N*]MUFA;<K?F#Z&IZXC1;Y
M].U#RI,B)VV2*?X3ZUV] &-XB\-6'B:Q2UOQ*H1]Z20OM=3T.#[CBJ&MC[-X
MNT:YZ+<03VA/^U\LB_HCUU%<]XSA<^'GO85+3:=(EZ@'?RSEQ^*;Q^- %JLJ
M^4R^)?#T>"56XEF/_ 874?\ H=:<<B2QI)&P9& 92.A!K-N"J^+M!8@[F^T(
M/^^,_P#LM,"/PM&8?#MO ?\ EB\D(Y[+(RC^5:[,$4LQ 4#))K&\*'?X<MI-
MQ;S&DDR>OS2,?ZT[Q+)*=(^PV[%;G4)%LXB/X=_#-_P%=S?\!H%U+W@^$/X.
MLVF3(O%>Y=6YSYK-)S_WW6KINF66D62V>GVR6]NI)")ZGJ?<U/!!';6\<$2[
M8XD"(/0 8%2TAA1110 4444 %%%% '(3E-(\:3QN#%;ZK$DD1(^1KA=RN/9B
M@C/OM-;%6-5TRVU>PDL[M24;!5E.&1A]UE/9@><USNAZG-(B:9JBR0ZQ;Q_O
MDD3;YN.#(AZ,I]NF>U &U1113$%07EG!?VCVURA>&0;77<5W#N..U3T4 1P0
MQVUO'!"@2*- B*.R@8 J2BB@ HHKG]5\4PZ5J$<)M)KFV((EGMOWGDO_ '64
M=* -V65(87ED8+&BEF8] !U-5AJNGM;"X^VV_DF+S=YD &S^]]*\^\1^/GOK
M2>QLH6M895*/+-_K2IX.U/X?JQZ5Q >2]?R5WB,QK"L<?S%D4[MH]>1N+=/Y
M4#/?8KRUF6)HKF)Q,NZ/:X.\>H]:GKQKPA91:EXILS.+N;[*5\MK=1Y,6SD
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MLO'TKOH+:TT^WV6\,-M"O.$4(HK-_MN;4IC;^'K9+]E.)+EG*6T?_ \'<?\
M97/OB@"S=75AX?TU (Q'&N(X+>%/FD;LB+W)I-/T&[U&XAU+7R 8V\RWTY,&
M.$]BY_C<?]\CMZU:TCPX+2Z_M+4IA>ZJP(\[&$A!_@B7^$>_4]S6_2 ****
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M5?+S-([K@'D@MQN_V5_^O2&?15%%% !4-S,MM:33L,K$C.1]!FIJ8Z+)&R.
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MN6-M':I_OO\ O'_014TD)XZU1%Y$EC:R-C^%MTR_R JQX0&^SU*['_+SJ4[
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M2PR,TDY6-HURI4;/E8D_,V34^D>'KG3[3P[%*\#/IENT4I4GDE OR\>H[XH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M2%0!M9G&&W=!U[5N>&-#_P"$?T9;1Y5FN'D::XE5=H>1CDG Z=A^%;6 #G%
M'(?\*U\-F9WDAO)4?;OBDO)61MOW01NY ]ZZN&&.WACAAC6.*-0J(HP% Z "
MI:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?Q'U,:D?HU 'H%%<C!\2O"D_!U(Q'TD@<?TQ6G#XN\.W! CUNQR> &G53^M
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M*?;G_OIZ[NB@#AQXC\<1;?.\%H^?^>=^G_U\5)_PEOB9/];X&NP3T\N[1_\
MV6NTHH X\>+]:VC=X,U0-W =#4J>+=3*_/X0UA6]%\L_^S5U=% '+?\ "6:B
MW"^$=9W'@9$8'Y[J5?$>OOD)X.O<@?Q7<*@_FU=110!S2ZMXID V^%H8B1_R
MVU->/^^5:GJ_C"8<PZ); ^LDLQ'Z+_.NBHH P!IGB&8YN/$21 G[MG8JN/QD
M+U(GAFU<?Z;=:A?^US=-M/\ P!<)_P".UMT4 5K2QM-/A\FRM8+:/^Y#&$7\
MA5FBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>^'-+N[B747GGM(I)&_M*X&YF0$G ?UK0_X1;3/[VH_^#.Y_^.4 =C17'?\
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M:WCA+B_4;MJA<_=]JN>=XE_Z%Z'_ ,&"_P#Q-,#5HK*\[Q+_ -"]#_X,%_\
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M ,&"_P#Q- &K165YWB7_ *%Z'_P8+_\ $T>=XE_Z%Z'_ ,&"_P#Q- %O1?\
MD9]8_P"N%M_[5KH:Y[0+74EU+4;W4;..U\](41%F$F=N_)R /[PKH:0'.31^
M,S/)]GNM!$.\^6)+:8L%SQG#]:9Y7CC_ )^_#O\ X"S?_'*Z:B@#F?*\<?\
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@T]9EIH=A8_8/L\3+_9\#6]OER=J-MR/?[B\FM.@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>g2018030121531034432031.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g2018030121531034432031.jpg
M_]C_X  02D9)1@ ! 0$ W #<  #_VP!#  (! 0$! 0(! 0$" @(" @0# @("
M @4$! ,$!@4&!@8%!@8&!PD(!@<)!P8&" L("0H*"@H*!@@+# L*# D*"@K_
MVP!# 0(" @(" @4# P4*!P8'"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@H*
M"@H*"@H*"@H*"@H*"@H*"@H*"@H*"@K_P  1" #6 E0# 2(  A$! Q$!_\0
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHS0 44%E'4T;AZT %%(&4]#2T
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M)"NO\+'/0@U]O(P89:OR_%86M@\0Z-56:/O\-B:>*HJI3V9)1116)T!1110
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M\MS.[7%Y,TDTC%II'.6=R>6/N3DGZU\MPOET:>:8BHU\#Y5Y7_X![N?8V53
M48)_$DWZ=145YW6&)&9F.%55R2?3W-?L)_P30_X-_? K^"-,^-'[;&GS:CJ&
MJ6Z7%GX),C11V"MT^TD89G(QE 0%Z$YS7PY_P1I^ &A_M&?\%"_ _A?Q3:>=
MI.BRS:[J5NRY69;5"\2,.ZF;RL^HS7](L">7$J^E:\69QB,+-86B^6ZO)^3V
M0N'<LHXB+KU-4G9+S1YOX5_8_P#V8O!.CPZ#X9_9^\(6UK;Q^7&BZ! S;?0L
MRDM^).:\W_:(_P""3W[#W[2>F-#XS^"6EZ;?*FVWU7P[ ME<0GJ"/+ 4\_WE
M.>E?2A;TII&]<$5\%3QF*IU.:,VGWNS["6#PM2/+*"MZ'\UW_!2[_@FG\1O^
M">'Q)M;"[O&UKP?KK.?#OB%8=NYE !MY1_#*HP?0CD5\S1G*YK^E#_@KC^SS
MX?\ VA?V OB%X=U*P62^T71)M=T6;;\\-U:*TX(/;<JM&?9S7\UT8"I@<^_K
M7ZKPSFM3-,%^]^*&C^>Q^=Y[E\,!BOW?PRU/NK_@W>/_ !LCT_\ [$W5O_08
MZ_4/_@L_^V3J7[''[&FIZMX.OVM_%7BRY&B>&YHVP]N\B,9K@?\ 7.)7QZ.R
M5^7O_!NW_P I)--_[$_5?_08Z](_X.<_BQJFN?M,> _@W]J8:?X?\(OJ1A!X
M-Q=W#(6/T2V7'ID^]>-F6#CC>*J<)*Z44WZ*[_,]/ 8EX7A^<HNS<FEZO_@'
MYFRR3SR-<3R,[,=S,[$L3GJ2>3GW_'FO</V!_P!@SXL?M^?&>+X:?#T+9:;9
MJ)O$?B*>/=#IMN21G_;=CD*O<\]!7AX^8]*_HF_X(D?LNZ3^SE^P/X0U$V,9
MUSQO:KXAUJZ$8#O]H4/!&3UPD/EC!XR6QU->[Q!FDLKP-Z?Q/2*['E9+@?[1
MQ7O/1;G2?LG_ /!(W]C']E'0K>'0/A98Z]K MT6\U[Q%;K=33OCDA7RJ G.
M!QG&3Q7O5Q\&_A5>6']G7GPR\/R6X#!86T>$H,]>"N.:ZA0P.<49(YS7Y)5Q
M6*KU.>I-M^I^C4\+AZ4>6$$DO(^-_P!LK_@BO^QW^U+HM]J.D>";?P9XJFMV
M6S\0>'85B5)<?*981A'7UP ??-?A+^UG^RK\5OV-OC3JGP1^+NF>3?64F^QN
MH\F&^M6?$<\9_NLH/'4$$'!K^J @MU%?G7_P<9_LNZ7\5/V/XOV@-,L+==;^
M'.J0RS7'E#S)M/N9$@ECW#D@2/%(.P"OC&37TW#>>8C#XR-&K)RA)VUZ/^NA
MX.>910JX>56G&TEKIM8_"H'G&:_6'_@UFX\4_&P?]./A_P#]#U&OR=7AL 5^
ML7_!K/\ \C1\;/\ KQ\/_P#H>HU]IQ1_R**GR_-'R^0W_M*%^_Z'PO\ \%0_
M^4B7QE_['Z^_]#KPK3M.U#6=1M]'TJTDGNKR=;>U@B4LTDC,%50!R2Q( QSD
MU[K_ ,%0_P#E(C\9?^Q^OO\ T.E_X);>%;3QI_P42^#^B7\"S1KXXM;IHVQA
MC;EIU^O,8^H%=6%K?5\GC5_E@G]T3CJ4_;9G*'>7ZG[@?\$U/^"9/PC_ &)O
M@UI=M=^&K#5/'-]:QW'B/Q%=6BO()R"3!%NSY<<>2@Q@MC<>N!['^T%^R?\
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M5BZ_W=C#TKXG_P""W7[+NF_LP_M[:[;^%K&&UT'QC9Q^(M)M;>/:D!G9TGB
M' Q/%*P X"NM?;\+YU6KU/JN(E>RO%_H?SKX@<(RX;S"459I=MFGLU^J[H\)
M_9/_ &D/&O[)G[0?AGX]^!;N2*YT+4%>\@5N+NT;Y9[=AW#QEE]B0>H&/ZB/
MAQX^\,_%'P#HGQ(\&Z@MYI.O:7!?Z9=)TE@E0.C?]\D5_)DY);Y3]*_H?_X(
M+_%<_%'_ ()K>"[.YG,EUX6NKW0[@EL[1#.SQ#\()(1]*CC;!Q]C3Q26J]U^
M?4\?A7%2]I*BWHU='VA1117YV?<!1110 4444 %%%% !1110 4444 -)^;&:
MIZKK6EZ#:2:GK.H06EM"NZ:XNIA&B+ZEF( %?(/_  4:_P""PGPB_8!U-?AU
M?>&[[Q!XTN;..[M='A7RX$@<LJRR2GME3\HYXK\:/VP?^"I/[7'[:EW<6?Q&
M\?3:=X>>X,EOX9T>0P6T:XX5B/FEP.,MU]*^@ROAS'9HE+X8/J_T/#S#/<+@
M6X_%)=%^I_2?X;\3:!XPTBW\1>&=7MM0L;N/S+6\LYUDBE7IE64X(K3R!T-?
MC'_P03_X*F>%/A7ID?[%WQ_\11V&FR7DC^"=;O)<10R2R9:RD8\(I<LR$\ [
M@>HK]D;2]CN[9;F.9&5U!1T;*LN.H/TKS\SR^MEN)=&:TZ/NNYW9?CJ6.H*I
M'?JNQ<H(!ZBHU;/(:CS.V^O/.XXOXU? OX6_'SP1>?#[XN^!]/US2[Z%HYH+
MZW#D KC*MU4]P00:_G/_ ."H_P"QA:_L(_M:ZK\&=#U":ZT.\L8=8\-S7 _>
M"SF>15B8]S&T;IN[A0>M?TO7,\20F624*J@EF)Z"OYY_^"\'[2?@W]I+]N^^
M;P'K,.H:3X/T"#P\E];L&26XCFEEG*L/O!7E* ]"4)'!KZ_@VMBOKTJ<7>%F
MWV3Z'RO$]/#_ %53=E.Z2?5KJ?&M?JE_P;$^,K]?$OQB^&AOF^SW6BZ?J$-N
M6X$JM-$7'U$B@_[JU^5N:_4O_@U[\+3W'Q9^+'C0Q-Y-KX<TZQ\S^$F6>5\?
M7]S7V7$O+_8]1OI9_BCYG(>;^TH)=;_DS\O-=M9[+Q#?6-U_K8;R5)O=@Q!_
M7-?37_!%2_M-._X*=_"J>\E5(WU*]B1F/5WT^Z51_P!],*XG_@H_\"=0_9Q_
M;D^)7PMO(ML$?B6XO]+/9K.[8W$'_?*2!3_M*U>8_";XF^)O@Q\4/#_Q:\&7
M/DZMX;UB#4;"3MYD4BN ?8XP?9C7;)1QN4\L/M0=OFK(Y:<I8/,$W]F6OWG]
M9@8%N:0X'05YC^RA^T]\/OVN?@AH7QQ^&NIQS:?J]FK3V^X;[2Y'$L#CJ&1P
M5YZXR.#7IX//#U^)U*<J-1PFK-;H_5Z=2-6"G'5,<.G2FN,C-*S8%4-;\1:+
MX;TFYUS7]5M[.SLX6ENKFYF")%&HR68DX I).6Q;?*KL_&[_ (.B-8TR?XL_
M"?0(9T-Y;^'M2GEB!^98I)X A^A,3@?0U^61S'R*^A_^"I?[7UO^VI^V7XD^
M+&@W4DGA^R":1X6\SC-A 3MDQV\R1I)<=1OQVKYX?VK]IR/#U,+E-*G-6=E^
M+O\ J?E.:8B.)S"<X.ZO8_H2_9B_Y0,V'_9 =2_](+BOY[1_J_\ @-?T)?LQ
M?\H&;#_L@.I?^D%Q7\]H_P!7_P !KPN%_P#>,5_C7YL]'B'^#A_\/^1^@'_!
MMC_RD2U+_LF>I?\ I785^]B=%K\$_P#@VO\ ^4B.I?\ 9,]3_P#2NPK][$Z+
M7S7%W_(W_P"W5^1]+PU_R+5ZL=1117RY] ?DS_P=,?\ (G_!G_L*:W_Z)M*_
M'E^O_ J_8;_@Z8/_ !1_P9_["FM_^B;2OQY?K_P*OUSA'_D2T_67YH_,^(O^
M1E+T1^X'_!.^RN-3_P"#>7Q)IUFFZ:X\$>-8X_\ >,NH 5^'@'R G^[7] O_
M  0Y\-:=XU_X)&^&_!NL(3::LWB"SNE_Z9R:A=HP_)J_"CX_?!SQ#^SU\;/%
M7P1\5H1?^%=<N-/GDVX$H1R$D'LR88>S"N/AVM'^TL52OKS7^2.C.*4OJ6&G
MTY;'V%_P;IZ[IFC_ /!1>&QO2OG:EX*U.WLPW4R!H9CC_@$;_AFOW[B^9,YK
M^4W]F?X\>)_V8/C_ .$OCWX39_MGAC6(;OR4?;Y\0^66$^TB,R'_ 'J_IW_9
MS_: ^''[3GP?T7XS?"K7X[S2=8M5EBVR#S(6Z&*1?X'4\%3SFO!XRPE2&.C7
M^RU:_FCV.%L13EA72;U3>GD=_1GO49?'5_UIIE!&!)7QI]8>:_MF^)M*\'?L
ME?$OQ1K?E_9;/P)JLDHD^ZP^R2_*?J<#\:_E@A79$J,3TY)[U^RW_!PS_P %
M$]!T/X<3?L._##7H[O6=>:.3QE-:3 K96:LKI;$C^.1P-R]E7!^]7XU,P8_(
M/O=J_3^#<%4P^#E5J:<[5O1=3\]XFQ5.OBE"#ORIW]3[L_X-U+*\N_\ @HY:
MW-O;LZ6W@K5);AA_ I\I,_\ ?1 J[_P<?Q.O_!1"&5T;;-X!TXQ\<8$EUS^>
M?RKW'_@V&_9UU0ZI\0/VIM7MMMJ+>/PYHK;?]8Y99[EA[#$ 'NQ]*RO^#G[X
M&WVG_$/X<?M%Z?;EK/4-*G\/ZC(%_P!7+$YG@_[Z66;_ +]UA]<IRXPLM=.7
MYVN:_5:D>&KVZ\WR/RHDY##;_#^7^?ZU_5%^QI?Z=JG[)'PQO]'15M9O .D-
M;JO9/L<6*_E>?E2,]>*_>'_@W\_;8TCXX?LK6G[.?B'7H_\ A*_AT3:K:RMB
M2YTMF8V\B^H3F(XZ"-<_>%:<:8:I4P<*T=>5N_DFEJ1PMB*='%2A)_$M#]#J
M*9$X;G=3\CUK\S/T 3&1^%?,G_!82^TVP_X)M?%Z;5658CX7$:%N\CSQ*@^N
M]E KZ8:1%7)>ORM_X.2OVS]%T#X6Z5^Q?X0UY9-8\07<.J>*H(3G[/81DM!&
MQ[&290X'I#[BO0R?"U,5FE*$/YDWZ(X,TK4\/@9RGV9^-  ^]7ZQ?\&LW_(T
M_&S_ *\?#_\ Z'J-?DX 0V,U^L?_  :S'_BJ?C9_UX^'_P#T/4:_3N*/^1/4
M^7YH_/\ (?\ D90_KH?"W_!4/_E(E\9O^Q^OO_0ZW/\ @CS_ ,I,?A%_V,4G
M_I+-6'_P5#_Y2)?&;_L?K[_T.MS_ ((\_P#*3'X1?]C%)_Z2S5<O^2=?_7M?
M^DF=/_D=?]O_ *G]*R?>SBG4U.M.K\>/U,_%G_@Z,_Y+I\*O^Q5U#_THCK\M
M?X&XK]2O^#HS_DNGPJ_[%74/_2B.ORU_@:OV#A__ )$-/T_5GYEGG_(VG_70
M_K"^ ?\ R1'P?_V*^G_^D\==9W6N3^ ?_)$?!_\ V*^G_P#I/'76'JM?D=;^
M-+U9^DT?X,?1?D?$G_!P7_RC+\5?]A[2/_2R.OY[O^6=?T(_\'!?_*,OQ5_V
M'M(_]+(Z_GN_Y9U^F\%_\BF7^)_DCX#BC_D8?]NK\S]XO^#?RUEO/^"7=]:0
M!M\WBC6T7'7)5,8K\(=0AF@OYX9P1(DS!E9<'.X\5^]W_!NDN_\ X)RPQM_%
MXXU8'W&8Z_(;_@I[\ +C]FK]N[XB?#8636]C)X@FU315*85K.[8W$6WU"B0Q
M_5#6>1XB,<^Q=&^KE?[F[_F:9O3E+*</46R5CS#X#Z[8>%?CKX)\5:LP6UTO
MQ=IE[<LQX$<5W%(V?^ @U^W'_!P3X4U7Q'^RKX6\::1'YUEHWC*)[QDY"I-;
M3(KGVWE1GU8>M?@[Y;NRQ1!FD9L+LZD^F/\ /-?T:?L,>%?B!^U+_P $S/#/
MP[_;-\"S6][JGAL6%Y#??ZZZM5&+:[8=8Y3&L;<\AADUS<:4;>RJM[75O74]
M_P .LT_LK-X56KVDI?+9_.S/PO!XZ4IZ\M7V'^T[_P $6/VJ_@WXIN/^%3Z#
M-XWT!SNL;W3@HN$7GY9(R1\P]1P>U>;_  T_X)@?MQ?%'58]/TWX$ZIIT33>
M7)>:LHAABYQDDG.!]*^'T[G]CT>)<BQ&'^L*O%1WWLUZ^9V__!$3PKK'B/\
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MW7N?G7"].4L=*IV1] 4445^8GWX4444 %%%% !1110 4444 %%%% 'YT?\'
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MH+Y]\9?BOV%"*#D?^A4>]>Q'B3.HQLJOWV/)ED.5RE?V=C\U_@)_P;4_LM^
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M58%71MB\'H5XKY?^'G_!LO\ LT>&/&NG^)/&GQC\3>(M.M+E9;C1KB&&&.Z
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M9K^E7PAXP\-^-_#%EXJ\(ZU:ZEI=] LUG?64RR131GHRL"01VK^2L[6'S5]
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MT3K8RZK8K,8 V"P4L.,D#\JMQL.6'HT:D%4ORM)Z;JY';_M:_LT7]W#8:?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]"?9XAU3FD%O".=G%/GV.BGCJU.I2DO^7:LOO;_-LAA!^RK'M^95VU\7^&?
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
5BB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>35
<FILENAME>sgmo-20171231.xml
<DESCRIPTION>XBRL INSTANCE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Instance Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4841149+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<xbrl xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.xbrl.org/2003/instance" xmlns:sgmo="http://www.sangamo.com/20171231" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xbrll:schemaRef xlink:type="simple" xlink:arcrole="http://www.xbrl.org/2003/linkbase" xlink:href="sgmo-20171231.xsd" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrll="http://www.xbrl.org/2003/linkbase" />
  <unit id="U_shares">
    <measure>shares</measure>
  </unit>
  <unit id="U_iso4217USD">
    <measure>iso4217:USD</measure>
  </unit>
  <unit id="U_iso4217USD_shares">
    <divide>
      <unitNumerator>
        <measure>iso4217:USD</measure>
      </unitNumerator>
      <unitDenominator>
        <measure>shares</measure>
      </unitDenominator>
    </divide>
  </unit>
  <unit id="U_pure">
    <measure>pure</measure>
  </unit>
  <unit id="U_sgmoSegments">
    <measure>sgmo:Segments</measure>
  </unit>
  <unit id="U_sgmoProduct">
    <measure>sgmo:Product</measure>
  </unit>
  <unit id="U_sgmoProgram">
    <measure>sgmo:Program</measure>
  </unit>
  <unit id="U_sgmoTargets">
    <measure>sgmo:Targets</measure>
  </unit>
  <unit id="U_sgmoProperty">
    <measure>sgmo:Property</measure>
  </unit>
  <unit id="U_utrsqft">
    <measure>utr:sqft</measure>
  </unit>
  <unit id="U_sgmoInstallment">
    <measure>sgmo:Installment</measure>
  </unit>
  <unit id="U_sgmoOption">
    <measure>sgmo:Option</measure>
  </unit>
  <context id="C_0001001233_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20180215">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2018-02-15</instant>
    </period>
  </context>
  <context id="C_0001001233_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2017-06-30</instant>
    </period>
  </context>
  <context id="C_0001001233_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2014-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <instant>2015-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoPropertyAndEquipmentMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:PropertyAndEquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBuildToSuitLeaseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBuildToSuitLeaseMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapChangeInAccountingEstimateByTypeAxis_sgmoCollaborationContractPerformancePeriodMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:CollaborationContractPerformancePeriodMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapChangeInAccountingEstimateByTypeAxis_sgmoCollaborationContractPerformancePeriodMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">sgmo:CollaborationContractPerformancePeriodMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BiogenIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementScenarioAxis_us-gaapProFormaMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ProFormaMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170509_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">us-gaap:AccountingStandardsUpdate201409Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-09</startDate>
      <endDate>2017-05-10</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CashEquivalentsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:InvestmentTypeAxis">us-gaap:CommercialPaperMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:MajorTypesOfDebtAndEquitySecuritiesAxis">us-gaap:USGovernmentSponsoredEnterprisesDebtSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:InformationByCategoryOfDebtSecurityAxis">us-gaap:AvailableforsaleSecuritiesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170509_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-09</startDate>
      <endDate>2017-05-10</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoSBFiveTwoFiveMember_20170509_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-05-09</startDate>
      <endDate>2017-05-10</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-10</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoSBFiveTwoFiveMember_us-gaapRangeAxis_us-gaapMaximumMember_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:SBFiveTwoFiveMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-10</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoOtherProductsMember_us-gaapRangeAxis_us-gaapMaximumMember_20170510">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:OtherProductsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-10</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoCNineORFSevenTwoMember_20171228_20171228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-28</startDate>
      <endDate>2017-12-28</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoCNineORFSevenTwoMember_us-gaapRangeAxis_us-gaapMaximumMember_20171228_20171228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:PfizerMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:CNineORFSevenTwoMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-12-28</startDate>
      <endDate>2017-12-28</endDate>
    </period>
  </context>
  <context id="C_0001001233_20140101_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20140101_20140131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:BioverativIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-01-01</startDate>
      <endDate>2012-01-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2012-06-01</startDate>
      <endDate>2012-06-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20141231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2014-01-01</startDate>
      <endDate>2014-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:ShireAgMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20070101_20071231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2007-01-01</startDate>
      <endDate>2007-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:UpfrontLicenseFeesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2009-10-01</startDate>
      <endDate>2009-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2009-10-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:SigmaAldrichCorporationMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2005-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MinimumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2005-01-01</startDate>
      <endDate>2005-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:DowAgroSciencesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">us-gaap:LicenseAgreementTermsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131001_20131031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2013-10-01</startDate>
      <endDate>2013-10-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131031">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2013-10-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20150331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2015-03-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">sgmo:CeregeneIncMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoRichmondBuildToSuitLeaseMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoResearchAndOfficeSpaceMember_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseOneMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoResearchAndOfficeSpaceMember_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseOneMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">sgmo:ResearchAndOfficeSpaceMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseTwoMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseTwoMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PropertySubjectToOrAvailableForOperatingLeaseAxis">sgmo:PropertySubjectToOperatingLeaseTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoRichmondBuildToSuitLeaseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:RichmondBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapOtherCommitmentsAxis_sgmoTenantImprovementsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:TenantImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_us-gaapOtherCommitmentsAxis_sgmoTenantImprovementsMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:OtherCommitmentsAxis">sgmo:TenantImprovementsMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:IntellectualPropertyMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170625_20170626">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-06-25</startDate>
      <endDate>2017-06-26</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170626">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-06-26</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20161207">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-07</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170526">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-05-26</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">sgmo:AtTheMarketOfferingAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandFourStockIncentivePlanMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandFourStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20150622_20150622">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:TwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-06-22</startDate>
      <endDate>2015-06-22</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_20171110">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-10</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">sgmo:EmployeeStockPurchasePlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFourMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeFiveMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSixMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeSevenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeEightMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeNineMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">sgmo:RangeTenMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20160101_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheThreeMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapStatementScenarioAxis_us-gaapScenarioPlanMember_20180101_20181231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">us-gaap:ScenarioPlanMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-01-01</startDate>
      <endDate>2018-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20170101_20170331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20170401_20170630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2017-04-01</startDate>
      <endDate>2017-06-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_20170701_20170930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2017-07-01</startDate>
      <endDate>2017-09-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_20171001_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2017-10-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20160101_20160331">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2016-01-01</startDate>
      <endDate>2016-03-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_20160401_20160630">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2016-04-01</startDate>
      <endDate>2016-06-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_20160701_20160930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2016-07-01</startDate>
      <endDate>2016-09-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_20161001_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2016-10-01</startDate>
      <endDate>2016-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171101_20171130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-01</startDate>
      <endDate>2017-11-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapRangeAxis_us-gaapMaximumMember_20171101_20171130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-11-01</startDate>
      <endDate>2017-11-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171130">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:BuildingMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-11-30</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:BrisbaneBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2017-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20151201_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:PointPinoleBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20170101_20171231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:PointPinoleBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2017-01-01</startDate>
      <endDate>2017-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_us-gaapRangeAxis_us-gaapMaximumMember_20151201_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:PointPinoleBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-12-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20161231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">sgmo:PointPinoleBuildToSuitLeaseMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2016-12-31</instant>
    </period>
  </context>
  <context id="C_0001001233_20150901_20150930">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
    </entity>
    <period>
      <startDate>2015-09-01</startDate>
      <endDate>2015-09-30</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapLitigationStatusAxis_sgmoDisgorgementSettlementMember_20150101_20151231">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:LitigationStatusAxis">sgmo:DisgorgementSettlementMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2015-01-01</startDate>
      <endDate>2015-12-31</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <instant>2018-02-28</instant>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:RangeAxis">us-gaap:MaximumMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapProductOrServiceAxis_sgmoAchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <context id="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapProductOrServiceAxis_sgmoAchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228">
    <entity>
      <identifier scheme="http://www.sec.gov/CIK">0001001233</identifier>
      <segment>
        <xbrldi:explicitMember dimension="us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis">sgmo:CollaborationAndLicenseAgreementMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:CounterpartyNameAxis">sgmo:KitePharmaIncMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:ProductOrServiceAxis">sgmo:AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</xbrldi:explicitMember>
        <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
      </segment>
    </entity>
    <period>
      <startDate>2018-02-01</startDate>
      <endDate>2018-02-28</endDate>
    </period>
  </context>
  <dei:DocumentType id="F_000000" contextRef="C_0001001233_20170101_20171231">10-K</dei:DocumentType>
  <dei:AmendmentFlag id="F_000001" contextRef="C_0001001233_20170101_20171231">false</dei:AmendmentFlag>
  <dei:DocumentPeriodEndDate id="F_000002" contextRef="C_0001001233_20170101_20171231">2017-12-31</dei:DocumentPeriodEndDate>
  <dei:DocumentFiscalYearFocus id="F_000003" contextRef="C_0001001233_20170101_20171231">2017</dei:DocumentFiscalYearFocus>
  <dei:DocumentFiscalPeriodFocus id="F_000004" contextRef="C_0001001233_20170101_20171231">FY</dei:DocumentFiscalPeriodFocus>
  <dei:TradingSymbol id="F_000005" contextRef="C_0001001233_20170101_20171231">SGMO</dei:TradingSymbol>
  <dei:EntityRegistrantName id="F_000006" contextRef="C_0001001233_20170101_20171231">SANGAMO THERAPEUTICS, INC</dei:EntityRegistrantName>
  <dei:EntityCentralIndexKey id="F_000007" contextRef="C_0001001233_20170101_20171231">0001001233</dei:EntityCentralIndexKey>
  <dei:CurrentFiscalYearEndDate id="F_000008" contextRef="C_0001001233_20170101_20171231">--12-31</dei:CurrentFiscalYearEndDate>
  <dei:EntityWellKnownSeasonedIssuer id="F_000009" contextRef="C_0001001233_20170101_20171231">Yes</dei:EntityWellKnownSeasonedIssuer>
  <dei:EntityCurrentReportingStatus id="F_000010" contextRef="C_0001001233_20170101_20171231">Yes</dei:EntityCurrentReportingStatus>
  <dei:EntityVoluntaryFilers id="F_000011" contextRef="C_0001001233_20170101_20171231">No</dei:EntityVoluntaryFilers>
  <dei:EntityFilerCategory id="F_000012" contextRef="C_0001001233_20170101_20171231">Large Accelerated Filer</dei:EntityFilerCategory>
  <dei:EntityCommonStockSharesOutstanding id="F_000013" contextRef="C_0001001233_20180215" decimals="INF" unitRef="U_shares">86338976</dei:EntityCommonStockSharesOutstanding>
  <dei:EntityPublicFloat id="F_000014" contextRef="C_0001001233_20170630" decimals="0" unitRef="U_iso4217USD">734155954</dei:EntityPublicFloat>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000015" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">49826000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000016" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">22061000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000017" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">193482000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:AvailableForSaleSecuritiesCurrent id="F_000018" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">120474000</us-gaap:AvailableForSaleSecuritiesCurrent>
  <us-gaap:InterestReceivableCurrent id="F_000019" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">240000</us-gaap:InterestReceivableCurrent>
  <us-gaap:InterestReceivableCurrent id="F_000020" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">224000</us-gaap:InterestReceivableCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000021" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">3343000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:AccountsReceivableNetCurrent id="F_000022" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">4972000</us-gaap:AccountsReceivableNetCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000023" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1506000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:PrepaidExpenseAndOtherAssetsCurrent id="F_000024" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">1849000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000025" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">248397000</us-gaap:AssetsCurrent>
  <us-gaap:AssetsCurrent id="F_000026" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">149580000</us-gaap:AssetsCurrent>
  <us-gaap:AvailableForSaleSecuritiesNoncurrent id="F_000027" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1012000</us-gaap:AvailableForSaleSecuritiesNoncurrent>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000028" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">31066000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000029" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">6557000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:Goodwill id="F_000030" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1585000</us-gaap:Goodwill>
  <us-gaap:Goodwill id="F_000031" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">1585000</us-gaap:Goodwill>
  <us-gaap:OtherAssetsNoncurrent id="F_000032" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">4681000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:OtherAssetsNoncurrent id="F_000033" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">169000</us-gaap:OtherAssetsNoncurrent>
  <us-gaap:Assets id="F_000034" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">286741000</us-gaap:Assets>
  <us-gaap:Assets id="F_000035" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">157891000</us-gaap:Assets>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000036" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">11035000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent id="F_000037" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">6261000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000038" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">5479000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:AccruedEmployeeBenefitsCurrent id="F_000039" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">2885000</us-gaap:AccruedEmployeeBenefitsCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000040" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">28345000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:DeferredRevenueCurrent id="F_000041" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">4145000</us-gaap:DeferredRevenueCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000042" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">44859000</us-gaap:LiabilitiesCurrent>
  <us-gaap:LiabilitiesCurrent id="F_000043" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">13291000</us-gaap:LiabilitiesCurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000044" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">29244000</us-gaap:DeferredRevenueNoncurrent>
  <us-gaap:DeferredRevenueNoncurrent id="F_000045" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">4460000</us-gaap:DeferredRevenueNoncurrent>
  <sgmo:BuildToSuitLeaseObligations id="F_000046" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">24738000</sgmo:BuildToSuitLeaseObligations>
  <sgmo:BuildToSuitLeaseObligations id="F_000047" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">3945000</sgmo:BuildToSuitLeaseObligations>
  <us-gaap:Liabilities id="F_000048" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">98841000</us-gaap:Liabilities>
  <us-gaap:Liabilities id="F_000049" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">21696000</us-gaap:Liabilities>
  <us-gaap:CommitmentsAndContingencies id="F_000050" xsi:nil="true" contextRef="C_0001001233_20171231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommitmentsAndContingencies id="F_000051" xsi:nil="true" contextRef="C_0001001233_20161231" unitRef="U_iso4217USD" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" />
  <us-gaap:CommonStockValue id="F_000052" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">856000</us-gaap:CommonStockValue>
  <us-gaap:CommonStockValue id="F_000053" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">709000</us-gaap:CommonStockValue>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000054" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">682809000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:AdditionalPaidInCapitalCommonStock id="F_000055" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">576377000</us-gaap:AdditionalPaidInCapitalCommonStock>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000056" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">-495479000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:RetainedEarningsAccumulatedDeficit id="F_000057" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">-440911000</us-gaap:RetainedEarningsAccumulatedDeficit>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000058" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">-286000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax id="F_000059" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
  <us-gaap:StockholdersEquity id="F_000060" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">187900000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000061" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">136195000</us-gaap:StockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000062" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">286741000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:LiabilitiesAndStockholdersEquity id="F_000063" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">157891000</us-gaap:LiabilitiesAndStockholdersEquity>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000064" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockParOrStatedValuePerShare id="F_000065" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_iso4217USD_shares">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
  <us-gaap:CommonStockSharesAuthorized id="F_000066" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">160000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesAuthorized id="F_000067" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">160000000</us-gaap:CommonStockSharesAuthorized>
  <us-gaap:CommonStockSharesIssued id="F_000068" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">85598534</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesIssued id="F_000069" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">70871902</us-gaap:CommonStockSharesIssued>
  <us-gaap:CommonStockSharesOutstanding id="F_000070" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">85598534</us-gaap:CommonStockSharesOutstanding>
  <us-gaap:CommonStockSharesOutstanding id="F_000071" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">70871902</us-gaap:CommonStockSharesOutstanding>
  <sgmo:CollaborationAgreements id="F_000072" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">35960000</sgmo:CollaborationAgreements>
  <sgmo:CollaborationAgreements id="F_000073" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">18881000</sgmo:CollaborationAgreements>
  <sgmo:CollaborationAgreements id="F_000074" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">37844000</sgmo:CollaborationAgreements>
  <us-gaap:RevenueFromGrants id="F_000075" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">607000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000076" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">508000</us-gaap:RevenueFromGrants>
  <us-gaap:RevenueFromGrants id="F_000077" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1695000</us-gaap:RevenueFromGrants>
  <us-gaap:Revenues id="F_000078" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">36567000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000079" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">19389000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000080" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">39539000</us-gaap:Revenues>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000081" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">65728000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000082" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">65618000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:ResearchAndDevelopmentExpense id="F_000083" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">67198000</us-gaap:ResearchAndDevelopmentExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000084" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27200000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000085" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">26330000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:GeneralAndAdministrativeExpense id="F_000086" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">19197000</us-gaap:GeneralAndAdministrativeExpense>
  <us-gaap:OperatingExpenses id="F_000087" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">92928000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000088" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">91948000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000089" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">86395000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingIncomeLoss id="F_000090" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-56361000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000091" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-72559000</us-gaap:OperatingIncomeLoss>
  <us-gaap:OperatingIncomeLoss id="F_000092" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-46856000</us-gaap:OperatingIncomeLoss>
  <us-gaap:InterestAndOtherIncome id="F_000093" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1793000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000094" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">887000</us-gaap:InterestAndOtherIncome>
  <us-gaap:InterestAndOtherIncome id="F_000095" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">431000</us-gaap:InterestAndOtherIncome>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000096" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-54568000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000097" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-71672000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest id="F_000098" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-46425000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000099" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-14000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000100" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-5722000</us-gaap:IncomeTaxExpenseBenefit>
  <us-gaap:NetIncomeLoss id="F_000101" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-54568000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000102" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-71658000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000103" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-40703000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000104" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">-0.70</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000105" contextRef="C_0001001233_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">-1.02</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000106" contextRef="C_0001001233_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">-0.58</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000107" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_shares">78084000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000108" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_shares">70553000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted id="F_000109" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_shares">69757000</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000110" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-306000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000111" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000112" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000113" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-54874000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000114" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-71638000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:ComprehensiveIncomeNetOfTax id="F_000115" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-40678000</us-gaap:ComprehensiveIncomeNetOfTax>
  <us-gaap:CommonStockSharesIssued id="F_000116" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="INF" unitRef="U_shares">69062394</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000117" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20141231" decimals="-3" unitRef="U_iso4217USD">690000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000118" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20141231" decimals="-3" unitRef="U_iso4217USD">534518000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000119" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20141231" decimals="-3" unitRef="U_iso4217USD">-328550000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000120" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20141231" decimals="-3" unitRef="U_iso4217USD">-25000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000121" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">206633000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000122" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20150101_20151231" decimals="INF" unitRef="U_shares">1164033</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000123" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">12000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000124" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4336000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000125" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4348000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000126" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20150101_20151231" decimals="INF" unitRef="U_shares">128181</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000127" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000128" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">910000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000129" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">911000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000130" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">11730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000131" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">11730000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <sgmo:SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax id="F_000132" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">9495000</sgmo:SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax>
  <sgmo:SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax id="F_000133" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">9495000</sgmo:SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000134" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">25000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000135" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-40703000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000136" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231" decimals="INF" unitRef="U_shares">70354608</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000137" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20151231" decimals="-3" unitRef="U_iso4217USD">703000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000138" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20151231" decimals="-3" unitRef="U_iso4217USD">560989000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000139" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20151231" decimals="-3" unitRef="U_iso4217USD">-369253000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000140" contextRef="C_0001001233_20151231" decimals="-3" unitRef="U_iso4217USD">192439000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000141" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="INF" unitRef="U_shares">314583</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000142" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000143" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-484000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000144" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-481000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000145" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="INF" unitRef="U_shares">202711</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000146" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">3000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000147" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">815000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000148" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">818000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000149" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">15057000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000150" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">15057000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000151" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000152" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-71658000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000153" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="INF" unitRef="U_shares">70871902</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000154" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20161231" decimals="-3" unitRef="U_iso4217USD">709000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000155" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20161231" decimals="-3" unitRef="U_iso4217USD">576377000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000156" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20161231" decimals="-3" unitRef="U_iso4217USD">-440911000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000157" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20161231" decimals="-3" unitRef="U_iso4217USD">20000</us-gaap:StockholdersEquity>
  <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation id="F_000158" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">2101489</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000159" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">21000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000160" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15078000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation id="F_000161" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">15099000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000162" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">253994</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000163" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000164" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">816000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan id="F_000165" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">818000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000166" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="INF" unitRef="U_shares">12371149</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000167" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">124000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000168" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">81449000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000169" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">81573000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000170" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">9089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue id="F_000171" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">9089000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
  <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax id="F_000172" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-306000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
  <us-gaap:NetIncomeLoss id="F_000173" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-54568000</us-gaap:NetIncomeLoss>
  <us-gaap:CommonStockSharesIssued id="F_000174" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="INF" unitRef="U_shares">85598534</us-gaap:CommonStockSharesIssued>
  <us-gaap:StockholdersEquity id="F_000175" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20171231" decimals="-3" unitRef="U_iso4217USD">856000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000176" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAdditionalPaidInCapitalMember_20171231" decimals="-3" unitRef="U_iso4217USD">682809000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000177" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapRetainedEarningsMember_20171231" decimals="-3" unitRef="U_iso4217USD">-495479000</us-gaap:StockholdersEquity>
  <us-gaap:StockholdersEquity id="F_000178" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapAccumulatedOtherComprehensiveIncomeMember_20171231" decimals="-3" unitRef="U_iso4217USD">-286000</us-gaap:StockholdersEquity>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000179" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1498000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000180" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">997000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:DepreciationDepletionAndAmortization id="F_000181" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">988000</us-gaap:DepreciationDepletionAndAmortization>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000182" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">673000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000183" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-221000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments id="F_000184" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-827000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
  <us-gaap:GainLossOnSaleOfPropertyPlantEquipment id="F_000185" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-12000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
  <us-gaap:ShareBasedCompensation id="F_000186" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">9089000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000187" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">15057000</us-gaap:ShareBasedCompensation>
  <us-gaap:ShareBasedCompensation id="F_000188" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">11730000</us-gaap:ShareBasedCompensation>
  <us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1 id="F_000189" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-1800000</us-gaap:BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill id="F_000190" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1870000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000191" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-14000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:DeferredIncomeTaxExpenseBenefit id="F_000192" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-5722000</us-gaap:DeferredIncomeTaxExpenseBenefit>
  <us-gaap:OtherNoncashIncomeExpense id="F_000193" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-80000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:OtherNoncashIncomeExpense id="F_000194" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-99000</us-gaap:OtherNoncashIncomeExpense>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="F_000195" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="F_000196" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-83000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet id="F_000197" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-116000</us-gaap:IncreaseDecreaseInAccruedInterestReceivableNet>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000198" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-1629000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000199" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2144000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInAccountsReceivable id="F_000200" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-7847000</us-gaap:IncreaseDecreaseInAccountsReceivable>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000201" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">669000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000202" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1112000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets id="F_000203" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-376000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000204" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3219000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000205" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-2335000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities id="F_000206" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-764000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000207" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2594000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000208" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">137000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities id="F_000209" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-105000</us-gaap:IncreaseDecreaseInEmployeeRelatedLiabilities>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000210" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">48984000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000211" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-5214000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:IncreaseDecreaseInDeferredRevenue id="F_000212" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-8380000</us-gaap:IncreaseDecreaseInDeferredRevenue>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000213" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">11179000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000214" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-65883000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations id="F_000215" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-33720000</us-gaap:NetCashProvidedByUsedInOperatingActivitiesContinuingOperations>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000216" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">252328000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000217" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">218640000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:PaymentsToAcquireMarketableSecurities id="F_000218" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">257988000</us-gaap:PaymentsToAcquireMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000219" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">178675000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000220" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">237497000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities id="F_000221" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">337861000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000222" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3751000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment id="F_000223" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">732000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
  <us-gaap:PaymentsForLeasingCosts id="F_000224" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">3500000</us-gaap:PaymentsForLeasingCosts>
  <us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired id="F_000225" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">2411000</us-gaap:PaymentsToAcquireBusinessesNetOfCashAcquired>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000226" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-80904000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000227" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">18125000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations id="F_000228" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">77462000</us-gaap:NetCashProvidedByUsedInInvestingActivitiesContinuingOperations>
  <sgmo:NetProceedsFromIssuancePublicOffering id="F_000229" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">81573000</sgmo:NetProceedsFromIssuancePublicOffering>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000230" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">654000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000231" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">776000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation id="F_000232" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1546000</us-gaap:PaymentsRelatedToTaxWithholdingForShareBasedCompensation>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000233" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">16571000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000234" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1113000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <us-gaap:ProceedsFromIssuanceOfCommonStock id="F_000235" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">6804000</us-gaap:ProceedsFromIssuanceOfCommonStock>
  <sgmo:ProceedsFromClaimsSettlement id="F_000236" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">14452000</sgmo:ProceedsFromClaimsSettlement>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000237" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">97490000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000238" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">337000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations id="F_000239" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">19710000</us-gaap:NetCashProvidedByUsedInFinancingActivitiesContinuingOperations>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000240" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">27765000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000241" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-47421000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease id="F_000242" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">63452000</us-gaap:CashAndCashEquivalentsPeriodIncreaseDecrease>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000243" contextRef="C_0001001233_20151231" decimals="-3" unitRef="U_iso4217USD">69482000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000244" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">6030000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000245" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoPropertyAndEquipmentMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1214000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000246" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBuildToSuitLeaseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">20793000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:CapitalExpendituresIncurredButNotYetPaid id="F_000247" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBuildToSuitLeaseMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">3876000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
  <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock id="F_000248" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 1 &amp;#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Overview&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo Therapeutics, Inc. was incorporated in the State of Delaware on June&amp;#160;22, 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017 (the Company or Sangamo).&amp;nbsp;&amp;nbsp;Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&amp;#8217;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). Potential applications of Sangamo&amp;#8217;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutics. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&amp;#160;31, 2017, along with expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will need to raise substantial additional capital to fund subsequent operations and complete the development and commercialization of its products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&amp;#8217;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&amp;#8217;s stockholders, and any debt financing may include covenants that restrict the Company&amp;#8217;s business. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly-owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Business Combinations &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company accounts for acquisitions in accordance with Accounting Standards Codification (ASC) Topic 805, &lt;font style="font-style:italic;"&gt;Business Combinations&lt;/font&gt; (ASC Topic 805). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. &lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&amp;#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&amp;#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&amp;#8217;s investment securities consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&amp;#8217;s product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements prior to the adoption of ASU No.&amp;#160;2009-13, Revenue Recognition&amp;#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)&lt;font style="font-style:normal;"&gt;. For revenue arrangements entered into before January&amp;#160;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements after the adoption of ASU 2009-13.&lt;font style="font-style:normal;"&gt; ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: &lt;/font&gt;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, or TPE, if available and VSOE is not available; or the best estimate of selling price, or ESP, if neither VSOE nor TPE is available; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&amp;#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG, or Shire, in January 2012, Biogen MA Inc., or Biogen, in January 2014, and Pfizer Inc., or Pfizer, in May and December of 2017, were evaluated under these amended accounting standards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company&amp;#8217;s performance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received but not earned. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo&amp;#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of the Company&amp;#8217;s total revenue. During 2016 revenue related to Bioverativ, DAS and Shire represented 46%, 26%, and 17%, respectively, of total revenue.&amp;nbsp;&amp;nbsp;During 2015 revenue related to Shire and Biogen represented 40% and 35%, respectively, of total revenues. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&amp;#8217;s testing processes and procedures as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (RSUs) and employee stock purchases related to the Employee Stock Purchase Plan (ESPP), based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&amp;#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company adopted Accounting Standards Update (ASU) 2016-09 and accounts for forfeitures in the period they occur. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Indefinite-Lived Intangible Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As part of the Ceregene acquisition the Company recognized indefinite-lived intangible assets for in-process research and development and goodwill as further discussed below. ASC 350 and related updates require companies to test indefinite-lived intangible assets for impairment annually, and more frequently if indicators of impairment exist. ASC 350 includes an optional qualitative assessment for testing indefinite-lived intangible assets for impairment that permits companies to assess whether it is more likely than not (i.e., a likelihood of greater than 50%) that an indefinite-lived intangible asset is impaired. If a company concludes based on the qualitative assessment that it is not more likely than not that the fair value of an indefinite-lived intangible asset or, in the case of goodwill, that the fair value of the related reporting unit, is less than carrying value, it would not have to determine the asset&amp;#8217;s or reporting unit&amp;#8217;s fair value, as applicable.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;In-Process Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets related to in-process research and development costs, or IPR&amp;amp;D, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company did not believe the programs have an alternative future use for itself or other market participants. Accordingly, the Company recognized a $1.9 million impairment charge related to these assets during the year ended December 31, 2015, which was recognized as research and development (R&amp;amp;D) in the accompanying consolidated statements of operations.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate an impairment of goodwill has occurred. During the fourth quarter of 2017, the Company performed an assessment of the qualitative factors affecting the fair value of its reporting unit and concluded that it was not more likely than not that the fair value of its reporting unit was less than carrying value and that, as a result, it is not more likely than not that goodwill is impaired. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Liability &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the merger agreement with Ceregene, the Company is required to make contingent earn-out payments if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. These earn-out payments will become payable in the period they are earned. In accordance with ASC Topic 805, the Company determined the fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;amp;D assets acquired from Ceregene.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options and restricted stock units, which are all anti-dilutive. All stock options and restricted stock units outstanding were excluded from the calculation of diluted net loss per share for all periods presented. Stock options and restricted stock units outstanding at the end of 2017, 2016 and 2015 were 8,367,628, 9,578,322, and 9,008,185, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&amp;#160;31, 2017 and 2016, all of the Company&amp;#8217;s assets were maintained in the U.S. For the years ended December&amp;#160;31, 2017, 2016 and 2015, substantially all the Company&amp;#8217;s revenues and operating expenses were generated and incurred in the U.S. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In March 2016 the Financial Accounting Standards Board (FASB) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&amp;#160;Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period.&amp;nbsp;&amp;nbsp;The Company adopted the ASU in the first quarter of 2017 and it did not have a material impact on the Company&amp;#8217;s consolidated financial statements. The impact of ASU 2016-09 as it relates to stock-based compensation for deferred tax assets and liabilities balances were not material to the Company&apos;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016 the FASB issued ASU No. 2016-02 (ASU 2016-02) &amp;#8220;&lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;.&amp;#8221; ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. We are evaluating the impact of the adoption of this standard on our consolidated financial statements, and expect our operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption which will increase our total assets and total liabilities as compared to amounts prior to adoption.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014 the FASB issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with&amp;#160;Customers (Topic 606)&lt;/font&gt;, or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&amp;#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&amp;#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2017, including interim periods within that reporting period. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&amp;#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at December 31, 2017 and any future receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined under ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development reimbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition adjustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research and development reimbursements and up-front payments under ASC 606. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimates of the expected effects of the Company&amp;#8217;s adoption of ASU 2014-09 represent management&amp;#8217;s best estimates of the effects of adopting ASU 2014-09 at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of the Company&amp;#8217;s assessment in the first quarter of 2018.&lt;/p&gt;&lt;/div&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock>
  <us-gaap:FairValueDisclosuresTextBlock id="F_000249" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 2 &amp;#8211;FAIR VALUE MEASUREMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the contingent consideration liability.&amp;#160;Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The fair value measurements of cash equivalents, available-for-sale securities and the contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Investments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company generally classifies its marketable securities as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Liability &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In August 2013 the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. &lt;font style="letter-spacing:-0.1pt;"&gt;The Company has classified this liability as Level 3.&lt;/font&gt; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The subsequent changes in the fair value of the contingent consideration liability were recognized as a component of research and development expense line item in the accompanying consolidated statements of operations as operating expenses. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by the total fair value of the contingent consideration of $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;amp;D assets acquired from Ceregene (see Note 6).  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
  <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock id="F_000250" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 3 &amp;#8211; MARKETABLE SECURITIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The table below summarizes the Company&amp;#8217;s cash equivalents and available-for-sale securities (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,307&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,424&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2017, all of the Company&amp;#8217;s investments had maturity dates within two years as of the balance sheet date. The Company had no material realized losses from the sale of available-for-sale securities for the years ended December&amp;#160;31, 2017, 2016 or 2015. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. No investments were other-than-temporarily impaired at either December 31, 2017 or 2016.&lt;/p&gt;&lt;/div&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
  <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock id="F_000251" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 4 &amp;#8211; STOCK-BASED COMPENSATION &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table shows total stock-based compensation expense recognized in the accompanying consolidated statements of operations (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,594&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December 31, 2017, total stock-based compensation expense related to unvested stock options to be recognized in future periods was $16.1 million, which is expected to be expensed over a weighted-average period of 2.79 years.&amp;nbsp;&amp;nbsp;As of December&amp;#160;31, 2017, total stock-based compensation expense related to unvested RSUs to be recognized in future periods was $0.7 million, which is expected to be expensed over a weighted-average period of 1.03 years. There was no capitalized stock-based employee compensation expense as of either December&amp;#160;31, 2017, 2016 or 2015 respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation Assumptions &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employee stock-based compensation expense was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted-average estimated fair value per share of options granted during 2017, 2016 and 2015 was $4.10, $3.14, and $5.72, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81-2.28%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.13-1.61%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.46-1.58%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life of option (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.73-5.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28-5.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.25-5.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield of stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.71-0.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.68-0.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.66-0.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Employees purchased approximately 253,994, 202,711 and 128,181 shares of common stock through the 2010 Employee Stock Purchase Plan at an average exercise price of $3.22, $4.04, and $7.10 per share during 2017, 2016 and 2015, respectively. The weighted-average estimated fair value of shares purchased under the Company&amp;#8217;s ESPP during 2017, 2016 and 2015 were $2.37, $2.27 and $4.42, respectively based upon the assumptions used in the Black-Scholes valuation model.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The weighted&amp;#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.44-0.76%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.41-0.80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.06-0.33%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life of option (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield of stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.66-0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.71-0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.55-0.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
  <us-gaap:CollaborativeArrangementDisclosureTextBlock id="F_000252" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 5 &amp;#8211; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Collaboration Agreements &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Pfizer Inc. in Human Therapeutics &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;SB-525 Global Collaboration and License Agreement&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 10, 2017, Sangamo entered into an exclusive, global Collaboration and License Agreement (the &amp;#8220;with Pfizer pursuant to which Sangamo and Pfizer established a collaboration for the research, development and commercialization of SB-525, Sangamo&amp;#8217;s gene therapy product candidate for hemophilia A, and closely related products (the &amp;#8220;hemophilia A Pfizer Agreement&amp;#8221;).&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the hemophilia A Pfizer Agreement, Sangamo will be responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer will be responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525.&amp;nbsp;&amp;nbsp;Sangamo and Pfizer may also collaborate in the research and development of additional adeno-associated virus (&amp;#8220;AAV&amp;#8221;)-based gene therapy products for hemophilia A.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the&amp;nbsp;&amp;nbsp;hemophilia A Pfizer Agreement, Sangamo received an upfront fee of $70.0 million from Pfizer.&amp;nbsp;&amp;nbsp;In addition, Sangamo is eligible to receive $208.5 million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and $266.5 million in payments upon the achievement of specified first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer Agreement, is $475.0 million, which includes up to $300.0 million for SB-525 and up to $175.0 million for other products that may be developed under the hemophilia A Pfizer Agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property.&amp;nbsp;&amp;nbsp;In addition, Pfizer has agreed to pay Sangamo royalties for each potential licensed product developed under the hemophilia A Pfizer Agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property.&amp;nbsp;&amp;nbsp;To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the hemophilia A Pfizer Agreement. Sangamo in responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to the terms of the hemophilia A Pfizer Agreement, Sangamo granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by Sangamo for the purpose of developing, manufacturing and commercializing SB-525 and related products. Under the hemophilia A Pfizer Agreement, Pfizer granted Sangamo a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the hemophilia A Pfizer Agreement and controlled by Pfizer to manufacture Sangamo&amp;#8217;s products that utilize the AAV delivery system.&amp;nbsp;&amp;nbsp;During a specified period, neither Sangamo nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the deliverables within the hemophilia A Pfizer Agreement as a license to the technology and on-going services. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the hemophilia A Pfizer Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a thirty-two month estimated time over which the Company will perform services under the hemophilia A Pfizer Agreement. The recognition period will be reviewed quarterly and adjusted, as needed, to reflect the Company&amp;#8217;s current assumptions regarding the period of performance. As of December 31, 2017, the Company had deferred revenue of $53.0 million related to the hemophilia A Pfizer Agreement. During the year ended December 31, 2017 the Company recognized revenue of $17.0 million related to the upfront fee that was received.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;C9ORF72 Research Collaboration and License Agreement&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December&amp;#160;28, 2017, Sangamo entered into a Research Collaboration and License Agreement with Pfizer for the development and commercialization of potential gene therapy products that use zinc finger protein transcription factors (&amp;#8220;ZFP-TFs&amp;#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration, or ALS/ FTLD, linked to mutations of the C9ORF72 gene. Pursuant to this Pfizer Agreement, Sangamo will work together with Pfizer on a research program to identify, characterize and preclinically develop&amp;#160;ZFP-TFs&amp;#160;that bind to and specifically reduce expression of the mutant form of the C9ORF72 gene (the &amp;#8220;ALS/ FTLD Pfizer Agreement&amp;#8221;). This agreement was entered into as a separate and distinct agreement apart from the SB-525 Pfizer agreement. The Pfizer C9ORF72 agreement is related to research specific ZFP-TF gene therapy for the C9ORF72 gene, while the SB-525 Pfizer agreement was for the clinical stage development of &lt;font style="color:#000000;"&gt;AAV-based gene therapy products for hemophilia A.&lt;/font&gt; &lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo has granted Pfizer an exclusive, royalty-bearing, worldwide, sublicensable license under the Company&amp;#8217;s relevant patents and&amp;#160;know-how&amp;#160;to develop, manufacture and commercialize gene therapy products (&amp;#8220;Licensed Products&amp;#8221;) that use resulting&amp;#160;ZFP-TFs&amp;#160;that satisfy&amp;#160;pre-agreed&amp;#160;criteria. During a specified period, neither Sangamo nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins that specifically bind to the C9ORF72 gene.&lt;/p&gt;
&lt;p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the ALS/ FTLD Pfizer Agreement, Sangamo received&amp;nbsp;&amp;nbsp;a $12.0&amp;#160;million upfront payment from Pfizer. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of Licensed Products. Sangamo is eligible to receive up to $60.0&amp;#160;million in development milestone payments from Pfizer if a Licensed Product achieves specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&amp;#160;million commercial milestone payments if annual worldwide net sales of Licensed Products reach specified levels. In addition, Pfizer will pay royalties to Sangamo that are an escalating tiered,&amp;#160;mid-&amp;#160;to high-single digit percentage of the annual worldwide net sales of Licensed Products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Sangamo did not recognize revenue related to this Pfizer agreement as the basic criteria for revenue recognition was not satisfied as of December 31, 2017. &lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Collaboration and License Agreement with Bioverativ Inc. in Human Therapeutics &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2014, the Company entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen (the &amp;#8220;Bioverativ Agreement&amp;#8221;), and in January 2017 this agreement was assigned by Biogen MA Inc. to Biogen&amp;#8217;s blood disorder spin-off, Bioverativ.&amp;nbsp;&amp;nbsp;Pursuant to the Bioverativ Agreement, Sangamo and Bioverativ will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&amp;#8217;s zinc finger DNA-binding protein (&amp;#8220;ZFP&amp;#8221;) technology for beta-thalassemia and sickle cell disease (&amp;#8220;SCD&amp;#8221;). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the Bioverativ Agreement, Sangamo and Bioverativ jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first therapeutic developed under the Bioverativ Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (&amp;#8220;IND&amp;#8221;) application for a ZFP-based therapeutic intended to treat SCD. For both programs, Bioverativ is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Bioverativ Agreement. At the end of specified research terms for each program or under certain specified circumstances, Bioverativ has the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&amp;#160;licensed products to treat beta-thalassemia and SCD&amp;#160;developed under the Bioverativ Agreement, and Bioverativ agrees to compensate Sangamo for such co-promotion activities. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo received an upfront license fee of $20.0 million upon entering into the Bioverativ Agreement. In addition, the Company will also be eligible to receive $115.8 million in payments upon the achievement of specified clinical development and regulatory milestones, as well as $160.5 million in payments upon the achievement of specified sales milestones. Bioverativ reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, if products are commercialized under the Bioverativ Agreement, Bioverativ will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Bioverativ Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2016, the parties agreed on an updated beta-thalassemia development plan and budget using the &lt;font style="font-style:italic;"&gt;BCL11A&lt;/font&gt; erythroid enhancer target. In November 2016, Sangamo and Bioverativ agreed on an updated beta-thalassemia development plan and budget. As a result of this change, the Company updated the estimated performance period of the upfront license through June 2020, and updated the milestones to be received based on the updated schedule and targets under the Bioverativ Agreement.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;All contingent payments under the Bioverativ Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Bioverativ Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&amp;#160;that can be achieved based in whole or in part on either the Company&amp;#8217;s performance or on the occurrence of a specific outcome resulting from the Company&amp;#8217;s performance, (ii)&amp;#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&amp;#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Bioverativ Agreement, assuming all other applicable revenue recognition criteria have been met. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subject to the terms of the Bioverativ Agreement, Sangamo has granted Bioverativ an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Bioverativ Agreement. Sangamo has also granted Bioverativ a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, under Sangamo&amp;#8217;s interest in certain other intellectual property developed pursuant to the Bioverativ Agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Bioverativ apart from the research services to be performed pursuant to the Bioverativ Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-four month estimated research term as of the November 2016 modification date, during which time the Company will perform research services. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&amp;#8217;s current assumptions regarding the timing of its deliverables. As of December 31, 2017, the Company had deferred revenue of $4.6 million related to the Bioverativ Agreement. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the Bioverativ Agreement for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): &amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Bioverativ Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,321&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,945&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Amended Collaboration and License Agreement with Shire International GmbH in Human Therapeutics &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In January 2012, the Company entered into a Collaboration and License Agreement with Shire (the &amp;#8220;Shire Agreement &amp;#8221;), pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&amp;#8217;s novel ZFP technology. This agreement was amended on September 1, 2015.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the original Shire Agreement, the Company and Shire agreed to develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets would be used for treating or diagnosing hemophilia A and B. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington&amp;#8217;s disease. Shire had the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&amp;#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Shire Agreement, the Company was responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire was responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimbursed Sangamo for agreed upon internal and external program-related research costs. The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement in 2012. In 2014, Sangamo recognized a $1.0 million milestone payment related to the hemophilia program.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On September 1, 2015, the Shire Agreement was amended such that Shire agreed to return to Sangamo the exclusive, world-wide rights to gene targets for the development and commercialization of ZFP therapeutics for hemophilia A and B.&amp;nbsp;&amp;nbsp;Shire retains the rights and will continue to develop a ZFP therapeutic for Huntington&amp;#8217;s disease.&amp;nbsp;&amp;nbsp;Sangamo will provide certain target feasibility services, and upon Shire&amp;#8217;s request, certain research activities according to a research plan as agreed upon by both companies. Such research activities performed by Sangamo will be reimbursed by Shire. Shire&amp;#8217;s rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs, and Shire will reimburse Sangamo for any ongoing services provided by Sangamo for Shire&amp;#8217;s programs. In 2015, Shire reimbursed Sangamo $3.4 million related to obligations prior to the amendment date which was recognized in revenue as the expense related to those obligations was incurred. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs developed by Sangamo under the amended agreement. Under the amended agreement, Shire does not have any milestone payment obligations with respect to the retained programs, but it is required to pay single digit percentage royalties to Sangamo, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products from such programs. Under the Shire Agreement, Sangamo has full control over, and full responsibility for the costs of, the hemophilia programs returned to us, subject to certain diligence obligations and Shire&amp;#8217;s right of first negotiation to obtain a license to such programs under certain circumstances. The Company is required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of ZFP therapeutic products from such returned programs.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire amendment. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3 million of deferred revenue from the upfront payment during the year ended December 31, 2017. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the Shire Agreement for the years ended December&amp;#160;31, 2017, 2016 and 2015, were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Shire Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with Sigma-Aldrich Corporation (Sigma) in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2007, Sangamo entered into a license agreement with Sigma to provide Sigma with access to Sangamo&amp;#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to DAS. Sangamo developed laboratory research reagents using its ZFP technology over a three year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. Sangamo does not have additional ongoing performance obligations under the agreement.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues recognized under the agreement with Sigma for the years ended December&amp;#160;31, 2017, 2016 and 2015, were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Sigma Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalty revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Agreement with Dow AgroSciences in Plant Agriculture &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2005, Sangamo entered into an exclusive commercial license with&lt;font style="font-weight:bold;font-style:italic;"&gt; &lt;/font&gt;Dow AgroSciences, LLC, or DAS, with an initial three year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008 DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&amp;#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&amp;#160;million, payment of the remaining $2.3 million of the previously agreed upon $4.0&amp;#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&amp;#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010 the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&amp;#160;31, 2012. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years unless terminated at any time by DAS. The Company does not have any performance obligations. In the event of any termination of the agreement, all rights to use the Company&amp;#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&amp;#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&amp;#8217;s ZFP technology. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues under the agreement with DAS were $3.0 million during 2017 and $5.1 million and $3.0 million during 2016 and 2015, respectively. &lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
  <us-gaap:BusinessCombinationDisclosureTextBlock id="F_000253" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 6 &amp;#8211; ACQUISITION OF CEREGENE &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In August&amp;#160;2013, Sangamo acquired all the outstanding shares of Ceregene, a privately held biotechnology company focused on the development of AAV gene therapies. The acquired assets included certain intellectual property rights relating to manufacturing of AAV, and toxicology and data from Ceregene&amp;#8217;s human clinical trials. The acquisition closed in October&amp;#160;2013 (the Closing Date). &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The aggregate consideration transferred or transferable by Sangamo to former Ceregene stockholders at closing consisted of 100,000 shares of Sangamo common stock, with an approximate fair value of $1.2 million and a contingent earn-out of $1.5 million on the Closing Date. The $1.8 million fair value of the contingent earn-out liability was reduced to zero in March 2015 upon Sangamo&amp;#8217;s decision not to pursue development of Ceregene&amp;#8217;s technology as discussed below.  &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Intangible Assets Acquired&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets acquired included In-Process Research and Development (IPR&amp;amp;D), which consisted of Ceregene&amp;#8217;s two clinical product candidates, CERE-110 for the treatment of AD and CERE-120 for the treatment of Parkinson&amp;#8217;s disease. The Company determined that the combined Closing Date estimated fair values of CERE-110 and CERE-120 was $1.9 million. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the year ended December 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intangible assets also included $1.6 million in goodwill, the excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed. Goodwill represents benefits that Sangamo believes will result from combining its operations with the operations of Ceregene and any intangible assets that do not qualify for separate recognition, as well as any future, yet unidentified products.&amp;#160; The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There have been no changes to goodwill since the Closing Date, and no impairment has been recognized.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessCombinationDisclosureTextBlock>
  <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock id="F_000254" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 7 &amp;#8211; PROPERTY AND EQUIPMENT &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Property and equipment consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,367&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in Progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,650&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Depreciation and amortization expense was $1.5 million in 2017, $1.0 million in 2016 and $1.0  million in 2015.&amp;nbsp;&amp;nbsp;In 2017 the Company capitalized $20.9 million related to the fair value of the Brisbane building and $0.3 million of construction costs in Construction in Progress under the build-to-suit lease guidance (see Note 14). In 2016 the Company capitalized $3.9 million related to the costs of the Richmond construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. Both buildings will depreciate over the period of their lease, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
  <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock id="F_000255" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 8 &amp;#8211; COMMITMENTS AND CONTINGENCIES&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Sangamo occupies office and laboratory space under operating leases in Richmond, California. In August&amp;#160;2013, Sangamo amended its lease agreement for our corporate headquarters wherein the lease was extended through August 2019. The Company has three additional properties located in Richmond, CA. This includes two leases, one to occupy approximately 7,700 square feet of research and office space that expires in August 2019, and another to occupy approximately 6,200 square feet of office space that expires in July 2021. Sangamo also has two build-to-suit leases to occupy approximately 41,400 square feet of space in Richmond that expires in December 2021 and approximately 87,700 square feet of space in Brisbane that expires in May 2029. Rent expense related to these lease agreements was $1.1 million, $1.0 million, and $0.9 million for 2017, 2016 and 2015, respectively. Future minimum payments under lease obligations at December&amp;#160;31, 2017 consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fiscal Year:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For 2018, the company is committed to spend $8.8 million for tenant improvements related to the Brisbane build-to-suit lease and $8.7 million as part of our services agreement with Brammer Bio MA, LLC, or Brammer, to provide dedicated capacity to supply our preclinical and clinical programs.&amp;#160;The Company also has $5.2 million of license commitments related to its intellectual property.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingencies&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo is not party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
  <us-gaap:StockholdersEquityNoteDisclosureTextBlock id="F_000256" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 9 &amp;#8211; STOCKHOLDERS&amp;#8217; EQUITY &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Preferred Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has 5,000,000 preferred shares authorized, which may be issued at the discretion of the Company&amp;#8217;s Board of Director&amp;#8217;s discretion. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Common Stock &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On June 26, 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5 million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $78.1 million. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;At-the-Market Offering Agreements&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 7, 2016, we entered into an &amp;#8220;at the market&amp;#8221; offering agreement with an investment bank, pursuant to which we may issue and sell from time to time up to $75.0 million of our common stock through the bank as the sales agent (&amp;#8220;ATM Agreement&amp;#8221;). Under the ATM Agreement, if we decide to sell shares, the sales agent will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us.&amp;nbsp;&amp;nbsp;Sales of the common stock, if any, will be made at market prices by any method that is deemed to be an &amp;#8220;at the market offering&amp;#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The Nasdaq Global Market and any other trading market for the common stock, and sales to or through a market maker other than on an exchange. In addition, with our prior written consent, the sales agent may also sell our common stock in negotiated transactions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On May 26, 2017, the Company entered into an Amended and Restated At-the-Market Offering Program Sales Agreement (the &amp;#8220;2017 ATM Agreement&amp;#8221;) with an investment bank pursuant to which the Company may issue and sell from time to time after the date of the 2017 ATM Agreement, shares of its common stock having an aggregate offering price of up to $75.0 million through the investment bank acting as the Company&amp;#8217;s sales agent. Under the 2017 ATM Agreement, if the Company decides to sell shares, the Company will notify the sales agent, and the sales agent will use its commercially reasonable efforts to sell on the Company&amp;#8217;s behalf all of the shares of common stock requested to be sold.&amp;nbsp;&amp;nbsp;Sales of the Company&amp;#8217;s common stock, if any, will be made at market prices by any method that is deemed to be an &amp;#8220;at the market offering&amp;#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The NASDAQ Global Select Market and sales to or through a market maker other than on an exchange. In addition, with the Company&amp;#8217;s prior written consent, the sales agent may also sell shares of its common stock in negotiated transactions under the 2017 ATM Agreement.&amp;nbsp;&amp;nbsp;During the three months ended March 31, 2017, the Company issued a total of 871,149 shares of its common stock under the original At-the-Market Offering Program Sales Agreement entered into with the sales agent in December 2016, and received net proceeds of $3.4 million, after deducting offering expenses, including $0.1 million of commission paid to the sales agent. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior to the time the shares were sold.&amp;nbsp;&amp;nbsp;Consequently, the Company may be subject to claims for rescission by purchasers who purchased shares of common stock under the ATM Agreement in March 2017.&amp;nbsp;&amp;nbsp;Under Section 12(a)(1) of the Securities Act, a purchaser of security in a transaction made in violation of Section 5 of the Securities Act may obtain recovery of the consideration paid in connection with its purchase, plus statutory interest, or, if it had already sold the shares, recover damages resulting from its purchase. While the Company believes it is unlikely that a successful claim will be asserted against the Company by any purchasers who purchased shares of common stock under the ATM Agreement in March 2017, the Company cannot guarantee that no such legal claims will be asserted against the Company by any purchasers. In addition, the Company could become subject to enforcement actions and/or penalties and fines by federal authorities, and the Company is unable to predict the likelihood of any such enforcement actions being brought, or the amount of any such potential penalties or fines. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Incentive Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In April&amp;#160;2013 Sangamo&amp;#8217;s Board of Directors adopted, subject to stockholder approval, the Company&amp;#8217;s 2013 Stock Incentive Plan (the 2013 Plan) as the successor to the Company&amp;#8217;s 2004 Stock Incentive Plan (the 2004 Plan). At the Annual Meeting of Stockholders held on June&amp;#160;12, 2013, the 2013 Plan was approved by the Company&amp;#8217;s stockholders and became effective. In connection with the approval by stockholders of the 2013 Plan, outstanding awards under the 2004 Plan were transferred to the 2013 Plan. The 2004 Plan was terminated and no further awards will be made pursuant to the 2004 Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the 2013 Plan, the exercise price per share of options granted will generally not be less than 100 percent of the fair value per share of common stock on the grant date, and the option term will not exceed ten years. If the person to whom the option is granted is a 10 percent stockholder, and the option granted qualifies as an Incentive Stock Option Grant, then the exercise price per share will not be less than 110 percent of the fair value per share of common stock on the grant date, and the option term will not exceed five years. Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination. Certain options previously granted under the 2004 Plan to the Company&amp;#8217;s non-employee directors are structured so that they may be exercised prior to vesting, with the related shares subject to Sangamo&amp;#8217;s right to repurchase any shares that have not vested pursuant to the vesting schedule in effect for such award at the exercise price paid if the option holder&amp;#8217;s board service terminates. Approximately 14.1&amp;#160;million shares were initially reserved for issuance under the 2013 Plan, including 9.7&amp;#160;million shares of common stock subject to outstanding awards previously granted under the 2004 Plan that were transferred to the 2013 Plan, and an additional 4.4&amp;#160;million shares of common stock. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The number of shares of common stock reserved for issuance under the 2013 Plan will be reduced: (i)&amp;#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&amp;#160;on a 1-for-1 basis for each share of common stock issued pursuant to a full value award granted under the plan prior to the plan effective date, and (iii)&amp;#160;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan on or after the plan effective date. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares subject to any outstanding options or other awards under the 2013 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those options or awards will be available for subsequent issuance under the 2013 Plan. Any unvested shares issued under the 2013 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2013 Plan, will be added back to the number of shares reserved for issuance under the 2013 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In June 2015 Sangamo&amp;#8217;s stockholders were asked to vote to approve the amendment and restatement of our 2013 Stock Incentive Plan in order to increase the number of shares in our common stock reserved for issuance over the term of the 2013 Plan by 5,300,000 shares. At the Annual Meeting of Stockholders held on June&amp;#160;22, 2015, the amendment and restatement of our 2013 Stock Incentive Plan was approved by the Company&amp;#8217;s stockholders and became effective.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&lt;font style="Background-color:#FFFFFF;"&gt;On November&amp;#160;10, 2017, the Compensation committee of the Company&amp;#8217;s Board of Directors approved the amendment and restatement of the Company&amp;#8217;s Amended and Restated 2013 Stock Incentive Plan, to reserve an additional one million shares of the Company&amp;#8217;s common stock to be used exclusively for grants of awards to individuals who were not previously employees or&amp;#160;non-employee&amp;#160;directors of the Company (or following a bona fide period of&amp;#160;non-employment&amp;#160;with the Company), as an inducement material to each such individual&amp;#8217;s entry into employment with us within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, or Rule 5635(c)(4). The 2013 Plan was amended and restated by the Compensation Committee without stockholder approval pursuant to Rule 5635(c)(4).&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Employee Stock Purchase Plan &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo&amp;#8217;s 2010 Employee Stock Purchase Plan (&amp;#8220;Purchase Plan&amp;#8221;), which supersedes the Company&amp;#8217;s 2000 Employee Stock Purchase Plan, provides a total reserve of 2,100,000&amp;#160;shares of common stock for issuance under the Purchase Plan. Eligible employees may purchase common stock at 85&amp;#160;percent of the lesser of the fair market value of Sangamo&amp;#8217;s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock Option Activity &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of Sangamo&amp;#8217;s stock option activity is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise per&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;font style="font-family:Calibri;"&gt;&amp;#160;&lt;/font&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&lt;font style="font-family:Calibri;"&gt;&amp;#160;&lt;/font&gt;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,256,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,030,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,029,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,881,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&amp;#8217;s right of repurchase as of December&amp;#160;31, 2017. The intrinsic value of options exercised was $12.3 million, $0.1 million and $6.4 million during 2017, 2016 and 2015, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;At December&amp;#160;31, 2017, the aggregate intrinsic values of outstanding and exercisable options were $71.7&amp;#160;million and $28.9 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December 31, 2017, 2016 and 2015 was $71.7 million, $0.0 million and $14.0 million, respectively.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information with respect to stock options outstanding at December&amp;#160;31, 2017: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding and Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;common&amp;#160;stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject&amp;#160;to&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.55 &amp;#8211; $3.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;612,318&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.50 &amp;#8211; $3.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,527,625&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.55 &amp;#8211; $5.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,212,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;672,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$5.42 &amp;#8211; $7.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;967,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.20 &amp;#8211; $9.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,199,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;551,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$9.45 &amp;#8211; $13.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;885,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.54 &amp;#8211; $15.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,148,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$15.11 &amp;#8211; $18.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$19.51 &amp;#8211; $19.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$19.80 &amp;#8211; $19.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,881,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Restricted Stock Units &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2017, 2016 and 2015, the Company awarded 12,600, 60,000, and 446,000&amp;nbsp;&amp;nbsp;Restricted Stock Units (RSUs), respectively. The RSUs awarded in 2017, 2016 and 2015 had an average grant date fair value per award of $15.85, $5.16 and $9.45, respectively. These awards generally vest as follows: one-third of the award will vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2017, 2016 and 2015 was $1.2 million, $4.8 million and $4.1 million, respectively. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A summary of Sangamo&amp;#8217;s RSU activity is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&amp;#160;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;321,816&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs awarded&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112,917&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(141,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs vested and expected to vest at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs that vested in 2017, 2016 and 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees&amp;#8217; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 42,243, 165,181, and 172,807 for 2017, 2016 and 2015, respectively and were based on the value of the RSUs on their respective issuance dates as determined by the Company&amp;#8217;s closing stock price. Total payments for the employees&amp;#8217; tax obligations to taxing authorities were $0.7 million, $0.8 million and $1.5 million in 2017, 2016 and 2015, respectively and are reflected as a financing activity within the accompanying consolidated statements of cash flows.&amp;#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;As of December&amp;#160;31, 2017, there were 3,601,633 shares reserved for future awards under the Company&amp;#8217;s 2013 Plan and 835,674 shares of common stock reserved for future issuance under the Purchase Plan. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
  <us-gaap:IncomeTaxDisclosureTextBlock id="F_000257" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 10 &amp;#8211; INCOME TAXES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The benefit for income taxes consisted of the following (in thousands):&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefit for income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax&lt;font style="color:#000000;"&gt; rate &lt;/font&gt;(34%)&lt;font style="color:#000000;"&gt; to loss before taxes is explained as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,369&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(747&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal Rate Change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,085&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,424&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,043&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&amp;#8217;s deferred tax assets are as follows (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,276&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,833&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,833&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liability related to intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In October 2013, we acquired Ceregene.&amp;nbsp;&amp;nbsp;The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Ceregene. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;amp;D and are considered indefinite-lived assets with no tax basis. In 2015, the Company impaired these intangible assets and reversed the corresponding deferred tax liability.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In 2015 the Company received a $14.5 million Section 16(b) disgorgement settlement that was recognized as additional paid-in capital. The disgorgement settlement was recognized net of taxes of $9.5 million, which resulted in an income tax benefit of $5.0 million being recognized in the accompanying consolidated statements of operations for the year ended December 31, 2015.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&amp;#8217;s analysis of these factors the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance (decreased) increased by $(28.9) million, $23.8 million and $5.0 million for the years ended December&amp;#160;31, 2017, 2016 and 2015, respectively. As of December&amp;#160;31, 2017, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $475&amp;#160;million and $142 million, respectively. If not utilized, the net federal and state operating loss carryforwards will expire in 2018 and 2017, respectively. The Company also has federal and state research tax credit carryforwards of $10.8&amp;#160;million and $11.8 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&amp;#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act ("Tax Reform") into legislation.&amp;#160; The Tax Reform makes significant changes to the US corporate income tax law including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21% from 35% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of US subsidiaries.&amp;#160; Under ASC 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted.&amp;#160; In the case of US federal income taxes, the enactment date is the date the bill becomes law.&amp;#160;&amp;#160;&amp;#160; With respect to this legislation, we expect no financial statement impact due to the Company&apos;s valuation allowance.&amp;#160; The Company performed a re-measurement of deferred tax assets and liabilities as a result of the decrease in the corporate Federal income tax rate from 35% to 21%. In addition to the reduction of U.S. federal corporate tax rate, the Company has also considered the impact of the foreign transition tax for which it has estimated that it would not need to accrue any amounts.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No.118 (SAB 118) to provide guidance on the application of the Tax Reform when a company does not have the necessary information available, prepared, or analyzed in reasonable to detail to reflect the effects of the Tax Reform.&amp;#160; SAB 118 provides guidance for companies under the three scenarios (1) measurement of certain income tax effects is complete, (2) measurement of certain income tax effect can be reasonably estimated, and (3) measurement of certain income tax effects cannot be reasonably estimated.&amp;#160; Companies are to complete the accounting under ASC 740 in regards to the Tax Reform within a measurement period that does not extend one year from the date of enactment (i.e., December 22, 2018).&amp;#160; In accordance with SAB 118, companies must reflect the tax effects of the Tax Reform for which the accounting under 740 is complete. If certain income tax effect can be reasonably estimated, then the companies must report provisional amounts in the reporting period in which the companies can determine the reasonable estimate during the measurement period.&amp;#160; In the case that certain income tax effects cannot be reasonably estimated, companies do not have to report effects of the Tax Reform.&amp;#160; However, they should continue to apply ASC 740 based on the rules before the enactment of the Tax Reform and report any income tax effects in the first reporting period in which reasonable estimates become available.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;We expect the new law to significantly reduce our tax rate in future periods, and our tax footnote reflects the effects of a Federal tax rate reduction net of our valuation allowance, which resulted in a net overall reduction of $0.&amp;#160; &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the company has utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries.&amp;#160; In accordance with SAB 118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.&amp;#160; We currently anticipate finalizing and recording any resulting adjustments by year ending December 31, 2018.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files a UK income tax return, and the tax years from 2008 and thereafter remain open to examination.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&amp;#160;31, 2017, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes the activity related to the Company&amp;#8217;s unrecognized tax benefits (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,438&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;622&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions for tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
  <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock id="F_000258" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 11 &amp;#8211; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accounts payable and accrued liabilities consist of the following (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,318&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,035&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
  <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock id="F_000259" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 12 &amp;#8211; EMPLOYEE BENEFIT PLAN &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company sponsors a defined-contribution savings plan under Section&amp;#160;401(k) of the Internal Revenue Code covering all full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan is intended to qualify under Section&amp;#160;401 of the Internal Revenue Code. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company matched employee contributions equal to 50% for the first 8% in 2017 and 6% in both 2016 and 2015, respectively, up to a limit of $4,000 in 2017 and $3,000 in both 2016 and 2015, respectively. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $0.5 million, $0.3 million, and $0.3 million for the years ended December&amp;#160;31, 2017, 2016 and 2015, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
  <us-gaap:QuarterlyFinancialInformationTextBlock id="F_000260" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 13 &amp;#8211; QUARTERLY FINANCIAL DATA (UNAUDITED) &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&amp;#160;31, 2016. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,812&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,843&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,491&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:QuarterlyFinancialInformationTextBlock>
  <sgmo:BuildToSuitLeaseObligationDisclosureTextBlock id="F_000261" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 14 &amp;#8211; BUILD-TO-SUIT LEASE &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Brisbane Build-to-Suit Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In November 2017, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 87,700 square feet of space, in Brisbane, California. Substantial completion of the building is estimated to occur in the last quarter of 2018. The lease agreement expires in May 2029, approximately ten years after substantial completion of the building. A letter of credit for $3.5 million was established as the deposit and is classified within other noncurrent assets in the financial statements. The Company has two options to extend the lease term for up to a combined additional ten years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner as a result of the cold shell condition of the building and involvement in the construction process. In connection with the Company&amp;#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation, including interest. Fair value of the building was estimated at $20.9 million using comparable market prices per square foot for similar space for public real estate transactions in the surrounding area and is considered a Level 2 fair value measurement. As of December 31, 2017, $21.2 million was capitalized with a corresponding build-to-suit lease obligation recognized related to this lease for the building and construction costs.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Point Pinole Build-to-Suit Lease&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In December 2015, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 41,400 square feet of space, in Richmond, California. Substantial completion of the building was accomplished in December 2016 at which time the lease commenced. The lease agreement expires in December 2021, five years after substantial completion of the building. The Company has two options to extend the lease term for up to a combined additional ten years.&lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner. In connection with the Company&amp;#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. As of December 31, 2016, $3.9 million of costs were capitalized in buildings with a corresponding build-to-suit lease obligation recognized related to this lease. &lt;/p&gt;
&lt;p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction has completed on the facility and as such a portion of the monthly lease payment is allocated to land rent and recorded as an operating lease expense and the non-interest portion of the amortized lease payments to the landlord related to the rent of the building is applied to reduce the build-to-suit lease obligation. &lt;/p&gt;&lt;/div&gt;</sgmo:BuildToSuitLeaseObligationDisclosureTextBlock>
  <sgmo:ClaimsSettlementDisclosureTextBlock id="F_000262" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 15 &amp;#8211; CLAIMS SETTLEMENT&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;In September 2015, the Company received $14.5 million as a settlement with certain institutional investors that were beneficial owners of Sangamo&amp;#8217;s common stock related to the disgorgement of short-swing profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.&amp;#160; The settlement of $9.5 million, net of a $5.0 million income tax benefit and certain expenses, was recognized as additional paid-in capital. &lt;/p&gt;&lt;/div&gt;</sgmo:ClaimsSettlementDisclosureTextBlock>
  <us-gaap:SubsequentEventsTextBlock id="F_000263" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;NOTE 16 &amp;#8211; SUBSEQUENT EVENT&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;"&gt;In February 2018, the Company entered into a Collaboration and License Agreement with Kite Pharma, Inc. (&amp;#8220;Kite&amp;#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc. (&amp;#8220;Gilead&amp;#8221;), for the research, development and commercialization of potential engineered cell therapies for cancer. The Company will work together with Kite on a research program under which the Company ZFNs and AAVs to disrupt and insert certain genes in T cells and NK cells, including the insertion of genes that encode CARs, T-cell receptors (&amp;#8220;TCRs&amp;#8221;) and NK cell receptors (&amp;#8220;NKRs&amp;#8221;) directed to mutually agreed targets.&amp;nbsp;&amp;nbsp;Kite will be responsible for all clinical development and commercialization of any resulting products. Except for confidentiality obligations and certain representations, warranties and covenants, which are effective upon execution, the effectiveness of the Kite agreement is subject to the expiration or termination of all applicable waiting periods under the Hart&lt;font style="Background-color:#FFFFFF;color:#000000;"&gt;-Scott-Rodino Antitrust Improvements Act of 1976, as amended&lt;/font&gt; and other customary closing conditions.&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Under the terms of the Kite agreement, the Company will, upon the effectiveness of the Kite agreement, receive a $150 million upfront payment from Kite. Kite will reimburse the Company&amp;#8217;s direct costs to conduct the joint research program under the Kite agreement, and Kite will be operationally and financially responsible for all subsequent development, manufacturing and commercialization of licensed products. The Company is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01 billion if all of the specified milestones set forth in the Kite agreement are achieved.&amp;#160;Of this amount, approximately $1.26 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75 billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&amp;#160;Each development- and sales-based milestone payment is payable (i) only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&amp;#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event.&amp;nbsp;&amp;nbsp;&lt;font style="color:#000000;"&gt;In addition, &lt;/font&gt;the Company &lt;font style="color:#000000;"&gt;will be entitled to receive escalating, tiered royalty payments with a percentage in the mid-single digits based on potential future annual worldwide net sales of l&lt;/font&gt;icensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&amp;nbsp;&amp;nbsp;At this time the Company is assessing the accounting impact of the agreement.&lt;/p&gt;&lt;/div&gt;</us-gaap:SubsequentEventsTextBlock>
  <us-gaap:BasisOfAccountingPolicyPolicyTextBlock id="F_000264" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Basis of Presentation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly-owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. &lt;/p&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
  <us-gaap:BusinessCombinationsPolicy id="F_000265" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Business Combinations &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company accounts for acquisitions in accordance with Accounting Standards Codification (ASC) Topic 805, &lt;font style="font-style:italic;"&gt;Business Combinations&lt;/font&gt; (ASC Topic 805). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. &lt;/p&gt;&lt;/div&gt;</us-gaap:BusinessCombinationsPolicy>
  <us-gaap:CashAndCashEquivalentsPolicyTextBlock id="F_000266" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Cash and Cash Equivalents &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts.&amp;nbsp;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
  <us-gaap:MarketableSecuritiesPolicy id="F_000267" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Marketable Securities &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company&amp;#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&amp;#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&amp;#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method. &lt;/p&gt;&lt;/div&gt;</us-gaap:MarketableSecuritiesPolicy>
  <us-gaap:FairValueMeasurementPolicyPolicyTextBlock id="F_000268" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&amp;#8217;s investment securities consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. &lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
  <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock id="F_000269" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Property and Equipment &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. &lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
  <us-gaap:UseOfEstimates id="F_000270" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Use of Estimates &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. &lt;/p&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
  <us-gaap:RevenueRecognitionPolicyTextBlock id="F_000271" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Revenue Recognition &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&amp;#8217;s product sales. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements prior to the adoption of ASU No.&amp;#160;2009-13, Revenue Recognition&amp;#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)&lt;font style="font-style:normal;"&gt;. For revenue arrangements entered into before January&amp;#160;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. &lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;"&gt;Multiple Element Arrangements after the adoption of ASU 2009-13.&lt;font style="font-style:normal;"&gt; ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: &lt;/font&gt;&lt;/p&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, or TPE, if available and VSOE is not available; or the best estimate of selling price, or ESP, if neither VSOE nor TPE is available; and &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;div align="left"&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" style="width:6.8%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" style="width:4.54%;white-space:nowrap"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-family:&apos;Times New Roman&apos;;font-size:15pt;line-height:11pt;"&gt;&amp;#x2022;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top"&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. &lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&amp;#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG, or Shire, in January 2012, Biogen MA Inc., or Biogen, in January 2014, and Pfizer Inc., or Pfizer, in May and December of 2017, were evaluated under these amended accounting standards. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company&amp;#8217;s performance. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received but not earned. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Sangamo&amp;#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of the Company&amp;#8217;s total revenue. During 2016 revenue related to Bioverativ, DAS and Shire represented 46%, 26%, and 17%, respectively, of total revenue.&amp;nbsp;&amp;nbsp;During 2015 revenue related to Shire and Biogen represented 40% and 35%, respectively, of total revenues. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.&lt;/p&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
  <us-gaap:ResearchAndDevelopmentExpensePolicy id="F_000272" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Research and Development Expenses &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&amp;#8217;s testing processes and procedures as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. &lt;/p&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
  <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy id="F_000273" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Stock-Based Compensation &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (RSUs) and employee stock purchases related to the Employee Stock Purchase Plan (ESPP), based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&amp;#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company adopted Accounting Standards Update (ASU) 2016-09 and accounts for forfeitures in the period they occur. &lt;/p&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
  <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy id="F_000274" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Indefinite-Lived Intangible Assets &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;As part of the Ceregene acquisition the Company recognized indefinite-lived intangible assets for in-process research and development and goodwill as further discussed below. ASC 350 and related updates require companies to test indefinite-lived intangible assets for impairment annually, and more frequently if indicators of impairment exist. ASC 350 includes an optional qualitative assessment for testing indefinite-lived intangible assets for impairment that permits companies to assess whether it is more likely than not (i.e., a likelihood of greater than 50%) that an indefinite-lived intangible asset is impaired. If a company concludes based on the qualitative assessment that it is not more likely than not that the fair value of an indefinite-lived intangible asset or, in the case of goodwill, that the fair value of the related reporting unit, is less than carrying value, it would not have to determine the asset&amp;#8217;s or reporting unit&amp;#8217;s fair value, as applicable.&lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy>
  <us-gaap:InProcessResearchAndDevelopmentPolicy id="F_000275" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;In-Process Research and Development &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Intangible assets related to in-process research and development costs, or IPR&amp;amp;D, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;amp;D projects below their respective carrying amounts. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company did not believe the programs have an alternative future use for itself or other market participants. Accordingly, the Company recognized a $1.9 million impairment charge related to these assets during the year ended December 31, 2015, which was recognized as research and development (R&amp;amp;D) in the accompanying consolidated statements of operations.&lt;/p&gt;&lt;/div&gt;</us-gaap:InProcessResearchAndDevelopmentPolicy>
  <us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy id="F_000276" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Goodwill &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate an impairment of goodwill has occurred. During the fourth quarter of 2017, the Company performed an assessment of the qualitative factors affecting the fair value of its reporting unit and concluded that it was not more likely than not that the fair value of its reporting unit was less than carrying value and that, as a result, it is not more likely than not that goodwill is impaired. &lt;/p&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsGoodwillPolicy>
  <sgmo:ContingentConsiderationPolicyTextBlock id="F_000277" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Contingent Consideration Liability &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Under the merger agreement with Ceregene, the Company is required to make contingent earn-out payments if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. These earn-out payments will become payable in the period they are earned. In accordance with ASC Topic 805, the Company determined the fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;amp;D assets acquired from Ceregene.&lt;/p&gt;&lt;/div&gt;</sgmo:ContingentConsiderationPolicyTextBlock>
  <us-gaap:IncomeTaxPolicyTextBlock id="F_000278" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Income Taxes &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. &lt;/p&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
  <us-gaap:EarningsPerSharePolicyTextBlock id="F_000279" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Net Loss Per Share &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options and restricted stock units, which are all anti-dilutive. All stock options and restricted stock units outstanding were excluded from the calculation of diluted net loss per share for all periods presented. Stock options and restricted stock units outstanding at the end of 2017, 2016 and 2015 were 8,367,628, 9,578,322, and 9,008,185, respectively. &lt;/p&gt;&lt;/div&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
  <us-gaap:SegmentReportingPolicyPolicyTextBlock id="F_000280" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Segments &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&amp;#160;31, 2017 and 2016, all of the Company&amp;#8217;s assets were maintained in the U.S. For the years ended December&amp;#160;31, 2017, 2016 and 2015, substantially all the Company&amp;#8217;s revenues and operating expenses were generated and incurred in the U.S. &lt;/p&gt;&lt;/div&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
  <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock id="F_000281" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;"&gt;Recent Accounting Pronouncements &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;"&gt;In March 2016 the Financial Accounting Standards Board (FASB) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&amp;#160;Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period.&amp;nbsp;&amp;nbsp;The Company adopted the ASU in the first quarter of 2017 and it did not have a material impact on the Company&amp;#8217;s consolidated financial statements. The impact of ASU 2016-09 as it relates to stock-based compensation for deferred tax assets and liabilities balances were not material to the Company&apos;s consolidated financial statements. &lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In February 2016 the FASB issued ASU No. 2016-02 (ASU 2016-02) &amp;#8220;&lt;font style="font-style:italic;"&gt;Leases&lt;/font&gt;.&amp;#8221; ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. We are evaluating the impact of the adoption of this standard on our consolidated financial statements, and expect our operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption which will increase our total assets and total liabilities as compared to amounts prior to adoption.&lt;/p&gt;
&lt;p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;In May 2014 the FASB issued ASU 2014-09, &lt;font style="font-style:italic;"&gt;Revenue from Contracts with&amp;#160;Customers (Topic 606)&lt;/font&gt;, or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&amp;#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&amp;#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&amp;#160;15, 2017, including interim periods within that reporting period. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&amp;#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at December 31, 2017 and any future receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined under ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development reimbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition adjustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research and development reimbursements and up-front payments under ASC 606. &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The estimates of the expected effects of the Company&amp;#8217;s adoption of ASU 2014-09 represent management&amp;#8217;s best estimates of the effects of adopting ASU 2014-09 at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of the Company&amp;#8217;s assessment in the first quarter of 2018.&lt;/p&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
  <us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock id="F_000282" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The fair value measurements of cash equivalents, available-for-sale securities and the contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;199,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value Measurements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Level 3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and marketable securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock>
  <us-gaap:AvailableForSaleSecuritiesTextBlock id="F_000283" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The table below summarizes the Company&amp;#8217;s cash equivalents and available-for-sale securities (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;font style="font-size:12pt;"&gt;&amp;#160;&lt;/font&gt;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gross&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Amortized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Unrealized&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Estimated&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cost&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Gains&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(Losses)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fair Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,290&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,595&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,885&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,365&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(118&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;110,247&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(131&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;75,755&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,749&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;194,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,634&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(255&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;223,379&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,992&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Available-for-sale securities:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Commercial paper securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,112&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;73&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,185&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Corporate debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,005&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,004&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;U.S. government-sponsored entity debt securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,307&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(25&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;87,285&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,424&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;120,474&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total cash equivalents and available-for-sale securities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,416&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;139,466&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:AvailableForSaleSecuritiesTextBlock>
  <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock id="F_000284" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table shows total stock-based compensation expense recognized in the accompanying consolidated statements of operations (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,031&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,444&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,058&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,594&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,286&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,089&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,057&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,730&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock id="F_000285" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The assumptions used for estimating the fair value of the employee stock options are as follows:&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.81-2.28%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.13-1.61%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1.46-1.58%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life of option (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.73-5.83&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.28-5.29&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.25-5.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield of stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.71-0.72&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.68-0.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.66-0.67&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock id="F_000286" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The weighted&amp;#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Risk-free interest rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.44-0.76%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.41-0.80%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.06-0.33%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected life of option (in years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.5-2.0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected dividend yield of stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;%&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.66-0.82&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.71-0.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.55-0.70&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000287" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the Bioverativ Agreement for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): &amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Bioverativ Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,321&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,176&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,489&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,769&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,258&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,886&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,945&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000288" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the Shire Agreement for the years ended December&amp;#160;31, 2017, 2016 and 2015, were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Shire Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Recognition of upfront fee&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,333&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,181&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,167&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research services&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;116&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,096&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,584&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,449&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,751&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock id="F_000289" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Revenues recognized under the agreement with Sigma for the years ended December&amp;#160;31, 2017, 2016 and 2015, were as follows (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenue related to Sigma Collaboration:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Royalty revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;452&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;137&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;390&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;License fee revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;267&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,140&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,463&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;719&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,277&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,853&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock>
  <us-gaap:PropertyPlantAndEquipmentTextBlock id="F_000290" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Property and equipment consist of the following (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Laboratory equipment&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,572&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,206&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;636&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Buildings&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,876&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16,367&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,048&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Less accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(6,951&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,639&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Construction in Progress&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,650&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;148&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;31,066&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
  <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock id="F_000291" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Future minimum payments under lease obligations at December&amp;#160;31, 2017 consist of the following (in thousands):&lt;/p&gt;&lt;/div&gt;&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Fiscal Year:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2018&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,685&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2019&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,925&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2020&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,798&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2022&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,896&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total minimum payments&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;39,434&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock id="F_000292" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;A summary of Sangamo&amp;#8217;s stock option activity is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted-&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise per&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Share Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&lt;font style="font-family:Calibri;"&gt;&amp;#160;&lt;/font&gt;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In&lt;font style="font-family:Calibri;"&gt;&amp;#160;&lt;/font&gt;thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,256,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options granted&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,091,125&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.48&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercised&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,030,815&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.76&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options canceled&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2,029,360&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options vested and expected to vest at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.77&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;71,658&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options exercisable at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,881,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;28,864&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock id="F_000293" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;The following table summarizes information with respect to stock options outstanding at December&amp;#160;31, 2017: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Outstanding and Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Options Exercisable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;common stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;common&amp;#160;stock&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject&amp;#160;to&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;subject to&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Range of Exercise Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Life&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;options&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Exercise&amp;#160;Price&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$2.55 &amp;#8211; $3.45&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;612,318&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;214,920&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3.13&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.50 &amp;#8211; $3.50&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,527,625&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$3.55 &amp;#8211; $5.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,212,567&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.24&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;672,930&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.34&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$5.42 &amp;#8211; $7.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,501,051&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.53&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;967,506&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.11&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$7.20 &amp;#8211; $9.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,199,546&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;551,162&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9.06&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$9.45 &amp;#8211; $13.35&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;885,599&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5.52&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;659,946&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11.92&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$13.54 &amp;#8211; $15.00&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,148,250&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;668,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;14.07&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$15.11 &amp;#8211; $18.26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;178,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7.31&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;124,561&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16.41&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$19.51 &amp;#8211; $19.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;10,000&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;9,583&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.51&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$19.80 &amp;#8211; $19.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,500&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,718&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;19.80&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,287,456&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6.69&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,881,078&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8.99&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock>
  <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock id="F_000294" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;A summary of Sangamo&amp;#8217;s RSU activity is as follows: &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Number&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Weighted&amp;#160;Average&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;of&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Remaining&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Aggregate&amp;#160;Intrinsic&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Shares&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Contractual&amp;#160;Term&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Value&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In years)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;(In thousands)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;321,816&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs awarded&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,600&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs released&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(112,917&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs forfeited&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(141,327&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs outstanding at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;RSUs vested and expected to vest at December 31, 2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;80,172&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;0.90&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,315&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
  <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock id="F_000295" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The benefit for income taxes consisted of the following (in thousands):&amp;nbsp;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Benefit for income taxes:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Current:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,563&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt; State&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(159&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Subtotal&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
  <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock id="F_000296" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax&lt;font style="color:#000000;"&gt; rate &lt;/font&gt;(34%)&lt;font style="color:#000000;"&gt; to loss before taxes is explained as follows (in thousands):&lt;/font&gt;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Year Ended December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Tax at federal statutory rate&lt;/p&gt;&lt;/td&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,553&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(24,369&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(15,785&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;State taxes, net&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;795&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(747&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,840&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Federal Rate Change&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;53,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Non-deductible stock compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,120&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,781&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,085&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research credits&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(869&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(1,424&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(814&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(36,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;23,773&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,043&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;37&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(28&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(91&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Income tax benefit&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(5,722&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
  <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock id="F_000297" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Significant components of the Company&amp;#8217;s deferred tax assets are as follows (in thousands):&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Assets:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;91,308&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;114,222&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Research and development tax credit carryforwards&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;15,147&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;12,518&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Stock-based compensation&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,168&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,565&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred revenue&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;934&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,918&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,276&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,492&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax asset&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,833&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Valuation allowance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;112,833&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;141,715&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&lt;font style="text-decoration:underline;"&gt;Liabilities:&lt;/font&gt;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net deferred tax liability related to intangible assets&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total deferred tax liability&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
  <us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock id="F_000298" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table summarizes the activity related to the Company&amp;#8217;s unrecognized tax benefits (in thousands): &lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2015&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Beginning balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,438&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions based on tax positions related to the current year&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;622&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,023&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;557&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Additions for tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(8&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;4,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Reductions for tax positions of prior years&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(4,335&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#8212;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Ending balance&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,659&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;5,045&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,330&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock>
  <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock id="F_000299" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;Accounts payable and accrued liabilities consist of the following (in thousands): &lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;December 31 ,&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accounts payable&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;16&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,580&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued research and development expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;7,898&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,887&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Accrued professional fees&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,318&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;270&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Deferred rent&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;417&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;498&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Other&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;1,386&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Total accounts payable and accrued liabilities&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,035&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;6,261&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
  <us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock id="F_000300" contextRef="C_0001001233_20170101_20171231">&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;"&gt;The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&amp;#160;31, 2016.&lt;/p&gt;&lt;/div&gt;&lt;div&gt;

&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;#160;&lt;/p&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;"&gt;&amp;nbsp;&lt;/p&gt;
&lt;div&gt;
&lt;table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2017&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;2016&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q1&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q2&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q3&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"&gt;
&lt;p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;Q4&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Revenues&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,425&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,253&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;11,812&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;13,077&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,942&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;3,702&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;2,823&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;8,922&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Expenses&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,217&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;21,021&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;24,847&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;26,843&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;20,623&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;30,544&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;22,029&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;18,752&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,632&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,491&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(12,354&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(13,091&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(16,494&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(26,575&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(18,965&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(9,624&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;tr&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;Net loss per share&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.17&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.15&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.23&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.38&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.27&lt;/p&gt;&lt;/td&gt;
&lt;td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;$&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;"&gt;
&lt;p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;(0.14&lt;/p&gt;&lt;/td&gt;
&lt;td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"&gt;)&lt;/p&gt;&lt;/td&gt;
&lt;/tr&gt;
&lt;/table&gt;&lt;/div&gt;
&lt;p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;"&gt;&amp;nbsp;&lt;/p&gt;&lt;/div&gt;</us-gaap:ScheduleOfQuarterlyFinancialInformationTableTextBlock>
  <sgmo:CashEquivalentMaturityPeriodHighlyLiquidInvestment id="F_000301" contextRef="C_0001001233_20170101_20171231">three months or less</sgmo:CashEquivalentMaturityPeriodHighlyLiquidInvestment>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000302" contextRef="C_0001001233_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <us-gaap:PropertyPlantAndEquipmentUsefulLife id="F_000303" contextRef="C_0001001233_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
  <sgmo:ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic id="F_000304" contextRef="C_0001001233_us-gaapChangeInAccountingEstimateByTypeAxis_sgmoCollaborationContractPerformancePeriodMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">-0.06</sgmo:ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic>
  <sgmo:ChangeInAccountingEstimateDecreaseInRevenues id="F_000305" contextRef="C_0001001233_us-gaapChangeInAccountingEstimateByTypeAxis_sgmoCollaborationContractPerformancePeriodMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">4300000</sgmo:ChangeInAccountingEstimateDecreaseInRevenues>
  <sgmo:ChangeInAccountingEstimateDecreaseInRevenues id="F_000306" contextRef="C_0001001233_us-gaapChangeInAccountingEstimateByTypeAxis_sgmoCollaborationContractPerformancePeriodMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">4300000</sgmo:ChangeInAccountingEstimateDecreaseInRevenues>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000307" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="2" unitRef="U_pure">0.47</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000308" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="2" unitRef="U_pure">0.34</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000309" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="2" unitRef="U_pure">0.46</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000310" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_20160101_20161231" decimals="2" unitRef="U_pure">0.26</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000311" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231" decimals="2" unitRef="U_pure">0.17</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000312" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231" decimals="2" unitRef="U_pure">0.40</us-gaap:ConcentrationRiskPercentage1>
  <us-gaap:ConcentrationRiskPercentage1 id="F_000313" contextRef="C_0001001233_us-gaapConcentrationRiskByBenchmarkAxis_us-gaapSalesRevenueNetMember_us-gaapConcentrationRiskByTypeAxis_us-gaapCustomerConcentrationRiskMember_us-gaapCounterpartyNameAxis_sgmoBiogenIncMember_20150101_20151231" decimals="2" unitRef="U_pure">0.35</us-gaap:ConcentrationRiskPercentage1>
  <sgmo:MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired id="F_000314" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_pure">0.50</sgmo:MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber id="F_000315" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">8367628</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber id="F_000316" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">9578322</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber id="F_000317" contextRef="C_0001001233_20151231" decimals="INF" unitRef="U_shares">9008185</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber>
  <us-gaap:NumberOfOperatingSegments id="F_000318" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_sgmoSegments">1</us-gaap:NumberOfOperatingSegments>
  <us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1 id="F_000319" contextRef="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapStatementScenarioAxis_us-gaapProFormaMember_20171231" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1>
  <us-gaap:LicenseAndServicesRevenue id="F_000320" contextRef="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">17000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000321" contextRef="C_0001001233_us-gaapAdjustmentsForNewAccountingPronouncementsAxis_us-gaapAccountingStandardsUpdate201409Member_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170509_20170510" decimals="-5" unitRef="U_iso4217USD">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000322" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000323" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000324" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">4595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000325" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">4595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000326" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">28885000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000327" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000328" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">4595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000329" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">110247000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000330" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">110247000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000331" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">75755000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000332" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">75755000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000333" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">8492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000334" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">8492000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000335" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">194494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000336" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">194494000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AssetsFairValueDisclosure id="F_000337" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">223379000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000338" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000339" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20171231" decimals="-3" unitRef="U_iso4217USD">199089000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000340" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000341" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000342" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000343" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000344" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231" decimals="-3" unitRef="U_iso4217USD">23185000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000345" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231" decimals="-3" unitRef="U_iso4217USD">23185000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000346" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">10004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000347" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">10004000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000348" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">87285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000349" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">87285000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000350" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">120474000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AvailableForSaleSecuritiesDebtSecurities id="F_000351" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">120474000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
  <us-gaap:AssetsFairValueDisclosure id="F_000352" contextRef="C_0001001233_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">139466000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000353" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel1Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000354" contextRef="C_0001001233_us-gaapFairValueByFairValueHierarchyLevelAxis_us-gaapFairValueInputsLevel2Member_us-gaapFairValueByMeasurementFrequencyAxis_us-gaapFairValueMeasurementsRecurringMember_20161231" decimals="-3" unitRef="U_iso4217USD">120474000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000355" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000356" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">4595000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000357" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20171231" decimals="-3" unitRef="U_iso4217USD">28885000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000358" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsAtCarryingValue id="F_000359" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000360" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20171231" decimals="-3" unitRef="U_iso4217USD">24290000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000361" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">4595000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000362" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20171231" decimals="-3" unitRef="U_iso4217USD">28885000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000363" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapMoneyMarketFundsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <us-gaap:CashAndCashEquivalentsFairValueDisclosure id="F_000364" contextRef="C_0001001233_us-gaapInvestmentTypeAxis_us-gaapCashEquivalentsMember_20161231" decimals="-3" unitRef="U_iso4217USD">18992000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
  <sgmo:AssetsAmortizedCost id="F_000365" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">110365000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000366" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">75886000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000367" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">8498000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000368" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">194749000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000369" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">223634000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000370" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231" decimals="-3" unitRef="U_iso4217USD">23112000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000371" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">10005000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000372" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">87307000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000373" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">120424000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAmortizedCost id="F_000374" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">139416000</sgmo:AssetsAmortizedCost>
  <sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax id="F_000375" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231" decimals="-3" unitRef="U_iso4217USD">73000</sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax id="F_000376" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">3000</sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax id="F_000377" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">76000</sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax id="F_000378" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">76000</sgmo:AssetsAccumulatedGrossUnrealizedGainBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000379" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">118000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000380" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">131000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000381" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">6000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000382" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">255000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000383" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">255000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000384" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">1000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000385" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">25000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000386" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">26000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax id="F_000387" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">26000</sgmo:AssetsAccumulatedGrossUnrealizedLossBeforeTax>
  <us-gaap:AssetsFairValueDisclosure id="F_000388" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20171231" decimals="-3" unitRef="U_iso4217USD">110247000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000389" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">75755000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000390" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">8492000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000391" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20171231" decimals="-3" unitRef="U_iso4217USD">194494000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000392" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">223379000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000393" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapInvestmentTypeAxis_us-gaapCommercialPaperMember_20161231" decimals="-3" unitRef="U_iso4217USD">23185000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000394" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapCorporateDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">10004000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000395" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_us-gaapMajorTypesOfDebtAndEquitySecuritiesAxis_us-gaapUSGovernmentSponsoredEnterprisesDebtSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">87285000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000396" contextRef="C_0001001233_us-gaapInformationByCategoryOfDebtSecurityAxis_us-gaapAvailableforsaleSecuritiesMember_20161231" decimals="-3" unitRef="U_iso4217USD">120474000</us-gaap:AssetsFairValueDisclosure>
  <us-gaap:AssetsFairValueDisclosure id="F_000397" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">139466000</us-gaap:AssetsFairValueDisclosure>
  <sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities id="F_000398" contextRef="C_0001001233_20170101_20171231">P2Y</sgmo:InvestmentsMaturityDatesAvailableForSaleSecurities>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000399" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000400" contextRef="C_0001001233_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses id="F_000401" contextRef="C_0001001233_20150101_20151231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:AvailableForSaleSecuritiesGrossRealizedLosses>
  <sgmo:OtherThanTemporarilyImpairedInvestment id="F_000402" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_iso4217USD">0</sgmo:OtherThanTemporarilyImpairedInvestment>
  <sgmo:OtherThanTemporarilyImpairedInvestment id="F_000403" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_iso4217USD">0</sgmo:OtherThanTemporarilyImpairedInvestment>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000404" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">5031000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000405" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">6463000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000406" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapResearchAndDevelopmentExpenseMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">6444000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000407" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">4058000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000408" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">8594000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000409" contextRef="C_0001001233_us-gaapIncomeStatementLocationAxis_us-gaapGeneralAndAdministrativeExpenseMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">5286000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000410" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">9089000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000411" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">15057000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:AllocatedShareBasedCompensationExpense id="F_000412" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">11730000</us-gaap:AllocatedShareBasedCompensationExpense>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000413" contextRef="C_0001001233_20171231" decimals="-5" unitRef="U_iso4217USD">16100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000414" contextRef="C_0001001233_20170101_20171231">P2Y9M14D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount id="F_000415" contextRef="C_0001001233_20150101_20151231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount id="F_000416" contextRef="C_0001001233_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount id="F_000417" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized id="F_000418" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20171231" decimals="-5" unitRef="U_iso4217USD">700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
  <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 id="F_000419" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231">P1Y10D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000420" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">4.10</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000421" contextRef="C_0001001233_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">3.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000422" contextRef="C_0001001233_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">5.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000423" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0181</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000424" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0228</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000425" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0113</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000426" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0161</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000427" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0146</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000428" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0158</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000429" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">P5Y8M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000430" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">P5Y9M29D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000431" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231">P5Y3M10D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000432" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">P5Y3M14D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000433" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231">P5Y3M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000434" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000435" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000436" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20160101_20161231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000437" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_20150101_20151231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000438" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000439" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0072</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000440" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0068</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000441" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000442" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000443" contextRef="C_0001001233_us-gaapDeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_us-gaapEmployeeStockOptionMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000444" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">253994</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000445" contextRef="C_0001001233_20160101_20161231" decimals="INF" unitRef="U_shares">202711</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans id="F_000446" contextRef="C_0001001233_20150101_20151231" decimals="INF" unitRef="U_shares">128181</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice id="F_000447" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">3.22</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice id="F_000448" contextRef="C_0001001233_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">4.04</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice id="F_000449" contextRef="C_0001001233_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">7.10</sgmo:StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue id="F_000450" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">2.37</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue id="F_000451" contextRef="C_0001001233_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">2.27</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue id="F_000452" contextRef="C_0001001233_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">4.42</sgmo:EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000453" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000454" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000455" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000456" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0080</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000457" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0006</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate id="F_000458" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0033</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000459" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000460" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000461" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000462" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000463" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231">P6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 id="F_000464" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000465" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20170101_20171231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000466" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20160101_20161231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate id="F_000467" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20150101_20151231" decimals="2" unitRef="U_pure">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000468" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0066</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000469" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0082</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000470" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0071</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000471" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20160101_20161231" decimals="4" unitRef="U_pure">0.0076</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000472" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMinimumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0055</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate id="F_000473" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20150101_20151231" decimals="4" unitRef="U_pure">0.0070</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000474" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170509_20170510" decimals="-5" unitRef="U_iso4217USD">70000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved id="F_000475" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170509_20170510" decimals="-5" unitRef="U_iso4217USD">208500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive id="F_000476" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoSBFiveTwoFiveMember_20170509_20170510" decimals="-5" unitRef="U_iso4217USD">266500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <sgmo:MilestoneRevenueReceivable id="F_000477" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170510" decimals="-5" unitRef="U_iso4217USD">475000000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestoneRevenueReceivable id="F_000478" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoSBFiveTwoFiveMember_us-gaapRangeAxis_us-gaapMaximumMember_20170510" decimals="INF" unitRef="U_iso4217USD">300000000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestoneRevenueReceivable id="F_000479" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoOtherProductsMember_us-gaapRangeAxis_us-gaapMaximumMember_20170510" decimals="INF" unitRef="U_iso4217USD">175000000</sgmo:MilestoneRevenueReceivable>
  <sgmo:MilestonePaymentsReceived id="F_000480" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</sgmo:MilestonePaymentsReceived>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement id="F_000481" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="INF" unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <us-gaap:RoyaltyRevenue id="F_000482" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RoyaltyRevenue>
  <sgmo:InitialResearchTermOfAgreement id="F_000483" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231">P32M</sgmo:InitialResearchTermOfAgreement>
  <us-gaap:DeferredRevenue id="F_000484" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20171231" decimals="-5" unitRef="U_iso4217USD">53000000</us-gaap:DeferredRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000485" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">17000000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000486" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoCNineORFSevenTwoMember_20171228_20171228" decimals="-5" unitRef="U_iso4217USD">12000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved id="F_000487" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoCNineORFSevenTwoMember_us-gaapRangeAxis_us-gaapMaximumMember_20171228_20171228" decimals="INF" unitRef="U_iso4217USD">60000000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive id="F_000488" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoPfizerMember_us-gaapProductOrServiceAxis_sgmoCNineORFSevenTwoMember_us-gaapRangeAxis_us-gaapMaximumMember_20171228_20171228" decimals="INF" unitRef="U_iso4217USD">90000000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <sgmo:NumberOfResearchProgram id="F_000489" contextRef="C_0001001233_20140101_20140131" decimals="INF" unitRef="U_sgmoProgram">2</sgmo:NumberOfResearchProgram>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000490" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">20000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved id="F_000491" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">115800000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved>
  <sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive id="F_000492" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20140101_20140131" decimals="-5" unitRef="U_iso4217USD">160500000</sgmo:AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive>
  <sgmo:MilestonePaymentsReceived id="F_000493" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</sgmo:MilestonePaymentsReceived>
  <sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement id="F_000494" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="INF" unitRef="U_sgmoProduct">0</sgmo:CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement>
  <us-gaap:RoyaltyRevenue id="F_000495" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:RoyaltyRevenue>
  <sgmo:InitialResearchTermOfAgreement id="F_000496" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231">P44M</sgmo:InitialResearchTermOfAgreement>
  <us-gaap:DeferredRevenue id="F_000497" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20171231" decimals="-5" unitRef="U_iso4217USD">4600000</us-gaap:DeferredRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000498" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">1769000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000499" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2321000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000500" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">6176000</us-gaap:LicenseAndServicesRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000501" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">10489000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000502" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">6565000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000503" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">7769000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <us-gaap:ContractsRevenue id="F_000504" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">12258000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000505" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">8886000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000506" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoBioverativIncMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">13945000</us-gaap:ContractsRevenue>
  <sgmo:AggregateNumberOfGeneTargets id="F_000507" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="INF" unitRef="U_sgmoTargets">7</sgmo:AggregateNumberOfGeneTargets>
  <sgmo:NumberOfInitialGeneTargets id="F_000508" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="INF" unitRef="U_sgmoTargets">4</sgmo:NumberOfInitialGeneTargets>
  <sgmo:NumberOfGeneTargets id="F_000509" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630" decimals="INF" unitRef="U_sgmoTargets">5</sgmo:NumberOfGeneTargets>
  <sgmo:NumberOfAdditionalGeneTargets id="F_000510" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120601_20120630" decimals="INF" unitRef="U_sgmoTargets">2</sgmo:NumberOfAdditionalGeneTargets>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000511" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20120101_20120131" decimals="-5" unitRef="U_iso4217USD">13000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized id="F_000512" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20140101_20141231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:RevenueRecognitionMilestoneMethodRevenueRecognized>
  <us-gaap:RevenueFromRelatedParties id="F_000513" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">3400000</us-gaap:RevenueFromRelatedParties>
  <us-gaap:DeferredRevenue id="F_000514" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20171231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:DeferredRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000515" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2333000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000516" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2181000</us-gaap:LicenseAndServicesRevenue>
  <us-gaap:LicenseAndServicesRevenue id="F_000517" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">2167000</us-gaap:LicenseAndServicesRevenue>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000518" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">116000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000519" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1096000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <sgmo:ResearchServiceRevenueUnderCollaborationAgreement id="F_000520" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">13584000</sgmo:ResearchServiceRevenueUnderCollaborationAgreement>
  <us-gaap:ContractsRevenue id="F_000521" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2449000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000522" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">3277000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000523" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoShireAgMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">15751000</us-gaap:ContractsRevenue>
  <sgmo:ResearchServicesPeriod id="F_000524" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20070101_20071231">P3Y</sgmo:ResearchServicesPeriod>
  <sgmo:UpfrontLicenseFee id="F_000525" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">20000000</sgmo:UpfrontLicenseFee>
  <sgmo:UpfrontLicenseFee id="F_000526" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">15100000</sgmo:UpfrontLicenseFee>
  <us-gaap:StockIssuedDuringPeriodValueNewIssues id="F_000527" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoUpfrontLicenseFeesMember_20091001_20091031" decimals="-5" unitRef="U_iso4217USD">4900000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000528" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031" decimals="INF" unitRef="U_shares">636133</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned id="F_000529" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned>
  <sgmo:ReducedRoyaltyRate id="F_000530" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091001_20091031" decimals="3" unitRef="U_pure">0.105</sgmo:ReducedRoyaltyRate>
  <sgmo:AdditionalMilestoneReceivableUnderAgreement id="F_000531" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20091031" decimals="-5" unitRef="U_iso4217USD">25000000</sgmo:AdditionalMilestoneReceivableUnderAgreement>
  <us-gaap:RoyaltyRevenue id="F_000532" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">452000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="F_000533" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">137000</us-gaap:RoyaltyRevenue>
  <us-gaap:RoyaltyRevenue id="F_000534" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">390000</us-gaap:RoyaltyRevenue>
  <us-gaap:LicensesRevenue id="F_000535" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">267000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000536" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1140000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000537" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4463000</us-gaap:LicensesRevenue>
  <us-gaap:ContractsRevenue id="F_000538" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">719000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000539" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1277000</us-gaap:ContractsRevenue>
  <us-gaap:ContractsRevenue id="F_000540" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoSigmaAldrichCorporationMember_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4853000</us-gaap:ContractsRevenue>
  <sgmo:InitialResearchTermOfAgreement id="F_000541" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231">P3Y</sgmo:InitialResearchTermOfAgreement>
  <sgmo:OneTimeLicenseFeeEarned id="F_000542" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20051231" decimals="-5" unitRef="U_iso4217USD">6000000</sgmo:OneTimeLicenseFeeEarned>
  <us-gaap:RoyaltyRevenue id="F_000543" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="-5" unitRef="U_iso4217USD">2300000</us-gaap:RoyaltyRevenue>
  <sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing id="F_000544" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="2" unitRef="U_pure">0.25</sgmo:PercentageOfRoyaltiesToBeReceivedFromSublicensing>
  <sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement id="F_000545" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="-5" unitRef="U_iso4217USD">4000000</sgmo:MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement>
  <sgmo:AnnualFeesRelatedToAgreement id="F_000546" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMinimumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="INF" unitRef="U_iso4217USD">250000</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:AnnualFeesRelatedToAgreement id="F_000547" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="INF" unitRef="U_iso4217USD">3000000</sgmo:AnnualFeesRelatedToAgreement>
  <sgmo:FeeDue id="F_000548" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231" decimals="-5" unitRef="U_iso4217USD">25300000</sgmo:FeeDue>
  <sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod id="F_000549" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20050101_20051231">P11Y</sgmo:MinimumSublicenseAnnualFeesSpecificReckoningPeriod>
  <us-gaap:LicensesRevenue id="F_000550" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">3000000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000551" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">5100000</us-gaap:LicensesRevenue>
  <us-gaap:LicensesRevenue id="F_000552" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoDowAgroSciencesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_us-gaapLicenseAgreementTermsMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">3000000</us-gaap:LicensesRevenue>
  <us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued id="F_000553" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131001_20131031" decimals="INF" unitRef="U_shares">100000</us-gaap:BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued>
  <us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable id="F_000554" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131001_20131031" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable>
  <sgmo:BusinessAcquisitionContingentConsiderationEarnOutPayment id="F_000555" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131001_20131031" decimals="-5" unitRef="U_iso4217USD">1500000</sgmo:BusinessAcquisitionContingentConsiderationEarnOutPayment>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000556" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131031" decimals="-5" unitRef="U_iso4217USD">1800000</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:BusinessCombinationContingentConsiderationLiability id="F_000557" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20150331" decimals="0" unitRef="U_iso4217USD">0</us-gaap:BusinessCombinationContingentConsiderationLiability>
  <us-gaap:ResearchAndDevelopmentInProcess id="F_000558" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131001_20131031" decimals="-5" unitRef="U_iso4217USD">1900000</us-gaap:ResearchAndDevelopmentInProcess>
  <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill id="F_000559" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">1900000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
  <us-gaap:Goodwill id="F_000560" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20131031" decimals="-5" unitRef="U_iso4217USD">1600000</us-gaap:Goodwill>
  <us-gaap:GoodwillImpairmentLoss id="F_000561" contextRef="C_0001001233_us-gaapBusinessAcquisitionAxis_sgmoCeregeneIncMember_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">0</us-gaap:GoodwillImpairmentLoss>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000562" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20171231" decimals="-3" unitRef="U_iso4217USD">7572000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000563" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapEquipmentMember_20161231" decimals="-3" unitRef="U_iso4217USD">6206000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000564" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20171231" decimals="-3" unitRef="U_iso4217USD">1494000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000565" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapFurnitureAndFixturesMember_20161231" decimals="-3" unitRef="U_iso4217USD">636000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000566" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20171231" decimals="-3" unitRef="U_iso4217USD">3425000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000567" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapLeaseholdImprovementsMember_20161231" decimals="-3" unitRef="U_iso4217USD">1330000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000568" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171231" decimals="-3" unitRef="U_iso4217USD">3876000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000569" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20161231" decimals="-3" unitRef="U_iso4217USD">3876000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000570" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">16367000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:PropertyPlantAndEquipmentGross id="F_000571" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">12048000</us-gaap:PropertyPlantAndEquipmentGross>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000572" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">6951000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment id="F_000573" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">5639000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000574" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20171231" decimals="-3" unitRef="U_iso4217USD">21650000</us-gaap:PropertyPlantAndEquipmentNet>
  <us-gaap:PropertyPlantAndEquipmentNet id="F_000575" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20161231" decimals="-3" unitRef="U_iso4217USD">148000</us-gaap:PropertyPlantAndEquipmentNet>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000576" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoRichmondBuildToSuitLeaseMember_20161231" decimals="-5" unitRef="U_iso4217USD">3900000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000577" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171231" decimals="-5" unitRef="U_iso4217USD">20900000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000578" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapConstructionInProgressMember_20171231" decimals="-5" unitRef="U_iso4217USD">300000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits id="F_000579" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_sgmoProperty">3</us-gaap:PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits>
  <us-gaap:LandSubjectToGroundLeases id="F_000580" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoResearchAndOfficeSpaceMember_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseOneMember_20171231" decimals="INF" unitRef="U_utrsqft">7700</us-gaap:LandSubjectToGroundLeases>
  <us-gaap:LeaseExpirationDate1 id="F_000581" contextRef="C_0001001233_us-gaapPropertyPlantAndEquipmentByTypeAxis_sgmoResearchAndOfficeSpaceMember_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseOneMember_20170101_20171231">2019-08-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LandSubjectToGroundLeases id="F_000582" contextRef="C_0001001233_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseTwoMember_20171231" decimals="INF" unitRef="U_utrsqft">6200</us-gaap:LandSubjectToGroundLeases>
  <us-gaap:LeaseExpirationDate1 id="F_000583" contextRef="C_0001001233_us-gaapPropertySubjectToOrAvailableForOperatingLeaseAxis_sgmoPropertySubjectToOperatingLeaseTwoMember_20170101_20171231">2021-07-31</us-gaap:LeaseExpirationDate1>
  <sgmo:BuildToSuitLeasePropertyLeased id="F_000584" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoRichmondBuildToSuitLeaseMember_20170101_20171231" decimals="0" unitRef="U_utrsqft">41400</sgmo:BuildToSuitLeasePropertyLeased>
  <us-gaap:LeaseExpirationDate1 id="F_000585" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoRichmondBuildToSuitLeaseMember_20170101_20171231">2021-12-31</us-gaap:LeaseExpirationDate1>
  <sgmo:BuildToSuitLeasePropertyLeased id="F_000586" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20170101_20171231" decimals="0" unitRef="U_utrsqft">87700</sgmo:BuildToSuitLeasePropertyLeased>
  <us-gaap:LeaseExpirationDate1 id="F_000587" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20170101_20171231">2029-05-31</us-gaap:LeaseExpirationDate1>
  <sgmo:NumberOfBuiltToSuitLeaseProperties id="F_000588" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_sgmoProperty">2</sgmo:NumberOfBuiltToSuitLeaseProperties>
  <us-gaap:LeaseAndRentalExpense id="F_000589" contextRef="C_0001001233_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1100000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000590" contextRef="C_0001001233_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">1000000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:LeaseAndRentalExpense id="F_000591" contextRef="C_0001001233_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">900000</us-gaap:LeaseAndRentalExpense>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent id="F_000592" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1685000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears id="F_000593" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">2925000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears id="F_000594" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">3795000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears id="F_000595" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">3798000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears id="F_000596" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">3335000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter id="F_000597" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">23896000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
  <us-gaap:OperatingLeasesFutureMinimumPaymentsDue id="F_000598" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">39434000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
  <us-gaap:OtherCommitmentDueInNextTwelveMonths id="F_000599" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapOtherCommitmentsAxis_sgmoTenantImprovementsMember_20171231" decimals="-5" unitRef="U_iso4217USD">8800000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
  <us-gaap:OtherCommitmentDueInNextTwelveMonths id="F_000600" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_us-gaapOtherCommitmentsAxis_sgmoTenantImprovementsMember_20171231" decimals="-5" unitRef="U_iso4217USD">8700000</us-gaap:OtherCommitmentDueInNextTwelveMonths>
  <sgmo:LicenseCommitments id="F_000601" contextRef="C_0001001233_us-gaapFiniteLivedIntangibleAssetsByMajorClassAxis_us-gaapIntellectualPropertyMember_20171231" decimals="-5" unitRef="U_iso4217USD">5200000</sgmo:LicenseCommitments>
  <us-gaap:PreferredStockSharesAuthorized id="F_000602" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">5000000</us-gaap:PreferredStockSharesAuthorized>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000603" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170625_20170626" decimals="-5" unitRef="U_shares">11500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <us-gaap:SharesIssuedPricePerShare id="F_000604" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170626" decimals="INF" unitRef="U_iso4217USD_shares">7.25</us-gaap:SharesIssuedPricePerShare>
  <sgmo:NetProceedsFromIssuancePublicOffering id="F_000605" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_20170625_20170626" decimals="-5" unitRef="U_iso4217USD">78100000</sgmo:NetProceedsFromIssuancePublicOffering>
  <sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance id="F_000606" contextRef="C_0001001233_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20161207" decimals="-5" unitRef="U_iso4217USD">75000000</sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance>
  <sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance id="F_000607" contextRef="C_0001001233_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170526" decimals="-5" unitRef="U_iso4217USD">75000000</sgmo:CommonStockCapitalSharesValueReservedForFutureIssuance>
  <us-gaap:StockIssuedDuringPeriodSharesNewIssues id="F_000608" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170101_20170331" decimals="INF" unitRef="U_shares">871149</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
  <sgmo:NetProceedsFromIssuancePublicOffering id="F_000609" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170101_20170331" decimals="-5" unitRef="U_iso4217USD">3400000</sgmo:NetProceedsFromIssuancePublicOffering>
  <us-gaap:PaymentsForCommissions id="F_000610" contextRef="C_0001001233_us-gaapStatementEquityComponentsAxis_us-gaapCommonStockMember_us-gaapSubsidiarySaleOfStockAxis_sgmoAtTheMarketOfferingAgreementMember_20170101_20170331" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:PaymentsForCommissions>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000611" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231" decimals="INF" unitRef="U_pure">1.00</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000612" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <sgmo:SpecifiedStockholderOwnershipPercentage id="F_000613" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_pure">0.10</sgmo:SpecifiedStockholderOwnershipPercentage>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder id="F_000614" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_pure">1.10</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder id="F_000615" contextRef="C_0001001233_20170101_20171231">P5Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights id="F_000616" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231">Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 id="F_000617" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000618" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231" decimals="2" unitRef="U_pure">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm id="F_000619" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231">P10Y</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance id="F_000620" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20171231" decimals="-5" unitRef="U_shares">14100000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance id="F_000621" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandFourStockIncentivePlanMember_20171231" decimals="-5" unitRef="U_shares">9700000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance id="F_000622" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20170101_20171231" decimals="-5" unitRef="U_shares">4400000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance>
  <sgmo:CommonStockExchangeRatio id="F_000623" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_pure">1.00</sgmo:CommonStockExchangeRatio>
  <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1 id="F_000624" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_pure">1.33</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance id="F_000625" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20150622_20150622" decimals="INF" unitRef="U_shares">5300000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000626" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoAmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_20171110" decimals="INF" unitRef="U_shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized id="F_000627" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20171231" decimals="INF" unitRef="U_shares">2100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent id="F_000628" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20170101_20171231" decimals="2" unitRef="U_pure">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
  <sgmo:PurchasePlanOfferingPeriod id="F_000629" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20170101_20171231">P2Y</sgmo:PurchasePlanOfferingPeriod>
  <sgmo:PurchasePlanPurchasePeriod id="F_000630" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20170101_20171231">P6M</sgmo:PurchasePlanPurchasePeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000631" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">9256506</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross id="F_000632" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">3091125</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
  <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised id="F_000633" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">2030815</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod id="F_000634" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">2029360</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber id="F_000635" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">8287456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber id="F_000636" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">8287456</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber id="F_000637" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">3881078</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000638" contextRef="C_0001001233_20161231" decimals="2" unitRef="U_iso4217USD_shares">8.31</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice id="F_000639" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">6.48</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice id="F_000640" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">7.76</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice id="F_000641" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">8.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice id="F_000642" contextRef="C_0001001233_20171231" decimals="2" unitRef="U_iso4217USD_shares">7.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice id="F_000643" contextRef="C_0001001233_20171231" decimals="2" unitRef="U_iso4217USD_shares">7.77</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice id="F_000644" contextRef="C_0001001233_20171231" decimals="2" unitRef="U_iso4217USD_shares">8.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 id="F_000645" contextRef="C_0001001233_20170101_20171231">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 id="F_000646" contextRef="C_0001001233_20170101_20171231">P6Y8M8D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 id="F_000647" contextRef="C_0001001233_20170101_20171231">P4Y1M17D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue id="F_000648" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">71658000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue id="F_000649" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">71658000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 id="F_000650" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">28864000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
  <us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation id="F_000651" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapEmployeeStockOptionMember_20170101_20171231" decimals="0" unitRef="U_shares">0</us-gaap:WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000652" contextRef="C_0001001233_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">12300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000653" contextRef="C_0001001233_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue id="F_000654" contextRef="C_0001001233_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">6400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000655" contextRef="C_0001001233_20171231" decimals="-5" unitRef="U_iso4217USD">71700000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000656" contextRef="C_0001001233_20161231" decimals="-5" unitRef="U_iso4217USD">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue id="F_000657" contextRef="C_0001001233_20151231" decimals="-5" unitRef="U_iso4217USD">14000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000658" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">2.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000659" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">3.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000660" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">3.55</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000661" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">5.42</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000662" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">7.20</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000663" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">9.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000664" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">13.54</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000665" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">15.11</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000666" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">19.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit id="F_000667" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">19.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000668" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">3.45</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000669" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">3.50</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000670" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">5.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000671" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">7.07</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000672" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">9.41</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000673" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">13.35</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000674" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">15</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000675" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">18.26</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000676" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">19.51</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit id="F_000677" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20170101_20171231" decimals="INF" unitRef="U_iso4217USD_shares">19.80</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000678" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20171231" decimals="INF" unitRef="U_shares">612318</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000679" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20171231" decimals="INF" unitRef="U_shares">1527625</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000680" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20171231" decimals="INF" unitRef="U_shares">1212567</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000681" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20171231" decimals="INF" unitRef="U_shares">1501051</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000682" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20171231" decimals="INF" unitRef="U_shares">1199546</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000683" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20171231" decimals="INF" unitRef="U_shares">885599</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000684" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20171231" decimals="INF" unitRef="U_shares">1148250</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000685" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20171231" decimals="INF" unitRef="U_shares">178000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000686" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20171231" decimals="INF" unitRef="U_shares">10000</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000687" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20171231" decimals="INF" unitRef="U_shares">12500</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions id="F_000688" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">8287456</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000689" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20170101_20171231">P7Y11M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000690" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTwoMember_20170101_20171231">P9Y25D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000691" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20170101_20171231">P5Y2M26D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000692" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20170101_20171231">P5Y6M10D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000693" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20170101_20171231">P7Y2M1D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000694" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20170101_20171231">P5Y6M7D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000695" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20170101_20171231">P6Y3M3D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000696" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20170101_20171231">P7Y3M21D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000697" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20170101_20171231">P6Y1M20D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000698" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20170101_20171231">P6Y2M23D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2 id="F_000699" contextRef="C_0001001233_20170101_20171231">P6Y8M8D</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000700" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20171231" decimals="INF" unitRef="U_shares">214920</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000701" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20171231" decimals="INF" unitRef="U_shares">672930</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000702" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20171231" decimals="INF" unitRef="U_shares">967506</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000703" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20171231" decimals="INF" unitRef="U_shares">551162</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000704" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20171231" decimals="INF" unitRef="U_shares">659946</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000705" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20171231" decimals="INF" unitRef="U_shares">668752</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000706" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20171231" decimals="INF" unitRef="U_shares">124561</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000707" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20171231" decimals="INF" unitRef="U_shares">9583</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000708" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20171231" decimals="INF" unitRef="U_shares">11718</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions id="F_000709" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">3881078</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000710" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeOneMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">3.13</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000711" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeThreeMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">5.34</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000712" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFourMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">6.11</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000713" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeFiveMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">9.06</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000714" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSixMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">11.92</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000715" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeSevenMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">14.07</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000716" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeEightMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">16.41</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000717" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeNineMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">19.51</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000718" contextRef="C_0001001233_us-gaapShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_sgmoRangeTenMember_20171231" decimals="2" unitRef="U_iso4217USD_shares">19.80</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1 id="F_000719" contextRef="C_0001001233_20171231" decimals="2" unitRef="U_iso4217USD_shares">8.99</us-gaap:SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000720" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_shares">12600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000721" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20160101_20161231" decimals="INF" unitRef="U_shares">60000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000722" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20151231" decimals="INF" unitRef="U_shares">446000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000723" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="2" unitRef="U_iso4217USD_shares">15.85</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000724" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20160101_20161231" decimals="2" unitRef="U_iso4217USD_shares">5.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue id="F_000725" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20151231" decimals="2" unitRef="U_iso4217USD_shares">9.45</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment id="F_000726" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_sgmoInstallment">3</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000727" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheOneMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000728" contextRef="C_0001001233_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheTwoMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage id="F_000729" contextRef="C_0001001233_us-gaapVestingAxis_us-gaapShareBasedCompensationAwardTrancheThreeMember_20170101_20171231" decimals="4" unitRef="U_pure">0.0033</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested id="F_000730" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">1200000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested id="F_000731" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">4800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested id="F_000732" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">4100000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights id="F_000733" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231">These awards generally vest as follows: one-third of the award will vest in a series of three successive equal annual installments.</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000734" contextRef="C_0001001233_20161231" decimals="INF" unitRef="U_shares">321816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod id="F_000735" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">12600</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod id="F_000736" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">112917</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod id="F_000737" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_shares">141327</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber id="F_000738" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">80172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber id="F_000739" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_shares">80172</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber>
  <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms id="F_000740" contextRef="C_0001001233_20170101_20171231">P10M24D</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm id="F_000741" contextRef="C_0001001233_20170101_20171231">P10M24D</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm>
  <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding id="F_000742" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1315000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding>
  <sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue id="F_000743" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1315000</sgmo:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000744" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20170101_20171231" decimals="INF" unitRef="U_shares">42243</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000745" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20160101_20161231" decimals="INF" unitRef="U_shares">165181</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation id="F_000746" contextRef="C_0001001233_us-gaapAwardTypeAxis_us-gaapRestrictedStockUnitsRSUMember_20150101_20151231" decimals="INF" unitRef="U_shares">172807</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000747" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoTwoThousandThirteenStockIncentivePlanMember_20171231" decimals="INF" unitRef="U_shares">3601633</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance id="F_000748" contextRef="C_0001001233_us-gaapPlanNameAxis_sgmoEmployeeStockPurchasePlanMember_20171231" decimals="INF" unitRef="U_shares">835674</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_000749" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-12000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalIncomeTaxExpenseBenefit id="F_000750" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-5563000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="F_000751" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-2000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit id="F_000752" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-159000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000753" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-14000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit id="F_000754" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-5722000</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000755" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_pure">0.34</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000756" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-18553000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000757" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-24369000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate id="F_000758" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-15785000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000759" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">795000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000760" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-747000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes id="F_000761" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4840000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
  <us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate id="F_000762" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">53045000</us-gaap:IncomeTaxReconciliationChangeInEnactedTaxRate>
  <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation id="F_000763" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">2120000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
  <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation id="F_000764" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">2781000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
  <sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation id="F_000765" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">1085000</sgmo:IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000766" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">869000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000767" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1424000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationTaxCreditsResearch id="F_000768" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">814000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000769" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-36575000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000770" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">23773000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance id="F_000771" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">5043000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000772" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">37000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000773" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">-28000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:IncomeTaxReconciliationOtherAdjustments id="F_000774" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">-91000</us-gaap:IncomeTaxReconciliationOtherAdjustments>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000775" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">91308000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards id="F_000776" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">114222000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000777" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">15147000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch id="F_000778" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">12518000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000779" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">3168000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost id="F_000780" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">8565000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000781" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">934000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsDeferredIncome id="F_000782" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">2918000</us-gaap:DeferredTaxAssetsDeferredIncome>
  <us-gaap:DeferredTaxAssetsOther id="F_000783" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">2276000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsOther id="F_000784" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">3492000</us-gaap:DeferredTaxAssetsOther>
  <us-gaap:DeferredTaxAssetsGross id="F_000785" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">112833000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsGross id="F_000786" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">141715000</us-gaap:DeferredTaxAssetsGross>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000787" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">112833000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:DeferredTaxAssetsValuationAllowance id="F_000788" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">141715000</us-gaap:DeferredTaxAssetsValuationAllowance>
  <us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation id="F_000789" contextRef="C_0001001233_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">-5000000</us-gaap:IncomeTaxExpenseBenefitIntraperiodTaxAllocation>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000790" contextRef="C_0001001233_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">-28900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000791" contextRef="C_0001001233_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">23800000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount id="F_000792" contextRef="C_0001001233_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">5000000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic id="F_000793" contextRef="C_0001001233_20171231" decimals="-6" unitRef="U_iso4217USD">475000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
  <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal id="F_000794" contextRef="C_0001001233_20171231" decimals="-6" unitRef="U_iso4217USD">142000000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
  <sgmo:OperatingLossCarryforwardsExpirationYear id="F_000795" contextRef="C_0001001233_us-gaapIncomeTaxAuthorityAxis_us-gaapStateAndLocalJurisdictionMember_20170101_20171231">2018</sgmo:OperatingLossCarryforwardsExpirationYear>
  <sgmo:OperatingLossCarryforwardsExpirationYear id="F_000796" contextRef="C_0001001233_us-gaapIncomeTaxAuthorityAxis_us-gaapDomesticCountryMember_20170101_20171231">2017</sgmo:OperatingLossCarryforwardsExpirationYear>
  <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal id="F_000797" contextRef="C_0001001233_20171231" decimals="-5" unitRef="U_iso4217USD">10800000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal>
  <sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal id="F_000798" contextRef="C_0001001233_20171231" decimals="-5" unitRef="U_iso4217USD">11800000</sgmo:DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal>
  <sgmo:FederalResearchTaxCreditCarryforwardExpirationYear id="F_000799" contextRef="C_0001001233_20170101_20171231">2018</sgmo:FederalResearchTaxCreditCarryforwardExpirationYear>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000800" contextRef="C_0001001233_us-gaapStatementScenarioAxis_us-gaapScenarioPlanMember_20180101_20181231" decimals="INF" unitRef="U_pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate id="F_000801" contextRef="C_0001001233_us-gaapRangeAxis_us-gaapMaximumMember_20170101_20171231" decimals="INF" unitRef="U_pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
  <sgmo:TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance id="F_000802" contextRef="C_0001001233_20170101_20171231" decimals="0" unitRef="U_iso4217USD">0</sgmo:TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance>
  <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued id="F_000803" contextRef="C_0001001233_20171231" decimals="INF" unitRef="U_iso4217USD">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
  <us-gaap:UnrecognizedTaxBenefits id="F_000804" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">5045000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000805" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">622000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions id="F_000806" contextRef="C_0001001233_20170101_20171231" decimals="-3" unitRef="U_iso4217USD">-8000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_000807" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">5659000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefits id="F_000808" contextRef="C_0001001233_20151231" decimals="-3" unitRef="U_iso4217USD">8330000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000809" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">1023000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions id="F_000810" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">27000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions id="F_000811" contextRef="C_0001001233_20160101_20161231" decimals="-3" unitRef="U_iso4217USD">4335000</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions>
  <us-gaap:UnrecognizedTaxBenefits id="F_000812" contextRef="C_0001001233_20141231" decimals="-3" unitRef="U_iso4217USD">3438000</us-gaap:UnrecognizedTaxBenefits>
  <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions id="F_000813" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">557000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
  <sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions id="F_000814" contextRef="C_0001001233_20150101_20151231" decimals="-3" unitRef="U_iso4217USD">4335000</sgmo:UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions>
  <us-gaap:AccountsPayableCurrent id="F_000815" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">16000</us-gaap:AccountsPayableCurrent>
  <us-gaap:AccountsPayableCurrent id="F_000816" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">2580000</us-gaap:AccountsPayableCurrent>
  <sgmo:AccruedResearchAndDevelopmentExpenses id="F_000817" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">7898000</sgmo:AccruedResearchAndDevelopmentExpenses>
  <sgmo:AccruedResearchAndDevelopmentExpenses id="F_000818" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">2887000</sgmo:AccruedResearchAndDevelopmentExpenses>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000819" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1318000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:AccruedProfessionalFeesCurrent id="F_000820" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">270000</us-gaap:AccruedProfessionalFeesCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000821" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">417000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:DeferredRentCreditCurrent id="F_000822" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">498000</us-gaap:DeferredRentCreditCurrent>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities id="F_000823" contextRef="C_0001001233_20171231" decimals="-3" unitRef="U_iso4217USD">1386000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:AccountsPayableAndOtherAccruedLiabilities id="F_000824" contextRef="C_0001001233_20161231" decimals="-3" unitRef="U_iso4217USD">26000</us-gaap:AccountsPayableAndOtherAccruedLiabilities>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent id="F_000825" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_pure">0.50</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000826" contextRef="C_0001001233_20170101_20171231" decimals="2" unitRef="U_pure">0.08</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000827" contextRef="C_0001001233_20160101_20161231" decimals="2" unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch id="F_000828" contextRef="C_0001001233_20150101_20151231" decimals="2" unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercentOfMatch>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000829" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_pure">0.08</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000830" contextRef="C_0001001233_20160101_20161231" decimals="INF" unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent id="F_000831" contextRef="C_0001001233_20150101_20151231" decimals="INF" unitRef="U_pure">0.06</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount id="F_000832" contextRef="C_0001001233_20170101_20171231" decimals="INF" unitRef="U_iso4217USD">4000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount id="F_000833" contextRef="C_0001001233_20160101_20161231" decimals="INF" unitRef="U_iso4217USD">3000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount id="F_000834" contextRef="C_0001001233_20150101_20151231" decimals="INF" unitRef="U_iso4217USD">3000</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000835" contextRef="C_0001001233_20170101_20171231" decimals="-5" unitRef="U_iso4217USD">500000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000836" contextRef="C_0001001233_20160101_20161231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:DefinedContributionPlanCostRecognized id="F_000837" contextRef="C_0001001233_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">300000</us-gaap:DefinedContributionPlanCostRecognized>
  <us-gaap:Revenues id="F_000838" contextRef="C_0001001233_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">3425000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000839" contextRef="C_0001001233_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">8253000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000840" contextRef="C_0001001233_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">11812000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000841" contextRef="C_0001001233_20171001_20171231" decimals="-3" unitRef="U_iso4217USD">13077000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000842" contextRef="C_0001001233_20160101_20160331" decimals="-3" unitRef="U_iso4217USD">3942000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000843" contextRef="C_0001001233_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">3702000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000844" contextRef="C_0001001233_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">2823000</us-gaap:Revenues>
  <us-gaap:Revenues id="F_000845" contextRef="C_0001001233_20161001_20161231" decimals="-3" unitRef="U_iso4217USD">8922000</us-gaap:Revenues>
  <us-gaap:OperatingExpenses id="F_000846" contextRef="C_0001001233_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">20217000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000847" contextRef="C_0001001233_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">21021000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000848" contextRef="C_0001001233_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">24847000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000849" contextRef="C_0001001233_20171001_20171231" decimals="-3" unitRef="U_iso4217USD">26843000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000850" contextRef="C_0001001233_20160101_20160331" decimals="-3" unitRef="U_iso4217USD">20623000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000851" contextRef="C_0001001233_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">30544000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000852" contextRef="C_0001001233_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">22029000</us-gaap:OperatingExpenses>
  <us-gaap:OperatingExpenses id="F_000853" contextRef="C_0001001233_20161001_20161231" decimals="-3" unitRef="U_iso4217USD">18752000</us-gaap:OperatingExpenses>
  <us-gaap:NetIncomeLoss id="F_000854" contextRef="C_0001001233_20170101_20170331" decimals="-3" unitRef="U_iso4217USD">-16632000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000855" contextRef="C_0001001233_20170401_20170630" decimals="-3" unitRef="U_iso4217USD">-12491000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000856" contextRef="C_0001001233_20170701_20170930" decimals="-3" unitRef="U_iso4217USD">-12354000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000857" contextRef="C_0001001233_20171001_20171231" decimals="-3" unitRef="U_iso4217USD">-13091000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000858" contextRef="C_0001001233_20160101_20160331" decimals="-3" unitRef="U_iso4217USD">-16494000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000859" contextRef="C_0001001233_20160401_20160630" decimals="-3" unitRef="U_iso4217USD">-26575000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000860" contextRef="C_0001001233_20160701_20160930" decimals="-3" unitRef="U_iso4217USD">-18965000</us-gaap:NetIncomeLoss>
  <us-gaap:NetIncomeLoss id="F_000861" contextRef="C_0001001233_20161001_20161231" decimals="-3" unitRef="U_iso4217USD">-9624000</us-gaap:NetIncomeLoss>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000862" contextRef="C_0001001233_20170101_20170331" decimals="2" unitRef="U_iso4217USD_shares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000863" contextRef="C_0001001233_20170401_20170630" decimals="2" unitRef="U_iso4217USD_shares">-0.17</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000864" contextRef="C_0001001233_20170701_20170930" decimals="2" unitRef="U_iso4217USD_shares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000865" contextRef="C_0001001233_20171001_20171231" decimals="2" unitRef="U_iso4217USD_shares">-0.15</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000866" contextRef="C_0001001233_20160101_20160331" decimals="2" unitRef="U_iso4217USD_shares">-0.23</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000867" contextRef="C_0001001233_20160401_20160630" decimals="2" unitRef="U_iso4217USD_shares">-0.38</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000868" contextRef="C_0001001233_20160701_20160930" decimals="2" unitRef="U_iso4217USD_shares">-0.27</us-gaap:EarningsPerShareBasicAndDiluted>
  <us-gaap:EarningsPerShareBasicAndDiluted id="F_000869" contextRef="C_0001001233_20161001_20161231" decimals="2" unitRef="U_iso4217USD_shares">-0.14</us-gaap:EarningsPerShareBasicAndDiluted>
  <sgmo:BuildToSuitLeasePropertyLeased id="F_000870" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171101_20171130" decimals="0" unitRef="U_utrsqft">87700</sgmo:BuildToSuitLeasePropertyLeased>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000871" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171101_20171130">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <sgmo:OperatingLeasesNumberOfExtensionOptions id="F_000872" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171101_20171130" decimals="INF" unitRef="U_sgmoOption">2</sgmo:OperatingLeasesNumberOfExtensionOptions>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm id="F_000873" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapRangeAxis_us-gaapMaximumMember_20171101_20171130">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <us-gaap:LettersOfCreditOutstandingAmount id="F_000874" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171130" decimals="-5" unitRef="U_iso4217USD">3500000</us-gaap:LettersOfCreditOutstandingAmount>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000875" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_us-gaapPropertyPlantAndEquipmentByTypeAxis_us-gaapBuildingMember_20171130" decimals="-5" unitRef="U_iso4217USD">20900000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000876" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoBrisbaneBuildToSuitLeaseMember_20171231" decimals="-5" unitRef="U_iso4217USD">21200000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <sgmo:BuildToSuitLeasePropertyLeased id="F_000877" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20151201_20151231" decimals="0" unitRef="U_utrsqft">41400</sgmo:BuildToSuitLeasePropertyLeased>
  <us-gaap:LeaseExpirationDate1 id="F_000878" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20170101_20171231">2021-12-31</us-gaap:LeaseExpirationDate1>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract id="F_000879" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20151201_20151231">P5Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesTermOfContract>
  <sgmo:OperatingLeasesNumberOfExtensionOptions id="F_000880" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20151201_20151231" decimals="INF" unitRef="U_sgmoOption">2</sgmo:OperatingLeasesNumberOfExtensionOptions>
  <us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm id="F_000881" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_us-gaapRangeAxis_us-gaapMaximumMember_20151201_20151231">P10Y</us-gaap:LesseeLeasingArrangementsOperatingLeasesRenewalTerm>
  <sgmo:BuildToSuitLeaseCostsCapitalized id="F_000882" contextRef="C_0001001233_us-gaapLeaseArrangementTypeAxis_sgmoPointPinoleBuildToSuitLeaseMember_20161231" decimals="-5" unitRef="U_iso4217USD">3900000</sgmo:BuildToSuitLeaseCostsCapitalized>
  <sgmo:ProceedsFromClaimsSettlement id="F_000883" contextRef="C_0001001233_20150901_20150930" decimals="-5" unitRef="U_iso4217USD">14500000</sgmo:ProceedsFromClaimsSettlement>
  <us-gaap:IncomeTaxExpenseBenefit id="F_000884" contextRef="C_0001001233_us-gaapLitigationStatusAxis_sgmoDisgorgementSettlementMember_20150101_20151231" decimals="-5" unitRef="U_iso4217USD">-5000000</us-gaap:IncomeTaxExpenseBenefit>
  <sgmo:MilestoneRevenueReceivable id="F_000885" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180228" decimals="-6" unitRef="U_iso4217USD">150000000</sgmo:MilestoneRevenueReceivable>
  <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived id="F_000886" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapRangeAxis_us-gaapMaximumMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228" decimals="INF" unitRef="U_iso4217USD">3010000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
  <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived id="F_000887" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapProductOrServiceAxis_sgmoAchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228" decimals="-7" unitRef="U_iso4217USD">1260000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
  <sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived id="F_000888" contextRef="C_0001001233_us-gaapCounterpartyNameAxis_sgmoKitePharmaIncMember_us-gaapProductOrServiceAxis_sgmoAchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_us-gaapResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_sgmoCollaborationAndLicenseAgreementMember_us-gaapSubsequentEventTypeAxis_us-gaapSubsequentEventMember_20180201_20180228" decimals="-7" unitRef="U_iso4217USD">1750000000</sgmo:ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived>
</xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>36
<FILENAME>sgmo-20171231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Schema Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4841149+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<schema xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2011-01-31" xmlns:naics="http://xbrl.sec.gov/naics/2017-01-31" xmlns:invest="http://xbrl.sec.gov/invest/2013-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:us-gaap="http://fasb.org/us-gaap/2017-01-31" xmlns:dei="http://xbrl.sec.gov/dei/2014-01-31" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:currency="http://xbrl.sec.gov/currency/2017-01-31" xmlns:sgmo="http://www.sangamo.com/20171231" xmlns:exch="http://xbrl.sec.gov/exch/2017-01-31" xmlns:sic="http://xbrl.sec.gov/sic/2011-01-31" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.sangamo.com/20171231" xmlns="http://www.w3.org/2001/XMLSchema">
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/instance" />
  <import schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" namespace="http://www.xbrl.org/2003/linkbase" />
  <import schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" namespace="http://xbrl.org/2005/xbrldt" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd" namespace="http://fasb.org/us-gaap/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd" namespace="http://xbrl.sec.gov/dei/2014-01-31" />
  <import schemaLocation="http://xbrl.fasb.org/us-gaap/2017/elts/us-types-2017-01-31.xsd" namespace="http://fasb.org/us-types/2017-01-31" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/numeric" />
  <import schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" namespace="http://www.xbrl.org/dtr/type/non-numeric" />
  <import schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" namespace="http://xbrl.sec.gov/country/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/currency/2017/currency-2017-01-31.xsd" namespace="http://xbrl.sec.gov/currency/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/exch/2017/exch-2017-01-31.xsd" namespace="http://xbrl.sec.gov/exch/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/invest/2013/invest-2013-01-31.xsd" namespace="http://xbrl.sec.gov/invest/2013-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd" namespace="http://xbrl.sec.gov/naics/2017-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd" namespace="http://xbrl.sec.gov/sic/2011-01-31" />
  <import schemaLocation="http://xbrl.sec.gov/stpr/2011/stpr-2011-01-31.xsd" namespace="http://xbrl.sec.gov/stpr/2011-01-31" />
  <annotation>
    <appinfo>
      <link:roleType id="TemplateLink" roleURI="http://www.sangamo.com/20171231/role/TemplateLink" xmlns:link="http://www.xbrl.org/2003/linkbase">
        <link:definition>00000 - Document - Template Link</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20171231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:title="Calculation Links, all" xlink:type="simple" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20171231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:title="Definition Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20171231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:title="Label Links, all" xlink:type="simple" />
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="sgmo-20171231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:title="Presentation Links, all" xlink:type="simple" />
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation" id="Role_DocumentDocumentAndEntityInformation">
        <link:definition>100000 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets" id="Role_StatementConsolidatedBalanceSheets">
        <link:definition>100010 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" id="Role_StatementConsolidatedBalanceSheetsParenthetical">
        <link:definition>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations" id="Role_StatementConsolidatedStatementsOfOperations">
        <link:definition>100030 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" id="Role_StatementConsolidatedStatementsOfComprehensiveLoss">
        <link:definition>100040 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" id="Role_StatementConsolidatedStatementsOfStockholdersEquity">
        <link:definition>100050 - Statement - Consolidated Statements of Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" id="Role_StatementCondensedConsolidatedStatementsOfCashFlows">
        <link:definition>100060 - Statement - Condensed Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
        <link:definition>100070 - Disclosure - Organization and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurement" id="Role_DisclosureFairValueMeasurement">
        <link:definition>100080 - Disclosure - Fair Value Measurement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecurities" id="Role_DisclosureMarketableSecurities">
        <link:definition>100090 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensation" id="Role_DisclosureStockBasedCompensation">
        <link:definition>100100 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliances">
        <link:definition>100110 - Disclosure - Major Customers, Partnerships and Strategic Alliances</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregene" id="Role_DisclosureAcquisitionOfCeregene">
        <link:definition>100120 - Disclosure - Acquisition of Ceregene</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment" id="Role_DisclosurePropertyAndEquipment">
        <link:definition>100130 - Disclosure - Property and Equipment</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingencies" id="Role_DisclosureCommitmentsAndContingencies">
        <link:definition>100140 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquity" id="Role_DisclosureStockholdersEquity">
        <link:definition>100150 - Disclosure - Stockholders&apos; Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxes" id="Role_DisclosureIncomeTaxes">
        <link:definition>100160 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" id="Role_DisclosureAccountsPayableAndAccruedLiabilities">
        <link:definition>100170 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlan" id="Role_DisclosureEmployeeBenefitPlan">
        <link:definition>100180 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited" id="Role_DisclosureQuarterlyFinancialDataUnaudited">
        <link:definition>100190 - Disclosure - Quarterly Financial Data (Unaudited)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLease" id="Role_DisclosureBuildToSuitLease">
        <link:definition>100200 - Disclosure - Build-to-Suit Lease</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlement" id="Role_DisclosureClaimsSettlement">
        <link:definition>100210 - Disclosure - Claims Settlement</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEvent" id="Role_DisclosureSubsequentEvent">
        <link:definition>100220 - Disclosure - Subsequent Event</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>100230 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementTables" id="Role_DisclosureFairValueMeasurementTables">
        <link:definition>100240 - Disclosure - Fair Value Measurement (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesTables" id="Role_DisclosureMarketableSecuritiesTables">
        <link:definition>100250 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationTables" id="Role_DisclosureStockBasedCompensationTables">
        <link:definition>100260 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
        <link:definition>100270 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables" id="Role_DisclosurePropertyAndEquipmentTables">
        <link:definition>100280 - Disclosure - Property and Equipment (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" id="Role_DisclosureCommitmentsAndContingenciesTables">
        <link:definition>100290 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityTables" id="Role_DisclosureStockholdersEquityTables">
        <link:definition>100300 - Disclosure - Stockholders&apos; Equity (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesTables" id="Role_DisclosureIncomeTaxesTables">
        <link:definition>100310 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" id="Role_DisclosureAccountsPayableAndAccruedLiabilitiesTables">
        <link:definition>100320 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables" id="Role_DisclosureQuarterlyFinancialDataUnauditedTables">
        <link:definition>100330 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" id="Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
        <link:definition>100340 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" id="Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
        <link:definition>100350 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail" id="Role_DisclosureFairValueMeasurementAdditionalInformationDetail">
        <link:definition>100360 - Disclosure - Fair Value Measurement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" id="Role_DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail">
        <link:definition>100370 - Disclosure - Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" id="Role_DisclosureMarketableSecuritiesAdditionalInformationDetail">
        <link:definition>100380 - Disclosure - Marketable Securities - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" id="Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
        <link:definition>100390 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" id="Role_DisclosureStockBasedCompensationAdditionalInformationDetail">
        <link:definition>100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail" id="Role_DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail">
        <link:definition>100410 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail" id="Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail">
        <link:definition>100420 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
        <link:definition>100430 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
        <link:definition>100440 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
        <link:definition>100450 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" id="Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
        <link:definition>100460 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail" id="Role_DisclosureAcquisitionOfCeregeneAdditionalInformationDetail">
        <link:definition>100470 - Disclosure - Acquisition of Ceregene - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" id="Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
        <link:definition>100480 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" id="Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail">
        <link:definition>100490 - Disclosure - Property and Equipment - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" id="Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
        <link:definition>100500 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail" id="Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail">
        <link:definition>100510 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" id="Role_DisclosureStockholdersEquityAdditionalInformationDetail">
        <link:definition>100520 - Disclosure - Stockholders&apos; Equity - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail">
        <link:definition>100530 - Disclosure - Stockholders&apos; Equity - Summary of Stock Option Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail" id="Role_DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail">
        <link:definition>100540 - Disclosure - Stockholders&apos; Equity - Summary of Stock Options Outstanding (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail" id="Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail">
        <link:definition>100550 - Disclosure - Stockholders&apos; Equity - Summary of Restricted Stock Unit Activity (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail" id="Role_DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail">
        <link:definition>100560 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" id="Role_DisclosureIncomeTaxesAdditionalInformationDetail">
        <link:definition>100570 - Disclosure - Income Taxes - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail" id="Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail">
        <link:definition>100580 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail" id="Role_DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail">
        <link:definition>100590 - Disclosure - Income Taxes - Schedule of Company&apos;s Deferred Tax Assets (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail" id="Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail">
        <link:definition>100600 - Disclosure - Income Taxes - Summary of Activity Related to Company&apos;s Unrecognized Tax Benefits (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" id="Role_DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
        <link:definition>100610 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetail" id="Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail">
        <link:definition>100620 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail" id="Role_DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail">
        <link:definition>100630 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" id="Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail">
        <link:definition>100640 - Disclosure - Build-to-Suit Lease - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail" id="Role_DisclosureClaimsSettlementAdditionalInformationDetail">
        <link:definition>100650 - Disclosure - Claims Settlement - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" id="Role_DisclosureSubsequentEventAdditionalInformationDetail">
        <link:definition>100660 - Disclosure - Subsequent Event - Additional Information (Detail)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </appinfo>
  </annotation>
  <element id="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" name="ResearchServiceRevenueUnderCollaborationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" name="IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BuildToSuitLeaseObligations" name="BuildToSuitLeaseObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CollaborationAgreements" name="CollaborationAgreements" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" name="SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" name="StockIssuedDuringPeriodSharesFinancingPlan" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NetProceedsFromIssuancePublicOffering" name="NetProceedsFromIssuancePublicOffering" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_ProceedsFromClaimsSettlement" name="ProceedsFromClaimsSettlement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_BuildToSuitLeaseMember" name="BuildToSuitLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_PropertyAndEquipmentMember" name="PropertyAndEquipmentMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" name="BuildToSuitLeaseObligationDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ClaimsSettlementDisclosureTextBlock" name="ClaimsSettlementDisclosureTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ClaimsSettlementDisclosureAbstract" name="ClaimsSettlementDisclosureAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ContingentConsiderationPolicyTextBlock" name="ContingentConsiderationPolicyTextBlock" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_BioverativIncMember" name="BioverativIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ShireAgMember" name="ShireAgMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_SigmaAldrichCorporationMember" name="SigmaAldrichCorporationMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" name="CashEquivalentMaturityPeriodHighlyLiquidInvestment" type="invest:dateStringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" name="OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" name="OrganizationAndSummaryOfSignificantAccountingPoliciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CollaborationContractPerformancePeriodMember" name="CollaborationContractPerformancePeriodMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_PfizerMember" name="PfizerMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_DowAgroSciencesMember" name="DowAgroSciencesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BiogenIncMember" name="BiogenIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" name="ChangeInAccountingEstimateDecreaseInRevenues" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" name="ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" name="MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" name="CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_AssetsAmortizedCost" name="AssetsAmortizedCost" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" name="AssetsAccumulatedGrossUnrealizedGainBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" name="AssetsAccumulatedGrossUnrealizedLossBeforeTax" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" name="InvestmentsMaturityDatesAvailableForSaleSecurities" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_OtherThanTemporarilyImpairedInvestment" name="OtherThanTemporarilyImpairedInvestment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" name="StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" name="EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" type="num:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_EmployeeStockPurchasePlanMember" name="EmployeeStockPurchasePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" name="AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_MilestoneRevenueReceivable" name="MilestoneRevenueReceivable" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_MilestonePaymentsReceived" name="MilestonePaymentsReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" name="CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_SBFiveTwoFiveMember" name="SBFiveTwoFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_OtherProductsMember" name="OtherProductsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CNineORFSevenTwoMember" name="CNineORFSevenTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_InitialResearchTermOfAgreement" name="InitialResearchTermOfAgreement" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfResearchProgram" name="NumberOfResearchProgram" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_AggregateNumberOfGeneTargets" name="AggregateNumberOfGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfInitialGeneTargets" name="NumberOfInitialGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfGeneTargets" name="NumberOfGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfAdditionalGeneTargets" name="NumberOfAdditionalGeneTargets" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ResearchServicesPeriod" name="ResearchServicesPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_UpfrontLicenseFeesMember" name="UpfrontLicenseFeesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_UpfrontLicenseFee" name="UpfrontLicenseFee" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_ReducedRoyaltyRate" name="ReducedRoyaltyRate" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_AdditionalMilestoneReceivableUnderAgreement" name="AdditionalMilestoneReceivableUnderAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" name="PercentageOfRoyaltiesToBeReceivedFromSublicensing" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" name="MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_OneTimeLicenseFeeEarned" name="OneTimeLicenseFeeEarned" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_AnnualFeesRelatedToAgreement" name="AnnualFeesRelatedToAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_FeeDue" name="FeeDue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" name="MinimumSublicenseAnnualFeesSpecificReckoningPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" name="BusinessAcquisitionContingentConsiderationEarnOutPayment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_CeregeneIncMember" name="CeregeneIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" name="PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BuildToSuitLeaseCostsCapitalized" name="BuildToSuitLeaseCostsCapitalized" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_RichmondBuildToSuitLeaseMember" name="RichmondBuildToSuitLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BrisbaneBuildToSuitLeaseMember" name="BrisbaneBuildToSuitLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_BuildToSuitLeasePropertyLeased" name="BuildToSuitLeasePropertyLeased" type="num:areaItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_NumberOfBuiltToSuitLeaseProperties" name="NumberOfBuiltToSuitLeaseProperties" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="sgmo_CommitmentsAndContingenciesLineItems" name="CommitmentsAndContingenciesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CommitmentsAndContingenciesTable" name="CommitmentsAndContingenciesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_PropertySubjectToOperatingLeaseOneMember" name="PropertySubjectToOperatingLeaseOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_PropertySubjectToOperatingLeaseTwoMember" name="PropertySubjectToOperatingLeaseTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ResearchAndOfficeSpaceMember" name="ResearchAndOfficeSpaceMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" name="ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_TenantImprovementsMember" name="TenantImprovementsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_LicenseCommitments" name="LicenseCommitments" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AtTheMarketOfferingAgreementMember" name="AtTheMarketOfferingAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_TwoThousandThirteenStockIncentivePlanMember" name="TwoThousandThirteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_TwoThousandFourStockIncentivePlanMember" name="TwoThousandFourStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" name="AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" name="CommonStockCapitalSharesValueReservedForFutureIssuance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_SpecifiedStockholderOwnershipPercentage" name="SpecifiedStockholderOwnershipPercentage" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="sgmo_CommonStockExchangeRatio" name="CommonStockExchangeRatio" type="num:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="sgmo_PurchasePlanOfferingPeriod" name="PurchasePlanOfferingPeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_PurchasePlanPurchasePeriod" name="PurchasePlanPurchasePeriod" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_RangeOneMember" name="RangeOneMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeTwoMember" name="RangeTwoMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeThreeMember" name="RangeThreeMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeFourMember" name="RangeFourMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeFiveMember" name="RangeFiveMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeSixMember" name="RangeSixMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeSevenMember" name="RangeSevenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeEightMember" name="RangeEightMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeNineMember" name="RangeNineMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_RangeTenMember" name="RangeTenMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_IncomeTaxesLineItems" name="IncomeTaxesLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_IncomeTaxesTable" name="IncomeTaxesTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_OperatingLossCarryforwardsExpirationYear" name="OperatingLossCarryforwardsExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" name="FederalResearchTaxCreditCarryforwardExpirationYear" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" name="TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" name="UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_AccruedResearchAndDevelopmentExpenses" name="AccruedResearchAndDevelopmentExpenses" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" nillable="true" abstract="false" xbrli:balance="credit" />
  <element id="sgmo_OperatingLeasesNumberOfExtensionOptions" name="OperatingLeasesNumberOfExtensionOptions" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" />
  <element id="sgmo_PointPinoleBuildToSuitLeaseMember" name="PointPinoleBuildToSuitLeaseMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ClaimsSettlementLineItems" name="ClaimsSettlementLineItems" type="xbrli:stringItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ScheduleOfClaimsSettlementTable" name="ScheduleOfClaimsSettlementTable" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_DisgorgementSettlementMember" name="DisgorgementSettlementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" name="ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="false" xbrli:balance="debit" />
  <element id="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" name="AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" name="AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_KitePharmaIncMember" name="KitePharmaIncMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
  <element id="sgmo_CollaborationAndLicenseAgreementMember" name="CollaborationAndLicenseAgreementMember" type="nonnum:domainItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" nillable="true" abstract="true" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>37
<FILENAME>sgmo-20171231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4841149+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef xlink:type="simple" xlink:href="sgmo-20171231.xsd#TemplateLink" roleURI="http://www.sangamo.com/20171231/role/TemplateLink" />
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseObligations" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseObligations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="sgmo_BuildToSuitLeaseObligations" order="10100.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10110.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="10120.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="10150.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10160.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Goodwill" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_InterestReceivableCurrent" order="10210.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10220.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10230.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestAndOtherIncome" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_Revenues" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingExpenses" order="10060.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10080.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="sgmo_CollaborationAgreements" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_RevenueFromGrants" order="10100.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20171231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForLeasingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="10080.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="10090.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="10100.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsForLeasingCosts" order="10110.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="10120.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetIncomeLoss" order="10130.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10140.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10150.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10160.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ShareBasedCompensation" order="10170.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10180.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10190.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="10200.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="10210.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="10220.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="10230.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="10240.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="10250.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="10260.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="10270.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10020.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAmortizedCost" xlink:type="locator" xlink:label="sgmo_AssetsAmortizedCost" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sgmo_AssetsAmortizedCost" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" order="10010.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sgmo_AssetsAmortizedCost" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="sgmo_AssetsAmortizedCost" xlink:to="us-gaap_AssetsFairValueDisclosure" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="10040.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_RoyaltyRevenue" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_LicensesRevenue" order="10040.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10060.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:type="locator" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10050.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10070.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10030.00" priority="2" use="optional" weight="-1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10050.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10060.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10070.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10080.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <calculationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="10010.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="sgmo_AccruedResearchAndDevelopmentExpenses" order="10020.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10030.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10040.00" priority="2" use="optional" weight="1.00" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="10050.00" priority="2" use="optional" weight="1.00" />
  </calculationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>38
<FILENAME>sgmo-20171231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4841149+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
  <arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
  <roleRef xlink:type="simple" xlink:href="sgmo-20171231.xsd#TemplateLink" roleURI="http://www.sangamo.com/20171231/role/TemplateLink" />
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedDuringPeriodSharesFinancingPlan" xlink:type="locator" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11600.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20171231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForLeasingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="sgmo_PropertyAndEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" order="10280.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain_2" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BuildToSuitLeaseMember" order="10360.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_2" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sgmo_PropertyAndEquipmentMember" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10750.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10810.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10990.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="11350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11590.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11950.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12010.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsForLeasingCosts" order="12070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="12130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="12190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="12250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="12370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="12550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12970.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10240.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" xlink:type="locator" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateDecreaseInRevenues" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:type="locator" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:type="locator" xlink:label="us-gaap_ProFormaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PfizerMember" xlink:type="locator" xlink:label="sgmo_PfizerMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationContractPerformancePeriodMember" xlink:type="locator" xlink:label="sgmo_CollaborationContractPerformancePeriodMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="sgmo_CollaborationContractPerformancePeriodMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_PfizerMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain_2" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10510.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_2" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember_2" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="10880.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain_2" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" order="11160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" order="11280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" order="11320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11390.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" order="11560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" order="11850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="11900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11920.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10030.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_2" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_2" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember_2" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11300.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAmortizedCost" xlink:type="locator" xlink:label="sgmo_AssetsAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10070.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_2" order="10410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="11340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="11660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAmortizedCost" order="12330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" order="12530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" order="12730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="12930.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10140.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:type="locator" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="10260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10560.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" order="10680.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_2" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10980.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_EmployeeStockPurchasePlanMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10820.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CNineORFSevenTwoMember" xlink:type="locator" xlink:label="sgmo_CNineORFSevenTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PfizerMember" xlink:type="locator" xlink:label="sgmo_PfizerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OtherProductsMember" xlink:type="locator" xlink:label="sgmo_OtherProductsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SBFiveTwoFiveMember" xlink:type="locator" xlink:label="sgmo_SBFiveTwoFiveMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ProductOrServiceAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain_2" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_SBFiveTwoFiveMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_OtherProductsMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_PfizerMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_CNineORFSevenTwoMember" order="10830.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10930.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="11480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="11500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="11520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="11600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="11620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="11670.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenue" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="11870.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="12260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="12280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="12320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="12410.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="12480.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10050.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="10780.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServicesPeriod" xlink:type="locator" xlink:label="sgmo_ResearchServicesPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_2" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchServicesPeriod" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="10650.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement" order="10690.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10620.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="10700.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="10850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="10890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="10960.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureAcquisitionOfCeregeneAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" xlink:type="locator" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CeregeneIncMember" xlink:type="locator" xlink:label="sgmo_CeregeneIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="10340.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="10380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10460.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10620.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10400.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10440.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseCostsCapitalized" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RichmondBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_RichmondBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_RichmondBuildToSuitLeaseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="sgmo_BuildToSuitLeaseCostsCapitalized" order="10280.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_LicenseCommitments" xlink:type="locator" xlink:label="sgmo_LicenseCommitments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfBuiltToSuitLeaseProperties" xlink:type="locator" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeasePropertyLeased" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeasePropertyLeased" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TenantImprovementsMember" xlink:type="locator" xlink:label="sgmo_TenantImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" xlink:type="locator" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RichmondBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_RichmondBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:type="locator" xlink:label="sgmo_ResearchAndOfficeSpaceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_CommitmentsAndContingenciesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="sgmo_PropertySubjectToOperatingLeaseOneMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="sgmo_PropertySubjectToOperatingLeaseTwoMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10160.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sgmo_ResearchAndOfficeSpaceMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10240.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_RichmondBuildToSuitLeaseMember" order="10290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" order="10430.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain_2" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="sgmo_TenantImprovementsMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10520.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_2" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_BuildToSuitLeasePropertyLeased" order="10900.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_NumberOfBuiltToSuitLeaseProperties" order="11140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="11200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="11290.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_LicenseCommitments" order="11330.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanPurchasePeriod" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanOfferingPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockExchangeRatio" xlink:type="locator" xlink:label="sgmo_CommonStockExchangeRatio" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:type="locator" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandFourStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:type="locator" xlink:label="sgmo_AtTheMarketOfferingAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_2" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sgmo_AtTheMarketOfferingAgreementMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10500.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10530.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10550.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10570.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember" order="10630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandFourStockIncentivePlanMember" order="10770.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" order="10910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_EmployeeStockPurchasePlanMember" order="10970.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="11100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain_2" order="11110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="11190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11640.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11690.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11710.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="11730.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" order="11780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="11890.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11940.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11980.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage" order="12020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" order="12060.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" order="12100.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12220.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" order="12260.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" order="12300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" order="12380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockExchangeRatio" order="12450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12610.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanOfferingPeriod" order="12740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanPurchasePeriod" order="12780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="12850.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12910.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="13000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13080.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" order="13470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="13630.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="13820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="13880.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="13970.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTenMember" xlink:type="locator" xlink:label="sgmo_RangeTenMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeNineMember" xlink:type="locator" xlink:label="sgmo_RangeNineMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeEightMember" xlink:type="locator" xlink:label="sgmo_RangeEightMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSevenMember" xlink:type="locator" xlink:label="sgmo_RangeSevenMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSixMember" xlink:type="locator" xlink:label="sgmo_RangeSixMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFiveMember" xlink:type="locator" xlink:label="sgmo_RangeFiveMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFourMember" xlink:type="locator" xlink:label="sgmo_RangeFourMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeThreeMember" xlink:type="locator" xlink:label="sgmo_RangeThreeMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTwoMember" xlink:type="locator" xlink:label="sgmo_RangeTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeOneMember" xlink:type="locator" xlink:label="sgmo_RangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeOneMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTwoMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeThreeMember" order="10130.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFourMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFiveMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSixMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSevenMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeEightMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeNineMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTenMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10300.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10660.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="11020.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="11380.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="12100.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" xlink:type="locator" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesTable" xlink:type="locator" xlink:label="sgmo_IncomeTaxesTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesLineItems" xlink:type="locator" xlink:label="sgmo_IncomeTaxesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxesTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_StatementScenarioAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_RangeAxis" order="10180.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10210.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10420.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10480.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10540.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear" order="10600.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" order="10840.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" order="11000.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11050.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseCostsCapitalized" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:type="locator" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeasePropertyLeased" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeasePropertyLeased" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PointPinoleBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RangeAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10270.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10280.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10310.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10330.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_PointPinoleBuildToSuitLeaseMember" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_BuildToSuitLeasePropertyLeased" order="10720.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10740.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10760.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_OperatingLeasesNumberOfExtensionOptions" order="10780.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="10800.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10820.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_BuildToSuitLeaseCostsCapitalized" order="10870.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureClaimsSettlementAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DisgorgementSettlementMember" xlink:type="locator" xlink:label="sgmo_DisgorgementSettlementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ScheduleOfClaimsSettlementTable" xlink:type="locator" xlink:label="sgmo_ScheduleOfClaimsSettlementTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementLineItems" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_ScheduleOfClaimsSettlementTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="sgmo_ScheduleOfClaimsSettlementTable" xlink:to="us-gaap_LitigationStatusAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain_2" order="10050.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="sgmo_DisgorgementSettlementMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10140.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10160.00" priority="2" use="optional" />
  </definitionLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <definitionLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="locator" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain_2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_KitePharmaIncMember" xlink:type="locator" xlink:label="sgmo_KitePharmaIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" order="10010.00" priority="2" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ProductOrServiceAxis" order="10040.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="10070.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" order="10090.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" order="10110.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="10120.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10150.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10170.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10190.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10200.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10230.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_KitePharmaIncMember" order="10250.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10320.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10350.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_CollaborationAndLicenseAgreementMember" order="10370.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10440.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain_2" order="10450.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10470.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10490.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="10580.00" priority="2" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" order="10600.00" priority="2" use="optional" />
  </definitionLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>39
<FILENAME>sgmo-20171231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4841149+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple" />
  <roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple" />
  <labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Central Index Key</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research service revenue under collaboration agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:type="locator" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income tax reconciliation nondeductible expense income share based compensation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:to="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="sgmo_DocumentAndEntityInformationAbstract" />
    <label xml:lang="en-US" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Document and entity information.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="sgmo_DocumentAndEntityInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_DocumentAndEntityInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document And Entity Information [Abstract]</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentType_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Type</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amendment Flag</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" />
    <label xml:lang="en-US" xlink:label="dei_AmendmentFlag_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amendment Flag</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Period End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentPeriodEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Period End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Year Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalYearFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Year Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Document Fiscal Period Focus</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Document Fiscal Period Focus</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Trading Symbol</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" />
    <label xml:lang="en-US" xlink:label="dei_TradingSymbol_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Trading Symbol</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Registrant Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityRegistrantName_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Registrant Name</label>
    <label xml:lang="en-US" xlink:label="dei_EntityCentralIndexKey_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Central Index Key</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current Fiscal Year End Date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" />
    <label xml:lang="en-US" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Fiscal Year End Date</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Well-known Seasoned Issuer</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Well Known Seasoned Issuer</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Current Reporting Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCurrentReportingStatus_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Current Reporting Status</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Voluntary Filers</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityVoluntaryFilers_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Voluntary Filers</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Filer Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityFilerCategory_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Filer Category</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Common Stock, Shares Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Common Stock Shares Outstanding</label>
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Entity Public Float</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" />
    <label xml:lang="en-US" xlink:label="dei_EntityPublicFloat_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Entity Public Float</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseObligations" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseObligations" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit lease obligations.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BuildToSuitLeaseObligations" xlink:to="sgmo_BuildToSuitLeaseObligations_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Financial Position [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASSETS</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents At Carrying Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesCurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestReceivableCurrent" xlink:to="us-gaap_InterestReceivableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestReceivableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest Receivable Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsReceivableNetCurrent" xlink:to="us-gaap_AccountsReceivableNetCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsReceivableNetCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Receivable Net Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Prepaid expenses and other current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Prepaid Expense And Other Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable securities, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Goodwill" xlink:to="us-gaap_Goodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Goodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Assets Noncurrent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Assets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">LIABILITIES AND STOCKHOLDERS&apos; EQUITY</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedEmployeeBenefitsCurrent" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Employee Benefits Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueCurrent" xlink:to="us-gaap_DeferredRevenueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total current liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues, non-current</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueNoncurrent" xlink:to="us-gaap_DeferredRevenueNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenueNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue Noncurrent</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-suit lease obligation</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Lease Obligations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Liabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; equity:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, $0.01 par value; 160,000,000 shares authorized, 85,598,534 and 70,871,902 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional paid-in capital</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital Common Stock</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated deficit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings Accumulated Deficit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated other comprehensive income (loss)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income Loss Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total liabilities and stockholders&apos; equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities And Stockholders Equity</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, par value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Par Or Stated Value Per Share</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Authorized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, shares outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Shares Outstanding</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAgreements" xlink:to="sgmo_CollaborationAgreements_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenuesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues [Abstract]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration agreements</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAgreements_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Agreements</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research grants</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromGrants" xlink:to="us-gaap_RevenueFromGrants_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromGrants_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Grants</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating expenses:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total operating expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss from operations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Interest and other income, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestAndOtherIncome" xlink:to="us-gaap_InterestAndOtherIncome_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InterestAndOtherIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Interest And Other Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Loss before income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Income Loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares used in computing basic and diluted net loss per share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Share Outstanding Basic And Diluted</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Income And Comprehensive Income [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetIncomeLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net loss</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in unrealized gain (loss) on available-for-sale securities, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Comprehensive loss</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Comprehensive Income Net Of Tax</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <label xml:lang="en-US" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Settlement recognized as additional paid-in capital, net of tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Stockholders Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Components</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Equity Components [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Component</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityComponentDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Component [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common Stock [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional Paid-in Capital [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Paid In Capital [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Deficit [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RetainedEarningsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Retained Earnings [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accumulated Other Comprehensive Income/ (Loss) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Other Comprehensive Income [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Statement [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balances</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning Balances, shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value Employee Stock Purchase Plan</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under employee stock purchase plan, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Employee Stock Purchase Plans</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under public offering, net of issuance costs</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Value New Issues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under public offering, net of issuance costs, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares New Issues</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedDuringPeriodSharesFinancingPlan" xlink:type="locator" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" />
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued during period shares financing plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" xlink:to="sgmo_StockIssuedDuringPeriodSharesFinancingPlan_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Issuance of common stock under public offering, net of issuance costs</label>
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Financing Plan</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value</label>
    <label xml:lang="en-US" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claims settlement under Section 16(b), net of tax benefit</label>
    <label xml:lang="en-US" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Settlement Recognized As Additional Paid In Capital Net Of Tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Comprehensive Income Loss Net Of Tax Period Increase Decrease [Abstract]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net unrealized gain (loss) on marketable securities, net of tax</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Comprehensive loss</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquity_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balances</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending Balances, shares</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Net proceeds from issuance public offering.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NetProceedsFromIssuancePublicOffering" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <label xml:lang="en-US" xlink:label="sgmo_ProceedsFromClaimsSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Proceeds from claims settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ProceedsFromClaimsSettlement" xlink:to="sgmo_ProceedsFromClaimsSettlement_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Of Cash Flows [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease Arrangement, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="us-gaap_LeaseArrangementTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseArrangementTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Arrangement Type [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BuildToSuitLeaseMember" xlink:to="sgmo_BuildToSuitLeaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-Suit Leases [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Lease [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Type [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="sgmo_PropertyAndEquipmentMember" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property and equipment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PropertyAndEquipmentMember" xlink:to="sgmo_PropertyAndEquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_PropertyAndEquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property And Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Depreciation Depletion And Amortization</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Amortization of premium (discount) on marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accretion Amortization Of Discounts And Premiums Investments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net loss on disposal of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Gain Loss On Sale Of Property Plant Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in fair value of contingent consideration liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Arrangements Change In Amount Of Contingent Consideration Liability1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intangible impairment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Impairment Of Intangible Assets Indefinitelived Excluding Goodwill</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit from income taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNoncashIncomeExpense" xlink:to="us-gaap_OtherNoncashIncomeExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherNoncashIncomeExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Noncash Income Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net changes in operating assets and liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Operating Capital [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Interest receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accrued Interest Receivable Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Accounts receivable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Receivable</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Prepaid expenses and other assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Prepaid Deferred Expense And Other Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable and accrued liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Accounts Payable And Accrued Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued compensation and employee benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Employee Related Liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Increase Decrease In Deferred Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by (used in) operating activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Operating Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maturities of marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Sale And Maturity Of Marketable Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Purchases of property and equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Property Plant And Equipment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForLeasingCosts" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Lease commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForLeasingCosts" xlink:to="us-gaap_PaymentsForLeasingCosts_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForLeasingCosts_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Leasing Costs</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Acquisition of Ceregene, Inc. net of cash received</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments To Acquire Businesses Net Of Cash Acquired</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash (used in) provided by investing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Investing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Financing Activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations [Abstract]</label>
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from public offering of common stock, net of issuance costs</label>
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Proceeds From Issuance Public Offering</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Taxes paid related to net share settlement of equity awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments Related To Tax Withholding For Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Proceeds from issuance of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Issuance Of Common Stock</label>
    <label xml:lang="en-US" xlink:label="sgmo_ProceedsFromClaimsSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claims settlement under Section 16(b)</label>
    <label xml:lang="en-US" xlink:label="sgmo_ProceedsFromClaimsSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Proceeds From Claims Settlement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net cash provided by financing activities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Net Cash Provided By Used In Financing Activities Continuing Operations</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net increase (decrease) in cash and cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Period Increase Decrease</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Cash and cash equivalents, beginning of period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Cash and cash equivalents, end of period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Supplemental disclosure of noncash investing activities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Noncash Investing And Financing Items [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment/build-to-suit leases included in accrued liabilities and obligation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Capital Expenditures Incurred But Not Yet Paid</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Policies [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements Disclosure And Significant Accounting Policies [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Disclosures [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Debt And Equity Securities [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments In Debt And Marketable Equity Securities And Certain Trading Assets Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disclosure Of Compensation Related Costs Share Based Payments [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization Consolidation And Presentation Of Financial Statements [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Customers, Partnerships and Strategic Alliances</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaborative Arrangement Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Acquisition of Ceregene</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationDisclosureTextBlock" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments and Contingencies</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stockholders&apos; Equity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payables And Accruals [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Accrued Liabilities Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Compensation And Retirement Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Benefit Plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pension And Other Postretirement Benefits Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information Disclosure [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationDisclosureAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Quarterly Financial Data (Unaudited)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_QuarterlyFinancialInformationTextBlock" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Quarterly Financial Information [Text Block]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build to suit lease obligation disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" xlink:to="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeasesOperatingAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leases Operating [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_LeasesOperatingAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Build-to-Suit Lease</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Lease Obligation Disclosure [Text Block]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementDisclosureTextBlock" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementDisclosureTextBlock" />
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Claims settlement disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ClaimsSettlementDisclosureTextBlock" xlink:to="sgmo_ClaimsSettlementDisclosureTextBlock_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementDisclosureAbstract" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementDisclosureAbstract" />
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Claims settlement disclosure.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ClaimsSettlementDisclosureAbstract" xlink:to="sgmo_ClaimsSettlementDisclosureAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementDisclosureAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Claims Settlement Disclosure [Abstract]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claims Settlement</label>
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementDisclosureTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Claims Settlement Disclosure [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Events [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Basis of Presentation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Basis Of Accounting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Combinations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationsPolicy" xlink:to="us-gaap_BusinessCombinationsPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationsPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combinations Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash and Cash Equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Marketable Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Marketable Securities Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Measurements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Use of Estimates</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UseOfEstimates_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Use Of Estimates</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenue Recognition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Option And Incentive Plans Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Indefinite-Lived Intangible Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Intangible Assets Indefinite Lived Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">In-Process Research and Development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">In Process Research And Development Policy</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill And Intangible Assets Goodwill Policy</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent consideration.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContingentConsiderationPolicyTextBlock" xlink:to="sgmo_ContingentConsiderationPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent Consideration Liability</label>
    <label xml:lang="en-US" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Consideration Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net Loss Per Share</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Earnings Per Share Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Segment Reporting Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recent Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncements Policy Policy [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Cash Equivalents and Available-for-Sale Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-Based Compensation Expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Assumptions Used for Estimating Fair Value of Employee Stock Options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Stock Options Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Payment Award Employee Stock Purchase Plan Valuation Assumptions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Research And Development Arrangement Contract To Perform For Others [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_CounterpartyNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CounterpartyNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Counterparty Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Counterparty Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Repurchase Agreement Counterparty Name [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BioverativIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Bioverativ Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BioverativIncMember" xlink:to="sgmo_BioverativIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BioverativIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Bioverativ Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BioverativIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Bioverativ Inc [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Shire ag.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShireAgMember" xlink:to="sgmo_ShireAgMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shire AG [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShireAgMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shire Ag [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Sigma-Aldrich corporation.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SigmaAldrichCorporationMember" xlink:to="sgmo_SigmaAldrichCorporationMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sigma-Aldrich Corporation [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_SigmaAldrichCorporationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sigma Aldrich Corporation [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues Recognized under Agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Collaborative Arrangements And Noncollaborative Arrangement Transactions Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Property and Equipment</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Future Minimum Payments under Contractual Obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Future Minimum Rental Payments For Operating Leases Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Option Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Stock Options Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Stock Options Outstanding</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Restricted Stock Unit Activity</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Restricted Stock Units Award Activity Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Benefit for Income Taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Components Of Income Tax Expense Benefit Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Effective Income Tax Rate Reconciliation Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule of Company&apos;s Deferred Tax Assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Deferred Tax Assets And Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Activity Related to Company&apos;s Unrecognized Tax Benefits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Summary Of Positions For Which Significant Change In Unrecognized Tax Benefits Is Reasonably Possible [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Accounts Payable and Accrued Liabilities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Accounts Payable And Accrued Liabilities Table [Text Block]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Summary of Quarterly Financial Data</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Quarterly Financial Information Table [Text Block]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:type="locator" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" />
    <label xml:lang="en-US" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash equivalent maturity period highly liquid investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" />
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Organization and summary of significant accounting policies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Summary Of Significant Accounting Policies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_RangeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RangeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MinimumMember" xlink:to="us-gaap_MinimumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MinimumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MaximumMember" xlink:to="us-gaap_MaximumMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Maximum [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Estimate by Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Estimate By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in Accounting Estimate, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Estimate Type [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationContractPerformancePeriodMember" xlink:type="locator" xlink:label="sgmo_CollaborationContractPerformancePeriodMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationContractPerformancePeriodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration contract, performance period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationContractPerformancePeriodMember" xlink:to="sgmo_CollaborationContractPerformancePeriodMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationContractPerformancePeriodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration Contract Performance Period</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationContractPerformancePeriodMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration Contract Performance Period [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PfizerMember" xlink:type="locator" xlink:label="sgmo_PfizerMember" />
    <label xml:lang="en-US" xlink:label="sgmo_PfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Pfizer.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PfizerMember" xlink:to="sgmo_PfizerMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pfizer [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_PfizerMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pfizer [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Dow agro sciences.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DowAgroSciencesMember" xlink:to="sgmo_DowAgroSciencesMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Dow Agro Sciences [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_DowAgroSciencesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Dow Agro Sciences [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Biogen Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BiogenIncMember" xlink:to="sgmo_BiogenIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Biogen Inc [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BiogenIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Biogen Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_ConcentrationRiskTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Customer Concentration Risk [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CustomerConcentrationRiskMember" xlink:to="us-gaap_CustomerConcentrationRiskMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CustomerConcentrationRiskMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Customer Concentration Risk [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk By Benchmark [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Concentration Risk Benchmark</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Benchmark [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total revenues [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SalesRevenueNetMember" xlink:to="us-gaap_SalesRevenueNetMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SalesRevenueNetMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sales Revenue Net [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Adjustments for New Accounting Pronouncements</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Adjustments For New Accounting Pronouncements [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Type of Adoption</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_TypeOfAdoptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_TypeOfAdoptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Type Of Adoption [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ASU No. 2014-09 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingStandardsUpdate201409Member" xlink:to="us-gaap_AccountingStandardsUpdate201409Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountingStandardsUpdate201409Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounting Standards Update201409 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StatementScenarioAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Statement Scenario [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario, Unspecified</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioUnspecifiedDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioUnspecifiedDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Unspecified [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:type="locator" xlink:label="us-gaap_ProFormaMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProFormaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Pro Forma [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProFormaMember" xlink:to="us-gaap_ProFormaMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProFormaMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Pro Forma [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Organization and Summary of Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Organization And Summary Of Significant Accounting Policies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liquid investments purchased with original maturities</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalent Maturity Period Highly Liquid Investment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated useful lives of related assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateDecreaseInRevenues" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" />
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in accounting estimate decrease in revenues.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" xlink:to="sgmo_ChangeInAccountingEstimateDecreaseInRevenues_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" />
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Change in accounting estimate, increase in income (loss) per share, basic.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" xlink:to="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Increase in basic net loss per share</label>
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Estimate Increase In Income Loss Per Share Basic</label>
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Decrease in revenues</label>
    <label xml:lang="en-US" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Change In Accounting Estimate Decrease In Revenues</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskPercentage1" xlink:to="us-gaap_ConcentrationRiskPercentage1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConcentrationRiskPercentage1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Concentration Risk Percentage1</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" xlink:type="locator" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" />
    <label xml:lang="en-US" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum percentage of likelihood of indefinite lived intangible assets being impaired.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" xlink:to="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of likelihood of indefinite lived intangible assets being impaired</label>
    <label xml:lang="en-US" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Percentage Of Likelihood Of Indefinite Lived Intangible Assets Being Impaired</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Impairment charge</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Change in fair value of contingent liability</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options and restricted stock units outstanding</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options And Restricted Stock Units Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of operating segments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Operating Segments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated impact of the adoption of standard</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">New Accounting Pronouncement Or Change In Accounting Principle Cumulative Effect Of Change On Equity Or Net Assets1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAndServicesRevenue" xlink:to="us-gaap_LicenseAndServicesRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License And Services Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Up-front payment received from agreement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Compensation Earned</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Measurement Frequency [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value, Measurement Frequency</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurement Frequency [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value on recurring basis [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsRecurringMember" xlink:to="us-gaap_FairValueMeasurementsRecurringMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsRecurringMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Recurring [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Major Types of Debt and Equity Securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Major Types Of Debt And Equity Securities [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Corporate debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Corporate Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">U.S. government sponsored entity debt securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">U S Government Sponsored Enterprises Debt Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value By Fair Value Hierarchy Level [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Hierarchy</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Measurements Fair Value Hierarchy [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level1 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level2 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Level 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel3Member" xlink:to="us-gaap_FairValueInputsLevel3Member_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueInputsLevel3Member_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Inputs Level3 [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investment Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_InvestmentTypeCategorizationMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InvestmentTypeCategorizationMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investment Type Categorization [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Money market funds [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Money Market Funds [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commercial paper securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommercialPaperMember" xlink:to="us-gaap_CommercialPaperMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommercialPaperMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commercial Paper [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total cash equivalents</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Fair Value Disclosure</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Debt Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total cash equivalents and marketable securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsFairValueDisclosure" xlink:to="us-gaap_AssetsFairValueDisclosure_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Fair Value Disclosure</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Decrease in the total fair value of contingent consideration</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents accumulated gross unrealized gain before tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Cash and cash equivalents accumulated gross unrealized loss before tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAmortizedCost" xlink:type="locator" xlink:label="sgmo_AssetsAmortizedCost" />
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets amortized cost.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AssetsAmortizedCost" xlink:to="sgmo_AssetsAmortizedCost_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" />
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets accumulated gross unrealized gain before tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" />
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Assets accumulated gross unrealized loss before tax.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Cash equivalents [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashEquivalentsMember" xlink:to="us-gaap_CashEquivalentsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CashEquivalentsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash Equivalents [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Debt Security Category</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Information By Category Of Debt Security [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other than Temporary Impairment, Credit Losses Recognized in Earnings, Categories of Investments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporary Impairment Credit Losses Recognized In Earnings Categories Of Investments [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Available-for-sale securities [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableforsaleSecuritiesMember" xlink:to="us-gaap_AvailableforsaleSecuritiesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableforsaleSecuritiesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Availableforsale Securities [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Available For Sale Securities [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Available For Sale Securities [Line Items]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Cash and cash equivalents</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Accumulated Gross Unrealized Gain Before Tax</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized (Losses)</label>
    <label xml:lang="en-US" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Cash And Cash Equivalents Accumulated Gross Unrealized Loss Before Tax</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Amortized Cost</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAmortizedCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Amortized Cost</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Gross Unrealized Gains</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Accumulated Gross Unrealized Gain Before Tax</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Gross Unrealized (Losses)</label>
    <label xml:lang="en-US" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Assets Accumulated Gross Unrealized Loss Before Tax</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AssetsFairValueDisclosure_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated Fair Value</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:type="locator" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" />
    <label xml:lang="en-US" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Investments maturity dates available for sale securities.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment" xlink:type="locator" xlink:label="sgmo_OtherThanTemporarilyImpairedInvestment" />
    <label xml:lang="en-US" xlink:label="sgmo_OtherThanTemporarilyImpairedInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other than temporarily impaired investment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OtherThanTemporarilyImpairedInvestment" xlink:to="sgmo_OtherThanTemporarilyImpairedInvestment_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments maturity period</label>
    <label xml:lang="en-US" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Investments Maturity Dates Available For Sale Securities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Realized losses from the sale of available-for-sale securities</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Available For Sale Securities Gross Realized Losses</label>
    <label xml:lang="en-US" xlink:label="sgmo_OtherThanTemporarilyImpairedInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Investments other-than-temporarily impaired</label>
    <label xml:lang="en-US" xlink:label="sgmo_OtherThanTemporarilyImpairedInvestment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Than Temporarily Impaired Investment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Statement Location</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Statement Location [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and development [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">General and administrative [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">General And Administrative Expense [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total stock-based compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Allocated Share Based Compensation Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Award Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AwardTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Award Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity Award</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Award Type And Plan Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted Stock Units (RSUs) [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RestrictedStockUnitsRSUMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Restricted Stock Units R S U [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total compensation cost related to unvested stock options and RSU</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average period of unvested stock options and RSU</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Capitalized stock-based employee compensation expense</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Service Share Based Compensation Allocation Of Recognized Period Costs Capitalized Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated fair value per share of options granted</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Compensation Arrangement With Individual Share Based Payments By Type Of Deferred Compensation [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Equity-Based Arrangements, Individual Contracts, Type of Deferred Compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equity Based Arrangements Individual Contracts Type Of Deferred Compensation [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Employee Stock Options [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Option [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Risk-free interest rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected life of option (in years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected dividend yield of stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expected volatility</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:type="locator" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Stock issued under employee stock purchase plans average exercise price.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" />
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan rights weighted average estimated fair value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock issued under employee stock purchase plans, average exercise price</label>
    <label xml:lang="en-US" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued Under Employee Stock Purchase Plans Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Weighted-average estimated fair value of shares purchased under ESPP plan</label>
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan Rights Weighted Average Estimated Fair Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Plan Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PlanNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Plan Name [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanMember" />
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Employee stock purchase plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_EmployeeStockPurchasePlanMember" xlink:to="sgmo_EmployeeStockPurchasePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2010 Employee Stock Purchase Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_EmployeeStockPurchasePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Employee Stock Purchase Plan [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate additional revenue recognition milestone method revenue achieved.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate additional revenue recognition milestone method revenue eligible to receive.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone&#8203; revenue receivable.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestoneRevenueReceivable" xlink:to="sgmo_MilestoneRevenueReceivable_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payments received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestonePaymentsReceived" xlink:to="sgmo_MilestonePaymentsReceived_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreements number of products approved under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ResearchAndDevelopmentAbstract_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductOrServiceAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProductOrServiceAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Product Or Service [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Products and Services</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="us-gaap_ProductsAndServicesDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ProductsAndServicesDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Products And Services [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SBFiveTwoFiveMember" xlink:type="locator" xlink:label="sgmo_SBFiveTwoFiveMember" />
    <label xml:lang="en-US" xlink:label="sgmo_SBFiveTwoFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">SB five two five.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SBFiveTwoFiveMember" xlink:to="sgmo_SBFiveTwoFiveMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_SBFiveTwoFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">SB-525 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_SBFiveTwoFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">S B Five Two Five [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OtherProductsMember" xlink:type="locator" xlink:label="sgmo_OtherProductsMember" />
    <label xml:lang="en-US" xlink:label="sgmo_OtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Other products.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OtherProductsMember" xlink:to="sgmo_OtherProductsMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_OtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Products [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_OtherProductsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Products [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CNineORFSevenTwoMember" xlink:type="locator" xlink:label="sgmo_CNineORFSevenTwoMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CNineORFSevenTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">C nine ORF seven two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CNineORFSevenTwoMember" xlink:to="sgmo_CNineORFSevenTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CNineORFSevenTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">C9ORF72 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CNineORFSevenTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">C Nine O R F Seven Two [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues under agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential amount eligible to receive for certain milestones</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Additional Revenue Recognition Milestone Method Revenue Achieved</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Potential amount to be funded for achievement of specified commercialized and sales milestones</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Additional Revenue Recognition Milestone Method Revenue Eligible To Receive</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone revenue receivable</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestoneRevenueReceivable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Revenue Receivable</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Milestone payments received</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentsReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payments Received</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of products approved</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreements Number Of Products Approved Under Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Royalty revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyRevenue" xlink:to="us-gaap_RoyaltyRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RoyaltyRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Royalty Revenue</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Initial research term of agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_InitialResearchTermOfAgreement" xlink:to="sgmo_InitialResearchTermOfAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research program to develop laboratory research reagents</label>
    <label xml:lang="en-US" xlink:label="sgmo_InitialResearchTermOfAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Initial Research Term Of Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenue" xlink:to="us-gaap_DeferredRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Revenue</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAndServicesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveTerseLabel">Recognition of upfront fee</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of research program.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfResearchProgram" xlink:to="sgmo_NumberOfResearchProgram_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of research programs</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfResearchProgram_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Research Program</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research services</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Service Revenue Under Collaboration Agreement</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License fee revenues</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicensesRevenue" xlink:to="us-gaap_LicensesRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Licenses Revenue</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractsRevenue" xlink:to="us-gaap_ContractsRevenue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ContractsRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contracts Revenue</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Aggregate number of gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AggregateNumberOfGeneTargets" xlink:to="sgmo_AggregateNumberOfGeneTargets_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of initial gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfInitialGeneTargets" xlink:to="sgmo_NumberOfInitialGeneTargets_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfGeneTargets" xlink:to="sgmo_NumberOfGeneTargets_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of additional gene targets.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfAdditionalGeneTargets" xlink:to="sgmo_NumberOfAdditionalGeneTargets_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate number of gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_AggregateNumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Aggregate Number Of Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of initial gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfInitialGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Initial Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Gene Targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of additional gene targets</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfAdditionalGeneTargets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Additional Gene Targets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Recognition of milestone</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue Recognition Milestone Method Revenue Recognized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amount reimbursed and recognized related to prior obligations</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Revenue From Related Parties</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServicesPeriod" xlink:type="locator" xlink:label="sgmo_ResearchServicesPeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServicesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research services period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchServicesPeriod" xlink:to="sgmo_ResearchServicesPeriod_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others By Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Development Arrangement, Contract to Perform for Others, Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development Arrangement Contract To Perform For Others Type [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fees.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFeesMember" xlink:to="sgmo_UpfrontLicenseFeesMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFeesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fees [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License agreement terms [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LicenseAgreementTermsMember" xlink:to="us-gaap_LicenseAgreementTermsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LicenseAgreementTermsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Agreement Terms [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServicesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Developed laboratory research reagents, research services period</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchServicesPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research Services Period</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Upfront license fee.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UpfrontLicenseFee" xlink:to="sgmo_UpfrontLicenseFee_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Reduced royalty rate.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ReducedRoyaltyRate" xlink:to="sgmo_ReducedRoyaltyRate_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Additional milestone receivable under agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upfront license fee</label>
    <label xml:lang="en-US" xlink:label="sgmo_UpfrontLicenseFee_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Upfront License Fee</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Common stock issued under license agreement</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Public offering, common stock shares issued</label>
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Reduced royalty rate</label>
    <label xml:lang="en-US" xlink:label="sgmo_ReducedRoyaltyRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Reduced Royalty Rate</label>
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Funding available under the amended agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Additional Milestone Receivable Under Agreement</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Percentage of royalties to be received from sublicensing.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Milestone payment and royalty revenue of previous agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">One time license fee earned.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OneTimeLicenseFeeEarned" xlink:to="sgmo_OneTimeLicenseFeeEarned_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">One-time license fee earned on exercise of option</label>
    <label xml:lang="en-US" xlink:label="sgmo_OneTimeLicenseFeeEarned_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">One Time License Fee Earned</label>
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of royalties to be received from sublicensing</label>
    <label xml:lang="en-US" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Percentage Of Royalties To Be Received From Sublicensing</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</label>
    <label xml:lang="en-US" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Milestone Payment And Royalty Revenue Of Previous Agreement</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Annual fees related to agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AnnualFeesRelatedToAgreement" xlink:to="sgmo_AnnualFeesRelatedToAgreement_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Fee due.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FeeDue" xlink:to="sgmo_FeeDue_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Minimum sublicense annual fees specific reckoning period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Annual fees</label>
    <label xml:lang="en-US" xlink:label="sgmo_AnnualFeesRelatedToAgreement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Annual Fees Related To Agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fee due</label>
    <label xml:lang="en-US" xlink:label="sgmo_FeeDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Fee Due</label>
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Minimum license annual fees specific reckoning period</label>
    <label xml:lang="en-US" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Minimum Sublicense Annual Fees Specific Reckoning Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_LicensesRevenue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Revenue attributable to research and development</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" xlink:type="locator" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" />
    <label xml:lang="en-US" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Business acquisition contingent consideration earn-out payment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Business Acquisitions By Acquisition [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Business Acquisitions By Acquisition [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition, Acquiree</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Acquiree [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CeregeneIncMember" xlink:type="locator" xlink:label="sgmo_CeregeneIncMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CeregeneIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Ceregene Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CeregeneIncMember" xlink:to="sgmo_CeregeneIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CeregeneIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Ceregene, Inc. [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CeregeneIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Ceregene Inc [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Business Acquisition [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock, transferred, shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Equity Interests Issued Or Issuable Number Of Shares Issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sangamo shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Consideration Transferred Equity Interests Issued And Issuable</label>
    <label xml:lang="en-US" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent earn-out</label>
    <label xml:lang="en-US" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Acquisition Contingent Consideration Earn Out Payment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fair value of contingent earn-out liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Business Combination Contingent Consideration Liability</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Estimated fair values of in-process research and development</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ResearchAndDevelopmentInProcess_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Development In Process</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Goodwill impairment recognized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillImpairmentLoss" xlink:to="us-gaap_GoodwillImpairmentLoss_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_GoodwillImpairmentLoss_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Goodwill Impairment Loss</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:type="locator" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property plant and equipment useful life and values.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Useful Life And Values [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Property Plant And Equipment [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Property Plant And Equipment [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Laboratory equipment [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EquipmentMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Equipment [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Furniture and fixtures [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Furniture And Fixtures [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Leasehold improvements [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Leasehold Improvements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Buildings [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BuildingMember" xlink:to="us-gaap_BuildingMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Building [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Construction in Progress [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Construction In Progress [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property, Plant and Equipment [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property and equipment, Gross</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Plant And Equipment Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Less accumulated depreciation and amortization</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accumulated Depreciation Depletion And Amortization Property Plant And Equipment</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseCostsCapitalized" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build to suit lease, costs capitalized.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BuildToSuitLeaseCostsCapitalized" xlink:to="sgmo_BuildToSuitLeaseCostsCapitalized_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RichmondBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_RichmondBuildToSuitLeaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RichmondBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Richmond build-to-suit Lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RichmondBuildToSuitLeaseMember" xlink:to="sgmo_RichmondBuildToSuitLeaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RichmondBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Richmond Build-to-Suit Lease [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RichmondBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Richmond Build To Suit Lease [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Brisbane build-to-suit lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BrisbaneBuildToSuitLeaseMember" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Brisbane Build-to-Suit Lease [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Brisbane Build To Suit Lease [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_BuildingMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Building [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Costs capitalized</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Lease Costs Capitalized</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeasePropertyLeased" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeasePropertyLeased" />
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeasePropertyLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Build-to-suit lease, property leased.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_BuildToSuitLeasePropertyLeased" xlink:to="sgmo_BuildToSuitLeasePropertyLeased_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfBuiltToSuitLeaseProperties" xlink:type="locator" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties" />
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Number of built-to-suit lease properties.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_NumberOfBuiltToSuitLeaseProperties" xlink:to="sgmo_NumberOfBuiltToSuitLeaseProperties_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesLineItems" />
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_CommitmentsAndContingenciesLineItems_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesTable" />
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Commitments and contingencies.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="sgmo_CommitmentsAndContingenciesTable_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Table]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property Subject to or Available for Operating Lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property subject to operating lease one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:to="sgmo_PropertySubjectToOperatingLeaseOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease One [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Operating Lease One [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Property subject to operating lease two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:to="sgmo_PropertySubjectToOperatingLeaseTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Lease Two [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Operating Lease Two [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:type="locator" xlink:label="sgmo_ResearchAndOfficeSpaceMember" />
    <label xml:lang="en-US" xlink:label="sgmo_ResearchAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Research and office space</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ResearchAndOfficeSpaceMember" xlink:to="sgmo_ResearchAndOfficeSpaceMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ResearchAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Research and Office Space [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ResearchAndOfficeSpaceMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Research And Office Space [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" xlink:type="locator" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" />
    <label xml:lang="en-US" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Services agreement to provide dedicated capacity to supply preclinical and clinical programs.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" xlink:to="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Services Agreement to Provide Dedicated Capacity to Supply Preclinical and Clinical Programs [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Services Agreement To Provide Dedicated Capacity To Supply Preclinical And Clinical Programs [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other Commitments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="us-gaap_OtherCommitmentsDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentsDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitments [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TenantImprovementsMember" xlink:type="locator" xlink:label="sgmo_TenantImprovementsMember" />
    <label xml:lang="en-US" xlink:label="sgmo_TenantImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tenant improvements.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TenantImprovementsMember" xlink:to="sgmo_TenantImprovementsMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_TenantImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tenant Improvements [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_TenantImprovementsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tenant Improvements [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets by Major Class</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets By Major Class [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Finite-Lived Intangible Assets, Major Class Name</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Finite Lived Intangible Assets Major Class Name [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intellectual Property [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IntellectualPropertyMember" xlink:to="us-gaap_IntellectualPropertyMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IntellectualPropertyMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Intellectual Property [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commitments And Contingencies [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CommitmentsAndContingenciesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Commitments And Contingencies [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional property available under lease</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Property Subject To Or Available For Operating Lease Number Of Units</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Area of space leased</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LandSubjectToGroundLeases" xlink:to="us-gaap_LandSubjectToGroundLeases_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LandSubjectToGroundLeases_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Land Subject To Ground Leases</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease expiration date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease Expiration Date1</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeasePropertyLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Property leased</label>
    <label xml:lang="en-US" xlink:label="sgmo_BuildToSuitLeasePropertyLeased_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Build To Suit Lease Property Leased</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of built-to-suit lease properties</label>
    <label xml:lang="en-US" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Number Of Built To Suit Lease Properties</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Rent expenses</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lease And Rental Expense</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2018</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2019</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Two Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2020</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Three Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2021</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Four Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2022</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due In Five Years</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Thereafter</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due Thereafter</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total minimum payments</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Future Minimum Payments Due</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_LicenseCommitments" xlink:type="locator" xlink:label="sgmo_LicenseCommitments" />
    <label xml:lang="en-US" xlink:label="sgmo_LicenseCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">License commitments.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_LicenseCommitments" xlink:to="sgmo_LicenseCommitments_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other commitments for next twelve months</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Other Commitment Due In Next Twelve Months</label>
    <label xml:lang="en-US" xlink:label="sgmo_LicenseCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">License commitments</label>
    <label xml:lang="en-US" xlink:label="sgmo_LicenseCommitments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">License Commitments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsidiary Sale Of Stock [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Sale of Stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sale Of Stock Name Of Transaction [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:type="locator" xlink:label="sgmo_AtTheMarketOfferingAgreementMember" />
    <label xml:lang="en-US" xlink:label="sgmo_AtTheMarketOfferingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">At the market offering agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AtTheMarketOfferingAgreementMember" xlink:to="sgmo_AtTheMarketOfferingAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AtTheMarketOfferingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">ATM Agreement [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_AtTheMarketOfferingAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">At The Market Offering Agreement [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Two thousand thirteen stock incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2013 Stock Incentive Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Thirteen Stock Incentive Plan [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandFourStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">2004 Stock Incentive Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TwoThousandFourStockIncentivePlanMember" xlink:to="sgmo_TwoThousandFourStockIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">2004 Stock Incentive Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Two Thousand Four Stock Incentive Plan [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" />
    <label xml:lang="en-US" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Amended and restated 2013 stock incentive plan.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:to="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Amended and Restated 2013 Stock Incentive Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Amended And Restated Two Thousand Thirteen Stock Incentive Plan [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_VestingAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Vesting</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_VestingDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_VestingDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Vesting [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Awards, Tranche 1 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche One [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Awards, Tranche 2 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Two [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-Based Compensation Awards, Tranche 3 [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Award Tranche Three [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Preferred shares authorized</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Preferred Stock Shares Authorized</label>
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/positiveLabel">Total shares issued</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Public offering price of common stock issued</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesIssuedPricePerShare_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Issued Price Per Share</label>
    <label xml:lang="en-US" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net proceeds from issuance of common stock, after deducting offering expenses</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock capital shares value reserved for future issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:to="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Common stock issuable and sellable under offering agreement</label>
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Value Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Commission paid to sales agent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsForCommissions" xlink:to="us-gaap_PaymentsForCommissions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsForCommissions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Payments For Commissions</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:type="locator" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage" />
    <label xml:lang="en-US" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Specified stockholder ownership percentage.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_SpecifiedStockholderOwnershipPercentage" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award options expiration term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of additional shares reserved for issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of shares initially reserved for issuance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percent of fair value per share of common stock on option grant date</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock option maximum term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1</label>
    <label xml:lang="en-US" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Specified stockholder ownership percentage</label>
    <label xml:lang="en-US" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Specified Stockholder Ownership Percentage</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase price of common stock percent under stock incentive plans for specified stockholder</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Purchase Price Of Common Stock Percent For Specified Stockholder</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock option maximum term for specified stockholder</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Maximum Term For Specified Stock Holder</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share based vesting rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Rights</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options vesting period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Award Vesting Period1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options granted vesting percentage</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Award Vesting Rights Percentage</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock options expiration term</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Expiration Term</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Stock reserved for issuance under plan</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Initially Reserved For Issuance</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additional shares authorized under 2013 stock incentive plan</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Reserved For Issuance</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockExchangeRatio" xlink:type="locator" xlink:label="sgmo_CommonStockExchangeRatio" />
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Common stock exchange ratio.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CommonStockExchangeRatio" xlink:to="sgmo_CommonStockExchangeRatio_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share of common stock subject to a stock option or stock appreciation right</label>
    <label xml:lang="en-US" xlink:label="sgmo_CommonStockExchangeRatio_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Exchange Ratio</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Fixed ratio shares of common stock</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stockholders Equity Note Stock Split Conversion Ratio1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock reserved for issuance under plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanOfferingPeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase plan offering period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PurchasePlanOfferingPeriod" xlink:to="sgmo_PurchasePlanOfferingPeriod_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanPurchasePeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Purchase plan purchase period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PurchasePlanPurchasePeriod" xlink:to="sgmo_PurchasePlanPurchasePeriod_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase plan offering period</label>
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanOfferingPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Plan Offering Period</label>
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Purchase plan purchase period</label>
    <label xml:lang="en-US" xlink:label="sgmo_PurchasePlanPurchasePeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Purchase Plan Purchase Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding at December 31, 2016, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options exercised, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Stock Issued During Period Shares Stock Options Exercised</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Options canceled, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding at December 31, 2017, Number of Shares</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest at December 31, 2017, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at December 31, 2017, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Options outstanding, Weighted-Average Exercise per Share Price, Beginning Balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options granted, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercised, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options canceled, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Options outstanding, Weighted-Average Exercise per Share Price, Ending Balance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest at December 31, 2017, Weighted-Average Exercise Per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at December 31, 2017, Weighted-Average Exercise per Share Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding at December, 31, 2017, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest at December, 31, 2017, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at December, 31, 2017, Weighted Average Remaining Contractual Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options outstanding at December 31, 2017, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest at December 31, 2017, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options exercisable at December 31, 2017, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares subject to repurchase rights</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Weighted Average Number Of Shares Common Stock Subject To Repurchase Or Cancellation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Intrinsic value of options exercised</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options outstanding, Aggregate Intrinsic Value</label>
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Options exercisable, Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options vested and expected to vest, aggregate intrinsic value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans By Exercise Price Range [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based Compensation, Shares Authorized under Stock Option Plans, Exercise Price Range</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeOneMember" xlink:type="locator" xlink:label="sgmo_RangeOneMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range one.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeOneMember" xlink:to="sgmo_RangeOneMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$2.55 &#8211; $3.45 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeOneMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range One [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTwoMember" xlink:type="locator" xlink:label="sgmo_RangeTwoMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range two.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeTwoMember" xlink:to="sgmo_RangeTwoMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$3.50 &#8211; $3.50 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeTwoMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Two [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeThreeMember" xlink:type="locator" xlink:label="sgmo_RangeThreeMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range three.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeThreeMember" xlink:to="sgmo_RangeThreeMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$3.55 &#8211; $5.41 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeThreeMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Three [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFourMember" xlink:type="locator" xlink:label="sgmo_RangeFourMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range four.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeFourMember" xlink:to="sgmo_RangeFourMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$5.42 &#8211; $7.07 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeFourMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Four [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFiveMember" xlink:type="locator" xlink:label="sgmo_RangeFiveMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range five.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeFiveMember" xlink:to="sgmo_RangeFiveMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$7.20 &#8211; $9.41 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeFiveMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Five [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSixMember" xlink:type="locator" xlink:label="sgmo_RangeSixMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range six.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeSixMember" xlink:to="sgmo_RangeSixMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$9.45 &#8211; $13.35 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeSixMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Six [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSevenMember" xlink:type="locator" xlink:label="sgmo_RangeSevenMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range seven.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeSevenMember" xlink:to="sgmo_RangeSevenMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$13.54 &#8211; $15.00 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeSevenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Seven [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeEightMember" xlink:type="locator" xlink:label="sgmo_RangeEightMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range eight.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeEightMember" xlink:to="sgmo_RangeEightMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$15.11 &#8211; $18.26 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeEightMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Eight [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeNineMember" xlink:type="locator" xlink:label="sgmo_RangeNineMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range nine.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeNineMember" xlink:to="sgmo_RangeNineMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$19.51 &#8211; $19.51 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeNineMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Nine [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTenMember" xlink:type="locator" xlink:label="sgmo_RangeTenMember" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Range ten.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_RangeTenMember" xlink:to="sgmo_RangeTenMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_RangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">$19.80 &#8211; $19.80 [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_RangeTenMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Range Ten [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lower Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Upper Range of Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding and Exercisable Number of Shares of common stock subject to options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Outstanding Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Outstanding Options Weighted Average Remaining Contractual Term2</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable Number of Shares of common stock subject to options</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Number Of Exercisable Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Options Exercisable Weighted Average Exercise Price</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Exercisable Options Weighted Average Exercise Price1</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award number of vesting installment.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Restricted stock units awarded</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Grant date fair value per award of restricted stock units</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Grant Date Fair Value</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Share-based compensation arrangement by share-based payment award, number of vesting installment</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Number Of Vesting Installment</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate fair value of RSUs vested in period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options released in period.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">RSUs outstanding at December 31, 2016, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">RSUs awarded, Number of Shares</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs released, Number of Shares</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Released In Period</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">RSUs forfeited, Number of Shares</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period</label>
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">RSUs outstanding at December 31, 2017, Number of Shares</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested and expected to vest at December 31, 2017, Number of Shares</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Outstanding Number</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs outstanding at December, 31, 2017, Weighted Average Remaining Contractual Term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Outstanding Weighted Average Remaining Contractual Terms</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested and expected to vest at December 31, 2017, Weighted Average Remaining Contractual Term</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Weighted Average Remaining Contractual Term</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" />
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">RSUs outstanding at December 31, 2017, Aggregate Intrinsic Value</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Outstanding</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">RSUs vested and expected to vest at December 31, 2017, Aggregate Intrinsic Value</label>
    <label xml:lang="en-US" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested And Expected To Vest Aggregate Intrinsic Value</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares withheld from issuance in order to pay employee taxes</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Shares Paid For Tax Withholding For Share Based Compensation</label>
    <label xml:lang="en-US" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Total payments for the employees&apos; tax obligations to taxing authorities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Shares reserved for issuance of future awards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Common Stock Capital Shares Reserved For Future Issuance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Benefit for income taxes:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Current:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current State And Local Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Current Federal State And Local Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Income Tax Expense Benefit Continuing Operations [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred State And Local Income Tax Expense Benefit</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Subtotal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Federal State And Local Tax Expense Benefit</label>
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefit_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Income tax benefit</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesLineItems" xlink:type="locator" xlink:label="sgmo_IncomeTaxesLineItems" />
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_IncomeTaxesLineItems_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesTable" xlink:type="locator" xlink:label="sgmo_IncomeTaxesTable" />
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Income taxes.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_IncomeTaxesTable" xlink:to="sgmo_IncomeTaxesTable_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Table]</label>
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Tax Authority</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxAuthorityDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Authority [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_StateAndLocalJurisdictionMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">State And Local Jurisdiction [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DomesticCountryMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Domestic Country [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Scenario Plan [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScenarioPlanMember" xlink:to="us-gaap_ScenarioPlanMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScenarioPlanMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Scenario Plan [Member]</label>
    <label xml:lang="en-US" xlink:label="us-gaap_MaximumMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Maximum [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Income Taxes [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxesLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Taxes [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal statutory income tax rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax at federal statutory rate</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State taxes, net</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation State And Local Income Taxes</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal Rate Change</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Enacted Tax Rate</label>
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Non-deductible stock compensation</label>
    <label xml:lang="en-US" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Nondeductible Expense Income Share Based Compensation</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Research credits</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Tax Credits Research</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Change in valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Reconciliation Other Adjustments</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Net operating loss carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Research and development tax credit carryforwards</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Stock-based compensation</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred revenue</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Deferred Income</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Other</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total deferred tax asset</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Gross</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Net deferred tax assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Net</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Liabilities:</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_LiabilitiesAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LiabilitiesAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Liabilities [Abstract]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Net deferred tax liability related to intangible assets</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Goodwill And Intangible Assets</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel">Total deferred tax liability</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Liabilities Noncurrent</label>
    <label xml:lang="en-US" xlink:label="sgmo_ProceedsFromClaimsSettlement_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Claim settlement received</label>
    <label xml:lang="en-US" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Settlement recognized as additional paid-in capital, net of tax</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Income tax benefit, claims settlement</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Income Tax Expense Benefit Intraperiod Tax Allocation</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear" />
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating loss carryforwards expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OperatingLossCarryforwardsExpirationYear" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research federal.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" />
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Deferred tax assets tax credit carryforwards research state and local.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" />
    <label xml:lang="en-US" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Federal research tax credit carryforward expiration year.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Increase (decrease) in deferred tax assets valuation allowance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Valuation Allowance Deferred Tax Asset Change In Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net operating loss carryforwards for federal</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards Domestic</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred tax assets, net operating loss carryforwards for state</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Operating Loss Carryforwards State And Local</label>
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating loss carryforwards, expiration year</label>
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Loss Carryforwards Expiration Year</label>
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal research tax credit carryforwards</label>
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research Federal</label>
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">State research tax credit carryforwards</label>
    <label xml:lang="en-US" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Tax Assets Tax Credit Carryforwards Research State And Local</label>
    <label xml:lang="en-US" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Tax credit carryforward, expiration year</label>
    <label xml:lang="en-US" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Federal Research Tax Credit Carryforward Expiration Year</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" xlink:type="locator" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" />
    <label xml:lang="en-US" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Tax cuts and jobs act of 2017, reduction of net of valuation allowance.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" xlink:to="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Federal tax rate reduction net of valuation allowance</label>
    <label xml:lang="en-US" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Tax Cuts And Jobs Act Of2017 Reduction Of Net Of Valuation Allowance</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued interest and/or penalties</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <label xml:lang="en-US" xlink:label="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Unrecognized tax benefits increase decrease resulting from prior period tax positions.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:to="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel">Beginning balance</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions based on tax positions related to the current year</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions</label>
    <label xml:lang="en-US" xlink:label="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Additions for tax positions of prior years</label>
    <label xml:lang="en-US" xlink:label="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Increase Decrease Resulting From Prior Period Tax Positions</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel">Reductions for tax positions of prior years</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions</label>
    <label xml:lang="en-US" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel">Ending balance</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses" />
    <label xml:lang="en-US" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Accrued research and development expenses.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AccruedResearchAndDevelopmentExpenses" xlink:to="sgmo_AccruedResearchAndDevelopmentExpenses_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accounts payable</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable Current</label>
    <label xml:lang="en-US" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued research and development expenses</label>
    <label xml:lang="en-US" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Research And Development Expenses</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Accrued professional fees</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccruedProfessionalFeesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accrued Professional Fees Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Deferred rent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Deferred Rent Credit Current</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Other</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Accounts Payable And Other Accrued Liabilities</label>
    <label xml:lang="en-US" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel">Total accounts payable and accrued liabilities</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, employer&apos;s matching contribution percent</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Percentage of employer matching contribution to employee contribution</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Employer Matching Contribution Percent Of Match</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Maximum percentage limit of employee contributions</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Percent</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Defined contribution plan, maximum employer&apos;s contribution per employee</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Maximum Annual Contributions Per Employee Amount</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Aggregate employers contributions to defined contribution plan</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanCostRecognized" xlink:to="us-gaap_DefinedContributionPlanCostRecognized_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_DefinedContributionPlanCostRecognized_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Defined Contribution Plan Cost Recognized</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract" />
    <label xml:lang="en-US" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Selected Quarterly Financial Information [Abstract]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_SelectedQuarterlyFinancialInformationAbstract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_Revenues_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Revenues</label>
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingExpenses_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Expenses</label>
    <label xml:lang="en-US" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel">Net loss per share</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:type="locator" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions" />
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Operating leases number of extension options.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:to="sgmo_OperatingLeasesNumberOfExtensionOptions_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Operating Leased Assets [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Operating Leased Assets [Table]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PointPinoleBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember" />
    <label xml:lang="en-US" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Point pinole build-to-suit lease.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_PointPinoleBuildToSuitLeaseMember" xlink:to="sgmo_PointPinoleBuildToSuitLeaseMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Point Pinole Build-to-Suit Lease [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Point Pinole Build To Suit Lease [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating Leased Assets [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_OperatingLeasedAssetsLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_OperatingLeasedAssetsLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leased Assets [Line Items]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Operating lease expiration period</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Term Of Contract</label>
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Number of lease term extension options</label>
    <label xml:lang="en-US" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Operating Leases Number Of Extension Options</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Lease agreement, extendable lease term</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Lessee Leasing Arrangements Operating Leases Renewal Term</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Letter of credit</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Letters Of Credit Outstanding Amount</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementLineItems" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementLineItems" />
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Claims settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_ClaimsSettlementLineItems_lbl" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ScheduleOfClaimsSettlementTable" xlink:type="locator" xlink:label="sgmo_ScheduleOfClaimsSettlementTable" />
    <label xml:lang="en-US" xlink:label="sgmo_ScheduleOfClaimsSettlementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Schedule of claims settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ScheduleOfClaimsSettlementTable" xlink:to="sgmo_ScheduleOfClaimsSettlementTable_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_ScheduleOfClaimsSettlementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Schedule Of Claims Settlement [Table]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ScheduleOfClaimsSettlementTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Schedule Of Claims Settlement [Table]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_LitigationStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LitigationStatusAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Status [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_LitigationStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Litigation Status</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="us-gaap_LitigationStatusDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_LitigationStatusDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Litigation Status [Domain]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DisgorgementSettlementMember" xlink:type="locator" xlink:label="sgmo_DisgorgementSettlementMember" />
    <label xml:lang="en-US" xlink:label="sgmo_DisgorgementSettlementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Disgorgement settlement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_DisgorgementSettlementMember" xlink:to="sgmo_DisgorgementSettlementMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_DisgorgementSettlementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Disgorgement settlement [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_DisgorgementSettlementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Disgorgement Settlement [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Claims Settlement [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ClaimsSettlementLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Claims Settlement [Line Items]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="locator" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" />
    <label xml:lang="en-US" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Contingent development and sales based milestone payments to be received.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:to="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_lbl" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Table]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTable_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Table]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" />
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified research, clinical development, regulatory and first commercial sale milestones.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:to="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Achievement Of Specified Research Clinical Development Regulatory And First Commercial Sale Milestones [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" />
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Achievement of specified sales based milestones if annual worldwide net sales of licensed products reach specified levels.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:to="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Achievement Of Specified Sales Based Milestones If Annual Worldwide Net Sales Of Licensed Products Reach Specified Levels [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_KitePharmaIncMember" xlink:type="locator" xlink:label="sgmo_KitePharmaIncMember" />
    <label xml:lang="en-US" xlink:label="sgmo_KitePharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Kite Pharma Inc.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_KitePharmaIncMember" xlink:to="sgmo_KitePharmaIncMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_KitePharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Kite Pharma, Inc. ("Kite") [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_KitePharmaIncMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Kite Pharma Inc [Member]</label>
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementMember" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation">Collaboration and license agreement.</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="sgmo_CollaborationAndLicenseAgreementMember" xlink:to="sgmo_CollaborationAndLicenseAgreementMember_lbl" />
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Collaboration and License Agreement [Member]</label>
    <label xml:lang="en-US" xlink:label="sgmo_CollaborationAndLicenseAgreementMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Collaboration And License Agreement [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Axis]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event Type</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventTypeDomain_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event Type [Domain]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Member]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventMember_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Member]</label>
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Subsequent Event [Line Items]</label>
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" />
    <label xml:lang="en-US" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Subsequent Event [Line Items]</label>
    <label xml:lang="en-US" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel">Contingent development - and sales-based milestone payments to be received</label>
    <label xml:lang="en-US" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived_lbl" xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label">Contingent Development And Sales Based Milestone Payments To Be Received</label>
  </labelLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>40
<FILENAME>sgmo-20171231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii" standalone="yes"?>
<!-- DFS ActiveDisclosure(SM) XBRL Linkbase Document - http://www.dfsco.com/financial-services/ -->
<!-- Creation Date      : 2018-03-01T21:07:54.4851146+00:00 -->
<!-- Version            : 2.9.6605.1333 -->
<!-- Package ID         : 068f557bb82c4e9f84f19fa30bba4daf -->
<!-- Copyright (c) 2018 Donnelley Financial, LLC. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <roleRef roleURI="http://www.sangamo.com/20171231/role/TemplateLink" xlink:href="sgmo-20171231.xsd#TemplateLink" xlink:type="simple" />
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation" xlink:href="sgmo-20171231.xsd#Role_DocumentDocumentAndEntityInformation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation">
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityPublicFloat" xlink:type="locator" xlink:label="dei_EntityPublicFloat" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:type="locator" xlink:label="dei_EntityCommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityFilerCategory" xlink:type="locator" xlink:label="dei_EntityFilerCategory" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityVoluntaryFilers" xlink:type="locator" xlink:label="dei_EntityVoluntaryFilers" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:type="locator" xlink:label="dei_EntityCurrentReportingStatus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:type="locator" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:type="locator" xlink:label="dei_CurrentFiscalYearEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityCentralIndexKey" xlink:type="locator" xlink:label="dei_EntityCentralIndexKey" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_EntityRegistrantName" xlink:type="locator" xlink:label="dei_EntityRegistrantName" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_TradingSymbol" xlink:type="locator" xlink:label="dei_TradingSymbol" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalPeriodFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:type="locator" xlink:label="dei_DocumentFiscalYearFocus" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentPeriodEndDate" xlink:type="locator" xlink:label="dei_DocumentPeriodEndDate" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_AmendmentFlag" xlink:type="locator" xlink:label="dei_AmendmentFlag" />
    <loc xlink:href="http://xbrl.sec.gov/dei/2014/dei-2014-01-31.xsd#dei_DocumentType" xlink:type="locator" xlink:label="dei_DocumentType" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DocumentAndEntityInformationAbstract" xlink:type="locator" xlink:label="sgmo_DocumentAndEntityInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentType" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_AmendmentFlag" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentPeriodEndDate" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalYearFocus" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_DocumentFiscalPeriodFocus" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_TradingSymbol" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityRegistrantName" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCentralIndexKey" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_CurrentFiscalYearEndDate" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCurrentReportingStatus" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityVoluntaryFilers" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityFilerCategory" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_DocumentAndEntityInformationAbstract" xlink:to="dei_EntityPublicFloat" order="10850.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedBalanceSheets" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockValue" xlink:type="locator" xlink:label="us-gaap_CommonStockValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingencies" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Liabilities" xlink:type="locator" xlink:label="us-gaap_Liabilities" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseObligations" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseObligations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRevenueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedEmployeeBenefitsCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedEmployeeBenefitsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Assets" xlink:type="locator" xlink:label="us-gaap_Assets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:type="locator" xlink:label="us-gaap_OtherAssetsNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrent" xlink:type="locator" xlink:label="us-gaap_AssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="locator" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsReceivableNetCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsReceivableNetCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestReceivableCurrent" xlink:type="locator" xlink:label="us-gaap_InterestReceivableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesCurrent" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsCurrentAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsCurrentAbstract" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesCurrent" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_InterestReceivableCurrent" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AccountsReceivableNetCurrent" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesNoncurrent" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Goodwill" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_Assets" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedEmployeeBenefitsCurrent" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredRevenueCurrent" order="11080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="sgmo_BuildToSuitLeaseObligations" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_Liabilities" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_CommonStockValue" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" order="11480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquity" order="11560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedBalanceSheetsParenthetical" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfOperations" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InterestAndOtherIncome" xlink:type="locator" xlink:label="us-gaap_InterestAndOtherIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:type="locator" xlink:label="us-gaap_OperatingIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:type="locator" xlink:label="us-gaap_OperatingExpensesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromGrants" xlink:type="locator" xlink:label="us-gaap_RevenueFromGrants" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAgreements" xlink:type="locator" xlink:label="sgmo_CollaborationAgreements" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeStatementAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_RevenuesAbstract" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_CollaborationAgreements" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RevenueFromGrants" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_Revenues" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpenses" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_InterestAndOtherIncome" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" order="11070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfComprehensiveLoss" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity" xlink:href="sgmo-20171231.xsd#Role_StatementConsolidatedStatementsOfStockholdersEquity" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="locator" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:type="locator" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedDuringPeriodSharesFinancingPlan" xlink:type="locator" xlink:label="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:type="locator" xlink:label="us-gaap_CommonStockSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquity" xlink:type="locator" xlink:label="us-gaap_StockholdersEquity" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="locator" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:type="locator" xlink:label="us-gaap_RetainedEarningsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sgmo_StockIssuedDuringPeriodSharesFinancingPlan" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" order="11030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_NetIncomeLoss" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquity_li0l2" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued_li0l2" order="11750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows" xlink:href="sgmo-20171231.xsd#Role_StatementCondensedConsolidatedStatementsOfCashFlows" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="locator" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:type="locator" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForLeasingCosts" xlink:type="locator" xlink:label="us-gaap_PaymentsForLeasingCosts" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="locator" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccountsReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:type="locator" xlink:label="us-gaap_OtherNoncashIncomeExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="locator" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementLineItems" xlink:type="locator" xlink:label="us-gaap_StatementLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertyAndEquipmentMember" xlink:type="locator" xlink:label="sgmo_PropertyAndEquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementTable" xlink:type="locator" xlink:label="us-gaap_StatementTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BuildToSuitLeaseMember" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10300.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sgmo_PropertyAndEquipmentMember" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10740.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" order="10800.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10980.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" order="11100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" order="11220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet" order="11340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsReceivable" order="11400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="11460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" order="11520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities" order="11580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="11640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" order="11760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" order="11940.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="12000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsForLeasingCosts" order="12060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired" order="12120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations" order="12180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" order="12240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="12360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="12420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="12540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" order="12660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_li0l2" order="12780.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid" order="12960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:href="sgmo-20171231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurement" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurement" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurement">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecurities" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecurities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecurities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensation" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensation" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensation">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliances" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CollaborativeArrangementDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_CollaborativeArrangementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregene" xlink:href="sgmo-20171231.xsd#Role_DisclosureAcquisitionOfCeregene" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregene">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_BusinessCombinationDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipment" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingencies" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingencies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingencies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquity" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquity" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquity">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxes" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxes" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxes">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities" xlink:href="sgmo-20171231.xsd#Role_DisclosureAccountsPayableAndAccruedLiabilities" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlan" xlink:href="sgmo-20171231.xsd#Role_DisclosureEmployeeBenefitPlan" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlan">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:type="locator" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited" xlink:href="sgmo-20171231.xsd#Role_DisclosureQuarterlyFinancialDataUnaudited" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationTextBlock" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_QuarterlyFinancialInformationTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLease" xlink:href="sgmo-20171231.xsd#Role_DisclosureBuildToSuitLease" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLease">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="sgmo_BuildToSuitLeaseObligationDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlement" xlink:href="sgmo-20171231.xsd#Role_DisclosureClaimsSettlement" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlement">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementDisclosureTextBlock" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementDisclosureTextBlock" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementDisclosureAbstract" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ClaimsSettlementDisclosureAbstract" xlink:to="sgmo_ClaimsSettlementDisclosureTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEvent" xlink:href="sgmo-20171231.xsd#Role_DisclosureSubsequentEvent" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEvent">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:href="sgmo-20171231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ContingentConsiderationPolicyTextBlock" xlink:type="locator" xlink:label="sgmo_ContingentConsiderationPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InProcessResearchAndDevelopmentPolicy" xlink:type="locator" xlink:label="us-gaap_InProcessResearchAndDevelopmentPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" xlink:type="locator" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UseOfEstimates" xlink:type="locator" xlink:label="us-gaap_UseOfEstimates" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:type="locator" xlink:label="us-gaap_MarketableSecuritiesPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsPolicy" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsPolicy" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:type="locator" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BusinessCombinationsPolicy" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueMeasurementPolicyPolicyTextBlock" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueRecognitionPolicyTextBlock" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_InProcessResearchAndDevelopmentPolicy" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="sgmo_ContingentConsiderationPolicyTextBlock" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" order="10350.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurementTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecuritiesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesTextBlock" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock" order="10230.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipmentTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingenciesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquityTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityAbstract" xlink:type="locator" xlink:label="us-gaap_EquityAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" xlink:type="locator" xlink:label="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureAccountsPayableAndAccruedLiabilitiesTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables" xlink:href="sgmo-20171231.xsd#Role_DisclosureQuarterlyFinancialDataUnauditedTables" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" xlink:type="locator" xlink:label="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_QuarterlyFinancialInformationDisclosureAbstract" xlink:to="us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" xlink:type="locator" xlink:label="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:type="locator" xlink:label="us-gaap_NumberOfOperatingSegments" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" xlink:type="locator" xlink:label="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskPercentage1" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskPercentage1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateDecreaseInRevenues" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" xlink:type="locator" xlink:label="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" xlink:type="locator" xlink:label="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProFormaMember" xlink:type="locator" xlink:label="us-gaap_ProFormaMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountingStandardsUpdate201409Member" xlink:type="locator" xlink:label="us-gaap_AccountingStandardsUpdate201409Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:type="locator" xlink:label="us-gaap_TypeOfAdoptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:type="locator" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SalesRevenueNetMember" xlink:type="locator" xlink:label="us-gaap_SalesRevenueNetMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskBenchmarkDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByBenchmarkAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CustomerConcentrationRiskMember" xlink:type="locator" xlink:label="us-gaap_CustomerConcentrationRiskMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskTypeDomain" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConcentrationRiskByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ConcentrationRiskByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BiogenIncMember" xlink:type="locator" xlink:label="sgmo_BiogenIncMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PfizerMember" xlink:type="locator" xlink:label="sgmo_PfizerMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationContractPerformancePeriodMember" xlink:type="locator" xlink:label="sgmo_CollaborationContractPerformancePeriodMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ChangeInAccountingEstimateByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:type="locator" xlink:label="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="locator" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ChangeInAccountingEstimateByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="us-gaap_ChangeInAccountingEstimateTypeDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="sgmo_CollaborationContractPerformancePeriodMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_PfizerMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BiogenIncMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByTypeAxis" xlink:to="us-gaap_ConcentrationRiskTypeDomain" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskTypeDomain" xlink:to="us-gaap_CustomerConcentrationRiskMember" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_ConcentrationRiskByBenchmarkAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="us-gaap_ConcentrationRiskBenchmarkDomain" order="10660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="us-gaap_SalesRevenueNetMember" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_TypeOfAdoptionMember" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TypeOfAdoptionMember" xlink:to="us-gaap_AccountingStandardsUpdate201409Member" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.12" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ProFormaMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesTable" xlink:to="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment" order="11150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" order="11200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic" order="11270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ChangeInAccountingEstimateDecreaseInRevenues" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ConcentrationRiskPercentage1" order="11380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired" order="11550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="11600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NumberOfOperatingSegments" order="11790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1" order="11840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="11890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel3Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel3Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel2Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueInputsLevel1Member" xlink:type="locator" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementsRecurringMember" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementsRecurringMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="locator" xlink:label="us-gaap_FairValueMeasurementFrequencyDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="locator" xlink:label="us-gaap_FairValueByMeasurementFrequencyAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="locator" xlink:label="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" order="10040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByMeasurementFrequencyAxis" order="10050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="us-gaap_FairValueMeasurementFrequencyDomain" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="us-gaap_FairValueMeasurementsRecurringMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10050.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" order="10050.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel3Member" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10050.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" order="10720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtSecurities" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="11290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureFairValueMeasurementAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:type="locator" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_AssetsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AssetsAmortizedCost" xlink:type="locator" xlink:label="sgmo_AssetsAmortizedCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="locator" xlink:label="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableforsaleSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_AvailableforsaleSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:type="locator" xlink:label="us-gaap_InformationByCategoryOfDebtSecurityAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CashEquivalentsMember" xlink:type="locator" xlink:label="us-gaap_CashEquivalentsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommercialPaperMember" xlink:type="locator" xlink:label="us-gaap_CommercialPaperMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MoneyMarketFundsMember" xlink:type="locator" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeCategorizationMember" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeCategorizationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentTypeAxis" xlink:type="locator" xlink:label="us-gaap_InvestmentTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:type="locator" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:type="locator" xlink:label="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis" xlink:to="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_MajorTypesOfDebtAndEquitySecuritiesDomain" xlink:to="us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InvestmentTypeAxis" order="10090.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeAxis" xlink:to="us-gaap_InvestmentTypeCategorizationMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_MoneyMarketFundsMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CommercialPaperMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentTypeCategorizationMember" xlink:to="us-gaap_CashEquivalentsMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_InformationByCategoryOfDebtSecurityAxis" order="10090.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InformationByCategoryOfDebtSecurityAxis" xlink:to="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherThanTemporaryImpairmentCreditLossesRecognizedInEarningsCategoriesOfInvestmentsDomain" xlink:to="us-gaap_AvailableforsaleSecuritiesMember" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesTable" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" order="11000.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedGainBeforeTax" order="11330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_CashAndCashEquivalentsAccumulatedGrossUnrealizedLossBeforeTax" order="11650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAmortizedCost" order="12320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax" order="12520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax" order="12720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AssetsFairValueDisclosure" order="12920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMarketableSecuritiesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OtherThanTemporarilyImpairedInvestment" xlink:type="locator" xlink:label="sgmo_OtherThanTemporarilyImpairedInvestment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" xlink:type="locator" xlink:label="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" xlink:type="locator" xlink:label="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="locator" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="sgmo_OtherThanTemporarilyImpairedInvestment" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:type="locator" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" xlink:type="locator" xlink:label="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" order="10550.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:type="locator" xlink:label="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:type="locator" xlink:label="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis" xlink:to="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityBasedArrangementsIndividualContractsTypeOfDeferredCompensationDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_EmployeeStockPurchasePlanMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" order="10630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:type="locator" xlink:label="us-gaap_RevenueFromRelatedParties" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" xlink:type="locator" xlink:label="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfAdditionalGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfAdditionalGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfInitialGeneTargets" xlink:type="locator" xlink:label="sgmo_NumberOfInitialGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateNumberOfGeneTargets" xlink:type="locator" xlink:label="sgmo_AggregateNumberOfGeneTargets" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfResearchProgram" xlink:type="locator" xlink:label="sgmo_NumberOfResearchProgram" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRevenue" xlink:type="locator" xlink:label="us-gaap_DeferredRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentsReceived" xlink:type="locator" xlink:label="sgmo_MilestonePaymentsReceived" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" xlink:type="locator" xlink:label="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CNineORFSevenTwoMember" xlink:type="locator" xlink:label="sgmo_CNineORFSevenTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PfizerMember" xlink:type="locator" xlink:label="sgmo_PfizerMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OtherProductsMember" xlink:type="locator" xlink:label="sgmo_OtherProductsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SBFiveTwoFiveMember" xlink:type="locator" xlink:label="sgmo_SBFiveTwoFiveMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ProductOrServiceAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_SBFiveTwoFiveMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_OtherProductsMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_PfizerMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_CNineORFSevenTwoMember" order="10820.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10920.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="11440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="11450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved" order="11470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive" order="11490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentsReceived" order="11570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement" order="11590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="11660.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_DeferredRevenue" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicenseAndServicesRevenue" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfResearchProgram" order="11860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AggregateNumberOfGeneTargets" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfInitialGeneTargets" order="12270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfGeneTargets" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_NumberOfAdditionalGeneTargets" order="12310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized" order="12400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenueFromRelatedParties" order="12470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ContractsRevenue" xlink:type="locator" xlink:label="us-gaap_ContractsRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServiceRevenueUnderCollaborationAgreement" xlink:type="locator" xlink:label="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAndServicesRevenue" xlink:type="locator" xlink:label="us-gaap_LicenseAndServicesRevenue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RevenuesAbstract" xlink:type="locator" xlink:label="us-gaap_RevenuesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShireAgMember" xlink:type="locator" xlink:label="sgmo_ShireAgMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BioverativIncMember" xlink:type="locator" xlink:label="sgmo_BioverativIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_BioverativIncMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_ShireAgMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10400.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RevenuesAbstract" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicenseAndServicesRevenue" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveTerseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_RoyaltyRevenue" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="sgmo_ResearchServiceRevenueUnderCollaborationAgreement" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_LicensesRevenue" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RevenuesAbstract" xlink:to="us-gaap_ContractsRevenue" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AdditionalMilestoneReceivableUnderAgreement" xlink:type="locator" xlink:label="sgmo_AdditionalMilestoneReceivableUnderAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ReducedRoyaltyRate" xlink:type="locator" xlink:label="sgmo_ReducedRoyaltyRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFee" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFee" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchServicesPeriod" xlink:type="locator" xlink:label="sgmo_ResearchServicesPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UpfrontLicenseFeesMember" xlink:type="locator" xlink:label="sgmo_UpfrontLicenseFeesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SigmaAldrichCorporationMember" xlink:type="locator" xlink:label="sgmo_SigmaAldrichCorporationMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_SigmaAldrichCorporationMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_UpfrontLicenseFeesMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ResearchServicesPeriod" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_UpfrontLicenseFee" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_ReducedRoyaltyRate" order="10640.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AdditionalMilestoneReceivableUnderAgreement" order="10680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicensesRevenue" xlink:type="locator" xlink:label="us-gaap_LicensesRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" xlink:type="locator" xlink:label="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FeeDue" xlink:type="locator" xlink:label="sgmo_FeeDue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AnnualFeesRelatedToAgreement" xlink:type="locator" xlink:label="sgmo_AnnualFeesRelatedToAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" xlink:type="locator" xlink:label="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" xlink:type="locator" xlink:label="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RoyaltyRevenue" xlink:type="locator" xlink:label="us-gaap_RoyaltyRevenue" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OneTimeLicenseFeeEarned" xlink:type="locator" xlink:label="sgmo_OneTimeLicenseFeeEarned" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_InitialResearchTermOfAgreement" xlink:type="locator" xlink:label="sgmo_InitialResearchTermOfAgreement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LicenseAgreementTermsMember" xlink:type="locator" xlink:label="us-gaap_LicenseAgreementTermsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DowAgroSciencesMember" xlink:type="locator" xlink:label="sgmo_DowAgroSciencesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentAbstract" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentAbstract" xlink:to="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_DowAgroSciencesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="us-gaap_LicenseAgreementTermsMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfResearchAndDevelopmentArrangementContractToPerformForOthersTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_InitialResearchTermOfAgreement" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_OneTimeLicenseFeeEarned" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_RoyaltyRevenue" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_AnnualFeesRelatedToAgreement" order="10840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_FeeDue" order="10880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems" xlink:to="us-gaap_LicensesRevenue" order="10950.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureAcquisitionOfCeregeneAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_GoodwillImpairmentLoss" xlink:type="locator" xlink:label="us-gaap_GoodwillImpairmentLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Goodwill" xlink:type="locator" xlink:label="us-gaap_Goodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationContingentConsiderationLiability" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationContingentConsiderationLiability" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" xlink:type="locator" xlink:label="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionLineItems" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CeregeneIncMember" xlink:type="locator" xlink:label="sgmo_CeregeneIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAcquireeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessAcquisitionAxis" xlink:type="locator" xlink:label="us-gaap_BusinessAcquisitionAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BusinessCombinationsAbstract" xlink:type="locator" xlink:label="us-gaap_BusinessCombinationsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessCombinationsAbstract" xlink:to="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAxis" xlink:to="us-gaap_BusinessAcquisitionAcquireeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="sgmo_CeregeneIncMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfBusinessAcquisitionsByAcquisitionTable" xlink:to="us-gaap_BusinessAcquisitionLineItems" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_BusinessCombinationContingentConsiderationLiability" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_Goodwill" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_BusinessAcquisitionLineItems" xlink:to="us-gaap_GoodwillImpairmentLoss" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="locator" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:type="locator" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FurnitureAndFixturesMember" xlink:type="locator" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquipmentMember" xlink:type="locator" xlink:label="us-gaap_EquipmentMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:type="locator" xlink:label="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_PropertyPlantAndEquipmentUsefulLifeAndValuesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" order="10390.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosurePropertyAndEquipmentAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseCostsCapitalized" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:type="locator" xlink:label="us-gaap_ConstructionInProgressMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RichmondBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_RichmondBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_RichmondBuildToSuitLeaseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_DepreciationDepletionAndAmortization" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="sgmo_BuildToSuitLeaseCostsCapitalized" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingenciesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_LicenseCommitments" xlink:type="locator" xlink:label="sgmo_LicenseCommitments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentDueInNextTwelveMonths" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentDueInNextTwelveMonths" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:type="locator" xlink:label="us-gaap_LeaseAndRentalExpense" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NumberOfBuiltToSuitLeaseProperties" xlink:type="locator" xlink:label="sgmo_NumberOfBuiltToSuitLeaseProperties" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeasePropertyLeased" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeasePropertyLeased" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LandSubjectToGroundLeases" xlink:type="locator" xlink:label="us-gaap_LandSubjectToGroundLeases" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesLineItems" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IntellectualPropertyMember" xlink:type="locator" xlink:label="us-gaap_IntellectualPropertyMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:type="locator" xlink:label="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TenantImprovementsMember" xlink:type="locator" xlink:label="sgmo_TenantImprovementsMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsDomain" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OtherCommitmentsAxis" xlink:type="locator" xlink:label="us-gaap_OtherCommitmentsAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" xlink:type="locator" xlink:label="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RichmondBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_RichmondBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ResearchAndOfficeSpaceMember" xlink:type="locator" xlink:label="sgmo_ResearchAndOfficeSpaceMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseTwoMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PropertySubjectToOperatingLeaseOneMember" xlink:type="locator" xlink:label="sgmo_PropertySubjectToOperatingLeaseOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:type="locator" xlink:label="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommitmentsAndContingenciesTable" xlink:type="locator" xlink:label="sgmo_CommitmentsAndContingenciesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="sgmo_CommitmentsAndContingenciesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="sgmo_PropertySubjectToOperatingLeaseOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseDomain" xlink:to="sgmo_PropertySubjectToOperatingLeaseTwoMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="sgmo_ResearchAndOfficeSpaceMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_RichmondBuildToSuitLeaseMember" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember" order="10420.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_OtherCommitmentsAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsAxis" xlink:to="us-gaap_OtherCommitmentsDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherCommitmentsDomain" xlink:to="sgmo_TenantImprovementsMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis" xlink:to="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FiniteLivedIntangibleAssetsMajorClassNameDomain" xlink:to="us-gaap_IntellectualPropertyMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesTable" xlink:to="sgmo_CommitmentsAndContingenciesLineItems" order="10580.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LandSubjectToGroundLeases" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_BuildToSuitLeasePropertyLeased" order="10890.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_NumberOfBuiltToSuitLeaseProperties" order="11130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_LeaseAndRentalExpense" order="11190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="us-gaap_OtherCommitmentDueInNextTwelveMonths" order="11280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_CommitmentsAndContingenciesLineItems" xlink:to="sgmo_LicenseCommitments" order="11320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="locator" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquityAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="locator" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" xlink:type="locator" xlink:label="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanPurchasePeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanPurchasePeriod" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PurchasePlanOfferingPeriod" xlink:type="locator" xlink:label="sgmo_PurchasePlanOfferingPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:type="locator" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockExchangeRatio" xlink:type="locator" xlink:label="sgmo_CommonStockExchangeRatio" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SpecifiedStockholderOwnershipPercentage" xlink:type="locator" xlink:label="sgmo_SpecifiedStockholderOwnershipPercentage" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PaymentsForCommissions" xlink:type="locator" xlink:label="us-gaap_PaymentsForCommissions" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" xlink:type="locator" xlink:label="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_NetProceedsFromIssuancePublicOffering" xlink:type="locator" xlink:label="sgmo_NetProceedsFromIssuancePublicOffering" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:type="locator" xlink:label="us-gaap_SharesIssuedPricePerShare" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:type="locator" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationAwardTrancheOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingDomain" xlink:type="locator" xlink:label="us-gaap_VestingDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_VestingAxis" xlink:type="locator" xlink:label="us-gaap_VestingAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_EmployeeStockPurchasePlanMember" xlink:type="locator" xlink:label="sgmo_EmployeeStockPurchasePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandFourStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandFourStockIncentivePlanMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TwoThousandThirteenStockIncentivePlanMember" xlink:type="locator" xlink:label="sgmo_TwoThousandThirteenStockIncentivePlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameDomain" xlink:type="locator" xlink:label="us-gaap_PlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PlanNameAxis" xlink:type="locator" xlink:label="us-gaap_PlanNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:type="locator" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AwardTypeAxis" xlink:type="locator" xlink:label="us-gaap_AwardTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AtTheMarketOfferingAgreementMember" xlink:type="locator" xlink:label="sgmo_AtTheMarketOfferingAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CommonStockMember" xlink:type="locator" xlink:label="us-gaap_CommonStockMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EquityComponentDomain" xlink:type="locator" xlink:label="us-gaap_EquityComponentDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:type="locator" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_StatementEquityComponentsAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="sgmo_AtTheMarketOfferingAgreementMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_AwardTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_RangeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10520.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10540.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" order="10600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandThirteenStockIncentivePlanMember" order="10620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_TwoThousandFourStockIncentivePlanMember" order="10760.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember" order="10900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain" xlink:to="sgmo_EmployeeStockPurchasePlanMember" order="10960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_VestingAxis" order="10030.10" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingAxis" xlink:to="us-gaap_VestingDomain" order="11120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheOneMember" order="11140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheTwoMember" order="11160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_VestingDomain" xlink:to="us-gaap_ShareBasedCompensationAwardTrancheThreeMember" order="11180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" order="11240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="11620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" order="11630.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" order="11680.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/positiveLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" order="11700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_NetProceedsFromIssuancePublicOffering" order="11720.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance" order="11770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsForCommissions" order="11880.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" order="11930.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11970.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_SpecifiedStockholderOwnershipPercentage" order="12010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder" order="12050.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights" order="12130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" order="12170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" order="12210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm" order="12250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance" order="12290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance" order="12370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_CommonStockExchangeRatio" order="12440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" order="12480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" order="12600.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanOfferingPeriod" order="12730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_PurchasePlanPurchasePeriod" order="12770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation" order="12840.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" order="12900.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="12990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="13030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" order="13070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="13220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" order="13340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment" order="13460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested" order="13620.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" order="13810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation" order="13870.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" order="13960.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" order="10210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_li0l2" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" order="10510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" order="10910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_li0l2" order="11110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" order="11210.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" order="11310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" order="11410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" order="11510.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" order="11610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" order="11710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" order="11810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" order="11910.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTenMember" xlink:type="locator" xlink:label="sgmo_RangeTenMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeNineMember" xlink:type="locator" xlink:label="sgmo_RangeNineMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeEightMember" xlink:type="locator" xlink:label="sgmo_RangeEightMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSevenMember" xlink:type="locator" xlink:label="sgmo_RangeSevenMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeSixMember" xlink:type="locator" xlink:label="sgmo_RangeSixMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFiveMember" xlink:type="locator" xlink:label="sgmo_RangeFiveMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeFourMember" xlink:type="locator" xlink:label="sgmo_RangeFourMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeThreeMember" xlink:type="locator" xlink:label="sgmo_RangeThreeMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeTwoMember" xlink:type="locator" xlink:label="sgmo_RangeTwoMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_RangeOneMember" xlink:type="locator" xlink:label="sgmo_RangeOneMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeOneMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTwoMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeThreeMember" order="10120.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFourMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeFiveMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSixMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeSevenMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeEightMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeNineMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeDomain" xlink:to="sgmo_RangeTenMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTable" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" order="10280.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions" order="11010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2" order="11370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions" order="11730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems" xlink:to="us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1" order="12090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" xlink:type="locator" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="locator" xlink:label="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="locator" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_li0l2" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_CurrentFederalTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalTaxExpenseBenefit" order="10310.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentStateAndLocalTaxExpenseBenefit" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefit" order="10430.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalIncomeTaxExpenseBenefit" order="10610.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" order="10670.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" xlink:type="locator" xlink:label="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" xlink:type="locator" xlink:label="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" xlink:type="locator" xlink:label="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLossCarryforwardsExpirationYear" xlink:type="locator" xlink:label="sgmo_OperatingLossCarryforwardsExpirationYear" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="locator" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesLineItems" xlink:type="locator" xlink:label="sgmo_IncomeTaxesLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioPlanMember" xlink:type="locator" xlink:label="us-gaap_ScenarioPlanMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:type="locator" xlink:label="us-gaap_ScenarioUnspecifiedDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:type="locator" xlink:label="us-gaap_StatementScenarioAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DomesticCountryMember" xlink:type="locator" xlink:label="us-gaap_DomesticCountryMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator" xlink:label="us-gaap_StateAndLocalJurisdictionMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxesTable" xlink:type="locator" xlink:label="sgmo_IncomeTaxesTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sgmo_IncomeTaxesTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_StatementScenarioAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_ScenarioUnspecifiedDomain" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScenarioUnspecifiedDomain" xlink:to="us-gaap_ScenarioPlanMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="us-gaap_RangeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesTable" xlink:to="sgmo_IncomeTaxesLineItems" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" order="10270.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" order="10470.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_OperatingLossCarryforwardsExpirationYear" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_FederalResearchTaxCreditCarryforwardExpirationYear" order="10830.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance" order="10990.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_IncomeTaxesLineItems" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" order="11040.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationOtherAdjustments" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationOtherAdjustments" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" xlink:type="locator" xlink:label="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="locator" xlink:label="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate" order="10200.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationTaxCreditsResearch" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" order="10380.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxReconciliationOtherAdjustments" order="10440.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10500.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesNoncurrent" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesNoncurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" xlink:type="locator" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LiabilitiesAbstract" xlink:type="locator" xlink:label="us-gaap_LiabilitiesAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNet" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsGross" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOther" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsDeferredIncome" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="locator" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AssetsAbstract" xlink:type="locator" xlink:label="us-gaap_AssetsAbstract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_AssetsAbstract" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" order="10290.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsDeferredIncome" order="10370.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsOther" order="10410.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsGross" order="10450.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNet" order="10530.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_LiabilitiesAbstract" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssets" order="10650.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNoncurrent" order="10690.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits_li0l2" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" xlink:type="locator" xlink:label="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:type="locator" xlink:label="us-gaap_UnrecognizedTaxBenefits" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" order="10090.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_UnrecognizedTaxBenefits_li0l2" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableAndOtherAccruedLiabilities" xlink:type="locator" xlink:label="us-gaap_AccountsPayableAndOtherAccruedLiabilities" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:type="locator" xlink:label="us-gaap_DeferredRentCreditCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AccruedResearchAndDevelopmentExpenses" xlink:type="locator" xlink:label="sgmo_AccruedResearchAndDevelopmentExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:type="locator" xlink:label="us-gaap_AccountsPayableCurrent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:type="locator" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableCurrent" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="sgmo_AccruedResearchAndDevelopmentExpenses" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_DeferredRentCreditCurrent" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndOtherAccruedLiabilities" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureEmployeeBenefitPlanAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanCostRecognized" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanCostRecognized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:type="locator" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch" order="10070.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount" order="10190.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanCostRecognized" order="10250.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:type="locator" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_NetIncomeLoss" xlink:type="locator" xlink:label="us-gaap_NetIncomeLoss" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingExpenses" xlink:type="locator" xlink:label="us-gaap_OperatingExpenses" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_Revenues" xlink:type="locator" xlink:label="us-gaap_Revenues" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:type="locator" xlink:label="us-gaap_SelectedQuarterlyFinancialInformationAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_Revenues" order="10010.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_OperatingExpenses" order="10170.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_NetIncomeLoss" order="10330.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SelectedQuarterlyFinancialInformationAbstract" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted" order="10490.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureBuildToSuitLeaseAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeaseCostsCapitalized" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeaseCostsCapitalized" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:type="locator" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_OperatingLeasesNumberOfExtensionOptions" xlink:type="locator" xlink:label="sgmo_OperatingLeasesNumberOfExtensionOptions" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" xlink:type="locator" xlink:label="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:type="locator" xlink:label="us-gaap_LeaseExpirationDate1" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BuildToSuitLeasePropertyLeased" xlink:type="locator" xlink:label="sgmo_BuildToSuitLeasePropertyLeased" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_OperatingLeasedAssetsLineItems" xlink:type="locator" xlink:label="us-gaap_OperatingLeasedAssetsLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_PointPinoleBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_PointPinoleBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_BuildingMember" xlink:type="locator" xlink:label="us-gaap_BuildingMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="locator" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_BrisbaneBuildToSuitLeaseMember" xlink:type="locator" xlink:label="sgmo_BrisbaneBuildToSuitLeaseMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:type="locator" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:type="locator" xlink:label="us-gaap_ScheduleOfOperatingLeasedAssetsTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LeasesOperatingAbstract" xlink:type="locator" xlink:label="us-gaap_LeasesOperatingAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesOperatingAbstract" xlink:to="us-gaap_ScheduleOfOperatingLeasedAssetsTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_LeaseArrangementTypeAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_BrisbaneBuildToSuitLeaseMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10260.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" order="10300.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_BuildingMember" order="10320.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeaseArrangementTypeDomain" xlink:to="sgmo_PointPinoleBuildToSuitLeaseMember" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfOperatingLeasedAssetsTable" xlink:to="us-gaap_OperatingLeasedAssetsLineItems" order="10700.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_BuildToSuitLeasePropertyLeased" order="10710.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LeaseExpirationDate1" order="10730.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract" order="10750.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_OperatingLeasesNumberOfExtensionOptions" order="10770.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm" order="10790.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="us-gaap_LettersOfCreditOutstandingAmount" order="10810.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeasedAssetsLineItems" xlink:to="sgmo_BuildToSuitLeaseCostsCapitalized" order="10860.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureClaimsSettlementAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail">
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator" xlink:label="us-gaap_IncomeTaxExpenseBenefit" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" xlink:type="locator" xlink:label="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ProceedsFromClaimsSettlement" xlink:type="locator" xlink:label="sgmo_ProceedsFromClaimsSettlement" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementLineItems" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementLineItems" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_DisgorgementSettlementMember" xlink:type="locator" xlink:label="sgmo_DisgorgementSettlementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusDomain" xlink:type="locator" xlink:label="us-gaap_LitigationStatusDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_LitigationStatusAxis" xlink:type="locator" xlink:label="us-gaap_LitigationStatusAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ScheduleOfClaimsSettlementTable" xlink:type="locator" xlink:label="sgmo_ScheduleOfClaimsSettlementTable" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ClaimsSettlementDisclosureAbstract" xlink:type="locator" xlink:label="sgmo_ClaimsSettlementDisclosureAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ClaimsSettlementDisclosureAbstract" xlink:to="sgmo_ScheduleOfClaimsSettlementTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ScheduleOfClaimsSettlementTable" xlink:to="us-gaap_LitigationStatusAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusAxis" xlink:to="us-gaap_LitigationStatusDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LitigationStatusDomain" xlink:to="sgmo_DisgorgementSettlementMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ScheduleOfClaimsSettlementTable" xlink:to="sgmo_ClaimsSettlementLineItems" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_ProceedsFromClaimsSettlement" order="10110.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax" order="10130.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="sgmo_ClaimsSettlementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" order="10150.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
  </presentationLink>
  <roleRef roleURI="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail" xlink:href="sgmo-20171231.xsd#Role_DisclosureSubsequentEventAdditionalInformationDetail" xlink:type="simple" />
  <presentationLink xlink:type="extended" xlink:role="http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail">
    <loc xlink:href="sgmo-20171231.xsd#sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" xlink:type="locator" xlink:label="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_MilestoneRevenueReceivable" xlink:type="locator" xlink:label="sgmo_MilestoneRevenueReceivable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventLineItems" xlink:type="locator" xlink:label="us-gaap_SubsequentEventLineItems" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventMember" xlink:type="locator" xlink:label="us-gaap_SubsequentEventMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_CollaborationAndLicenseAgreementMember" xlink:type="locator" xlink:label="sgmo_CollaborationAndLicenseAgreementMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:type="locator" xlink:label="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_KitePharmaIncMember" xlink:type="locator" xlink:label="sgmo_KitePharmaIncMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator" xlink:label="us-gaap_RepurchaseAgreementCounterpartyNameDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_CounterpartyNameAxis" xlink:type="locator" xlink:label="us-gaap_CounterpartyNameAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MinimumMember" xlink:type="locator" xlink:label="us-gaap_MinimumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_MaximumMember" xlink:type="locator" xlink:label="us-gaap_MaximumMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeMember" xlink:type="locator" xlink:label="us-gaap_RangeMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_RangeAxis" xlink:type="locator" xlink:label="us-gaap_RangeAxis" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" />
    <loc xlink:href="sgmo-20171231.xsd#sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" xlink:type="locator" xlink:label="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductsAndServicesDomain" xlink:type="locator" xlink:label="us-gaap_ProductsAndServicesDomain" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_ProductOrServiceAxis" xlink:type="locator" xlink:label="us-gaap_ProductOrServiceAxis" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventTable" xlink:type="locator" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:href="http://xbrl.fasb.org/us-gaap/2017/elts/us-gaap-2017-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:type="locator" xlink:label="us-gaap_SubsequentEventsAbstract" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventTable" order="10020.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ProductOrServiceAxis" order="10030.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductOrServiceAxis" xlink:to="us-gaap_ProductsAndServicesDomain" order="10060.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember" order="10080.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ProductsAndServicesDomain" xlink:to="sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember" order="10100.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_RangeAxis" order="10030.02" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeAxis" xlink:to="us-gaap_RangeMember" order="10140.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MaximumMember" order="10160.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RangeMember" xlink:to="us-gaap_MinimumMember" order="10180.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_CounterpartyNameAxis" order="10030.04" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CounterpartyNameAxis" xlink:to="us-gaap_RepurchaseAgreementCounterpartyNameDomain" order="10220.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RepurchaseAgreementCounterpartyNameDomain" xlink:to="sgmo_KitePharmaIncMember" order="10240.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" order="10030.06" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis" xlink:to="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" order="10340.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersTypeDomain" xlink:to="sgmo_CollaborationAndLicenseAgreementMember" order="10360.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTypeAxis" order="10030.08" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" order="10460.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" order="10480.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventLineItems" order="10560.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_MilestoneRevenueReceivable" order="10570.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived" order="10590.00" priority="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783843952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Feb. 15, 2018</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SGMO<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">SANGAMO THERAPEUTICS, INC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001001233<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">86,338,976<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 734,155,954<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word "Other".</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated) or (5) Smaller Reporting Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12b<br> -Subsection 1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate "Yes" or "No" if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Document and entity information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783783216">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,826<span></span>
</td>
<td class="nump">$ 22,061<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">193,482<span></span>
</td>
<td class="nump">120,474<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestReceivableCurrent', window );">Interest receivable</a></td>
<td class="nump">240<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">3,343<span></span>
</td>
<td class="nump">4,972<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">1,506<span></span>
</td>
<td class="nump">1,849<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">248,397<span></span>
</td>
<td class="nump">149,580<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesNoncurrent', window );">Marketable securities, non-current</a></td>
<td class="nump">1,012<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">31,066<span></span>
</td>
<td class="nump">6,557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">1,585<span></span>
</td>
<td class="nump">1,585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">4,681<span></span>
</td>
<td class="nump">169<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">286,741<span></span>
</td>
<td class="nump">157,891<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">11,035<span></span>
</td>
<td class="nump">6,261<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedEmployeeBenefitsCurrent', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">5,479<span></span>
</td>
<td class="nump">2,885<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueCurrent', window );">Deferred revenues</a></td>
<td class="nump">28,345<span></span>
</td>
<td class="nump">4,145<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">44,859<span></span>
</td>
<td class="nump">13,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenueNoncurrent', window );">Deferred revenues, non-current</a></td>
<td class="nump">29,244<span></span>
</td>
<td class="nump">4,460<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseObligations', window );">Build-to-suit lease obligation</a></td>
<td class="nump">24,738<span></span>
</td>
<td class="nump">3,945<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">98,841<span></span>
</td>
<td class="nump">21,696<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.01 par value; 160,000,000 shares authorized, 85,598,534 and 70,871,902 shares issued and outstanding at December 31, 2017 and December 31, 2016, respectively</a></td>
<td class="nump">856<span></span>
</td>
<td class="nump">709<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">682,809<span></span>
</td>
<td class="nump">576,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(495,479)<span></span>
</td>
<td class="num">(440,911)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income (loss)</a></td>
<td class="num">(286)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">187,900<span></span>
</td>
<td class="nump">136,195<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 286,741<span></span>
</td>
<td class="nump">$ 157,891<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit lease obligations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount due from customers or clients, within one year of the balance sheet date (or the normal operating cycle, whichever is longer), for goods or services (including trade receivables) that have been delivered or sold in the normal course of business, reduced to the estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedEmployeeBenefitsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations, excluding pension and other postretirement benefits, incurred through that date and payable for perquisites provided to employees pertaining to services received from them. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedEmployeeBenefitsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e681-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669686-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt and equity securities categorized neither as trading securities nor held-to-maturity securities and intended be sold or mature one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments in debt and equity securities which are categorized neither as held-to-maturity nor trading and which are intended to be sold or mature more than one year from the balance sheet date or operating cycle, if longer. Such securities are reported at fair value; unrealized gains (losses) related to Available-for-sale Securities are excluded from earnings and reported in a separate component of shareholders' equity (other comprehensive income), unless the Available-for-sale security is designated as a hedge or is determined to have had an other than temporary decline in fair value below its amortized cost basis. All or a portion of the unrealized holding gain (loss) of an Available-for-sale security that is designated as being hedged in a fair value hedge is recognized in earnings during the period of the hedge, as are other than temporary declines in fair value below the cost basis for investments in equity securities and debt securities that an entity intends to sell or it is more likely than not that it will be required to sell before the recovery of its amortized cost basis. Other than temporary declines in fair value below the cost basis for debt securities categorized as Available-for-sale that an entity does not intend to sell and for which it is not more likely than not that the entity will be required to sell before the recovery of its amortized cost basis are bifurcated into credit losses and losses related to all other factors. Other than temporary declines in fair value below cost basis related to credit losses are recognized in earnings, and losses related to all other factors are recognized in other comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26626-111562<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of consideration received or receivable as of the balance sheet date on potential earnings that were not recognized as revenue in conformity with GAAP, and which are expected to be recognized as such within one year or the normal operating cycle, if longer, including sales, license fees, and royalties, but excluding interest income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The noncurrent portion of deferred revenue amount as of balance sheet date. Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized, and is not expected to be recognized in the next twelve months. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(c).Q3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3(b).Q2)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestReceivableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of current interest earned but not received. Also called accrued interest or accrued interest receivable. For classified balance sheets, represents the current amount receivable, that is amounts expected to be collected within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.8)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestReceivableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6778208544">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement Of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">160,000,000<span></span>
</td>
<td class="nump">160,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">85,598,534<span></span>
</td>
<td class="nump">70,871,902<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">85,598,534<span></span>
</td>
<td class="nump">70,871,902<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782351232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAgreements', window );">Collaboration agreements</a></td>
<td class="nump">$ 35,960<span></span>
</td>
<td class="nump">$ 18,881<span></span>
</td>
<td class="nump">$ 37,844<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromGrants', window );">Research grants</a></td>
<td class="nump">607<span></span>
</td>
<td class="nump">508<span></span>
</td>
<td class="nump">1,695<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Total revenues</a></td>
<td class="nump">36,567<span></span>
</td>
<td class="nump">19,389<span></span>
</td>
<td class="nump">39,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">65,728<span></span>
</td>
<td class="nump">65,618<span></span>
</td>
<td class="nump">67,198<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">27,200<span></span>
</td>
<td class="nump">26,330<span></span>
</td>
<td class="nump">19,197<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">92,928<span></span>
</td>
<td class="nump">91,948<span></span>
</td>
<td class="nump">86,395<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(56,361)<span></span>
</td>
<td class="num">(72,559)<span></span>
</td>
<td class="num">(46,856)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestAndOtherIncome', window );">Interest and other income, net</a></td>
<td class="nump">1,793<span></span>
</td>
<td class="nump">887<span></span>
</td>
<td class="nump">431<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(54,568)<span></span>
</td>
<td class="num">(71,672)<span></span>
</td>
<td class="num">(46,425)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14<span></span>
</td>
<td class="nump">5,722<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="num">$ (71,658)<span></span>
</td>
<td class="num">$ (40,703)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Basic and diluted net loss per share</a></td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Shares used in computing basic and diluted net loss per share</a></td>
<td class="nump">78,084<span></span>
</td>
<td class="nump">70,553<span></span>
</td>
<td class="nump">69,757<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in collaboration agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=68072869&amp;loc=d3e41242-110953<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestAndOtherIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of interest income and other income recognized during the period. Included in this element is interest derived from investments in debt securities, cash and cash equivalents, and other investments which reflect the time value of money or transactions in which the payments are for the use or forbearance of money and other income from ancillary business-related activities (that is, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestAndOtherIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from non-repayable sum of money awarded to an entity to carry out a specific purpose as provided in grant agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6783836288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement Of Income And Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,091)<span></span>
</td>
<td class="num">$ (12,354)<span></span>
</td>
<td class="num">$ (12,491)<span></span>
</td>
<td class="num">$ (16,632)<span></span>
</td>
<td class="num">$ (9,624)<span></span>
</td>
<td class="num">$ (18,965)<span></span>
</td>
<td class="num">$ (26,575)<span></span>
</td>
<td class="num">$ (16,494)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="num">$ (71,658)<span></span>
</td>
<td class="num">$ (40,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Change in unrealized gain (loss) on available-for-sale securities, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306)<span></span>
</td>
<td class="nump">20<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (54,874)<span></span>
</td>
<td class="num">$ (71,638)<span></span>
</td>
<td class="num">$ (40,678)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784954768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Stockholders' Equity - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income/ (Loss) [Member]</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning Balances at Dec. 31, 2014</a></td>
<td class="nump">$ 206,633<span></span>
</td>
<td class="nump">$ 690<span></span>
</td>
<td class="nump">$ 534,518<span></span>
</td>
<td class="num">$ (328,550)<span></span>
</td>
<td class="num">$ (25)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Beginning Balances, shares at Dec. 31, 2014</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">69,062,394<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">4,348<span></span>
</td>
<td class="nump">$ 12<span></span>
</td>
<td class="nump">4,336<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,164,033<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 911<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">910<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="nump">128,181<span></span>
</td>
<td class="nump">128,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 11,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,730<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax', window );">Claims settlement under Section 16(b), net of tax benefit</a></td>
<td class="nump">9,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(40,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(40,703)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(40,678)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2015</a></td>
<td class="nump">192,439<span></span>
</td>
<td class="nump">$ 703<span></span>
</td>
<td class="nump">560,989<span></span>
</td>
<td class="num">(369,253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances, shares at Dec. 31, 2015</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">70,354,608<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="num">(481)<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="num">(484)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 3<span></span>
</td>
<td class="nump">815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="nump">202,711<span></span>
</td>
<td class="nump">202,711<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">$ 15,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,057<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="nump">20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(71,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(71,658)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(71,638)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2016</a></td>
<td class="nump">$ 136,195<span></span>
</td>
<td class="nump">$ 709<span></span>
</td>
<td class="nump">576,377<span></span>
</td>
<td class="num">(440,911)<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances, shares at Dec. 31, 2016</a></td>
<td class="nump">70,871,902<span></span>
</td>
<td class="nump">70,871,902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax</a></td>
<td class="nump">$ 15,099<span></span>
</td>
<td class="nump">$ 21<span></span>
</td>
<td class="nump">15,078<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock upon exercise of stock options and in connection with restricted stock units, net of tax, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,101,489<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of common stock under employee stock purchase plan</a></td>
<td class="nump">$ 818<span></span>
</td>
<td class="nump">$ 2<span></span>
</td>
<td class="nump">816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="nump">253,994<span></span>
</td>
<td class="nump">253,994<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock under public offering, net of issuance costs</a></td>
<td class="nump">$ 81,573<span></span>
</td>
<td class="nump">$ 124<span></span>
</td>
<td class="nump">81,449<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock under public offering, net of issuance costs, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,371,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,089<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net unrealized gain (loss) on marketable securities, net of tax</a></td>
<td class="num">(306)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(54,568)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">(54,874)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending Balances at Dec. 31, 2017</a></td>
<td class="nump">$ 187,900<span></span>
</td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 682,809<span></span>
</td>
<td class="num">$ (495,479)<span></span>
</td>
<td class="num">$ (286)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ending Balances, shares at Dec. 31, 2017</a></td>
<td class="nump">85,598,534<span></span>
</td>
<td class="nump">85,598,534<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement recognized as additional paid-in capital, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11149-113907<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96864182&amp;loc=d3e11178-113907<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e557-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=84228862&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of any shares forfeited. Shares issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock (or other type of equity) issued during the period as a result of any equity-based compensation plan other than an employee stock ownership plan (ESOP), net of stock value of such awards forfeited. Stock issued could result from the issuance of restricted stock, the exercise of stock options, stock issued under employee stock purchase plans, and/or other employee benefit plans.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AdditionalPaidInCapitalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_RetainedEarningsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784694768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Condensed Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract', window );"><strong>Operating Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="num">$ (71,658)<span></span>
</td>
<td class="num">$ (40,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash provided by (used in) operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">1,498<span></span>
</td>
<td class="nump">997<span></span>
</td>
<td class="nump">988<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premium (discount) on marketable securities</a></td>
<td class="num">(673)<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="nump">827<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property and equipment</a></td>
<td class="nump">12<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,089<span></span>
</td>
<td class="nump">15,057<span></span>
</td>
<td class="nump">11,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent consideration liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,800)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible impairment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,870<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(14)<span></span>
</td>
<td class="num">(5,722)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherNoncashIncomeExpense', window );">Other</a></td>
<td class="nump">80<span></span>
</td>
<td class="nump">99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet', window );">Interest receivable</a></td>
<td class="num">(16)<span></span>
</td>
<td class="nump">83<span></span>
</td>
<td class="nump">116<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">1,629<span></span>
</td>
<td class="num">(2,144)<span></span>
</td>
<td class="nump">7,847<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="num">(669)<span></span>
</td>
<td class="num">(1,112)<span></span>
</td>
<td class="nump">376<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">3,219<span></span>
</td>
<td class="num">(2,335)<span></span>
</td>
<td class="num">(764)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities', window );">Accrued compensation and employee benefits</a></td>
<td class="nump">2,594<span></span>
</td>
<td class="nump">137<span></span>
</td>
<td class="num">(105)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredRevenue', window );">Deferred revenues</a></td>
<td class="nump">48,984<span></span>
</td>
<td class="num">(5,214)<span></span>
</td>
<td class="num">(8,380)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations', window );">Net cash provided by (used in) operating activities</a></td>
<td class="nump">11,179<span></span>
</td>
<td class="num">(65,883)<span></span>
</td>
<td class="num">(33,720)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract', window );"><strong>Investing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(252,328)<span></span>
</td>
<td class="num">(218,640)<span></span>
</td>
<td class="num">(257,988)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">178,675<span></span>
</td>
<td class="nump">237,497<span></span>
</td>
<td class="nump">337,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(3,751)<span></span>
</td>
<td class="num">(732)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForLeasingCosts', window );">Lease commitments</a></td>
<td class="num">(3,500)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired', window );">Acquisition of Ceregene, Inc. net of cash received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,411)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations', window );">Net cash (used in) provided by investing activities</a></td>
<td class="num">(80,904)<span></span>
</td>
<td class="nump">18,125<span></span>
</td>
<td class="nump">77,462<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract', window );"><strong>Financing Activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Proceeds from public offering of common stock, net of issuance costs</a></td>
<td class="nump">81,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Taxes paid related to net share settlement of equity awards</a></td>
<td class="num">(654)<span></span>
</td>
<td class="num">(776)<span></span>
</td>
<td class="num">(1,546)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">16,571<span></span>
</td>
<td class="nump">1,113<span></span>
</td>
<td class="nump">6,804<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromClaimsSettlement', window );">Claims settlement under Section 16(b)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,452<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations', window );">Net cash provided by financing activities</a></td>
<td class="nump">97,490<span></span>
</td>
<td class="nump">337<span></span>
</td>
<td class="nump">19,710<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">27,765<span></span>
</td>
<td class="num">(47,421)<span></span>
</td>
<td class="nump">63,452<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, beginning of period</a></td>
<td class="nump">22,061<span></span>
</td>
<td class="nump">69,482<span></span>
</td>
<td class="nump">6,030<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents, end of period</a></td>
<td class="nump">49,826<span></span>
</td>
<td class="nump">22,061<span></span>
</td>
<td class="nump">$ 69,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember', window );">Property and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment/build-to-suit leases included in accrued liabilities and obligation</a></td>
<td class="nump">1,214<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember', window );">Build-to-Suit Leases [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosure of noncash investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Property and equipment/build-to-suit leases included in accrued liabilities and obligation</a></td>
<td class="nump">$ 20,793<span></span>
</td>
<td class="nump">$ 3,876<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromClaimsSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from claims settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromClaimsSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalents. Cash and cash equivalents are the amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Includes effect from exchange rate changes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount due from borrowers for interest payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedInterestReceivableNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period, excluding the portion taken into income, in the liability reflecting revenue yet to be earned for which cash or other forms of consideration was received or recorded as a receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInEmployeeRelatedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of financing activities, excluding discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) of investing activities, excluding discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 26<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3574-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, excluding discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3521-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncashIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncashIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForLeasingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for costs that are essential to originate the lease and would not otherwise have been incurred without the lease agreement. Amount includes, but is not limited to, cash outflows to evaluate the lessee's credit condition, guarantees, and collateral and cash outflows for costs incurred in negotiating, processing, and executing the lease agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForLeasingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of a business, net of the cash acquired from the purchase.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireBusinessesNetOfCashAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash outflow for purchase of trading, available-for-sale securities and held-to-maturity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities  (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26853-111562<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_PropertyAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774670832">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock', window );">Organization and Summary of Significant Accounting Policies</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 1 &#8211; ORGANIZATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Overview</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo Therapeutics, Inc. was incorporated in the State of Delaware on June&#160;22, 1995 and changed its name from Sangamo Biosciences, Inc. in January 2017 (the Company or Sangamo).&nbsp;&nbsp;Sangamo is focused on the research, development and commercialization of novel therapeutic strategies for unmet medical needs. Sangamo&#8217;s genome editing and gene regulation technology platform is enabled by the engineering of a class of transcription factors known as zinc finger DNA-binding proteins (ZFPs). Potential applications of Sangamo&#8217;s technology include development of human therapeutics, plant agriculture and enhancement of pharmaceutical protein production. Sangamo will require additional financial resources to complete the development and commercialization of its products including ZFP Therapeutics. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo is currently working on a number of long-term development projects that will involve experimental technology. The projects may require several years and substantial expenditures to complete and ultimately may be unsuccessful. The Company plans to finance operations with available cash resources, collaborations and strategic partnerships funds, research grants and from the issuance of equity or debt securities. Sangamo believes that its available cash, cash equivalents and investments as of December&#160;31, 2017, along with expected revenues from collaborations, strategic partnerships and research grants, will be adequate to fund its operations at least through the next twelve months from the date the financial statements are issued. Sangamo will need to raise substantial additional capital to fund subsequent operations and complete the development and commercialization of its products. Additional capital may not be available on terms acceptable to the Company, or at all. If adequate funds are not available, or if the terms of potential funding sources are unfavorable, the Company&#8217;s business and ability to develop its technology and ZFP Therapeutic products would be harmed. Furthermore, any sales of additional equity securities may result in dilution to the Company&#8217;s stockholders, and any debt financing may include covenants that restrict the Company&#8217;s business. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly-owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company accounts for acquisitions in accordance with Accounting Standards Codification (ASC) Topic 805, <font style="font-style:italic;">Business Combinations</font> (ASC Topic 805). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. </p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts.&nbsp;&nbsp;</p>
<p style="margin-top:8pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, or TPE, if available and VSOE is not available; or the best estimate of selling price, or ESP, if neither VSOE nor TPE is available; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG, or Shire, in January 2012, Biogen MA Inc., or Biogen, in January 2014, and Pfizer Inc., or Pfizer, in May and December of 2017, were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received but not earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of the Company&#8217;s total revenue. During 2016 revenue related to Bioverativ, DAS and Shire represented 46%, 26%, and 17%, respectively, of total revenue.&nbsp;&nbsp;During 2015 revenue related to Shire and Biogen represented 40% and 35%, respectively, of total revenues. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&#8217;s testing processes and procedures as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (RSUs) and employee stock purchases related to the Employee Stock Purchase Plan (ESPP), based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company adopted Accounting Standards Update (ASU) 2016-09 and accounts for forfeitures in the period they occur. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indefinite-Lived Intangible Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As part of the Ceregene acquisition the Company recognized indefinite-lived intangible assets for in-process research and development and goodwill as further discussed below. ASC 350 and related updates require companies to test indefinite-lived intangible assets for impairment annually, and more frequently if indicators of impairment exist. ASC 350 includes an optional qualitative assessment for testing indefinite-lived intangible assets for impairment that permits companies to assess whether it is more likely than not (i.e., a likelihood of greater than 50%) that an indefinite-lived intangible asset is impaired. If a company concludes based on the qualitative assessment that it is not more likely than not that the fair value of an indefinite-lived intangible asset or, in the case of goodwill, that the fair value of the related reporting unit, is less than carrying value, it would not have to determine the asset&#8217;s or reporting unit&#8217;s fair value, as applicable.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets related to in-process research and development costs, or IPR&amp;D, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company did not believe the programs have an alternative future use for itself or other market participants. Accordingly, the Company recognized a $1.9 million impairment charge related to these assets during the year ended December 31, 2015, which was recognized as research and development (R&amp;D) in the accompanying consolidated statements of operations.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate an impairment of goodwill has occurred. During the fourth quarter of 2017, the Company performed an assessment of the qualitative factors affecting the fair value of its reporting unit and concluded that it was not more likely than not that the fair value of its reporting unit was less than carrying value and that, as a result, it is not more likely than not that goodwill is impaired. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the merger agreement with Ceregene, the Company is required to make contingent earn-out payments if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. These earn-out payments will become payable in the period they are earned. In accordance with ASC Topic 805, the Company determined the fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;D assets acquired from Ceregene.</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options and restricted stock units, which are all anti-dilutive. All stock options and restricted stock units outstanding were excluded from the calculation of diluted net loss per share for all periods presented. Stock options and restricted stock units outstanding at the end of 2017, 2016 and 2015 were 8,367,628, 9,578,322, and 9,008,185, respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2017 and 2016, all of the Company&#8217;s assets were maintained in the U.S. For the years ended December&#160;31, 2017, 2016 and 2015, substantially all the Company&#8217;s revenues and operating expenses were generated and incurred in the U.S. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2016 the Financial Accounting Standards Board (FASB) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&#160;Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period.&nbsp;&nbsp;The Company adopted the ASU in the first quarter of 2017 and it did not have a material impact on the Company&#8217;s consolidated financial statements. The impact of ASU 2016-09 as it relates to stock-based compensation for deferred tax assets and liabilities balances were not material to the Company's consolidated financial statements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016 the FASB issued ASU No. 2016-02 (ASU 2016-02) &#8220;<font style="font-style:italic;">Leases</font>.&#8221; ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. We are evaluating the impact of the adoption of this standard on our consolidated financial statements, and expect our operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption which will increase our total assets and total liabilities as compared to amounts prior to adoption.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers (Topic 606)</font>, or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at December 31, 2017 and any future receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined under ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development reimbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition adjustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research and development reimbursements and up-front payments under ASC 606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimates of the expected effects of the Company&#8217;s adoption of ASU 2014-09 represent management&#8217;s best estimates of the effects of adopting ASU 2014-09 at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of the Company&#8217;s assessment in the first quarter of 2018.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the organization, consolidation and basis of presentation of financial statements disclosure, and significant accounting policies of the reporting entity. May be provided in more than one note to the financial statements, as long as users are provided with an understanding of (1) the significant judgments and assumptions made by an enterprise in determining whether it must consolidate a VIE and/or disclose information about its involvement with a VIE, (2) the nature of restrictions on a consolidated VIE's assets reported by an enterprise in its statement of financial position, including the carrying amounts of such assets, (3) the nature of, and changes in, the risks associated with an enterprise's involvement with the VIE, and (4) how an enterprise's involvement with the VIE affects the enterprise's financial position, financial performance, and cash flows.  Describes procedure if disclosures are provided in more than one note to the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI http://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI http://asc.fasb.org/topic&amp;trid=2197479<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureAndSignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918972352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 2 &#8211;FAIR VALUE MEASUREMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company measures certain assets and liabilities at fair value on a recurring basis, including cash equivalents, available-for-sale securities and the contingent consideration liability.&#160;Fair value is determined based on a three-tier hierarchy under the authoritative guidance for fair value measurements and disclosures that prioritizes the inputs used in measuring fair value as follows: </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 1: Unadjusted quoted prices in active markets that are accessible at the measurement date for identical, unrestricted assets or liabilities; </p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.53%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 2: Quoted prices in markets that are not active, or inputs which are observable, either directly or indirectly, for substantially the full term of the asset or liability; and</p>
<p style="margin-bottom:0pt;margin-top:6pt;margin-left:4.54%;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Level 3: Prices or valuation techniques that require inputs that are both significant to the fair value measurement and unobservable (i.e., supported by little or no market activity). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The fair value measurements of cash equivalents, available-for-sale securities and the contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,089</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Investments </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company generally classifies its marketable securities as Level 2. Instruments are classified as Level 2 when observable market prices for identical securities that are traded in less active markets are used. When observable market prices for identical securities are not available, such instruments are priced using benchmark curves, benchmarking of like securities, sector groupings, matrix pricing and valuation models. These valuation models are proprietary to the pricing providers or brokers and incorporate a number of inputs, including, listed in approximate order of priority: benchmark yields, reported trades, broker/dealer quotes, issuer spreads, two-sided markets, benchmark securities, bids, offers and reference data including market research publications. For certain security types, additional inputs may be used, or some of the standard inputs may not be applicable. Evaluators may prioritize inputs differently on any given day for any security based on market conditions, and not all inputs listed are available for use in the evaluation process for each security evaluation on any given day. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In August 2013 the Company acquired Ceregene and recorded a liability for the estimated fair value of contingent consideration payments to former Ceregene stockholders, as outlined under the terms of the merger agreement with Ceregene. These contingent payments are owed if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. The fair value of this liability is estimated using a probability-weighted discounted cash flow analysis. Such valuations require significant estimates and assumptions including but not limited to: determining the timing and estimated costs to complete the in-process projects, projecting regulatory approvals, estimating future cash flows and developing appropriate discount rates. <font style="letter-spacing:-0.1pt;">The Company has classified this liability as Level 3.</font> </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The subsequent changes in the fair value of the contingent consideration liability were recognized as a component of research and development expense line item in the accompanying consolidated statements of operations as operating expenses. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by the total fair value of the contingent consideration of $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;D assets acquired from Ceregene (see Note 6).  </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -URI http://asc.fasb.org/topic&amp;trid=2155941<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774760528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 3 &#8211; MARKETABLE SECURITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,365</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,886</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,498</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,749</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,634</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,112</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,005</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,307</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,424</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,416</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, all of the Company&#8217;s investments had maturity dates within two years as of the balance sheet date. The Company had no material realized losses from the sale of available-for-sale securities for the years ended December&#160;31, 2017, 2016 or 2015. Sangamo has the intent and ability to hold its investments for a period of time sufficient to allow for any anticipated recovery in market value. No investments were other-than-temporarily impaired at either December 31, 2017 or 2016.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for  investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI http://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=4738149<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 320<br> -URI http://asc.fasb.org/subtopic&amp;trid=2289146<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6933918512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 4 &#8211; STOCK-BASED COMPENSATION </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table shows total stock-based compensation expense recognized in the accompanying consolidated statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,463</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,594</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December 31, 2017, total stock-based compensation expense related to unvested stock options to be recognized in future periods was $16.1 million, which is expected to be expensed over a weighted-average period of 2.79 years.&nbsp;&nbsp;As of December&#160;31, 2017, total stock-based compensation expense related to unvested RSUs to be recognized in future periods was $0.7 million, which is expected to be expensed over a weighted-average period of 1.03 years. There was no capitalized stock-based employee compensation expense as of either December&#160;31, 2017, 2016 or 2015 respectively. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Valuation Assumptions </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employee stock-based compensation expense was determined using the Black-Scholes option valuation model. Option valuation models require the input of subjective assumptions and these assumptions can vary over time. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company bases its determination of expected volatility through its assessment of the historical volatility of its common stock. The Company relied on its historical exercise and post-vested termination activity for estimating its expected term for use in determining the fair value of these options. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted-average estimated fair value per share of options granted during 2017, 2016 and 2015 was $4.10, $3.14, and $5.72, respectively, based upon the assumptions used in the Black-Scholes valuation model. The assumptions used for estimating the fair value of the employee stock options are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81-2.28%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13-1.61%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46-1.58%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.73-5.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28-5.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.25-5.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.68-0.70</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.67</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Employees purchased approximately 253,994, 202,711 and 128,181 shares of common stock through the 2010 Employee Stock Purchase Plan at an average exercise price of $3.22, $4.04, and $7.10 per share during 2017, 2016 and 2015, respectively. The weighted-average estimated fair value of shares purchased under the Company&#8217;s ESPP during 2017, 2016 and 2015 were $2.37, $2.27 and $4.42, respectively based upon the assumptions used in the Black-Scholes valuation model.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.44-0.76%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41-0.80%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06-0.33%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.55-0.70</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774822704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization Consolidation And Presentation Of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Major Customers, Partnerships and Strategic Alliances</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 5 &#8211; MAJOR CUSTOMERS, PARTNERSHIPS AND STRATEGIC ALLIANCES </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Collaboration Agreements </p>
<p style="margin-top:6pt;margin-bottom:0pt;margin-left:2.26%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Pfizer Inc. in Human Therapeutics </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">SB-525 Global Collaboration and License Agreement</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 10, 2017, Sangamo entered into an exclusive, global Collaboration and License Agreement (the &#8220;with Pfizer pursuant to which Sangamo and Pfizer established a collaboration for the research, development and commercialization of SB-525, Sangamo&#8217;s gene therapy product candidate for hemophilia A, and closely related products (the &#8220;hemophilia A Pfizer Agreement&#8221;).</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the hemophilia A Pfizer Agreement, Sangamo will be responsible for conducting the Phase 1/2 clinical trial and certain manufacturing activities for SB-525, while Pfizer will be responsible for subsequent worldwide development, manufacturing, marketing and commercialization of SB-525.&nbsp;&nbsp;Sangamo and Pfizer may also collaborate in the research and development of additional adeno-associated virus (&#8220;AAV&#8221;)-based gene therapy products for hemophilia A.&nbsp;&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the&nbsp;&nbsp;hemophilia A Pfizer Agreement, Sangamo received an upfront fee of $70.0 million from Pfizer.&nbsp;&nbsp;In addition, Sangamo is eligible to receive $208.5 million in payments upon the achievement of specified clinical development, intellectual property and regulatory milestones and $266.5 million in payments upon the achievement of specified first commercial sale milestones for SB-525 and potentially other products. The total amount of potential clinical development, intellectual property, regulatory, and first commercial sale milestone payments, assuming the achievement of all specified milestones in the hemophilia A Pfizer Agreement, is $475.0 million, which includes up to $300.0 million for SB-525 and up to $175.0 million for other products that may be developed under the hemophilia A Pfizer Agreement, subject to reduction on account of payments made under certain licenses for third party intellectual property.&nbsp;&nbsp;In addition, Pfizer has agreed to pay Sangamo royalties for each potential licensed product developed under the hemophilia A Pfizer Agreement that are an escalating tiered, double-digit percentage of the annual net sales of such product and are subject to reduction due to patent expiration, entry of biosimilar products to the market and payment made under certain licenses for third party intellectual property.&nbsp;&nbsp;To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the hemophilia A Pfizer Agreement. Sangamo in responsible for internal and external research costs as part of the upfront fee and has the ability to request additional reimbursement from Pfizer if certain conditions are met.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the hemophilia A Pfizer Agreement, Sangamo granted Pfizer an exclusive, worldwide, royalty-bearing license, with the right to grant sublicenses, to use certain technology controlled by Sangamo for the purpose of developing, manufacturing and commercializing SB-525 and related products. Under the hemophilia A Pfizer Agreement, Pfizer granted Sangamo a non-exclusive, worldwide, royalty free, fully paid license, with the right to grant sublicenses, to use certain manufacturing technology developed under the hemophilia A Pfizer Agreement and controlled by Pfizer to manufacture Sangamo&#8217;s products that utilize the AAV delivery system.&nbsp;&nbsp;During a specified period, neither Sangamo nor Pfizer will be permitted to clinically develop or commercialize, outside of the collaboration, certain AAV-based gene therapy products for hemophilia A.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the hemophilia A Pfizer Agreement as a license to the technology and on-going services. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Pfizer apart from the services to be performed by the Company pursuant to the hemophilia A Pfizer Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a thirty-two month estimated time over which the Company will perform services under the hemophilia A Pfizer Agreement. The recognition period will be reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the period of performance. As of December 31, 2017, the Company had deferred revenue of $53.0 million related to the hemophilia A Pfizer Agreement. During the year ended December 31, 2017 the Company recognized revenue of $17.0 million related to the upfront fee that was received.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">C9ORF72 Research Collaboration and License Agreement</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December&#160;28, 2017, Sangamo entered into a Research Collaboration and License Agreement with Pfizer for the development and commercialization of potential gene therapy products that use zinc finger protein transcription factors (&#8220;ZFP-TFs&#8221;) to treat amyotrophic lateral sclerosis and frontotemporal lobar degeneration, or ALS/ FTLD, linked to mutations of the C9ORF72 gene. Pursuant to this Pfizer Agreement, Sangamo will work together with Pfizer on a research program to identify, characterize and preclinically develop&#160;ZFP-TFs&#160;that bind to and specifically reduce expression of the mutant form of the C9ORF72 gene (the &#8220;ALS/ FTLD Pfizer Agreement&#8221;). This agreement was entered into as a separate and distinct agreement apart from the SB-525 Pfizer agreement. The Pfizer C9ORF72 agreement is related to research specific ZFP-TF gene therapy for the C9ORF72 gene, while the SB-525 Pfizer agreement was for the clinical stage development of <font style="color:#000000;">AAV-based gene therapy products for hemophilia A.</font> </p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo has granted Pfizer an exclusive, royalty-bearing, worldwide, sublicensable license under the Company&#8217;s relevant patents and&#160;know-how&#160;to develop, manufacture and commercialize gene therapy products (&#8220;Licensed Products&#8221;) that use resulting&#160;ZFP-TFs&#160;that satisfy&#160;pre-agreed&#160;criteria. During a specified period, neither Sangamo nor Pfizer will be permitted to research, develop, manufacture or commercialize outside of the collaboration any zinc finger proteins that specifically bind to the C9ORF72 gene.</p>
<p style="Background-color:#FFFFFF;margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the ALS/ FTLD Pfizer Agreement, Sangamo received&nbsp;&nbsp;a $12.0&#160;million upfront payment from Pfizer. Each party will be responsible for the cost of its performance of the research program. Pfizer will be operationally and financially responsible for subsequent development, manufacturing and commercialization of Licensed Products. Sangamo is eligible to receive up to $60.0&#160;million in development milestone payments from Pfizer if a Licensed Product achieves specified preclinical development, clinical development and first commercial sale milestones, and up to $90.0&#160;million commercial milestone payments if annual worldwide net sales of Licensed Products reach specified levels. In addition, Pfizer will pay royalties to Sangamo that are an escalating tiered,&#160;mid-&#160;to high-single digit percentage of the annual worldwide net sales of Licensed Products. These royalty payments are subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third party intellectual property. Sangamo did not recognize revenue related to this Pfizer agreement as the basic criteria for revenue recognition was not satisfied as of December 31, 2017. </p>
<p style="margin-top:18pt;margin-bottom:0pt;text-indent:2.5%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Collaboration and License Agreement with Bioverativ Inc. in Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2014, the Company entered into a Global Research, Development and Commercialization Collaboration and License Agreement with Biogen (the &#8220;Bioverativ Agreement&#8221;), and in January 2017 this agreement was assigned by Biogen MA Inc. to Biogen&#8217;s blood disorder spin-off, Bioverativ.&nbsp;&nbsp;Pursuant to the Bioverativ Agreement, Sangamo and Bioverativ will collaborate to discover, develop, seek regulatory approval for and commercialize therapeutics based on Sangamo&#8217;s zinc finger DNA-binding protein (&#8220;ZFP&#8221;) technology for beta-thalassemia and sickle cell disease (&#8220;SCD&#8221;). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the Bioverativ Agreement, Sangamo and Bioverativ jointly conduct two research programs: the beta-thalassemia program and the SCD program. For the beta-thalassemia program, Sangamo is responsible for all discovery, research and development activities through the first human clinical trial for the first therapeutic developed under the Bioverativ Agreement for the treatment of beta-thalassemia. For the SCD program, both parties are responsible for research and development activities through the submission of an Investigational New Drug (&#8220;IND&#8221;) application for a ZFP-based therapeutic intended to treat SCD. For both programs, Bioverativ is responsible for subsequent world-wide clinical development, manufacturing and commercialization of licensed products developed under the Bioverativ Agreement. At the end of specified research terms for each program or under certain specified circumstances, Bioverativ has the right to step in and take over any remaining activities of Sangamo. Furthermore, Sangamo has an option to co-promote in the United States any&#160;licensed products to treat beta-thalassemia and SCD&#160;developed under the Bioverativ Agreement, and Bioverativ agrees to compensate Sangamo for such co-promotion activities. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo received an upfront license fee of $20.0 million upon entering into the Bioverativ Agreement. In addition, the Company will also be eligible to receive $115.8 million in payments upon the achievement of specified clinical development and regulatory milestones, as well as $160.5 million in payments upon the achievement of specified sales milestones. Bioverativ reimburses Sangamo for agreed upon costs incurred in connection with research and development activities conducted by Sangamo. In addition, if products are commercialized under the Bioverativ Agreement, Bioverativ will pay Sangamo incremental royalties for each licensed product that are a tiered double-digit percentage of annual net sales of such product. To date, no milestone payments have been received and no products have been approved and therefore no royalty fees have been earned under the Bioverativ Agreement.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2016, the parties agreed on an updated beta-thalassemia development plan and budget using the <font style="font-style:italic;">BCL11A</font> erythroid enhancer target. In November 2016, Sangamo and Bioverativ agreed on an updated beta-thalassemia development plan and budget. As a result of this change, the Company updated the estimated performance period of the upfront license through June 2020, and updated the milestones to be received based on the updated schedule and targets under the Bioverativ Agreement.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">All contingent payments under the Bioverativ Agreement, when earned, will be non-refundable and non-creditable. The Company has evaluated the contingent payments under the Bioverativ Agreement based on the authoritative guidance for research and development milestones and determined that certain of these payments meet the definition of a milestone and that all such milestones are evaluated to determine if they are considered substantive milestones. Milestones are considered substantive if they are related to events (i)&#160;that can be achieved based in whole or in part on either the Company&#8217;s performance or on the occurrence of a specific outcome resulting from the Company&#8217;s performance, (ii)&#160;for which there was substantive uncertainty at the date the agreement was entered into that the event would be achieved and (iii)&#160;that would result in additional payments being due to the Company. Accordingly, consideration received for the achievement of milestones that are determined to be substantive will be recognized as revenue in their entirety in the period when the milestones are achieved and collectability is reasonably assured. Revenue for the achievement of milestones that are not substantive will be recognized over the remaining period of the Bioverativ Agreement, assuming all other applicable revenue recognition criteria have been met. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subject to the terms of the Bioverativ Agreement, Sangamo has granted Bioverativ an exclusive, royalty-bearing license, with the right to grant sublicenses, to use certain ZFP and other technology controlled by Sangamo for the purpose of researching, developing, manufacturing and commercializing licensed products developed under the Bioverativ Agreement. Sangamo has also granted Bioverativ a non-exclusive, world-wide, royalty free, fully paid license, with the right to grant sublicenses, under Sangamo&#8217;s interest in certain other intellectual property developed pursuant to the Bioverativ Agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has identified the deliverables within the arrangement as a license to the technology and on-going research services activities. The Company concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Bioverativ apart from the research services to be performed pursuant to the Bioverativ Agreement. As a result, the Company will recognize revenue from the upfront payment on a straight-line basis over a forty-four month estimated research term as of the November 2016 modification date, during which time the Company will perform research services. The estimated period of performance is reviewed quarterly and adjusted, as needed, to reflect the Company&#8217;s current assumptions regarding the timing of its deliverables. As of December 31, 2017, the Company had deferred revenue of $4.6 million related to the Bioverativ Agreement. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the Bioverativ Agreement for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): &#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Bioverativ Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,176</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,489</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,565</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,769</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,258</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,886</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,945</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Amended Collaboration and License Agreement with Shire International GmbH in Human Therapeutics </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In January 2012, the Company entered into a Collaboration and License Agreement with Shire (the &#8220;Shire Agreement &#8221;), pursuant to which the Company and Shire collaborate to research, develop and commercialize human therapeutics and diagnostics for monogenic diseases based on Sangamo&#8217;s novel ZFP technology. This agreement was amended on September 1, 2015.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the original Shire Agreement, the Company and Shire agreed to develop potential human therapeutic or diagnostic products for seven gene targets. The initial four gene targets selected were blood clotting Factors VII, VIII, IX and X, and products developed for such initial gene targets would be used for treating or diagnosing hemophilia A and B. In June 2012, Shire selected a fifth gene target for the development of a ZFP therapeutic for Huntington&#8217;s disease. Shire had the right, subject to certain limitations, to designate two additional gene targets. Pursuant to the Shire Agreement, the Company granted Shire an exclusive, world-wide, royalty-bearing license, with the right to grant sublicenses, to use Sangamo&#8217;s ZFP technology for the purpose of developing and commercializing human therapeutic and diagnostic products for the gene targets. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Shire Agreement, the Company was responsible for all research activities through the submission of an IND or European Clinical Trial Application (CTA), while Shire was responsible for clinical development and commercialization of products generated from the research program from and after the acceptance of an IND or CTA for the product. Shire reimbursed Sangamo for agreed upon internal and external program-related research costs. The Company received an upfront license fee of $13.0 million upon entering into the Shire Agreement in 2012. In 2014, Sangamo recognized a $1.0 million milestone payment related to the hemophilia program.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On September 1, 2015, the Shire Agreement was amended such that Shire agreed to return to Sangamo the exclusive, world-wide rights to gene targets for the development and commercialization of ZFP therapeutics for hemophilia A and B.&nbsp;&nbsp;Shire retains the rights and will continue to develop a ZFP therapeutic for Huntington&#8217;s disease.&nbsp;&nbsp;Sangamo will provide certain target feasibility services, and upon Shire&#8217;s request, certain research activities according to a research plan as agreed upon by both companies. Such research activities performed by Sangamo will be reimbursed by Shire. Shire&#8217;s rights with respect to other targets contemplated in the original agreement revert to Sangamo. Under the revised agreement, each company is responsible for expenses associated with its own programs, and Shire will reimburse Sangamo for any ongoing services provided by Sangamo for Shire&#8217;s programs. In 2015, Shire reimbursed Sangamo $3.4 million related to obligations prior to the amendment date which was recognized in revenue as the expense related to those obligations was incurred. Sangamo has granted Shire a right of first negotiation to license the hemophilia A and B programs developed by Sangamo under the amended agreement. Under the amended agreement, Shire does not have any milestone payment obligations with respect to the retained programs, but it is required to pay single digit percentage royalties to Sangamo, up to a specified maximum cap, on the commercial sales of ZFP therapeutic products from such programs. Under the Shire Agreement, Sangamo has full control over, and full responsibility for the costs of, the hemophilia programs returned to us, subject to certain diligence obligations and Shire&#8217;s right of first negotiation to obtain a license to such programs under certain circumstances. The Company is required to pay single digit percentage royalties to Shire, up to a specified maximum cap, on commercial sales of ZFP therapeutic products from such returned programs.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has concluded that the license is not a separate unit of accounting as it does not have stand-alone value to Shire apart from the research services to be performed pursuant to the Shire amendment. The Company satisfied the deliverables and research services responsibilities within the amended arrangement which were completed in 2017. As a result, the Company recognized the remaining $2.3 million of deferred revenue from the upfront payment during the year ended December 31, 2017. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the Shire Agreement for the years ended December&#160;31, 2017, 2016 and 2015, were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,181</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,167</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,584</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,449</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p>
<p style="margin-top:18pt;margin-bottom:0pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Sigma-Aldrich Corporation (Sigma) in Laboratory Research Reagents, Transgenic Animal and Commercial Protein Production Cell-line Engineering </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2007, Sangamo entered into a license agreement with Sigma to provide Sigma with access to Sangamo&#8217;s proprietary ZFP technology and the exclusive right to use the technology to develop and commercialize research reagent products and services in the research field, excluding certain agricultural research uses that Sangamo previously licensed to DAS. Sangamo developed laboratory research reagents using its ZFP technology over a three year research services period. Sangamo has since transferred the ZFP manufacturing technology to Sigma.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2009, Sangamo expanded its license agreement with Sigma. In addition to the original terms of the license agreement, Sigma received exclusive rights to develop and distribute ZFP-modified cell lines for commercial production of protein pharmaceuticals and certain ZFP-engineered transgenic animals for commercial applications. Under the terms of the agreement, Sigma made an upfront cash payment of $20.0 million consisting of a $4.9 million purchase of 636,133 shares of Sangamo common stock, valued at $4.9 million, and a $15.1 million upfront license fee. Sangamo is also eligible to receive commercial license fees of $5.0 million based upon a percentage of net sales and sublicensing revenue and thereafter a reduced royalty rate of 10.5% of net sales and sublicensing revenue. In addition, upon the achievement of certain cumulative commercial milestones, Sigma will make milestone payments to Sangamo up to an aggregate of $25.0 million. Sangamo does not have additional ongoing performance obligations under the agreement.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2017, 2016 and 2015, were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,277</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,853</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:18pt;margin-left:3.33%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Agreement with Dow AgroSciences in Plant Agriculture </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2005, Sangamo entered into an exclusive commercial license with<font style="font-weight:bold;font-style:italic;"> </font>Dow AgroSciences, LLC, or DAS, with an initial three year research term. Under this agreement, Sangamo is providing DAS with access to its proprietary ZFP technology and the exclusive right to use the technology to modify the genomes or alter the nucleic acid or protein expression of plant cells, plants, or plant cell cultures. Sangamo has retained rights to use plants or plant-derived products to deliver ZFP TFs or ZFNs into humans or animals for diagnostic, therapeutic or prophylactic purposes. In 2008 DAS exercised its option and obtained a commercial license to sell products incorporating or derived from plant cells generated using the Company&#8217;s ZFP technology. The exercise of the option triggered a one-time commercial license fee of $6.0&#160;million, payment of the remaining $2.3 million of the previously agreed upon $4.0&#160;million in research milestones, development and commercialization milestone payments for each product, and royalties on sales of products. Furthermore, DAS has the right to sublicense Sangamo&#8217;s ZFP technology to third parties for use in plant cells, plants, or plant cell cultures, and Sangamo will be entitled to 25% of any cash consideration received by DAS under such sublicenses. In December 2010 the Company amended its agreement with DAS to extend the period of reagent manufacturing services and research services through December&#160;31, 2012. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The agreement with DAS also provides for minimum sublicense fees each year due to Sangamo every October, provided the agreement is not terminated by DAS. Annual fees range from $250,000 to $3.0 million and total $25.3 million over 11 years unless terminated at any time by DAS. The Company does not have any performance obligations. In the event of any termination of the agreement, all rights to use the Company&#8217;s ZFP technology will revert to Sangamo, and DAS will no longer be permitted to practice Sangamo&#8217;s ZFP technology or to develop or, except in limited circumstances, commercialize any products derived from the Company&#8217;s ZFP technology. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues under the agreement with DAS were $3.0 million during 2017 and $5.1 million and $3.0 million during 2016 and 2015, respectively. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -URI http://asc.fasb.org/topic&amp;trid=5833765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6922863664">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Ceregene<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsAbstract', window );"><strong>Business Combinations [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationDisclosureTextBlock', window );">Acquisition of Ceregene</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:9pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 6 &#8211; ACQUISITION OF CEREGENE </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In August&#160;2013, Sangamo acquired all the outstanding shares of Ceregene, a privately held biotechnology company focused on the development of AAV gene therapies. The acquired assets included certain intellectual property rights relating to manufacturing of AAV, and toxicology and data from Ceregene&#8217;s human clinical trials. The acquisition closed in October&#160;2013 (the Closing Date). </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The aggregate consideration transferred or transferable by Sangamo to former Ceregene stockholders at closing consisted of 100,000 shares of Sangamo common stock, with an approximate fair value of $1.2 million and a contingent earn-out of $1.5 million on the Closing Date. The $1.8 million fair value of the contingent earn-out liability was reduced to zero in March 2015 upon Sangamo&#8217;s decision not to pursue development of Ceregene&#8217;s technology as discussed below.  </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Intangible Assets Acquired</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets acquired included In-Process Research and Development (IPR&amp;D), which consisted of Ceregene&#8217;s two clinical product candidates, CERE-110 for the treatment of AD and CERE-120 for the treatment of Parkinson&#8217;s disease. The Company determined that the combined Closing Date estimated fair values of CERE-110 and CERE-120 was $1.9 million. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company does not believe the programs have an alternative future use for itself or other market participants. Accordingly, during the year ended December 31, 2015, the Company recognized a $1.9 million impairment charge related to these assets. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Intangible assets also included $1.6 million in goodwill, the excess of the consideration transferred over the fair values assigned to the assets acquired and liabilities assumed. Goodwill represents benefits that Sangamo believes will result from combining its operations with the operations of Ceregene and any intangible assets that do not qualify for separate recognition, as well as any future, yet unidentified products.&#160; The Company tests goodwill for impairment on an annual basis or sooner, if deemed necessary. There have been no changes to goodwill since the Closing Date, and no impairment has been recognized.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for a business combination (or series of individually immaterial business combinations) completed during the period, including background, timing, and recognized assets and liabilities. The disclosure may include leverage buyout transactions (as applicable).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -URI http://asc.fasb.org/topic&amp;trid=2303972<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774780400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 7 &#8211; PROPERTY AND EQUIPMENT </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,572</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,367</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,048</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in Progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,650</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Depreciation and amortization expense was $1.5 million in 2017, $1.0 million in 2016 and $1.0  million in 2015.&nbsp;&nbsp;In 2017 the Company capitalized $20.9 million related to the fair value of the Brisbane building and $0.3 million of construction costs in Construction in Progress under the build-to-suit lease guidance (see Note 14). In 2016 the Company capitalized $3.9 million related to the costs of the Richmond construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. Both buildings will depreciate over the period of their lease, respectively. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6929103888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 8 &#8211; COMMITMENTS AND CONTINGENCIES</p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Sangamo occupies office and laboratory space under operating leases in Richmond, California. In August&#160;2013, Sangamo amended its lease agreement for our corporate headquarters wherein the lease was extended through August 2019. The Company has three additional properties located in Richmond, CA. This includes two leases, one to occupy approximately 7,700 square feet of research and office space that expires in August 2019, and another to occupy approximately 6,200 square feet of office space that expires in July 2021. Sangamo also has two build-to-suit leases to occupy approximately 41,400 square feet of space in Richmond that expires in December 2021 and approximately 87,700 square feet of space in Brisbane that expires in May 2029. Rent expense related to these lease agreements was $1.1 million, $1.0 million, and $0.9 million for 2017, 2016 and 2015, respectively. Future minimum payments under lease obligations at December&#160;31, 2017 consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,685</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,795</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,434</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:5%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For 2018, the company is committed to spend $8.8 million for tenant improvements related to the Brisbane build-to-suit lease and $8.7 million as part of our services agreement with Brammer Bio MA, LLC, or Brammer, to provide dedicated capacity to supply our preclinical and clinical programs.&#160;The Company also has $5.2 million of license commitments related to its intellectual property.</p>
<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingencies</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo is not party to any material pending legal proceeding. From time to time, we may be involved in legal proceedings arising in the ordinary course of business.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774823392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 9 &#8211; STOCKHOLDERS&#8217; EQUITY </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Preferred Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has 5,000,000 preferred shares authorized, which may be issued at the discretion of the Company&#8217;s Board of Director&#8217;s discretion. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Common Stock </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On June 26, 2017, Sangamo completed an underwritten public offering of its common stock, in which the Company sold an aggregate of 11.5 million shares of its common stock at a public offering price of $7.25 per share. The net proceeds to Sangamo from the sale of shares in this offering, after deducting underwriting discounts and commissions and other offering expenses, were approximately $78.1 million. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">At-the-Market Offering Agreements</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 7, 2016, we entered into an &#8220;at the market&#8221; offering agreement with an investment bank, pursuant to which we may issue and sell from time to time up to $75.0 million of our common stock through the bank as the sales agent (&#8220;ATM Agreement&#8221;). Under the ATM Agreement, if we decide to sell shares, the sales agent will use its commercially reasonable efforts to sell on our behalf all of the shares of common stock requested to be sold by us.&nbsp;&nbsp;Sales of the common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The Nasdaq Global Market and any other trading market for the common stock, and sales to or through a market maker other than on an exchange. In addition, with our prior written consent, the sales agent may also sell our common stock in negotiated transactions.</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On May 26, 2017, the Company entered into an Amended and Restated At-the-Market Offering Program Sales Agreement (the &#8220;2017 ATM Agreement&#8221;) with an investment bank pursuant to which the Company may issue and sell from time to time after the date of the 2017 ATM Agreement, shares of its common stock having an aggregate offering price of up to $75.0 million through the investment bank acting as the Company&#8217;s sales agent. Under the 2017 ATM Agreement, if the Company decides to sell shares, the Company will notify the sales agent, and the sales agent will use its commercially reasonable efforts to sell on the Company&#8217;s behalf all of the shares of common stock requested to be sold.&nbsp;&nbsp;Sales of the Company&#8217;s common stock, if any, will be made at market prices by any method that is deemed to be an &#8220;at the market offering&#8221; as defined in Rule 415 under the Securities Act, as amended, including sales made directly on The NASDAQ Global Select Market and sales to or through a market maker other than on an exchange. In addition, with the Company&#8217;s prior written consent, the sales agent may also sell shares of its common stock in negotiated transactions under the 2017 ATM Agreement.&nbsp;&nbsp;During the three months ended March 31, 2017, the Company issued a total of 871,149 shares of its common stock under the original At-the-Market Offering Program Sales Agreement entered into with the sales agent in December 2016, and received net proceeds of $3.4 million, after deducting offering expenses, including $0.1 million of commission paid to the sales agent. These shares were inadvertently sold under a registration statement filed with the SEC that had in fact expired prior to the time the shares were sold.&nbsp;&nbsp;Consequently, the Company may be subject to claims for rescission by purchasers who purchased shares of common stock under the ATM Agreement in March 2017.&nbsp;&nbsp;Under Section 12(a)(1) of the Securities Act, a purchaser of security in a transaction made in violation of Section 5 of the Securities Act may obtain recovery of the consideration paid in connection with its purchase, plus statutory interest, or, if it had already sold the shares, recover damages resulting from its purchase. While the Company believes it is unlikely that a successful claim will be asserted against the Company by any purchasers who purchased shares of common stock under the ATM Agreement in March 2017, the Company cannot guarantee that no such legal claims will be asserted against the Company by any purchasers. In addition, the Company could become subject to enforcement actions and/or penalties and fines by federal authorities, and the Company is unable to predict the likelihood of any such enforcement actions being brought, or the amount of any such potential penalties or fines. </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Incentive Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In April&#160;2013 Sangamo&#8217;s Board of Directors adopted, subject to stockholder approval, the Company&#8217;s 2013 Stock Incentive Plan (the 2013 Plan) as the successor to the Company&#8217;s 2004 Stock Incentive Plan (the 2004 Plan). At the Annual Meeting of Stockholders held on June&#160;12, 2013, the 2013 Plan was approved by the Company&#8217;s stockholders and became effective. In connection with the approval by stockholders of the 2013 Plan, outstanding awards under the 2004 Plan were transferred to the 2013 Plan. The 2004 Plan was terminated and no further awards will be made pursuant to the 2004 Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the 2013 Plan, the exercise price per share of options granted will generally not be less than 100 percent of the fair value per share of common stock on the grant date, and the option term will not exceed ten years. If the person to whom the option is granted is a 10 percent stockholder, and the option granted qualifies as an Incentive Stock Option Grant, then the exercise price per share will not be less than 110 percent of the fair value per share of common stock on the grant date, and the option term will not exceed five years. Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination. Certain options previously granted under the 2004 Plan to the Company&#8217;s non-employee directors are structured so that they may be exercised prior to vesting, with the related shares subject to Sangamo&#8217;s right to repurchase any shares that have not vested pursuant to the vesting schedule in effect for such award at the exercise price paid if the option holder&#8217;s board service terminates. Approximately 14.1&#160;million shares were initially reserved for issuance under the 2013 Plan, including 9.7&#160;million shares of common stock subject to outstanding awards previously granted under the 2004 Plan that were transferred to the 2013 Plan, and an additional 4.4&#160;million shares of common stock. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The number of shares of common stock reserved for issuance under the 2013 Plan will be reduced: (i)&#160;on a 1-for-1 basis for each share of common stock subject to a stock option or stock appreciation right granted under the plan, (ii)&#160;on a 1-for-1 basis for each share of common stock issued pursuant to a full value award granted under the plan prior to the plan effective date, and (iii)&#160;by a fixed ratio of 1.33 shares of common stock for each share of common stock issued pursuant to a full-value award granted under the plan on or after the plan effective date. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Shares subject to any outstanding options or other awards under the 2013 Plan that expire or otherwise terminate prior to the issuance of the shares subject to those options or awards will be available for subsequent issuance under the 2013 Plan. Any unvested shares issued under the 2013 Plan that the Company subsequently purchases, pursuant to repurchase rights under the 2013 Plan, will be added back to the number of shares reserved for issuance under the 2013 Plan on a 1-for-1 basis or a 1.33-for-1 basis (depending on the ratio at which the share reserve was debited for the original award) and will accordingly be available for subsequent issuance in accordance with the terms of the plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2015 Sangamo&#8217;s stockholders were asked to vote to approve the amendment and restatement of our 2013 Stock Incentive Plan in order to increase the number of shares in our common stock reserved for issuance over the term of the 2013 Plan by 5,300,000 shares. At the Annual Meeting of Stockholders held on June&#160;22, 2015, the amendment and restatement of our 2013 Stock Incentive Plan was approved by the Company&#8217;s stockholders and became effective.</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="Background-color:#FFFFFF;">On November&#160;10, 2017, the Compensation committee of the Company&#8217;s Board of Directors approved the amendment and restatement of the Company&#8217;s Amended and Restated 2013 Stock Incentive Plan, to reserve an additional one million shares of the Company&#8217;s common stock to be used exclusively for grants of awards to individuals who were not previously employees or&#160;non-employee&#160;directors of the Company (or following a bona fide period of&#160;non-employment&#160;with the Company), as an inducement material to each such individual&#8217;s entry into employment with us within the meaning of Rule 5635(c)(4) of the NASDAQ Listing Rules, or Rule 5635(c)(4). The 2013 Plan was amended and restated by the Compensation Committee without stockholder approval pursuant to Rule 5635(c)(4).</font></p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Employee Stock Purchase Plan </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s 2010 Employee Stock Purchase Plan (&#8220;Purchase Plan&#8221;), which supersedes the Company&#8217;s 2000 Employee Stock Purchase Plan, provides a total reserve of 2,100,000&#160;shares of common stock for issuance under the Purchase Plan. Eligible employees may purchase common stock at 85&#160;percent of the lesser of the fair market value of Sangamo&#8217;s common stock on the first day of the applicable two-year offering period or the last day of the applicable six-month purchase period. </p>
<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock Option Activity </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of Sangamo&#8217;s stock option activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual<font style="font-family:Calibri;">&#160;</font>Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In<font style="font-family:Calibri;">&#160;</font>thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2016</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,256,506</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,030,815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,029,360</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest at December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,864</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Newly created shares are issued upon exercises of options. There were no shares subject to Sangamo&#8217;s right of repurchase as of December&#160;31, 2017. The intrinsic value of options exercised was $12.3 million, $0.1 million and $6.4 million during 2017, 2016 and 2015, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">At December&#160;31, 2017, the aggregate intrinsic values of outstanding and exercisable options were $71.7&#160;million and $28.9 million, respectively. The aggregate intrinsic value of options vested and expected to vest as of December 31, 2017, 2016 and 2015 was $71.7 million, $0.0 million and $14.0 million, respectively.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information with respect to stock options outstanding at December&#160;31, 2017: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding and Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common&#160;stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject&#160;to</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.55 &#8211; $3.45</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612,318</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,920</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.50 &#8211; $3.50</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527,625</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.55 &#8211; $5.41</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212,567</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672,930</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.42 &#8211; $7.07</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501,051</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">967,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.20 &#8211; $9.41</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,546</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551,162</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.45 &#8211; $13.35</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885,599</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.52</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659,946</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.92</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.54 &#8211; $15.00</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,148,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668,752</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15.11 &#8211; $18.26</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.41</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.51 &#8211; $19.51</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.80 &#8211; $19.80</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Restricted Stock Units </p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, 2016 and 2015, the Company awarded 12,600, 60,000, and 446,000&nbsp;&nbsp;Restricted Stock Units (RSUs), respectively. The RSUs awarded in 2017, 2016 and 2015 had an average grant date fair value per award of $15.85, $5.16 and $9.45, respectively. These awards generally vest as follows: one-third of the award will vest in a series of three successive equal annual installments. The aggregate fair value of RSUs vested during 2017, 2016 and 2015 was $1.2 million, $4.8 million and $4.1 million, respectively. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A summary of Sangamo&#8217;s RSU activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate&#160;Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2016</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,816</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,917</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,327</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested and expected to vest at December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs that vested in 2017, 2016 and 2015 were net-share settled such that the Company withheld shares with value equivalent to the employees&#8217; minimum statutory obligation for the applicable income and other employment taxes, and remitted the cash to the appropriate taxing authorities. The total shares withheld were approximately 42,243, 165,181, and 172,807 for 2017, 2016 and 2015, respectively and were based on the value of the RSUs on their respective issuance dates as determined by the Company&#8217;s closing stock price. Total payments for the employees&#8217; tax obligations to taxing authorities were $0.7 million, $0.8 million and $1.5 million in 2017, 2016 and 2015, respectively and are reflected as a financing activity within the accompanying consolidated statements of cash flows.&#160;These net-share settlements had the effect of share repurchases by the Company as they reduced and retired the number of shares that would have otherwise been issued as a result of the vesting and did not represent an expense to the Company. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">As of December&#160;31, 2017, there were 3,601,633 shares reserved for future awards under the Company&#8217;s 2013 Plan and 835,674 shares of common stock reserved for future issuance under the Purchase Plan. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774824080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 10 &#8211; INCOME TAXES </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The benefit for income taxes consisted of the following (in thousands):&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax<font style="color:#000000;"> rate </font>(34%)<font style="color:#000000;"> to loss before taxes is explained as follows (in thousands):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at federal statutory rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,553</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,369</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(747</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Rate Change</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible stock compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,120</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,085</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(869</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,424</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(814</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,773</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred income taxes reflect the net tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets:</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,147</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">934</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,492</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Liabilities:</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability related to intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In October 2013, we acquired Ceregene.&nbsp;&nbsp;The Company recorded goodwill and intangible assets as part of accounting for the acquisition of Ceregene. A portion of the intangible assets acquired were for the use in a particular research and development project IPR&amp;D and are considered indefinite-lived assets with no tax basis. In 2015, the Company impaired these intangible assets and reversed the corresponding deferred tax liability.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:2pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In 2015 the Company received a $14.5 million Section 16(b) disgorgement settlement that was recognized as additional paid-in capital. The disgorgement settlement was recognized net of taxes of $9.5 million, which resulted in an income tax benefit of $5.0 million being recognized in the accompanying consolidated statements of operations for the year ended December 31, 2015.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The changes in the fair value of the unrealized gain/loss on securities investment are recorded as a component of accumulated other comprehensive income, net of a provision for income taxes.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">A valuation allowance is recorded when it is more likely than not that all or some portion of the deferred income tax assets will not be realized. We regularly assess the need for a valuation allowance against our deferred income tax assets by considering both positive and negative evidence related to whether it is more likely than not that our deferred income tax assets will be realized. In evaluating our ability to recover our deferred income tax assets within the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred income tax liabilities, projected future taxable income, tax-planning strategies, and results of recent operations. Accordingly, based upon the Company&#8217;s analysis of these factors the net deferred tax assets have been fully offset by a valuation allowance. The valuation allowance (decreased) increased by $(28.9) million, $23.8 million and $5.0 million for the years ended December&#160;31, 2017, 2016 and 2015, respectively. As of December&#160;31, 2017, Sangamo had net operating loss carryforwards for federal and state income tax purposes of approximately $475&#160;million and $142 million, respectively. If not utilized, the net federal and state operating loss carryforwards will expire in 2018 and 2017, respectively. The Company also has federal and state research tax credit carryforwards of $10.8&#160;million and $11.8 million, respectively. The federal research credits will begin to expire in 2018 while the state research credits have no expiration date. Utilization of the Company&#8217;s net operating loss carryforwards and research tax credit carryforwards may be subject to substantial annual limitations due to the ownership change limitations provided by the Internal Revenue Code and similar state provisions. The annual limitation could result in the expiration of the net operating loss carryforwards and research tax credit carryforwards before utilization. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On December 22, 2017, President Trump signed the Tax Cuts and Jobs Act ("Tax Reform") into legislation.&#160; The Tax Reform makes significant changes to the US corporate income tax law including, but not limited to, (1) reducing the U.S. federal corporate tax rate to 21% from 35% and (2) requiring a one-time mandatory transition tax on previously deferred foreign earnings of US subsidiaries.&#160; Under ASC 740, the effects of changes in tax rates and laws are recognized in the period in which the new legislation is enacted.&#160; In the case of US federal income taxes, the enactment date is the date the bill becomes law.&#160;&#160;&#160; With respect to this legislation, we expect no financial statement impact due to the Company's valuation allowance.&#160; The Company performed a re-measurement of deferred tax assets and liabilities as a result of the decrease in the corporate Federal income tax rate from 35% to 21%. In addition to the reduction of U.S. federal corporate tax rate, the Company has also considered the impact of the foreign transition tax for which it has estimated that it would not need to accrue any amounts.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2017, the Securities and Exchange Commission staff issued Staff Accounting Bulletin No.118 (SAB 118) to provide guidance on the application of the Tax Reform when a company does not have the necessary information available, prepared, or analyzed in reasonable to detail to reflect the effects of the Tax Reform.&#160; SAB 118 provides guidance for companies under the three scenarios (1) measurement of certain income tax effects is complete, (2) measurement of certain income tax effect can be reasonably estimated, and (3) measurement of certain income tax effects cannot be reasonably estimated.&#160; Companies are to complete the accounting under ASC 740 in regards to the Tax Reform within a measurement period that does not extend one year from the date of enactment (i.e., December 22, 2018).&#160; In accordance with SAB 118, companies must reflect the tax effects of the Tax Reform for which the accounting under 740 is complete. If certain income tax effect can be reasonably estimated, then the companies must report provisional amounts in the reporting period in which the companies can determine the reasonable estimate during the measurement period.&#160; In the case that certain income tax effects cannot be reasonably estimated, companies do not have to report effects of the Tax Reform.&#160; However, they should continue to apply ASC 740 based on the rules before the enactment of the Tax Reform and report any income tax effects in the first reporting period in which reasonable estimates become available.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">We expect the new law to significantly reduce our tax rate in future periods, and our tax footnote reflects the effects of a Federal tax rate reduction net of our valuation allowance, which resulted in a net overall reduction of $0.&#160; </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The final transition impacts of the Tax Act may differ from the above estimate, possibly materially, due to, among other things, changes in interpretations of the Tax Act, any legislative action to address questions that arise because of the Tax Act, any changes in accounting standards for income taxes or related interpretations in response to the Tax Act, or any updates or changes to estimates the company has utilized to calculate the transition impacts, including impacts from changes to current year earnings estimates and foreign exchange rates of foreign subsidiaries.&#160; In accordance with SAB 118, the Company is allowed a measurement period of up to one year after the enactment date of the Tax Act to finalize the recording of the related tax impacts.&#160; We currently anticipate finalizing and recording any resulting adjustments by year ending December 31, 2018.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company files federal and state income tax returns with varying statutes of limitations. The tax years from 2002 forward remain open to examination due to the carryover of net operating losses or tax credits. The Company also files a UK income tax return, and the tax years from 2008 and thereafter remain open to examination.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s practice is to recognize interest and/or penalties related to income tax matters in income tax expense. As of December&#160;31, 2017, the Company had no accrued interest and/or penalties. The unrecognized tax benefits may change during the next year for items that arise in the ordinary course of business. In the event that any unrecognized tax benefits are recognized, the effective tax rate will not be affected.</p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,438</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,659</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774826144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 11 &#8211; ACCOUNTS PAYABLE AND ACCRUED LIABILITIES </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accounts payable and accrued liabilities consist of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,898</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,386</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,035</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657621760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 12 &#8211; EMPLOYEE BENEFIT PLAN </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company sponsors a defined-contribution savings plan under Section&#160;401(k) of the Internal Revenue Code covering all full-time employees (Sangamo 401(k) Plan). The Sangamo 401(k) Plan is intended to qualify under Section&#160;401 of the Internal Revenue Code. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company matched employee contributions equal to 50% for the first 8% in 2017 and 6% in both 2016 and 2015, respectively, up to a limit of $4,000 in 2017 and $3,000 in both 2016 and 2015, respectively. Matching funds are fully vested when contributed. Contributions to the Sangamo 401(k) Plan by the Company were $0.5 million, $0.3 million, and $0.3 million for the years ended December&#160;31, 2017, 2016 and 2015, respectively. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for pension and other postretirement benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI http://asc.fasb.org/topic&amp;trid=2235017<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6919280544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationTextBlock', window );">Quarterly Financial Data (Unaudited)</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 13 &#8211; QUARTERLY FINANCIAL DATA (UNAUDITED) </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2016. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All data is in thousands except per share data. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,812</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,077</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,702</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,922</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,847</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,843</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,623</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,544</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,752</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,491</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,091</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,494</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,624</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.14</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for quarterly financial data. Includes, but is not limited to, tabular presentation of financial information for fiscal quarters, effect of year-end adjustments, and an explanation of matters or transactions that affect comparability of the information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -URI http://asc.fasb.org/topic&amp;trid=2126967<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657079264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Build-to-Suit Lease<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeasesOperatingAbstract', window );"><strong>Leases Operating [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseObligationDisclosureTextBlock', window );">Build-to-Suit Lease</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 14 &#8211; BUILD-TO-SUIT LEASE </p>
<p style="margin-top:12pt;margin-bottom:0pt;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Brisbane Build-to-Suit Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2017, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 87,700 square feet of space, in Brisbane, California. Substantial completion of the building is estimated to occur in the last quarter of 2018. The lease agreement expires in May 2029, approximately ten years after substantial completion of the building. A letter of credit for $3.5 million was established as the deposit and is classified within other noncurrent assets in the financial statements. The Company has two options to extend the lease term for up to a combined additional ten years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner as a result of the cold shell condition of the building and involvement in the construction process. In connection with the Company&#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation, including interest. Fair value of the building was estimated at $20.9 million using comparable market prices per square foot for similar space for public real estate transactions in the surrounding area and is considered a Level 2 fair value measurement. As of December 31, 2017, $21.2 million was capitalized with a corresponding build-to-suit lease obligation recognized related to this lease for the building and construction costs.&nbsp;&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-style:italic;font-family:Times New Roman;font-size:10pt;font-weight:normal;text-transform:none;font-variant: normal;">Point Pinole Build-to-Suit Lease</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2015, the Company entered into a long-term property lease which includes construction by the lessor of a building with approximately 41,400 square feet of space, in Richmond, California. Substantial completion of the building was accomplished in December 2016 at which time the lease commenced. The lease agreement expires in December 2021, five years after substantial completion of the building. The Company has two options to extend the lease term for up to a combined additional ten years.</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is deemed, for accounting purposes only, to be the owner of the entire project including the building shell, even though it is not the legal owner. In connection with the Company&#8217;s accounting for this transaction, the Company capitalized the costs of construction as a build-to-suit property within property and equipment, net, and recognize a corresponding build-to-suit lease obligation for the same amount. As of December 31, 2016, $3.9 million of costs were capitalized in buildings with a corresponding build-to-suit lease obligation recognized related to this lease. </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction has completed on the facility and as such a portion of the monthly lease payment is allocated to land rent and recorded as an operating lease expense and the non-interest portion of the amortized lease payments to the landlord related to the rent of the building is applied to reduce the build-to-suit lease obligation. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeaseObligationDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build to suit lease obligation disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeaseObligationDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesOperatingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesOperatingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6657616160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Claims Settlement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ClaimsSettlementDisclosureAbstract', window );"><strong>Claims Settlement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ClaimsSettlementDisclosureTextBlock', window );">Claims Settlement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 15 &#8211; CLAIMS SETTLEMENT</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">In September 2015, the Company received $14.5 million as a settlement with certain institutional investors that were beneficial owners of Sangamo&#8217;s common stock related to the disgorgement of short-swing profits pursuant to Section 16(b) of the Securities Exchange Act of 1934, as amended.&#160; The settlement of $9.5 million, net of a $5.0 million income tax benefit and certain expenses, was recognized as additional paid-in capital. </p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ClaimsSettlementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Claims settlement disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ClaimsSettlementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ClaimsSettlementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Claims settlement disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ClaimsSettlementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774780400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Event</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">NOTE 16 &#8211; SUBSEQUENT EVENT</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:6.67%;">In February 2018, the Company entered into a Collaboration and License Agreement with Kite Pharma, Inc. (&#8220;Kite&#8221;), a wholly-owned subsidiary of Gilead Sciences, Inc. (&#8220;Gilead&#8221;), for the research, development and commercialization of potential engineered cell therapies for cancer. The Company will work together with Kite on a research program under which the Company ZFNs and AAVs to disrupt and insert certain genes in T cells and NK cells, including the insertion of genes that encode CARs, T-cell receptors (&#8220;TCRs&#8221;) and NK cell receptors (&#8220;NKRs&#8221;) directed to mutually agreed targets.&nbsp;&nbsp;Kite will be responsible for all clinical development and commercialization of any resulting products. Except for confidentiality obligations and certain representations, warranties and covenants, which are effective upon execution, the effectiveness of the Kite agreement is subject to the expiration or termination of all applicable waiting periods under the Hart<font style="Background-color:#FFFFFF;color:#000000;">-Scott-Rodino Antitrust Improvements Act of 1976, as amended</font> and other customary closing conditions.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:10pt;margin-top:0pt;text-indent:6.67%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Under the terms of the Kite agreement, the Company will, upon the effectiveness of the Kite agreement, receive a $150 million upfront payment from Kite. Kite will reimburse the Company&#8217;s direct costs to conduct the joint research program under the Kite agreement, and Kite will be operationally and financially responsible for all subsequent development, manufacturing and commercialization of licensed products. The Company is also eligible to receive contingent development- and sales-based milestone payments that could total up to $3.01 billion if all of the specified milestones set forth in the Kite agreement are achieved.&#160;Of this amount, approximately $1.26 billion relates to the achievement of specified research, clinical development, regulatory and first commercial sale milestones, and approximately $1.75 billion relates to the achievement of specified sales-based milestones if annual worldwide net sales of licensed products reach specified levels.&#160;Each development- and sales-based milestone payment is payable (i) only once for each licensed product, regardless of the number of times that the associated milestone event is achieved by such licensed product, and (ii)&#160;only for the first ten times that the associated milestone event is achieved, regardless of the number of licensed products that may achieve such milestone event.&nbsp;&nbsp;<font style="color:#000000;">In addition, </font>the Company <font style="color:#000000;">will be entitled to receive escalating, tiered royalty payments with a percentage in the mid-single digits based on potential future annual worldwide net sales of l</font>icensed products. These royalty payments will be subject to reduction due to patent expiration, entry of biosimilar products to the market and payments made under certain licenses for third-party intellectual property.&nbsp;&nbsp;At this time the Company is assessing the accounting impact of the agreement.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784092816">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Basis of Presentation </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. Actual results could differ from those estimates. The consolidated financial statements include the accounts of Sangamo and its wholly-owned subsidiaries, Ceregene and Gendaq Limited, after elimination of all intercompany balances and transactions. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationsPolicy', window );">Business Combinations</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Business Combinations </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company accounts for acquisitions in accordance with Accounting Standards Codification (ASC) Topic 805, <font style="font-style:italic;">Business Combinations</font> (ASC Topic 805). ASC Topic 805 establishes principles and requirements for recognizing and measuring the total consideration transferred to and the assets acquired, liabilities assumed and any non-controlling interests in the acquired target in a business combination. ASC Topic 805 also provides guidance for recognizing and measuring goodwill acquired in a business combination; requires purchased in-process research and development to be capitalized at fair value as an intangible asset at the time of acquisition; requires acquisition-related expenses and restructuring costs to be recognized separately from the business combination; expands the definition of what constitutes a business; and requires the acquirer to disclose information that users may need to evaluate and understand the financial effect of the business combination. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Cash and Cash Equivalents </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Sangamo considers all highly-liquid investments purchased with original maturities of three months or less at the purchase date to be cash equivalents. Cash and cash equivalents consist of deposits in money market investment accounts.&nbsp;&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Marketable Securities </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Sangamo classifies its marketable securities as available-for-sale and records its investments at estimated fair value based on quoted market prices or observable market inputs of almost identical assets, with the unrealized holding gains and losses included in accumulated other comprehensive income. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company&#8217;s investments are subject to a periodic impairment review. The Company recognizes an impairment charge when a decline in the fair value of its investments below the cost basis is judged to be other-than-temporary. The Company considers various factors in determining whether to recognize an impairment charge, including the length of time and extent to which the fair value has been less than the Company&#8217;s cost basis, the financial condition and near-term prospects of the investee, and the Company&#8217;s intent and ability to hold the investment for a period of time sufficient to allow for any anticipated recovery in the market value. Realized gains and losses on available-for-sale securities are included in other income, which is determined using the specific identification method. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Fair Value Measurements </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The carrying amounts for financial instruments consisting of cash and cash equivalents, accounts receivable, accounts payable and accrued liabilities approximate fair value due to their short maturities. Marketable securities and contingent consideration liabilities are stated at their estimated fair values. The counterparties to the agreements relating to the Company&#8217;s investment securities consist of the US Treasury, governmental agencies, various major corporations and financial institutions with high credit standing. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Property and Equipment </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Property and equipment are stated at cost, less accumulated depreciation and amortization. Depreciation is calculated using the straight-line method based on the estimated useful lives of the related assets (generally three to five years). For leasehold improvements, amortization is calculated using the straight-line method based on the shorter of the useful life or the lease term. The Company reviews its property and equipment for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and the accompanying notes. On an ongoing basis, management evaluates its estimates, including critical accounting policies or estimates related to revenue recognition, clinical trial accruals, and stock-based compensation. Estimates are based on historical experience and on various other market specific and other relevant assumptions that the Company believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results could differ from those estimates. During the fourth quarter of 2016, we revised our estimated performance period under the Bioverativ license agreement from June 2019 to June 2020, which also extended the recognition period of the related up-front payment we received upon entering this agreement (See Note 5). This change decreased revenues by $4.3 million and increased net loss and net loss per share by $0.06 for the year ended December 31, 2016. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue Recognition</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Revenue Recognition </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues from research activities made under strategic partnering agreements and collaborations are recognized as the services are provided when there is persuasive evidence that an arrangement exists, delivery has occurred, the price is fixed or determinable, and collectability is reasonably assured. Revenue generated from research and licensing agreements typically includes upfront signing or license fees, cost reimbursements, research services, minimum sublicense fees, milestone payments and royalties on future licensee&#8217;s product sales. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements prior to the adoption of ASU No.&#160;2009-13, Revenue Recognition&#8212;Multiple Deliverable Revenue Arrangements (ASU 2009-13)<font style="font-style:normal;">. For revenue arrangements entered into before January&#160;1, 2011, that include multiple deliverables, the elements of such agreement were divided into separate units of accounting if the deliverables met certain criteria, including whether the fair value of the delivered items could be determined and whether there was evidence of fair value of the undelivered items. In addition, the consideration was allocated among the separate units of accounting based on their fair values, and the applicable revenue recognition criteria are considered separately for each of the separate units of accounting. Prior to the adoption of ASU 2009-13, the Company recognized nonrefundable signing, license or non-exclusive option fees as revenue when rights to use the intellectual property related to the license were delivered and over the period of performance obligations if the Company had continuing performance obligations. The Company estimated the performance period at the inception of the arrangement and reevaluated it each reporting period. Changes to these estimates were recorded on a prospective basis. </font></p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-style:italic;font-size:10pt;font-family:Times New Roman;font-weight:normal;text-transform:none;font-variant: normal;">Multiple Element Arrangements after the adoption of ASU 2009-13.<font style="font-style:normal;"> ASU 2009-13 amended the accounting standards for certain multiple element revenue arrangements to: </font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">provide updated guidance on whether multiple elements exist, how the elements in an arrangement should be separated, and how the arrangement consideration should be allocated to the separate elements; </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">require an entity to allocate arrangement consideration to each element based on a selling price hierarchy where the selling price for an element is based on vendor-specific objective evidence, or VSOE, if available; third-party evidence, or TPE, if available and VSOE is not available; or the best estimate of selling price, or ESP, if neither VSOE nor TPE is available; and </p></td></tr></table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:6.8%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" style="width:4.54%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:6pt;font-family:'Times New Roman';font-size:15pt;line-height:11pt;">&#x2022;</p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">eliminate the use of the residual method and require an entity to allocate arrangement consideration using the relative selling price method. </p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">For revenue agreements with multiple element arrangements, such as license and development agreements, entered into on or after January&#160;1, 2011, the Company allocates revenue to each non-contingent element based on the relative selling price of each element. When applying the relative selling price method, the Company determines the selling price for each deliverable using VSOE of selling price or TPE of selling price. If neither exists the Company uses ESP for that deliverable. Revenue allocated is then recognized when the basic four revenue recognition criteria are met for each element. The collaboration and license agreements entered into with Shire International GmbH, formerly Shire AG, or Shire, in January 2012, Biogen MA Inc., or Biogen, in January 2014, and Pfizer Inc., or Pfizer, in May and December of 2017, were evaluated under these amended accounting standards. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additionally, the Company may be entitled to receive certain milestone payments which are contingent upon reaching specified objectives. These milestone payments are recognized as revenue in full upon achievement of the milestone if there is substantive uncertainty at the date the arrangement is entered into that objectives will be achieved and if the achievement is based on the Company&#8217;s performance. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Minimum annual sublicense fees are also recognized as revenue in the period in which such fees are due. Royalty revenues are generally recognized when earned and collectability of the related royalty payment is reasonably assured. The Company recognizes cost reimbursement revenue under collaborative agreements as the related research and development costs for services are rendered. Deferred revenue represents the portion of research or license payments received but not earned. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sangamo&#8217;s research grants are typically multi-year agreements and provide for the reimbursement of qualified expenses for research and development as defined under the terms of the grant agreement. Revenue under grant agreements is recognized when the related qualified research expenses are incurred. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">During 2017, revenues related to Pfizer and Bioverativ represented 47% and 34%, respectively, of the Company&#8217;s total revenue. During 2016 revenue related to Bioverativ, DAS and Shire represented 46%, 26%, and 17%, respectively, of total revenue.&nbsp;&nbsp;During 2015 revenue related to Shire and Biogen represented 40% and 35%, respectively, of total revenues. Receivables from collaborations are typically unsecured and are concentrated in the biopharmaceutical industry. Accordingly, we may be exposed to credit risk generally associated with biopharmaceutical companies or specific to our collaboration agreements. To date, we have not experienced any losses related to these receivables.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Research and Development Expenses </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Research and development costs are expensed as incurred. Research and development expenses consist of direct and research-related allocated overhead costs such as facilities costs, salaries and related personnel costs, and material and supply costs. In addition, research and development expenses include costs related to clinical trials, validation of the Company&#8217;s testing processes and procedures as well as related overhead expenses. Research and development costs incurred in connection with collaborator-funded activities are expensed as incurred. Costs to acquire technologies that are utilized in research and development that have no alternative future use are expensed as incurred. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-Based Compensation</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Stock-Based Compensation </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company measures and recognizes compensation expense for all stock-based payment awards made to Sangamo employees and directors, including employee share options, restricted stock units (RSUs) and employee stock purchases related to the Employee Stock Purchase Plan (ESPP), based on estimated fair values at the award grant date. The fair value of stock-based awards is amortized over the vesting period of the award using a straight-line method. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">To estimate the fair value of an award, the Company uses the Black-Scholes option pricing model. This model requires inputs such as expected life, expected volatility and risk-free interest rate. These inputs are subjective and generally require significant analysis and judgment to develop. While estimates of expected life and volatility are derived primarily from the Company&#8217;s historical data, the risk-free rate is based on the U.S. Treasury yield curve in effect at the time of grant commensurate with the expected life assumption. Further, the Company adopted Accounting Standards Update (ASU) 2016-09 and accounts for forfeitures in the period they occur. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy', window );">Indefinite-Lived Intangible Assets</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Indefinite-Lived Intangible Assets </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">As part of the Ceregene acquisition the Company recognized indefinite-lived intangible assets for in-process research and development and goodwill as further discussed below. ASC 350 and related updates require companies to test indefinite-lived intangible assets for impairment annually, and more frequently if indicators of impairment exist. ASC 350 includes an optional qualitative assessment for testing indefinite-lived intangible assets for impairment that permits companies to assess whether it is more likely than not (i.e., a likelihood of greater than 50%) that an indefinite-lived intangible asset is impaired. If a company concludes based on the qualitative assessment that it is not more likely than not that the fair value of an indefinite-lived intangible asset or, in the case of goodwill, that the fair value of the related reporting unit, is less than carrying value, it would not have to determine the asset&#8217;s or reporting unit&#8217;s fair value, as applicable.</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InProcessResearchAndDevelopmentPolicy', window );">In-Process Research and Development</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">In-Process Research and Development </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Intangible assets related to in-process research and development costs, or IPR&amp;D, are considered to be indefinite-lived until the completion or abandonment of the associated research and development efforts. If and when development is complete, which generally occurs if and when regulatory approval to market a product is obtained, the associated assets would be deemed finite-lived and would then be amortized based on their respective estimated useful lives at that point in time. Prior to completion of the research and development efforts, the assets are considered indefinite-lived. During this period, the assets will not be amortized but will be tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate a reduction in the fair value of the IPR&amp;D projects below their respective carrying amounts. In the first quarter of 2015, the Company decided to discontinue the CERE-110 and CERE-120 clinical trial programs. As such, the probability of achieving projected revenues and cash flows associated with these programs were adversely affected. The Company did not believe the programs have an alternative future use for itself or other market participants. Accordingly, the Company recognized a $1.9 million impairment charge related to these assets during the year ended December 31, 2015, which was recognized as research and development (R&amp;D) in the accompanying consolidated statements of operations.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy', window );">Goodwill</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Goodwill </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Goodwill represents the excess of the consideration transferred over the estimated fair values of assets acquired and liabilities assumed in a business combination and is considered to be indefinite-lived. Goodwill is not amortized but is tested for impairment on an annual basis and between annual tests if the Company becomes aware of any events occurring or changes in circumstances that would indicate an impairment of goodwill has occurred. During the fourth quarter of 2017, the Company performed an assessment of the qualitative factors affecting the fair value of its reporting unit and concluded that it was not more likely than not that the fair value of its reporting unit was less than carrying value and that, as a result, it is not more likely than not that goodwill is impaired. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentConsiderationPolicyTextBlock', window );">Contingent Consideration Liability</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Contingent Consideration Liability </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Under the merger agreement with Ceregene, the Company is required to make contingent earn-out payments if the Company grants a third-party license to develop and commercialize certain product candidates acquired from Ceregene, or if the Company commercializes any of such product candidates itself. These earn-out payments will become payable in the period they are earned. In accordance with ASC Topic 805, the Company determined the fair value of this liability for contingent consideration on the acquisition date using a probability-weighted discounted cash flow analysis. During the year ended December 31, 2015, the recognized amount of the liability for contingent consideration decreased by $1.8 million due to the decrease in the probability of incurring potential future royalty payments associated with the impairment of IPR&amp;D assets acquired from Ceregene.</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Income Taxes </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Income tax expense has been provided using the liability method. Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities as measured by the enacted tax rates that will be in effect when these differences reverse. The Company provides a valuation allowance against net deferred tax assets if, based upon the available evidence, it is not more likely than not that the deferred tax assets will be realized. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Net Loss Per Share </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Basic net loss per share has been computed by dividing net loss by the weighted-average number of shares of common stock outstanding during the period. Diluted net loss per share is calculated by dividing net loss by the weighted average number of shares of common stock and potential dilutive securities outstanding during the period. </p>
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Because Sangamo is in a net loss position, diluted net loss per share excludes the effects of common stock equivalents consisting of options and restricted stock units, which are all anti-dilutive. All stock options and restricted stock units outstanding were excluded from the calculation of diluted net loss per share for all periods presented. Stock options and restricted stock units outstanding at the end of 2017, 2016 and 2015 were 8,367,628, 9,578,322, and 9,008,185, respectively. </p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segments</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Segments </p>
<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The Company operates in one segment. Management uses one measure of profitability and does not segregate its business for internal reporting. As of December&#160;31, 2017 and 2016, all of the Company&#8217;s assets were maintained in the U.S. For the years ended December&#160;31, 2017, 2016 and 2015, substantially all the Company&#8217;s revenues and operating expenses were generated and incurred in the U.S. </p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:18pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Recent Accounting Pronouncements </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.17%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:6pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.17%;">In March 2016 the Financial Accounting Standards Board (FASB) issued ASU 2016-09, Improvements to Employee Share-Based Payment Accounting (Topic 718). The amendments in ASU 2016-09 affect all entities that issue share-based payment awards to their employees and involve multiple aspects of the accounting for share-based payment transactions, including income tax consequences, classification of awards as either equity or liabilities, and classification on the statement of cash flows. The ASU is effective for annual periods beginning after December 15, 2016, and interim periods within those annual periods.&#160;Early adoption is permitted for any entity in any interim or annual period. If an entity early adopts the amendments in an interim period, any adjustments should be reflected as of the beginning of the fiscal year that includes that interim period. An entity that elects early adoption must adopt all of the amendments in the same period.&nbsp;&nbsp;The Company adopted the ASU in the first quarter of 2017 and it did not have a material impact on the Company&#8217;s consolidated financial statements. The impact of ASU 2016-09 as it relates to stock-based compensation for deferred tax assets and liabilities balances were not material to the Company's consolidated financial statements. </p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016 the FASB issued ASU No. 2016-02 (ASU 2016-02) &#8220;<font style="font-style:italic;">Leases</font>.&#8221; ASU 2016-02 amends a number of aspects of lease accounting, including requiring lessees to recognize almost all leases with a term greater than one year as a right-of-use asset and corresponding liability, measured at the present value of the lease payments. The guidance will become effective for the Company beginning in the first quarter of 2019 with early adoption permitted and will be adopted using a modified retrospective approach. We are evaluating the impact of the adoption of this standard on our consolidated financial statements, and expect our operating lease commitments will be subject to the new standard and recognized as a right-of-use assets and operating lease liabilities upon adoption which will increase our total assets and total liabilities as compared to amounts prior to adoption.</p>
<p style="margin-top:6pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In May 2014 the FASB issued ASU 2014-09, <font style="font-style:italic;">Revenue from Contracts with&#160;Customers (Topic 606)</font>, or ASC 606. This standard outlines a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most current revenue recognition guidance, including industry-specific guidance. The main principle of ASU 2014-09 is to recognize revenues when promised goods or services are transferred to customers in an amount that reflects the consideration that is expected to be received for those goods or services. ASU 2014-09 provides companies with two implementation methods: (i)&#160;apply the standard retrospectively to each prior reporting period presented (full retrospective application); or (ii)&#160;apply the standard retrospectively with the cumulative effect of initially applying the standard as an adjustment to the opening balance of retained earnings of the annual reporting period that includes the date of initial application (modified retrospective application). This guidance is effective for annual reporting periods beginning after December&#160;15, 2017, including interim periods within that reporting period. Under Topic 606, an entity recognizes revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of Topic 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. Topic 606 also impacts certain other areas, such as the accounting for costs to obtain or fulfill a contract. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company will adopt ASC 606 during the first quarter of 2018 and using the modified retrospective method. The Company has substantially completed its evaluation of the impact of adopting ASC 606 on its contracts with Bioverativ, Shire, DAS, and Sigma (as defined below). The Company&#8217;s performance obligations with respect to Shire, DAS and Sigma were substantially complete at December 31, 2017 and any future receipts are contingent upon these counterparties achieving specified development, commercial, and/or sales targets and would be in the form of milestones or royalties, all of which management concluded are constrained at December 31, 2017 as defined under ASC 606. The Company has also performed an assessment of the impact of adopting ASC 606 on its Bioverativ collaboration arrangement and has preliminarily concluded that the timing of the recognition of up-front payments and research and development reimbursements will be decelerated under the new guidance while development and commercialization milestones are constrained at December 31, 2017, as defined under ASC 606. Based on this assessment, management has preliminarily concluded that the transition adjustment to be recognized on January 1, 2018 will be less than $5.0 million and will result in a decrease to accumulated deficit and an increase to deferred revenue at that date as a result of decelerating the recognition of amounts related to research and development reimbursements and up-front payments under ASC 606. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company has not completed its assessment of the effect that the adoption of ASC 606 will have on its agreements with Pfizer that were entered into during 2017. The Company has preliminarily concluded that any potential milestone and royalty payments payable under these agreements are constrained at December 31, 2017, as defined under ASC 606, and thus will not result in a change upon adoption of ASC 606 from the accounting for such payments under ASC 605. No revenue or other amounts were recognized in 2017 related to the agreement that was entered into with Pfizer in late December 2017 and, accordingly, management does not expect any amounts to be recognized as part of the January 2018 transition adjustment related to this agreement. During 2017, the Company recognized as revenue $17.0 million of the $70.0 million up-front payment received from agreement the Company entered into with Pfizer in May 2017, the amount and timing of which may change upon adoption of ASC 606.&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The estimates of the expected effects of the Company&#8217;s adoption of ASU 2014-09 represent management&#8217;s best estimates of the effects of adopting ASU 2014-09 at the time of the preparation of this Annual Report on Form 10-K. The actual, final quantitative effects of the adoption of ASU 2014-09 are subject to change from these estimates and such change may be significant, pending the completion of the Company&#8217;s assessment in the first quarter of 2018.</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentConsiderationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent consideration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentConsiderationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for completed business combinations (purchase method, acquisition method or combination of entities under common control). This accounting policy may include a general discussion of the purchase method or acquisition method of accounting (including for example, the treatment accorded contingent consideration, the identification of assets and liabilities, the purchase price allocation process, how the fair values of acquired assets and liabilities are determined) and the entity's specific application thereof. An entity that acquires another entity in a leveraged buyout transaction generally discloses the accounting policy followed by the acquiring entity in determining the basis used to value its interest in the acquired entity, and the rationale for that accounting policy.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -Subparagraph (a)-(d)<br> -URI http://asc.fasb.org/extlink&amp;oid=6909625&amp;loc=d3e227-128457<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill. This accounting policy also may address how an entity assesses and measures impairment of goodwill, how reporting units are determined, how goodwill is allocated to such units, and how the fair values of the reporting units are determined.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsGoodwillPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for indefinite-lived intangible assets (that is, those intangible assets not subject to amortization). This accounting policy also may address how the entity assesses whether events and circumstances continue to support an indefinite useful life and how the entity assesses and measures impairment of such assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsIndefiniteLivedPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InProcessResearchAndDevelopmentPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs assigned to identifiable tangible and intangible assets of an acquired entity to be used in the research and development activities of the combined enterprise. An entity also may disclose the appraisal method or significant assumptions used to value acquired research and development assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.15)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InProcessResearchAndDevelopmentPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investments in debt and equity securities that have readily determinable fair values (marketable securities). At a minimum, the disclosure might address accounting policies for investments classified as trading, available for sale, or held to maturity and may include how the entity determines whether impairments of available for sale or held to maturity investments are other than temporary, how the fair values of the entity's securities are determined, and the entity's accounting treatment for transfers between investment categories.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.M)<br> -URI http://asc.fasb.org/extlink&amp;oid=65877573&amp;loc=d3e87990-122713<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section S50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6381980&amp;loc=d3e87707-122711<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62652-112803<br><br>Reference 8: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 9: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue recognition. If the entity has different policies for different types of revenue transactions, the policy for each material type of transaction is generally disclosed. If a sales transaction has multiple element arrangements (for example, delivery of multiple products, services or the rights to use assets) the disclosure may indicate the accounting policy for each unit of accounting as well as how units of accounting are determined and valued. The disclosure may encompass important judgment as to appropriateness of principles related to recognition of revenue. The disclosure also may indicate the entity's treatment of any unearned or deferred revenue that arises from the transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18823-107790<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.B.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18726-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6061-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6143-108592<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6132-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774898928">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock', window );">Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The fair value measurements of cash equivalents, available-for-sale securities and the contingent consideration liability are identified at the following levels within the fair value hierarchy (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.46%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.1%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.42%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.1%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">199,089</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.42%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.04%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:55.54%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value Measurements</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.14%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Level 3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Assets:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Marketable securities:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:42.08%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.4%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:42.08%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and marketable securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.02%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.4%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19279-110258<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2C<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=SL7498348-110258<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19190-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774853152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesTextBlock', window );">Summary of Cash Equivalents and Available-for-Sale Securities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The table below summarizes the Company&#8217;s cash equivalents and available-for-sale securities (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;<font style="font-size:12pt;">&#160;</font></p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gross</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Amortized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Unrealized</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Estimated</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Cost</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Gains</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(Losses)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fair Value</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,290</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,595</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,885</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,365</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(118</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">110,247</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,886</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(131</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75,755</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,498</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,492</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,749</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">194,494</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,634</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(255</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">223,379</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cash equivalents:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Money market funds</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,992</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Available-for-sale securities:</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Commercial paper securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,112</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">73</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,185</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Corporate debt securities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,005</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,004</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">U.S. government-sponsored entity debt securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,307</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(25</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">87,285</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,424</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">120,474</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total cash equivalents and available-for-sale securities</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,416</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">76</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">139,466</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27198-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62586-112803<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 6: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br><br>Reference 7: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27290-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774822704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Stock-Based Compensation Expense</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table shows total stock-based compensation expense recognized in the accompanying consolidated statements of operations (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,031</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,463</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,444</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,058</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,594</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,286</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation expense</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,089</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,057</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,730</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Assumptions Used for Estimating Fair Value of Employee Stock Options</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The assumptions used for estimating the fair value of the employee stock options are as follows:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.81-2.28%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.13-1.61%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.46-1.58%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.73-5.83</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.28-5.29</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.25-5.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.72</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.68-0.70</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.67</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock', window );">Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchase Rights</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The weighted&#8211;average assumptions used for estimating the fair value of the ESPP purchase rights are as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Risk-free interest rate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.44-0.76%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.41-0.80%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.06-0.33%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life of option (in years)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.5-2.0</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield of stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.66-0.82</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.71-0.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.55-0.70</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the allocation of equity-based compensation costs to a given line item on the balance sheet and income statement for the period. This may include the reporting line for the costs and the amount capitalized and expensed.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of employee stock purchase plans, including, but not limited to: (a) expected term, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardEmployeeStockPurchasePlanValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784612240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the Bioverativ Agreement for the years ended December 31, 2017, 2016 and 2015 are as follows (in thousands): &#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.16%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.8%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Bioverativ Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,769</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,321</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.98%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.36%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,176</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,489</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,565</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,769</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,258</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.74%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,886</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:0.98%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.36%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.06%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.8%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,945</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the Shire Agreement for the years ended December&#160;31, 2017, 2016 and 2015, were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Shire Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Recognition of upfront fee</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,333</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,181</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,167</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research services</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,096</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,584</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,449</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,277</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,751</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock', window );">Revenues Recognized under Agreement</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Revenues recognized under the agreement with Sigma for the years ended December&#160;31, 2017, 2016 and 2015, were as follows (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenue related to Sigma Collaboration:</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Royalty revenues</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">452</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">137</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">390</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">License fee revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">267</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,140</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,463</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">719</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,277</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,853</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contractual arrangements that involve two or more parties that both: (i) actively participate in a joint operating activity and (ii) are exposed to significant risks and rewards that depend on the commercial success of the joint operating activity. Additionally, the element may include all other transactions of the entity categorized collectively, if such comparison of collaborative arrangements as a component of all transactions of the entity is desired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 808<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6931272&amp;loc=SL5834143-161434<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCollaborativeArrangementsAndNoncollaborativeArrangementTransactionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6934775616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property Plant And Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Property and equipment consist of the following (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Laboratory equipment</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,572</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,206</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and fixtures</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,494</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Buildings</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,876</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16,367</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,048</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(6,951</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,639</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in Progress</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,650</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">148</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">31,066</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:6pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6634039472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Summary of Future Minimum Payments under Contractual Obligations</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Future minimum payments under lease obligations at December&#160;31, 2017 consist of the following (in thousands):</p></div><div>

<p style="margin-bottom:0pt;margin-top:8pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Fiscal Year:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2018</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,685</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,925</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,795</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,798</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:80.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,896</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:80.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total minimum payments</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.82%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39,434</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6656567184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">A summary of Sangamo&#8217;s stock option activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted-</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise per</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Share Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual<font style="font-family:Calibri;">&#160;</font>Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In<font style="font-family:Calibri;">&#160;</font>thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2016</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,256,506</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.31</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options granted</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,091,125</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.48</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercised</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,030,815</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.76</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options canceled</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2,029,360</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options outstanding at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:9.18%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options vested and expected to vest at December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.77</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,658</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Options exercisable at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">28,864</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock', window );">Summary of Stock Options Outstanding</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:0pt;margin-left:4.54%;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following table summarizes information with respect to stock options outstanding at December&#160;31, 2017: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:6pt;text-indent:4.54%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Outstanding and Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Options Exercisable</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">common&#160;stock</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject&#160;to</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">subject to</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Range of Exercise Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Life</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">options</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise&#160;Price</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.18%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$2.55 &#8211; $3.45</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">612,318</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.92</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">214,920</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.13</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.50 &#8211; $3.50</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,527,625</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.07</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$3.55 &#8211; $5.41</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,212,567</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.24</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">672,930</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.34</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$5.42 &#8211; $7.07</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,501,051</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.53</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">967,506</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.11</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$7.20 &#8211; $9.41</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,199,546</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.17</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">551,162</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.06</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$9.45 &#8211; $13.35</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">885,599</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.52</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">659,946</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11.92</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$13.54 &#8211; $15.00</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,148,250</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.26</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">668,752</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14.07</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$15.11 &#8211; $18.26</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">178,000</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7.31</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">124,561</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16.41</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:50.34%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.51 &#8211; $19.51</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,000</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,583</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.51</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$19.80 &#8211; $19.80</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,500</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,718</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19.80</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:50.34%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,287,456</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.69</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,881,078</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:9.18%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.99</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Summary of Restricted Stock Unit Activity</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">A summary of Sangamo&#8217;s RSU activity is as follows: </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted&#160;Average</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Arial;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">of</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Aggregate&#160;Intrinsic</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual&#160;Term</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Value</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In years)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(In thousands)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2016</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">321,816</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs awarded</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,600</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs released</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(112,917</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs forfeited</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(141,327</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding at December 31, 2017</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:10.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs vested and expected to vest at December 31, 2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">80,172</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.90</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,315</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:8pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of option exercise prices, by grouped ranges, including the upper and lower limits of the price range, the number of shares under option, weighted average exercise price and remaining contractual option terms.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939735680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Summary of Benefit for Income Taxes</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The benefit for income taxes consisted of the following (in thousands):&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Benefit for income taxes:</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current:</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred:</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,563</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> State</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(2</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(159</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Subtotal</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate</a></td>
<td class="text"><div>

<p style="margin-top:2pt;margin-bottom:0pt;text-indent:4.54%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p>
<p style="margin-top:2pt;margin-bottom:0pt;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The difference between the benefit for income taxes and the amount computed by applying the federal statutory income tax<font style="color:#000000;"> rate </font>(34%)<font style="color:#000000;"> to loss before taxes is explained as follows (in thousands):</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Year Ended December 31,</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Tax at federal statutory rate</p></td>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,553</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,369</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(15,785</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">State taxes, net</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">795</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(747</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,840</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Federal Rate Change</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">53,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Non-deductible stock compensation</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,120</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,781</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,085</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research credits</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(869</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(1,424</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(814</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Change in valuation allowance</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(36,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">23,773</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,043</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(28</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(91</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Income tax benefit</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(14</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(5,722</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Company's Deferred Tax Assets</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:2pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Significant components of the Company&#8217;s deferred tax assets are as follows (in thousands):</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.88%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Assets:</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred tax assets:</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net operating loss carryforwards</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">91,308</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,222</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development tax credit carryforwards</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,147</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">12,518</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock-based compensation</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,168</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,565</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred revenue</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">934</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,918</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,276</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,492</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax asset</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Valuation allowance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">112,833</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">141,715</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:66.98%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;"><font style="text-decoration:underline;">Liabilities:</font></p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-style:italic;color:#000000;font-family:Times New Roman;font-size:10pt;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.62%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net deferred tax liability related to intangible assets</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:66.98%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total deferred tax liability</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.62%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.88%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:4.54%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock', window );">Summary of Activity Related to Company's Unrecognized Tax Benefits</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:12pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits (in thousands): </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="10" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.1%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-top:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2015</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning balance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,438</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions based on tax positions related to the current year</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">622</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,023</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">557</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:57.48%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Additions for tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(8</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.38%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,335</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Reductions for tax positions of prior years</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,335</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8212;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:57.48%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Ending balance</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,659</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,045</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.38%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,330</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of unrecognized tax benefits for which a material change is reasonably possible in the next twelve months, typically including the nature of the uncertainty, the event(s) that could cause a material change, and an estimate of the range of the reasonably possible change or a statement that an estimate of the range cannot be made. An unrecognized tax benefit is the difference between a tax position taken in a tax return and the amounts recognized in the financial statements for which it is more likely than not, based on the technical merits of the position, that the tax position will not be sustained upon examination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfPositionsForWhichSignificantChangeInUnrecognizedTaxBenefitsIsReasonablyPossibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774770432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock', window );">Summary of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">Accounts payable and accrued liabilities consist of the following (in thousands): </p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="6" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.78%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31 ,</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.86%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accounts payable</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">16</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,580</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued research and development expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,898</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,887</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued professional fees</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,318</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">270</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:58.14%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Deferred rent</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">417</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.04%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">498</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,386</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-bottom:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:58.14%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accounts payable and accrued liabilities</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,035</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.04%; border-bottom:double 2.5pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.86%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6,261</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the (a) carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business (accounts payable); (b) other payables; and (c) accrued liabilities. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). An alternative caption includes accrued expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6936300752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract', window );"><strong>Quarterly Financial Information Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock', window );">Summary of Quarterly Financial Data</a></td>
<td class="text"><div>

<p style="margin-bottom:0pt;margin-top:6pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:4.54%;">The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December&#160;31, 2016.</p></div><div>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;">&nbsp;</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2017</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="14" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.6%; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2016</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:20.32%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q1</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q2</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q3</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.22%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td colspan="2" valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:7.72%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Q4</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Revenues</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,425</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,253</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,812</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,077</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,942</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,702</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,823</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%; border-top:solid 0.75pt #000000;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,922</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expenses</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,217</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">21,021</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">24,847</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">26,843</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20,623</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,544</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22,029</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,752</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,632</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,491</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(12,354</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(13,091</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(16,494</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(26,575</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,965</p></td>
<td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(9,624</p></td>
<td valign="top" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
<tr>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.32%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net loss per share</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.17</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.15</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.23</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.38</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.27</p></td>
<td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.22%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&nbsp;</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:6.72%;white-space:nowrap;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(0.14</p></td>
<td valign="top" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</p></td>
</tr>
</table></div>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:10pt;">&nbsp;</p></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_QuarterlyFinancialInformationDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_QuarterlyFinancialInformationDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of quarterly financial data. Includes, but is not limited to, financial information for fiscal quarters, cumulative effect of a change in accounting principle and earnings per share data.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 270<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)-(j)<br> -URI http://asc.fasb.org/extlink&amp;oid=84173487&amp;loc=d3e1280-108306<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfQuarterlyFinancialInformationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786738352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>May 10, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2012 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Segments </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment', window );">Liquid investments purchased with original maturities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">three months or less<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired', window );">Percentage of likelihood of indefinite lived intangible assets being impaired</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Change in fair value of contingent liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1,800)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber', window );">Stock options and restricted stock units outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,367,628<span></span>
</td>
<td class="nump">9,578,322<span></span>
</td>
<td class="nump">9,008,185<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments | Segments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,769<span></span>
</td>
<td class="nump">$ 2,321<span></span>
</td>
<td class="nump">$ 6,176<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Up-front payment received from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member] | Customer Concentration Risk [Member] | Total revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="nump">46.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member] | Collaboration Contract Performance Period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic', window );">Increase in basic net loss per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ChangeInAccountingEstimateDecreaseInRevenues', window );">Decrease in revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="nump">$ 4,300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Up-front payment received from agreement</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer [Member] | ASU No. 2014-09 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Up-front payment received from agreement</a></td>
<td class="nump">$ 70,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer [Member] | Customer Concentration Risk [Member] | Total revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Dow Agro Sciences [Member] | Customer Concentration Risk [Member] | Total revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,333<span></span>
</td>
<td class="nump">$ 2,181<span></span>
</td>
<td class="nump">$ 2,167<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Up-front payment received from agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member] | Customer Concentration Risk [Member] | Total revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17.00%<span></span>
</td>
<td class="nump">40.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember', window );">Biogen Inc [Member] | Customer Concentration Risk [Member] | Total revenues [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Percentage of revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful lives of related assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | ASU No. 2014-09 [Member] | Pro Forma [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Organization and Summary of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1', window );">Estimated impact of the adoption of standard</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalent maturity period highly liquid investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CashEquivalentMaturityPeriodHighlyLiquidInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>invest:dateStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ChangeInAccountingEstimateDecreaseInRevenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in accounting estimate decrease in revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ChangeInAccountingEstimateDecreaseInRevenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Change in accounting estimate, increase in income (loss) per share, basic.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ChangeInAccountingEstimateIncreaseInIncomeLossPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum percentage of likelihood of indefinite lived intangible assets being impaired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MinimumPercentageOfLikelihoodOfIndefiniteLivedIntangibleAssetsBeingImpaired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Organization and summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OrganizationAndSummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options and restricted stock units outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAndRestrictedStockUnitsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6351-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13531-108611<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84177426&amp;loc=d3e6404-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77997519&amp;loc=d3e13537-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cumulative effect of the change in accounting principle or new accounting pronouncement on retained earnings or other components of equity or net assets in the statement of financial position as of the beginning of the earliest period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22580-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=64853466&amp;loc=d3e22499-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementOrChangeInAccountingPrincipleCumulativeEffectOfChangeOnEquityOrNetAssets1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_CollaborationContractPerformancePeriodMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=sgmo_CollaborationContractPerformancePeriodMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201409Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BiogenIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ProFormaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6785604832">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">$ 223,379<span></span>
</td>
<td class="nump">$ 139,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">28,885<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">194,494<span></span>
</td>
<td class="nump">120,474<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">223,379<span></span>
</td>
<td class="nump">139,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Commercial paper securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">110,247<span></span>
</td>
<td class="nump">23,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Level 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Level 1 [Member] | Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">194,494<span></span>
</td>
<td class="nump">120,474<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total cash equivalents and marketable securities</a></td>
<td class="nump">199,089<span></span>
</td>
<td class="nump">120,474<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Level 2 [Member] | Commercial paper securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">110,247<span></span>
</td>
<td class="nump">23,185<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Corporate debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">75,755<span></span>
</td>
<td class="nump">10,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | Corporate debt securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">75,755<span></span>
</td>
<td class="nump">10,004<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | U.S. government sponsored entity debt securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">8,492<span></span>
</td>
<td class="nump">87,285<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair value on recurring basis [Member] | U.S. government sponsored entity debt securities [Member] | Level 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Total marketable securities</a></td>
<td class="nump">$ 8,492<span></span>
</td>
<td class="nump">$ 87,285<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of debt securities categorized neither as held-to-maturity nor trading.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 25<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=75030427&amp;loc=d3e22054-111558<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82896770&amp;loc=d3e26610-111562<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27161-111563<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)-(g)<br> -URI http://asc.fasb.org/extlink&amp;oid=75019621&amp;loc=d3e62557-112803<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774707552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurement - Additional Information (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1', window );">Decrease in the total fair value of contingent consideration</a></td>
<td class="num">$ (1,800)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the value of a contingent consideration liability, including, but not limited to, differences arising upon settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e7008-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784865616">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2014</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 49,826<span></span>
</td>
<td class="nump">$ 22,061<span></span>
</td>
<td class="nump">$ 69,482<span></span>
</td>
<td class="nump">$ 6,030<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">223,634<span></span>
</td>
<td class="nump">139,416<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">223,379<span></span>
</td>
<td class="nump">139,466<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember', window );">Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">194,749<span></span>
</td>
<td class="nump">120,424<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">76<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
<td class="num">(255)<span></span>
</td>
<td class="num">(26)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">194,494<span></span>
</td>
<td class="nump">120,474<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">24,290<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">4,595<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember', window );">Commercial paper securities [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">110,365<span></span>
</td>
<td class="nump">23,112<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">73<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
<td class="num">(118)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">110,247<span></span>
</td>
<td class="nump">23,185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember', window );">Cash equivalents [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">28,885<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Total cash equivalents</a></td>
<td class="nump">28,885<span></span>
</td>
<td class="nump">18,992<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate debt securities [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">75,886<span></span>
</td>
<td class="nump">10,005<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
<td class="num">(131)<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">75,755<span></span>
</td>
<td class="nump">10,004<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember', window );">U.S. government sponsored entity debt securities [Member] | Available-for-sale securities [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Schedule Of Available For Sale Securities [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAmortizedCost', window );">Amortized Cost</a></td>
<td class="nump">8,498<span></span>
</td>
<td class="nump">87,307<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized (Losses)</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(25)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Estimated Fair Value</a></td>
<td class="nump">$ 8,492<span></span>
</td>
<td class="nump">$ 87,285<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets accumulated gross unrealized gain before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AssetsAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets accumulated gross unrealized loss before tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AssetsAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AssetsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Assets amortized cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AssetsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=66048111&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3044-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InformationByCategoryOfDebtSecurityAxis=us-gaap_AvailableforsaleSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CommercialPaperMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentTypeAxis=us-gaap_CashEquivalentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MajorTypesOfDebtAndEquitySecuritiesAxis=us-gaap_USGovernmentSponsoredEnterprisesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6923161360">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments Debt And Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities', window );">Investments maturity period</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses', window );">Realized losses from the sale of available-for-sale securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OtherThanTemporarilyImpairedInvestment', window );">Investments other-than-temporarily impaired</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investments maturity dates available for sale securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InvestmentsMaturityDatesAvailableForSaleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OtherThanTemporarilyImpairedInvestment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Other than temporarily impaired investment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OtherThanTemporarilyImpairedInvestment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This item represents the gross loss realized on the sale of debt or equity securities categorized neither as held-to-maturity nor trading securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82897076&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesGrossRealizedLosses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769417568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock-Based Compensation Expense (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,089<span></span>
</td>
<td class="nump">$ 15,057<span></span>
</td>
<td class="nump">$ 11,730<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">5,031<span></span>
</td>
<td class="nump">6,463<span></span>
</td>
<td class="nump">6,444<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Employee Service Share Based Compensation Allocation Of Recognized Period Costs [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 4,058<span></span>
</td>
<td class="nump">$ 8,594<span></span>
</td>
<td class="nump">$ 5,286<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5047-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772247936">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 16,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">2 years 9 months 14 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount', window );">Capitalized stock-based employee compensation expense</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted-average estimated fair value per share of options granted</a></td>
<td class="nump">$ 4.10<span></span>
</td>
<td class="nump">$ 3.14<span></span>
</td>
<td class="nump">$ 5.72<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of common stock under employee stock purchase plan, shares</a></td>
<td class="nump">253,994<span></span>
</td>
<td class="nump">202,711<span></span>
</td>
<td class="nump">128,181<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice', window );">Stock issued under employee stock purchase plans, average exercise price</a></td>
<td class="nump">$ 3.22<span></span>
</td>
<td class="nump">$ 4.04<span></span>
</td>
<td class="nump">$ 7.10<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue', window );">Weighted-average estimated fair value of shares purchased under ESPP plan</a></td>
<td class="nump">$ 2.37<span></span>
</td>
<td class="nump">$ 2.27<span></span>
</td>
<td class="nump">$ 4.42<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total compensation cost related to unvested stock options and RSU</a></td>
<td class="nump">$ 700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Weighted-average period of unvested stock options and RSU</a></td>
<td class="text">1 year 10 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Employee stock purchase plan rights weighted average estimated fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_EmployeeStockPurchasePlanRightsWeightedAverageEstimatedFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Stock issued under employee stock purchase plans average exercise price.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_StockIssuedUnderEmployeeStockPurchasePlansAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the compensation cost capitalized during the period arising from equity-based compensation arrangements (for example, shares of stock, units, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsCapitalizedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772312224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail) - Employee Stock Options [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.81%<span></span>
</td>
<td class="nump">1.13%<span></span>
</td>
<td class="nump">1.46%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
<td class="text">5 years 8 months 23 days<span></span>
</td>
<td class="text">5 years 3 months 10 days<span></span>
</td>
<td class="text">5 years 3 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.68%<span></span>
</td>
<td class="nump">0.66%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">2.28%<span></span>
</td>
<td class="nump">1.61%<span></span>
</td>
<td class="nump">1.58%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
<td class="text">5 years 9 months 29 days<span></span>
</td>
<td class="text">5 years 3 months 14 days<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.72%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
<td class="nump">0.67%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredCompensationArrangementWithIndividualShareBasedPaymentsByTypeOfDeferredCompensationAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772187680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail) - 2010 Employee Stock Purchase Plan [Member]<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield of stock</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.44%<span></span>
</td>
<td class="nump">0.41%<span></span>
</td>
<td class="nump">0.06%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">6 months<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.66%<span></span>
</td>
<td class="nump">0.71%<span></span>
</td>
<td class="nump">0.55%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected life of option (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">0.82%<span></span>
</td>
<td class="nump">0.76%<span></span>
</td>
<td class="nump">0.70%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=27013229&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6786152224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 28, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 10, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 31, 2014 </div>
<div>USD ($) </div>
<div>Program</div>
</th>
<th class="th">
<div>Jun. 30, 2012 </div>
<div>Targets</div>
</th>
<th class="th">
<div>Jan. 31, 2012 </div>
<div>USD ($) </div>
<div>Targets</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Product</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2014 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfResearchProgram', window );">Number of research programs | Program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember', window );">Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 70,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved', window );">Potential amount eligible to receive for certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">32 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 53,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">17,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved', window );">Potential amount eligible to receive for certain milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 160,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentsReceived', window );">Milestone payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement', window );">Number of products approved | Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">44 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,769,000<span></span>
</td>
<td class="nump">$ 2,321,000<span></span>
</td>
<td class="nump">$ 6,176,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRevenue', window );">Deferred revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,333,000<span></span>
</td>
<td class="nump">$ 2,181,000<span></span>
</td>
<td class="nump">2,167,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateNumberOfGeneTargets', window );">Aggregate number of gene targets | Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfInitialGeneTargets', window );">Number of initial gene targets | Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfGeneTargets', window );">Number of gene targets | Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfAdditionalGeneTargets', window );">Number of additional gene targets | Targets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized', window );">Recognition of milestone</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Amount reimbursed and recognized related to prior obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember', window );">SB-525 [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">266,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember', window );">C9ORF72 [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="nump">$ 12,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | SB-525 [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">300,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | Other Products [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 175,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | C9ORF72 [Member] | Pfizer [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved', window );">Potential amount eligible to receive for certain milestones</a></td>
<td class="nump">60,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive', window );">Potential amount to be funded for achievement of specified commercialized and sales milestones</a></td>
<td class="nump">$ 90,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue achieved.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueAchieved</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate additional revenue recognition milestone method revenue eligible to receive.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateAdditionalRevenueRecognitionMilestoneMethodRevenueEligibleToReceive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AggregateNumberOfGeneTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of gene targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AggregateNumberOfGeneTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Collaboration and license agreements number of products approved under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CollaborationAndLicenseAgreementsNumberOfProductsApprovedUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payments received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfAdditionalGeneTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional gene targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfAdditionalGeneTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfGeneTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of gene targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfGeneTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfInitialGeneTargets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of initial gene targets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfInitialGeneTargets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfResearchProgram">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of research program.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfResearchProgram</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 13.A.4(a).Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=65893310&amp;loc=d3e214044-122780<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6488393&amp;loc=d3e606610-122999<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of consideration recognized during the period for the milestone or milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 605<br> -SubTopic 28<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=68058744&amp;loc=SL6892177-166501<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_PfizerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_PfizerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=sgmo_SBFiveTwoFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=sgmo_CNineORFSevenTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=sgmo_OtherProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=sgmo_OtherProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772607824">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember', window );">Bioverativ Inc [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
<td class="nump">$ 1,769,000<span></span>
</td>
<td class="nump">$ 2,321,000<span></span>
</td>
<td class="nump">$ 6,176,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
<td class="nump">10,489,000<span></span>
</td>
<td class="nump">6,565,000<span></span>
</td>
<td class="nump">7,769,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
<td class="nump">12,258,000<span></span>
</td>
<td class="nump">8,886,000<span></span>
</td>
<td class="nump">13,945,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember', window );">Shire AG [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicenseAndServicesRevenue', window );">Recognition of upfront fee</a></td>
<td class="nump">2,333,000<span></span>
</td>
<td class="nump">2,181,000<span></span>
</td>
<td class="nump">2,167,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement', window );">Research services</a></td>
<td class="nump">116,000<span></span>
</td>
<td class="nump">1,096,000<span></span>
</td>
<td class="nump">13,584,000<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
<td class="nump">2,449,000<span></span>
</td>
<td class="nump">3,277,000<span></span>
</td>
<td class="nump">15,751,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenuesAbstract', window );"><strong>Revenues:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
<td class="nump">452,000<span></span>
</td>
<td class="nump">137,000<span></span>
</td>
<td class="nump">390,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">License fee revenues</a></td>
<td class="nump">267,000<span></span>
</td>
<td class="nump">1,140,000<span></span>
</td>
<td class="nump">4,463,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractsRevenue', window );">Total</a></td>
<td class="nump">$ 719,000<span></span>
</td>
<td class="nump">$ 1,277,000<span></span>
</td>
<td class="nump">$ 4,853,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServiceRevenueUnderCollaborationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research service revenue under collaboration agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchServiceRevenueUnderCollaborationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractsRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue earned from products sold or services provided under the terms of a contract, including, but not limited to, government contracts and construction contracts, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractsRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicenseAndServicesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue from multiple-deliverable arrangements that include licensing fees and services revenue. Licensing revenue is consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity. Services revenue may be derived by providing other, nonspecified, services during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(d),(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicenseAndServicesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_BioverativIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_ShireAgMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772661152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2009</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2007</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under license agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ResearchServicesPeriod', window );">Developed laboratory research reagents, research services period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="nump">$ 20,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Public offering, common stock shares issued</a></td>
<td class="nump">636,133<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ReducedRoyaltyRate', window );">Reduced royalty rate</a></td>
<td class="nump">10.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AdditionalMilestoneReceivableUnderAgreement', window );">Funding available under the amended agreement</a></td>
<td class="nump">$ 25,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member] | Upfront license fee [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UpfrontLicenseFee', window );">Upfront license fee</a></td>
<td class="nump">15,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued under license agreement</a></td>
<td class="nump">$ 4,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember', window );">Sigma-Aldrich Corporation [Member] | License agreement terms [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned', window );">Revenues under agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AdditionalMilestoneReceivableUnderAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Additional milestone receivable under agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AdditionalMilestoneReceivableUnderAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ReducedRoyaltyRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reduced royalty rate.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ReducedRoyaltyRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ResearchServicesPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Research services period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ResearchServicesPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UpfrontLicenseFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront license fee.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_UpfrontLicenseFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of compensation earned (contract income) under a research and development arrangement accounted for as a contract to perform research and development for others.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23199-108380<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=6420387&amp;loc=d3e23221-108380<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersCompensationEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_SigmaAldrichCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_UpfrontLicenseFeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_UpfrontLicenseFeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6772793328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail) - Dow Agro Sciences [Member] - License agreement terms [Member] - USD ($)<br></strong></div></th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2005</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_InitialResearchTermOfAgreement', window );">Research program to develop laboratory research reagents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OneTimeLicenseFeeEarned', window );">One-time license fee earned on exercise of option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyRevenue', window );">Royalty revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,300,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing', window );">Percentage of royalties to be received from sublicensing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement', window );">Previously agreed research, development and commercialization milestone payments, and royalties on sales of products</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FeeDue', window );">Fee due</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod', window );">Minimum license annual fees specific reckoning period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">11 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LicensesRevenue', window );">Revenue attributable to research and development</a></td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="nump">$ 5,100,000<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems', window );"><strong>Research and Development Arrangement, Contract to Perform for Others [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AnnualFeesRelatedToAgreement', window );">Annual fees</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AnnualFeesRelatedToAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Annual fees related to agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AnnualFeesRelatedToAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FeeDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fee due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_FeeDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_InitialResearchTermOfAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Initial research term of agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_InitialResearchTermOfAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone payment and royalty revenue of previous agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestonePaymentAndRoyaltyRevenueOfPreviousAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum sublicense annual fees specific reckoning period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MinimumSublicenseAnnualFeesSpecificReckoningPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OneTimeLicenseFeeEarned">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>One time license fee earned.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OneTimeLicenseFeeEarned</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of royalties to be received from sublicensing.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PercentageOfRoyaltiesToBeReceivedFromSublicensing</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LicensesRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period relating to consideration received from another party for the right to use, but not own, certain of the entity's intangible assets. Licensing arrangements include, but are not limited to, rights to use a patent, copyright, technology, manufacturing process, software or trademark. Licensing fees are generally, but not always, fixed as to amount and not dependent upon the revenue generated by the licensing party. An entity may receive licensing fees for licenses that also generate royalty payments to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LicensesRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Revenue earned during the period from the leasing or otherwise lending to a third party the entity's rights or title to certain property. Royalty revenue is derived from a percentage or stated amount of sales proceeds or revenue generated by the third party using the entity's property. Examples of property from which royalties may be derived include patents and oil and mineral rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_DowAgroSciencesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=us-gaap_LicenseAgreementTermsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769477808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Acquisition of Ceregene - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Oct. 31, 2013</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Mar. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,870,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,585,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=sgmo_CeregeneIncMember', window );">Ceregene, Inc. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionLineItems', window );"><strong>Business Acquisition [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued', window );">Common stock, transferred, shares</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable', window );">Sangamo shares of common stock</a></td>
<td class="nump">$ 1,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment', window );">Contingent earn-out</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationContingentConsiderationLiability', window );">Fair value of contingent earn-out liability</a></td>
<td class="nump">1,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Estimated fair values of in-process research and development</a></td>
<td class="nump">1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment charge</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 1,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Business acquisition contingent consideration earn-out payment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BusinessAcquisitionContingentConsiderationEarnOutPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of equity interests issued or issuable to acquire entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionEquityInterestsIssuedOrIssuableNumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of equity interests of the acquirer, including instruments or interests issued or issuable in consideration for the business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6578-128477<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=6911251&amp;loc=d3e6613-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferredEquityInterestsIssuedAndIssuable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationContingentConsiderationLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized arising from contingent consideration in a business combination.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 35<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6911338&amp;loc=d3e6819-128478<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 25<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=6911189&amp;loc=d3e6408-128476<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationContingentConsiderationLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated impairment loss of an asset representing future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13770-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=77989000&amp;loc=SL49117168-202975<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of loss from the write-down of an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13854-109267<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6388280&amp;loc=d3e13777-109266<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=35741047&amp;loc=d3e13816-109267<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=sgmo_CeregeneIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=sgmo_CeregeneIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769470592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">$ 16,367<span></span>
</td>
<td class="nump">$ 12,048<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less accumulated depreciation and amortization</a></td>
<td class="num">(6,951)<span></span>
</td>
<td class="num">(5,639)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">31,066<span></span>
</td>
<td class="nump">6,557<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Laboratory equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">7,572<span></span>
</td>
<td class="nump">6,206<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">1,494<span></span>
</td>
<td class="nump">636<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">3,425<span></span>
</td>
<td class="nump">1,330<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember', window );">Buildings [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, Gross</a></td>
<td class="nump">3,876<span></span>
</td>
<td class="nump">3,876<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">$ 21,650<span></span>
</td>
<td class="nump">$ 148<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6787374768">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 1,498<span></span>
</td>
<td class="nump">$ 997<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="nump">300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember', window );">Richmond Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="nump">21,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="nump">$ 20,900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,900<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeaseCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build to suit lease, costs capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeaseCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6782350976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Property</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits', window );">Additional property available under lease | Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NumberOfBuiltToSuitLeaseProperties', window );">Number of built-to-suit lease properties | Property</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember', window );">Intellectual Property [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_LicenseCommitments', window );">License commitments | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember', window );">Richmond Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeasePropertyLeased', window );">Property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeasePropertyLeased', window );">Property leased | ft&#178;</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member] | Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Other commitments for next twelve months | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember', window );">Services Agreement to Provide Dedicated Capacity to Supply Preclinical and Clinical Programs [Member] | Tenant Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCommitmentDueInNextTwelveMonths', window );">Other commitments for next twelve months | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember', window );">Operating Lease One [Member] | Research and Office Space [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Aug. 31,  2019<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseTwoMember', window );">Operating Lease Two [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Area of space leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jul. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeasePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit lease, property leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeasePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_LicenseCommitments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License commitments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_LicenseCommitments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NumberOfBuiltToSuitLeaseProperties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of built-to-suit lease properties.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NumberOfBuiltToSuitLeaseProperties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentDueInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Minimum amount of other commitment maturing in the next fiscal year following the latest fiscal year for commitments not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in this taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentDueInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of units (items of property) under operating lease arrangements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseNumberOfUnits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FiniteLivedIntangibleAssetsByMajorClassAxis=us-gaap_IntellectualPropertyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_RichmondBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCommitmentsAxis=sgmo_TenantImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCommitmentsAxis=sgmo_TenantImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_ServicesAgreementToProvideDedicatedCapacityToSupplyPreclinicalAndClinicalProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=sgmo_ResearchAndOfficeSpaceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertySubjectToOrAvailableForOperatingLeaseAxis=sgmo_PropertySubjectToOperatingLeaseTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769342240">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments And Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2018</a></td>
<td class="nump">$ 1,685<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2019</a></td>
<td class="nump">2,925<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2020</a></td>
<td class="nump">3,795<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2021</a></td>
<td class="nump">3,798<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2022</a></td>
<td class="nump">3,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">23,896<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total minimum payments</a></td>
<td class="nump">$ 39,434<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789089648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Additional Information (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jun. 26, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 22, 2015 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>Installment </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 10, 2017 </div>
<div>shares</div>
</th>
<th class="th">
<div>May 26, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 07, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 81,573<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SpecifiedStockholderOwnershipPercentage', window );">Specified stockholder ownership percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder', window );">Purchase price of common stock percent under stock incentive plans for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder', window );">Stock option maximum term for specified stockholder</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockExchangeRatio', window );">Share of common stock subject to a stock option or stock appreciation right</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Fixed ratio shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,300<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="nump">$ 6,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71,658<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">28,864<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Options vested and expected to vest, aggregate intrinsic value | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 71,700<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation', window );">Total payments for the employees' tax obligations to taxing authorities | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 654<span></span>
</td>
<td class="nump">$ 776<span></span>
</td>
<td class="nump">$ 1,546<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember', window );">Share-Based Compensation Awards, Tranche 2 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember', window );">Share-Based Compensation Awards, Tranche 3 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember', window );">2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock options vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm', window );">Stock options expiration term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance', window );">Stock reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance', window );">Additional shares authorized under 2013 stock incentive plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,601,633<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_TwoThousandFourStockIncentivePlanMember', window );">2004 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance', window );">Stock reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember', window );">Amended and Restated 2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember', window );">2010 Employee Stock Purchase Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Percent of fair value per share of common stock on option grant date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Stock reserved for issuance under plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanOfferingPeriod', window );">Purchase plan offering period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_PurchasePlanPurchasePeriod', window );">Purchase plan purchase period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Shares reserved for issuance of future awards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">835,674<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member] | 2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock option maximum term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation', window );">Shares subject to repurchase rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Employee Stock Options [Member] | 2013 Stock Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Options granted under the 2013 Plan generally vest over four years at a rate of 25 percent one year from the grant date and one thirty-sixth per month thereafter and expire ten years after the grant, or earlier upon employment termination.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights', window );">Share based vesting rights</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">These awards generally vest as follows: one-third of the award will vest in a series of three successive equal annual installments.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Restricted stock units awarded</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,600<span></span>
</td>
<td class="nump">60,000<span></span>
</td>
<td class="nump">446,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value per award of restricted stock units | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.85<span></span>
</td>
<td class="nump">$ 5.16<span></span>
</td>
<td class="nump">$ 9.45<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment', window );">Share-based compensation arrangement by share-based payment award, number of vesting installment | Installment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested', window );">Aggregate fair value of RSUs vested in period | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,200<span></span>
</td>
<td class="nump">$ 4,800<span></span>
</td>
<td class="nump">$ 4,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Shares withheld from issuance in order to pay employee taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,243<span></span>
</td>
<td class="nump">165,181<span></span>
</td>
<td class="nump">172,807<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Share-Based Compensation Awards, Tranche 1 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Stock options granted vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.33%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember', window );">ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance', window );">Common stock issuable and sellable under offering agreement | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Total shares issued</a></td>
<td class="nump">11,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,371,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Public offering price of common stock issued | $ / shares</a></td>
<td class="nump">$ 7.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="nump">$ 78,100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Stock [Member] | ATM Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Total shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">871,149<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_NetProceedsFromIssuancePublicOffering', window );">Net proceeds from issuance of common stock, after deducting offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsForCommissions', window );">Commission paid to sales agent | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock capital shares value reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockCapitalSharesValueReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_CommonStockExchangeRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Common stock exchange ratio.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_CommonStockExchangeRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_NetProceedsFromIssuancePublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Net proceeds from issuance public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_NetProceedsFromIssuancePublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanOfferingPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan offering period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanOfferingPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_PurchasePlanPurchasePeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase plan purchase period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_PurchasePlanPurchasePeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of additional shares reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of shares initially reserved for issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesInitiallyReservedForIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award number of vesting installment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfVestingInstallment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options expiration term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options maximum term for specified stock holder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsMaximumTermForSpecifiedStockHolder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award purchase price of common stock percent for specified stockholder.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardPurchasePriceOfCommonStockPercentForSpecifiedStockholder</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SpecifiedStockholderOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Specified stockholder ownership percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SpecifiedStockholderOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for commissions during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow to satisfy an employee's income tax withholding obligation as part of a net-share settlement of a share-based award.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 25<br> -Paragraph 19A<br> -URI http://asc.fasb.org/extlink&amp;oid=96949009&amp;loc=SL79513924-113897<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsRelatedToTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Description of award terms as to how many shares or portion of an award are no longer contingent on satisfaction of either a service condition, market condition or a performance condition, thereby giving the employee the legal right to convert the award to shares, to sell the shares, and be entitled to the cash proceeds of such sale. For example, vesting may be expressed as being 25 percent of the shares under option on each anniversary of the grant date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of shares (or other type of equity) originally approved (usually by shareholders and board of directors), net of any subsequent amendments and adjustments, for awards under the equity-based compensation plan. As stock or unit options and equity instruments other than options are awarded to participants, the shares or units remain authorized and become reserved for issuance under outstanding awards (not necessarily vested).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards vested. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For net-share settlement of share-based awards when the employer settles employees' income tax withholding obligations, this element represents the number of shares the employees use to repay the employer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock subject to repurchase or cancellation determined by relating the portion of time within a reporting period that these shares have been outstanding to the total time in that period. Common stock subject to repurchase are outstanding common shares that are contingently returnable (that is, subject to recall).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=96947427&amp;loc=d3e2646-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesCommonStockSubjectToRepurchaseOrCancellation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_TwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_TwoThousandFourStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_TwoThousandFourStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_AmendedAndRestatedTwoThousandThirteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=sgmo_EmployeeStockPurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=sgmo_AtTheMarketOfferingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773193696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Option Activity (Detail)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2016, Number of Shares | shares</a></td>
<td class="nump">9,256,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Options granted, Number of Shares | shares</a></td>
<td class="nump">3,091,125<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Options exercised, Number of Shares | shares</a></td>
<td class="num">(2,030,815)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Options canceled, Number of Shares | shares</a></td>
<td class="num">(2,029,360)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding at December 31, 2017, Number of Shares | shares</a></td>
<td class="nump">8,287,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Options vested and expected to vest at December 31, 2017, Number of Shares | shares</a></td>
<td class="nump">8,287,456<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Options exercisable at December 31, 2017, Number of Shares | shares</a></td>
<td class="nump">3,881,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise per Share Price, Beginning Balance | $ / shares</a></td>
<td class="nump">$ 8.31<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted, Weighted-Average Exercise per Share Price | $ / shares</a></td>
<td class="nump">6.48<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Options exercised, Weighted-Average Exercise per Share Price | $ / shares</a></td>
<td class="nump">7.76<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Options canceled, Weighted-Average Exercise per Share Price | $ / shares</a></td>
<td class="nump">8.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, Weighted-Average Exercise per Share Price, Ending Balance | $ / shares</a></td>
<td class="nump">7.77<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Options vested and expected to vest at December 31, 2017, Weighted-Average Exercise Per Share Price | $ / shares</a></td>
<td class="nump">7.77<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Options exercisable at December 31, 2017, Weighted-Average Exercise per Share Price | $ / shares</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding at December, 31, 2017, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Options vested and expected to vest at December, 31, 2017, Weighted Average Remaining Contractual Term</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Options exercisable at December, 31, 2017, Weighted Average Remaining Contractual Term</a></td>
<td class="text">4 years 1 month 17 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding at December 31, 2017, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 71,658<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Options vested and expected to vest at December 31, 2017, Aggregate Intrinsic Value | $</a></td>
<td class="nump">71,658<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Options exercisable at December 31, 2017, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 28,864<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84159872&amp;loc=d3e21463-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6773347520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Stock Options Outstanding (Detail)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">8,287,456<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">6 years 8 months 8 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">3,881,078<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 8.99<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeOneMember', window );">$2.55 &#8211; $3.45 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">2.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 3.45<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">612,318<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">7 years 11 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">214,920<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 3.13<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTwoMember', window );">$3.50 &#8211; $3.50 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">3.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 3.50<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">1,527,625<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">9 years 25 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeThreeMember', window );">$3.55 &#8211; $5.41 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">$ 3.55<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 5.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">1,212,567<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">5 years 2 months 26 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">672,930<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 5.34<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFourMember', window );">$5.42 &#8211; $7.07 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">5.42<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 7.07<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">1,501,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">5 years 6 months 10 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">967,506<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 6.11<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFiveMember', window );">$7.20 &#8211; $9.41 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">7.20<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 9.41<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">1,199,546<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">7 years 2 months 1 day<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">551,162<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 9.06<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSixMember', window );">$9.45 &#8211; $13.35 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">9.45<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 13.35<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">885,599<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">5 years 6 months 7 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">659,946<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 11.92<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSevenMember', window );">$13.54 &#8211; $15.00 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">13.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 15<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">1,148,250<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">6 years 3 months 3 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">668,752<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 14.07<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeEightMember', window );">$15.11 &#8211; $18.26 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">15.11<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 18.26<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">178,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">7 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">124,561<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 16.41<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeNineMember', window );">$19.51 &#8211; $19.51 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">19.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 19.51<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">10,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">6 years 1 month 20 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">9,583<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 19.51<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTenMember', window );">$19.80 &#8211; $19.80 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems', window );"><strong>Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit', window );">Lower Range of Exercise Price</a></td>
<td class="nump">19.80<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit', window );">Upper Range of Exercise Price</a></td>
<td class="nump">$ 19.80<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions', window );">Options Outstanding and Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">12,500<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2', window );">Options Outstanding and Exercisable Weighted Average Remaining Contractual Life (In years)</a></td>
<td class="text">6 years 2 months 23 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions', window );">Options Exercisable Number of Shares of common stock subject to options | shares</a></td>
<td class="nump">11,718<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1', window );">Options Exercisable Weighted Average Exercise Price</a></td>
<td class="nump">$ 19.80<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The floor of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding exercisable stock options as of the balance sheet date in the customized range of exercise prices for which the market and performance vesting condition has been satisfied.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfExercisableOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares reserved for issuance pertaining to the outstanding stock options as of the balance sheet date for all option plans in the customized range of exercise prices.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeNumberOfOutstandingOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The ceiling of a customized range of exercise prices for purposes of disclosing shares potentially issuable under outstanding stock option awards on all stock option plans and other required information pertaining to awards in the customized range.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average exercise price as of the balance sheet date for those equity-based payment arrangements exercisable and outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term of outstanding stock options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeOutstandingOptionsWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFiveMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeFiveMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSixMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSixMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSevenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeSevenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeEightMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeEightMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeNineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeNineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis=sgmo_RangeTenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784052608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at December 31, 2016, Number of Shares</a></td>
<td class="nump">321,816<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">RSUs awarded, Number of Shares</a></td>
<td class="nump">12,600<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">RSUs released, Number of Shares</a></td>
<td class="num">(112,917)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">RSUs forfeited, Number of Shares</a></td>
<td class="num">(141,327)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">RSUs outstanding at December 31, 2017, Number of Shares</a></td>
<td class="nump">80,172<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber', window );">RSUs vested and expected to vest at December 31, 2017, Number of Shares</a></td>
<td class="nump">80,172<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms', window );">RSUs outstanding at December, 31, 2017, Weighted Average Remaining Contractual Term</a></td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm', window );">RSUs vested and expected to vest at December 31, 2017, Weighted Average Remaining Contractual Term</a></td>
<td class="text">10 months 24 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding', window );">RSUs outstanding at December 31, 2017, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue', window );">RSUs vested and expected to vest at December 31, 2017, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 1,315<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options released in period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest aggregate intrinsic value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest outstanding number.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award equity instruments other than options vested and expected to vest weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedAndExpectedToVestWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for equity-based awards excluding options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=96867065&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsOutstandingWeightedAverageRemainingContractualTerms</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Intrinsic value of equity-based compensation awards outstanding. Excludes stock and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6774770432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Benefit for Income Taxes (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (12)<span></span>
</td>
<td class="num">$ (5,563)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State</a></td>
<td class="num">(2)<span></span>
</td>
<td class="num">(159)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Subtotal</a></td>
<td class="num">(14)<span></span>
</td>
<td class="num">(5,722)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (5,722)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784667328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromClaimsSettlement', window );">Claim settlement received</a></td>
<td class="nump">$ 14,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,452,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax', window );">Settlement recognized as additional paid-in capital, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,495,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation', window );">Income tax benefit, claims settlement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase (decrease) in deferred tax assets valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (28,900,000)<span></span>
</td>
<td class="nump">$ 23,800,000<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Deferred tax assets, net operating loss carryforwards for federal</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">475,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Deferred tax assets, net operating loss carryforwards for state</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal', window );">Federal research tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal', window );">State research tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_FederalResearchTaxCreditCarryforwardExpirationYear', window );">Tax credit carryforward, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance', window );">Federal tax rate reduction net of valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Accrued interest and/or penalties</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">35.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember', window );">Scenario Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal statutory income tax rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards, expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research federal.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets tax credit carryforwards research state and local.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_DeferredTaxAssetsTaxCreditCarryforwardsResearchStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_FederalResearchTaxCreditCarryforwardExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Federal research tax credit carryforward expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_FederalResearchTaxCreditCarryforwardExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income taxes.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromClaimsSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from claims settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromClaimsSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement recognized as additional paid-in capital, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax cuts and jobs act of 2017, reduction of net of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_TaxCutsAndJobsActOf2017ReductionOfNetOfValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income tax expense (benefit) for continuing operations, discontinued operations, other comprehensive income, and items charged (credited) directly to shareholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507043&amp;loc=d3e38679-109324<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitIntraperiodTaxAllocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=us-gaap_ScenarioPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6658053488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Tax at federal statutory rate</a></td>
<td class="num">$ (18,553)<span></span>
</td>
<td class="num">$ (24,369)<span></span>
</td>
<td class="num">$ (15,785)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net</a></td>
<td class="nump">795<span></span>
</td>
<td class="num">(747)<span></span>
</td>
<td class="nump">4,840<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate', window );">Federal Rate Change</a></td>
<td class="nump">53,045<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation', window );">Non-deductible stock compensation</a></td>
<td class="nump">2,120<span></span>
</td>
<td class="nump">2,781<span></span>
</td>
<td class="nump">1,085<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research credits</a></td>
<td class="num">(869)<span></span>
</td>
<td class="num">(1,424)<span></span>
</td>
<td class="num">(814)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="num">(36,575)<span></span>
</td>
<td class="nump">23,773<span></span>
</td>
<td class="nump">5,043<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">$ 37<span></span>
</td>
<td class="num">(28)<span></span>
</td>
<td class="num">(91)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (14)<span></span>
</td>
<td class="num">$ (5,722)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income tax reconciliation nondeductible expense income share based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_IncomeTaxReconciliationNondeductibleExpenseIncomeShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations, attributable to increase (decrease) in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32059-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6784029568">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 91,308<span></span>
</td>
<td class="nump">$ 114,222<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="nump">15,147<span></span>
</td>
<td class="nump">12,518<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock-based compensation</a></td>
<td class="nump">3,168<span></span>
</td>
<td class="nump">8,565<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">934<span></span>
</td>
<td class="nump">2,918<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">2,276<span></span>
</td>
<td class="nump">3,492<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred tax asset</a></td>
<td class="nump">112,833<span></span>
</td>
<td class="nump">141,715<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="nump">$ 112,833<span></span>
</td>
<td class="nump">$ 141,715<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=96869850&amp;loc=d3e28680-109314<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6769255808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 5,045<span></span>
</td>
<td class="nump">$ 8,330<span></span>
</td>
<td class="nump">$ 3,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Additions based on tax positions related to the current year</a></td>
<td class="nump">622<span></span>
</td>
<td class="nump">1,023<span></span>
</td>
<td class="nump">557<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions', window );">Additions for tax positions of prior years</a></td>
<td class="num">(8)<span></span>
</td>
<td class="nump">27<span></span>
</td>
<td class="nump">4,335<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions', window );">Reductions for tax positions of prior years</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,335)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 5,659<span></span>
</td>
<td class="nump">$ 5,045<span></span>
</td>
<td class="nump">$ 8,330<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized tax benefits increase decrease resulting from prior period tax positions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_UnrecognizedTaxBenefitsIncreaseDecreaseResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from tax positions taken in prior period tax returns.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6920824816">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables And Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 2,580<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_AccruedResearchAndDevelopmentExpenses', window );">Accrued research and development expenses</a></td>
<td class="nump">7,898<span></span>
</td>
<td class="nump">2,887<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">1,318<span></span>
</td>
<td class="nump">270<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">498<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities', window );">Other</a></td>
<td class="nump">1,386<span></span>
</td>
<td class="nump">26<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Total accounts payable and accrued liabilities</a></td>
<td class="nump">$ 11,035<span></span>
</td>
<td class="nump">$ 6,261<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_AccruedResearchAndDevelopmentExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_AccruedResearchAndDevelopmentExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndOtherAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities incurred and payable to vendors for goods and services received, and accrued liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndOtherAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6918169424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan - Additional Information (Detail) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Compensation And Retirement Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined contribution plan, employer's matching contribution percent</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch', window );">Percentage of employer matching contribution to employee contribution</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Maximum percentage limit of employee contributions</a></td>
<td class="nump">8.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
<td class="nump">6.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount', window );">Defined contribution plan, maximum employer's contribution per employee</a></td>
<td class="nump">$ 4,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Aggregate employers contributions to defined contribution plan</a></td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage employer matches of the employee's percentage contribution matched.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercentOfMatch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum amount the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeeAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789661152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="8">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Sep. 30, 2017</div></th>
<th class="th"><div>Jun. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Sep. 30, 2016</div></th>
<th class="th"><div>Jun. 30, 2016</div></th>
<th class="th"><div>Mar. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract', window );"><strong>Selected Quarterly Financial Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">$ 13,077<span></span>
</td>
<td class="nump">$ 11,812<span></span>
</td>
<td class="nump">$ 8,253<span></span>
</td>
<td class="nump">$ 3,425<span></span>
</td>
<td class="nump">$ 8,922<span></span>
</td>
<td class="nump">$ 2,823<span></span>
</td>
<td class="nump">$ 3,702<span></span>
</td>
<td class="nump">$ 3,942<span></span>
</td>
<td class="nump">$ 36,567<span></span>
</td>
<td class="nump">$ 19,389<span></span>
</td>
<td class="nump">$ 39,539<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Expenses</a></td>
<td class="nump">26,843<span></span>
</td>
<td class="nump">24,847<span></span>
</td>
<td class="nump">21,021<span></span>
</td>
<td class="nump">20,217<span></span>
</td>
<td class="nump">18,752<span></span>
</td>
<td class="nump">22,029<span></span>
</td>
<td class="nump">30,544<span></span>
</td>
<td class="nump">20,623<span></span>
</td>
<td class="nump">92,928<span></span>
</td>
<td class="nump">91,948<span></span>
</td>
<td class="nump">86,395<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (13,091)<span></span>
</td>
<td class="num">$ (12,354)<span></span>
</td>
<td class="num">$ (12,491)<span></span>
</td>
<td class="num">$ (16,632)<span></span>
</td>
<td class="num">$ (9,624)<span></span>
</td>
<td class="num">$ (18,965)<span></span>
</td>
<td class="num">$ (26,575)<span></span>
</td>
<td class="num">$ (16,494)<span></span>
</td>
<td class="num">$ (54,568)<span></span>
</td>
<td class="num">$ (71,658)<span></span>
</td>
<td class="num">$ (40,703)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share</a></td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.15)<span></span>
</td>
<td class="num">$ (0.17)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.14)<span></span>
</td>
<td class="num">$ (0.27)<span></span>
</td>
<td class="num">$ (0.38)<span></span>
</td>
<td class="num">$ (0.23)<span></span>
</td>
<td class="num">$ (0.70)<span></span>
</td>
<td class="num">$ (1.02)<span></span>
</td>
<td class="num">$ (0.58)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=98514028&amp;loc=d3e3602-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879574&amp;loc=d3e536633-122882<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 225<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879464&amp;loc=d3e573970-122913<br><br>Reference 5: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 225<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=63488584&amp;loc=d3e20235-122688<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SelectedQuarterlyFinancialInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SelectedQuarterlyFinancialInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6789650688">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Build-to-Suit Lease - Additional Information (Detail)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2017 </div>
<div>USD ($) </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2015 </div>
<div>ft&#178; </div>
<div>Option</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2016 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeasePropertyLeased', window );">Property leased | ft&#178;</a></td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">87,700<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">May 31,  2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease expiration period</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLeasesNumberOfExtensionOptions', window );">Number of lease term extension options | Option</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Letter of credit</a></td>
<td class="nump">$ 3.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 21.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member] | Building [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember', window );">Brisbane Build-to-Suit Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_PointPinoleBuildToSuitLeaseMember', window );">Point Pinole Build-to-Suit Lease [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeasePropertyLeased', window );">Property leased | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">41,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract', window );">Operating lease expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_OperatingLeasesNumberOfExtensionOptions', window );">Number of lease term extension options | Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_BuildToSuitLeaseCostsCapitalized', window );">Costs capitalized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseArrangementTypeAxis=sgmo_PointPinoleBuildToSuitLeaseMember', window );">Point Pinole Build-to-Suit Lease [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasedAssetsLineItems', window );"><strong>Operating Leased Assets [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm', window );">Lease agreement, extendable lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeaseCostsCapitalized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build to suit lease, costs capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeaseCostsCapitalized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_BuildToSuitLeasePropertyLeased">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Build-to-suit lease, property leased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_BuildToSuitLeasePropertyLeased</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_OperatingLeasesNumberOfExtensionOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Operating leases number of extension options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_OperatingLeasesNumberOfExtensionOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888426&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasingArrangementsOperatingLeasesTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasedAssetsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasedAssetsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_BrisbaneBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_BuildingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=sgmo_PointPinoleBuildToSuitLeaseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=sgmo_PointPinoleBuildToSuitLeaseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6939842480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Claims Settlement - Additional Information (Detail) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2015</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ClaimsSettlementLineItems', window );"><strong>Claims Settlement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ProceedsFromClaimsSettlement', window );">Claim settlement received</a></td>
<td class="nump">$ 14,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax', window );">Settlement recognized as additional paid-in capital, net of tax</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,495<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">5,722<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LitigationStatusAxis=sgmo_DisgorgementSettlementMember', window );">Disgorgement settlement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ClaimsSettlementLineItems', window );"><strong>Claims Settlement [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Benefit from income taxes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ClaimsSettlementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Claims settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ClaimsSettlementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ProceedsFromClaimsSettlement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Proceeds from claims settlement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ProceedsFromClaimsSettlement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Settlement recognized as additional paid-in capital, net of tax.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_SettlementRecognizedAsAdditionalPaidInCapitalNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a),(b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32639-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LitigationStatusAxis=sgmo_DisgorgementSettlementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LitigationStatusAxis=sgmo_DisgorgementSettlementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.8.0.1</span><table class="report" border="0" cellspacing="2" id="idp6935345056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Event - Additional Information (Detail) - Kite Pharma, Inc. ("Kite") [Member] - Collaboration and License Agreement [Member] - Subsequent Event [Member]<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
</tr>
<tr><th class="th">
<div>Feb. 28, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_MilestoneRevenueReceivable', window );">Milestone revenue receivable</a></td>
<td class="nump">$ 150,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RangeAxis=us-gaap_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">3,010,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember', window );">Achievement of Specified Research, Clinical Development, Regulatory and First Commercial Sale Milestones [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">1,260,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember', window );">Achievement of Specified Sales-based Milestones if Annual Worldwide Net Sales of Licensed Products Reach Specified Levels [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Subsequent Event [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived', window );">Contingent development - and sales-based milestone payments to be received</a></td>
<td class="nump">$ 1,750,000,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contingent development and sales based milestone payments to be received.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_ContingentDevelopmentAndSalesBasedMilestonePaymentsToBeReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_sgmo_MilestoneRevenueReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Milestone&#8203; revenue receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">sgmo_MilestoneRevenueReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>sgmo_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CounterpartyNameAxis=sgmo_KitePharmaIncMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CounterpartyNameAxis=sgmo_KitePharmaIncMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CollaborationAndLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentArrangementContractToPerformForOthersByTypeAxis=sgmo_CollaborationAndLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RangeAxis=us-gaap_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RangeAxis=us-gaap_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedResearchClinicalDevelopmentRegulatoryAndFirstCommercialSaleMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProductOrServiceAxis=sgmo_AchievementOfSpecifiedSalesBasedMilestonesIfAnnualWorldwideNetSalesOfLicensedProductsReachSpecifiedLevelsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>108
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_O"["5NOS=[\8^.K8-?"K[OHO@!02P,$%     @ JHMA3)E<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M6W1WDZZC>-O?NZ+A\K?Z!U!+ P04    " "JBV%,TX!+LM,#  "%$0  &
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MKA_'2]B+XB4T*7Y-P<A (MM+1?MV!UH/7'C%%P_%%0_\JDC1P@!2-;5W,-C
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M] ;1W=(YG[E4.J]UQ,ZJ[A3HVJ7S62SQN%R1+E>&9=='H%ZQ2V7+@&2.(\T
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M3Q&7DZ8\#9]9IM=O/?/_ 5!+ P04    " "JBV%,?2('=+,!  #2 P  &
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MEXW]KQ$=>"F;"S]"K?]@LR&A=N%X[<]F'+/1<-A-/XC-W[CX!U!+ P04
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M<_B[2+;JJ0+;QFERI#*#CI.\\BX#^YC&-_D#GZ;]*[>MT(Y<C,>7C?UOC/&
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MR6V]G9)(O4[3)FW2J=.ZSUSB)*B ,R"7[M\/2)IE:]0O@(W?\[,Q^8CFR78
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MQH7CK3^;:<PFPV$__R"V?./R#U!+ P04    " "JBV%,3W4DHK0!  #2 P
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MV4YC-AG>]/,/8LLW+G\"4$L#!!0    ( *J+84R 4OX:LP$  -(#   9
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M1U!FR.B&OCCN9-WXX&!YVHD:?H+_U9TL6FQF*:6&UDG3$@M51J\WA^,NQ,>
M>PF#6YQ)J.1LS&,POI<938(@4%#XP"!PN\ -*!6(4,;OB9/.*0-P>7YA_QIK
MQUK.PL&-40^R]$U&]Y244(E>^3LS?(.IG@^43,7_@ LH# ]*,$=AE(LK*7KG
MC9Y84(H63^,NV[@/XPW?3[!U )\ ? ;L8QXV)HK*OP@O\M2:@=BQ]YT(3[PY
M<.Q-$9RQ%?$.Q3OT7O+-YR1EET TQ1S'&+Z,F2,8LL\I^%J*(W\#Y^OP[:K"
M;81O_U+X3O[=*L$N$NS^6^):S+\JV:*G&FP=I\F1PO1MG.2%=Q[8:Q[?Y#5\
MG/9;86O9.G(V'E\V]K\RQ@-*2:YPA!K\8+.AH/+A^ G/=ARST?"FFWX0F[]Q
M_@=02P,$%     @ JHMA3$:559VT 0  T@,  !D   !X;"]W;W)K<VAE971S
M+W-H965T,C(N>&UL?5/;;MLP#/T501]0)8[;=8%MH.DP;, &!!W6/BLV;0O5
MQ97DN/O[4;+C>JO1%TFD> X/*2H;C'UV+8 GKTIJE]/6^V[/F"M;4-Q=F0XT
MWM3&*N[1M USG05>19"2+-EL;ICB0M,BB[ZC+3+3>RDT'"UQO5+<_CF -$-.
MM_3B>!!-ZX.#%5G'&_@%_G=WM&BQF:42"K031A,+=4[OMOM#&N)CP*. P2W.
M)%1R,N8Y&-^KG&Z"()!0^L# <3O#/4@9B%#&R\1)YY0!N#Q?V+_&VK&6$W=P
M;^23J'R;TUM**JAY+_V#&;[!5,\U)5/Q/^ ,$L.#$LQ1&NGB2LK>>:,F%I2B
M^.NX"QWW8;Q)+[!U0#(!DAEP&P%L3!25?^&>%YDU [%C[SL>GGB[3[ W97#&
M5L0[%._0>RZVGW<9.P>B*>8PQB3+F#F"(?N<(EE+<4C>P9-U^&Y5X2["=_\H
M3-<)TE6"-!*D'Y:X%G/]7Q*VZ*D"V\1I<J0TO8Z3O/#. WN7Q#=Y"Q^G_2>W
MC=".G(S'EXW]KXWQ@%(V5SA"+7ZPV9!0^W#\A&<[CMEH>---/XC-W[CX"U!+
M P04    " "JBV%,D*0'<K0!  #2 P  &0   'AL+W=O<FMS:&5E=',O<VAE
M970R,RYX;6Q]4V%OVR 0_2N('U 2DK5I9%MJ.DV;M$E1IW6?B7VV48'S ,?=
MOQ]@U_,V:U^ .^Z]>W<<V8#VQ;4 GKQJ95Q.6^^[(V.N;$$+=X,=F'!3H]7"
M!],VS'461)5 6C&^V=PR+:2A199\9UMDV'LE#9PM<;W6POX\@<(AIUOZYGB2
M3>NC@Q59)QKX"OY;=[;!8C-+)348)]$0"W5.'[;'TS[&IX!G"8-;G$FLY(+X
M$HU/54XW41 H*'UD$&&[PB,H%8F"C!\3)YU31N#R_,;^(=4>:KD(!X^HOLO*
MMSD]4%)!+7KEGW#X"%,][RB9BO\,5U A/"H).4I4+JVD[)U'/;$$*5J\CKLT
M:1_&&WX_P=8!? +P&7!(>=B8*"E_+[PH,HL#L6/O.Q&?>'ODH3=E=*96I+L@
MW@7OM=C>WV;L&HFFF-,8PY<Q<P0+[',*OI;BQ/^!\W7X;E7A+L%W?RB\6R?8
MKQ+L$\'^OR6NQ1S^2L(6/=5@FS1-CI38FS3)"^\\L \\O<GO\'':OPC;2./(
M!7UXV=3_&M%#D+*Y"2/4A@\V&PIJ'X]WX6S',1L-C]WT@]C\C8M?4$L#!!0
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M=',O<VAE970R-2YX;6QM4VUOFS 0_BN6?T"=F*2K(D!J.DV;M$E1IVV?'3C
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M4!FWO;=[-0W,%!C9SV\!61ZD_"]02P,$%     @ JHMA3*%>OU_V 0  YP4
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M[MYD)80&XR5X,->K,5-W#AA4VFXW9B_'T3,&6O336"7S;,__ E!+ P04
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M[']MC =,);G#$6KQ@RV&@MJ'XSV>[31FD^%-/_\@MGSCXB]02P,$%     @
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M]VH>F-DP<EC> K(^2,5?4$L#!!0    ( *J+84SS457(W@$   $%   9
M>&PO=V]R:W-H965T<R]S:&5E=#,R+GAM;'54VVZ<,!#]%<L?$ .["\D*D+*)
MJE9JI56JIL]>&"Z*C:EMEO3O:QN64NJ\8,_XS#DS@\?I*.2;:@ T>N>L4QEN
MM.Z/A*BB 4[5G>BA,R>5D)QJ8\J:J%X"+5T09R0*@IAPVG8X3YWO+/-4#)JU
M'9PE4@/G5/X^ 1-CAD-\<[RT=:.M@^1I3VOX#OI'?Y;&(@M+V7+H5"LZ)*'*
M\&-X/"46[P"O+8QJM4>VDHL0;];X4F8XL D!@T);!FJ6*SP!8Y;(I/%KYL2+
MI U<[V_LGUSMII8+5? DV,^VU$V&[S$JH:(#TR]B_ QS/0>,YN*_PA68@=M,
MC$8AF')?5 Q*"SZSF%0X?9_6MG/K.//?POP!T1P0;0+().0R?Z::YJD4(Y)3
M[WMJ?W%XC$QO"NMTK7!G)GEEO-<\BN.47"W1C#E-F&B%"1<$,>R+1.23.$7_
MA4?^\)TWPYT+WZW5DP<_P=Y+L'<$^W]*3#8E^C#W?I&#5^3@(7C8B'@P2> 7
MB;TBL8<@W(CX,!_T._&*)!Z"W4;$A]EO1,CJ"G*0M1L^A0HQ=&[P5]YEOA\C
M=X7_PJ?'X1N5==LI=!':#(*[KI40&DPJP9WI:F/>H\5@4&F[3<Q>3E,Y&5KT
M\X-#EE<O_P-02P,$%     @ JHMA3.9A7@JX 0  T@,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S,N>&UL=5-9;MLP$+T*P0.$-FW'AB$)B%,4*= "1HHV
MW[0T6A N"DE9Z>T[I!1%2=4?DC-\[\W"8=(;^^QJ $]>E=0NI;7W[9$QE]>@
MA+LQ+6B\*8U5PJ-I*^9:"Z*()"497ZUNF1*-IED2?6>;):;SLM%PML1U2@G[
MYP32]"E=TS?'8U/5/CA8EK2B@I_@?[5GBQ:;5(I&@7:-T<1"F=*[]?&T#?@(
M^-U [V9G$BJY&/,<C&]%2E<A(9"0^Z @<+O"/4@9A#"-EU&33B$#<7Y^4_\:
M:\=:+L+!O9%/3>'KE!XH*: 4G?2/IG^ L9X=)6/QW^$*$N$A$XR1&^GB2O+.
M>:-&%4Q%B==A;W3<^^%FQT?:,H&/!#X1#C$.&P+%S+\(+[+$FI[8H?>M"$^\
M/G+L31Z<L17Q#I-WZ+UF?+]+V#4(C9C3@.$SS'I",%2?0O"E$"?^#YTOTS>+
M&6XB?3./?OB/P'918!L%MA]*O/U4XA)F_RD(F_54@:WB-#F2FT['29YYIX&]
MBX_(WN'#M/\0MFJT(Q?C\65C_TMC/& JJQL<H1H_V&1(*'TX[O%LAS$;#&_:
M\0>QZ1MG?P%02P,$%     @ JHMA3%U9NVNX 0  T@,  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S0N>&UL;5/;;IPP$/T5RQ\0LUZ2T!4@91-%K=1*JU1M
MGKTP@!5?J&V6].]K&T))PHOM&9]SYN)Q/FKS8CL AUZE4+; G7/]@1!;=2"9
MO=(]*'_3:".9\Z9IB>T-L#J2I" T26Z(9%SA,H^^DRES/3C!%9P,LH.4S/P]
M@M!C@7?XS?'$V\X%!RGSGK7P$]RO_F2\11:5FDM0EFN%##0%OML=CFG 1\!O
M#J-=G5&HY*SU2S"^U05.0D(@H')!@?GM O<@1!#R:?R9-?$2,A#7YS?UQUB[
MK^7,+-QK\<QKUQ4XPZB&A@W"/>GQ*\SU7&,T%_\=+B \/&3B8U1:V+BB:K!.
MRUG%IR+9Z[1S%?=QNKE.9]HV@<X$NA"R&(=,@6+F#\RQ,C=Z1&;J?<_"$^\.
MU/>F"L[8BGCGD[?>>RGI;9:32Q":,<<)0U>8W8(@7GT)0;="'.DG.MVF[S<S
MW$?Z?AT]R[8%TDV!- JD[TK\\J'$#4R6? A"5CV58-HX3195>E!QDE?>96#O
M:'R3__!IVG\PTW)ET5D[_[*Q_XW6#GPJR94?H<Y_L,40T+APO/5G,XW99#C=
MSS^(+-^X_ =02P,$%     @ JHMA3")]%3P\!   AQ8  !D   !X;"]W;W)K
M<VAE971S+W-H965T,S4N>&ULE9C;;NLV$$5_1=![(Y)#71S8!IK$<0NT0'"*
MML^*3<?"T<65E/CT[ZM;'(G<=*V76%+VS)##64-*RW-1?J^.2M7.CRS-JY5[
MK.O3O>=5NZ/*XNJN.*F\^<^A*+.X;F[+-Z\ZE2K>=T99Z@G& B^+D]Q=+[MG
M+^5Z6;S7:9*KE]*IWK,L+O]]4&EQ7KG<_7SP+7D[UNT#;[T\Q6_J#U7_>7HI
MFSOOXF6?9"JODB)W2G58N3_S^ZTO6H-.\5>BSM7HVFFG\EH4W]N;7_<KE[4C
M4JG:U:V+N/GY4(\J35M/S3C^&9RZEYBMX?CZT_MS-_EF,J]QI1Z+].]D7Q]7
M;N0Z>W6(W]/Z6W'^10T3\EUGF/UOZD.EC;P=21-C5Z15]]?9O5=UD0U>FJ%D
M\8_^-\F[W_/@_],,&XC!0%P,Q'4#&@SHRX!?-9"#@;S5P!\,_(L!^5<-@L$@
M^#((KQJ$@T'X-:3.P.NSVRW74US'ZV59G)VRK[A3W!8VOP^;@MBU#[OU[_[7
MK%C5//U8BX@OO8_6T:!YZ#5BHA%3S2/2T%3SA#1RJMD@C3_5/"--,-5LD2:\
M:+PF)Y?$")@8T3F@B8,(.R#H@#H'<N)@H<T6:!8,!Y$PB 0.M.7;((W 07P8
MQ <.M+7=]IJ@T^2=AD>A92H!C!* *%IU; ,CRD\\8I8P(0P3@C!:@6UZC3\*
M$U$0!B+2"M'4+?PP(J'!L04ZQB(^*NS)P",X\ @,7*OZ360$XCC$ H98F"&D
M98R<X7;";L>&6SH2!Q,-]3;!S7H+@X7>*$R5(,'U5F&J@L:99="X6W !!AWI
M/5*8PV',5KX<MQ6.>L;"X@(W#2YG+!)N"=SL"32:R+!(2,3U-4(B2WOBN'-P
MLW40(XL+W!5X.",EF$]N DI,ZK/M1>&H!-@=L]4:II2;F!+36]@@&M>:-%;H
M^?]4TWT2(R\8&(YE1@(C+_CMV1>6[1H!J'>-033ICZ$50($!% A #?6'031.
M;&A'76!.A;ES$[,=8C"GPI^164R70!NSD5ES9[Z660RA0'NSD=EP5F8QJP*Q
M:DL+IE L9AP0,3F$R-&;*!19^CUAO,C<48E;$D88+YIS'+:<ATUNS(:$1-QR
MAB%,#8'SKK0E#%-#,Z@A3 W=0@V9U @BTG,"5%Q_2=M"56#I%H0!I!L ?"(3
M0$Y6  D#2 ! ;MGU"0-(,P"4&$!Y X#/2,3UUQ\HDI;!8$HEHM1R^I:84CF#
M4HDIE3=0ND4B;MGRI>7%%>QMW%*M$E,J9U J,:42G!RY5O ;*+(T%(G!DB98
M)&PO^I@8&<V8+29&@H.C.5L@$I8.[&.L? "#L'UQP##X,TZ$/H;!-T^$)#1N
M-[[Y2N:;O<P;?4UK/]'^'I=O25XYKT5=%UGW^>Q0%+5J/+*[IBJ/*MY?;E)U
MJ-O+L+DN^T^C_4U=G(;/OM[EV_/Z/U!+ P04    " "JBV%,]@,[H.0#  !2
M%0  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R5F.UNFTH0AF\%<0&%
MW1D,1+:ETQP=M5(K1:W:_B;V.D8%U@=(W-Y]^8IKL^\2^!,#>7>8F=UG9MGU
M69<_JZ-2M?,KSXIJXQ[K^G3G>=7NJ/*D>J=/JFC^<]!EGM3-;?GD5:=2)?MN
M4)YYTO=77IZDA;M==\\>RNU:/]=96JB'TJF>\SPI?[]7F3YO7.&^/OB2/AWK
M]H&W79^2)_55U=].#V5SYUVL[--<%56J"Z=4AXW[C[B[Y[@=T"F^I^I<75T[
M;2B/6O]L;S[N-Z[?>J0RM:M;$TGS\Z+N59:UEAH__A^,NI=WM@.OKU^M_]<%
MWP3SF%3J7F<_TGU]W+B1Z^S5(7G.ZB_Z_$$- 06N,T3_2;VHK)&WGC3OV.FL
MZOXZN^>JUOE@I7$E3W[UOVG1_9X'^Z_#\  Y#)"7 8(G!] P@$8#O-ZS+M1_
MDSK9KDM]=LI^MDY)NRC$'37)W+4/N]QU_VNBK9JG+UN2O/9>6D.#YGVOD5<:
M>:NX-Q7T5^(U#ER\D- +V8VGF_$!-D#0 '4&^,; :A1&KUEUFJ(/0Q*%\2@6
M4R8HYM4*N\/0'0;NA-A   T$\Q.R@@96P(-HE)!>$UPGA&7LC_)AJD04QY;I
M#:$S(7 FQ@8B:"":GXX8&HAGI",V N4@MKQ%^)@FWWP/^183%B#%_%@%IDG(
M&=$.HIO9CZ(H&)-MRB:F7V Z!<"3Q-@A,M\4,\<\]@CHI,\A6US"A J$Z+AB
M#*+@K9(!=%,U0V#F10"R9$LTIEZL%BP>S*I L!J+)YQ5.H!L:O%@]D4$TD(6
M$YA^$<]/B\1D2T"VD99!-*^$2,R_%#-8&40WB16^Y' T 4 G240VCRS-&903
MLM F<0&0M& ",+ 2 6M,   6K$L@FUB7$N,J :Y&!1E$;SIDRJ8<PO!+T//)
MEF0,OPP7S!/&50)<S7F*YJ7%E$VE!<,O0>\G2V4F##_Y"_:G&&L"6!MI(1-7
M>_T@3"LA6L?U@T!71[T6Z29Z+5DVY[-VYZC]QWYD;,^7M7_"U81 -2'+#ITP
M_[1@CTZ86)JS2R=S SZQ*##7!)JZN2A MT9-!>@FF@KA,D&HJT<6$QAL6M#5
M&8/-:+\^S@N;73T,PF"\4P8RX?N^95TR+A.,NK_E4XEQ > %'].,@>4Y^W4V
M081I ;Q.I,7R/0UP9<MW%6-<>0&NC'%EU&"-M)BX1AR/#TR0*I0VAAA3S8!J
M%A83&$->\&7-&$-&_=7(2FR<JJ"L !7(BG=UN-6>-GY.RJ>TJ)Q'7=<Z[TZS
M#EK7JC'IOVM2?%3)_G*3J4/=7H;-==F?\O4WM3X-)YC>Y1AU^P=02P,$%
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M3@MR]40+YA0Q=(-)5P1Q[&L*NI?B1/\+S_)LGR#;U9@%@FR;_W#8)\AW"?)
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M4>VY'2GV(%DW3DLTC>SL'U!+ P04    " "JBV%,LSPN?4X"  !)!P  &0
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MIJ)'J9>Y6G,[6=B-9&TW-87]Z+;\"U!+ P04    " "JBV%,$1>!7HX"
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M +-V(0*8F?VG@S!V(0XQV']01\B'SQ=_N$WPH);1@R,*C2]&!!Y!*Q2,*$<
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MC@4KPL7G4GW4MH1P+!+&#R+A7AR]AD&#MUS>%N*>ZO.''G#2F[-5-!SPYO\
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MU!EQ((1CD:7_((IV$A>3;E+B Y?#F1A3?3KK"2>-N7EXW?5G^0]02P,$%
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M!,<V2'#9D2MD1W#9$411$)FY)]8\=T]S@NN.8+HS]8V!P+$4$5Q.!)-3XJ#
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MDXW=15MMX\]1YOO?Q%S]!U!+ P04    " "JBV%,?ZGX#/T"  "V"P  &0
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MXH"*_P-A!'<7 E"IVU[(_R(XQRCG 5:@DS' RES6*,KG=2W20#-AL)_O,0%
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M9J2"H4T 1W;N2 1K*A/%.8+,/0B*D/QH-%5))U<I&)$(3*>0$:*'1IP?#+%
M%,]U+T*,2:B,.#U@C 7B>*[\T>AZFR8#NG:$41:(988>@2$5]@;Y8P(%0C"0
MOPOD+Q-.E!A4D<6H/P/+RO@AC#,AG.?B'XVF2A&:K"'.%R::$-%S]2,C3I*$
M@28 -'%A&(-*-\11P@P28G"NE-%HMH/<LF(""1$XEPJ%!.I$<8N""21$8*"5
M,)P*$J2-97QA5 D%U$ KP(B8_( PSX1XGE\I1Z.KB[^E3'*"P$@30GI^I:00
M:9U(A1U)S+0$3!-SL94852GB]2\QA1*%U;G^1Z/L6I;,%DHFY47Q<J[_T6BZ
MKC9)&4U*3+2,R8UE&%6%3D6J&=8DAEK&I,?(B#BM8*9E3(8L0Z8S8W7*Y/L2
M(RUC<F09)LDF$=S:8:8E8)H+51*S*F](E!6F4,4DRBI,E&W"R%]A5%5,GJS"
M/#EC+_\* ZUB\F05YLE"9)E6C%849EK%),K(B#@_3+4;DRBK$&FMA3#</F&B
M54RBK,(PG24<9PHCK0#2Q%SI%$95W9 H*PRABDF459@H=[)4V?2/\8JY53%I
MLPICK)")9*X0&N.M8Q)G'2;.SFG-34ICPG5,WHR,B*D:-09<(\#G,&A0"'<3
MXOC6F&^-^)[#H,.8+422,=AI3+@&A!.W_LR=*AU/@\9,:A1FYS2,1MFU+C43
MT#5&5Z,H.R=@-#)720KC!N.M$=Z!_,.\60CE2'.+AZ'6".I _\"(2] -1MH@
MI(.[A2'2QCBKN=N2&&F#D)[KWX1!6R@V:348:@.@EDS@-QA6<T,Q;#"%)J88
M'HVN]*_9Y,]@6$U,-6S","M<PN4.AKFW'%,.&U .6Y>FW/)AJ$U,-8R,)"=+
M3+6)J88-H)J4-MP^8:A-3#5L0*0V;-YJ,=868"V9<MAB7.T-Y;#%'-J8<MB&
MY;#($JYTM!A7&U,/6Q!;?^ )4VUC"F(+"N*4!<!BJFU,.8R,N%LG%C-M8\IA
M"\IA[3A%,<^+HAX8A<7PCS8),VT!TURN:S&K]H9JV&$(74PU[,)JN)LOD\0Z
MC*J+*8<=B*R\(PRTBRF''2B'N_2'6SL,M(LIAI&19 *:PSB[F&+8 9R%Y9Y/
M.8RSBZF%'0C2X2:M)D_O2U^_#N\M-(MM]79L^X?UD[.7=R,>:'CZ_[_Y^<6*
MW_/Z]7!L%L]5VU;E\*3_I:I:WPTF3;K!['V^NQP4_J7MO_87G?K\0L/YH*U.
MX\L:J\L;(YO_ %!+ P04    " "JBV%,]Y'E!$X"  "!!P  &0   'AL+W=O
M<FMS:&5E=',O<VAE970U-BYX;6R5E=N.FS 0AE\%<=\%FV,B@I1L5;52*T5;
MM;UVB!/0&DQM)VS?OK8AE,*@JC?Q@7_^;X9@3]9Q\2I+2I7S5K-&[MQ2J7;K
M>;(H:4WD$V]IHY]<N*B)TDMQ]60K*#G;H)IYV/=CKR95X^:9W3N*/.,WQ:J&
M'H4C;W5-Q*\#9;S;N<A];+Q4UU*9#2_/6G*E7ZGZUAZ%7GFCR[FJ:2,KWCB"
M7G;N'FT/*# !5O&]HIV<S!U3RHGS5[/X=-ZYOLF(,EHH8T'T<*?/E#'CI//X
M.9BZ(],$3N</]P^V>%W,B4CZS-F/ZJS*G9NZSIE>R(VI%]Y]I$-!D>L,U7^F
M=\JTW&2B&05GTOXZQ4TJ7@\N.I6:O/5CU=BQ&_P?87  '@+P&( 36TL/LIF_
M)XKDF>"=(_J7WQ+S'Z,MUN^F,)OV5=AG.GFI=^]Y'"29=S=&@^;0:_!$@T:%
MI]U'!(80![P(CX,4-@C ' -K$$SY\4H&(6@06H/PKPPVLR)[360UC=4$&*4H
MACD1R(F6G-"?<:(%!^'8]V%,#&)B (-FF'B!>8<0WJ $!B4@* % > 9* %"(
M KP"2D%0"H""&2A=@%(?)1C&;$#,!L"$,\SF?S#(AP^5#X"B^:F"1"N?&UHY
MO BP6)Q>2+3& 4_P'F' (IUS>E$\_;(#%*V X).. @ T/ZF#Z!\@;W(#UE1<
M[=TOG8+?&MMX)KMC?]EC>X/^D??-Z0L1UZJ1SHDK?0_;V_+"N:(Z&?])?RFE
M[H?C@M&+,M-$ST7?%/J%XNW0\+RQZ^:_ 5!+ P04    " "JBV%,#@.V"QD"
M   $!@  &0   'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q]5-N.FS 0_17$
M>]=< K010=I0K5JIE:*MMGUVR'#1^L+:3MC^?6U#6,)Z^X(]PSEGSA@\^<#%
MLVP!E/=*"9,[OU6JWR(DJQ8HEG>\!Z;?U%Q0K'0H&B1[ ?AD292@* A21'''
M_"*WN8,H<GY6I&-P$)X\4XK%WST0/NS\T+\F'KNF52:!BKS'#?P"]=0?A([0
MK'+J*##9<>8)J'?^?;@M,X.W@-\=#'*Q]TPG1\Z?3?#]M/,#8P@(5,HH8+U<
MH 1"C)"V\3)I^G-)0USNK^H/MG?=RQ%+*#GYTYU4N_,_^]X):GPFZI$/WV#J
M)_&]J?D?< &BX<:)KE%Q(NW3J\Y2<3JI:"L4OXYKQ^PZ3/I7FIL0381H)H3I
M?PGQ1(C?"!O;_.C,MOH5*USD@@^>&#]6C\T_$6YC?9B52=JSL^]TMU)G+T6:
M!#FZ&*$)LQ\QT0(3S@BDU><2D:O$/GI'CZ/;"N5[2/K%72)V=A%;?GS3Q0<>
M-TZ!C178W BL3.Y'3&HQS&(^A>M&')@D26.WE<1I)7%8B5=61DRR++-VXH"$
MR0>'FCJ-I XCFY61U%%EA2D=F"2+(K>5S&DE<UA)5E8RQ^=96W%@'%;0XO)0
M$(V=,]*K^)DI\Y<NLO,HNX_,Y5OE]WK$C1/I36:<CS^Q:#HFO2-7^FK;"UAS
MKD";#.[T4;5Z),\!@5J9;:;W8AQ,8Z!X/\U<- _^XA]02P,$%     @ JHMA
M3"W:,?Y$ P  ) X  !D   !X;"]W;W)K<VAE971S+W-H965T-3@N>&ULE5=1
M;YLP$/XKB/<5?("!*(G4IJTV:9.J3MN>:>(DJ( S<)+NW\\&EQ+[0&D> C;?
M=]^=S1V^^9G7K\V>,>&\E475+-R]$(>9YS7K/2NSYH8?6"6?;'E=9D(.ZYW7
M'&J6;5I267C@^]0KL[QRE_-V[JE>SOE1%'G%GFJG.99E5O^[8P4_+USBOD\\
MY[N]4!/><G[(=NPG$[\.3[4<>;V535ZRJLEYY=1LNW!OR>P18D5H$;]S=FX&
M]XX*Y87S5S7XMEFXOO*(%6PME(E,7DYLQ8I"69)^_-5&W5Y3$8?W[]8?V^!E
M,"]9PU:\^)-OQ'[A)JZS8=OL6(AG?O[*=$"1Z^CHO[,3*R1<>2(UUKQHVG]G
M?6P$+[45Z4J9O777O&JOY^X)I9J&$T 3H"=([2E"H G!!V%:(=2$\(,03A(B
M38BN)5!-H ;!ZQ:K7?W[3&3+><W/3MV]0(=,O:=D1N7^KM5DNYWM,[D!C9P]
M+6E$Y]Y)&=*8NPX# TP8)I>8E8TA/<*3'O1N .;&'5AT&L6&!(8QW+BW,7")
M>+ 1@0%Y1(12/)@ 7=.@Y0<7CHX8"%$#86L@'!J@OA&IC0G\D26/4)$($2'&
MSG<8VF*J;E?#R%<_8\DP8!C!$'CA$D5=HHA+YN9TF&B@E(9I-"H4HT(Q(A08
M0K$EU$4^(I2@0@DB%!H[F5AK]P62%%GE!QL)08)MAPV<]#U%?4\1WR/#]]1:
MI#">E"(^7H9\1,RH0_<:%%V\93"I-E+T"*(6FVK$5O.3*3&TM-T20,3,NJ5!
M%PE$)L7PTD,"1"PUQ0(K,O!),B*$ERB"U*C8K%$:-(QJ+!R\1A&D2,7$5+&+
MSY@*7G:(77<"&#.!%Q027U_S"5XJ"%8KK!6U00&A(SIX6A,DKV/ 30">K>!?
M'RW@*0A8"AK1KC!0'(SHX-D'2/;%X8@)/*?@$]]SP+,%L&PQ:ZD&79>6@"<,
M8 DS\GX G@U /Q$NG@V ?%_M<.T/K PW-H2\P4&V9/6N;4,:9\V/E5!GM,%L
MW^K<@CH(&_,KV0)U#<N'F:Y_^I'5N[QJG!<NY#&[/0QO.1=,.NG?2/?VLF7K
M!P7;"G4;R_NZZUNZ@> 'W9-Y?6.X_ ]02P,$%     @ JHMA3+Z\3)"U @
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M51B]%?QLZ"#O^H')9,_YFQE\.:[#R !11@_*.!#=7&E%&3-&&N/WY!G.2YK
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MH*$4W9L]%KC(&.T=-OR['58OT6H3RNZ7*JB;K9_)]G 9O16)YV?HIH1&S';
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M&HM.C0.X@$6GE;Z9%0SWM F&48^#:9JB&(-N]Q@F!-P#9P@6"@IB/F!F02C
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MAP"B14Y8@E)EG#(MKDY$BAK1P<*,*(I9$AHU95ZX>$@DTV3^:#9W:$FH8QQ
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MXVU$,LF[9]^5/->\>.'HUB?.!)/ J,3& V &SST:R$QPA5JM /79>9]!>:(
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M-X5MZN.#L& 4(9JSC&&%K<(F2-:V+S[DZ0K<[I6T>U1U1@,E9@9YSJ_ YKA
MN(FW#N4WTZOP$HF#56@&;?.MC2#2B<[/KC]_F/1=%?PC[3 N(7MZV!CS;2-K
MLXMAB4?92IR 6T_GF(;#7, LYYC!^\#:P"[-I&+SO,BDK[;4]C5:];]_N&G?
M?2B-9DV Q:X/H(>]Y,!5X(SGE*6.7NARODJ+W)1()M#G$G\ LG=^GV!!(*EV
M1H0:-CG[>/M#].'NXWN,^-_\PF>WWN_$D6Z"3.2D.*;YQJ,S,-TKQA=@V+_
MLP_<YT*#67)A370^EQ&G%@=,^$%'Q&+>6&T3P_-8> 8$JO(H 13#^C[;T#XH
MCUG:IDFG'#@1\MT6F/_I\I5QQ]SJ8UVW9\]094%VP$IUYZ7G5^L,$$^R+$,2
M9(%7S%7CP9 -B)1E>(1/Z>1;LV@W2%9?7\-VDV/ ^9AKL%^#P-BU#JR$MFG>
MM4:!DA2PP*[T[:*!COPY*$8'LK,G+UJIC^)2# ]O=LL Y-*GA%C=S@9U_;+)
MG]O45MP&X\>>,%>-S*_?I+GD'XU:?"._N.MN* >S::39'J*C>[Y<XI!I6_1Q
MTUCX-Q4**\9C?\.A@'A0/J38JAI*:+:D[ZNYR%4:]*4^':/Y;M:9#X%[];V*
M%[Y<XYD/+\B40:IXDTV7M\H="]$M[]7."IIZ"*WKA&"W04Q<UW*CRJP1_6JT
M(C?;CIL95P7Q.J\91L7$-=96L,QOYU)CA0B4[*0RL3'GE1I7'9T/2GC5?'N,
M*5&RHF0+9WH+ZIV:Y5/S&3(<.5.]9T*JP#$J.&/*;H9SPNN-:2SG)B_*=J8Z
M!+YB\%IGBS:%/(+LW<9P'"Q^==CZ=>PF3/)2-6/@[V4@^TWLEP:0IEAC5;$)
MR^I4^)K8E;BEN^W<SEV(JZW=34L%)LZ2#ELGYW>.%TM5I;8#7LW+L">[EM\#
MT5A<GY\M97\?W*;S"L7XEM5B"U\M-*D-5,0E4PQ5+WX2[:HB%"8U/6Q8\?5;
MTTOK8OC&E>M989LT$*LX9[7<9IMVOES&"I:A*)M&=<N,/8>:>H(NKG:HF4X_
M3]A:T'+*,DU_J6U:Q8'&H:RPTR=J4SQ# Y%FH.^O9FWDE)+Z2VJ%4B"<-.&,
M'CCU?;I+,$@9<\72-2 TB<O9_)<5FL)66*V\I!PC,];M^?LZ/^PWP>QG['_%
ME<V(\*-1(&2*Y5N^;N'ZC'Y@:G7 >AP?-66DF][R?'XA'TUXMQSC?:";K_+X
MZA@E9CR/="$#[[&1"_@1=;:UQL0Z4-HA2/$S G2X30< !968"[/8XIA%56;Y
MUJT"W5]G5G6"_7+&EM0%A0U?I<_1^V+_8+'F\LIBC4F&MH$)"8FSC.0:-A36
M+[VS6-^%7?$6>4>"*/HRUYUKZ&5O$]NK%RN.E)E"'U9Y]$%VHIE7.]Y)!_80
M6)9UGC-!> SH]'B@<C;KAD4>.(PWQ!J^RUVZY8+.6 _X%[&[L6D':[,'(0T8
M4, WQO9+Q981L:>)V?:9G!"+.;#KW(46?-E0;BT%%'$N<15\]HAKZ1%B\[$
MCD-B0]S#YNI2-'/J>3VXR)E9M@JSS5(E"]?%&QC=T<0=]/W2>?F&^2V7+C_
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MED0UU]1%34M RX3;_ #GH1B(_"59 =^R-U(T1JEBG3S8Z*<UR)AHQUNA=/V
M K0-X'$2CRGC=!BS0I'RNGA(-H86(>1O51U E>ZE<CMN<@ 7,L\3\ZGBWWV7
M2';MC>*\1VE%M6\2.62_IR6:=8;YB'M(HF_2U!)3)1V3.8H.Z<*SNP!EGF?;
M%07042D)C%/;)**^H,"3_)(&$:6 <?NU,1%1N!D'XHMB2U$K'+'M\KN\X@.U
M:Y?X%E>O *.J*;&9BB,:_RA3;#]L&3NHV"5*<8)7YQ,SHE"PN2UD8P(/2%;=
ME0TR/65EFU(=].Q/(%PD?P4=@C+[3'O8%,,J?"F'; (F*EABN*0.CM= O.HY
MY( _9(SW,F8E6*OV(3^RT^R537"V]H@-FM:1OPKM;VT0]3E(74N3J'0RNST_
MC>[R;3:/IEU0T8]:YCG6K,,MTX<+6VHQ?+#^DC2^;0_/F-S9M?^8/3S"$:XR
M>'*A:DZ4JM,H=X8W75X DXS^;6N92KMC@!H142&_MH;W0E(S[Z5FHZL?"6=I
M5QS^I&/9Q%='!P&34<\T<E;H*AER>A7TJ(<4MTHF7J=,"A9*QAM81AR@:A]6
M)3I0<#:)%-19A\0%9P_C=S5042&S'AGEY[!$^Z_[G-B5YXI!J_T]+EN[:;+-
M=B]I%*MUCE5F2>%!$8?]E*IIG"HW@ATH$&>I. 8G1W+(LUSZA>#Z$15%Z@.4
MO>T6J=\$C'46N ]<]8;.#3-MT^=J^2 RJG##$/<P(!1HE2;C;Y&B6&>9H5]G
M)80]!\L8H[/$Q<#_?MXO'E+38)UVV\;:'6U;[,M?FKL_3YBAMR]MA8C,93N1
MJT-*@WA1VG6["55YP/X'O'$L/TEMV)TP'6=24+NU$4"N?V2=<N3V'0<>;.>8
MY0H?26&]3!3@904C!FBJNDI6SW]GU'=5L>31M%Q6%Y9+M[B<"-IMN5^BC5%V
M2VD4-O#'I2XL3 F4%RL(J?8=G>BSKJ[CH;G.^W1W5E]J*I7@[@+CORE#(GXV
MKR0K.U*5%C27NV@YP1HP 4.50EI/SELJ:QQ]<I[.XRA]P[O,XL,J='ZMN8P<
M!6M-9"6%9-Y$C&/''%ENY;S98T-QM<ZD$=<E960%FX,5?\& R5JRNUEH[=9O
M&.Y-6DB-"].>$B:I([]6,-I3GA-6!E,JG%%7)0B>SKH^:E_AMEIN$)+]Y3:Z
M*^C 7N+H 7%X@V\@V8;MS$EZ,I1EG?Q,UBQ.%[?F*_\DQ6@O2@(R=!,)8VI2
M'\D1;[1+[<*XU**;6D]; %PD+;%P?\4\%JEJ[TBXP=X=\;*\US]C.(!)_/(N
M%<A^&#/9)E+/5\G/KW1GNB]3;+..A=@LR3)."(G>.7%B/PLOE%-E7,2GG>@#
MB3$P/M&L3)G-8F_YOV+!A.G.>6M7O4QM=R#K40X9(S)+%BSJ7:"<+.-X#+)*
MS%QEO=1+R$.=*"O@M!!1YO0%Q5VF3H4.* G;7QF4I /;=%NBQIQ1&E*Y+YR5
M<V'4D*.0,7SI?X"BUZC;&3TKU.^NJ<A=OGG(.:>%&+=:FA0($QG5+E#+$W,D
M0G.7-$$;-EIZ7JA=*5^=E,0T8@N;,*P!;4<-VQ+)=HDEK:^^Y&9''6"BJZ$_
M9NA=I/'0G5:0ZX>SAS>6_#'K%<YN>6MB:\1CI?ZGA /S_-/0!FJ0^]!,4XJ$
MI]*BG>77NP:Q\2^9FF+,]"D[FWS'MNTL( 8"%"5(.<U[;/7F71S7]:>A((FD
MM*52V#M99"LJ2YP4U@;.VRUS4*B^3^]__W^K^[+>-I(LW>?AKTC,N&[+0)+-
M+;FX@0'DK:Y[7&6U9-_&13]1(F41(Y%N+EZ ^O%SUM@CF:3DF7L?JDR1D1&1
M$2=.G/4[-JL.JW3#F? #-T>$VX+,A?9G[]Z3 KE"FJ\(:W;A7B[IW.^67]52
MYMAW:2Y:IW.*ZR]_]+O&H4+FZ^^:*'+G$9TK&SJ,?/^E[?L):.KB\6:?#-[C
M_,)HZ#,3.KL"?O\[IJ17E+J"'%S2#A5W38F?4EV?#9T,"0F+EV8KC8]F@3D,
MEJ:GNYWNJ EJY"CFF9H%<VE7HT$339Z1?%.;I<5IAP3Q,)LKX2N*W@V!H:XD
M_<>*.RQG.9[@"*%((FFE>C?_;!"VO@F^!,&[X\IL][.MAZ,H"9D%.=V4IWT'
MSK!%IRY>XAN.O**XXXTF9')I<3R"5&QYO3'"N BE,F_@QZJ!$'ZE081 =K%!
MEX,N(5\0)!3ZZT9'%<DZ6)K=CR_(N^Y_V) [=5X1; )*TQMS(C#5K63MRWBO
M1* P0^D:EK9T!H56.ATD/#5D:R!C\9)U&S'URH,+)VV8K-=L[@7!&KVG<.45
M;R0RXMQNP=:OTSR;:\WNV^+\ZA/"]F B\[2-0, )&I1,3#/":]Y(8KC:W!OM
M#'N5'I\7+'_I#31S&WI!"H*F\=?9BD(:^"#U2J8I-6 ^Z"3F=A**?*6U'] M
M0W%0-K(!298JD.I@6Q8[\. LQ>9BK].E@DC9(5#H,TYFO((1'\*]EHUM(+):
M.%WAZ)3TS S^>N$JG;CS3B\;KLULCA9*1PG4V:#GP$NAUFBK35&XI@G[8E +
M/O$U"^**NC %1\^R5@/'GYV0-LR:A6#+.JYX?\@EI1[(FBEUL 9:GJ0-.0<Q
M5 :9>+W:+#!G3ZIST@$OS?'6(KI:G5=K;>*I+2A"B%^0&**4 X>9[,6%C083
M8E9XIQN9/@B=TK&8-LTNDBRD!:/M;>E>V6[LP](OZHOI^P)A(P$%J:=\!<1%
M$UND9 .1OH#6%V:1:=$=)L\F4A5?D1AY*T,PFXZ4)E!EW!5J>"E,X"&%X:BY
M"C=!,+?K.9W%W<C01,?]PX1).(Z1&$1%S[UA/L)JTDQMMWY!R>O]T5]:BG[&
MV"ES#P5-SWK8ZY9OS+*X$^.F^9XALMUE%]2B:WM8!-M+GW4;^XS /NI%@7H'
M3T?^BWDAT:=P'N3Y_*$V/5(R\Z-I-6A=.<-1,'P1I#'6VF!A[I;P"%R?/W!]
M!%S);\&V0]/3TG&0PF[,T0"HBL6:#-4^LC$\_7^N/KPIR3.O=L._%%3NK8UB
MTP^_\<>+H"VM+W:A8=9.+YI#@%&P!@X+[R/W#:C;-U<7U.UJL20JH Y7/![Y
MLFVG,)Y9?W6Q+=3,8$7I+=775NL$'\C3-LL:/M@^]C7< K5^>A>[E:5(18\.
MBWM(2KFAMU;'"& ';'>E+R9P0!4?\X2LX**Z\(M:=JU$B+S=,3=&-%GSYH@D
MY]!QI_@[^2W<DC.U:^9/T=S^VPR=+SCDP\I;O#5$+"%9";%&WS.0LI 9"^/>
M)/9H1 =R%+T&4?7L@%:BMER",46] ';5#(A'WY!&>E@*>.!@HF!!V6X;1JM&
MJF@@/#)TTQU2N^ .2,SNKP_7_YM"3!\HA9N;G/]*9Y#^H P8)22@HGZ)*C 0
M1O';.<6M4E/^*FP[9&9[<0N+L+&-^>]2LR.QB5$063L?EWS9V0O3*.#XDG(I
MI2XDN+Y,0#)ECS@[*1C+J9 4<X7%&H>-@W3.!"G=%(A$HYM8),-13?VUE X3
MZ91*"TO&4^?N@U J#G[1SEBP84W3I/=@A.9*7@6MI"R8&'!;EZ,M P)AS'XS
M>Q._8V*4R!AP&\5XN==+RD/@R$L@FHBB)W$Y@;['T7%H'LDNCB/T&=0_XI3F
M^3DYPR2:R%@V\!=K$PT/)H*ER1L&6G1@APFBE')*=L:O&ZO#YM68NIUC_=4[
MRF)U,-/(8=%P$"CE+;H&B@T>%YI96 /(Q@/S"$YFBAG$4>L-!1OCDV)8\Q)V
MX@+GV@L5J17L4V-*H#NPS7APOA5&!4,;^^XN&TR/X57PR&ER K7-+@W5E+QE
M[V4ZY)?+Z)IY6,[.[8.?MUHA).3PNDEV@F9.9J;B<24+3\>O-VQ(UE&'A'_B
M*SG61[-UT&@X9N3OP?"7$-)EG8:MYS!7&<V=P\BA#3,#.VQ9O#Z_XN XNBJ\
M68Q@]#[^#W_OC9-SR8U;I<;E,>3%/R]6_G!=>>GJX$!;W$UUXBIT8FSHLY2Y
M7Y$_4[B",'^,1-S,'/_&]7+]A5)!;A9[=CHL5_/]=H<1%%X-CF\+<_E\Q]Q&
M!GUDG^5FN?U/UV%C0SCITH['L)BN>-!5ED?1;[\)10-#KE@;E6X"FHP4/-@Y
MKH@Y!1Q(S("OBV_5VDRKUXG-LLZ9>^V<.84":>3^.MA+D:V2QFR/,A6X+5T;
M]H!E'S0'T@V\XGCZF5.5H&T<JD;&P^-PMR!K HZMTKKD&RZ%VZ,</[NG $'I
M\%X=#%O,,[W75OBC@JJR>VE/X+J24NW9K XBD1EC(,_-V4O?HT5N=PJ+=(P6
M$9^06JP"1; P[!DH9K]A<\\WS)N9V9',XNB,:K: YZA[);Y,+P/74C2HKFB3
M(LG/F/?SV_Y*4R*D,!J\R\W=:GV__NPYH0P.*V.\9@KQ86LM$P(R $O07Q=J
M?D9-,S^31@> B_B])&'*@V!SQ0F!!U!R<F0+YP%-/C4I&8ZO4D67F98=F9/>
MIU& %OV,5H#.PGKC.5@-&!F[?20_G.A22]US+N3>*77/'GOS)-=L-I6& ].?
M0:FC)?'KXA9GH(I=/"^MU)F,;U'9EPO3\]W-)5T^1@9H=WED63@I0[)RC;E1
MZQ+[3CH>@A7/63(4@GBO,7?$%G T6F$G9:QWDL?Q?@;SN[JY6U/@^A>!!EE2
MC9"'-6BCXMFCS]:E+_&2RIM,M76,NBCMGU_7J(^;+&F\CMJW&"9B\I4WNG"$
M04J=.G&.6B7+E:_YO+DE4DR9*6RJ[F.N,$"G#"T%2P^X&TT)[I3I27>R9!?>
MD!@*JX&@HV@D5_#JD)$Y_G=$Q1*7MWE9AO<.E!FJ8:&Q2\6/)59/AS--\:"*
M."^$1J%\F(BXD7*D\'[P%&.G2E!J\#K&A=\IWJ*'6K#6K8$&#;2+>3KN^A-9
M3,F5])S$MG9W:L+F;03<>G.[6.[V@A/AJ$\[!'4G+V.JTK0I\/B>EO>=+='(
MM4^/?P+Q!+3N);VD"9=W*EYFO!%1P<FX9"1C>;?EEJI1 U9N@4YXCA<>DU)O
M]ELJ/89!LQV"M1]47>_:5H1OI6\KB"'CPI/2=*8V6(E58901209 #]_MAO/G
MT-=ZJQ%*:TX^=YXD4Y6=J,6O6PF/ $HG)60G^B35$30!4WJQ'S]EN@N_H&%N
MM_770$H5-B@1*$4F9OS#\F[-_!3$U1G[)Z!=U?WEN?&8'YPF@>%)95$RZ=GR
M*"BZ\]IXISNS.%HS1JS7^0J'249^>)YKMGQQR P;J)4BRUS'OO:O+B.\8,N"
M\# T"-H/PBG]VC=:^\&O4$&S,FR2=&AW /.+G1$GT!I_9J00O%NU+^0@YJ3Z
M$QYQ>8H0IH?S??CPB[ -KVCJVY:AOY5#IJ)=1/Y[+^YBBY^#)2IAD/7*M=$Y
M"EQ>5+_%+-$MT^E*K =N Z^L#=NY[/U*;%M2)^59-ZT3 X^_,C"L1)+-3#0$
MYI-=,_AE&<Y6:VA:WSO"\Q1^J5\<D/-D<=AK%[TD\();C3P7KCI37D)IRDO.
M9G0\US%4T:$%+2U%;P^5+79BQ#A:9[F>>\][F.?V+?<[8QS=,8IMP!_7[(9D
M&Z> D:[FIFBZ_(#/1OYIK3R&XN!"4_\UC)5"@B30)AO0RN EM$,FMA71&K0T
M2+9 KRWY+)!*3OZ(OYMAK+T!G>>T5#_.K@H].C=+ 4C&*]=4D\$F;R[?M'L]
MOG+YCWXW#,*4%/8MX1.A9*L!4NMKQV;+!FI16Z7*JK4%:[#_+15]#^TM;._0
M<=@-,9M3,6JTSGC8]^:MEG,A% J\U"EQ#\1UD2#26B,C_4/GMY3UM',"0+EB
M]_++C!;9,RAE)"6$%W#0F>(THLBP([3N%"&H*_:LO"B&@<F>S#,AJ^=*>L?7
MH0XOF+3^_*N*=>9#8-Q&=%R;\!SXWS';4FSC1M]+:Y9.7*L67 \#7$FT7TB)
M'JW-(.!HUF?GHP&F+YZ.?1OUIGN<:+G]_X8)>>3H"#U>O./AP-T @-8IC[AR
MI3C995?&TZPU/L-FD"B%SI=_-/E&\J-,1<'9\>)AHG/L)B>]2>C8;%>Z(*-E
M(]GTLT,U5BJ.D?Z-0_.5=QRT L2/XY]P$%4>%L!R-FZ<(3)8U?RB"D*B5LU-
M H(;@S#;K-H8:6Y<4 '1JG_)"U11OY4U,Q0A\(AU_:J(=(,I1*SHF0-.5@4[
M<3QJ_O!>EULZ,1IFF>B7^;V:5.)W^V:KD)H\LX3Z3@9'<;PE*C6A9NCD8B<#
M*^9):0!5"K.? B^43CY;*T^W2CS9)=0<YES,[6\$!+^8\\V_)Q^.N8B-@<CC
M /5WT>[.]Z.;A!V.'VST C8,_IJ036Q!:J=\4E@N-1 WV-#+B28! D6$:Y$0
M-P*^: 6Q\)KQJ+#9I?B.@=T^4GVS=U'5(Q=)7X+8;7"374$U8[YN4FUVXT7M
M>AHW9VQ0N*Y>1"PWQC5SB?<A'-ULNZC+)9EMU29N*EQ+76"GWC#?1R*T6].=
M^FRW[LPXWF"S#<OP:CW39'U[X'&8=KNCO(A43=[EK5JL#6Z4#9BS\71-S0ZI
M(2S>&&<"Q^P>$>[?8]+&!58D0>M],W#&Z+'B)84Q)9) ##VAC(<5/7!3*+*<
MLKST =DIY0CM&7J7/[LH--2=X*0Z^(K )C7'TY59-7CV]?*>!DW,S,]=;#*K
MHO&LR"5FCOX<)\$!;B8E]L"\7TH90W7#<&&'F?,>4A>JY-[3KTCQV/-%5'72
MFVL";T)2H17I5UR?"6>."PI'&&WPPFU]7:Y+(=MTL"MO13C6Z[N(6,:$K_LE
M!H":-U=/ER+$F2"!COB0CIR0'#,JF:M2IU<(AJ<\*0>C<3GJ3\IB6E9C^!.+
MY6*;:=GM3LK>Y&#%F*O%Y^89\-K8XTRL)[$8CI%A6VZ$N>0F;W+/0  &7IQ"
MY@E_5%D\J6U:+1BZ0(0H](B@&4 5&#:R2]4B(\AF8<IUL1!PS^*F16#*PKUP
M/;$PH%1F63H>F+<G5>IQ0*_O*=HU.;QG%K HOL:73O.RV5*2$F><U6:.<5#$
MS2* BMJL5VL,STOM]\'V*.#]1@HVO2:.:\L%)3U$+]?HESQ[>W[U\KG6)N?0
M?G(6E3X^(D@ZUNV*9TH\T1?B+W:&.&.A<DPEH9$2*1[3A. [8VB.,"X^15T:
MQSO-AP]OVC%M,!)\C[143+#1TS,?K2. YDX-X (K^14&C'2$?)%\,)2>IL@X
MMAJ[S!&=JA(V#$P59<&-*YM(7E[PM.3#&T%',2C(&L7KB2N(\9D&=I-#^DEC
M5PYW;2H=<JBW.0](^G+H5E*@<OE@'A,L<4Z7];M$ #T, 39Y(6P5?5CNU+P@
MN+F47K@JN%8S=Q_.3PS;VGIA.Y:J3![%S%;!/+E^KUN$R69C2&EEMCHI^K59
M#/GB=HD0<ZP^N/EQ2GW>:,# ; ( (<AR[>:%OQQ4*IS^<MF9_R:TM8BBKCV[
MC%K]N3O=XKS5E'DG2(-J660CHHT1XDJWN:#;@X!G/#'MY-8_LZB?%@ZL8R[5
MG6@B)8F&,KK!-2-F2M*MOH>/*_*G1E,/@)V%&0*;<[D<)VWB&_4UWY+^>%X(
MJF\AE97>:8F>WC#9$?Y [%+#05D+PS)U5(:9;1I &\ \$#28F>.H.WH>(RHS
M]:!>#K^[<F"*!KAPKE7''@AIC2S9.R?KRX28.(/=S;;!]6>1\0DXP:HPBG)D
M2('I'<;4:2(G8%G1?6,W(E3R!%Z?7S'3N5I^?I@59T[(+7D2GF?J^V92]V@8
M$9Y,+*@3?DJ#$$6E7Q6%N+1,XI14H[C&+]99Y,7WLVH8@.18WX*-^O<05JTI
MB%8#RP(SY*3 0SL^M&L+Y(50"[#Z#C(J>F(UT=E(4"Q_.X@8UC*I[BX,0*)P
M]N3KAV'0LLLQ_5 @_@'KZF&J<>*5@\C4(#D2AP1!E].W*)(GL+E*D(W#Y-W$
MF?5M!))@A/VT7\+/2S?:\QR6[%Z$/1LHOEI\L[F)WRA0Z3!RM[.73?:FK-F<
ME]:*LMPZ&^&!HS1;0EM;WMZO!BC$V-+6JR!Y;&)6R)JKO1("1-7L=:%:6$N!
MJV/#&45ANBA)"'DFF&DK S+!AMH@14&]Q&17#*IMF=VRR64>35A@&@?JI1E!
M$/.-2.K H<&[S6>U\:%9*&Z.ABAZ>;A\>L0O\G6AYRC,'I24 %NJPDOFF=N,
M@GB.M21"IBYCR;#I1A9VP;%EJFG:R\UR\C@>1?2:.;]W'/$N:0F,"6=*)9;0
M6!%"E8!L\JG]K#H@-1BR,\Y8I2&3?6VBTIBE!L&KUMO!FS-+9>+)]D$7^*Q7
M#XJNJ%*,^>+M=0ZYT=$YF) %99EA=(IG?LR=DYDWR3""L-*.DP[CI:GD_,\V
M6^L9T%[7K1.$CSP;=SLN^GT :V/2BFCSW)7,%.X(%E,$.9F?^ .(C,S%H1?H
MCT,$Q ?'"T?=N3&<CGTM:=:(LNM)C+0^:6=3S4->7O369QC;X)JU7081J.R@
M\&##:"O/64&[)+L-\I6W*'/TNNW_$"V>\!A*$KHI<A U(O:<!N^:>[< _%06
M6 ^B!V7 .0ZP$])(LF.<B.$2A(^500B-0X%2=B1AM#6*U20*5DNC2H(<3\DN
M$9JW PF>PZ.$GT(LXK(X]R XKV8^""^%O!SMC/WHN^X>@DDD$"WK<4!76J'L
M -(D>QX5\7-A$#!LV6B&Y+?6!A^[U4 8G+G5BY^_:$770RNSQJV/F-W5XOJ)
M/?FW+_\.6AQR_*+U*EB!%ZW?7"AE*DK.58G[TZ[[02!]G$^O;(F$+S,R/)N%
M:PW+:EJ9EOY?/-'^I)Q,*NW?;Y&$_'Q1.V"OURW[P['I(OS[E>!GHI1Z[4)S
MML95.:[LV,&?9,FT")UMJNZQ1FXKYI&PNTDYG/;-X_Y?_.:]Z9!*,)NI!G]3
MJQ@)FQ.B$@M#!:('Y6 \=?>K-YV6W<G4]!KAC?WW$!*6E9[VW0\Q(<FR< /Y
M1W][!$G FO0F=B>#/_,$ 933[3K;X_]Y/$&,R[XS;O"GO'N_6P['SIC!WR>0
M1&\P+8>CD;<%TJM9^9![IN'0&_#]"&@>9U;+WU.,FT?F$,LM=4Z1(TES7FHI
MZGEYR%E_W6 %=?[_N4:0M3X9E'3WHP)8SEN80=?Z%3W;K;/WE!GZW#E("79]
M+,.-CX?YL3G#]1FOQW##)O+U>=W:'6:]@Y'M^:S7PVKORH%K.>]D,G*>&V"-
M>F' )S'>B>UL!%TQ][5<=SRT_/"L7V&=>F6^-2>LEJR$^8X&0V>_I&_+EV/F
M>RS[3)&%_.BQSW![Y>M';"_RS5Z_-1Z$G/0 !W4) A>:V>@I['/0';<&N*BX
MI<P^';;9'[;&(_@5-UPYW"-VD_AF#_GF>$1;.:*=%'8:\<!<AFJ6:>8>D)SN
MI$!KA$CA\W<8I<W9_%E/A(8S^>KY:='&$>_\O^A%>A-YG5O$\8B^T>'<RJ4X
MPWI691=.^[/6"%9UP/\.AZU?.:&#-VJ.()B$3PH*%["R;C6!$UW!8:V !D:R
MR8<6 /IF00CV$ :MQOBA5XX'W7"ISQT X4];<? )Y\>E<N0E!*7V,W(_?$D6
M<OEXYV8U;C'J@/M=V'Y3X8:+,#/81&MLR.+')+%MOA/I%-96KS/IM?N=_N07
M^-@;M'N=40\_#D?PL8)OWW@)FB8DABB"P=);56<\:%>=R0 ^]2?PJ3_%3Q5\
M@BTV'3"8)FPL)XUJEG&KV_K%_/<FSL!M=3OC7AO^UX=/HPE^ZN*G$7P:C</U
M_KN&3YU+H-*1FWIU<6&3JR\)IC&UI1H/)956-2KJM)VF04V=',&&?.)][G:&
M0URZT2_X$==STL6/75S&P:#1/G<[%9!*-_KW"7:8=G/2-WL]PLXKVNM81L5R
M",:[6!87C%N\O5M^80Y_92"-S^]!/R<W:XX=.\Z8=ZN;XA^_T<I&E76S"7@.
MD&1I/* $4,-N(J* #V@TW1;_>(_YA>\0<S4Q@,3<7%IV+898-?EE']F$CR!1
M.2]FR_7>GA U%%#BZ5=!#8*.7VOX1>LR=&.Q3?1V@=P<>/>(--URT.<;I ?T
M8G9(89Y0X!@"VQ^5%<BF8WJ(I094A,H^7";/6A,20/%V+Z?#*KJK!?FMABSJ
MMD >?]3J"^C;3UE_GM\Q2P]+/AC0O[U)C_\=C5-+#Z/VRNYTA M;389FX?MP
MR^/>#<K^>,PW\KCJ1>N.?NSV^?U\@X;I5[;RR8D;$61;L)O\_[G=H%F%NQ&@
MML&2#2M2Y0>X? -0"M];N#C;K _;TBM[0S2LH7REZS_ND1PDJS\L)]4@7,I,
M 9@&1H#TD[7]VX(E08$<*_+6&$0+=UW?*R#.#]LKOG%9C?O$)?K=4>OM?K-:
M2AU,C*7Y3C@0L""H HX&T$NRY@O0ZQ"TCQZ0?[?U<K^DZFGX[00X#_]?%)(1
MAK\B?^D.)]#9,95P0&4MIQ6J2F<5Z)-3^/"*7(4V3?4"$RBATU:_5XZJ;JLW
M1"8&]-4E0P^PNBJ2B%"U6VHI-M>F?M/0MO.6PT(4J/#"]Q/JG8=^E \V5"5R
M*7 G"FL?.!NYT(U7H#L5J=&81MYRK!L>QA=('1,B^A&:F[MP OKEM(\?^UW8
MO/&4/O;HXP0_]N'C8  Z)H))4B@A:KR3J6H<X4O002R'@V%2UT-B@MO_3W0B
M@.P;K+BK46"=#\1UBCP=YV(BXR<"C$%79U!D**X4[8B41E9NB;!LOBGTB_//
M$O7<^ET#_D&"0TO!E@+Z@)%A@#+L0>L=T,$2]N>F1;&R6_X',]=O%BV'2EIL
M*#M[9^1*^-@2]2F,.(_M)E.XN8'.NTCO$]0O]$G*=EO,8>^Z4V!]L,%P(#IP
M0+3!0N8]!YT>E,]N.>FQD6:,\J:VND%Y\5X:]:=PG+O4: *J3=-9CD&NZ$_&
MY; :<?=CF G)+&,\M[:?KYRG2IQ0Y6*X"O#K1_4KK\K0TZE^@)PGP#7&) -U
MIM/6$)0_O)]!(!K%=)PFS6WQP:Y#([N%M>DNJ3C3S$*:.5%MOL)[:*U?M!*S
MX2O(KH)IXWYG2=I^NM)L%N>3FRL2'Q'O5^OJ=4Z&\V7T]"6Y>E'SU%/%!T;>
MWCTXQ7O0S,P/07OG.#WK@^I4B&:*]=J'56L$-]( V."X,^W#Y3$$!HBVY@'M
M^J!3==WV>+&451^S.*K6M-,=IXR/ V^0"G1*%"M@F KN/]#^X3H= Y\=X#!5
M9S!L89N^?6*,_<(P72!#N/2J3C5H34=C.=FC3@_DRW&G[TQLRF.@7ZL:CN!5
M@(ZK"KX8X?T.\X0'H8TSJ]Z@ VQ\,JG*:HHF"9"<1M44)'T2^7NX%MBF&CJ/
M5)UNET0G.&JP$*-.?]0:C28@II+8-<1I8ZM>SWEH@JUZXTG9A8?'R)5Z_2&L
M!,K(O1'.^UEOVJG<1_!/MHGB(+TA,+9J,B"_'?Z"#29=K_VDBW)%1>W[ [)A
M\<5&/UG.0"PA/. U1_K2YO[PZ?Z$6=@G73N75Y^RMPV?L?@$P &S1\7<-T5T
MG;@GX>-B\Y"\1QPIH(4@>X?O$] AX2(8<6M*8@#>#^L\@G6F[["^V(QNC1Y\
M/06BDZX%2(Q^&8)HV#>_'+X>NJ"SHK6#/;5P-"M^\O@+(>XIQA%R\ET;2!\O
M%ZO%[9+55??91NE8'RGUP'9@,T@LI.AB?EB":ZA'O<P,]:+U"O.15CN0!1<8
MK'&?<:'HIRNT?$?.$_/K_IJL[=D&F@6<'NZLUR<9 N3Z"I2QY\%H9_CK6:]"
MB3\:"6B+-8)Q'YLY^<JRS,%(0QV)VL>Y=3=WB_G^GJZ<US;U^*6D'N?VGBA2
M7@WSJ79[4K1LD^(2WJ@QA622GK.$HV$X$K[F)M)Z=11N989;,T,G@XD\57"8
M.*^5*T=Q]TM"@KR7D,Q'*_>X'+-=8C)DB<5-FH"B-N"-@GMB,)KR9[2&3"JE
M#YY<B;F=+512SL9#Y#"@M(-:KWN!RR[U<5H5B+[#V,'[^WK5GC/8$0EAQ.-=
M3PF:<4 <Z,/@>,%V)X[CA@&9MZVS"4WRK$?^-O@P(4KCD5$U362 M\X&(*F/
M\85 ?QJ/!^CT&0Y:9 YM#<;P\N@G/IOVGIBP;>J,R<['/4GC-%XYB)RX*NN5
M^K]2<0?)W)YZDU#.8*&!- D$ ;@M$17/I%X2R1(2"E M)=JAQ /<ODL" ,AS
M?5B4+* PY>\QLK;?"1!<;TCFB@I$B:N,)PV$B=Z(7&^CJA7"Y;>F(-OAO3B1
M?>V7?3**&,][8LU:>)5.!B#$#%&*J>@N#ZDG;/-[&D<@R<[?VU2K%_&#-FC/
M0\L+H/2B@Y1X&]-3:A8U=ZQ*5R!\F0E8JL7 $V/&1,H5MIQT1=4H6>SLE9&"
MF.R0L/?NF,XIK*7GQ'VL68>2X,:>WF%%MO8!:0- &H-)2TN2N "4,*HF]4<
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MLB(IO/53S]*@2HVL3OC<4V_2J.)T&N\=1/-H--9RXBOZ>^UP5;/':N@;?KH
MNL*\RUF#M[+H"F'2I5:[;)C+V"[^)[,6K=S4+D10." L.5/4XB$K7U'\32$?
M/ZPPB%#0-['5[UBY7+]X2;C'=4+$L;E&T>Y'>0S9C4T/E8I@R20G9'M^ZX@
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MVM7%Z\4<RU"B!7WV979#]0Y![-UC5CDT6MS<@W!U(V[>5_K'A5H>3WT?DQ?
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M%TU17/I]]]5M+=O]W3VV*W'/_@502P,$%     @ JHMA3!>M++HY @  7B@
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M-!^4Z$'W\T'W]*"'^: '>M#C?- C/2BN@8QK?A+"FJ]U!%Q'OM<1@!WY8D=
M=N2;'0':D:]V!&Q'OML1P!WY<D= =^3;'0'>D:^W +V%K[< O66!=VWTLLW7
M6X#>PM=;@-["UUN WL+76X#>PM=;@-["UUN WL+76X#>PM=;@=[*UUN!WLK7
M6X'>NL!>"=HLX>NM0&_EZZU ;^7KK4!OY>NM0&_EZZU ;^7KK4!OY>MM0&_C
MZVU ;^/K;4!OX^MM0&];8*\;;7;S]3:@M_'U-J"W\?4VH+?Q]3:@M_'U-J"W
M\?5VH+?S]7:@M_/U=J"W\_5VH+?S]7:@MR_PK1)]K.3K[4!OY^OM0&_GZ^U
M;^?K[4!OY^N=@-Z)KW<">B>^W@GHG?AZ)Z!WXNN=@-Z)KW<">J<%SIJ@PR9\
MO1/0._'U3A.]R['N\^[[T)^:0[EUR3_#/ZV9P%V&]W.^?<9UZJ?'@29*#^,J
M.5RO-X?P.O5/1)A6E.??4$L#!!0    ( *J+84QP+9 <_ $  *$G   3
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M2P$"% ,4    " "JBV%,9O,+8((   "Q    $               @ 'I
M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0    ( *J+84R)M#M@[P   "L"   1
M              "  9D!  !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    (
M *J+84R97)PC$ 8  )PG   3              "  ;<"  !X;"]T:&5M92]T
M:&5M93$N>&UL4$L! A0#%     @ JHMA3$]E3T>I @  " H  !@
M     ( !^ @  'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    (
M *J+84S3@$NRTP,  (41   8              "  =<+  !X;"]W;W)K<VAE
M971S+W-H965T,BYX;6Q02P$"% ,4    " "JBV%,[?W+=/<!  "'!0  &
M            @ '@#P  >&PO=V]R:W-H965T<R]S:&5E=#,N>&UL4$L! A0#
M%     @ JHMA3 F*K\U> P  <0T  !@              ( !#1(  'AL+W=O
M<FMS:&5E=',O<VAE970T+GAM;%!+ 0(4 Q0    ( *J+84P)NG]YTP(  %P*
M   8              "  :$5  !X;"]W;W)K<VAE971S+W-H965T-2YX;6Q0
M2P$"% ,4    " "JBV%,J(08YA@%  #'&0  &               @ &J&
M>&PO=V]R:W-H965T<R]S:&5E=#8N>&UL4$L! A0#%     @ JHMA3*@W6> W
M!0  ]QD  !@              ( !^!T  'AL+W=O<FMS:&5E=',O<VAE970W
M+GAM;%!+ 0(4 Q0    ( *J+84Q](@=TLP$  -(#   8              "
M 64C  !X;"]W;W)K<VAE971S+W-H965T."YX;6Q02P$"% ,4    " "JBV%,
M.FNEIK0!  #2 P  &               @ %.)0  >&PO=V]R:W-H965T<R]S
M:&5E=#DN>&UL4$L! A0#%     @ JHMA3+404Z.T 0  T@,  !D
M     ( !."<  'AL+W=O<FMS:&5E=',O<VAE970Q,"YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J+84S_FL??M $  -(#   9              "
M <\P  !X;"]W;W)K<VAE971S+W-H965T,34N>&UL4$L! A0#%     @ JHMA
M3/6PRK.T 0  T@,  !D              ( !NC(  'AL+W=O<FMS:&5E=',O
M<VAE970Q-BYX;6Q02P$"% ,4    " "JBV%,0J)$>K4!  #2 P  &0
M        @ &E-   >&PO=V]R:W-H965T<R]S:&5E=#$W+GAM;%!+ 0(4 Q0
M   ( *J+84Q/=22BM $  -(#   9              "  9$V  !X;"]W;W)K
M<VAE971S+W-H965T,3@N>&UL4$L! A0#%     @ JHMA3(!2_AJS 0  T@,
M !D              ( !?#@  'AL+W=O<FMS:&5E=',O<VAE970Q.2YX;6Q0
M2P$"% ,4    " "JBV%,MT/)6;4!  #2 P  &0              @ %F.@
M>&PO=V]R:W-H965T<R]S:&5E=#(P+GAM;%!+ 0(4 Q0    ( *J+84QKEOEI
MLP$  -(#   9              "  5(\  !X;"]W;W)K<VAE971S+W-H965T
M,C$N>&UL4$L! A0#%     @ JHMA3$:559VT 0  T@,  !D
M ( !/#X  'AL+W=O<FMS:&5E=',O<VAE970R,BYX;6Q02P$"% ,4    " "J
MBV%,D*0'<K0!  #2 P  &0              @ $G0   >&PO=V]R:W-H965T
M<R]S:&5E=#(S+GAM;%!+ 0(4 Q0    ( *J+84S.8OPCHP(  *L*   9
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M970R."YX;6Q02P$"% ,4    " "JBV%,CT/%$+8!  #2 P  &0
M    @ 'V3   >&PO=V]R:W-H965T<R]S:&5E=#(Y+GAM;%!+ 0(4 Q0    (
M *J+84R2H5C/M@$  -(#   9              "  >-.  !X;"]W;W)K<VAE
M971S+W-H965T,S N>&UL4$L! A0#%     @ JHMA3,K?-V/3 0  G 0  !D
M             ( !T%   'AL+W=O<FMS:&5E=',O<VAE970S,2YX;6Q02P$"
M% ,4    " "JBV%,\U%5R-X!   !!0  &0              @ ':4@  >&PO
M=V]R:W-H965T<R]S:&5E=#,R+GAM;%!+ 0(4 Q0    ( *J+84SF85X*N $
M -(#   9              "  >]4  !X;"]W;W)K<VAE971S+W-H965T,S,N
M>&UL4$L! A0#%     @ JHMA3%U9NVNX 0  T@,  !D              ( !
MWE8  'AL+W=O<FMS:&5E=',O<VAE970S-"YX;6Q02P$"% ,4    " "JBV%,
M(GT5/#P$  "'%@  &0              @ '-6   >&PO=V]R:W-H965T<R]S
M:&5E=#,U+GAM;%!+ 0(4 Q0    ( *J+84SV SN@Y ,  %(5   9
M      "  4!=  !X;"]W;W)K<VAE971S+W-H965T,S8N>&UL4$L! A0#%
M  @ JHMA3)(ZGPS  0  U@,  !D              ( !6V$  'AL+W=O<FMS
M:&5E=',O<VAE970S-RYX;6Q02P$"% ,4    " "JBV%,%5(271L$  !=%0
M&0              @ %28P  >&PO=V]R:W-H965T<R]S:&5E=#,X+GAM;%!+
M 0(4 Q0    ( *J+84SL<AG$!P(  +X%   9              "  :1G  !X
M;"]W;W)K<VAE971S+W-H965T,SDN>&UL4$L! A0#%     @ JHMA3+,\+GU.
M @  20<  !D              ( !XFD  'AL+W=O<FMS:&5E=',O<VAE970T
M,"YX;6Q02P$"% ,4    " "JBV%,3%]W2[T"  #&"0  &0
M@ %G;   >&PO=V]R:W-H965T<R]S:&5E=#0Q+GAM;%!+ 0(4 Q0    ( *J+
M84P1%X%>C@(    *   9              "  5MO  !X;"]W;W)K<VAE971S
M+W-H965T-#(N>&UL4$L! A0#%     @ JHMA3%G5*_63 @    H  !D
M         ( !('(  'AL+W=O<FMS:&5E=',O<VAE970T,RYX;6Q02P$"% ,4
M    " "JBV%,>$=(!XX$  "Y&   &0              @ 'J=   >&PO=V]R
M:W-H965T<R]S:&5E=#0T+GAM;%!+ 0(4 Q0    ( *J+84P36%L&& ,  '0,
M   9              "  :]Y  !X;"]W;W)K<VAE971S+W-H965T-#4N>&UL
M4$L! A0#%     @ JHMA3&PK&-F@ @  BPD  !D              ( !_GP
M 'AL+W=O<FMS:&5E=',O<VAE970T-BYX;6Q02P$"% ,4    " "JBV%,,6-[
MXJ4"  #["0  &0              @ '5?P  >&PO=V]R:W-H965T<R]S:&5E
M=#0W+GAM;%!+ 0(4 Q0    ( *J+84S2B<AGL (  .P)   9
M  "  ;&"  !X;"]W;W)K<VAE971S+W-H965T-#@N>&UL4$L! A0#%     @
MJHMA3$])DU&C @  2@H  !D              ( !F(4  'AL+W=O<FMS:&5E
M=',O<VAE970T.2YX;6Q02P$"% ,4    " "JBV%,!!W7G8@"   *"0  &0
M            @ %RB   >&PO=V]R:W-H965T<R]S:&5E=#4P+GAM;%!+ 0(4
M Q0    ( *J+84PX283Z1 ,  ( .   9              "  3&+  !X;"]W
M;W)K<VAE971S+W-H965T-3$N>&UL4$L! A0#%     @ JHMA3'+EU +_ 0
MQ@4  !D              ( !K(X  'AL+W=O<FMS:&5E=',O<VAE970U,BYX
M;6Q02P$"% ,4    " "JBV%,S@1]Y_8%   ?(P  &0              @ 'B
MD   >&PO=V]R:W-H965T<R]S:&5E=#4S+GAM;%!+ 0(4 Q0    ( *J+84Q_
MJ?@,_0(  +8+   9              "  0^7  !X;"]W;W)K<VAE971S+W-H
M965T-30N>&UL4$L! A0#%     @ JHMA3.:$G,RS!0  /2(  !D
M     ( !0YH  'AL+W=O<FMS:&5E=',O<VAE970U-2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( *J+84Q,H\,$0 (  " '   9              "
M 6FK  !X;"]W;W)K<VAE971S+W-H965T-C N>&UL4$L! A0#%     @ JHMA
M3$Q.5#-7 @  3@<  !D              ( !X*T  'AL+W=O<FMS:&5E=',O
M<VAE970V,2YX;6Q02P$"% ,4    " "JBV%,)"A+]B8"  "#!@  &0
M        @ %NL   >&PO=V]R:W-H965T<R]S:&5E=#8R+GAM;%!+ 0(4 Q0
M   ( *J+84R^'A3300(  %('   9              "  <NR  !X;"]W;W)K
M<VAE971S+W-H965T-C,N>&UL4$L! A0#%     @ JHMA3#&85%E_ P  H0X
M !D              ( !0[4  'AL+W=O<FMS:&5E=',O<VAE970V-"YX;6Q0
M2P$"% ,4    " "JBV%,(OLS(18#  #S#   &0              @ 'YN
M>&PO=V]R:W-H965T<R]S:&5E=#8U+GAM;%!+ 0(4 Q0    ( *J+84RDYB;%
M00(  +4&   9              "  4:\  !X;"]W;W)K<VAE971S+W-H965T
M-C8N>&UL4$L! A0#%     @ JHMA3,.5TV$F @  L08  !D
M ( !OKX  'AL+W=O<FMS:&5E=',O<VAE970V-RYX;6Q02P$"% ,4    " "J
MBV%,,Z-T26RD  "TA@( %               @ $;P0  >&PO<VAA<F5D4W1R
M:6YG<RYX;6Q02P$"% ,4    " "JBV%, :SQRSL"  !\"@  #0
M    @ &Y90$ >&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *J+84P/UHMCX00
M /@K   /              "  1]H 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "JBV%,%ZTLNCD"  !>*   &@              @ $M;0$ >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "JBV%,<"V0'/P!  "A
M)P  $P              @ &>;P$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    3 !, ,84  #+<0$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/**
 * Rivet Software Inc.
 *
 * @copyright Copyright (c) 2006-2011 Rivet Software, Inc. All rights reserved.
 * Version 2.4.0.3
 *
 */

var Show = {};
Show.LastAR = null,

Show.hideAR = function(){
	Show.LastAR.style.display = 'none';
};

Show.showAR = function ( link, id, win ){
	if( Show.LastAR ){
		Show.hideAR();
	}

	var ref = link;
	do {
		ref = ref.nextSibling;
	} while (ref && ref.nodeName != 'TABLE');

	if (!ref || ref.nodeName != 'TABLE') {
		var tmp = win ?
			win.document.getElementById(id) :
			document.getElementById(id);

		if( tmp ){
			ref = tmp.cloneNode(true);
			ref.id = '';
			link.parentNode.appendChild(ref);
		}
	}

	if( ref ){
		ref.style.display = 'block';
		Show.LastAR = ref;
	}
};

Show.toggleNext = function( link ){
	var ref = link;

	do{
		ref = ref.nextSibling;
	}while( ref.nodeName != 'DIV' );

	if( ref.style &&
		ref.style.display &&
		ref.style.display == 'none' ){
		ref.style.display = 'block';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '+', '-' );
		}else{
			link.innerText = link.innerText.replace( '+', '-' );
		}
	}else{
		ref.style.display = 'none';

		if( link.textContent ){
			link.textContent = link.textContent.replace( '-', '+' );
		}else{
			link.innerText = link.innerText.replace( '-', '+' );
		}
	}
};
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='UTF-8'?>
<FilingSummary>
  <Version>3.8.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>242</ContextCount>
  <ElementCount>336</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>80</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>12</UnitCount>
  <MyReports>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>100000 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>100010 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>100020 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>100030 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>100040 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>100050 - Statement - Consolidated Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementConsolidatedStatementsOfStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>100060 - Statement - Condensed Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/StatementCondensedConsolidatedStatementsOfCashFlows</Role>
      <ShortName>Condensed Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>100070 - Disclosure - Organization and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>100080 - Disclosure - Fair Value Measurement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurement</Role>
      <ShortName>Fair Value Measurement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>100090 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>100100 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>100110 - Disclosure - Major Customers, Partnerships and Strategic Alliances</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>100120 - Disclosure - Acquisition of Ceregene</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregene</Role>
      <ShortName>Acquisition of Ceregene</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>100130 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>100140 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>100150 - Disclosure - Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquity</Role>
      <ShortName>Stockholders' Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>100160 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>100170 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>100180 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>100190 - Disclosure - Quarterly Financial Data (Unaudited)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited</Role>
      <ShortName>Quarterly Financial Data (Unaudited)</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>100200 - Disclosure - Build-to-Suit Lease</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLease</Role>
      <ShortName>Build-to-Suit Lease</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>100210 - Disclosure - Claims Settlement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlement</Role>
      <ShortName>Claims Settlement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>100220 - Disclosure - Subsequent Event</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEvent</Role>
      <ShortName>Subsequent Event</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>100230 - Disclosure - Organization and Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>100240 - Disclosure - Fair Value Measurement (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementTables</Role>
      <ShortName>Fair Value Measurement (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurement</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>100250 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecurities</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>100260 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>100270 - Disclosure - Major Customers, Partnerships and Strategic Alliances (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesTables</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliances</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>100280 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipment</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>100290 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingencies</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>100300 - Disclosure - Stockholders' Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityTables</Role>
      <ShortName>Stockholders' Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquity</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>100310 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>100320 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>100330 - Disclosure - Quarterly Financial Data (Unaudited) (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables</Role>
      <ShortName>Quarterly Financial Data (Unaudited) (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnaudited</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>100340 - Disclosure - Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureOrganizationAndSummaryOfSignificantAccountingPoliciesAdditionalInformationDetail</Role>
      <ShortName>Organization and Summary of Significant Accounting Policies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>100350 - Disclosure - Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementSummaryOfFairValueMeasurementsOfCashEquivalentsAvailableForSaleSecuritiesAndContingentConsiderationLiabilityDetail</Role>
      <ShortName>Fair Value Measurement - Summary of Fair Value Measurements of Cash Equivalents, Available-for-Sale Securities and Contingent Consideration Liability (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>100360 - Disclosure - Fair Value Measurement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail</Role>
      <ShortName>Fair Value Measurement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>100370 - Disclosure - Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesSummaryOfCashEquivalentsAndAvailableForSaleSecuritiesDetail</Role>
      <ShortName>Marketable Securities - Summary of Cash Equivalents and Available-for-Sale Securities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>38</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>100380 - Disclosure - Marketable Securities - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMarketableSecuritiesAdditionalInformationDetail</Role>
      <ShortName>Marketable Securities - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>100390 - Disclosure - Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetail</Role>
      <ShortName>Stock-Based Compensation - Stock-Based Compensation Expense (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>100400 - Disclosure - Stock-Based Compensation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail</Role>
      <ShortName>Stock-Based Compensation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>100410 - Disclosure - Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForEstimatingFairValueOfEmployeeStockOptionsDetail</Role>
      <ShortName>Stock-Based Compensation - Assumptions Used for Estimating Fair Value of Employee Stock Options (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>100420 - Disclosure - Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockBasedCompensationWeightedAverageAssumptionsUsedForEstimatingFairValueOfESPPPurchasedRightsDetail</Role>
      <ShortName>Stock-Based Compensation - Weighted-Average Assumptions Used for Estimating Fair Value of ESPP Purchased Rights (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>100430 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>100440 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesRevenuesRecognizedUnderAgreementDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Revenues Recognized under Agreement (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>45</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>100450 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithSigmaAldrichCorporationAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Sigma-Aldrich Corporation - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>100460 - Disclosure - Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureMajorCustomersPartnershipsAndStrategicAlliancesAgreementWithDowAgrosciencesInPlantAgricultureAdditionalInformationDetail</Role>
      <ShortName>Major Customers, Partnerships and Strategic Alliances - Agreement with Dow AgroSciences in Plant Agriculture - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>100470 - Disclosure - Acquisition of Ceregene - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAcquisitionOfCeregeneAdditionalInformationDetail</Role>
      <ShortName>Acquisition of Ceregene - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>100480 - Disclosure - Property and Equipment - Summary of Property and Equipment (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentSummaryOfPropertyAndEquipmentDetail</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>100490 - Disclosure - Property and Equipment - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosurePropertyAndEquipmentAdditionalInformationDetail</Role>
      <ShortName>Property and Equipment - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>100500 - Disclosure - Commitments and Contingencies - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail</Role>
      <ShortName>Commitments and Contingencies - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>100510 - Disclosure - Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureCommitmentsAndContingenciesSummaryOfFutureMinimumPaymentsUnderContractualObligationsDetail</Role>
      <ShortName>Commitments and Contingencies - Summary of Future Minimum Payments under Contractual Obligations (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>100520 - Disclosure - Stockholders' Equity - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquityAdditionalInformationDetail</Role>
      <ShortName>Stockholders' Equity - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>100530 - Disclosure - Stockholders' Equity - Summary of Stock Option Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Option Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>100540 - Disclosure - Stockholders' Equity - Summary of Stock Options Outstanding (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfStockOptionsOutstandingDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Stock Options Outstanding (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>100550 - Disclosure - Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureStockholdersEquitySummaryOfRestrictedStockUnitActivityDetail</Role>
      <ShortName>Stockholders' Equity - Summary of Restricted Stock Unit Activity (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>100560 - Disclosure - Income Taxes - Summary of Benefit for Income Taxes (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfBenefitForIncomeTaxesDetail</Role>
      <ShortName>Income Taxes - Summary of Benefit for Income Taxes (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>100570 - Disclosure - Income Taxes - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesAdditionalInformationDetail</Role>
      <ShortName>Income Taxes - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>100580 - Disclosure - Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfDifferenceBetweenBenefitForIncomeTaxesAndFederalStatutoryIncomeTaxRateDetail</Role>
      <ShortName>Income Taxes - Schedule of Difference Between Benefit for Income Taxes and Federal Statutory Income Tax Rate (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>100590 - Disclosure - Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesScheduleOfCompanySDeferredTaxAssetsDetail</Role>
      <ShortName>Income Taxes - Schedule of Company's Deferred Tax Assets (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>100600 - Disclosure - Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureIncomeTaxesSummaryOfActivityRelatedToCompanySUnrecognizedTaxBenefitsDetail</Role>
      <ShortName>Income Taxes - Summary of Activity Related to Company's Unrecognized Tax Benefits (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>100610 - Disclosure - Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureAccountsPayableAndAccruedLiabilitiesSummaryOfAccountsPayableAndAccruedLiabilitiesDetail</Role>
      <ShortName>Accounts Payable and Accrued Liabilities - Summary of Accounts Payable and Accrued Liabilities (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>100620 - Disclosure - Employee Benefit Plan - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureEmployeeBenefitPlanAdditionalInformationDetail</Role>
      <ShortName>Employee Benefit Plan - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>100630 - Disclosure - Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedSummaryOfQuarterlyFinancialDataDetail</Role>
      <ShortName>Quarterly Financial Data (Unaudited) - Summary of Quarterly Financial Data (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.sangamo.com/20171231/taxonomy/role/DisclosureQuarterlyFinancialDataUnauditedTables</ParentRole>
      <Position>64</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>100640 - Disclosure - Build-to-Suit Lease - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureBuildToSuitLeaseAdditionalInformationDetail</Role>
      <ShortName>Build-to-Suit Lease - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>100650 - Disclosure - Claims Settlement - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureClaimsSettlementAdditionalInformationDetail</Role>
      <ShortName>Claims Settlement - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="sgmo-20171231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>100660 - Disclosure - Subsequent Event - Additional Information (Detail)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.sangamo.com/20171231/taxonomy/role/DisclosureSubsequentEventAdditionalInformationDetail</Role>
      <ShortName>Subsequent Event - Additional Information (Detail)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>sgmo-20171231.xml</File>
    <File>sgmo-20171231.xsd</File>
    <File>sgmo-20171231_cal.xml</File>
    <File>sgmo-20171231_def.xml</File>
    <File>sgmo-20171231_lab.xml</File>
    <File>sgmo-20171231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2014-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/us-gaap/2017-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>114
<FILENAME>0001564590-18-004163-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001564590-18-004163-xbrl.zip
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M^.G!-*>%]^ /!;?8S,FV)V36^8/_]!I^P,N[V<LM?^9%P;SX%OECP5NL61"
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MW;,+,PU&G0,-Q08;>W<<BMT<B6%N>KC;2'P)'DQ/;A+#_1^^Z]BFW-]X X^
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MKAF&^">'VPJ<*7_:V+0B/PB-/SS_NV< BO\&&(TQ;IT+C/>?+\[N00#Q(=/
MCY@#$ZJ7_^_J)GQU;MS 9["&T!]S.@5%DO,M>$-1QY16PPO<F<TR0PMW/<Y
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M48_390J;G^SY7"#&]>WTQ?J7V+,I5NICB6PL>W VUARGDZ/KU<!VIE5XLKM
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M'H80<[^(58H(#6X<"T5O\92!I#;Q3!RRP6)OA%<,"_RQDVP=XN%3GPEZAT>
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M0[8'%)"#R)!IB(R8M1(T^D%#[*\K,D0J>J! I*(I,D0JND)#I*(K,D0J>J!
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MUM!.$@<>+[;$@54$2 <4(-4>J-IN=+7]V;W+C/;YZ1$E7^ U+#-\--B?,P=
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MS'WJ=@=/E?*FR4/49\@UU'DRP=LTS+ =!LJ68B4L\$"?H+$2&H+%2EB(3ZR
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MBAA&8PYXYR6F!=B!S[L6(JQZVR$^7+2X?$2G/,T?0<46T"Z!#QN@Y^B>JR\
MSX:;P^F6OCF\$U/H2W3#+&0!*C(?"B[W<98%DU*B?'* JZ2!KZ&B:N"O]0X-
M@R?$*>"%*L0?"SF]AG#;J%B%6Y@<%<A@@"5-,DW4D*E(MLLD:B-W7Y;JCM("
M44]5+M(-J7L,=6',E#U1'Q(5,:&3Z\W)-:"(EILIO&,&U3I:PYYA4W21:(JY
M43CX;0IQ;8Y)(OQ)& 71>*XGPV((_: )UZ4[RL= ,)B:P2@$^Y3YG"P*K07
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M_BC0Y+8B/;F?QK%1MC)=-@Q<>#S,QQ]9_1AKFS[QT!<:!?BJFGPTFR1,:K:
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M=5D/G-KFNLH3VO-6MQ1A;"R5CP]4 D$EQ+?JW@ZS;@K0H+W?#9N3JN::(12
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M-?,W_\1KJ-[?66&RP.!H-HU8ZH \(;&4O=@LRT?W[(&YYU;,"L6]E*"(Q);
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M\PL6Q4=))C+N^\ R//1%O4/0UE(I31VY!<="3J_!V-!\C&8;\1D?G$)G, ;
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M2QZ.^31B^E)S,81N)Q'C(1/?_2!5\D8P/YI.1>Q+'K @V\".$L/^8_FY"#;
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M;">$[AC,JN'\X(GCJ0;@\HPG&PB6S6'IN8/V%F>#C)\F&R(;L@$6^RYUS(*
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M'%U5JT!G IX*4[;"",9DPM.N;9&<M#_(!(NEUTHIAY>F+>!!T@2XRRPR\UN
ML!ZG9I(PP8A1&[-RE(FW*,E,K%=>0$!$/(4 *LD&Z^#41VFL@_:LIMJXICJ8
MKE6^JWEO&PRJ-DC.,<"/XCL.5B'Z-,/U8L%"S[[.C/,?:XH<&K%!Q(J4 TR/
M_'F-R1>5,J,A#]?XH#@1ECD-RV3+M:)K])T-A74U>CJBY##3!(UH,2['\99
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MN95[QF,0\?'9EC745.6AW:!%TZ16T-4Z,',1'IW9F8N\[3 Y(J_]8[!#MW>
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ML7PC<:-8_H# )%:C=93# ,R&,(3641HP]CHZZ[DTQPMH:&45*H?ATP[07!H
M#-F+C;!L>5R53(A,B& ARJ$XVG*4*(ZV$15R:@0,V<LAP4)Q='.P(A.B]8/#
M ,S^&('6#VC<LP^4_&@ZC4)S:8BU]D,\9"4L-/0AOV8K2O^KVR"&Y75 YS<B
MYN-]GW F)T=.[G" (2=G0?!6NCB*XFQ#B!P< 4/V<DBPT 1V<[ B$Z()[,,
MS/X8@2:P:0RT#Y2RB_7+05 266M&1$=6PD(C(')OMJ+T54RY#$$DUEH/.34K
M82&G1D[-5I3*9$C6F@]Y-2MA(:]&7LU6E&C+01-0:OKTZ):9# X)PJ\\'.MT
M=UGB L&^Q-+?MYE1.J4#)3+*';($R2R_H!TV1SRV?PPH9Q(YOF- \@)^B;F?
MI#PH _U?Y,B2\&-S&R27N6^L:#*#7&&3D;0L!B3'1X[O % @QV<]DOF\4QD
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M$9TU""RR+8*+Z.RP,"23:_0NVG53Q\,HO0X$:[M'.G5\S[6LF\V*/-$Z])H
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M6UI@+LW05*\!<<P,%1KO=7YA$7V &\P@V3T 56:&"*,E,!FF_D*MN/1#E0]
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MR%XK1:L!6G$=/^V[O#0 &B8L)JS]%<"QTQ]MYA9DPF*MR(35 &B8L)BP]E<
M>SUGW-LL>L^,154MLO^OG3 P->VP+#[S$B4(>P.G>[)5[2TFI99J0R8E.E8;
M\Q(OF?:5F@;.Z9!73,1 :8!69!\?66B8L)BP]E< !\Y)EPF+&"@-T(I,6&2A
M8<)BPMI? >P[XSYG41 #A=U_# ,S$\>DVDM+8^>TOU6A ^:D&I5A;<<CK$6K
M-9O8WO]8R##9;A/;DZ/ !L.&%O73(]%2[;7M8O7) =%6 9.^6HMVG?Z&A\"Q
MZ+!28^]I Z!IJ= PWS0 I'[/Z?8WJS7*HL-*C?FF ="T5&B8;QH 4G_HC(>\
MOB&&"HW2A>P[(PY#2Z5CJU@:L\ISLLHQL$JM]7%9:!JFRYA2V.9J *OP<J7N
M<,SQUKF!+#KM56KL'B,+34N%AOFF 2 -NLYHN%DM>Q8=5FK,-PV IJ5"PWS3
M )#Z?:?;/Z6*5%M%AWUG# -+!X=CFHI0;^R<C&H]HY6%AL_?:A(\GV4J@BCA
M\[>HRP@7 Z!+^;75V6#6Q]X>](Z=XP%7?B(&RR%90-AG21::ELH*\TP#0#KH
M]9WAZ;9[EEAVF&=:(BC,,U2189YI $C(,X/1MLD8+#NU\@S[R$AP"E<FHT0H
M]93[8S;1;#)PNANN6EAJF$KV?_1Y>4(5&5Z>-  D#+<,3WEY0@P6=H-10X1Y
MABHRS#,- .F@?^R,3D94H6JK[##/4$.$>88J,LPS#0#IH#=V3H^99XC!PCZR
M!G$*.XXI$0J'6VIDDU/GN+^9<XR%IG8FX4.3:M]Y)!8R%LF5&\MMA(;W'%-9
M1/(.2F*+2-YY_)RTW^UPN3YJH&SKJN2J2<PR;9,59ID&@ 0LPV?T40.%688:
M(LPR5)%AEFD 2,@RVX;#6'(HA</8.T8B',9"02D<QEQ"DDM89IA(]G_T>6E"
M%1E>FC0 ) ZS$ 2%'6#4$&&6H8H,LTP#0 *6&8RI M56R6&6H88(LPQ59)AE
M&@ 2KF4XF$\,%/:.-8A1V&5,B4XXS%)OF&6K34<L,\]/)/:FHY]3=Q+(XBK/
MO]YB9"H#\9/5N5/X<:UBW9^7V$/W]Y^SY.C2=1>O_I6Y<2KCX.:#'[KAU'>#
MCR$BYZ9^%%[ B]X$T?2/?_SU+T+\/;F<1Z_>9'[@743GF9]^DFXB?YN R*BK
MW_G)-(B2+);%?<+W?GGQX3\PT?K'O1=B"BV%G[[*V2\OWN*W/?BG/QC\I]_M
MG<"'GOH#ONF]^ <VU[3VKW_9P0"9B3N) F_EQ+Y3!AZQ@>NWB_>B-Q0*D;^-
M^[W>:_'FV\=/[XXN?CLZ__;Q0GQZ?W;^7MPS&;!GO?YBE4JV6NBGH+^FCY3I
MC?MGC_*P,QH:V^M-["<3-Y1"S11H^1'.%:$FRP:]/%[9R=OOJE=Q?0S%Y^A:
MSB<R%CAG'9%>2?$VFB_<\$9 *V4L/>&':21<$42@\^&;N5C$T4+&Z8T(<#0$
MZ/SI%5PU#3(/.@#BD:1Q-D5A$I,;]<A )DD4BV@&SYG@@ )_B.]^>B7<!3SM
MAP^2*H,;,3YQ3KI=D?P)\BS%3,H4[U%TXL ;1(Z*(]["'($NAK[;$>?9)$FA
M<R#V\/;Y(I#JW7 GOKMXGY\(F:3J59Z +D73:1;C4U4+W205?VHU@G?"<(P[
MXD*U'3OI7L92SF%(A/RQ\&/H)]SXJWL#%_9/G:5NI#(4-]*-$^'.\'G)1@WL
MB#-X66H:,(6AAPD'?10O!YV1@"D2X$W?7=4-H!(_N8*.P$=\B"<740+7NZ&'
M'9U"?Q)_YL,%.,S0U@BNB@']$#H=8S_@ IDF>?]GN>*$R0R=P)XFNO_Y=+C"
M-WV'85M@XQ,<09AL$MZ7%J.DI@<V.5L(-6F@MQ,_Q&:"S8#WP0N*T>ELKRZH
M29(]4##\'LX5SU%#X4ZG40;8PPQ<9#&@!$V+PN#&P1&:2#5ZT?=0HXX?H$\P
MP5#*?I?3U @6WEZ9S0!^$#A"7DL$,,HN0013?'<8I0:12QAL_62 SA4P:;,@
MS=\"!I2G'X(2J\&Y)3)J-H7747"MY[Z9+!41AW9.0;P[ K0)_!!*_;62;DN=
M%-1Q\CJQQP2'""8HS"<<:U?=7-5#4W>A*.'_2<^\/8%YBR)B-T-U<9(KZP25
M=:&GC @4G[%;\L_,7V"G'!%*^!=^%\MI=!G"B]3,!3%)%C@TT,KJ@_5DCPJ;
MP;% \I763-*.^.#Z,=KBF;PUKD:(C2YR4_&RW^V<%C*>)7@1:@HW1IM1@ #\
M(;%#/@RUWD5M5&04:1V1^'"S&VM=J;Y99-"^*?0)9H%40FT/<2'X8.G$@(6&
M&RXN- A<XWN* %R@O6L9B+Z8E5V:PQB D80C"(I+X?%.3C67#'J.X9.7_5ZG
M7]%=-IJ: 1XTU"5&"%>0ZW(U@_2U>D(M3>+*5%$3J&-9EYL:LP]F]CH,&J6/
MOD0P#\47/XR"O3=ABFD'4VY4NPDS[#G#NTR8K_"F.4SUK4P8%"#4G7"!9G^_
MVOUCU"6Z,Z!<I,7,< ^(ZE1Z]QHUUO/Z(,<S_UIN9<RP[; 7MD.;>;W@DL0%
M87+GV+=U9'?LH)U><KCJ!W;H.VB@2E^AQ3D2R9-08.<1ZW!JPO'6G@NH1HS*
M@3Y'9N7B3OW -^C#!4DVQ1%=1+&MET#EIE=!KN\7[HVV9V%R!4$TS<<PT+,E
M3(MI$WMZC>7"DV"2N6INZX> SI0A:E&CQJ G1[GUM_QZF#OP&1&K-"#1P$GU
MX@!>5@54ZK:L6,@"YP2^O@SX+9O*\HJU\\:>%E4WVL-=8I8K[6W@^O/D'!:N
M@>*2>QQH_18[T$85!]K;3V<??ST7Y^\O+CZ]__7]YXNMC;+:1'2-\PP8XUPN
MTG56&<B5!*O"$R][0\NSH31]4LPCK1JGH-A=T)@^J $_S8P9 &M2$+(H1M\'
M6CRH8B<RE#-?N3 4<2DM?>Z&ER![%9)"4PA>!_?#S%R2-\]/+J/X4C< [;8K
MD-NCY+MBX#B:^2"RP,1)!J. ]YP;5NP='TP.<T&%+[,8+!; X?V/Z14T08JS
MJ7I>[W0P=%1/X0V@6O0JY&^]X^YK93!9W8>K7YZ6PZ/H3)N?+T>=;C%J0/$1
M6GKN#S,"6G?EXV:45.(HV]%B#FQ#:5<M7-\#('.>ND=5;"#R6D'D_GDT;X&8
MX=+WUZCV5FJ&08LUPW%%,YQ_>W/^_E_?0"6(]_^^7S$\K)^;Z8E=17E(J*;C
MSO%)J9H^R$D,B[,;Y>.]<[WX-@H"=Q+%VNQ"L?KD3Q7GGQ4K)Z6E_MM/I?AR
MY<*;';"7IQUQD./9[[[&7XN/O=>'H !@D0;/OCE"3>6I)97O^=@F$/!_^L#<
MGCB?^KA@2U8\4%]1?61NJH+U >NCZ94#"XEK&43*%C8^$%@"QJ@@_?_GYL;)
M(DJE7LO)$'"3JOM3] JBOQBT 2"&CYZZT):XNJK[#BI(?(_B/T 37DKE7RY'
M P>L: SJSLO8G8L, (GS%:KUJ/_OP^=$-?+L[-_** )%'&<+X\^&$8_30J5=
M@II3*]4+U5!]W^?_UA^<I36/OM=T5M^I* .&-O+@_6=?X9:+(]5CY*6%8A5[
ML"_>?DWLH;9?M^:6S_^]=(L'B[*IH9EYEF9@=-[HU3=\!0(CU_BCU$BJ89XH
M9!?HE$.'H%H<HNLV\$-_"NAM!+8F7_0"&SX#RQ'=_,!2T N-<Q3.?$]/"32J
M2_,QJ?!*+!<(;ICJWY!>XAB] M)<%X&BA\_XBT(;O2%R-D.^O):PQH^0FX H
MRW5A\2N E.1<JD:@]%/X:-]/U-K6,+;R7)@>QLJ)X(=EAV&(E*D\56[4[ZZO
M>RYC/_(2,QOQ*?_EQBDJ-E0EN6Y[XT[_N%2^T2.3;: S*)9R#Y1:.3J?@@H\
M^AK!Q(O$&8P#+%I@&?!Q#J.LG>=):0.<'-LV@-*M^&)\D!H\':N9P@- 3X)2
M0'+5'F'CJ+_7_5$C)5CY-[]##_S9S9+%VKNG55I;/Y2"=[OL_%;,#)Q1:V9C
ME3M03!T]L3><S4YN":--UQN5-EVVF,4X$?-E*GR:JWL[HM0(L?3G$S!%Y5IO
MC-8ZQ@T!XH+3)YMJ#\_ORD&\1C^O:BK.RXHZ,LMA-!\#O?@N8HC!S4IEE116
MH*VN' $89K"*3\%H+MSU*[17H+G7LQ37DNO,#9)(2)AZZK5J;:S'%^U*>/;2
MFX_4NQ(WD,G1Q,4G P"XK@CM!3JRQ33* E3>8!H;]^3+0:?;$Y/<"->JQJ"<
M+.14QUZ+YR5HV>- I%=YX&5)LZ%^=*=7/C3/7A7\-M..'>U\6@XTO^QU^L=%
M*_1:IO IF*<52YFB5:6)L(H^<%9>9O"D*,YAC9/4@D2-F-4U/3=N->QD]."&
MK80B4:,;AD"::&P$WG?@)[484I>OG!D8]8)973XYP/XEUKB^Q]\?-A=PAL&?
MBDD._$/EB(5_F7";>N%R0]18NK$76#H@S-2R&#\I/:8FF!J6)(E@?-/*N]%'
MJ_U49FY@/$*YN&Z_"WMPX/N'92]5$W/+4..('O2M7GQW7VY#H!X_=V_R!^A6
M+[U@;13.)N(5? MF?+YZ=42%0&V5O,&#<FV&%@^L9CU;:\@$1$-Y_$#3^\HR
MCJ,;-P"SJ% /QG\+NG"*QM"ES,5[#@MJ).T G0J7Z#?0TPHCYH7-/0-;$.7^
M[ME=Z=]*)0@DL*)ENF>6O:1<A4J=>IG2CPLW+:(_)I(-G_4R9.)'>5"YQ%0+
ML E'XWPK7C=WH=V:/G(;T<R))(\%Q-[1PD4_/7I)@P :A;W.O?<KI\)9:H((
M>33+UO8)/#O)#7TK].##)=/";5JHV,XZG\:]7HJJ,^.-F_C);[.SXH5?(NCI
MC?[W2L_&\'D\&[WQQJZ-6W'IS2RMAQE1:J 0AB_64N&^V,3JKAT7*8(U6(1K
MO)QH?, B"',T<A-E5185*@1<5<&S?!.S4@O16-M-4UQZH3_."O6!'33U%RC^
M,8:S,# +O7*-6Q+7D.X?LD@@24SD(\GF>7@55:^K#- \^I"%BA4Q+*%#4'D>
M#\Q:3ZG^E6U73U8!9Q Z;%L(N@MTSIF67;V83(Q]Y/GPREA;J^E5E%A-U*;:
M_>\S(7A;HFT_KG8'H');Z3[QT1AY"XH:QU==^T]88;E_BD^@R%*D,!W"!A-Q
M>96H C>FGZ"I W1WZ.[;23/K_:(/4PY+"@7S?4"5O54!;[V@UC?82F1$S3WZ
M/#K$C(VP!V>_=$A.:<5\UY%_$/S$+U*U\,?8PUFI-4@YP<1Y"M,4##,<(Q!!
ML.?5Q#XX.W][*"ZBA3\5X^[(N64-W49Q_8A7?13XZ/+)AZ .[,]6>FIBZS(=
M4E7Z3 L[]C./2.0K/YU6EI.Z7G'EJ6BZ7WJT91QK8RV/OIIT5C5N,8IZX+L3
M# PKCQ0J1U2RJ,Y@J#%4B\(4@Q:QD_:*K+C\,<8[IQ 0DWQDIN7(+/==+4'1
MY^-C(M%EYFO,[N[J911YREPK7KOV?:]+2EADL(93-B5,<).%6:[H\0VV4U G
MC-AY", 15CZ?CG'#0("F5<MG-:#"+!&4_86JLIR65DNL;X_R@%H>>#*PZR"^
M[F[AD%!.S2(BE6@JQ>6CH1"Y9@C@V?#4//$9B*3(7OVN5^LF6"@3:Q1?VQ,P
ML5&.C<,9W6QHOQ<[1S219@D&$W$E$TH]YR0.&294XA.5S8L94=Y2(K7V )71
M^U63YUXZ64L-50IYZR979Z&'_WD/?8+VH83=89(>MY)-<'P4:.H/:Z3VAU%R
M2RE7FBK#15S!2\%>"GSHLF?"YUH)EUI$\4H4PV(5(\(@ 7D06\U@6$3I))H$
M_>S*"6!T0_X$X:D<8Z-G8'QE.;X=40S]\D^ZI8D2%+.+0:EA>)F\R9>:98L+
MFKPG@7>U/&TD)U71^E6U +T^95S_MG5VTDIY*L?&3GK8/UG*=],D:O$Q+WN=
ME+U& KUV_0"_/X+W'2DW:9E'IN^U10_#D,4F (N*"T?1GUFDG'*5['],0IX
M)5W;.P/\<)'IE9(;S(%>A8[AH6M7&T9.F;B9A;@G0%$NK*)4I/32]4U\#X]I
MD\4ZS#.F9S;/-*N;R!18K+&\ GY'-YG.0+DWZ7"-SZ)_1_9\7=$?RRJO!%0J
MX,45UYIK@HI@!J+[R8^5KHKEM2^_5^,4A<6C#:[R8E"B8&N""2/1^/,D.N<+
M=^*LLIED>29-P,S[7B31X@3R$W21_9YYE]IDP8 -8G<$)@V,O)POHMB-;ZI-
M*SD#AR7*$DRN5-%M:(4G=7!5Y:%?Z7"_=I;FN;4K>K,<C@=U>XDLHYW?.F'W
M1VKLTS(MP.HMYGQ.) R)HAQL_=IX5]EW9\D4*W<XX1M#L)"+;0 8(T@+A[8>
M5"F=8EVQ>AZD>9Q=KS%NL/DH3-9#=.0.EW)F:A2]3K(9)JJ97F,"ZG=](2X"
M46K]A1(V'-IK&=\4+F4MZVI<.N)K+L2WA!>[>5L3V:HJEA4)UU*MY3B/UZM,
M=(TX7)05?E834YD:#5,L-^<P(R+O?HMV/9U6:1=W3_T;>_IKN='H7D?KN)V.
M5K733 V6L$9KCXA8.0_=.%8NR-R;B2)3BKBO\L3GMD6)%V,:_CK+TRE=+CKD
M@[/2^C(/]ADG:)QA(-'V*I0A3UMCF=@*"(L?ZP12RYCNB%]76P]ZDUH>I:ZZ
M/"HO1=Y)\WV#^B6KK(C"Y9JA;P/C+KX5@<UC(HF.S2KACN[0=X5"LYILV>UX
MX[=S<1&KV7?CB$M47"'>@18(=&FJ?+,YK<S=WU6N4;PPR75)-8' 3O<U,39<
MP>2;HM5J6VTRND_;;*Q%JLKGBXE)?0E@<L)ZX7V^J>0.W7/:3MWSQ=Y\4XS3
M_JB>+RLW%RV)(5H>CED46]:RATER&%G/+0^S#<0X?][9/^.66S>8FCLMOH6V
M8P^/E#6H6;9<(:A,HT+ZLT3.L@#4Q;4L+)K<'V?\HP=EZ$FOZ4'LRRU^AQWQ
M0:WNX?G*G/&M_#6GTOQ'-%CIQ'+/6M'JF10F5:'<$;AL.Z,]K5=2JW=]*5:P
MS%"TIN4UQGQ42!=?H#/R=5S.CP$M5"=3]86'UHPL,R.6.$?G4!K/J'((1FGN
MQ(1WH$Z_7R5MJENJ&NE;(G^;O2\B?J7>.>FV4^]\2]1*J!R2O=$XS8\KKPTE
MYV'=Y7#R;Z':8!=>1FK[HU["64W+'>Y:\HL&VJO+*5HERM]A=1@ERM<^D[)7
MUI:?&+5"5D0A= 9,D127QKY^7IRY@4ES4[N&3(88]D.&B='FY4Q$;B@4WI6/
M&Y74\S D$JND?IWE&Q;VD%Z F?5=L<(J4X&AR3 $NFA+%0T[)V8B TRT*D,K
M;A*%RM LTSHK&L_)=PRH(+X*G^#2#Z>4CEDH/P)J5)@8.*#H3S!H3J)L24=J
MLU/I2!.+"ZOVLIX^L51J$UKG^3A1%S#1BR17W=TDRN+I=FD&[\K@X0R> C)1
M+>IS#.M;J7A$X9/9QC.@HT(_")!9LI<#]\97*C[UK_.\)BMY4[7E_V; =_"*
M4QQ_\Z'?+?+?56ZJVO1N]CM;D\[V$%B<G2V.JHG JNEF\YQ.H4?C7G<8,Z**
M!AV< [5_!N$2&)Z]P!_-1C1/3G%B*/>"FOP)9A2^''8&Y48\M><BOPQST="Q
M8%PGYH.J07*E9CK<W>UTCXL\0[0DA.[FK4W2]]-CE>BJ)/A5M_AK.7#K[?&3
M9ZK41HT7S1@):Y#VAQJ_YE-6"5P9Z\9$>ZUCK#1$-$13>0F*%%>_H983:^6K
ME]S6#B^MN:M[))6]*N-KY7IW=6D%C.U[VD^+ZDJJQ&")FT*5/USB[^'4F)%H
M+^+.F)S)?@ ?)+@Y"ZWT6)?&4)7(5-*"BJ>AGQ^?.?-_H(Z*"T><\4^8=@,+
MY]Y'/RFU_8TBB1@K?>1S09L%RC]0'3>EH%&9+0U->K- Q@INRIHH^9Z$Q+]4
M+F!<)A@].)-()<K[6FQ*,"N&XE7Y& *M [O.LSDZSZL/6)%\KZ(G*K'5UWY-
MDS!K;I05+X7)4M6)LT\1CMA2?E=(Q@.C;+AA"\PV\=YL#3XK)Y3*L(GBPK'C
MZ1(KR"1GY]^  JR<]WZW>WK4&SABA8XH1K)?ONZ=GJ/*@LAOJ;SZ %]AGGIX
M1WJ1W1F]PLP-+]=^7&7WY43"T$CQ?]T0]VJ6G=!$TG.T=.7Y@O.\S5[99F/>
MR, \'K<:J-H0Y=Y-%%Y0^KZ7OS7/00$5XIMXFI57/#,9)^4K<'U;Y#NC"0I:
MQK7-TB)2<BN&8ST*WPYF<F[@3*3M>D<9L)X22UT]+%<RN#JX]5Q4@)4GJRHN
M9<9\GOQ9NAA59:&B% 88]OEJ_JX!L5?UT 3+^5C&3ZSM=RNL[6+,E&ZU:H[9
MR4#Y[HI\>\T=3>J(+W>)0R$!2^4(<H4/@AC+&8R>=L]J5><4BBY2!12/Y ]
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M*Y4E@*T]-(Z5,ZI&Y&=4TWCLI$AQ5X]9"!6;]_+U*XP (E!4^]6[@//S+8O
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MGAT&R9JR/:XI0;)X$<5N*H4G)^DC0V2<9T."=CCHWTY8V!JP=M!WG6YW*VN
MI:>=TL/<0@,&E@Z*L#"W[,R5R2+43A%B@J$! TL'15B88$JH#GHD(6JKY!S2
M1(/IA 0,+14*XK PG2SYPH8D86+IV6%DK-&'!C8C7/:M<]X1E]&UC,.YQ$<M
MHC")8ND)^.2G-[N(HG&9[+HECT:9;*Z"W2SH^(#CA\$Y/G$&W1,"&I*+7#=
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M#*<]4$>H\"9X_K4/3?3$C2\##_T*:J\T6?\<<Q)9:%C9_?_L?6MOVTC2]?<
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M,:-UA1HX59/::@ADJ]ENOXKO')'5,60$4D4&U@_63VD@N?435SWZ+5@_8LC
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M:X:YH@Z\S>6R_'EN]^*?Y^9T5C]]:3_GQB]>X9.0O5F\>*O-#&2_E;R;MOF
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M-NY,S;S[4FB02OM2G- 6=D++K)"-?7>H.?>3P'^8W8$B&]R!AT 6&M@WJLC
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MJ* $%>F(19I_<K":L+K9[)&'[<:/+/=9<922G?\4=P4%\)3:5J, 7HUO9:
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M/3F A )0,(35#_ZB%0(Y:D/RK&JXH$6%DKBA146%P$3HGB8LV*$IMT.#3[B
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MM>H1(B.&"6ZE44=(')RM%7C4S:8IUUB(3%)-U6T;LFR #'R$_='J]SN-SF!
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M@&44 $FP3-[C,&@.I>,P1,=('(=!*2@=AX%+2'()= 9$4GWI8VM"%1EL310
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MBO:GPI_PAG]P.+R0G7)S$U-?^&TJ!G,Q6J!R.ID$_L,\?7;YL:0 )#8G!Q!
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M25&G[1$WADO,[>$2DV\,2]W@)>98YHK?,KJDV-/VAWG%3FJR&U9[>&DY0^[
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M_63(@[-2WASY;K@*EM:(-]+ZEK/4=94F IY3 .#\%ID >L%])RP \"'&R0F
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M8_T@R03V/8\X#EFC&\7HC^CN[O(0G3L.F@A@'TV(X)W8AS$N/^HZD(;GGWF
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M4T!$:#)EJP^),T8DFNKDR?7,0CIW71KZ ;]'+L)/SIB@GU&@@:68CF$0UWZ
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M^;!:3>*0K JK>12:4H(DB*RE!NG7C<M:-/7@O"Q5;QDD4A-V#HE&6!=2$DM
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M6.9'UB8@N?785C]2:Z'(G7\*!6.7YUB38.3G'PM<1G>&O%!4UKK$HD@S\ET
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MYFSB/:-;ZE8LT#<4CJ<3ZW5=42[;,HB??NA:3\CE[D<]F6.](M"!XA'O2!!
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MV(]@?!*T*=<FP3[?US5UHL@*(?ZE^\BWYW21L&G4W@NL&J+'-UK*5EMON&*
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M,RRWH[8_IO;PL<>8C&?; PY^"*Y!JZ":#O2M;6\\UT&(J2N6*QA)]FLI&Z]
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MZ98+O_2CX,GNWPK_D9Z;X  7"6([)4X'O:V*> ""=4I)=(;7*> @N%CE?FN
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M$QLA)[CQR2(E=!\]N=A.PQ[27$M2ZR1YS@:GTY=-53H[^6?P#'DAD2["&?'
M5Y&(.L4,?4,O_$\PUTR2HO9.*(C. #_9^)K$J.HH:1:$KK^03HDP&9^CD1\>
MO\,[IM80ZN>@P"S]A.X%]AQ-Z'" !DN*A/L7$]+P2HEL[R*"&F4ID=4L8G)
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MD(]R4+(J@O_Z^M7K-V";%."9L/L3>//[UR>O7]/_9RUV\<2PJYY0D?X3KD[
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M4?60\M*)2J33PJ0@1^^K74$NVZLG"+:P2-$*$%.CN<ZD2B1[:E?N-@"M <8
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M*B)1^!M@OY9U<(OL$:^7:47M+ )J1_2ZHA$5-+(")JR8D:FXH"4OH *#ML1
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M%*1<TG K.1\6AGQ!^0*LJ3]F3S0AVQ5%=!KBX53XF:2DZS5H1&/-OFLE4>E
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MS<P.;=<.QZ4ED:XCSI.P/F2Q@20W>6XI?X[+#JCP@$M/[WX:^0'3/!T!D(8
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M=,I?-<Q!RKF#M&8?SN0,<4066CV> -)3N:F)'EM8I.B@_W3LP\H.1R3X RK
M\#E'X'>Q='EP*RU,7#V.51)V_.)2P<.]J=[*R9,83>+>]#45G=C0NIGN5%<!
M4=P &*&N]9RV5_/'@G#WHD!Y!,G6SK?RREF-:&Q395^H142&4S)GGJKFS&,8
M6M9[P4I&(KA*MZ4SW_-\V&PSM(?8AHOG= GOGI("GB4E.3?9;&%>LI>B&0VK
M^*?K=7/Y>T/G/W+Z,257V*D $V\7',KB]WY)" JXI("*"JBL0!86--*2[TDW
M]TQ@>G@56=:R#Y-47EHYA_NEF9_B$FPFR_.4B;I$&WB'=V3TT?L5%\\\^W2
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M*KHAJ0(!39WQ$ 06V-)7<$6?E905J8?K8Q$QD8O%RG0*0S];"B81K<=<<)D
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M:'W=W(0G.[>A4<SMS4V;&R+:;)[;93N_E[8EB-PCI:Y/Q"F/U_-ZS,V5EZE
MG<VC1&.>IE4D.S^1#G",CUWG$69&[S.0*U*?S.O^3DG3$Y0?"K>.@\.? \]J
MRI-]V-@T9O=L?C668_&2+-L'=6P=60+X];A8T;NUN)L78WAQ7FU@QLZ<6M<N
M/)<II&(\C(_CP7B/;IQ&X4D*^SM_+P)Y2.3@9U#84]=)6O"+V"WV7>;<W3,K
M_ -;1H-'/)PJ>-O4&4RPFR'B$=D7:6YRCLJ#(FU3FE/.]D#Z&)>5)W8*:7EZ
MR_4:M&Y9N<CS97_9:+S>6&%ATY+<?O\5IH]/%5PMGF&1/,);2)YBI?GC.<JK
M(EE6NR0CFR^C9LQ!Q)O7=.TE]9&PQ"R0QT7YO.\H(Z,#(W41,J="_'49I*,@
MRX<!I'$ ,1# 1P+JH0!I+( .QC9G9]9;\M;[$.TK\J,86M8=E<04U%S!S?11
M'><5;SN'6>MVEJ6GJ:JKE/TWMU^96N7HHWR:HP@__',VBSR:1*2T\=GU/O,M
M92MT]:TZ(C++F=7CS [%/,@%IY.;RNK GY5ZG?,9Z#@(]']XM8=;,I>;561W
MR=;E6T,;"3P],.5GH,^\HD9!>05?_#NVE?%7IO:(O R[<!9^V/^* BVW2G.*
M-\:PYW_F1Q;.^(:S)BZ"W\F^K /-EK([^D#3-1C7D::%R@LQ#D^QALL8]S'J
M8?PVR_GW+,"\)T]#LOB.0_0.2%KX#)^61'_RJ657+LXVQS%[:3;DZ'Q2M3 *
M>9KE,?VQW^LZ^8LO:=#.-_"-D'0//[NNYL[D45U,*3-N^+DF.<=\\4IQ9E5,
M<-I*B:4UU;*#UH/>OI>\+R\AM%6A^B"#LZGXP\VMMU+YR]>4!R.4%,[M4<L*
MC4M@?/BR?"*RW1))M9,R^PE,*F?0HN6_4 7D[ "=1:*H0J&&0U%G0J&JV%1_
M>)3:O8<K=P]_A\N*O-1/1!(:N_- XEHNV6X+N$R9']'#5P>U(SP,EH> UI66
M8 ,HGWGVW<V%4/GA'[NTVG]$%60UR+996IVC'"\CR/-\*I/909XQ;;N=CB$;
M]\9ZD7[!898&!3';=2PWZ!;8%F(T5<='!*>8D27F@'$'A+VHE$<$ (T$S%%G
M/"&;OL*V*T+I@?F\9Z]]<OC:G]OLLZ(_IQ^U)!>']<-(O22K\;<5[2_EJ;?>
MKS.(L&Y%=3]V&Z"]XA\B8;[P[*?F9=7?I(.1ID%-94O*,=RZ7P,6I*DPTQ=^
M,KWZ9WN+Z)*89A%M:C-81%/,)2*+Z(%%91$JA<7GE.H$385'VN[P? \@Z\A.
M6Y#5+9IOG,GNP_[[E=\Q_E@'H%1^\R^E['$MW/F]Q?6N*JLD7V&;81/]+ OW
M?N;S+L'ZY'!40IQ5)Z^2HN*V+BZ+4,,0)!5X#Y>T>P#X[LT).;G^_8E8=2&Q
MZCK*)?VHC;E8T@]C^)+LR?F=I20G-[BCB%D_D620\C)G8?:G I7SY!D/L0]B
M9PI)W,_/U^T4G)<5FH9,R6%PZ@7J99F-\P#%) 67.5]2 2KL?'<7?;U&Z!_;
M+S$-CSPMJ-L?>!LQFF@*[Y@IY/"1M$_NQ! HF$061>RQ[EYC6*CZ.'!57&6(
M-B!, .&B_)20?:+SS'?.ICD3 N0%*M8P):7RZR@YYP)#R3[(3*&0Q&=X6))[
MC"RZZ.#1FARN,7JQ>B&6XVN-(4G:+#2F-"F+<_/(#B,^Y%V?&SF*^,.X+T89
MPDGF-EPM\M6'+UNXQ#_>(_*KH,==^C(%<5E=\?QM,9^I!+1I#^0RD&PL\FM+
MVSRF><+89!U.'F;8?P7FZ7R:8>(#+#\0 P#WB/[Z6,_AI-H]\P=3!?,@9GD@
MA[_P"*5:22\_'/9;E\.XUX/>2[(DYY%,+MEU1-%*"K*=BFGB<(*6 @IT_SDL
M4NA;K"'I9KPK/:E+Q)V*$G%"%%I)EMDNE>H$G,''-*?%X\Z2K.^-U+$$0U/C
M]7.Q.FX&+]]0O5["'E1 K,V;CB"..%L:72_-%FM=BN7'C-U).,,MKW:DC3JL
M>K!5D]#J&O&OPRX-0FQI>8_\(@*MD#F^6&LH61BS-A+2^Z[^ZXFY=F;K,NQ:
M(/_5F*C[X%L/XJ7%7\4=9S01V%BV, 9N**:_*-RD'GP=0=C6=EV&82OPOR([
M=1^*E;D.IL'XI9[L:&1(&!U ?F!G.CVGCU&>D8_?L<9R=#Y5TDBOL,-,?N9Y
M%_UN<'-$D^0\WC!KFD:D1_0Q6'ZPE(ZCV.SH7T[',@5HBQ3Z-C_HN=) MLC+
MV.DX-EP_R261AN59C=1K(DHT,?9A'(T'X]U.7T^_M\;Q=F[Q@C1'M)#47QSN
M2; _401BC<:'P4-Q(/MVV.C3VCJ^+EN6P_6#7K1^L$USZ;?WMT<1N8VW-U&T
M7W8I=1#?<#> X&<K7^%TX,%I',X2KFWK?QS$_9QB?0#CMK&T*[2"]?0V.#YP
M%*>B/..23.82BY_F9;K\2Y+M0KT)Z H1.KFZ+<_L.R;)\A:/CP6M( !JF0 5
M*OA\Z-7\_&3UJV!]B:;F-7-_Q ZCC'?CJX/:S\+%PPE"1GK3U2-O\"W(2X^O
MT\U]UIO<03/Y&DT[V/VMMC=$>38E[2K:J,QZUC0D19"M<;] (:]DXPV\?BW0
MX<'-&+ OTMH<'ZS(-ZL=0YRG'U'G_*/=*D7JG7;'>K;=HULH*L=?%^<TESMC
MS14,8IQ#IE9&YHR_IXYYI=PBKZAYLT9X06N-N#<7Y V6EV :/-P<'  >] HZ
MESL0<N'(&JL1#UP70!;P*';.!^^R[E&59.$VR7KRA$PQ&A3-?;QJ)JUGPH!4
M1$+=]Y;!EU1S&:#[E#8--%^XL?E*9FL]S*'2Z^P$7L8!;;NEO/+YC='^Z(6L
M[=5JD?:2!FJ)<C;M.5>2]!KO.;2.D#$=UHW+&^0<^@0DM0FG[;G[F*?IZ9;M
M_\A9UR*^1BN>]<A9/G0)'-"73W"URR#?8![@QS9W31_83Z3SL-1T@G3#*\_V
MK3<$MT11]V1P1E';LR1V1NU5* ^'-US>>E^N,F6^86^D!E3L5A\/VN:0/C5O
MOZX 5'KP"Y7__P8-V/-8+IK7&%ZLE691&.B,BV)KI2^^I Z:W$UD[W ),$D2
M]R%292[Q+3S=6,_HDM(!-B_+4L:6@2Y"$Y$V^LATJ.3WB*3\SA29^MG/;6]]
MDGBZ>3L]O-,]45C=KL?J3I0V=Z3Q;=0&W<2W881?EKTYC&_JX,:$'0MOI',[
M#5IOWO*017NY4QK7.?P9ZO8847[-"#(%!3>J7J'ECIP+L-OF_V#Z03E\%<(;
MA]2+!I00ARKE*/FO;U_]\ /X[;_\^/;-FS^!?_WNU?<_@%\8,^5^-)3,W-,8
M[)AVKY &KG'_&=FXAO0U2SQK"AY=H_J, KO&H7K1@!+B4&7+-;Y[]<-KV37P
MOYRXAF.96ZZ!:3MQ#?P1JWFC]45;3!L:/AV$< GM(@HUHT%5Q*+2KJ-(<\@/
MK[Y_X\A17$O==A5"W86S7& Y;'Q%_IXEK@T)CYZRQF0".XI"Q6A(#Y&HL^4E
MV"_>-E[RAU>O_^#&2UP+W7(20MR)CZ3/5O.)_#U;4&L2/GT$,PGM(X<J1D-Z
MB$2=+1_YPZNWTI+KG;.9Q+70;1_!Q%WXR%WZQ<9%I*]90EI3\.@@9?HEL'\<
MJA<-*"$.5;:<XQW9G-?.\>:[5]\YVJL[%KKE')BV$]^ SS"W\@[YB[:@-C1\
M>@CA$MI'%&I&@ZJ(1:4M3\&^\</WDJO\\.JUH[V[<[G;SD*HNW"7#^1]B8V[
MM+YHB:U$PZ.[T"<T@=U%I68TJ(I85-IVEQ]>O7DCN<N/K][^WHV[.)>[Y2Z4
MN@MW^9C:W9+(W[-$MB'AT5?R-/A%B4+%:$@/D:BS[2?O7OT@^PG]IQ,_<2UV
MRTT(<2>'PG8KL/O)ZZ_[&59?5?"UUZ%ZT8 2XE!EUSU^?-URCQ]=W9AX7'/=
MZZ^X(DPCNL*^?5G!S5PYCH,2A$_NJ(7QE$_D)<F#" VHU&%3P/W:I:_LH@[D
M+\X&LX#F=P3Q#WV&!5?[)JW"1<&N'!'885LD]Q&1,N!6A-8:S0^/,Y+U6)BW
M>*:"[85:D^_8)ELH%?OX MRG[3:* '<@1WB3[(CD/L!1!B\^P/59F*\ IX3M
MA5J3[P G6^B1!CA1DDNJD<(??0>+=4,BA3?4?NG\5:"0J[HF] U^\^2>URY#
M=>TR_-.2E2\KJ1E+Q>]X+:D7$SLUC-=7&!TS@Y=OJ+Z#:U.43S;_:[4)SUC"
MV!*.0QCF:Y880&2'Y6IGESY,(-=L2W.5KB'XYC('>Y@4Y>^"Q_+P</7&^O"B
M.2_=?*2^(,\5BCK/4Z<*Q001:;-&UY.[%$!B6;:K1(IG-70HG;]H_S_+=&UC
M];U,[X/]Y1OF?,MTV=R/=IE^",-0AWD'O4CFDC/\(L10Y'GB\L$R(;)CYM!V
M[6M-;64,7ZD->UX]*^+VF%N,=5/IR6-43YP:957%)$D*CM(JWGBYGV7DS]K)
MD%YXFZ<!>A##2UHF6R\P:UO*UI9(M6,?]J"4/K?EM6,36CLVKU>\STQDD#8R
MATOV]&F#R#?(WX;8HFK(_>$?N[3:$W$+:D3E=?4$B_NG).<!Y2=,HJK;&TS?
MH_J0:=Y*T8;BN5\-W6(;P[&<!'FV ]WE:54RYSW2+B.V9NBB6KD5GE^!R8WM
M/[5KD3/I@20^H/(#,H!ZX<*&T#0CB;N3A"$BG;4F_>/[I((725K,UUG"O=!1
MN\&H_.Y#,^4!5J2._AISX<V@2*X)6UKA-56AC-Y?0]36=X( 85W36/['X(-/
M#(=;7.9U9*2 #-6Z05/<^[R^(KVCF[Q3Q2;O9'B7]^*4Y\QFFU-S+BJX[%=;
M7/VY1Z-)3VL;UD-F^H'Y#"+.VVMYFK3NHT+3Q$=:?& 'O[W[5#?#2G.R'%&L
MK\,?D,]GPBZZ?[L _^LSUY$3<=V^X7HKA]ZF5KPMULQGX:/ZOX49)%\R.6V;
M7:093\Z-I8OT0!TR:TTE:T746BMBK3QI!&\,V6":$'V$9^WV-C[Y"-[26O[_
M]IZV-V[>R+]"]$/1 @X.AP/NT!8X8+U)"K=.[-INBR*?Y%VNK58KNI(VB>_7
M'U^UE$1*)$6*E/U\>OQL=F>&\\:9X7"HK<PO;OZ:MP>E'CD6?";@%LQ)3<E=
MF%*]:C<R\NBI_+0QS__>HHNQMJ/PKL=.\U9[6/@5E4S]S!U5!*(2J^'UZ//C
M?%@ <=]D52-.#4D2*#N K $?X8X.\ '_]9\7 &O+?U\,VEVCIXF+*NHBA6>E
MP-^#4BY<.&[7P)7:H:BYSI/;[[!Z1.=V 6+XO#G S+[?5%+W.\:3DA8"]C)/
M1,+U#ID2QR#%(M[,(?]G5!U@WMA5;**0E=CV,J PF)$?!*;W$MKH=7*1X$8C
MV3>N?W'\:;L*O4--@ML!,YQ/9<?:)_*;_UG#5K]LE:K36"J=$RKK1[^P-$$O
MP!8'-G0J 1?8 Z(?=^Y7JY.@1(O>AK?<TRV%&R]@!05RP[6\V;+Y#]%PEO&&
MLZJ=2+"3)A)@5WI\1_5T6Q.-5F6W4M_5UMXE5V^X8 \3)Z(1GE@^X;"&0.&;
M)@*^D.(UBP$K;S-%GF,JBR31SNKTBUE$"<'E,-O"NM:3*2T: 7I(26>ZN%]D
MD% ..T.6B2:WFC[;=)-9+<$K2%XUM+_99#5KFY[SMNF9W@1X1ZGIE(%%2T5'
ME7&)U'/)>P-25)3TY:$.G>NXDB&1'/4T17O#(GKB&%O18UXQ&FC'.U7J1"X;
M2>M:3;(1-&KRD.!9.9[WQ^&$TC=C284+>NK;+-]_1M5#]O/O>?/\C IBB_@#
MM="M@Q5K^.[^V!)5H,D#-?A!D,-B#\C6"_*Z/F5X7R97UU!%1AABZ\6)#8#'
MEP*]0@B:[&<"#5>NBM#?S)VDL#*A%QUY$PI(OQ' - ")"/J9SLW,:$;B7HCT
MO6;49493^ ?49(7(TFD_(<[%8:O9]:^S%U3_@2@X0(]%_I0QEX@- ']$(V<V
MWK/)AP80Q.5MZ7!R.D-TF[WDF'HFPSM8P^H[)(KT^=2<*GC%K=;&WSD =])[
M:SS!/%W%,5+)MXX.'<"!XF=UFZBNS5W@:#;#UR1<[M$8=CYDE^,7HW@%!=2M
M,1J (&(1X[TJ=^@(L;,C<519PTM8PD/>D$)W7I[H*R"P8BYF\UC3XK>-^3J!
M=Y*Q R;_)LR1,M.E!+% Y/<QS76.B)$'!J]+G-QH&7X:?7 *@!#NF09P)@)\
M$V0L\SCW]E15.#X(;+YSL+AY:F>$_HV9TQ+5=CV(&?GC[BI%6G2D"59BV)\A
MSFJS8L O!^O5@YHC3QU4_W;(,25@AI-"&=K:.)O2%4#/:C@RE=DL:17W#4[.
M-^7^&NN]%]N8 CA'0..P ^2/!%\"5F(HI*&MF# L=8'T[(:BI'5JBC2V_7 S
M]FY&AG ]N+M%C(I4X(11G1[I_R9@5W;"TVY%H:UL04%I-JE4C.XC/$!,V3YP
MDC8+C9.D9V#TO^T)8J+F:3Y$C3PR>)UB+;H233Y7$X1RQZ/AFXLM3T&<)=]Q
MX&\R@;.4E,(439B6O%3Z!B9V3+VA+6I'G9C!HS69P9TE/1,4;S#E<Y*<PKK,
MV;<2*?4MK1^3)F)QWA-"2\ ^/.9[3 G=Y*??UH(EA1%DI=OD'-+"^0>6_M7O
MJCU7!H]&'D-S"ZTE&-;7>0FO&FAV07_DQ_:WLU1P@MR4.G,-UO$N)HWR'$WR
MQ'9TO 3I@3S:[")>_L-9HJ4PWH=8NWQ6B%3B12H\E2/*<UP"<3I-D0QRZ;C4
M#AHT](2&[9CBSZ@WKYN?N=5H$QV$>8TR'6 A%0.TF)+H:E*+0=6XI.!0<BP?
MMA^U2, W@B:6DG]$Y!+\/#47,#QQG8%[CZK>$\:HLLM<2I#QHPK/$"VC\IW4
MY$^G*J_W^8Y$&5^@]=L24Z#<KF:,0PU470+?&'AE%+#891I#V2!+;J4KAT(6
MP3EGE=%I)1.F8H3-LV[RW1:=RJ9ZM3<*#0"WJH(*5K"#BR1,8)S_R(@WJ?%:
M5&HX!L!1+*O8]SM89E6.;C$K'%R]XM=N7F4 *(!#YS@ 09*$5H\P'TWS)BE&
M%[8\-J3W2_8S/YZ./DGMOM?"$<RA-7 M3U^@((@ Q90@V<I*Q0C%0=S;I\,!
MXG#A.VS7>8=#BCM(C#,O<C9U0&[:.F%G]]KYLHT_](+.R:X]8 X70=0"GW0M
M#%21#V]]J@8*((AUJP&W_I8>^<B78 %=FL"FV\#(M*7WFV5K/UT"-0=<'GV'
M9\3SBAT^: @P'  K0M: P\"MQ/8E891&5=CR)YBWHB##$EK/M8ST4:;N==0=
M.]#MO,44M$_%T&$)5:ZC1Z$7H(3*9H;([F!2FM,&/\[/]4ANTFCU'6,+S771
ML&7[3"9Y796?RHP.%_.VS^L ^Y2I&D>XN)\&>@QI@N8X(<II8QQCYUK$-FF(
M##EY\HZCUVZ,UB6'+J:OJ-S#_0EG"X\%Y!LU^^I2LZ<P!1_.).#PDHRLV<V;
ML)7>BB<EWB&K#9GX]TV'CRWID_$'VPKN\X:.-,*.X=F#/U8!]6G40_A!'F7E
ML,&.X4K0#8](;]H%Z[B8M*1,#9%\Q#$#@3J%V$?T%I.FB+J&34T&C++24E&@
M'[9#[GQ@"['=&B .,':';;=Y25\1X,\9"'0)6J^+3IA'5L8B6+7\+6*PMJV?
MM@I1JD!+%MCH%&5)+T$'%F_V_SS5#9WAZ<$5#$'ZE'<?NG^CIA@2-%ZMJ*8M
M5,VT],4R:6MLWK:$=]$;::VO^0J;.=,0U'!FW6%2@0PWSX >$6847Q*C#48%
MH[A9IN=6HD(H>OR7-AB,*]9L@7:]?,Q!^72-ZGJ;5=7K 55T%O L\Q@#ZT=0
M>@P!"AA84$C@ P5&"'8RQJ0,R4"B8W8UQ==U2&_$ZEK4@. &VS%!+F.#;2+<
MH<6EYF(-VH\TQ[&$Z"YKZR_DL94]_ X+]$+?^R#;&ZO))&RBA@(?,U,3EJ]'
MN"/F>B[6=$UUV<J-BBOB,U[)E:NVFW+/C\)K=<EYB^IY\:<7_-X49"XI(8ZM
MT>Y?'X9O6*;F![PIT82S\".A-Z8P$VZG_5R<U6P[CT_AG4<0JCV^ 838.!ZJ
M.W=MEK/I@_*C!EVH 5/>"L<'9=S''$VE,V;%*GZE*XD1V^I-XHN4^))ZU+P<
MET'PE! 18&^P0CK!]]%,],R2Y'@\EE^J6+Z,3O^QPAGM+)WF$/SPFP+S/ZJ(
M/66V'Q0TDU+SKBC&U%SB4G)L'U%SBB6.FL\[%@]W[AWE8/MO:1UG.YY7ASV0
M7OK$.:739-4)Q]R3+X^'+?ZW!U*L'VX.:14 91E,'')Y/MQ:XE!K$;V^SK/'
MO*#OD;H<Z"I_[L1E!23_7EY"$O78=HSKR( G:7&X&# WXGFL1,4?$=K_R(MB
M4^*4O,'\(1W#S+X<7;<I\+E^Q@Q/B([<@=LO."FOH&*O+Y/'C/.6DK2V!4OA
MJ_<,&^:O0M CNXULLX( 6I(]D\!WI(AV_!7K 'M%9K[9RK \"N\,UJM1/HSG
MZZUMIF=^"IE-6EN?B2G*Q]"6SOA<+^7<5F@'X;[^C)F]+;+\6-_#IBG@T=L:
MNJT % >H6QS8W>]@_AWN71=P)I>T,#Z5^?_!_:;>[/<Y2=^RXC;+L:/C3V[C
M;>?F@)D88F7WG35Q2O"^!;*6%O""B?F0EV#'R*%7=,FS[MC*8K[TC;UPE;W
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MHCLCXM9ZQCEV.I3,:A2G)\8+"1/HY$W^1+6=/ ASJC<_<ZN2JOKW;GNH E2
M(*;% AB:J%',&/>1"6L2XW2A83+X1G#$4>F/Z)CEY1RE%A"\,)L!>V>*W9/!
MB&K+[$F.WWKU9E@<S[H_YO431D2]_WD?L#SF'@=BO[N/P0L2;,D(DPBSC,2"
MC-F5H@@Z%T+4_)]]=AU^%85B ??^%A X#95EH @&1PX0$UE X4*[84$"E:0.
MB(%)$]DVY?X^*V!]20Y:O^3XKP:5\#9[I=7#!W0)[^ .YM_-;GGXP>-0W)B'
M,DP)I*6I,]2/C"^I"5E\U/Y1$$8&G+"2;8/ (WFUA1$7L7+B26&03RF%[BT]
M/=;PWR<R(/&[3:5F_/=N?8@*4 'J "T60-$DT1@Z)@1DPJ'$&%[8\=ITUO-S
MCNWH2*<GW+_ 77[(S],^MQA OLL*R=3NX-.I(+K[BHWN<U[5S18=C[ B%T:(
M#;;65UN&RPM0XC)C.C!1@>93MU230FDMZ&ZGQ%Z '2==WE;(>Z>">KK%' C]
M8-<N@.XYY\TFZGCKI=06+:L);U9%NT-D._K9$MV._+T @FYY\.\%N.OJ)R4>
MG*D'A'QPIG]VHK$2WA9#MMZHV*KDJLS4S1RFSMEP%-%;?75@M]C_CJIB_R/?
MPZ^PH=^[.5SG.W*7CHS9)4]^U'<PVSVWP*[)XOQL/P'I\F7IP4A<=FM2IC,U
MR _8TNDL@Q]B+?1-9O9UTC3'UT,F4M,%X4T,KTB"7- UI;97A=?X\9TKL-J\
M$^TVVM4H;1^8:G_IJ#8?T]$NA#ZV?2]46RP&B-4 NAP),EM0H&TN<=9/;7J,
MC9=]KE^-<OW& ]?-]L$_YPV\?<ZJ8W95[BSW*N5O[2U. 2:(SR=X $-$GG&+
MYXG'>(ZFF)(0?V6O(S'W@G(7_.97Y+-?_7:V6PA&?S$@G5 ^TZ"VJ, _0^P.
M" YDN1UO1)^RI8V9@G.I,YM #E1.EE#3%(J'3^=V[IB58BL!(@=VIBVLSKG3
M0%(<,VA1SS]&6W!MA6I9&ZME+5*JQPNT[;C2@O!2/^;0%JC9$U0I%>S[HABI
MV7>8E![;=95[@F7)1BS%(NU[L4: ^.)\J(ZL-:B\OC%K@E$I,G]<\<U:M(*H
MOGDP. ' !]=#Q1##D\*1@"&2R@^#.@,FI<9T[<ELQ$CFVF4>AQZ&#Y9?AVO3
M&K+^.HWA&Y-2T6O\M8>!&V$EH-7[">:OIANKFY$I6[$^G)NQ/A@V8ZV:)<6
M&_)9(LGHE(57("@B@XLN(;A3\(+_C97G7_C_\?_A/PA+__?_ 5!+ P04
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M,W9&UFOBWT?$_>/^R:'HS^,HD<!4*L,X;::D@?5+[*'@C!Z/%0FV,%[W/M7
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MPD:('1G! R3<IQ"2PX#(KZE=(BFQ&+/T!CITZBJ0,8A7$NA; %5PIKM;R/Z
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MDX36SRXI4]TE2$K.B)#J6](T\J@YZM)]0HO80_/E0?>9V0\G6.2E8!(6;^/
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M.MM!\ #P%D+]3 .>2=% QEAPMYK3WB$07"D#FF'C%R(KAL'9NT.)\2SA))G
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M<=WYIMDQNT-)/ZX'\N"\_(:C)[8:]&!2AA(.3YGCC'+/'!O@ACCR8^CN29"
M?^M@!KR&B<O1-S'IQ_UA2Y&OIUO^*]G2S7XXP2(]F5=)5=AD/1,WSL.3X\\3
MV1O.5JL@Z9IVY4<!]D/L)GVD_XK"2*RN6N\L@FO"5"[A(:.G^XSFSE8V,-T-
MC&/'\]:"YA%]8YO8>S(\MR[LKY1$%%[YMXAJ!HO?$%X]T16=/5,%8X62'[*
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M1[,UO(Y#9.T>TWH][@11[MR.QU:"615K>@C'_MUX?&RML*^.$6XW6U0'-'/
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M'BFO__[_ 5!+ 0(4 Q0    ( *J+84S'LLG,[<8! ,$:*P 1
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2      8 !@"* 0  3P\#

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
